<SEC-DOCUMENT>0001144204-15-019667.txt : 20150331
<SEC-HEADER>0001144204-15-019667.hdr.sgml : 20150331
<ACCEPTANCE-DATETIME>20150331081010
ACCESSION NUMBER:		0001144204-15-019667
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150331
DATE AS OF CHANGE:		20150331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		15736525

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>v397831_20f.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>United
States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Securities
and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 20-F</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ANNUAL REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the fiscal year ended December 31, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Bio
Blast Pharma</B></FONT><B> <FONT STYLE="font-size: 12pt">Ltd.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>State of Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Jurisdiction of incorporation or organization)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>37 Dereh Menachem Begin St.,</B><BR>
<B>15th Floor</B><BR>
<B>Tel Aviv 6522042 Israel</B><BR>
(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Mr. Colin Foster</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Chief Executive Officer and President</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>37 Dereh Menachem Begin St.,</B><BR>
<B>15th Floor</B><BR>
<B>Tel Aviv 6522042 Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tel: +972 722409060</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, Telephone and/or Facsimile number
and Address of Company Contact Person)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered or to be registered
pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of each class:</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ordinary Shares, par value of NIS 0.01</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nasdaq Global Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered or to be registered
pursuant to Section 12(g) of the Act: None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities for which there is a reporting
obligation pursuant to Section 15(d) of the Act: None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares
of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">14,230,480
Ordinary Shares, par value NIS 0.01 per share<I> </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>
Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT> No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition
report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>
Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT> No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">x</FONT>
Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT> No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">x</FONT>
Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT> No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>
Large Accelerated Filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT> Accelerated Filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>
Non-Accelerated Filer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">U.S. GAAP&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">International Financial Reporting
Standards as issued by the International Accounting Standards Board <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Other <FONT STYLE="font-family: Wingdings">&uml;</FONT>
If &ldquo;Other&rdquo; has been checked in response to the previous question, indicate by check mark which financial statement
item the registrant has elected to follow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Item 17 <FONT STYLE="font-family: Wingdings">&uml;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Item 18 <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by
check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>
Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT> No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 15%"><B>Item Number</B></TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 72%; border-bottom: Black 1pt solid; text-align: justify"><B>Title</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right; vertical-align: bottom"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_001"><B>PART ONE</B></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 1.</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_002">Identity of directors, senior management and advisers</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 2.</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_003">Offer statistics and expected timetable</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 3. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_004">Key information</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 4. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_005">Information on the company</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 4A. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_006">Unresolved staff comments</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">73</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 5.&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_007">Operating and financial review and prospects</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">73</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 6.&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_008">Directors, senior management and employees</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">79</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 7.</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_009">Major shareholders and related party transactions</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">94</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 8. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_010">Financial information</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">95</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 9. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_011">The offer and listing</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">96</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 10. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_012">Additional information</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">97</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 11. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_013">Quantitative and qualitative disclosures about market risk</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">110</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 12.&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_014">Description of securities other than equity securities</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">111</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_015"><B>PART TWO</B></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 13. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_016">Defaults, dividend arrearages and delinquencies</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 14. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_017">Material modifications to the rights of security holders and use of proceeds</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 15. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_018">Controls and procedures</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 16A.&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_019">Audit committee financial expert</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 16B.&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_020">Code of ethics</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 16C.&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_021">Principal accountant fees and services</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">113</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 16D. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_022">Exemptions from the listing standards for Audit Committees</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">113</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 16E. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_023">Purchases of equity securities by the issuer and affiliated purchasers</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">113</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 16F.</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_024">Change in registrant's certifying accountant</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">113</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 16G. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_025">Corporate governance</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">113</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 16H. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_026">Mine safety disclosure</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">116</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_029"><B>PART THREE</B></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">117</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 17. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_027">Financial statements</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">117</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 18. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_028">Financial statements</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">117</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Item 19. </TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_030">Exhibits</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">117</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tpg4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INTRODUCTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are a development-stage biopharmaceutical
company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare
genetic and metabolic diseases. We seek to identify therapeutic platforms that offer solutions for several diseases that share
a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. We focus
on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action
is understood and for which there is no satisfactory treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Unless otherwise indicated, all
references to the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; &ldquo;us&rdquo; and &ldquo;BioBlast&rdquo;
refer to Bio Blast Pharma Ltd. and its subsidiary, Bio Blast Pharma, Inc., a Delaware corporation. References to &ldquo;U.S.
dollars&rdquo; and &ldquo;$&rdquo; are to the currency of the United States of America, and references to &ldquo;NIS&rdquo;
are to New Israeli Shekels. References to &ldquo;Ordinary Shares&rdquo; are to our Ordinary Shares, par value of NIS 0.01 per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We do not endorse or adopt any third-party
research or forecast firms&rsquo; statements or reports referred to in this annual report and assume no responsibility for the
contents or opinions represented in such statements or reports, nor for the updating of any information contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">This annual report contains express or implied
&ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S.
Federal securities laws. These forward-looking statements include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify; width: 93%">our expectations regarding the timing of commencing clinical
studies with respect to SBMA, BB-FA, BB-OTC, BBrm1 and other product candidates;</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our expectations regarding the progress of our clinical studies, including the duration, cost and whether such studies will be conducted at all;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the number, scope, size and design of our planned development programs, including pre-clinical and clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our intention to apply for regulatory approval for our product candidates, and the costs and timing of such regulatory approvals;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the likelihood of regulatory approvals for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the timing, cost or other aspects of the commercial launch of our product candidates, including our intention to a build a commercial infrastructure to support commercialization of our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">future sales of our product candidates or any other future products or product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our ability to achieve favorable pricing for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the potential for our product candidates to receive designation as an orphan drug and implications if it does not receive such designation;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>that our product candidates potentially offer effective solutions for various diseases;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our expectations regarding the manufacturing and supply of our product candidate for use in our clinical trials, and the commercial supply of our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">third-party payor reimbursement for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our estimates regarding anticipated expenses, capital requirements and our needs for substantial additional financing;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>the ultra-rare diseases patient market size and market adoption of our product candidates by physicians and patients;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">completion and receiving favorable results of clinical trials for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">protection of our intellectual property, including issuance of patents to us by the U.S. Patent and Trademark Office, or USPTO, and other governmental patent agencies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the development and approval of the use of our product candidates for additional indications other than ultra-rare diseases; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our expectations regarding licensing, acquisitions and strategic operations.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In some cases, forward-looking statements
are identified by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;potential,&rdquo; or &ldquo;continue&rdquo; or the negative of these terms or other comparable terminology. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ
materially from those projected. These statements are only current predictions and are subject to known and unknown risks, uncertainties,
and other factors that may cause our or our industry&rsquo;s actual results, levels of activity, performance or achievements to
be materially different from those anticipated by the forward-looking statements. In addition, historic results of scientific research
and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different
conclusions or that historic results referred to in this annual report would not be interpreted differently in light of additional
research and clinical and preclinical trials results. The forward-looking statements contained in this annual report are subject
to risks and uncertainties, including those discussed under Item 3.D. &ndash; &ldquo;Risk Factors&rdquo; and in our other filings
with the Securities and Exchange Commission, or the SEC. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required
by law, we are under no duty to (and expressly disclaim any such obligation to) update or revise any of the forward-looking statements,
whether as a result of new information, future events or otherwise, after the date of this annual report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B><U>PART ONE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify; text-indent: 0in; text-transform: uppercase; font-weight: bold"><FONT STYLE="font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify; text-indent: 0in; text-transform: uppercase; font-weight: bold"><FONT STYLE="font-size: 10pt"><A NAME="a_002"></A>Identity of directors, senior management and advisErs</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify; text-indent: 0in; text-transform: uppercase; font-weight: bold"><FONT STYLE="font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify; text-indent: 0in; text-transform: uppercase; font-weight: bold"><FONT STYLE="font-size: 10pt"><A NAME="a_003"></A>Offer statistics and expected timetable </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify; text-indent: 0in; text-transform: uppercase; font-weight: bold"><FONT STYLE="font-size: 10pt">Item 3. </FONT></TD>
    <TD STYLE="width: 88%; text-align: justify; text-indent: 0in; text-transform: uppercase; font-weight: bold"><A NAME="a_004"></A><FONT STYLE="font-size: 10pt">Key information</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify; font-weight: bold">3.A. </TD>
    <TD STYLE="width: 93%; text-align: justify; font-weight: bold">Selected financial data&nbsp;&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our historical financial statements are prepared
in accordance with generally accepted accounting principles in the United States and are presented in U.S. dollars. The selected
historical financial information as of December 31, 2013 and 2014 and for the years ended December 31, 2012, 2013 and 2014 have
been derived from, and should be read in conjunction with, the financial statements of BioBlast Pharma Ltd. and notes thereto
appearing elsewhere in this annual report. The selected financial data as of December 31, 2012 have been derived from the audited
financial statements of BioBlast Pharma Ltd. not included in this annual report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The information presented below is qualified
by the more detailed historical financial statements set forth in this annual report, and should be read in conjunction with those
financial statements, the notes thereto and the discussion under Item 5 &ndash; &ldquo;Operating and Financial Review and Prospects.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">As an &quot;emerging growth company,&quot;
and pursuant to the Jump Start our Business Startups Act of 2012, or the JOBS Act, we are not required to include selected financial
data for periods before the earliest audited period presented in our initial public offering registration statement. Accordingly,
we are not yet required to present five years of historical financial data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statement of Operations Data &ndash;
Year Ended December 31</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(in thousands of U.S. dollars, except
share and per share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 0; padding-bottom: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; padding-left: 0; padding-bottom: 0; text-indent: 0">Research and Development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,441</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">732</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">140</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 0; padding-left: 0; text-indent: 0">General and Administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,639</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">416</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">86</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0; padding-bottom: 0; text-indent: 0">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">226</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 0; text-indent: 0; padding-left: 0">Financial expenses (Income), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(58</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; padding-bottom: 0; text-indent: 0">Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 0; padding-left: 0; text-indent: 0">Deemed dividend</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 0; padding-left: 0; text-indent: 0">Net loss attributable to holders of Ordinary Shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,022</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,171</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">229</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0; padding-bottom: 0; text-indent: 0">Net basic and diluted loss per Ordinary Share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 0; padding-left: 0; text-indent: 0">Weighted average number of Ordinary Shares used in computing basic and diluted net loss per share</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,259,600</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,423,018</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,551,427</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Balance Sheet Data &ndash; Year Ended
December 31</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(in thousands of U.S. dollars, except
for share data)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; padding-left: 0">Working capital</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">30,605</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">168</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Shareholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,674</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0">Number of Ordinary Shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,230,480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,182,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,551,427</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify"><B>3.B.</B></TD>
    <TD STYLE="width: 93%; text-align: justify"><B>Capitalization and indebtedness</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify"><B>3.C.</B></TD>
    <TD STYLE="width: 93%; text-align: justify"><B>Reasons for the offer and use of proceeds</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><B>3.D.</B></TD>
    <TD STYLE="width: 93%"><B>Risk factors</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">You should carefully consider the risks described
below, together with all of the other information in this annual report. The risks described below are not the only risks facing
us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially
and adversely affect our business operations. If any of these risks actually occurs, our business and financial condition could
suffer and the price of our shares could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Financial Condition
and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are a development-stage company and have a limited
operating history on which to assess our business, we have incurred significant losses since our inception, and anticipate that
we will continue to incur significant losses for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are a development-stage biopharmaceutical
company with a limited operating history. We have incurred net losses since our inception in January 2012, including a net loss
of $7.0 million for the year ended December 31, 2014. As of December 31, 2014, we had an accumulated deficit of $8.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have devoted substantially all of our
financial resources to identify, acquire, license, and develop our product candidates, including conducting preclinical and clinical
studies and providing general and administrative support for these operations. To date, we have financed our operations primarily
through the sale of equity securities. The amount of our future net losses will depend, in part, on the rate of our future expenditures
and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product
development is a highly speculative undertaking and involves a substantial degree of risk. With respect to most of our product
candidates, we are in the early stages of clinical development. We have commenced a Phase 2/3 clinical trial for two of our product
candidates, and it may be several years, if ever, before we have any product candidates approved for commercialization. Even if
we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which
our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, reimbursement from
third-party payors, and adequate market share for our product candidates in those markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have incurred continuing losses. We depend
on outside financing resources to continue our activities. On August 5, 2014, we completed a successful initial public offering
that raised net proceeds of approximately $31.4 million. In the opinion of our management and based on our current business plans,
our balances of cash and cash equivalents including short-term bank deposits will enable us to fund our activities until the end
of 2016 or early 2017. However, the actual amount of cash we will need to fund our operations is subject to many factors, including,
but not limited to, the timing, design and execution of the clinical trials of our existing drug candidates, any future projects
which may be in-licensed or any other business development activities. For example, changing circumstances and/or acquisition of
new technologies may cause us to consume capital significantly faster than management currently anticipates and we may need to
spend more money than currently expected because of, among others, circumstances beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Additionally, we expect to continue to incur
significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase
substantially if and as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">continue our research and preclinical and clinical development of our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">expand the scope of our current clinical studies for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">advance our programs into more expensive clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">initiate additional preclinical, clinical, or other studies for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">change or add additional manufacturers or suppliers;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">seek regulatory and marketing approvals for our product candidates that successfully complete clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">seek to identify, assess, acquire, license, and/or develop other product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">make milestone or other payments under any license agreements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">seek to maintain, protect, and expand our intellectual property portfolio;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">seek to attract and retain skilled personnel;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">experience any delays or encounter issues with any of the above, including but not limited to failed studies, complex results, safety issues, or other regulatory challenges that require longer follow-up of existing studies, additional major studies, or additional supportive studies in order to pursue marketing approval.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Further, the net losses we incur may fluctuate
significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may
not be a good indication of our future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have never generated any revenue from product sales
and may never be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have no products approved for commercialization
and have never generated any revenue. Our ability to generate revenue and achieve profitability depends on our ability, alone or
with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals
necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for
the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas,
including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">completing research and preclinical and clinical development of our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">obtaining regulatory and marketing approvals for product candidates for which we complete clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">developing a sustainable and scalable manufacturing process for any approved product candidates and establishing and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market demand for our product candidates, if approved;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">launching and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">obtaining market acceptance of our product candidates as viable treatment options;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">addressing any competing technological and market developments;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">identifying, assessing, acquiring and/or developing new product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">attracting, hiring, and retaining qualified personnel.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Even if one or more of the product candidates
that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any
approved product candidate. Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration,
or the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or foreign, to change our manufacturing
processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate.
In cases where we are successful in obtaining regulatory approvals to market one or more of our product candidates, our revenue
will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory.
If the number of our addressable rare disease patients is not as significant as we estimate, the indication approved by regulatory
authorities is narrower than we expect, or the reasonably expected population for treatment is narrowed by competition, physician
choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Additionally,
if we are not able to generate revenue from the sale of any approved products, we may never become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We expect that we will need to raise substantial additional
funding before we can expect to become profitable from sales of our products. This additional financing may not be available on
acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or terminate our
product development efforts or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are currently advancing our Cabaletta
platform product candidates through clinical development and advancing our other product candidates, BB-FA, BB-OTC, and BBrm1,
as well as our other early stage research projects, through preclinical development. Developing our product candidates is expensive,
and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly
as we advance our product candidates through clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">As of December 31, 2014, our cash and cash
equivalents including short-term bank deposits were $32.6 million. We expect that our existing cash, cash equivalents and short-term
bank deposits will be sufficient to fund our current operations for at least the next 12 months; however, we expect that we will
require substantial additional capital to obtain regulatory approval for, and to commercialize, our product candidates. In addition,
our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional
funds sooner than planned. Our future funding requirements will depend on many factors, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the scope, rate of progress, results and cost of our clinical studies, preclinical testing, and other related activities;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products that we may develop;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the number and characteristics of product candidates that we pursue;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the cost, timing, and outcomes of regulatory approvals;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the cost and timing of establishing sales, marketing, and distribution capabilities; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the terms and timing of any collaborative, licensing, and other arrangements that we may establish, including any required milestone and royalty payments thereunder.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Any additional fundraising efforts may divert
our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product
candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable
to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders and
the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market
price of our Ordinary Shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations and
we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely
impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners
or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies
or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business,
operating results, and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may
seek additional capital if market conditions are favorable or if we have specific strategic considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If we are unable to obtain funding on a timely
basis, we may be required to significantly curtail, delay, or discontinue one or more of our research or development programs or
the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities,
as desired, which could materially affect our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Raising additional capital would cause dilution to our
existing shareholders, and may restrict our operations or require us to relinquish rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We may seek additional capital through a
combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest
will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder.
Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants
limiting or restricting our ability to take specific actions such as incurring debt, making capital expenditures or declaring dividends.
If we raise additional funds through collaboration, strategic alliance and licensing arrangements with third parties, we may have
to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that
are not favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the Discovery and Development of Our Product
Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are heavily dependent on the success of our product
candidates, which are in the early stages of preclinical or clinical development. We cannot give any assurance that any of our
product candidates will receive regulatory approval, which is necessary before they can be commercialized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">To date, we have invested substantially all
of our efforts and financial resources to identify, acquire, license, and develop our product candidates, including conducting
preclinical and clinical studies and providing general and administrative support for these operations. Our future success is dependent
on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize one or more product
candidates. We currently generate no revenue from sales of any drugs, and we may never be able to develop or commercialize a marketable
drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Each of our product candidates is in the
early stages of development and will require additional clinical development (and in some cases additional preclinical development),
management of nonclinical, clinical, and manufacturing activities, regulatory approval, obtaining adequate manufacturing supply,
building of a commercial organization, and significant marketing efforts before we generate any revenue from product sales. We
currently have one product candidate in Phase 2 clinical studies and another one of our product candidates has advanced into a
Phase 2/3 trial which, if the results are positive, we believe could be a pivotal trial. We are not permitted to market or promote
any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities,
and we may never receive such regulatory approval for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We as a company have never submitted marketing
applications to the FDA or comparable foreign regulatory authorities. We cannot be certain that any of our product candidates will
be successful in clinical studies or receive regulatory approval. Further, our product candidates may not receive regulatory approval
even if they are successful in clinical studies. If we do not receive regulatory approvals for our product candidates, we may not
be able to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We generally plan to seek regulatory approval
to commercialize our product candidates in the United States, the European Union, and in additional foreign countries where we
have commercial rights. To obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements
of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales,
pricing, and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot
ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates
in multiple jurisdictions, our revenue and results of operations could be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The regulatory approval processes of the FDA and comparable
foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory
approval for our product candidates, our business will be substantially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The time required to obtain approval by the
FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies,
and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary
to gain approval may change during the course of a product candidate&rsquo;s clinical development and may vary among jurisdictions,
which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval
for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek
to develop in the future will ever obtain regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Applications for our product candidates could
fail to receive regulatory approval for many reasons, including but not limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&rsquo;s safety-benefit ratio for its proposed indication is acceptable;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a new drug application, or NDA, or biologics license application, or BLA, or other submission or to obtain regulatory approval in the United States or elsewhere;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">This lengthy approval process, as well as
the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market any
of our product candidates, which would significantly harm our business, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Clinical drug development involves a lengthy and expensive
process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Clinical testing is expensive and can take
many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process.
The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of
later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer
significant setbacks in subsequent registration clinical studies. For example, the safety or efficacy results generated to date
in preclinical and clinical studies for Cabaletta, BBrm1, BB-FA and BB-OTC do not ensure that later clinical studies will demonstrate
similar results. There is a high failure rate for drugs and biologics proceeding through clinical studies, and product candidates
in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical
studies and initial clinical studies. A number of companies in the biopharmaceutical industry have suffered significant setbacks
in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. We do not know whether any
Phase 2, Phase 3, or other clinical studies we may conduct will demonstrate consistent or adequate efficacy and safety sufficient
to obtain regulatory approval to market our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may find it difficult to enroll patients in our clinical
studies given the limited number of patients who have the diseases for which our product candidates are being studied. Difficulty
in enrolling patients could delay or prevent clinical studies of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Identifying and qualifying patients to participate
in clinical studies of our product candidates is critical to our success. The timing of our clinical studies depends in part on
the speed at which we can recruit patients to participate in testing our product candidates, and, although we have not yet experienced
difficulty enrolling patients in clinical studies in the past, we may experience delays in our clinical studies if we encounter
difficulties in enrollment in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Each of the conditions for which we plan
to evaluate our current product candidates is a rare genetic disease. Accordingly, there are limited patient pools from which to
draw for clinical studies. For our current product candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we estimate that several thousand patients in the United States suffer from OPMD for which Cabaletta is being studied;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we estimate that a few thousand patients in the United States suffer from SCA3 for which Cabaletta is being studied;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we estimate a few thousand patients in the United States suffer from SBMA for which Cabaletta is being studied;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we estimate that several thousand patients in the United States suffer from Friedreich&rsquo;s Ataxia for which BB-FA is being studied;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we estimate that a few thousand patients in the United States suffer from OTC deficiency for which BB-OTC is being studied;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we estimate that several thousand patients in the United States suffer from SMA deficiency for which BBrm1 is being studied; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we estimate that the worldwide prevalence of the foregoing diseases is similar and sometimes higher than the total number of patients in the United States.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In addition to the rarity of these diseases,
the eligibility criteria of our clinical studies will further limit the pool of available study participants as we will require
that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced
to include them in a study. Additionally, the process of finding and diagnosing patients may prove costly. We also may not be able
to identify, recruit, and enroll a sufficient number of patients to complete our clinical studies because of the perceived risks
and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical studies, the
proximity and availability of clinical study sites for prospective patients, and the patient referral practices of physicians.
If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies,
and obtaining regulatory approval of potential products may be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If we experience delays in the completion
of, or termination of, any clinical study of our product candidates, the commercial prospects of our product candidates will be
harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition,
any delays in completing our clinical studies will increase our costs, slow down our product candidate development and approval
process, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may harm our business,
financial condition, and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement
or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may encounter substantial delays in our clinical studies,
or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Before obtaining marketing approval from
regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety
and efficacy of the product candidates in humans. Clinical testing is expensive, time consuming, and uncertain as to outcome. We
cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or
more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may
prevent successful or timely completion of clinical development include but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">inability to generate sufficient preclinical, toxicology, or other&nbsp;<I>in vivo</I>&nbsp;or&nbsp;<I>in vitro</I>&nbsp;data to support the initiation of human clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">delays in reaching a consensus with regulatory agencies on study design;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical study site;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">imposition of a clinical hold by regulatory agencies, after review of an investigational new drug, or IND, application, or equivalent application, or an inspection of our clinical study operations or study sites;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">delays in recruiting suitable patients to participate in our clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">difficulty collaborating with patient groups and investigators;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">failure by our CROs, other third parties, or us to adhere to clinical study requirements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">failure to perform in accordance with the FDA&rsquo;s good clinical practices requirements, or applicable regulatory guidelines in other countries;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">delays in having patients complete participation in a study or return for post-treatment follow-up;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">patients dropping out of a study;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the cost of clinical studies of our drug candidates being greater than we anticipate;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">clinical studies of our drug candidates producing negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon drug development programs; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Any inability to successfully complete preclinical
and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, we may
need to conduct additional studies to bridge our repurposed product candidates to generic products in the market. We may also be
required to conduct additional safety, efficacy and comparability studies before we will be allowed to start clinical studies with
our repurposed drugs. Clinical study delays could also shorten any periods during which our products have patent protection and
may allow our competitors to bring products to market before we do, which could impair our ability to obtain orphan exclusivity
and to successfully commercialize our product candidates and may harm our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our product candidates may cause undesirable side effects
or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label,
or result in significant negative consequences following marketing approval, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Undesirable side effects caused by our product
candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result in a more restrictive
label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Patients enrolled in our
studies of Cabaletta for OPMD, known as our HOPEMD study, and for Spinocerebellar Ataxia, known as our SCA3 study, may suffer side
effects associated with the use of Cabaletta. Other enzyme replacement therapies have been associated with infusion-associated
reactions due to a developing allergy to the product, which can cause rashes, pain, significant clinical disease, or even death.
Our BB-FA and BB-OTC product candidates may also cause these or similar side effects. Results of our studies could reveal a high
and unacceptable severity and prevalence of these or other side effects. In such an event, our studies could be suspended or terminated,
and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw approval
of our product candidates for any or all targeted indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The drug-related side effects could affect
patient recruitment, the ability of enrolled patients to complete the study, or result in potential product liability claims. We
do not currently hold product liability insurance and do not anticipate obtaining product liability insurance until such time as
we have received FDA or other comparable foreign authority approval for a product and there is a product that is being provided
to third parties outside of clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Additionally, if one or more of our product
candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, or if
a patient suffers a serious complication, including death, with respect to one of our products, a number of potentially significant
negative consequences could result, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">regulatory authorities may withdraw approvals of such product;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">regulatory authorities may require additional warnings on the label;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we may be required to create a Risk Evaluation and Mitigation Strategy, or REMS, plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we could be sued and held liable for harm caused to patients; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our reputation may suffer.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Any of these events could prevent us from
achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if we obtain regulatory approval for a product candidate,
our products will remain subject to regulatory scrutiny.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If our product candidates are approved, they
will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling,
record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including
both federal and state requirements in the United States. In addition, manufacturers and manufacturers&rsquo; facilities are required
to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current
Good Manufacturing Practices, or cGMP, regulations. As such, we and our contract manufacturers will be subject to continual review
and inspections to assess compliance with cGMP and adherence to commitments made in any NDA or BLA. Accordingly, we and others
with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing,
production, and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Any regulatory approvals that we receive
for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed
or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical
trials, and surveillance to monitor the safety and efficacy of the product candidate. We will also be required to report certain
adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion
for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory
restrictions and must be consistent with the information in the product&rsquo;s approved label. As such, we may not promote our
products for indications or uses for which they do not have FDA approval. The holder of an approved NDA or BLA must also submit
new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing
process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in
general or in specific patient subsets. If original marketing approval were obtained via the accelerated approval pathway, we could
be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our products. An unsuccessful
post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. Furthermore, any
new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased
costs to assure compliance. Foreign regulatory authorities impose similar requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If a regulatory agency discovers previously
unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where
the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose
restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable
regulatory requirements, a regulatory agency or enforcement authority may, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">issue warning letters;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">impose civil or criminal penalties;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">suspend or withdraw regulatory approval;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">suspend any of our ongoing clinical studies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">refuse to approve pending applications or supplements to approved applications submitted by us;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">impose restrictions on our operations, including closing our contract manufacturers&rsquo; facilities; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">seize or detain products, or require a product recall.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Any government investigation of alleged violations
of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure
to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate
revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company
and our operating results will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to our Reliance on Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We rely on third parties to conduct our preclinical and
clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties,
meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize
our product candidates and our business could be substantially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have relied upon and plan to continue
to rely upon third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties
for execution of our preclinical and clinical studies, and control only certain aspects of their activities. Nevertheless, we are
responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and
scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other
vendors are required to comply with cGMP, current good clinical practices, or cGCP, and Good Laboratory Practices, or GLP, which
are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area,
or EEA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities
enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites, and other contractors.
If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data generated in our clinical studies
may be deemed unreliable and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional clinical
studies before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority,
such regulatory authority will determine that any of our clinical studies comply with cGCP regulations. In addition, our clinical
studies must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require
us to repeat clinical studies, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If any of our relationships with these third-party
CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms.
In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot
control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical, and preclinical programs.
If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced
or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols,
regulatory requirements, or for other reasons, our clinical studies may be extended, delayed, or terminated and we may not be able
to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than
anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our
costs could increase, and our ability to generate revenue could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Switching or adding additional CROs involves
additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences
work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though
we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or
delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We rely completely on third parties to manufacture our
preclinical and clinical drug supplies. Our business could be harmed if those third parties fail to provide us with sufficient
quantities of drug product, or fail to do so at acceptable quality levels or prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We do not currently have, nor do we plan
to acquire, the infrastructure or capability internally to manufacture our preclinical and clinical drug supplies for use in the
conduct of our clinical studies, and we lack the resources and the capability to manufacture any of our product candidates on a
clinical or commercial scale. We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce
our product candidates for our clinical studies. There are a limited number of suppliers for raw materials that are used to manufacture
our drugs, and there may be a need to identify alternate suppliers to prevent a possible disruption of the manufacture of the materials
necessary to produce our product candidates for our clinical studies, and, if approved, ultimately for commercial sale. We do not
have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Although we generally
do not begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete such study, any
significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for an ongoing
clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies,
product testing, and potential regulatory approval of our product candidates, which could harm our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are subject to a multitude of manufacturing risks,
any of which could substantially increase our costs and limit supply of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The process of manufacturing our product
candidates is complex, highly regulated, and subject to several risks, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the process of manufacturing biologics, such as BB-FA and BB-OTC, is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any of our product candidates could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, and numerous other factors.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Any adverse developments affecting manufacturing
operations for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls,
or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges
and expenses for product candidates that fail to meet specifications, undertake costly remediation efforts, or seek more costly
manufacturing alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The drug substance and drug product for our product candidates
are currently acquired from single suppliers. The loss of these suppliers, or their failure to supply us with the drug substance
or drug product, could materially and adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In specific instances we may rely on a single
provider or manufacturer for our product candidates. For example, the raw materials used to manufacture our Cabaletta product candidate
are acquired from a single third party drug products supplier. Additionally, Cabaletta is manufactured by a single third party
manufacturer. It is possible that we will be required to switch providers in the future. In such case, the process of switching
suppliers and/or manufacturers may be costly and/or time consuming for us, and that may include the temporary or permanent suspension
of a clinical study or commercial sales of our candidate products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We do not currently have any other suppliers
for the drug substance or drug product of our product candidates and, although we believe that there are alternate sources of supply
that could satisfy our clinical and commercial requirements, we cannot assure you that identifying alternate sources and establishing
relationships with such sources would not result in significant delay in the development of our product candidates. Additionally,
we may not be able to enter into supply arrangements with alternative suppliers on commercially reasonable terms, or at all. A
delay in the development of our product candidates or having to enter into a new agreement with a different third party on less
favorable terms than we have with our current suppliers could have a material adverse impact upon on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We and our collaborators and contract manufacturers are
subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we
rely may not continue to meet regulatory requirements and have limited capacity.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">All entities involved in the preparation
of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates,
are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage
clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures
(including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational
products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to
inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.
We, our collaborators, or our contract manufacturers must supply all necessary documentation in support of an NDA, BLA, or Marketing
Authorization Application, or MAA, on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA and other
regulatory agencies through their facilities inspection program. Some of our contract manufacturers have never produced a commercially
approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities
and quality systems of some or all of our collaborators and third-party contractors must pass a pre-approval inspection for compliance
with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products.
In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation
of our product candidates or our other potential products or the associated quality systems for compliance with the regulations
applicable to the activities being conducted. We do not control the manufacturing process of, and are completely dependent on,
our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval
plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are
corrected to the satisfaction of the regulatory authority, if ever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The regulatory authorities also may, at any
time following approval of a product for sale, audit the manufacturing facilities of our collaborators and third-party contractors.
If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications
or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require
remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary
or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial
measures imposed upon us or third parties with whom we contract could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If we, our collaborators, or any of our third-party
manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions
including, among other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal
of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially
harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Additionally, if supply from one approved
manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA or BLA supplement or MAA amendment,
or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional
studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and
is likely to result in a delay in our desired clinical and commercial timelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">These factors could cause us to incur higher
costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization
of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one
or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or
we could lose potential revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our reliance on third parties requires us to share our
trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated
or disclosed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Because we rely on third parties to develop
and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology
in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements,
consulting agreements, or other similar agreements with our collaborators, advisors, employees, and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose
our confidential information, such as trade secrets. Despite the contractual provisions employed when working with third parties,
the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our
competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.
Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&rsquo;s discovery of our
trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect
on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Commercialization of Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If the market opportunities for our product candidates
are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because the target patient
populations of our product candidates are small, we must be able to successfully identify patients and achieve a significant market
share to maintain profitability and growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We focus our research and product development
on treatments for rare and ultra-rare genetic diseases. Given the small number of patients who have the diseases that we are targeting,
it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these rare
and ultra-rare genetic diseases. Our projections of both the number of people who have these diseases, as well as the subset of
people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs
and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics,
patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence
or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients
with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might
be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or
may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or
gain access to, which would adversely affect our results of operations and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We intend to rely on third-party manufacturers to produce
our product candidates, but we have not entered into binding agreements with any such manufacturers to support commercialization.
Additionally, these manufacturers do not have experience producing our product candidates at commercial levels and may not achieve
the necessary regulatory approvals or produce our product candidates at the quality, quantities, locations, and timing needed to
support commercialization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have not yet secured manufacturing capabilities
for commercial quantities of our product candidates. Although we intend to rely on third-party manufacturers for commercialization,
we have only entered into agreements with such manufacturers to support our clinical studies. We may be unable to negotiate binding
agreements with the manufacturers to support our commercialization activities at commercially reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Manufacturers may not have the experience
or ability to produce our product candidates at commercial levels. We may run into technical or scientific issues related to manufacturing
or development that we may be unable to resolve in a timely manner or with available funds. We also have not completed all of the
characterization and validation activities necessary for commercialization and regulatory approvals. If our manufacturing partners
do not conduct all such necessary activities, our commercialization efforts will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Even if we timely develop a manufacturing
process and successfully transfer it to the third-party product manufacturers, if such third-party manufacturers are unable to
produce the necessary quantities of our product candidates, or in compliance with cGMP or other pertinent regulatory requirements,
and within our planned timeframe and cost parameters, the development and sales of our products, if approved, may be materially
harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face intense competition and rapid technological change
and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which
may adversely affect our financial condition and our ability to successfully commercialize our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The biotechnology and pharmaceutical industries
are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing
therapies in the market and in development that may in the future compete with our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Gene therapy, cell therapy, bone marrow transplantation
and other approaches may also emerge for the treatment of any of the disease areas in which we focus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have competitors both in the United States
and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology
companies. Some of the pharmaceutical and biotechnology companies we expect to compete with include Shire, Sanofi, BioMarin, Alexion,
Ultragenyx and Roche, other smaller companies or biotechnology startups, as well as other large multinational pharmaceutical companies.
Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development
staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical
industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory
approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or
early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large,
established companies. Competition may increase further as a result of advances in the commercial applicability of technologies
and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring, or
licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop,
or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally,
technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not
be successful in marketing our product candidates against competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We currently have no marketing and sales organization.
If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our
product candidates, we may be unable to generate any revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Although our employees may have sold other
similar products in the past while employed at other companies, we as a company have no experience selling and marketing our product
candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result
from our development programs, we will need to develop these capabilities, either on our own or with others. If our product candidates
receive regulatory approval, we intend to establish a sales and marketing organization with technical expertise and supporting
distribution capabilities to commercialize our product candidates in major markets, which will be expensive, difficult, and time
consuming. Any failure or delay in the development of our internal sales, marketing, and distribution capabilities would adversely
impact the commercialization of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Further, given our lack of prior experience
in marketing and selling biopharmaceutical products, our initial estimate of the size of the required sales force may be materially
more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such, we
may be required to hire substantially more sales representatives to adequately support the commercialization of our product candidates
or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical
markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but
we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient
resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our
own, we will be unable to generate sufficient product revenue to sustain our business. We may be competing with companies that
currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party
to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The commercial success of any current or future product
candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical
community.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Even with the requisite approvals from the
FDA and comparable foreign regulatory authorities, the commercial success of our product candidates will depend in part on the
medical community, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe.
Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors, and others
in the medical community. The degree of market acceptance of any of our product candidates, if approved for commercial sale, will
depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&rsquo;s approved labeling;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the clinical indications for which approval is granted;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">relative convenience and ease of administration;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the cost of treatment, particularly in relation to competing treatments;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>the strength of marketing and distribution support and timing of market introduction of competitive products;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">publicity concerning our products or competing products and treatments; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">sufficient third-party insurance coverage and reimbursement.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Even if a potential product displays a favorable
efficacy and safety profile in preclinical and clinical studies, market acceptance of the product will not be fully known until
after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the product candidates
may require significant resources and may never be successful. If our product candidates are approved but fail to achieve an adequate
level of acceptance by physicians, patients, third-party payors, and others in the medical community, we will not be able to generate
sufficient revenue to become or remain profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>While orphan drug products are typically sold at a high
price relative to other medications, the market may not be receptive to high pricing of our products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We develop our product candidates to treat
rare and ultra-rare diseases, a space where medications are usually sold at high prices compared with other medications. However,
several of our product candidates are repurposed drugs, which means, among other things, that they are available in pharmacies
for the purpose of treating indications that are different from the indications for which we plan to use. Accordingly, even if
regulatory authorities approve our product candidates, the market may not be receptive to, and it may be difficult for us to achieve,
a per-patient per-year price high enough to allow us to realize a return on our investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The insurance coverage and reimbursement status of newly-approved
products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit
our ability to market those products and decrease our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our target patient populations are small,
and accordingly the pricing, coverage, and reimbursement of our product candidates, if approved, must be adequate to support our
commercial infrastructure. Our per-patient prices must be sufficient to recover our development and manufacturing costs and potentially
achieve profitability. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors
are essential for most patients to be able to afford expensive treatments such as ours, assuming approval. Sales of our product
candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates
will be paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed
by government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available,
or are available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage
is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to
realize a return on our investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">There is significant uncertainty related
to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage
and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within
the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed
under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It
is difficult to predict what CMS will decide with respect to reimbursement for products such as ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Outside the United States, international
operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing
emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing
and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms
as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the
United States. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company
profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to
charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be
reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Moreover, increasing efforts by governmental
and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit
both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate
payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product
candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional
legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures
and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Healthcare legislative reform measures may have a material
adverse effect on our business and results of operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In the United States, there have been and
continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the Health Care Reform Law, was passed,
which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts
the U.S. pharmaceutical industry. The Health Care Reform Law, among other things, subjects biologic products to potential competition
by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increases the minimum Medicaid rebates owed
by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed
care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and promotes a new
Medicare Part D coverage gap discount program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In addition, other legislative changes have
been proposed and adopted in the United States since the Health Care Reform Law was enacted. On August 2, 2011, the Budget Control
Act of 2011, among other things, created measures for spending reductions by the U.S. Congress. A Joint Select Committee on Deficit
Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was
unable to reach required goals, thereby triggering the legislation&rsquo;s automatic reduction to several government programs.
This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year. On January 2, 2013, President Obama
signed into law the American Taxpayer Relief Act of 2012, which, among other things, delayed for another two months the budget
cuts mandated by these sequestration provisions of the Budget Control Act of 2011. On March 1, 2013, the President signed an executive
order implementing sequestration, and on April 1, 2013, the 2% Medicare payment reductions went into effect. We expect that additional
state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and
state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates
or additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to obtain and maintain effective patent
rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We rely upon a combination of patents, trade
secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product
candidates. Our success depends in large part on our and our licensors&rsquo; ability to obtain and maintain patent and other intellectual
property protection in the United States and in other countries with respect to our proprietary technology and products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have sought to protect our proprietary
position by filing patent applications in the United States and abroad related to our novel technologies and products that are
important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary
or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify
patentable aspects of our research and development output before it is too late to obtain patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The patent position of biotechnology and
pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles
remain unsolved. The patent applications that we own or in-license may fail to result in issued patents with claims that cover
our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant
prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from
issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates,
third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable
or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our
intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any
of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We, independently or together with our licensors,
have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about
which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable
or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to
us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that
we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product
candidate under patent protection could be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have a number of patent applications directed
to methods of use and certain compositions of matter. For example, we have a pending patent application covering the use of intravenously
administered trehalose in several orphan diseases associated with trinucleotide repeat expansion (PolyA/PolyQ) diseases. With regards
to our mitochondrial protein replacement therapy we do not have patent protection for the concept of attaching TAT to a protein
generally but do have patent protection for attaching TAT to our mitochondrial protein targets, such as for example, frataxin.
With our read-through technology, we do not have composition of matter protection. Instead, we have filed a use patent application
of a generic family of molecules in a non-systemic route of administration for genetic neuro degenerative and neuro developmental
diseases and new route of administration through direct injection to the central nervous system. In addition, our patent applications
have not resulted in issued patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If we cannot obtain and maintain effective
patent rights for our product candidates, we may not be able to compete effectively and our business and results of operations
would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not have sufficient patent terms to effectively
protect our products and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Patents have a limited lifespan. In the United
States, the natural expiration of a patent is generally 20 years after it is filed. Although various extensions may be available,
the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained,
once the patent life has expired for a product, we may be open to competition from generic medications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">While patent term extensions under the Hatch-Waxman
Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity
term for Cabaletta, BB-FA and BB-OTC as well as the BBrm family of molecules we cannot provide any assurances that any such patent
term extension will be obtained and, if so, for how long. In addition, upon issuance in the United States any patent term can be
adjusted based on certain delays caused by the applicant(s) or the USPTO. For example, a patent term can be reduced based on certain
delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent terms or regulatory exclusivity
to protect our products, our business and results of operations will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patent policy and rule changes could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Changes in either the patent laws or interpretation
of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent
protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications
of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States
and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot
be certain that we or our licensors were the first to make the invention claimed in our owned and licensed patents or pending applications,
or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for
patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the
patent, while outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013,
under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September 16, 2011, the United States has moved to
a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications
will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as USPTO, must still
implement various regulations, the courts have yet to address any of these provisions and the applicability of the act and new
regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the Leahy-Smith
Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and
the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are unable to maintain effective proprietary rights
for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In addition to the protection afforded by
patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable
or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate
discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents.
However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering
into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve
the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and
electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems,
agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets
may otherwise become known or be independently discovered by competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Although we expect all of our employees and
consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access
to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances
that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will
not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive
position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets
are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Third-party claims of intellectual property infringement
may prevent or delay our development and commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our commercial success depends in part on
our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings
involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement
lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices.
Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields
in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued,
the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Third parties may assert that we are employing
their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials,
formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. We
have conducted freedom to operate analyses with respect to only certain of our product candidates, and therefore we do not know
whether there are any third-party patents that would impair our ability to commercialize these product candidates. We also cannot
guarantee that any of our analyses are complete and thorough, nor can we be sure that we have identified each and every patent
and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates.
Because patent applications can take many years to issue, there may be currently pending patent applications that may later result
in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim
that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction
to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any
final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate
unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid
or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Similarly, if any third-party patents were
held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use, the
holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless
we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such
a license may not be available on commercially reasonable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Parties making claims against us may obtain
injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more
of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and
would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against
us, we may have to pay substantial damages, including treble damages and attorneys&rsquo; fees for willful infringement, pay royalties,
redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial
time and monetary expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be successful in obtaining or maintaining necessary
rights to our product candidates through acquisitions and in-licenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We currently have rights to the intellectual
property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs
may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability
to acquire, in-license, or use these proprietary rights. In addition, our product candidates may require specific formulations
to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or
in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that
we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights
is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party
intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over
us due to their size, cash resources, and greater clinical development and commercialization capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">For example, we sometimes collaborate with
U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these
institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&rsquo;s
rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within
the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual
property rights to other parties, potentially blocking our ability to pursue our program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In addition, companies that perceive us to
be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual
property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully
obtain rights to required third-party intellectual property rights, we may have to abandon development of that program and our
business and financial condition could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may face competition from biosimilars, which may have
a material adverse impact on the future commercial prospects of our mitochondrial protein replacement platform.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Even if we are successful in achieving regulatory
approval to commercialize a product candidate faster than our competitors, we may face competition from biosimilars with respect
to BB-FA and BB-OTC and future product candidates based on our protein replacement platform. In the United States, the Biologics
Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biological products that are demonstrated
to be &ldquo;highly similar,&rdquo; or biosimilar, to or &ldquo;interchangeable&rdquo; with an FDA-approved biological product.
This new pathway could allow competitors to reference data from innovative biological products 12 years after the time of approval
of the innovative biological product. This data exclusivity does not prevent another company from developing a product that is
highly similar to the innovative product, generating its own data, and seeking approval. Data exclusivity only assures that another
company cannot rely upon the data within the innovator&rsquo;s application to support the biosimilar product&rsquo;s approval.
In his proposed budget for fiscal year 2014, President Obama proposed to cut this 12-year period of exclusivity down to seven years.
He also proposed to prohibit additional periods of exclusivity due to minor changes in product formulations, a practice often referred
to as &ldquo;evergreening.&rdquo; It is possible that the U.S. Congress may take these or other measures to reduce or eliminate
periods of exclusivity. The Biologics Price Competition and Innovation Act of 2009 is complex and only beginning to be interpreted
and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it
is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect on
the future commercial prospects for BB-FA and BB-OTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In Europe, the European Commission has granted
marketing authorizations for several biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar
approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological
product, but will not be able to get on the market until 10 years after the time of approval of the innovative product. This 10-year
marketing exclusivity period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization
holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing
therapies. In addition, companies may be developing biosimilars in other countries that could compete with our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If competitors are able to obtain marketing
approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the
attendant competitive pressure and consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The patent protection and patent prosecution for some
of our product candidates is dependent on third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">While we normally seek and gain the right
to fully prosecute the patents relating to our product candidates, there may be times when patents relating to our product candidates
are controlled by our licensors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In addition, even where we now have the right
to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely
affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to us assuming control
over patent prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to comply with our obligations in the agreements
under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business
relationships with our licensors, we could lose license rights that are important to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are a party to a number of intellectual
property license agreements that are important to our business and expect to enter into additional license agreements in the future.
Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone
payment, royalties, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject
to a bankruptcy, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license, or the
licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered
by the license. Additionally, the milestone and other payments associated with these licenses will make it less profitable for
us to develop our drug candidates. See Item 4.B. &ndash; &ldquo;Business&nbsp;Overview &ndash;&nbsp;License Agreements&rdquo; for
a description of our license agreements with the Hebrew University in Jerusalem and the Tel-Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In certain cases, we control the prosecution
of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may
incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business
and involves complex legal, business, and scientific issues. Disputes may arise regarding intellectual property subject to a licensing
agreement, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the scope of rights granted under the license agreement and other interpretation-related issues;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the sublicensing of patent and other rights;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the priority of invention of patented technology.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If disputes over intellectual property and
other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms,
we may be unable to successfully develop and commercialize the affected product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"><B><I>We may not be able to identify infringements
of our patents and accordingly the enforcement of our intellectual property rights may be difficult. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The drug substance in some of our product
candidates is a repurposed drug. It is possible that if we receive FDA approval of such drug candidates patients that we target
with this drug would receive prescriptions for the same substance but not by using our product. It would be difficult, if not impossible
for us to identify such instances that may constitute an infringement of our patents. In addition, because the drug substance of
some of our product candidates is a repurposed drug, such substance may not be eligible for protection by composition of matter
patents. Patent protection for these product candidates is limited to method of use formulation and other types of patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be involved in lawsuits to protect or enforce our
patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Competitors may infringe our patents or the
patents of our licensors. If we or one of our licensing partners were to initiate legal proceedings against a third party to enforce
a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate
is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or
unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an
allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading
statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Interference proceedings provoked by third
parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our
patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not
offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if
successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated
with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials,
continue our research programs, license necessary technology from third parties, or enter into development partnerships that would
help us bring our product candidates to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings,
motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be subject to claims that our employees, consultants,
or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have
wrongfully used or disclosed alleged trade secrets of their former employers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We employ individuals who were previously
employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or
know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors
have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information,
of any of our employee&rsquo;s former employer or other third parties. Litigation may be necessary to defend against these claims.
If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights
or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be subject to claims challenging the inventorship
of our patents and other intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We may be subject to claims that former employees,
collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor.
For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in
developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship.
If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights,
such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse
effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. Therefore, we may receive less revenue from future products if such claims
are successful which in turn could impact our future profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in U.S. patent law could diminish the value of
patents in general, thereby impairing our ability to protect our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">As is the case with other biopharmaceutical
companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in
the biotechnology industry involves both technological and legal complexity. Therefore, obtaining and enforcing biotechnology patents
is costly, time consuming, and inherently uncertain. In addition, the United States has recently enacted and is currently implementing
wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available
in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty
with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to
the value of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws
and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to
enforce our existing patents and patents that we might obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employees may be entitled to seek compensation for their
inventions irrespective of their agreements with us. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In 2012, the Israeli Supreme Court ruled
that an employee who receives a patent or contributes to an invention during his or her employment may be allowed to seek compensation
for it from his or her employer, even if the employee&rsquo;s contract of employment specifically states otherwise and the employee
has transferred all intellectual property rights to the employer. The Supreme Court ruled that the fact that a contract revokes
the employee&rsquo;s right for royalties and compensation, does not rule out the right of the employee to claim his or her right
for royalties.&nbsp; However, in a more recent ruling, issued in May 2014, the government-appointed Compensation and Royalties
Committee, established under the Israeli Patents Law, 5727-1967, determined that an employee&rsquo;s remuneration rights for service
inventions may be waived by an explicit contractual waiver. It is our understanding that a petition has been filed with the Israeli
Supreme Court. In light of the petition and the inconsistency in rulings it is still unclear if, and to what extent, our employees
may be able to claim compensation with respect to our future revenue. Therefore, although we enter into agreements with our employees
pursuant to which they waive their right to special remuneration for inventions created in the scope of their employment or engagement
and agree that any such inventions are owned exclusively by us, we may face claims by employees demanding remuneration beyond their
regular salary and benefits, and we may receive less revenue from future products if such claims are successful, which in turn
could impact our future profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to protect our intellectual property
rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Filing, prosecuting, and defending patents
on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights
in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.
Among these countries is China where we intend to protect our intellectual property rights to the extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Competitors may use our technologies in jurisdictions
where we have not obtained patent protection to develop their own products and may also export otherwise infringing products to
territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may
compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them
from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property
protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our
patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and
attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our
patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our
efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our future success depends in part on our ability to retain
our executive officers and management level employees and to attract, retain, and motivate other qualified personnel. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are highly dependent on Colin Foster,
our Chief Executive Officer, and Dalia Megiddo, M.D., our Founder and Chief Development Officer. The loss of their services without
a proper replacement may adversely impact the achievement of our objectives. Mr. Foster and Dr. Megiddo may leave our employment
at any time (subject to contractual notice periods, as applicable), as each one is an &ldquo;at will&rdquo; independent contractor.
Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical
personnel, will also be critical to our success. There is currently a shortage of skilled personnel in our industry, which is likely
to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to
attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies
for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical studies may make it more challenging
to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel, or the loss of the services
of Mr. Foster or Dr. Megiddo without proper replacement, may impede the progress of our research, development, and commercialization
objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to obtain or maintain orphan drug exclusivity
for our products, our competitors may sell products to treat the same conditions and our revenue will be reduced.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our business strategy focuses on the development
of drugs that are eligible for FDA and European Union orphan drug designation. Under the Orphan Drug Act, the FDA may designate
a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than
200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation
that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&rsquo;s
Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are
intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not
more than five in 10,000 persons in the European Union Community. Additionally, designation is granted for products intended for
the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when,
without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment
in developing the drug or biological product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In the United States, orphan drug designation
entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages,
and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation,
the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same
drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority
over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. In the European
Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers and ten years
of market exclusivity is granted following drug or biological product approval. This period may be reduced to six years if the
orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not
to justify maintenance of market exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Because the extent and scope of patent protection
for our products may in some cases be limited, orphan drug designation is especially important for our products for which orphan
drug designation may be available. For eligible drugs, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain
a competitive position. If we do not obtain orphan drug exclusivity for our drug products and biologic products that do not have
broad patent protection, our competitors may then sell the same drug to treat the same condition sooner than if we had obtained
orphan drug exclusivity and our revenue will be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Even though we have obtained orphan drug
designation for OPMD in the United States, we may not be the first to obtain marketing approval for any particular orphan indication
due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity
for a product, that exclusivity may not effectively protect the product from competition because different drugs with different
active moieties can be approved for the same condition. Even with orphan drug exclusivity, if a third party were to prepare or
market a trehalose IV preparation which infringes upon our intellectual property, we may need to initiate litigation, which may
be costly, to enforce our rights against such party. Even after an orphan drug is approved, the FDA can subsequently approve the
same drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective,
or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review
time of a drug nor gives the drug any advantage in the regulatory review or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need to expand our organization and we may experience
difficulties in managing this growth, which could disrupt our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">As our development and commercialization
plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal, and other
resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and
devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion
of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities,
loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures
and may divert financial resources from other projects, such as the development of additional product candidates. If our management
is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue
could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to
commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future
growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be successful in our efforts to identify, license,
or discover additional product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Although a substantial amount of our effort
will focus on the continued clinical testing, potential approval, and commercialization of our existing product candidates, the
success of our business also depends upon our ability to identify, license, or discover additional product candidates. Our research
programs or licensing efforts may fail to yield additional product candidates for clinical development for a number of reasons,
including but not limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our product candidates may not succeed in preclinical or clinical testing;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">competitors may develop alternatives that render our product candidates obsolete or less attractive;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">product candidates we develop may be covered by third parties&rsquo; patents or other exclusive rights;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If any of these events occur, we may be forced
to abandon our development efforts for a program or programs, or we may not be able to identify, license, or discover additional
product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.
Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus
our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We incur significant costs as a result of operating as
a public company, and our management is required to devote substantial time to new compliance initiatives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">As a public company, we incur significant
legal, accounting, and other expenses. In addition, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act, or the Dodd-Frank Act, as well as rules subsequently implemented by the SEC and the NASDAQ Stock Market, or NASDAQ, have imposed
various requirements on public companies. Emerging growth companies may implement some of these requirements over a longer period
and up to five years from the date of their initial public offering. We intend to take advantage of this legislation but cannot
guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected
expenses. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory
reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact
the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need
to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our
legal and financial compliance costs and will make some activities more time consuming and costly. For example, these rules and
regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required
to incur substantial costs to maintain our current levels of such coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The Sarbanes-Oxley Act requires, among other
things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular,
we will be required to perform system and process evaluation and testing of our internal control over financial reporting to allow
management to report, commencing in our annual report on Form 20-F for the year ending December 31, 2015, on the effectiveness
of our internal control over financial reporting, if then required by the SEC&rsquo;s rules pursuant to Section 404 of the Sarbanes-Oxley
Act. Our testing may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses.
Our compliance with the SEC&rsquo;s rules pursuant to Section 404 will require that we incur substantial accounting expense and
expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting
and financial staff with appropriate public company experience and technical accounting knowledge. Moreover, if we are not able
to comply with the SEC&rsquo;s requirements in a timely manner or if we identify or our independent registered public accounting
firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market
price of our stock could decline and we could be subject to sanctions or investigations by NASDAQ, the SEC, or other regulatory
authorities, which would require additional financial and management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">New laws and regulations as well as changes
to existing laws and regulations affecting public companies, including the provisions of the Sarbanes-Oxley Act and rules adopted
by the SEC and by NASDAQ, would likely result in increased costs to us as we respond to their requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be subject, directly or indirectly, to federal
and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable
to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If we obtain FDA approval for any of our
product candidates and begin commercializing those products in the United States, our operations may be directly or indirectly
through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback
Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things,
our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the
federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the federal physician sunshine requirements under the Health Care Reform Laws requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Because of the breadth of these laws and
the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could
be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these
laws. For example, the Health Care Reform Law, among other things, amends the intent requirement of the federal anti-kickback and
criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent
to violate it. Moreover, the Health Care Reform Law provides that the government may assert that a claim including items or services
resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False
Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">If our operations are found to be in violation
of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including
civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare
and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability
to operate our business and our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>International expansion of our business exposes us to
business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United
States or Israel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Other than our headquarters and other operations
which are located in Israel, we currently have limited international operations, but our business strategy incorporates potentially
significant international expansion, particularly in anticipation of approval of our product candidates. We plan to maintain sales
representatives and conduct physician and patient association outreach activities, as well as clinical trials, outside of the United
States and Israel. Doing business internationally involves a number of risks, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">failure by us to obtain regulatory approvals for the use of our products in various countries;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">additional potentially relevant third-party patent rights;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">complexities and difficulties in obtaining protection and enforcing our intellectual property;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">difficulties in staffing and managing foreign operations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">limits in our ability to penetrate international markets;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">certain expenses including, among others, expenses for travel, translation, and insurance; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions, or its anti-bribery provisions.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Any of these factors could significantly
harm our future international expansion and operations and, consequently, our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to comply with environmental, health and safety
laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on
the success of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our research and development activities and
our third-party manufacturers&rsquo; and suppliers&rsquo; activities involve the controlled storage, use, and disposal of hazardous
materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers
are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials.
In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&rsquo;
facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of
our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly
clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials
and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling
and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee
that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may
be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable
authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws
and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such
changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be a &ldquo;passive foreign investment company&rdquo;,
or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable year. There
generally would be negative tax consequences for U.S. taxpayers that are holders of our Ordinary Shares if we are or were to become
a PFIC. &#9;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We would be treated as a PFIC for U.S. federal
income tax purposes in any taxable year in which either (1) at least 75% of our gross income is &ldquo;passive income&rdquo; or
(2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive
income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether
a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly
or indirectly, at least a 25% interest (by value) is taken into account. Based on the nature of our business, the projected composition
of our income and the projected composition and estimated fair market values of our assets, we cannot rule out that we will not
be a PFIC for our current taxable year or in the future. The tests for determining PFIC status are applied annually, and it is
difficult to make accurate projections of future income and assets which are relevant to this determination. In addition, our PFIC
status may depend in part on the market value of our Ordinary Shares. Accordingly, there can be no assurance that we currently
are not or will not become a PFIC in the future. If we are a PFIC in any taxable year during which a U.S. taxpayer holds our Ordinary
Shares, such U.S. taxpayer would be subject to certain adverse U.S. federal income tax rules. In particular, if the U.S. taxpayer
did not make an election to treat us as a &ldquo;qualified electing fund,&rdquo; or QEF, or make a &ldquo;mark-to-market&rdquo;
election, then &ldquo;excess distributions&rdquo; to the U.S. taxpayer, and any gain realized on the sale or other disposition
of our Ordinary Shares by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&rsquo;s holding period for the
Ordinary Shares; (2) the amount allocated to the current taxable year and any period prior to the first day of the first taxable
year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years
would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest
charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable
year. In addition, if the Internal Revenue Service, or IRS, determines that we are a PFIC for a year with respect to which we have
determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S.
taxpayers that have held our Ordinary Shares during a period when we were a PFIC will be subject to the foregoing rules, even if
we cease to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election.
A U.S. taxpayer can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the
instructions thereto. We do not intend to notify U.S. taxpayers that hold our Ordinary Shares if we believe we will be treated
as a PFIC for any taxable year in order to enable U.S. taxpayers to consider whether to make a QEF election. In addition, we do
not intend to furnish such U.S. taxpayers annually with information needed in order to complete IRS Form 8621 and to make and maintain
a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. U.S. taxpayers that hold our Ordinary Shares
are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing requirements and the eligibility,
manner, and consequences to them of making a QEF or mark-to-market election with respect to our Ordinary Shares in the event that
we are a PFIC. See Item 10.E. &ndash; &ldquo;Taxation&nbsp;&ndash;&nbsp;United States Federal Income Tax Consequences&nbsp;&mdash;&nbsp;Passive
Foreign Investment Companies&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not know whether a market for our Ordinary Shares
will be sustained or what the market price of our ordinary shares will be and as a result it may be difficult for you to sell your
shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Although our Ordinary Shares are quoted
on the NASDAQ Global Market, an active trading market for our Ordinary Shares may not be sustained. It may be difficult for you
to sell your Ordinary Shares at all or without depressing the market price for the Ordinary Shares. As a result of these and other
factors, you may not be able to sell your Ordinary Shares at or above the price you paid for such shares or at all. In addition,&nbsp;the
trading price of our Ordinary Shares is likely to be volatile. The following factors, in addition to other risk factors described
in this section, may have a significant impact on the market price of our Ordinary Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">inability to obtain the approvals necessary to commence further clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">unsatisfactory results of clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">announcements of therapeutic innovations or new products by us or our competitors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">changes or developments in laws or regulations applicable to any candidate product of our in each of our platforms;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">any adverse changes to our relationship with manufacturers or suppliers;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">any intellectual property infringement actions in which we may become involved;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">announcements concerning our competitors or the pharmaceutical industry in general;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">achievement of expected product sales and profitability or our failure to meet expectations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our commencement of, or involvement in, litigation;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>low daily trading volume of our shares;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">any major changes in our Board of Directors or management; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">legislation in the United States relating to the sale or pricing of pharmaceuticals.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In addition, the stock market in general,
and NASDAQ in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our
Ordinary Shares, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related
factors beyond our control may cause our share price to decline rapidly and unexpectedly. If our share price falls below the listing
standards of NASDAQ, our Ordinary Shares may be delisted from trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be subject to securities litigation, which is expensive
and could divert management attention.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">In the past companies that have experienced
volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of
this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&rsquo;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us
to significant liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>As of March 20, 2015, our officers and directors beneficially
own approximately 71% of our Ordinary Shares. They will therefore be able to exert significant control over matters submitted to
our shareholders for approval. &#9;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">As of March 20, 2015, our officers and directors,
in the aggregate, beneficially own approximately 71% of our Ordinary Shares. This significant concentration of share ownership
may adversely affect the trading price for our Ordinary Shares because investors often perceive disadvantages in owning stock in
companies with controlling shareholders. As a result, these shareholders, if they acted together, could significantly influence
or even unilaterally approve matters requiring approval by our shareholders, including the election of directors and the approval
of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests
or the interests of other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sales of a substantial number of our Ordinary Shares in
the public market by our existing shareholders could cause our share price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Sales of a substantial number of our Ordinary
Shares in the public market or the perception that these sales might occur, could depress the market price of our Ordinary Shares
and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect
that sales may have on the prevailing market price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities or industry analysts do not publish or cease
publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish
negative reports regarding our business or our Ordinary Shares, our share price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The trading market for our Ordinary Shares
will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market
or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover
us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our Ordinary
Shares, or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any
analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility
in the financial markets, which in turn could cause our share price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Because we do not intend to declare cash dividends on
our Ordinary Shares in the foreseeable future, shareholders must rely on appreciation of the value of our Ordinary Shares for any
return on their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have never declared or paid cash dividends
on our Ordinary Shares. We currently anticipate that we will retain future earnings for the development, operation and expansion
of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The requirements associated with being a public company
require significant company resources and management attention.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are subject to the reporting requirements
of the Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act, the Listing Rules of NASDAQ, and other applicable
securities rules and regulations. The Exchange Act requires that we file periodic reports with respect to our business and financial
condition and maintain effective disclosure controls and procedures and internal control over financial reporting. In addition,
subsequent rules implemented by the SEC and NASDAQ may also impose various additional requirements on public companies. As a result,
we will incur additional legal, accounting and other expenses that we did not incur as a nonpublic company, particularly after
we are no longer an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act. Further, the need to establish the corporate
infrastructure demanded of a public company may divert management&rsquo;s attention from implementing our development plans. We
made changes to our corporate governance standards, disclosure controls and financial reporting and accounting systems to meet
our reporting obligations. The measures we take, however, may not be sufficient to satisfy our obligations as a public company,
which could subject us to delisting of our Ordinary Shares, fines, sanctions and other regulatory action and potentially civil
litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The JOBS Act and our status as a foreign private issuer
will allow us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors
and to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence
in our company and adversely affect the market price of our Ordinary Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">For so long as we remain an &quot;emerging
growth company&quot; as defined in the JOBS Act, we intend to take advantage of certain exemptions from various requirements that
are applicable to public companies that are not emerging growth companies including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">Section 107 of the JOBS Act, which provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. This means that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are electing to delay such adoption of new or revised accounting standards. As a result, our financial statements may not be comparable to companies that comply with the public company effective date;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&rsquo;s report on the financial statements; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">our ability to furnish two rather than three years of income statements and statements of cash flows in various required filings.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We intend to take advantage of these exemptions
until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last
day of the fiscal year (a) following the fifth anniversary of our initial public offering which occurred in 2014, (b) in which
we have total annual gross revenue of at least $1.0 billion, or (c) in which we are deemed to be a large accelerated filer, which
means the market value of our Ordinary Shares that is held by non-affiliates exceeds $700 million as of the prior June 30<SUP>th</SUP>,
and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our status as a foreign private issuer also
exempts us from compliance with certain SEC laws and regulations and certain regulations of NASDAQ, including the proxy rules,
the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination
of directors and executive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We cannot predict if investors will find
our Ordinary Shares less attractive because we may rely on these exemptions. If some investors find our Ordinary Shares less attractive
as a result, there may be a less active trading market for our Ordinary Shares, and our share price may be more volatile and may
decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Israeli Law and Our Operations in Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our headquarters and other significant operations are
located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our executive offices are located in Tel
Aviv, Israel. In addition, the majority of our officers and directors are residents of Israel. Accordingly, political, economic
and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number
of armed conflicts have taken place between Israel and its neighboring countries. Any hostilities involving Israel or the interruption
or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations.
During the summer of 2006, Israel was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite militia group and
political party and since March 2011, there has been a civil war in Syria, Israel&rsquo;s neighboring country to the north. Occasionally,
violence from Syria has spilled over into Israel, and Israel has responded militarily several times since the onset of the civil
war. During November 2012 and July 2014, Israel was engaged in an armed conflict with a militia group and political party which
controls the Gaza Strip. These conflicts involved missile strikes against civilian targets in various parts of Israel, including
areas in which our employees and some of our consultants are located, and negatively affected business conditions in Israel. Any
potential future conflict could also include such missile strikes against other parts of Israel, including our offices and laboratories.
Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions, could
harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may sometimes
decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary
in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in
parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments
under those agreements pursuant to force majeure provisions in such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our commercial insurance does not cover losses
that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government
has in the past covered the reinstatement value of certain damages that were caused by terrorist attacks or acts of war, we cannot
assure you that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages
incurred. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political
instability in the region would likely negatively affect business conditions generally and could harm our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Further, in the past, the State of Israel
and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel
and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial
conditions or the expansion of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our operations may be disrupted as a result of the obligation
of management or key personnel to perform military service.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our employees and consultants in Israel,
including members of our senior management, may be obligated to perform one month, and in some cases longer periods, of annual
military reserve duty until they reach the age of 40 (or older, for citizens who hold certain positions in the Israeli armed forces
reserves), and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity,
there have been periods of significant call-ups of military reservists. It is possible that there will be similar large-scale military
reserve duty call-ups in the future. Our operations could be disrupted by the absence of a significant number of our officers,
directors, employees and consultants. Such disruption could materially adversely affect our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Exchange rate fluctuations between the U.S. dollar and
the New Israeli Shekel may negatively affect our earnings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">We incur expenses both
in U.S. dollars and NIS, but our financial statements are denominated in U.S. dollars. As a result, we are exposed to the risks
that the NIS may appreciate relative to the U.S. dollar, or, if the NIS instead devalues relative to the U.S. dollar, that the
inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind
inflation in Israel. In any such event, the U.S. dollar cost of our operations in Israel would increase and our U.S. dollar-denominated
results of operations would be adversely affected. In 2014, approximately 23% of our expenses were denominated in NIS. Changes
of 5% and 10% in the U.S. Dollar/NIS exchange rate would increase/decrease our operating expenses by 1.7% and 3.5%, respectively.
These historical figures may not be indicative of future exposure, and we cannot predict any future trends in the rate of inflation
in Israel or the rate of devaluation (if any) of the NIS against the U.S. dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">Furthermore, currently
we do not hedge our foreign currency exchange risk. Even if we attempt to decrease the risk of financial exposure from fluctuations
in the exchange rates of our principal operating currencies, these measures, may not adequately protect us from the material adverse
effects of such fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Provisions of Israeli law and our articles of association
may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control,
even when the terms of such a transaction are favorable to us and our shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Israeli corporate law regulates mergers,
requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions.
For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal is filed
by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders
of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must
approve a merger. Moreover, a tender offer for all of a company&rsquo;s issued and outstanding shares can only be completed if
the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion of the tender
offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless, following
consummation of the tender offer, the acquirer would hold at least 98% of the company&rsquo;s outstanding shares. Furthermore,
the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following
the completion of the tender offer, claim that the consideration for the acquisition of the shares does not reflect fair market
value, and petition an Israeli court to alter the consideration for the acquisition, unless the acquirer stipulated in its tender
offer that a shareholder that accepts the offer may not seek such appraisal rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Furthermore, Israeli tax considerations may
make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with
Israel exempting such shareholders from Israeli tax. See Item 10.E. &ndash; &ldquo;Taxation&nbsp;&ndash;&nbsp;Israeli Tax Considerations&rdquo;
for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our articles of association also contain
provisions that could delay or prevent changes in control or changes in our management without the consent of our Board of Directors.
These provisions include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">no cumulative voting in the election of directors, which limits the ability of minority shareholders to elect director candidates; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">the right of our Board of Directors to elect a director to fill a vacancy created by the expansion of the Board of Directors or the resignation, death or removal of a director, which may prevent shareholders from being able to fill vacancies on our Board of Directors.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>It may be difficult to enforce a judgment of a United
States court against us and our officers and directors and the Israeli experts named in this annual report in Israel or the United
States, to assert United States securities laws claims in Israel or to serve process on our officers and directors and these experts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We were incorporated in Israel. Substantially
all of our executive officers and directors reside outside of the United States, and all of our assets and most of the assets of
these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including
a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States
and may not necessarily be enforced by an Israeli court. It also may be difficult for you to affect service of process on these
persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it
may be difficult for an investor, or any other person or entity, to initiate an action with respect to United States securities
laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of United States securities laws reasoning
that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear
a claim, it may determine that Israeli law and not United States law is applicable to the claim. If United States law is found
to be applicable, the content of applicable United States law must be proven as a fact by expert witnesses, which can be a time
consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law
in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against
us in Israel, you may not be able to collect any damages awarded by either a United States or foreign court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Your rights and responsibilities as a shareholder will
be governed by Israeli law which differs in some material respects from the rights and responsibilities of shareholders of U.S.
companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The rights and responsibilities of the holders
of our Ordinary Shares are governed by our articles of association and by Israeli law. These rights and responsibilities differ
in some material respects from the rights and responsibilities of shareholders in typical U.S.-based corporations. In particular,
a shareholder of an Israeli company has certain duties to act in good faith and fairness towards us and other shareholders, and
to refrain from abusing its power in us. See Item 16G. &ndash;&nbsp;&nbsp;&ldquo;Approval of Related Party Transactions under Israeli
Law&rdquo; for additional information. There is limited case law available to assist us in understanding the nature of this duty
or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on
holders of our Ordinary Shares that are not typically imposed on shareholders of U.S. corporations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-align: left; text-indent: -1in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-align: left; text-indent: -1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; font-size: 10pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Item 4. </B></FONT></TD>
    <TD STYLE="width: 87%; font-size: 10pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><A NAME="a_005"></A><B>Information on the company</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-align: left; text-indent: -1in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.A.</B></TD><TD STYLE="text-align: justify"><B>History<FONT STYLE="font-family: Times New Roman, Times, Serif">
and</FONT> development</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are an Israeli corporation based in Tel
Aviv and were incorporated on January 22, 2012. Our principal executive offices are located at 37 Dereh Menachem Begin St., Tel
Aviv 6522042, Israel, and our telephone number is: +972 722409060. Our wholly owned U.S. subsidiary, BioBlast Pharma, Inc., incorporated
in Delaware, has been appointed our agent in the United States and its registered address is 1811 Silverside Road, Wilmington,
Delaware 19810. Our website address is http://bioblast-pharma.com. The information contained on, or that can be accessed through,
our website is not part of this annual report. We have included our website address herein solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are an emerging growth company, as defined
in Section&nbsp;2(a) of the Securities Act, as implemented under the JOBS Act. As such, we are eligible to, and intend to, take
advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging
growth companies including but not limited to not being required to comply with the auditor attestation requirements of the SEC
rules under Section&nbsp;404 of the Sarbanes-Oxley Act. We could remain an emerging growth company until the earlier of (1) the
last day of the fiscal year (a) following the fifth anniversary of our initial public offering, which occurred in 2014, (b) in
which we have total annual gross revenue of at least $1.0 billion, or (c) in which we are deemed to be a large accelerated filer,
which means the market value of our Ordinary Shares that is held by non-affiliates exceeds $700 million as of the prior June 30th,
and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our capital expenditures for 2014, 2013,
and 2012 amounted to $63,000, $2,000, and $0, respectively. These expenditures were primarily for computers, other electrical equipment
and office furniture. Our current capital expenditures are primarily for leasehold improvements, computers and other electronic
equipment, and we expect to finance these expenditures primarily from cash on hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.B.</B></TD><TD STYLE="text-align: justify"><B>Business overview</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Who We Are</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are a development-stage biopharmaceutical
company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare
genetic and metabolic diseases. We seek to identify therapeutic platforms that offer solutions for several diseases that share
a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. We focus
on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action
is understood and for which there is no satisfactory treatment. Since our inception in 2012, we have developed and in-licensed
potential treatments for six diseases. Our three principal product candidate platforms are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our current pipeline is based on three platforms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-indent: 15pt">&bull;</TD>
    <TD STYLE="width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.35pt"><B><I>Protein Stabilizing Platform</I></B>: Cabaletta&nbsp;is
        a mutant protein stabilizing and autophagy enhancer based on a small repurposed molecule, namely, trehalose. Trehalose is currently
        used as an excipient, or non-active ingredient, for protein-based drugs that are administered intravenously, such as Avastin&reg;
        or Herceptin&reg;. Mutant unstable cellular proteins are the cause of several genetic diseases known as PolyA/PolyQ, including
        oculopharyngeal muscular dystropy, or OPMD, spinocerebellar ataxia type 3, or Machado Joseph disease, or SCA3 and spino bulbar
        muscular atrophy, or SBMA. These pathological proteins aggregate within cells, eventually leading to cell death. Our data to date
        from preclinical studies from both cells and animal models, indicates that our Cabaletta platform has the potential to prevent
        mutant protein aggregation and enhanced autophagy in humans.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.35pt">We are currently conducting a Phase 2/3
clinical trial for Cabaletta in treating OPMD. In March 2015, the FDA granted us clearance to proceed with an IND with respect
to the Phase 2/3 clinical trial for OPMD with Cabaletta. Concurrently, we are conducting a Phase 2 clinical trial to assess Cabaletta&rsquo;s
efficacy and safety in treating SCA3. Subject to planned discussions with the FDA regarding trial design, we intend to pursue
a multicenter clinical study in 2015 for SCA3. With respect to OPMD and SCA3, we plan to continue to pursue pre-commercial activities
in 2015.&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 15pt">&nbsp;</TD>
    <TD STYLE="padding-left: 13.35pt">Additionally, Cabaletta is in preclinical development for SMBA. In 2015, we plan to continue to pursue preclinical studies as well as clinical planning for SMBA. Based on the biology of trehalose and our intellectual property, we believe that this drug platform has the potential to treat several diseases.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 15pt">&nbsp;</TD>
    <TD STYLE="padding-left: 13.35pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-indent: 15pt">&bull;</TD>
    <TD STYLE="width: 91%; padding-left: 13.35pt"><B><I>Read-through Platform</I></B>: BBrm&nbsp;is our lead product candidate in our read-through platform and is a proprietary formulation of a small repurposed molecule, azithromycin for intrathecal delivery. The platform enables the read-through (or bypassing) of genetic defects called nonsense mutations or stop codons that interfere with normal protein formation and cause disease. Based on our preclinical data, we believe that this drug platform has the potential to treat several diseases caused by nonsense mutation. Subject to regulatory approval, we plan to conduct Phase 2 clinical studies in 2015 for our lead indication in spinal muscular atrophy, or SMA. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-indent: 15pt">&bull;</TD>
    <TD STYLE="width: 91%; padding-left: 13.35pt"><B><I>Mitochondrial Protein Replacement Platform</I></B>: mPRT&nbsp;is a mitochondrial protein replacement platform that is based on biological components that we synthesize in bacteria. Mitochondria are cell components that supply chemical energy for normal cell functioning. This platform is currently in preclinical development for two diseases: Friedreich&rsquo;s Ataxia and ornithine transcarbamylase deficiency. These diseases are among hundreds of genetic diseases that are caused by a missing or mutant protein that has a critical role in the normal mitochondrial function. While lysosomal protein replacement platforms have been successful in replacing a missing protein in lysosomes, we believe that our mPRT platform is the first one to potentially be successful in replacing mitochondrial proteins. Our product candidates are new &ldquo;fusion proteins&rdquo; that are a combination of the replaced protein fused with two additional sequences that facilitate its transport through biological membranes. Based on the biology of this platform and our intellectual property, we believe that this drug platform has the potential to treat a significant number of diseases.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Two of the drugs in our current drug candidate
pipeline has been in-licensed from academic institutions and one was developed internally. Our strategy is based on risk diversification
through multiple therapeutic platforms, diversified clinical and pre-clinical stages of our programs, and diversified diseases
addressed. We use strict selection criteria for our pipeline platforms and focus on drugs that we believe will be cost-efficient
to develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We believe that our strategy and special
business operation model is especially suitable for commercializing effective and safe products in a timely and cost efficient
manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Strict selection criteria of our platforms and clinical program.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We target rare and ultra-rare diseases that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">cause severely shortened life expectancy or severe debilitation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">do not have an approved or effective therapy currently available;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">have a drug candidate that we believe will either be lifesaving or significantly ameliorate the disease course;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">have tangible and validated tests where initial efficacy can be demonstrated in a reasonable time frame; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">preferably have validated biomarkers and where natural history study is available.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">As part of this selection process, we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">estimate the scope and availability of research tools for the preclinical studies required;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">limit the diseases selected to those in which the full pre-clinical tool kit is available or can be obtained through collaboration with patient organizations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">estimate the size and structure of the clinical studies that will be required and confine our selections to fit what we believe will be a cost effective program that will not require unreasonable financial resources;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">select diseases in which the regulatory path to approval is clear and well defined;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>strictly evaluate the strength of the intellectual property that we license for further development;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">estimate the required chemistry, manufacturing and control development program; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">exclude drug candidates that are known to have any safety issues and prefer, when possible and feasible, repurposed drugs; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%">part of our screening and selection criteria involves accessing key opinion leaders and aligning ourselves with the patient advocacy group for the specific disease we are considering our decision to move forward is often taken in consensus with them.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Because these diseases are rare or ultra-rare,
no prenatal diagnosis is widely offered that might reduce the incidence of the diseases. Optimally, our target diseases have geographic
clusters around a small number of clinics with a sufficient number of patients to avoid large multi-center studies. Due to our
location in Israel, we prefer to focus on diseases for which we can find a disease cluster in Israel where we can start a proof
of concept study promptly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Risk diversification through multiple platforms, clinical
programs and stages of development.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Drug development is a complex and unpredictable
process with multiple risks. We believe that a biopharmaceutical company such as ours should diversify the inherent risk associated
with drug development. Drug development occurs in both the preclinical and clinical stages, each of which must satisfy separate
criteria with different risks, including safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have begun to diversify risk by initially
focusing on three therapeutic platforms that each can be applied to several diseases. In each case, we have identified a lead program,
but we believe we have the opportunity to benefit from the shorter and less expansive route to additional indications based on
the same platform. In addition there are different risks associated with the development of a small molecule drug, a biological
drug, or a repurposed drug. Our portfolio is comprised of all three, thereby balancing the systemic risk associated with it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Variable lean cost structure.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We believe in keeping a small, select and
highly professional core team while relying on experienced service providers and CROs for an efficient and time&nbsp;&ndash;&nbsp;saving
development process. We carefully screen our service providers and CROs for their expertise in the specific project required and
work with them closely to complete the task assigned to them efficiently and professionally. This business operation model enables
us to develop multiple programs while avoiding the exorbitant costs associated with learning curves, setup times, and high fixed
costs associated with in-house development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Current Product Pipeline </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The following table summarizes our product
candidate pipeline:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tpg44.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Product Candidates&nbsp;&mdash;&nbsp;Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our current product candidate pipeline has
been either in-licensed from academic institutions or developed internally. Where possible, our strategy is to acquire and retain
global commercialization rights to our products to maximize long-term value. Over time, we intend to build our own commercial organization,
which we believe will be of modest size due to the relatively small number of specialists who treat patients with rare and ultra-rare
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The diseases which we are addressing have
devastating consequences on the patient&rsquo;s health, quality of life and life expectancy. In addition these diseases create
significant burdens on the patient&rsquo;s family and care takers as well as on the public health resources. In all the diseases
we are addressing, patients cannot be offered an alternative therapy or the current solutions are inadequate in their abilities
to change the course of the disease. We believe that prompt and efficient drug development can be of substantial benefit to the
patients who are suffering from these incurable diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have assembled an experienced team of
employees, consultants, service providers and Board of Directors with extensive drug development and commercialization capabilities,
particularly in the orphan drug area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cabaletta for the treatment of OPMD</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Cabaletta is our proprietary intravenous
(IV) solution of trehalose for the treatment of OPMD. OPMD is an inherited myopathy. It is a muscle disease caused by a primary
defect in muscle cells caused by aggregation of a protein called PABPN1, and is characterized by dysphagia (difficulty in swallowing),
the loss of muscular strength and weakness in multiple parts of the body. As the dysphagia becomes more severe, patients become
malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia. These last
two are often the cause of death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Trehalose is naturally occurring and is well
known for its protein-stabilizing and autophagy enhancing properties. It is used in several biological systems, such as freeze
drying of red blood cells and the preservation of organs for donation and as a protein stabilizer in IV pharmaceutical products.
Trehalose is approved by the FDA as a GRAS (Generally Recognized as Safe) food ingredient and is listed in the U.S. National Formulary,
which is a compendium of public pharmacopeial standards, which are guidelines for the identification of compound medicines, as
well as in Europe and Japan. It is a disaccharide chemical chaperone, which is a chemical molecule comprised of two sugar components
that stabilize the folding of proteins and that buffer abnormal protein aggregation, thus protecting against pathological processes
in cells. It has been shown to prevent pathological aggregation of proteins within cells in several diseases associated with abnormal
cellular-protein aggregation as well as acting as an autophagy enhancer. Autophagy is the basic catabolic mechanism that involves
cell degradation of unnecessary or dysfunctional cellular components. Autophagy in healthy adults, or if regulated in those with
abnormalities, ensures the synthesis, degradation and recycling of cellular components. Trehalose has been documented as demonstrating
significant efficacy in preclinical animal models of OPMD and other PolyA/PolyQ diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Trehalose is not effective when given orally
since it is almost completely metabolized in the small intestine into glucose and often causes diarrhea and flatulence after ingestion
of more than 50g. Cabaletta is our proprietary IV solution of trehalose that has been designed to circumvent the breakdown of trehalose
in the gastrointestinal tract, and to enable therapeutic doses of trehalose to reach muscles and nerve cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We are currently conducting a Phase 2/3 trial
of Cabaletta to treat OPMD; if the results are positive, we believe this could be a pivotal trial. We believe, based on discussions
with the FDA, that if the Phase 2/3 trial shows positive results, the data could be considered pivotal data, considering, among
other things, the applicable FDA guidance for the industry called &ldquo;Providing Clinical Evidence of Effectiveness for Human
Drug and Biological Products.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The study is planned to include 70 patients
in three centers in Israel, Canada and the United States. All patients will be treated with 30g trehalose IV weekly for the first
6 months. After 6 months, patients will be randomized into a treatment arm that will continue with the weekly IV 30g regimen and
a non-treatment control group that will be followed up under the same protocol for an additional 12 months. As of the date hereof,
all 14 patients in Israel have been treated. 13 of them have completed the first six months of the study and are randomized into
a treatment and non-treatment control group. In Canada, we are targeting to treat 40 patients. Treatment started in January 2015,
and eight patients have already been dosed. In March 2015, the FDA granted us clearance to proceed with an IND with respect to
the Phase 2/3 clinical trial for OPMD with Cabaletta. If the trial is successful, we are planning to submit an NDA to the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cabaletta for the treatment of SCA3</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">SCA3, also known as Machado Joseph disease,
is the most common of the cerebellar ataxias, and is one of a group of genetic diseases that are characterized by memory deficits,
spasticity, difficulty with speech and swallowing, weakness in arms and other muscular disorders. Symptoms can begin in early adolescence
and get worse over time. Eventually SCA3 leads to paralysis, and severe cases can lead to an early death in the fourth decade of
life. SCA3 is incurable, and there is currently no approved treatment for the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">SCA3 is caused by a mutation in the DNA that
leads to the creation of a pathological protein&nbsp;&mdash;&nbsp; Ataxin 3. Ataxin 3 is unstable, and aggregates within the cells,
and eventually leads to cell death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Multiple reported studies in cell models
have shown that trehalose, both as an anti-mutant protein aggregation agent and as an autophagy enhancer, is able to reduce protein
aggregates and improve cell survival in several spinocerebellar ataxias including SCA3 cells. Additional animal studies show that
activation of autophagy may be beneficial in alleviating disease symptoms. We recently started our Phase 2 clinical trial of Cabaletta
to treat SCA3 in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cabaletta for the treatment of SBMA&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">SBMA, also known as
Kennedy&rsquo;s disease, is characterized by the degeneration and loss of lower motor neurons in the brainstem and spinal cord.
Patients with SBMA often have weakness in muscle function, severe difficulty in swallowing, repeated aspiration pneumonia, and
other symptoms. SBMA is caused by an abnormal androgen receptor (AR) protein. Patients suffering from SBMA suffer from progressive
neuromuscular deterioration that can end up in extreme disability and repeated aspiration pneumonia. There is currently no approved
therapy for SBMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Studies in cell models have shown that trehalose
is both an anti-mutant protein aggregation and an autophagy enhancer is able to reduce protein aggregates and improve cell survival
in SBMA cells. Additional studies in animal models show that activation of autophagy may be beneficial in alleviating disease symptoms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have entered into an agreement with NINDS
(a group within the U.S. National Institutes of Health, or NIH) pursuant to which NINDS will conduct animal studies on SBMA mouse
models to validate the potential efficacy of Cabaletta. NINDS will conduct the study using its own resources, and we will supply
the research material. If the animal studies are successful, and subject to regulatory allowance, we may commence a Phase 2/3 clinical
trial for this application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>BBrm&nbsp;&mdash;&nbsp;our read-through platform</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">BBrm is our family of small molecule non-glycosides
repurposed drugs for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense
mutation (stop codon). The platform enables the read-through (deactivation) of the genetic defects that stop synthesis of normal
full length proteins. Deactivation of disease-causing nonsense mutation can alleviate the symptoms of genetic diseases caused by
these mutations. Our BBrm family of repurposed drugs is able to induce translational read-through, restoring full-length functional
proteins in diseases where the nonsense mutation results in truncated ineffective proteins. We licensed the exclusive worldwide
commercial rights for our BBrm technology for stop codon inhibition of orphan diseases from the Tel Aviv University in January
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>BBrm1 for the treatment of SMA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Using our BBrm platform, we developed a unique
therapeutic candidate for SMA, a proprietary intrathecal formulation of azythromycin. SMA is the leading genetic cause of infantile
death and is caused by the loss of a functional Survival Motor Neuron 1 (SMN1). The disease is manifested by loss of muscle mass
and mobility as well as severe compromise of vital functions such as respiration. Another protein called SMN2 is a nearly identical
copy of SMN1, differentiated only by a silent, single-nucleotide mutation within the DNA. SMN2 partially compensates for the dysfunction
of SMN1; however, the small amount of the functional protein that is produced from the SMN2 gene is not able to fully compensate
for the loss of SMN1. Prior independent studies proposed that read-through agents, such as aminoglycosides, can induce the read-through
of the stop codon located in the SMN2-protein, thus elongating the SMN2 and creating a full length functional protein that can
compensate for the non-functioning SMN1 and alleviate the disease. This approach was also successfully tested in SMA animal models.
Nonetheless, chronic administration of aminoglycosides was found to be associated with prohibitive toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Nevertheless, we believe that drug-induced
read-through of premature stop codons remains a promising approach to elevate active protein expression from the SMN2 gene which
is an ideal therapeutic target as it is found in all SMA patients. Our family of repurposed FDA-approved non-glycosides molecules
(BBrm) induced significantly higher levels of full length functional SMN2 protein in several <I>in vitro</I> and <I>in vivo</I>
studies. These molecules are ineffective if administered orally or intravenously since they do not penetrate into the brain to
create high enough therapeutic levels within nerve cells. Our BBrm1 product can be injected directly into the central nervous system
(CNS), creating adequate drug concentration. This method of administration has the added benefit of further protection against
off label use. We plan to continue our preclinical development of BBrm1 for SMA through 2015, and, if successful and subject to
regulatory approval, expect to start a Phase 2 study in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mitochondrial protein replacement platform (mPRT)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Mitochondrial disorders are diseases, for
which no cure has been found that are caused by a missing or mutated critical enzyme or protein in the cell organelle called mitochondria.
Our fusion proteins, comprised of two delivery moieties, transactivator of transcription, or TAT, and mitochondrial targeting sequence,
or MTS, and the replacement proteins, help move proteins across biological membranes to facilitate the creation of mature proteins
inside the mitochondria. Our replacement proteins are able to enter human cells and mitochondria and replace the damaged or missing
proteins in the mitocmtshondria. Our breakthrough platform technology demonstrated efficacy in several mitochondrial protein deficiencies
in cells and animal models. Currently, Frataxin for Friedreich&rsquo;s Ataxia (BB-FA) is our most advanced mPRT preclinical program,
followed by Ornithine Transcarbamylase (BB-OTC) for Ornithine Transcarbamylase Deficiency (OTCD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our studies demonstrated the superiority
of our proprietary approach of using a heterologous (non-native) MTS as part of our fusion proteins in four different aspects:
expression by bacteria, cell penetration, mitochondrial processing and anchorage of target proteins, and rescue of cells in oxidative
stress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">We have an exclusive worldwide royalty-bearing
license to commercialize, develop and use the technology, including certain patent applications, from the Hebrew University in
Jerusalem. These patent applications, as well as our internally developed intellectual property assets, cover our unique approach
of using homologous and heterologous MTS in the fusion proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>BB-FA for the treatment of Friedreich&rsquo;s Ataxia (FA)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Friedreich&rsquo;s Ataxia is an inherited
disease characterized by progressive deterioration of muscles and nerves, resulting in gait disturbance (ataxia), cognitive impairment,
progressive heart disease and diabetes. Patients are usually diagnosed in the first or second decade of life, and are typically
wheelchair-bound within 15 years of diagnosis. Most do not survive beyond the fourth decade of life. In many cases the cause of
death is myopathic heart disease. The underlying cause of Friedreich&rsquo;s Ataxia is reduced levels of Frataxin&nbsp;&mdash;&nbsp;a
protein responsible for iron sulfur clusters in the mitochondria that are critical for mitochondria activity. Our preclinical data
demonstrated successful placement of Frataxin into the mitochondria and in the treatment of oxidative stress in Friedreich&rsquo;s
Ataxia patients&rsquo; cells. In addition, our studies in FA mice models demonstrate improvement in the biochemical as well as
the clinical characteristics of the disease following treatment with BB-FA. We are advancing the Friedreich&rsquo;s Ataxia program
through its preclinical development throughout 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>BB-OTC for the treatment of ornithine transcarbamylase deficiency
(OTCD)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">OTCD is the most common disorder among urea
cycle disorders&nbsp;&mdash;&nbsp;a group of rare genetic diseases characterized by the body&rsquo;s inability to detoxify ammonia.
Ammonia is a toxic breakdown product of proteins. OTCD is caused by a mutated and ineffective form of the enzyme, ornithine transcarbamylase,
that is part of the urea cycle complex in the mitochondria. As a result, the normal breakdown of ammonia is disrupted and toxic
ammonia accumulates in the blood causing severe damage to the brain and other vital organs. Newborn males affected with OTCD may
suffer devastating hepatic coma in the first few days after birth, and survivors typically suffer from severe cognitive, mental
and metabolic disorders and growth retardation. Many do not survive the first decade of life. We are using our mitochondrial protein
replacement platform to replace this enzyme in the mitochondria. Our preclinical data indicates that our OTC fusion protein is
well able to be transferred into the mitochondria and be processed in it, resulting in improved mitochondrial metabolism. We are
advancing the BB-OTC program through its preclinical development during 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Approach </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our approach is to identify, acquire, license,
develop, and commercialize novel products for the treatment of rare and ultra-rare diseases in the United States, the European
Union, and select international markets, with the goal of becoming a leading rare disease biotechnology company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The patients we seek to treat have diseases
with limited or no treatment options, and their lives and well-being are highly dependent upon our efforts to develop new therapies.
We strive to build a company that is faster, better and smarter about advancing multiple product candidates through approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The critical components of our business strategy
include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%"><I>Focus on rare and ultra-rare diseases with significant unmet medical need</I>.&nbsp;&nbsp;There are numerous rare and ultra-rare metabolic genetic diseases that currently have no approved drug therapy and for which no therapies, to our knowledge, are currently in development. Patients suffering from these diseases often have a high unmet medical need with significant morbidity and/or mortality. We are focused on developing and commercializing therapies for multiple such indications.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%"><I>Focus on diseases and therapies with clear mechanisms of action</I>.&nbsp;&nbsp;We also focus on diseases that have biology and root causes that are well understood. For example, several of our product candidates are replacement therapies for a single deficient enzyme or substrate in the body. We believe that developing drugs that directly impact known disease pathways will increase the probability of success of our development programs.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%"><I>Leverage our experience and relationships to in-license promising product candidates</I>.&nbsp;Our management and Board of Directors has strong relationships with key opinion leaders in the metabolic genetic field, as well as a history of success in the development and commercialization of therapies for rare and ultra-rare genetic diseases. Accordingly, we enjoy access to many in-licensing opportunities. Most of our current product candidates are in-licensed from academic institutions. We believe these parties have agreed to license product candidates to us because they are confident in our drug development capabilities and experience in bringing rare disease therapies to market.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%"><I>Develop and commercialize multiple product candidates in parallel</I>.&nbsp;Clinical studies for rare and ultra-rare diseases can often be smaller, fewer in number, and less expensive than those for larger market indications. Development of multiple programs in the metabolic genetics field also generates organizational efficiencies and economies of scale. As a result of these efficiencies, we can feasibly develop multiple clinical-stage product candidates in parallel, resulting in a more diversified portfolio that provides multiple opportunities to create value.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%"><I>Focus on excellent and rapid clinical and regulatory execution</I>.&nbsp;We believe that building a successful and sustainable rare disease-focused company requires very specific expertise in the areas of patient identification, clinical study design and conduct, and regulatory strategy. We have assembled a team with a successful track record in managing global clinical development activities in an efficient manner, and with multinational experience in obtaining regulatory approvals for rare disease products.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 4%">&bull;</TD>
    <TD STYLE="width: 93%"><I>Seek to retain global commercialization rights to product candidates</I>.&nbsp;We intend to seek and retain global commercialization rights to our product candidates whenever possible to maximize the potential value of our product portfolio. Our plan is to establish our own commercial organization in major pharmaceutical markets and develop a network of third-party distributors in smaller markets. We believe this commercial organization can be modest and targeted due to the relatively small number of specialists who typically treat patients with the diseases to be addressed by our product candidates. As a result, we do not expect that we will require pharmaceutical partners for commercialization of our product candidates, although we may consider partnering for certain territories or indications or for other strategic purposes.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Product Candidates&nbsp;&mdash;&nbsp;Disease background,
rationale for treatment, development plan and market potential </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Oculopharyngeal Muscular Dystropy (OPMD)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Disease background:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">OPMD is a rare inherited myopathy characterized
by dysphagia (difficulty in swallowing), the loss of muscular strength and weakness in multiple parts of the body. Patients typically
suffer from severe dysphagia, ptosis (eye lid drooping), tongue atrophy, lower limb proximal weakness, dysphonia (altered and weak
voice), limitation in looking upward, facial muscle weakness and upper limb proximal weakness. The disease is most often diagnosed
in the fifth or sixth decade of life and progresses throughout the patient&rsquo;s life. As the dysphagia becomes more severe,
patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia.
These last two are often the cause of death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">OPMD is one of a larger group of diseases
called tri-nucleotide repeat diseases that are associated with the presence of an abnormal cellular protein, that aggregates in
the cells eventually causing cell death. In OPMD the mutant protein PABPN1 was found to be correlated with disease severity in
animal models and was identified within the typical cellular protein aggregates-the intranuclear inclusion body (INI) that are
the diagnostic hallmark of the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">There is no medical treatment or, to our
knowledge, potential cure for OPMD. Current therapeutic strategies are confined to surgical interventions that have limited efficacy
and need to repeated often while the progressive loss of muscle&rsquo;s contractility continue relentlessly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Rationale for treatment:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The naturally occurring disaccharide trehalose
is well known for its protein-stabilizing properties. It is used extensively in many applications as a stabilizer of frozen food,
in freeze drying of biological systems and cells, as a stabilizer of therapeutic parenteral proteins and as an excipient in tablets
and IV solutions. Trehalose has been shown to prevent pathological aggregation of proteins within cells in several diseases associated
with mutant cellular-protein aggregation such as PolyA/PolyQ and taupathy diseases (for example OPMD, Huntington&rsquo;s disease,
Spinocerebellar ataxia, Parkinson and Alzheimer disease and more). Recent studies demonstrated that trehalose enhances autophagy&nbsp;&mdash;&nbsp;a
natural mechanism of debris-clearance within cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tpg49.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Trehalose was found to be effective in cell
studies and in a mouse model of OPMD. In this disease there are characteristic intracellular aggregations of the abnormal protein
PABPN1 (INI). Animal studies showed a direct correlation between reduction of mutant PABPN1 aggregates (INI) in cells and reduced
cell death. Trehalose effectively reduced the aggregation and toxicity of mutant PABPN1 proteins in OPMD cell models. Furthermore,
treatment of an OPMD mouse model with trehalose resulted in the attenuation of muscle weakness, decreased aggregate formation and
a reduced number of TUNEL-positive nuclei in skeletal muscle fibers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Like all disaccharides, trehalose is metabolized
at the epithelial brush border of the intestine into two D-glucose molecules. Less than 0.5% of ingested trehalose is absorbed
into the blood stream where it is further metabolized by the liver and kidney. Oral trehalose in amounts exceeding 40&nbsp;&ndash;&nbsp;50
g per day causes diarrhea, bloating and abdominal pain. To achieve therapeutic amounts of trehalose in the muscle cells, it is
necessary to circumvent the massive metabolism in the gastrointestinal tract. Cabaletta is our proprietary IV formulation of trehalose
developed for the treatment of diseases characterized by unstable mutant protein aggregates causing cellular damage and eventually
cell death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">During 2014, we showed both in preclinical
and human pharmacokinetic studies that Cabaletta is able to reach muscle cells and remain within the cells for considerable periods
of time consistent with our dosing regimen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Trehalose was approved by the FDA, EMEA and
several other authorities as a GRAS food ingredient and is also registered on the U.S. National Formulary, as well as in Europe
and Japan. Its safety in preclinical studies was extensively researched and validated. In addition, we have conducted a 3 month
safety study in two animal species of Cabaletta with amounts that far exceed the intended dose we will be using in clinical trials.
These studies showed that Cabaletta is safe and well tolerated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical development plan:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Our clinical plan will include eventually
three centers that will look at the safety and efficacy of trehalose in OPMD patients across centers in Israel and North America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The study is planned to include 70 patients in 3 centers, in
Israel, Canada and the United States. All patients will be treated with 30g trehalose IV weekly for the first 6 months. After 6
months, patients will be randomized into a treatment arm that will continue with the weekly IV 30g regimen and a non-treatment
control group that will be followed up under the same protocol for an additional 12 months. As of January 2015, all fourteen patients
in Israel have been treated. Nine of them have already completed the full six months treatment and are randomized into the second
phase of the study. In Canada, we are targeting to treat 40 patients. Treatment started in January 2015, and eight patients have
already been dosed. Subject to regulatory approval the U.S. center is planned to start recruiting patients in 2015. During 2014,
we released the interim results from the Israeli center showing that Cabaletta is safe and well tolerated by patients. There were
no drug related serious adverse events. During the trial we had two non-drug related adverse events. One of our patients suffered
aspiration pneumonia as a complication of her disease and later on passed away. Another patient was hospitalized for urinary tract
infection probably as a complication of prior renal surgery. This patient fully recovered and returned to the study. If the trial
is successful, we are planning to submit an NDA to the FDA. Endpoints in the trial include (i) penetration aspiration scale based
on video fluoroscopy, (ii) muscle strength, and (iii) quality of life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The market potential for OPMD:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">The prevalence of OPMD is estimated at 1:100,000.
The disease is more prevalent among people of French Canadian origin residing in Canada and in the United States, and among Hispanics
in New Mexico, Arizona and the other U.S. Southwestern states and in Israel. The prevalence of OPMD among French Canadians in the
Montreal, Canada area is 1:1,000. There are estimated 4,000&nbsp;&ndash;&nbsp;5,000 patients in Canada. In Israel, the prevalence
of OPMD among Bukharian Jews is 1:600. There are an estimated 1,200&nbsp;&ndash;&nbsp;1,500 patients in Israel. It has been reported
to occur in 33 countries in the world. In the United States, the estimated number of patients is approximately 6,000, and accordingly,
the North American opportunity for OPMD represents approximately 10,000 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Spinocerebellar Ataxia type 3 (SCA3 or Machado Joseph disease)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Disease background:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Spinocerebellar ataxia Type 3, also known
as SCA3 or Machado-Joseph disease, is a dominantly inherited ataxia, and is the most common disease among the cerebellar ataxias.
SCA3 is characterized by memory deficits, clumsiness in movements in the arms and legs, unstable gait, difficulty with speech and
swallowing, impaired eye movements that may be accompanied by double vision or bulging eyes, and lower limb spasticity. In most
individuals with SCA3, symptoms typically begin in the third to fifth decade of life but can start as early as young childhood
or as late as 70 years of age. The cause of death is often aspiration pneumonia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">SCA3 is a caused by a repeat expansion in
the DNA code causing the creation of an abnormal and unstable cellular protein Ataxin 3. Typically the longer the expansion, the
more severe the disease which may manifest earlier in life and exert a broader range of neurological symptoms. Cellular aggregations
of Ataxin 3 inclusion bodies are found in SCA3 patients&rsquo; brain and nerve cells.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">There is no medical treatment for SCA3 and current
approaches are focused on alleviating disease symptoms and supportive care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Rationale for treatment and development plan:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">It has been established that enhancement of autophagy in SCA3 is
an effective approach that reduces intracellular aggregates and increase cell survivals. Trehalose was found to be effective in
SCA3 cells as a stabilizer of the mutant Ataxin 3 and as an enhancer of autophagy. We have conducted animal studies in several
disease models. We have found that treatment with trehalose reduced the level of the pathological protein in nerve cells and reduced
the disease symptoms in the model animals. We recently started our Phase 2 clinical trial of Cabaletta to treat SCA3 in Israel.
This randomized trial will treat patients for six months. We intend to enroll twelve to twenty patients. Subject to regulatory
approvals we intend to conduct a multicenter pivotal study in the United States and Europe. Most recently, we announced positive
<I>in vivo</I> proof of concept results for Cabaletta for SCA3 in two different mouse models of the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Market potential:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The prevalence of SCA3 is estimated as 1&nbsp;to&nbsp;2
cases per 100,000 people. The prevalence of the disease is highest among people of Portuguese/Azorean descent. For example, among
immigrants of Portuguese ancestry in New England, the prevalence is around one in 4,000, and the highest prevalence in the world,
about one in 140, occurs on the small Azorean island of Flores. There are an estimated 4,000 to 6,000 patients in the United States,
and an estimated 2,000 patients in each of Portugal and Brazil. SCA3 has been reported in over a dozen European countries with
a few effected families mentioned in each of the reported case studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Spino Bulbar muscular atrophy (SBMA)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Disease background:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">SBMA, also known as Kennedy&rsquo;s disease,
is a rare inherited X linked disease, characterized by the degeneration and loss of lower motor neurons in the brainstem and spinal
cord resulting in progressive muscle weakness, atrophy, and fasciculation. The disease is typically manifested in the fourth or
fifth decade of life. As the disease progresses, disability is increased until the patient is wheelchair bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Rationale for treatment and development plan:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">SBMA is caused by an expansion of the CAG trinucleotide
repeat in exon 1 of the human androgen receptor (<I>AR</I>) gene. A disease causing protein&nbsp;&mdash;&nbsp;a mutant AR - has
been identified in a patient&rsquo;s cells, where it aggregates both in the cytoplasm and in the nucleus. Several studies demonstrated
the ability of trehalose as a protein stabilizer and an autophagy enhancer to protect SBMA cells from the toxic effects of the
mutant AR protein. We are now conducting a study in animal models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Market potential:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The estimated incidence of SBMA in the United
States is approximately 1 case in 40,000 men, or approximately 3,775 patients. There is a general impression that SBMA may be
under-diagnosed, owing in part to misdiagnosis and to the mild symptoms exhibited by some patients. The estimated prevalence in
the rest of the world (Europe, Japan and Australia) is similar. Some regions, such as western Finland and Japan, may have a higher
prevalence. There are an estimated 10,000 patients in Europe, 1,500 patients in Japan and 300 patients in Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Friedreich&rsquo;s Ataxia (FA)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Disease background:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Friedreich&rsquo;s Ataxia is a rare inherited
disease that causes muscle and nerve damage. It usually begins in childhood and is caused by progressive degeneration of the spinal
cord and peripheral nerves. The cerebellum&nbsp;&mdash;&nbsp;the part of the brain that coordinates balance and movement, also
degenerates. This damage results in clumsy, unsteady movements and gait and impaired sensory functions. The disease also causes
severe heart disease, spinal deformity and diabetes. Typically patients are diagnosed within the first two decades of life and
may become wheelchair bound within 15 years of diagnosis. Life expectancy is severely shortened and most patients do not live
beyond the fourth decade of life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Friedreich&rsquo;s Ataxia is caused by a defect
(mutation) in a gene labeled <I>FXN</I>. As a result, the corresponding protein called Frataxin is mutated and dysfunctional.
Fratxin plays a pivotal role in the normal mitochondrial metabolism: Without a normal level of Frataxin, certain cells in the
body (especially peripheral nerve, spinal cord, brain and heart muscle cells) cannot effectively produce energy, and buildup toxic
byproducts leading to what is called &ldquo;oxidative stress.&rdquo; Frataxin deficiency may also lead to increased levels of
iron in the mitochondria. When the excess iron reacts with oxygen, free radicals can be produced. Although free radicals are essential
molecules in the body&rsquo;s metabolism, they can also destroy cells and harm the body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Rationale for treatment and development plan:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Unlike successful lysosomal Enzyme-Protein Replacement
Therapy (ERT)- mitochondrial ERT has yet to be established. We have developed a novel mPRT platform based on a recombinant protein
containing targeting signals (TAT-MTS-protein). Based on our approach, PRT therapy has been studied in a FA mouse model with some
success, using the native MTS of Frataxin (MTSfa). We have made a scientific leap by replacing the native MTS with a heterologous
MTS (one that is native to another protein). Our approach was tested in preclinical studies and was found to be highly superior
in four major parameters: The expression of the fusion protein by bacterial cells, the penetration of the protein into FA patient&rsquo;s
cells, the breakout of the fusion protein into its components leaving the Frataxin protein in the mitochondria, and finally, the
correction of the pathological &ldquo;oxidative stress&rdquo; of the cells. Most recently, we announced positive <I>in vitro</I>
and <I>in vivo</I> proof of concept results for BB-FA in several patient cell lines and in two different and well established
animal models of Friedreich&rsquo;s Ataxia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We continue our preclinical development of our
BB-FA candidate and will advance into a full preclinical regulatory route and manufacturing scale-up in 2015 and 2016. Upon completion,
we plan to initiate clinical studies in the United States and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Market potential for BB-FA:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Although rare, Friedreich&rsquo;s Ataxia is
the most common form of hereditary ataxia, affecting about 1 in every 50,000 people in the United States. It is estimated that
the number of Friedreich&rsquo;s Ataxia patients in the United States is about 6,000, with approximately 15,000 patients worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Ornithine transcarbamylase deficiency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Disease background:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Ornithine transcarbamylase deficiency (OTCD)
is the most common urea cycle disorder, a group of rare genetic metabolic disorders characterized by the body&rsquo;s inability
to detoxify ammonia. OTCD is caused by a mutated and ineffective form of the enzyme ornithine transcarbamylase (OTC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">OTC is one of the critical enzymes that participate
in the &ldquo;Urea cycle&rdquo;&nbsp;&mdash;&nbsp;a metabolic process that helps the body get rid of ammonia, the toxic breakdown
product of proteins. As a result, the normal breakdown of ammonia is disrupted and toxic ammonia accumulates in the blood causing
severe damage to the brain and other vital organs, especially in the highly vulnerable nervous system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Ornithine transcarbamylase deficiency often
becomes evident in the first few days of life; however, it can present at middle age. The typical initial symptoms of a child
with hyperammonemia are failure to feed, loss of thermoregulation with a low core temperature, and somnolence. Symptoms progress
from somnolence to lethargy and coma. Abnormal posturing and encephalopathy are often related to the degree of central nervous
system swelling and pressure upon the brain stem. In cases where OTC enzyme production is low or non-existent, death can occur
within the first days of life. Complications from ornithine transcarbamylase deficiency may include developmental delay and mental
retardation. Progressive liver damage, skin lesions, and brittle hair may also be seen. Other symptoms include irrational behavior
(caused by encephalitis), mood swings, and poor performance in school. In milder (or partial) urea cycle enzyme deficiencies,
ammonia accumulation may be triggered by illness or stress at almost any time of life, resulting in multiple mild elevations of
plasma ammonia concentration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Rationale for treatment and development plan:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="tpg53.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Loss of OTC blocks the normal metabolism of
ammonia into the less toxic urea that can be cleared from the blood by the kidneys. Replacement of the missing or mutated protein
can restore the normal function of the urea cycle and prevent the toxic accumulation of ammonia. Based on our PRT platform, we
have developed a fusion protein that is comprised of TAT-MTS OTC. We are developing it towards proof of concept in human cells
and in animal models. We continue our preclinical development and expect to start a full preclinical regulatory phase in mid-2015.
We expect to start a Phase 1 study late in 2016 in the United States and Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Market potential for BB-OTC:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The incidence of OTCD is 1 in 70,000, with approximately
4,000 patients in the United States, of which 2,000 males suffer from the severe lethal form. This incidence may be an underestimation
due to under diagnosis. In some affected individuals, signs and symptoms of ornithine transcarbamylase may be less severe, and
may not appear until later in life. Some female carriers become symptomatic later in life in times of metabolic stress. Despite
milder presentations in adulthood, hyperammonemia, encephalopathy, cerebral edema, and death can occur. On February 1, 2013, the
FDA approved RAVICTI&reg; (glycerol phenylbutyrate) Oral Liquid for use as a nitrogen-binding agent for chronic management of
adult and pediatric patients 2 years of age or older with urea cycle disorders (UCDs) who cannot be managed by dietary protein
restriction and/or amino acid supplementation alone. In clinical studies, RAVICTI was shown to be noninferior to sodium phenylbutyrate,
and kept ammonia at safe levels throughout the day and night and over the long-term (1 year). Despite RAVCITI&rsquo;s effectiveness
in lowering blood ammonia levels it has some significant limitations in that it is not approved for patients suffering from liver
or kidney disease and many OTCD patients have some disturbance in liver or kidney functions. In addition, over 10% of RAVCITI
users suffer from diarrhea, bloating, and abdominal pain. We believe there exists a place for a therapy that will prevent the
accumulation of ammonia in the first place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Spinal Muscular atrophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Disease background:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">SMA is a neuromuscular disorder for which there
is no available therapy. SMA is the number one autosomal recessive cause of infantile death. SMA is caused by loss or mutation
of the survival motor neuron 1 gene, SMN1, while the nearly identical copy gene, SMN2 is retained. In contrast to SMN1, most SMN2
DNA lack a segment called exon 7. The alternative, &Delta;7-SMN, translates into a prematurely terminated protein that is rapidly
degraded. It has been established that read-through of the stop codon in exon 8 of the &Delta;7 -SMN2 protein increases the amount
of full-length SMN2&nbsp;&mdash;&nbsp;a protein that can significantly attenuate disease severity in SMA patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Rationale for therapy and development plan:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Drug-induced read-through of the premature termination
codon enables full-length translation of SMN, thus serving as an ideal therapeutic target as it is found in all SMA patients.
This approach was successfully tested in SMA cells and animal models using a known family of antibiotics called aminoglycosides.
Unfortunately, chronic administration of aminoglycosides is impossible due to their well-known prohibitive toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our family of FDA-approved molecules (BBrm)
are non-glycosides that were found to be significantly superior to aminoglycosides (Gentamycin) in enabling read-through and enabling
the expression of full length functional SMN2 and rescue of cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We continue our preclinical development of our
BBrm program and expect to start Phase 2 clinical study by 2015 in Israel to be expanded to the United States and Europe in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Market potential for SMA:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">SMA has a carrier frequency of one in every
35 to 40 people, affecting every one in 6,000 live births. It is estimated that some 30,000 children suffer from SMA in the United
States and in similar numbers in Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">There are several drugs in development for SMA;
however, there is no approved therapy for this disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The commercialization of new drugs is competitive,
and we may face worldwide competition from individual investigators, major pharmaceutical companies, specialty pharmaceutical
companies, biotechnology companies, nutraceutical companies, and ultimately biosimilar and generic companies. Our competitors
may develop or market therapies that are more effective, safer, or less costly than any that may be commercialized by us, or may
obtain regulatory approval for their therapies more rapidly than we may obtain approval for ours. Many of our competitors have
substantially greater financial, technical, and human resources than we have. Additional mergers and acquisitions in the pharmaceutical
industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result
of advances made in the commercial applicability of technologies and greater availability of capital for investment in these fields.
Our success will be based in part on our ability to build and actively manage a portfolio of drugs that addresses unmet medical
needs and creates value in patient therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The acquisition or licensing of pharmaceutical
products is also very competitive, and a number of more established companies, which have acknowledged strategies to license or
acquire products, may have competitive advantages as may other emerging companies taking similar or different approaches to product
acquisitions. These established companies may have a competitive advantage over us due to their size, cash flows, and institutional
experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">With respect to our programs in Cabaletta for
OPMD, although we are not aware of any other products currently in clinical development for the treatment of OPMD, it is possible
that competitors may produce, develop, and commercialize therapeutics, or utilize other approaches, such as gene therapy, to treat
OPMD. An academic based study testing the use of injected myoblasts has completed a Phase 2 study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">With respect to our programs in Cabaletta for
SCA3, although we are not aware of any other products currently in clinical development for the treatment of SCA3, it is possible
that competitors may produce, develop, and commercialize therapeutics, or utilize other approaches such as gene therapy, to treat
SCA3. In the last few years several academic researches where conducted to explore the efficacy of approved drugs such as Lithium,
Varenicline (Chantix), riluzol, and Dalfampridine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are not aware of any competitive products
approved or in late-stage clinical development for the treatment of SBMA. However, it is possible that competitors may produce,
develop, and commercialize therapeutics, or utilize other approaches such as gene therapy to treat SBMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Although we believe that Cabaletta should be
considered a drug and that only insignificant amounts of trehalose can be absorbed through an oral administration&nbsp;&mdash;&nbsp;it
is possible that other companies or individuals may attempt to use food grade trehalose as a substitute, and others may attempt
to sell the product via a nutraceutical or food pathway. We believe that following the approval of our patent applications, if
approved, we will be well protected in our intellectual property from the use of trehalose as an IV product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">With respect to our programs in protein replacement
platform although we are not aware of any other similar products currently in clinical development for the treatment of Friedreich&rsquo;s
Ataxia, there are a number of competitors trying to develop and commercialize therapeutics, or utilize other approaches such as
mitochondria protecting agents, anti-oxidants, HDAC inhibitors, cell therapy or gene therapy, to treat Friedreich&rsquo;s Ataxia.
The table below from www.curefa.org, describes, to our knowledge, the current therapeutic approaches for Friedreich&rsquo;s Ataxia
in different stages of development. To our knowledge, none of these product candidates have received regulatory approval in the
United States or Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="tpg55.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">With respect to our programs in protein replacement
platform, although we are not aware of any other similar products currently in clinical development for the treatment of Ornithine
transcarbamylase deficiency, there are a number of clinical approaches currently used to treat OTCD patients in emergency situation:
Intravenous administration of sodium benzoate, arginine, and sodium phenylacetate might be beneficial for patients in hepatic
coma; however, they can only be administered in a large medical facility setting with close laboratory monitoring available. Intravenous
sodium benzoate and phenylacetate (Ammonul) was approved in the United States in February 2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Glycerol phenylbutyrate (Ravicti) is a pre-prodrug
that undergoes metabolism to form phenylacetate. Results of a Phase 3 study comparing ammonia control in adults showed glycerol
phenylbutyrate was non-inferior to sodium phenylbutyrate. In a separate study involving young children ages 2 months through 5
years, glycerol phenylbutyrate resulted in a more evenly distributed urinary output of phenyl butyrate main metabolite (PAGN)
over 24 hours and accounted for fewer symptoms from accumulation of phenylacetate. Ravicti was approved by the FDA early in 2013
(Hyperion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">With respect to our program in BBrm- read-through
platform there are a number of competitors developing read-through molecules, both small molecules (PTC) and exon- skipping RNA
based platform (ISIS, Prosensa, Sarepta). Although not all have focused so far on SMA, it is possible that they will develop in
the future programs that will attempt to utilize their technology for SMA. In addition it is possible that competitors may produce,
develop, and commercialize therapeutics, or utilize other approaches such as gene therapy, cell therapy or bone marrow transplantation,
to treat SCA3. The table below, from www.curesma.org, outlines, to our knowledge, the different approaches for developing drugs
for SMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="tpg56.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We believe that our read-through platform could
be synergistic to most technologies outlined above since most are focused on either generally enhancing the total production of
SMN2 through exon skipping, or focused on the downstream effects of lack of SMN1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>License Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We have entered into two license agreements
with respect to two of our three platform technologies. On December 18, 2011, we entered into a Research and Exclusive License
Agreement with Yissum Research Development Company of the Hebrew University in Jerusalem Ltd., whereby we licensed exclusively
two patent applications covering our mitochondrial protein replacement platform. One patent application covers the use of TAT-MTS-Protein
for protein replacement in mitochondrial diseases. The second patent application covers the use of heterologous MTS in a fusion
protein for treatment of mitochondrial protein deficiency diseases. These patent applications, if issued, will expire in 2029
and 2033, respectively. In addition, on January 1, 2014 we entered into an Exclusive License Agreement with Ramot at Tel Aviv
University Ltd. for the use, development and commercialization of our read-through platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Intellectual Property and Patents and Proprietary Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The proprietary nature of, and protection for,
our product candidates, processes, and know-how are important to our business. Our success depends in part on our ability to protect
the proprietary nature of our product candidates, technology, and know-how, to operate without infringing on the proprietary rights
of others, and to prevent others from infringing our proprietary rights. We seek patent protection in the United States and internationally
for our product candidates and other technology. Our policy is to patent or in-license the technology, inventions and improvements
that we consider important to the development of our business. In addition to patent protection, we intend to use other means
to protect our proprietary rights, including pursuing marketing or data exclusivity periods, orphan drug status, and similar rights
that are available under regulatory provisions in certain countries, including the United States, Europe, Japan, and China. See
&ldquo;U.S. Government Regulation&nbsp;&mdash;&nbsp;Orphan Designation and Exclusivity,&rdquo; &ldquo;U.S. Government Regulation&nbsp;&mdash;&nbsp;Pediatric
Studies and Exclusivity,&rdquo; &ldquo;U.S. Government Regulation&nbsp;&mdash;&nbsp;Patent Term Restoration,&rdquo; &ldquo;U.S.
Government Regulation&nbsp;&mdash;&nbsp;Biosimilars and Exclusivity,&rdquo; &ldquo;U.S. Government Regulation&nbsp;&mdash;&nbsp;Abbreviated
New Drug Applications for Generic Drugs,&rdquo; &ldquo;U.S. Government Regulation&nbsp;&mdash;&nbsp;Hatch-Waxman Patent Certification
and the 30-Month Stay,&rdquo; and &ldquo;European Union/Rest of World Government Regulation&nbsp;&mdash;&nbsp;Orphan Designation
and Exclusivity&rdquo; below for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We also rely on trade secrets, know-how, and
continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted with
respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can
we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting
our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We seek regulatory approval for our products
in disease areas with high unmet medical need, great market potential, and where we have a proprietary position through patents
covering various aspects of our products, such as composition, dosage, formulation, use, and manufacturing process, among others.
Our success depends on an intellectual property portfolio that supports our future revenue streams and erects barriers to our
competitors. We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing
applications, and licensing and acquiring new patents and patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Despite these measures, any of our intellectual
property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated, or such intellectual
property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to
provide competitive advantages. For more information, please see Item 3.D. &ndash; &ldquo;Risks Related to our Intellectual Property.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">As of December 31, 2014, we own and/or are the
exclusive licensee of five pending U.S. patent applications, one issued U.S. patent and corresponding patents and patent applications
internationally. With respect to any patents that may issue in the United States and Europe, we may also be entitled to obtain
a patent term extension to extend the patent expiration date. For example, in the United States, we can apply for a patent term
extension of up to five years for one of the patents covering a product once the product is approved by the FDA. The exact duration
of the extension depends on the time we spend in clinical studies as well as getting a new drug application approval from the
FDA. The patent portfolios for our three leading platform and product candidates as of December 31, 2014 are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Cabaletta</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We have filed two patent applications that relate
to the use of trehalose for the treatment of PolyA/PolyQ diseases and Taupathies. The patent applications are directed to a novel
therapeutic regime using parenteral administration of trehalose, thereby achieving higher bioavailability and therapeutic efficacy
in the treatment of myopathic and neurodegenerative diseases associated with abnormal protein aggregation, specifically polyalanine
or polyglutamine expansion protein and tauopathies disorders such as OPMD, SCA, SBMA, Huntington and more. We have received a
notice of allowance from the USPTO relating to a patent for Cabaletta and OPMD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The expiring patent terms for such pending patent
applications in the United States would be 2034. We intend to pursue marketing and orphan drug exclusivity periods that are available
to us under regulatory provisions in certain countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition we have received orphan drug designation
for the use of trehalose in OPMD and SCA3 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>mPRT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We have filed two patent applications and have
licensed exclusively two patent applications from the Hebrew University in Israel that relate to our mitochondrial protein replacement
platform. These patent applications, as well as our internally developed intellectual property assets, cover our unique approach
of using homologous and heterologous MTS. We have one granted patent covering TAT-citrate synthase MTS-fraxatin fusion proteins
that expires in 2033.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Read-through</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are the exclusive licensee of one Patent
Cooperation Treaty, or PCT, patent application and one U.S. patent application covering our read-through platform that we licensed
from Tel Aviv University (See &ldquo;License Agreements&rdquo; above). We also filed one U.S. patent application that relates
to our read-through platform. The licensed PCT patent application and the patent application that we filed are directed to a method
of treatment for orphan genetic neurodegenerative and neurodevelopmental diseases through non-systemic administration and specific
injectable formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The expiration dates on these patents are 2027
and 2033, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Trademarks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We have filed with the USPTO an intent to use
application for the trademark Cabaletta in International Class 5 for certain pharmaceutical preparations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Other</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We rely upon unpatented trade secrets, know-how,
and continuing technological innovation to develop and maintain our competitive position. We seek to protect our ownership of
know-how and trade secrets through an active program of legal mechanism including assignments, confidentiality agreements, material
transfer agreements, research collaborations, and licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We currently contract with third parties for
the manufacturing and testing of our product candidates for preclinical studies and clinical studies and intend to do so in the
future. We do not own or operate manufacturing facilities for the production of clinical quantities of our product candidates.
We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. The use of contracted manufacturing
and reliance on collaboration partners is relatively cost-efficient and has eliminated the need for our direct investment in manufacturing
facilities and additional staff early in development. Although we rely on contract manufacturers, we have personnel with extensive
manufacturing experience to oversee our contract manufacturers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">To date, our third-party manufacturers have
met our manufacturing requirements. We expect third-party manufacturers to be capable of providing sufficient quantities of our
product candidates to meet anticipated full scale commercial demands. To meet our projected needs for commercial manufacturing,
third parties with whom we currently work might need to increase their scale of production or we will need to secure alternate
suppliers. We believe that there are alternate sources of supply that can satisfy our clinical and commercial requirements, although
we cannot be certain that identifying and establishing relationships with such sources, if necessary, would not result in significant
delay or material additional costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The drug substance for Cabaletta is purchased
from a third party supplier and drug product for Cabaletta is manufactured by a third party manufacturer. There are other suppliers
for pharmaceutical grade trehalose in the market. We have not yet started the development of our clinical trial material for our
pre-clinical programs in mPRT and read-through platforms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We intend to build the commercial infrastructure
in the United States and Europe necessary to effectively support the commercialization of all of our product candidates, if and
when we believe a regulatory approval of the first of such product candidates in a particular geographic market appears imminent.
The commercial infrastructure for orphan products typically consists of a targeted, specialty sales force that calls on a limited
and focused group of physicians supported by sales management, medical liaisons, internal sales support, an internal marketing
group, and distribution support. One challenge unique to commercializing therapies for rare diseases is the difficulty in identifying
eligible patients due to the very small and sometimes heterogeneous disease populations. Our management team is experienced in
maximizing patient identification for both clinical development and commercialization purposes in rare diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Additional capabilities important to the orphan
marketplace include the management of key accounts such as managed care organizations, group-purchasing organizations, specialty
pharmacies, and government accounts. To develop the appropriate commercial infrastructure, we will have to invest significant
amounts of financial and management resources, some of which will be committed prior to any confirmation that any of our product
candidates will be approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Outside of the United States and Europe, where
appropriate, we may elect in the future to utilize strategic partners, distributors, or contract sales forces to assist in the
commercialization of our products. In certain instances we may consider building our own commercial infrastructure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Clinical trials, the drug approval process,
and the marketing of drugs are intensively regulated in the United States and in all major foreign countries. Governmental authorities
in the United States (including federal, state, and local authorities) and in other countries, extensively regulate, among other
things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval
monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical products, such as those
we are developing. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state,
local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>U.S. Government Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the United States, the FDA regulates drugs
under the Federal Food, Drug, and Cosmetic Act, or FDCA, and related regulations, and biologics under the FDCA and the Public
Health Service Act, or PHSA, and its implementing regulations. FDA approval is required before any new unapproved drug or dosage
form, including a new use of a previously approved drug, can be marketed in the United States. Drugs and biologics are also subject
to other federal, state and local statutes and regulations. Failure to comply with the applicable United States regulatory requirements
at any time during the product development process, approval process or after approval may subject an applicant to administrative
or judicial sanctions. These sanctions could include the imposition by the FDA or an IRB of a clinical hold on trials, the FDA&rsquo;s
refusal to approve pending applications or supplements, license suspension or revocation, withdrawal of an approval, warning letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties
or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA and comparable regulatory agencies in
state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture
and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development
activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, record keeping,
approval, advertising and promotion of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA&rsquo;s policies may change and additional
government regulations may be enacted that could prevent or delay regulatory approval of our platforms and candidate products
or any future product candidates or approval of new disease indications or label changes. We cannot predict the likelihood, nature
or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the
United States or abroad.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Marketing Approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The process required by the FDA before product
candidates may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>completion of extensive preclinical laboratory tests and
                                         preclinical animal studies, all performed in accordance with GLP regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>submission to the FDA of an IND which must become effective
                                         before human clinical studies may begin and must be updated annually;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>approval by an IRB or ethics committee representing each
                                         clinical site before each clinical study may be initiated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>performance of adequate and well-controlled human clinical
                                         studies to establish the safety and efficacy of the product candidate for each proposed
                                         indication;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>preparation of and submission to the FDA of an NDA or BLA
                                         after completion of all pivotal clinical studies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>potential review of the product application by an FDA advisory
                                         committee, where appropriate and if applicable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>a determination by the FDA within 60 days of its receipt
                                         of an NDA or BLA to file the application for review;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>satisfactory completion of an FDA pre-approval inspection
                                         of the manufacturing facilities where the proposed product drug substance is produced
                                         to assess compliance with cGMP; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>FDA review and approval of an NDA or BLA prior to any commercial
                                         marketing or sale of the drug in the United States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The testing and approval process requires substantial
time and financial resources, and we cannot be certain that any approvals for our candidate products will be granted on a timely
basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">An IND is a request for authorization from the
FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational
plan and the protocol(s) for human studies. The IND also includes results of animal and&nbsp;<I>in vitro</I>&nbsp;studies assessing
the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing,
and controls information; and any available human data or literature to support the use of the investigational new drug. An IND
must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt
by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical studies. In such a case,
the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before
clinical studies can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical studies to commence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We will need to successfully complete extensive
additional clinical trials in order to be in a position to submit a new drug application to the FDA. Our planned future clinical
trials for our candidate products may not begin or be completed on schedule, if at all. Clinical trials can be delayed for a variety
of reasons, including delays in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>obtaining regulatory approval to commence a study;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>reaching agreement with third-party clinical trial sites
                                         and their subsequent performance in conducting accurate and reliable studies on a timely
                                         basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>obtaining institutional review board approval to conduct
                                         a study at a prospective site;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>recruiting patients to participate in a study; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>supply of the drug.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We must reach agreement with the FDA on the
proposed protocols for our future clinical trials in the United States. A separate submission apart from any IND application we
submit must be made for each successive clinical trial to be conducted during product development. Further, an independent IRB
for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences
at that site. Informed consent must also be obtained from each study subject. Regulatory authorities, an IRB, a data safety monitoring
board or the sponsor, may suspend or terminate a clinical trial at any time on various grounds, including a finding that the participants
are being exposed to an unacceptable health risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Clinical Studies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Clinical studies involve the administration
of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with current
cGCPs which include the requirement that all research subjects provide their informed consent for their participation in any clinical
study. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the parameters
to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent
protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical
study site&rsquo;s IRB before the studies may be initiated, and the IRB must monitor the study until completed. There are also
requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our objective is to conduct additional clinical
trials for our candidate products and, if those trials are successful, seek marketing approval from the FDA and other worldwide
regulatory bodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">For purposes of NDA approval, human clinical
trials are typically conducted in phases that may overlap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Phase 1</I>.&nbsp;&nbsp;The drug is initially introduced
                                         into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism,
                                         distribution and excretion. In the case of some products for severe or life-threatening
                                         diseases, especially when the product may be too inherently toxic to ethically administer
                                         to healthy volunteers, the initial human testing is often conducted in patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Phase 2</I>.&nbsp;&nbsp;This phase involves trials in
                                         a limited patient population to identify possible adverse effects and safety risks, to
                                         preliminarily evaluate the efficacy of the product for specific targeted diseases and
                                         to determine dosage tolerance and optimal dosage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Phase 3</I>.&nbsp;&nbsp;This phase involves trials undertaken
                                         to further evaluate dosage, clinical efficacy and safety in an expanded patient population,
                                         often at geographically dispersed clinical trial sites. These trials are intended to
                                         establish the overall risk/benefit ratio of the product and provide an adequate basis
                                         for product labeling.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Phase 4</I>.&nbsp;&nbsp;In some cases, the FDA may condition
                                         approval of an NDA or BLA for a product candidate on the sponsor&rsquo;s agreement to
                                         conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily
                                         conduct additional clinical studies after approval to gain more information about the
                                         drug. Such post-approval studies are typically referred to as Phase 4 clinical studies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A pivotal study is a clinical study that adequately
meets regulatory agency requirements for the evaluation of a drug candidate&rsquo;s efficacy and safety such that it can be used
to justify the approval of the product. Generally, pivotal studies are Phase 3 studies, but the FDA may accept results from Phase
2 studies if the study design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations
where there is an unmet medical need and the results are sufficiently robust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA, the IRB, or the clinical study sponsor
may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being
exposed to an unacceptable health risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Additionally, some clinical studies are overseen
by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board
or committee. This group provides authorization for whether or not a study may move forward at designated check points based on
access to certain data from the study. We may also suspend or terminate a clinical study based on evolving business objectives
and/or competitive climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">All of these trials must be conducted in accordance
with good clinical practice requirements in order for the data to be considered reliable for regulatory purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The clinical study process can take three to
ten years or more to complete, and there can be no assurance that the data collected will support FDA approval or licensure of
the product. Government regulation may delay or prevent marketing of product candidates or new drugs for a considerable period
of time and impose costly procedures upon our activities. We cannot be certain that the FDA or any other regulatory agency will
grant approvals for our candidate products or any future product candidates on a timely basis, if at all. Success in early stage
clinical trials does not ensure success in later stage clinical trials. Data obtained from clinical activities is not always conclusive
and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The NDA Approval Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Assuming successful completion of all required
testing in accordance with all applicable regulatory requirements, detailed investigational new drug product information is submitted
to the FDA in the form of an NDA or BLA requesting approval to market the product for one or more indications. Under federal law,
the submission of most NDAs and BLAs is subject to an application user fee. For fiscal year 2014, the application user fee exceeded
$2.1 million, and the sponsor of an approved NDA or BLA is also subject to annual product and establishment user fees, set at
$104,060 per product and $554,600 per establishment. These fees are typically increased annually. Applications for orphan drug
products are exempted from the NDA and BLA user fees and may be exempted from product and establishment user fees, unless the
application includes an indication for other than a rare disease or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">An NDA or BLA must include all relevant data
available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings,
together with detailed information relating to the product&rsquo;s chemistry, manufacturing, controls, and proposed labeling,
among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use
of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval,
the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational
new drug product to the satisfaction of the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA will initially review the NDA for completeness
before it accepts it for filing. The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted
for filing based on the agency&rsquo;s threshold determination that the application is sufficiently complete to permit substantive
review. After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the
proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with
cGMP to assure and preserve the product&rsquo;s identity, strength, quality and purity. The FDA may refer applications for novel
drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel
that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be
approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers
such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Based on pivotal Phase 3 trial results submitted
in an NDA, upon the request of an applicant, the FDA may grant a priority review designation to a product, which sets the target
date for FDA action on the application at six months, rather than the standard ten months. Priority review is given where preliminary
estimates indicate that a product, if approved, has the potential to provide a significant improvement compared to marketed products
or offers a therapy where no satisfactory alternative therapy exists. Priority review designation does not change the scientific/medical
standard for approval or the quality of evidence necessary to support approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">After the FDA completes its initial review of
an NDA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter
to communicate that the NDA will not be approved in its current form and inform the sponsor of changes that must be made or additional
clinical, nonclinical or manufacturing data that must be received before the application can be approved, with no implication
regarding the ultimate approvability of the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Before approving an NDA or BLA, the FDA will
typically inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines
that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production
of the product within required specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Additionally, before approving an NDA, the FDA
may inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines the application, manufacturing process
or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing
or information. This may significantly delay further review of the application. If the FDA finds that a clinical site did not
conduct the clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded
from the primary efficacy analyses provided in the NDA. Additionally, notwithstanding the submission of any requested additional
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The testing and approval process for a drug
requires substantial time, effort and financial resources, and this process may take several years to complete. Data obtained
from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit
or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or
unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing
our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA may require, or companies may pursue,
additional clinical trials after a product is approved. These so-called Phase 4 studies may be made a condition to be satisfied
for continuing drug approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate and can provide
important safety information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-market
studies to specifically address safety issues identified by the agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Any approvals that we may ultimately receive
could be withdrawn if required post-marketing trials or analyses do not meet the FDA requirements, which could materially harm
the commercial prospects for our candidate products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA also has authority to require a REMS
from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. A sponsor may also voluntarily
propose a REMS as part of the NDA submission. The need for a REMS is determined as part of the review of the NDA. Based on statutory
standards, elements of a REMS may include &ldquo;dear doctor letters,&rdquo; a medication guide, more elaborate targeted educational
programs, and in some cases restrictions on distribution. These elements are negotiated as part of the NDA approval, and in some
cases if consensus is not obtained until after the Prescription Drug User Fee Act review cycle, the approval date may be delayed.
Once adopted, REMS are subject to periodic assessment and modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Even if a product candidate receives regulatory
approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant
limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans,
restrictions on distribution, or post-marketing study requirements. Further, even after regulatory approval is obtained, later
discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal
of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval for our candidate products, or obtaining
approval but for significantly limited use, would harm our business. In addition, we cannot predict what adverse governmental
regulations may arise from future U.S. or foreign governmental action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Expedited Review and Accelerated Approval Programs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A sponsor may seek approval of its product candidate
under programs designed to accelerate the FDA&rsquo;s review and approval of NDAs and BLAs. For example, Fast Track Designation
may be granted to a drug intended for treatment of a serious or life-threatening disease or condition that has potential to address
unmet medical needs for the disease or condition. The key benefits of fast track designation are the eligibility for priority
review, rolling review (submission of portions of an application before the complete marketing application is submitted), and
accelerated approval, if relevant criteria are met. Based on results of the Phase 3 clinical study(ies) submitted in an NDA or
BLA, upon the request of an applicant, the FDA may grant the NDA or BLA a priority review designation, which sets the target date
for FDA action on the application at six months after the FDA accepts the application for filing. Priority review is granted where
there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment,
diagnosis, or prevention of a serious condition. If criteria are not met for priority review, the application is subject to the
standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change
the scientific/medical standard for approval or the quality of evidence necessary to support approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the accelerated approval program, the
FDA may approve an NDA or BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit,
or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to
predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,
or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of
ongoing studies after marketing approval are generally required to verify the drug&rsquo;s clinical benefit in relationship to
the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the Food and Drug Administration
Safety and Innovation Act which was enacted and signed into law in 2012, established the new Breakthrough Therapy designation.
A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the drug is intended, alone or in combination
with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints,
such as substantial treatment effects observed early in clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>FDA Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Drugs manufactured or distributed pursuant to
FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating
to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences
with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims
are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products
and the establishments at which such products are manufactured, as well as new application fees for supplemental applications
with clinical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Drug manufacturers are subject to periodic unannounced
inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly
regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations
also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon
us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money
and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We rely, and expect to continue to rely, on
third parties for the production of clinical quantities of our product candidates, and expect to rely in the future on third parties
for the production of commercial quantities. Future FDA and state inspections may identify compliance issues at our facilities
or at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources
to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements
may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including withdrawal or recall of the
product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Also,
new government requirements, including those resulting from new legislation, may be established, or the FDA&rsquo;s policies may
change, which could delay or prevent regulatory approval of our products under development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA may withdraw approval if compliance
with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later
discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to
add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of
distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>restrictions on the marketing or manufacturing of the product,
                                         complete withdrawal of the product from the market or product recalls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>fines, warning letters or holds on post-approval clinical
                                         studies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>refusal of the FDA to approve pending NDAs or supplements
                                         to approved NDAs, or suspension or revocation of product license approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>injunctions or the imposition of civil or criminal penalties;
                                         or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>product seizure or detention, or refusal to permit the
                                         import or export of products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA strictly regulates marketing, labeling,
advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications
and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations
prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject
to significant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Orphan Designation and Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA may grant orphan drug designation to
drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it
affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and
making the drug for this type of disease or condition will be recovered from sales in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Orphan drug designation entitles a party to
financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and user-fee waivers.
In addition, if a product receives FDA approval for the indication for which it has orphan designation, the product is entitled
to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication
for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with
orphan exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Pediatric Studies and Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">NDAs and BLAs must contain data (or a proposal
for post-marketing activity) to assess the safety and effectiveness of an investigational new drug product for the claimed indications
in all relevant pediatric populations in order to support dosing and administration for each pediatric subpopulation for which
the drug is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission
of some or all pediatric data until after approval of the product for use in adults or full or partial waivers if certain criteria
are met. Discussions about pediatric development plans can be discussed with the FDA at any time, but usually occur any time between
the end-of-Phase 2 meeting and submission of the NDA or BLA. The requirements for pediatric data do not apply to any drug for
an indication for which orphan designation has been granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Pediatric exclusivity is another type of non-patent
exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection
to the term of any existing regulatory exclusivity, including the five-year and three-year non-patent and orphan exclusivity.
This six-month exclusivity may be granted if an NDA or BLA sponsor submits pediatric data that fairly respond to a written request
from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather,
if the clinical study is deemed to fairly respond to the FDA&rsquo;s request, the additional protection is granted. If reports
of FDA-requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory
or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term
extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application
relying on the NDA or BLA sponsor&rsquo;s data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Patent Term Restoration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Depending upon the timing, duration, and specifics
of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension
under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Hatch-Waxman Amendments permit a patent
restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review
process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&rsquo;s
approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the
submission date of an NDA or BLA, plus the time between the submission date and the approval of that application. Only one patent
applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior
to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent
term extension or restoration. In the future, we may apply for restoration of patent term for one of our currently owned or licensed
patents to add patent life beyond its current expiration date, depending on the expected length of the clinical studies and other
factors involved in the filing of the relevant NDA or BLA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Biosimilars and Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Patient Protection and Affordable Care Act,
or Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation
Act of 2009, or BPCI Act, which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable
with, an FDA-licensed reference biological product. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in
terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies.
Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can
be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic
and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks
of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger,
and often more complex, structure of biological products, as well as the process by which such products are manufactured, pose
significant hurdles to implementation that are still being worked out by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A reference biologic is granted twelve years
of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated
approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting
under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(ii) eighteen months after approval if there is no legal challenge,
(iii) eighteen months after the resolution in the applicant&rsquo;s favor of a lawsuit challenging the biologics&rsquo; patents
if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within
the 42-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Abbreviated New Drug Applications for Generic Drugs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In 1984, with passage of the Hatch-Waxman Act,
the U.S. Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under
the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application,
or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing
previously conducted for a drug product previously approved under an NDA, known as the reference listed drug, or RLD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Specifically, in order for an ANDA to be approved,
the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration,
the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &ldquo;bioequivalent&rdquo;
to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if &ldquo;the rate and extent of absorption
of the generic drug do not show a significant difference from the rate and extent of absorption of the listed drug. . . .&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Upon approval of an ANDA, the FDA indicates
that the generic product is &ldquo;therapeutically equivalent&rdquo; to the RLD and it assigns a therapeutic equivalence rating
to the approved generic drug in its publication &ldquo;Approved Drug Products with Therapeutic Equivalence Evaluations,&rdquo;
also referred to as the &ldquo;Orange Book.&rdquo; Physicians and pharmacists consider an &ldquo;AB&rdquo; therapeutic equivalence
rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous
health insurance programs, the FDA&rsquo;s designation of an &ldquo;AB&rdquo; rating often results in substitution of the generic
drug without the knowledge or consent of either the prescribing physician or patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDCA provides a period of five years of
non-patent exclusivity for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA
may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification,
in which case the applicant may submit its application four years following the original product approval. The FDCA also provides
for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than
bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the
application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage
form, route of administration, combination or indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Hatch-Waxman Patent Certification and the 30-Month Stay</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Upon approval of an NDA or a supplement thereto,
NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&rsquo;s product or a method of
using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files
its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference
product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Specifically, the applicant must certify with
respect to each patent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the required patent information has not been filed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the listed patent has expired;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the listed patent has not expired, but will expire on a
                                         particular date and approval is sought after patent expiration; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the listed patent is invalid, unenforceable or will not
                                         be infringed by the new product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A certification that the new product will not
infringe the already approved product&rsquo;s listed patents or that such patents are invalid or unenforceable is called a Paragraph
IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented
method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If the ANDA applicant has provided a Paragraph
IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders
once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit
in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after
the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months
after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable
to the ANDA applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>European Union/Rest of World Government Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition to regulations in the United States,
we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any
commercial sales and distribution of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Whether or not we obtain FDA approval for a
product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of
clinical studies or marketing of the product in those countries. Certain countries outside of the United States have a similar
process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical
studies. In the European Union, for example, a clinical study application, or CTA, must be submitted for each clinical protocol
to each country&rsquo;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively.
Once the CTA is accepted in accordance with a country&rsquo;s requirements, the clinical study may proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The requirements and process governing the conduct
of clinical studies vary from country to country. In all cases, the clinical studies are conducted in accordance with cGCP, the
applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">To obtain regulatory approval of an investigational
medicinal product under European Union regulatory systems, we must submit a marketing authorization application. The content of
the NDA or BLA filed in the United States is similar to that required in the European Union, with the exception of, among other
things, country-specific document requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">For other countries outside of the European
Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product licensing, pricing, and
reimbursement vary from country to country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Countries that are part of the European Union,
as well as countries outside of the European Union, have their own governing bodies, requirements, and processes with respect
to the approval of pharmaceutical products. If we fail to comply with applicable foreign regulatory requirements, we may be subject
to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating
restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Authorization Procedures in the European Union</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Medicines can be authorized in the European
Union by using either the centralized authorization procedure or national authorization procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Centralized procedure.</I>&nbsp;&nbsp;The EMA implemented
                                         the centralized procedure for the approval of human medicines to facilitate marketing
                                         authorizations that are valid throughout the EEA which is comprised of the 28 member
                                         states of the European Union plus Norway, Iceland, and Lichtenstein. This procedure results
                                         in a single marketing authorization issued by the EMA that is valid across the EEA. The
                                         centralized procedure is compulsory for human medicines that are: derived from biotechnology
                                         processes, such as genetic engineering, contain a new active substance indicated for
                                         the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative
                                         disorders or autoimmune diseases and other immune dysfunctions, and officially designated
                                         orphan medicines.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>For medicines that do not fall within these categories,
                                         an applicant has the option of submitting an application for a centralized marketing
                                         authorization to the European Commission following a favorable opinion by the EMA, as
                                         long as the medicine concerned is a significant therapeutic, scientific or technical
                                         innovation, or if its authorization would be in the interest of public health.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>National authorization procedures</I>.&nbsp;&nbsp;There
                                         are also two other possible routes to authorize medicinal products in several European
                                         Union countries, which are available for investigational medicinal products that fall
                                         outside the scope of the centralized procedure:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Decentralized procedure</I>.&nbsp;&nbsp;Using the decentralized
                                         procedure, an applicant may apply for simultaneous authorization in more than one European
                                         Union country of medicinal products that have not yet been authorized in any European
                                         Union country and that do not fall within the mandatory scope of the centralized procedure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Mutual recognition procedure.</I>&nbsp;&nbsp;In the
                                         mutual recognition procedure, a medicine is first authorized in one European Union Member
                                         State, in accordance with the national procedures of that country. Following this, further
                                         marketing authorizations can be sought from other European Union countries in a procedure
                                         whereby the countries concerned agree to recognize the validity of the original, national
                                         marketing authorization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In some cases, a Pediatric Investigation Plan,
or PIP, and/or a request for waiver or deferral, is required for submission prior to submitting a marketing authorization application.
A PIP describes, among other things, proposed pediatric studies and their timing relative to clinical studies in adults.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>New Chemical Entity Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the European Union, new chemical entities,
sometimes referred to as new active substances, qualify for eight years of data exclusivity upon marketing authorization and an
additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European
Union from referencing the innovator&rsquo;s data to assess a generic (abbreviated) application for eight years, after which generic
marketing authorization can be submitted, and the innovator&rsquo;s data may be referenced, but not approved for two years. The
overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the
marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific
evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Orphan Designation and Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the European Union, the EMA&rsquo;s COMP
grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment
of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the European Union Community
and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant
benefit to those affected). Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment
of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that
sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the European Union, orphan drug designation
entitles a party to financial incentives such as reduction of fees or fee waivers and 10 years of market exclusivity is granted
following medicinal product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer
met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Orphan drug designation must be requested before
submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration
of, the regulatory review and approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Exceptional Circumstances/Conditional Approval</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Orphan drugs or drugs with unmet medical needs
may be eligible for European Union approval under exceptional circumstances or with conditional approval. Approval under exceptional
circumstances is applicable to orphan products and is used when an applicant is unable to provide comprehensive data on the efficacy
and safety under normal conditions of use because the indication for which the product is intended is encountered so rarely that
the applicant cannot reasonably be expected to provide comprehensive evidence, when the present state of scientific knowledge
does not allow comprehensive information to be provided, or when it is medically unethical to collect such information. Conditional
marketing authorization is applicable to orphan medicinal products, medicinal products for seriously debilitating or life-threatening
diseases, or medicinal products to be used in emergency situations in response to recognized public threats. Conditional marketing
authorization can be granted on the basis of less complete data than is normally required in order to meet unmet medical needs
and in the interest of public health, provided the risk-benefit balance is positive, it is likely that the applicant will be able
to provide the comprehensive clinical data, and unmet medical needs will be fulfilled. Conditional marketing authorization is
subject to certain specific obligations to be reviewed annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Accelerated Review</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Centralized Procedure in the European
Union, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when
additional written or oral information is to be provided by the applicant in response to questions asked by the EMA&rsquo;s Committee
for Medicinal Products for Human Use, or CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when
a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation.
In this circumstance, EMA ensures that the opinion of the CHMP is given within 150 days, excluding clock stops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Pharmaceutical Coverage, Pricing and Reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Significant uncertainty exists as to the coverage
and reimbursement status of any drug products for which we obtain regulatory approval. In the United States and markets in other
countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability
of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers,
private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug
product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party
payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved
drugs for a particular indication. Moreover, a payor&rsquo;s decision to provide coverage for a drug product does not imply that
an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain
price levels sufficient to realize an appropriate return on our investment in product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Third-party payors are increasingly challenging
the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety
and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct
expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition
to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective.
If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover
the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow
a company to sell its products at a profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The U.S. government, state legislatures and
foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid
health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products
for branded prescription drugs. By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act, collectively, the Healthcare Reform Law, contains provisions that may reduce the profitability
of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates
to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical
companies&rsquo; share of sales to federal health care programs. Adoption of government controls and measures, and tightening
of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the European Community, governments influence
the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems
that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems
under which products may only be marketed once a reimbursement price has been agreed to by the government. To obtain reimbursement
or pricing approval, some of these countries may require the completion of clinical studies that compare the cost-effectiveness
of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices
for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription
drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition,
in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The marketability of any products for which
we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate
coverage and reimbursement. In addition, an increasing emphasis on cost containment measures in the United States and other countries
has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party
reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products
for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Other Healthcare Laws and Compliance Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If we obtain regulatory approval for any of
our product candidates, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry.
These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject
to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may
affect our ability to operate include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the federal Anti-Kickback Statute, which prohibits, among
                                         other things, persons from knowingly and willfully soliciting, receiving, offering or
                                         paying remuneration, directly or indirectly, to induce, or in return for, the purchase
                                         or recommendation of an item or service reimbursable under a federal healthcare program,
                                         such as the Medicare and Medicaid programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>federal civil and criminal false claims laws and civil
                                         monetary penalty laws, which prohibit, among other things, individuals or entities from
                                         knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid,
                                         or other third-party payers that are false or fraudulent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>HIPAA, which created new federal criminal statutes that
                                         prohibit executing a scheme to defraud any healthcare benefit program and making false
                                         statements relating to healthcare matters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the federal transparency laws, including the federal Physician
                                         Payment Sunshine Act, that requires drug manufacturers to disclose payments and other
                                         transfers of value provided to physicians and teaching hospitals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>HIPAA, as amended by HITECH, and its implementing regulations,
                                         which imposes certain requirements relating to the privacy, security and transmission
                                         of individually identifiable health information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>state law equivalents of each of the above federal laws,
                                         such as anti-kickback and false claims laws which may apply to items or services reimbursed
                                         by any third-party payer, including commercial insurers, and state laws governing the
                                         privacy and security of health information in certain circumstances, many of which differ
                                         from each other in significant ways and may not have the same effect, thus complicating
                                         compliance efforts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Healthcare Reform Law broadened the reach
of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the
applicable criminal healthcare fraud statutes contained within 42 U.S.C. &sect;1320a-7b, effective March 23, 2010. Pursuant to
the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate
it in order to have committed a violation. In addition, the Healthcare Reform Law provides that the government may assert that
a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute. Many states have adopted
laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services
reimbursed by any source, not only the Medicare and Medicaid programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are also subject to the FCPA, which prohibits
improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Safeguards we implement to discourage improper
payments or offers of payments by our employees, consultants, and others may be ineffective, and violations of the FCPA and similar
laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely
harm our reputation, business, financial condition and result of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If our operations are found to be in violation
of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including
civil and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and
imprisonment, damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability
to operate our business and our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Labeling, Marketing and Promotion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The FDA closely regulates the labeling, marketing
and promotion of drugs. While doctors are free to prescribe any drug approved by the FDA for any use, a company can only make
claims relating to safety and efficacy of a drug that are consistent with FDA approval, and the company is allowed to actively
market a drug only for the particular use and treatment approved by the FDA. In addition, any claims we make for our products
in advertising or promotion must be appropriately balanced with important safety information and otherwise be adequately substantiated.
Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, injunctions
and potential civil and criminal penalties. Government regulators recently have increased their scrutiny of the promotion and
marketing of drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Pediatric Research Equity Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Pediatric Research Equity Act, or PREA,
amended the FDCA to authorize the FDA to require certain research into drugs used in pediatric patients. The intent of PREA is
to compel sponsors whose drugs have pediatric applicability to study those drugs in pediatric populations, rather than ignoring
pediatric indications for adult indications that could be more economically desirable. The Secretary of Health and Human Services
may defer or waive these requirements under specified circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Anti-Kickback and False Claims Laws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the United States, the research, manufacturing,
distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal,
state and local authorities in addition to the FDA, including the Centers for Medicare &amp; Medicaid Services, other divisions
of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state
Attorneys General, and other state and local government agencies. For example, sales, marketing and scientific/educational grant
programs must comply with the Anti-Kickback Statute, the False Claims Act, as amended, the privacy regulations promulgated under
HIPAA and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the
Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made
available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements
apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the United States, we are subject to complex
laws and regulations pertaining to healthcare &ldquo;fraud and abuse,&rdquo; including, but not limited to, the Anti-Kickback
Statute, the federal False Claims Act, and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal
for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit,
receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or
prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The federal False Claims Act prohibits anyone
from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims
for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or
claims for medically unnecessary items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">There are also an increasing number of state
laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities
as to what is required to comply with the laws. In addition, a similar federal requirement will require manufacturers to track
and report to the federal government certain payments made to physicians and teaching hospitals made in the previous calendar
year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens
on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could
be subject to the penalty provisions of the pertinent state, and soon federal, authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Patient Protection and Affordable Health Care Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In March 2010, the Patient Protection and Affordable
Health Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively PPACA, was enacted, which
includes measures that have or will significantly change the way health care is financed by both governmental and private insurers.
The fees, discounts and other provisions of this law are expected to have a significant negative effect on the profitability of
pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Many of the details regarding the implementation
of PPACA are yet to be determined, and at this time, it remains unclear the full effect that PPACA would have on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Other Regulations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are also subject to numerous federal, state
and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard
control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws
and regulations now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Clinical Testing in Israel</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In order to conduct clinical testing on humans in the State of
Israel, special authorization must first be obtained from the ethics committee and general manager of the institution in which
the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented
pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), as amended from time to time, and other
applicable legislation. These regulations require authorization by the institutional ethics committee and general manager as well
as from the Israeli Ministry of Health, except in certain circumstances, and in the case of genetic trials, special fertility
trials and complex clinical trials, an additional authorization of the Ministry of Health&rsquo;s overseeing ethics committee.
The institutional ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived from
the project to determine if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee
must ensure that adequate protection exists for the rights and safety of the participants as well as the accuracy of the information
gathered in the course of the clinical testing. Since we perform a portion of the clinical studies on certain of our therapeutic
candidates in Israel, we are required to obtain authorization from the ethics committee and general manager of each institution
in which we intend to conduct our clinical trials, and in most cases, from the Israeli Ministry of Health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.C.</B></TD><TD><B>Organizational structure</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">Our sole wholly owned subsidiary is BioBlast
Pharma, Inc., incorporated in Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.D.</B></TD><TD STYLE="text-align: left"><B>Property, plants and equipment</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our headquarters is currently located in Tel
Aviv, Israel and consists of approximately 3,390 square feet of leased office space under a lease for a period of three years
with an option to extend the lease period for two additional consecutive three-year periods. We may require additional space and
facilities as our business expands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">We consider that our current office space
is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>ITEM&nbsp;4A.</B></TD><TD STYLE="text-align: left"><B><A NAME="a_006"></A>UNRESOLVED STAFF COMMENTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>ITEM&nbsp;5.</B></TD><TD STYLE="text-align: left"><B><A NAME="a_007"></A>OPERATING AND FINANCIAL
                                         REVIEW AND PROSPECTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are a development-stage biopharmaceutical
company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare
genetic and metabolic diseases. We seek to identify therapeutic platforms that offer solutions for several diseases that share
a common pathophysiological mechanism. We focus on diseases with severe and debilitating manifestations, where the unmet medical
need is clear, the biological mechanism of action is understood and for which there is no satisfactory treatment. Since our inception
in 2012, we have developed and in-licensed potential treatments for six diseases, one of which is in a Phase 2/3 clinical trial
which, if the results are positive, we believe could be a pivotal trial, another one which is in Phase 2 clinical studies and
an additional one of which we expect will be in mid/late stage clinical studies by 2015. We believe, based on discussions with
the FDA, that if the Phase 2/3 trial shows positive results, the data could be considered pivotal data, considering, among other
things, the applicable FDA guidance for the industry called &ldquo;Providing Clinical Evidence of Effectiveness for Human Drug
and Biological Products.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our current drug candidate pipeline has been
either in-licensed from academic institutions or developed internally. Our strategy is based on risk diversification through multiple
therapeutic platforms, diversified clinical and pre-clinical stages of our programs, and diversified diseases addressed. We use
strict selection criteria of our pipeline platforms and cost-efficient drug development. This allows us to pursue multiple programs
in parallel with the goal of promptly delivering safe and effective therapies to patients in dire need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">To date, we have not generated revenue from
the sale of any product, and we do not expect to generate significant revenue unless and until we obtain marketing approval of,
and commercialize our product candidates. As of December 31, 2014, we had an accumulated deficit of $8.4 million. Our financing
activities are described below under &ldquo;Liquidity and Capital Resources.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Operating Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our current operating expenses consist of two
components&nbsp;&mdash;&nbsp;research and development expenses, and general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our research and development expenses consist
primarily of the cost of third party clinical consultants and expenses related to conducting clinical and preclinical trials,
salaries and related personnel expenses, share-based compensation expenses, travel expenses and other related research and development
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">The following table discloses the breakdown
of research and development expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: justify">(in thousands of U.S. dollars)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify">Cost of third party clinical consultants and expenses related to conducting clinical
    trials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,697</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">470</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Salaries and related personnel expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">561</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Travel expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">21</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">16</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">23</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">4,441</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">732</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">140</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We expect that our research and development
expenses will materially increase as we plan to initiate additional clinical activity for our product candidates and prepare to
conduct clinical trials in the near future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">General and administrative expenses consist
primarily of salaries, share-based compensation expense, professional service fees for accounting, legal, bookkeeping, intellectual
property and facilities, travel expenses and other general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">The following table discloses
the breakdown of general and administrative expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: justify; border-bottom: Black 1pt solid">(in thousands of U.S.
    dollars)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify">Share-based compensation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">654</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">210</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Professional services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Intellectual property expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Rent and office related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Salaries and related personnel expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Travel expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">92</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">8</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 9pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">2,639</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">416</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">86</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Comparison of the Year ended December 31,
2014 to the Year Ended December&nbsp;31, 2013 to the Year Ended December&nbsp;31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Results of Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid">(in thousands of U.S. dollars)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,441</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">732</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">140</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,639</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">226</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Financial Expense (income), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Deemed dividend</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">26</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 2.5pt">Loss attributable to holders of Ordinary Shares</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">7,022</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,171</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">229</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our research and development expenses for the
year ended December 31, 2014 amounted to $4,441,000, representing an increase of $3,709,000, or 507%, compared to $732,000 for
the year ended December 31, 2013. The increase was primarily attributable to an increase in third party clinical consultants expenses
and expenses related to conducting clinical trials in an amount of $3,227,000, an increase of $390,000 in salaries and related
personnel expenses, reflecting an increase in the number of employees and salary increases and an increase of $39,000 in share
based compensation expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our research and development expenses for the
year ended December 31, 2013 amounted to $732,000, representing an increase of $592,000, or 423%, compared to $140,000 for the
year ended December 31, 2012. The increase was primarily attributable to an increase of expenses related to third party preclinical
consultants and other expenses related to conducting preclinical trials in an amount of $395,000 and to an increase of salaries
and related personnel expenses in an amount of $137,000, reflecting an increase in the number of employees engaged in research
and development related activities from one to three, as well as an increase of stock-based compensation expenses of $44,000 in
2013 from $0 in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and development expenses by
project</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">(in thousands of U.S. dollars)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.9pt; padding-left: 9.9pt">Cabaletta projects:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-indent: -9.9pt; padding-left: 9.9pt">OPMD</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,865</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">407</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9.9pt; padding-left: 9.9pt">SCA3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">141</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.9pt; padding-left: 9.9pt">SBMA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">mPRT projects:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.9pt; padding-left: 9.9pt">Freiedrich&rsquo;s Ataxia</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.9pt; padding-left: 9.9pt">OTC def</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9.9pt; padding-left: 9.9pt">Read-through project:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9.9pt; padding-left: 9.9pt">SMA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt; padding-bottom: 1pt">Other costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">347</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">47</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">3,697</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">732</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">140</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our research and development expense is highly
dependent on the development phases of our projects and therefore fluctuates highly from year to year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The variances in expense between the year ended
December 31, 2014 and the corresponding period in 2013 and 2012 are mainly due to the following projects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Cabaleta projects</I>.&nbsp;&nbsp;Our expenses related
                                         to OPMD, SCA3 and SBMA for the year ended December 31, 2014 amounted to $1,865,000, $141,000
                                         and $2,000, respectively, compared to $407,000, $39,000 and $22,000, respectively, for
                                         the year ended December 31, 2013. These projects were initiated in 2013; therefore, there
                                         were no expenses in 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>mPRT projects</I>.&nbsp;&nbsp;Our expenses related to
                                         Freiedrich&rsquo;s Ataxia and OTC def for the year ended December 31, 2014 amounted to
                                         $276,000 and $59,000, respectively, compared to $75,000 and $94,000, respectively, for
                                         the year ended December 31, 2013, and $64,000 and $64,000, respectively, for the year
                                         ended December 31, 2012. The increase in 2014 was primarily attributable to growth in
                                         the preclinical trials and activities, and the increase in 2013 was primarily attributable
                                         to an increase in the number of employees involved in these projects from one to two
                                         and to an increase in the activity in these projects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD><I>Read-through project</I>.&nbsp;&nbsp;Our expenses related
                                         to SMA for the year ended December 31, 2014 amounted to $1,007,000, compared to $48,000
                                         for the year ended December 31, 2013, and $12,000 for the year ended December 31, 2012.
                                         The increase in 2014 was primarily attributable to growth in the preclinical trials and
                                         chemistry manufacturing control activities, and the increase in 2013 was primarily attributable
                                         to an increase in the number of employees involved in this project from one to two and
                                         to the initiation of pre-clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>General and administrative expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our general and administrative expenses totaled
$2,639,000 for the year ended December 31, 2014, an increase of $2,223,000, or 534%, compared to $416,000 for the year ended December
31, 2013. The increase resulted primarily from an increase of $444,000 in share-based compensation expenses, an increase of payroll
in an amount of $552,000, reflecting an increase of payroll to our employees, an increase of $191,000 in intellectual property
expenses, reflecting the progress in our IP portfolio, including the grant of a new patent application and the submission of an
additional patent application, an increase of $345,000 in rent and office related expenses, primarily due to the our new offices,
communication and information technology systems, and an increase of $507,000 in professional services for accounting, legal,
bookkeeping, transfer agents and facilities, which increased after our August 2014 initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our general and administrative expenses totaled
$416,000 for the year ended December 31, 2013, an increase of $330,000, or 384%, compared to $86,000 for the year ended December
31, 2012. The increase resulted primarily from an increase of $201,000 in share-based compensation expenses, an increase of payroll
in an amount of $48,000, reflecting an increase of payroll to our employees, and an increase of $2,000 in professional services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Operating loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">As a result of the foregoing, our operating
loss for the year ended December 31, 2014 was $7,080,000, as compared to an operating loss of $1,148,000 for the year ended December
31, 2013, an increase of $5,932,000, or 517%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our operating loss for the year ended December
31, 2013 was $1,148,000, as compared to an operating loss of $226,000 for the year ended December 31, 2012, an increase of $922,000,
or 408%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Financial expense and income</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Financial expense and income consist of bank
fees and other transactional costs and exchange rate differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We recognized financial income of $58,000 for
the year ended December 31, 2014, compared to financial income of $3,000 for the year ended December 31, 2013. The increase is
primarily due to interest on bank deposits, offset by exchange rate differences during 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We recognized financial income of $3,000 for
the year ended December 31, 2013, compared to financial expenses of $3,000 for the year ended December 31, 2012. The increase
is primarily due to interest on bank deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">As a result of the foregoing, our loss for the
year ended December 31, 2014 was $7,022,000, as compared to $1,145,000 for the year ended December 31, 2013, an increase of $5,877,000
or 513%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our loss for the year ended December 31, 2013
was $1,145,000, as compared to $229,000 for the year ended December 31, 2012, an increase of $916,000 or 400%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Critical Accounting Policies and Estimate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We describe our significant accounting policies
more fully in Note 2b to our financial statements for the year ended December 31, 2014. We believe that the accounting policy
below is critical in order to fully understand and evaluate our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We prepare our financial statements in accordance
with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of the financial statements
in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. Our management believes that the
estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates,
judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could
differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Stock-Based Compensation and Fair Value of Ordinary Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We account for stock-based compensation in accordance
with ASC 718, &ldquo;Compensation&nbsp;&mdash;&nbsp;Stock Compensation,&rdquo;, or ASC 718, which requires companies to estimate
the fair values of equity-based payments awards on the date of grant using an option-pricing model. The value of the stock options
is recognized as an expense over the requisite service periods in our statement of operations. We recognize compensation expenses
for the value of our awards granted based on the accelerated method over the requisite service period of each of the awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We selected the Black-Scholes-Merton, or Black-Scholes,
option-pricing model as a fair value method for our options awards. The option-pricing model requires a number of assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt"><I>Expected dividend yield</I> -
The expected dividend yield assumption is based on our historical experience and expectation of no future dividend payouts. We
have historically not paid cash dividends and have no foreseeable plans to pay cash dividends in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt"><I>Volatility - </I>Since the Company&rsquo;s
shares started trading on a stock exchange market only in July 2014, quoted prices data of our Ordinary Shares is limited. According
to ASC 718-10-30-20, in case of insufficient historical data for a company, the expected volatility was based on similar companies'
stock volatility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt"><I>Risk free interest rate </I>-
The risk free interest rate is based on the yield of U.S. Treasury bonds with equivalent terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt"><I>Expected term</I> - ASC 718 provides
the factors to consider when estimating the expected term of an option: An option&rsquo;s expected term must at least include
the vesting period and the employees&rsquo; historical exercise and post-vesting employment termination behavior for similar grants.
It also determines that if the amount of past exercise data is limited, that data may not represent a sufficiently large sample
on which to base a robust conclusion on expected exercise behavior. In that circumstance, it may be appropriate to consider external
data or the SEC staff&rsquo;s &ldquo;simplified&rdquo; method for the expected term. Accordingly, we used the &quot;simplified&quot;
method, meaning the expected life is set as the average of the vesting period for each vested tranche of options and the contractual
term for those options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt"><I>Share price </I>&ndash; Up until
our initial public offering, because there had been no public market for our Ordinary Shares, the fair value of the Ordinary Shares
underlying the options had been determined by our management, using the assistance of an independent valuation firm. Following
our initial public offering, fair market value has been determined by NASDAQ Global Market quotes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt">Options granted during 2014 were
mostly granted at the initial public offering price or the last known closing price of our Ordinary Shares at the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-indent: 0.8pt">During 2014, our Board of approved
the grant by us of options to purchase 380,222 of our Ordinary Shares, subject to the terms and condition of our 2013 Incentive
Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Since our inception through December 31, 2014,
we have funded our operations principally with $38 million from the issuance of Ordinary Shares and preferred shares. As of December
31, 2014, we had $10.6 million in cash and cash equivalents, and an additional amount of $22 million in short-term bank deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The table below presents our cash flows for
the years 2014, 2013 and 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(in thousands of U.S.
    dollars)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(4,409</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(865</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(149</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,063</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,785</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">991</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">295</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">146</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Net cash used in operating activities of $4.4
million during the year ended December 31, 2014 was primarily used for payment of $2.3 million for clinical trials and other third
party expenses and an aggregate of $1.2 million in salaries and related personnel expenses. The remaining amount of $0.9 million
was for (travel, patent, rent) and other miscellaneous expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Net cash used in operating activities of $0.9
million during the year ended December 31, 2013 was primarily used for payment of $0.6 million for clinical trials and other third
party expenses and an aggregate of $0.2 million in salaries and related personnel expenses. The remaining amount of $0.1 million
was for travel, patent, rent and other miscellaneous expenses. Net cash used in operating activities of $0.1 million during the
year ended December 31, 2012 was primarily used for salary payments and for clinical trials and other third party expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Net cash used in investing activities of $22.1
million during 2014 primarily reflected investments of our cash in short term bank deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Net cash used in investing activities during
2013 primarily reflected an increase in property and equipment. In 2012, we had no investment activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Net cash provided by financing activities in
the year ended December 31, 2014 consisted of approximately $36.8 million of net proceeds from issuance of Ordinary Shares. Net
cash provided by financing activities in the year ended December 31, 2013 consisted of approximately $1 million of net proceeds
from issuance of Ordinary Shares. Net cash provided by financing activities in the year ended December 31, 2012 consisted of approximately
$0.3 million of net proceeds from issuance of Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Current Outlook</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We have financed our operations to date primarily
through proceeds from sales of our Ordinary Shares and preferred shares. We have incurred losses and generated negative cash flows
from operations since inception. To date, we have not generated any revenue from the sale of products and we do not expect to
generate revenues from sale of our products in the next few years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">As of December 31, 2014, our cash and cash equivalents
including short-term bank deposits were $32.6 million. We expect that our existing cash, cash equivalents and short-term bank
deposits will be sufficient to fund our current operations until the end of 2016 or early 2017; however, we expect that we will
require substantial additional capital to obtain regulatory approval for, and to commercialize, our product candidates. In addition,
our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional
funds sooner than planned. Our future capital requirements will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the progress and costs of our preclinical studies, clinical
                                         trials and other research and development activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the costs of manufacturing of our drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the scope, prioritization and number of our clinical trials
                                         and other research and development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the costs and timing of obtaining regulatory approval for
                                         our drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the costs of filing, prosecuting, enforcing and defending
                                         patent claims and other intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the costs of, and timing for, strengthening our manufacturing
                                         agreements for production of sufficient clinical and commercial quantities of our drug
                                         candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the potential costs of contracting with third parties to
                                         provide marketing and distribution services for us or for building such capacities internally;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the costs of acquiring or undertaking the development and
                                         commercialization efforts for additional, future therapeutic applications of our drug
                                         candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the magnitude of our general and administrative expenses;
                                         and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>any cost that we may incur under current and future in-
                                         and out-licensing arrangements relating to our drug candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Until we can generate significant recurring
revenues, we expect to satisfy our future cash needs through debt or equity financings, or by out-licensing applications of our
drug candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds
are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization
efforts with respect to, one or more applications of our drug candidates. This may raise substantial doubts about our ability
to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.E</B></TD><TD><B>Off-Balance Sheet Arrangements</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">We currently do not have any off-balance sheet
arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.F</B></TD><TD><B>Contractual Obligations</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">The following table summarizes our contractual
obligations at December 31, 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Less than 1 <BR> year</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">1-3 years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">4-5 years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">More than 5 <BR> years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="18" NOWRAP STYLE="font-weight: bold; text-align: center">(in thousands of U.S. dollars)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Operating leases:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: justify">Facility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">288</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">117</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">171</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Motor vehicles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>ITEM&nbsp;6.</B></TD><TD STYLE="text-align: justify"><A NAME="a_008"></A><B>DIRECTORS, SENIOR
                                         MANAGEMENT AND EMPLOYEES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.A.</B></TD><TD STYLE="text-align: justify"><B>Directors and executive
                                         officers</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following table sets forth information regarding our executive officers, key employees and directors as of March 20, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 15.75pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 63%; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Fredric Price</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">69</TD>
    <TD>&nbsp;</TD>
    <TD>Executive Chairman of the Board of Directors</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Colin Foster</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">52</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Chief Executive Officer, President and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Dr. Dalia Megiddo</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">63</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Development Officer, Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ehud (Udi) Gilboa</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">48</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer, Senior Vice President of Operations and Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Prof. Avizohar Argov</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">67</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Chief Medical Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Michael Burshtine<SUP>(1)(2)</SUP></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">51</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Gili Cohen<SUP>(1)(2)</SUP></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">48</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Marlene Haffner</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">74</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Isaac Krymolowski<SUP>(1)(2)</SUP></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">52</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ran Nussbaum</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">42</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 15.75pt">(1)</TD><TD>Member of our Audit Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 15.75pt">(2)</TD><TD>Member of our Compensation Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Fredric Price</I>&nbsp;has been Executive
Chairman of our Board of Directors since April 2014, having served as our Chairman of the Board of Directors from April 2012 until
April 2014. Since 2013, Mr. Price has served as a member of the Advisory Board of FDNA Inc. From 2013 until 2014, he was Executive
Chairman of the Board of Directors and from 2008 to 2013 Chairman of the Board of Directors and Chief Executive Officer of Chiasma,
Inc. From 2004 to 2008, Mr. Price was Executive Chairman of the Board of Directors of Omrix Biopharmaceuticals, Inc., from 2006
to 2012 a member of the Board of Directors of Enobia Pharma Corp., from 2007 to 2010 a member of the Board of Directors of Pharmasset
Inc., from 2007 to 2011 Executive Chairman of the Board of Directors of Peptimmune, Inc., from 2004 to 2005 Executive Chairman
of the Board of Directors of Zymenex A/S, from 2000 to 2004 Chairman of the Board of Directors and Chief Executive Officer of
BioMarin Pharmaceutical Inc., and from 1994 to 2000 Chief Executive Officer and a member of the Board of Directors of Applied
Microbiology Inc. As chairman and/or chief executive officer, he has raised more than $600 million in a variety of securities
transactions, led a total of 21 M&amp;A and licensing transactions, built FDA approved facilities and had drugs approved in the
United States as well as in international markets. His earlier experience includes having been Vice President of Finance and administration
and Chief Financial Officer of Regeneron Pharmaceuticals, Inc., the founder of the strategy consulting firm RxFDP, and Vice President
of Pfizer Pharmaceuticals with both line and staff responsibilities. Mr. Price is a co-inventor of 13 issued U.S. patents. He
received a B.A. from Dartmouth College and an M.B.A. from the Wharton School of the University of Pennsylvania.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Colin Foster</I> has been our
President, Chief Executive Officer and a director since January 2015. Mr. Foster has extensive experience in leading
therapeutic, diagnostic, and medical device companies in the United States and internationally, working across the
R&amp;D-to-commercial continuum. He was a founder of iSci Management LLC, a life sciences advisory firm, and served as its
Chief Executive Officer from 2011 until 2015. In 2005, Mr. Foster co-founded Optherion, Inc., a venture backed biologics and
diagnostics company targeting ultra-orphan diseases of the immune system and age-related macular degeneration, and served as
its Chief Executive Officer from 2006 until 2012. Prior to that, and from 1994 until 2004, he held various senior executive
positions at Bayer AG, including President and Chief Executive Officer of Bayer Pharmaceuticals Corporation USA and Region
Head of the North American Pharmaceuticals business of Bayer AG. In 1988, Mr. Foster began his post-graduate career with
Sandoz Canada Inc. before embarking on an international career with Bayer in Canada, the USA, and Europe. Mr. Foster
currently serves as Chairman of Ivenix, Inc., and is a board member of Optherion, iSci Management LLC, and Vista Vocational
&amp; Life Skills Center. Mr. Foster has a B.Sc. in Zoology and Microbiology from the University of Toronto, and an M.B.A.
from Western University in Canada. He is also an active member of The Jackson Laboratory National Council and Jackson
Society.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Dr. Dalia Megiddo</I>&nbsp;has been a director
since our inception and currently serves as our Chief Development Officer. From our inception until February 2015, Dr. Megiddo
was our Chief Executive Officer. Dr. Megiddo co-founded Alcobra Ltd., a NASDAQ traded company primarily focused on the development
and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder in February 2008 and became
a Director at that time. She is an entrepreneur and a medical doctor in family medicine. Since 2000, she has been a manager of
InnoMed Ventures, an Israeli venture capital fund focused on life sciences. From 2006 to 2010, she was also a manager of 7 Health
Ventures, a Israeli venture capital fund. She is also the founder of a number of life science companies. Dr. Megiddo received
her M.D. degree from Hebrew University Hadassah Medical School and holds a specialist degree in Family Medicine, and also holds
an M.B.A. from the Kellogg-Recanati School of Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Udi Gilboa</I>&nbsp;has been a director,
our Chief Financial Officer and our Senior Vice President of Operations since our inception. In addition, Mr. Gilboa co-founded
Alcobra Ltd. in February 2008, became a director at that time and served as its Chief Financial Officer and Chief Accounting Officer
until May 2014. From 2007 until 2014, Mr. Gilboa served as a director of Insuline Medical Ltd., a public company whose shares
are listed for trading on the Tel Aviv Stock Exchange. Mr. Gilboa is the founder and managing partner of Top Notch Capital, a
prominent Israeli life sciences investment bank. He is a director of Samson Neurosciences Ltd., and has founded a number of medical
device and pharmaceutical companies. Mr. Gilboa holds a Bachelor&rsquo;s degree and M.B.A. from Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Prof. Avizohar Argov</I>&nbsp;has been our
Chief Medical Officer since June 1, 2014. Since 1991, Prof. Argov has been a professor of Neurology &amp; Josephine Frank Kanrich
Chair of Neuromuscular Diseases, Hadassah-Hebrew University Medical Center in Jerusalem, Israel, and since 1996, has been an adjunct
professor in the Department of Neurology/Neurosurgery at the Neurological Institute at McGill University in Montreal, Canada.
Since 2010, Prof. Argov has been a member of the executive committee of the World Muscle Society. From 2010 until 2011 he served
as the President of the European Neurological Society and the Chairman of its subcommittee of Muscle &amp; Neuromuscular Disorders.
In addition, he has served as the Chairman of the Israeli Society of Neuromuscular Diseases. Prof. Argov&rsquo;s primary research
fields include hereditary inclusion body myopathies, hereditary neuromuscular disorders, particularly in Jewish ethnic clusters,
and latrogenic neuromuscular disorders, particularly drug-induced myasthenia. He received his M.D. from the Hebrew University-Hadassah
Medical School in Jerusalem, Israel and was a Resident in Neurology at the Hadassah University Hospital in Jerusalem, Israel.
He received training in neuromuscular diseases from the Muscular Dystrophy Association in Newcastle Upon Tyne, England and further
training in biochemistry and biophysics from the University of Pennsylvania in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Michael Burshtine </I>has been a director
since October 30, 2014. Mr. Burshtine served as the president and Chief Executive Officer of Flight Medical Innovations Ltd.,
a med-tech company specializing in the development, manufacturing and marketing of portable ventilators, between 2009 and May
2014. Prior to that, between 2007 and 2009, he served as President and Chief Executive Officer of Recoly N.V., a bio-med company
engaged in the research, development and commercialization of drug enhancement technologies. From 2004 to 2007, he served as the
Chief Financial Officer of Omrix Biopharmaceuticals Inc., a public biotechnology company that develops, manufactures and commercializes
plasma derivative products. Mr. Burshtine has been a certified CPA since 1994 and was a senior partner at Kesselman &amp; Kesselman
PricewaternhouseCoopers (PWC) auditing firm, until 2004. He holds an M.B.A. and a B.A. in economics and accounting, both from
Tel Aviv University. Mr. Burshtine serves on our Audit Committee and our Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Gili Cohen</I>&nbsp;has been a director since
July 30, 2014. Mr. Cohen has been a member of the Board of Directors of Harel Pension Funds Management Ltd. and Harel Atidit Provident
Funds Ltd., which are both members of the Harel Insurance Investments and Financial Services Ltd. group, since March 2012. In
addition, Mr. Cohen has been a member of Israel Land Development Co. Ltd., which deals in real estate and investments, since June
2012. He also currently serves as an independent financial consultant and is an economics professor at The College of Management
Academic Studies. From 2000 to 2011, Mr. Cohen was the Chief Investments Officer and head of the Investments Department at Excellence
Investments Ltd. Mr. Cohen has a degree in economics and geography and an M.B.A., both with honors, from the Hebrew University
in Jerusalem. Mr. Cohen serves on our Audit Committee and our Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Dr. Marlene Haffner&nbsp;</I>has been a director
since July 1, 2013. From 1986 until 2007, Dr. Haffner served as the Director of the Office of Orphan Products Development (OOPD)
of the FDA. As OOPD Director she was responsible for the leadership and management of the FDA orphan products development program,
the first Orphan Products program in the world. After leaving the FDA, and from 2007 until 2009, she served as Executive Director,
Global Regulatory Policy and Intelligence at Amgen, Inc., and since 2009 has held the position of Chief Executive Officer at Orphan
Solutions and Haffner Associates, services companies for the Orphan Drugs industry. In addition to her consulting activities,
Since 2009, Dr. Haffner has been an Adjunct Professor at the Department of Preventive Medicine and Biometrics and a Clinical Professor
at the Department of Medicine of the F. Edward H&eacute;bert School of Medicine, Uniformed Services University of the Health Sciences
in Bethesda, Maryland. For 36 years she served in the United States Public Health Service beginning her career with the Indian
Health Service in Gallup, New Mexico. She received her M.D. from the George Washington University School of Medicine where she
then interned in Internal Medicine. She received further training in internal medicine, dermatology and hematology at the Presbyterian
Hospital, New York and at the Albert Einstein College of Medicine, New York. She received an M.P.H. from the Johns Hopkins University
Bloomberg School of Public Health. During her public health career, she rose to the rank of Rear Admiral in the United States
Public Health Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Isaac Krymolowski </I>has been a director
since October 30, 2014. Mr. Krymolowski&nbsp;served as the Chairman of the Board of directors of Solcon Industries Ltd., a company
focused on designing, developing and manufacturing industrial electronic systems from 2013 until 2015. From 2009 to 2011, he served
as the global head of consulting and research of DTZ PLC, a professional services firm focused on commercial real estate. Prior
to that, between 2006 and 2009, Mr. Krymolowski served as head of Barclays Group Strategy and Planning of Barclays PLC, a leading
international bank. From 2004 to 2006, he served as a principal at Booz Allen Hamilton, a global management consulting firm. He
holds an M.B.A. with distinction from Carnegie-Mellon University and a B.A. in Economics, cum laude, from Tel Aviv University.
Mr. Krymolowski serves on our Audit Committee and our Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><I>Ran Nussbaum</I>&nbsp;has been a director
since July 1, 2013. Mr. Nussbaum is a managing partner and the co-founder of The Pontifax Group, which established three funds
with over 30 portfolio companies. Over the past 10 years, Mr. Nussbaum has been co-managing The Pontifax Group. From 2006 to 2008
he also served as Chief Executive Officer of Biomedix Ltd. and Spearhead Ltd., as well as Chairman of the Board of Nasvax Ltd.
Mr. Nussbaum&rsquo;s experience in the life sciences arena coupled with a 10-year experience in the business intelligence field
creates a unique blend of skills, enabling him to support companies from inception to commercialization. Mr. Nussbaum also serves
on the Board of Directors of many of The Pontifax Group&rsquo;s portfolio companies including, Kite pharma Inc., c-CAM Ltd., Insuline
Ltd. (TASE: INSL), Eloxx Pharmaceuticals Ltd., Theracaot Ltd., CollPlant Ltd. (TASE: CLPT), Protab Ltd., Quiet Therapeutics Ltd.,
Fusimab Ltd. and as Chairman of the Board of Ocon Medical Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.B.</B></TD><TD><B>Compensation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">The table below reflects
the compensation granted to our five most highly compensated officers during or with respect to the year ended December 31, 2014.
All amounts reported in the table reflect the cost to the Company, in U.S. Dollars, as recognized in our financial statements
for the year ended December 31, 2014. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.58= U.S.$1.00,
based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel in
the year ended December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid">Name and Position</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Salary / Fees</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Share-Based<BR> Payment (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Bonus</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Fredric Price, <I>Executive Chairman of the Board of Directors</I> (2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">105,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">542,921</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">647,921</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dr. Dalia Megiddo, <I>Chief Development Officer</I> (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">200,432</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">290,432</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Udi Gilboa, <I>Chief Financial Officer, Senior Vice President of Operations</I> (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">119,926</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">269,926</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Professor Argov Avizohar, <I>Chief Medical Officer</I> (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">44,847</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27,949</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">97,618</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gili Cohen, <I>Director</I> (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,812</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,278</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18.05pt">(1)</TD><TD>Represents the equity-based compensation expenses recorded
                                         in the Company&rsquo;s financial statements for the year ended December 31, 2014 based
                                         on the options&rsquo; grant date fair value in accordance with accounting guidance for
                                         equity-based compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18.05pt">(2)</TD><TD>Mr. Price has been the Executive Chairman of the Board of
                                         Directors, since April, 2014, having served as our Chairman of the Board of Directors
                                         from April 2012 until April 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18.05pt">(3)</TD><TD>Until January 2015, Dr. Megiddo was the Company&rsquo;s Chief
                                         Executive Officer. Dr. Megiddo was engaged as a service provider during fiscal year 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18.05pt">(4)</TD><TD>Mr. Gilboa was engaged as a service provider during fiscal
                                         year 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18.05pt">(5)</TD><TD>Prof. Avizohar&rsquo;s engagement with the Company began in
                                         June 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18.05pt">(6)</TD><TD>Includes payment of mandatory and customary social benefits
                                         made by the Company on behalf of such officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18.05pt">(7)</TD><TD>Mr. Cohen&rsquo;s engagement with the Company began in April
                                         2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The aggregate amount of compensation paid or
accrued to all of our directors and executive officers as a group with respect to the year ended December&nbsp;31, 2014 was approximately
$0.79 million. The amount does not include business travel, relocation, professional and business association due and expenses
reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition, stock based compensation in the
amount of $0.56 million was accrued in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B><I>Employment Agreement with Mr. Colin Foster</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Through our wholly owned subsidiary, BioBlast
Pharma, Inc., we have entered into an employment agreement, dated January 29, 2015, with our Chief Executive Officer, Mr. Colin
Foster. Pursuant to the terms of his agreement, Mr. Foster is entitled to a gross annual salary of $380,000. Mr. Foster is further
entitled to participate in a benefits plan customary for chief executive officers in our industry. He is also entitled to a yearly
bonus payment based on achievement of performance goals as shall be annually determined by our Board of Directors, subject to
our Compensation Policy. The maximum bonus payable to Mr. Foster for fiscal year 2015 is an amount equal to 40% of his annual
gross salary. We granted Mr. Foster an aggregate of 498,067 options to purchase our Ordinary Shares at an exercise price of $8.47,
of which none have vested as of March 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B><I>Terms of Employment with Dalia Megiddo</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Pursuant to the terms of her employment, and
starting from January 29, 2015, our Chief Development Officer, Dr. Dalia Megiddo is entitled to a gross annual salary of $250,000.
Dr. Megiddo is further entitled to benefits that are provided for by Israeli law or that are customary for senior executives in
Israel, including the right to use (and all related fixed and variable costs in respect of) a leased car and cellular telephone.
Dr. Megiddo is entitled to company contributions of her gross monthly salary towards certain pension, severance, disability and
study funds. Dr. Megiddo is also entitled to a yearly bonus payment based on achievement of performance goals as shall be annually
determined by our Board of Directors, subject to our Compensation Policy. The maximum bonus payable to Dr. Megiddo for fiscal
year 2015 is an amount equal to 30% of her annual gross salary.&nbsp;In August 2014, Dr. Megiddo received, through her consulting
company, a special bonus of $90,000 in recognition of efforts and contribution to consummate our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B><I>Services Agreement with Udi Gilboa through
Top Notch Consultancy (2009) Ltd.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We have entered into an amended and restated
service agreement, dated April 22, 2014, with our Chief Financial Officer, Mr. Udi Gilboa, through his wholly-owned company Top
Notch Consultancy (2009) Ltd. for part time CFO services, effective as of August 1, 2013 and terminable by either party upon 60
days&rsquo; prior written notice, and contains provisions standard for a company in our industry regarding non-competition, confidentiality
of information and assignment of inventions. The monthly amount payable under the agreement is NIS 57,861 (approximately $12,857)
plus Value Added Tax (currently at 18%). In August 2014, Top Notch Consultancy (2009) Ltd. received a special bonus of $80,000
in recognition of efforts and contribution to consummate our initial public offering. In addition, Top Notch Consultancy is entitled
to an additional bonus of $70,000 with regards to services provided during 2014; such bonus was paid in 2015. In addition, effective
as of September 10, 2013, we entered into an agreement with Top Notch Consultancy (2009) Ltd. to provide us with office space
and services for a monthly fee of NIS 14,832 (approximately $4,250), plus Value Added Tax (currently at 18%). Either party may
terminate the agreement on 30-days' notice. The office space and services were terminated in September 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B><I>Engagement Letter with Fredric Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Fredric Price, our Executive Chairman of the
Board of Directors, has been appointed by us to our Board of Directors pursuant to an engagement letter agreement, effective April
24, 2012, as amended on April 22, 2014 and October 30, 2014. The annual amount payable under the agreement is $180,000 and may
be terminable by either party upon 30 days prior written notice. In April 2013, we granted Mr. Price options to purchase an aggregate
of 319,531 Ordinary Shares, at an exercise price of $0.0004 per share, all of which have vested as of March 30, 2015. In October
2014, we granted Mr. Price options to purchase an additional 206,702 Ordinary Shares at an exercise price of $11.00 per share,
which options vest over a period of four quarters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B><I>Engagement Letter with Marlene Haffner</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Marlene Haffner, one of our directors, has been
appointed to our Board of Directors pursuant to an engagement letter agreement, effective May 13, 2013, which is terminable by
either party upon 30 days&rsquo; prior written notice. We granted Mrs. Haffner an aggregate of 83,579 options to purchase our
Ordinary Shares, of which 55,719 have vested as of March 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We do not have written agreements with any director
providing for benefits upon the termination of his or her service to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In December 2012, an amendment to the Israeli
Companies Law, or Amendment 20, became effective, requiring companies to appoint a Compensation Committee. Our existing Compensation
Committee as detailed in Item 6.C. &ndash; &ldquo;Board Practices &ndash; Board Committees &ndash; Compensation Committee&rdquo;
below meets this requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Amendment 20 also requires us to adopt an office
holder compensation policy no later than nine months from our initial public offering that will set forth company policy, or the
Compensation Policy, regarding the terms of office and employment of office holders, including compensation, equity awards, severance
and other benefits, exemption from liability and indemnification, referred to as the Terms of Office and Employment. The term
&ldquo;office holder,&rdquo; as defined in the Israeli Companies Law, includes directors, executive officers and any manager directly
subordinate to the Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Compensation Policy must be approved by
the Board of Directors, after considering the recommendations of the Compensation Committee. The Compensation Policy must also
be approved by a majority of the company&rsquo;s shareholders, provided that (i)&nbsp;such majority includes at least a majority
of the shareholders who are not controlling shareholders and who do not have a personal interest in the matter, present and voting
(abstentions are disregarded), or (ii)&nbsp;the non-controlling shareholders and shareholders who do not have a personal interest
in the matter who were present and voted against the policy hold two percent or less of the voting power of the company. The Compensation
Policy must be approved by the Board of Directors and the shareholders every three years. If the Compensation Policy is not approved
by the shareholders, the Compensation Committee and the Board of Directors may nonetheless approve the policy, following further
discussion of the matter and for specified reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under Amendment 20, the &ldquo;Terms of Office
and Employment&rdquo; of office holders require the approval of the Compensation Committee and the Board of Directors. The Terms
of Office and Employment of directors and the Chief Executive Officer must also be approved by shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Changes to existing Terms of Office and Employment
of office holders (other than directors) can be made with the approval of the Compensation Committee only, if the committee determines
that the change is not substantially different from the existing terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under certain circumstances, the Compensation
Committee and the Board of Directors may approve an arrangement that deviates from the Compensation Policy, provided that such
arrangement is approved by the special majority of the company&rsquo;s shareholders mentioned above. Such shareholder approval
will also be required with respect to determining the Terms of Office and Employment of a director or the Chief Executive Officer
during the transition period until the company adopts a Compensation Policy. Notwithstanding the foregoing, a company may be exempted
from receiving shareholder approval with respect to the Terms of Office and Employment of a candidate for Chief Executive Officer
if such candidate meets certain independence criteria, the terms are in line with the Compensation Policy and the Compensation
Committee has determined for specified reasons that shareholder approval would prevent the engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law and related
regulations, the compensation payable to statutory independent directors and independent directors is subject to certain further
limitations.&nbsp;See Item 6.C. &ndash; &ldquo;Board Practices &ndash; External Directors&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.C.</B></TD><TD><B>Board practices</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Board Practices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Board of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, setting up
our policy and oversight over our business is vested in our Board of Directors. Our Board of Directors may exercise all powers
and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible
for our day-to-day management and have individual responsibilities established by our Board of Directors. Our Chief Executive
Officer is appointed by, and serves at the discretion of, our Board of Directors, subject to the employment agreement that we
have entered into with him. All other executive officers are appointed by our Chief Executive Officer, and are subject to the
terms of any applicable employment agreements that we may enter into with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under our articles of association, our Board
of Directors must consist of at least five and not more than eleven directors, including at least two external directors required
to be appointed under the Israeli Companies Law. Accordingly, at any time, the minimum number of directors (other than the external
directors) may not fall below three. Currently, our Board of Directors consists of eight directors, including two external directors.
We have only one class of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Other than external directors, for whom special
election requirements apply under the Israeli Companies Law as detailed below, our directors are each elected at a general meeting
of our shareholders and serve for a term of one year. Directors (other than external directors) shall nevertheless be removed
prior to the end of their term by the majority of our shareholders at a general meeting of our shareholders or upon the occurrence
of certain events, all in accordance with the Israeli Companies Law and our articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition, our articles of association allow
our Board of Directors to appoint directors, other than external directors, to fill vacancies on our Board of Directors, for a
term of office equal to the remaining period of the term of office of the directors whose offices have been vacated. External
directors are elected for an initial term of three years and may be elected for additional three-year terms under the circumstances
described below. External directors may be removed from office only under the limited circumstances set forth in the Israeli Companies
Law. See &ldquo;External Directors&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In accordance with the exemption available to
foreign private issuers under the Listing Rules of NASDAQ, we do not follow the NASDAQ requirements with regard to the process
of nominating directors, and instead, follow Israeli law and practice, in accordance with which our Board of Directors (or a committee
thereof, or a certain number of directors serving thereon) is authorized to recommend to our shareholders director nominees for
election. Under the Israeli Companies Law and our articles of association, nominations for directors may also be added to the
agenda of future general meetings, which has yet to have been summoned, upon the request of any one or more shareholders holding
at least one percent (1%) of our outstanding voting power. Furthermore, under the Israeli Companies Law either: (a)(i) two directors;
or (ii) no less than one quarter of the directors in office; or (b) one or more shareholders holding, in the aggregate, either
(i) 5% of our outstanding shares and 1% of our outstanding voting power; or (ii) 5% of our outstanding voting power, may request
the Board of Directors to call a general meeting in order to nominate one or more persons for election as directors at a special
meeting. However, any such shareholders may make such a nomination only if a written notice of such shareholder&rsquo;s intent
to make such nomination has been given to our Chairman of the Board of Directors (or, if we have no Chairman, our Chief Executive
Officer). Any such notice must include certain information we are required under the Israeli Companies Law to provide to our shareholders,
the consent of the proposed director nominee(s) to serve as our director(s) if elected and a declaration signed by the nominee(s)
declaring that there is no limitation under the Israeli Companies Law preventing their election and that all of the information
that is required under the Israeli Companies Law to be provided to us in connection with such election has been provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition to its role in making director nominations,
under the Israeli Companies Law, our Board of Directors must determine the minimum number of directors who are required to have
accounting and financial expertise. Under applicable regulations, a director with accounting and financial expertise is a director
who, by reason of his or her education, professional experience and skill, has a high level of proficiency in and understanding
of business accounting matters and financial statements, sufficient to be able to thoroughly comprehend our financial statements
and initiate debate regarding the manner in which financial information is presented. In determining the number of directors required
to have such expertise, our Board of Directors must consider, among other things, the type and size of our company and the scope
and complexity of its operations. Our Board of Directors has determined that our company requires one director with such expertise
and that Gili Cohen has such expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>External Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, the boards
of directors of companies whose shares are publicly traded, including companies with shares listed on the NASDAQ Global Market,
are required to include at least two members elected to serve as external directors. Accordingly, Gili Cohen and Isaac Krymolowski
have been elected to serve as external directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The definitions of an external director under
the Israeli Companies Law and independent director under the Listing Rules of NASDAQ are similar such that it would generally
be expected that our two external directors will also comply with the independence requirement under the Listing Rules of NASDAQ.
The definition of an external director includes a set of statutory criteria (which are described below) that must be satisfied
and for which the candidates must attest to the company, while the definition of an independent director requires a company&rsquo;s
Board of Directors to consider any factor which would impair the ability of a director to exercise independent judgment. In addition,
while external directors serve for a period of three years pursuant to the requirements of Israeli law, independent directors
serve for one year pursuant to the provisions of our articles of association. External directors must be elected by a special
majority of shareholders who are not controlling shareholders, while independent directors are elected by an ordinary majority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law provides that external
directors must be elected by a majority vote of the shares present and voting at a shareholders meeting, provided that either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the majority voted in favor of election includes a majority
                                         of the shares held by non-controlling shareholders who do not have a personal interest
                                         in the election of the external director (other than a personal interest not deriving
                                         from a relationship with a controlling shareholder) that are voted at the meeting, excluding
                                         for such purpose any abstentions, which we refer to as a disinterested majority; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>the total number of shares held by non-controlling disinterested
                                         shareholders (as described in the previous bullet-point) that voted against the election
                                         of the director does not exceed two percent (2%) of the aggregate voting rights in the
                                         company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The term controlling shareholder is defined
in the Israeli Companies Law as a shareholder with the ability to direct the activities of the company, other than by virtue of
being an office holder. A shareholder is in any case deemed to be a controlling shareholder if the shareholder holds 50% or more
of the means of control, which include the right to vote at a shareholders meeting and the right to appoint the directors of the
company or its general manager. In connection with approval of certain extraordinary and interested party transactions as well
as corporate approval of executive employment and compensation and private placements, by shareholders, any shareholder (or group
of shareholders having interest in the same matter being brought for approval) who hold(s) in the aggregate 25% or more of the
means of control if no other shareholder holds more than 50% of the voting rights, would be deemed a controlling shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">After an initial term of three years, external
directors may be reelected to serve in that capacity for up to two additional three year terms, provided that either (i) (1) his
or her service for each such additional term is recommended by one or more shareholders holding in aggregate at least one percent
(1%) of the company&rsquo;s voting rights and is approved at a shareholders meeting by a majority of the shares held by non-controlling
shareholders who do not have a personal interest in the election of the external director (other than a personal interest not
deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding for such purpose any abstentions,
where the total number of shares held by non-controlling, disinterested shareholders voting for such reelection exceeds two percent
(2%) of the aggregate voting rights in the company, and (2) the external director who has been nominated in such fashion by the
shareholders is not a linked or competing shareholder, and does not have or has not had, on or within the two years preceding
the date of such person&rsquo;s appointment to serve as another term as external director, any affiliation with a linked or competing
shareholder. The term &ldquo;linked or competing shareholder&rdquo; means the shareholder(s) who nominated the external director
for reappointment or a material shareholder of the company holding more than 5% of the shares in the company, provided that at
the time of the reappointment, such shareholder(s) of the company, the controlling shareholder of such shareholder(s) of the company,
or a company under such shareholder(s) of the company&rsquo;s control, has a business relationship with the company or are competitors
of the company; the Israeli Minister of Justice, in consultation with the Israeli Securities Authority, may determine that certain
matters will not constitute a business relationship or competition with the company; or (ii) his or her service for each such
additional term is recommended by the Board of Directors and is approved at a shareholders meeting by the same disinterested majority
required for the initial election of an external director (as described above). The term of office for external directors for
Israeli companies traded on certain foreign stock exchanges, including the NASDAQ Global Market, may be further extended, indefinitely,
in increments of additional three-year terms, in each case provided that, in addition to reelection in such manner described above,
(i) the Audit Committee and subsequently the Board of Directors of the company confirm that, in light of the external director&rsquo;s
expertise and special contribution to the work of the Board of Directors and its committees, the reelection for such additional
period is beneficial to the company, and (ii) prior to the approval of the reelection of the external director, the company&rsquo;s
shareholders have been informed of the term previously served by such nominee and of the reasons why the Board of Directors and
Audit Committee recommended the extension of such nominee&rsquo;s term. If an external director no longer complies with the applicable
requirements, the external director must notify the company, and his term shall terminate upon such notification. Furthermore,
where concerns regarding an external director's compliance with any requirements under Israeli Companies Law, or regarding an
external director's breach of any fiduciary duty, have been brought to the Board of Directors&rsquo; attention, the Board of Directors
is required to discuss such concerns in its following meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If the Board of Directors resolves that an external
director no longer complies with any requirement for qualification as an external director, or that such external director has
breached any fiduciary duty, a special general meeting shall be convened at which the termination of such external director's
service shall be included in the agenda.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If an external directorship becomes vacant and
there are less than two external directors on the Board of Directors at the time, then the Board of Directors is required under
the Israeli Companies Law to call a shareholders&rsquo; meeting as soon as possible to appoint a replacement external director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Each committee of the Board of Directors that
is authorized to exercise the powers of the Board of Directors must include at least one external director, except that the Audit
Committee and Compensation Committee must each include all external directors then serving on the board of directors. Under the
Israeli Companies Law, external directors of a company are prohibited from receiving, directly or indirectly, any compensation
for their services as external directors, other than compensation and reimbursement of expenses pursuant to applicable regulations
promulgated under the Israeli Companies Law. Compensation of an external director is determined prior to his or her appointment
and may not be changed during his or her term subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law provides that a person
is not qualified to serve as an external director if (i) the person is a relative of the controlling shareholder of the company,
or (ii) if that person or his or her relative, partner, employer, another person to whom he or she was directly or indirectly
subject, or any entity under the person&rsquo;s control, has or had, during the two years preceding the date of appointment as
an external director: (a) any affiliation or other prohibited relationship with the company, with any person or entity who is
a controlling shareholder of the company at the date of appointment or a relative of such person, or with any entity controlled,
during the two years preceding the date of appointment as an external director, by the company or a controlling shareholder of
the company; or (b) in the case of a company with no controlling shareholder, any affiliation or other prohibited relationship
with a person serving, at the date of appointment as external director, as Chairman of the Board of Directors, Chief Executive
Officer, a substantial shareholder or the most senior office holder in the company&rsquo;s finance department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The term relative is defined as a spouse, sibling,
parent, grandparent or descendant; spouse&rsquo;s sibling, parent or descendant; and the spouse of each of the foregoing persons.
The term affiliation and the similar types of prohibited relationships include (subject to certain exemptions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>an employment relationship;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>a business or professional relationship even if not maintained
                                         on a regular basis (excluding insignificant relationships);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>control; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>service as an office holder, excluding service as a director
                                         in a private company prior to the first offering of its shares to the public if such
                                         director was appointed as a director of the private company in order to be nominated
                                         to serve as an external director following the initial public offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The term office holder is defined under the
Israeli Companies Law as the general manager (Chief Executive Officer), chief business manager, deputy general manager, vice general
manager, any other person assuming the responsibilities of any of these positions regardless of that person&rsquo;s title, a director,
or a manager directly subordinate to the general manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition, no person may serve as an external
director if that person&rsquo;s position or professional or other activities create, or may create, a conflict of interest with
that person&rsquo;s responsibilities as a director or otherwise interfere with that person&rsquo;s ability to serve as an external
director or if the person is an employee of the Israel Securities Authority or of an Israeli stock exchange. A person may furthermore
not continue to serve as an external director if he or she received direct or indirect compensation for his or her role as a director,
other than compensation paid or given in accordance with Israeli Companies Law regulations or amounts paid pursuant to indemnification
and/or exculpation contracts or commitments and insurance coverage. Following the termination of an external director&rsquo;s
service on a Board of Directors, such former external director and his or her spouse and children may not be provided with direct
or indirect benefit by the company, its controlling shareholder or any entity under its controlling shareholder&rsquo;s control.
This includes appointment as an office holder of the company or a company controlled by its controlling shareholder, employment
as an employee, or receipt of professional services for consideration, either directly or indirectly, including through a corporation
in his or her control. These restrictions extend for a period of two years with regard to the former external director and his
or her spouse or child, and for one year with respect to other relatives of the former external director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If at the time at which an external director
is appointed all members of the Board of Directors, who are not controlling shareholders or relatives thereof, are of the same
gender, the external director must be of the other gender. A director of one company may not be appointed as an external director
of another company if a director of the other company is acting as an external director of the first company at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">According to the Israeli Companies Law, a person
may be appointed as an external director only if he or she has professional qualifications or if he or she has accounting and
financial expertise (each, as defined below). In addition, at least one of the external directors must be determined by our Board
of Directors to have accounting and financial expertise. However, if at least one of our other directors (i) meets the independence
requirements under the Exchange Act, (ii) meets the standards of the Listing Rules of NASDAQ for membership on the Audit Committee,
and (iii) has accounting and financial expertise as defined under Israeli law, then neither of our external directors is required
to possess accounting and financial expertise as long as both possess other requisite professional qualifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A director with accounting and financial expertise
is a director who, due to his or her education, experience and skills, possesses an expertise in, and an understanding of, financial
and accounting matters and financial statements, in such a manner which allows him or her to understand the financial statements
of the company and initiate a discussion about the presentation of financial data. A director is deemed to have professional qualifications
if he or she has any of (i) an academic degree in economics, business management, accounting, law or public service, (ii) an academic
degree or has completed other higher education, in the main field of business of the company or a field relevant for the position,
or (iii) at least five years of experience as one of the following, or at least five years accumulated experience as two or more
of the following&nbsp;&mdash;&nbsp;(a) a senior officer in the business management of a company with a significant volume of business,
(b) a senior public officer or senior position in the public service, and (c) a senior position in the company&rsquo;s main line
of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our Board of Directors has determined that both
Gili Cohen and Isaac Krymolowski have accounting and financial expertise as required under the Israeli Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Leadership Structure of the Board</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In accordance with the Israeli Companies Law
and our articles of association, our Board of Directors is required to appoint one of its members to serve as Chairman of the
Board of Directors. Our Board of Directors has appointed Fredric Price to serve as Executive Chairman of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Role of Board in Risk Oversight Process</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Risk assessment and oversight are an integral
part of our governance and management processes. Our Board of Directors encourages management to promote a culture that incorporates
risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational
risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include
a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the
Board of Directors at regular board meetings as part of management presentations that focus on particular business functions,
operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Audit Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, the Board of
Directors of a public company must appoint an Audit Committee. The Audit Committee must be comprised of at least three directors,
including all of the external directors, one of whom must serve as Chairman of the committee. The Audit Committee may not include
the Chairman of the Board of Directors, any director employed by or otherwise providing services on a regular basis to the company,
to a controlling shareholder or to any entity controlled by a controlling shareholder, any director whose main livelihood is dependent
on a controlling shareholder, nor a controlling shareholder or a relative thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, the Audit Committee
of a publicly traded company must consist of a majority of unaffiliated directors. An &ldquo;unaffiliated director&rdquo; is defined
as either an external director or as a director, classified as an &ldquo;unaffiliated director&rdquo; by the company, who meets
the following criteria:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>he or she meets the qualifications for being appointed
                                         as an external director, except for (i) the requirement that the director be an Israeli
                                         resident (which requirement does not, in any event, apply to external directors at public
                                         companies such as ours whose securities have been offered outside of Israel or are listed
                                         outside of Israel) and (ii) the requirement for accounting and financial expertise or
                                         professional qualifications with respect to the proposed unaffiliated director; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>he or she has not served as a director of the company for
                                         a period exceeding nine consecutive years. For this purpose, a break of less than two
                                         years in the service shall not be deemed to interrupt the continuation of the service.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our Audit Committee provides assistance to our
Board of Directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial
reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants
and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our Audit
Committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy
itself that the accountants are independent of management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, our Audit Committee
is responsible for (i) determining whether there are deficiencies in the business management practices of our company, including
in consultation with our internal auditor or the independent auditor, and making recommendations to the Board of Directors to
improve such practices and amend such deficiencies&nbsp;&mdash;&nbsp;where material deficiencies have been revealed, at least
one meeting of the Audit Committee is required to be convened, with the presence of our internal auditor or the independent auditor,
and without the presence of any members of the Board of Directors who are not members of the Audit Committee (unless their presence
is required for the purpose of presenting their position to matters under their responsibility); (ii) determining whether certain
related party transactions (including transactions in which an office holder has a personal interest) should be deemed as material
or extraordinary, and to approve such transactions (which may be approved according to certain criteria set out by our Audit Committee
on an annual basis) (see Item 16G. &ndash; &ldquo;Approval of Related Party Transactions under Israeli Law&rdquo;), (iii) to establish
procedures to be followed in respect of related party transactions with a controlling shareholder (where such are not extraordinary
transactions), which may include, where applicable, the establishment of a competitive process for such transaction, under the
supervision of the Audit Committee, or individual, or other committee or body selected by the Audit Committee, in accordance with
criteria determined by the Audit Committee; (iv) to determine procedures for approving certain related party transactions with
a controlling shareholder, which having been determined by the Audit Committee not to be extraordinary transactions, were also
determined by the Audit Committee not to be negligible transactions; (v) where the Board of Directors approves the working plan
of the internal auditor, to examine such working plan before its submission to the Board of Directors and propose amendments thereto,
(vi) examining our internal controls and internal auditor&rsquo;s performance, including whether the internal auditor has sufficient
resources and tools to dispose of its responsibilities, (vii) examining the scope of our auditor&rsquo;s work and compensation
and submitting a recommendation with respect thereto to our Board of Directors or shareholders, depending on which of them is
considering the appointment of our auditor, and (viii) establishing procedures for the handling of employees&rsquo; complaints
as to the management of our business and the protection to be provided to such employees. In compliance with regulations promulgated
under the Israeli Companies Law, our Audit Committee will also approve our financial statements, thereby fulfilling the requirement
that a board committee provides such approval. Our Audit Committee may not approve an action or a related party transaction, or
take any other action required under the Israeli Companies Law, unless at the time of approval a majority of the committee&rsquo;s
members are present, which majority consists of unaffiliated directors including at least one external director, and it further
complies with the committee composition set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Audit Committee &ndash; Charter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our Board of Directors has adopted an Audit
Committee charter setting forth the responsibilities of the Audit Committee consistent with the rules of the SEC and the Listing
Rules of NASDAQ, as well as subjecting the Audit Committee charter to the requirements under the Israeli Companies Law, as described
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>NASDAQ requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Listing Rules of NASDAQ, we are required
to maintain an Audit Committee consisting of at least three independent directors, all of whom are financially literate and one
of whom has accounting or related financial management expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 15pt; margin-right: 0; margin-left: 0">Our Audit Committee consists
of Mr. Isaac Krymolowski, who serves as the chairperson, Mr. Gili Cohen and Mr. Michael Burshtine. Our Board of Directors has
determined that Gili Cohen is an Audit Committee financial expert as defined by the SEC rules and has the requisite financial
experience as defined by the Listing Rules of NASDAQ. All of the members of our Audit Committee meet the requirements for financial
literacy under the applicable rules and regulations of the SEC and the Listing Rules of NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Each member of the Audit Committee is required
to be &ldquo;independent&rdquo; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act, which is different from the
general test for independence of board and committee members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Compensation Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We chose to rely upon the exemption available
to foreign private issuers under the Listing Rules of NASDAQ with respect to the determination of the compensation of our Chief
Executive Officer and other executive officers in lieu of forming a Compensation Committee consisting entirely of independent
directors (or the determination of such compensation solely by the independent members of our Board of Directors), and rather
form a Compensation Committee in compliance with the Israeli Companies Law. See Item 16G. &ndash; &ldquo;Corporate Governance.&rdquo;
However, all of the current members of our compensation committee are independent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, the Board of
Directors of a public company must appoint a Compensation Committee. The Compensation Committee must be comprised of at least
three directors, including all of the external directors, which shall be a majority of the members of the compensation committee
and one of whom must serve as Chairman of the committee. However, subject to certain exceptions, Israeli companies whose securities
are traded on stock exchanges such as NASDAQ, and who do not have a controlling party, do not have to meet this majority requirement;
provided, however, that the Compensation Committee meets other Israeli Companies Law composition requirements, as well as the
requirements of the non-Israeli jurisdiction where the company&rsquo;s securities are traded. Other than the external directors,
the rest of the members of the Compensation Committee shall be directors who will receive compensation for their role as directors
only in accordance with Israeli Companies Law regulations or amounts paid pursuant to indemnification and/or exculpation contracts
or commitments and insurance coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Compensation Committee may not include the
Chairman of the Board of Directors, any director employed by or otherwise providing services on a regular basis to the company,
to a controlling shareholder or to any entity controlled by a controlling shareholder, any director whose main livelihood is dependent
on a controlling shareholder, nor a controlling shareholder or a relative thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our Compensation Committee consists of Mr. Gili
Cohen, who serves as the chairperson of the committee, Mr. Michael Burshtine and Mr. Isaac Krymolowski.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, our Compensation
Committee is responsible for (i) proposing a Compensation Policy to the Board of Directors, (ii) propose necessary revisions to
the Compensation Policy and examine its implementation, (iii) determining whether to approve transactions with respect to the
terms of office and employment of office holders, and (iv) determining, in accordance with our Compensation Policy, whether to
exempt an engagement with an unaffiliated nominee for the position of Chief Executive Officer from requiring shareholders&rsquo;
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, our Compensation
Policy must generally serve as the basis for corporate approvals with respect to the financial terms of employment or engagement
of office holders, including exemption, insurance, indemnification or any monetary payment or obligation of payment in respect
of employment or engagement. The Compensation Policy must relate to certain factors, including advancement of the company&rsquo;s
objective, the company&rsquo;s business plan and its long term strategy, and creation of appropriate incentives for office holders.
It must also consider, among other things, the company&rsquo;s risk management, size and nature of its operations. The Compensation
Policy must furthermore consider the following additional factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>The knowledge, skills, expertise, and accomplishments of
                                         the relevant office holder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>The office holder&rsquo;s roles and responsibilities and
                                         prior compensation agreements with him or her;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>The relationship between the terms offered and the average
                                         and median compensation of the other employees of the company, including those employed
                                         through manpower companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>The impact of disparities in salary upon work relationships
                                         in the company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>The possibility of reducing variable compensation at the
                                         discretion of the Board of Directors; the possibility of setting a limit on the exercise
                                         value of non-cash variable equity-based compensation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>As to severance compensation, the period of service of
                                         the office holder, the terms of his or her compensation during such service period, the
                                         company&rsquo;s performance during that period of service, the person&rsquo;s contributions
                                         towards the company&rsquo;s achievement of its goals and the maximization of its profits,
                                         and the circumstances under which the person is leaving the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Compensation Policy must also include the
following principles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21pt">&bull;</TD><TD>the link between variable compensation and the long term performance
                                         and measurable criteria;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -21pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21pt">&bull;</TD><TD>the relationship between variable and fixed compensation,
                                         and the ceiling for the value of variable compensation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -21pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21pt">&bull;</TD><TD>the conditions under which an office holder would be required
                                         to repay compensation paid to him or her if it was later shown that the data upon which
                                         such compensation was based was inaccurate and was required to be restated in the company&rsquo;s
                                         financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -21pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21pt">&bull;</TD><TD>the minimum holding or vesting period for variable, equity-based
                                         compensation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -21pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21pt">&bull;</TD><TD>maximum limits for severance compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the amendment to the Israeli Companies
Law, we are required to adopt a Compensation Policy no later than nine months following our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Compensation Committee&nbsp;&mdash;&nbsp;Charter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our Board of Directors has adopted a Compensation
Committee Charter setting forth the responsibilities of the Compensation Committee, pursuant to the Israeli Companies Law, as
described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Nominating Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our Board of Directors does not currently have
a nominating committee, as director nominees are presented by our Board of Directors to our shareholders based upon the nominations
made by the Board of Directors itself. We currently rely upon the exemption available to foreign private issuers under the Listing
Rules of NASDAQ from the NASDAQ requirements related to independent director oversight of nominations to our Board of Directors
and the adoption of a formal written charter or board resolution addressing the nominations process. See Item 16G. &ndash; &ldquo;Corporate
Governance.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Other than with Gili Cohen, Isaac Krymolowski
and Michael Burshtine, we have service contracts or employment agreements with our directors, Colin Foster, Ehud Gilboa, Dr. Dalia
Megiddo, Fredric Price, Marlene Haffner and with Pontifax (Cayman) III Limited Partnership and Pontifax (Israel) III Limited Partnership,
who are affiliated with our director, Ran Nussbaum. All of the foregoing service contracts have been approved by our shareholders.
Please see Item 6.B. &ndash; &ldquo;Compensation&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Internal auditor</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, the Board of
directors of an Israeli public company must appoint an internal auditor recommended by the Audit Committee and nominated by the
Board of Directors. An internal auditor may not be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>a person (or a relative of a person) who holds more than
                                         5% of the company&rsquo;s outstanding shares or voting rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>a person (or a relative of a person) who has the power
                                         to appoint a director or the general manager of the company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>an office holder (including a director) of the company
                                         (or a relative thereof); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33.75pt; text-indent: -18.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 18.75pt">&bull;</TD><TD>a member of the company&rsquo;s independent accounting
                                         firm, or anyone on his or her behalf.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Guy Sapir from PriceWaterhouseCoopers (PWC)
Israel was appointed as our internal auditor. The role of the internal auditor is to examine, among other things, our compliance
with applicable law and orderly business procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.D.</B></TD><TD><B>Employees</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 14.2pt">As of March 30, 2015, our staff included 12
persons, comprised of 11 full time employees and one officer, who engaged with us as a service provider. Our management consists
of our Chief Executive Officer, our Chief Financial Officer, our Chief Development Officer, our Chief Medical Officer and our
VP Finance. We believe that we maintain good relations with all of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.E.</B></TD><TD><B>Share ownership</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">As of March 20, 2015, each of our executive
officers and directors, other than Mr. Price, Mr. Foster, Mr. Gilboa, Dr. Megiddo and Mr. Nussbaum, beneficially owned less than
1% of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">For information regarding the share ownership
of Mr. Gilboa, Dr. Megiddo and Mr. Nussbaum, see Item 7.A. &ldquo;Major Shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt">As of March 20, 2015, Mr. Price owns 131,752
Ordinary Shares, or approximately 1% of our outstanding Ordinary Shares. In addition, Mr. Price and Mr. Foster each own options
to purchase our Ordinary Shares as set forth in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt; color: #1F497D">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">NUMBER<BR> OUTSTANDING</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">EXERCISE PRICE <BR>
PER SHARE</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">EXPIRATION<BR> DATE</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Fredric Price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">319,531</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">0.0004</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 15%; text-align: center">April 2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206,702</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">October 2024</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Colin Foster</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">498,067</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">March 2025</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>2013 Incentive Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We maintain one equity incentive plan&nbsp;&mdash;&nbsp;our
2013 Incentive Option Plan, or our 2013 Plan. As of March 30, 2015, 30,269 Ordinary Shares remained available for issuance under
our 2013 Plan. In addition, options to purchase 1,325,399 Ordinary Shares were issued and outstanding. Of such outstanding options,
options to purchase 501,795 Ordinary Shares were vested as of that date, with a weighted average exercise price of $6.072 per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our 2013 Plan, which was adopted by our Board
of Directors on November 13, 2013, provides for the grant of options to our and our affiliates&rsquo; respective directors, employees,
office holders, service providers and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The 2013 Plan is administered by our Board of
Directors, which shall determine, subject to Israeli law, the grantees of awards and various terms of the grant. The 2013 Plan
provides for granting options in compliance with Section 102 of the Israeli Income Tax Ordinance, 1961, or the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Options granted under the 2013 Plan to Israeli
employees have been granted under the capital gains track of Section 102 of the Ordinance. Section 102 of the Ordinance allows
employees, directors and officers, who are not controlling shareholders and are considered Israeli residents, to receive favorable
tax treatment for compensation in the form of shares or options. Our Israeli non-employee service providers and controlling shareholders
may only be granted options under Section 3(9) of the Ordinance, which does not provide for similar tax benefits. Section 102
of the Ordinance includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the
benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly to the grantee.
Section 102(b)(2) of the Ordinance, the most favorable tax treatment for grantees, permits the issuance to a trustee under the
&ldquo;capital gains track.&rdquo; However, under this track we are not allowed to deduct an expense with respect to the issuance
of the options or shares. In order to comply with the terms of the capital gains track, all options granted under the 2013 Plan
pursuant and subject to the provisions of Section 102 of the Ordinance, as well as the Ordinary Shares issued upon exercise of
these options and other shares received subsequently following any realization of rights with respect to such options, such as
share dividends and share splits, must be granted to a trustee for the benefit of the relevant employee, director or officer and
should be held by the trustee for at least two years after the date of the grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Options granted under the 2013 Plan will generally
vest over four years commencing on the date of grant such that 25% vest after one year and an additional 6.25% vest at the end
of each subsequent three-month period thereafter for 36 months. Options that are not exercised within ten years from the grant
date expire, unless otherwise determined by the Board of Directors or its designated committee, as applicable. In case of termination
for reasons of disability or death, the grantee or his legal successor may exercise options that have vested prior to termination
within a period of six months from the date of disability or death. If we terminate a grantee&rsquo;s employment or service for
cause, all of the grantee&rsquo;s vested and unvested options will expire on the date of termination. If a grantee&rsquo;s employment
or service is terminated for any other reason, the grantee may exercise his or her vested options within 30 days of the date of
termination. Any expired or unvested options return to the pool for reissuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the event of a merger or consolidation of
our company subsequent to which we shall no longer exist as a legal entity, or a sale of all, or substantially all, of our shares
or assets or other transaction having a similar effect on us, then any outstanding option shall be assumed, or an equivalent option
shall be substituted, by such successor corporation or an affiliate thereof or, in case the successor corporation refuses to assume
or substitute the option, our Board of Directors or its designated committee may (a) provide the grantee with the opportunity
to exercise the option as to all or part of the shares, vested or otherwise, and (b) specify a period of time, no less than 7
days, following which all outstanding options shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;7.</TD><TD STYLE="text-align: left"><A NAME="a_009"></A>Major Shareholders and Related Party
                                         Transactions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.A.</TD><TD STYLE="text-align: left">Major shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The following table sets forth information regarding
the beneficial ownership by each person or entity known to beneficially own more than 5% of our Ordinary Shares as of March 20,
2015, or a different date, if so provided in the table below or footnotes thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">According to our transfer agent, as March 20,
2015, there were 21 record holders of our Ordinary Shares, among whom are 13 U.S. holders who beneficially owns less than 5% of
our Ordinary Shares. None of our shareholders has different voting rights from other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are not owned or controlled, directly or
indirectly, by another corporation or by any foreign government. We are not aware of any arrangement that may, at a subsequent
date, result in a change of control of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Except as indicated in footnotes to this table,
we believe that the shareholders named in this table have sole voting and investment power with respect to all Ordinary Shares
shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below,
each beneficial owner&rsquo;s address is: c/o BioBlast Pharma Ltd., 37 Dereh Menachem Begin St., Tel Aviv 6522042, Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Ordinary Shares</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Beneficially Owned</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">Name</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Percentage</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 9pt">Udi Gilboa (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">3,320,512</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">23.3</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Dr. Dalia Megiddo</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,311,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23.3</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Ran Nussbaum (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,529,008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.8</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Visium Asset Management, LP &nbsp;(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">844,160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.9</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">__________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Based solely on a Schedule 13G filed with the SEC on February
                                         17, 2015, and which reflects holdings as of December 31, 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Comprised of Pontifax (Cayman) III Limited Partnership that
                                         holds 804,909 Ordinary Shares and Pontifax (Israel) III Limited Partnership that holds
                                         1,724,099 Ordinary Shares. These two entities are under common control of, and are affiliated
                                         with, our director, Ran Nussbaum. The address of Ran Nussbaum is 14 Shenkar St. Herzliya,
                                         46140, Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Comprised of Visium Asset Management, LP, JG Asset, LLC,
                                         Jacob Gottlieb and Visium Balanced Master Fund, Ltd, of 888 Seventh Avenue, New York,
                                         NY 10019. Based solely on a Schedule 13G filed with the SEC on February 13, 2015, and
                                         which reflects holdings as of December 31, 2014.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.B.</TD><TD STYLE="text-align: justify">Related party transactions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">For a description of the compensation to our
directors and officers and agreements related thereto, see Item 6.B &ndash;&rdquo;Compensation&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Indemnification Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our articles of association permit us to exculpate,
indemnify and insure each of our directors and office holders to the fullest extent permitted by the Israeli Companies Law. We
have entered into indemnification agreements with each of our directors and other office holders, undertaking to indemnify them
to the fullest extent permitted by Israeli law. We have also obtained directors&nbsp;and officers insurance for each of our officers
and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.C.</TD><TD STYLE="text-align: left">Interests of experts and counsel</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not<B> </B>applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;8.</TD><TD STYLE="text-align: left"><A NAME="a_010"></A>Financial Information</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.A.</TD><TD STYLE="text-align: left">Financial statements and other financial information</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">See Item 18 &ndash; Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Legal Proceedings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">From time to time, we are involved in various
routine legal proceedings incidental to the ordinary course of our business. We do not currently believe that the outcome of these
legal proceedings have had in the recent past, or will have (with respect to any pending proceedings), significant effects on our
financial position or profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We have never declared or paid any cash dividends
on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if
any, in the future will be at the discretion of our Board of Directors and will depend on then-existing conditions, including our
financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our
Board of Directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law imposes further restrictions
on our ability to declare and pay dividends. See Item 10.B. &ndash; &ldquo;Articles of Association &ndash; Rights, Preferences
and Restrictions &ndash; Dividend and Liquidation Rights&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Payment of dividends may be subject to Israeli
withholding taxes. See Item 10.E. &ndash; &ldquo;Taxation&rdquo; below for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.B.</TD><TD STYLE="text-align: left">Significant changes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Except as disclosed elsewhere in this annual
report, there have been no other significant changes since December 31, 2014, until the date of the filing of this annual report.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item 9.</TD><TD STYLE="text-align: left"><A NAME="a_011"></A>The Offer and Listing</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-right: 0; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.A.</TD><TD STYLE="text-align: left">Offer and listing details</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">Our Ordinary Shares have
been listed on the NASDAQ Global Market under the symbol &ldquo;ORPN&rdquo; since July 31, 2014. Prior to that date, there was
no public trading market for our Ordinary Shares. Our initial public offering was priced at $11.00 per share on July 30, 2014.
The following table sets forth for the periods indicated the high and low sales prices per ordinary share as reported on the NASDAQ
Global Market:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Low</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">High</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Annual Information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">4.53</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">9.79</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Quarterly Information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">6.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">9.79</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">4.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">7.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter 2015 (through March 27, 2015)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">5.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">8.85</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Monthly Information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">September 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">7.27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">9.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">October 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">5.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">7.40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">November 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">4.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">7.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">December 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">5.71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">7.78</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">January 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">6.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">8.47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">February 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">6.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">8.37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">March 2015 (through March 27, 2015)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">5.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">7.70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.B</FONT>.</TD><TD STYLE="text-align: justify">Plan of distribution</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.C.</TD><TD STYLE="text-align: left">Market for Ordinary Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our Ordinary Shares have been quoted on the
Nasdaq Global Market since July 31, 2014 under the symbol ORPN.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.D.</TD><TD STYLE="text-align: left">Selling shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.E.</TD><TD STYLE="text-align: left">Dilution</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.F.</TD><TD STYLE="text-align: left">Expenses of the issue</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;10.</TD><TD STYLE="text-align: left"><A NAME="a_012"></A>Additional information</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.A.</TD><TD STYLE="text-align: left">Share capital</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.B.</TD><TD STYLE="text-align: left">Articles of Association</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Securities Register</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are registered with the Israeli Registrar
of Companies. Our registration number is 51-471648-9. Section 1.2 of our articles of association provides that we may engage in
any type of lawful business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Board of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law requires that certain
transactions, actions and arrangements be approved as provided for in a company's articles of association and in certain circumstances
by the Audit Committee, the Compensation Committee, by the Board of Directors itself and by the shareholders. The vote required
by the Audit Committee, Compensation Committee and the Board of Directors for approval of such matters, in each case, is a majority
of the disinterested directors participating in a duly convened meeting. If, however, a majority of the members participating in
such meeting have a personal interest in the approval of such matter, then all directors may participate in the discussions and
the voting on approval thereof and in such case the matter shall be subject to further shareholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law requires that an office
holder promptly disclose to the Board of Directors any personal interest that he or she may have concerning any existing or proposed
transaction with a company, as well as any substantial information or document with respect thereof. An interested office holder's
disclosure must be made promptly and in any event no later than the first meeting of the Board of Directors at which the transaction
is considered. A personal interest includes an interest of any person in an act or transaction of a company, including a personal
interest of one's relative or of a corporate body in which such person or a relative of such person is a 5% or greater shareholder,
director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding
a personal interest stemming from one's ownership of shares in the company. A personal interest furthermore includes the personal
interest of a person for whom the office holder holds a voting proxy or the interest of the office holder with respect to his or
her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder itself has no personal interest
in the approval of the matter. An office holder is not, however, obliged to disclose a personal interest if it derives solely from
the personal interest of a relative of such office holder in a transaction that is not considered an extraordinary transaction.
Under the Israeli Companies Law, an extraordinary transaction is defined as any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>a transaction other than in the ordinary course of business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>a transaction that is not on market terms; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 15pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>a transaction that may have a material impact on a company's profitability, assets or liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If it is determined that an office holder has
a personal interest in a transaction, approval by the Board of Directors is required for the transaction, unless the company's
articles of association provide for a different method of approval. Further, so long as an office holder has disclosed his or her
personal interest in a transaction, the Board of Directors may approve an action by the office holder that would otherwise be deemed
a breach of duty of loyalty. However, a company may not approve a transaction or action that is adverse to the company's interest
or that is not performed by the office holder in good faith. Approval first by the company's Audit Committee and subsequently by
the Board of Directors is required for an extraordinary transaction in which an office holder has a personal interest. Arrangements
regarding the compensation, indemnification or insurance of an office holder require the approval of the Compensation Committee,
Board of Directors and, in certain circumstances, the shareholders, in that order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Pursuant to Israeli law, the disclosure requirements
regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder of a public
company. In the context of a transaction involving a controlling shareholder or an officer who is a controlling shareholder of
the company, a controlling shareholder also includes any shareholder who holds 25% or more of the voting rights if no other shareholder
holds more than 50% of the voting rights. Two or more shareholders with a personal interest in the approval of the same transaction
are deemed to be a single shareholder and may be deemed a controlling shareholder for the purpose of approving such transaction.
Extraordinary transactions, including private placement transactions, with a controlling shareholder or in which a controlling
shareholder has a personal interest, and engagements with a controlling shareholder or his or her relative, directly or indirectly,
including through a corporation in his or her control, require the approval of the Audit Committee, the Board of Directors and
the shareholders of the company, in that order.&nbsp;In addition, the shareholder approval must fulfill one of the following requirements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>a disinterested majority; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -21.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>the votes of shareholders who have no personal interest in the transaction and who are present and voting, in person, by proxy
or by voting deed at the meeting, and who vote against the transaction may not represent more than two percent (2%) of the voting
rights of the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">To the extent that any such transaction with
a controlling shareholder is for a period extending beyond three years, approval is required once every three years, unless the
Audit Committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Arrangements regarding the terms of engagement
and compensation of a controlling shareholder who is an office holder, and the terms of employment of a controlling shareholder
who is an employee of the company, require the approval of the Compensation Committee, Board of Directors and, generally, the shareholders,
in that order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our articles of association provide that, all
actions done bona fide at any meeting of the Board of Directors or by a committee thereof or by any person(s) acting as director(s)
will, notwithstanding that it may afterwards be discovered that there was some defect in the appointment of the participants in
such meeting or any of them or any person(s) acting as aforesaid, or that they or any of them were disqualified, be as valid as
if there were no such defector disqualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pursuant to Israeli law, a director who has a personal interest in an extraordinary transaction which is brought for discussion
before our Board of Directors or our Audit Committee shall neither vote in nor attend discussions concerning the approval of such
transaction. If the director did vote or attend as aforesaid, the approval given to the aforesaid activity or arrangement will
be invalid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our articles of association provide that, subject to the Israeli Companies Law, our Board of Directors may delegate its authority,
in whole or in part, to such committees of the Board of Directors as it deems appropriate, and it may from time to time revoke
such delegation. To the extent permitted by the Israeli Companies Law, our Board of Directors may from time to time confer upon
and delegate to a President, Chief Executive Officer, Chief Operating Officer or other executive officer then holding office, such
authorities and duties of the Board of Directors as it deems fit, and they may delegate such authorities and duties for such period
and for such purposes and subject to such conditions and restrictions which they consider in our best interests, without waiving
the authorities of the Board of Directors with respect thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Arrangements regarding compensation of directors require the approval of the Compensation Committee, our Board of Directors
and the shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Rights, Preferences and Restrictions of Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>General.</U> Our share capital is NIS 500,000, divided into 50,000,000 Ordinary Shares NIS 0.01 par value per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The Ordinary Shares do not have cumulative voting rights in the election of directors. As a result, the holders of Ordinary
Shares that represent more than 50% of the voting power have the power to elect all the Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Dividend and liquidation rights.</U> Our Board of Directors may declare a dividend to be paid to the holders of our Ordinary
Shares according to their rights and interests in our profits and may fix the record date for eligibility and the time for payment.
The directors may from time to time pay to the shareholders on account of the next forthcoming dividend such interim dividends
as, in their judgment, our position justifies. All dividends unclaimed for one year after having been declared may be invested
or otherwise used by the directors for our benefit until claimed. No unpaid dividend or interest shall bear interest as against
us. Our Board of Directors may determine that a dividend may be paid, wholly or partially, by the distribution of certain of our
assets or by a distribution of paid up shares, debentures or debenture stock or any of our securities or of any other companies
or in any one or more of such ways in the manner and to the extent permitted by the Israeli Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Transfer of shares; record dates.</U> Fully paid up Ordinary Shares may be freely transferred pursuant to our articles of
association unless such transfer is restricted or prohibited by another instrument or securities laws. Each shareholder who would
be entitled to attend and vote at a General Meeting of shareholders is entitled to receive notice of any such meeting. For purposes
of determining the shareholders entitled to notice and to vote at such meeting, the Board of Directors will fix a record date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Voting; annual general and extraordinary meetings.</U> Subject to any rights or restrictions for the time being attached
to any class or classes of shares, each shareholder shall have one vote for each share of which he or she is the holder, whether
on a show of hands or on a poll. Our articles of association do not permit cumulative voting and it is not mandated by Israeli
law. Votes may be given either personally or by proxy. A proxy need not be a shareholder. If any shareholder is without legal capacity,
he may vote by means of a trustee or a legal custodian, who may vote either personally or by proxy. If two or more persons are
jointly entitled to a share then, in voting upon any question, the vote of the senior person who tenders a vote, whether in person
or by proxy, shall be accepted to the exclusion of the votes of the other registered holders of the share and, for this purpose
seniority shall be determined by the order in which the names stand in the shareholder register.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Quorum for general meetings.</U>The quorum required for our general meetings of shareholders consists of at least two shareholders
present in person, by proxy or written ballot who holds or represent between them at least one-third of the total outstanding voting
rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time
and place or to a later time/date if so specified in the summons or notice of the meeting. At the reconvened meeting, any two or
more shareholders present in person or by proxy shall constitute a lawful quorum.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Notice of general meetings.</U> Unless a longer period for notice is prescribed by the Israeli Companies Law, at least 10
days and not more than 60 days&rsquo; notice of any general meeting shall be given, specifying the place, the day and the hour
of the meeting and, in the case of special business, the nature of such business, shall be given in the manner hereinafter mentioned,
to such shareholders as are under the provisions of our articles of association, entitled to receive notices from us. Only shareholders
of record as reflected on our share register at the close of business on the date fixed by the Board of Directors as the record
date determining the then shareholders who will be entitled to vote, shall be entitled to notice of, and to vote, in person or
by proxy, at a general meeting and any postponement or adjournment thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Annual; agenda; calling a general meeting.</U> General Meetings are held at least once in every calendar year at such time
(within a period of 15 months after the holding of the last preceding General Meeting), and at such time and place as may be determined
by the Board of Directors. At a General Meeting, decisions shall be adopted only on matters that were specified on the agenda.
The Board of Directors is obligated to call extraordinary general meeting of the shareholders upon a written request in accordance
with the Israeli Companies Law. The Israeli Companies Law provides that an extraordinary general meeting of shareholder may be
called by the Board of Directors or by a request of two directors or 25% of the directors in office, or by shareholders holding
at least 5% of the issued share capital of the company and at least 1% of the voting rights, or of shareholders holding at least
5% of the voting rights of the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.3in">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Majority vote.</U><FONT STYLE="font-family: Symbol"> </FONT>Except as otherwise provided in the articles of association,
any resolution at a General Meeting shall be deemed adopted if approved by the holders of a majority of our voting rights represented
at the meeting in person or by proxy and voting thereon. In the case of an equality of votes, the chairman of the meeting shall
not be entitled to a further vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Discrimination against shareholders.</U> According to our articles of association, there are no discriminating provisions
against any existing or prospective holders of our shares as a result of a shareholder holding a substantial number of shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>Modification of Class Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If, at any time, the share capital is divided
into different classes of shares, the rights attached to any class (unless otherwise provided by the terms of issuance of the shares
of that class) may be varied with the consent in writing of the holders of all the issued shares of that class, or with the sanction
of a majority vote at a meeting of the shareholders passed at a separate meeting of the holders of the shares of the class. The
provisions of our articles of association relating to general meetings shall apply, mutatis mutandis, to every such separate general
meeting. Any holder of shares of the class present in person or by proxy may demand a secret poll.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Unless otherwise provided by the conditions of
issuance, the enlargement of an existing class of shares, or the issuance of additional shares thereof, shall not be deemed to
modify or abrogate the rights attached to the previously issued shares of such class or of any other class. These conditions provide
for the minimum shareholder approvals permitted by the Israeli Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>Restrictions on Shareholders Rights to Own Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our articles of association and the laws of the
State of Israel do not restrict in any way the ownership or voting or our shares by non-residents of Israel, except with respect
to subjects of countries which are in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Acquisitions under Israeli Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Full tender offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A person wishing to acquire shares of an Israeli
public company and who would as a result hold over 90% of the target company&rsquo;s issued and outstanding share capital or of
the issued and outstanding share capital of a certain class of shares is required by the Israeli Companies Law to make a tender
offer to all of the company&rsquo;s shareholders for the purchase of all of the issued and outstanding shares of the company or
of all of the issued and outstanding shares of the same class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If the shareholders who do not respond to or
accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class of the
shares, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares
that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will be
accepted if the shareholders who do not accept it hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Upon a successful completion of such a full tender
offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may,
within six months from the date of acceptance of the tender offer, petition the Israeli court to determine whether the tender offer
was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may determine in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition
the Israeli court as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If the shareholders who did not respond or accept
the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable class, the acquirer
may not acquire shares of the company that will increase its holdings to more than 90% of the company&rsquo;s issued and outstanding
share capital or of the applicable class from shareholders who accepted the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Special tender offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law provides that an acquisition
of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser
would become a holder of at least 25% of the voting rights in the company. This rule does not apply if there is already another
holder of at least 25% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Similarly, the Israeli Companies Law provides
that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the
company who holds more than 45% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">These requirements do not apply if the acquisition
(i)&nbsp;occurs in the context of a private offering, on the condition that the shareholders meeting approved the acquisition as
a private offering whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no person
who holds at least 25% of the voting rights in the company, or as a private offering whose purpose is to give the acquirer 45%
of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii)&nbsp;was from
a shareholder holding at least 25% of the voting rights in the company and resulted in the acquirer becoming a holder of at least
25% of the voting rights in the company; or (iii)&nbsp;was from a holder of more than 45% of the voting rights in the company and
resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The special tender offer may be consummated only
if (i)&nbsp;at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror
and (ii)&nbsp;the special tender offer is accepted by a majority of the votes of those offerees who gave notice of their position
in respect of the offer; in counting the votes of offerees, the votes of a holder of control in the offeror, a person who has personal
interest in acceptance of the special tender offer, a holder of at least 25% of the voting rights in the company, or any person
acting on their or on the offeror&rsquo;s behalf, including their relatives or companies under their control, are not taken into
account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the event that a special tender offer is made,
a company&rsquo;s Board of Directors is required to express its opinion on the advisability of the offer or shall abstain from
expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">An office holder in a target company who, in
his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable
special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for damages
resulting from his acts, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting
for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order
to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If a special tender offer was accepted by a majority
of the shareholders who announced their stand on such offer, then shareholders who did not respond to the special offer or had
objected to the special tender offer may accept the offer within four days of the last day set for the acceptance of the offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the event that a special tender offer is accepted,
then the purchaser or any person or entity controlling it and any corporation controlled by them shall refrain from making a subsequent
tender offer for the purchase of shares of the target company and may not execute a merger with the target company for a period
of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger
in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law permits merger transactions
if approved by each party&rsquo;s Board of Directors and, unless certain requirements described under the Israeli Companies Law
are met, a majority of each party&rsquo;s shareholders, by a majority of each party&rsquo;s shares that are voted on the proposed
merger at a shareholders&rsquo; meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Board of Directors of a merging company is
required pursuant to the Israeli Companies Law to discuss and determine whether in its opinion there exists a reasonable concern
that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors,
taking into account the financial condition of the merging companies. If the Board of Directors has determined that such a concern
exists, it may not approve a proposed merger. Following the approval of the Board of Directors of each of the merging companies,
the Boards of Directors must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">For purposes of the shareholder vote, unless
a court rules otherwise, the merger will not be deemed approved if a majority of the shares voting at the shareholders meeting
(excluding abstentions) that are held by parties other than the other party to the merger, any person who holds 25% or more of
the means of control of the other party to the merger or any one on their behalf including their relatives or corporations controlled
by any of them, vote against the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If the transaction would have been approved but
for the separate approval of each class of shares or the exclusion of the votes of certain shareholders as provided above, a court
may still rule that the company has approved the merger upon the request of holders of at least 25% of the voting rights of a company,
if the court holds that the merger is fair and reasonable, taking into account the appraisal of the merging companies&rsquo; value
and the consideration offered to the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Israeli Companies Law, each merging
company must send a copy of the proposed merger plan to its secured creditors. Unsecured creditors are entitled to receive notice
of the merger, as provided by the regulations promulgated under the Israeli Companies Law. Upon the request of a creditor of either
party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the target company. The court
may also give instructions in order to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition, a merger may not be completed unless
at least 50 days have passed from the date that a proposal for approval of the merger was filed with the Israeli Registrar of Companies
and 30 days from the date that shareholder approval of both merging companies was obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Potential Issues that Could Delay a Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Certain provisions of Israeli corporate and tax
law may have the effect of delaying, preventing or making more difficult any merger or acquisition of us.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Requirement of Disclosure of Shareholder Ownership</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">There are no provisions of our articles of association
governing the ownership threshold above which shareholder ownership must be disclosed. We are subject, however, to U.S. securities
rules that require beneficial owners of more than 5% of our Ordinary Shares to make certain filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Changes in Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our articles of association do not impose any
conditions governing changes in capital that are more stringent than required by the Israeli Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.C.</TD><TD STYLE="text-align: left">Material contracts</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">For
a description of the agreements related to our directors and officers, see Item 6.B &ndash;&ldquo;Compensation&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.D.</TD><TD STYLE="text-align: left">Exchange controls</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">There are currently no Israeli currency control
restrictions on payments of dividends or other distributions with respect to our Ordinary Shares or the proceeds from the sale
of our Ordinary Shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding certain
transactions. However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action
at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Non-residents of Israel who purchase our securities
with non-Israeli currency will be able to repatriate dividends (if any), liquidation distributions and the proceeds of any sale
of such securities, into non-Israeli currencies at the rate of exchange prevailing at the time of repatriation, provided that any
applicable Israeli taxes have been paid (or withheld) on such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Neither our articles of association nor the laws
of the State of Israel restrict in any way the ownership or voting of our Ordinary Shares by non-residents of Israel, except with
respect to citizens of countries that are in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.E.</B></TD><TD><B>Taxation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The following is a summary of the current tax
structure, which is applicable to companies in Israel, with special reference to its effect on us. The following also contains
a discussion of material Israeli and U.S. tax consequences to persons purchasing our Ordinary Shares and government programs from
which we and some of our group companies benefit. To the extent that the discussion is based on new tax legislation, which has
yet to be subject to judicial or administrative interpretation, there can be no assurance that the views expressed in the discussion
will accord with any such interpretation in the future. The discussion is not intended and should not be construed as legal or
professional tax advice and is not exhaustive of all possible tax considerations. An Israeli company that is subject to Israeli
taxes on the income of its non-Israeli subsidiaries will receive a credit for income taxes paid/withheld or that will be paid/withheld
by the subsidiary in its country of residence, according to the terms and conditions determined in the Israeli Tax Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The following summary is included herein as general
information only and is not intended as a substitute for careful tax planning. Accordingly, each investor should consult his or
her own tax advisor as to the particular tax consequences to such investor of the purchase, ownership or sale of an Ordinary Share,
including the effect of applicable state, local, foreign or other tax laws and possible changes in tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Israeli Tax Considerations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The following is a summary of the material Israeli
income tax laws applicable to us. This section also contains a discussion of material Israeli income tax consequences concerning
the ownership and disposition of our Ordinary Shares. This summary does not discuss all the aspects of Israeli income tax law that
may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors
subject to special treatment under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities
who are subject to special tax regimes not covered in this discussion. To the extent that the discussion is based on new tax legislation
that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities
or the courts will accept the views expressed in this discussion. This summary is based on laws and regulations in effect as of
the date of this annual report and does not take into account possible future amendments which may be under consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General corporate tax structure in Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Israeli resident companies, such as us, are generally
subject to corporate tax at the rate of 26.5% as of 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Capital gains derived by an Israeli resident
company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli tax legislation, a corporation will
be considered as an &ldquo;Israeli Resident&rdquo; if it meets one of the following: (a) it was incorporated in Israel; or (b)
the control and management of its business are exercised in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Taxation of our Israeli individual shareholders on receipt of
dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Israeli residents who are individuals are generally
subject to Israeli income tax for dividends paid on our Ordinary Shares (other than bonus shares or share dividends) at a rate
of 25%, or 30% if the recipient of such dividend is a &ldquo;substantial shareholder&rdquo; (as defined below) at the time of distribution
or at any time during the preceding 12-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">As of January 1, 2015, an additional income tax
at a rate of 2% is imposed on high earners whose annual income or gain exceeds NIS 810,720.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A &ldquo;substantial Shareholder&rdquo; is generally
a person who alone, or together with his relative or another person who collaborates with him on a regular basis, holds, directly
or indirectly, at least 10% of any of the &ldquo;means of control&rdquo; of the corporation. &ldquo;Means of control&rdquo; generally
include the right to vote, receive profits, nominate a director or an officer, receive assets upon liquidation, or instruct someone
who holds any of the aforesaid rights regarding the manner in which he or she is to exercise such right(s), and all regardless
of the source of such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The term &ldquo;Israeli Resident&rdquo; is generally
defined under Israeli tax legislation with respect to individuals as a person whose center of life is in Israel. The Israeli Tax
Ordinance New Version, 1961 (the &ldquo;Israeli Tax Ordinance&rdquo;) provides that in order to determine the center of life of
an individual, account will be taken of the individual&rsquo;s family, economic and social connections, including: (a) place of
permanent home; (b) place of residential dwelling of the individual and the individual&rsquo;s immediate family; (c) place of the
individual&rsquo;s regular or permanent occupation or the place of his permanent employment; (d) place of the individual&rsquo;s
active and substantial economic interests; (e) place of the individual&rsquo;s activities in organizations, associations and other
institutions. The center of life of an individual will be presumed to be in Israel if: (a) the individual was present in Israel
for 183 days or more in the tax year; or (b) the individual was present in Israel for 30 days or more in the tax year, and the
total period of the individual&rsquo;s presence in Israel in that tax year and the two previous tax years is 425 days or more.
The presumption in this paragraph may be rebutted either by the individual or by the assessing officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Taxation of Israeli Resident Corporations on Receipt of Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Israeli resident corporations are generally exempt
from Israeli corporate income tax with respect to dividends paid on our Ordinary Shares as long as the profits from which the dividends
were distributed were derived in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Capital Gains Taxes Applicable to Israeli Resident Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The income tax rate applicable to Real Capital
Gain derived by an Israeli individual from the sale of shares which had been purchased after January 1, 2012, whether listed on
a stock exchange or not, is 25%. However, if such shareholder is considered a &ldquo;Substantial Shareholder&rdquo; (as defined
above) at the time of sale or at any time during the preceding 12-month period, such gain will be taxed at the rate of 30%. As
of January 1, 2015, an additional tax at a rate of 2% is imposed on high earners whose annual income or gains exceed NIS 810,720.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Moreover, capital gains derived by a shareholder
who is a dealer or trader in securities, or to whom such income is otherwise taxable as ordinary business income, are taxed in
Israel at ordinary income rates (26.5% as of 2014 for corporations and up to 50% for individuals).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Taxation of Non-Israeli Shareholders on Receipt of Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Non-Israeli residents are generally subject to
Israeli income tax on the receipt of dividends paid on our Ordinary Shares at the rate of 25% (or 30% for individuals, if such
person is a &ldquo;substantial shareholder&rdquo; at the time receiving the dividend or on any date in the 12 months preceding
such date), which tax will be withheld at source, unless a lower tax rate is provided in a tax treaty between Israel and the shareholder&rsquo;s
country of residence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A non-Israeli resident who receives dividends
from which tax was withheld is generally exempt from the duty to file returns in Israel in respect of such income; provided such
income was not derived from a business conducted in Israel by the taxpayer, and the taxpayer has no other taxable sources of income
in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">For example, under the Convention Between the
Government of the United States of America and the Government of Israel with Respect to Taxes on Income, as amended (the &ldquo;U.S.-Israel
Tax Treaty&rdquo;), Israeli withholding tax on dividends paid to a U.S. resident for treaty purposes may not, in general, exceed
25%, or 15% in the case of dividends paid out of the profits of a Benefited Enterprise, subject to certain conditions. Where the
recipient is a U.S. corporation owning 10% or more of the voting shares of the paying corporation during the part of the paying
corporation&rsquo;s taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year
(if any) and the dividend is not paid from the profits of a Benefited Enterprise, the Israeli tax withheld may not exceed 12.5%,
subject to certain conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Capital gains income taxes applicable to non-Israeli shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Non-Israeli resident shareholders are generally
exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition of our Ordinary Shares, provided
that such gains were not derived from a permanent establishment or business activity of such shareholders in Israel. However, non-Israeli
corporations will not be entitled to the foregoing exemptions if an Israeli resident (i) has a controlling interest of more than
25% in such non-Israeli corporation or (ii) is the beneficiary of or is entitled to 25% or more of the revenues or profits of such
non-Israeli corporation, whether directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Regardless of whether shareholders may be liable
for Israeli income tax on the sale of our Ordinary Shares, the payment of the consideration may be subject to withholding of Israeli
tax at the source. Accordingly, shareholders may be required to demonstrate that they are exempt from tax on their capital gains
in order to avoid withholding at source at the time of sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Estate and gift tax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Israeli law presently does not impose estate
or gift taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>United States Federal Income Tax Consequences</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">THE FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION
AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR
HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY SHARES,
INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>U.S. Federal Income Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Subject to the limitations described in the next
paragraph, the following discussion summarizes the material U.S. federal income tax consequences to a &ldquo;U.S. Holder&rdquo;
arising from the purchase, ownership and sale of the Ordinary Shares. For this purpose, a &ldquo;U.S. Holder&rdquo; is a holder
of Ordinary Shares that is: (1) an individual citizen or resident of the United States, including an alien individual who is a
lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax laws;
(2) a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than
a partnership that is not treated as a U.S. person under any applicable U.S. Treasury Regulations) created or organized in or under
the laws of the United States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which
is subject to U.S. federal income tax regardless of source; (4) a trust if a court within the United States is able to exercise
primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial
decisions of the trust; (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in
U.S. Treasury regulations; or (6) any person otherwise subject to U.S. federal income tax on a net income basis in respect of the
Ordinary Shares, if such status as a U.S. Holder is not overridden pursuant to the provisions of an applicable tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">This summary is for general information purposes
only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations that may be relevant
to a decision to purchase or hold our Ordinary Shares. This summary generally considers only U.S. Holders that will own our Ordinary
Shares as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences
to a person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer's status as a U.S. Holder.
This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed
U.S. Treasury Regulations promulgated thereunder, administrative and judicial interpretations thereof, and the U.S./Israel Income
Tax Treaty, all as in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and
all of which are open to differing interpretations. We will not seek a ruling from the U.S. Internal Revenue Service, or the IRS,
with regard to the U.S. federal income tax treatment of an investment in our Ordinary Shares by U.S. Holders and, therefore, can
provide no assurances that the IRS will agree with the conclusions set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">This discussion does not address all of the aspects
of U.S. federal income taxation that may be relevant to a particular shareholder based on such shareholder's particular circumstances
and in particular does not discuss any estate, gift, generation-skipping, transfer, state, local or foreign tax considerations.
In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank, life insurance
company, regulated investment company, or other financial institution or &ldquo;financial services entity&rdquo;; (2) a broker
or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares in connection with employment or other
performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our
Ordinary Shares as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction
transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment trusts; (8) a U.S. Holder
that expatriates out of the United States or a former long-term resident of the United States; or (9) a person having a functional
currency other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that
owns, directly or constructively, at any time, Ordinary Shares representing 10% or more of our voting power. Additionally, the
U.S. federal income tax treatment of persons who hold Ordinary Shares through a partnership or other pass-through entity are not
considered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">You are encouraged to consult your own tax advisor
with respect to the specific U.S. federal and state income tax consequences to you of purchasing, holding or disposing of our Ordinary
Shares, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Distributions on Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Subject to the discussion under the heading &ldquo;Passive
Foreign Investment Companies&rdquo; below, a U.S. Holder will be required to include in gross income as ordinary income the amount
of any distribution paid on Ordinary Shares (including the amount of any Israeli tax withheld on the date of the distribution),
to the extent that such distribution does not exceed our current and accumulated earnings and profits, as determined for U.S. federal
income tax purposes. The amount of a distribution which exceeds our earnings and profits will be treated first as a non-taxable
return of capital, reducing the U.S. Holder's tax basis for the Ordinary Shares to the extent thereof, and then capital gain. Corporate
holders generally will not be allowed a deduction for dividends received. For noncorporate U.S. Holders, to the extent that their
total adjusted income does not exceed applicable thresholds, the maximum federal income tax rate for &ldquo;qualified dividend
income&rdquo; and long-term capital gains is generally 15%. For those noncorporate U.S. Holders whose total adjusted income exceeds
such income thresholds, the maximum federal income tax rate for &ldquo;qualified dividend income&rdquo; and long-term capital gains
is generally 20%. For this purpose, &ldquo;qualified dividend income&rdquo; means, <I>inter alia</I>, dividends received from a
&ldquo;qualified foreign corporation.&rdquo; A &ldquo;qualified foreign corporation&rdquo; is a corporation that is entitled to
the benefits of a comprehensive tax treaty with the United States which includes an exchange of information program. The IRS has
stated that the Israel/U.S. Tax Treaty satisfies this requirement and we believe we are eligible for the benefits of that treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition, our dividends will be qualified
dividend income if our Ordinary Shares<B> </B>are readily tradable on NASDAQ or another established securities market in the United
States. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend is paid or in the prior
year, as a PFIC. A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder has not held our Ordinary
Shares or ADRs for at least 61 days of the 121 day period beginning on the date which is 60 days before the ex-dividend date, or
(2) to the extent the U.S. Holder is under an obligation to make related payments on substantially similar property. Any days during
which the U.S. Holder has diminished its risk of loss on our Ordinary Shares are not counted towards meeting the 61-day holding
period. Finally, U.S. Holders who elect to treat the dividend income as &ldquo;investment income&rdquo; pursuant to Code section
163(d)(4) will not be eligible for the preferential rate of taxation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The amount of a distribution with respect to
our Ordinary Shares will be measured by the amount of the fair market value of any property distributed, and for U.S. federal income
tax purposes, the amount of any Israeli taxes withheld therefrom. (See discussion above under &ldquo;Israeli Tax Considerations
- Taxation of Our Shareholders &ndash; Dividends.&rdquo;) Cash distributions paid by us in NIS will be included in the income of
U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible in the
income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such
U.S. dollar value. If the U.S. Holder subsequently converts the NIS, any subsequent gain or loss in respect of such NIS arising
from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Distributions paid by us will generally be foreign
source income for U.S. foreign tax credit purposes. Subject to the limitations set forth in the Code, U.S. Holders may elect to
claim a foreign tax credit against their U.S. income tax liability for Israeli income tax withheld from distributions received
in respect of the Ordinary Shares. In general, these rules limit the amount allowable as a foreign tax credit in any year to the
amount of regular U.S. tax for the year attributable to foreign source taxable income. This limitation on the use of foreign tax
credits generally will not apply to an electing individual U.S. Holder whose creditable foreign taxes during the year do not exceed
$300, or $600 for joint filers, if such individual's gross income for the taxable year from non-U.S. sources consists solely of
certain passive income. A U.S. Holder will be denied a foreign tax credit with respect to Israeli income tax withheld from dividends
received with respect to the Ordinary Shares if such U.S. Holder has not held the Ordinary Shares for at least 16 days out of the
31-day period beginning on the date that is 15 days before the ex-dividend date or to the extent that such U.S. Holder is under
an obligation to make certain related payments with respect to substantially similar or related property. Any day during which
a U.S. Holder has substantially diminished his or her risk of loss with respect to the Ordinary Shares will not count toward meeting
the 16-day holding period. A U.S. Holder will also be denied a foreign tax credit if the U.S. Holder holds the Ordinary Shares
in an arrangement in which the U.S. Holder's reasonably expected economic profit is insubstantial compared to the foreign taxes
expected to be paid or accrued. The rules relating to the determination of the U.S. foreign tax credit are complex, and U.S. Holders
should consult with their own tax advisors to determine whether, and to what extent, they are entitled to such credit. U.S. Holders
that do not elect to claim a foreign tax credit may instead claim a deduction for Israeli income taxes withheld, provided such
U.S. Holders itemize their deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Disposition of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Except as provided under the PFIC rules described
below, upon the sale, exchange or other disposition of our Ordinary Shares, a U.S. Holder will recognize capital gain or loss in
an amount equal to the difference between such U.S. Holder's tax basis in the sold Ordinary Shares and the amount realized on the
disposition of such Ordinary Shares (or its U.S. dollar equivalent determined by reference to the spot rate of exchange on the
date of disposition, if the amount realized is denominated in a foreign currency). The gain or loss realized on the sale or exchange
or other disposition of Ordinary Shares will be long-term capital gain or loss if the U.S. Holder has a holding period of more
than one year at the time of the disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In general, gain realized by a U.S. Holder on
a sale, exchange or other disposition of Ordinary Shares will generally be treated as U.S. source income for U.S. foreign tax credit
purposes. A loss realized by a U.S. Holder on the sale, exchange or other disposition of Ordinary Shares is generally allocated
to U.S. source income. However, U.S. Treasury Regulations require such loss to be allocated to foreign source income to the extent
specified dividends were received by the taxpayer within the 24-month period preceding the date on which the taxpayer recognized
the loss. The deductibility of a loss realized on the sale, exchange or other disposition of Ordinary Shares is subject to limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Tax on Net Investment Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">U.S. Holders who are individuals, estates or
trusts will generally be required to pay a 3.8% tax on their net investment income (including dividends on and gains from the sale
or other disposition of our Ordinary Shares), or in the case of estates and trusts on their net investment income that is not distributed.
In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder's total adjusted income exceeds applicable thresholds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Passive Foreign Investment Companies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Special U.S. federal income tax laws apply to
a U.S. Holder who owns shares of a corporation that was (at any time during the U.S. Holder's holding period) a PFIC. We would
be treated as a PFIC for U.S. federal income tax purposes for any tax year if, in such tax year, either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">75% or more of our gross income (including
our pro rata share of gross income for any company, U.S. or foreign, in which we are considered to own 25% or more of the shares
by value), in a taxable year is passive (the &ldquo;Income Test&rdquo;); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">At least 50% of our assets, averaged over
the year and generally determined based upon value (including our pro rata share of the assets of any company in which we are considered
to own 25% or more of the shares by value), in a taxable year are held for the production of, or produce, passive income (the &ldquo;Asset
Test&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">For this purpose, passive income generally consists
of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from notional principal
contracts. Cash is treated as generating passive income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">If we are or become a PFIC, each U.S. Holder
who has not elected to treat us as a qualified electing fund by making a &ldquo;QEF election&rdquo;, or who has not elected to
mark the shares to market (as discussed below), would, upon receipt of certain distributions by us and upon disposition of our
Ordinary Shares at a gain, be liable to pay U.S. federal income tax at the then prevailing highest tax rates on ordinary income
plus interest on such tax, as if the distribution or gain had been recognized ratably over the taxpayer's holding period for the
Ordinary Shares. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the
tax basis of such shares would not receive a step-up to fair market value as of the date of the decedent's death, but instead would
be equal to the decedent's basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may
also be subject to special U.S. federal income tax rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The PFIC rules would not apply to a U.S. Holder
who makes a QEF election for all taxable years that such U.S. Holder has held the Ordinary Shares while we are a PFIC, provided
that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election is required for
each taxable year that we are a PFIC to include in income such U.S. Holder's <I>pro rata</I> share of our ordinary earnings as
ordinary income and such U.S. Holder's <I>pro rata</I> share of our net capital gains as long-term capital gain, regardless of
whether we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain
required information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the
consent of the IRS. U.S. Holders should consult with their own tax advisors regarding eligibility, manner and advisability of making
a QEF election if we are treated as a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A U.S. Holder of PFIC shares which are traded
on qualifying public markets, including the NASDAQ, can elect to mark the shares to market annually, recognizing as ordinary income
or loss each year an amount equal to the difference as of the close of the taxable year between the fair market value of the PFIC
shares and the U.S. Holder's adjusted tax basis in the PFIC shares. Losses are allowed only to the extent of net mark-to-market
gain previously included income by the U.S. Holder under the election for prior taxable years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Based on the nature of our business, the projected
composition of our income and the projected composition and estimated fair market values of our assets, we cannot rule out a PFIC
designation. In particular, in light of the complexity of PFIC rules, we cannot assure you that we have not been a PFIC in prior
years or are not a PFIC or will avoid becoming a PFIC in the future.&nbsp;U.S. Holders who hold Ordinary Shares during a period
when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC, subject to specified exceptions for U.S.
Holders who made a QEF or mark-to-market election. U.S. Holders are strongly urged to consult their tax advisors about the PFIC
rules, including tax return filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market
election with respect to our Ordinary Shares in the event we that qualify as a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Information Reporting and Withholding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A U.S. Holder may be subject to backup withholding
(at a rate of 28%) with respect to cash dividends and proceeds from a disposition of Ordinary Shares. In general, back-up withholding
will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply with
respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding
is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided
that the required information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Under the Hiring Incentives to Restore Employment
Act of 2010 (the &ldquo;HIRE Act&rdquo;), some payments made to &ldquo;foreign financial institutions&rdquo; in respect of accounts
of U.S. stockholders at such financial institutions may be subject to withholding at a rate of 30%. U.S. Treasury Regulations provide
that such withholding will only apply to distributions paid on or after January 1, 2014, and to other &ldquo;withholdable payments&rdquo;
(including payments of gross proceeds from a sale or other disposition of our Ordinary Shares) made on or after January 1, 2017.
U.S. Holders should consult their tax advisors regarding the effect, if any, of the HIRE Act on their ownership and disposition
of our Ordinary Shares. See &ldquo;Non-U.S. Holders of Ordinary Shares&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Non-U.S. Holders of Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Except as provided below, an individual, corporation,
estate or trust that is not a U.S. Holder generally will not be subject to U.S. federal income or withholding tax on the payment
of dividends on, and the proceeds from the disposition of, our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">A non-U.S. Holder may be subject to U.S. federal
income or withholding tax on a dividend paid on our Ordinary Shares or the proceeds from the disposition of our Ordinary Shares
if: (1) such item is effectively connected with the conduct by the non-U.S. Holder of a trade or business in the United States
or, in the case of a non-U.S. Holder that is a resident of a country which has an income tax treaty with the United States, such
item is attributable to a permanent establishment or, in the case of gain realized by an individual non-U.S. Holder, a fixed place
of business in the United States; (2) in the case of a disposition of our Ordinary Shares, the individual non-U.S. Holder is present
in the United States for 183 days or more in the taxable year of the sale and other specified conditions are met; (3) the non-U.S.
Holder is subject to U.S. federal income tax pursuant to the provisions of the U.S. tax law applicable to U.S. expatriates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In general, non-U.S. Holders will not be subject
to backup withholding with respect to the payment of dividends on our Ordinary Shares if payment is made through a paying agent,
or office of a foreign broker outside the United States. However, if payment is made in the United States or by a U.S. related
person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides on an applicable Form W-8 (or
a substantially similar form) a taxpayer identification number, certifies to its foreign status, or otherwise establishes an exemption.
A U.S. related person for these purposes is a person with one or more current relationships with the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The amount of any backup withholding from a payment
to a non-U.S. Holder will be allowed as a credit against such holder's U.S. federal income tax liability and may entitle such holder
to a refund, provided that the required information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The HIRE Act may impose withholding taxes on
some types of payments made to &ldquo;foreign financial institutions&rdquo; and some other non-U.S. entities. Under the HIRE Act,
the failure to comply with additional certification, information reporting and other specified requirements could result in withholding
tax being imposed on payments of dividends and sales proceeds to U.S. Holders that own Ordinary Shares through foreign accounts
or foreign intermediaries and specified non-U.S. Holders. The HIRE Act imposes a 30% withholding tax on dividends on, and gross
proceeds from the sale or other disposition of, Ordinary Shares paid from the United States to a foreign financial institution
or to a foreign nonfinancial entity, unless (1) the foreign financial institution undertakes specified diligence and reporting
obligations or (2) the foreign nonfinancial entity either certifies it does not have any substantial U.S. owners or furnishes identifying
information regarding each substantial U.S. owner. In addition, if the payee is a foreign financial institution, it generally must
enter into an agreement with the U.S. Treasury that requires, among other things, that it undertake to identify accounts held by
specified U.S. persons or U.S.-owned foreign entities, annually report certain information about such accounts, and withhold 30%
on payments to other specified account holders. U.S. Treasury Regulations provide that such withholding will only apply to distributions
paid on or after January 1, 2014, and to other &ldquo;withholdable payments&rdquo; (including payments of gross proceeds from a
sale or other disposition of our Ordinary Shares) made on or after January 1, 2017. You should consult your tax advisor regarding
the HIRE Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.F.</B></TD><TD><B>Dividends and paying agents</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.G.</B></TD><TD><B>Statement by experts</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.H.</B></TD><TD><B>Documents on display</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are subject to certain of the information
reporting requirements of the Exchange Act. As a foreign private issuer, we are exempt from the rules and regulations under the
Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders
are exempt from the reporting and &ldquo;short-swing&rdquo; profit recovery provisions contained in Section 16 of the Exchange
Act, with respect to their purchase and sale of our Ordinary Shares. In addition, we are not required to file reports and financial
statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.
However, we are required to file with the SEC, within four months after the end of each fiscal year, an annual report on Form 20-F
containing financial statements audited by an independent accounting firm. We publish unaudited interim financial information after
the end of each quarter. We furnish this quarterly financial information to the SEC under cover of a Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">You may read and copy any document we file with
the SEC at its public reference facilities at 100 F Street, NE, Washington, D.C. 20549. You may also obtain copies of the documents
at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, NE, Washington, D.C. 20549. The SEC
also maintains a website that contains reports, proxy and information statements and other information regarding registrants that
file electronically with the SEC. The address of this website is http://www.sec.gov. Please call the SEC at 1-800-SEC-0330 for
further information on the operation of the public reference facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.I.</B></TD><TD><B>Subsidiary information</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">item&nbsp;11.</TD><TD STYLE="text-align: left"><A NAME="a_013"></A>Quantitative and Qualitative Disclosures About Market Risk</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In the ordinary course of our operations, we
are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Quantitative and Qualitative Disclosure About Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We are exposed to market risks in the ordinary
course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in
financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that have
a credit rating of at least A-minus. Accordingly, a substantial majority of our cash and cash equivalents is held in deposits that
bear interest. Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced.
Our market risk exposure is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following
paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Foreign Currency Exchange Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">Our results of operations
and cash flow are subject to fluctuations due to changes in NIS/U.S. dollar currency exchange rates. The vast majority of our liquid
assets is held in U.S. dollars, and a certain portion of our expenses is denominated in NIS. For instance, in 2014, approximately
23% of our expenses were denominated in NIS. Changes of 5% and 10% in the U.S. Dollar / NIS exchange rate will increase/decrease
our operating expenses by 1.7% and 3.5%, respectively. However, these historical figures may not be indicative of future exposure,
as we expect that the percentage of our NIS denominated expenses will materially decrease in the near future, therefore reducing
our exposure to exchange rate fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">We do not hedge our foreign
currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial
exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately
protect us from the material adverse effects of such fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;12.</TD><TD STYLE="text-align: left"><A NAME="a_014"></A>Description of Securities other than Equity Securities</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We do not have any outstanding American Depositary
Shares or American Depositary Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in"><A NAME="a_015"></A><U>Part
two</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;13.</TD><TD STYLE="text-align: left"><A NAME="a_016"></A>Defaults, dividend arrearages and delinquencies</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">None.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 70.9pt; text-transform: uppercase; text-align: left; text-indent: -70.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 70.9pt">Item&nbsp;14.</TD><TD STYLE="text-align: left"><A NAME="a_017"></A>Material modifications to the rights of security holders and use of proceeds</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">None.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;15.</TD><TD STYLE="text-align: left"><A NAME="a_018"></A>CONTROLS AND PROCEDURES</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(a) Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our management, with the participation of our
Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2014, or the Evaluation Date.
Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures
are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic
filings under the Exchange Act and that such information is accumulated and communicated to management, including our principal
executive and financial officers,&nbsp;as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(b) Management's Annual Report on Internal Control over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">This annual report does not include a report
of management&rsquo;s assessment regarding internal control over financial reporting due to a transition period established by
rules of the SEC for newly public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(c) Attestation Report of the Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">This annual report does not include an attestation
report of our registered public accounting firm due to a transition period established by rules of the SEC for newly public companies
and because we are an emerging growth company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(d) Changes in Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">During the year ended December 31, 2014, there
were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="text-transform: none">ITEM&nbsp;16A.</FONT></TD><TD STYLE="text-align: left"><A NAME="a_019"></A><FONT STYLE="text-transform: none">Audit Committee Financial Expert</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our Board of Directors has determined that Gili
Cohen, a member of our Audit Committee, is an audit committee financial expert, as defined under the rules under the Exchange Act,
and are independent in accordance with applicable Exchange Act rules and Nasdaq rules.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="text-transform: none">ITEM&nbsp;16B.</FONT></TD><TD STYLE="text-align: left"><A NAME="a_020"></A><FONT STYLE="text-transform: none">Code of Ethics</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">We have adopted a written code of ethics that
applies to our officers and employees, including our principal executive officer, principal financial officer, principal controller
and persons performing similar functions as well as our directors. Our Code of Business Conduct and Ethics is posted on our website
at www.bioblast-pharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="text-transform: none">ITEM&nbsp;16C.</FONT></TD><TD STYLE="text-align: left"><A NAME="a_021"></A><FONT STYLE="text-transform: none">Principal Accountant Fees and Services</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Kost Forer Gabbay &amp; Kasierer (a Member of
EY Global), has served as our principal independent registered public accounting firm for each of the two years ended December
31, 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The following table provides information regarding
fees paid by us to Kost Forer Gabbay &amp; Kasierer and/or other member firms of EY Global for all services, including audit services,
for the years ended December&nbsp;31, 2014 and 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -12.25pt; padding-left: 12.25pt">Audit fees <SUP>(1)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">49,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">60,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 0.25in">Audit-related fees <SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.25in">Tax fees <SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 0.25in; padding-bottom: 1pt">All other fees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 0.25in; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">57,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">302,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; border-bottom: Black 1pt solid">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.75pt">(1)</TD><TD>Includes professional services rendered in connection with the audit of our annual financial statements and the review of our
interim financial statements.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.75pt">(2)</TD><TD>Includes fees for our initial public offering.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.75pt">(3)</TD><TD>Includes professional fees related to tax returns and other tax related services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 17.75pt; text-indent: -17.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Pre-Approval of Auditors' Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Our Audit Committee has adopted a pre-approval
policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services.
Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the
Audit Committee pre-approves annually a catalog of specific audit and non-audit services in the categories of audit services, audit-related
services and tax services that may be performed by our independent registered public accounting firm. If a type of service, that
is to be provided by our auditors, has not received such general pre-approval, it will require specific pre-approval by our Audit
Committee. The policy prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit
functions defined in applicable SEC rules. All of the fees in the table above were either pre-approved according to this policy,
or otherwise pre-approved by our Audit Committee or Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="text-transform: none">ITEM&nbsp;16D.</FONT></TD><TD STYLE="text-align: left"><A NAME="a_022"></A><FONT STYLE="text-transform: none">Exemptions from the Listing Standards for Audit Committees</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="text-transform: none">ITEM&nbsp;16E.</FONT></TD><TD STYLE="text-align: left"><A NAME="a_023"></A><FONT STYLE="text-transform: none">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="text-transform: none">ITEM&nbsp;16F.</FONT></TD><TD STYLE="text-align: left"><A NAME="a_024"></A><FONT STYLE="text-transform: none">Change in Registrant's Certifying Accountant</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="text-transform: none">ITEM&nbsp;16G.</FONT></TD><TD STYLE="text-align: left"><A NAME="a_025"></A><FONT STYLE="text-transform: none">Corporate Governance</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Sarbanes-Oxley Act, as well as related rules
subsequently implemented by the SEC, require foreign private issuers, such as us, to comply with various corporate governance practices.
In addition, we are required to comply with the Listing Rules of NASDAQ. Under those Listing Rules, we may elect to follow certain
corporate governance practices permitted under the Israeli Companies Law in lieu of compliance with corresponding corporate governance
requirements otherwise imposed by the Listing Rules of NASDAQ for U.S. domestic issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In accordance with Israeli law and practice and
subject to the exemption set forth in Rule&nbsp;5615 of the Listing Rules of NASDAQ, we have elected to follow the provisions of
the Israeli Companies Law, rather than the Listing Rules of NASDAQ, with respect to the following requirements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD><I>Distribution of periodic reports to shareholders; proxy solicitation.</I>&nbsp;&nbsp;&nbsp;&nbsp;As opposed to the Listing
Rules of NASDAQ, which require listed issuers to make such reports available to shareholders in one of a number of specific manners,
Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice
in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. In addition
to making such reports available on a public website, we currently make our audited financial statements available to our shareholders
at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt
from the SEC's proxy solicitation rules.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -21.05pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD><I>Nomination of our directors.</I>&nbsp;&nbsp;&nbsp;&nbsp;With the exception of our external directors and directors elected
by our Board of Directors due to vacancy, our directors are elected by an annual meeting of our shareholders to hold office until
the next annual meeting. See Item 6.C. &ndash; &ldquo;Board Practices &ndash; Board of Directors.&rdquo; The nominations for directors,
which are presented to our shareholders by our Board of Directors, are generally made by the Board of Directors itself, in accordance
with the provisions of our articles of association and the Israeli Companies Law. Nominations need not be made by a nominating
committee of our Board of Directors consisting solely of independent directors, or by a majority of independent directors, as required
under the Listing Rules of NASDAQ. Nominations may also be made by one or more of our shareholders, as provided under the Israeli
Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -21.05pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD><I>Compensation of officers.</I>&nbsp;&nbsp;&nbsp;&nbsp;Israeli law and our articles of association do not require that the
independent members of our Board of Directors (or a Compensation Committee composed solely of independent members of our Board
of Directors) determine an executive officer&rsquo;s compensation, as is generally required under the Listing Rules of NASDAQ with
respect to the Chief Executive Officer and all other executive officers. Instead, compensation of executive officers is determined
and approved by our Board of Directors, our Compensation Committee, and in some events, our shareholders, either in consistency
with our Compensation Policy or, in special circumstances, taking into account certain considerations stated in the Israeli Companies
Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: 0">Shareholder approval is generally required in
the event (i) approval by our Board of Directors and our Compensation Committee is not consistent with our office holders Compensation
Policy, or (ii) compensation required to be approved is that of Our Chief Executive officer or an executive officer who is also
the controlling shareholder of us (including an affiliate thereof). Such shareholder approval shall require a majority vote of
the shares present and voting at a shareholders meeting, provided either (i) such majority includes a majority of the shares held
by non-controlling shareholders who do not have a personal interest in the compensation arrangement that are voted at the meeting,
excluding for such purpose any abstentions disinterested majority, or (ii) the total shares held by non-controlling disinterested
shareholders voted against the arrangement does not exceed two percent (2%) of the voting rights in us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: 0">Additionally, approval of the compensation of
an executive officer, who is also a director, shall require a simple majority vote of the shares present and voting at a shareholders
meeting, if consistent with our office holders Compensation Policy or a special majority as set forth above if the proposed compensation
for the director is not consistent with our Compensation Policy. Our Compensation Committee and Board of Directors may, in special
circumstances, approve the compensation of an executive officer (other than a director or a controlling shareholder) despite shareholders&rsquo;
objection, based on specified arguments and taking shareholders&rsquo; objection into account. Our Compensation Committee may exempt
an engagement with a nominee for the position of Chief Executive Officer, who meets the non-affiliation requirements set forth
for an external director, from requiring shareholders&rsquo; approval, if such engagement is consistent with our office holders
Compensation Policy and our Compensation Committee determines based on specified arguments that presentation of such engagement
to shareholders&rsquo; approval is likely to prevent such engagement. To the extent that any such transaction with a controlling
shareholder is for a period extending beyond three years, approval is required once every three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: 0">A director or executive officer may not be present
when the Compensation Committee or Board of Directors of a company discusses or votes upon the terms of his or her compensation,
unless the Chairman of the Compensation Committee or Board of Directors (as applicable) determines that he or she should be present
to present the transaction that is subject to approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD><I>Independent directors.</I>&nbsp;&nbsp;&nbsp;&nbsp;Israeli law does not require that a majority of the directors serving
on our Board of Directors be &ldquo;independent,&rdquo; as defined under NASDAQ Listing Rule&nbsp;5605(a)(2), and rather requires
we have at least two external directors who meet the requirements of the Israeli Companies Law, as described above under Item 6.C.
&ndash; &ldquo;Board Practices &ndash; External Directors.&rdquo; We are required, however, to ensure that all members of our Audit
Committee are &ldquo;independent&rdquo; under the applicable NASDAQ and SEC criteria for independence (as we cannot exempt ourselves
from compliance with that SEC independence requirement, despite our status as a foreign private issuer), and we must also ensure
that a majority of the members of our Audit Committee are &ldquo;unaffiliated directors&rdquo; as defined in the Israeli Companies
Law. Furthermore, Israeli law does not require, nor do our independent directors conduct, regularly scheduled meetings at which
only they are present, which the Listing Rules of NASDAQ otherwise require.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -21.05pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD><I>Shareholder approval.</I>&nbsp;&nbsp;&nbsp;&nbsp;We will seek shareholder approval for all corporate actions requiring such
approval under the requirements of the Israeli Companies Law, rather than seeking approval for corporation actions in accordance
with NASDAQ Listing Rule&nbsp;5635. In particular, under this NASDAQ rule, shareholder approval is generally required for: (i)&nbsp;an
acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer's shares or voting rights
or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received;
(ii)&nbsp;the issuance of shares leading to a change of control; (iii)&nbsp;adoption/amendment of equity compensation arrangements;
and (iv)&nbsp;issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for,
equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is
issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Israeli Companies Law, shareholder
approval is required for, among other things: (i)&nbsp;transactions with directors concerning the terms of their service or indemnification,
exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the
Compensation Committee, Board of Directors and shareholders are all required, (ii)&nbsp;extraordinary transactions with controlling
shareholders of publicly held companies, which require the special approval described below under &ldquo;Approval of Related Party
Transactions under Israeli Law<B> &mdash;</B> Disclosure of personal interests of controlling shareholders&rdquo;, and (iii)&nbsp;terms
of employment or other engagement of the controlling shareholder of the company or such controlling shareholder's relative, which
require the special approval described below under &ldquo;Approval of Related Party Transactions under Israeli Law<B> &mdash;</B>
Disclosure of personal interests of controlling shareholders&rdquo;. In addition, under the Israeli Companies Law, a merger requires
approval of the shareholders of each of the merging companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Approval of Related Party Transactions under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Disclosure of personal interests of a controlling shareholder
and approval of transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law also requires that
a controlling shareholder promptly disclose to the company any personal interest that he or she may have and all related material
information or documents relating to any existing or proposed transaction by the company. A controlling shareholder&rsquo;s disclosure
must be made promptly and in any event no later than the first meeting of the Board of Directors at which the transaction is considered.
Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including
a private placement in which a controlling shareholder has a personal interest, and the terms of engagement of the company, directly
or indirectly, with a controlling shareholder or a controlling shareholder&rsquo;s relative (including through a corporation controlled
by a controlling shareholder), regarding the company&rsquo;s receipt of services from the controlling shareholder, and if such
controlling shareholder is also an office holder of the company, regarding his or her terms of employment, require the approval
of each of (i) the Audit Committee or the Compensation Committee with respect to the terms of the engagement of the company, (ii)
the Board of Directors and (iii) the shareholders, in that order. In addition, the shareholder approval must fulfill one of the
following requirements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting
must be voted in favor of approving the transaction, excluding abstentions; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36.05pt; text-indent: -21.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15pt"></TD><TD STYLE="width: 21.05pt"><FONT STYLE="font-family: Wingdings">&Yuml;</FONT></TD><TD>the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent
no more than 2.0% of the voting rights in the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">In addition, any extraordinary transaction with
a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three years requires
the abovementioned approval every three years, however, such transactions not involving the receipt of services or compensation
can be approved for a longer term, provided that the Audit Committee determines that such longer term is reasonable under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">The Israeli Companies Law requires that every
shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling
shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question.
Failure to so indicate will result in the invalidation of that shareholder&rsquo;s vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="text-transform: none">ITEM&nbsp;16H.</FONT></TD><TD STYLE="text-align: left"><A NAME="a_026"></A><FONT STYLE="text-transform: none">Mine Safety Disclosure</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: left; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_029"></A><U>Part
Three</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;17.</TD><TD STYLE="text-align: justify"><A NAME="a_027"></A>Financial statements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;18.</TD><TD STYLE="text-align: justify"><A NAME="a_028"></A>Financial statements</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following financial statements, and the
related notes thereto, and the Reports of Independent Public Accountants are filed as a part of this annual report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><A HREF="#f_001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#f_002">Balance Sheets</A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#f_003"><FONT STYLE="font-size: 10pt">Statements of Operations</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#f_004">Statements of Changes in Shareholders' Equity</A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#f_005">Statements of Cash Flows</A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#f_006">Notes to Financial Statements</A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item&nbsp;19.</TD><TD STYLE="text-align: justify"><A NAME="a_030"></A>Exhibits</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: Black 1pt solid"><B>EXHIBIT</B><BR>
<B>NUMBER</B></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; border-bottom: Black 1pt solid"><B>DESCRIPTION OF DOCUMENT </B></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">1.1</TD>
    <TD>&nbsp;</TD>
    <TD>Articles of Association of the Company, filed as Exhibit 3.2 to Form F-1/A filed on July 8, 2014 (File No. 333-193824) and incorporated herein by reference. &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">4.1</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Services Agreement between the Company and Top-Notch Consultancy 2009 Ltd., dated April 22, 2014, filed as Exhibit 10.2 to Form F-1/A filed on July 15, 2014 (File No. 333-193824) and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">4.2</TD>
    <TD>&nbsp;</TD>
    <TD>BioBlast Pharma Ltd. 2013 Incentive Option Plan, filed as Exhibit 10.3 to Form F-1/A filed on March 17, 2014 (File No. 333-193824) and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">4.3</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Indemnification Agreement, filed as Exhibit 10.4 to Form F-1/A filed on April 8, 2014 (File No. 333-193824) and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">4.4</TD>
    <TD>&nbsp;</TD>
    <TD>Engagement Letter between the Company and Fredric Price dated April 24, 2012, filed as Exhibit 10.8 to Form F-1/A filed on July 15, 2014 (File No. 333-193824) and incorporated herein by reference. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">4.5</TD>
    <TD>&nbsp;</TD>
    <TD>Engagement Letter between the Company and Fredric Price dated April 22, 2014, filed as Exhibit 10.6 to Form F-1/A filed on July 15, 2014 (File No. 333-193824) and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">4.6</TD>
    <TD>&nbsp;</TD>
    <TD>Engagement Letter between the Company and Marlene Haffner dated May 13, 2013, filed as Exhibit 10.7 to Form F-1/A filed on March 17, 2014 (File No. 333-193824) and incorporated herein by reference.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">12.1</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%">Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">12.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">13.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">13.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">101</TD>
    <TD>&nbsp;</TD>
    <TD>The following materials from our Annual Report on Form 20-F for the year ended December 31, 2014 formatted in XBRL (eXtensible Business Reporting Language) are furnished herewith: (i) the Balance Sheets, (ii) the Statements of Comprehensive Loss, (iii) the Statements of Changes in Shareholders' Equity, (iv) the Statements of Cash Flows and (v) the Notes to Financial Statements, tagged as blocks of text and in detail.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioBlast Pharma Ltd. hereby certifies that
it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
annual report on its behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt; text-transform: uppercase">BioBlast PharMa LTD.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Colin Foster</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Colin Foster</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chief Executive Officer and President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Date: March 30, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in"></P>

<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%"><i>20-F BioBlast Pharma Ltd.</i></TD><TD STYLE="text-align: right; width: 50%"><i>Page</i> <i><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></i></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-transform: uppercase; text-align: left; text-indent: -1in"></P>
<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.4pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: center"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS OF DECEMBER 31, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>U.S. DOLLARS IN THOUSANDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 86%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 14%; border-bottom: Black 1pt solid; padding-left: 2.85pt; text-align: center; font-weight: bold"><FONT STYLE="font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#f_001"><B>Report of Independent Registered Public Accounting Firm</B></A></TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center"><B>2 </B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#f_002"><B>Balance Sheets</B></A></TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center"><B>3</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#f_003"><B>Statements of Operations</B></A></TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center"><B>4</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#f_004"><B>Statements of Changes in Shareholders' Equity</B></A></TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center"><B>5</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#f_005"><B>Statements of Cash Flows</B></A></TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center"><B>6</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#f_006"><B>Notes to Financial Statements </B></A></TD>
    <TD STYLE="padding-left: 2.85pt; text-align: center"><B>7 - 18</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: justify"><IMG SRC="tlogo.jpg" ALT=""></TD>
    <TD STYLE="width: 30%; text-align: left; vertical-align: bottom"><B>Kost Forer Gabbay &amp; Kasierer</B><BR>
    3 Aminadav St.<BR>
    Tel-Aviv 6706703, Israel</TD>
    <TD STYLE="width: 50%; text-align: left; vertical-align: bottom">Tel: +972-3-6232525<BR>
    <FONT STYLE="font-size: 10pt">Fax: +972-3-5622555</FONT><BR>
    <FONT STYLE="font-size: 10pt">ey.com</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="f_001"></A><B>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>To the Shareholders and Board of Directors
of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">We have audited
the accompanying balance sheets of BioBlast Pharma Ltd. (&quot;the Company&quot;) as of December&nbsp;31, 2014 and 2013, and the
related statements of operations, changes in shareholders' equity and cash flow for each of the three years in the period ended
December 31, 2014. These financial statements are the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">We conducted our
audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our audits included
consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the
circumstances but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial
reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts
and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by the and
management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis
for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">In our opinion,
the financial statements referred to above present fairly, in all material respects, the consolidated financial position of the
Company and its subsidiary as of December 31, 2014 and 2013, and the consolidated results of their operations and their cash flows
for each of the three years in ended December 31, 2014, in conformity with U.S. generally accepted accounting principles<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-left: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="width: 50%; padding-left: 14.2pt; text-align: center; font-weight: bold; text-indent: -11.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">/s/
    KOST     FORER GABBAY &amp; KASIERER</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">March 31, 2015</FONT></TD>
    <TD STYLE="padding-left: 14.2pt; text-align: center; text-indent: -11.35pt">A Member of EY Global</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 121; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><A NAME="f_002"></A><B>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1pt solid"><B>BALANCE
SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S. dollars in thousands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10,583</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">270</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Short-term bank deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,028</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">Receivables and prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">274</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0"><U>Total</U> current
    assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,885</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0">LONG-TERM ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Long-term deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">60</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Total long-term assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">69</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,954</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">306</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 28.35pt">LIABILITIES AND SHAREHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Trade payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">46</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">Other accounts payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">995</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: none; text-align: left; padding-bottom: 2.5pt; padding-left: 0"><U>Total</U> current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,280</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">131</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0">SHAREHOLDERS' EQUITY:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 0.25in">Ordinary shares of NIS 0.01 par value - 50,000,000
    and 16,613,139 shares authorized at December&nbsp;31, 2014 and 2013, respectively; 14,230,480 and 9,182,867 issued and outstanding
    shares at December&nbsp;31, 2014 and 2013, respectively;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Additional paid- in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,057</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,551</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,422</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,400</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: none; text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt"><U>Total
    </U>shareholders' equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,674</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">175</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.5pt; padding-left: 19.85pt">TOTAL LIABILITIES AND SHAREHOLDERS'
    EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,954</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">306</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral
part of the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 122; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><A NAME="f_003"></A><B>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1pt solid"><B>STATEMENTS
OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S. dollars in thousands, (except
share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended <BR>December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,441</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">732</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">140</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,639</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">416</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">86</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">226</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Financial expenses (income), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(58</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,022</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,145</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">229</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deemed dividend</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss attributable to holders of Ordinary shares</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,022</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,171</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">229</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.57</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Weighted average number
    of Ordinary shares used in computing basic and diluted loss per share</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,259,600</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,423,018</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,551,427</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral
part of the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 123; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="f_004"></A>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1pt solid"><B>STATEMENTS
OF CHANGES IN SHAREHOLDERS' EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S. dollars in thousands, except share
data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Ordinary
    shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Preferred
    A shares</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Additional</FONT><BR>
    <FONT STYLE="font-size: 8pt">paid-in</FONT><BR></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Accumulated</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Total</FONT><BR>
    <FONT STYLE="font-size: 8pt">shareholders'</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Number</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Number</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">capital</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">deficit</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">equity</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 8pt">Balance as of January
    22, 2012 (date of inception)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 8pt">Issuance
    of Ordinary shares to founders</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">7,551,427</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">20</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">(20</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 8pt">Issuance of Preferred
    A shares, net ($0.53 per share)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">566,357</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">294</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">295</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 8pt">Share based compensation</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 8pt">Loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(229</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(229</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 8pt">Balance as of December
    31, 2012</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,551,427</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">566,357</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">283</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(229</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">75</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Conversion of Preferred
    A shares into Ordinary shares</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">566,357</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(566,357</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Deemed Dividend</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">26</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(26</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Issuance of Ordinary
    shares, net ($0.95 per share)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,065,083</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">988</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">991</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Share based compensation</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">254</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">254</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(1,145</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(1,145</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 8pt">Balance as of December
    31, 2013</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9,182,867</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,551</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1,400</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">175</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Issuance of Ordinary
    shares, net ($0.95 per share)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,065,076</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,009</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,012</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Issuance of Ordinary
    shares upon private placement, net ($6.07 per share)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">782,537</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,365</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,368</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Issuance of Ordinary
    shares upon initial public offering, net ($11 per share)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,200,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">31,396</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">31,405</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Share based compensation</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">736</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">736</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt"><FONT STYLE="font-size: 8pt">Loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(7,022</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(7,022</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"><FONT STYLE="font-size: 8pt">Balance
    as of December 31, 2014</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">14,230,480</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">39</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">39,057</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">(8,422</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">30,674</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral
part of the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<!-- Field: Page; Sequence: 124; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><A NAME="f_005"></A><B>BIOBLAST PHARMA LTD.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; border-bottom: Black 1pt solid"><B>STATEMENTS
OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S. dollars in thousands, except share
data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended <BR>December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left; padding-left: 0; text-indent: 0">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(7,022</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(1,145</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(229</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Adjustments to reconcile loss to net cash used in
    operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;- *)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">736</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Interest on short-term bank deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Receivables and prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(245</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Long-term deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Trade payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,239</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">Other accounts payables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">910</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 28.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,409</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(865</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left; padding-left: 0">Cash flows from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;Short-term bank deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2.85pt">&nbsp;Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(63</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22,063</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left; padding-left: 0">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">Issuance of shares, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,785</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">991</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">295</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,785</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">991</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">295</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Cash and cash equivalents at the beginning of the year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">270</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">146</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Cash and cash equivalents at the end of the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,583</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">270</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">146</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"></TD><TD STYLE="text-align: justify">*) Represents an amount lower than $1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral
part of the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 125; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><A NAME="f_006"></A><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; border-bottom: Black 1pt solid"><B>NOTES
TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S. dollars in thousands, except share
data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.8pt; text-align: left">NOTE&nbsp;1:-</TD><TD STYLE="text-align: justify">GENERAL</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left">a.</TD><TD STYLE="text-align: justify">BioBlast Pharma
                                         Ltd. (the &quot;Company&quot;) was incorporated in Israel and commenced its operations
                                         on January 22, 2012. The Company is a clinical-stage biotechnology company committed
                                         to developing clinically meaningful therapies for patients with rare and ultra-rare genetic
                                         diseases. The Company is rapidly building a diverse portfolio of product candidates with
                                         the potential to address unmet medical needs for incurable diseases. The Company's platforms
                                         are based on deep understanding of the disease-causing biological processes, and potentially
                                         offer solutions for several diseases that share the same biological pathology. The Company
                                         seeks to identify therapeutic platforms that offer solutions for several diseases that
                                         share a common pathophysiological mechanism. The Company's objective is to conduct additional
                                         clinical trials for its drugs (the &quot;Drugs&quot;) and, if those trials are successful,
                                         seek marketing approval from the U.S. Food and Drug Administration (the &quot;FDA&quot;)
                                         and other worldwide regulatory bodies.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left">b.</TD><TD STYLE="text-align: justify">The Company is
                                         engaged in the research and development of products in the biopharmaceutical field, has
                                         not generated revenue from the sale of any product, and does not expect to generate significant
                                         revenue unless and until the obtaining of marketing approval, and commercializing its
                                         Drugs. The Company has incurred losses in the amount of $7,022 during the year ended
                                         December 31, 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left">c.</TD><TD STYLE="text-align: justify">During August
                                         2014, the Company completed an Initial Public Offering (&quot;IPO&quot;) in United States
                                         in which it issued 3,200,000 Ordinary shares in consideration of approximately $31,405,
                                         net and its Ordinary shares began trading on the &quot;NASDAQ Capital Market&quot;.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.8pt; text-align: left">NOTE&nbsp;2:-</TD><TD STYLE="text-align: justify">SIGNIFICANT
                                         ACCOUNTING POLICIES</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">The financial
statements have been prepared in accordance with accounting principles generally accepted in the United States (&quot;U.S. GAAP&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">a.</TD><TD STYLE="text-align: justify">Use of estimates:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">The preparation
of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The
Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses
during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 126; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;2:-</TD><TD STYLE="text-align: justify">SIGNIFICANT
                                         ACCOUNTING POLICIES (Cont.)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left">b.</TD><TD STYLE="text-align: justify">New accounting
                                         pronouncements:</TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In
                                         June 2014 the Financial Accounting Standards Board (&quot;FASB&quot;) issued Accounting
                                         Standards Update (&quot;ASU&quot;) 10-2014 (&quot;ASU 10-2014&quot;) regarding development
                                         stage entities. The ASU removes the definition of development stage entity, as was previously
                                         defined under U.S. GAAP, from the accounting standards codification, thereby removing
                                         the financial reporting distinction between development stage entities and other reporting
                                         entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development
                                         stage entities to (i) present inception-to-date information in the statement of income,
                                         cash flow and stockholders' equity, (ii) label the financial statements as those of a
                                         development stage entity, (iii) disclose a description of the development stage activities
                                         in which the entity is engaged, and (iv) disclose in the first year in which the entity
                                         is no longer a development stage entity that in prior years it had been in the development
                                         stage. The amendments to ASU 10-2014 are effective for annual reporting periods beginning
                                         after December 15, 2014. The Company has applied the ASU in these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In 2014, the FASB issued
ASU 15-2014, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's
Ability to Continue as a Going Concern, which defines management&rsquo;s responsibility to assess an entity&rsquo;s ability to
continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue
as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption
permitted. The Company is currently evaluating the effect, if any, that the adoption of this guidance will have on the Company&rsquo;s
financial statements.</P>

</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">c.</TD><TD STYLE="text-align: justify">Financial statements in U.S. dollars:</TD></TR>                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The
                                         Company finances its operation in U.S. dollars. The majority of the Company's operations
                                         are currently conducted in Israel, a significant part of the Company's expenses are denominated
                                         and determined in U.S. dollars. The Company's management believes that the dollar is
                                         the currency of the primary economic environment in which the Company operates and expects
                                         to continue to operate in the foreseeable future. Thus, the functional currency of the
                                         Company is the U.S.&nbsp;dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company's transactions
and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been
remeasured to U.S. dollars in accordance with Accounting Standards Codification (&quot;ASC&quot;) 830, &quot;Foreign Currency
Matters&quot;, of the FASB. All transaction gains and losses from remeasurement of monetary balance sheet items denominated in
non-dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate.</P>

</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">d.</TD><TD STYLE="text-align: justify">Cash equivalents:</TD></TR>                                                                                                                                                                                                                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">Cash
                                         equivalents are short-term highly liquid investments that are readily convertible to
                                         cash with original maturities of three months or less at acquisition.</P>


</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 127; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;2:-</TD><TD STYLE="text-align: justify">SIGNIFICANT
                                         ACCOUNTING POLICIES (Cont.)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">e.</TD><TD STYLE="text-align: justify">Short-term bank deposits:</TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">Short-term bank deposits are deposits with maturities of more than
                              three months but less than one year. Short&ndash;term bank deposits are presented at their cost,
                              including accrued interest, which approximates fair value. As of December&nbsp;31, 2014, the Company's
                              bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.66%.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">f.</TD><TD STYLE="text-align: justify">Property and equipment, net:</TD></TR>                                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property
                                         and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated
                                         using the straight-line method over the estimated useful lives of the assets at the following
                                         rates:</P>

</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.03in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; padding-left: -0.125in">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left; padding-left: 0in">Computers and software</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Electronic equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">Office furniture and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                                                                                                                                                                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">The Company's property and equipment are reviewed for impairment
                              in accordance with ASC 360, &quot;Property, Plant, and Equipment,&quot; whenever events or changes
                              in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
                              of assets to be held and used is measured by a comparison of the carrying amount of an asset to
                              the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
                              to be impaired, the impairment to be recognized is measured by the amount by which the carrying
                              amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported
                              at the lower of the carrying amount or fair value less costs to sell. In 2014, 2013 and 2012 no
                              impairment losses have been identified.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">g.</TD><TD STYLE="text-align: justify">Long-term deposits:</TD></TR>                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">Long-term deposits include long-term deposits for motor vehicles
                              under operating leases, presented at their cost.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">h.</TD><TD STYLE="text-align: justify">Research and development costs:</TD></TR>                                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Research
                                         and development costs are expensed as incurred. Those expenses includes payments to third
                                         party clinical consultants, expenses related to conducting clinical trials, salaries
                                         and related personnel expenses, travel expenses, and share based compensation expenses
                                         related to research and development employees.</P>


</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 128; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;2:-</TD><TD STYLE="text-align: justify">SIGNIFICANT
                                         ACCOUNTING POLICIES (Cont.)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">i.</TD><TD STYLE="text-align: justify">Income taxes:</TD></TR>                                                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">The Company accounts
                                         for income taxes in accordance with ASC 740, &quot;Income Taxes&quot;. This topic prescribes
                                         the use of the liability method whereby deferred tax assets and liability account balances
                                         are determined based on differences between financial reporting and tax bases of assets
                                         and liabilities and are measured using the enacted tax rates and laws that will be in
                                         effect when the differences are expected to reverse. The Company provides a valuation
                                         allowance to reduce deferred tax assets to the amount that is more likely than not to
                                         be realized.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">The Company implements
                                         a two-step approach to recognize and measure uncertain tax positions. The first step
                                         is to evaluate the tax position taken or expected to be taken in a tax return by determining
                                         if the weight of available evidence indicates that it is more likely than not that, on
                                         an evaluation of the technical merits, the tax position will be sustained on audit, including
                                         resolution of any related appeals or litigation processes. The second step is to measure
                                         the tax benefit as the largest amount that is more than 50% (cumulative basis) likely
                                         to be realized upon ultimate settlement. As of December 31, 2014 and 2013, the Company
                                         has not recorded a liability for uncertain tax positions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">j.</TD><TD STYLE="text-align: justify">Concentrations of credit risk:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">Financial instruments
                                         that potentially subject the Company to concentrations of credit risk consist principally
                                         of cash and cash equivalents.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">Cash and cash equivalents
                                         are invested in major banks in Israel. Management believes that the financial institutions
                                         that hold the Company's investments are financially sound and, accordingly, minimal credit
                                         risk exists with respect to these investments.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">The Company has
                                         no off-balance-sheet concentration of credit risk such as foreign exchange contracts,
                                         option contracts or other foreign hedging arrangements.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">k.</TD><TD STYLE="text-align: justify">Fair value of financial instruments:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">The Company has
                                         no financial instruments that are measured at fair value.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -32.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt"></TD><TD STYLE="text-align: justify">The carrying amounts of cash and cash
                                         equivalents, short-term bank deposits, accounts receivable and accounts payable, approximate
                                         their fair value due to the short-term maturities of such instruments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -25.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">l.</TD><TD STYLE="text-align: justify">Basic and diluted loss per share:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">Basic net loss per
                                         share is computed based on the weighted average number of Ordinary shares outstanding
                                         during each year. Diluted loss per share is computed based on the weighted average number
                                         of Ordinary shares outstanding during each year plus dilutive potential equivalent Ordinary
                                         shares considered outstanding during the year, in accordance with ASC 260, &quot;Earnings
                                         per Share.&quot;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 129; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;2:-</TD><TD STYLE="text-align: justify">SIGNIFICANT
                                         ACCOUNTING POLICIES (Cont.)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">For the years ended
                                         December&nbsp;31, 2014, 2013 and 2012, all outstanding options have been excluded from
                                         the calculation of the diluted net loss per share since their effect was anti-dilutive.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt">m.</TD><TD STYLE="text-align: justify">Accounting for stock-based compensation:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">The Company accounts
                                         for stock-based compensation in accordance with ASC 718, &quot;Compensation - Stock Compensation&quot;
                                         (&quot;ASC 718&quot;) that requires the measurement and recognition of compensation expense
                                         based on estimated fair values for all share-based payment awards made to employees and
                                         directors. ASC 718 requires companies to estimate the fair value of equity-based payment
                                         awards on the date of grant using an option-pricing model. The value of the option award
                                         is recognized as an expense over the requisite service periods in the Company's statements
                                         of operations based on the accelerated method.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify">The Company selected
                                         the Black-Scholes-Merton (&quot;Black-Scholes&quot;) option-pricing model as the fair
                                         value method for of its stock-options awards. The option-pricing model requires a number
                                         of assumptions as noted below:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify"><I>Expected dividend
                                         yield</I> - The expected dividend yield assumption is based on the Company's historical
                                         experience and expectation of no future dividend payouts. The Company has historically
                                         not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Volatility
                                         </I>- </FONT>Since the Company's shares started trading on NASDAQ in July 2014, sufficient
                                         quoted prices of the Company's share are unavailable. Due to insufficient historical
                                         data for the Company, the expected volatility determination was based on similar companies'
                                         stock volatility.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify"><I>Risk free interest
                                         rate</I> - The risk free interest rate is based on the yield of U.S. Treasury bonds with
                                         equivalent terms.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 18pt; text-align: left"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Expected
                                         term</I></FONT> -<FONT STYLE="font-size: 10pt"> ASC 718 provides the factors to consider
                                         when estimating the expected term of an option: an option's expected term must at least
                                         include the vesting period and the employees' historical exercise and post-vesting employment
                                         termination behavior for similar grants. It also determines that if the amount of past
                                         exercise data is limited, that data may not represent a sufficiently large sample on
                                         which to base a robust conclusion on expected exercise behavior. In that circumstance,
                                         it may be appropriate to consider external data or the SEC staff's &quot;simplified&quot;
                                         method for the expected term. Accordingly, the Company used the &quot;simplified&quot;
                                         method, meaning the expected life can be set as the average of the vesting period for
                                         each vested tranche of options and the contractual term for those options.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 130; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;3:-</TD><TD STYLE="text-align: justify">RECEIVABLES
                                         AND PREPAID EXPENSES</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 87%; font: 10pt Times New Roman, Times, Serif; margin-left: 56.7pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 0in">Government authorities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">93</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">26</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0in">Prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">181</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 2.85pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">274</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left"><B>NOTE&nbsp;4:-</B></TD><TD STYLE="text-align: justify"><B>PROPERTY
                                         AND EQUIPMENT, NET</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 87%; font: 10pt Times New Roman, Times, Serif; margin-left: 56.7pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Cost:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 11.35pt">Computers and software</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">19</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 11.35pt">Electronic equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 11.35pt">Office furniture and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 2.85pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Accumulated depreciation:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11.35pt">Computers and software</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 11.35pt">Electronic equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 11.35pt">Office furniture and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Depreciated cost</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">60</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;*)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal">Represents
                                         an amount lower than $&nbsp;1.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">Depreciation expenses for the
years ended December 31, 2014, 2013 and 2012 were $5, less than $1 and $0, respectively.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;5:-</TD><TD STYLE="text-align: justify">OTHER
                                         ACCOUNTS PAYABLE</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 87%; font: 10pt Times New Roman, Times, Serif; margin-left: 56.7pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 0">Employees and payroll accruals</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">235</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">26</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0">Accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">760</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 2.85pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">995</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">85</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<!-- Field: Page; Sequence: 131; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;6:-</TD><TD STYLE="text-align: justify">INCOME TAXES</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt; text-align: left">a.</TD><TD STYLE="text-align: justify">Tax laws applicable
                                         to the Company:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">Taxable
income of Israeli companies is subject to tax at the rate of 25% in 2012 and 2013 and a rate of 26.5% in 2014 and afterwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">b.</TD><TD STYLE="text-align: justify">Net operating losses carry forward:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">The Company
has accumulated losses for tax purposes as of December&nbsp;31, 2014 in the amount of $684, which may be carried forward and offset
against taxable income in the future for an indefinite period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">c.</TD><TD STYLE="text-align: justify">Deferred income taxes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 82%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.19in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Operating loss carry forward</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">181</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">166</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">923</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net deferred tax asset before valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,791</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(312</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">Management
currently believes that since the Company has a history of losses it is more likely than not that the deferred tax regarding the
loss carry forward and other temporary differences will not be realized in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">d.</TD><TD STYLE="text-align: justify">No liability for uncertain tax
                                         positions was recorded as of December 31, 2014 and 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">e.</TD><TD STYLE="text-align: justify">The main reconciling item between
                                         the statutory tax rate of the Company and the effective tax rate is the recognition of
                                         valuation allowances in respect of deferred taxes due to the uncertainty of the realization
                                         of such deferred taxes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 132; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;7:-</TD><TD STYLE="text-align: justify">CONTINGENT
                                         LIABILITIES AND COMMITMENTS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: -27.75pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.75pt"></TD><TD STYLE="width: 28.3pt">a.</TD><TD STYLE="text-align: justify">The Company is engaged in an
                                         operating lease agreement for its office facilities. The rent expenses for the years
                                         ended December 31, 2014, 2013 and 2012 amounted to $88, $14 and $0. Future minimum payments
                                         under the lease are as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: justify; text-indent: 0in">2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">117</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in">2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">288</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">The Company
has provided bank guarantees in the amount of&nbsp;$25 as security for the performance of its lease agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.75pt"></TD><TD STYLE="width: 28.3pt">b.</TD><TD STYLE="text-align: justify">During 2014 the Company entered
                                         into a new operating lease agreement for its vehicles until 2017. Future minimum payments
                                         under the lease are $8. The lease expenses for the years ended December 31, 2014, 2013
                                         and 2012 amounted to $25, $11 and $0.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.75pt"></TD><TD STYLE="width: 28.3pt">c.</TD><TD STYLE="text-align: justify">License agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: left; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">The Company entered into a Research
                                         and Exclusive License Agreement with Yissum Research Development Company of the Hebrew
                                         University in Jerusalem Ltd., for the use, development and commercialization of TAT-MTS-
                                         Protein for protein replacement in mitochondrial diseases. The consideration to Yissum
                                         is composed of a tiered low single digit royalties on net sales and a sublicense fee
                                         that will not exceed the mid-high ten to twenty percent range of the sublicense consideration,
                                         but, if the sublicense arises from the sales of a product, the sublicense fee shall not
                                         be less than a low single digit percent of the gross sales of such product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company entered into an Exclusive License
Agreement with Ramot at Tel Aviv University Ltd. for the use, development and commercialization of our read-through platform. The
consideration to Ramot is composed of a tiered low single digit royalties on net sales and a sublicense fee that will not exceed
the mid to high single digit percent range of payments or other consideration that the Company receives in connection with a sublicense.</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;8:-</TD><TD STYLE="text-align: justify">SHAREHOLDERS'
                                         EQUITY</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">a.</TD><TD STYLE="text-align: justify">General:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in">All Ordinary
shares, options, per share data and exercise price included in these financial statements for all periods presented have been
retroactively adjusted to reflect the issuance on January 26, 2014 of 6.55-to-one bonus shares (equivalent to a 7.55-for-1 stock
split).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 133; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;8:-</TD><TD STYLE="text-align: justify">SHAREHOLDERS'
                                         EQUITY (Cont.)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">b.</TD><TD STYLE="text-align: justify">Share capital:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify; text-indent: 0in">The Ordinary
shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share
in the distribution of dividends, if any, declared by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">c.</TD><TD STYLE="text-align: justify">Issuances of share:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.05pt"></TD><TD STYLE="width: 28.35pt">1.</TD><TD STYLE="text-align: justify">On January 22, 2012 (inception
                                         day), the Company issued 7,551,427 Ordinary shares in consideration of their par value.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.05pt"></TD><TD STYLE="width: 28.35pt">2.</TD><TD STYLE="text-align: justify">In February 2012, the Company
                                         entered into an investment agreement, according to which the Company issued 471,964 Preferred
                                         A shares in consideration of $250. In addition, in August 2012, the Company issued 94,393
                                         Preferred A shares in consideration of $50. The issuance expenses amounted to $5.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 85.05pt"></TD><TD STYLE="width: 28.35pt; text-align: left">3.</TD><TD STYLE="text-align: justify">In June 2013,
                                         the Company entered into a share purchase agreement according to which, the Company issued
                                         a total of 2,130,159 Ordinary shares in consideration of $2,024, in two equal installments
                                         in 2013 and January 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in">Prior to
the closing of the share purchase agreement above and as a condition to it, the Company affected an equity restructuring, under
which, all of the Company's Preferred shares (566,357 Preferred A shares) were converted into Ordinary shares at a 1:1 ratio.
As a result and in accordance with ASC 718-20-35-6, the Company recorded compensation expense in the amount of $183 and a deemed
dividend in the amount of $26 in the year ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.05pt"></TD><TD STYLE="width: 28.35pt">4.</TD><TD STYLE="text-align: justify">On February 6, 2014, the Company
                                         issued 782,537 Ordinary shares to private placement investors in consideration of $4,368,
                                         net.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 85.05pt"></TD><TD STYLE="width: 28.35pt">5.</TD><TD STYLE="text-align: justify">On August 5, 2014, the Company
                                         completed a successful IPO of 3,200,000 Ordinary shares at a price of $11.00 per share
                                         generating net proceeds of $31,405, after deducting underwriting discounts and commissions
                                         and other issuance expenses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">d.</TD><TD STYLE="text-align: justify">2013 Incentive option plan:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">In December
2013, the Company authorized through its 2013 incentive option plan (the &quot;2013 Plan&quot;) the grant of options to officers,
directors, advisors, management and other key employees. The options granted have a graded vesting schedule of generally four
years and expire ten years after the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 134; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;8:-</TD><TD STYLE="text-align: justify">SHAREHOLDERS'
                                         EQUITY (Cont.)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">A summary
of the Company's options activity (for employees and directors) under the 2013 Plan is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR> average
    <BR> exercise<BR> &nbsp;price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR> average<BR>
    &nbsp;exercise<BR> &nbsp;price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: 0; padding-left: 0; padding-top: 0; padding-right: 0">Outstanding at
    beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">403,110</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.0004</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">319,531</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.0004</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0 0 1pt; text-indent: 0">Granted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">380,222</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9.21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,579</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.0004</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0; padding-top: 0; padding-right: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0 0 2.5pt; text-indent: 0">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">783,332</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.47</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">403,110</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0004</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0; padding-top: 0; padding-right: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0 0 2.5pt; text-indent: 0">Vested and expected to vest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">783,332</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.47</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">403,110</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0004</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0; padding-top: 0; padding-right: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0 0 2.5pt; text-indent: 0">Options exercisable at the end of the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">429,589</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.33</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">134,370</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0004</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">As of December
31, 2014, the weighted-average remaining contractual term of the outstanding and exercisable options is 5.6 years and 2.3 years;
the aggregated intrinsic value of the outstanding and exercisable options is $2,664 and $2,174. As of December 31, 2014, the unrecognized
compensation cost is $889 to be recognized through 2017.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">e.</TD><TD STYLE="text-align: justify">Options granted to service providers:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">The Company
granted options to certain service providers and accounted for these options in accordance with ASC 505-50, &quot;Equity-Based
payment to non-employees&quot;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">The outstanding
options granted to the Company's service providers are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 85.5pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Grant date</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise<BR> price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration<BR> &nbsp;date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 37%; text-align: justify; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: right; padding-left: 2.85pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0; padding-left: 0">December 2, 2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">7.78</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1pt; padding-left: 2.85pt">December 2, 2024</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">*) All options
were fully vested on the grant date.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">f.</TD><TD STYLE="text-align: justify">Share-based payment:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">The share
based expense recognized in the financial statements is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 85.05pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended <BR>December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left; padding-left: 0in">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">83</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">44</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0in">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">653</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">210</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.5pt; padding-left: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">736</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">254</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<!-- Field: Page; Sequence: 135; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;9:-</TD><TD STYLE="text-align: justify">RELATED
                                         PARTY BALANCES AND TRANSACTIONS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt; text-align: left"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Balances
                                         with related parties:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 85.05pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Trade payable (d)</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">2</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right">1</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 2.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Other accounts payable (a) (b) (c)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">123</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt; text-align: left"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">Related
                                         parties' expenses:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 85.05pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">Amounts charged to: *)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Research and development expense (c)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">145</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">99</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">34</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0in">General and administrative expense (a) (b) (c) (d)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">467</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">257</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">55</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">a.</TD><TD STYLE="text-align: justify">In August, 2012, the Company
                                         signed an agreement with a consultant, who is also one of the Company's shareholders
                                         and a director, to render management, finance and operation services. The Company pays
                                         the consultant an amount of approximately $6 per month. During August 2014, the monthly
                                         fee was increased to an amount of $15 effective immediately. In August 2014, the Company
                                         granted the consultant bonus in the amount of $80 in connection with the consummation
                                         of the IPO. The Company granted an additional bonus in the amount of $70 with regards
                                         to services provided during 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">b.</TD><TD STYLE="text-align: justify">The Company signed an agreement
                                         with a company owned by one of its related parties. Under the agreement, the related
                                         company renders the Company with office services and an office lease for a monthly fee
                                         in the amount of approximately $4 since September 10, 2013. The parties terminated the
                                         agreement on September 1, 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">c.</TD><TD STYLE="text-align: justify">An agreement was signed on August
                                         20, 2013 between the Company and one of its shareholders, as a consultant to render management,
                                         finance and operation services for an amount of approximately $15 per month. During August
                                         2014, the monthly fee was increased to an amount of $19 effective immediately. In August
                                         2014, the Company granted the consultant a bonus in the amount of $90 in connection with
                                         the consummation of the IPO.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">d.</TD><TD STYLE="text-align: justify">On July 1, 2013, the Company
                                         signed an agreement with a consultant, who is also one of the Company's shareholders,
                                         to render advisory services. The Company pays the consultant an amount of $1 per month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 136; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: right"><B>BIOBLAST PHARMA LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share data</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;10:-</TD><TD STYLE="text-align: justify">FINANCIAL
                                         EXPENSES (INCOME), NET</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 56.7pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended <BR>December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0">Financial expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Interest expense</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">*</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">*</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Bank fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">Exchange rate</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 11.35pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0">Financial income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">Exchange rate</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">85</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -8.5pt; padding-left: 19.85pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(58</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">*)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal">Represents
                                         an amount lower than $1.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 56.7pt; text-align: left">NOTE&nbsp;11:-</TD><TD STYLE="text-align: justify">SUBSEQUENT
                                         EVENTS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt; text-align: left">1.</TD><TD STYLE="text-align: justify">During January
                                         2015, a wholly-owned subsidiary was established in the state of Delaware named BioBlast
                                         Pharma Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">2.</TD><TD STYLE="text-align: justify">On February 2, 2015, the Company
                                         appointed a new President and Chief Executive Officer and a member of its board of directors.
                                         As part of the agreement the new CEO was granted 498,067 options to purchase Ordinary
                                         shares with exercise price of $8.47 per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.7pt"></TD><TD STYLE="width: 28.35pt">3.</TD><TD STYLE="text-align: justify">On February 16, 2015,<B> </B>the
                                         Company's board of directors resolved to issue 24,000 options to employees with an exercise
                                         price of $7.17 per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">- - -
- - - - - - - - - - -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 137; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>v397831_ex12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>Exhibit 12.1</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO EXCHANGE
ACT RULE 13a-14(a) or 15d-14(a)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Colin Foster, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on
Form 20&ndash;F of Bio Blast Pharma Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this annual report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this annual report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The Company&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the Company and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">a) Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">b) Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">c) Evaluated the effectiveness
of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">d) Disclosed in this report any
change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report
that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial
reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The Company&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s
auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: March 30,
2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>&nbsp;&nbsp;&nbsp;&nbsp;/s/Colin Foster&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Colin Foster</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>v397831_ex12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit 12.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT
RULE 13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Ehud (Udi) Gilboa, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this annual report on
Form 20&ndash;F of Bio Blast Pharma Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this annual report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this annual report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The Company&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the Company and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">a) Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">b) Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">c) Evaluated the effectiveness
of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">d) Disclosed in this report any
change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report
that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial
reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The Company&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s
auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">b) Any fraud, whether or not material,
that involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: March 30,
2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Ehud (Udi) Gilboa&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ehud (Udi) Gilboa</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>v397831_ex13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit 13.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. <FONT STYLE="font-family: Times New Roman, Times, Serif">Section
1350</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the filing of the Annual
Report on Form 20-F for the period ended December 31, 2014 (the &ldquo;Report&rdquo;) by Bio Blast Pharma Ltd. (the &quot;Company&quot;),
the undersigned, as Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)&#9;the Report fully complies with the
requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2)&#9;the information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Colin Foster</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Colin Foster</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 30, 2015</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>5
<FILENAME>v397831_ex13-2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit 13.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. <FONT STYLE="font-family: Times New Roman, Times, Serif">Section
1350</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the filing of the Annual
Report on Form 20-F for the period ended December 31, 2014 (the &ldquo;Report&rdquo;) by Bio Blast Pharma Ltd. (the &quot;Company&quot;),
the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)&#9;the Report fully complies with the
requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2)&#9;the information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Ehud (Udi) Gilboa</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ehud (Udi) Gilboa</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 30, 2015</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<BR>
</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`<`!B`P$1``(1`0,1`?_$`,@```(!!0$!`0``````
M```````'!@0%"`D*`@,!`0$``@("`P``````````````!@<("00%`@,*$```
M!@$#`@(%!0<-$0`````!`@,$!08'`!$($A,A%#%!42(584(6&`DR4H(T5W<X
M<9$C,V.S-556EK;61V*B0U-S)%34)76%E;75%S<9$0`!!``#`@D)!`<)````
M`````0(#!!$%!A('(3%!46$3%`@)<8&1H3)"4C,T(F)RHH*2LB-38Q720U34
M-546%QG_V@`,`P$``A$#$0`_`._C0!H`T`:`-`&@#0!H`T!0R$G'1+<[R4?L
MXYJ3?J</7*+9$-@WV[BQR%WV]7I'4:U7K/2.A,HDU!K;-,ORC(XD^U/<L15X
MDP3'#;E<QJKS-155>)$53E5*5R_,E>C%)-.O$UC5<OH1%425DY"4Z)[B,*D[
MLCHNX`9N464<!@^^>.2=TX;^M-(Y1]NM:^^/Q9^[SH+K<NW<PW]89ZS%$=`U
M:=!')R.MV&=:Y,>)T%69CDXI.)2SLEW0ZCS#"3,W1TH%Y'?;DP_`U<$_2>U>
M@0%DSI?)[N)-7B5?9'W`$(@@IN!+ZNY(+"H[ZMO2*8I`/LUJDWQ>)YWH=Z2R
MT<CS"#2FG9,42'*F+'.K>)-N]*LEK;YW5WUFK\"%M9+NLTKE.$D\;K=E/>F7
M%N/1&F#,/Q([RBR^*RG\9/\`[KSOXXX_'/\`2_VS\9_=/N_EUA;_`,YUM_O&
M:\?;/JY_J_\`%?,^H_G_`#/O$W[!1_@Q<6Q[#?8^#B]G[O%T&T?7V]&"P:`-
M`&@#0!H#PHHFD0RJIR))D*)CJ*&*0A"AXB8QS"!2E`/6.N/;MU:%9]V]+'#3
MB:KGR2.1C&-3A5SG.5&M:B<:JJ(AY,8^1R,C17/5<$1$Q55Z$%19,UT*N]Q(
MLF,V])N'E(0I7A0.'AL=Z)TV!`ZO`=E#&#V:P2WQ^)'W6MT76T8<Y74NHH\4
M[+D[6VF[2<&#[BO92:B+P.1MA\C>']VJI@3[)=V6K,XPD6#LM9??F78X.AF"
MR+T?91.DQ_LG(FU27<1K[-G7FQMP*N(%D9(2CX;]U=,K1(1#U`B(@/H-K5)O
MC\7;?EK+K<MW49?E^D\G=BB3*B9AF"HO!CUL\;:L>*<.#:CGL7V95P12V\EW
M.Y#2PES>22Y,GN_+C]#55Z^=Z(O,(V4F9:<<B[F))])N1$?V9\Y5<&*`_-3[
MAC`D0/44H``>S6LG7&\;7N\O-W9_O!SG,LYSAV/[VY8EG<U%]UG6.<D;.9C$
M:Q$X$:B%I4,MR_*X>SY=!%!#S,:C4\^"<*]*XJ6W4+.:&@*C_5]=O_E#T_VS
M:MK[HS`L-`&@#0$%LF2J55.X26G6OFR`/^SF1O//^H/F&;-NX9`1]JHD+\NL
M8=\7?)[N&XQ):^N]3T?Z[$BXT*B]MO;2>XZ"OMK`J\BV5A9SN0E62Z*U-GV#
MLOJR=G7^\?\`8CPYT<[#:_1VEZ#'^R<DW:O<0JD(FU(.Y2R$R;OK[>HZ;!L<
MJ*1@]74JH'M+K5)OC\9'/KO6Y9N*TU%2@7%&WLW=UTV'Q,I5WMAC<G&BR6;#
M?BC+:R7<M79A+G]I7NY8X4V6^19')BJ>1C5Z1!V"Z6JTG$T]./GY!-U`U,KV
M6*8[[AVV+<$FA!#V@3?Y=:K-['>0WX[\++I]Z&I<SS2LKMI*SI.JIL7'%.KI
MP)%58J<6TV)'<"8N4MG*--9#D+=G*JL43L,-K#%Z^5[L7KZ<"+ZI$[TKV45*
M29@)&QK^0.([`5DS<.C;_J()J#J5Z:T)K?6<R5]'Y-FN:V%7#9IU)[+L>;"&
M-ZG$M7Z-)NU<FAA;SO>UO[2H3N-Q!D>3Z11J[UL0WSY%1M&@4/:8CQ=);]8H
MCK*#1_A]][_6BL=0T3F-.N[W[[Z^7HU.=67)H9?,D:KT$5N[Q-&T<4DO1/<G
M)&CI/6QJIZR>QO&ZWN>DTE*P<:4=MRIG=/UR_@$001$0^1365&C_``==_P#F
MZ-EUAGNFLG@7#%K'V;LS>?%C((855.BPJ=)$[N^?3L.*4J]J=W.J-C;Z5<YW
MY2?1W&B#2Z1EK)*O1#83$8MFL>0?:`&6^('V_6'64^C_``8]V5+8DUWK'.\Q
M>F"N;2K5J#5YTQF6^[#I397R$3N;[,T?BE"E!$G(KW.D7\O5H2GZOF/OO)K]
MI[/\*>O_`!OXO^V?WG]SJ\/_`"=[IWP:C^FZK_44X_XOT_S.CY7\LZ+_`+=U
M?SUO:Q^5ZO:XO7TCPULP*O(_.VJN5E'O3TRPC"B'40CA<H.%0_<&A.MTN/R$
M(8=53O.WY;H=S-#^H[T-197DT2MVFLGF;VB1/Y-5FW9F7HBB>IV^59#G.=R=
M5E5:6=<>%6M793\3UP:WSJ@BI[D7'`<[2G03V;<CN5-T\(HV:B;?8#)LT`5?
M."C[#=@=:PMZ7B\:1CLOR#N^:7S+4F<KBUEFVU]>NJ\CHZD*27)VK\+^QN+3
MRK<Y<5J6-1VHJL'*UBHYWD5[L&-7I3;06,F^SM?NH@Q]A;,%MP!HR9J0$<)!
M^:=5P9LHY3\?\*JIK"K6>I_%`[U"/KORG5E/2]C%$J4ZDF1T'-7C:Z6=U=]B
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M,.+">TV:;'IV\2)W=7ZHS#@MW[3FKR(]6M_5;LM]1+DTTT2`FDF1),O@4B9"
MD(4/D*4``-7Y4IU*$#:M&*.&JQ,&LC:UC6IS(UJ(B>9"//>^1VW(JN>O*JXK
MZ5/>N2>(:`-`&@+!*0CB6ZDU9V78M3;?YO#JH1QS%]8*/BH*R`"/M252U56M
M]VN:Z\5]2_J?4&69&Y?I\IEAR][F\S[K89+Z*O*M>S6\AVU',X<OP?'5KRSI
M[TR.D1/(Q7)'^LUQ'FF+*"T6%R-;9OW9S=:CN84=3+A4_I$ZBDHN[$QA'539
M%W'^ZQD=YV;2:/H9IG4C]N2SFLEG-YY7\KY'YE-:VG+SX>1#N+&N]66(^H2[
M)%71,$9"C86HG,B1-9@31G'1\>3ML&+-BGZ.VS:H-B;>SI1(0NLC=/Z1TII.
MOV/2V69=EE1$PV*E:&NS#FV86,3U$:L7+=MVW;EDE?SO<YR^E54K-2$XP:`-
M`&@#0!H`T`:`-`&@$_)\A,$0LB^B)?,>,HR5BW:["2C7]WKK1\P>M5#(N6CM
MJO($6;N4%2B4Y#@!BF#80T!0_66X\?EQQ/\`S_K'_<]`2>IYAQ/?)-2%I.2J
M+;9A)HH_4BZY:869D",D5$DEG9F;!ZNX!LDJN0IC]/243@`CXAH"-J\DN/B*
MJJ"V;L5)+(*J(+(JWRM)JHK(G,FJBJF>2`Z:J2A1*8H@`E,`@/CH":T[)>/,
MAA(#0KS4[F$2+<LG]%[!%SGP\7@*BU![\-=./+"Y!N?HZ]NOH-MOL.@)7(/V
M,4P>RDF\:QT;&M'#^0?O5TVK-BR:(G<.G;MRL8B+=LV03,<YSB!2%`1$0`-`
M)P.2_'<0`0SEB<0$-P'Z?UCT#_Q/0#)JESJ-[BAG*59H*V0H.EV/Q:NRK*8C
MO.-@(+AJ#Q@LNW%=#N%ZR]6Y=_'0$ET`:`-`&@#0'(MR1*7ZPF;_`'2_^U;S
MZ@_E"^T!"JKC3(-Z;O'=)H-ON#6.73;2#FL5F7G4&+E9,5D6[M6,9N4VRRJ0
M"8I3B!C%#<`VT`\L0TODUA;)-3R;5<*Y8"5JTFF[.T^@%L21F(I8HMYB#=F)
M%E$6DO&JJ(F^\,8IP]XH#H!U_:!X.;5BV5[/E2@9*'H><6R,U(Q4G%.(E]4[
M^[:!(2L5*QKI)->,<S:(F==I0I1!XF[*`;`7<!0\+<\CQ]SG7Y^0<BWI5J%*
MGWQ/?9!*&DG*?DIM0NPAUUR3[;@3![WEN\4/N]`;1?M0N0)*GCJ)PG6WY?CV
M3D2R5F5:JE$[*@,G`;("8F_2%IDT00*(#L=JW<%'P,&@-'V-<=6'*]\JV.JD
MU*XG[;+(1;,QDQ,@R2/U*OI5X)0$2,(A@DJY7-ZDTAV\=M`=;.*,:5O#V/*I
MC:IH=F$JD4A'(J&(4J[]U[RTC+/>D1`[^6D%57*P[CNHH.WAL&@&%H`T`:`-
M`&@.1CDA^D)F_P#.K>?Z0OM`94\(^9-)XNUN_0MKJ=LL;BVV&*F&:U<&&!%L
M@QBS,%4G7Q228J=XRFQB]`&+T^D0'0&;W_UNP]^2_)WJ^?4O7X?Q_H#/S-&*
MJ[R!Q#8L?SQ.PTM4,DXBGYTR*.8&<33(^@IE#;JV7C'X)F.!1#N)]:8CTG'0
M')M<JA/4*U6.CVMB,?8:M+/H*99&\2$=LE12.=$P^"S-TGTJHJ![JB*A3!X&
M#0'Y9[;9+G(-I:U3+V=DF<-"UYL\?J]U9&&KT>C%P[`IM@_8F;)`I=Q]XYA,
M<PF.8QA`W?\`V7G'/Z,U1]R`M+#HGKLV5B*&BY3#NQM,37#SLTF!P$R2]H?-
MP!,P;#Y)N00$2KCH#;?H`T`:`-`&@#0'(QR0_2$S?^=6\_TA?:`?7$GA:XY4
MP-SFT,B(TCZ(3<=#"V5JY[!\0^(1QG_F`6+/0_ENSL!.CI4ZM]]P]&@,N!^R
M"D!_M\:>K^S=7U#O_+70&ZI@V\DQ9,^ON>4:-VW<Z>GK[")$NOIW-T]71OMN
M.V@-&OVL^-:["6S&>48U$6L_=VTW6[(1,I2H2/T50BUX>45'[KSZ323,V.;Y
MZ*20?,#<#6O@ZCQF3,R8OQ[-+.$(:XW:"@I91H(%<_#73H#/DD#CX)JN&R9D
MP/Z2=?4`"(;:`Z[XR-80T;'P\4T0CXN*8M(V-8-2`DV9,&*";5FT;IE]U-!L
MW2*0A0\`*`!H"NT`:`-`&@#0!H#D8Y(?I"9O_.K>?Z0OM`?#&'(',N%V4M&X
MNOLG3F,Z\;R$NW8,8-V5Z\:MQ:MUU#2T5(J)F3;CT[$$A1#T@(^.@&A]>KEO
M^6ZQ?\FIO]6M`9]_9T\DLY9AS3:*WDS(LK;H)CCB2F6D<^CX!JDA)HV*N,TG
MA5(J(8.!4(V>*DV$XDV..X;["`%P^U\_@#`W^_;]_P!,K6@-9/$C]*'`GYS:
M]^^*Z`ZR=`&@#0!H`T`:`-`8I6+A!Q9M<_-6>P8DBY*=L,H]F9F04G;:B=[)
MR+@[IZZ.DVL"+=,RZZAC"4A"D#?P``T!9_J`\0?R+Q'\X;I_630!]0'B#^1>
M(_G#=/ZR:`96+>,&",*S[RT8PQ\QJD\_BE81W(-I2P/E%HM=TT>JM!2E9=^W
M*4[IBD?J*0#[DVWV$0$"^Y8P-B7.2$&VRK3FEO0K:[YS")NI"88`P6DTVR+Y
M0@Q$C'F5%PFT3`04$X!T^&VX[@+>J\*>+](LL%<*MB>,B+)6I)O+P<HE-VM=
M1A(M1$4')$7<\X:JF3$1]U0ARCZPT!E-H`T`:`-`&@#0!H#4>IR<SNQR').3
MVZ;/5X[E`?$[B/F,-Q[7$;&E*W1O7>N5S,T\NO&V!LS=@":9NLYG/:(<#`<=
M`94R?*V->5:&=Q]<GXAW<YGD%4(M^1>'=N8"1PC"W1ZYFSM7(&9O0E#U(QFR
M!MRE,H4%=R@;0"IIO+:UL';MM*1DSDN0L$+Q?A,851HA6*S-S=LRIC.8NMF?
MSTL91M!1H*)QJCE<W5Y5L"0)HD`#";0$6JW,BX0L,O>,AH3TA\'H_(&Y2M"C
M&%39-S(T;.,108.*5ER]QXE.U^.>^6W15.S=;***&,?H'0#M/S&<-ADZU(X7
MM[#+:%[I=%AL8'L=16<3;B_5M_;X"4"U(2)Z_',25Z)=*O.Z<3-54NV/4)MP
M`8M<Y'1\]@:=SB[JRU:1@'=KC7M7L=GK<2JC)U2SO:HY9.K([=HUUH9S)LA*
M0XJF*(F`I1.82@($3KO*!+)6`LWY,J$6E`63%<7?&9VSJ0C[3"!8:Y40LD:_
M82L4HDTG85=-V@8=@1/U%.F8I1#<0%K"\Y4:[1$SY4H$[7\@MJKB*5BHY].5
M!K'Y!2RBDLQBK*A.-WX5^HQ@R<8[6?D>G3^'-R@)@$WN`!31/,6\9`R/AAAC
M?&3Z6JELC,KM[7&DL5*4<N;5074?'OF<-9%98(MS"UP'2#L'B!NU*H2C<4!_
M8EB`!9*;SGL,+B&E6;*-!$]VO5FR,TK;<;91ZE`S5?I$I(J2\F$K*RA(Z%"!
M`489!LY.9W*2"74D`D4!30#ZQSRG-EJ^1U8H.++3+U52L4*VS]^=2]?BV%7B
M\AUI[/PR,A!O'19AW)(N&"C-9%J58"*%$_5T``B!EIH`T!A+]7+C\ZF'T\\R
MM:96L3-VG\POJ$YRNP#&4C88.>2F)Z=<P#$C5-[&UN=02.Z!1<Z#95(A5_$-
MM`?-#CKQR-D*0=MLH3)Y9-/(MU;XX)E"'7@:RURY7I1C=;)#U,Z2KV+CYEA/
M*NRN3&,BF<Y3D,"8B0P$&E,<\5S2],H\'>K&^EK4M44X.\T7($`X7QR]XT8Q
M>C#33FQL3*)5]^O3'RA''=17(\!<3BFF0O4`'M#`W&M1"RT64L-M9U:-QN\@
MS9$GLD5`T-9X7.=W-DF1583AW2S]S-GGJT4Z;IRW22505$$C.!ZSD`FN5\6X
M*LL'9\K,,@Q;:P7>7HT_2+@CEZ(IL-].\9P<M7JBG4[JV93"$:J^9/G+9\)$
M9`5"G,/:W+L`%1CC`50;<8:QAC*%UC)?Z7S[JQ-['6K64AWENF;B]R-"JTNR
M2``YGY2,>E(JBY,DH=Z*!U3I=)C%`"7UC&>$JKC_`"G6#9/<3\-F%E:+3>[1
M9[_7Y&8?L)&(:4:Q6-&8319LFD<T(T30,N"0MFSGW/=\$P`5R/';BQ#T\YIC
M+LC)-KBUI!*;D2SY@AEIV&88P?&^AB.-K,<S5F@RKDG)&`H)D<E.HOT*]8&*
M70%`BYP"G1:/E^;R1DV(5P+:LRLJW,6>]Q+"^Y$<UJ?=)WZM.4G*B)+=&6)[
M62E;L$/+*&;`DF'9(82Z`F56XHXILM#J$I7[)EZN-W#Z0R30Y!I=@:V+'C3)
MD;\0L-3K:X,7;-A7)8),QW310CH1<!W"J]12FT!D32,3UJA6*T6B(=3SR8N$
M+0X.;<3<H,F*[;'<*Z@H)P4ZB)%S/W#1X<SQ90ZAG"P]?N^("`S=`&@-1N1.
M"V5)_(5\E:Y,QC"GR>0DF%4BRRA&R+3#V7#OY/D+'JL@;B"#QS,/2"T1W'O$
M2'82[@&@)8]XF90_\@S"$=5:*UA6N4<IY4C,PHSJ9;O8(&Z4.:K$!B![$C$I
MOFC"/6DTFCA91V>/"/:IBDEW`Z1`I;EP:L=HP_QSQQ!LJ_CZ0J&/[6RRG*U9
M6,8'DKF^QK'0T:$HHVCRFMT7,V=B"$D=0!458&.`CL?;0%ZF^,V6+[9$;!<*
M92&[6<?<.W=JKB4M'NH4B6'W]I4R3'-6167E5XA!*52\B@)0*X1/V^DO2(:`
M6^6<%6'$+"P9*EZ=C.9QW7\C<CW<=0;#,MHVOQU=S1'5=E3K'!L4X"88I3K*
M5BE4`C$6H.#^:`J!@.<1`!^/<+7^Y\&,04ZJH%K^8:13<46NDA-'"+/"76L-
M(U4I'YU4E1CW'PUPZ;J%.41(902F#TZ`2$7P2R+5X&\QK(]>M[&L6/$Q\3U:
MQRYB1=KQ_5K2KDR_T>RN!9.2QC:U7>56$G>371,9HB*A>V/N@,3&7$NU(Y*Q
M_<<AT/'R512M/("\2.-B+QECKV-G&1PI:=2K\$T<Q2$;*K('@'+IRNV;H-T'
M*XBD7QWT`OK-Q+S02,>JML?X^R(YG:[R>I24'9K.R9-:.OEG)TI<ZADB&<O(
M:4;K29(IPDBY1232=)'*0I5``#&*!L\QU"OZWCZB5V5*F24@*;6(62*BJ"Z)
=7\5",6+PJ2X``+)@X0-TFV#J#QT!,M`&@#0'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tpg4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg4.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`6@%:`P$1``(1`0,1`?_$`,4``0``!@,!````````
M```````$!08'"`D"`PH!`0$```<!`0```````````````0(#!`4'"`8)$``!
M!`$#`P($`P0%!P@+```"`0,$!08`$0<A$@@Q$T$B%`E1,A5A<3,T@4)28B.1
MH7(U%C8WP=%38R149`KPL;+"@R55%Q@X.1$``0,#`P($`P0&!P8'`0```0`"
M`Q$$!2$2!C$'05$3"&%Q(H&1,A2AL4)2(Q7PP=%RDC,DX6)31!87\8*B8S14
M)0G_V@`,`P$``A$#$0`_`/?QHB:(FB)HB:(FB)^[K_Z?^O1%K$^XA]PS"O##
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MPB`G]/31%8O_`/-'Q-.>-<'D;P\4Y'ECK#'/*+WE>W0?:4$DDJDA?NU&A2H5
M\\<RW',OB!/QO(Z3)(#@^X+]+8P;!M05505[H4EU1]/BB;ZA1*A4!SYS-C?C
M_P`29UR]ESRM4F$T<RR<C..M@=G,)OLKZV-W*BN/RI2B("GS+W+^&B+P(<X\
MX9KY%<OY;R]G<V1)N\JN9$R/'=<<(*>J$B"KJ(@$2C'8@1-@[0[1[NY=NJZ(
MI=0"B+V[)VJ&ZILFVZ]57;TW5=$5[Z,6T;:)Q%)L1`'&AWW<!Q%$4$4_`O7]
MFB+U$?:2YNFYQP]<<5WTL9%[QC*:*O-72,G\=LB)&^U2)5[(+_:VB>B*NB+;
M@V2**(G]5-OC\%44ZKZK\NB+LT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%)+BZJ\;JYUY?V<>KIZ
MN,_-L;2<ZW'A1(C`D;CTEP^U&@:'\.J[:(M!WEQ]W696RK?$/&@V7FHKCHS>
M2+&$MBTZS%)!>/%*O;L`'$15&1,0FR%=Q34^#>S+S312`,;"XBO2M%;R3"[_
M`-)!5LITJ-/TK!C%.+Y.?TL+G;S#RW-.3;'+$<MN/N,9F16;#5A4/NFIY-E,
MIB0DFOQJ0:HW$8A(VYMU7IKF'OY[A,1V:#RXLF<VM&Z/)\>@D8:+=/:+L'G.
M691NZ69\``<XN<XL`)(+16,C>.NWRZJK)F45S+"1<8X^XLQ.N8$6HE=`X[QB
M8L:.TG8TRY:6E<[:V+@(GS/2#)TUZJNN![_W<=R.87,V6PI_+8J1]8@#,SZ:
M>392/#P*[;L_:YQ/'"-]X3)<2`;A_#<`=!H/3J/-1N!\S9MA.40K7$(-?6Y"
M<MIAI_%Z@,8;>GO=C$%)T#%PB-Y&Y,-$9!F4)MAZ[:O^WGNX[N9#D,>`=;-N
M=[@VI;<//S)]4_?19KEGM3X'C./2Y7U6Q.8PN^HQ-!\P*Q#I\U*_O`^7^29C
MB?%/C9-EQH>00:R#FO,\"!,24W&OI3*+24\TF%1E9-,P7U+["I\CKJ#ZCKZN
M<*?D+[CEM>\D=Z.9D;N?&TD`5Z"C_J&GFOF+R:WCM,_<VV$;ZN*C?M:\BI--
M"06Z$5Z+0@T2HX!F/:XJHK@;]W:2?*G7X][:"2_M77K-L]/],T/^>OZEB(S;
MQZWAV?</UJY-%+'=O9$]=OCU39.F_P`=4K2WO/YLQUZ`UFT?3J`17K0^*H3R
MV;Y@;%Y?!2A-0=?'IHKU4<M.T%1=MC1?W=$7;KJ/)=\4C76S2&#]T?V*:.)L
MQVAU/M6X7[269N4GDVWC39=L7-,/R*'(!#4`0ZB*MTPJCOVJ3LAE$_:NC;ME
MU#'M:&N8VATH2?,^:F=;&W.KB[=\:KU`MB0HB%MT`$4D]2)$7O5?Z=%*NS1$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1<%547X_Y]M2E[6]:J8`$+K(
MNG7O3]V^K9]YL.C:_8I3!NT#B/M75[I=VR>XJ=.JHNVI&W^X[=AK\E,VUH*E
MY^]=Z*J]5W3T_%%U=L)>-=$):WXKF/I\?7XZGI12`[M>BY:**:(FB)HB:(FB
M)HB:(FB)HBDMC;1JJ#+LK&4S"@5[$F3.FR21B-%C0P)V5,?=->T8[;0JO7UV
MT1>73S]\];KGS(;#CGCZREUO$-+(>%U(TAR,]F$R*\;+DNX<`A[:]";[H[2_
M*X"IT7?1%K=XPHHW(_+O&N"NGO$R?.<=JY9B*1@%F5;06IPBVG:(H56\9("]
M.\4Z:HY:F+X_<WF-TNBPDTTUI\-5/9,@CR,;A^(FI"V<<Q786W(&1*,88E93
MS7L=IJ]$0!C4]*OZ?`C"T&P---M,[H(HB;KKX!]_.47O,NY$N*STCO0$NT5-
M0!7PW:+Z\]C,!+A^'17UNP$O9N).A<2*[C3Q/BK5P**^R&RC4]!4SK><\?R1
MH$4WW=^G4D07#^G`?4T411/76#PO;SFN?OAQWA,KORL9`;1X;H=>@!`UJMK7
MO(^/\=L1G.2R,C8^NAH=M/*I!7W,^7<0\4I+S58,'E3R>E07F<,P#'53(:?C
MR?+9^;(<OD04D#,N(49Q#@UZ=R@]U<5.B:^D'M]]M&1XB8LSR4M.9H"-SF$C
MIXT!7`W?/OQ?\T?+A.+WDC<`*M<YKJ;O]T-J12G4_8L*,?\`"/R(Y=L9W*O-
M.04O%M3F4[];L<VY9GK!O;I^P=62V]!QILW+^8Z[O^00:3T3TUVUG.2<4X[B
MJ9VY:W.L95P):?I'X=2X'44\%R7B./<OO;X08V*2?%.>`'C<?J=U'TM+:`^-
M?FLBL?\`%+PZP<P;R$N4N;IJ![<R6S81^/,7.>BK[X5C4+W+XXK9+N)NJA&B
M_#7&O-/=_C>)RO9BWF21KJ`#?3[VN72>"]KO).2R,_F$,,=D6BKG.;OKX_2X
M#17`7A'PIL(JP1X=Y`P=V0;;4;(J#DNSR"=7;KLY*6EOT=AV01@7N<!4%53T
M7?7E^/>^2VS3_7S-8K@/+&_YAJ!J/Q.'BLMR?VC9'C=G_P#A%EPT@.=N]-H!
M/6FT&IH.BQ/Y[\>;W@.?46\*[9S/B_,4D2</SNICJK4L("B4RDN8FY%1Y`C+
MR*(%LA]NX]-=T]L^X>)[@XL7((<"VO\`2I7+'*^%93CMP^)P+7QNH174'[M1
M\>BRO^U2^]9^9O'K#**HMTN7225#4E%B+2NDHN)\#0512_$NNO82L@CF<V&E
M`=5X^VEGDW"?JTT"]=+`&`EWDI*I(J*J_P!P$+;\-S1=2*Y7)PE%0V7JJJG9
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M14+_`$51>NVL5+FK**=UJ\_6TT*@;:<CU&.T*[$)23IM^U%5$5/Z/VZOH9;2
MX%6T5%[;EFO7[53\[(:J!,2!,MH<&60(X#$F5'84@7;8A%UT"7=5]=MM86YY
M5@,;E'8FY>UMVT`TT_:%1XJNS"YN]M?SULV0PUI4`D:?('53V*XKK:.=Z&))
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M[;XDJ+LNOAM[BNT.5X=W(FR6<C-Q:3O+HR:`4)T'T$_A^*^LW83N5;93A<''
MY9`,M$`PCQZ:'04`(Z:K=!PUXL<19'P'@D.?7V4=R_IX5SD]KCUU+HK*YE21
M4WXTRV@.L68PE4NSVVG6Q4$ZZ^FGMN[=<&PO`,5R''X^!N>GM@^28;]SWDG4
MU<1H--`!HN`^^/+^49_G&5PV9NY9<7!<OC9"ZFUC!3Z10#QUKU^*OIQ=XF>-
MO#B"[QQPW@^/3"?>EE;)5#:W3LF0:N/23NKDI]H3[QKW$7N]5UT/>0LN[T23
MM#G`^*TC;116$)@LQZ<1\`JGM^`^&KJ6LZZX\QVWGR"+W9UI&<GS#1=U_FI3
MKKXJGHFQ)LGIKQ/)NVW`.4Y3\YR+&6]U?S-#7/?OJ6M%&@[7`:#IT7K<-W`Y
MKQJRBQ^"R-Q:V3)"X,80`"XU)Z'J=2L:N;/%+QH=HV@/%H.%7]O+"IQVSQXW
M8TN3;RN]N(TXVZZ;3K8NJA&O;OV[JJZU=R3VH]F\JR>2RP-G'<-MR009-'4-
M#0R]:K9V']P/=RSO[>WDSEV^S=,S<P^F0X$@$5+"=1Y%:';"`[4W-A`E(*3:
MFQF0''FCW1TX[SC#B*0*GNMHHJB">Z=-?$;,\4EQ/*LE89)N^*WNIFQ@T^AC
M7D`"A\@/$E?6AERRXP5D^(DOGACD=\7.8*GRJ2:^"KJJI8_)_&7+'#]FC;D*
MWPZ[RO&7"V$Z;-\/KWKF#.B;=OM.2J^,\V7]4D1$5%Z:[D]E?<3*R\N=QN6Y
M><74`1T%/*GX:_I7(GNMX-:8SC#.1XZ)L=]0MD>.I:=:FKB-#Y#Q4/\`8QPJ
M1EO/>;\E.M`[`P/!UBL2A`]FK;)B2"44CZ-K).O4W"3\-?6V9D+92^%H:'&J
M^;$>\QM,NLA&I^*]5+6_8F^^_5>OP[B)=OZ-4U,M2WWH_(+,_'OPVGW/'.56
M.(YQEF;8]BM3:4Y(U:,PI039%M(B/JA>Q].PR'<2"JHA)J9@J?@BT7\2^,?W
M->6O&)CR]PORQMPK2J;G**K$;3D#+V+R?58^#AOS@*?%;HU4_9-Q1,D!1'9/
M74]&UHH+9O\`9.\^^9?*B#R%Q-SC8#F=UQO5U=G2Y\]'9;M;6"Y(&/-BWZPA
M^@)X'";.,2$A$WW(2*HKHYHZHH&P\3N;<X^Z9$YXH_*?#YO'51DC5VU@U;R%
M*D9!&K*Z`]$FX@UBT5]V,XHRR)#`VA#8-R)%VU`;:51;V\@S3%,(JG;_`##(
MZ3%:=@0&1:9#81*6OCMF9;`$F2\,9QU3_,B$JI\=M2'I514@P3F_B/D]^1$X
M[Y1P/-IL/YY43%LEJ+N0RUNNQ&Q"EN.IO^.VH(L-?NK<X9)P/X2<NYEAN2S,
M3S*>W18UAV107&QDQ+JVMV'-X6_4)*P8KP;K\%7\-3-U=JB\ZWC+XV_<P\L^
M`[CR6P+RPOJRHAV>31Z_&\@SC+(UQ=S<6;4;4HZ16BJH@?5!_@DX8MKO^":G
MHP:%06P/[*_W`/(#FKD7._&WGRXD9K,Q/&I-]C^6VOL.7L:756L:HM<?ESHK
M8-648`<)QIU1[D[.JKW)HY@ZA%@SYG6MCY'?>JQ+CFJLY4FCQ[D/C+"HL=J6
M^TP\SC85^49;'((Y-H*"]`E-$2_,G9ZII04K35%[#ILNOHH!R'Y$.K@06`]R
M3.D,L1&8T4.ULRD2G&F41I@.JD>Z(F_74AZ**LNGE=XW?J7Z67/?$23>[L2&
M&>4"R^[;;8F/J^B[_MU*BO.M[5N5(7;-O!<IW8;,]NU9EQ2@'!-I9(R_KE<2
M&$5YE-T=[^S;1%:2'Y.^/EE;+15O-_%TR]<D+"9IV,VH'K`YJ.(P$9F*DP3-
MYQY4%$1=E)>FIJ:(L1_N0_<%KO!CBB)DE)#Q?->2;B[@4]=A-ID+%:_%C2(D
MF<_;2F&$>E&P#$8NU.U!)>B+J8-K\D57?;_\K+[RDX%PG/\`/;O"(?)64P+^
M\L\'Q>8Q]104\6[FUU83T$Y+\U5*,RV9.D@B7>B[)OJ2Q_B0R/E%2)RT?(4T
M5)V]V)GFZ3->X-<*:``?TU"RZY*R4\5XWR_(SDE&<K,<M)02$)$-M\(3@L&*
MK\J&+Y"NO(<KR\N%XUF\H9#$^VL[E\+OW'MA>8R-#T>`16OQ6>X5C_YUD\?8
MS-]5\TD;7`_M5<-P/3J-%I8X>Q[R4Y_9O[O'.2[*$N/S6?J7[*\L8T>4]/;)
MT8P-QFA9`F0'=.WIUU\JO;_D/<)WU@R.4L>77TF4M9&>JQT5N`-S20-[F-!K
M36G1=V<_Q'8SMPS'P7^(CEFN8G;F-,GTEM`2?XE:`E7K\=O(3E[#^;XW!'*-
MW(N6)%K-Q\7I*_5R*NP8C/3(ZM2S:;>>8G#VFBGW;(6R=->][&][N[%K[B)>
MUW<&:6ZQ,;Y(W;G,(:YD1>'`1LUJ1^]1>0[L=F.,WG9MG<O@T;+,LC;(YK!7
M<Q\HC%2]YIM\@VJH[R@FV6=>85'AL"?)0*]W%JI3!PQ&4+SK-E8AV-&(-_3Q
MQ4"4O@FK+NMSN\Y1[KW<<X[>OML5#%:"3:!1U(@9`0\#QKT/R6>[;XO&83V]
M2\GO[5LTLSIPP$N^A['%FX;22:G7446V6HY`P#]1:Q.IR_'G[:*TVP%-&LHK
MDM?8!&B!P!-5][Y4Z>NOHSQ[EG#[B\AX_C+MGYUL326@$;M*'KYE<.Y2WS#K
M*7)S6KRPO=]1J`*FH\%6Z27U;-YI[9!<[%;,$5/E3YME7M5"W7UZIKU8RMN7
M/;.!'$UY;OU/3]"PTC+BSM&EC?5N'@.H33J.E0J&M^6,"QAPV,BSK':N4)=I
M0IMK!"0TJ_VQ]Q"147X;:\W<<RXOAIB+_(AX/@6]/N64Q]AE<K"0+1T4I&E*
MG[=113/'<[QO*X\F1C.555ZW&1#D'!D,/MQ@(5V5UQDC0/3?K\-7>,Y3A>4N
MDM,-<4>!4/:*T`_O4'WJQNL9E,&TS7V^5I<``X;>ORZJ(C9YB\L9YPLFIIH5
M**MFXQ813"%N6R%)<0^UK;?T7JNVK?%\LPOYJ?$7%VV6YMG4<\Z5)UUIH*=.
MJNY;').8S9;N'J]#KI\JC503?).'R*=G(HV743E`Y,<@A;G/8:KCDM$8/L?5
MJ7MDZT39=$^*:NH\YCLF1?VEWZ>.MR2\@"DGAMU\B/V5!^,RMM*;5T+GS-:"
M:]0':@D!<;#DC#*9F+8VN:4L.!8-"]7NRYT5AF6V>_:<=2+N>%5^*=%UA[GN
MOPB)XMVW#3)6A-'?V460.+OYH_0AMC^9^%:U_4HYS.,>;IV\A<R*J"A>1%"Y
M6PBA`45W551XB[245';UUEKGEW&K>T9?RWH;;3'8PTK]1%0?_%86*QSL4_Y=
MUL9)`[4$T('G0!=]'FE!DT5V5CE]67L9A>Q^35S&)8,&OY4<1HB5"5/AK-XJ
MYL[Z#_37+9W/U!T!^X'S5+)_S#$N]>]MW,MP-:U^_I53&5;QX,49<BQ::80"
M(WI*M1F1%%ZF;CQ`*=O^?5+(9*QP$#Y<U.(V`UW'PTZ4'FI+:2?*AE_BF&2W
MH06"HJ?/45T5#)S3QFLA8J<A8DDA%(%:*ZA^XA(BIL@B2IW(O[=>1M.XG%LC
M.ZXM+UIM8^HH17[Q7[EG(L5E7`/FM7-C\:5/]2JS_:2L_P#K<3^2_4OXS/\`
MJ_\`[]Z_RO\`?]-5O^Z'$?\`B#_"_P#L53\K_P"WX^:\2/W*.6)^=>:_.\F9
M+63!QK*1PVE[G%(3I**,TVC`M=1$6$/9>FY>JZ]TL0L!Y&0$XB=A*2?U5V3=
M4^"KT]=M$4B?F./].\@545-P+L5$4T<W51V7="3=/PU/C&0WOJW5W_\`*@<0
MP?!NK>FG7S5QAY!9B9UQU<XEJSP\0?*NGX[KK/@SF<I,O@[-)XRJ^QB-C(O^
M,,J=$6O]I*9%5.VJG/;'-CDOMN1]S0>_KK6G=CM_ANY_&)[>]8#F&,(CZUK0
MTI0M'7S7LNV?/LKQ?E#<A&^D;)`=:$$`BH.GB.A\%ZY_#7)II<54N$V%C"N#
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MY_F<;DFEM[^;G-#3H9'4Z>8*^X';V]_G7`\9G#_EF*,'X;6C^G10>.92UQ]C
M?*>?/@[(6EXZR*MJXC2IWV>3Y=%/&L>IHP]3<L+%RP>5@1ZJK1;]-;N]EO$;
MT]RG7>H8UP\/]JU'[ON3V$/;MECHYTIZ5H0/$]-:4"W0_:R\5WO&+Q>H:[(X
M?TV?<B.MYQF($/:]"<L8P?I5*9(B*I5D+\W5=C-?PU]FY(S$\QGPT7RDAF$\
M+9!T(6R-U>T=@-0)=T141"ZDO:._=OLB$2+J15%Y;/\`S'?(CC[GC?Q#&E20
M?;/*<^LH,4E[Y\62L;'ZX29%%%Q&9D-PD[MD^?52/Q4"L*N9;S[M7`OAWBG'
MN;TTK!/&']!H\?;FX=!Q8%9QJV$9L&JO;JK5[(($6U9E*CKI$**9=AJJ=-34
M:3\46XS[0Y>)W'WA7R3S#PK'OUR2#5WDWFN;EKL=S*&;K&*B99)6`L,6X,>A
M8;</Z16@!71^8^XDWU!U=P1:POL:0SRCRY\B/(C*IKAUG'O'F89/>RIKSC@P
MG,QMW9\B2G>7MB<&#2/;*FW:*JJ;;KJ+NE$5%8V_RQ]Z/SMO,6R[-L@Q?@S$
M7+B\:JJ>:9P,:P:KF.5]<S71%)(06F4FVA?4NB9;GUW3IJ#@`U%;CSV\<Q^U
MMY4\1W?CGR+F8-SJBLR^L6XM6/U>!(K+48UC$FOP&HL:?!L!-&E:)M14"5%W
M35)16R[[\G-\N[\1?%O%G`&&_P`RW$7/+5E@NUJ._0X[7OHUWBGN#W2LB=04
MZ(I!U].DS?Q!%KZ6S^[9X\>$<&JQ^@FX5XRNXTL]ZZQZMQ)+UG&\H;]R5+L+
M&($V_B-/B]W.25)MSM+J6VJFA/Q"@MJ?V(,?\5V.&N0^1N,F[V3SA6.!4\TS
MLN?CN3*R0+4FSB-XZXR(A_L[:LQ5=]U?G=,%[U5$'4'_`*$6N_[7D&+Y#_=K
MY'YFF/%*AT5QRWRG#ENHOLLO2;']$A`JC_AM?X5TYV;]$0%743HVB*9>2W._
M/'W7/-QSQ-X<SB7AO!>,9':U`_I$J9#@6E7BTM0R?.KY8Q`Y+$4`ACLN$K2K
MLG;OI0-&O5%BC]TKPIXB\-.2>'>*>)<BS3)+S(\96TS:RRJ?#G2#FSK"+`K)
M<)BL:AG6QGA5XD%P2W+M1%5$5=45%;.?N^N<S<$>"/AYPW@LR\J^.W,;@4/+
M-O4N38+KTJCQ6B*FK[><"[L0K>4[+[XKA()]NRKT31%0'VS_``L^W+Y'TW&>
M847*F>R^?,$_0\KS[C:VO:^N61=UDQ)SB1*MZO;DVV..OB!?]F=]T03YU'T6
ML21\E!66^_IQ7B&,^5&`9#09!DUEF/+..`615,N1#DUV.QH<^OIL<CXQ`BL1
MY+"RVGWR<623HJ(JB=.B&UIJBWD?;R^V=Q5X;N0>7L?R#.KGD3.>.Z6#DM=E
MEA5N5%`[90X$ZYA4C$*LC/-L+9-_(+AN$(IMOU75!SS;VTC!T^I_]/N4[7C>
M;']E[=WZEDYYPY05#X^Y"RVJ(>0SZ_'!1"5"[+!Q3>VZ"6PML=5^&^N6_=GR
MIW&.R-U?QFC[[T[?Y^J'#Q!_J^:W1[;L&W.=S8;)PJVV<Z2G]RA'B//XK6[P
M1Y-6_"^`6>-8UQS-R"XO+<YC%T\DM:TC::%F-'6O:@F]/5IO?8P=057]VOGS
M[=_<;%VAX=D..<:PLMQRFY>RLS9PW>X`AI#'QN:*5Z`T/BNMNZ78'`\[Y9)E
M[[,PV98/KC=&]VV@!-7"1K1H/)7X\7N&N0\[Y??\@>3*^34M-3YUM&9LFW(D
MR?9/1R%GVX*BV;-?%&0@@9#W;-[;[:WU[6NUO=G-=TLAW;[EPOM[>XW/8'LB
M%2]A&AB=^[3]D+57=/N;C..=L_\`M;Q^X;<VVUL9+/PAHE#M:@GJ/WJK&NLQ
M_(N>O*B^BT=T]7.V.5W,U^Z@J:G6U4)QV$XY$<0D,?88'L3==E4M]<Y8+AUW
MW+]QUW#Q^2DK[Q^^0"M(V[FUH2WI1;M?D\?VR[$LML\SU+:.V:6-KMW2/(?3
MQZN-5!\Y<3)P5S?C5%A^16]G,-S'[)F=()&[1VPF2%<-7'6%0WFG"!43OW4D
M]=]5.Z';3D79'W#X6;$9!TLERZV+_HI3<2'#ZG.!K\.BM>W/<3%]TNSF5BSE
MG''#`V<-()`(:*MZ`&H\3759W>;//%]Q_CU%QMB,MZ'DV4535A>V$8S6Q@0'
M1&''2%LNX.39B$)*.RBG5%UV)[J>_=YP^PQW;/`-/_4V2L89B\%M6MEJT?0Y
MA!W.#M0X4\ESUV`[;XKE7(KGDG(8O4XS9%P#:N:'N!K3<UP<-K:'H:K&C+O%
M*!@?`%IRMR/DUS/SN97PGHE:4T2BQ;"T)GZ87I$Q7I$J4+/>X7>2I\-NFM"\
ME]M7(;;M=_UURW(OAR$C&/#2P_27BK0=DE#7Y!;,QG?2VR?=5G#.#V,1P44A
MC>20Y[FL-'$%PT'3S.BO3X-1FL:X4Y7SR>#H-R!LFHQO$OM"Q3U3K;Y`BK[9
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MV<[7\4[:8>[,F7N+R\=.\-`):XM?'4.+O%Y&CO#5:A[#YBU[B]R.2\VR-J(\
M:VRMF1,)J*T+7:M#=0&@ZCQ5*9[XUVE?XZP>7,SRZU=R6'%J7Z"A(P<IX%9)
M=3Z&I['E5???$_S)MUZ:\5F.R7(N,]FW<_R=T_\`-&+</IIUZ5H\C]"K<%Y]
M@+WO@.)V5HP6KY7ASBXDAVNHTZ:4HNOQZ\?;SFGB.]M<NSV\JL$QK]49Q&IB
MOD3,RW:;.78R;-N01`C49Q`0!3Y=B7X=-5^S7:;E_=;M]E,EG+U\>%QT,LML
M[8-96L)&K7M=TK^($*Z[Q]SN/=LNZUO#BK.%^0OO19*'%Q&TNVT`((!)Z&O@
MJN^WO(G0,ZY&>.;(#'X-"EA.;]MQ(@BC[K3;_0UBM&#,=55!%.BJOPUD_90>
M70<JRU]GKMS\-8N>!5H`JSIJ"3TKU!6-]TV2P><Q.,QL-JUF2E#2*.ZM?4%M
M*#J?&M5([O)^0/,_G-<-I;BPQ[C^K>F*$:/)-AN#0Q%./(GRV6U$9EA(<#N:
M%Q"1"7ILFJ/<CD?+_<OW^C[8<;N70<3;ZCWR!K7`?EZ.)Z1OU&E-WWJXQ7%^
M+>W;M2WEV1A;/R2<L8QI+FZ2=10E[3M&ITK16D\B>%<;XGY/QGCC$["RL9$B
MMJI4QV6XU[\J7:R589)QMA$4#0FE7;I^9->&[U=O+_M1W`Q'$./WSY3-0R?2
M=27M`%'.=X'P*V!VHY_;]Q.W&5R^1M+=KHRYK0RHH`TD&IZ_[%N-_P#L\S_T
MS_\`PG_V,_,[_$_Z?\_YO\^OHK_V4M/^)_R'^]^+_&N`/^I(O+_G]WA^'RZ+
MR6_=V\8\MX5\JLZY&*HF.<>\R6\K.*2]!ES]+A6=BC4>XII$UH58KYL5X$)F
M.YM[P=4UTBO!K528DSV>]OVHA"C@-JC3QIT#YE)4#N_9TT1=([CU4/F7\Y(7
MN"*[=11`'JB:FMVV\T_J/!$S.E#0:>8'7[5/EH"VWC>SH6@E?"<9W7N-HO>0
M6W=A78S85?;)T%ZJXRG0=UZ)JE^7#,U'EIG!LL;JC]W0UU;T/VJPC+9X/2C8
MXR'R.JV<_;_^Y3EWB!>1\?R5Q<WX0E30.WQMZ3_\YQ'ZMQ`DVF(+)4G2]YS8
MWXH+[1***B(NKFZP]U?9NXY)$T%UT\/+FMHPT`'TM&@&G@LDS/106#,3</I+
M"*$$_56M=:Z^*]EW#G,&`<WX#2<C<;9!"R7&+N*$N-*AR&G'HQNJ2N0;".!J
M["FQW-P)MQ$7<>G34L[`P@3.HX'QT5D)(WG?"QQ^15397DL+%:>VR:VG1X-+
M1P9-E8.R.U!!F&R3A;&71'#4>Q$].Y4UA<WF\+@<<[+9F5K;>,$M.[:-P\*^
M-5=08[+YO(66+Q#?]9)-1[2-QVGI0>'B:KR$?=EY3M.0LH\<^0&YSH3I&-Y=
MD5-LJHY4H_E\4ZA6-E_PB>CPD[R3T7?7G^R?,<WRCB,W)LN8GS27US`"(VM'
MH,>/3%!IN#3J[J5[/N?Q;#83D=E86;'B^A]/U*O)^L#70]`7>'EHLA)-^YY-
M\<\<>0&'Q9=KE%W&JN/>8:&"VLN71<F4T0(#,]]AI"=;J\JKXH2P?V]IOYAW
MW5-<#^Y3V^9O-]S7\QXI$X6]Q$W?]+G#?5Q<=*"A%%VK[<^_6'Q_"9^'\L<W
M?;W3W1.!:SZ#3Z?$DM=7["!X+8AXO^$\NRF8IFG*T%MO%\6LV<GI\1D,^ZSD
MV:,`X$#(+E'$57L?H6SV@-$FRO=SVVY:Z*]M':9G#<>[,Y*%S,PX#6I`KY[>
MFBYW]R7<V/EV2&-Q4N[%L--NAIKTJ/VCT)\J+<;`79M6_@UV`B(G:*;`G0`^
M`)\/Q373[;EMQ-*`:ECJ%<\PVXM[>-@_=44Z(D/:HJO=\NX]%1/BO=_5VU54
MZ\5'WH^38UQ]R2E"ZAVMOBO$--QG`F0JZ!)5^76E-AY?=UT>0\VM>X4OW7FB
M557;=$7TU$$CHBO'YH_=GMO,CA:1XO\`CAXW\@0H^7_I-);V-I$*]L`K8*M)
M%K*>'21BCPY4@&0%79)=@C^79?0"1JBO=QCX]<@?;]^T;Y1Y)R=&EU')G-55
M`9>Q@9#;D_'XF2&QB]7`=;9W;28U'MG'7Q%%/L%4+TU'<3JBG'V)^#)%UX=^
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MU[Y8[QK9Y`[&QFLOW%;;2/,;CB\^^#@]RA(3NZ(FI47H%\YON?>-O!/*M]XN
M>0?!^1<BX&6+5$B\N':R--Q]RSLHA/C5QX-BP(S`:@&WVOQS0A=,AW14T1:*
M/`'C6RYC^Y=B?)OBW@&:X7P3AG(;F;`[;++"-C6#2X\F-*Q^=<D#<5^1*[A0
M8S9.(H(B+Z;ZF+B11%<7[W=Y=XK]QG#\WRW&+"UPC&L1XQLZ>O=$DILD&HM+
M";*C5TQ1;&/8N&7:]WFJ-[)NG74`X@:(O4SXH>0\#RIX!P7G:JP^VPRIS6%9
M/0<:O7HTBQC1ZBTF5`...Q-HZ#(<KU<!/5`)-]8W)F:'+P6`>TVTT+=^FOUU
MJ*^&A\%)(0V5EQ!_G@;3XZ?)8K_<@R"8.-<?XI%W=6?;S[>2T"&;BC&C-L,*
MB`);JCIKMOMK@OWZV'*\UQ[$\+P`KA'2ME>T,W/W1N(8=]00!4U'BNI_;!=X
MKC'*YLW=$-?(`TU/GJXBN@J%FEX[8)6XUPEQG4RJN$<Z+C,)R4\_"CK(.1+[
MY?N.&39&CO:\B;[[]-=*=CN&8W`]I./8S)V=L;Z+'L#W.ACWEVXNJYQ:7$Z]
M2:K5W=KE$N?[G9O+64\K;:6\=M#9'[=H`;H*TIIY*L>3[=_%>/\`,[YA6FG*
M;&[>1%)&T4^YN"X38#OT55,4UZSNU<9''<%NI^/;8[\1N#:-!&K2/PBBU]PB
MW.1Y-;XS*[GXYTS`[4@[=PW?5UZ5U6L/[=.-3+',.2<SDL&RK%1!A1'51/<^
MIL9DF;*[R41125LTWV_IUP5[$.W-]A>79_D.>9)^9;#'Z+G5_$^20R=2:Z4T
M\%VK[P>6X^]X-BL/@7M]5TQW@'<-K(VAFFFM:JA\EC3N2//./'<!R1#K<TJ8
M!=RK[05N/@#I]HJG3N,E].FO&<QX7R3N-[N+3)Y,228ME_;@[06M$41/2AH/
MB0%Z+#\BQ'#_`&O1X^,Q,R]Q;OW#0.+Y!K73RZ"NBFWGS57F/\X8OF15TJ53
M+1TK;$YO^5;=K)SDR3#?-S_#;$D`5ZKMLNKCWAV.=XUWJP_-+7'SW.,M\;;Q
M;@&EH=')*XM.[2M""IO:Z<9E>W62Q5Q>007QNIB&.!#MCXV@.TU(K54[Y*\]
M9/SOQ91NT.&W5-@5%84S%[82'6@;M+XV7@99A$`(#L*.V/?OU5>_;TUA?<KS
MSN1W?[;XN+CV/NV8:-\3I-C6BI`(I5CAI3PZ)V`X-QOA'<7(3Y+(V<N4]*<1
M4:XT^H;G$.'R`*OO6RF\,^WLX[%[T?R*`[%+=";=*3D$Y8SA(K0]Z(*!\$^&
MMNXMF*Q?M&FPN#L[^WN76[6W4;YMTLDNM7,=6K`?*O1:BOKBX=[G'Y+D5S;7
M-I#?A\;V,V-$;0"UIK77S\"JB^W=BST3BK++UYEUF9;Y$S"-3;)!<BU,5DQ,
M-T%PA-99)NOJJ:]'_P#SVM[6TXQ?O?9S6]UZM`92'/(_O:GJ?$K$>]O.VW)\
M]:V>$=NMXH6N)!)!+G:Z"@%`%8KS=63E_D/@6%"+LN)$3'ZA^.RV^B"Y<SS]
MPT=V40!N&^.^R^J==:5]UN1RG+^]^'P5G9SR6%K<[=XH6C>X$^-?!;7]O6>Q
M7#NS^7O"YC<P6;H]U"?I:`*@_BUJ>OBK]?<#GN8QPCA>"UXFK5K:5\-T$17U
M;CX_";=8ZMHJBHFWT5?5=;H][=SFN/\`9?$\;X]!)+8W+Q',Q@!=L;"#^(D$
M?5XA:N]M,F&/=&?F')3_`!XR][#NV#>YQ(J-010]%4F)0SXP\&I;SZ''GS\(
ML2-V.*;K89#[\:')1I$W%P`E-J2HFY=NL]QVXQ_!_9L?2M;AMS<XV1HC#P)3
M<2QZ'=X@.I]->@(\5;\IR4?,_<TR\ED8<5'?Q$%P!:(XW`T&GP.OQ5EO`_"Y
M4[B?F6XC@;-EDT6?BE<3R.-^X_&II0@^(&@F(')G^J=-TUJSV<=M.3Y#M5R3
M)97=%=74LX@!:YKC6W&W4'ZJ./WK8ON:Y#%=\_P4ME-"ZTMHHGOVL!``N"37
MS^D=%C)XX<OR_&_D7+6LIQ.VNK"S@NTDBOAB(VC-G%ED_#=C*8=\MB82?/M\
M/VZT;[<^Y>0[*\\S;>68FZN<J?5CBV^FQPH""1OJ2#\UM;OCQ3%=RL!B;C!W
M]NR2)@+R2]["UX!_`/I:X'Q\!HI@P[E_)7E?B-YF=8]7VMUEM)<.4XBX"1,=
MCO,DPP][H[DX#3>Z@*H@*JKK'<=N,MW1[\P\FY)CK^W@%VU[#(\;6MJ-H(:2
M-#J?"BMGVMEV\[.7N-XU>VKVOMGM>0W<72;2U^TGIU-/(]%ON]M?[9_P_9_^
M%_9]?S_MU]E?]/\`_;B_RJ>/1?.3TH_CUKU\5(,XXSP+DK&9F&Y_BM-E^,3Q
M(9-/?0F;"*:D)![@^^).MOB!*@N"2.#\%WUZ16:UE9C]DWP3RN>_.@8EF6$"
M_M_V##<N>A5[.WI[$>SA6ZAM\/F71%TXQ]E'P8H93<B?C&=9:,91#Z;)\SD/
MQGD!-MW6ZR)5J7=MUV5/74LE(Z.;^,JG',^?<R2NQIIJK3^6/!?"/BA78P7!
MWC]Q)7@^W(6P?R'&7,LEF9'[3)13O)DP$^G#YWR(3[!)%77-WN#YGR#A?'79
M7'-?1H<=`X]/DX+?_83AG'^9Y\XG*/#0XANCF@T/B*M)JL%HG+<R0DF/8<8\
M)W,20V;95TSBK$HK;S+G\6,DBOKX,QL07=!)MT2^.^OGM:^[?O7%M<X1C"$_
M1_#FKMKXGUMI\>FB[JN?:=V2M&N<V:Y=F0TAP=-$[ZB*?A,5?E759&^+/./$
M'!V9/V]/AECQ)`NQ%<FH\(F2K+C^[<%/GGS<4LGWWJV[!!0&G6)/;V=>Q5UT
M+P'WF<=)CCY@]S9Z_51T;1_ZY25SIS;VK\B#Y'\3#'V0;]%6O<\GX[(P#73H
MKB>9/FU1\M8JSQ[QDY8!C4AP9>17LF.[$>L6XZJ?Z%[!=AHTI@)NILON(@[;
M:\5[J?<3BN;\9Q^'[?3_`,&:9P>0YI<7`#0&*0Z$Z4(ZKV?M>["7_'>7WN>[
MA6[FW5E`Q\37-+6?42*N;+'K1HJ#44ZK2/\`<MG-0>4.(^/XP@C.`\(X2D]P
M4[28L,C";=3X,H5ZJX(R&BVZ*B%KZ!]H\>_C?:?&<=GTR`LHYW^9=*QKB=:$
M]:$D?:N)^Z65CRO>#+Y"W=NQS;I^RAJ*-<1I33P5G_"CR\RSP^Y?K<\JE>N\
M/M7H]1GV*/A[\:VQTY(*2L1'2]C]4@M(I1I/:KC/M]N_:9:V7?263H(+22(/
M>Z)KB=H.I'2IU7E;*UN(727;92QKY"0`XC0ZUH%[JN,<[PWEC!<8Y'P6WCW6
M)9A6Q+JEGQR$FRBR6D,8CC;>PQY$(E5HVR1%0AZIOJ$#HK>/TXVAK:=``%C+
MVTDN9_4)+B#4ZDU^*N5&;[$<5=^\RW)5VW5$_+Z(GHBZMH;5MN^1X-3(ZI5P
M)2]H:13:*+O,!<$@+?M)-EV517^A4V5-7"*@+OB?B_)IYVF2\>83D5D[_%G7
MN+4=M*=V$0'W'Y\!]PU`!0455W1.FB*/H..L`Q1UQ[%L(Q'&G71[7':#&J6H
M<,43;M(X$%@B';X;[:(IA>XEC&40%JLFH*C(ZPG!=<KKZMA6\%XVS)QHGHD]
MB0PXK#A;@JCN"^FB+[0XGC6+0EK,9H:?'JXG"=.OI*NOJH1O&2DX\<:#&895
MUPEW)=NJIHBIW*^).+L]=9>SSCK!LW>C;?2NY?B6/Y&Y&V]?IW+:NEFUW*FZ
M[+ZZ(JFHL7QS%X#=7C5'4X]5LFKC5;1UT.HKVW%]7`@U[,:*!JG150$5=DW]
M$T14_>\6\;91/&SR?`\/R2<#)1VY-_C5+<O@T9][@B_8P9+^SBHFZ*2IT39-
M$7=0<9\=8H^4G%L#PW&I!(J$]C^,TM,Z7<NZ[G70HY*J_CZZ(J@MJ"EOH;];
M>U5?=5LIKV95;;0X]C726>X3%J1!EMNQ7P`P14[Q545.FB*78WA.(8;&>A8A
MC-#BT.2:.R8F/5%=3QI#R`+://,P(S#;COMB@[JGIHBD-YQ#Q9DUVQDV1<=X
M3>Y)%5E8N0V^+45E?14CGWL#%N9D!ZRBBP2?(C;H]FWR[:(H^;QKQ]9WD;)[
M7"L4M<FA?2_2Y'9XY33;Z.L!SW8"LW$B"=@TL$^K/:XGMKU3KUT10F6\3\9Y
M^\$C.\!P_-'6FFF&RRO&J7(/;99=1YML!M(,H007=UZ(B[JNB*>XYAF(8?7_
M`*5B.+X]BU9TWK\=IJZEAJJ+NBK'KHT=I53X+MNFB*3YAQ;QOR$U&8S[!,0S
M9B%_)LY;C-'D;<-"-#<2*-Q`F?3^\J?,H[*OXZ(IW28Q18S71J7':BLHJ6`!
MM5]-308M950&#52)F'7P66(D=HC525!!/F55^.K*YA]>ZCGZO937Y%21,VN+
MG=*U"Z+#$\=M3%VVIJVS<;`FVBFP8LLV@(E(D:)]DR;W5?@J:QG(.+XODMQ%
M-DXVR>D*"H:?&OB"LDS-7EEK:2/8ZM?I)'ZBIQ&C-Q60CL@+3#0`VRV(H`-M
MMB@@`BB((HB)LB)K*RPQM@9:6C0UD8```H`!X4'18EDLS[B2[N22Z5U23Y_:
MOLROAV,21#FL-28TILFI#+S8/-.MD*BHFVZ)@0J*^BIMJE<V<>0LS97@#F$:
M@BOZP5>03OMIQ<VY(E::@C_8I/58W18\#HT]7"K1=)''1@PXD0'B%%$$,8[#
M2'V)Z;ZQ^!XWA^-AT6/C9&^X-#0-%::^`']:KWF5R.9F:R]EDEC9TWN<X"OS
M)4!'Q"@AS2MF*:K;MG",CM`KH0ST5S?N-98QQ?1Q=]M]_36-Q7#<+C<O+G)8
MH_S8J0ZC:C6M:[:_;5,QG<Q=VK,=%/,ZV&FW<XM``IH*T'W+MNL6H\@C''O*
MBMN8WM=@LVL"+8M*2*B;^U,8>:W4?P'69SW&\%RFR_)96VAGC<[>'/C8^E1X
M%S745/'9+*8C)-N;2ZFMX_0##LD<RIK77:17[5P:P_&?TZ/5KCM+^D,B"-52
MU,#]-CF`]H.,0?IOI6R%%W1>WHNK=O&N/8K$,PT%A;OM&``-]&,CYD;0/T*9
MV4S,>9.6M;ZX;*YI!>)G@D'J*AWC\U%%BV.O5P5#M+6'51R:5BM.!$6"!,DI
MM$W$]GZ<>TU5>@IU75";BF!;#'%);6XL`WZH_38&$^&YFW:?M"K?S2[%VZ^]
M>1][)J7[RY_EUK7]*BZNEKJACV*Z'#KXW<I)&A1V8K"&J+W%[3+;8=Q(O5?V
M:OK##8*RA+,!;V]JVNHA8R,'YB,"JEO<G/?N]2_>][Z4K(2XT'35Q*ELS$\>
MF6:6<FGJG[3Y>RQ>@Q79HDVG^&8R'&3-#:V^54ZIMK'SX[A\V29'=6%I)DW'
M21T,3GU`K7<1NKIX:J^M\QD(;,VD4TS;0C5H<0T_,`T(439XU27#8C;U=?;J
MTB]GZC#C3?;0DV+M1YDD!21/5-EUD,O8X+(Q?ELU:P74$(W!LL;)`/#0/!`T
M5K;96\LG;K"5['$_L$C[Z%<GJ:F?JPJ7JZ'(K$]MK].?BQW(0@SV*T(QU;]O
ML;4$[4VZ:LQ!QG(XIME+;6_\H<_TFQ&./TP::490M%!Y!21WU[^===MD>W(4
M+MU2'5/C6M5]B4E?6-JS60:ZOC%NY[4*''B,":[H1J$=IL>\DV15^*(FJF,L
MK+C=RW$XFW$6-D^HM8QK6U.G1H`_0K'(39O*#?>7#Y+ENC2Y[R:>522:?!2.
M1AF)N36;>1C>.2+5G;V[!RGKW)*%OT<5\HWN^ZF_KOK%WG#>"'D;+V;%VTF5
MD8X_Y$))'B7594_.JR,.6Y>W%?RYE]*'!PT]27;0>%*_U44<.+4!3/U3]#HU
MLD)#"P*NBK.;)$VW:E*U[S?3I\JIK-7'%^'MU_(6<4H_:9#"QX_\P;56L^6Y
M>;063KMQM1^P'R;?\-:?H4Y]@_Q7\?4O75C_`"C"?OR_XQT^Y8?=DOA]Q4[U
MZI9!-$740[*J[KU^">G7_EU2]$.E$I<33P\%(\AK2UH&O]:U_P#W"\"M[?A!
M[D#'*J1D=UQ38/9+/Q]H2>D76"3XZ0,^K(T<$4WI14Z)(9[=E$XW3U77B^XW
M%[#FN!?A,DS_`$SAU:`7"NAI4$+TW;[-Y'AN<;F,9*[\R#4;B:5!J.E/Z=%H
MLF458_4T^68A9CE/'^0MMR\4RAI!:;DMD"*%-8$T3HP,@8V47X[R-.`J=R"N
MZ)KXO]X>TG(.#\ER%A;OR!XK!+_`/U&K"T'P8&=21HOK%VV[IXGG&!M;JX98
MCDDD0]<=*2`D:%SB\Z4UU4I",R8FVX+ACW^X^!-B0Q7.JJXJFY[PBUZ=W:/=
MMOLF^N:XKJP9=&*V@FN+FO26/=K]FJV\;;+-;ZKYH8HJ`_0]P^/E3]*N-QYA
M$&[MBR3)'1I.-L'0<FS7)YI$E.Q5045R0*27P$'[6Q!H([$4=R)7$+TUT-V/
M[/<G[D\SMKB\MGV^`9*TAK&/:T%M*D!S"WZO%:@[L=V+'MSPN]DMY8IL]<QF
M.KGASJ$4`.UP<-O@3I31:</)+D&;S=S7R'R8\ALQ\DO3<K(1ILE?2U[85]+#
M1-^W9NLBM*6W1")43TU]V9L<;1]O+*/3+;.*W#&Z-V1@`.H?VCX^'P7Q^MC;
MY">ZN9WO,DKGN)TZN<2:$_/16'?:>;)3-L2<%15@T39(Z=4,0%/E+W=D[N[?
MY=T]%5%SEPV"WEC=&`^D8_$*JA+<?GV!D3BR./Z/I\=OB?BO1/\`8E\J)[.0
MY3XI93/=.MLH<W-N.ED/$HPY\5&TR"G:)TU`6I0N#);;!$7W%/X;(EE.1._>
M0&_)58286;*[OB>J]03*KL0DJ*8%LJ]-U'9.TE_TDT)JH'4UT7=J")HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB+AV>O4NN_P`?3?\`#4D<8CK0DU-=4=]3
M=O1!!!WZJN_X]=M3FI%*D*FR)K/C\U\5M%14[BZJB^OX?AJE!$("2"7$^:FF
M:)F;#H/@OHAVHB;JNW[=5'#<[=T*A&WTV[0:_-<3:$^BJJ?NV_YM4);<2SQ3
MES@8B2`.AKIJJK'>G^$"JXJPBCMWG^_=-_3;\-1NH!=121.):)&%I(ZBOB/B
MI(1Z-2-23XKY]..^_>:IV]O8JIV_Z6VWYM3QQF*%D+7.HQH%?$T%*GXJ:3;+
M&8W@&IK7Q^2+'3<=G'!0?ZJ*G:O[TVU&)IB))<YU?/6GR1FQD?IAK2/DN2L"
MJ[]Q)\JCLBIMU3;?T]4U)Z(+RYY+FG]DZC[E3#&MD$C0`1X>!^:ZTBH@=GNN
MKUW[E5.[]V^WIJKLC`I$UL8/[HHHW;1=@!WTT\ER6,*DA=YHJ(B)LJ?#X^GJ
MNJ0MK3U!.8HS.WHXM&X?(JJR0LC]+J/CU7`HB$BI[KH[JBJHDB+LGP]/34S8
M8O5?+(T/WMH0[444EL!;5I]5?-<OI0^78B3MV7X?,OXETZ[ZHPV5G#'Z+8F>
MGO+P*"@<?$>2I2QF683!SFN'D:`_`H482)%]QQ$1-NQ%1`7]Z;;:O=S>I:TN
M\Z:A4G6[W3B?U9!3PKH?FNMR"TYV_,8H*;;#VHB_'=?E]=0'IB;\R6,-P!0.
M(^H#R!ZT4UU#+<O#Q-+'04HQU*_-?6X8`)#[CA=R;;DJ*H_NZ?#5J;=CKG\P
M^KB?`ZC[E4MF/MA0R/D_O&JX_0I_WB1Z;?G3_F]=7&RV_P"#%_A"OOS1_<9]
MRCM%:IHBZ]]U5/P74NU[=1T5,$.<6^(*@Y,"/*9D1Y("_&E-O,R&7@0P<CR`
M5N1'/NW[FG@)45%3T7;41MD&HJJPD](5KT7EF\T_'SFWP`Y+RGD_Q^,+GQLY
M,M)-GD6#WE2F1X=C&2SS]V1#OZ9P5;8JY1&7T<MI6R8,OF79$UB>4<<X!S/#
M-P&5M(C?`%KW%F[=7I4D@=%D,9GN7X*[.9Q-S(&L.Y@#]NS2GT@"OWU6-D'S
MMJ76P>E>,/&WZ@2M=[HY-E`UAO\`8/>P4%@"B_3D:*JBAJ&_HNVM`V7LW[48
MR_.5-M"7%V[_`"V>?D'+9]M[HN[-XX6$UU,(-H:1N=J1I7<6JSG-/DMRQS;7
M1\5N7J?%\#AOI)CX)A58W28\KP+W,G9`P:NW+L9?RN/JJJB)TUN[C/'N*<(D
M%O@[:-EK'THTMUIKT)6L.6<OY-R?(OARD\DDCP*DNK6NOE18OR,=`138"W04
M3YDWW55(E7?]JJJZ]1=7K\Q.UY'T#Y_UJ&/QMM;6>U[OXC@:]%3TND`6BV;]
M-]]Q_H_R)JZNPP/:V/H&#[UB(;,66Z,&H<XN^_Y+(_P!F7.,>:WCK84GU`R'
M>08D`VF-]Y+$J'-:DL$B?,;91S52'TV%-6BK+WE,+W"IIZ$J]OR]I(`_*(DG
MJI)LO^71%WZ(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+CV]57?UU$FHHI&LVN+O-?"'=-M_Z
M=M2L&PUZI(WU&[>BIC(</I,MJ+;'LH@0K['[N(]`LJ:SB-R84N'(;5N0P^TX
MJB8N`O1=D4?AJD^TLGO,WI`3GJZIU5&V9>6TN[UW&'P;0``>5>JT'^4'V=7V
M+"QRWQ=F1&8:FZ4CC.]E(PP(F(&@8_8ND<=L6.]4;:?5K9$VW7U4(3T<:L\E
MEKF\$\.R-@CF_>&OZ"M0>;<&<E<7V)U&?8#DV*SVW%CMMVM6Y'CRW`W[G(TK
M<HSK+JIN)H:B2=454U7++3T1$(AH>M2L1!;RQO,L\ADE/B13]2MW+J5!.TQ%
M%[E`T423VR'U'J*=Q#O\-T_;JJ)(V0^E&S::=:JG/:W$LF\3%K?*@5+2J.3+
M=:C0H<B8[(=)EEJ*TK[[A(B=B-16T.0\;I+L*"*[KJQMH9(6ELCR\EQ-:4I7
MP5ZW=M`>=Q'BMWGVL/MZ9K1<C4_DOS!CLK&XF.QG)7&^+V[)Q+Z5;36CCMY!
M*KW>TX,6+&>/L1Q$(U+?9$3?5PHKT@,$)>YV[*@ND*JF_4Q1$(OPZK^&B+OT
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$70Y^8?X?YB_-Z_D3T_O\`_)HBM7RM_NM;
M?\.?Y)W_`(C_`.K/RE_-?]3_`.[HBT/\C_ZU?_\`YO?QI/\`)^OYB_F?_%?V
M_P!NB+*3PI_WP3_]&/Y`/^%7^^WYGOYG_P`%_8_OZ(MQ9?PC_A?PV_X/K^0?
MR_\`5_A_=T1=L?\`AI^3X?P_R>G_`+7X_MT1=^B)HB:(FB)HB:(FB)HB:(FB
K)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tpg44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg44.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!E0)E`P$1``(1`0,1`?_$`/$``0`"`@(#`0``````
M```````'"`8)!`4!`PH"`0$``@("`P$``````````````0@'"0(#!08*!!``
M``8"`0`%"`8'`@D&"@<)`@,$!08'``$($1+66`D3%!57EQB8&2'3U1:6%S$B
M5)345:8CM4%1,B0V5G8W.$(S)76V>&&14K(TE29WM]>!<F-S1&2X<<%B@D.S
M=&5&$0$``0(#!`4%"@8.!P<%`0```0(#$00%E`8'&"$Q$A,(0=/455;1(C+2
M4Y.S5'0V<4(4%68748&Q4B/CM#5UE=46"1EAH6)R,W,TD<&2LD,D1(*#)44W
M9?_:``P#`0`"$0,1`#\`I3*'-SU)Y)K3BX:UJ0O>M:TM4_1_TFJ_^US],=3J
M=%Z4<_YDX?OJGZW`>E'/^9.'[ZI^MP'I1S_F3A^^J?K<!Z4<_P"9.'[ZI^MP
M'I1S_F3A^^J?K<!Z4<_YDX?OJGZW`>E'/^9.'[ZI^MP'I1S_`)DX?OJGZW`>
ME'/^9.'[ZI^MP+95*M6&<3>9!YBQ6,],[\8M)SAJ3Q&D:/GDO`?HDS9FQE:.
M"'6A]7>NMK7TY$]<'D5-]*.?\R</WU3];DAZ4<_YDX?OJGZW`S*#0ZU+/>1Q
MRM8Q/["D)2$YS-8H2TR"4/!;:F,))4.!C:RDK%8$1!RDL`S=@Z@1&!UO?3O6
M.KK'&F,;LBNWU1%K!89Q!9,D)(4*H],&Y^C3VG3J@;,2J#6MX*1K0$*0:WLL
M>P=4>M;Z-[Z,8Q(Q;THY_P`R</WU3];@/2CG_,G#]]4_6X#THY_S)P_?5/UN
M`]*.?\R</WU3];@6QEZQ8'A!0JD*Q6%2;R-Y#$FJ-*3]'F$DPVG!$E&&Z,\H
M,HH1@MA#O>]!V+?1^G>/+^T>14[THY_S)P_?5/UN`]*.?\R</WU3];@/2CG_
M`#)P_?5/UN`]*.?\R</WU3];@/2CG_,G#]]4_6X#THY_S)P_?5/UN`]*.?\`
M,G#]]4_6X#THY_S)P_?5/UN`]*.?\R</WU3];@/2CG_,G#]]4_6X#THY_P`R
M</WU3];@/2CG_,G#]]4_6X#THY_S)P_?5/UN`]*.?\R</WU3];@/2CG_`#)P
M_?5/UN`]*.?\R</WU3];@6RO]8L*HO@X:4L5EF*J2LDU286I/`-0:#D+9A(#
M#QA'H1HP%`T'6Q=.]!UK7Z-9%/E_"3Y%3?2CG_,G#]]4_6Y(>E'/^9.'[ZI^
MMP'I1S_F3A^^J?K<!Z4<_P"9.'[ZI^MP'I1S_F3A^^J?K<!Z4<_YDX?OJGZW
M`>E'/^9.'[ZI^MP'I1S_`)DX?OJGZW`>E'/^9.'[ZI^MP'I1S_F3A^^J?K<!
MZ4<_YDX?OJGZW`>E'/\`F3A^^J?K<"U/%I:M/)Y.^66*SO(<0[C4$^54GF>1
M4%KX9HL\KKF;\F<7H6^J+70+73OHWD2*K>E'/^9.'[ZI^MR0]*.?\R</WU3]
M;@/2CG_,G#]]4_6X#THY_P`R</WU3];@/2CG_,G#]]4_6X#THY_S)P_?5/UN
M`]*.?\R</WU3];@/2CG_`#)P_?5/UN`]*.?\R</WU3];@/2CG_,G#]]4_6X#
MTHY_S)P_?5/UN`]*.?\`,G#]]4_6X'J4.CGYN?\`]).'_,F__C57_D"_^UP+
M9<UUJQ-R&>B4ZQ6G*U6]`CT42I/*+T,VA*V--'H`#`AT(TT>Q"WT=(A;WO?T
M[R(ZB54O2CG_`#)P_?5/UN2'I1S_`)DX?OJGZW`>E'/^9.'[ZI^MP'I1S_F3
MA^^J?K<!Z4<_YDX?OJGZW`>E'/\`F3A^^J?K<!Z4<_YDX?OJGZW`>E'/^9.'
M[ZI^MP'I1S_F3A^^J?K<!Z4<_P"9.'[ZI^MP'I1S_F3A^^J?K<!Z4<_YDX?O
MJGZW`LQ'%Z_?#6Y3MKEFS@<H^-!0#MJC]F@*,J+ED,PH)GE.N$LP90=B#K?1
MO8=;W^C61Y17:4_Z3R7_`&A>_P"\U63'4.BP&`P&`P&`P&`P+;U%_P`)',[_
M`*WXN_\`;Z89$]<'D5(R0P+?<2D*Q^3<F(>S22-QJ537CDX,$1/E$\CE;H7)
M[*MRI'TUK32J5/+`SI5QC*S*S@EC5%B,`2/0>G]&15Y/PD+=.<OAU<T@U1"T
MG:D+XY`4GQZN-XCP96^1Z[(G%5T]N^G":ZK]&]A=%C%-Y7%XP*1NP&Y&J7)F
MTE>(.^D(3`:CIQZ.K%/[J08)4O%$Z3O4MF1O'UX@EE.'#)35\:CDG9760)U9
M4-3);<1/$)C"@Z:0R.JK+*`1*BQD$*1HA'G!ULC0C=1C/5Y4X*Q<ZH03%:XX
MHO#U`N/D%LR9,ET.$[!QQU&QPA[3,]@(V>)KC%,3='AA4*TK8483O24\118M
M"#O03?*AU,3C,_L(EKCSD@P+;S'_`(&:!_[R7(O_`+%TSCR_M'D5(P&`P&`P
M&`P&`P&`P&`P&`P&!;?D'_N'X*_^XZS/_P!1-GY%/E_"3Y%2,D,!@,!@,!@,
M!@,!@,"UW%7_`)GE#_W/;F_O"%9$_P#>*HY(8#`8#`8#`8#`8#`8'I4?^CG_
M`/W)O_F"P+<\W?\`B*>__=KQ]_\`@!6>1'42J9DA@,!@,!@,!@,!@,!@6;C?
M_!A<_P#WI^,O_P`(.6N1Y1`,I_TGDO\`M"]_WFJR8ZAT6!G57P<^SK,KJM4K
MD0SJ;#G<1@R=W5)S%:9J/EC^WL)3DH2$F%'*B$(U^C1E@$$0P@V'6];WTXD7
M,8^#D;L%*M=:CY!(YDS1R:2"!357(ZAF-=J6%^::[L*PVX32F=W=Q22Q`[)J
MV7)#!)50#T(S"332ME#UO([6'7"</V$3U]PEY+3]SJXD%7/\<CUKR2%1UCF3
MZ%O)8VW4\!M6P.KZ24X"=6E`O:"S5B72D@DQ>25O2;1@Q`")-4082DR7^'3R
M`B\0K5Q0Q]WEM@V/N;.FJWCC2W*P12%PM\51\Z52:=!DPXTA](K221%IQZ`6
M`M64':C9^]DZ=J#"4)M/$'E$^#7E-5%6"J/;)LLK5:F&VI42PJP4`D>ED,+1
MN"U(K5R(@+B0/:8@!@Q%&A,#TE[ZV,81A+\RGB'R?A,=?Y=+*-GK%&(LTIG]
M_?5:)"8W-S&J/+2!>/+)'!3M8VIE9P"51R?1Q:$X6@*=E#WT8Q@PF%<\D,"V
M]1?\)',[_K?B[_V^F&1/7!Y%4$J52O5I4"(@U6M7*DZ%$E)#USE2Q8<!,E3$
MA_Y1IYYH0!U_AWO62+;6/Q?A]>M\^81<CJ[>KMJA-HVP:ATP29E3EN21>F:Y
M)$X)8SH$,<L&:Q-P5A*5MR8E/L_91_FABGR.^F(G'\!@Q@_A?RK+<8RRG4%/
MS'28J71%&FTI`W+%;BXL;$.4.[6:0F<3Q-+PVQPL2XU&M\V5A3!$/R?0'?0Q
M@PF'N8^%_)YZGJFMR:2G!$D9R(DYR!*%L1GDL;#-E6TT<?O.R7#T8ZIWD`#A
MHBD2@\]=Y`P)`1B`+6F,&$LN4<4[_@MI(&ZD&ZP)?/XDZV(\()5"6)7#Q-'Y
M4VF]UA][XW*%3V6':-<_,P0DG[-2FEK3](@!.-UTC8QATF'2S+D/QJYGRJT+
M-^]8;0Y%JJA/41)WL9>-4J'L$<C2"8/K,Q-<@=1/*D,41/`C%R5O+4;3;ZQA
MN@['D1-.'0F8E@4PX*<EHS-AP1IKMTG+LG@L!GBU3$S&U4W)4%@LQ3HT-FU:
MAR)*->M+/.$):0._.ERA(:),4:5H(]SVH1A*HJA.H2*%"160<E5I#SDJI*I*
M,(4I5*<P1*A,H(-"`TA00<#8!@%K0@"UO6]:WK)%L9C_`,#-`_\`>2Y%_P#8
MNF<>7]H\BI&`P&`P/R8/R98Q]'3U`"'T?X^KK>^C_P"GHP+G2K@=R+136>1>
MN8!)+@9J^<F=E=YE$6DI*TFO;M!F.?\`H1.C<G,*TUX3LKX$04I7ECU`2Q"*
M"+Z=:CM1Y3"74UUPQNJ<5](K7=8I)8=735%&:4L,E<8X:N!-MOEFPZLT+1'V
M\MP1N.E:U;*35",T\LM,N]''$DCV/]8#&.KRF#$G/BG?Y#5*Y6SU+8;Y`HK*
MI#%3I8&,F(Q*%,<D_P!T5RC<>\\5O0`)GTTI(J$26I3HUAOD##^OK>3C!A+/
MXUP)Y0O3XY,3S6CK"E"*O+'L-*HDI[04A=R*S;TJM\C2-<D=3T*>4;5N*5,-
M(I-).2"/T,\(`:WO(QA.$L,)XDWZ_*I5NOZJL*<,\,1Q]0_NZ:+;:1I%3[!V
MV>^C"FU4Y'GN;B0QK]J2R$0E2D]"$"K10`&A#IC",)8T]\:;_C5;);B?ZCF;
M35ZULC[VEFRM"GTSFLDKV4"-O?5+5F+RV5Z./`20K&0%,)1OR.QZ-UL&IQ@P
ME!^`P&`P&!;?D'_N'X*_^XZS/_U$V?D4^7\)/D5(R0P/>F(VI5)4H1:`)4I3
MI@CWK>]`$H.`3H>]:^G>@['T[U@7WGG!UO:55Q1:K+G';EGT6[QIGG$`!4$O
MA(%RJ3S9@KM"FA<N<W9V8)&Z"EDG1$E)#-I#511@S"NMHH>M<>U^R8?L(,/X
MB\G4PY86=2,X";!@],L(`F;CSV@T+/\`>`]#LA.Y&G.+L@9/\Z5HD85"Q$3^
MLH**R<8,)=]7?#>]INHK=Q=X-)(-7EG*B4[%9;XS#41\HMP87]^8%JQ$E5@=
MDB"2DQT\#><H+3DK-ZV(@9F@_2FJ$Q#\-_#7D/+3>O6-3V%8#82PP-U7N">-
M$,8TCE/(2VSIL8RD3@]&G."A4T..C&\1(A&NB?6CB2==;R87:A&$NDCW%B[Y
MX<P)*QK>=3Q<Z0!@GKFF21O3.6SI9'(7R--24I8Z.8$KL!R=6,PA",`BCUZK
M1A)*?8R1=+&/*8/RT<4>0+BR-,P6U9,&2!N#ZS,Z^7N+866G84[O,$\%V^.S
M&)65(TS(BDA^THU0TI:;:@&R]&Z%C&.HPE%EEPH^MK&GU=*G`AV50*9R:&J'
M5,08E3.9\:>%C.:O3ICAFFIR5@TFS`@$(0@!%T;WO>NG)B<8Q&$X#`M=Q5_Y
MGE#_`-SVYO[PA61/_>*HY(8#`\"%U0B%^GHUO?1@;%7O@<P%R"QX'#N0:*4V
M54"&)/5B1IRJ&8Q-A;F*1O<09'!8QSM4\.;&]KF,R9IC0I!@2#<`@,`0+9FM
M!W':_9ZDX>3RH8GO"CDQ!+%_+E14DR<ESF_3IHA[F2V)DC?+D-?JS`/KX0<>
MXB2L*5*U^17*"G$Y,:D2J2Q&ZUH6A;8QABC"6/:XB<GA+I8V:HZ>;70=.W*I
M.G\Q1?YB0[L9TF:1(3MK])Y$-SCB<Q>G`UC6F')`;-`'8/IQC!A+"W*B;D9Z
MX;[>=:VE*"LW0M`H0S%0C*"VF(W92:B:7(Y-I1MU1-#NL($4D6GIRDBHW75*
M,&+8=;G&,</*)/JWCG%[5@[BXM%Z1-);)$(LNQD-.;BDJ7'`BE5H%SN^BE4_
M3E@C$.>W=H:E"IL2G@/`H*T3Y4XD1Y8<B9P_`?NJKA%H00BUT]`M:%KI^C?1
MO73].O\`!O)'G`8'I4?^CG__`')O_F"P+<\W?^(I[_\`=KQ]_P#@!6>1'42J
M9DA@9Y5D%46C9U=5FD<B&=78DYBL'2NZI.:K2M:B5/:)D)<5*4D91RDA$8MT
M8,L`@B&$.]:WK>^G$]$8B[$,X%M%OB"91M\%6`E;[$45A)PO=.S*`.C;*3H9
M-Y='B8^WNCPYIYH2^&0-4B&%(I`H1F'$FF%;*%TYQ[6'6G!7@GB%R@.E9\&W
M2$T)EB6.-$M5-:G3,E3D1Q_6F-C*[>G5+L3'#4KHZDF)$_45B&:J+&4$.S`"
M#J<81A..#HG+C1R!9XG*)T[U!-VN*0ES>V>6.SBVEH]L3C&G@F/2,I8V*%!;
MR(A@?E`$:Q04F,3)E(M%F&!%]&,8,'36)15R5*U,;Y9=;2F%M,D&(EF7/20@
MLI2L`B(<A-BD*=2H-:7G3>I+/VA6A3+/(BT/R75Z=ZG&)$IJ^-T>6U!(K#@-
MW1:QYC`V6M7VQ*V8(G+$Y,=(M.1-\38&AIL!:3J.RJ4M<@=TR9R0$E$[)&(W
MR)BC1!F]1CT])@S]QX5HDK%=)C=>\1?IO2+3.9!*(:UPN9G-;<U5V>G0/R.6
M6*$D4/A4L>74*LA@:E)AQCUYKK99A8CRB]L3!1;)#`8%FXW_`,&%S_\`>GXR
M_P#P@Y:Y'E$`RG_2>2_[0O?]YJLF.H=%@2)4$X(K&VJMLI4W'NZ:N[%A,Z4-
M*4\I*J="(E)6Q_-;TRHX!A*90M`@V6`P81!`(6M[UO6L3U"QK!S<M]7;;38-
MN3NR[8C<>!:^H]#I!,5"M.R'V3!I;"TREO+6Z-;2%#43(RMF&:)\H801LL.P
M];61A&'08_LK+-_B%TU'JXAL*B7'Y^CA\?G_`!EL%Q2-KC6C='QK>/[^T/;H
M@2.35!$,]D.YL>D5'!6R%T<U*)0H"$&M%A%UH[,^64XHAURSIA;%E50/E668
M?2[M5[_6;MMFG$79[1*)WR"D-[0YY;WC[M*HL?M`8]!;W-&H1;3K-A$<7Y,0
M2]:G">ORF/D90X^($U.5DT?./RU?4#92ES3&Q&UD)EB9:N71ARJ2!U'#FDYZ
M4-Y(U,P:&J#`4N#H:7H*HY0+18"]:UK([/68HG:.6C6VP>*Q`Z'OBDR-\1KK
MXT"5^G4OFZAWMNS'>P"YB2G&F$(EM;"G$"=0EWO9Z@TOKZ'K71K4S'[J,5)M
M?1K6O\62&!;>HO\`A(YG?];\7?\`M],,B>N#R*JMKBM9W)N=VU0)*Y-#@A=6
MY4#_`"TR]M5%+42@/TZZ1$J2`B_3_@R1<NR+_P".<X56-92?CS(S+SMS:A;*
MC958")WIZ(2>0NA+O.9K6T:;V!MEZ9_>U0#O1Y;DY*4[/YX;LO1VPE=6(B?V
MDS,?MK6RGQ**D.A1\,KZB)9#$)KS93XC2IG.K61L8OS!I:=5*F8VXJ"P*+KW
M='&Q2TE0%Q=SW!W6D)Q@./ZXM;SCV9_9,80NQ\U*S75K6%3655=@/$3JZ-T&
MK:E<$L%HB,B6670Z^>#0K5+BLCSP`,%D35-Q$C3@"!Q0*$^CB#ND>]9/9Z<8
M,782SG'6EDL<N@%@U3/3*XG()@L?`Q"<L3%-T;ZNY'S:_P"%J&EY7QYV;1M+
M<&8":W1,H(%L\9>E1`@#`7K&&'48ILCWB9TFRS2=6`'CG*4LHEDBGB\#HD?:
MT=GIP8IC!VN%-"&12^4P-XF+>LAJ=(>(L+"N:D[EH_I5:V+K=,=F<,#%@T+\
M1:&QA(O;`0&S6)&],]".KNXPY[J-1("K)HZOBZR`>T*;!K":-J.#R2.H4J@O
M_-@O34X@,,(4B+'LO)[)BUAS*2KII+Y7,G,Q0:Y2V2OLF7FJSB5*LQ8^NBIS
M4&*U*9(@3J58S56]FF@((`89TBT6#6^KKDA9.8_\#-`_]Y+D7_V+IG'E_:/(
MJ1@,!@,#\&@\H68#IZ.N`8.G_%U@[UT__1TX&S!XY\,#I94&G9=<R1.AB/*R
M&<CU+1]Y6[RKB@BE1PNLA1DHX"()!3JH/BYRHM6((BBRE.B^KL6A;WQ[/[B<
M>G%[P\Z*R4DO$N<ZFL#=P2*KJJIUX=&^P68BM=Q*G[4@4[CCDAAXHZ%S)D3H
MQ0<M$K\HM,2%+#!*2`:T:8'3L_\`88NBD7,*D9L[M4XG-&V#(IQ%5,[C\<9T
MEOJ(O6CS6TXN>2VV<USMJ8&M/*'!]2DR]>VJ"4J\IH<P^0,4D"T5L`IPF.J3
M''K2]/?$0I66QMC@+=1\[9H.E1\A6IV3H7&GHNX%--[UT1""R(VW02MXW&25
M4/-1$#"H7IEBEP(T/RYWE-AZL13,&/D1ZS\Z*Q&ZPJ02^H;`<WBE;(C5O4O]
MV[*01QL',V:IJOKM:V6>C$P+QNT94O%4H7`HQK&C<`I#ST8A[`:(6.R8H2E/
M*DB4MMF(U49=P&S_`(M4QQX2:V\$#1,;E5\PK^7NDB)3")W_`-!/BR(*O-T0
M-A-(,6Z&,8MZ'UIB,/\`M1BISDA@,!@,"V_(/_</P5_]QUF?_J)L_(I\OX2?
M(J1DA@<A(=I,L1J1!V,*96E4B!K>M;&%.>6=L&M[Z=:V/0.CIW_CP+US[GQ;
M=B<@FJRI!,K/<Z>8KTB%O,M(N<V.4L[:W0^3-K\V1X@H`"V;:I&0B&4F.&0(
ML@9G6T'Z,X]F,,/+@8LQI7GX96-8.<$<&FPD[RUV9:EHP:40!WK%O<%#O:R5
M*%T03ARG]:3UZ)TW.#<2<6O8SD*TXHPX@[8P[*$6FGI3BXS9S-J=)+XS<"NI
M+*47+MCKJ-SQ01;'FE8*4%;P57!4+C$X2E:DYYCB](0)#!IGI0O;VLW2@Q$6
M$TT(P3,3/1Y#'IQ>CWY672ZDU((!(@$51;W&6SW%,"1H`!?RN/M/1RKU3:FT
M%'H"5:_JV0U8E.,T,*4I1Y,6A"T(6X[)B]1W,&IYC'BH':56V6NA*=)6#NF,
MKVQVN(2TN<U;-;<D;8<8X*F)T;S(L\,UL')30Z*"X(5B4M6E-"9H.M3A..,&
M/D2LT>(93;#54GA4>X]2"+R"8Q9IC[VJ:Y'"G9O&XM-E,]@&R9?-Y!#U=US%
MS?@LQ2=46[R`]*4;O9I173O6@QV9QQQ,8:VK9FI%DVI95BI6\]I2SV>RV9)F
MI2>6J4MA$E?5SP4@4*20%DJ#T@%>BQ#"$(1B#TZUK6^C)B,(P0C_`"0P+7<5
M?^9Y0_\`<]N;^\(5D3_WBJ.2&`P/R,/6"(/3T=.MZZ<"\5Q<Z+=MJT@OJN;6
M:12Z:=U[+VZDU\T/51Y&B@1\>5I6CS1.$AI._P`[91FI^N4(LDPW0NKL0>G(
MBF(C_28_]C/H5S:KEN5O89_3[Q-&YZO_`)$W>2-0Y1%Z5,"RZV!C:&!2C9IK
M'I#$I!(H4>SB&/3JC4MRH!_3HH)A8!:B:9_U)Q3@Z^)E5[W+WUY=J<L9VA:^
M%UK&`52]OU-N\`DJBO(FZQ+1\I85=4"2Q90ZI%975=(CZ#<D:?9J8GJEZ*V"
M.S)B@JT>>8[*H#57!9)O&Y4XUI7E2R),S.%8IZH<(M7)C66VK/-0UH*UU:Q<
MB840AH3Y%M`G7%B4$]&NJ3KEV>G$Q1[";WH.+\:W>GBX7=<<L.9$O8K/L&!R
M>N4:2R@>=;50N'O8W^+.DH:ZRCII!!JMI;U273HJ\H<I$9L)`2F$XXG0I/KI
MZ-=;HZW1KK='3T=/1]/1T_3T=.2AYP&!Z5'_`*.?_P#<F_\`F"P+<\W?^(I[
M_P#=KQ]_^`%9Y$=1*IF2&!(].SI-5UNU;9BQM/>4E>6)#)PJ9TJ@I(J=4\5D
M+>]G-R94>6:2F/6EHME@,&$00"%K>];UKHQ/3&`L=$^<5RZN&,6/;5@6?;$>
MB"JQUL>B#Y-51Q;,KG4-E$13*VSSORC>E6-9+^7L1VBO*"))$``@];([,8="
M<>E*=,\V:E@4+JN+3BD7B5NM5U2UU\SR]$HKEV<DRM#:DUL1Q&SM%EPN:QEK
M:Y(BE)"(]5I&)V1F(O*)3@:,$'(F),6;33Q%8)*VZ[!*:DETC<+#GMCSR!QF
MQ'FN)5`:X>YY*DTN1/C.KU`4UEQYRC;L`9IB%I>R&EX4!`<J)UL1@-HIP,42
M<P.;9?)V.#:FUKL".FR*PMVC,6*0N=8*80BE'H5<V%$Q%-#*TB<M7D)3W=5Y
M%:_.C@N`C,TG%LS?2;B*<"9Q=LAY2<:F"$4U%(M5]Y,*6J'F'S]XBB67UF5!
MK8MV,C+6'3ZRCP1'<SD!@UH=E-R42W29H0_V28H(Q&C,828PP"I^4,"K:'S=
M>I@5B.UT3F,VI&96X$V<(JE+*,L\EW(+EEH5DM:EA[G(H24_J1-Q2)2G1F*"
MB#QA`:$P1DS&/X#%2,`>H`(.G8NJ$(>D6^D6^KK6NG>_\.]]&2A^L!@6;C?_
M``87/_WI^,O_`,(.6N1Y1]6J[P%."K@M6N"A5>7EUZM2M/\`)V6E`7Y96>-0
M;U`_=??5!Y0S?1KIWT:SJ[RIS[,.+\@C@A^U7K[34O9?'>5)[,'R"."'[5>O
MM-2]E\=Y4=F#Y!'!#]JO7VFI>R^.\J.S!\@C@A^U7K[34O9?'>5'9@^01P0_
M:KU]IJ7LOCO*CLP?((X(?M5Z^TU+V7QWE1V8/D$<$/VJ]?::E[+X[RH[,'R"
M."'[5>OM-2]E\=Y4=F#Y!'!#]JO7VFI>R^.\J.S#/X_X*/#*-0"QZV;5%R;C
MMI*(0IDXE-A)SG$)E?NKB\,/HQ7J.@"C#M8YF^7UL`_*@ZNOU>CIQVZL<3LP
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MD6J^(/*BY--%1QAZB43VCL),G5B:GZ7O<V7;=3]QPS2Y5IZ?S]`'H)?5)ZH.
MC?5Z=HKF/VSLPP#Y!'!#]JO7VFI>R^.\J.S!\@C@A^U7K[34O9?'>5'9@^01
MP0_:KU]IJ7LOCO*CLP?((X(?M5Z^TU+V7QWE1V8/D$<$/VJ]?::E[+X[RH[,
M'R"."'[5>OM-2]E\=Y4=F#Y!'!#]JO7VFI>R^.\J.S!\@C@A^U7K[34O9?'>
M5'9@^01P0_:KU]IJ7LOCO*CLP?((X(?M5Z^TU+V7QWE1V8/D$<$/VJ]?::E[
M+X[RH[,'R"."'[5>OM-2]E\=Y4=F&>07P3>&%>!FX(^HN7>K`KV1UF_>D+"3
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M\C\`;@>,`@"57KT#"(.^BS4O3T"UO6^C_P!EOT]&\=Y4=F&?V9X)_#&V)>IF
M\J47(%Z5LT38C=-=A)T2+S&&11EAK/L"<4</V$_;.PD;.%UO[0[K#Z-=;HTB
MN8.S#`OD$<$/VJ]?::E[+X[RH[,'R"."'[5>OM-2]E\=Y4=F#Y!'!#]JO7VF
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M!@,!@,!@,!@,!@?@TPLDLPXX8"BB@#,--,%H!9998=B&,8Q;T$(`!UO>][^C
M6L#4:L\3RP2H"X<IF[AC/7?@$UC5NI_)))9\._,E;5K<YF-KCR!9>->VL4@<
MJ13)R#'8"O;Z3(U$>!Z1)93"A`"(+62+Q".%L4MI91D@Y$U^W6BW,ZAZ<(R)
M2Y*"T12>%'V0)I5OZ1M/C*>6'P!.-Z(8QK-/*ELUYR4E&5O0MA@_);Q%J.H2
MDP6U&W%OMMV>:KKJ]()`65W/C[C.::L.UZHJA+8K6[.#(N2I61O<K@:3]A.*
MTH-T:$O0`[%L8`DQ)SOXA+KU>^-".^X,IN^.F/J5U@I1[B,\MXBS#]Z91%D;
MWIO^[+K-HU&M;7N+&D6GO"%&$1QZ8``[%H*N6)XQ?"YOXZ<@+[H>TH?R-5T#
M2Q=\N4#BS\MBJV45Z<H:TP9$P/TBCWF*^/)%+L40N<$1*Y.V+=^:J_(J=^2T
M$]-/B1\&WVLI[<#7R.@BF`5G+62"3-TV!_3NC;,)2!.;#X\BB2EE)F$@<IN0
MJ`:Q`;D"OTX3ORB':@O6Q:#BG>)=P9*C=2RK7(>*J6J]'Z6Q6J2&]GF3G()=
M*H`[L[#.HN1$6Z-*I8V26%NC^D+=F]<B2JVX)NS%!998#!A#+)7SXX=0>OX;
M:LMY`0-BKJP*T>[DB4P6J7`+*YU=&W.',K_.35);>9MJ8&=WL!F2J#EFD_DE
M"\LL6M"T/00Q5!XEO!9SJ64W@BY'0DVMX7/6VK9&YC229.^HK&?$:9SC\*(@
MJAA*GKI(Y*T+"US8E2-AYCD@%YTET:GULS0<1;XG?`E#54:NT?)F`JJQF4OF
M,%BDE:2I&][D,EKM2-)8"9I9&9B7R):WP4X'_3#@!)MO;`;T-2>6`01;#)[(
M\0KA74DD@T3L#D77K&[V-'XC+HL,E6X/C(9$9^L]'P27OTHCS<[1B&Q.:+=;
M*:7-Y6($+B,(M)S3.J+H#,^-?(Y+R+'R!`EB*J)?D-R8M#CBIVJ>"'?[SJJT
M(CAYLN3:)0(/125XU(=:`C'Y89/DM])H^MKH"R^`P&`P-4GB(\G+IH285FTU
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MZ?,7Y>>LIM_`D)^P\<R_&?UI:V3*^:.5K@?ZIN[9FO.GS%^7GK*;?P)"?L/'
M,OQG]:6MDROFCE:X'^J;NV9KSI\Q?EYZRFW\"0G[#QS+\9_6EK9,KYHY6N!_
MJF[MF:\Z?,7Y>>LIM_`D)^P\<R_&?UI:V3*^:.5K@?ZIN[9FO.GS%^7GK*;?
MP)"?L/',OQG]:6MDROFCE:X'^J;NV9KSI\Q?EYZRFW\"0G[#QS+\9_6EK9,K
MYHY6N!_JF[MF:\Z?,7Y>>LIM_`D)^P\<R_&?UI:V3*^:.5K@?ZIN[9FO.GS%
M^7GK*;?P)"?L/',OQG]:6MDROFCE:X'^J;NV9KSI\Q?EYZRFW\"0G[#QS+\9
M_6EK9,KYHY6N!_JF[MF:\Z?,7Y>>LIM_`D)^P\<R_&?UI:V3*^:.5K@?ZIN[
M9FO.GS%^7GK*;?P)"?L/',OQG]:6MDROFCE:X'^J;NV9KSI\Q?EYZRFW\"0G
M[#QS+\9_6EK9,KYHY6N!_JF[MF:\Z?,7Y>>LIM_`D)^P\<R_&?UI:V3*^:.5
MK@?ZIN[9FO.GS%^7GK*;?P)"?L/',OQG]:6MDROFCE:X'^J;NV9KSI\Q?EYZ
MRFW\"0G[#QS+\9_6EK9,KYHY6N!_JF[MF:\Z?,7Y>>LIM_`D)^P\<R_&?UI:
MV3*^:.5K@?ZIN[9FO.GS%^7GK*;?P)"?L/',OQG]:6MDROFCE:X'^J;NV9KS
MI\Q?EYZRFW\"0G[#QS+\9_6EK9,KYHY6N!_JF[MF:\Z?,7Y>>LIM_`D)^P\<
MR_&?UI:V3*^:.5K@?ZIN[9FO.GS%^7GK*;?P)"?L/',OQG]:6MDROFCE:X'^
MJ;NV9KSI\Q?EYZRFW\"0G[#QS+\9_6EK9,KYHY6N!_JF[MF:\Z?,7Y>>LIM_
M`D)^P\<R_&?UI:V3*^:.5K@?ZIN[9FO.GS%^7GK*;?P)"?L/',OQG]:6MDRO
MFCE:X'^J;NV9KSI\Q?EYZRFW\"0G[#QS+\9_6EK9,KYHY6N!_JF[MF:\Z?,7
MY>>LIM_`D)^P\<R_&?UI:V3*^:.5K@?ZIN[9FO.GS%^7GK*;?P)"?L/',OQG
M]:6MDROFCE:X'^J;NV9KSI\Q?EYZRFW\"0G[#QS+\9_6EK9,KYHY6N!_JF[M
MF:\Z?,7Y>>LIM_`D)^P\<R_&?UI:V3*^:.5K@?ZIN[9FO.K.\7?$LF()KJ-\
MD'A"ZQ60FIT[?,TK*V,QD/7[WY,`G9*S)$I"Q@6"%K1QVP;.2BUH?2(OK:#E
M;A/XH]:IUS\U\3K]N]I.9F(HS--JBU.6KZH[RFW33%5FK\:K#M6Y]]TTXX8B
MXP>$[0JM`_.O"JQ<LZSE8FJO*U7;EV,U1USW=5VJJ:;U/XM./9N1[WHJPQWD
M)U"=8G(5I#R525424H3*4YH#TZA.>`)I)Y!Q0A%G$G%BT((@[V$0=ZWK?1E]
M[=RW>MTWK-5-=JNF)IJB8F)B8QB8F.B8F.F)CHF&O&[:NV+M5F]351>HJFFJ
MFJ)BJFJ)PF)B>F)B>B8GIB7NSFZS`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`X3FW)'=M<&E>7Y9"Z(5;<M)ZP@>52+2#$RDOK@WH0>N2:+73K>MZZ<#
M2<3Q=\0ECXM'^&M'D''P5$:KQ?Q_8^9B^P)/JPF+C8K2FQ)(U*^-8*\&@=;Q
M9JM.VTDN6I@6PJ'(HMR-)`$0T.!WC-P[Y4P,^^^,,*A7'%VXPWS;5D6N#D%-
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MQJJ2BW!J"8_G.4A6&J=&E$E``,-DW+_A5R>GULWE:5+:C:IDG$DX7NJF"MUQ
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MHB91L^,REZ2JFD:PD#<<,DQP)Z`J3Q^X0\D[JKRM.8D*B#?)7J07'XCJY75,
M2Y2<CN$C.YP+E/R@1V;#+.K*UZTCZ::O<'&7#M;.0/;*F*E#*M2KR`)C"B@F
M!(/)7PB^74TJM_H*`,=12"!*>+%`UG5I8.3W(>L:KHV:TX2-;,613313=+E_
M(G[Y/>M;C<CG3\X*&(@82SD^RR1`4!NYX7T//J*WRO,GVF(([IYFW1?40+8G
M0YU\E![`;X60QE/`SF]OTC?"SF)1H\@&C2P:ZN]&"ZW1H+J8#`8#`T4>+G_O
M!IC_`&-EG]]M.4`\9'WCT/[#F/I;;8OX)/NQKWV_+?17&HW*;KM&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/&$MHW!7G*HJE2VU#;;F:HK%
M6>%+&9*L&8<?`%)X^@M"K'T#,-B*@X?^'Z4`A;%K^QZP0VPX`<?+FZ-VUN9O
ME=FK=6NKLV+]4S,Y2J>JBJ>N<O,_-3.,>\QB*?>(OP[VM\[5[?C<FS%&]U%,
MU9BQ3$1&=IB.FNF.B(S-,1_]Z(PGW^$U;_DZ@A600J2GDJ4JDDM0F4IS`'$*
M"#@!,)/(.+$(LTDTL6A!$'>PB#O6];Z,V*6[EN];INVJJ:K55,335$Q,3$QC
M$Q,=$Q,=,3'1,-:-VU<LW*K-ZFJB]15--5-43$TS$X3$Q/3$Q/1,3TQ+W9S<
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'J.-"02:>/IV`DHPT>@ZUL6P
ME@V,75UO>M;WT:^CZ<#3>P>-OQZEK4QNL2XY\WY-J;5?)+GJ]$TT&W"66M65
M?N2)HM:70@:N?)6_T;5B]S2@<_2A[8-;M6G]$!<_+E=<+'%^)CQJ5P.XK*:?
MS!>X?2@N+XI$Y-T43A&]I>73-7+]4BZ*I'!Y0JEJ;;=:+8)TTJ"B-0BT<'0#
M-EZZP<>%^)A0\S<+Q<`P^[(W3E`$W6.9\F)'`4@*!4JN/+XLCEMM+=*621OD
MC:WB.N[8K+3)GMG9S'G20X;;I8`/6V'%A'B759*5]?LTIH_E92S_`&C;E95)
M!V.ZJ:#"5;\HM^*6)+X)-DBPN3.S(.'+FZKG8E:7I7M^9U8"B7!L2B.+WL,!
ME?B8L31R29Z_9XJ\N%01RN^>SC:ZU-"9+(K7%8_"V?<=H48RUC%HDO=S90RR
M8VXUFB2](C%RPTE/L&DX=&Z$'4D>,CQU'%IDY**DY-)K$@UV5!0#S0B>`P>0
MW(985^-#V[U"F0-T1L^0PA2WS(J/*RM&;?0&MYQ6]+RDH="'H+@WKRWB-`PR
MJW^15Q<DPG=U/*"-5K0M;Q!KE-U2*2G11QF[ZR^@A25NBK8*$1=E6JWM:K>2
M&M"!*+7G0Q#)":%)^,'BTP&SZFL6P[HBLGK97"XES&NY$C^Y+JP:749Q6O\`
MF-0/#4:SR1^4/I=X1Y`TM(W]B$`D)2YV(T3O0#0@`$FMOB>P&:.UP1RL>/7*
M2>+:=CTN#*)`V5K'380UVK$JM(M)QI&1.09[Z8BTZ)0+"F[:ES0HHV>[[VC3
MNIQVP:&$*<=/&3KVPJTJ1ZNBE+PK*7O7#6&<T;U?T\&:#Z:I*II0T6`L(F3_
M`"K4]=';[MOZVLG+3$E3IU[XN3'HQB1@$,\*<)//\76@F2)2M_GU.<KZPE$9
M,I-8AJ"=TIYG<,YB/(>P4U651/J_AK+)WW4FC;]/5.FQ2G`I+>FI7KR*Y`F-
M$6`81W//%K);Y?QW:(#QUOMZ=)K>]OT)>''MUJXL/*:#3*$<>G"\8>VL4633
MU/7X$TF:SFQRV]*7M0P#850C@JRS`BZ@3HR>*EQ8>J\?+.ZUE,\<8>+TFY7*
M29#!QL[VIAD$L.25+84%0,RISTL46W`;-CFF1T9=Z"`M<Y(`E*#@*@#T&Q%E
M<1/#.TNXVYR9QNC8@<1-+R22G=VL2Y*4I$W.J=,H5IR')#LWR1X"S30!-"+0
M1BUK6]AV6`P-%'BY_P"\&F/]C99_?;3E`/&1]X]#^PYCZ6VV+^"3[L:]]ORW
MT5QJ-RFZ[1@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>/T_
M1O"6TW@CSB75HN9J9M5:L<J]<E:=LA[^9HY:OA*]8>`A(TG@#HQ0JBRL\W00
M!#H0T(]ZZFME;V$%M/#]QZO[KW[&X^]U==W=R[73;RUZ<:J\K75.%-N>NJJQ
M5,X1$8S:F>B)HF8IIUXC?#SE][,O?W]W-MV[6\]FBJYFK,8449NBF)FJY'53
M3F*8C&9G"+L1TS%<1-5W^1GBF<5N+W(:N.--HO4I06-8BMU3HV])"Y6L5B+3
MPD<NCZF'LJ=E.>[>#*G#060DN($/9J)Y'Y!:%-T;WK8FUI-C@!Z,``P.A:T,
M(1ZT,`BQZT+6MZT(`]!&`6M;^G6]:WK?Z<#]8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8'H5$^<IE*?K=3RY!Q/7Z.MU?*EB!UNKTZZ>KUNGHZ=8&JVJO#7
M<JV2<84IEOHW;W=^#UZ</E`RX6<BU*UEQNE6N),^*#N2J?0Z>/ZKD01-PO.1
M*=J];TH+\GT#"NSUX/\`;I$1?*O@7*V,1JKK.@W!MNNEF>*./D,ID,[X1D5D
MS-+K"9459K01#X;9T;K1(2Z-RA`Z+$9X-#2K0:,-"(.\E?@VE6G>=X6):5M0
M0J)W#7_(NN'QPIJBFRE[TLZ,<A61T8DK3R2G\8F!E=7."E4SF$V,KAPYO=U"
MU"C5."M086;I0$LS;@]S5M:)Q%PM/FQ7<BN&D;>IRW>/;@T\9"V"H6605*WS
MF/NKS:,&#:RZ;S>16W&;!6)7D2"4,K:VB3IC6M&F&$[9P0;)?!OGLX9943,.
M60UDMF<<YYH)#,F6J@Q_:]\YJ6YQZMGI&P(YT-."%1,=&&,;@SA4Z&]L;L,C
M:M.,`S30[*J_"#E,'L'5B.5L4<P"7W[PPOE;7=!\9$%&51&E/$U/;;8IA<$B
M#38#Z-"U3ANL<@S:]P4KEY"Q,<(8CB#""$X;"^5O&^=7.YTA9U,6:Q5+?''6
M;R&75S*)C!3[+@+JVS>$/E>3R&3B%HI3"'9P99!'GO1I2A`[H%J)>B3F@,$#
M1I1@:C;&\-N>E$\(^,+C)[(MR7(>8UZ\DN0/(ICK$N!U(X\<+>M"57=>%+3<
MPMX>&1M<;3F*6+,R1E2&*#U12;:GR9:8DX00MK+_``O'R>\V4O*:26Q7"1G:
MY=(I8A=850C=7_)Q\CLC@#S`S./]E7Q#9HS1ZTJ";`OABU.E?8FN?]:3)DPG
M+8"=&[#'*5\)AVBM7V35-QWFWS5EGW`"I^`!+K7=?*J]=V:'TP[W-]S;'(]-
M3*<I3)F&.V:AT>7L/F8G-K&?H&B5&DQ01%R0X$\PG=C:[9EO(%#<7)LVQ^#=
M/U[+ZHX_@B,1J>HZFY61"UY':<JK9TL&;&323+7(GTK)S?2;>U%-J#R")*D#
ML9FPMA6/A[V(S7S67)^V[VCT]NAMOFQKSML^*5>H@D)DIDGXN%<681!:^CRF
M;RESA\>@41;DBH2AQ<'I<Z*M'B-,!Y4'D@J39?A\2(<P\/3C0U%SR7MU87]>
MMX<@+@103;'3SWQFGERS#D6Z4'+7I<YN)"Z12B[V6!)R6A.8H4J$;8I7#`0F
M$/6@^@7`8#`T4>+G_O!IC_8V6?WVTY0#QD?>/0_L.8^EMMB_@D^[&O?;\M]%
M<:C<INNT8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'L().4
MGDIDQ)RE2I.*3IDR<L9RA0H/,"40G()+"(PX\XT>@@`'6Q"%O6M:Z<Y6[=R[
M<IM6J:J[M=44TTTQ,S5,SA$1$=,S,]$1'3,N-RY;LVZKUZJFBS13-5554Q%-
M-,1C-4S/1$1'3,ST1'3+?QP6X*DU:2VV_;[:2ILI20%5&(LJ`6>G@"=07^JL
M6@WH91\P-*%].]=(6\.]A#O9NQ"#L1X`\`:-TJ+6^>^=JFO>BNGM6+%41-.4
MB8^%5'5.9F/+U6HQBGW^,QK5\17B*N;XUW=Q]Q[M5&Z=%79S&8IF8JSE43\&
MF>B8RL3Y.N],155[S")D._\`PON'W)>](AR%MBNQOU@1E0X'."L3JNZTD+,A
M)L)CZ7;H<<=(H.1#0#"YMNXJM83-/!>E9PCC=BV*VBG38.6`)18"P:WH!8`@
M!K8A#WH(-:"'6Q#V(8M]&OT[WO>_\.!^\!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,#CJU`$:52K&$8P)4YR@8"@]<P0""Q&""6#7TB&+0>C6O\`#O`T(5=:
M-U<OUO#2N)IR,M.BXCRXX]WES4<WRJ']I@EC2E>*?5N16O&JOI<[-#BXP]@J
M&KK`*6OA#44%Z=%"+S@9Y9&UVC`KK9MLWZZ6G%>+A%S\V>04%J3EIR`J%#-^
M(D^K2`<C+4BD7XM4O;S8QV+-G1]K"!RIQHJ<V*XQ][6)U*)4M-2$;4$#7`5=
M8.V17_S;XM7OPN'?EF66RTVR1OD?,+KKZYY)`)9-TO&F8<D:=IFDIGR`FT((
M5Q==9U(IK3;W1R<6I8,L+9LXE8<J/`<:,/;7UK<CN5-BR"&SSD)?];0NZ.?5
M7+H4WU1+R:PF]:\>)[P=M>ZH#633(F=F&N3-SCZ`97MVV:`Q0H6'FA$8$&M:
M"$XNUWW+QG:N9\9;+ZLJ\8CP+NSB++(U);"=&J23N4P^[4C2WW%QML^8-C*A
M*FR^-,<DV\M*Q2G]-(CW9JTH,-TG+&8&_7`8#`8#`8#`8#`8#`T4>+G_`+P:
M8_V-EG]]M.4`\9'WCT/[#F/I;;8OX)/NQKWV_+?17&HW*;KM&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/822<H.)3)R35"E0<4G3ITY0SE"
MA0<,)9)!!)01&''G&"T$``ZV(0MZUK73G*BBN[73:M4U57:IB*:8B9F9F<(B
M(CIF9GHB(Z9EQKKMVK=5V[531:HIFJJJJ8BFFF(QF9F>B(B.F9GHB.F6_?@O
MP5(J\ALM^WVPE592DD*N,1=6`L]-`$YX.DM8M+%URCY@<4+IWOZ0M^M]0']M
MUA!V(\`>`%O=.W:WSWSM4U[TU4]JQ8JPFG*4S'155'3$YF8\O59CHCW^,QK5
M\1/B*N;WW+VX^X]ZJC=.BKLYC,4S,59RJ)Z::9ZXRT3Y.N],8U>\PB=IV6T4
MZ,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4O!P(XVO5+%\>;1KZ/7#
M43'/Y?.*[BT_9TC@.M"I9(7>2EQ^(/)'D'EL11I5(5J-M4$G$JB&DP"(0QE%
M_K!,<)XVT'6J.KVZOJB@4*04LFDZ2JD48CJ!E2P8J:I0))@)B(0%$%)U,H)!
MTN!PM".5F;$8:(0Q"%L/=9_':C;I&^#MBK8;8`I-5TOI.0?>AH)=`N]33]P8
MW69P%<6?T@/CDC<HT@/5$;UT#-2%"Z=;#K`CFTN#7$>ZV5WCMHT'7\N9GZ30
MR9NR-:W'I-*Y37D*-KF$/FSVM4A4DKHQ!#AM*018P:+0BV5T;#O`ZPW@]0+5
M54$H>MX8QU-2<4M:*6Q(:V@C&V(&>QG6&O!,M:&V9J#R5"YT3*ITT-#HO4&C
M-6K]-)28TW9`AAV%P,!@,!@,!@,!@,!@,"BG+GA7KE/(86^[L44)^Z#,[-/F
MH8P%_P#/_2BY(L\OY83VT^;>0\UZO5ZH^MUNGIUT=&8`XR<#?UM:ED=0_.<Y
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M,?RFFB]-VYF(Q][157W=OLVHZZJ(B>W.':GLQV9V&Y9%6`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&!BDA:)0Y'IS&"7_=LDLH0%!'H!N>/.3=CZP3
MO*K32QD]0'ZO5#]&_P!.!CWW7L;UI_T0Q?Q&`^Z]C>M/^B&+^(P'W7L;UI_T
M0Q?Q&`^Z]C>M/^B&+^(P'W7L;UI_T0Q?Q&`^Z]C>M/\`HAB_B,!]U[&]:?\`
M1#%_$8#[KV-ZT_Z(8OXC`?=>QO6G_1#%_$8#[KV-ZT_Z(8OXC`?=>QO6G_1#
M%_$8#[KV-ZT_Z(8OXC`?=>QO6G_1#%_$8#[KV-ZT_P"B&+^(P'W7L;UI_P!$
M,7\1@/NO8WK3_HAB_B,!]U[&]:?]$,7\1@/NO8WK3_HAB_B,!]U[&]:?]$,7
M\1@/NO8WK3_HAB_B,!]U[&]:?]$,7\1@/NO8WK3_`*(8OXC`?=>QO6G_`$0Q
M?Q&`^Z]C>M/^B&+^(P'W7L;UI_T0Q?Q&`^Z]C>M/^B&+^(P'W7L;UI_T0Q?Q
M&`^Z]C>M/^B&+^(P'W7L;UI_T0Q?Q&`^Z]C>M/\`HAB_B,!]U[&]:?\`1#%_
M$8#[KV-ZT_Z(8OXC`?=>QO6G_1#%_$8#[KV-ZT_Z(8OXC`?=>QO6G_1#%_$8
M#[KV-ZT_Z(8OXC`?=>QO6G_1#%_$8#[KV-ZT_P"B&+^(P'W7L;UI_P!$,7\1
M@/NO8WK3_HAB_B,!]U[&]:?]$,7\1@/NO8WK3_HAB_B,!]U[&]:?]$,7\1@/
MNO8WK3_HAB_B,!]U[&]:?]$,7\1@/NO8WK3_`*(8OXC`?=>QO6G_`$0Q?Q&`
M^Z]C>M/^B&+^(P'W7L;UI_T0Q?Q&`^Z]C>M/^B&+^(P'W7L;UI_T0Q?Q&`^Z
M]C>M/^B&+^(P'W7L;UI_T0Q?Q&`^Z]C>M/\`HAB_B,!]U[&]:?\`1#%_$8#[
MKV-ZT_Z(8OXC`]FHS8>BC`;L[I,$84(!OW*9->3``)VC2^IYQU1^6$,&^G?T
MAZGT?Y6\##.0_)FG>+$1CLUNA^?65FETY8ZUBJ:+P*?V9)9).I(C=G!EC;%#
MJSC,NECHX+D3$K-UHE$,`0$"V(6OHZ0X-`<K*-Y.`F9=12AX<'FNG%I:Y_#I
ME`;"JJP88KD#>)VCPI+7MIQ:&S5I0R)K`)0WJC4(4JTHL>R3!^3'H(6)P(YJ
M2VZYO:NHO;522I!-ZYFB12OBLK:P*RVY[0I'!8U'+$05R=(JVG\^0&@"(18=
M#T'K:Z0[UO8=\S2]G?GZ71M`6]!<H0N:VY\&XQJ1,[68I>&5&_(]L#X[-:)E
ME:4*!<7H\]K4+"4JG0TYP@'EC+"&48#`8#`8#`8#`8#`8#`8#`;WK6M[W]&M
M?3O?_@U@:W*O\3"O+3EU?)VVAN3##2]PSMRK2GN4#]!(L.D[$EZ%4_($!"4,
M?G;]:$1894X1M40SN\AC;0UN!OD@A/#L\GR@6#5<RN-2R-VJ]U_=51VX[T[7
MCC9LSA=<V_5#K)FR+H6]6O3KW3;C-6ICBZ!S\S$62O>5K<V`'OI.4E`T(>@R
M1#RFXXK)S':I.O:G&^X)0$);14"RTX!NS5:_3&WR-2TI8<ED2EX<'%$RNA"H
MP"8L[6TYH#@[$4((]ADD=OJCI?8DOJ&*7)5DFM>OB`*IY63!8$4>)_"TQ@BP
M!42J'M[LHD$?(ZYH-;$J3E!UL8=;WTBUTAC;%RKXP2B(6#8$:Y&T5(('4RU0
MVVE-62VH$Z1.MW!+KI4(9U(D+\>T1-43_P`HM><0+7^+`\+.5G%]NC5>S-?R
M,HM%$;;'Y.JI0JMB"$1ZRS?2;4R^1@+P:_!;Y@=IX?$238&\Q0+2E447O77,
M#K88?8O-;C=`8;R'E""TX193SQ;A[_,[GK6KIK"Y?9T.0QU$H6K&][B*61%+
M&%V.TF$444X[1AV=KJ"$'>M]`9Q$.3W'.>0.76=$KVIY_@%>&+$UCS!HLV$N
MD9KE>VI2UCLVSR0-SXJ9HFX-!!FA*BEIY(B=?2+HU].!`=Q>(QQNJ:-UQ-6Y
M_-N.#VK7G(RS(;-J3=(?/HBYQ_C'5#Q;T^+3R%'*$[6K7KF%C/2-X4YIQ8W'
M7DCQD!T(P(3&P\N..#NZ5'%'"YZQB-F7?#(Q.JYIZ86%"V*V9$RRQG)>FKT;
M`E#]M^=%`DQ@@;\T*4%B,*,T`8]`WO`SR!7C2UJ/<LC-8VY6=BR.`J"DDY88
M-.HQ+'F&*SU[LUDI)6V,3FO61Y4:Y,*U.$M6`D>SDAP.CK%CUH($M7Q".&]2
M5UR,L=VY"5/*$W%.&2";7=$H!8L%EL_AJ-@`<6)F<XD@D>E[=)7=W*"V($:S
MS82ET.+3:WHP>M8&<1_F-Q6D2FGFE+R(I--*;^BC#-*>A:VU8$1,+%C\E1Z6
M-#A#([]X!.4I3+`Z&`HUO+4E&F%C"6(6P[P.VFW)NF(?7KG8:6P(-+$9$6M*
M4QUI8;#KM(NFY-,)5Y]DH(PYR>5QZ+#4PQ2W&)G<Y6X)43,?K>EYZ4(1""'+
M!R:X^ESR&5([734S!<L_8&Z216G'BS(*1:#VUN3>)R3J&B&DR`]W>B-I2S!!
M.1%J$YH"AC+,&`/6P)TP-5_B$\IKFX^RZM6BKWQH:4,DC;^Y.Q;E'6YZ&<K0
M.;>E2C*-7!$(@("5`M;"'Z!;WT[_`$94GQ'\6=]^'.LZ7D]T\Q9LY?-96]7<
MBNS1=F:J*Z*:9B:XZ.B9Z(ZUQ_#'P=W#XFZ'JV>WOR]^]F<IF[-%N;=^NU$4
MUVZZJHF*.B<9B.F>IKV^91RW_P!<HM^`V#ZO*X<T'&/Z]E-DL^XLYRH<$_J&
M<VR][I\RCEO_`*Y1;\!L'U>.:#C']>RFR6?<.5#@G]0SFV7O=/F4<M_]<HM^
M`V#ZO'-!QC^O939+/N'*AP3^H9S;+WNGS*.6_P#KE%OP&P?5XYH.,?U[*;)9
M]PY4."?U#.;9>]T^91RW_P!<HM^`V#ZO'-!QC^O939+/N'*AP3^H9S;+WNGS
M*.6_^N46_`;!]7CF@XQ_7LILEGW#E0X)_4,YME[W3YE'+?\`URBWX#8/J\<T
M'&/Z]E-DL^X<J'!/ZAG-LO>Z?,HY;_ZY1;\!L'U>.:#C']>RFR6?<.5#@G]0
MSFV7O=/F4<M_]<HM^`V#ZO'-!QC^O939+/N'*AP3^H9S;+WNGS*.6_\`KE%O
MP&P?5XYH.,?U[*;)9]PY4."?U#.;9>]T^91RW_URBWX#8/J\<T'&/Z]E-DL^
MX<J'!/ZAG-LO>Z?,HY;_`.N46_`;!]7CF@XQ_7LILEGW#E0X)_4,YME[W3YE
M'+?_`%RBWX#8/J\<T'&/Z]E-DL^X<J'!/ZAG-LO>Z?,HY;_ZY1;\!L'U>.:#
MC']>RFR6?<.5#@G]0SFV7O=/F4<M_P#7*+?@-@^KQS0<8_KV4V2S[ARH<$_J
M&<VR][I\RCEO_KE%OP&P?5XYH.,?U[*;)9]PY4."?U#.;9>]T^91RW_URBWX
M#8/J\<T'&/Z]E-DL^X<J'!/ZAG-LO>Z?,HY;_P"N46_`;!]7CF@XQ_7LILEG
MW#E0X)_4,YME[W6SGA/SF0WL057=FGMS-;J0LT:%02`IO:9VB*ULP9[6GZVB
MT;ZD+UO9Z,.]Z&`/E2OU>N`NU7`KC[E^(%N-V]Z:K5C?.B)FF8B*+>;ICIF;
M<=5-VF/AVXZXCMT=':BFHWB`\.^8X<W)WHW2INW]R*YB*Z9F:[F3KGHBFY5U
MU6:I^!=GJF>Q7T]FJK9!EFU53`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&KSQ1J
MPM>V&'A4P4X^S.%2MLY\TS(5-F0B#,UA.-6,:"O[C3+YXX1Z3LS]$]LK><O)
M2G'NJ8:$H2P'6_7V7TA4'EIX=SVI(HXVT9[<_,^77WSSXBM_)"4OL9CL4;@\
M?:HCMS)VV)+H=1<8A<<B]4-2J9+#7DQ0`8'$]V,TM.&68`H(5W0<<3O>;1PP
MCC=R!3\N2_$!<%,BN@V+V""C%?AAC=U;1J`IK;/WNFCJ+.XT[31)-7P5(W@F
M5%[.]'@4ZVX8&N6/\2;*C5!\4JX>ZBM:M:@KWCG<]:[AY/`SD/R-5QSG43?$
MN%*I/&8-7-MT:\US:4N@GW?,A5G+A+8R,I(HTG<D/2:,X-ARGBE<%K7?"*]Y
M'P*Z[4A3ISNX5N-N/$O8Y"S-L]CD2\(":16>R2>[@[V[PXR*KKD`2WR5.D=7
M".GOYXD)IZGRFM&!N*\,>!2&J>-;_5[PP2V*L-><E^6L0JZ-S`+]I8QTPT<C
M[*)J1L8S9*(UV4PI)`]H@,9@C#2=M6B-$CV3HO`V%X#`8#`8#`8#`8#`8#`8
M'I4A/&G/`E-+(5#)-"F/-*V>42>(`M$FF$:,)V<669O6]@T,'6UKHZ=?IP/G
M:IOBWRNAUZ5`XP?B;)>)=H-5ZM\KY97E37)%G3\!;\K$EV=5MG.40XHJ+.E3
M\EE]U)3O+HT!\+8UD<>EPE1KTH\U$8K"B7'CB;?/)C@A3+;4W$%CJE/7/"WG
MW'&ZW$TWJ4`.5<CY0P*:0>#0F+IV1^#+4J>02IQ(D4F/F9#.E;75K3EIQ+>M
MI26&PTGP^[8WN\94HHZ,[L62^)=X?E_PV7>=P$<M'4U#Q'B(Q3F4HY'MR](-
MP8@&!RM.4WC/*5*2@GA((,`LUY8(-:O#PY72N#5KQF*X\1BFI;0+/SG3/W.\
MV>P52DOQ3R.K*YH-$S8HCB3TYW@:KLN0V8VOTT^\Z%L"TGLG0F,<#])!@#NK
MGX@<D+ZHBM&^!^'P+B!)>.,LXFKY8VUO:W%=';O(J-463/6]VKFHE8VJQJ9'
M"*Q=)61)H@LL$:$;FY)_-QMK8(7G80D#C+X>MLQZZ^*5ERBI+#8(ZR3;Q"K2
ME:F_;(H.U;-K*87Y#*%BU<2QU:Z<B4(JV+RZ8*H,ZKSFJ($/")J4&&F*',Q0
MK-WH*;USX6_+9JI6QZKD=47Z]V36_"[EO0\>EL_OWB5^0=NS&Z&#3"WHJJ8*
MMK%@NY_8+5<2BW]S.LEW:C(VO`'8_2JSI48$RW3P%Y4W^QSZ?03BNHX@(8A&
M>!<)+X\P2R>/*::W^'B?<\MLF:/46>F]+.Z(:"65@DJ9O@IDQ2F^E#&[0'1&
MVIME!`'5+_#GY0NE?G.<7INY$+K/Q^)?)Y`Q7W<_'"4V:GD-^<$$-`U>XR9+
M2$>KRF(4Z63.F0HD]KCXWQ.DWL+BXN7EE*D)`8U;'A_\W97/&=,&AY\J%'KH
M\.:T8W(*_LWC-!*.'7O'$KC498)MI(C=`Y#VAR3CCC`)(C2$'K@Q'T2!O&A4
M`&5LD\-U_AZ<=ICQZXY6)%I+`8S!K.F/(?F%8RC70R*@R%%9G(^VIQ7+_)W:
M+'*C'(+K$)$W'C`8<)8F(,\@,)9A>RPA\_\`&O#'YO2MG7L<AX^3R+.ZOPWN
M??%>3*)G9_%@BG4UVW-"H7NNF?CY4]*`9T<.H-?+H\IVUNK_`->1`&8GVY$D
M"(&J."1N0?"+F]<TD?GIIXI6K$SGZ4\!;&A;/$[2XAUW6L<C-"DT4*P6F]/0
M3BXV]:'(.&N<.?DK.D1O`X4)H"@VE6%&%&%'!/%B<$>4SD]>(_93+03*I*Y\
M\>^7-55?6+;+XP0Y\9)!N/NZ.)O:@;M-`0X"CGF\IR9!-ML@=^B9"F:0K3#@
M>>*B0C*T>!W-23<@FYZ!1,^5M\:YE<&[V8Y-![,XTP:B#Z>I3=`))8[2Z/DA
M3<AK0Y,LI$,>T2D#PM#'`-1"4;8?O9)*4\/J@P-%'BY_[P:8_P!C99_?;3E`
M/&1]X]#^PYCZ6VV+^"3[L:]]ORWT5QJ-RFZ[1@,!@,!@,!@,!@,!@,!@,!@,
M!@<M`O7M2]$Z-:U4VN;:J(7-SBA/,2K4*U*8$Y,K2*21`-(4$&AT((@[UO6]
M9W9?,9C)YBWF\I<KM9NU7%=%=$S35153.--5-4=,3$],3#IS.6RV=RUS)YRW
M1=R=VB:*Z*XBJBNBJ,*J:J9Z)IF.B8E]#?!WFZAN]M25K9:Y(W6ZU)-`1+3/
M)I4E@H$Q?0)>B!KJ$DR(@L/65I0]&C-=)Q.NKUP%[).`O'?+[^96C=?>BY1:
MWRLT>]JG"FG.44Q\.GJB+T1TW+<=?PZ(P[44ZP/$-X?,QP]S=>]FZ=NN[N1>
MKQJHC&JK)5U3T45]<S8F>BU<GJ^!7./9FO9'EG54S`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`KMR6Y)1?C+#8O)'V*3BPI#85BQ>HJQK:MV]E732P;*F);FI8XRS
MCD[]%8HU`]&LBU:K7.CF@0HT2,XTPW75"$05,D7BN<?:M9&8[DC$;2XM3%QY
M&5?QD70"\4,'8US9-;;;0OL5E"6:L,ZD563"M"X\$Y6M>6%]="T'FQI*@LM0
M#96!926<UN+\94W1'&^[:NF]GT)`9Q8EBTK![%@[_;[0S5^Q+'Z0)CX&5(2W
MA"XD)T?DM@5`3@*.,`$T9>A=.!BT5Y\<:[%IE=<M6V57UD(V$-3ES6(1NVJ>
M+DU=.=O.D7:X_'["4/$_;(O$)$E-E`-#1+7$I0K/3F)4052O91!@8O%O$;X[
MO(I`Y2Q[0U!"HD\<C623SRX)W5$"9613QJO!FH25KU+8[S\$J.CD@F+V2)O=
M26\QN(+,))7G(EBI*F.#.XYSLXM3XZ++*KO"G;7A3XYV`TOMBP"Z:?>HC!5E
M;U_NS)&3(S?OT0ZK#TD3$!6H*:TK@<WHS`K%H4R/_.-!F\2Y=<4Y]';$E\&Y
M+T',8I41(%-JR:+V]`'Z/UNE,2&+RE<Z>6M_5-T52&HR3#0&KC""Q@+'L.]]
M470&85+?%(WXT.+_`$;;]97$Q,ZI"A=GFL)S&9VUM:YS:4+\WH7%?&'-S2HE
MJQD<TZLLHP03!)SP&:UU1:WL)7P&`P->=I>(;'8/,;:C5><<>2_)!BX\*BF[
MD)8-%Q2"O44JYZ^[S;+W*)ITTML2'2RTIS'8F\(W!S98:V/[@A)6$%C+\Y,T
M1H)\-YA\5D3U5$7>N0M/Q:97G'XW**C@<SGT;A=@SUEF"8E5&54?@4J<&B7J
MC7H*@)9!&T03QGZ$3U/*A$#08K2/./C=>TWE%51FRHBSW)%)W;4'64M))E"T
MEM+`TY-WJ"R66((`AD;A(S8BM7L1JE(J&0`0D0@F&`*Z=AT&/6=XAO$VOZUY
M'V''[CKZYE_%6%2"<W%6M,6!`9S9L:;8WLPIP1KXPEE!`VEQTL*$FT%>8D+"
MIUY,8PB^C`F,WE%QQ1S\%2.MZU$RV[]SQ3U14SO8\.064AB!+,*1*W];"3GD
M,@(:T+$`:PX_9'DBTH!';%Y(.QX%+N.?C'<#.4<ZJ^NJNN6-GRBV*GM2Y&)`
M[RB#HS6J*U-,A1)\120E-*URAJDB](F6/29'U![TQMRI6:,L)(M8%Z*<Y#4+
MR(:'A_H*Z:JNMCCSIMC?G>JI_%I^W,KQHORVFMU619T="&]<(G]<)1H@#$#]
M;6MZ^G`F'`ZQZ=4S"SNSXL*7GHV9L7NJLAK;5SPYG)FY*:L/*;FAK3JW-U7F
M%$[T2F3E&GGF;T`L`ABUK8:SN)7BN<=^2_'L5YR8$DI)0TTO87(:90R?Q&>M
M*I@IRO)Q*X8^3)K<W^&QXJ:-S<=&=>=;:RE`BE"DLKJ;V85UPS.O/$8X*;L1
MGXW028J(I(&^>-U,IH^52EH0BNXE:+W'&B91NIG:8J8`TUE#IY*V20D'M+*J
M<$RQR-&(E.48?K9>!+-4<Y^,EV6BNJ&N9ZYN\M+#+!QY<X5_8L:@EE!@#F6R
M6!NG;-DT4:*[N'[AO!H4[Q]VG-T\P,Z=F=``B%H(1Y9\U+IXOV?"2CN/T(D-
M"R"?4W6(96Y7RU,5YV7,+AFK/"U"3CQ0J"(2-58P:I]/)W)_)<G=A6'MX%)J
M(HXI*,X0;)L!@,!@,!@,!@,!@,!@:*/%S_W@TQ_L;+/[[:<H!XR/O'H?V',?
M2VVQ?P2?=C7OM^6^BN-1N4W7:,!@,!@,!@,!@,!@,!@,!@,!@,!@<MN<'!H<
M$+LTKE;8ZMBM.O;7)`>8E6H%R0P)R96D4E"":0H(-#H01!WK>MZSNRV9S.2S
M-O.9.Y7:S=JN*Z*Z)FFJBNF<::J:HZ8F)Z8F'3FLKEL]EKF2SMNB]D[U%5%R
MBN(JHKHJC"JFJF>B:9CHF)?1)P;YK)[[0%5O8`P([=9&TQ2%643Y)!.&A#H`
M3WA,`L.BD3PE`,.UB?Z`"WORI7ZNQ`+V4\!..EOB'EXW8WBF*-\[%J:NU$84
M9JW1AC<IPZ*;E.,=Y1T1/PZ.B9IIU=>(?@!=X;9FK>O=F)KW'S%Z*>S,XUY2
MY7C,6JIGIKM583W5?3,?`KZ8BJK8UEF%63`8#`8#`8#`8#`8#`8#`8#`8#`8
M%$_$'J:;W'2C+&8O0M9<HHRCL2./EI4%83N7#WR>0-O2NNA*J:LA4YM#;7-T
MPR3G-KTRN*M4C3FA0GI?/$1B@M44&J+7#KF$?7K8^--$VJFJRK>>'#+D'1/#
MJYN2L%O&YX57-1JG%+?.VNSYE8,IA;,CDYSV2X,\9/G+J406V*-@4)S%H4@`
M@`CPZN=;Q:<7D,@I65)U</WXC[/)G4JX./+-0JE3R=HR]([6SEQOIR`$1Z2,
M\2D<IDS1I^<IL;]Z@.BP1AP%16U2TD,T6^']RVL:K(JA0<.(5QI>*7XF<2.+
MYD+8[,J-U%>4D@'+3C3=,RF#0X0UV"Q(ZWJB)52]'M1D@.1/RYQ?%I12$'T&
MJPS)3Q=\0&@+#D=Y4YQ>:[BFJ5D\4=AA<9<+"IY,VE.?+#GQ4-K5#*W=#+YU
M'6QY;4E5Q]QD9S8-8C,,-0`;CSDB@\.PAVCIPKO><594S!`>(MGU*^0V.^(.
M7:KQ=]B<:5UC79;7)?B!+H.VW)(G&GK6FL8.<+$M%]):QE;/3`94Q11):=,T
MI4_4#!.47#UXH*$5#:3Y7M.UW6%3<0O#<K>PXW*I-`X)6EKVEQ_Y:16:JN.D
MU=R3#H^UI)*0K$D:WYY*^ZA3HI)`M6%(S%!@0NQX0+P3/K&\3JY&>M8O545M
M+F7%%S+%(;)X+.&),XQOBO0<=EIA\SJQ<\U@_P`J,DR-0)]VPN3HB3.^U"<2
MQ0<4:9L-V.`P&!J#:V7FGP\G'*J*4;Q43<FXKR)O.<\B:@LI'<59UPPUU,K5
M8HZ1)X9?[+-G=HF88U&9JQGKDCK%$<F5K&566E\S)4)_[0-=7-G@EX@MUSBV
M5"RL%ME2J8LO#23(9U1]CT71?'Z4R2C#:Y>[4%946EH1\C9K8*67L;U]R4*U
MV,BY#.H0@.5I%!:GRH3E">&_)LZW4<3WQ&@=;)H]XF/(KG(5R_73ZM7,,F@T
MF=+9##8T=&HLXJ+=%.[&:I:WL3JE4D$M26)>5V-8)3H#>`*#!\,CGV_Q)Z*<
M*$G*"5?+BY@<67M+*+OXT%UXMN>S5E*/<7:>/=9507%(S6W'=Y>(*Z[9CWD7
MWA"`U.!X)(&3YR>%R8;X<_)%GYIJW6:1.\IG7J[G(BY@-5J-U_<=XU0+5'BD
MS6XHFV40$^L'OE*Z6G%T24<1"S(UVHL[,X`;$ZHT0S4.@BAGX#<W(G5,5AD4
MXMQ!1-&WA-STX<#<IE(J$?8(FDTTOJ+6Y4]D/+*X2!U`^P"W(8UKFQO3G-ZQ
M8TO!I('ML*;QGF["\/A@\5.05)<I.5%Q6I6UP0>"731O%V,1!7?%T4S;-L+I
M/4;S>),I131+1H4==0\21MFK;Z-0L1)[2%#K0]'@4C/2D!O%P/&]=.MZ^G73
MKHZ=?1O73_BW_@W@?+_-^"]EL;1X=?!IY?X^XV8R69<\'MUPK)GL)UB4Y\,2
M2V"*Y;'#8LL>XJR,D*ETAF5=PYBVU[6K`B7N!@$8CR5!@RPF"IN,G)[D!;7,
M:O%QM50KB</Q;=7]*'YX;+`1<A'1;22#CK8C''X"WG,X*_=8G-YA!FXO<E&O
M+4-J$M8G(2JCO(GIPSS@+X3$OXC7E`)+)6;CZ]PRBDEJ(JVMAIG7)^5W=-29
MV!T8F$YWK2>S8=#TFZ-L-?%*9^51\AZT_*.@28MI*&87L)_YR</N6/*B2OU>
ML\KXU+./<S-KUPCLWL*)OZ;DGQ"D<<<F\Z:2_C@ZQ=@/;93*Y,2T)ES0O=7A
MD4,#OH6QB<$6@(PAMFP&`P&`P&`P&`P&`P&!HH\7/_>#3'^QLL_OMIR@'C(^
M\>A_8<Q]+;;%_!)]V->^WY;Z*XU&Y3==HP&`P&`P&`P&`P&`P&`P&`P&`P&!
MF,`@$OM&7,T%@K,I?I,_*=)T*)/KJEE@UT;4+UZC>O)(6Q"5TF'GF;T`L&M[
MW]/1K?F]W-W-9WLUFQH&[]BK,:IF*L*:8ZHC\:NNKJHHHCIKKGHIC]J'@MYM
MYM#W/T2_O%O%F*,MI.6H[5=<]<S^+113UUW*Y][11'35/[<OICXG\3HAQFB.
MBB=)GZQGQ,3N8S,1/08H'KH-TR,FC->50QY";_D`^@Q0/7E3>D75"#:7P@X0
M:+PLT;L6^SF-Y<Q3'Y3F<.FJ>ONK6/319HGJCKKGW]?3A%.I;C1QIUSBWK?;
MN=O+;K9>N?R7*X]%,=7>W<.BN_7'7/3%$>\HZ,9JMKF86%#`8#`8#`8#`8#`
M8#`8#`8#`8#`8&O;Q&>4-E<6JZH]UJQ]HJ'R"XN3->44NGO(XE_/JB`L4PC$
M^?UTJ?B8[-:]6F&I3X@2G)T-V3$[$I_6WO?5U@4JA'B>7>"?LM2OSEQ*O5>5
MS`XH4,_7EQI<)BIIYRB/)&)6Q(WMC;FMPF\U/CMRUF*MDYRI.)_>$1K<]HSS
M"2!F^1"&=77XTM/PFN.2"Z`5#?2ZUZKXS7;R0IV*635;I!&2^HK3)*9*_P`G
MBFG!V32I'"6!Q=T2UT-=4+.X;81'+$:=3HOJ[",H#XRDH=[WL5FLSC[:=4TU
M6U3\<2$48=J3D3[R!N;DKR73%.D'K.LD<:LIV8DQBMMT=M$TJ&Y6H6)TBU>H
M<D"9"8$T+=)/%;X]N:NFXTQUWR2?;1N2S+-IXFE6VFU^K8K6Q*;;(A(;+8K<
MC:YV1)(61%XC.FUZ$O\`.U+:K:5):A*H/"<GT:$9M'C7<8I(F:5$4ISF7*QS
M"$2^Q:N31_C7)UIMP0^M'I,P6V]5N>)P)0.B&J7!<1IX.6'(23-*"?,!K1&E
MA$&S2'2FL^1=.Q2;,I#5/:CNFOV&6,Y#^R!4M$J@TZ8DCRVA>(Z^I-Z$G<F=
MQ!Y=(K(ZP>MLLP&MZWK`RR)0^)0".M4/@D6CD*B3$GVD9(O$F1LCD=9TNS3#
MMIFID9TJ-L;T^SC1#ZA)0`]86]]'3O>!D>`P&`P&`P&`P&`P&!PW!8!O0+G`
MP`S"T*-2L&67KI,,`F)&<(`-;_2,6@=&O_#@?.=8%T\G[;KGC98#'R'M!K#-
M^,3YS!GE7<<[/X\5C>$31V3+DCS"984T<A(\."6[1%,PLX]E6LR1\9U8UJ,)
MRT2LUQ2A+"38Y=4IY&)[OOI]\2"3<9HQQJ;J6=:[;VB+5A%J^DU?32AZJMHB
M]^0%53IE>IC,F6\'^7N+>ULR)Y:26\EN&B;3AN83U&!YBOB-2QX\1^61U5*[
M%:N*$X6RWBI6K\_T1.6N@6"Z:GB8YN&VD-_.D;;:^D[]-Y^7,X,LCI3\)2`^
M*MP=%%&B4;T$O\$++OQ%>-Z4A*[W!R49"VV@[QKVQII/J_EZ&5TO:Q=BM,BL
MZ!O-.0!A:88EG,DAY9T;KYP`N(:6P@2DA^6E*]@3ACW)GFQ9?%KGS.QR26J'
M;C>HXNU?$V"L#6]O$43RLL)]Y`/E/*69T)0;>PN-M@JU3%-I!GB3'KC&[8``
M,"+8PJA#O%@Y#<<ZQH&#65%$')Z<-4F&W\J;14.K]&GV-H)]S?L[C;&'5(DC
M%8GU1'B&S49Z6Q$YOB!>])R`$H49OD5*D(37:'/KEY/X=2$WJJ#TE#VBW.6U
M31:DF5#R(,43Z:PH-RR&L)9%.0\755,J,KIL<2$1*]V%'AR!4T"T-J,UY_H.
MQAUDY\:&S(0=424WC?$'M<5(8_&>42.-V).WI/5BMZY=3?B#IWB\FU42*%#8
MG"55VO=V8J0.30]OB,X!"9NV-.J.`'4/7BA<@M73`IZ"%56@JBPJ<NM+2%8H
MK]0*!R29J^7O&WC/74LY0*#Z_+.I/42>):N4.`VTQ]3MZ=Q5MQVC'1+Y/8;2
MN-O+4-C5I9,EO<BLJAD]+7T]<<[$<(_9R>5U&X3Q`LAZ)C60J?/K/#E*E#*5
MD];$!:->A1N"1[&:W&EB/*Z1AK0:O$WNFM66X=D1F`7(U4U+^7MWV;*;+N-#
M6KP=QYA',^X*6@\'H-N:X7(&VPY@P,,',))TN4-J'0B4"$:HQ8X%B"'#FGC:
MS:O'"_V68<9@-$EC4R9HEQVB6G*W'J06F@>;X:*(!/50XC2DG8)O#&U9*F=U
M7:KM=,71`8XDLZE&2Y&!#H.X3^,3<+I#6^7MW&>!L&H+2%H7G>[':UM2^H),
M7'Z3O1QI>9M-,Q.=U"URZ1/DJ`B`YL2>2((V82<>4VN&DZLXG8P[BE^8/*B:
M%3VHI<G:&)':CQXD:OC3?B>;A<K)8W+BM>SLWL+?8]9G0)#%V:&I&:0MK<@+
M(=G%<:B:#@+@%#4@&$-P]!V0=<E&4S;JAN]$*+1JJOK#4-6M&:"VJ)G$VF1'
MH`>6_M=EI#7'98=B^G80ZWO`EG`T4>+G_O!IC_8V6?WVTY0#QD?>/0_L.8^E
MMMB_@D^[&O?;\M]%<:C<INNT8#`8#`8#`8#`8#`8#`8#`8#`8&8P"`2ZT9<S
M06"LRE]DS\HTG1(D^MZ`66'HVH7KU&];*0MB$KI,//,WHLL&NG>^GHUOS>[N
M[FL[V:S8T#0+%68U3,584TQU1'XU==75111'377/13'[4/!;R[RZ)N?H=_>+
M>*_1EM)RU&-==77,_BT44]==RN>BBBG&:I_;?3'Q/XGQ'C+$?(D^;/UBOJ8@
M4RF0B.J8H,#U3-,C)HS7E4,=0G?Y`/H&H'KRIOZW5"#:7P@X0:-PLT;L4=G,
M;RYBF/RG,X=-4]?=6L>FBS1/5'77/OZ^G"*=2W&CC1KG%O6^\N=O+;K9:N?R
M7*X]%,=7>W<.BN_7'7/51'O*.C&:K:YF%A0P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P*A\N^*3-RR1<?&22J8R9%Z<Y+0*^9+%Y=$4<T89^SPR,SM@.A2QI<CRVX
MGTB?,"U`5)Y2HLK:7_F1"$$0`Z"]>%L1L:/\=(G5@(?1D:HCE'7_`"-&RPF#
M-30V._W-9I@UK69I;6`3&VL;TZ&2@!P'`1*C18TVNL29TZZ`U4Q#P*I.V(CV
MB0W?21"8SB;R]XDN\MKSC..(VM:J+E!"6B+_`)]WQ9+G:4GD-GW2V.#*2K<-
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MU45>5@IDJ9O&TIW\^#Q5KCAKR2UF*W`QN*<AMVS@D"/.V5H?5V,71T["<\!@
M,!@,!@,!@,!@,!@>-ZUO6];UK>MZWK>MZZ=;UOZ-ZWK?T;UO6!3HK@5Q6=:^
MB-7V=3%;WA"ZUDTL?JJ:[F@,-L'=9-TJ?US_`*B4142!D6'((VP[7^9(2NG8
MP-R=.08(P)!>]!)DTXL<9K'G$(LRP./E+3:Q*T*0$5[.)564-?I5"R&I4!<T
M$1E]<V=2Y,Y#.N+T>C`08`*0_7E"M`'^M@9D73M3E19C@Y=:P4,-C,G0S6.Q
M;469?0#%,6V3F39!*FEJ\S\R02)',#1NA:TH`5`7`8C]#\J+8MA&T<X@<9H,
MF3HJWI&M*L1EVJSW4L2UA"XU`B'JRF("PMNDSX7&FMOTZ+BBUQH-B,Z1;+%L
MOIZ@A!$$ER2GZGF+MM_EM:023O>W*!O.W>01-C>'+TO5CVXR6M'32U>A4*-.
M,`D3PK7,QW6\HVJU)IJ?98S!"V$6RCA=Q"G#Y')-,^+]`RN11#TIN*OLBJ2"
MO+M'1/4E<IFZ#9G!P8U"IN,6S!Y5NHQ%""+TBJ.4ZWHXP8]AVS-Q,XNQR:R.
MR(_QUI)CL&7RQIGDIFS16$,;I5(9LQ."EV9Y:[OJ1F)<E\C;G98<K*6&&"4!
M5&C.ZWE!"%L.IE'"[B%-W]@E4RXOT#*Y-%37=1&G^15)!7EX85#_`"ITG3RI
M:'%P8U"I`I<9J^+7<PPH01[<U9RKI\L:,8@Y(N'?$P3M9C\+C-0NWJZ&V0,U
MNNWY3073A9S3+#6Q1*&R>*],?EY4@D:MF2'KBEHC@*E"<!IFA&!T+`RIMXZT
M$ST^JX^--*54VT2N:5[$MIQ#`8NEK-8T.IQBES;U<));`1U2F<51HCC]#3B\
MJ<+9@ND>^M@8NMX>\3W)MJ5G<.--$+FFA!%CI)M5U1!U*&IA%*$RP&Z\2G,@
MR8CT+D1*C?F.B>E026;OI,`$6@]?N<\2_+VPI]V:AO.+W*-(ND[\IX-Y6U23
MUXG4\N?C]"=:5!/=A;6#\\\KUU?]OOI-UH>!%AWAS\0U-KUO9BFCZN4MM.5H
M@KFIJP45G7YU;UH8VSXZQ4DU@S`9&Q?=F9EOA^^E6D&5UOH,V'9W]I@35/.-
MM3S>'/L23Q9DAISVT6BRDRJ(,#"URR/)KO5^>7$KB[N)M.,8WFQU`QG.BPG6
MCU*L6E(]B.`$>@F1@8F>+L3+&8\WIFE@CK2W,3&U(P;+2-C.T(R6]L;TH-[%
ML"9$B3@+!KIWT!#K`[;`H-S$X6N7*610A]0V"BA88BRN[28F51P]\$N$Z+D:
MP)X#2GELTGT3I+U=AV$?6ZW3TZZ,KQQJX&YKBSJ>0U#+ZE;R,9.Q<MS359F[
MV^\KIJQB8NV\,.SAAA..*RG`OCYE.#NE:AIV8TRYGYSV8M7(JIOQ:['=T54X
M3$VKG:Q[6..,88=2G7RAY!Z]6?\``"SM9F%>334O:"QLE7I#.G.]IGLY?VRG
MT8^4/(/7JS_@!9VLQR::E[06-DJ](.=[3/9R_ME/HQ\H>0>O5G_`"SM9CDTU
M+V@L;)5Z0<[VF>SE_;*?1CY0\@]>K/\`@!9VLQR::E[06-DJ](.=[3/9R_ME
M/HQ\H>0>O5G_```L[68Y--2]H+&R5>D'.]IGLY?VRGT8^4/(/7JS_@!9VLQR
M::E[06-DJ](.=[3/9R_ME/HQ\H>0>O5G_`"SM9CDTU+V@L;)5Z0<[VF>SE_;
M*?1CY0\@]>K/^`%G:S')IJ7M!8V2KT@YWM,]G+^V4^C'RAY!Z]6?\`+.UF.3
M34O:"QLE7I!SO:9[.7]LI]&/E#R#UZL_X`6=K,<FFI>T%C9*O2#G>TSV<O[9
M3Z,?*'D'KU9_P`L[68Y--2]H+&R5>D'.]IGLY?VRGT8^4/(/7JS_`(`6=K,<
MFFI>T%C9*O2#G>TSV<O[93Z,?*'D'KU9_P``+.UF.334O:"QLE7I!SO:9[.7
M]LI]&/E#R#UZL_X`6=K,<FFI>T%C9*O2#G>TSV<O[93Z,?*'D'KU9_P`L[68
MY--2]H+&R5>D'.]IGLY?VRGT8^4/(/7JS_@!9VLQR::E[06-DJ](.=[3/9R_
MME/HQ\H>0>O5G_`"SM9CDTU+V@L;)5Z0<[VF>SE_;*?1CY0\@]>K/^`%G:S'
M)IJ7M!8V2KT@YWM,]G+^V4^C-B'%CB9".,4:4)VTX$EG3V$/WHG*I$!(K7%@
M'UR&IJ2[.5":6-+OHWHD)HQ'&:\H:(6^KH%D^$O!_0>%6EU6LK,9K7[\?P^:
MJI[-5<1TQ;MTXU=W:I_>Q5,U5>^KF9PPJ]QCXU;P\7=6INYNF<IN[EY_]OE*
M:YJIHF8PFY<JPI[R]5^_FF(II][1$1CVK79EYA@P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P,5D#7*UYZ<<>E:2/D%E"`H(
M4QLE[$H-V/I`:$XQS0;(T$'T=7JBZ?T].!C_`-W;,]937^`$O:'`?=VS/64U
M_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VAP'W=LSUE
M-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]
M937^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS
M/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VAP'W=
MLSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]
MW;,]937^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`
M?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VA
MP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]
MH<!]W;,]937^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$
MO:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@
M!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?
MX`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]93
M7^`$O:'`?=VS/64U_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/6
M4U_@!+VAP'W=LSUE-?X`2]H<!]W;,]937^`$O:'`?=VS/64U_@!+VAP/WJ/6
M1HL8=V.V;-$,H19GW#2ZT`L(3M&@V7]X-]?9HA@WK?3KJ]3>NC?6^@)'P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&!&+/=M,2*PGRI(_;E8OMK1A.)5):R9Y]%7.
MPH\E!Y+0U+Y"T3L?)&E.#9P.D:A,6'77#]/TZP,X?GYBBS([263O33'(XP-R
MQX?7]^<4;0R,K2W$&*G!T=G5P.3H6UN0I2A&''G&`**+#L0A:UK>\#GIE*9:
MF3K$:@A6D5D%*4JI,:6>F4ICRPFD*$YY0AE'$'%#T(`P[V$0=ZWK?1@<9V=F
MI@:G-]?7-O961E;UCL\/#LL3-S4TM3<F,6.#FYN"PPE(@;T"0D9IQQHP%E%@
MV(6]!UO>![D"]"Z(4;FV+$CBVN*1.O;W!`H)5H5Z%62!0D6(U:<9A"I(J(,"
M,LP`A`&`6MZWO6];P.G?YA$HH8UE2B41V-FOBA<D92W][;&<QX5-;.X2%R3-
M8'%2G$X*&Y@:5:X\!6AB)1IC3AZT66,6@[)I=FI_:FQ]8G-O>F1Z;T;LSO#2
ML3.+4[-3BF+6-[FV.",PY(O;UZ0X!I)Q0QEFECT(.]AWK>!V&`P&`P&`P.EC
MLDCLO94$DB3^RRB.NI8SFQ^CKJA>V5R)*.,3F&H'1M/4H5A9:@D98A%F"UH8
M-AW].MZP.ZP&!J[Y_P#*^X..LMKAGK-7&TR*31U^<W4+XP:>#1JF]S;TJ;:<
MS:Q+Y`O12@76#T;Z=]&_\&5/\17%_?3AKK&F9+=:O*TV,UEKM=SO;/>3VJ*Z
M*:<)[5.$83.,=.*X'AHX+[C<4=$U7/[VT9NO,93-6;=ON;W=1V:[==57:CLU
M8SC3&$]&#7_\SGE9_-*__!`?M?*Z\U/%WY;3MECSBR_*-P9^1U/:_P"+/F<\
MK/YI7_X(#]KXYJ>+ORVG;+'G#E&X,_(ZGM?\6?,YY6?S2O\`\$!^U\<U/%WY
M;3MECSARC<&?D=3VO^+/F<\K/YI7_P""`_:^.:GB[\MIVRQYPY1N#/R.I[7_
M`!9\SGE9_-*__!`?M?'-3Q=^6T[98\X<HW!GY'4]K_BSYG/*S^:5_P#@@/VO
MCFIXN_+:=LL><.4;@S\CJ>U_Q9\SGE9_-*__``0'[7QS4\7?EM.V6/.'*-P9
M^1U/:_XL^9SRL_FE?Z_\/W(#]KXYJ>+ORVG;+'G#E&X,_(ZGM?\`%MLO#GF1
M'>2<?TR/GF,?MMB1A,?XZ69Y-(^)2MZ+%(XR$X8C3D(][UYPGZ1&(S!=&]B!
ML`Q7"X*<;-,XH:;^0Y[N\MOCEZ,;UF)PINTQT=]8QG&:)Z.W1TS;JG"<:9IJ
MFEG'7@3JG"C4_P`X:?WF:W)S-S"S?F,:K54]/<7\(PBN.GL5]%-VF,8PJBJF
M+OYGA7LP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P/0J-$0F4'@(/5#)(--"F3>3\X4"++$,)"?RIA)7E
MS=ZZH.L,(>MO73O6OIP/DNXT2BA8#8'#9D@+OQ<Y)L+KRX"EAM:O$*=J(\6[
MC18\WD,Z^^KQ>9,!F+\&R4=3*7AU*G8G]L96YU8R##SU#@(2<1X1/#N8EP*>
M*:">0GGW8O)*W+,X/>(5*N4]7R9SKV4M?&\^EZXF#C4D^20]LB"-TJ!T89ZD
M;HZ#;Z8I)F9;D)3Y-3Y$!A87$2V?R4W9=GWRFY:W6E;J>\2'@9QMC5$DKH0"
MC7"IKUKKB$@M".R>.&1(;TZN<B5W$YKD*W;D48S+`DC2!`'9P30KM*>3UD36
MHY"L>N8,XLZ][^I7Q,8KS3X0/9T170_C;$JRH>_5K$<WUPW1M)-:`#6DMC<;
M8"7%X7F:F);V(P0U9AY!I(=*W<K+(J#CL0+CASKLGD+5\?XA<#[MO6P%CQ"I
M(FXO38[E/Q[A<SC"%WAL4:$E4Q6;4(NEHWF&.8#UC(U,`UHO-]#/./">.0G(
M]DY(<E75=$+5:[?JFO.:]APNKG-D=D#Y#&Q&J\%R\Y'+FZ$/B#0D#PS+94ZJ
MSSE24]2G,5#.T6;O01:T%=*.Y@2"@N)M>"H_G);7(*(+_"PKB;W:%L65!(A\
M/+L,F?&2G*C31EP<883%>/3,YM%A2I*YMTF*<@LC1$S)`>D4#2*!*@RBGN1'
M)RR7MWXQ!YNS4^*J/$@XC5<V6G2]_LE^3-!4]U\6+JGUBUW'^2KW3L#(GJ)1
M,(.7LMS3Q\930N+.)0J!"3=!0;HN:K39LEY$^'QQKAG(V[:5AMIE\ET-GR.K
M)#'VNQYLTUQ2C<Z1PHR3O\9D13<[D20XE>8O3I`J>L$T(-@T=O>@TA(N3W-"
M.\,*MY""Y@WK/+!Y)>&%R%O^9IW+4'#'X/,^/-K<;&YDG=3QZ*0IJ-B"AOKJ
M;/H9`((UA;L$0E9X-'`"((6>Y;<Y)!:,^Y/E<;N<D&9*>BL_X),*!Y:KT:*F
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M`%H'..:4LL<8PG)MJ#1F+S3$X?17X>\ELZZ>1_.*V9[?%H2MB@=KP&JZ[IO3
MZR@I:'QZ4\5^,EPNSPU1]"T>DUTB6RV:+S2%:AQ/+3HU0BB0:",0Q!MWP-%'
MBY_[P:8_V-EG]]M.4`\9'WCT/[#F/I;;8OX)/NQKWV_+?17&HW*;KM&`P&`P
M&`P&!WT7E$BA,A:)9$WA:P2-A6E.#2[MYNRE2145OZ-ZW](#23`[V`PL>A%F
MEBV$>MAWO6>0TG5M2T+4K.L:/>KR^IY>N*[=RB<*J:H_=B>JJF<8JB9B8F)>
M.UC1]+W@TN_HNM6+>9TK,VYHN6ZXQIJIG_7$QUTU1A53,1,3$P^D[AQS$CW)
M*-A9GL:%AMM@2!W(8\`?DD[VF*T`&Y+'"S!B&:WGCW_;D=(C$AF^@727L`Q;
M0."G&K3>)^E_D6>FWE]\<O1_#68G"+M,81W]F)Z9HF?A4],VZNB?>S35.J+C
MMP+U3A1JWY?I\7,SN3F:Y[B_,8U6JIQGN+\QT17$?`KZ*;E/3'OHJIB[N9W5
M\,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,",IJJJ:J6B=WE-4T0AR")Q!ZDE@68L:$"9>V0R,-9KL]+W
MI]3HANIS6TM3>(T8-B,T$!7T!WT:U@1MQBX\4W15#P.LJR1?>"$)(.U,Z222
MEN9E<HFD7/+4KVH4P7)6-E"\]")V$``#DP`EE"ZG4U^MTA/OW=C_`%3P>@F;
MJ*5Z-U4@]&(NJH=&X*4#>Y'A\AT&KT`$)&B3A=)A6B0:#O74#T!%RJ8T<VW6
M"G5.HNGNNS*VD%A'L.HP/;Q+ZUACQ'X@^NKR^%-`FY>VM+K+D"/S98KV:+2K
M7DRA`T/80DI#$XJUI'5`V1J/MR%],/.?$2%F;DB1Y-5)@(E)KJF3IBR7$Q0C
M+"4,1P1[&4'0=](=:U@>E'"H:WITJ1!$HRA2(>IYDE1L+4F3I/)MIC,7YJ22
MD`6GZC.<-)KJ:UT)A[*U^IO8<#](8;$&Q*[HFV*QMN1OX=`?DB%C:TB5[!I$
M%MT!W3ITI93D'3<`*?H.T/7D=:!_DZZ,#PAA<.:RT)39$XTW%-86\+86A8FM
M(6W!:2UA+6%"!.E+"D"VE."@*?1>@^1">9H'1H8ND.Z.0(5"I&N4(DAZUN\X
M]'K#DQ)JI#YV7HE5YFH&`1R;SDH.@F=38>N'71OIU@=>GC4<2%(B4K`R)B6U
M`J:VXI.U(22D#8NV4)<W(BRR`@2H%FR"]FD@T$LS8`];6^C6!U8*]@);(JC1
M<'B`(XN2)D"U@!&F4+(L0(CC5*-$J:M(M(5"1(H/&846,O8"QC$(.M;WO>!S
M%T/B+HD94#G%HXXH8VH1*XZB7,C8K2,*MM+T2W*F5.H2F$M:A`5K021D:+$4
M'70'>M8'L.BD74/&Y"HC;`?(!%(B!/AS.W&O&R&U1M6W$[<QIA+=E(%8MFDA
MZ_049OK!Z-_3@<0Z"0A0)K$HAL5/$R)G!$RB.CS0:)H1NY8R75(U[&C%M`F<
MR3!!4%E=0!P1;T/6];P.Z;VAI:='Z:FQN;-*C"356F]$F1Z4FITB=`08?I,4
M7HXPA"D*)!L73L)10`:Z`AUK0=A@:*/%S_W@TQ_L;+/[[:<H!XR/O'H?V',?
M2VVQ?P2?=C7OM^6^BN-1N4W7:,!@,!@,!@,!@9!%)7(X-)&>7Q%W6,,D8%I;
M@TNR`SR:A*I+W_A_2`Y.<#>P&E#T(LTL0@#UL.]ZSR.D:OJ>@:G8UG1KU>7U
M3+5Q7;N43A--4?NQ,=%5,XQ53,Q,3$O&:SHVE;Q:5?T/6[%O,Z3F;<T7+=<8
MTU4S_KBJ)Z::HPJIJB*J9B8?2APXY@L'):-#:'8*9CMB-("CI1'RM["D=481
M@3?>>/\`7WL0VU0>,.CB=[V-(</0-[V`0!BV@\$^-&G<4=+G)YR*,OO?E;<3
M?LQ\&Y3C%/?V<?Q)G"*J>F;=4X3C$TS.J'CMP-U+A-JT9W)37F-R\W<F,O>G
MX5NK":OR>]AU7*8B9IJZ(N4Q-483%5,79S.JOY@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<%S-4IVUP/1)
M#%ZPE"K-2(23RTIJU2608,A(4I.ULI.8H-UH`1BUL(-[Z=_1K`^&Q@X]W';(
MK0;@U#=QJ[D-X>'B$1?D35[AQ_Y315I;^4+:Q0B>4S6ML75=$XE2KDU>$<ER
M%>)JD34B:6`W97DVP.R5>D8`M_'^,YSW7?-2WZ4IKD*D:V"&^''"ZK9XRV75
M`+#3\3CJFHKWS(%0$+E:B./#3.Y)"&J0M;H!&G*?SU9.D@#0JM$:P,;G<<J-
MG>(<4WU9RL8/"^E7B`U"&M:E(B?(E@DKZUMG#'D(9R/=(K3[L6CY!#X]KIT2
MRGO#,4WA+<EC<['I$)Q(S=GAG]9<*4]_6W4S/<=,7PJXY,7&7Q'W7C9&[`/N
M.+R&!U:^<CZJ7\9HK-EXW1%+6^4ML6(5N4197]8:\-;8%&+R):E'K2<,RB$6
MY"O4@\.N@)BGLY01XDW&+A):_*-ZECM)&Z30V6\!8'#Y;R)225&O4I'N,/MX
MMSO!XZY@V6088L(5Z/Z331`$'U*X#`8#`8#`8#`8#`8&BCQ<_P#>#3'^QLL_
MOMIR@'C(^\>A_8<Q]+;;%_!)]V->^WY;Z*XU&Y3==HP&`P&`P&`P&!(-75=-
M+CFK/`("TF.S^\&]&NGK`0MB(O>O.W=W5Z"("%K0E[ZQA@OIW]`0:$,00[]C
MW3W3UW?;7;.[N[UF;VHWI_!1;HCX5RY5^+;HCIF?P1$35,1/K.^&^&@;B;OW
M]Y=Y+T6=,L1^&NY7/P;5JGKKN5ST4Q'5TU53%,3,?3;Q@XOPKC/"PLK*$MWE
M[N60?,IF>0$"Y[6@UO84J76^L)`Q(!#V%.G#O]'2,>Q&"$+-J/"GA3H7"W0H
MR.1B+VLWHB<SF9C"N[7'XM/7V+5'511$_P"U5C5,RU(<7N+V\'%K7YS^H3-C
M0[$S&5RL3C1:HG\:K]_>KPB:ZYC_`&:<*8B%F\RFQ&8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'X-,+)+,
M.-&`HHH`S#3!BT$!98`[$,8Q;Z-!``.M[WO?T:U@:?K-\423Q]GIF00*G:H(
MCMW0N?6K!9ER.Y+H>.->S"!1V;-<3@$:A<^7UA.8PY77;C2^(7QN8')0T(43
M<N3Z/<1&F""6&,2WQ;'6)\GGVBG&M:";$L8MGC942^OI%RV8VGF5(GGD5"*:
ME!;K6W&-#6CVRV$SP)QN$*9<<BF7D5:=C<5*8P6BP`&&$6!XG=3S#CP;R>E/
M&A?)[:XQ<X7^E*^JS\Q?-5;?)RG655QJ\D4F2M"=/N)+:"?'J0&$*6Q7Y(`%
M"'6A*"P*`A?6)\YXU).75O<8E,)=6N/UU%%JR+6^6YA=FFS;$@;3%Y)>=6QR
M+(&P3QN15)&;*BRDW9)BL;B8XJR2R@&-QO7"->3=V\4.'LFJ;GC8D>1LBB]E
M[%14HNNP9#.(\JK&I5M4V+=Z;T;`I0G<-Q]>^NE5MZ%8PMS4T.[NYGI=*_+*
M4A)&!FB7Q"ZL@\9K=WY.)3>/TFN8#A+X#7OF\KM621JFS')O;HW9=[.-;PY[
MBE*-BSTHEV[+'1PW&V52J"E&\'&EG;`'L</%&X,-#]<4>=KM$V*Z%:K3>+/<
M7"M[91QAG3T@^)8[;J5EF*B"EQ2;O-=N*]/MT;V):Y+DZ906HV5L@>C,#UF>
M*/PA)A2*>'6R_$M2R:RB`GLIU,WD78#$]PAG8I+,ETMJX=;ZLB&Q"*164M;L
MX/[JU(V-(U.:-68K"0J(&,,6MKQ3N,=;7!!*?9Y(.>N3K*'YNLB01MBGKE%*
M_B\;X]3_`)$/#TT2]D@[W"[)E+5$XFWFK(RSN9KVE0/1"PPG1>@@-"7;!YP5
M!7ZN0R):]MBNE:OB1\DO2VT^Y&H;:U6/\?KR45)'V]N;8LY`GSW:C+8"8Q$A
M:5)SCH9J0LM,>-6$(`XML<SX^R</Y!ROI"/"M1,2ICS-%(E-M3*DCG"3/]GL
M54FLDR*ET!63BOCV&1/`]+RE<>,6D>;##YOO>]8$/HN?$WKF?*ZCY=5E4G'Z
M>MZZM'X+VS7G)+(J:3518I%HE'2:+S(VDH7($<RAKO4[B2YM+^R,C8!,(I26
M[#`9U-!G";Q0N%"RKV>X$MG2M1#Y#*SH>PIB*+OTZ<O3@GBR2=J79JK`NL16
M2X0I-!'`A[,D)+2-A`TGEJ=J]%#"+89/(?$8X8Q2S(=5$ANUJ;)'/XX3*8>^
M'QJ;BK!]:E,$46>F+1W,5&3*D]+J:[3[>BT`GH*X3<,L[175-*ZX8NE\43A.
MNJYJN!'9\K5PY^E1D0CZ=-1E^'SB1.!,523LYWCU8E5B*R'V$DP1>2]CD21J
M.80M)@56U>BM];`G^N.0T6LFSY37+/YBJ3):RJ^[*ZE[.\$/4>LZIK1`^H6R
M5,BE.0462-MD<76)SR@C/!M*>A4A,Z%7DRPU5^+G_O!IC_8V6?WVTY0#QD?>
M/0_L.8^EMMB_@D^[&O?;\M]%<:C<INNT8#`8#`8#`8$@5=5TUN.:M$!@+08[
MO[L9^C]8"%L0@$'2MX>%>@B`A:D(!=8PP7Z=]``Z$,00[]CW3W3UW?;7;.[N
M[MF;VHWI_!1;HCX5RY5U46Z.N9G_`$1$35,1/K.^&^&@;B:!?WEWEOQ8TRQ'
MX:[E<X]FU:IZZ[E>&%-,?Z:IF*8F8^F_C!QAA7&>%!9&4)3O+G8L@^93,Y.$
MM<^+@!Z=)4NM]8Q"Q(1[WI,FT+>M=.QCV(P0A9M1X4\*="X6Z%&0R$1>UB]$
M3F<S,85W:X_%IZYHM4SCV*,>CX4XU3,M1_%[B]O!Q:U^=0U"9L:)8F8RN5BK
M&BS1/XU7DKO5QAWES#I^#3A3$0LUF4V)#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'&6)"5Z-4A4AV).M
M3'I#PA%L.Q$J"A$FAT+7TAWL`]_3_@P-2C7X>-O.M%575!/)J=T@KJ^M5/&6
M2M\8CM97%6%TT+"I"YE59('JM+EBDNB\8M,N*^;&&/*5,6L3JCU2<W2M,%+Y
M(.E,\(1C1SEPW&N2,[C]$OCU0;S(*;,K"FI%*EXN/5<5%7$42H.1$DB+G<T=
M+=4%*M"A88@7D'EG&*MI!IA']<(=NN\'ZH5RI^6BM6QBCY%64[KY>F+21GT0
M-VFW(9YO@-CC:O1OD3IQ'FZ0K8@C4B%L.HXH&6(.S=Z'H,LC_A241`G^#7/7
MRDYAY<P^T9?;S[RF]!,&[*M:1V)]\2[%8K$WYB-I61*:M\R,1')"DX0I"$2'
MR.NE&5K`M--..'YT1OBQJ[7Y%(YEQ\L&(W`_J4,?93XU/K&9Z?L&KGS:EH<F
MWS9N8W!392YQ(TF)(-(-()"#0`=8.!KNLKP/J-L9?77GEFR?[N5=J2P2&Q>4
M0"K;+0QKC8_RQ+.&OC]&E%AQF0G,K;7[Z8X)HX^ZT:ZM[$M`VF;4$)$NRPGB
MP/"[K:?5\IKDZS)PSLY\AY:OY1R%OC9AR;WM9,*2R%`66H0"3B30L8O(-N]A
MZQI7TG]?>\"/N5O@[T[RJG,FLM_L)]8YM);*D$T&N<8#6=D,C=&9E5--U3,(
M0ABMB1Q^8]#7(Z0:'!"[B+$O;E8SP!\HG,\E@9@C\-]-6,^CL^K6VK)>*JJ:
M92*\:^X<J&^K6ZNWJX'.AIE23JG-GJJ(%RQKC<P9I.8<%M,5;:&QT4'GEE:3
MF:3DA^^.OA]FQ/P\7KB?.W;[K3&W4<HD-BKME1*[$<6>I6XISX[!#B+.BKO#
MK,B]5P-G8X:#3@U:3N;4QAV`)`A@&6&21GPXV>(<$W_A.QW?/4WIN0&3%);!
MC!#SUL2E/YGM5KH@PBMSFX=>QB$,C^SE$H8Z0E]&IDFQ`T'>QBWL.B)\-11*
MWA/8%\\HK4NVZ@S.N'HVT%\-J>%@10BJFJTT42K.-0&,1`J$,K&)WM]W=G%2
M<D7*G-?LG2G8TQ):<(51,\`^H5-9HX>MNY\5RMILUWGT??ATG19-:QQLD4(:
M8%)(PP<=T\0*IUC.D#8Q(UBMT1-Z9:8Z)"3OH+!L@022Z>"G5:FZ:]LYGN^>
M,$7K!VJ5\AT$)KBC'5T9%51U*"EV9B9;+>:[72^-5PKB?E%0XHU[11X+P<-0
M)(83O2701P;X"-0J*U*B*N[WY5*VRS'&?1E\,I6BRZRC#>]PQ#!7^.,O'1-#
MR*;:U,@:VU.J6NJ-O2K3G-*G._5+*\@(-C]#<7"Z=MPZ0-B=$V5U67&JF>*M
M(M"<3<%Q,AD`4/4CDLC?$C*V-#*VG.;BYMK>F2)4Y))(&<PT!91:D!80P7FG
MPQE7**2P1]CTWC\4)B3&\M*E.\M;BO-6&N:]$L+.(&A/*"6`H*781:%T[WO>
MNC*W<<N!^K\6-4T_4--S^6R=&3R]RW5%VW77-4UUTU1,33,81'9PG%9[@'QZ
MT;@_I.HZ=JFGYK.W,[F;5RFJU<HHBF+=%5,Q,5Q,S,S5C&"EORC[+]<4%_#C
M_P#QF8-Y.-Z?76G_`#-[XS/O.UNGZBU'Y^S\4^4?9?KB@OX<?_XS')QO3ZZT
M_P"9O?&.=K=/U%J/S]GXI\H^R_7%!?PX_P#\9CDXWI]=:?\`,WOC'.UNGZBU
M'Y^S\4^4?9?KB@OX<?\`^,QR<;T^NM/^9O?&.=K=/U%J/S]GXI\H^R_7%!?P
MX_\`\9CDXWI]=:?\S>^,<[6Z?J+4?G[/Q3Y1]E^N*"_AQ_\`XS')QO3ZZT_Y
MF]\8YVMT_46H_/V?BGRC[+]<4%_#C_\`QF.3C>GUUI_S-[XQSM;I^HM1^?L_
M%>-^$?9G1OHN&"]/^#ICC_T=/_A_SS')QO3ZZT_YF]\8YVMTO+H6HX?\^S\5
MM&XP\8(3QGA861D"6[RUV+(.F4S/3A*7OBT&M["F3!V(P2!C0B%O2=,$6]:^
MD8]B,$(66PX5<*="X6Z%&0R&%[6+T1.9S,QA7=JCR1U]BU1U441/^U5C5,RI
M]Q=XO;P<6M?_`#AJ,S8T6Q,QE<K%6-%FB?QJNKMW:^NNY,?[-.%,1"S.938E
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@5$6>('P.;E:IO<.
M:O$U"O0J#D:U$LY$U$F5I%:8P1*A,I3G2\!Q"@@X&PC`+6A!%K>MZUO6!QOF
M'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO
M\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ
M>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^
M8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_
M`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^G
MNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F
M'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO
M\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ
M>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^
M8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_
M`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^G
MNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F
M'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO
M\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ
M>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^
M8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_
M`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^G
MNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F
M'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ>[8X#YA_`/OO
M\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^8?P#[[_$7XCZ
M>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_`!%^(^GNV.`^
M8?P#[[_$7XCZ>[8X#YA_`/OO\1?B/I[MC@/F'\`^^_Q%^(^GNV.`^8?P#[[_
M`!%^(^GNV.`^8?P#[[_$7XCZ>[8X'*!X@/`\Q$I<2^:G$XQO1JD2)6O!R(J,
M2-*L<BG`]N2*%09=L@E2O(:50R2Q"T(T"8W8=;T6/H"7SJ!HA0::H44I4AYY
MY@SCCCJXAQIIQI@MC,--,&S"&888/>]B%O>][WOIW@>OW>Z#]1]0>S2&?8N`
M]WN@_4?4'LTAGV+@/=[H/U'U![-(9]BX#W>Z#]1]0>S2&?8N`]WN@_4?4'LT
MAGV+@/=[H/U'U![-(9]BX#W>Z#]1]0>S2&?8N`]WN@_4?4'LTAGV+@/=[H/U
M'U![-(9]BX#W>Z#]1]0>S2&?8N`]WN@_4?4'LTAGV+@/=[H/U'U![-(9]BX#
MW>Z#]1]0>S2&?8N`]WN@_4?4'LTAGV+@/=[H/U'U![-(9]BX#W>Z#]1]0>S2
M&?8N`]WN@_4?4'LTAGV+@/=[H/U'U![-(9]BX#W>Z#]1]0>S2&?8N`]WN@_4
M?4'LTAGV+@/=[H/U'U![-(9]BX#W>Z#]1]0>S2&?8N`]WN@_4?4'LTAGV+@/
M=[H/U'U![-(9]BX#W>Z#]1]0>S2&?8N`]WN@_4?4'LTAGV+@/=[H/U'U![-(
M9]BX#W>Z#]1]0>S2&?8N`]WN@_4?4'LTAGV+@/=[H/U'U![-(9]BX#W>Z#]1
M]0>S2&?8N`]WN@_4?4'LTAGV+@/=[H/U'U![-(9]BX#W>Z#]1]0>S2&?8N`]
MWN@_4?4'LTAGV+@5CON3<2./3M'6B7<=84ZJ)*W+W)$9'JJK=0222WJ2$IP%
M.W`IN&$T8U&MAT$(M;UK?3O6!`GO5\&NZ^U^R.J/XS`>]7P:[K[7[(ZH_C,!
M[U?!KNOM?LCJC^,P'O5\&NZ^U^R.J/XS`>]7P:[K[7[(ZH_C,![U?!KNOM?L
MCJC^,P'O5\&NZ^U^R.J/XS`>]7P:[K[7[(ZH_C,![U?!KNOM?LCJC^,P'O5\
M&NZ^U^R.J/XS`LY697&:WZ\43^O^-=?OHTKJ8U'Q(,"J%+)R#2SBR]G*RE:@
MEK0EC('Y<`3E)9AA.ND(=[WK6PD-14E2DQE(^%\2H.I=U"GR)\0*@],A>T)7
ME5`/.U"P]:5'1D]0D(^J4M,,Z#0ZZO3H6@AX<JEJ5$Q-+JDXD0AW<G#J^>QM
M%!Z9)=&/I*&9OT@J<%J-E/ZHPZ!OS54H_6%K>OU>G>@/M2U*U(&96W<281(U
M+FFV<O;&N#TRF5L!OD$YOFCD:\K6Q"H.V8<(OI2&J2^L4+?6ZNP[$'ZD%1U(
MT'M939Q+@TG+7$!-6*6F#4VE*9S!&%@$F7`?%C2<<:`(]BWM,$\'0'?0+>^C
M6P]KS4%0MKX@:T'%&!O[>K\T\YD3=!*?3M;9YPI$0=YVF=E#<\F^8E!T<9Y!
M*;U@"UH'7'TAT'A74%0IY.G8R.*$$7-!PTP39@G@M/%LB4)Q>QFC.1*E*>1C
M"D'KJ#ZB(>][WT@T+7TX'D%05".4B81<48&6SA&,.IF*"T]MB&$*3S@)@40%
M(I)H(S_[#6MH=;\I].]:!^O@?A%4E.GR!P:E_%2`,S*ATN$"8N$'IT3$K*1B
MUY,XI,B4JGX@M87TC!LY&5U`AWY3J;^C`S$F@>/J@HH\BE*</(/+`<2<37$)
M,*.*,#H99I1@&80#"S`"UL(M;WK>M].L#V>[W0?J/J#V:0S[%P'N]T'ZCZ@]
MFD,^Q<![O=!^H^H/9I#/L7`>[W0?J/J#V:0S[%P'N]T'ZCZ@]FD,^Q<![O=!
M^H^H/9I#/L7`>[W0?J/J#V:0S[%P'N]T'ZCZ@]FD,^Q<![O=!^H^H/9I#/L7
M`>[W0?J/J#V:0S[%P'N]T'ZCZ@]FD,^Q<![O=!^H^H/9I#/L7`>[W0?J/J#V
M:0S[%P'N]T'ZCZ@]FD,^Q<![O=!^H^H/9I#/L7`>[W0?J/J#V:0S[%P'N]T'
MZCZ@]FD,^Q<![O=!^H^H/9I#/L7`>[W0?J/J#V:0S[%P/:&@:)"28G#2M2A3
MG&DG'$!KB':)-.3!4`3FF%:9NH,U.!6;H`MZWL&C!ZUT=;?2&M3QF&V12.J.
M(L)CD3=K$,GO/*F(FZUBUW)*:#*LMF6P"XUJF'/%HPXXM[CC.K4-Q*DS8`FA
M,,2@#L&][UO0:TZBY*6WPUK#GO8%<TS(*CD4+NKBWQ5BW`V4W=9'+M^JBZK'
MFVF`_D8Y.\ZD,:VJAESPNRF-?'&=BD"=KD`&4K1RM"O/5`3A8T7B(\Z$M;-]
M<2&OW^*<AY-R('6=:*W+BP0JNBVJS1TR"UI#)(YQ/;N4"V)Q*10IU$)&[.$D
ML=I8PL/DW%.6<I/+28&"P+Q$.;G,&@D$;B+A1-!V8T<.>6UYW1(YE#I#(44O
M<Z4Y"VSQ?9X?"FZ,VRF35PF6&5P>\R1\3/4F"QK5B-.ATJ)WY<P-CWAD\DV.
M;\7^'%1N+9>KI8R/A=QSE4DGTNI^YORZD"E93-?.2Y41R!D,3!6LSD:XYZ",
MT"=[5+3S]']8.S"CNJ&T#`8#`8#`8#`8#`8#`8#`8#`]03R!&C("<4(\L(1&
M$A,!LTL(O\D0R];ZX0B_P;WKZ<#]C&`L(AF""```[$,8Q:"$(=:Z=B$+>]:"
M'6OT[W@>=;UO6MZWK>MZZ=;U].MZW^C>M_X=;P`A!"'8A;T$(=;$(0MZT$(=
M:Z=[WO?T:UK6`UO0M:$'>A!%K6PBUO6];UO73K>MZ^C>MZP/.`P&`P/R$8!]
M;J#"/JB$`75%H75&'?0(`NC>^@0=_IU^G6!^L!@,!@,!@:;/$]_TXJ;_`&4D
MW][MF!K"P&`P&`P&`P&`P&!,%)W;,Z)F2>61)3Y0@WR::01]28/35(VL(^L-
M&M`'I\DH+Z=B3J`Z\H09].ND.Q!$'T.4]<,-NV&(IE#5GE"#.JG=6I0(`71@
M=0EA&H:W0@`M^3.+ZW2`>NDLXO>A@WO6\"5,!@,!@,!@?@THLXLPDXL!Q)P!
ME&E&@"86:68'8!EF`'K81@&'>];UO6];UO`B`P<;H:-)BR4DB,@HY$;YP<`P
M#FV5NUN8-B+WHD6P."*$(%X-!T$&E`6\*CIWU$P/[,)@`,!@`F%B",`PA&`8
M!:$`8!:T((@B#O>A!%K?3K>OHWK`_6`P($A7)^AY^RS^2,5D,":/UC8S]5,T
M>I.:=#6MKFD<*3*%Z(I=*RF9,Y-QZ566<D<$HCD"XG>QISC`A%O0>X_DC3HY
M<Y5_'IHQS6>L2NK0R.%Q%Z87*1QQEN%S2M\)ESL@4.R'JQ9:2J"K$I)$</:3
MH$46:,PH!@=V.[:ZV_-K.@D30\H%9$UVZRYHD$66Q&).$#4QE*\,,L=-/P#V
ME\-/E)`2B-$&]391FC]D[\EHT,@3VA6:LJ,GI+$@JHF:A7"AIR>7,!Q4M"UZ
M,$YBC)A;@(#\%N"4/9^TNS?(Z#OK]'1O`QB"\@Z+LR-0R80&WJZE49L16K;X
M([M,N9#DTO<4!OD5S9'@B6`.=7-&;O034Y(1'%[WKK!UTZZ0CRQ>8M'5;/7J
MMY<[25-)6!N9ECF8DA4G6QQ,OD[!+9-$XT;+BFW473R>6-4'<MMZ,U66(\XD
M!/2$TXD!@2!#>0--SFNHG:;/8L.3PV9%,(6ER=9/'D`2G>1-:)W015P&-T&F
M1RX"5>7HUMV9M269OJ]7>!ECC9U;,Y$F5.]A0=K2PM6A03%2XRQA0D1-<Z>2
M]&(Y,<I<"BV)6X^7!Y`M5LH9W7#U-;Z=8&&W/R`K:@HF1/+)5R%#">H)6[2U
MBA\IET?BS(4-&!3)Y:YQ=I=D\=C23T@4(Q8IV`O1>Q&:Z0%FB`&0/UKQ&*2=
M5'92L+C*%%$")DJF<@<H^S0LA&I>C6,IL-=7%Z3JRG?9Y7E>@28*;9(M=!VQ
M](-!B#QR7IF-2IDBLKFS#%-S%QA++7,@?WZ.(XU9[]/F.5R1C8X$XEO)Y[RX
M>A(<J/'UR2"3`C)T08<(SHT')3<BZD)A>YM+)>R5TF30-ZLUY89T_P`:;)1'
M8)'`KAOLG>6=O>W;9;,UE-QHSE))AY`-!Z-CZW2'0?ECY&5$^(G.0%S%@;8&
ME00=S9K,>9)%&^OIBBL!K4NS`;$Y"8_BTOZQ"40!Z/*3;$;^J5Y76A;"$DII
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MIV.\[:0`0G:&D`$G0>M_\,[@7)H)":Q=^+U9#@%<K9ZKA$30(7%E9XZFM)W.
M?['CR%.RN3?TPF;O1^U3FP&;&R*SPEC,2"V67U0MW`('$*M@L-K.OV%%%H)7
ML68(3"XRW>6]'QZ*Q=K2LD?9$/G!IY_F;6U(BB"^N,8^H#73O>_IP.W&_L13
MXFBYCTTER58U+'U''1N*,#XJ9&Y6B0.#PF:1':7GM2%<Y)R3E`2]DE&J"P"%
MH0PZV';8#`8#`8$0+.0E!-T\!5;A>%0(;/-7IFHNN%EEPM+/#'-:46>C;@1`
M]Z!(1KU9!P!E$Z3^4,`+6PZWK>L#PX\A:":)X55CM>%/M=G'KD3837+C9<+1
M3PYR<2BCV]O*B"EZ*D!BY>2<`9)6D^S#0C#L.MZWK`F#`8&)L$]@LK=Y1'XM
M-(G)'^$.!33-&1@D;.\.\0=3RA'$-DH;6Y8I6L#@<2'8P$JP%&"#K>]:Z,#O
M4#JUNFUVFQR0..VQ>>U.6D"Q.KVWNB4)0U+:NTG,,VD7IP'`V829U3`:&'>]
M:Z=8'/P&!Z%1X4J90I&$X8$Y!IXP)R1J%`@E%B,$$A.4$9IYPM!Z`@"'8A"Z
M-:UO>\#Y2N-D:K*HYQQ`Y"#;*@O:.7CRN3Q:O^?%!VY,JSYH3Z4VO))@D15Q
MS#HZQF1<ZV.Q-JAU&T3./D/X]QP#7M8!H;0M^RTP=8IYT<ME_#B+698G)2I.
M2A7*_AAXALEDU/#IBK"F"FW;CI6<PD4;DA*-G3'JY4PIG)I)B\T;Y.6L;E;J
MZI])BT(>LF."T+;REYH))_/K%;+^CB&F:9Y\\(.)R'CJ52]?E,4BJ_D!7W%P
MJ>J76P"489NVR9G>KM4KH^-O.2I4>DFB%9*TDT`4X4OM#Q$.6MB;DT>?YW]Z
M.-',3C%XI9$-+?F*A(6D61VC*$MR00R7TI!8*^R7D1&&5L4Q?36[+K"=CC7`
M\W9A2!O&,HL`;:+"LV](%P2\+]DH&QVVKIE=DRX/TD_3=WAS+8'HV"SFJC3Y
M<8WL$BT)O/?Q(F;0T)QF^J6K"#9FC"MF%C"GL=Y9<^XFT@F4FY/-5E(FKE-S
M\X7E1#\A*UCHI*1QPI+D?/ZQNMU<F-*)P*MPR44^A`Y(&\*>*K41XRBVHDW^
MVV'<SGQ$>4$@@%+MU*7=2([2L#PJ*$Y,/(I:Z5)%FE1<MHW?Q^@BYZ;9)+#$
M<%C4LF<=E\B;H>V.YQ,:524U(6>4,H&PX'<UIS1Y&W4\T3Q=;N34]HBRGJV^
M4T,O*U[QX_<?F>\H3)Z*K>J;'BW']`QQMXF_%^62Q[CENDOJF1M"<9"Z/,Z@
M)*!"J\L:2'`L/Q&KTKVEO$*>1\FJ4G4GH*E.#+S1MGP:-PM'`YM+KH*=8Y-9
MI"F9<XR8,D8K!F3282A2FKG5,C6`-3I3=Z!O6@KL@Y(\AZX5WY47&J?/L8G,
MKY[>+-<,I*8FZ@$BQ%`J?MN#M896_P!G<H7@=80BN(L]S4H+PB1,;Y(G`L\L
M23S$A.H.&%Z/#FY6<JN9UM5/+)Q<K5%ZW1^''P/Y,36HH57,(-:+`MKDRW\A
MT4T6F3=X;G.7L,/1J*\;UB)"WJ2A^7*#KR_FXCB3PWK8#`8#`8&FSQ/?].*F
M_P!E)-_>[9@:PL!@,!@,!@,!@,!@,"8*3NR943,DTMB2GRA!NRD\ACZ@PP+7
M)&H(^L-$M+#OH+4%Z$(2=1K6QIS-].ND.Q!$'T.4]<,-NV&HIE#5OE"3.JG=
MFI1L`71@=0EA&H:W0@.^DLXK>^D`]=)9Q?0,&]AW@2I@,!@,!@,#\B"$81`&
M$(P##L(@BUH01!%KH$$0=].A!%K?1O6_TX&!ZU,&:8.:Y:Z-"RMEK2):+S[9
M+6Y0IR;""`'`*4`*"F=8\ZIP#/&(\19R(X`OUAE#T$L,Z).)4DE*$YI1Z<\H
MLX@\DP)I)Q)H=#*-*-!L0#"C`"UL(M;WK>M].L#IY,WNSM&Y"U,#YN,OKFQN
MS>RR32`IUW'W9:@4)FU\TUG'IB7+;2L,`?YN,PL)WD^IL0=;Z=!K*AWA7P*"
M.T&,:K=L&2Q>+/?&:5O,7L\!-CADDNXR;FR>.2`EQ>UX-,"B1M4TV0M`4G-"
M`QO2G`WUR\#LX=X:S7#VYK84]LG*F-.T\5TKH;]PT:23*W+BK9;A-HRI:9`1
M)O),K4_L"\+28DVD4C0C2D*B#^@'FVPC&UO#.F#Q0T2KV-6#`I')JLJE^I:`
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M2I0B9;'CTM<YHW,-NQV62!WG;99)QBP3,]1EM`Y($Z_S`:DQ:)4$WW!Q#>YW
M5="TE!+"B,#J.H!14J65D\UB[S.%VRS5^U-:6!0Y]3)+2A[VV05@>6LIP4->
MURXIU$G3IE8C$H#RE(<N[>%\>O"ZH=<4AE82=11OJ!"=$5$2;7II>/RDNI-=
M*,T\YP7])&G5S2@2]7R1GFO5">#8QAT'`B"'>'`@@;O`I`PVJ4I=:]F%,R5E
M+?JX;W)I]'U/KD2V',/F":3MQR4EZBW(I:C1FDG@"TGM20\)2@'73X$;,GA.
MHVURKXAQOU[>H;`*\G<"21XZ$;1KSR)]2EI4N[>;JDTXU$B&@*>S3'GR:EA7
M.@G-&`OTD%%L"4D,N4^&PXC6MTJ3W+&1SM'"X3"#QO5'H'VM5:&-T=)Z+>7'
M=;*[`!O3H[,<CVM1"&ZFEMQX3B!A5)51Q6!(]->'K"*3GT(G<=FKFYK(19#K
M.25#Q'VLZ3/S4NXK0'B\DBTBEQ*@I>YE(4%?IGL2D1>M&JQ:)T0`!0#,#85@
M,!@5#YVUM6]B\3^0?YBP"#SPN,T;<K]'@S>*,$I*8'DBM9)HMX:`OR!>6UN1
M0-=&CR=`,UK_`)71@:<)!Q\ARJ*^`U"JA<O=D5V*8>^R>=T!&*_A\Y<U.O#S
MG1SLK1."J+.C07(7M&(2<QU.0JUA*8PSR6PC%H80B:N.2G-.:RHPM)R.MF<R
M+C/X?'.FXV.OX\VP-`7R<N[BESDO/CU3ZBV4+5#3'!R^]<8KE`D>V]B&TENJ
MY0(6ME[T$&PQ.7\V;7KFLY2\4?XALMY41ARXD<;^3=VV<O-JM]WQSGSIRXX_
MQ69Z1NT$AC.TUA"K(J.3S'SR'/1:A;'T,;/4!&3T'CV%D+.YP.5I<G+7KJ.\
MUS:IXB.O,6IZB?\`DE7$KK1.T5HVD\&D]N)*PAMHR=CD,-B^KDN,O11[V=YW
MO1Q!K<E-+.5@T$*:\='>X^6-PTA+U?-FY13*-\/O&#U'N2U=(:Q8YU:4#J/Q
M"*DB=3&*O/X&YQ8B'@;&1J5FEM[:0!R+1EE",T0:/0@^FWA19TKNOAYQ8M^>
M+4CG-[/X]T]/)@YH$9#>B<I1*H"PO+\XI6]+K25"G7NBPTT))6M%%:'U0:T'
M6L"SN`P&`P/B_P"6#/&G!S\;!2Y6/X<<6-0<F)`ZGQ^\8(W+>:CN6P\9>.#R
M<CH2Q16"C7Q*42$E)YE"E`8N[C0R4?EB]&C_`%0AQ>1Q$<ES?XPS\[3GP]*Z
M.<;":I*KA_*6`MSASF(*]QCBS(E+15-@'6*C7Q">FI][;HTHU&7LU!,0&J"@
MGF?V80NK++<Y1S!PYE36(<LK\J+44YJ>'CQAJ6O59%>N373D"ONON#,GL83R
MS/T.<'*26>J'9KP0,YT6J"$BE8?L)`NOT:#ELD_Y<U_+G-Q1<U+SLD%7^*VI
MX$P^#V`FJ0]@E]33NGV^7IRK-7,==L3W*K':9C-"1-CX6I0&HTC<G(V28$2@
M1P=5X>C70<CF?AOQOC0[Q-BN%SX$<AF?GX]4\K0-UK,<A=DM3MZUTN]R*(4O
M*&V$/)W;V>TG2,LQT+<"W,PD(BO..D-E7A+5_&JJJ_EA7$0&[FQZ&^(-RS94
M"F0R)YETC6[*ES8<K<9'*9$N<WZ0/SDM/,4*U:Q0:><>8(0M_3K6@VJX#`8%
M9Q<:N(-7SV5<GMT7Q[KZS$R%]D4QOO\`+FOHS,$:+:%0?)I$_6+MI1.J4`VX
M)HUZPY6'8R>OLX>P[%@0SQ+\/;BOQWHYO@;%6E0V(OF-8!K^S[;4U/!&^1WW
M"';:M8-'8BM"@6&2IB=D+CH!J96H5IU!>@['H7T=`6L#1U,@(=4H:HKH*9]F
MD5L=Z(##8_HEVL""DQQ/"INXEZ;^HME<23P]I`VN!FA*D0&Q+HD8-$%=4(++
MXV\"6.UG*,DT-Q::;JLUIGUDNS416-9(K#G#(\(#J[LV8KBBF0M]?&QW;I^:
MT/2H?E"U)3P,A1L6E(@C"QRFLZZ6M$)CZR"1!4Q5JY1YXKQF41UI.:X,[1)$
M8VQ9SB2$Q()-'E\<;CAD(34@2AI21;`7L(=[U@88Z0/CW`A1I4[PZJ8H8NMY
M?*HD<K8(RU&J[SM`E\9G61L.QI"1G65.4LB<B%2LCI<%Q*Q3HP8P&&](5#J5
MD\)&1V!9W'>D(]P*=[)<&>61RVZ>KB/T:ID;NP+WQ(\S>/S&'L"$2AY:=2-O
M(4.:,\DXHA80`1P`&`UT!F".L_#+EW$O9:*`\+Y#PCB*I\FP@DQFG7#CG&7*
M+K5Z:2RHSH1&0-F=F-P3J25RT7DU!!@32S1ZWU@X&1SZG_#VE;W12FS*KXE2
M"0SR-E5=QO.F4%JEP=I/$4$;4SQ-`:B$[M1BIPC[=%6<UU(;6KI3IT9`SBRP
M@UL6!F#QQRX9V<^.,:D%&\=9Y(ZZL57;3FR/5<5](G>'6E90`/[A8JI`O9U:
MIHET]TF"K4.>P@4.8B.N,PP172$)9@=,U%5IPU-:5A`*_/'%XW"1'0R(L,9,
MW#8<K?U\2B?69T*/>HY&%LJ<S6]%_P"C(S'!0(H`-G&=8)+P&`P&`P--GB>_
MZ<5-_LI)O[W;,#6%@,!@,!@,!@,!@,!@>=:V+>@A"(0A"T$(0!V(8Q"WH(0@
M"'6Q"$(6^C6M:WO>\#=IP3XSRNKD:NS9LN=65YEC4!(B@Q:@PA,E:#!EJ4Z^
M3I=;\F>]#V'I()WKI1EC%H6_*#$$`;&\!@,!@,!@,#!I!,$**1,4(*:%LA=Y
M(6<>N0IB2A(6>+E[&G<']^4J^JC*;M';TG+(Z1GJCC.H6`0=&"`'8PV(,T$C
MR.+Q\*LMG;S%HT)"Q8<M$D*6K5"[S),,X6_-V]&)1LM,0#02DY`0E@#H(=:P
M,HP&`P&`P&`P&`P&`P--<MY7\FJUEE[)X+51;M&H),;ZGB\J6M%SS9VG+5!+
M&X[P]HBD!<54FVW0W4JCMD/*U&%"F6-:8UJT)*W"*\[WH)?Y:W#)(_R;H2LJ
MCL.:,5JJ4:V=R",..SR:9?J\1M$Z9&>#K4RQF]$2>S+9L)4A1("$R[2YH1MA
MKB8-(4666XA15?R"O=%QFLB<$\A;Q8C&>`<-I(\21WAZ<R0E\J'EVEJKDM0+
M`D?JZ6K6R.$-36SGNS6V)]^A/*')DJA+HTX`0O?";.EX.=CI'&N>/EU0&SR7
M=[3LK2LGK&U<98LT5'7S@Q"D<>4,XJ]E$>L*3D*3D#IYTF=?/GX)10%!"=1L
M@-F&`P&!6SE'R:J/BY!(])[A039\:+%GK)3\8BE>5C,;@ELRF<P;'U:VQ=K@
M<%9)"_/'I!K8%HC-!3#*T65O0]]&]:V$#PGG]P\FIT-;-)IG")DT7+7-!1^N
M+4H"R*LLR`V#;\8D2FM2!0:=PMBD,2C$TBL;<BT3R626TFD)CD_E]"`86$+-
M3V<T+04'LZZI:J@\+BU,0:72VR90W-;=MQBD-;?2<]E.UI#(D.>M@7+2U+@)
M&66(U<N&(82S#Q].PABMN0_$"2V]-..=5-C$NE3G6+3>EL:B%6J2JX31BPDY
MGH53:4[;H^5!"I=,FGRJ@MN<E8G)4A`,T1?D_IV'GD)Q4K"XJWBT2AUEN?&I
M*UOC3(F%\IA#494=DJ-O9CHVCCDQKBQX+/:=M&%Z:W0O25`\,2\I"K*2*4>R
M#R2A8&;\>:$H_C/5<>K>'.*5^2PI!)-NL\G3LQ/LZ?%=K2]=.YN^RR1%I$!!
M0[&G#D<XJ$R<E&V#/V`M,F+)))*+"RC<W-[0@1-32A1MC6VI2$+>VMR4A$@0
M(DI824R-$C3`*3I4J<D&@%E@"$``ZUK6M:U@<S`8#`8$7K:0I=SEX;!<JAJ]
MPGH%B=P!-UL`BBN7@7HP%EI%P9*>TF/(5B4LH(2S='=<`0ZT'>M:U@'&D*7>
M)<"?N]0U>Z3PM4E7`FSC`(HNEP%J$!92)8"2*6DUY"J1EE`"49H[KEA#K0=Z
MUK6!EXXC%#1N!AD8CQACN\-\A=1C96T8W-_:`(2VI\<!"3;$M>&PMK3!3J3.
ML<2%,5H`@Z+!T`W$8IL8S-QB/;,,D!<M,'ME;>N9*B22DY4F&+S;K#D!2<D`
M`K=_YR$``AT/HUK6!^&:&P^..D@>X]%(VPO4M6E.4J=V9B:VMTDS@2`11*^0
M+T*4A6]+2BQ["$U2,P80[WK6^C>!VC>TM33I9IJ;&]LTXN"IV<--Z-,BTN=5
MPM#7.:S28LO2IP6##K9IP^L89O72+>\#L,!@<%S5#1-K@L+3JU9B1"K5%I$!
M8#ERD:=.8:!.B),WHLU6<('5+"+>@B'O6M_1@?#."U[TY"L-Q0A9=]HS^+<E
M/#8\0]_LJG`7?R;L>P(O<-?Q6%S6K89<_P!X6N#T]35ZLHU;FV+('6[(R)!-
MY*M(M(7(#"!FA=9B?9X"L^9UJTER+Y7O%84U$/#;@5:.\(N2WK';*UXV6C4U
M$JN6-M5U%5[G(BYQ937!5SZO"]K4CPZL:E$-2A"0K`=LP/1+KZCS=)FJ.Q[F
MGRH2^&R?SYI6&QKD0DNBWG=\=V!]X?WG*K]K!OY(.2I=:,CHEGL9EC9R]^&Z
MJ0QM>L7%)G-)I'K:,/=6-?2KDMR&J/[Q7=RMW7L7XJ^)F;QVNB/VE95:W'9%
M'1KDU423CY)IM9K;Z`L.4IDJ(L2II-<#BAR9`WH%KB!P)-'L\);A-U\K9@JX
M!4Z[63="UZ\4CCAP0NMXGB-\>V,RJ5W'6"L4WYV%QI8W"2!KTVWH5J*DB3)M
M)@G.CZX#T7UC![P-I7))P<E7B#<)8XZ(W-VB;71'-RS(E&D2HM"3++LC332<
M.CZ,I:J5)4">2-U9V'*@-NS1E[`6O5G:&$)(Q!#4'Q1L2$L%D<!:9J:81;DA
M&(M<YB!MXDW3QS50+G7X>/EH/8),JELPM*NC62/&)*J\^5L+XNDS"61+DRS0
MDSJY*%!)ZD*"5^PR9%X?+EP%3Q&4_EAR7X<R[Q%I`K3,;@%C1,=2539:2Y:[
M7&^0+TE<Y;R-KFN5^V_HZZM/)G`?5V+K[V%R[D8^8W)!@BD\XP<>(]:HO#_X
MP<662F)K+;C'6RN%\KXM&:CY-VXOAD%,K:4BLA2^5\WQ>#*@Z<VD.@KGAOV9
MK9I@RPVV5Q<T=N7G?P^NVGC%WW2Y0^'%9L_L%`<F.(5%Q>,V10[_`$>HE:,6
MB]M,@CCO;$N;20'`T:(:E<5K7]@/0`VV8#`8#`8#`TV>)[_IQ4W^RDF_O=LP
M-86`P&`P&`P&`P&`P/.M;%L(0A$(0A!````[$,8Q;T$(`!#K8AC&+>M:UK6]
M[WOHU@;CN&?#0,9"UVY;;7H4E%HI?#X@N*T($<`(.C$[V])S-;T)_%K>A$$"
MUT(M=`A?VW_-AM!P&`P&`P&`P,2DCHYG(GMFA2Z.&SE,A1GIT+RL&(AJ*<U`
MTR9W=D*'RC@)(`!!YA1?07I4,C9>A@Z=C"';L3>L:V=M;W%W5/[BD1DD+7M<
M0D3*W12$/2<K-3H22$B?RIN]["66'00!Z-?3T=.P[;`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`UF^)I3MIW6S<,(]4SG8T6>&#GA3DQD%D5<P1>12>J8BTP*WT;K
M8`D4XB\TAA+8VJW1,E..=&M:D!M8'0B]B$#>@KGR"X,S.OI'QRLF-2R^N6=R
MRCGYQ5FEPV78VH8:[L]74S$+I0QE+IFJB`UW`:\K>(N,V4&'GI&<K?GSP:I4
M&&F&!ZH:*F'@]R(G[79R0?$RY6Z1V]X=/B$5G=D1=^*335%=#Y,/L/A\SI2"
MN%E2"136UN6,K;;):%AL>LB6/3FB5KBDYS:J*5J%!)(6J)X.H4#I:MNPCP_Y
MLT4<[/OA>/5HU!%J(*K*S+;XZPNK9>GO^J4=;>8,#S-B8W::*+O$LA/6ZSX6
MRA3F$JA[*)-"9Z)X6N,_Y1\3GN2\/YM%.%K-R:YZV]2U,6Y!#4\?H6!O5(<;
MFFKCY-5SH)8AII#+;PBTKD$3BR\D@;28H`<6D1J-`)(#"*)\+:*FH^%2>R>'
M3@XER+@CS'#R>(FD0=EQ,EO%9,*M=J7:[J3+S1II',(\%U?Q0M.[!/,9"M&^
MC/-_(@V`/H,X),LYC?"CB3';.025JL5@XWTNR3AKF6ENI:VRIJKR/H'Q!)O2
M0S''TZC<4YA:KRXA'>6"+K[V+IW@6MP&`P&`P&`P&`P&`P&`P/SH`-?3H(=;
MZVQ_0'6OU]ZZ-B_1_E;U]'3^G`!``&N@`0@U_B"'0=?1^CZ-:U^C`BFPJ7A%
MFR:G99)R7,3M1D_663`_1SB8@2%25?!I?7:G;NE*`(#HW"C<X7A\@/H#HX0#
M/T@UK82OT:Z>GHUT]'1T]&NGH_Q=/^+`@,CCC`0\BU'*!Q<)J_V,37:BL(FW
M/\L<7*!UO&'9>RN4O%74*'U&B,/4^61AJ$]KP!&J6@;$Y?7`6$0!AF4_J6'6
M2\5G(I"F6E2*HIT184#?6E8)N=6A[]"/,8=4FU98!"4,,FB\A6MSFB'TDJTJ
MC?3K1@"C`!).@!T(0]!#H8M:T(6M:T(6@]/5T(71T[T'I^C_`!8#JAZ.CJAZ
M.C8>CHUT=&_TZZ/T=&\#SH.@ZZ`ZT'7T[Z-:UK7T_3OZ-?X]X$8LM0PEBM:;
M72F1*E-A3R+P^#N;PO6#5@;8;!E#\XL<8CJ40=$LK0)[E#@X*@%:ZRM:JV8:
M(6BR0EA)^`P&`P&`P-5'B'5;9-@3"M%<%@DIER5MC4@3."B/M"ER)1*%#HWF
MD$J1D!%HHPTLL0@ZW^G6MX&O'W;>0?J5LG\+N'U>`]VWD'ZE;)_"[A]7@/=M
MY!^I6R?PNX?5X#W;>0?J5LG\+N'U>`]VWD'ZE;)_"[A]7@/=MY!^I6R?PNX?
M5X#W;>0?J5LG\+N'U>`]VWD'ZE;)_"[A]7@/=MY!^I6R?PNX?5X#W;>0?J5L
MG\+.'U>!L`X7<4U,<>5U@7#`).FDC&26X0YE>D#5Z%(%U>N!PT#TH<I52<(]
M=!)*@D@M)_E;WLW>MEALG89PN>VY[7GU[/H^8SI_+DMK\ACQ#B^"\B>;YNR%
MM\E<DQRCI)T#H/-3AZXP_K='3O0?ELG2YQC[N^F5Y8#6>U;Z"HZYH8\7('G]
M0L?6:"$LE5MQNND?5_ME)'ZP=_X.C>P\D3E<=%E4EW7L_(4IE?FH8H>ACP92
MK#Y4@OSM*F+DIC4))T';%TC6`'U2Q?J].M:V`V<KBHJGDVJ]GYJD]7YJ*)E(
M8]N5)P^5-+\\4)AR4#2%)T%:'TA6"'U1A_5Z>G6@.,Y7((ZTOY=>S]R/=!]0
MV-MR&/&2)HUU31==V(4R5*VE`_LM:_L51V^D8?H_3T!Y?9PM96ME<B:^GS\8
M\$>6.:F)#'SW1CWY$H[R#T6ODC<E)/Z3=@Z"#E`>N`7T]'1O8>9%-UK`)H"1
M7\]DFG5.%0:*.H8^H"SB%LK7FSOZ2DC7LI0'RG3O1.CP]`!?K?HZ0][U*GEO
MD#*P-<%DCX!T&E,62(DUF11IC1C.-"M,<5BISTY#7)$Y.Q@3DHS?+"&`.AAZ
M=["'.C<-8(H8]J&A(,*^2.ZE[?718H/7NCHO4#WY/SI>J&:H&E0)^J0E(T+1
M*9.`("PAUKZ0RC`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%75?.'A6@5*4*[E_Q
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MW%T:%(H1I%2P%_U.)(F5N):XYO2J%`9;LDE0N);%(R0"WH1H4YNPZWHL?0&5
MJ.+/&-6><J5<<Z(4J5)IAZA2HJ&OCCU!YP]F&G''&1X1AIII@MB$(6][%O?3
MOZ<#T^ZEQ<[ME!>QVN^SN`]U+BYW;*"]CM=]G<![J7%SNV4%[':[[.X#W4N+
MG=LH+V.UWV=P'NI<7.[907L=KOL[@/=2XN=VR@O8[7?9W`>ZEQ<[ME!>QVN^
MSN`]U+BYW;*"]CM=]G<![J7%SNV4%[':[[.X#W4N+G=LH+V.UWV=P'NI<7.[
M907L=KOL[@/=2XN=VR@O8[7?9W`>ZEQ<[ME!>QVN^SN`]U+BYW;*"]CM=]G<
M![J7%SNV4%[':[[.X#W4N+G=LH+V.UWV=P'NI<7.[907L=KOL[@/=2XN=VR@
MO8[7?9W`>ZEQ<[ME!>QVN^SN`]U+BYW;*"]CM=]G<![J7%SNV4%[':[[.X#W
M4N+G=LH+V.UWV=P'NI<7.[907L=KOL[@/=2XN=VR@O8[7?9W`>ZEQ<[ME!>Q
MVN^SN`]U+BYW;*"]CM=]G<![J7%SNV4%[':[[.X#W4N+G=LH+V.UWV=P'NI<
M7.[907L=KOL[@/=2XN=VR@O8[7?9W`>ZEQ<[ME!>QVN^SN`]U+BYW;*"]CM=
M]G<![J7%SNV4%[':[[.X#W4N+G=LH+V.UWV=P'NI<7.[907L=KOL[@0M:<(X
M4U"N:&^4<8J@4'O212L2;9Z/K%66$I*<629H\2AL1[`/8S==&M:%K>O\.58\
M0GB]X7>&G5=-TCB#8UB]FM4R]R]9G)6+-VF*+5=-%45S=S-B8JF:HPB(JC#K
MF&2]Q.%6\G$/*YC-Z%7E*+66N4T5]]751.-435'9[-NO&,(Z<<$5_>C@!W6Z
MY]@E4_4Y7C_-6\-?U+>O8LI_:#WSEGXA?+:7\]<\P?>C@!W6ZY]@E4_4X_S5
MO#7]2WKV+*?V@<L_$+Y;2_GKGF#[T<`.ZW7/L$JGZG'^:MX:_J6]>Q93^T#E
MGXA?+:7\]<\P?>C@!W6ZY]@E4_4X_P`U;PU_4MZ]BRG]H'+/Q"^6TOYZYY@^
M]'`#NMUS[!*I^IQ_FK>&OZEO7L64_M`Y9^(7RVE_/7/,'WHX`=UNN?8)5/U.
M/\U;PU_4MZ]BRG]H'+/Q"^6TOYZYY@^]'`#NMUS[!*I^IQ_FK>&OZEO7L64_
MM`Y9^(7RVE_/7/,'WHX`=UNN?8)5/U./\U;PU_4MZ]BRG]H'+/Q"^6TOYZYY
MAY^]'A_]UNN=?^'\@ZI^C_P_01TY,?XJOAKF</R+>N(^Q93^T$<L_$+Y;3/G
MKGF%GHSQXX@3%C;Y''./G'QR:'(G1R9233U=_P#[#"3B]QS0R%)`^D)A8M:$
M`6MZWK+_`&X6_NZ?$W=/)[[;DYRUG]V\]:BNU=HG_P`5%=,^^MW;=6-%RW7$
M5T5Q--41,,':WHFJ;N:I>T;6;-5C4+%6%5,_ZIB>JJFJ.FFJ,8F)QAWWNI<7
M.[907L=KOL[GM[Q1[J7%SNV4%[':[[.X#W4N+G=LH+V.UWV=P'NI<7.[907L
M=KOL[@/=2XN=VR@O8[7?9W`>ZEQ<[ME!>QVN^SN`]U+BYW;*"]CM=]G<![J7
M%SNV4%[':[[.X#W4N+G=LH+V.UWV=P'NI<7.[907L=KOL[@/=2XN=VR@O8[7
M?9W`>ZEQ<[ME!>QVN^SN`]U+BYW;*"]CM=]G<![J7%SNV4%[':[[.X#W4N+G
M=LH+V.UWV=P'NI<7.[907L=KOL[@/=2XN=VR@O8[7?9W`>ZEQ<[ME!>QVN^S
MN`]U+BYW;*"]CM=]G<![J7%SNV4%[':[[.X#W4N+G=LH+V.UWV=P'NI<7.[9
M07L=KOL[@/=2XN=VR@O8[7?9W`>ZEQ<[ME!>QVN^SN`]U+BYW;*"]CM=]G<!
M[J7%SNV4%[':[[.X#W4N+G=LH+V.UWV=P'NI<7.[907L=KOL[@/=2XN=VR@O
M8[7?9W`]P>+7&0"<Y(#CG1`4J@Y,H4)@U%7X4YZA&!44C/.)U'M%FG)2UQX2
MQ"UL0`G#T'>M#%TA.^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P-;7.C_2:O_P#J)Z_O!'FBG_%V^_.YO]$YS^46UT?"S_,FK_:K
M/T=:BF:@%J#`8#`8#`8#`8$Z4?>#Y3[Y_P#UG*(N1X-OS%U]?XM%[<VSK[T`
MAR(+UK_#H)X==0?_`"1!N!X2/%OO9X9MZXHJ[W/<-<]>I_+\AVOP4_E65[7O
M;>9MTQ'EBB_13%JY,847+>+.*'"_2^(FF?BV=X;-,]Q?P_;[JYATU6ZI_#-$
MSVJ?+%6WZ,R9DF#&WR..KR7)H<R-'I5)6_\`^4PDX&^@9*@@S6P&%BUH0!ZW
MK>L^F;</?S=3B9NGDM]]R<Y:SV[>?M17:NT3^U5173/OJ+ENJ)HN6ZHBJBN)
MIJB)AKNUO1-3W=U2]HVL6JK.H6*NS53/^J8GJJIJCIIJCHF)B8=]GM[Q1@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@5Q>N8
MG$>-V6*EY%REXZ,%P@=D#".J7J[*U:[("^.A*=0V,HH.NDQ$F"[.)"LH9";:
M7RQP30;`'>A!Z0\R'F)Q'B5E;IF5\I..L9M_3FVLNZJD%V5JS6/IX>2$REH:
M10AQDJ:2Z<W5.L)&F(VF\J>`T&P!%H0>D):L*QZ\J2(.]@6K/(96<#CX$HWZ
M;6!)V2&Q)E`M6)VY$-VD<B7-S.W!6."LH@K9QP/*'&@`'I$+6MA@%3\G>-E\
MIY,KHWD)2%RI842B43%355K02PD\33N0%YK>?)3HD_.Y;$2O*:U0B1*ME!-"
MG-V'>]%BZ`E.+2N+SF.,DQA,D8)C$9*VI7B.2F+/#=(8X_M"XO1R)U9'QI4J
MVQU;5A(M#*/(-,*,#OI"+>L#O\!@,!@5@B/-SAC8$Z0U?`^7'&2:V6Z.2UG;
M*\B5\U;(YPXN[:6I.<&M#$V>5+'Y6XH"D1PCB2TXC"@E#V+6M!%T!/XI9%02
MHB"CDK`";*H^JEB:'B>&X,I415"XHV=;)2(_M1IV-8$;LXITIJP).TY:@\LL
M0]#&$.PR#`Z"/RR+2P#L;%9*P24M@?W:*/ID?>&YY`RRAA/TE?8V[#;E"D+<
M_LJK?DU:,[J*$YGZI@`[^C`_$LET4@4<=YC.9/'H9$8^C$X/TIE;RW1Z.LB`
M`@@&M=WMW4I&UM2`&,.MF'&@!K>]:Z?IP.T<W-M96UP>7EP1-+0TH5;FZNKF
MJ(0MS8VH"#%2YP<%RHPI,C1(TI0C#33!!+++#L0MZUK>\#'5=AP!!#D-B+IQ
M$$5?NB2/KVR<JY*S)X>XH)8H;DD66H9*:M`RJTDE5NZ0IO,+/$!88J*"3L>S
M`:V&88#`Z=HD+`_B=@L+XSO8F%X51Y\"TN2)R$S/Z`M.<N8W72,X[;<\(RE9
M0C4QW4.+"8#8@ZT+72'<8&/1^7126[?-1631^2[C$A<8C)-,#RW/&X]*V?2<
M3O&7OT<I4>BI`UA5%;4(S_)J2-&!ZX`];72&0X#`8#`UM<Z/])J__P"HGK^\
M$>:*?\7;[\[F_P!$YS^46UT?"S_,FK_:K/T=:BF:@%J#`8#`8#`8#`8#`G>C
M;R>Z?>MAWY9SB#F<#;XQ]?Z0"_5!Z4:^OO0"'(D&OIU]`#P:ZHOIT$0;B>$;
MQ<[U^&;>KNKG>Y_AGG[M/Y=D.UTTST4_E65[4]FWF:*8C&.BB_1$6[F$Q;N6
M\5<4>%NF<1-,QCLV-XK%,]Q?PZ_+W5W#IJMS/5/71/OJ>CM4U;?8W)&27,C?
M(8ZX$.;0YD!/2JB!=.MZW]`RC0;Z!D*"1](3"QZT,`M;UO6MZSZ9-QM^=U>)
M.ZN3WUW*SEK/[MY^U%RU=MST3'XU%=,^^HN458TW+=<1717$TU1$PUWZUHNI
M[O:G>T?6+-5C4+%79JIJ_P!4Q/553,=--48Q5$Q,3@[S/;7BS`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`K?R:Y7TOQ#B\"FEYOKG'(Q8MMPJE6-W
M;V!T?TZ29SW3H)B-?@M*=2<S1LHMG/&M<C@Z2H2@;,.$`O0AA#'+6YJT53]Y
M1OC9(W.1NEVRZF+-ON/P.+QEP>5J^O*I2&J']6)RZ$S&B=70].:F:D9ZHHY>
MH*,T#6@%C&$,FKGEA15HR.X8E&YRUIY%0.X:7<+:^*D+..!JIO"FF?-:1\/4
MK/-"3$3"]D:6F!,$G2J_*)Q&>6*-``)C73J$-<?12QSF,5;HLY[0Z;9*ND+0
MDC[AMSWK3;I$\J%A;<KVX;WKR'DS!>5Z?U>G`B^(<EJBFEMVW2#;(P(+$IF4
MQ2'2EF?M$,NW1]F-=,-I-*>'"6J0&RH!40D:8Y2)*`7FYFQ`%K]7>\"6@RV*
MB>G*-!DT?%(F9M+>'A@"\MVWIJ:#NKLIU<FK2GSY"VF];75/-+"4+IUT"P/2
MRS6&R03H".RV,OPF,*43T%E?FIT$SA6I=K40G32%6?MO"K1Z\L5LWJ>4*_7#
MTA^G`A6*\M*%F-AVS6[//6;3E3#-6+],9"M<&U'!S$%MM\V<XCZ`F!J[T,^'
M^9UZZ"6`),Z4GD/U_P!.^@,S8;OK]VCSY*W5T+@T=99V_5^%YGRUEC#8]NC&
MX&-Y3G'W%2[&(7-BD/DMG-A^C`C5I]Z'HL/Z,#TQN]H!*[LLF@&=2Z'6#5,(
MK6P9868V&E,@(Y;"J9HX@<V/.Q;3.2H\Z!N'ER@:Z2`Z+WO>_*:P)CP/BZY7
MR"*F2/QIH.]\O.$E;J'7DH^N`.+UJU%$I=RNN<)'&?CLK`STQ-5-IHYI'7NP
MQMOH:,*V^$2`]F>];6)M&'`ZI8<3D=+XZ[:\7N,RGE5PQH9PF%@,STLXE7]4
MT3G7+R?C<^#G%Y8KB5:3E?:R&:L\MD)J<4<9%K?"I(J:Y*F-7)0GJ=>2`&T#
MQ,)UR-L;A%)(0^\;4U(P$RR_#Q,JZU[`L>/V^J<92\<ON+X6]EL"E2D,?DFM
M1M<XFZ="%SH#TAZ/,*$87M1H8`E#E4P<EZ,XF2FAMO=/WKR1YH60P<?:H::!
MIMMXAC.AC\S.+U<6W1Q=;&N-,G6QFF8_*ER9_/,+3MZPU*7L@0AAV8&4>$I*
MIQ62CD7P2MBG$O'=^H";%6U1-0)IXS6.@9.*/(5Q?I)"VR/2]B;6EM>6:O[2
M:99'RBRB0^C4"5`F%^@(AAN8P&`P/P9_S8__`*@O_-W@?-EX9-2W_$/#P8;T
M.M.AA5PVT7R8D,)B$;XN_=:[XN])G>T]QMU-Y#AMYS$Y.;,XD;.,/+BZ4Q2$
M6@:V7O6QB"K<GN3EM0M%5M+ZMOR\+4M&P?!SBW)"82ZVY@Z3EQ9)A8W(CB,P
MVU:;7Y&)2L<1;*XK*4R!P0DMS*O3LI(3504*L8!@-#):]Y'VKJNCX[8'/!K;
M^%KQR_IR"V)R3HGEK8G(]YI"%R2D+)E3Y"GGGE/*1J8IKC-AW`T1)*J<T"E:
MKA(7@YO/<6\*M,40&'\'W><3&XXQ#:5Y+WW.JW#;'C`W\P*(U.U444<I9G3U
M]\?2Z6<+9=&9M8SIFR.Q<B/)5:+`C(?TRL0SNNG4#"8$!Q[E]R_?N)O):?N/
M+N*R29.W`>?6A>,`CG(^R[LM2I[_`$4VJU&V.RJK'KC56<-X.N43<WA_854%
M$]FA<2_)B2)5HFTYQ&&Q6Q+FCTGFG--/</.6X(CR@:;)Y?5)$.#"9W&H@DDX
M[,U-S<59DF\?$K`O4?<N3P4I+,#[6WHCR3B(24;J41UF_89WX=-9.+2_<6..
M4[M:V;SHZ\/"9H#D7)ZUNF4_>^-1VU:WE]'H(TMKE&4B;`P&*E('T!1K`AV!
MK.]'IC#"AF^7,.#B\.>3$S*\3B9T]-;\E?(E?8D\Y3M:,%?<C7)QC=2,E?25
MQ>(Y#^07`RP:Q893QC40%B;B8ZR2]A=!M$R5B*5F&+-.10@!6_Q;^9MUU5R5
MO8^K.2+O4,DXSH>,+M!JXDU\/,('/031Y8GN:.-7\5H57J])R6@*UD=5".3R
M>:O8FB.*$:A.00ETE$H,"''&?$4)(.2=)1ODW.JL=;6\6/E\MLYVLCF1(>/T
M`AS&UUZP3JO$TXN5JC$ZM&NW.S4DAVXQECCI34KGQC7LD:[9"(10PRBM.:/(
MZ9<=^#\I>.4=O*BI=7<M8?$=FT:3NNC*(XOUORVE];0'DXWK5H6-\K&VYD8P
MF19V<A(37E9%!.T@4HRU,<"<$,IO#E#98I%855.')5]J)AE'B#\^D;5/9/R6
M>>+5:$Q:I8W1`8+`OS>KZ`3.V9/+4Q\Y4+HQ!H\<WCE`"U@U)YX4I1`PWN>%
MG;U@7UX>7$BVK5DQTRLB84^Q*)M*52+3:N?9$V'K6-R<'1!YLB,1NYQ[7OSP
MLTDD\*K1FC2P&=8.@OW@,!@:VN='^DU?_P#43U_>"/-%/^+M]^=S?Z)SG\HM
MKH^%G^9-7^U6?HZU%,U`+4&`P&`P&`P&`P&![4Z<]6>0E2DFJ52DXM.F3D%C
M-///.'HLHDDHO0AF&F#%K00ZUO>][S]61R.=U/.VM.TZU<OZA?N4V[=NW3-=
MRY<KF*:****8FJJJJJ8IIIB)F9F(B,77=NVLO:JOWZJ:+%%,U5553$4TTQ&,
MS,ST1$1TS,]$-N'&.H9!5T55GR5S6:<Y().M.C(3]#;&'J`WU.D&MB`-X/`+
M6E`P;T#6@A!^MU>MOZ5/`-X:=\O#[P\S&:WZU#-?G_7)MWZ]+BYVLKI^$3A[
MWIB<[<IF(S-=$Q1$4T6H[<V^W.OGC?Q#TC?K7K=K1;%O\AR4541F>SA=OXST
M]/1,6:9Q[NF8QZ9JZ.UA%F\ONP@8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8&M[Q*>.CSRBAO&^K$L8=9'%'#DVCW9ZIJ`0(41KU[H#D%"'*9J]G*
M$XBDS(]RYOT`9?6-`I-*V'7_`"@AI/<^)O.^W(H&Z[LHZ9*[]G?%#Q$:!EC*
M2:TN:AI0PGB-'..U#I=G[<O)@WR/LMHDTP;20B$`(I0$!H@]3K;#+5O#.<Q"
M<V$[R'@K*+.@QEY>'OR$N2'QB"5]L/(*GX#PY*J.=U\$"MY;4EHR^HN329%-
MG:'.X@%.^FKRY6E1ZG03`[:,<5)+$)'#K:N+P\;$M7A.YV#S97U5P4;XE7$]
ME''$R[EM*#J^:NM"N4N+@3*GEJ>$SC9:-O6*/N)]\@%]5*$Y6).'<A\/Z0.S
M;RYM(?"11!+8!:OA<O?&=(Y.3+9-EUE$*.B?&LJ81RN[@->'!T.!60FI^;W=
M:D7%Z<0IE!)ABPC1?6#A,W$:X"K$CL72<-9NR<GH'RMYG73>'.H::$D1F]:!
MM1CY#AAT2:K%22<^;V&=8['8$.CY,*7(0)XV8Q;-,+3%(DQIH1^E\,^UH/QY
MX]Q.C>+@H%)W_P`'TNM.4,7BVF.O5UP6O$KEX93=THVRI0E=D);A9T_@;;9#
M.A='%0:$H+BN),6%)S=X'&2\(%=P<H7>41'PX972/%.<<Z/#?L9PJ>PZUKB+
M1EWAE/<?.7T:M&<R"HH[('R+1V.L,SDT?1+FX9?^>&G$JS$Y@59@MAZ+>X67
MRX."B%.W%>PEU2.?*_Q.)+'EM9TMQ]MV7(#K9MB$:HUI;8GR"6.M.U-5%EUZ
MF<E&IUMA7NK()O3)2C6U.I/\N&PCPC*%Y!5"\H'"\JZFT-7$>'-X>%/N3C,C
MDBQ6HLVFTM\M%BQ<YQ3KUHG%SBNW=O\`+':_L3259(RA""+H"&\K`QXR)10U
MV"_&QF/&/H30'A>C&5M&[!/*#H!9P7$2;:S1I80ZT$77Z=:U]&`-B44/=@/Q
M\9CQSX6:4>!Y-96TQV`>2'023@.(TVU@32@AUH(M#Z0ZU]&!W*E(E6E>06)D
MZLCRA)WD5))9Y7EDYP%"<WR9H1@\H0>4$8!='2$8=;UT;UK>!Y,2ICCDZ@U.
M0:H2;-$D/,)+&<E$<7LDX2<T0=C)V:5O81;#O76#OHW]&!X\T2>=[7^:I_/M
MI])-K?(E^=[2!,$<%+M1U?+;3A.%L>@=/5T+>]]'3@<C`8#`8'%)0HDZ32!.
MC2D(=`,*TB)3E%)-%F[%LTO2<``DZ`9L>^MKHZ-].^G].!^"FUO(&282@1$C
M3H_1R<924@L9#?K98M("1`!K92/K%!WY(/0#I#KZ/HU@<4J/L!#48Q$,C02Q
MF@.+-9BFU$6U&@4#$8H`8W`)TD&`\P>Q#UL&]"WO>]].]X'O3M#4D-`>E;&]
M,<7I1HLY.B3$F@TK$4-5H!A901ATI$0#9G1O]?8`]/3T:P/3I@8M>D]:96G7
MIL837GH;4?\`TN8`/4"8Y_V/^?C"'Z-;-Z^]:P/88S-!RX;F<U-IKD:A&UF.
M!B%*8N,;3![,&W#5B*V>-",S>Q;)V+R>]_3T=.![R6]`G&2:0B2$&)D@6].8
M2F)+&G0!V`041(P`"(I($10=Z+#T`UL.OH^C6!ZR6IK3N"MV3MK>0Z+RR25S
MD2C3E."TI,'JIRE:P!85"DL@.N@`1B%H.OT=&!ZU3*S+E.UBUI;%BO:(YMVJ
M5($JA3MN4BT-0@V><4,WS(\>M;&5T]06]=.];P/4HCS`K&H-5L;.J,5*4*Q4
M8H;$1XU*QL#H+:J4#,($(Y2WAUT$#%TB*U_D[U@>T+*S`"O`!I;``=2QE.80
MH$H0N11@E(S"UX=%:TL+,&M.V+1G6UO9H][_`,H72'X&P,1@"BC&5I&60XE.
MY!8VY&(!+L1K6B7,H&R=A+<2=:UH)VN@P.M?0+`YZ9*F1DA3I$Y"4@(C!A(3
M%%D$A$<8,XT02R@A!H1IQ@ABWT=(A"WO?T[P/?@,!@:VN='^DU?_`/43U_>"
M/-%/^+M]^=S?Z)SG\HMKH^%G^9-7^U6?HZU%,U`+4&`P&`P&`P&`P/:G3J%9
MY"5(0<I5*3BTZ9,G+&<>H/.'HLHDDHO0AF&F#%K00ZUO>][S]>1R.=U3.V=-
MTVU<OZAF+E-NU;MTS7<N7*YBFBBBBF)JJJJJF(IIB)F9F(B,77>O6LO:JOWZ
MJ:+%%,U5553$4TTQ&,S,ST1$1TS,]3:7QPXXD5^G3S.:)B5,V5%:&@0#T`XF
M+)S0_2$.^D19KR:#?08;KIT3K]0&^GK"%]"_@:\#>3X+Y*QQ0XHV+=_BOF+?
M:L6*L*Z-*MUQU1TS37G:Z9PNW8QBS$S:M3CWE==$^,W&6[O;>KW;W:KJHW8H
MJPKKC&*LU5$]<^6+,3\&F?AS[ZK\6(N!FS-78P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&!3SF;R@E?%^)5(N@--CO2P+KO>&T)"()NP&JL$(Y#,
M8_,9&2[.TP>&21)&YL0(H8?H>M)#!C&8'6NCZ<"#(OXF,#A7YJL7.&)-G"J=
MU&\5.W/+;([*8K5A$E3WFWS5=5HH3.X>U(%#R^R$^N'Q(-H4-*-P+5(@A*`>
M`\@PP)R)\0+ABHLHVGB.1%>FV<2Q&OYD+`M7;>M$D0\%@GLVB?,/)BFI$',"
M[#CVA;?@-^_+;1Z!].!`-,^+[PBM#C?2W)266RPTQ&[RW*_NI&[#4*TLC2EP
MQ^-8I(X.R5,W"VBCD?&-,-R>AA"QM^U98#EFNG6Q!,\QY^<<*H?;-273:M7U
MM'(/8T`JY@?E$["_+Y=,+"ILN[&*.&1ML8]+&>4.\1)5*6EM)-<3WA"0!0GW
MUC@$8%E*CMZL;YKN,6U3DWC]BUO,DARV-2^,K0KFAT)2K5+:N+`9T`-3K&US
M1')528X!:A*J),).``P`@Z"1\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@:_N9D-ETGD4'.C<8?W\E(RNY2HUF:5SD6G,,7)!EEGC2$&A*&,(
M=[UH71O>M9IC_P`4?A?Q(X@;Y[IYG<70-9UC+9?3,W3=KR63S&9IMU57[<TT
MUS9MUQ15,1,Q%6$S'3"W'ANWCW>T/1]4MZUGLIE+ES,VIIB]=HMS5$45Q,TQ
M75&,1/7,*8_E+:7JXG'X7>?X/-6'+=X@_8?>S^J<]YA9+]8&XGKG2]JL_'/R
MEM+U<3C\+O/\'CEN\0?L/O9_5.>\P?K`W$]<Z7M5GXY^4MI>KB<?A=Y_@\<M
MWB#]A][/ZISWF#]8&XGKG2]JL_'/REM+U<3C\+O/\'CEN\0?L/O9_5.>\P?K
M`W$]<Z7M5GXY^4MI>KB<?A=Y_@\<MWB#]A][/ZISWF#]8&XGKG2]JL_'/REM
M+U<3C\+O/\'CEN\0?L/O9_5.>\P?K`W$]<Z7M5GXY^4MI>KB<?A=Y_@\<MWB
M#]A][/ZISWF#]8&XGKG2]JL_'/REM+U<3C\+O/\`!XY;O$'[#[V?U3GO,'ZP
M-Q/7.E[59^.?E+:?JXG'^+_1=Y_@\F/#;XA)F(C<?>S&?_\`*SWF#]8&XGKG
M2]JL_';#^.''$BOTZ:9S-,2IFZDKKH4(]!.(BQ!P.C8`[_6`8\F@%T&FZ^@K
M6^H#_E"%NX\#?@;R7!?)6.*'%"Q:S'%>_;[5BQ5A7;TJW73AA'735G:Z9F+M
MV,8LQ,VK4X]NNNGO&;C+=WMNU[M[MUU4;L4585UQC%6:JB>N?+%F)^#3/PY]
M]5Y(BX&;,E=S`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`U]^(7
MQ%5\RXSQG@"AL0/$&@G+FL;<MEM4S"309P55K%(C9+4\`CS_``]4VR,M_P!.
MTE0[)+2K$0QEZ,Z3M:UL(PBBSO#8KB(-?&5CXH5C#H6A@?.^B^3=QN$@DDC>
MY3*X[63#-&=0YN,SF2J83"9R-D+>4934F7K]@3$A$$@9(0]&PAE-PCY4;LIM
MJ!3%*.+X\,WB3*_$0)Y%ES%V-M1S0&V(OM\BJ%=3;AA8-60*6N(H^HE&Y$)`
M.(@UT)]J!>;:"CC9X3?,*,PZDRU4+;9LZP#C'8/"]_B$$YWWMQ>;G".`NV:V
M+!+<?933L92*[`KF=1^;&II1"G!,!:B,1)MI#U&]F=`7#KSPTKBKV]JND2!!
M6_Y85IRYXK6PW)4\FD#@:BK:BO#*E?$EQ]$I982_/YSJW6FY)--A;@Y*EIC2
M#SHY7M0'81!L>X24;,N/]86+#YN2Q)W"2\H>5MMLY,>6[7(`1"X^0-@65#_+
M"VC0A3.8H[)4^U:<(-A(4[&#0QZUU]A</`8#`8&$SFRZYJ]L3/5ES^$UVSK5
M@6Y&[3F5,42;%;@,DU0!`F7OZ]O2GK!$$#'HH`]CV``M]'1K>\"+/>^XF=Z'
MCM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[3
M8#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>
MAX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>
MTV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9
MWH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK
M7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^X
MF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;
M*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WO
MN)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>
MVRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`]
M[[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.
MWMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@
M/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'
MCM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[3
M8#WON)G>AX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>
MAX[>VRM>TV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>
MTV`][[B9WH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9
MWH>.WMLK7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV`][[B9WH>.WMLK
M7M-@/>^XF=Z'CM[;*U[38#WON)G>AX[>VRM>TV![P\M.*HTQRP')GCZ)&G/3
M)5"L-S5R),0I6%JS4:<X_4DV44>K*0'B+`+>A&!),V'6]`%T!4?Q4^4=B<4Z
M=I&35W949ITVS.4E:TW+[/E%/R.^$\+A4KB]AO+J[MM6Q-Y8WZ3O&E\72%%%
MISMB``T8M@WK6]Z"HO'#Q5SV.L^4%RW-<<<Y3<:*=65%&ZUY,UOQ]D_%[5BW
M?8LO?Z]DG&]NAUNSA3'GJ2P>4D,@5;Z!T;VIK$]&$.8TXD1YH`G%@\8:N9DP
MQ%%7_'ZW[,NJ3WBY<>%%%5G,./L_>&&Q2:;<KV953A9\5N)TI$^"/U?MPE'I
MPB1F)4!@32E>B32#"]!TK/XIYC_;8GE#7<])IQ@X8W+;TYJ$Z$(S.0L9ORF^
M4D=X\RVO'+1,I'%$1,;<U"\A8H,5Z90$`"ZC<BVX(CL#NJU\8RI[7ADC'!Z5
MLZ8WJRWO'N.;3QYKZ:T%9KS,;&E-<.%O-1D<MZ`VX_T".)(*U97!T>'11)B"
M64+>>2J"`_R19H+<\9*FZ6)B#?.J5N*+S\^NGJW+>JR>OE&U1.Z1KN-RZ2P=
MV>'1#:ENPUOM-T<'R&NAK&W0=3(U4@;$GGJ+1A!R;9P>^7^,)6<?F+LV1?CE
MR/M6MFFUZ:I,-UUTU5NN@[[8W(^N8'8=!,D6;'VQ&":R`BPBK&:T)RPELTC8
ME"HHQR-3D&>5"'!D?C)U)%HK&B'NE['8KY=[#N2N)!QRF5A\;ZZE,+<Z!71A
M)9SH[6385TQBDG9F1ES=E&U":Y$N4/0G0H"4H0BU/D`X,B\:BF"$:^7UY0G(
M.WZ=B?':F>6%IW)"$-:$1.K:&N!QG+9]YG]NDEBLDG?9%!3Z\<S'=D9$3FX:
M3I#C4X3@E;Z0L=PDY6V_R0M+G7$+)J$VNXUQMY2+J7K&0A>(FX$3"*(ZX@,H
M*/7$,<LD+H%_-W)`NQAIY")-Z/>428(/.TRT!87$LNGJDNAG1QZX:MKFV(^W
M.`'=O8[+A$9G;.A=2R#TH'-&V2AL=425P`E4F%Z.``)FBS!!Z>@6];"$_<(X
M+=R[B;\.=/\`8[`>X1P6[EW$WX<Z?['8#W"."W<NXF_#G3_8[`>X1P6[EW$W
MX<Z?['8#W"."W<NXF_#G3_8[`>X1P6[EW$WX<Z?['8#W"."W<NXF_#G3_8[`
M>X1P6[EW$WX<Z?['8#W"."W<NXF_#G3_`&.P'N$<%NY=Q-^'.G^QV`]PC@MW
M+N)OPYT_V.P'N$<%NY=Q-^'.G^QV`]PC@MW+N)OPYT_V.P'N$<%NY=Q-^'.G
M^QV`]PC@MW+N)OPYT_V.P'N$<%NY=Q-^'.G^QV`]PC@MW+N)OPYT_P!CL![A
M'!;N7<3?ASI_L=@/<(X+=R[B;\.=/]CL![A'!;N7<3?ASI_L=@/<(X+=R[B;
M\.=/]CL![A'!;N7<3?ASI_L=@/<(X+=R[B;\.=/]CL![A'!;N7<3?ASI_L=@
M/<(X+=R[B;\.=/\`8[`B^?\`&OPUJQ5MR*9\1N*;8H=DYZI"`KC!6*_1I*8P
M!1PMC00-0$O81F:UT"WK>_\`!E?^,WB?X,\`=0R.E\4=3NY#.ZC9KNV*:,IF
MLQVZ+=445S,Y>S<BG"JJ(PJF)GKB,'O.Z7#C>[?C+WLSNWEJ;]G+UTTUS-VW
M;PJJB9B,+E5,SC$3U8H__+OPHNZUQ7^%"`?_`"[S"_\`F0>$;VBS7]6:EZ*]
MM_4!Q3]7V]HR_G3\N_"B[K7%?X4(!_\`+O'^9!X1O:+-?U9J7HI^H#BGZOM[
M1E_.GY=^%%W6N*_PH0#_`.7>/\R#PC>T6:_JS4O13]0'%/U?;VC+^=/R[\*+
MNM<5_A0@'_R[Q_F0>$;VBS7]6:EZ*?J`XI^K[>T9?SI^7?A1=UKBO\*$`_\`
MEWC_`#(/"-[19K^K-2]%/U`<4_5]O:,OYU)4!XP^&S9P5_W,XF<27,ULV7YZ
MD,XU54@6DEF_\TH\T7P=,>8F&+I#Y0(=@T+71O>M]&9WX-^(_@YQ]HSD\+M8
MHS^8R$T]_9KM7LO?HIK^#<[G,6[5RJU,XT]Y3351%<=F9BK")]+WMW`WLW(F
MU_>3*56+=_'L5Q51<HF8ZZ>W;JJIBJ.OLS,3ATQ&"1O<(X+=R[B;\.=/]CLS
MB]-/<(X+=R[B;\.=/]CL![A'!;N7<3?ASI_L=@/<(X+=R[B;\.=/]CL![A'!
M;N7<3?ASI_L=@/<(X+=R[B;\.=/]CL![A'!;N7<3?ASI_L=@/<(X+=R[B;\.
M=/\`8[`>X1P6[EW$WX<Z?['8#W"."W<NXF_#G3_8[`>X1P6[EW$WX<Z?['8#
MW"."W<NXF_#G3_8[`>X1P6[EW$WX<Z?['8#W"."W<NXF_#G3_8[`>X1P6[EW
M$WX<Z?['8#W"."W<NXF_#G3_`&.P'N$<%NY=Q-^'.G^QV`]PC@MW+N)OPYT_
MV.P'N$<%NY=Q-^'.G^QV`]PC@MW+N)OPYT_V.P'N$<%NY=Q-^'.G^QV`]PC@
MMW+N)OPYT_V.P'N$<%NY=Q-^'.G^QV`]PC@MW+N)OPYT_P!CL![A'!;N7<3?
MASI_L=@/<(X+=R[B;\.=/]CL![A'!;N7<3?ASI_L=@/<(X+=R[B;\.=/]CL!
M[A'!;N7<3?ASI_L=@/<(X+=R[B;\.=/]CL![A'!;N7<3?ASI_L=@/<(X+=R[
MB;\.=/\`8[`>X1P6[EW$WX<Z?['8')!P5X1%HU#<7PXXK`;U:E&M5(0<>JD"
MC4K&\I<0@5J$VHAHDY2A)<U("3!!V(H*@W0=ZT8+I#O>0G'E%?R_CTO62M?%
MQ4!R,A/(9$6A;4[CJ3K89&IO&RXHM$H4I]MR!R*FHS1J2_*&`VGT'0-Z'O>@
MJ#>7A;P"Y7?D]YI9C_!X1R;<:@M5TKY%$8G*8Y!N5M+2-L>(_P`C8RTS`AVB
MZQ5,6N.-+?+(XO:U#5(PM^CU`@GGJ!F!6J8>'7R-@SUQ$;*CO8ILG;)R9L^V
MYM>5<\:J-KNMZK;%'&*?UY'&$OC['A-;,ZP:1N:PE"OTH=%[ZH7.9B@#@G"`
MD)`9I*_!DB<OB3RRN_(J?.$HE%,S"#S*;O$)A3JHFEJSCEO$>94DM:51<9:>
M(NT:>K*B8&Q;"Q(],RR,GC;QF=3I&(.=%?"5D\.6R^QV#EJZ,?(9TM2I+I@U
MFQF@JNBD&KB9UK34HH!XC;723`H0Q5TJ2<U5*3F]0R'*BW%,?KSP+J-7U3@!
M^[.\)>2V7)(G9[KRT7/MXJ*]65A<]IVEQDX]W"9/HT9/I58,?65Q$IE&S8]1
M<CKI=.'5OCI[>!Q1)VHXHIP2.9R8I1H)U>O#CC#FG?42:TI"A1N_,GC-R\3E
MBCC0H-0K.-,=I^.-$`V,I4C3GM\J35$28I7@*)&F&M'HHCJE@UL(3MGPAV"=
M39\MN(W$S1NW'.Y[ZL=&_6+QYJN^X2EA/(8FL39A6BZM[(V>V*SV5^J9J<VA
M_3*D#@F4!-*-`>D..3FAGKKX7$;<H!RC@0KJE(R^3W"FL.&SP^GPJ&)5\<1U
MPU6^WF68F:HPGB\54/4D4VZH4&M:1O;&Q)M(`M.`!8]A`%I>/W&1705J<H9P
MW6.HDD/Y)65&[>#`5L2;&Y1`IXCK6'5K,%:.8(UYBZ1LTN0P)L5%)%24O;:>
M$[0#30G=``M?@,!@,!@,!@,!@=<\+3FQI='%.B/<CV]N6K2&Y-T><KSDB8T\
MM$GZ?H\NJ&7H`.G_`)0M8'SMIF:S)'X:RWQ4S>:%]L'*$=!O7*Q.8&W7\OC%
M%%S6VK9QKC0MXTC5ET^M@;1I%]S'`Y4U"EYJPLU5Z0+<=_JAGC[XC7.5=NW'
M^$P+BZW1]F\0:E>`M8Q:<H;:#*BGZTD=,N;U/[+?6B4%-R=%$4]H*"`MK<V>
M<+#T.A",3Z%U-A"_([G3RV4Q.=0ESW6\%Y%U1$/%;KQ1:%7/EQM%;#?>.G&V
MJK:A-C1NL3+`+*-='".6*2$I-(E#\9'GM()0A4"+&9HX,8J[EYS\IQWY*6NZ
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MJ&!Z=]4>MZZ=X'/P&`P&`P&`P&`P-;7.C_2:O_\`J)Z_O!'FBG_%V^_.YO\`
M1.<_E%M='PL_S)J_VJS]'6HIFH!:@P&`P&!DL1ET@@L@02:,KS&]U;S.L68'
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M$`?89:CF[1R",;'%9J_NB]Q=&-$8,I"VJ%.RB!;#K6M"W@45B]P\J:_DE4%,
MUD\T@<:)KXA'#>N*[D/-2&H8'?<Q9Y1"KJ6<B80M;7Z%PF=J*;/7,D;,0*'Y
MJ1+/2&EP4IPT0"Q:"-[5\:KD9.JQY71>L(%54,DZGA1S$OOC[;<0?;>E##`7
M7C<SM:A^;'^?2:EF"F;:FFHS)`NC0L@+M)HX6Z)B2%1YB,\*K8=S`N97B(QK
ME;/!V6*M;%?0POA#QKH>CX3;,SC%)'7;RD@<@M5UMBUE#]5`Y"N;6.)P5[7N
M"X@9S@2!"G;V]":-8:<6%R&?Q'^5<DNFE^*C9Q]I%JY#/%Z<A*6O58]VQ,#:
MCC2.@:PI>ZA6#5[PUP(Z6RMLL*N;D1>CVUR;VU8@=!>15C"428<((I@7BC<\
M[-0U"*,<2N-[:LY)\>KHY"TT;)>0LW3)8_&>.TECC+.2+43-M3."DI98J*7M
MI\8*9AK?-/.!>DS"O)#U@;I>.5PIN0O'ZD;X2,2B+IKFJ>O[0*C2M84XJH\&
M=15KDNV0]P(*((7FM0G+9&SP``$[9?7T$.M]&@F?`8#`8$(N7)GC>S6""I7?
MD%2+5:ICBD:`5FY6O`T-@C=G`HH]`U@ABI^*D8G%:2>`9)&DWE#`C#L(=ZWK
M`._)GC?'[`+J=^Y`TBR6F:O0M15:.]KP-ML`QS="R3FQN+AJQ^)D0U[B2I+&
M03I-LPX)@=@UO0M=(34::4048>>862226,TXXT82RBBBP[&8888/>@`+`#6]
M[WO>M:UKIW@1"P<B./TJCLRF$7O2G9)$JZ"I'8,H8+-A3Q'8*%&6<<L%,GMN
M>U#9&`I24Y@S-K32-`"`6Q=&@[Z`Z:!\J^+UJ21'#*PY(T)8\P<4JM<WQ2!W
M#7DODB]$@),4KE:-BCTB<714E1)RA&&F`*$`L`=B%O6M;W@9I#;CJ*Q7R31B
MOK4KB=R2%*-))E'H;.(Q)WR)*Q&#)"EDS2R.BY>PJ!'%"!H"HLH6Q!WKHZ=;
MP)'P&`P*$J_#0X4N\W4SH^J5:E*NL/\`-ARK,JS+1UQ]=+83OVI`.Q'3CL1-
M0T:X3(,G(\^-5FL`AC<0[4F:$HV(S82J;PTXYG>G=F0#8OO+R>CW,=Y_]I97
MKSOD3%@Q8+'/?H>]>0TB#"VW_HTOJM1GF_ZZ877,ZP=8[<&^+S]+'F;/=8)W
M202)XNU\?#ELBE9J-T7\BJ^B%67'M6U^G--HTLQ@D$:T`R=%:*3!3[,3A)-,
M-&,,=BWAZ\4HA7=@5:V0%\61"TXG4T'GQ4CLJRI4]R2,4<C"W5:VK93(Y:YR
M77W4;BP)RC0*PG'$%@`<,P(`ZT&;Q/AMQU@]E$V[&(")NL!.X\A'8E]^\LJ5
M:`OY3RN%S:\S_1RQZ/:]_?22UZT*-!V3L*#S7J(]$%F&A&$*O?AA<''L%=,R
MVKG!$FK^LHS43:Q,EL6O&4$VJ"`.ISQ%J\MEEC\Z:T=TP>-/+H:>0AE!3NF*
M,5&!WKJ'#`,-@Q999)8"B@`***`$LLLL(0%EE@#H(```'6@@``.M:UK6NC6L
M#]X#`]!*I,IV>%.H(/$E/$E4A)-+-VG4@`68).?H`A;)/"6:$6P"Z!:"+6^C
MHWK`]^`P&`P&`P-;7.C_`$FK_P#ZB>O[P1YHI_Q=OOSN;_1.<_E%M='PL_S)
MJ_VJS]'6HIFH!:@P&`P&`P,FA\PD$$D""31E>-O=6\?2`>OUB5!`MZ\NB6$[
MWH"E$I!KJF`%]&]?3KHWK6]>_P##'B=OIP?WTR>_NX6<KR>\.3KQIJCIHN43
MAWEB]1U7;%V([-RW5T3'3$TU135'A-XMW=(WJTB[HFMVHO9"]'3'5--4?!KH
MJZZ:Z9Z::H_!.,3,3N%IBYX_<$?TM1;+02)O+*!((^,SK'(3Q?JZ5)=BZ!*F
MM2+6]EFZ_P`G?Z@^@6OI^G3PM^*3<OQ,[EQJNE31D]]<G11&HZ=-6-=BY/1W
MMK'";N5NS$S:NQ&-,_P=S"Y'3KIXD\-M7X=ZO^39G&[H]Z9G+YB(][73^]JP
MZ*;M,?"I\OPJ<:93+EHF-S`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`AVW*,@=VJJC63DIW-.I*XHS><&VU.AS8$J>1)FDS"T&NH2@"TYM`
M6^6K-&)1]`#![`+>^D&L#BW7Q_KJ_P`NKR+&2.BTBHK=BMV1(AM<S6TD4UA[
M<_M33IY`6`>G5C,1254!0C'T`.ZP>G?ZNL"C$;\';B.P%)D*YXY!35B9Z3NC
MC5$8O/[YG4MC,"X\7K$D$*F--09F<E8DT=AR)C:4@&T97_2:7:-/H2LPL@D`
M`SH7A><:U4/E<9>'>Z7Y]E:?CP=NU7*V'XJX(W+N++0XLM+V5#[`:@-CK';%
MCB%T.">Y$Z_S\(Q%J2S"3#2S`R^I/#NX[4U+ZFL2-ZL9[L6II#=\T+L"<6"]
MR^86-.^0[!$HO9\XM9Z=Q&J)E(W%@@K4C1C%Y!.VI411"4DH@LLL(=U".!?'
M^O@TD".HY>#7'ZD;5X^UYY[*UBOR-=W(NB+A-"7G8R@^EWDU1"4/FJP?0-,'
M0]!UOK[P+$T]5D4HVJ*VIB"%N!4*JF#1:O(D4[+S'1T+CD/94;"S`<7(X(#5
MZT+>A+T:<+6A&#Z1;_3@2/@,!@,#XL>6A<55R/QJ$+O>WAQPLPODL_.A]57A
M63$[<U)L6U\9^.3H8WT)9AUKH'F(R66E(/1\,4%0F0&-DDWYP3HTS]4L.+R4
M6QJ3:\7X]^N;P]:G/>K#9Y"NIGE'6#(^\YG4M1P<XMO2IAJ>R5EM-[U$9RX%
M%[:(VI+A<D.;)>2:J)"H-_L@!N9YM69<5@<6U4>G/%RY:^XLL\AXJR:\Y\XS
MF(RV1S[C`*QJS<;]BZZ"P&2+[D0;;8&I7:E85[<FVH9$+H$S0@F=088>J+X'
MV?S=X2MG`E#QTFSD%EN)!R>(XT-]>O-7;X>NE1R%$@B]^$5T0HA9R5PN<45W
M%6M[#M;I24L&C*"2%9O816[4:WM/&#QLG+C94L8C]PL7)VWXY$G2HH)'6&T6
MV#CX]<9SK!B]:.L;:$S^V2!T@BQY+;4Z`8#AN"H.RM>6,UO86CI::>$$Z7GP
MZ2\/FBGI1<I4?FK?5YG$LEE"[5S59]>*!2];R4)@+DUJ62N3/,$"+269E*#Q
M2TY#LE-M<`9Q(;H,!@=:\HU+BT.K>B=%K&L7MJY&D>FTM"<XLZE4E-((=$!+
MHD7MIJUO-'HTH*@@X@1@-:,+&#I#L/DZ\/2ZN0E?53QVAYW,.<(*=I_P_P#E
M;S+L].OK2IK"D4KEU8\GI%%`1"2*D\4;Y*.',C:<L.<6YM5M[^O4]4D+FEWK
MIT&('^)+X@<7CE^1H^^]%RATXL<1[\K*3SU'Q-L.9U[(+KYDU+2#N^[@E!,0
M(1%X!+8//S3FZ,2%XD[PF\D$?I7K"V,07%N3D-SNK"3W-QOC?)ERM%[K+E;5
M;`AE99?$:G^5]BU'8_$]7<[O6E-%6M#V;C'+K#B$^3[<-)UK2B<5T1*4$%&[
M5D^<B#LH-S=LWDH)F<(]XA+9Q5@%9<+*OY"$3RW*2I&/O%ZS5WM"WJ^LB37'
M$I0Y.\?9:OKQ?4Q;2Z-D"?&\1CD\><IWD!`F\!@1QOQ%^42SFE32N)W#N2<=
M;?YO7%Q*+C3\GXYQ.*N+)7<`N(3@HJZJ6TF5<JQ/T(GU8`VMETFD#>T.)1X/
M(L0$JY$/01)4,UY$VW,_"WMVX?$;-J:T>0_A\\KKDD%Q.];\<V0#$G&JXJ2(
MRN:XC\@AJ:`IXRV'(@O3RI=B'5X4($*T)"I$4;HQ&&(7]XLO-45`-=]5W9R>
M)2>FN*7%>X;9C0&GCY`*<=9O="A<YD'R)';Y,TO.VT=SQ1&4JC['`B(V2S%J
MP%&O*I4/7D`N1);YYUR"VE;C'>8RR%PN9^+7/N`;!7Z.E*8?&Z&TQ^5[]+@2
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MU([A<30(S.JD2X%CZYYW<V)[S5<0`>F=BJ%L\0:<<0EU73&?\2HI`159%W1Y
MC[>L98FYNZ?F,Y<D'MG0$3%"7KKLKBU'Z*);O,MA7[#Z0L!@,!@:VN='^DU?
M_P#43U_>"/-%/^+M]^=S?Z)SG\HMKH^%G^9-7^U6?HZU%,U`+4&`P&`P&`P+
M#<:X78$DL%O=H2N/84S">4:^R/90C$)"$P6MG-1I`MA*<CW,H.PA3;WT='ZX
MMAT'0LN[X$.%G&G?GC/DMY.%.;O:/I^CW::\_J4TS5E[=BJ??Y2NW.%&9KS5
M$333EIG"8_A:IHIHBN,/\:=Y=T=%W0O:?O-:HS=_-T3%C+XX5U5QU78JZ[=-
MN>F;D?[L8S.#<5GT\-<Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,"/%515.NE(9RMK"O%DU`J(7`F"J%1M1*0+4H`%
MIE@9`:VC=@JDY980@,T=UP:#K6MZUK6`6U%4[G*`3=RK"O'":%J4ZPN7K85&
MU<H`K1@`6D5`?SVPQV"I2EEA"6/1O6!H.M!WK6M8$AX&,1J$PR%@<2X=$8Q$
MP/"T;D[`C3`U,0'1Q,ZWE'!Q"UI$NEJT?6WTFF]8S?3OIW@=TC;6YO&N,0($
M2$QS6C<G(:-*0F&X.)A)"8Q>N$26`2M:-.E*+V:9UA[`6$.]]`=:T'2,4(A<
M6<'MVC,0B\==)*I"MD;DQ,#2T.#^L#LP05;VL;TB=0ZJ0B-'O1AXC!ZV+?T_
M3O`RC`8#`J\D9.(U)VS"*U9X'4%<6W?C5<*V'L\9K1D8GFP&EE61Z:76(]T8
M(X4D&G5.;ZW.3N6N4%^DE9H#MA/-"+80P6RJN\/_`(DU!*K&G5'<<ZDJ*-%M
MQ4D4LU$Q(*`1DBG\17LS4FBT+A:YVD+H_6>W,1Z)`C1*E2I[3(C"2A*2B=A#
M-VJ'<4.7-?OLD<::@%HP:Q)`E4RI);M"&-QTND=>Z.BS0Z2F(6]!F=^=%L:3
M)1)6Q:M1"\FDUKS4S9`@[V'+W4/%&W5[?'72B*HERCC')&^+P]+,:*:M(*K>
MR&".R5N+JE7+8:G:TB!(T.3>(M9&C#$))Y?D/*A4)C"B@RK7&7C?J=.]H:X_
MTGJRW][:Y*^V'JJX-J</,C9"C"&=_=99IB]/.#TU$'#`G5&J!GD@&((1:UO>
ML#BRCBQQCF\<BL.FG'2BI?$8(TEL$(BTGJ2`O\=AS$2J:UQ3+%F1U8%;:P-(
M%C(C-TF2%%$Z,2$BZO26#>@Y<QXS\<;$?FZ53^@*4G$G:(NHA#3(Y?5D&DKZ
MUPQ66:2IB3>[/+$M7HHRH).&`:$LP*401BUL'0+?2&`S>9\.:H,GNYZ*F805
M206SDW83B]1IB;&JO':3:D$:9;7=WH;2%K:Y_(BFAP1I%.CM/JPK0@%Z&`T.
MAA0-5;W`;D;/(7:D4O4U-57"E]=N5DAXO1SC=-8K*7JUY*;*F&.<E%,&7U:V
M7M,VAO6V"[GE&1YH5MSH^JREIYYIQ6@C"18/RD\)KERMFT<;HY6D^20^3S&[
M;&<;;XAV'$()%K`KUI:F^<6%-9O=-*1B",=E1AB;DA"U2N7E/921*`L7]F3T
M`#WU]>WA$7LX)C(HQ<=']WXYPR77?#?O7QR-B;I"Z_0NRJ736UZ3!8-7Q]8^
MQ$$@6C<ESU#]+4@UZD!PS=GGEB&'<43RS\+?D?R&BDVJ4%:+^3<_B2E37MES
M'C5-ZEM"QH@F8]."LBNK.MJIH,[S]O)BXO.1IFAQ6["V=)NP>;ZV+`V(U_8<
M,M2)MLXK]_22:+.QSHE1.J,"DD.UK&[KF![;U21:0E7M[FS/C6I1JTR@HI0F
M5$&%&`",`M:#,\!@,#6USH_TFK__`*B>O[P1YHI_Q=OOSN;_`$3G/Y1;71\+
M/\R:O]JL_1UJ*9J`6H,!@,!@,"8:;IN0V_(=-[?H:!A0#*'()`85L2=O('^M
MI.GUOH"I<U00[T45K?1K_*'T!UEG_"[X7=]?$SOI&CZ/%63W.R=5%6HZC53C
M;R]N>F+=N.B+N:NQ$Q:M1/1TW+DTVZ9ECKB/Q'T?AWI'Y7F\+NJW8F,OEXG"
MJY5'XU7[VU3/PJO_`*:<:I;AH;#8]`H\@C,90`0-:`'0$.N@1ZH\71L]:M/Z
M-#4K%(]=88Q?I_1KH#K6M?3KPOX7[E\'=R\GN%N%DZ,GH&3HPB(Z;EVY/P[]
M^YA$W;UV??5UU?Z*:8IHIIIC71O)O)J^]FKW=;UN[-W/79_!333'P:**>JFB
MF.BFF/PSC,S,Y3F07@C`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'7NP7(;4Y@9S$Y3N)O6!:C58=C2
ME.0DQFD)BD`?UAIP*MAV/6OIV'6\#XM2*BNDQVI=SXW5!R^C?B+1[@YXBC!R
MLM.Q(?=Q#4Y<R)+7M9DMSJP6).O,ZNDDTEKZA=3H4Z1I:!N$S#;DQ:D@!!)"
M<.W:>)!MI<?+-CH(I8]N4\??7AI..JI%PQY8\;8.P6B@Y51]JNZ;MS-R)O.U
M;3EEH#IU]5)+$=FM*CC.D0"%@UJE8`XXH)Z3UDTM3LG;N;E0<LI?PZ;;C\5!
MNKR)UE#.1TN5,EYN'-EX444_+HS4*578(!N5#%&E5G(%0=Q]N%LXPA2F-.3G
M["/+SKKDD]N]BF21AO..<4EO.9$[VVW7[17('E`XJ(R+PXN*K13JRW*KXZV9
M$;&L>)-5HM[ZD>ET==W5E13H)9ZXI0,L9I89JR<-9S<,?*;;[;^3ELE5MX25
MR/M-227QRZZ1>VNV".1]M/M&#(@R>SYV^M]P5]7_`*'(C!+Z^NLO2M>B35A9
M*PX\H`3]7$=87WD0C?\`FA5'-Z><K9)*^)CGQ5FE:1N[ONXS4<MHNG$<\:U$
MR8E#'2=<1MOM0<Y-MEGE:Q`XNJ)4/?FZ[RC>4$)^\,V,66\\E;=AMCF2D4=\
M,B,R/@K62YW<52QKL#\P9HCN9KG^C=JS@.#LR<9457LYIJCRBDI:<XZ_4Z^]
M"#`YW!;`E:_F),`U[)+=F-"^,!1'(*S:E94Q;I.9]QNK&F:*75ZF@,=4'D%R
MTV(L2H$G8V?0P^E7MC5)D_66&:#L+/,%EM?-#G3Q6MNCJQN1J@'&6$\@Q6Q=
M%L4G:%#(%X[9BT=BL>HF*M]NQ:#S&<N@Y(VE2%VVF0',K9IC3;$I$I4$@T$(
M/-#V[8?![Q+("Q5S(GR4/_B!7K9S#6KR@-83[JKV)WO7MD.D+8QR`"%"XM%O
MP^++F="?L?F"T2W0=F^2$,6@D2Z.4L,Y?PRP8?2W$N])A(6'BMRH%(+7MSCI
M95)N?'EXDU-O$?05C$/S<KM@>IW9MH/XTK6I:8B>J2A0I3%"A4,!:<HX*[5=
M:#;RGHGPI.-=1UA>RZS>/,UX7V7=,HL/CE>],PVBF?CS7:0%D:<)W;]=P=D=
MY5)!D*8L@0,BAP.<-N9PA;TC`<9L-C'`;R^IOXA06GR^ZY#SWL?<%WOI]&^E
M!U;3AEPA8][_`%-H0WB*1^=^3_L]//GVM_VNC<#8K@,!@:V>=.]:DU?].]:_
MZ">O\/\`_L$>:*?\77[];F_T3G/Y1;72\+,3^9-7^U6?HZU$^L'_`!Z_\>LU
M`X2M1A)U@_X]?^/6,),).L'_`!Z_\>L8282=8/\`CU_X]8PDPDZP?\>O_'K&
M$F$ICIJFY#<$AT@;]#0L"`98Y!(!E[$G;R!?K:3I];Z`JG12'7045K?T?Y8^
M@&M]-GO"[X7-]?$SOI&CZ1%>3W.R=5-6HZC51C;R]N>GN[>.$7<U=C&+5J)Z
M/^)<[-NF98YXD<1](X=Z1.;S>%W5KL3&7R\3A5<J_?5>6FU3^-5Y?@TXU2W#
M0R&1Z`QY#&(RA`A:T`.@.NGKJ%1X^CRZU:?T:$I6*1ZZ1CW^G]&M:#K6M?3K
MPNX7;E\'-RLGN#N%E*<IH&3IZ(Z[EVY.'>7[]S")NWKLQC77/^BFF*:*::8U
MT;R;R:OO9K%W7-;NS=SUV?P4TTQ\&BBGJIHICHIIC\,XS,S.4YD%X(P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!&!MW4P0:80?;M8$G$F
M#*.)-GT4+-*-+%L!A9A8W;0P&`%K>MZWK6];U].!Z_SSI/UQ59[08E]KX#\\
MZ3]<56>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?
M:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.D_7%5
MGM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@/SS
MI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]
MKX#\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56
M>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.
MD_7%5GM!B7VO@?D=X4B8`98[AJW81A$`6M6%$P[V$6MAWK0@O&A:WO6_TZWT
MX$14D3P\XZ0U3`J?G-7Q>.N$GD<U=]++@(EK[()?+7`;G(Y-)9;,YA(99)7Q
MT5"UH:E>M4&A)+*)!L))118`RA#+.+S78,BM1NL6ID,\EL9CD0D[\ELJ/DB?
MF&(KGQPC*9T;P2#34K5,BB2+M)U8B-JP$J1%>5V5H(`AF_YYTGZXJL]H,2^U
M\!^>=)^N*K/:#$OM?`?GG2?KBJSV@Q+[7P'YYTEZXJL]H,2^U\#"*ZE?%VIH
MBWP6O;#J.-19L5/*],VIK'CJH1CE(GIPDDA=5RYP?U;BYNS[('94M6*E)QJA
M2J4&&F#$,6]X&;_GG2?KBJSV@Q+[7P'YYTGZXJL]H,2^U\!^>=)^N*K/:#$O
MM?`X:FXZ#6B`)9:E0*Q%ZV$`E,XAAX@!%O6]Z!LUT'L.M[U]/1GC,_HNC:K5
M37J>4RV9KHB8IF[:HN33$]<1-=,X1/EP?HL9S-Y:)IRUVY;B>OLU54X_APF'
M&_-;COZR:7_&,'^T<_!_=#=/U7IVS6?B._\`.NJ?6;_SE?NGYK<=_632_P",
M8/\`:./[H;I^J].V:S\0_.NJ?6;_`,Y7[I^:W'?UDTO^,8/]HX_NANGZKT[9
MK/Q#\ZZI]9O_`#E?NGYK<=_632_XQ@_VCC^Z&Z?JO3MFL_$/SKJGUF_\Y7[I
M^:W'?UDTO^,8/]HX_NANGZKT[9K/Q#\ZZI]9O_.5^ZYJ:Z*(1@V6DMBI$I8A
M;&(M-.X<0#8]ZUK8]A*=0AV+>@ZUT_IZ-9Y7(Z;IVF6IL:;E[.7L35VIIM44
MVZ9JPB,9BB(B9PB(QZ\(A^:]F+^9J[>8KKN5Q&&-4S5.'[&,S/0Y'YYTGZXJ
ML]H,2^U\_:Z3\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX
M#\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T
M&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.D_
M7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@
M/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[0
M8E]KX#\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]
M<56>T&)?:^`_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`
M_/.D_7%5GM!B7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.D_7%5GM!
MB7VO@/SSI/UQ59[08E]KX#\\Z3]<56>T&)?:^`_/.D_7%5GM!B7VO@>S5VTP
M(DQ0&W:PV04842:?J?139)9QX3AD%&&:=NH`PX"8S8`[WTBT6+>O\G?0$"K?
M#H\/AR6*W%QX)<-G!P7J3UJY>MXPTDJ6+5BHT1ZE6K5'P<P]2I4'#$,PP8A"
M&+>][WO>\#B_+:\.ON#\+/A9HWL+@/EM>'7W!^%GPLT;V%P'RVO#K[@_"SX6
M:-["X#Y;7AU]P?A9\+-&]A<!\MKPZ^X/PL^%FC>PN`^6UX=?<'X6?"S1O87`
M?+:\.ON#\+/A9HWL+@/EM>'7W!^%GPLT;V%P'RVO#K[@_"SX6:-["X#Y;7AU
M]P?A9\+-&]A<!\MKPZ^X/PL^%FC>PN`^6UX=?<'X6?"S1O87`?+:\.ON#\+/
MA9HWL+@/EM>'7W!^%GPLT;V%P'RVO#K[@_"SX6:-["X#Y;7AU]P?A9\+-&]A
M<!\MKPZ^X/PL^%FC>PN`^6UX=?<'X6?"S1O87`?+:\.ON#\+/A9HWL+@/EM>
M'7W!^%GPLT;V%P'RVO#K[@_"SX6:-["X#Y;7AU]P?A9\+-&]A<!\MKPZ^X/P
ML^%FC>PN`^6UX=?<'X6?"S1O87`?+:\.ON#\+/A9HWL+@/EM>'7W!^%GPLT;
MV%P'RVO#K[@_"SX6:-["X#Y;7AU]P?A9\+-&]A<!\MKPZ^X/PL^%FC>PN`^6
MUX=?<'X6?"S1O87`?+:\.ON#\+/A9HWL+@/EM>'7W!^%GPLT;V%P'RVO#K[@
M_"SX6:-["X#Y;7AU]P?A9\+-&]A<!\MKPZ^X/PL^%FC>PN`^6UX=?<'X6?"S
M1O87`?+:\.ON#\+/A9HWL+@/EM>'7W!^%GPLT;V%P'RVO#K[@_"SX6:-["X#
MY;7AU]P?A9\+-&]A<!\MKPZ^X/PL^%FC>PN`^6UX=?<'X6?"S1O87`?+:\.O
MN#\+/A9HWL+@/EM>'7W!^%GPLT;V%P'RVO#K[@_"SX6:-["X#Y;7AU]P?A9\
M+-&]A<!\MKPZ^X/PL^%FC>PN`^6UX=?<'X6?"S1O87`?+:\.ON#\+/A9HWL+
M@/EM>'7W!^%GPLT;V%P'RVO#K[@_"SX6:-["X#Y;7AU]P?A9\+-&]A<!\MKP
MZ^X/PL^%FC>PN`^6UX=?<'X6?"S1O87`?+:\.ON#\+/A9HWL+@/EM>'7W!^%
MGPLT;V%P'RVO#K[@_"SX6:-["X#Y;7AU]P?A9\+-&]A<!\MKPZ^X/PL^%FC>
MPN`^6UX=?<'X6?"S1O87`?+:\.ON#\+/A9HWL+@/EM>'7W!^%GPLT;V%P'RV
MO#K[@_"SX6:-["X#Y;7AU]P?A9\+-&]A<!\MKPZ^X/PL^%FC>PN`^6UX=?<'
MX6?"S1O87`?+:\.ON#\+/A9HWL+@/EM>'7W!^%GPLT;V%P'RVO#K[@_"SX6:
M-["X#Y;7AU]P?A9\+-&]A<!\MKPZ^X/PL^%FC>PN`^6UX=?<'X6?"S1O87`?
M+:\.ON#\+/A9HWL+@/EM>'7W!^%GPLT;V%P'RVO#K[@_"SX6:-["X'+!X=7A
M]%H%+67P4X;EMBQ6B<%C<#C%284"I>VDN"=N6J4881I.>K;T[LJ+(,$'8R@*
M30AWK1@];"Y&`P/FKYP6?9C#RIMYI8K&GK*THW*.A1M;1,I&V-R0)L+C9Y@4
MJ%$Y$)4X3#S1#%H`-:V,6][^G>]YJ]X];U;TZ?Q;UG)Z?J>HV,G1=L]FW;S-
MZBBG'+69GLT4UQ3&,S,SA'7,SURVP^'O='=+4>#>AYW4=*TW,9VY9O\`:N7<
MK8N5U89J_$=JNNW-56$1$1C,X1$1U0JG^<UQ>MJS_:!+?M?,0_WWWU]<ZMMF
M8\XS-_</<7U)H^Q9;S1^<UQ>MJS_`&@2W[7Q_???7USJVV9CSA_</<7U)H^Q
M9;S2;:#YE7#2DZ2R1?*I//XRK\DBE$3E,C=7@AP:_*=81S2>[*EGHA[1].QD
M'`UH(M])9FA`%OH]\X><;M]=Q=?HU/,9O-ZCI5>%-_+W[URY%=O'KMS<JJ[N
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M<I^WUX*4VHF;6V1#H_D#7M`7:.<)6F+N#I6Z9L?ISM1'C3M+?2Z5/Y10!`(0
M"1A[[`\1!V&;<K`QU-9D49ZGEZ2`.ER,Y+.\,9%A1VSJ>ALOB8"9C&DL;-;W
M<5CFE-BPL]8J5HTAYXTJ`8T8C`G>@^9BB\Y)+XL.LMP!6D@LKL*OG)XFS4^-
MLKC<0M.<4^ZK9#IL;DPX887*8:!0$K8UW6;EH!B&6>6<0`*MU9S\NI')*PKR
MWHE#=3$M_M9NY3C?E*>M`4>=!*,BEV(2Z\4LCU:$0N&%/;`]'N+4^!=FXU2S
M;)TL3(UA:D`0Q!^\4N:N#S7\GAU9($L:8-<G_P`VZ]?YHWQU1(6>I*"I7D+&
M91$)?,H:PNOE38#:`#R4/HQ,%6H._M#PHB_/<#)@<[)HY6X0UM4BD(:_7S)*
MQ)&Y='("AD>G%ZY94%4[*@.5*$!A2")%1BT#4BH1P1NY98S#?*>=%E"T&4;\
M1B1[^ZTT45:Y%MDF06FVP.%QZ?0UZB%L$1_D7QSX_1.T&RP'>+,#\U1][DMN
M*#&O>TQ:58SE&+1`.">@'L,D9?$J^\%SU+0;92@Q67-9`],$]93K)1>3@^XI
M<-J4[,G>,K4L05I;`:(JYT\Z.*D9PV(XQO4(MDE&'''%)@VD8'SY<K[%L)HY
M%6LVM,^FS4VI'](6D;VV6/Z!"E+$Q-!FRTR-*X%)R`;,'L6]`#K76WO?Z=X%
M>OS7M/UFV)^-Y/\`:F`_->T_6;8GXWD_VI@2?47*.VJIF2*2[E4BE[7OJI7R
M,R:0NKJ@=6P1@1FED"<5*S3:XE='6(4%AT(`OH%H0-B#L-_M5VI#[BAS=-86
MX!6-JT/DU24SJ@<&=Q```E32ZIM"$)*N2B'KK:WTA$'>AAV(`@[V$C8#`8#`
M8#`8#`\;$'6PZWO6MBZ=!UO>M;%O6M[WH.OT[Z-:Z<#S@<=7O84JG>M[UO2<
M[>MZWT;UO18MZWK>OIUO6\_#J=55.FYBJF9BJ+%R8F.B8GLSTP[LO$3?HB>K
MMQ^[#1,*P)[UA_\`MQ,?\L7_`/T[W_Y6_P#\]GR$W>-?&2F[5$;V[S815/\`
M^TSWGVU&G='=/LQ_^+T[JC_XUGXCQ^8$]_UXF/XG>_X[.'Z[.,OM;O-_6F>\
M^G^Z.Z?JO3MFL_$/S`GO^O$Q_$[W_'8_79QE]K=YOZTSWGS^Z.Z?JO3MFL_$
M6`HCDL_0-YTU39T=)##W50'SI0X*E+DY,*@?0#T@D.4C.4'(^C6O+)^MOZ-=
M<'ZVMZ'<_P`'_CSWQX0[T1N[Q8U#/ZUPTU&]'>W<Q=NYG-9"Y.%/Y19KN55W
M*[/1'?Y?'"8CO+41<BJF[B/BKP4TG>O3?R_=BQ8R>\5BB>S3;IIMV[],=/=U
MQ3$4TU_O+F'7[VKWN$T[5F]P0NR%(YMBM.O;UZ<I4C6)30G)U*<X.AE'$F@W
ML(P##OIUO6?1+HNM:1O'I&6U[0<S9SFBYRS1=L7[545V[MNN(JHKHKIF8JIJ
MB<8F%#,YD\UI^:N9'/6Z[6<M5S3715$Q535$X3$Q/3$Q+F9Y-^8P&`P&`P&`
MP/&Q!T+0=BUH0M;V$.]ZZV]!Z.MO6OT[T'K:Z?\`%TX'G`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'RY\]O^+JYO^M(S_P!AHQFI_P`0O_\`
M9-;_`.;8_DMAN"\-W_\`$=!_Y-_^5YA4+,,,WF!X_1].\);MO"^I*WHYMUME
MX>7*+5G*6[:=LA2DGI^_*C6NA'*S4JG72UH6W6Q:2J"]!.6:%O73Y#6NO>SP
MH[B;YZ9-[?#.W[N4W6S=K"C+51_U4_BYB::O^'31T]W7&%5S&?\`T^O7YXON
M(&X^JQ9W*R-BUG-[<G=[5S-4S_TE/XV7BJG_`(E=?1-RB<:+6$?^ICV=RF7;
M40,#'2XA$B6Y&SE1>.E-+>\ZD2!K+9&T#<AD`7<V0!?4:(*;29,\A?SAKM*@
M!"?I8,1W6\IO8L#'3ZAJ94IF:U35]=J%ECH?1EAJSX3&CE,\;=@$7MOF9YC8
M(V4(=@'L/DEVSR^C>]='TX`-0U,%Q<W@-7UV%W>D+6V/#H&$QK3B[-K&8WFL
MC>YKM-GG*]"SFM"024HT0RTXDI6R]!V6#H#($$-A[49LYKBD;;3MMZMHV:@8
MFM&9MJ<'%0\+VS8TZ4L7H]:[*S51Q/3Y,Q2:,P0=C%L6P@NQ@<5>/$-C;K.8
M96<&B"6=I@PU"U5<C<=%V1(VUQ1$J(I&(C%W-RW+75G*5EC/1)=J1I`FZ&+R
M?6P,:K9LX2VRV+HU6L!H:4QN'KXG)@H6JLHEJ)IG.T(<P2^,2"/[-CI+$O7R
M>(^CCO.D.S#=@)**,%H96@!#)I'..,#5(X@QK$U<R&5V99CW7#`VQN,-$Q=W
M&Q(^(^<R]`[:86YS-:E<3-B`G5W4+Q$A0'H2S3Q!/"5TA(+#3]'Q=N(0QBKJ
MICK0C4F>:HV&$Q!H;DJS;HQKC?()V]L3IB%.WJ--IPNKK0O.F],/?]H05L(1
MA)^)=!3&U&ZUE[(:FE21=$EBUL9'P]HCT@>:YF,@LN(.+XP(!E$*79@G$O7/
M`S"MDC6JE'77><AT`.@M+@?.#S`_XE[>_P!HD?\`V?9L"MN`P&!M8\.VH;00
MNJNUCW9?%ZY<T1J(EB-+ZP;`."$PM.X^:GZZJ5M:#A;$4L#K1IQG26#>R^OO
M`V\8#`8&H?Q2:YO">.--**@8)Z]!9*XY1Z`?"F.;O_HFU'*(P3\E5?4A4YA6
MXQ*!2)`K"RR)S](-+&H\H<I2FEBV`059,B7/.(7!R&LVLH%8[;9#XFY&#:]+
M&5Y?&-O%(([2BZIEXI#*)JMJRZ$3!(V5V;V9F:F9G.;_`#E6K..V3Y0HT+AV
M:A\05).)DVP"U;'%$&B5N<0BSA^5E#.:A\BK1P_.L1#8)RY5"B"S)!(^3K<5
M&Q]1,2V%IEAR8M"`>R%R</1R2I'DIR=.XB)4H#*V?%U"6<JM6<Z=YHQE45;D
ME0T,I9IA$F.&R%"%YM*&NB5\''DCFIVUA$0H"H.$6(19X1*QK^>5<6S"JY@L
M$L1JK"2\K+P=;#DJABB[^WO5:V_R<O$U7-BG%5&7PR*+X'!1L<@0;4.;:0I"
MYD`+;G(H*L@@,!A5:<W&-35=S.3QR&F]DP'A)%JY?G>QH-4S_*F&QWCD;'VN
M_'B)L)D09/O#93-42->Y,!@#3$TC+0H0J-N(#MDGA.6I5XD3C'+5=FQ5.48(
MC15ZO%'IW:KZM3R>TYX"S9BQT:JL]G4,J331+M5RG;W%2R-Y+"G4GB),4EI=
MB/18$U4T?S49[R<66U)-*YW3NY'?\63NDA@=8QPHN*QAHJ9[I^<&.<'96)<>
M]REUD,G;!;T`M`>C;B=;1%*23%:O\&J_S9F?^1<_\DN[+?\`46_]^G]V%#A_
MY8__`*X__.WGQ?7O^-7_`+T_NMN5/P8_!#QG4DP/T``S!@++`(PPP00%E@#L
M8QC'O00```.MB&,8MZUK6M=.]YV6;-W,7:;%BFJN_75%---,3-554SA$1$=,
MS,]$1'3,HJJIHIFNN8BB(QF9Z(B(ZYF?)$>66W#BU7LX@4'-!,')266\'%KV
MJ)'A"/<;)'H0C!&';Z3"5;CL>AF)@[ZA.]:Z=>4$/H^E;_#XX*\6>#O":NUQ
M-S]^BSJ=RG,932+D1/YMHJBJ:JJJYQKHO9GM4UW<M$Q19FF)JB+]=V(U[\=M
M[]U][-Z*:MW;-$UY>F;=W-TXQ^43&$1$1U31;PF*;D^^KQZ/>13C9[+]L'F`
MP-:-P#YS/')!W9ZYF$QA%'"FU%1%O61^NZH?TY$-ED#M=RN2>$/$R8WIV,?8
MC+F.-)48C=#0(Q+AZ-1+@FZ\@%0$%`\V+<?K%O.<)'VN9PFX\P-T&0V/,L;9
ME-[#<N'LJB$SIN(19ND`:^CD0.M^2D.:X\7E5A+VVE:3!`+R2T@.KAO#RWC:
MH:(#95?SY\?HYRQX;2-#IG?I@S05'24@::((O4,71KK&?Y*WDZ^[SZ&>H5KH
MM(5NGG*M*6$A:$D(6PY%<:+IM?F)4A]?.*^OJH@-)Q,T-E`?Y<4.&2B*7O&I
M,K98+'FAU3L3S+YA`6,UE7&/(1)@,RTS8M*=:&E,"K<'#XB$98JWH>&0JSZ[
MB*FKK<8']\`W1-:<T2"9Q'D5)XO.625N47>0QB2PZR4<4;B"7!Z,\MIPT9Z*
M&F%YX6&5Q:"<N8U(S+Q`Z<@WY[?*+X-UC))7+*VJ=[MN(1C<FM-;R1<H+$CJ
M^2J3[!8W+;6)P3#2KDIZ9Q$MVA<CDR3102F@?O$C>81-'Q8XRJ,R5LK[CZV0
M!C3UI5)QLA>)I?4L9;/G\I0K43@-/.XU0S>S.2YD3*4C.U.2U3T$'=!9!`3Q
MQH4<PT%M+6>\9!)IE6Z^*W5YH[2.#UU%]L;U`>1;O"ZB-)6P5J935SG9]&C3
MOCCY<L20T\L)R,AN`(Q*(+_X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`^7WGD6BWRWN79JM469MTC76`6WDG`#_`.P\8Z.J:)S($+IU_P#P:_\`
MWYJD\0=-B>,6MS777%7>V.B*(G_XMCR]N/W(;??#A5?C@GH,44433W-_IFN8
MG_J\QY.[G]V51?)-W[<M_P#51'VSF&NQEOE*_FX\XS;V\S\G;^<GS1Y)N_;E
MO_JHC[9QV,M\I7\W'G#MYGY.W\Y/FEB^+9/'S5O1LR^W%\%%0+DND"3;*@!%
M5#P(W_-!SEPV_#6I(X0;H/7"2F/`:+>O+"+)T/8LE\)J.'']\\K5Q#NYC\T1
M<I[%/=4?D\W,?>SFJ^]FJFS$X8Q315%4S[^::(JQQ;QAN<3O[D9NGAM:R\:S
M-NKMU=[7.8BUA[Z,I1W,457YC'":KE$TQ'\'%5<TX?50B\S\S2>CO-O1_FQ'
MF/F7DO,_,_)`\U\T\A_8>;>0ZOD^I^IU.CH^C-N%CN>YH_)NS^3]F.QV<.SV
M</>]G#H[.&&&'1AU--E_O^_K_*NW^4]N>WVL>UVL??=K'I[6.../3CU]+DYV
MNHP&`P&`P-?'B)E,YD'X^[>%UP(@%<J*V-1!H=K4.=GK5H8O80=(8^-"\-+H
MUZ-1B.$H5)`K%)9`!A`G'U]C`&D'ED@IHZ`V,.@I5+V^E%"FHR:[30Z`-KP[
MM3R9Q,KP%,.,!7/%EL=G2">(P$GF%(M)VQ2I>5!A;@J(&G`:I"9).CXICL-3
MJ.22&II5KF5XDID,,I^%5DMN\5IJN.5J@D:5J)!/V\\%EL4J'Y6&GIC!+'54
M6W%'$MQIFS2@[3CFCX^`OGCN=()'"U$.!9<##'F^+PMF1\:%-I%<.I:F:C27
MAWGR\A%>2X>DZV1EFH5!Z60;:D6AJ%NO2&PPSBNAXL@FO&O\M926ILXM/X>F
MDFVF!1Y%-%<H2BY);M\;EI)9"]T;I:^18U)JQ0AVJ6M302V;6B<$QR?2</J`
MP/G*Y>@1[Y*VYLQ4I`/<A1]8($)1@0[^[[-]`3!.)6Q:Z/\`#U=8%;_)H?VQ
M7_ZM)^U<!Y-#^V*__5I/VK@3%1)5+?F0P#N=>_?<X"Q/L:=(T)?12E8(X&B-
M2A9I[\^11PK?ZRC:8A0:8']7>@`ZPL#Z56OT;Z-;_0WF7HCS)+Z+]&^0]'>C
MO(`\R\P\V_S;S/S;J^2\G^IU.CJ_1T8'.P&`P&`P&`P&`P&!QEG_`*(J_P#\
M8_\`_M"S\&J?S9F?^1<_\DN[+_\`46_]^G]V&@(0$?7'_G"G_+'_`/@RO_*W
M_P#GL^,V];TOO:L;V8Q[4_\`HT?L_P#/;:Z:LQV8]Y1U1^//Q'CJ(_VA3^YE
M?QV=?=Z5\MF/F://N7:S'[RC_P`<_$.HC_:%/[F5_'8[O2OELQ\S1Y\[68_>
M4?\`CGXBV?$P%4!G!(I0I5&S(0^B(DNR%(GCQ2G71T#3*=."DQ1(#.G?D`FE
M%`!K7]F(1NP]79)_AOVO#E1Q8MU[^W\S<XHS5AI%&<L6;>G478PPFW=_*+M5
MS4*L9_)Z;MFU11V?X&NYF*K<45_\0%6_T[KU1H=%NG=N(_\`=S:KKJS$T_L5
M4]W3%.7CH[<TU5558^_BFB)QVJ9]$*AA@,!@,!@,!@,!@,!@,!@,!@,!@,!@
7,!@,!@,!@,!@,!@,!@,!@,!@,!@?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tpg49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg49.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!9P)8`P$1``(1`0,1`?_$`0(``0``!P$!`0$`````
M```````!`@,&!P@)!`4*"P$!``(#``,!``````````````($`0,%!@<("1``
M`0,#`@,"!@@,$`H$"`@/`0(#!``%!A$'(1((,1-!4=$B%`EA<9$RU!47&/"!
M0I(CE1965W<X6*&Q4G*R,U.3M'6UU9:V&3GA8L)#PR15=I=9TB76F,'Q@C0U
M)Z<*XG.4A39&*$AC@[-$5&2D1:7%9H9GATD1``(!`@,$!P,*`@8&"0,$`P`!
M`A$#,1($(5$3!4%AD3(4!@=Q@2+PH;'!T?%2,Q4(0B/A<I)3-!9BTN*35!>"
MHK+")#55&`E#8R6#H\/3<Z0V_]H`#`,!``(1`Q$`/P#](/3-ME"W1Z?]N<ZS
M/+L^O&293;Y3TI:[TVTVP85^N3;0T3#'*`EH5W(:24G0X/C(5Z:&=U=/.'O.
MNO\`W19F7'E@NI%_'F+2E+?*=8@X\J15VWHY4H9\;!;R;YNN'G_ZP9I]OT_!
M*M>%:7R^PUW-9"4:+'Y=8^;IA_WP9K]OQ\$IX9]17\1\ODQ\W3#_`+X,U^WX
M^"4\,^H>(^7R9`].V'C_`/?^:_;X?!*SX5O<:YZA5'S=L0_V_FOV^'P6GA7U
M?+W$/$(?-VQ#_;^:_;X?!:>%?5\O</$(?-VQ#_;^:_;X?!:>%?5\O</$(?-V
MQ#_;^:_;X?!:>%?5\O</$(?-VQ#_`&_FOV^'P6GA7U?+W#Q"'S=L0_V_FOV^
M'P6GA7U?+W#Q"'S=L0_V_FOV^'P6GA7U?+W#Q"'S=L0_V_FOV^'P6GA7U?+W
M#Q"'S=L0_P!OYK]OA\%IX5]7R]P\0A\W;$/]OYK]OA\%IX5]7R]P\0A\W?#_
M`+X,T^WX^"4\*R+U45L'S=L/^^'-/M^/@E/"L>+B/F[X?]\&:?;\?!*QX1O8
M9CJXJ2:Q'S=\.^^#-?M\GX)4?`/Y?<6?&OY?>/F[X=]\&:_;Y/P2G@'\ON'C
M7\OO'S=\.^^#-?M\GX)3P#^7W#QK^7WCYN^'??!FOV^3\$IX!_+[AXU_+[Q\
MW?#OO@S7[?)^"4\`_E]P\:_E]X^;OAWWP9K]OD_!*>`?R^X>-?R^\?-WP[[X
M,U^WR?@E/`/Y?</&OY?>/F[X=]\&:_;Y/P2G@'\ON'C7\OO'S=\.^^#-?M\G
MX)3P#^7W#QK^7WCYN^'??!FOV^3\$IX!_+[AXU_+[Q\W?#OO@S7[?)^"4\`_
ME]P\:_E]X^;OAWWP9K]OD_!*>`?R^X>-?R^\?-WP[[X,U^WR?@E/`/Y?</&O
MY?>/F[X=]\&:_;Y/P2G@'\ON'C7\OO'S=\.^^#-?M\GX)3P#^7W#QK^7WCYN
M^'??!FOV^3\$IX!_+[AXU_+[Q\W?#OO@S7[?)^"4\`_E]P\:_E]X^;OAWWP9
MK]OD_!*>`?R^X>-?R^\?-WP[[X,U^WR?@E/`/Y?</&OY?>/F[X=]\&:_;Y/P
M2G@'\ON'C7\OO'S=\.^^#-?M\GX)3P#^7W#QK^7WCYN^'??!FOV^3\$IX!_+
M[AXU_+[Q\W?#OO@S7[?)^"4\`_E]P\:_E]X^;OAWWP9K]OD_!*>`?R^X>-?R
M^\?-WP[[X,U^WR?@E/`/Y?</&OY?>/F[X=]\&:_;Y/P2G@'\ON'C7\OO('I[
MP]K10R#,-5*0V._O^C6KJ@V.;EAJ5Q*N'C-96DX;S[OEN(RU3N+)O+4@;=;,
M7">K'+'N[)N=R@SI-OD6JW[IV"=/<DMO*3-M_P!S;"%7*,_"D`I62"1RG45A
M*YQ'7+PJ;-Y"NSK+O7T]86@*8>ON=H0A1[E#=^"^]<U())]#!XFME$8JRBWT
M^88^[]AR7-W);33R7H<.\L2I#?F$H])26VRA'*/>=JJSX*&I6:3IEZZ#:>&-
ML;MZ_+7"3DV4O36K;#$QAK)(RW&$*:"5=W9`V),)_0\5J40:RN3P?3\YGXBG
M<=B<!M$`/S,JS*V0HH2R+E)R2%:&8EI94EGD;D2D*;MLAQYQM*G'-0[KH--:
MA+E$6G"VUQ4EB]_N,JM=O=*CVQN"M38%L=RK)6KY=+?)5:+6SD,4R9,9A;"9
MLY+!'.^VSWB0E8X,\WG=HK+MJU_+Z(["-64I>QNW-G<8;N.891`FO7!5MAQK
MSEUOA.3HL?S6&X2'T-,W&>A*B#RK"G-?-2=#4(R326+:&T]4S8'`8S3+3N99
ME;8LZ7%C6M4K(H4/OG7N=45AF/+#+<NXO<JN2.EWOG-."3I1Q5Q9'2LMAE5K
ML/).V<VNMDJVF[9CDT&<_)N,EBVW#-+=;9TM.C"0ZBVS&VGE)41_FRNI+E5M
MW'&N"73O]PVTV'U$].^%\H[N_P":%!',GEO_`#)Y5><-"88)'&MBY/;IC\_]
M`^+>3_-WP[_;^;#_`.?A\$J$^5QMTR[:]=?J)1O.S[Q\W?#OO@S7[?)^"5K\
M`_E]Q/QK^7WCYN^'??!FOV^3\$IX!_+[AXU_+[Q\W?#OO@S7[?)^"4\`_E]P
M\:_E]X^;OAWWP9K]OD_!*>`?R^X>-?R^\?-WP[[X,U^WR?@E/`/Y?</&OY?>
M/F[X=]\&:_;Y/P2G@'\ON'C7\OO'S=\.^^#-?M\GX)3P#^7W#QK^7WCYN^'?
M?!FOV^3\$IX!_+[AXU_+[Q\W?#OO@S7[?)^"4\`_E]P\:_E]X^;OAWWP9K]O
MD_!*>`?R^X>-?R^\?-WP[[X,U^WR?@E/`/Y?</&OY?>/F[X=]\&:_;Y/P2G@
M'\ON'C7\OO'S=\.^^#-?M\GX)3P#^7W#QK^7WCYN^'??!FOV^3\$IX!_+[AX
MU_+[Q\W?#OO@S7[?)^"4\`_E]P\:_E]X/3MAY'_T@S7[?I^"5">AI'Y?8;+6
MN^+XL/EUDOS=</\`O@S3[?I^"UI\%[?E[BQXZWU_+WF(.H':*UX/L?N_EF-Y
M7G5OOF.83<GX#B[VE2.^C,J7#7QB']J65:^P:>"1CQT.LO#HE:`Z6MHU\[I4
MJVW$D%UPC7[H+IP">;0"NC;E%>TX;A.K-JE@$E7+RE7$\HTU.NFITTU.@JY;
ME'W&,MP@$^R?=/EK?<G&-NH5N<MGU$>4>,^Z?+53C1^3)>'EO(@\"EQ*65IX
MMJ=[U#3Y\">\)Y`3[=.-`QX>6\F*4<J%+"FW%#5;??MJ0DZ_4*&I*2/'QK/&
MB3CIIO!5)=&OU1_?D4XT"7A9[OI&C7ZH_OR*<:`\+/=](T:_5']^13C0'A9[
MOI&C7ZH_OR*<:`\+/=](T:_5']^13C0'A9[OI&C7ZH_OR*<:`\+/=](T:_5'
M]^13C0'A9[OI&C7ZH_OR*<:`\+/=](T:_5']^13C0'A9[OI&C7ZH_OR*<:`\
M+/=])!+2D+7W[;Q0"Q+:<9;=<;7%25EYEQQ.J4K6-.(T(H[T:43VE.>GFIM4
MZ2BCD6ELI7JHM@N(!/FJYE:<>W4ITX>Q6>/`CP+FYDW)[)^N/EJ4;T7)+K'`
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M)>]`G);4M$CFC`-%M(U*17+;HJE\RQ;>H_J!LV);*.9UU6#!)65=-Z.H!>5Y
M/B>#IE;AYS='[4_;=LXUM5:_1H>.NBYF&?1D(NJW^12%:<U`:T1.JCJ?P61E
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M'>[3@V19;E>V4/'I60VM29$`2<BA"4Y"+Z"E887K5J$Y359US4J8-6^K7/\`
MJ.M.062T7G<2Z;KW/I[W4P_*;1(EX/AL=W-;AD,:6^BPW6!9[2S!C1\9;:<<
MCNQ$(6$\W>*-2!?&Z?4%N)D=\VLQP;PP>I[&L=Z@.EW<NRY=;[1C;+MKRB_P
M<[>DXF^QA,2+8K@S&>A)0VKD5-CAM7?G52:U2=/YL:\2-:`Q%DF^.Y>1;U[/
M[@WK>JP;R9U?<<9FW*P3,7PI]&V#TIZX"798\9NW?]7--(AMI8$T>F:I5S'L
MJO'5ZN*I%.GL&TV"MW5[U<XKM+LENC=-S4YX]U$;%;Q;A-VG[B;'$L>V%PV]
M,9$-^UR+3;6IDT1&Y(6\B<IQM7*-!IK6?&ZWK[`;T]$.]N7[B9]O/@E_WSA;
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M2Y\D:]=62`.FC?(:NGO=NLE*R5K)/I$9"7#J3KKHD:?J?!3-`QDN'P>B7\E?
M:+^++C_6"ZZ5SHPE3$L.\JO8;2J4=1IP[?V1JY;M.E*CBK<2ZULO0?":JR,M
M2H+-E3(\?'^@/)5*5EQCFS%G678Z2PKV7-5)T]IQGWZZI^L*%U/;E;6;0[F[
M:8'@^%0[:VU;,DVH&;R9LF9:8LY<HS',EM)8(7(TY0DZZ5XIS;S!+E=:6\].
MNGU'NGTX]*+?G[0^-EK7I>KAY_GS(Q^SU!>L-0RV/G$;(E6A*E?-Q2-=5$C4
M'/O`#I7C-GU!N7DWX9*CIW_Z#SRQ^WRTG."YH_AFU^2MM/\`IDXZA_6&_G$;
M(_\`=R3_`-O:W_Y[N?\`#_\`7_H,S]`K<<.9-_\`Z*_UQ\X;UAGYQ.R/_=R'
M_;VG^>[G_#_]?^@U_P#(1?\`J$O]RO\`7'SAO6'?G$;(_P#=Q3_V^K'^?9?W
M"_M_T%N/[?=,XIOFS3I_<_[8^<-ZP[\X?9'_`+N*?^W]8_S[+^X7]O\`V27_
M`+?-+_ZL_P#<_P"V/G#>L._.'V1_[N*?^W]/\^R_N%_;_P!D?^WS2_\`JS_W
M/^V/G#>L._.'V1_[N*?^W]/\^R_N%_;_`-D?^WS2_P#JS_W/^V/G#>L._.'V
M1_[N*?\`M_3_`#[+^X7]O_9'_M\TO_JS_P!S_M@=0WK#OSA]D?\`NY)_[?5G
M_/DWAIU_;_H(O]OEC^#FK?\`^C_MD?G"^L-_.(V1_P"[DG_M]3_/=S_A_P#K
M_P!!C_V^6_\`U1_[E?ZX^<+ZPW\XC9'_`+N2?^WU/\]W/^'_`.O_`$#_`-OE
MO_U1_P"Y7^N6K>^K;KRP"];;3[UO+LSD-AO6Z^'V#(K1:]BEX_<+K`OTQ3$E
M";O]VUP$8H0WPT9()-6N5><Y\RUKTCL9$GCFK\U#Q7S?Z(6_+7+?U1<P=YRJ
M\O"4<.O,SOK$>4_$B2%J<+LF(Q)>1S`1PZZVE:RPT$ZM))/9JJO8WA)*VKF?
M%5P/G2.H4M2]/EPE2IZ1Q'TJS:TTI+/FP):FZK,U;I7,2ZCQ5LRO>R&:.X:C
MQ4RO>QFCN&H\5,KWL9H[AJ/%3*][&:.X:CQ4RO>QFCN&H\5,KWL9H[AJ/%3*
M][&:.X:CQ4RO>QFCN&H\5,KWL9H[AJ/%3*][&:.X:CQ4RO>QFCN&H\5,KWL9
MH[AJ/%3*][&:.XF`&FM:+D[D9Y5M0E)*.9(:"MT8R>+HRD];1TR;?:0^E^C4
MW"G\1T+&2]'-@.&M2G:<552J:+=Z$Y4DDAP]OZ=56[RP3+2C9Z6B"]0G5/=C
M0ZJ+B^1(3]4=0"20.P>&L3\8U33VY7+NY,I:S6:316'J+THJ":6WK`/,A2TI
M*D#WB^Q+A]@G3A5FS&*BGK[G`EN>WZ#N<NL\EYOI'J.5ZR%Z['&,8O8^E59%
M'+WR&W4K2TIA4LR4IYV#'3JG5!!YE.=X@CET\%2G:5R->7S=Z5,%LV^\\;MZ
MK6:C7>#TFF=V-=LD\*8[.HBE).@4@H64<P3J@DDDE`&BOJD:'CH>-5-.]7.+
M\5!VKBE2C=:K>=K5V;>FFH1:DW&KZ*/<4@O57*.0%/[:A2BEU'BY4<IYN/L]
ME;\LMY4S1W$^H\5,KWL9H[B8?MO+W;A:4!R.I2""OPI()&FAI"%R3I5FV<81
MAF(J24.(26G7BM2$%F,&UR6^=82'EMN.--]PD'B0HJ_Q:W7-/<MJK;H^SV&B
M-VU*5-@84^$EYL(2`[)C]X>=(4$+6PH-!:6EJ=*=>S@GP$Z55R:B=Q68Q<JE
MMQL1MNY&2<ET4/E1<?L<*UNV.-:H:++*=G*FVOT1E,20W<RZ[<AW32&T"1.D
M.E;KB@HN`J"M2=:W>`UO1;=/=]I6XZ/C7?;_``B^1,=M]TP_&;E`Q%ONL:A7
M.PP)L:U,IX,L,(<:YDQXP`[M"2E*%)!'949<NUK3RP:D^G9]H6H2>U;#S73;
M+;Z]JG&\81B]R5=4P4W:3,L4)^?.%N;#4/GDN(4GFB-CD:44E2&]4ZD$UMCH
MM6G65IOWH<=;CW1\#PB',M]PBXACK$ZSO,.6B4W98+3MO3'9<C,+84PRUW<Q
MB.XIMMU'*4(40!H:GX34U7\C93J^T<>.X^C"QZS6N-<H-KM-N@6ZY3)DV1;F
M8$?T&1)N2E.7&9/C%'=S;A+6=5/+&IU.H).HQ+1ZEM?R:)8X;?G''6[:6GC^
MS^UF,6V_66Q[?XS;[-DZUOWVU,VF-Z%/D..I?<><0M*EGG?0%<BE*;21YJ4U
MKEH=9)UC;:5<-GVCCQW%Q2<+P^9/7=Y>+V63=WD,19$YVVQU*5`BMJ:CM-H4
MA01,9;64A\E2M"1X:P]!K:[(/YOM,<='S[/MOM]8(PAV7!<3M<1-UB7YN+"Q
M^!&89OD'OO1KFRAEM!;DLF0OD.OF\QT[36?`ZI;96WE7L,J^JE-K;+;MA,ON
ML%Q%+DZZF\S%_<Y;4F=<E$ER;.6TPV^_*/U)"TH3^IXFI2L-II02J3XL*XGQ
M<VVCQ7+L(NF$063B4:5C=VQFR7#'8D*+*P^/>FPBXSL72N,XS;I\KE3WAY5-
MK"1JBL+3TVY-M?FW#BPWF+>F;I=L/3C"RQ<?()F79'F5S3-NM^EVZ';.Z@1T
M(3`LT&'#2$LP(:PMP<ZEK4ZZL\VA`"[;EL5N&5D)78>TV@60A*E<BU<H)Y4I
MU4K3P`>,UF.GNRQ;3(\2&XF*1JXL%+<9IM"UNO\`,VH*4/>\@2OL]NM\=&Y8
MS?8.)#<B"N0'S%!:2`0H`@'4`\`0#X:J3@X7';S/894XOH(</%4XVI.GQ#-'
M<1.@\%;'IFDY.>Q*N!AS5'2-70</%^B*I\6Q_>KL*_&U/]P^T</%^B*<6Q_>
MKL'&U/\`</M(</%^C4H.%R66W.K-EN\]KU,.'!+8VZU>X</8\==&YR^Y"WGA
M)R>ZA6M\ST<KW#E**C7$<*XT5S.=W)&Q)QWU1WO_`,'&TKES605>ID0`>/@\
M=7UI[L52\W"YN-4K,;ECQ6A_G:5MI26Q.F.(T'BK1.L<'4T:.5B_/)?:MK?B
M-!XJ1S-5J6-7^DZ78]3%R>&QDNH\52RO>RIFCN&H\5,KWL9H[B8::]E.&Y[,
MS'$4-M")X?\`BK#T]%7,(ZA-TRFOG5H=.FG>W\7-^_@XK2X-.E2S&C=*%N]$
MOY*^T/\`%EP_E^ZU&.!2EBS:0]ON_LC5ZWB99"I7>XS3>[A&JUS\M^PN<X_P
M$?ZL3@CNQ^6_U!_K+!_5NV5ZI\V?Q'V?^W/_`,C7L/=QY$:?J:];Z+NS_K'N
M-7,E^Y%]-Q_2-0--2$^,DZ`#QD]@`\)J[0Z]BPKD<T\"!)#?>*2H!2@&4E)[
MR2DK""]%1IS2&$D\5IU`'&AF[&S:V?452@=\(Z5(<?43R,M+2MQU"4E:WFDI
MU[QEK312AP2K@:YLW<S.F%2OX*Y/XE@]I*D!:F$(^R.25*2PVCSEN\B5*6I"
M0-5(1RZ$C@#PJ.:Z/`7=_P`X(*4ME;;B"Z2$H6DI<'$)',@C5/,H@#7M)%,U
MWY,SX"[O^<F+;J5AE;+R)9*DB"M"DSBI'OT"*0'>9/:1IV4S73'@;F_YR/)H
MAYU2D(:CM!Y]U:TI;9;40$*<6>"`X3YNO;6,UT>`N;_G)%Z(3S$@^<E/*DA2
M_.]XHI''NU@<#V&K6G<FGF'`E8[W23:$\VG$H/*M(XJ2?&H=H`\=63!"@,(;
MX$=QM5QT`WQVQXG@/_2;XTU-=/RM_P"<2]J/`/5?_P#Y>/\`5E]!^CRW*3\7
M6X!05_U;#]Z>8?M"/"*^BVO_``T?ZI^>5MUYE/\`KOZ3W)4-/#V'P'V:QI_R
MI&W7O^?#VHEU'L^X?)6H#4>S[A\E`-1[/N'R4`U'L^X?)0#4>S[A\E`-1[/N
M'R4`U'L^X?)0#4>S[A\E`-1[/N'R4`U'L^X?)0#4>S[A\E`-1[/N'R4`U'L^
MX?)0$W-P\/N'R5=M6(SL9WC4V97*%%B1[==-2>WL/'V!PXFJ-V2C*BQ.?<T[
M3KTDZD]VH)<*&U*;+J0M83JA.FNFOAX]E(V;DHYMO:9M:EV:0?=*?,->P^/4
M`^2N;:U=VY++3IITG8O:"-M53W;ND#S@L_N:>96O#AQ\![>RNGGE"&"J<S@N
MM$WVDA^R)04!IQ*B%*#I\P-I.KBU>((%1T_,7;O+(EFIUE_2V>0Z6:U'FJY.
MWR=+:XQXCS_P++1[&\738:Y=0_5EL1TQX[*R#>7.+79UM-E=AQB,^EZ_7@I&
MH%OM$=9FRPI7`<J36_4V]/K:2U$G'?0X]_3/G'-8:+EJEH[<]D/#K)F_"Y4V
M5:I4_-GU:>NJWBW41>,7V!MR]F<1G-KY<BF%$G+9;:>9M,5]3O/$M4:0A(6#
M%2VXGGXGF%<#4^9^6>5_YEJ7$G'HE%M?,?57*/VL^?.9<G6NY_;_`$_1M1RW
M=/>M.Y)-+*Y+&LNDZF^J(ZUF^HW;B3M1N+>.\W=P",N4W<)T_P#US);&I)=;
MN[)DN>DSP)16VKF*E`(\6E9Y/YKM>;;5SF=N$+<8W,E(II;$G@]IZ>]0/3_G
MGIUS>WR7GB_FW+*N6WGC<<K;;BI2<=B;IM3VG8M+BG$M%Y+7I6BBXHME#BF>
M*6WD$@<[:B-.8<->%=D\%)Z`DF29*(MQ7%AFXRHT-;MHM;<EN*J?,2V5)94\
MX4I:*W.&I.E;](T[FW"NTUZR<HVMFXX*=6/79ZP+"<F&'XYTSR]K,<EW+T%[
M<=Y^WY`ME"9&@N<6Z2TRL:M:$QDZ_P"M)U!X]E>66=)I[\8SFZP74J,\0O:V
M_;N.*;[6;*]/>^G63.VV@2X&RBM_4+F2E2<^?WLVO6^[(>=<=,9QBR2&;?;D
MH!TY4H2H::&JVJT_*H2:U-R5J"6UP2S>XWZ37ZFY/(]L?:S-_P`MG6M^96U_
MQOP?X=5')Y9_X[6?V7]ATN-<'RV=:WYE;7_&_!_AU,GEG_CM9_9?V#C7!\MG
M6M^96U_QOP?X=3)Y9_X[6?V7]@XUP?+9UK?F5M?\;\'^'4R>6?\`CM9_9?V#
MC7!\MG6M^96U_P`;\'^'4R>6?^.UG]E_8.-<'RV=:WYE;7_&_!_AU,GEG_CM
M9_9?V#C7!\MG6M^96U_QOP?X=3)Y9_X[6?V7]@XUP?+9UK?F5M?3WOP?X?4H
M6_+[DE8UFJG>Z(RBU%O<]F!AWKE-F(^6WK7_`#*F/^-V#?#JM<&UU?,0XU_=
M\Y*-\>M(AU1Z,(:$L#5Y:]\<$2AOV%J,_0'V*C*W9CCOZC/%O_)A6^'6LE*5
M#HI:<[Q(7'2UO9@[BI2?"8J4SB7^0<5<NN@(UK"\'GR3DE*G5LIOW&R$KLJY
MJ]I.-ZNMI:21T4MM@#7O%;VX,A*5?J2HSM`Y_B]M0NJQ!I)[2>:>]F7=IMR>
MHC+[_,M^[73RWMACBHZ?1KRQN)C&4NK?2#P7"M<AYX`*\8JC.XHO8,TMYL>M
M2E'5:^=79S<H3J``$\``!YH%<IMN[)LZ-EUMIO$AV`$]G,E.O@U4=!K].K,.
M@V,L/<[<K$MH<(ONX6<3),'%\<CF5=)<&#(N<AII*BG[%"B)7(?45#0!()-7
M]/IY:R]'20[]UY5[9;$:KM^.FM2U$^Y"+D_8E4T)3ZW3HK6AQQ&3;DN-M!HJ
M6C:7-%)T>"2V4J$'10(4.RO(?^5'.?P_]>/V'B__`#&Y3NC_`&)%3^UPZ+/O
MGW'_`.$V:?`:?\J.=?A_Z\?L,?\`,;E.Z/\`8D2+];IT3M)4X]EFX;+:$K6I
MQ[:C,D(2E"2I1*E0@!HD5E>D'F"^GP4XN*;;5R*V=@_S_P`JU,HVDHMM_@D6
M^/7/=`10%IW'S-0+@:T&V.6%7,4%P>:(NNG**]=<V\O\[Y1J>!>NSV?_`'$_
MH9[C\N^6--S[2>)M6H_V4OI1-_;.=`7'_P!8^9ZG_P#QCENG\$J_H;=_36U<
MO3>S?*I+7>G&KO7.#:BZ?]%$/[9[H"&H.X^9H2GB5*VPRU*-`-3YQB:'0"J>
MJYC&]JWE?0MYHU7DGS-RGDWA[%I/3Q;=7-)[=N".AFTV[&$[W8'9-R=N[A*N
MN(Y"PB3:I\NWR;8^\RM(4DN0Y:$/LD@]BAK5BW'/%2>#/7NBT&OCJN'K*QWT
M=3(P'#4?^/\`1K5<DX2RO8>7:CR]RN_:4[EV:FMN"Q*=;CB"@)D]OTJG#$A<
MP]Y,>P_1X:E/`A#O&OG5K^33O;^+F_?P>J<\?<=&&);O1+^2OM#_`!9</Y?N
MM:HX%.6+-I#V^[^R-7K>)ED*E=[C--[N$:K7/RW["YSC_`1_JQ.".['Y;_4'
M^LL']6[97JGS9_$?9_[<_P#R->P]P]ZC]:/TS7K;1M*,Z_B/<"_Q<_Z[_P"T
M3`K2H%`25$A`*E\B4A?FE2U$*'*D*U(TXBKJ:Z#N1N.%FB-$^O/=GJ*V7VT&
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M9U;K/=F[[`1;(]HQ"U7>;!@).76^YW"'<'+TQ,GM-N(@)E\A*O%6/"=3)?YT
M7R2^TLK#O6!6&V1]RV=SK?(R&XV?>O=/"<"Q?;&PKG9!><+P:^+M\G)?1I4V
M,I2;<RIM4J4XXT1S<$$G2MCT.U)+:T:H>>,T6W14;6"Z/>9!G>L+V"M=[V^M
M-E:R7,&LKM<.ZLWC'XD.;8++;LD2AVU/Y2U,FQ+Y-<ELI4HHCPWO12@A6FM8
M\"TFVL'0E_GA.2BNE5K14^DN/;7KKV0W0WJD;&8[(R`7V/+R*QV.^78VH6*_
MW7$78S%YAV-Z//>GOL6UV8VDN/L,A?..3FXZ5K]AV4F\&=[D_/K?-<ZG)*4*
M46Q8^\W,#@"DAY(9GKCNIDH;(6A13RC4Z:\O-K5<[R^+N[2E2J,M...PU^ZB
M;S:<>L&W5_OUW@V*PVK>S;23=+E<G6HT.-'9N4A3K[\A]3;+++8&I6I02/":
MZ?E9_P#YF7M1X!ZK1D_*T71TRR^@[6P^N;H_1`@1W.I39EON($1LHD9MC+:T
MN!AL+!*;H3J/9KZ*JO#K;_"?GG"$_P!1F\KIG?1LQ/2.N;HZT/\`]I;9+@#_
M`/7O&^'_`/$_%4;$HJU+:C;KX3=^#2>.X?/EZ.?SE=DOZ=8W_.=:L\-Z[1DG
MN?8/GR]'/YRNR7].L;_G.F>&]=HR3W/L'SY>CG\Y79+^G6-_SG3/#>NT9)[G
MV#Y\O1S^<KLE_3K&_P"<Z9X;UVC)/<^P?/EZ.?SE=DOZ=8W_`#G3/#>NT9)[
MGV#Y\O1S^<KLE_3K&_YSIGAO7:,D]S[!\^7HY_.5V2_IUC?\YTSPWKM&2>Y]
M@^?+T<_G*[)?TZQO^<Z9X;UVC)/<^P?/EZ.?SE=DOZ=8W_.=,\-Z[1DGN?8/
MGR]'/YRNR7].L;_G.F>&]=HR3W/L'SY>CG\Y79+^G6-_SG3/#>NT9)[GV#Y\
MO1S^<KLE_3K&_P"<Z9X;UVC)/<^P?/EZ.?SE=DOZ=8W_`#G3/#>NT9)[GV$?
MGR]'/YRVR8'^_6-_I_&=;O$Y+&2+Z39;4ZY:.A>F`]4/3ANGD3&*;?;T[;9K
MD+K+LQ%FQ?*[)<KIZ-'Y0]*$6).>>+#)6.8\N@U%<JU>XEY+>RQ>LO(Y21C;
MKAZ@\MZ;=C9FY&'1+??+PQ?[%:6H]Q1HWW=Q,H$<Q&A'V*O8/)>6V-;<A8GF
MV[,:?:>&<QOJQF=5LV]AR#'K;NIE24G[B=M1JE)XNR0>(UX_8--17N70^D6E
M<5-K%)OX_P#9/6&N]3;J^'^%/\*_UBFOUM74L5H2,,VVYW/-6@.R=`CP*4>X
MX#MJ?,/2W3V++X2;?]9O_NFOEGJ).]=I-I*JQ27_`'C6+?;US/5N8<["+-9L
M(P29<V%-1LLLZ'WKI%000X+8IUI#;,MP'1#WGAL\>4UZ,\_\M?D+D]SG\[-Z
M<5-6Z1@YNLW1;*+9UUV'TAZ1\HTGJWYHL>3KMVVK=RW.Z_C4'2TJO:LSK[CC
M-E>6Y=GE]>R//LAN>491+DKE7*_7^X2+I>%J<5S$N17%&+W:?`XV6R!]1PKY
MFYKS'G7FZ5-%"=J,OQQE#Z*GZ:^GWD+TT]%-!<YAI)*YJDFY\:[:O;6J/(IJ
M+6&S<;H]+7JX^I+JL?A7'&<6?P[`S)3Z7N5E[3\2`J.5`K%I@R&T2[RX4'S4
MK;93V`*TXUU_+7IKK>(KW-+L90;P5Q_6CT_ZH?O`U49SY)Y$MP5WNR=_3QE#
M8]N5QN;L#]/W1IZL[9?H^DC++*]<\MW.GQ$1;QFLQST9MAL(U<@Q;9SK3#B2
MW%*2&PI8`5KKQTKVO8Y7HN41\'H4U;3JZT>WVJA\5<]YYSKS%S&?-.>SA/6W
M-OPURI;DFW1=2V'1X$NK5*7]D*TA@'L]"#1U^+TCAS('[9S#AJJMQQR:@//=
M;O;+1:IUXR"9`C6:T1G9LN[7!U,-BWQHZ"Z^\_()"&X\9M)4M:B$I2"2=*I6
M=1*%Q[JFR];C.W[C5V7UO]%<EIZ+=NH_8RY0U-N,2H,W-<7EPEA8*"PZ7ICI
MYU)/`A)&E=*7,G&/PMIHY2Y7&Y-53H_EN/CX_P!8/0SC,!5EQK?[8BT6UN2N
MY"#:\YQEN)'>?*@M:PF9%2HJ[P\`DZ:U0GSF_*ZN'3BTHJK8=!<GC:LNXL5U
M^[<?=^?'T=?G+[*_T[QK^<ZE^J\TWV>PT>$>Y]@^?'T=?G+[*_T[QK^<Z?JO
M--]GL'A'N?80^?'T<_G,;*?T[QK^<Z?JO--]GL'A);GV#Y\?1S^<QLI_3S&O
MYSI^J\TWV>P>#EN?8/GQ]'/YS&RG]/,:_G.GZKS3?9[!X.6Y]@^?'T<_G,;*
M?T\QK^<Z?JO--]GL'@Y;GV#Y\?1S^<QLI_3S&OYSI^J\TWV>P>#EN?8/GR='
M(X_.8V3^GG>-:?RG65S7F-?YCM9.FBV^XV6M"YW%%IT;W$WSYNCK\Y?9'^G>
M-?SI4_U2>\Z/Z1'Y/^@PGU">L6VBP7;&]Y-L+NGT];J;EPVN2V8'>MY;!B4.
M]PTA7,B+?VFKJJ+<5]B&E,*03IJY6B6OG.L9/X:U]_V&5RBWBZF@.TO_`+QE
MT;2,CMVVW4_;<@Z9MQTM1T7!C)9=CS#;B5*DNJ9+L/,\2NMU?EQ&%)YDJ7&8
M.BN(K,]?*4E+;F2IL,/EBM;8[4SN1M?O)M3OCC,7+-H]Q\0W2QV2AN2Q?\-N
MD:<PPRL!88=B,.N.L("3Q+H0L>*M\-=.6/T&IZ2*='2OM,DZCP#W:LQGGVO$
MCX2WO7;_`$$#X*T-4NR-3BH2<5@B!2'$I:/`..LZGQ`.`D^Q5B#V(B:A===F
MNE^Z4]VK/CD*7<KA\4%34.(R[(F2BF1S%J.RTA;CBU>#E!KO<BNPM<ZTMV;2
MA'40;PP4D<WF]N5WE.IM0[TK$TO?%GY9HN*[@)AL).`;CPS$B6YI^*G%KTKO
M'$M-`\?0/.T/;7UT_-7*:_F6NV'^L?+2\M<SIW+G9+[#U)Q7<`:Z[>;C#52E
M:?<O>3P4=1Q]`\1I_FKE/]Y:[8?:9_RUS/\`!<[)_8?#R?"]R+AC]X@0]M]Q
M'I<NWR6HZ5XO>4@.%I1&A]`X$]E<OG.M7/\`EMW2<HU&EM:J,'*MR<8IJF":
M>/4>3>4=3;\F\ZM\QYSI]5>TLVH4MVW-IMXM-))=9II$Z=]^U(B.*V=W`82R
M^`XK[GKUJZ3$6D$I]!UXDU^;7J-Y8\]ZKS#-:>]I7;4\5.;6WK2/V"]&_53T
MUTWEB,M99OQN95LE"TGAN<D5?F[[\_@?W`_H_>NS_P"0U!^E7GK5<NKXO1IR
MCAQIKZCR?5?N"]--)KVEI]0X1:PLVG_W@OIZWT[I\?(YN$ZL-+YD*Q^]=VD%
MLZ$?ZCQ/M5L\L\FYSY<TZY1S1QN:R$VW*#E*+3=5231J\X>MGD?FW()7.7VI
M*,EL4K=I2]Z4C]IOJW[#=\;Z/-IK5?K=-LEWCV6,F1:)\=Z+*CD,HU[YE]#;
MK:@>&A`KV[H/R?BQH?GYYI\Q6N<<SN+1P<8MO:XI+'J-Y./L>Q]'8-:IZQ99
M+IVK`\:GY4YEKZ7XWK:BFG1W&L-N!)H?$?<JP=142H-#XC[E#-41`.O94H['
MM(3VK9O)CV'Z/#4I-4Q1&&QFOG5K^33O;^+J_?P>JD\?<7X-5+=Z)?R5]H?X
MLN'\OW6M4<"I+%FTA[?=_9&KUO$RR%2N]QFF]W"-5KGY;]A<YQ_@(_U8G!'=
MC\M_J#_66#^K=LKU3YL_B/L_]N?_`)&O8>X>]1^MKU9:_B_K'N!*NKF]TW])
M.UQ4L?8M2T[R%]UIEL+[I7(2X]]C20O337M/"NC#%'>A)*S1XFDW63+QC<3;
M?(=B[E9]UQ+RA>'W-Z^8-M?D&;,0G<6OMHR%]CO;'"?03,3:E:>/FJ]:DH-2
M>U4/!/,&DGJ$XP=)?TFC&1;0[*YG8=^K#?K;U'-1MZLJP/-,1ECI_P`V=EV2
M[;>8^+.OT^W7.V/,S%S)#6GH;R%!3"E%">8`CI6M<H12>"1X+>\M7;N:44U*
M3K6CWGCQ7:G;>QO;87N;:=]6KE@\G,+K>WV^F6^XC:YKN6VFZVIGNX%@L-O0
MPN`F[?8DO`O.<H+A4KC4GKZ_)&+?EBY!-.+VMO!])@>\=).'WN+8;(U?]_9-
MMLEGMD9LW[IES>[S(+EHOUIO"/BUSXG7(LQNOQ=YSS10HZZ:\:PM?3Y(D_+,
MY*CBZ>R1F-_:##K;=;YN%AE\ZH<4W$G9GNA?(%]8Z:LQD62)9=U;JW.R3%)L
M6YV5]+Z@XVCNUD'0H'&CU]?DC$/+$XKNO:]S+<RSI=VAN+6UD"#)ZI++%V^L
M\2W7'((G3CF=KRBXF/W2ILJTY';[.Q<V)=P4@^E(+O<(!T:2D$BL>/ZR7^6K
MGX7V,S7T];/;+[0;Y?=AC]@WQN6/W>Y7.Y8_;LIZ:[]`F_&V5N,NSGW\R38V
MKQ%L%O<BI]"=1(2E"5J,DJ/+I3U^KC>M*VEMJ7>5\CU&DU#N2[KKT/W=AV9X
M(9BA?^K]RP651DR;=(>?<?`+;\E]I/I+O=@'4!7`]M<D]M<H@[<%FW%/7M]B
MA9USSQ:?=VFOG4GB]@S3&L!Q+*K9;;]C>4;L[?8_>\>NC"9T&X6V?<7VY0D1
MW0M'*I`T(TKK^5E7FTMU3UYZIZM6_*%NS+NY)?0=8X_JNO5[/P81E='VR@F*
MB15OAW`+3JL&.URN=[Z'JLN$:FOH"Y%<"+_T3\^H<SN/72MM_P`M3:6!4'JL
M_5XIUTZ/]CP#VC[@K3P__9*U6+:N0<,6S;K.8RA=BHNB;ZA_9:^KQ_,^V/\`
MZ`VGX+4OT[J?SC]0N;_H']EKZO'\S[8_^@-I^"T_3NI_./U"YO\`H']EKZO'
M\S[8_P#H#:?@M/T[J?SC]0N;_H']EKZO'\S[8_\`H#:?@M/T[J?SC]0N;_H'
M]EKZO'\S[8_^@-I^"T_3NI_./U"YO^@?V6OJ\?S/MC_Z`VGX+3].ZG\X_4+F
M_P"@?V6OJ\?S/MC_`.@-I^"T_3NI_./U"YO^@?V6OJ\?S/MC_P"@-I^"T_3N
MI_./U"YO^@?V6OJ\?S/MC_Z`VGX+3].ZG\X_4+F_Z!_9:^KQ_,^V/_H#:?@M
M/T[J?SC]0N;_`*!_9:^KQ_,^V/\`Z`VGX+3].ZG\X_4+F_Z!_9:^KQ_,^V/_
M`*`VGX+3].ZG\X_4+F_Z!_9:^KQ_,^V/_H#:?@M/T[J?SC]0N;_H(_V6OJ\2
M.7YG^Q_'_P#H*T_!*O6N7J.FS4VU>\T/FDXWU%O9[C)>T70OT?;#YG$S[:3I
MZVNVZRYF/(MJ,BQO&+19[EZ!,Y52829:HR=&I"F4E20=24BN;&SPKJDE1HZ<
MM4KEK+BVCY_6QL%E_4ML1<-N,*N%KLU[<R*TW9F3?6'Y<7DMJI!\T0BE(&CO
M@KSODG,HZ6_"Z\$J]!Z]YSRR6H<HTJFJ=)QZ3ZICJG2E*?NSVK/*`-?B^^<=
M!IK_`.<5[CCZP1C%1S8*G>@>N'Z6J3;IB]T_M*BO5)]4I94H9GM6DO'NWE?%
M]\'V-/O1^W^R:?\`.*/XGVP^PQ_RKCN79/[2Q,X]2UU*9S$CQ)6;[6PY493;
M;%P3`O(4W#4=)?*5/\VI1^HT7^I.M>*^=?45>9.0SY6I-YKD)8Q?==>A5/8'
MIEIY>DWFNWYRM)J=JS<M;-C_`)JR_P`=8]'V&_W27ZGK8/8)JT93N6TC=K<2
M"4.-N9"&6,6C/<"1;K)<4GXT`7V":EU)KTPU6JWH]J>8?5+6>;)-M3^)_P"@
M_H1UTA0X<*!'M\:)#M5IMP'H%NM;+4=H%(`0VAIA*6D)3H``D!(`T'"LX'BN
MCT[E<5VXJ+K/22I9+BFEM%P\W*M7,HZ`)!/BUT[*R=+5NVYKAX4(4*@H#Q7R
MQV?(+1<<8R.#"FX[?[1=<=R2TS(Z;E&NEHO$)]J>AUEQ+B2F1!DJ:(T\.E59
M6ZO:GB8-%T^JV]7@VQ'CM]'NRJ41VRVV[)P"T]_(9U)9<=/H@)46].VH\%/;
M0WQU-^*RI[%U$I]5OZO(C\D'8X__`-@VGX)3PZELH9\;?CM;V>Q$O]EMZO+\
MS_8_^@=I^"5+P2W&?U&>_P"@?V6WJ\OS/]C_`.@=I^"4\$MP_49[_H(CU6GJ
M\5?_`'/]C_IX%:?@@K#T=.@V6]?.2[R(_P!EEZO+\S_8[^@5I^"UCPG4;/&R
M_$A_99>KR_,_V._H%:?@M/"=0\;+\2']EEZO+\S_`&._H%:?@M/"=0\;+\2'
M]EEZO+\S_8[^@5I^"T\)U#QLOQ(@?59>KQT.O1_L=I_N%:?@M8EI$XM4,QUL
ME)-R5"G_`&6/J[_S/]D/Z!VKX+6CP2W%C]01A3J"]4KTRY5M3D./=.?3QTO8
M!NI+\RW9/FFVENN]ILT%8(,QJWLQ#*?GM:DI0=620-4UCP2KA](_4%2G1[C2
M'93_`-V5Z+[/D<;</J5G7;J0SB1'AR9=GMEFMFV&W,:<PZMYR/:,;P"+8)TN
M&V3H0]SE2=.?6MMK3.W&;5%)K$U:C7N5%:V+IZ3O-L[L9LST_P"-LX?LSMEA
M&V5D82W'1%P6V6BP35-(2E`CWF+&8:?N"5(&BW9'.^>WFUXU:RMM13^%4^\Y
MTIN<G.7>9E^MQ`4`H!0$W'Q#W!Y*QF6\EEEN''Q#W!Y*50RRW$02.W3W!Y*G
M!ILUW(NF!-S>R/<'DK95&G*]PYO9'N#R4V#*]Q`J/L>X/)6J;68S1[B';4*H
M48K*:KB*,CJ/'6^J%'N8U'CI5"CW,5JO-9/>9BFGM(54-AK[U9_DT[V_BYOW
M_P"0%`6[T2_DK[0_Q9</Y?NM1C@9EBS:0]ON_LC5ZWB99"I7>XS3>[A&JUS\
MM^PN<X_P$?ZL3@CNQ^6_U!_K+!_5NV5ZI\V?Q'V?^W/_`,C7L/:/>H_6_P#A
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MNJ5KI["E$"F:[O8\-I]R(!QQ*G%]XL*=)*SSD\VO:`-2$I]@:"I)S?>VD9:.
MU.C@EL)/JN8`<W*4:Z#7E/:/:J6!9MQX2H!P^@4Q,S_F&%M[R?1MJP3P5O?M
MF@Z?J57-_5.HX@&NOY6_\UE[4>K_`%=MR_RQ'9LRR^@_1Y;=3;[:I1)4;="!
M)))X,(`UX^(5]`W?\/'^K]1^=\(S_4IU_']9[B./^&L:)I--X(W:Z$N+!]&8
MEX>S[IKK<6&]&SA3WL</9]TTXL-Z'"GO8X>S[IIQ8;T.%/>QP]GW33BPWH<*
M>]CA[/NFG%AO0X4]['#V?=-.+#>API[V.'L^Z:<6&]#A3WL</9]TTXL-Z'"G
MO8X>S[IIQ8;T.%/>QP]GW33BPWH<*>]CA[/NFG%AO0X4]['#V?=-.+#>API[
MV.'L^Z:<6&]#A3WLC[7Z=9>JMJ&2IHG8F[F;:.PA7:4G4:@'0^`C77B-:H7$
MINJ+MN[PU\3V)$225<VI!T(U'#@K34:#0<=*A"Y<@J*HG*-QUDD2\OT<?+4/
M#^TV>*EN(D:H+9U*%=J=3H?T:>']H\3+<%`*"$KU4ELZH!)\TCLTK,;+@\R-
M&HTMOF]OP5Y+AMI[\.K81^J*^U1&A*M%'Z7-KI]*MA9TG*.6<N5/@V=0&H"4
M_J3JD</-\.H]NANU4[<H9=-NZ"F$I25%(T*SS*/'BK@->/L"LG.L0O0BU?KF
MKT[B-#>*`FU.FFO:GE/ZW773VM:V9$*D.4<REG4J7R\Q))UY$A*>WLT2-*SP
MT8J1!">)T(T.O-V:$:$^V/![-8:4%GW&)1<XY5BRWLAOUNQ#%LBRZ]*D?$&)
MVB[9!=G$ZF:Y"ML*1<'4M:<2E++)TT'94/$1ZC3X:9J=M7UIX1NE>,7M=VP+
M<;:1C<#'&LMVSR'<MJQV+%<VLBE,/"19+M`O-S<E&;%<[QE,MJ(KNS6/$+91
MKK'AI[C;)C-\&F2($>#F.(.NW63(7:VU9+9N:Z&(X43(%K0U.=7<9,!?FNI;
M!2@)/,I.E1EJ(THL7\W6;;>FEMKL+`PC??:#<BR7O(\8W%QE./V//\HVYO-R
MG7NV1&F,XQRZKML[&XC\B6T@R%2F5I80WWG>(22DD5B.HBDHMU=,3;X;K/OC
M<_#T7++(=]N#.(Q\;D6^(Y.O]UL4"(X_-0LH]">=NOV=D.)"5J>#"DE0Y0K7
MAEZB*6]F/#/>6IO?OS@_3]@UIW#SB0[(@W_);=AU@L]KE6L/9)D]S4M%JM=F
MF72X6^V*<F-(<='.^A#R6CRJ)`U+4VW5)JJ,^&>\]FX&^>W>V6VV:[GWN]1[
M[8]MK*U=<O@V";;G[Y!F//18_HLF`W-4(2FG90`8=4CO=#RJX5CQ%<&EM[4/
M#=;+-W,ZIMJ=KKKCF/7&X+R+(<@L4_(H5@Q>ZV6;>HL6"+>J3%R>WS;C`?L$
MET7)OT<.`I5RK\[A2.IC)TIL,/3M;:[3.3&38^N[BR1\CQR7D/<"[,XRY>K?
M\>-L2&D.O(N%LB2)4E%N801RN<OV,ZZC0U'-\<I5^%K#=UC).E.D]%GRK%[]
M/+.-Y%9;NN(XQ%N4>VWF!<[@VEM;G>QFS;W)2&IKJB4KC2"RMH)!X\U:EJI-
MR2CFIA[=S^T<&?2V?5[]R7'3WB(Z&5*4IM##CQ=92%J`CR%N-,+<>1RZE:1R
MG70=E;H35R+36TQDE'$J=ZLI"=1H$\OO4\VG9H5<O,?IFM@*=`*`=XAKF<4A
MQQ8;<2PVA`6VJ2M)2PJ0-01'0Z05GL">W05&3RJIDPAO=OCB^P]LM5TR6-?<
M@7D#\EJ);[#&MD5:'X4+TF7_`-87JY6RSP6&VT$LB1(:$AS1*2216&WPV^FA
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M-)V\D8>C(<ND/V)&*LSLOMT>7`BKE"['(DL]Y+2VI*+>M'>D`+*?.K"G<?Q-
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MUM\`Z$$@&W&[)Q3:HS'"ZCW6#JUZ=<LDJM5CW6L4V<]'GRUQ'(EXM$M#%K6V
M)$N(N9;D$I:[SSVDA25:CE4:9Y-[!P^H^>YUG=.;F0Y3:7\\9@-8Y:</NDB:
MNVW1FQRX>;(N2K!(@7=$-WD[\6IXNJ*.1OE`41J*Q*4G&BQ-=R&6-:'H^=[L
M(]-QVV6O.X>1W#)<SQ'#;<Y;K=>&4/W#+ES&[`KT9%O=BLVB:J$Z%S5/!*N3
MLK5\6;;W33LIUGV>K0$=-6]P.FHVZOXX=G[2.SV/%4S!;G1+^2OM#_%EP_E^
MZU&.!F6+-I#V^[^R-7K>)ED*L1MQNO))T1IO=PC_`.&JVHM9(-1PH6Y/]1LJ
MS<^&-%AU>TXO=073QU0Q^IW<W=';/9:)NAB6<Q+0+9(8W*Q+$WFYL6VPX#[;
MR;YJ`V@L'7AKK7KWGG*7K:U;5=U#WEZ?>HVN\D:-:/16;-V&^>:O_5:+#.TG
M6XE1;/25'<+:6PH1]_-LG^[6I`4IMQ2"4A8)KQ6SY)BZN,IO;O7V'LO1>MEJ
MRIOFD+5N].3:48S:IV[R/R2];>GY(Q_X[;:U9CY-E%UK/YBS_P`[N35K5?V)
M_:0^23K;_-%)_P#][;:UM_RE<WR[4;H^NO*(1RK*_;"?VD?DFZW!_P#=$/\`
MQVVTJ$/)[G*E9=J^PJOUJNSDW:M67;;V.D\.CI)5;4=;HY>7I#*M3HK_`-?&
MV0(\TD$(]\KB/!6R?DQQBW67:C;#UCO257:L]D_M-9]SMUNHG:7?/8SI[RSI
M.N;6X/4"Y=&<$CM;R[>^A/N6<*,TR)2DEM#:.7377MKG+RQ<XZM.M&^HW/UC
MA:CQ=1"TK2Q:4]B]E39OY)NMS\T7_P!NVVM7?\GRWR[5]AK_`.>7)MZ_L3^T
MA\DW6W^:+_[=MM:?Y/EOEVK[!_SQY-O7]B?VCY)NMO\`-%_]NVVM8?DV3Z9+
ML-MOUVY1;K3*Z[X3^TA\DG6W^:*?^.VVM8_R9+?/YC$O7;E$L<B_Z$_M'R2]
M;?YHI_X[;:T_R9+?/YB*]<^3K#+_`&)_:6S?NF?K1W#O&W%JN_3E!P:U6/=/
M!\HR"]S]X<%OAM^/6R<Z]Z?$M5J*9MT=>`5]A:U<'+Q[170Y5Y6L\OU7'4YN
MZ\4Z4/"?.?JQJ_,F@>@A9L+0JN6:4E)I]+39W\@QU1XL%MY>C<>,TU*2&G-8
MJ8[*$*2X_P#M)D$@GD'$`BO9-N7&BK<]B2Z#YGOV5:U3O6]M74KL:N%*5(4Z
MX70'6HY!5&;UXI=YM0MXH((`[==!5Z&EM6H2VOYA<A._2;265U#:'G&4J2R2
M_P!Z2ID*!*T-J)7"CD?MUR4T`0D<`5#455F[<8MYG5(E_-_"B*P0T@H2'''N
M<M]VZVXEM/O4E]*?/1R.>:OLT(-348-5S2,5N_A1,A(<6VV@Z]^XW':<TU0'
MUD)YG1P*(Y<.G-V#M-8EPXQ<G*5$@G=;IE1*A2%B&I![Y$UR9&26EI*H\F"'
M"^'VR.;NREO5!'O]0!QJ*E:;IFE6E>TS_-_"B52T]T^M"2I2&!(;0XI+"B@.
M=TM*DN#4J)!4"."4]M2I!.CE+:8K=_#$%25!*DI*0I"%:*4E1!4D*(YD`)4`
M3VBF1=#=#.9K9)*HUIDZV,_4AK3)UL9^I#6F3K8S]2&M,G6QGZD`I/,E*@?/
M)`4"`$D)*AS:^`Z:#V365!=+9F,DW1HJ<O*TIYX*C\J$_8G4GO5NNZ*::;2.
MU7)KS>(BLY(?BD;*(I-$.I(0MM9<6Z(SNBD(>=CJ"9%M2TO[*NX-E7'3S4Z'
M45JDXJ5,SIT[<-QFD2J4GO6T*Y8B'W.[8>E*!86I?%D)<1HE:%`'58\W72M-
MR*;S5>!JG*CRI(I*)2RM2VU,J$B1&#RUH4RER*I(?[Q*='.5HK`YNQ6O"ML+
MN792K15E!2]A5"%*"EMMOJ;"6R5K:4@-K=YN[8<YA^VJY3V<!4G?;V42(\+K
M9(E#JEM\C2Y#<E+##"65)[U$Y17WR'0K4%`3RZ)'G#PUAWY)5>Q%Q68LD:49
M"(RF4*/?MO%:PZAQ$9Y)Y6F70CSB>9)YM*<:0X4#T?ZN>5UIY3C+R`J-J.[<
M4M)*5MNA8T07E#1L]FHXU.$W.65X&';<=MO9(D*2"$`ZJ3%:D.KY%);[YUUQ
MM,!"C_GR$#17O=35A0ATUQZMJWE"]H+MYU=R:]Y%:5(9[X,2%!#S'?K'+R-Q
MWE]WKKI^V-J!YO!I3)#-2OPTV>TM:2S<TCS+X_ZVT+;*'9*5)6I+'<+3RI*2
MIE]SD!"B"EUWP\J>.E0FHQDE%XEG4WI7YJ4HQBTL%@4N9LJ=0A0=4PYW+Q0=
M"PZ0'`A]E0[QK5M0TU[342N0H".M3SL4&M9SL4!Y2%!2>;5)2!Q/G*&B.`X^
M^(J%S^9!P>Q,S%Y74L#=ZU7?(-K]SL?LT0W2_73;'-+/;8"2D(>ND_%KE#AL
MK0??<RW1IX=:JO3P2JY.AMXSW(Y,M]!MZC]'>(.9#>\[W'WCM&S>`X]$QJ^S
MDL6?!EJ?L`O5IL,>VICN-.Q64.-I=7J\E`*0K0D4\-'\3'&>Y%C;A]*^X]IR
MK*<)P_9F\7:YYY:]CFMC<ZM"V85JV<CXE'M(W5,N2PE'Q,]DPCOB4^V6W9[K
MGV92UJUK3*PK>R+;-]JXY5V(P=DG27U`V>_W"'8,!O5AP*-N9U12)EFQK%<=
MN\:[W+<7<*->=GLGBVJY6R9&CW+'\;9?:7/0@2H"G>+@U.L5;;V]!MKU(R%M
M;T;[YG<JT#>;%+YEF)XYM(W%O\C*[JS>8%RS:)C,R#:$W68.:S9=<A,?YN^2
ME>CJ0??:&L\-X5,9GN1L]GO35GN>]`W2SLQDF%.Y9N#A2]N'LKM>7-_'"F)]
MML%_CF8?C@27$7:RS)#7V8GO&2?-*=:QPFFV9S=2--KCTM=1&0[-WW`+#M9D
MF.9=B_39F>V.[<^]7%2F=[=X+U><9?Q#+6E+5_U_)L,6V2RTM_O5I#IT(K/#
MK@]AC-U(MK=WH[WRR.`JQ8OL/?YN[>*81N?%RS>%ZZ1N^S.5E<G"EVR2_='=
M9EV,ENSO]Q%4M0LP0H<J.^XQX>2>=R>VBH8G)Y'L6PSW>>DW>.VM;C9O9+)>
M,/W"N75'G%W?W'7<IK%RM>T]RL>+LLRUS5/>EC#EN0GTIBM*3&1HHA(U-;,L
MBJ[[?0L"[N@*X09?5+DEKQ3`9F-VNS[$8,,MNL*[MHL.4WV3=LG;EY'W+"PU
M+ESRR"F\N\S\XCD"SW6@9:8$>-+<CMHXXI3RTOJ'>E*7H;90Z'4VE?FQ5K*C
MR:*>2O0`:^$]M;K&,J=!B4W+%$*L$!0"@(*;64EYIE]];12A2&VW5L&/(/<R
MDRRT0I#*V21Q.A\-1EE=(RIM!@/?W8FT[[8E!QJXY/*L=JM4^<VON;7C62QK
MQ%GP3'-NNMHRV!=+5,:B*<*F''&E.1E`+;*5)!$;EM2@XU:742BZ23-4]R_5
MG;>YG)E37=Y-T\9L+5QPF]SXEI5CUQM"AB%NM$2(EJ8Y"=?C#O+8E3JPL*B-
M:]T4(0D"E&$)JL6Z%WBR70B3(_5X;>9!:L23GN]N=WQ[#+P]>L7O-R1AL)TV
M&[7%R1$QYAVT6Z*U,A2;G*3R/.<\QY1"E.$DDYX4=['&EN1]FZ>KFPV=E=SR
M=O=_<E-AN3*$S<)3&Q5S'862.V@V!.2)E2K<Y<XMY@6IU3('>@%`)(K,8)/8
M]IKN7I)+8>5CH2VSQ&-;4+WMR>SN6>T06,EN]WA8+'&98Y8,HM]WMD/)&7K4
M(C-OB7.WQT-2HZ6Y3A2D*</,K633JJ8=)IX\MR-BLCZ7]K<]N6[67!"7;QO9
M]P<NXY;;;=:&KK91AUKB?$[MANBXRI3#$MV"TZIQY:F3[U`"3I6(ITV[QQY;
MD8UPWHCPO$;[9,HF[DYODMVL&69%G#D^XQK!(DSKSD:)\>9;9#=GA,<T=E-S
M6&RUIS%(4K4`UN\-"=OB;7<W;/I,J_+J+`'JWMKV[QF%^D9MF<FS9(_!NJL8
M5%Q69`M5V@W6)<O3(UQ-O5<D79;L<MN-.NJ91SJ"4@@5FWI;%R-5)YMJ?M0=
MZ:Z$6EF?1%-&\%L?M6<R[=@N9;MQMX;Y#N'W.F\+O:+5>(\;&W4W&*Y=DS6D
M71;MMD,*3&$9EQ#P4I2:BM-9:JFZQQPQ'&ETI&><2Z0-O-NH-OB/9]>7>^MF
MY,=5TNB+%;49$YNC>+/>[Q-FPX,:/&5,3*L[:8C2$A"$K4%)-25I-53=1QI'
MP+]T%8'DLY5V8S#-+'=CCMZLL"=;H6-OS+&]>E1C\:L/+@+B,S;6W'(0TZDL
M.!PD).E8X3P=:4'&D8IS#U:6WV91WL?/4!NG`59-J\?VVF-6E6(,R;C9K'Z0
ME.67"W&W=Q(F77T@\A*.Z5RGN0GSJUN5O^%MO9\^!&<Y2C1I4,P87TM[.VB\
M8]CN'[IW>XY#M&G91FX6Z`BR&9.A[4.9$[:XF20Q&*;7&OQO;@F/+`)[M/=E
M.AJ,<RQ6Q[7MPZC49GZM#KTU;WGLUVZOYT'$#5G70$<"!6PP6YT2_DK[0_Q9
M</Y?NM1C@9EBS:0]ON_LC5ZWB98%;LV3XC,4FZ/`<12F?8^D.MMU1,7%_8PR
MD1T,$]VV3Z0G57%QSS@CD4HJ)TXTCH825)]XQ+6W(85)5DG0)UX#BMT!Q2R3
MJ3]1R@$]G&L2C8T;R-8[=Y.&GM<S_FZB34H[%\67K)=%?JD?O0_Z=8\3I]WS
M(E^BZ/\`O'_O!HK]4C]Z'_3IXG3[OF0_1='_`'C_`-X.579JC37]R_\`A5JL
MZC3<1T6WW',<]7;N.W;=;<718X(@6AS!P]V2!RA7<^<G4Z\#SZ#LK?=U.GRX
M?06;=[7=+V/VG#'KX<?/K9O50=\X7>[F;CLQ>8CE0ROO%OE:.7BKO$CEX]E<
M:.HTWC(MK^+J+-=1J?\`P]^5+,MCVM;/:=T"%:GSD=I_S0\?Z^NOXG3[OF1G
M]%T?]X_]X0T5^J1^]#_IT\3I]WS(?HNC_O'_`+P:*_5(_>A_TZ>)T^[YD/T7
M1_WC_P!X-%?JD?O0_P"G3Q.GW?,A^BZ/^\?^\&BOU2/WH?\`3IXG3[OF0_1=
M'_>/_>%H;C7:Z8U@N37BR385MR.VV&Y72RS[K'D3[?;9"6=6YKUIBM/.7"*X
MH><RA7.>7B$Z<:CM6;\YRM;);*O#9U=9AZSPW_A8.MN&Q=/SUVG'R'U=[W;;
M9)B%EFW6XY3:[A9,ZDW.WWB5\>6F\93Z'&=Q:!C>:I988<#\PK`C3T0_100'
M%`$$Z;GP-J/0;[:XBS2/-BWK!-Z\PV^R#<I[![?'5?,'^._DYM_QHUF]EN;U
MPNEGC2H%J5;T/.6O'G+;Z5(=5RE27-4!0T)I/4334-IT(1A&TUU'KQ;KHWJL
MFW.VTTVJ)E6X&6(EW69:;RIRPS,OM5B?<E7IW'&92`FWWN!;`$M-D][+<2$H
M25<*V9I%?)`N9[KXWER+&F7?DSM.U]SG[D*Q1J_3Y#\J'D%ED0;<ZQ:[6JV,
M3F_NA](EK2L++;86?.6#J`4I^X98&;L]ZJM\+%D]ZM&-[;XM?;'CDB]V1V;<
MKG=+9<5.XKMW;L\NK3C<>UR6'$W%F:6$K2X3SGAJ1I3-(9(&&K_U^[IW.P81
M=+)CEDQE;^W!W'SVV>AW1Q26&<GN-E:QI,DP$O6N6(4!#S8?0V^]S@I04J23
MAU;3Z4,D#R6OUB.^>5P\W>M&SMAA*Q&UX<Y>;K=I,YRXR9N89!`LUDN%OB1X
M+D:1\66Z>PXN*TXM;G(2YR$J`A%R@\KPKL,Y(,Z4;!95D^:;5X[D68RX$W(Y
MC]X:N,JVMJ9B.KAW67%;*&%I2J.L-M`+;(\Q6H\%=.RV[:;Q*%Y)7&E@9CK:
M:A0"@($D<Q4DI2-.51TT</A"!KS$I/;PH#3_`*P[MNE!M6S=BVGE95%OF9[L
MPL>N"\4O`L;QMCF-WV:V+M-5&DI%G;N$5E;Z"$\R4Z:Z\*KZEM036-39;Q-6
M,>ZVM\;;F[6S\S:ZPY-GMLLDE@9C(NMQAV*Y99BMTM^/Y%($XVU=P$%]R>MY
MEUR*V@!'*R7DJYQ1SSVO:;:F+'>O_?O;IS?F-EN$1MPK]A^Z1LEF;M(>B<F'
M,7MJTF3;%R6&(ZVX*):2ZMM2I\H#F$?0**2G-[15EVXSUJ;TV/?[=W;F\8ZG
M*,?O&X#6![23I\>3%L2<YN#BGL;PQ<PLJ1$M5_MK$MWTCB$*B@?558@VXJN-
M31<[QL'U!=8.7[5Y[GN`8UMU:<BR2Q8+B>2VN#<)MSB0YEQR$N(=85<&+;)8
M]"@N-D]Z@K4H>^":F:S72-UK]0S>]^YEIO&,6`6;;BP6FRS4W.9>(6(2;O;T
MJ5D#S$R/:9#TBZ7(2FDVUIMM:4%MS11U.F,N[>#X&:=>>]>/73<HV_#52X>%
M[UXZU:\9[JXMY7EN,W4`KQJQ1&HCO,NPJ05R99(24/HU`K);+VM/75O)F=TV
MWMRMO;?MD_(ZA,"P/)9ES===D9CC]^GMMRW<29M35P@7&=`:7I*#;Q9:U3S+
MU)`&3(F0]5^YFV^ZN=VG)(,2_8Y?]ZMP=N\12(\UH?$V%XWCEXM325)BEMB5
M+F7MU(7KR*(T"B0:A<GDCFZ2=M)RHRP-NNJO?65TK99O)D;-UNV36?J+M&*,
M8XW:GD.R<*9N4)3EEAM<H>=?6P^H!XI"./;PK3XB18RQ*>#>L$WUS7+LBM<O
M8:WVG%\5R3"&KM_US*>7<H.8WX680+:]%AOQ)4Z$TCO'P'`VUS:%6H(&'J)T
M=.]T#+$QWN;UU]3%[S?;/&,!@8+CC=QWL:Q:^Q+;/N5Y9=LCLF)%ML._23;&
ME69T.*T=4@.J2.(2>&MRQ<<K3G+%%+4I*:IA0ZQ[&YYD.Y>V&+Y=EM@M]AR"
M9<,DA7.#;7GG&F95IOMSLK<PR'669-P8GMPD]V7&F].85N2=5)-T>UU-!F$`
M*">504I;JV@V-0OF;05JU"@``--/;J9@E[.!X'PCQ4`H"(`/`K4WP)"TCF(4
MGBC@2.!4!K[%`"4N*=?<;*)7?,.-R&7%))"(Y9<"QIP"B>SPBG3U`<[J22VY
MRIY02V$CE>6"#R.\/VL']*@(A2D(<98=DLQI#@5+CMR"D/MO`N2V`X$%3;:W
MP--/!6NY:5RC_B6!.,U#$F4LK:7';[^%'*4AMJ/(4I2$-GE0SWBD!13R$A2N
MU0J,;3RK-WJ;27%AO#:RV^74!:.Z:$>("X7&XS;@/?J:84GD0R5`<K)UT_5<
M*BK,G&DM_P`WVF>-#>2*">Y2V0X^6^=;16ZI"DN$C7SP%*(?[5'M!`TK9PD8
MXL2N7E%;+J2YYJF0XP\LOH2SRJ#Z6G"$J#J3IRK(UTIPD.+$\I2X$!I#BN0%
MQ''7E*&B/0'%H&G>*8"E@I)T5S<3PJ,K-6I+%!W8M9:XDCS33P=;4RIR(-&8
MT"8^J8QW!24OIE%:$=_%D!7%@CE&GOJC;LS<*7N_U&MY:UC@8XV[V2VAVC1>
MF=K\"QO!59)+=N]YG62VK2[*O/,76US&7I+AF0''5J)8YVVT?4CB:G*S5453
M&PR:5'E;0`>5"`%*<5WKSCO'G<+I"2EM7U+>FB/'4H0<*UWC80J8%`*`D6AI
MP*2L(*RAP,I<)Y"OD/%2.9(<"1QT)]JE`:(=:3>Y]SR[IPL.W4'/&XUXRW/H
MUTN&!W`V-FSRH^WTAW%[Q?E*0N-\5P\F"''4K6'%MI/*E1(!@Z97&O1[S*Q1
MK!E?3'UG7#:LV!_<3.+[G6X&.7*#>GF\O4Q8;+DZ[]+B7)UV*F,EVWX[D>!I
M$;E0%K=E/%1"`K45ULV%DLC+^F;K9N3>2V?`\PRZRXW:+#A5LPC'I4YAJ!:(
MU@QVU6J[V=B8X^NY/27,NBNW!M*65->CD:NA?FUC,LV7I'6;9V_9+J!M^R6]
M6()SG+?NVR+Y,+GAEQGWQ\R(<ZSV"QC-F8[`BJ$>/<LACR4IT6KF2X"=-2*S
M6IJNX&HN6=)76#G6W6[T7/+]E&47?*-N8EFQ.%%R5$%Z)>&\XLTYNW,I*4*4
MB-;&%O.:<3W9'&AH-G+;L+U'X9TV;M8#@N97RSY,]9-J(^WMP<N(NMWLEQM=
MEM8W+MD,R7&"\C()3$H(9)2C[(!SBL;,U.FAFFRO0::WW:SKHP&Y2KYE-]W6
MR[`;\W98.-8;B^4HL^5VRYS)<-UA^W0&VY,'&7+39TO1I.DF0'5+/CUHVTZ(
MP9=OG3GU\7?,[\&=T<HM>(W,XV[AN/1IC,-6/X4TXQ]T6,W?(FWGI$/*IY*5
MO!$=]$Q3:EEQL@`QJUM,GV;_`-._5JK,=OHS-\RN\1['OA>\KP:YO7Q";98-
MOK-9L@MD>V9M'42<DG-R;C&5;F%+:;;0A1*R0`7$I7JQ,T99N-]/?6:'-OIF
MXV3Y]E]J?RZ-<+B[<[C'ABS/VZ2476?>X4-Z6;O:+HIX&-Q:(2-2D5=4HMT6
M*!D)_">IS.,MWED81.W+L<*QY[N%C,6<]DR8L*^XVQ<;;\4XKA%L6WWULNWH
M[3@C7-P=W'3S`<W/J(RG&+4?XG@9ITF/+EM)U:X[O5;YQS#)FK1O,]8=M+;B
MXFRY5ZQ'!WF):;I?;[<Q&$&5DV$.=V$OJ6T'A*44!6ATQ-?"89L_M1MKN]BN
MZNTN(3=N';19=J++D<7*]]XLYMQ[.+C<5PR_$?BEWO;BQ?DQP);SI*FBVGD3
MQ-:2)LYU9Z?-IWNT[/DZOY]UD?H4!;O1+^2OM#_%EP_E^ZU&.!F6+-I#V^[^
MR-7K>)ED*VM)K;@$VG5$?;J,I)1^'$V*DE\>)'AXJU/47D]E2:LVGMJ@=/!3
M(M5\5YT:V;35>Y9'4-3A>MPV8,A]/]#_``4\%9WHT?HC_P")M=@^G^A_@IX*
MSO0_1'_Q-KL'AU\%1MZ&TI=Z*VDHY[,LC3:CLKT/HK[P?>GL]\GW*W7='ILG
MYD*TWEJW?3>&TX7=?`(];+ZI[C_^?[D_Z7V*X\=#:\5%YHTJ6+UN6IL.UW%)
M=YX+K9W2/:>/A/@]GVJZG@K.]'+_`$1_\3:["'T_T/\`!3P5G>A^B/\`XFUV
M#Z?Z'^"G@K.]#]$?_$VNP?3_`$/\%/!6=Z'Z(_\`B;78/I_H?X*>"L[T/T1_
M\3:["V<QRFQX'B>39WE;BXV+6&R3Y%V9#1F#N(J`79C*`%2P\^E>A;:4D'0#
M2M#F[3=NM4G14W&F&DE:O.'>4?XE@^M&GD7J>Z2)*%XO&QR2E,>=(BW3&AM2
MXJ5'NMS98<:@OX^Y"4EB^Y6DAN.IQ!<E%O3CI6JXTUO;.["D8X]!;T/K/Z1[
M7E<]4K$7L?F^CN6JSY"G"Y#$C)[(XDL7!Q-X=9+S-ALJ01+4%=U'T5J`!6N-
MF&9-TK4YUR_?5S9&66OS%X;4=0?2]OSD.&V6RXK`GY3Z1DR,:D7#`H]TQN)-
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M18[3+*`Z^HO2'5H80ALO/O+4MQ6FJEDD\36U14=BP(.69YCT4,"@%`2\R$=X
MZEE+LEE(+:%N'BD]JPWX0@GC0&%]YMZMO-E3CKV<N9%*N-ZF,/65NPXT[D9C
MR%`\SZXS##SC,1+!4EQU.A2%::\:A..=4JE[39;[W48<@]5/2S<DKRW'[6Y=
M;[>,BO\`C\%I.&/IOMQO=F8F7"1:$%U@W9<!*+>OT<*66DE(Y0!6M6(Y$LRX
ME,>LW/&O06=;.L?I+OK&)R[IA<F)?<UM$;<*/B<W;QRY9+=+F_&<DK?:!C+A
MKOUG;4OTIP-]Z%'S2-33AQP35:>X'IA[Z].&=WF1GCF&Y$&-K;3A.9X[DS^)
M7.V0[H]N##N$NUS[=B(0VSDM]BMVY:&WGFW7XW.H,E`6H'5."XGPOX33<3KL
MVEQS.K#IGNEQE*7;[O?LH1:;!"N;#.WETEWK&)EU$ERV8UDMMF,O2[?.?;C.
MJC6]6CSR6UG0\G",6W6BI273T]9!PEUEF0.N'I0R>7<H#T!V#'N&;WS%(MPG
MX.%VJ[2\31'4J]"Y*BE#<%Y<O1N:X2B&0>8\:S*3BU1550H-E_;1]2W3OO7=
M+0_C^/*.0J:OBU7=W"U./3$XDAM63L67)VXX:O=PMT:2R9'HR@MQ#B0K705A
MT@G)5;QH;U);T8^OO6/TBV?';/<L.Q^QY(Y8<REXU9K;9\?2P,3N:'F_3[Q9
M(1;,N+(4XX"GT+NW7W$D:DBI;)*CP8S1WEV[+]5^Q_43=\@B2\%N6,7+%,MR
M&-$5N)B'Q/;[FJQVRW3;M?+1+D1VN_EL1WT*D!14^RCE4LZ*%&DU1X#/3;':
M^HH6WKEZ1DNPK%'OZ[.N[9!*C6N),PU#";Q?(3@:$NS6Q<4(N<#O$@"6E)'#
MMX5#AP,<6:QBRA'ZP^D.P2[9:&6E8].O%VCP6+!*VXFV"X]V)RE(RIF`IAN,
MG"7IZW`F\.(,4/H=`/,A5:U#-+<D^TSQ9T[K,6X5O?T-[3X;FV3;88;?)TZX
MW'(MSHUIN.+WR]Y-F,VUNR&[WEED<NZI<A..PG+<X/C2-RPHP:*AIR&KME*,
M:+"IJG)R=6J,R7*]8+TY6/&KH_8WKM<[[8L%?S^!B=ALKBI5[:$!R\RQ9'&6
MRB^"SN\ZYB&M2T$*>5P-;6GT$#<W#\BCY;C.)Y9#[Y4/*L<MF0L19+9C38RK
MU:6;NIEYI02M#C+<K0CM&E9!<8[!IV:#3P_HT`H!0"@%`3@\/IU.#2-<TV]A
M'4>,5.J(97N8U'C%*H97N8U'C%*H97N8U'C%*H97N8U'C%*K>$G7`EK-5O-P
MI5;P0-0FTZ4,HA6L"@%`04=4+:24AUY"VFRIM#A!6.4J0%)*DK2#J%#3E/&@
M-7.IS>C+MEX6'/X?;\4D)O$R^(N5PS,WR3:VWK-8%W&';S%@2VE/7G(Y;284
M%U/F"0X@$'32M>19G/\`BI3W$D\%T5->'^K;>>#T\VK>#)(6UVV=WW*S&/9+
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MA0`6"A*T@A7CUK+L6NAKM!(A*-`?1W3+E!V3WC4UUF.TUJGOX+C3JR@<A4"T
M-/.Y:T-5?L^DR2:.+Y%LI?44R$AM*51(,JX6Q'[<;G-+:5H>)Y24ZAQSP'@:
MBOAI!+HQZ#/65P6V%29:='WUK#RE.>DO%QMG004--O+5W+D0+5IRZ%6O'7A4
M7";DWC'91;MYB35.L.I+3J0-"PP^VXQ(2XZXA0>U+G>0N8A021Q)'#6HY)+H
M9%;<#7WJT_)IWN)\.W5_]C_,`]G@!J-&24)/!,MWHE_)7VA_BRX?R_=:C'`Q
M+%FTA[?=_9&KUO$RR!K9/NF"6M)D4`H!0"@*GU)^CQ5'I+,^XO82'WA_7)JM
M<[WO*L>][SACU]?WLOJG_P",-RO])6BU^>O;]1VKG^!E[#N<>T^V?TZZ1QB%
M`*`4`H#%F]NW#VZ^T.X^VS5U=L*]Q\9F8FQ<8'_G<%QY(YIZ9?%Z"XH+[4-K
MTTJK.#=RJ6S:6X32@C!V*=$>S]@C7^6_>\PF7S+)>(3;]EDO(9$^8S?,*0KX
MBOEDGN0F9ENN4:0\LH6EI?'3@=*QE>6N7W&<Z+?E>KRV"N*L3N(D;A-/85#G
MP;:VK.I$"/R7A]UR[3'4BUR'9*+Z'.26E:$I<0D`\M24)53I3:8E-96J=!D/
M:GI(V;V1=LS^%1,E4UC>1Y=DUBB76\.7)<.^999H5KO4B2E4>-I;7HD1L,^#
MF!K>I)NA4-H=%#0+"`K1)(;2$H!4`K1*0I6G;XZD!0"@%`*`4`H!0$ZEK;2A
M\R`EIE#C)9[OBM;ZM4CGTXZDT!AO=#;3;G.56M_/Y#=NEQ61;XB'+O%M??-/
MK0IMH/S'66D]XI`\WF!5V"M=UI1V[S9;Q-:)?2CTR87E&%72?EN38[<K+F%Y
M>LED9SEJW&Z9;E<*X,B!=;;'CRHTJ,]!D/JMSDAZ/W;2>&IT%58RD^]%K;3W
M;S>TNAF(X72!T/["[D;<7&5G&X*LNQB3=DX];+GF%TRJV6IR^H5&E&\B-:EV
MUI]:G]&7ITB(A''E"J3<TG**K18;S"HW1F=<SZ1]OGL3NF'XIE^08C>,N9VW
MQU5W:R-AN^Q+3MU%N;=L>QE3Y;3#N,INXJ](N$8/E:@DE`I'>W6NT'TSTH;`
M16)#JLDR*)?\FR#%;]<\C1G\:)FTW-\5CSXMON%DN@94FXY2\BY/"0^TEU+P
M5P2-*S\-R%<8L;4^LM&!T(=,%MNMO=M-XR.VIQN\78SL>9W&CKMTB9?NY^.U
MW5)C*$ZU*+*"]'/=E*E><4ZBL[=X+UZ>]C^FK$9<VV[)7N?>IFTF2[HXE?(K
MN0OW)-CS#-(=F;RJ$[%=B1_2!(8BL",ZD]Q'T)0M>ITP[5QOJK7^@J4/A6#U
M=?31C5WN5^M^.9`U<KU-Q.XSTOWT=U;+CB%SN=T@RV4-)>:?D.2+JLR%)X2D
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M==9)]1;CWJY^GYEFZQK7-W1L+5RQUK&+?(L&:>@KQ:TN6QNWW@8\QZ`Z;1>,
M@M_.B>0M??MN*&B=:W5Z>FF!I-T\:QN-B>.8_C,65/N5LQ^QVRUMR+LZF1>Y
M,2V1VK9:=+DC12WFX[#??D(X@'6HQ5-E**IDN'Z6GL<Q5I[',0"KV_#4S`H!
M0"@%`*`4`H!0"@%`*`4`H!0"@%`.\[L\P6I)X@)2CG+@/:G7ZCAX:`H2V;<]
M'2U/BVJ=;4.)DI8N%O;N9:F-GG:<0%I7W;B'4@@\-#QHU4%NY)@V*Y?%L\#(
M\=L-T@VJ9\;1H]QAL_$Z'N8K0\J&XDMF0#Q'#76@/I/V6SK:<"K9;WW%QVV6
MDQK-&8?<AMNI0([4DI"VF8#0[QGP!2`146Y)I+:GCU`\6)8-C&"65_&<<MT>
MU6%N3<)'HYBLR9+Z,DE.7&\J>E(U46YDF6XZXD\"X23QHG7XEM!<@2&T-L]T
MTB$Q(9B08\-(8Y8$6*IN&I24@>:EI"?I4@J1,BI&!0"@%`*`4!,GM^E4X8D+
MF'O)CV'Z/#4IX$(=XU\ZM?R:=[?Q<W[^#U3GC[CHPQ+=Z)?R5]H?XLN'\OW6
MM4<"G+%FTA[?=_9&KUO$RR!K9/NF"6M)D4`H!0"@*GU)^CQ5'I+,^XO82'WA
M_7)JM<[WO*L>][SACU]?WLOJG_XPW*_TE:+7YZ]OU':N?X&7L.YQ[3[9_3KI
M'&(4`H!0"@)@D`I6."D\4J'`I)\*3V@U-0352#N23HL"/*!R_P"*4J3_`(JD
MGF21XBDG4>*LY$1XD@L<Y6I9*U+24+4KSBI![4J)XE)\796'!4,JY)NA`K65
M+45**G&T,N*).JVF]2AM9[5(03P!X"H41L):`4`H!0"@%`*`4!/SGN5*0$I#
M+H0X7`%(<+C:E((0>',V.P]H-`:1=6>U^X6Y65;26_!K!9<@MZ9CZ+ZK*G;J
MJRA*VW&A,6+;*BK,ZVE??QRM10'&P"#6J\FX41LM]XU;O_J_-SH?Q)(R+<T9
MI8]N[UD>0OW*W0<CE9KN%.N"9$W&X5P85,6VY<,8FH;98')RJC%SNP$UH4MM
M'LD^@W4Z>@^WAW3#U48SM)>KAC][PZ?N3O\`VG';IN_!W-M\^5&M$Y*TO7&/
MC%D@R(T]$1QM:^5AQ2EMN)04Z`*!53!EW>[I/W(SZ9C;6*9O&Q^"NR8O:H-Q
MN\F\2\@Q%.-PWHMW3BTFW3&(\21DJY0,I<E+@5W2>330T65NBZ$"R-X>EK<"
M_9'T[[?8+'LL/&<1VHW5Q>_YG+NM\>N6'9%='<9-IR*S3DSTI3E#ABO&.N3W
MKC8YPT4ZJUPHJ+JL-W0#%%QZ.-\L;RS;QV%F+U^=N5LL6!94BWQ;NQ`=V]2)
M:=P<]R:]3)#MK8S#)5+AF"0E#[ACN:E6@TRI)O9@@;6=*'2MEG3MEU^R.^;A
M2\[;W"QS&;-DSCUOC6^4Q?+!)NSG?V1N*RR+A%G,7!M$F;)#K[@;&J^`JY)-
M0:BOCILW,J]/4;SDL(BJ9*$LEEMN,YZ`TMV)#4'%J+:'W"M;G!0*E:Z$FI6X
M+(J8!L+0X9"FWM)#324N1)&O!)<'*Z>0\`XXE(!/;PJ7#C6O21<FE5%0#3B"
M0=`.!\"3JD>TDGAXJ9$1XLB)U/)JI1[M/(WQ]XG4JY4_J4\Q)T'A-.'%8&.+
M(I\B4J2I*0%)7WJ5`#5+G[H#IJ%\.WMJ$H13-D9.2JR/A4?"MTOJ/ZIXI""Z
MKQN%(`YNW2L45:])DAH`4D=J-0D^%(5KS<I[1S:\=.V@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0$02.PD:^(Z4!*D!((2`D*.J@D:`GQG3M-`16.]3R._9$'
MM2OSTG3L\U6HX4!-SJX><K@CNQQ/!&FG(/$G3P=E`1;<#94WWCC"'QW:U--!
M>J>W1?`\J21VT!,4KUT4%1G&N#+[QY4OH`T\P<`?-.@H"E0"@%`*`4`H"9/;
M]*IPQ(7,/>3'L/T>&I3P(0[QKYU:_DT[V_BYOW\'JG/'W'1AB6UT1=]\UK9X
M/M(::?L%R6RXVYWO+(&17A(*M`-1P'"M:P-;MQJ9F5NGM[%R69BETS'';/=X
MX3#99OMW@61<NZ.@%#,5%QD1_34I[Q)4B/WKJ0=2D#2MG%G%50X<3QQ]X-LY
M67W+!&,[Q>7?[3CK&33U0;W:G($6UNS7K>IQ^3(ELI1*;DL+YFN)2T`L]M8G
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MOJG_`.,-RO\`25HM?GKV_4=JY_@9>P[G'M/MG].ND<8A0"@%`*`FYC[%2S-$
M7!-U',?$/T?+3,QDB.;VJ9F,D5M):B2%`*`4`H!0"@%`*`BD\I2??!+B7>17
M%"EI24CF3V$:&@(\R]'D=XONGU%3C'-]A\Y864I3VI3S#L!K$HJ6)E-K`D"4
M(4A3*$QPAUQ[D8U0A2W25+YQJ>9.IX>*H\.)+B2(Z#O%.A(#CH2F6L:\TY+?
M!A,LDGO$QDZAO3EY0:CP8U;V[1Q)$P6L=Z.92FY','VE'5MU!]ZVM/[FW]2`
M1I4N'$<211[I/<^C#5,?N4,!D>\"6]2E0[5=YJ=>;76G#B,\BL#H2L@*?+C;
MWI*M3($AG7NI`7KIWS?,=#IH/%4/#V\G#VY3/$EB5D:ID)>"CWDMKNI2B=?2
M.7L=<\'>^>>(TJU=@K,5DKLWBQ%7:YCE9TI=3V[NY/K#^O7IYRN]0YFV6Q6(
M;1S-O[<S;T,3XKV6W/)X]X-RGA:E7!*F[<WW>J4\FA[=:IQOW,^792I<EI;2
MMJ2K6N\ZG<Y(2G0:-^8GAQY1V:GP]M=!_E*?2<Z:6;+T$.8^(?H^6M.9F,D1
MS'Q#]'RTS,9(D"=:PVWB922P(5@R*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0&M?6/N1E.T?2QOSN-A4IB%E&'[:Y1D-DDR8XE,,W*T6J3/AK>CJ4
M@/-"0PGF3J.9.HK1?G*W%2CC4WZ>W&Y*DL#X/0ANCE^^?1YT[[K[B2X]SS#.
M]O,:R._R(\<182[G=+-'G2E1(B5K$9GOW#RIYCRCA6J%^<EMH;;EF$9-*M$S
M;,U:@VU5E622=$0J1$4`H!0"@)D]OTJG#$A<P]Y,>P_1X:E/`A#O&OG5K^33
MO;^+F_?P>J<\?<=&&);/1$4-=*FT#3:0"+/.E)"2>:.A&2W<J;422"I?+PT\
M=:U@8>)8F[O1A8MV]T5YW<;O8W"W;<U9M=NN]N]*F6J\9=BPL%MO%H<>"FTW
M*U3`'D%D)>)2-#V5AM+$&NSGJV<P5;;Y:K=N%A$63\F\+;2TRW\7NC$^?W][
MEW*]7S)9[<E$RXY-,C7!<:.6EH2VE+?."`=876N&WT&"YY7J\Y<W#Q@SV2X5
M)7:+#&M5IOMUP0G+I$U+*8\J]YK=G`+C<)\!/,U`6IPH;8::X:C6M5IIQ]X1
M\JP^K/3#G8K)R'*L6R&U89B68X?%;F8RZN??I>66.Y08^37V<X5-W*_62Y7(
M&,`-4Q&6TIT4`:N0?\*#,V[M]&;FY]IP3'X.1VR)`P_;/&-OKY(N5EE7&4FW
MXS<8-V5=L1E..*-LO-YN<$1)8<*T_%[KC>@5QK<MG3M-5S$V@VEVZMVUV!6C
M";<F!&AV65*=:;LL46Z"MZX..S'&C%(*@D%TDCPKXU(UF2J`J?4GZ/%4>DLS
M[B]A(?>']<FJUSO>\JQ[WO.&/7U_>R^J?_C#<K_25HM?GKV_4=JY_@9>P[G'
MM/MG].ND<8A0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`5E8@]`_;(
MGMJ_R*VZON]GUF[2=/N.%70M_>_^M7_W%Z??Y:S6N7'\WWG2G^2O:SN;X5?K
MC^D*ZS_PZ.//\SW"JX%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`:7^L3_(>ZH?Q,YY_5ZX56U7<7M+>D_,9;/JLO[O+I%_$]A/]6H=5K>"-
MU[\Q^TWW/;5^WW2C/O$*F0%`*`4`H"9/;]*IPQ(7,/>3'L/T>&I3P(0[QKYU
M:_DT[V_BYOW\'JG/'W'1AB6QT2,)5TM[4-%90EZUS$%_4Z!L9%=2H#3SNRM2
MP-;G&N)K+U!9SUCQ.I"SPMML(RSY)X=KR(WRY6RZ194#T.%9E/V>[QK$^XRQ
M$N<^Z!4=B4ETO%:`%H0@!1FK3;JEM:&>.\Q):%]94O(;-G<JU[LQW,AV44UG
MT"(_9EW2VY'`SR_NXW`L-D=NS=MAY-*MR(KDZ2A]2'X3@05!6H$;EFXX-91G
MCO,9X)+ZT]]L)PJ==)FY$"3;GKXC(;K)]`@6NVW:W9A<XL)G'&6[@93ERD6E
MAEF:74I;0LK+:EZ#77;LSBJ-&5..\R3EV['7#B.;K?NN*9'8L)MDBS8SE&:&
MZQ)%F.!>B17+C?[?B[SK4>!DK+ZG$_'`=*DJ3IRZBK4(TQQ1ASCO+QZ*-W>H
M/<O<:)AV=9-D]UP^VR\TW-L5\GN,R77<2C7>YX?8L2NRX[CA;F2X@:NP+F@>
M2KG':*DH13S46;>:YNN&!UH;>"R^V&M5//-3$A6G,W&0QW'?`CS2'%Z<!QXU
M,@5:`J?4GZ/%4>DLS[B]A(?>']<FJUSO>\JQ[WO.&/7U_>R^J?\`XPW*_P!)
M6BU^>O;]1VKG^!E[#N<>T^V?TZZ1QB%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!65B#T#]LB>VK_`"*VZON]GUF[2=/N.%70M_>_^M7_`-Q>GW^6
MLUKEQ_-]YTI_DKVL[F^%7ZX_I"NL_P##HX]QTN5>XCH:KD<T1H:#-$:&@S1&
MAH,T1H:#-$A0D*`4`H!0"@%`*`4`H!0"@%`1H8;2Q&AH8S1&AH,T1H:#-$:&
M@S1&E#.9$*&10&E_K$_R'NJ'\3.>?U>N%5M5W%[2WI/S&6SZK+^[RZ1?Q/83
M_5J'5:W@C=>_,?M-]SVU?M]THS[Q"ID!0"@%`*`F3V_2J<,2%S#WDQ[#]'AJ
M4\"$.\:^=6OY-.]OXN;]_!ZISQ]QT88EN]$OY*^T/\67#^7[K6J.!3EBS:@`
MZ.M=\^RF<Q(C*+3*%I5R)4L!2U)*AKS=FNE7H8HRPVL+5&6DMLNLP6V4*4T@
M*<[AY2@%#ET.NE3DJ19@^?$B08-O,2UP&HMO,E=PCMQV$-I6Z9*G9BBE"1Q<
MD\Y]G6M1DA/@6NZ1WX]PA6R9!DLE*X%XAO2HTYESSEV>ZHEK=:$5U2BMM@`!
M2B#X:U[%5X/![.G>9/E6;&[!8FW6\9QZ%CHE-]W<W+5;H,20N*G@B&\J(PU]
M@C@!#*3Q2T$CP5*&?+\?>#ZC[Z`.Y:;"!']&'(UWH^SR(^A"02?%KK4C`H"I
M]2?H\51Z2S/N+V$A]X?UR:K7.][RK'O>\X8]?7][+ZI_^,-RO])6BU^>O;]1
MVKG^!E[#N<>T^V?TZZ1QB%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!65B#T#]LB>VK_(K;J^[V?6;M)T^XX5="W][_ZU?_<7I]_EK-:Y<?S?>=*?
MY*]K.YP]\?UQ_2KJS:6F39QKJK.G43>/_%]]['M^*JG$B:\K'B/@/8?'[7CI
MQ(C*QH3V<:<2(RL?^/Z6NGZ=.)$96-#^@3](=I]H4XD1E9#0_1[OZ59XD3>H
M2HB&AUT\/B\/C[/:IQ(F>'($$#4]FNFO@U[=/;THIQ;HL0X22KT$/!KX/'X*
MF0%`*`4`H!0"@%`*`4!,/#[`U/L`=I.G@%89&46\!J/&./90ADD-1XQVZ?3\
M7MT,Y)$?9\'CJ+FDZ,QE8TK'$B,K('L/TZ*<:F5%U)3PTUX:]FOA]JMAL%`:
M7^L3_(>ZH?Q,YY_5ZX56U7<7M+>D_,9;/JLO[O+I%_$]A/\`5J'5:W@C=>_,
M?M-]SVU?M]THS[Q"ID!0"@%`*`F3V_2J<,2%S#WDQ[#]'AJ4\"$.\:^=6OY-
M.]OXN;]_!ZISQ]QT88EN]$OY*^T/\67#^7[K6J.!3EBS:0DZCCX_T5&KUO'W
M&60-;)]TP2^(>`=@\6O;I[=:3)$\>WCQ!X^,=A]L4`U/'B>/;[/MT!"@%`5/
MJ3]'BJ/269]Q>PD/O#^N35:YWO>58][WG#'KZ_O9?5/_`,8;E?Z2M%K\]>WZ
MCM7/\#+V'<X]I]L_IUTCC$*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H
M!0"LK$'H'[9$]M7^16W5]WL^LW:3I]QPJZ%O[W_UJ_\`N+T^_P`M9K7+C^;[
MSI3_`"5[6=A-Y,QG[>;3;EYY:X[4BXX?A][R&$EYQ33+<BVQ2^V\Z4I4I2&U
M#4@`DUT-2Z:1/K7TG,BJWJ=1J+"Z][9RN,.[:9:Y/N3N(V2R*@BUN-Y7>\M2
MQ%3+D+N4^$EO'H$I?,XZX4/H3J4MJT%<IW-V)OR%MWWUDV'8WFTG!;YM1N=#
MN,+-).$KFMVBTWBUQ[E:[3;KQD$JSBPW2Y:XVW;9Z-)2^50=2L*2-**XDND9
M/8>"W^L_VKEWQRT0,0SIV:'C)2J''=E0K=8F9"F)=SO\AX-Q&BV&5J2N*M^"
MT`#(>:T7RN(EB%`^);?6AX+F>+9`]MMMWFKV1.XMGU[PWX\C0X,*>UAT2Y2K
ME=;C/5*,(6)"K>XILLK=:4H:A1UTIG5:[1E]AF'=[KNQ/8^T;<RLVQV_W*?F
M&V5@S^ZO6@0BC'F+S:F$/1"UZ4`FW3WU*2@*T2YSZME2R$U&4HS6VM/L,J+1
M:N4=?,"TYQ!LMBVZNE\Q>,,3C7"Y0+M'3<).09W8K=-QFQPQ/<B-0(JQ=V&Y
M/?J;<0GF+:5D`',INCR]XV*WAN+"R[UF+2;?=_N(VFRB?>86Z6/[1(<D*M33
MC>7N/0Q?;8\6YZW$0($3OF&G%I"G@D.:>=2$Y95G[_49=O;LP,A*]9!@$#+,
M#P67@F7KN6:W#-;8F,RRU<[?C^08/'N[]RC7*7&=<,"=+^*'$,M.!+Q96'0@
MM`KK9:H[RDN]2AJNP:MO<?*L?K!8M_S/#L4MNV^7MW#+,;R*;:L4=78'3<[S
M`N:YG>2IZ+LJ*S:V;,PZH/<_OP`YR:G2]\?53I_H*9T2QZ[*O]ALM\7%,%=X
MM<*Y*A%R(\8:IC"'C&+L!^5!<+)7R\S+CC9T\U1'&I+88/L4`H!0"@%`*`4`
MH""^;N)24+4AQR*\VGNW)#;AYTZ*"@PRZ%1]/VSF(\WLK3=BIY8O?7L-UE-U
MIN-4NI+J4F;!9ML;9HF,(RBW;L9#?,0$"&W&+[=U;M]O^*7+=)DO,JCQE2Y!
MYUJ`T(-22S)8FW(^HUTP/U@LK,;/G<R3MU?+=`8D[J(QF\.PK,F;`=VJQMF^
MWGXVM@N?^L7R,%$H4DEEQKDU6#J!FB577%C(S&V)>LPRR_85M5)E;:.1LNW%
MQO(LM2Q*>@N8[+Q6#*N5LCW)4J/(>>A7-URW+6XPA"DI/AJI<FE-IF5`R#B7
MK*;5+QO")<K;;+;S?LGRU>V,7XOCV13$K.FWDRQ;(B'KHV&[<BT2V%I?[5K)
M2H)'&M?$76,AGZX=7MBM^UN$;G#",E>3G,W/X=OQF9\61IL:X;<-721F";J(
MLV0S&89M]H>+`0M8=4`"1K68W(N:CMJ8<7E+EZ9=Y[]OMBV2YO=[,BV6IZ\-
M'#V%\JI$:V_%K,EGG;A&0O7O3IV5T2H;.I6'4(<#I>*T(4M90\WJX4CO!R/M
MM.CE7J.*16(R4E5`TP]8G^0]U0_B9SS^KUPJOJNXO:6])^8RV?59?W>72+^)
M["?ZM0ZK6\$;KWYC]ION>VK]ONE&?>(5,@*`4`H!0$R>WZ53AB0N8>\F/8?H
M\-2G@0AWC7SJU_)IWM_%S?OX/5.>/N.C#$MWHE_)7VA_BRX?R_=:U1P*<L6;
M2'M]W]D:O6\3+(&MD^Z8):TF10"@%`*`J?4GZ/%4>DLS[B]A(?>']<FJUSO>
M\JQ[WO.&/7U_>R^J?_C#<K_25HM?GKV_4=JY_@9>P[G'M/MG].ND<8A0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`5E8@]`_;(GMJ_R*VZON]GUF[2
M=/N.%70M_>_^M7_W%Z??Y:S6N7'\WWG2G^2O:SMAD\&P7.P7BVY4F,[CLZ(_
M%O$>8E1ARH#J.61&ED*0$1G4<%J4>4#MKIW$I:9)JJJCDR;C=JL:&HD;+NBO
M<"`]99-]P!,-C-96$Q1+FR;:)V2V6'`DLMV2YLRX[EQCQD2FT]]'+24*!"3J
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M`J5:[9-"+=:_B\N=U=8UJN+?=,,.I(;>;!'94%I[,:1C'9[S+NW'M;,B)Z8]
MBA`N"1@=OEA^_,WZ7'3(FE^5<C%;A"X+<5)+KSD.,`(NI(B\B2UR%*=-G`M;
MAQKN\MK'NCS8C&<RS',(F-"YRLLN]AOB6+@[*0S:9MD@PX\5]J(EU,9VZ!R(
ME2YJTJE.<0M9!.N%9MM;8T,\>[O+DO73'LI>I,RY?<='M-\D-WQV-?+,N3%F
MP[U?HTN-)R`,,NIC2KQR3%H,AQ"G?1U*:YN[)34E:A%YHK:1E=N25)/86!M=
MT5[';:X3;L7E6Z?F\V-(FJFYG=W9,&_H$ZYFZ*MD25!<C/V^WN2M`ZVR4(=;
MU0H%"B#-.IK-LXL.+;HT>!"C1X4.$RW%BPXK2&(T6.PD-M,1V6TI;:9:0D!*
M4@``5D%>@%`*`4`H!0"@%`-4D.-DOI66G'&BP7$GO&AS)"U(4E/(2>(5J#XJ
MRE;?YFU=!E3E#NNAB+=,[)IONWTS=F7AL"\(R$KV\:R&Y16I;%^[N.&UVUDI
M0KOG7.75(.AJ:G8KEIM^8D[ERF)AZ'<^BJRP[I:47W:Z(RS<KNU=(IO#>K%Y
MS!/Q7D<-=QY^#=\A)2U()U3R>:3PJ$W8GC3*GV[AQ;BZ=I;=@QSH.Q2'#QFS
M73:V)!9NEVM=OA?'3SJFKI?H2$7"P6BZ39;R+;&,.0ESN&N5DEPJ2`M1-:+D
M+;N*D:J73NI]IE7)M5J>VV1>A>S*LEXMUPVUAP[/D4?'K),CW!UV&<S@2$7"
M.BSH4^&CE/>NH:6I*0^IL)YE*;T36N5J$7LA7#Y_L'$GO*=@W5Z--T,,APTY
M!BD/"XF9WVRV=J[O.6U'W8BX23>XEH++C4F0Q-EJ<$WSDH=2I:%:IU%;>!;3
MJEM#N3>RNPRGB>[_`$TX[#9BXCN)@6/03?$XXU&M-QCQ2N_-!(1;?1$:!V0X
M0`AIL!26B%$Z5-OHI5&LV'YU.:.J45ET!T++A=YT.#G0L+))(6D@CQ:U+#8#
M2[UB?Y#W5#^)G//ZO7"JVJ[B]I;TGYC+9]5E_=Y=(OXGL)_JU#JM;P1NO?F/
MVF^Y[:OV^Z49]XA4R`H!0"@%`3)[?I5.&)"YA[R8]A^CPU*>!"'>-?.K7\FG
M>W\7-^_@]4YX^XZ,,2W>B7\E?:'^++A_+]UK5'`IRQ9M(>WW?V1J];Q,L@:V
M3[I@EK29%`*`4`H"I]2?H\51Z2S/N+V$A]X?UR:K7.][RK'O>\X8]?7][+ZI
M_P#C#<K_`$E:+7YZ]OU':N?X&7L.YQ[3[9_3KI'&(4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%96(/0/VR)[:O\`(K;J^[V?6;M)T^XX5="W][_Z
MU?\`W%Z??Y:S6N7'\WWG2G^2O:SM%G>)Q<\PK+L)G2784+++%<;#+EL)"GHT
M>X,=RX\VE2D!2VP=0-1KXZZS_P`.CCS_`#/<<RLI]5['RB3F%QO.]+MSO.67
MIN^7V*G"+5CL&[VJ';H5O@6:RF#<'1C-R0U`'>W)@*>>YAS)\T57!2P3H)S_
M`"S%<G<W'SJ7BU^M^Z^8Y1BLJUXA91'8L-_P/'\+BJGPFIY;D/,,6;5V9Q=E
MIX+2-*QE2>;IH#[5G]6K<K#A^)8;`ZC;L^QC>+WZRR+TK;^T.W69=;Y-N4YN
M^VF<]<&WK$8/Q@ELL-!3;J6N)XFLK:MNP'AM_JOH3%IW3M5SWNN%S1NO9\2M
M-Y=:P&S6\P%8K=(]R^,+:EBYGN)MS[CE=4DC12BL:J-`92QWH&M-IR+(\INV
MY4V^W;)+?MI;Y#BL4MD!F$WMAD5KO=I7;V6ICJ8BY\:T-1I/)IWA*G#JI1%`
M=!E=XXXR\XO[,TXM16VD-!Q*E$I;4E.H`0#H*`F5RE:EI24E9U5JHJU/9PU`
MT&E`!V@ZJ!!!24J*2%#BDZCQ'W:`.J<?<[YUQ2G5)"7=/-;<T'FJ+0\T*&G;
M0$!V#CK[/C]F@%`*`4`H!0"@%`*`CH%`I4`4JX*.GG\OA"%]J-?#6F]790PS
M4;J<Z6)/47>-N[JWN5>,,8V]FRKBQ:8ED@WU-X??;:2E#CTV7%5%*%->:4Z]
MM:/B,'.Z5T-=14FYQ;@9]LCN,66Z[0-29F-V@/Q,8ODN:XY?Y3IG%N1'[N[+
M)FNE-P9*3W;*N5.N&W3>9,ZY+ZL.R7?"<'L<#<%X7W%L%8Q6Y,S\<@R8V92<
M8NUPRNUR9\U,STBR6\7&<6S)82])6TD:I^IK>IRC%))]'TF46KC'J_\`<C<"
M:K+=Q-WIV,OL;QX9N/"Q>#AEH>@.0<"8L4:'9KI$,YMF'.F.V+1,IDN*<AK;
M4L!PJ2-X+^L/JUH>.Q-PV+;O/<6']T+[<9^5O-X/:$,BR3KP]>D6BQ1/C$MV
M.X,2'RDW!D]\XD:%-`??R7U=]JNK6&M8_NE+Q1S$IJ'V[G$PRU3+X8J(@BK9
ML]U=GM.6&=/`(ERD)<<D-K6@@!5`=$+/;S:;1:K493TTVRW0K>9D@ZORO0X[
M<?TAXZG[([W?,?9-`:@>L3_(>ZH?Q,YY_5ZX56U7<7M+>D_,9;/JLO[O+I%_
M$]A/]6H=5K>"-U[\Q^TWW/;5^WW2C/O$*F0%`*`4`H"9/;]*IPQ(7,/>3'L/
MT>&I3P(0[QKYU:_DT[V_BYOW\'JG/'W'1AB6[T2_DK[0_P`67#^7[K6J.!3E
MBS:0]ON_LC5ZWB99`ULGW3!+6DR*`4`H!0%3ZD_1XJCTEF?<7L)#[P_KDU6N
M=[WE6/>]YPQZ^O[V7U3_`/&&Y7^DK1:_/7M^H[5S_`R]AW./:?;/Z==(XQ"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`K*Q!Z!^V1/;5_D5MU?=[/
MK-VDZ?<<*NA;^]_]:O\`[B]/O\M9K7+C^;[SI3_)7M9W)=0EQMYM2"L+"D:!
M7(4D@`+!_P`6NL_\.CCS_,]Q6;*M0A\M2&VHW=LJ<:U<Y]#H"0==!KVU7!(Z
M5%$=*"L"'%D0XJ6W5I)24*=8<F%Q2DR$^D.J'+IP2*A246W';5U^XR3K*ENN
M.*<<=4YW94I?(E`4&D)4&6VTI#;84GL\?&I)45#!+60*`4`H!0"@%`*`4`H!
M0"@%`*`4!$5.&3^,PR8*T((4H$'4$::CVM01K6RMGY(4)6THY'$J0UR)*I,2
M))5)DP_3?`[<AWH?F'@.710"*U34*I07P[:NBJMU#)%M7("XD%#S*%F,`0KD
M<=3H[RJ(("==>4*U2!H"#4<4!JGDY>7S@O7FU)U"D@J`U\[]L))YB3KV>;H`
M0):`4`H#2_UB?Y#W5#^)G//ZO7"JVJ[B]I;TGYC+9]5E_=Y=(OXGL)_JU#JM
M;P1NO?F/VF^Y[:OV^Z49]XA4R`H!0"@%`3)[?I5.&)"YA[R8]A^CPU*>!"'>
M-?.K7\FG>W\7-^_@]4YX^XZ,,2W>B7\E?:'^++A_+]UK5'`IRQ9M(>WW?V1J
M];Q,L@:V3[I@EK29%`*`4`H"I]2?H\51Z2S/N+V$A]X?UR:K7.][RK'O>\X8
M]?7][+ZI_P#C#<K_`$E:+7YZ]OU':N?X&7L.YQ[3[9_3KI'&(4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%96(/0/VR)[:O\`(K;J^[V?6;M)T^XX
M5="W][_ZU?\`W%Z??Y:S6N7'\WWG2G^2O:SN;X5?KC^D*ZS_`,.CCS_,]PJN
M!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0&E_K$_R'NJ'\3.
M>?U>N%5M5W%[2WI/S&6SZK+^[RZ1?Q/83_5J'5:W@C=>_,?M-]SVU?M]THS[
MQ"ID!0"@%`*`F3V_2J<,2%S#WDQ[#]'AJ4\"$.\:^=6OY-.]OXN;]_!ZISQ]
MQT88EN]$OY*^T/\`%EP_E^ZUJC@4Y8LVD/;[O[(U>MXF60-;)]TP2UI,B@%`
M*`4!4^I/T>*H])9GW%["0^\/ZY-5KG>]Y5CWO><,>OK^]E]4_P#QAN5_I*T6
MOSU[?J.U<_P,O8=SCVGVS^G72.,0H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*RL0>@?MD3VU?Y%;=7W>SZS=I.GW'"KH6_O?_6K_`.XO3[_+6:UR
MX_F^\Z4_R5[6=S?"K]<?TA76?^'1QY_F>X57`H!0"@%`*`4`H!0"@%`*`4`H
M!0"@%`*`4`H!0"@%`*`4`H#2_P!8G^0]U0_B9SS^KUPJMJNXO:6])^8RV?59
M?W>72+^)["?ZM0ZK6\$;KWYC]ION>VK]ONE&?>(5,@*`4`H!0$R>WZ53AB0N
M8>\F/8?H\-2G@0AWC7SJU_)IWM_%S?OX/5.>/N.C#$MWHE_)7VA_BRX?R_=:
MU1P*<L6;2'M]W]D:O6\3+(&MD^Z8):TF10"@%`*`J?4GZ/%4>DLS[B]A(?>'
M]<FJUSO>\JQ[WO.&/7U_>R^J?_C#<K_25HM?GKV_4=JY_@9>P[G'M/MG].ND
M<8A0$0">P:^.K>FN:.$9+522;PV5(N$I-9>@CP\/"JUZQQ'733;783A\$OBV
MH:#3MK,+]W3*ERS&76V6H7M.G\48CAP&OM\*U/5WKDW2Q%1>#3(2G:<FXI)#
MAXN/M5MCI+NJ5$W!]1'-;ZNPCP^@5&7E^_;_`/$>*NN,=N791TZ,1FM]0'+]
M`J.T.5MX)$I[>%9-3I79@0H8%`*`4`H!0"@%`*`4`H!0"@%96(/0/VR)[:O\
MBMNK[O9]9NTG3[CA5T+?WO\`ZU?_`'%Z??Y:S6N7'\WWG2G^2O:SN;X5?KC^
MD*ZS_P`.CCS_`#/<*K@4!$#7Z7@K*U\-,^%*U&==M7B8=N<]L6TB.G_CJ+=B
M_P#$KF1OH2-<FX/:R('AK?&,K27#BKOMV&%JK<=CH2CV=*JK4<JA)N6I;NU[
MN5T3Z5[L#?XFU3!#37PZ>#A6;O-I1C31::W>?6Z5[4/$V5_#$E"2%>^)'B/9
M^E5-:WS!K9K2SY;"Q8GC=C--QZ=B^8FM39ELRQJ5.'^'2NG:L3TJ_P#$;5UD
MLUOJ(:5HU-Z,UEL['U&EO;LP('3RU7TD+T%+C2<JO97<$0JV!0"@%`*`4`H!
M0"@%`*`4`H!0"@-+_6)_D/=4/XF<\_J]<*K:KN+VEO2?F,MGU67]WETB_B>P
MG^K4.JUO!&Z]^8_:;[GMJ_;[I1GWB%3("@%`*`4!,GM^E4X8D+F'O)CV'Z/#
M4IX$(=XU\ZM?R:=[?Q<W[^#U3GC[CHPQ+=Z)?R5]H?XLN'\OW6M4<"G+%FTA
M[?=_9&KUO$RR!K9/NF"6M)D4`H!0"@*GU)^CQ5'I+,^XO82'WA_7)JM<[WO*
ML>][SACU]?WLOJG_`.,-RO\`25HM?GKV_4=JY_@9>P[G'M/MG].ND<8A0$%+
MY>1*$*==+J"IH>:5QTZ]]W2CP5(&H*4]JAK7.U_(9<X=N[Q96X6I4V2R][?U
M;,>@RKF0UWWEZJ=DMC'$P,RRTS<@F)5(LF(XI;W,CRV^PT_MKL&R1'T/)3$4
MI(=*U#E*APK9/7:/RSIE=U<VX)=+4G]11OZE5=,32R\^L-W(OKTAK;38%R+;
M#S>B9'N#E46R/%.OFN.XIZ()X.G$I#^OLUZYYQZ_>4.63=NXY-K_`.TW]$CG
MW;]SH+0'69U<#E>%@V>+7OE,/V;(8@<&I\QF>N^.-*UTTYN33V*\&N?NB\K.
MZ[-M8/\`N9?ZY8MZJ:MI2QH719?6,;C8_)C)W.Z?7Y]G6M+<F];:Y/&R&X-K
M)TU8Q?T/TQY+G@^S#ETXUY-R;U?Y=Y@FEIY9:_Z+C_WB7BY&].SO4YLSOBP\
MG",MA/WR,4)N>'2W41LNL+JM-(=WLKQ0\W+4>`2@JXU[>Y>KNMTWB8W:P2K3
M/]53#U;IM,_N!(`;0I/,6R^J2=5,-1QKS/\`(G1;K3?*0L@ZI(-;<T:5KL)6
M]2Y*B)"#PU'+V<`0001P6"/J5CSA[!J52_:DYI5!&E$S=**6!+62`H!0"@%`
M*`4`H!0"@%`*`5E8@]`_;(GMJ_R*VZON]GUF[2=/N.%70M_>_P#K5_\`<7I]
M_EK-:Y<?S?>=*?Y*]K.YOA5^N/Z0KK/_``Z.//\`,]PJN!0`K0D+Y]4E">=&
MO$/G7BRV`-0X`-=3PXU3N\ZTNDU,>6WHUNW%5/+79ACT&ZW=A"+4MY9&X&YN
M!;6V!S)-P,GL^)VA##KZIEYGM1.*$DAMN.K5V0LD::)[:N/R_I]1<S\:<9-5
MIG212U+S1S*AS\R'UDMKO'V/9'9O,MQVT.K;<OM^D-8'B\IAM1"IMAO-RC3$
M7L`#4,H2A2NS6O7GF;U4Y'Y#S6-;/,XU_ASX>R2/'[TKJE5&,G^M?JJFR'7;
M?A>U6/05Z^B,7Y-VGR^8\4LN.Q+G&;4M/82$C4UZR7[J_(-RYEC;N9Z_\+/'
MVYBU&<G%5W'T;;UX]1]C6TO)=E\-S:.VDJGMXCD1QV:E(/9#9NIN9E+*.(2-
M-3PKR_DWKUY3YS-*P\M=]IQ^F0K)[39G:?K_`-B]Q9L6P9.N^[/YC+?1%8QK
M<:WKLZ9<HD#T>VW=>D2>%G@E82@>&O:VA\X\GU=I7;%R+D\%LQ]E:A3<&IMN
MB-X6E,/)+J)#:H[J$O1GFE)?"DJ3S!L]VHI=0M)U#R3R'Q<:VZCF4>817#V2
M+D=2Y;42Z@Z%(T!XZ<P5H/UP`"O;J.FTTXSS7,"_:^.E2!J_?<&UDW&V<5'`
MA6@@*`4`H!0"@%`*`4`H!0"@%`*`4!I?ZQ/\A[JA_$SGG]7KA5;5=Q>TMZ3\
MQEL^JR_N\ND7\3V$_P!6H=5K>"-U[\Q^TWW/;5^WW2C/O$*F0%`*`4`H"9/;
M]*IPQ(7,/>3'L/T>&I3P(0[QKYU:_DT[V_BYOW\'JG/'W'1AB6[T2_DK[0_Q
M9</Y?NM:HX%.6+-I#V^[^R-7K>)ED#6R?=,$M:3(H!0"@%`3]H(]NMD;+EMJ
MBS<[B?4>>5(9APY4N0ZAN/#9=F2W%*2/1X45M3TF6XG7F$=AM)*E::"JU^R[
M?Q-IHJ1>WWGY[NK_`'>VWW+]9AZJ[<C!\PL>0X%;+QO/%F95`N$9RU,R,;5)
M3=V5.AS7OH@965HTYDA)U`KF:>_">KC;2:;>+P.Y).6C<>H[SX'N!ANZ&(6S
M/<"R&W9+B=Y:9DVV^6U]+UNF17P5)D,2TGN'4C@-`HJU/973G=4+G#HV^HXT
MUDQ+N?)84E*D+/,'%G1/%++9`+JDG16J@=4M_MBAV"KT=,W;XDI12ZZE2>KA
M!T:>PY>]5_5_D3V1W'8'IYE(&91T-.9KN*MMMZU8)#?"@RF.A1YCD;B`O1A8
M2XP4_9`DD5Z<]2?527I['3>%J[VJA/!1E1*FQJ35'M.?K)3U;4;#2RXUZ?90
MT>QK`;%C\V?>I"Y>493>G4R;YF5_?7<[[/EIYB^\9,@J++;ZUG1*"`V!PKX?
M]0?5[G_F&<E":C"3?\$5L]S*T-+J%BXEY=VT5ZJ:0-/>N)\]P'74>:H!/Z->
MC977K+SNZ_-*OX6T7%:Z65U%(U+;DE#ATYEAT\JSX?L7O6P?$*O2Y;R=P4K4
M+JN=<F:)Z><I.2:I4!PG4%;K:BE04\ATK4XDC13*VE`([IT<%<=0*VZ'6<ZY
M7=XG+KL(I/95-F/"SWHQ[DVWUJOLR'D=K<G8OG5H(<QW*L6DKL][L\AM7.PI
MFX1BAV4SW@U4RYYBNPFO;_E#UC\W\EYOI+O,;MNYRNW>B[L86XYY6T_B46VJ
M-K`P]+<:=&JF^O2/UB9'DE]^0C?^7`M.>VZ,N1@V=14>@6W<5J&V%27VVB$_
M$]]@LI!=CM!299["2HBONWRIZD\C\ZM/EUN]:C)?_4<5L_Z+>TQ:MW++VM5.
MG>O,M*>[#14@.!*0`#JD**].T*=/G$>-5>UI:.5NPKJE%QIUU.IIK\<V5UWD
MB5I<22#HH+*2@@A0T\/BT-4+5U7).*3JCJ7.Y%BMQH%`*`4`H!0"@%`*`4`H
M!0"@+-W`W,P/:C%KEG>X^2P,0Q+&H,FX7R^7=2V85M8CEH*](<"5<I)4-/!4
M-5JH.&#+>DM2S4V;3A'TE;K;<[<^M)]:CN-G68V/&<(DX?TRQ(N17&<PB!+=
MO]YS15H$925J4\9J5#D"02:Y4-5!W%L>)U)V)<)*JQ/T&M+:D-B1%>:E1E]T
MM#[+B5(4V^PU(8<`U"BAYIT$'2NG>UUJUIDY*70<*_'AO.\".NITJ]J]-+2:
M7Q=QIVZ+#':+47=69;$5BPX&TO:`MK0E392I*BI16I*F^4$J2ML#4Z@<#5/E
M=Q<UBYV4X13:^+J]AME8E%5;1JYU.]3V/]..)HE(B_=1GV3.JM6"8/!46;E?
MKD`%/27G2`MBU6UM8<=/^<"2D:US^=Z[E?*N7W-;JW!:BT^F:3R_Z,6]K.!S
M#5PLWU;<9.3CL:P..MSM.:;F90-Q=[+\K,,MEJ,ZTV5UIS[BL:A.DAF+8,77
M_J%OGV]>J7)('>/J20K@=:_/;U0]??-<^97.6>6]19M:=2:_F6X2V5WIL:>%
MR\LRK[R^@QHE(#"0VV4DQ@P.X>=&G+(T`'HRD$#1"`4\*])7>8<UY]6_YGU%
MF[7;_+>0Q<MJWWXLHDJT2@-MQ`VLN)T0V\5N*.I)"E:I"CX*W<WU4;&EC"W*
M$H94DE1M+K*7+]=^H7W8A8OPRRI64:)TV5743*;4^OO5J80HD:J3%;2XHI["
METD*2.'8.%>(Z?27M7=SR5Q*O1F7T'?N:#A+XYP7O/EWS'++DD"5;K_;8UVA
MOQW&W6U)#3H1R$]X'4`N:M$<PT.O"O87DKF>FY'YETM^7&=Z$F^\VL'78V1E
MRN5^P\MRW%;V]GO9=6R_4EG/2G=++!S2[7/<#IX?+5H==N3KL[(]ID35I1"F
MKE*YW+]CRE+3W<=1/HJ5).@Y*^M_2CU^\O>9N>W>1>%UMJ[9O.$IS4(P;3I5
M-2PJ<:[_`.`D\TX7$OPNIW#L5^M%]LEOO]IN"+C8IT*#.CWAM:78[T*XQDR8
M,LK;*@L265!7FZ\NNAT-?97,]=I+'*KFNA+-&,$_AVYE5)TZ'2IU^6WX:A;/
MA7718GVCKYIT\U20I"M>#B%<4K2.T!0\=<#0RE<L\=M.%Q)I=*3Z'UG:UVG\
M/D^.$\RK\+K3J9+5TH"@%`*`4`H!0"@%`*`4`H!0"@!X+"/_`,`J2I78EMM+
MG=^<>W4J\6M`<[?6-[L[;Q>FWJ.V8D9A:&-T;UT\[@Y5:,-?>[FZW+'F+)/C
M/72(AT)0\PU(\Q6A)!\&E4M=<5NVF]_U%O2?F4^6):_JL-V]M'.D+I-V58S*
MSR-U8G3UA.8RL(9>4N\1\7%EML!=Z>0E);;B(G2$-<2"5*!`TXU7L3S_``I/
M"IOO+XW[3IX15Y7%"-'4H3?Q$M;834XYE@0%2`H!0"@)D]OTJG#$A<P]Y,>P
M_1X:E/`A#O&OG5K^33O;^+F_?P>J<\?<=&&);O1+^2OM#_%EP_E^ZUJC@4Y8
MLVD/;[O[(U>MXF60-;)]TP2UI,D=/-*OJ0H))\`4>P'V30$#P4I!X*3H%)\*
M=1J-1X-0:`4`H"?V?;K-N]\65XEFY^6O8>2?!B7*(]!F(#L.4V6+HRE)2[(M
M3OV.3'[_`%XL/<X2MO350-1U&U855"I#%^T_G2^LEVMZBNG+UE^.]'6S]I6]
M8=R]S,AS+I_N%N$MF+9[3O9=5WG<2W61L.*[EZS1ICC2U).B$ZC3C7C5U3L7
M.)'&+J>0TKI'*3V4^X_?ATS[*8UTV[![3[&8C'93C^WV"6"P/R=%R!<7XL%E
M$J6F(XHN)=<D)YN]*CX]*[_*4]5_,DFVN@XE[XGM+-ZP]\)&P^R%_P`BLZ42
M,URUQ>)X`T^[WBKEETL]U!C>-A;</OW6WNS5OB.-5O//.;?(>4SNQK&<8;.B
MG;7$X6JQ?O.0F!XLUBEA<@ORGKY>[R[*OV49/</]6N]^R"Y*2]/DW,\5/O*=
M)`7P0KZE(K\S/5/U"N^9>:VXN>:%C-'&+VM[<$MQKTO27=S+68ZBGT=MN.IL
M,-><"KAIWI[>/CKU--O4M-K$MDW9X*L:?10VN2&(I.*A)Q6",D*B!Q/`'0GL
M.NFA\!U]BHSED@Y;D&67N'BK^1VA*[7(1"R;&I47)<)R)![NYVG);4X)<28Z
M4:*%M:=:25M^]>`(/"O=GI+YYGRO4V[$ITDY;TOJ*US$['=)>](WXV-Q7-YX
M]'RN)'59<J8YO.CY!;75Q)"'VO?,O3$-)?"3]2Z*_1SRQSA<[Y:KM:NF^O0;
M--LN>XV62I;C:75);`5]4CM4H:@@^T170E85J[*G2=VY^7$4-`H!0"@%`*`4
M`H!0"@%`*`C0&".J#8ZP=2O3[N]LGET1J;C>>XA>\;N2U*+,UB=(BJ,:0RM)
MYDE3Z4\I'A%5=1!8=!;TMUJ=:UVGX'?5P[:=174[ZT"^]*V[]MD-8MM3?L$O
M/4<_-]*<<OT7IOOEVO6'6RY/<Z0!?(EX+82K7G"-*Y=J'\U;.DZ]V;5G,GBS
M^BI&C-1H[#3*FF6D1V6(<9B.6VC:XZ0U!2MPJ)](80C10[=`*W\RMR>B>5?%
MF6T\=U,LZRIE4#B>%=[G.IS<G5MK;2'U&[3++&C9XKQ,MUE@W&]W"0BU1;;`
M1<K_`#7'M+=!C1%+=F.(4KS4*]$0"KQ5CD,(:;EKNR:592?N2(ZG414'MVGY
M;][.KB-E&_F0;IY7BM[OTJ^I?MFV-J2HM#"L(M4^3!:N3,8@H3<KU/C/+4OM
M5'<37J;FGIWS_P!6N-J^1:S@Z2%V5N4%;XGQ);TU3'`]:^8/,NEY9KHVK[2;
MBFJNFRKZCX)ZPK3WBPO;W)RLD*+BGB$GAH41R![PGSC[)->KY_\`Q\><.::A
MZVYK-K=:^$N.O_[A5L^HW++<:9X)_P!=?81^>#:N/_J^R?P<.^5[OO:AK/\`
MX_?.-NVH6M9__J7/_P"P7?4?ED]F:#_Z:^PMV_\`7?A>*AGX[P&^Q_2%%MEQ
M*%K4M81WA2"3H5A'$UP?,?[(O,WE?30UG,M:E9RUVZ:<?GXC/+/)WG?2^:=2
M^7<JM.6HB\OPS4MOLHBW!ZQC:_1"_N:R925#4`QR.4<04C1)[#7A&E]).5Z5
M/23YCI^-7\$OHS'MO4>BWJ)S:*U6FTNK=EK92S5=M25SUC.UP02G&\F0I)"D
MJ$<D<R3S)"QI^UJ(T5_BZUQ=7Z):C0:^//;&LA>L6ZO)&W)5KL[V;K+^E]$O
M/NMTCY.]/J8W[G2[+Z-N%3(^U?5OMSOAE'R>VS&[JS\<0)#SR+G&2];H\AY"
MDRFT(4")466E:@"1]BYM1V5A^1[_`)!\M\P\W68N%U2C<KE:[TDL6VL7N/`O
M,7ICS[R;F7.(W$XXYK;A];.JOJ\MR[IC&2Y-TRY1,^,K;;84_+ML/2'UNJ.,
MF:E-XL+KCA)=39KK(0U%'@CHX5]<>@_F>[ZC>GVKEKY.=_3W86ZMIT35<(I;
MCP"QKN)/PVE?QMTV49UD`!0VYSE2G4A2@G]J;\3+7L-#@?9KV5RRQ?TRN:>\
MFE"=%7<CRK1Z;7Z>#>NS5DZQJJ;!74+@H!0"@%`*`4`H!0"@%`*`4`H"FMKG
M<;2ZHEE24+<[L^=W#3P<5%4=>"G%)U`]F@/S9?\`O'6S>66_8''.MW:ZW)&?
M[$0<IP;.D,K>0;[L[N3`N.,_%CC3)^SNVZ\W]J1YP(2&M?!7,YE&3M1IM^+#
MW%W197<:ELV8EK_^[6;/9=DFQ5YZV-V;<VG)]Q[)CNS^T+Q+J56;:W:^W1<6
MNMN:9<)Y!=;_`&)$I1``43K6S0PKT;O=L+%_+FI''>?I[/\`X*MWK3ILQ.9<
M[Q+6+*I;2(BMH%`*`4!,GM^E4X8D+F'O)CV'Z/#4IX$(=XU\ZM?R:=[?Q<W[
M^#U3GC[CHPQ+=Z)?R5]H?XLN'\OW6M4<"G+%FTA[?=_9&KUO$RR!K9/NF`$E
M78"?:K29/DN7NRQ5S(LJ[6&VO-.-+#*Y:"^X3RGB@JU"R>T4V@^PM2'R)+*=
M6WD-K#J1YCNB$CG21P(X4!3H!0%0=GT>*N="X^/*/0G]99N?E^XG;4A&CKR>
M9#6JXO+X)Q24([[QL*94I.AX<Y%=.;;BE%55=O4BI#O.N\U*W1Z--G-V>HW8
MOJ@R^S1WMQ>GZ->8N"S4QD.KC+R)U#\WXQ!22MR,MOD;UUT237-O:?C3R16)
MWG_A'NH;9O/+2N:K1R7+*VT%;C7=,-,\>`!T``KJ\N@M"J?+YCC7L#D1ZQ"\
M.WK?7IXV[96F188UDS;/9D=)YFDWRQ2[3$@+`[.9#=Q<T/@UKT]ZS\RE=Y-.
M$&ZY7O.%J<6:_-%8!2X.5YL\C@\6FH`-?EIK[5Q\RORFVZW)?20TN$O<5-:Z
M^DT](9F6R/T>U4KU[@5!`U64^(L^\R0K()D<5)XZ<>T]@K,8<62M_BV=H//%
M3WZV-6W&YZ7'4)6L_876==-".P@BJUC4WN4\W@K;::N)8TW;BM=Q-D/5RW61
M:,]ZB<*8*B9=WL^91HY/^I0TW$Q[6X8R->5"5*A$G3PU^J7H=J9:SR^IW'6D
M5U]!LTU.)[CK(EIEO]K<+JDZH=4/>=YJ5J"?!KJJO;&MIQG145?J.]=_+B35
M3*XH!0"@%`*`4`H!0"@%`*`4!!'(7V5!T!08EN-S%G_4V9+*6SI,U\TGSO#4
M]5!4J0TTZRIUFJ6T_1WLSLSU$[Y=3.#VA,/<'?\`8L</,I34-)CMW:SN2W(-
MS9="?-CW9R6I+O@4&QK7+5%-)+:V=*4I9:5=$;8GNR5!Q29$IB0ZAYULZ);D
M%".]>"!V1Y"-$H\',DUUUIHW[2LOJ9R6\T\H!''Q5#S#:X>EC%8;/F+D'2-7
MO-2>N3)9..=,>[;D*4J+)N]D=QR))2=%>G94RJSH`/`ZL!04/%K5?F5U<O\`
M*][4KO\`":_J[*U]YQ.877%=1^:7>[#<FBY-MZ]9\6NM\M<';BSVJ>[;8ZG2
MNYI=>=?*E('OU][S'VZ]:?MK]<O(GECE_,-!YOUZT^NGS&<H1<+LZPV*M8Q:
M6U/8>K/,7E35>8M2M;9<LD(9=E-]>EI])B9JQ9P''TM;=9:RE)!0%PGE+XZ>
M]21KI7W%/]T_HGR_E]5S:W5)?_1O_P#]9X!JO(/,83IFN4_Z/VE;XCS_`.\+
M+OM>]Y*X?+/W7>BO,=0X2YO;HO\`[.H?_P#&8L>G_,I[:W*?]'[3">[VU6[6
M=-X^S9MNLI6[!NS[DHR(3R$EH0%GB=!PTKPKU>_<!Z/^:^4K0:'FT5<4''X;
M-ZOSP2/>'H=/R_Y'YZ];S16Y)7*O-&N#V]U,Q"ST[[WJ1JWMO?6VRI00(X*4
MG0D$J!*?.U%?!5[EGDV_K7KX<ZOJ#DW3A.F/L/U*Y+^\7T@Y/RR&@U%GE[N1
M5&W;OU^:V55=.F^:DJ`V]R))"5**G4EQ&B`5*U2%'75(T[*Z_P#F7R1;M_I&
MCYE+4\RGW+<K<UFICMI146W$7?W9^EDXOF>BM:%2CA2%Y8]?#J;5=&FS^XV)
M;SP[_E&%7NQVU=H=;9G2([B&`L(T)!(`TU%>*>J7F#2ZKTMYIH8**DK<%T]%
MR/4?+OJUZK<F]1L\N6QM+/7NY_\`O11U[PVYOXOU*]-F4VYU3+DO.Y6)7UQ)
MY2_CEQL5UG/)7V:H7<V&E:'PU2_:/YMM\GY)S70W6G;GJ;3HVZ=QKH5#Y?T/
M+)<LUOB[VV&:NVF_J/T!JU2>0)T:3YS)_5)<\XFOMJY=MWU'46TJ36;9UGG>
MHYSIN;QAX917"CE=*XOVHDK4510"@%`*`4`H!0"@%`*`4`H!0"@,7[U[28EO
MOM+N%M!G,3TO&=P\5O&*W$=R)!B_',)Z"Q<4-*!"G;<^^E]![0I`/@JIK%6"
M]I:TO?;ZCR;`;(X5TY[.[;;+X'$1'Q;:[$[+B<:6&TL29DZTVUFWR+TN*D#C
M=UM*=>5IYSKA)XU:T,84R_Q-(LSQ9ETZ$5;NV]FXYUSOD*J1654(D*R!0"@%
M`3)[?I5.&)"YA[R8]A^CPU*>!"'>-?.K7\FG>W\7-^_@]4YX^XZ,,2V^B=03
MTK[1$^&UW'^L%U[-*Y<+'^=8/66)2M1MO(U!Y,-N&W>5VI1ET&S-QN,&SQI-
MTN<M,"!%CK6]/?*!&MZ4\RC*U4IM*'N7L*R4$CLKK:>^K:7+;VS*L>ETWR9H
MN7XX/$Y:[J>L&NE^O,W$^F#%K5ERK:Z_#O&[>3L3I>#I?84IN2FQHAR;>J^2
M&%`I=Y"VEIP'WP''UAZ@^LO+?)%KPEJ6;55V1=O/%[ZM-,YU_/.#A'%]IJ#D
MKV\.X9<D[L;XYOD$.<HJ%FQZXIQ?$8)6=?1[8BTLQ[XT4G@"]+<KYL\Q_NCU
M5Q/@V[<7U6IKZ)G/>FO?BEVLM)&SV#J)CH1DJ`4CO9,S<#+)$AY0'%7?.792
M]5'CVUZT_P#<IS>5S9A7\%S_`%QX:]^*7:>^T8-=<4EF=MUN7NK@%RCG5F99
M<MN61%QU/%"W(63NW:"8@'`MI0DD=AKS/RW^XJ["ZN9<Q;7"EL62;3]J<]IJ
MEI=0Y)J4J?UF;*;?=;N^VT03'WCL;.\6'QW$_&.<8[$./9A:(',$JGW*R.JG
M,7TQQYSR8R8Y*`2*^AO*_P"Y'D/FV\M#!*-^E-EEQ6WK<V7[#NV_AFWE.K6U
MVZ^WV]..0\RVXR&!EV.W&.%MR(KH97!E`?9D28949%LDQE@A3;Q5S$<*]W\F
MT"<?U&W<<XRVT<D\>HZL-9""H9"T(X%?>$<"X0`5D?5Z``#F[:MSC'.W15JS
M?F<OBZ&/!IX#IP\'`ZCA[!%8,$=3YQU/GGF7_CJ_5*_5'V36RS-6KJN-*B98
MT\GQ8IMY:DQ4H@ZJ)"M->)/-^N\=4[LGK-72VVDV\-AHYDZUR;#CUU]056;J
M0V(OBD%NTWC;G<JU/2M.5#5_-WQM5IB!8X)7+80Z0G757+7JCUBT$['EFY<I
MMHSQM6Y1FV]J,*O%TNK6Z`"Z>].@`.J^)2?:K\L='=E=YIKE/:HWME?:R];:
M:KL*==A2DL&S8*P_BQV@4PV("@(*`*5!2N5)!!5^I&G$_2K99FK=V-QX1:8*
MB"MM*%+/I$@#DCI3PY4?JB!IPJG>B^9<YC*"VNXL-FXKW<38/U>,&7/WGZ@L
MF99:DPH%JL."R4M*(Y)T20;LKET\WO4MW!/'MK]0O0ZS<T_EY1;:^%?02TWY
MAUL2TVEAA3/?(;Y%(4RZC3E<2M7,KFT!6HCQU[<N5\5-MOH.]<[D26AH%`*`
M4`H!0"@(%03[[L)'@JKJ^3/G<(Z93G!PDIUC+*]G0WNZB$XRDJ1Q)BCF5KQ]
M@:Z:_P#CJQK.>:;DL%HIQS7HJFV.;M9<M78QCEHJTW$ZTJC?95:K2K_,LZ*Y
M?URCKRZ"J&AY=?YIJ/&3DX6WMV.B[&<_6SS+X,#$.Y^_>TVSD$W#<//L5Q)A
M2`4,W6Y,QID@*!(:;"/2EO*5IH$AI)]DUU];R_EK;N7KTH36ZY%+9U;&G])S
M;?-%HX\&YMECA7'K-4)?K)=E"XH8OAF\.71SKW=QL6!2G<8EI'^<CW5Z:''G
M%'WFB4A0->&\QYGY?Y;/+XFXZ/\`$G]9+]>AN78>:+ZR;:]M9%ZVEWVM+.G_
M`)PU@CKR-!VJ/-+/!(X^U7*7J)Y;T[RN[)O#!/\`[P_78;E_9,[[5=7W3ENW
M+;L^*;BV>/?),=8D6'(VEV&^A:^!2NU3G0WSDC0GF.IKS31RY3S^WQ]%>GF=
M-F9?4V0L\RA.=%B^HV4[MQN-'(6A+2FVPA##O.E]A"B6GQRDITU4=--0/!6W
M4\ZN\HNK2W;=N45TY<S[3K:?6YX4V8E;6.%@1P0%H'>\.)(.H"CX=#V57YER
M>TX1\P6[MY:FL:0STA1OIC_27FH*WFV8AL<3QX=M=+SFIW/+K<-ES-;VX/'>
M;I.+2HD::]>]F7>>F+<&<A"U&Q-Q\T4A`*@A6,.?&'QBIL#SHZQ'Y"@^:>4\
M*K<JBKGE746KJS3\/)?%M3V.E*]*.'KXJ5EQHJU.85EN!N&-6*XL*1Z/+L]M
MND6&I2=4O*BM/K[Q*4AU8<7J=.8``Z5^2?F;RGSC5W-7H=+<=KB:F3JKCA-?
M&WL:VI'`MW+FFL2FEL3.?4OJ>WXEW:^&V_<#`ML"XS+=$1=,?NLAU8CS'4:J
M?9O3.I"1XJ_4?R?^R[DO._(&CYIYCUG,H2N::RY<+40>,8O96VW[3P+G'G6U
MH9.$HQ;K^&OUGG^<MU!^"?M;KI][E^]S_P!/5[!\P?\`Q\^@/-=/8A?YQYNL
M7.%&O`OVH5?3M5D\<AYX6I?\M4INBU]94^<MU$MAHMS=M664*;=<!QZ\$NGO
M0%<JE7LD!2>'M'2N-JOV)^C6@TF6/-O,LH0A1.6HM.32PK_*QWF.4^?^<<YU
MRT&GL:5999:Y&F]M*MUVLUTD>L+WTMTNX6Y-EVX68-QGLJ=7:;NP'2F6[YR4
MJNZ]4Z5\Q>>?VU^C_E_4M+F_F503PXT7]$$?</I=Z)\_\Z::-V=G3?$E_%%8
M^V+*?]HOOL4J'Q%MDKS2=%P;NE)T!.A*;H#Q`KP/6^E'H7=Y+>TVKYIYFMUI
M_,M2CQ5M7=DHU5>GJ/<\?V@<]\3">HX<=/TJ-Z'T9*8E_;7]>6\F8YOC6,WB
MR8>U:+]?($&6;5$N'.PR[&(<#1>GN%`/;PT&IKK>HWI/Z%<O\@VN>\IYIYIN
M1TNDMJXKK665<J3E')\3S-8^T]3^H'H-=\JJ?QRC2N%V/U11U4MT)^Z[^],>
M/6A/>RIN[:W)S:`3Z/9H>+7R0N402I26DK92C4GWRAQUKC_M=Y)RC4>8;G..
M22OST.DN4E&\DHR<HNF:-*2V85P/0$>7O27^%.4I4?3*I^@\_P";T)*3'CJ;
MU\#*VP6OI\G;7VXKVHO7KBOQA&,9M1R[NL[KA""61)570J$*F1%`*`4`H!0"
M@%`*`4`H!0'P<JR&%B.,9#E=RYC;\:LESOL[D:4^OT2UQ'9DCD90I"G5=TR=
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M<#GGI\T43DFJ;#-6?`Q[K)Z;;S;C<6MV;#:(JLFRC'$(NJ7K=):N6,7F19;[
M'8:D-R=64W-A242'"E!;XA.AU$G*>]F*(]D7JVZ=)C]W[C='$7+59+];[3*G
MQKTJY^G7*;;Y$E%EM[4:&AR7.<+9/>#1E/*>)X5JE.XI+IBU\_V&:1IUGS<,
MZRNG;-K_`)]B$+<&V1LMV[BVN[WZ)=EJ;CP+-<Y$=BW3F&VD-*E"&](:BON\
MRD(>>2"E6NHR^(YXT@**G67[F74CL/MY>;]C^<[L8=C=^QBT?=SD>/7*X?%\
MRSX[<'6&F+UDK2V9#J+/Z1,:0R6"DJ+B>%/BS98MXJO4NH-*F"+5F=5>Q9O>
MWMBL>=V'(KUN+D-KQ6S,8[(>N%R<EW6)+F-+?B%"&VX)1$/GJ[M>G@J\538Y
M(2`=->91*GARK2@/'WX:"U*5W0/9QH"HGM^E4X8D+F'O)CV'Z/#4IX$(=XU\
MZM?R:=[?Q<W[^#U3GC[CHPQ+2Z)27NE#9TNN&,N3C\Z3JA`=5$9;R:\AYU:#
MP7+4VC]J/```^&N7R:3\O77I],G*S/:\6JOK>'N*VMEP8Y^HYW]3^_EYZC]Q
M;KM=B=TF0=@-O+HJV9G-M[JXLG<Z]@(3+M#+K!#KMEB(4`ZE/F%7.DUZL]>O
M4C1>5.1/4:.Y!\RDJ4BX2:KL[K==C/&/%UN*.\L*VVVWV:VHM-MB1K?'C/<C
M<2V!/HQ@(0GT)4Q2=`7F0`D$\=4U^=%[S3KO,;N<_P":5;A/+@HUKA18=)UK
M*3AG9[DK6CG#;BF@Z.5\-GE$A/ZE\#]L3[=<B[S#07<83I[4;LT>H`I#9:*&
MBGP>8"I/B"3IJ`*C9O\`*X3JX3[4,T=Z).'+R*\]KM[E?G-$^!10>!5IX:YO
M,]+:YSS.Q9TB<=-EI*KZ:[U4FG!JNPF;U"P6P@%"5EM"_P!K20DZ!M!X%>OO
M1X3H*\EN\NM>3(1YCH)Q=ZB=%)R?8RC><7W<2R,8RG*>FO,QN_M:T],LLF2'
M]U-O8JBQ;,RM:CK=+Q)AI(9M]XL3/,XGD`4Z6O9KZ\]!?6F>LN0T?.YN,(NE
M:0@NK:VCEW>(ZY3OAMYG^,;EX-C&XF)3(USQ'*;0Q<[/,:D%R4ZW*;1HQ*9!
M)8EV]UP)=21J%)(-?9O&CJ5Q[33C/XD^BCV['@SR.Q7@PKCE7T%[*1W:4)*N
M\4$`*=`Y4NJ`\Y:0.`!/@J1M)1490=R+@L694LCS;B:J.AN2TNM2N8UI\JD9
MMW4^LT6]8#L]>=R]DG,HQ2*9&;;2WRV;AX_`C#O9.0,V-J2U.L#:`"1Z5&EJ
M=4/"613U$Y.^=^6KNGAM=&^GI]B.7JK;MK,CFQC&3V;+K+;LEM\Q2X=XMK4Y
MEN0CN76G'$CS7VQQ8?2L$*;('*17Y2></)][RGSF[&[%KQ$Y27>Z'_I);^@J
MZ.>=SZFC[FO(66GPXVXXP7D.(1SLNGAHGF[$5XH7B-`*`4!`I"@4E:$`@@K7
M[Q/LJ]@5KO)NU)+&@/@Y7E=NPVRW/*+JE;#$:(N$&!QEOS7T%N/"A1TZEVY+
M4I*FVT@]YS`#4\*]E>EGE&YSC6PO2BV\W^E]2*UW&AT]Z"MI+MM-L)#D9-#7
M'W#W,NZ\VREE37=OL2YZTIMW?2??I_ZD:C\S>NB5Z^'6OTN\E\FER;E<;4E1
MT6_"G63TWYG4;KJ4HI*.\"DMN*24!TNE+FFJN)[!QKR*4E*])H[US\N)2H:!
M0"@%`*`4`H"190"WWO,F.IQ"'WVP5O1TK/*AQI@`]^HO%((\"23X*C/F$^6Q
MXUM5D]E#**DAQF,7DR'>[?"W(RVTA'H,`PD*,B89RR$N!Q*"I25$)15.SRFS
MK]5+F>O=(8NK:.=>O.VZ(Y)=0G6AF6:WJ\;4]-DZ';[-;WW+=F^]RH[=RM,6
M2E1;78,1C2=&KI>@0H/K'V%HI\Q1X5X5ZH>JG*?)O*)6]-=MRU<4Z996Y46Z
MCE5LK/4*Y@:>6?;/'+;<7;]=T/Y=ETKSKGE.3R7KY/DOD\RA#?G*7Z/;FU$]
MRTCS&TG0<*_.KS'ZO>;/,7,;G,--<IIYNB3MKH_JU0\!;O\`\QXOK+];:;;3
MR)0CEU!3P'F::Z!&F@0GCV"O!-3YA\U:Z?\`-NQJ_P#1H/TJUU=K*G,LC1:U
M.)TX)<)6D?\`DG4"MEG1\^U$<SO6^QF'RJU1X=K+4R+"L3RQM#EXQ^VW#1!1
M*N++:$W>(?J7(4QH)?C+1V@I.NM=3E/JYYN]+-;"XI.Y9S)_#:4O^W0\?6BO
M0ELK2O67MM7U"[O=+\^.[-NM]WAV29)5*L]ZDNW+,\1MR-.]<LDU]2I5PM4)
MHZKC+XH2/L(42JON[TE_<5R7U`TO`YFI6];/\?"A276E*ON.OIG*RTI8([7;
M<[AX?NMA]FSW`[O$OV-Y!"9N-ONL%P.1GX[^J0WRC[)'F1WT+0ZVL)Y>7A7O
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M3Z#T_P"8O)$^97G*RJQK7^)_0B?YKV^O;Z=M5Q[1Z;EW9]JJ\PU?_P`E7I]R
M>UI[^MY3SB<7:CMC'3;NNX<K0^0;FF_,5%_TOL)5]+F^ZTJ;;E;6OQ2`%.(G
MWQ;C2@>8^^A!?FK\!%4E_P#()Z(\XM2E/R_YC<KFUNNG2==NRETGR+R3YFY!
MS)ZZ*7"<\R_ES>RM5C&GVF!I7JZ]X9<Z=,3ENWC29<IV3W)<O>K:WU%QQ(/H
M7%)6HU\\>H/[I/0[G=YN/E[S'M?X[7U3/O7TS]<O-/E'0QM6VJI4_)@_I/.Y
MZN+>?NU=SENWCKBM$I0A^\H4.8@%SF5"``;!U(\(%>K_`/GIZ)VM-+5Z?R_Y
MAC>BU1RG!KWK/0\^M?N^\XW.?6M)KZ_IU6I?^'M1P3I\5=FTO';7H%W3Q#/L
M>RJ\9=@KT+'I\:?-9A*NDI5Q;8'(7`@Q>6,A".TC2O)M;ZZ^G?GCR!KO)_+^
M5\TAKM6H1@INWBI1EA&3D\.A'J?U3]<=;YDE<5JKS/\`!#ZFSN-T$X4=SM]\
MHWI>AN.XIM=;)V&XFZ4NL1+E=I3B7KS>(2EI'?BUNL.1DZ\2E5>[/V]^5]-Y
M9\G:^"LW=-J=;J+<XQNYE*D8-/9)5[-A\W<NUNLU>L<KL99:U[M#LJ2-&^8G
MO2PRYIIH!$<0%05>P5L'4CP5[8MV969SS2C)N3PZ*'L"XFHQK^$A6TU"@%`*
M`4`H!0"@%`*`4`H"VLSQJ-FF(93A\QYZ-$RK'KOCTJ1'T+[$>[P7H+KK()`+
MK:'B4Z^&L/!F5BC2G.?5R;,93)M%RQX6[&)&.X';,5B/,XQ9;M9;C+C*0Q<,
M@NV/R7C#N-VFQ0I@AP<P6><<=*JED^0SZN7$K9:KIBN.[DW7'L9F[?6K%<:Q
MJ!B%AM\>R,P<[BY[<KY#E]\A3MRG94PX0TZ0TPPOE!`2!4:OIP!ZKYZO3%KW
M9+U;)FX%WGQ[G<;/?S&N.)6V\0G<SMZ6(3E\N5ME%3%Q(MB%I$-S6$LD/)45
M`5&-V,DFDZ-T%"Z,,Z/\!VGSS%<LM&X$6QVS&;\WFS^!HM.+6&QSLL^(Y&)G
M)5+3+3-MC=RC7!8]#926`\Z$CP5/*LV?II0%KWOH#Q^3;\PML7=&^PL>W)RV
M]Y3G,?[F[8)]RFW]Z6518LSF[^S0[99YKL!`:T#X4'CJH"LIU!X,.]7S@NT%
MOO-PQ?=#([!WUMM6-_&DQFWR#%VPM?<18&&MSKH\VRB0VRTSK*U])6AL@:A1
MHVDZ/$'D>Z!K"SO1BFXN(W]5RLCF1V"_Y,9:&(<:[XKC=KF08V#,-Q2IB]PK
MY(D,W!Q4PI0T[$2$DDBHRGDVO"O0"]-WNAS"MS=TKWNYD6>WB#'O%MM4$0)%
MDQYWO(EJEQ9"+%`N#DKXS6V^]&0I<9Q`">[\T<*S7;U`^A;NBC',>W+&YELS
M:^0+?*W)C;OY/CR,>M$BWW^^Q&9D6P<URN#K,ZW)A1;F_P`P:2$O$@GB!5M4
MIL*INXAYEY(]'F,3V6OL*)3#Q>4XEO@#)\#,H:^>@<$FD<U/BQ!43V_2K9#$
MA<P]Y,>P_1X:E/`A#O&OG5K^33O;^+F_?P>J<\?<=&&)H^C=2X[3^K5P^\X]
M+7&R_)[>O!\<=96&WH<S*<HNMK@7UKF"N\DQ)+^JDC3F2D#A5-ZJ&BY7>O:A
M*[:BF\^%-F#]F)SN=W5:M4I63-1L!QX8=BUDMK*4*FQX3BWY;R"I;]PN#CCM
MYE/))U4Y*?=61S$E)/;7Y1>:><<R]2?-VHAJ;[T_+HW9I1DE)?!)I.J47MH>
M-Z+ETM7-7%.B7472&F6TI2R@L);Y@E*%?MR5DJ5Z25<Q<(<42G332O&=%>TN
MIY=?TT;/#M6[SA2M<^5]Y;J[CM27"CX:M:[:D>;V/TJC'3<OC_\`17:S1PI;
MQS?1H*C+3:)O9;2]['">\:UMM1LZ>W*.GCDNO"6XFH-=(/(K4*!*3Q\T\JDJ
M'%*TGP*0K0CV17*EI-??N5UNHXMJO=RTV;C&0D"&E)<2\@.)>\R0C@$2V5<'
M1*3I]D=?3J%$:`Z]E=W2ZF7+X4Y?_*GO6W;OVF.$C97U<F7JQ/)MU]A'2AN+
M:9JL]P&&^I3B6L>O[X>OS,5DGS&(MXGAM/+YJ1X*_43T6\SKSQY&AKIQX-W0
MQM6)U:D[DE;VSV)9:M8=9.SS!2D[>5_#LQW;#JTTP8[9:6I:G`Z\M14KF"4N
M+*FVTC0:!M/#7PU[*^'PMW4IIJWT;SIVOYL<V!4T]G]#6LVKRM7+5R2K&:K0
MA<KMBL2/T_\`P53UND\5J5J+<U!)UI2OSF;4Y0V2391<92L!.H`4F0VZ"`L+
M;?'*I.BM0#R$I.NO`FNY#61\,]->6=-)8TV%?56WJ%2E$<3^ICIJR#IMR;(=
MWMN+2_D^RF5S'KCG&+1FUOW3`;S+65R+K:8K:5%W')"E*4I+:08O*!YW-P^6
MO6WT@U_G6_I>8<C<EP(S4XQ@Y['2C;S*E*'%<)<L>U.>?W4H8OLU[L][L\.Y
M6.<Y=;:ZT%L26>5:B'-#W?<!1<0A!X$JY2/%7Q'YI\H<^\KW96]3IKLHQZ<N
M7ZV;(ZUR7<:?M/JN)#2TH4]'25HYD!3O*K4]B5IY3R'Z9KQ30:C2ZJ675W8Z
M=_Z1;5Q,I=XA#9<>6@I02AP1B9!0X/J."4`U7UVKCI;TK=A<:W%[)+"2WHGF
MCO(!:UJ2E#2ASI*T)</(XM">*BE&AU('@U%:-/K-=J9Y;6EN.NYH9DCXU_R2
MPXU:)%]R*X,6FRL)6'9$Y26I#BDCBU&ADEV2XHG1(3Q)KV1Y7\B\Z\Q\TTO+
MG;N6+>IO1@YN.904G3,TFJI$9S48.6-$9HZ4^FW*]^<VM6\6[N,7&P;6X9<(
M\[;W!;ZTIB]Y#<4*0];LNR""L!+%KAK"'H:EA>B@2L*3PK[Q]/\`T=CY':XF
MKAJ<NZW*'TR91C?=YKX6D=J6U!+/<I("4N@M%HI*4-H`0&TJ"1J-$]HT'L5[
MZ>IAPN';C3X:8G3TUAMUKL)0$MH4TVVVALNEW4)/>E:D@*YUDGF!T\5481RR
M;WG6N+X$2UL-`H!0"@%`*`4!.AUQIQ!8"%2%$H8"TZI[Q:2GM/FH/*3H2#H:
M</3W&O%-*TG7;@:KUZ=B.:$'-X41S`]83OA<;?$QSIOP7(#8<AW"B2G<]OB)
M28J\8PB&\RW=%-.:AU%XN<AQI"5<Z2MM:R!7@WJIYMU'EGR9+7\ELRU>MNZI
M68V[<DI1C*,GGVIIJ-$J=9Q-1>M7FG>DK2Z^@THL,;&L8LEKL%C<M,.VVMA,
M1F,B=$[I<4`#[(.^"G)2R-5/J)=5X55^9_FGE7J;YLYQ==_1ZWPKBY*L(M?U
M:JG::K$^60I*>LM5/I_&UJ2\VP;G;&FBA1;#ESB:,H1V-(`<U[L:\->-4>5^
M4O-UGD7'?+-3;NQG)<-I5?76O2=362TUCE/ZMI]5"=O/ERI?/4J-W.W+;2[\
M:V@-KY^57QI#.O+IX"X.W6JG+O*?GOFM[A^`U>GCO<4RGRC6:7FNG=Y:NW"X
MF_AQ>S[0+E;M/_2MIX=@-SA_H_9>RK/-_*OJ)R/*[&FU=^K7=@E2OMK@2Y=?
M6LU+LZF\M/!)O-*C3IT>\BS<K6TH.)N=F;6?V[N;G$0AS_R%.J%6[OD[S5JK
M:_7.2:O4JF,EE^AG4>K\NW--*Y;UEB5R+IE3VNA*;E`7([N/<+),DRE(+4$S
M&9"7A%)4E$EEEP*=9\_@$%&O'FUK3RGR]S3R[KEK-%HKNABG6E*_.ZFOD&BT
M7F.]*U/56]-&-=LEFK3V4Q+FZ9MS7NF??&)8G)+[.RN^M];CRK?WH3;L,W&N
M*FXL!%KB$=W$M]Z?Y$=RWR(;*"K0E1K[:]'?5+4<_P"9V?)VM4L\K<FI.4:+
M(J]U13V^T\5YCJ'RWS-^BVUQM.H9N,MD:[J8_.=UPKG91):^R1UZD+2?.Y$#
M52^3MT">-?36MA^C67?G_-VKX<,<-IY5HKKP>U%4*;[R,\$GO(K/+'5KP#JE
MJ*W5)\(4V0`/`13E>E?,HK71>2*E3+CUXG4N6LT>LY_]9'2E.W8=MFZ^UJ8-
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MA:>`U(!UTKR;DN@YES:4>76G*\[E/A2Q-FLO7;D'*<LU.@M/$<8SKJ;RN1M;
MLTT(6/1YZ$;@[G%AZ!8[=CZ5:7'&;5<EEUN9DQ:U3R-G1*@>/"OHGTI]%>96
M/-NA\P:R3CH]/<S3LNVUGV-4S9MF\J6(Z>XUQ;:?6V=W]J]L,1V@P.R[=85$
M7$QFQ1V$V]3B0FZ29*4I](F760$@R7IK@*W01J5*K]"-;I7?NV=78E&Q8M0H
M[:5:KHVMUV'D.EAHHI<*UE?M>TR*I2E>_P"4JYEJY@G0@*.H;'B;:'!`\`X5
MQ[4'"<VY9DY5]A:OM-JFXDK<5Q0"@%`*`4`H!0"@%`*`4!;>9(R%W$<H;Q$H
M&5N6"[(QHN26X38OJH+PM1<F/-/LQ4":4:N*0M*!Q((&E8DZ1?L)1[R]IPAR
MJQ=8N`H3;MPG[JV<HW:V\.U%GPV^3XL['IXO=FD[A9(D/)N/I]M>@B9W\&2L
MHDI*GF%,I6A"*'&ZB]P>LO;$<2ZG]WK]N*<#RC)\>M^([DYRU>+E<[\^;-E$
MQ_$+I#QJ$8\R-Z5%M+E[<8=<C1E([ES516H)(.%<BFVEM8X+Z66EE^.=8V&V
M'!\(OTZ^R=S,BQ5#>#X_C^4W!FSVO,HE_:?O-P?N"VI3LJUR;:S(>6W)>.C2
MB6^5("*V6<LGDCL6)KNQX:S/:75:^FSK4O,W*\DRBV6IO)YN`PL/V]D6?)9;
MMJQRYNY3:LHO&2(@W-4O_4Y5QAN*<E23(!=<"6D--D)&YP2:3>UX&CB=1E.S
M=/75\<PR3(IU]O<&RV?$\6N6*VT9VB7#3G\/(+$WN+DSC*X7/I?;?\8K8BNE
MQ@-O`-I1YNF7;H.)U%[=7.PG4+O!DT^VX8XY<<(R6_[?7"T(.7O6:W1]L[2(
MK^;8[=K>PVA]N1<[TRU*"@XF0%-<B5AM2DF,;>95PD.)U%_[G;![J9+N6_+Q
M>\WBU8#!OF&6['L:L^2OQ(AQ*%@E[8NC;S7*I]J:YEH@O#59)""?>Z@RX=.D
M<3J-:'NGKK*O>*X7CNX#,G+G<&LN=W>5?I&=+CN9!G-ZO%OF8U;I0M4>#W\^
MQQ6WD)<3HV$<P4@Z\(JTU-MRJNA;@[FS`M[%>G#KMO$G,T[B7-NPP6-L)URQ
M2RX_FT]RUKW*O%QM+C=^=$E4B6[<?0$24J9[WT1)6>1I.FE;5E7=6+Z-YK.G
M73)MW>=KMLON3OUM-MN#&27N:I*KQ+OCLUN8ME2+D_.FN.N]]+*25(!"$'L`
MJ9@V'3V_2J<,2%S#WDQ[#]'AJ4\"$.\:^=6OY-.]OXN;]_!ZISQ]QT88G)7=
M!]?S4>BK'R"84_*+W,D:<6UHL=[DW"`5:'E*FI1)2.TG@*]?\_UE^WZ0<XYD
MF^-;N1BG7;MHGMQP.1Y@_*3Z:E).BVTO!PN)?+CB1H4]V.\6DHT/$'5.OTZ_
M*?4:FYH;%_7V=E[BOJ[TMNWWE;DV&S`F/9[OZ%8NKPVKMV;?<NV\[Z-K^GVF
M[4?XA>SZV4ZM$10"@%`*`OSI8<-KZV,:F-:NR9.RV1V=UH<$NLS\DMSS:UDZ
M)(CE(.I/#32OOW]J^LN_Y"YS#HAJK5-N^!R+'^(G_6^L[;:*;<,=Q7.Y%2B*
MXOM"UL([M3@5V*YR-:^A]-<D^6:I/J/*=+^57K(%24\Q40$@G4DZ`#7PDU?N
M+^18ETJVC%*W57>$J2H<R2%#70:#M/L#M-:<TMY8RQW(*6A)Y2I(5XO"/8/B
M/L&F>6\98[D4W8K,Y"8SJ&7D.D\S$M(3'6WRE+B^<@N)=0%:#0$$$ZUIN\\7
M*6H2I6YOJ\.KI6WI-%[31O4K%.AS[W:]7CA>17*Z9CLADS^RF8W*>JX7=VUQ
MFKIA^3R"5*7\<X>Z3:H2W5GSWV4EQ?:>RO#_`#!Y$Y5YUMN4[%I-IX0B_P#M
M',NZ10PZ#3^]].W6+B*Y$65MECNZ<*&HE%VP'(+=#N$QE.OGR;9EDFUPH:E`
M>]8*M/!7HWG'[5-'J;F>Q*4,SV4A97UE*["XG\):2<8ZA97<VY733N5WSJ.=
MBW,Y#AL=E#X.@:>F?'894`H>^YB.->*2_;9J-+>>GE"4HVW2K5JK]NTQ%RRK
M-6I=]BZ:>L3/7TQ7-O<5VD;=4@29N<Y,FZ/18X.K#L9.).W7OGQJ2I#FB#PU
MKSCRYZ$Z+178O4VH['TPMOZR57O-PMH/5\[>XE>X>=[KWJ1O)N##6RY$.5V^
M-)P2R2FE!3<FP8BLK@-O1U\42%H2\"`=-:]_<G]/N1\LLJ]9LVU>MJL6H133
M72FNDSCL;V'09@,QT-L,,!M$1YKT!L*_U9A"`D$J4/L[T8:>:PH<B1P%>0J$
MJ.LFW2G])8AI\N"V$B0M(T<4VI?.I2E-)Y&SS+*M4)T'*-#V:5L6!T;$7%*N
MPF40>RB+$Y)JB):R:Q0"@%`1`)(`[20!KPXGAV^"@)0I)2M?,D);4I"BI02"
MI+@:(3J1S^>=.&M`12%+4$!MWG*E)"2TX%$H)!.A2/-X<#V&@*C3:724+=[I
ML+2AWS3WBCS#E;1PU2>?0Z]@`K?8C<E)\.W&[))[)4I\Y?Y?P>++C)..1XJN
MT_)YUQY3)W#S;>_<"=/=9$K>V'ME#Y)/H;L4;;-7:Q36X[KBF](<]S13H2>5
MQ8!XZ5PO37F5OS%ZQ:GR1YEY5I+G++'+_$14_P"8FZQRO(_A6R3VXGI3S_K-
M19<UHFT^IT--/N5M`;:6IMW1P<-9TG4^,J'-JGM\-?<5KR=Z66^50E'D/*7K
M<U'_`.'C6GMRGHM7_,^IOM6YW:-]%S^DK)QRR-(<5R.++:5)*1-40"HCZIQP
M'4Z<:K:3TU]%>;ZNFLT>ATERGY4-)%Q]O=Z3.I_6I-\OUO-=;IVEFX49-QV]
M.-*LP-O?'78;78OBJ9-A/NRFPXAJ8KE#;FNNJTN\FAT\=>I_6;R-Z6>3>6/4
M\CT^D=W)79IXP^=(]T_MTY39UOG:QRSF6LO:C2W)JJN+,L578]A@5V^7=+[8
M%\N9'.MI7++<(#K03SIX.Z<.:OSUUGG/E%[5SM2TFFE%5I5/H]Q^X_./V\^G
MND\LV=?H^7:.Y>E.VJO3VDVI+;MQ*9O-\U.E[N/_`,M6.)__`!M<WE_G^/,F
M[5S0:9+-3&3]F*-6J_;EY)L78VH^7^66[;@FVK%GI-C^D>[7R3U`8)"=OMR6
MQ(DNI]'=FJ7'>(+7,E;?>*`[>U7`UP?-\M+J=+*Y&Q:A*G\*/D[]R/D+RUZ<
M<NAJ>3:73Z6<\J?#MQACCW#MON[:%WG!,K9M@;;OMD:?OF.OAYM2X61VA*9-
MKEM)"N<+8?&H4.`\=>G?3/FUSDWJ=I]75J"4UB^GV'QII;'*]=R2YSB-USYD
MKV1)Q_AV;<S]N!W>V$S1.XNT.`9RVX"[?<2B(?"3JE4QJ"W;Y[O=#50(>C*5
MJ1Q)X5^E6HU'ZIR17UM;47[J]9>T%:)O`RN$\H2-==$@$^UPUX\>-=3RO1:&
M4%T7']"/(6_A9!2`X2A8#C7*E7<)5HX\XE6J./[9&2V1J%MZJ/9X*X"TFHCJ
MY*TVM*YNM,/>CG3T=W41<XURIT-8]^.D;:?J%4BZ9+$G8YN'$C=U;\_Q-]-F
MR@1FB5M077&%,JN$%M7OXSI[ET:E7%1JU?\`+WEW5V79UNFL7I.+^*5N+:>[
M^DX6JY7>;JFUV'/S)>C+JLVV;<:Q:]85N_BQ6I,:#,@M8SFB6-?,;D,+;8QU
MIT)T!>:?*R>/;7H?SIZ*\NYE<=SE-B"3_#"$<?:U@1L<KU,G5.6SV&+7L,ZE
MK6ZJ+>.E_<&W.I&B1&RK$KBQ(2.`<;<BWI[D;<`U3S:$`\:]+S_:1KK\W>E.
M]DDZX6>E_P!8V-2B\KQ6P^Q;MH.K;)WF8UFZ=)V,0Y*>%WSG-+`JUAXG1,AV
M+9KG,N3+:4]JD-E8[-*\DY+^U'2Z:XGJ7)^V%E_68JUTF=\-]7/E.6NLS^I#
M=!=XA((<.W^V$?[G["\WIJB!=,F4(=_OL12]`\B0CE4C4#7A7O#RIZ%\A\KZ
M^SS3)&[.S_#*W;2==CK3<G7W&5%7/@DZ)G3;!L&QG;?';)BN$V.U8CC]KA^A
M-VS'K?&:BA"4:!)B.);8BE6FID-$OK5Q4.)KV;?L\MY?-/2QC&*N-T4$MFVF
MU;67+=A06"K0N]("4@`J.G#5:N91_7*/%1]FIOF,]7\$'L?6R_9^&E=B"O!4
MU8G8[^,MIMG)2>PEK)`4`H!0"@%`*`4`H!0"@%`63N9E3V";<Y[FT:)&N$C$
M,/R+)6(,U:VX<QZRVN3<&XLIQL%Q$=]3`2LI!(23I6);8OV$H[)+VG-JS]=6
M[UY@Q'[=MEM7E2(DZT+N5[QK)[_+P5VWY-BT.YL7/TAJ(MYV-B4RX!JZ%:0B
M.(SI2>9.E4%#JVES.][,<J]8/U$6F_WXM;7;8YIR2)<#&H6+W\6O%YYAVMQQ
M>1MYMDHM<M-IENM&%$>6H-N35(9222*9*=`SO>S).P_69OEN.S@*[SMEB5ML
M5ZN]PBYO%%RO5QO5IGMW&0EB&E2(KMKDF'R)2ZI;H2YRDH*DD$[;5M-NNQTV
M/<:KTFXK;TG59QGO775N):[Z0RR^VM3STF)&;4A/V.+&DA*+>E:%<I#0[?!5
MCAK8WM<?LH5ZDZ0V`M7)RN*+,=8"$=V\PVWJAQU.NFD?D"&QV]FM3,$4J'GA
M:&UAU/=K4IE`*D$\R'7`G_/LZ#WO`TH!&/</LNH<<00\GTATMM%]]#33B&WM
M0=$O@'E3XDJ-8EM6\$(Q[M:B@EAIQUR2[&6A"V4(4?>Q@">6Y.%6JG#HG37C
MQJ,DVTUT,R3H&BXCJG&0W&>E/]PED%Q?.H>C-E9'+HRG4=NG&I)4;:Z3!(2A
M1*T)<0'#SE#A25(4KB4@H)3RBL@BGM^E4X8D+F'O)CV'Z/#4IX$(=XU\ZM?R
M:=[?Q<W[^#U3GC[CHPQ.8NYN,O3?5U=/F?VY)6YMGD-JRJ:XD%:FK+<<VGPK
MVDE()2W;8,0O*UX:*XUXQS7E4;_DW7<C69PU"K1852JMM*>W8<CS!7AI%CM2
MHLZ/&N$3E1&G,-2VT@@(2B2VEULI(.GV1"PKZ=?E%RW0K7\ZU'*-1\"C>N=[
MX>[)K^+V;BIR:22HVJE0\0=/``3[&IX$^P:Y.B_\6KVHN;)6+TK:Z-BV=/U;
M"QJ/ST^HDJV1%`1J.:*Q:!#Z/<[:DJ2[NWV;01\7^-Q3[(TUU'CX5F2<=LMB
MZP97Z'[,O,.JW,<Q2";-MEMF]@LQ[0E"[YD]SM^30W4.>\4IF%%4C@21V5^B
M_P"UCECM^G7,[DXM.]JK=*[*K(]JJMJZSDZ>-=1<]K^D[+M:AM*CJ>;F<"U=
MJN<\Q*O#VU[YAI>'RS5>X\GTOY='O)G'$L-+D.%*64:*6XL`M)23[Y95H@)&
MOA-;(TEX:'1DV]AHOW%&K3548,W"ZF.G_;*:N/N!N[@UC>0USML&69;C:P/>
MNMVQQ]:%CP@@&KKCI$JRN6HJO3.*^DJ>)F8?;]87TFR6C&3N[9EQFR)#LPV>
MY)BNM_JH[Y9#JV5#L)XD5#/RW_B=-7__`"V_M'B9F6MO>J7IQW3F-LX!NSA=
MWE/)T:C^EKA*94WP4B1\9K8#:G2?-`[=*T7M3R6S*/B+EF;>%)0D_I98T^J=
M7&32]IGIM+;R#.;6@"1]C;1&=0Y&D^):%I4I!:5XP2/9JT^<::U!1TT)4;QR
M?86H-79=%"D$N-(,ED=RYKR.-K]ZI/A/$:$?H50U&KUVLG2VX+WT?TEB.AC<
MV[/F*J67.'*T\H+.I6EA);0?"&2$Z\H]@U8L\RLVHJS?BG?@J-Y:IOV])HGH
M4I-=!5[AY/F=VI>G'G[I86?87P\&E2O:VU>3<$D_90UK0CN'OW%W][7Y*H9[
MN94>RN\G'14:9'T=[]R>^L7_`-&MN9=1O=BA*8[^O[2]^]K_`.C65*.]&IQ:
M=$G0=P_^XN_O:_)6<T=Z,99;F.X?_<7?WM?DIFCO0RRW,=P_^XN_O:_)3-'>
MAEEN8[A_]Q=_>U^2F:.]#++<QW#_`.XN_O:_)3-'>AEEN8#$C4:,N@Z\#R*3
MH?`>8H4$^WH=*9H[T,LMS,=;P;EV39W;7*-S\HM^4W2RXC:7)=P.,6TY'E49
M*9C)=5;+'&CQTSF$`DE6A5IQJ&=9\M5O,Y72M&:O]/\`ZQSHVZF5LP-M-[\9
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MI9LJV+<G]2-;2WB97(9>V3PU`=5R_P#TDR,D.#M((NFE?;/+/0WSE<TWZYH]
M5=5E3E&ES52C/8]OPM5IN?2>)W_42.BM^&L:737$V_BE94I[>NN!3DPL1>[E
MN3L7M\^EK1#3EPOF0R6AJ>`Y#=."_$?!7D>F](N=<_LRT_-[KE%+IO5_[29Q
M-3J.;6K?Z_HI6K%VM5DEPVJ;=B33^<QOG>3[58-(M<6Y].VWTEZ;/N!2J+<;
M^$G4,=G_`%H=:]->>/2#DOE.3OSBY.*S.F2>SIP@CW1Z1<R]1?5O4ODMSFFL
MMVG+*J:N_;751RG)?,6*=W=G./\`]FO`NW_:=^UX?_.E>DO\W>2K,N';L2C-
M;-MB,=O8CZ[TG[1_4G165S.YSWFTFE6DN:W9?,7!BO4;M[@E]AY/BW3]A-HO
M5M)5#G,7&[J6TMSAJGOY[J-1R^*N/S./*?,5MVM.E%/>HPQ.ER_]KGG#SOFT
M?--9J;L(=-S5R>'7.,D;D;/=:>3[P95<,"O6/0[-$DXMDMS>N$9^.XR#$@AQ
MMK]H#J@LG37GX>&O4WFGTV_RSHO\U6FGDNPBJ23[SW))_.>E/47THYGZ7R_3
M;]):;-BIY]OM44C]-W1)#D0.EG9QAQM4=YS''`J2HD^>BZW!]:E`^]YV'$_2
MK[0\J)7O)VGS-5X*<J]:V8]9X/H(O(FUN-KTG4@!043X01JKV0!VZUJY)J96
MG<2JXYGA@=R<HJ.UHL;,=RL!V]BN7'-\TQ?%8#""MY^]SV&2A*==3W*'A+T]
MI-7M-K;4%*S?:A.4J_%1;/>4)<UAHXNWL==N_P"LULD^L%Z/VI2F&=Y<<O'(
MHI<5:H-U5'0L:CC-4US)`5XM0:E^C:?53XJU=B*W<>"^:IP;_/JSJH[/ZKWG
MVL>ZX^DO*KBW:H.].)(N:R`RQ=3<8["3KP"GWFVV_P!&KD-1HN60X=R_9EUQ
MN0D_I)6.?-;<O3^%FT-COMAOT1NX8[?X-UC/\@$BW2H=QC+0L:H4VXRX[R-K
M204A6AT-59:_47I98*.7HZUT':CIXW%Q-GQ*N*Z=I]%2@''&SSCN2$J+N@]\
M`00!H`DZ\*A+1\PNQ<TXQ77*B)>!740^JY>.NNF@UUX^#3VJI7.5<TR.YQ(N
MVL:3J3CHLK4B<>'0$\N@5H"2DZZ:*`[#4K/E^Y>2G<GC_I?T&UV5O)N[<\#;
MG`^%"O)727+8:&/$33IUIFF46G0@6G?W)SZQ7DJO/6QU3Z%EV;@D0[IW]R<^
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M2B.(0@J9AV^)%87<&74:A2G7%)7J2L*U.NF;CQ%#:I/=U$JNAZEX3ATA`AKP
MW%4VR/:&8QB_<]:7@A#5S0ZU']#1$;;#'I8#R61H&U_9/!I4I22DHI;6Z&-I
MZV,>L,-I#,"QV.W1^\*FXL*!#B$.=_HN:M$=AOG=4O4<Q/A[*V&#[[HY'I#*
MVRZREEGD<!TT(Y-![0H"2@%`*`4`H!0$R>WZ53AB0N8>\F/8?H\-2G@0AWC7
MSJU_)IWM_%S?OX/5.>/N.C#$QGTN8A8,]Z+]N\&R1EAVSYAC>58_=($=/V-U
M$JY75MZW+\`C]RZ%<W9JHU7T/,8Z6YX+35EG5=E)15=C]Y5YJW.RX=!R=@6B
M_P"SFX61;`9^RXW><6DR7\2E7-!$#)<0>=6NU/0I2_L;LN$%%CD!U"6A7P_^
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M.92CD^XZV5@L0;W?%&6U:K>LZ%R+8T2"RG3@$HK]*8<HAY+Y#IN7<NC_`"])
M8MVE2LJY(J-?BQPQ>TLV;>6ES\6TR'OIO[M]T^8:_D>=W<.R42'H%EQFWMJG
MY-E4M"RW"BV>W,!;\QQW0`I"2E(U6K1*21:Y=SO2ZK32>O:@UM^)J*+MZZN'
MLZ4<@MPMX^H+J%DR9.9Y!>MGMOGTJ^)=KL(N_HEY=MSI'(]EN21G4=_='VR"
MY%:<7%8U4D'@*^7/53U\TWE75W.6Z&>=-M5CPI;$][=3A1MUU<9K"I8^.;7X
M)AZGF;3CEH8E/`RG[]'ABXWR7(5YQ7<;HXEPK=43J3S=M?)_F7U=UGF5.*<U
M7JBO^RSK=!=?<L++;Y:+#B$`:N-MJ1(T[%$!'8JO6UF[?E>XUV4TJUQ:^LP6
MS>]OL,RS[%?L2L4Q3JN^0^B*V)Z'6_>/17"$,)>03[U:@%'VJ\RY7YI?(M1#
M7VY2E*TZXU^ET*6LTKU+BUA&I<.";@;\=/$PW3;/,)N?8PPI*INUNY5TD76V
MK@M'SH-@OKRWY]EG+1P:AME,0J`!.@KZW\C?NML<U5OD?,E<BHJ*3I9@MFQ;
M<U25BW.QLZ*'7+IVZG,%ZA\8<NN,,W*!EUJ>3;\QV^RI#</)K!=$C1ZR2K2M
M7+%9202S*0/1I2?VM:BE6GTURJ/+N?17---<C+/\6R=:=;RMHZEO6JVJ+$Q?
MU7]%\GJJGX=-@=2_4)L6,>:O2(<79#<:\X9`OK;K<7O7[OZ),AMK<@%/FCCJ
M2=*Z\K3BW&46I+M.G:NJ4(SQJC3A7J>KL^.9/K)NO^8EM2F43&=\,C0924:'
MO7%?'`YE@JY?I5!136#1MXNVM$4_['.[_P#,=]8+_P`=LC'_`/.:2MYHM;=I
M*-]1DFTJ+J1+_8Y77_F/>L&_X\9+_/55?!+K+/CK>Y?,/['*Z_\`,>]8-_QX
MR7^>J>"76/'6]R^8?V.5U_YCWK!O^/&2_P`]4\$NL>.M[E\P_L<KK_S'O6#?
M\>,E_GJG@EUCQUO<OF']CE=?^8]ZP;_CQDO\]4\$NL>.M[E\P_L<KK_S'O6#
M?\>,E_GJG@EUCQUO<OF']CE=?^8]ZP;_`(\9+_/5/!+K'CK>Y?,13ZG*[<R=
M/60>L$2=1HI6_&3!(.O:HB]:@#PZ4\$NL>.M[OH,;[L>JGS/;W`LIS#&^NCU
MD.Z5XMD1TV7`\<WXN;5SOMT*>1#3-POE_BV5$5:SQ[UU*^7P:UCPJSY*/"O2
M9\;!JOV'#^W_`/N\G6YUC[E6C<O?'<3+>G['8\STF-\H.X]VW,WSDQX[FC$]
MVXO2Y>(6Q:$:*#/I:0OP:UB6D5*[:=52<=?:BZ-5[#]7?0QT._,LV]7A;W45
MO?U&S"TAI%VW9R6;<;?!99Y5)@8[8#*D6NQ1F'$I/+'T2KD%=3EEN.EO2N/9
M+(TO;[SB\ZC'F6G5F"PGF[/8:-]06(+V@ZK<RLY96C#]\K3`SVPW98Y6/NFM
MS?<YLWSJT1\82;M/26D'BML*/8#7RO\`N"\FWN=Z.=ZU!RHFULD_H3.+#4+0
M0X<MWRQ-9^I';#)]U<4L=KQEZ!$N-CR^Q7:,U.$<-/(B0I[1U-O+I.O>\:]+
M_MO]08^C?FR.JU;R4FI-O*J4>#XC78>&\[Y?+G55%5K[?J-7G>GC>\]T?0L$
M95W2.\2J1<&U+<T\YPI6R%:K/'Q5^G'F'_Y!?3R?-DN9<OYCK-6K5NMS3RTR
MMM4PV3I5=)Z]T_E*[HN;K2N+VJO\73[44?FY[XNCD[K`@#IS%4R:/-U_^*[:
MYVH_?OZ6WK#IR7G6U=$K'^N/-OI[J=9;C.,7E37X_J1C;<7HTWNW`>L[JY."
MP7[5.N`B:2YVBM`QQ'V+CV5ZE\P_O9],=0KF7D?.W6+_`(K+VT_KGMWT2C/R
MG>A*[L=J>9='=VKO&//[/3>DD\UZPK74Z^;.[?#_`)CQU\[>4?63TP]1>-J/
M,7+]?;UD;LLJE=MVFTGL^&,MI]I:O]TWF"Y)0BIY(I+\JUT>\(]7GO:5H[J^
MX2]J%AV*M,[D"-!HLGN-!K_X*XW,?5;TWY?S7P7,M#KUH*X\6$4]WQ.2/)K'
M[M.?6.7\.DDZ?W5G[2[=K>CC=W!MT<(LTBXX].GYV]*P./:K$)8?B0<I+4&9
M>YJU-(#-IM3?GR'-?,1QKZ'\A\Y\@^HKCY6L:;5:;RZ[4KSO7;G\O-:691XD
M6VY2_ABL6?+?G_UNYWY\U3Y7JHRX3GGJ[<(JJZXG[.L?@V+;7;JTP9-PBV;'
M<0L-HA29JRB/"2NW1T)N,U]E?*DV=XH.LG37@>/"O:MG1V6OTZ%ZT^60CL2>
MW+'!9MYX+I]=?N?"_ACUI'*C=[K<W'W<OMVQ'IXUPK;=OTB)*W6FVGTW([BM
ME:V9(P:V+;6[$M_.@_ZY-2R4CSD'0`UZN]4_4OE'I-R^-KE&LT]S6W(YG&%R
MW<:;Z)1E*M5TJAS==/477_+3[#56/M=C$FX"^YD]<-PLA=\]S)LRO;V0S7G"
MLDB#+=>?0F"%ZGNP>5MSF`[*^,_-OK_YN\ZWUJ-=?MQG"&2"X5N'P=&R./M*
M.BY=.XG*XGCUF1&(3<=*8[=N@E`04Q&(S#`0AK30ZD('O45Z3YEK/-',[[OV
M]3"CZG]1Y+9TW!AU'DG6&P7&.Y;KQ:;;<H[W[9'E,H`3X2.=*-1[M=/E7-/,
MVA2C/4V]C6*^TI:C6<)N+^HM.R8E?-NKA\:[&9CD&U]\AN&6Q9[6X7<&N:]>
M\4W+L+[GH%Y6\20MSE4\T2>4:@5[Q\F_N>\^Z_76]'K8W%I--2U7P]M)J/PI
MJ72J+%E1-N2GMWG1+ILZX%YC?[5M/OO9;=AFXTM93CUU$E;&+;AEI)0[&B39
M?=R&;TA22\B.^$$<O*@%.E?;OE'SGRWU"Y;X!W::AI.2<X[&MKI&#;2ZJ'6M
MZR5%FIL]AT>2VTMUUUU;KQ;U#,ACOFY:D(5YZ9<6,"[&>AD<J74I\]*>W0UY
M58C9Y+%\LMYEQFWM;VY=G3M:=.@O1UG$_E53K[##>_NV-SWFVBR_;2R;GY;M
M!=,E@--,[@[=N%C*;*RW=HTEN[,.3%QW/3''&@RH`Z\BS5I4)G+A/JD=\0D!
M?K4NM,K`',?C>V\5>$\;EKQ-3JS!,/5);W_\U'K3^VUM_G*J>IL<9I[D6],T
MDZ[R/]DEO?\`\U'K3^VUM_G*JO@O;\Y9S(?V26]__-1ZT_MM;?YRIX+V_.,R
M']DEO?\`\U'K3^VUM_G*G@O;\XS(?V26]_\`S4>M/[;6W^<J>"]OSC,A_9([
MW_\`-1ZT_MM;?YRJ4='22:^LPYI*I/\`V2&]O_-0ZT_MO;?YSJQX:7RJ:?$+
M>A_9(;V_\U#K3^V]M_G.GAI?*H\0MZ)3ZI'>X?\`_5#K3^VUM_G.M5W2.5*_
M63A=4R']DEO?_P`U'K3^VUM_G*M7@O;\YLS(?V26]_\`S4>M/[;6W^<J>"]O
MSC,C>+I(Z4LUZ:;?D\+*NIG>+J:5>WPXGY79GI#EDT0@:VS1]Y@:::^8=-:Z
M-F'#MJ&XY][\QFXRR2M/G)="&@@..<92-%'5E9\+2/!6PUD*`4`H!0"@%`*`
M4`H!0"@)D]OTJG#$A<P]Y,>P_1X:E/`A#O&OG5K^33O;^+F_?P>J<\?<=&&)
M;'14GFZ5=I$\H/-9KJP=`->Z=OUV2Z`H`*"EI.G,#S>S5#R9H7I=/<O\X5+Z
MF\N;8TMZH:;N6<J-[#ZO4ITR8;U%8G'MUR<78<ZLA](V\S6WA+=ZLEY:`*2F
M2H*$Z,GE251G00Z-4I*2=:K^8M#H_-=J7*]3!/E]'C5I=>QI_.<B>EI*J1QV
MRR'N3L#<SBN_F.O0+5WQCX[NO9&I#N&Y3,!Y'7[FR$O/6>]+:&BXJE%`5YX7
MH=!\5^IGHS/R[JGK-!IW>Y.]K48M1JWL=7)L9U:74?<@W*-<8K<NWR6;G;GT
MA:+E'+2&FTGCYW=O25#Z:4FOGWFG)K>D3;Y>U[_Z1XNW\F>_NW%:<REN=G)W
M*/1PI)T()*RYSZCP\-:\?M7;$9T\`Z5_$/&6_DR,A!9;*Y*EPF$IYUR7&D<J
M6QV\[BGD-LIU_P`X=1X-/#6V]R+S!SS40O>7=+>MV[:I)02E5UQVO=L,>.MQ
MV5568[3N`Y?KR,.VHL%VW4SF0KT2-:,;CN28D53OF/.WZYMI,2VPV65%9DH6
MLMZ<W)PKWYZ;^BG.N?7+<O-5FXK-?_J6]E/^C)&N5WC;$ZG1OI;Z+).WV0Q=
MZ]\Y<+*MU5QDP\5L:09-BP2!(T4&+>A*DB9<6P>4W5?G.\1W8"N'W-Y6\H<H
M]/M)"QY<A'C.-&[::HGC7,WM>!K>AE<3EA0WNS[+K#M[A]]SK)WF[;;L.M5P
MNLMY;O*AIMC5YUYX@I0MV4A)91J-"XXD`5Y?I]5'5QF^:?!:3_C?\-.K<7I6
MW;M*O0D<!W<CR+?K.YF_6X'?1H-\6^YM7C+Y*T8KA2G-;6^TTOBQ<[Q%[MY]
M9U<2O5((!(KXC_<%ZIW?+%R>C\N7:QP_ER7UQ9S;M_XJ%Y!3[SI<44N%G@EQ
M7O@WKIH$^])XCP<:^.=/#5><D^9<VD^)7&2KC[*$[=M54Z$VNB2E)*4DZJ2G
MS`?;Y=-:ZUCDG*]%BX;/;]I:VD@0D*"M..G#4D@>T"2D52YC"$DXZ7;[`3J\
MY"D*/FN$%0'#BGWNA3H4Z:^#2N5RK07;NI=OF":LR_%A\QNM2BD\V),T6DNI
M6\5A`'*I2`%+`.NBDA04GO`>Q1&M=?GG(>7\ETRU_*Y0>K2;^%.O1O;^@TWI
M1ELBBP+JYEVVF4VS>K;12H6:X9RW'+(7?.(.98M$6E<RS3@E6DYQ#)/(5`N(
MU/*1J:^DOVZ^L&NT.JCH/,ER7@,'GE&*:?LC4Y=Q77+978=Y=JMS<<WFVOQ/
M<;%'D/8[EUM5,C)82/2(<EMMKOV'V^)8<;?Y@4Z#4`:ZU^@%G5Z?F5M:W324
MK%V*E%K:FGA1])W=-=E'3P3W&2`4+7)=;T3WLE2R.5*=?L3:>;NT@(1KIX`*
MVQM**HL#>[TGMZ2/'Q@_^2/)6<B6T<64OAWD-?\`%'N#R5'B6S/#N;V-?\4>
MX/)3B6QP[F]C7_%'N#R4XEL<.YO8U_Q1[@\E.);'#N;V-?\`%'N#R4XEL<.Y
MO8U_Q1[@\E.);'#N;V-?\4>X/)3B6QP[F]@'0@A(U!U'`'L]@C0TXEL<.YO9
M``!M303HTITOJ;'O"Z225\O8#J:QGMCAW-X7]E&CG,X-0K1:BL$CLU"B00/`
M.P44[2P'#N;V54K4"IT``H1VC1(2DZ)X)`">P^*J^I:E%*WC4LZ9JU-RN]W*
MS5/JQZ=8G4+MT+'!D_$^>XC<V<NP7)&P&Y5OO,"+(1':9<(+?<S&GU,N(6E3
M:@OF*20"-?,N26>=<OE8N14G*/7]J/&^:Z>5^YFMK94X]XWDE\<N-PP7-+0[
MA>YV'EO[H<8O*1%6X4\R&[A:5D(]*M$M(*HSR2KO4G4A/97YW^M_I-S727;N
MKY7;FG5TRP^V1CE5N&GN?SMGMV%])4E:0H!P$]K<CSGF5>%EQP@]ZIO7WPT2
M?!7S#RO]9Y19\)S*[.&KC-U4DDTN@MZK36+_`#5<PBEDRI=G6%(2I.A2-#[`
M'Z0KR6QSR^DHO4[%[/L/(.-H=58X4E%OVD5\JRRI:4DQEK<9/*G5M3FG>*3H
M!J5<H[:L2U_$=97U3<>,ZFP]%)RL*BZB?G92GO05)9:[?21YSRO8"=-1K5S2
MZK06K3YAR_E_#NK912JY-=-7O]A+1<WL7TZVJM=-2V<NRRRX?8Y]_O<YBSPD
M-MK#JFG'GI2-5<T6WP6U^DSYAX`,HT4X5``UCD'(?,WJYSJ'+8\EU,=.MCGL
MFHY7BTLIQ>9^:[6GN<#AT2Q^+^@W*Z%^FS(GKXYU-;HV5Z!D-VB&-M+@]VB+
M5<,-PJ:GD7<[M$4^VB/E%\!47F'.\"&$M%(!)K]2/(/DSD?E/R;:\L:C1PT^
MOA2;O/,F]BK'+F>-,:ESE<=+K9>)G;4(M=YNIB?K2WCNN\^Z,[8/%I5P@[8[
M9IC1=U[O#D>AJRG([@XI2<++C*E%<*V,J;=D);*1W;^E>L?6WU,Y9Y'Y*['E
MF4)\UFU^7-*4.AJDDUUEZ_J-!IW3-&GM,50[=#@0VX$%IF)$9;:::9C=XR`T
MR@-MM\S80M2.1(!&NBO#KK7Y^ZJ_KO-\I\X\R-W+ZF]DZ5:Q3K&GT&;7->5M
M_%*':SU!L`J;3'*@I'V,MM(3%;5V#1/*@(4?"!H..M>*:'4PYC*5_P`&X6[4
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MYH"4D@`:`:D\![9UK()P3XS[M,T8]XG"YD(ZJ\9]W_#6>):)\<:J\9]W_#3B
M6AQPZ'4#O-4%+Y9;9<;*BTP4!0=#Z=>;O'%$$\=-16%.'4..:CYUU0R,,WYE
M[(,XI:Y;MNL.-721?+QE"[8]<9&1Q9TMEBQ6IFT347%,=BWN%[O'V.0\HXZT
MSVQQC&*_6,[3_=MC&*,X7N1)AWC$,BW!NUZ;LJ$IMF(VAZ"S`R"-",A7I&/7
M%<ASO)!<26`V#RJYN#BP3P#N.XLF\O*Y=>^QT"_7W&(S>=WK(["U;Y0@6;$?
MC)J=;KP5^A2H/=W1`NJ4!E1<6%L]WIV&HO4)NBV*AJ\,]Y6R7KUV&QFV7&X2
MF\\FPH]Z5B]JN-HQQ5R3D>2-ML.7&PXXR)#"KO>K`F2VJ:UJTEA+J-%*UX%J
M85RU3DEM'A98UV%T89U8X/N7NGB>VF#VC(KI'R:'F/>YFY&3"QZ%<L1M5NN<
MF"VXXM;C\E*+@E+C>@*%:\34N-"6XE"+L;=YM.UWBASZHT84ZAYQPD,OE:`E
MM+*=>;O$*!*?!J:.=OH)\<AJKQGW?\-9XEH<<D)45)45*U0"$D*4-`3KV`@'
MMK%4]JP-4GF=2'L^$]I\)^GVT,"@%`*`4`H!0"@%`*`4`H"9/;]*IPQ(7,/>
M3'L/T>&I3P(0[QKYU:_DT[V_BYOW\'JG/'W'1AB6[T2<.EC:,]NMLN/Z-_NE
M:N>.7.I*5IO2QW6\"JW1X&T:QJ%``:K'*HK2'$A(43JA"]4MN`]BQYPJSI[,
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M+DL).O%GL]AN?M_M;MUM5:F['MSAMAPJTH4%F!C<!BTQBM)U[Y#<5"`U(</[
M8L><ZDD*X$UY-J;6GO6/#Z>U:T\$VT[<5%[>BJZ"[;T5NU@VV7\"`F2.4%4A
MP.%?A:4"#HT.Q"/\7LJIRK12Y;==RY=GJ$WA/!'0A)05&DSF?ZRC)I#N#[8;
M/Q)+S*MT<\8M>7H2HA<W$[=%E7]M"B"#W?QM;(X5X"G4'MKQCU.YI+2^1^9\
M\TO\J_I+:<8QJDZM1HVMO378<J]K976X.*2BVOG-.C%980W%CJ0AIEMC1MK3
MNF^5L`LMH]ZTTC30)'`#A7Y5^8.;7O,,-5S/F'QSM/9%MR3J][*/AU*56WB5
M"E'.7$IY24\I`)Y>&G'3Z5:M`_\`\7FLKAIQ_AV%R*450`Z?1_@KE7M+>O.K
MOW%[R5!K6_26GI99I2=S^L*#7L]BNAKM2M9;C"W"-J4>F.)AQZR!`((5Q![1
MJ1^B.-<6&BO<3/>OW;D/PR=48R!Q*'&RA:.96H(<62LZ*!2^E85P<0^G0$'A
MPKM1U4K,,ND2LRIC#8S'#B;.>K7RB58[GOALLY*\S'LAB9UC3*@`8UCS!3K#
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MU#])FV_4/:X2KN9.-Y[:0Y)L6Z-B(%RM\U6BC'FO.E'IUG>6!SQ7"6N`X<*X
M'F#DVA\Q6G:UD()/I44_I*5_0QO82E#V',',=DNJ39I<EG(L(1O#BEN&C.9X
M!.@*NJH`U[I4G&'7FY;[[+:?.;AM.<>`%?,/G/\`;!>Y[S.?,^0J5RW*%:4L
MQ2<<5M:?24+KO:*SX./QQK7.W\6WH]ABEK=K%T`B[Q,HQ=Q)*%M9;BE^QEU#
MPX=T6;S!ANGCKH0-#X*]"\Y_;UZ@\MU#MV.6PG#>[EE?1(HZ>]J=//-M?4V3
M*W9PI0Y(4^9=G^WN;):;E?'/:[JUQY+H/TJW\L]`_/U^DM1RZ$4FJTN6GLZ?
MXBY?YC?OJDK<>TO3$K-OKNO*;1M3LOD\F(A:&4Y1N+'^X+'V@X=._9BY#\7W
M6\\NFH$-MTFO8>F_;AH>9ZR%]\RUFG@E%.W"%O)58])8Y;K8:>+C'2V95VNO
MSF^FPW0/8<1O]OW,WNR)&Z^X<.3Z=9[<M*48CACBN526+=:_>O72"M.K,I]`
M?9/G)TUK[)\D^6N0>3N3PTG*M'I?%P>V_P`**N-T6+2V[RMJ>3Z/F=_CW81A
M6FQ)&YN[6:,;:;89[G[X[Q&%8S=LCC*>*5MQEVR(MUEZ0A?F2_1RD%)7Q&G"
MO(].OU37>'N1BLT'MHMGLKL1VM:K&DY*]-9MP4HR34DJ/9T>\_'KN(_ED#(<
M7[W+,JMEPRZP/YS>S9KO<X+]SNMYO%S<7<)8A+`<>5;T,H!.OF(`KJ>B_EKR
MKZD<IU7.?,7ESE&IU%G7W-.HW+4+B:A2DVYJN9UVK`])^8-9KK2<K;DWNJ6Z
M)&4A0UW&W0.O'1O<*_)T'@&BI0Y?:\%>\.=_MN],]-SNPH\@Y5#1SM1G**TU
ME1J\51+:>O)>8><VYT4?A_KLJ./Y6"TA6X&YCH[Q*BAS/KL\O0D#7F5+)"?8
MKS:YZ%>A]_2K@>4_+]EQ5&H:*RLSIWG\.++NA\VW?&*QK7EOM5BJR=4NLUAW
M)W1W6QK+9UFM.Z&X,6$VTTXEES+K@IQ95IPYS()`3[%?(_K#Z>^F/E&-R]HO
M*G(KL8U?Q::W'Z(GUO\`MJY-I?5;F%W1<SO3TEFU=<<UM*3HE6M)=)8?RV;T
M#MW4S_\`I=<?A';7RORWG_II>U7"UODSRY;A6B:TZ?\`W3]"KW[:_3KEOEF[
MSF[SW6N_;:61Z>W1U=,5MZ2'RV[S_A4S_P!K[KKCQ[?_`-8I%Z/D7-5=TGEK
ME-W13K*,91BHJ+>Q));$E@CQGF'[7]-8MV]1/6:E:2[!2C++:[LMJ=*[C?7U
M?VX6?9CN1G%HRW+,CRNW1\+C7#T&\WA^>(ZV;U'TDQWWG5NLJ3RZ%*>!%>+^
MN?)N2\V\M1UNFY5HN7:J,([;$(INK3=7B?-OK=Z<<J].>?Z#DW+=5=U4=;I'
M>E*Y",7&2DXY5EV-=-6=4\%RQS;'J7V/W&B2A`M=_N\_;S.%)0$KGXQ=8\NX
M6YEPCM[O(!'T!X'37MK/[:/.?,7J/\D7EFTDY.2FY2<EEBZ)1[M#YYU"YAH^
M:0C"S%Z3;63>U>X_0"0E"DI<)'?,J?CZ#4J1W@2GG\1*#K7V5?M<&-<6COZ>
MZ[SHU0AH/`=?%[-58W&W0M."2J.P#V:E<MIM;32G6HU^C6M?!6]F:#7Z-:<%
M;V*`K9#C:DJ5'47F1)Y@%LI0AMSD6E'8I;Y/'4>"G!ZV*&FV[%AZ>L?W*7D^
M:Y/DEBS+);)!;OR;+E60VO'DPH[3T>UR,V]&4FUVRT,,RG4I>E*0TDKTUXUC
MA4P;Q,T1"R]+O2KD;C=WM,!VX6M>U,C9UMV'E\N*T_A<!2')L5@JD(;G/\SR
M298)?"3YQXBM?!E&,FVVVW0DI99*2Z#X>+]$/2O@MVOF8V!FYL7K+8+35TE+
MSR_/V.3"ADIC/8_&>?\`0(\6U!9YUHT42OC6GANN+H_F-WB=G=1]2_=%O33D
M[62Q%G)XR)4^!D4YJ%N)>84>T7J.>:0]97(LH-8[<+RVE"9$AHH;DI0D%2N7
MACAT=4G6M.C`SXI[D7[A_31L?@>X2<]QF'>X^1L1ID^W6Y>7SI$&&;Q$CP9=
MX8QQR06&EW1J$E$AY"-70V"HFM]NU6NUFJ=SB4JDJ&RR4G0R)!"T,RI##JM1
MW'?O,,^C)9;1J=4K/$D<#6W@[<70U4(:_1K3@K>Q0A6V*RJADA60*`4`H!0"
M@%`*`4`H!0"@)D]OTJG#$A<P]Y,>P_1X:E/`A#O&OG5K^33O;^+F_?P>J<\?
M<=&&);O1+^2OM#_%EP_E^ZUJC@4Y8LVD/;[O[(U>MXF60-;)]TP2UI,B@%`*
M`4!R-]8/WK>^^P/?N*<M_P!S>1.!PCS/CCTXIC,LJ[%.IMY6/'7IWU7X_P#R
MQY_NR+?^.)P)?F3_`*S,!<@:^PA`'*.]"P=2M$@=X@+\3B$\%#P&ORWMN?Z1
MKV_Q+Z2Q#%$?`?H\==OEO_DR_JHV$M:"0H!0$%'E!.A.@UT'$GVJ`-J2Z-6U
MI4>PH!U6#XB/!0&7NAY"_G9[OO1PI<SY*MOXCC+>BD!AN9D!*W-#P<5S\/'I
M7W_Z(2U3\L\NK^7P]F.!SX_XF7M.R[BF^9+:%I4IEI"%I&O,E0)4>;@/'7U9
M?MVO"?'C3ZCR?2KX*DO@\-<*W*2E2/=%_$EJP:10"@%`*`4`H!0"@%`*`>Y]
M/L^G[%`2+[WN@R"A33O%]GEY6DGMT2GB5#7V:`F#?+RE*UMI0.5#44,QRV!K
MY\=U;3I9<7]43S:^*JDM=S2SJ'I]*K;L-+O5KUFN=CB;3Y%PQ;%KR2N]XY8;
MP[J%I<N]H@W):E)UY3)7(847GQKP6.5(X^::ZZL\WU$%*4;#]V!#P*?0CR0L
M+PR&X7H>'8Q;Y"3YJV;%:4-\#VA,2'%<&GLJ-<+6/GMB>2$-/E>S#H(O0ES'
M0Z*/GK9T[EIP)5&&G9Z.P1RPR!V<M6M'RFU8EFIM>UX8]/04[>F<=JP!"??)
MX%?G+!">"SVCF2E/..':>-=::C&&5%ZU%Q6TU1ZYD2G.D;J`;C$);<VUR-,\
MZ%2Q;#"<]-+201S.]U[T:CC7!N<MU7-LVCTDLMZ4);<V7HWHU\TN1>C:ZT<*
M<DV#P3=2+B>4W!^^VN=`Q;'[-$<M=Q3%+D)N$RMPH;4RYJ>5TG3QU\/^6?5O
MSSZ0<OUW+N77-.[TN87+B5V4Y*KE3;2<=QX9?Y3#6PS)53]GV&LFZ>WVS>U=
M^@XW<'MT[Y/N,!%R:3:9,.0A$9QYQE/>N>CH*'.9HZC2OK#TA];?W/\`J]RJ
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M[BO&M-#U`YD^$UR=W;*R2I-4JMCIMPJ>2ZOSQZX\XY-/E\+-E0T3C93RZA-Y
M*1QKMPQV5,O;.[_]+.Q]YNV18)C>XBKC=[8FSS%7>.W)2B&9"7M0MM;`2CO$
MCAH>/AKUYZA<A]3>?:3],L_I.%/S*=/O^@\1\Y^F/JSYG\Q<IYOS2$.%;T='
M2=W^+XL)1?2S>K&]X+!O=9L`R;&XDN+&B[DX9&;B38W<25%O);<RZI+86LE/
M=`GMXIKC>AWIGZC^6/4?0\SYW^GKE2E/B<.ZY3H[<J4C15VT]QZNU#UNCO7N
M7:V,>+"Y*#='_"Z/:^M'ZE>Y4B0T%E*U)+NJ^;5I,317(E"@.+@X<*^[-:ZI
MOY8F[0]XD\W3S=2G3S=>WE\&OLZ5S(=Y'4EW6#V#Z/%5N7U%2.+]I+4"8H"F
M4<'.4!*N^8?0H^>%*:"]4*2=`$$F@-5L_P!J-S96Y.>9?A#^'R6-V<;QO'LD
M>RZ$U<H.+-XVU+:;5!Q]U!1>H\],P]XWWC0*D))[*PE14!HO*]7CO3'S+<'(
MK+NB_%9R>PW!%ACL7Z5#L]GN4I39-N>L20I)9D!)TD,K9#>@"DJX:)=U@HV_
MU=^\;6/Y8Y=,^GW')W;YAPP65]V]P9N%@Q>`;@<NA&XAHV@R[R'F-"87+HWI
MRZ\:K$3Z^(^KVW-Q:T;>7&7D\/(LEQ+/,NS++;;)RK(HT;<*R7-BU-V7")]S
M%P7'B,QUQ'M))86ADN$ALZZ"$LU'D[U-FXRJ5VX&8M@^CK<+:O?R'N?>,TN#
MF,PHN6SH.(P<EF3,2M#V50XT>+B=KL-S$ZZB!CSL8N)E/SGDO+>5RMMZ:5OM
M5Z<0CI"E*6U+7'U865%3I42\U++H`=5W1T#*T@>:>.E;C)&@%`*`4`H!0"@%
M`*`4`H!0"@%`3)[?I5.&)"YA[R8]A^CPU*>!"'>-?.K7\FG>W\7-^_@]4YX^
MXZ,,2W>B7\E?:'^++A_+]UK5'`IRQ9M(>WW?V1J];Q,L@:V3[I@EK29%`*`4
M`H#F[ZRS")4[:S`MWK&PZ^O9G<BW7R\-QVEO2)-CND.58I,/E0"HH1<+JA\@
M\`ALJ/`5XEZCZ73:WTWYQH=,U<U=S35R1=9N2G'X5%;6Z;:)'"G'+.;>SXC2
MN//CW&(U<8SS3L61SA#[:TK:<<;5R/<CB24J"5\.%?E)S?EU[E/*M=9U\)V+
MS:I&XG%O;T*5*DX7+;:557VGH4"E7(K@HH[P)/!1;.FBPGMY>/;V50Y=<;Y4
MFMMM157T+VLLJ+:K382U%7+<L))^\"LYX;UV@5!W[,9*$IQ4G@JK;[`2K&J%
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M:T&D4`H!0"@%`*`4`H!0"@%`*`F'9I^C6^&GNRAQK5RW%[GB9SN.!'3VOT?+
M526NYO9^"-R#2W1'&EUCR5<L>.OP;O7K:?6J#BR(\/8^CZ=4'J+R=*/L-SA!
M(@=/8^CZ=95Z[-;4U[C3-)/X<"P=TL-B[B[:9]@4TI$7,,3O6/O+40$-IN,-
MQGO%$Z`)23QUJ_HH:CCUT<E#4TV-IOYMM3E\VC-Z-JTFY56&T_/]M9(E,X\_
MB%];=;R3;R;,Q>YQ74J;E1Y=JE.N+5,94`XP7;4ZP4\P&J2#V5^8GK/Y"YE_
MF?52YQ?LQM3NRDJJ4*MOK2.=H[D+=JEQI2Z]AJ=U,8EFD_<VT9#C^*76\0)6
M)1XH5;VGWD-O)FS"4E3(4E+@20=.W0U]K_L&\Y^EGIQZ5<TO>:M18L\T_6KC
MC;GJK=J<K:MVZ2C"Y--Q;KMI0\'\U/6W8R>BM7+KZ,D7+Z#"/W+[AJ`!VXRA
M:D#12O15.:J[=>9X<WTAPK[@M_NT]#^8:6=Q7(JY"66CU>FJZ=*_F8'JGDWE
MKS)S;S3;N:JU<TVEX<OS;<X+!TVTH!BVXR"%IVWRO5)"CW48,K(3Q*0XC10Y
MNP^.N1;_`''>D7-,UGQ=BU%U[^KL+_\`D+$_2J]RJU?UT:7+RN.24<[;JZ[%
M0UNS[8;>K(LQN%^A;;9)$B2B4MGSW7!_J*$\_*"3[X:>W7RUZR>:/3?GF:YH
M.9:*:DL(ZJ$GMV?PS/N;]GWKU<],>5ZS1\VT6KA'C4CFA;C595M7$I55+*3T
MT[\:#_U=W]6@`YBEP$\!Q([055Z/]-^5>2Y1U+N<YY7&;O;$]3&M*;LQ]H6_
MWD^5]#Y/YC<M\MUSU\M1%QBN`Y2JU5J-=J]A.WTR;ZJ67'=MKRMCS&I*5(?6
MXMEQ8"0TA&I44N*"C[`K1:T_EJ'F96Y\RT/!XLMO'C1[73;F.C:_>=R+S)H;
M5G4Z346)1M**XGAXTV4Z&=9/5J;1Y9=MR-H]L\EL[T#[BLHO>YF;LO-.>=C\
M03[198#J5)\UY-R?CNA)XZ)UKWMR?E7+[/F#1ZWEUVW>L1C)N4)YHIT=*M51
M^:G./-;\R>9.97>#=A&>MNRBVDE).XVFJ8JG2C]73REJ0AEHD-CG<U/`\JI0
M')P\/=G73Q5["U<E*+HTWU&S1Q<95DJ%5P)2M:4'S`2$]G8.SLX=E<Z">9;#
MHR:RDA[!]'BJS+ZBM'I]I+420H!0"@(UB7=?L!-5?++<R(IEEN8)36VVFJU,
MHA6PR*`4`H!0"@%`*`4`H!0"@%`*`4!,GM^E4X8D+F'O)CV'Z/#4IX$(=XU\
MZM?R:=[?Q<W[^#U3GC[CHPQ+=Z)?R5]H?XLN'\OW6M4<"G+%FTA[?=_9&KUO
M$RR!K9/NF"6M)D4`H!0"@/@Y9CEHS/'+WAU\@MW*R93;)%HNL%6B$S84ELLR
ME(\#,QAE2@TYX%`&MNFY)H;EJY<:C66UNCV/M-6IT/$A5=)P`R##KQTS;BR-
MELS$F%A,J9,<V5RR6V78-TQ@/*3!Q:\2U>8+Y:&E(9*R>:04E=?"W[C/3/4:
MJ<M5I(.7351_VCQZYIW9N.FS:70&^Z4IF2E<=:'RH.<W>J6^H*TA*5_FV2G4
M@?XM?(6ATG,^7Z>?+]3"<=-+8ZT2V=1>LZRL>"\&5_I_I5LX.CLM5RIFVJ'N
M?H5+-HGLK$50T\-4=59T,M19NK+FB]A%RZ$1#9>^Q!8;Y^'.H`I2!QU(/:.%
M=/F&MYQJ[,=)HXW)6Z4V4--Q9D8^-IRO?/,X&RFUSSS-RN$ABX9OF<%)?M^W
MF(M.`7!QY2=4O7*>UJF''40=4KYO!7U?^VWTNO<UU<=5SFVTG)5S1QIUJ2*$
MM.YNB._NWV#8_MQ@^/;?8U!C6?$\:MD6W18<-(#B^X1S*<==2/.6^\I2SXBJ
MON=:6SHEX33TX-OX53<NT\CTL';T\(/%1+PU4L\Y9[D`!".9SG<4A.O*5#M2
M-#PH;R-`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`2+9[\!K30*4-7O_`-%'
MAE<AX.]QV\IX&H3URY>EJ91S)-*E:8]9.W;=R618T./76ULA==KL[;ZD=O+=
M.F8EDI=@[Y8E:XZI,YA<%`5!S^VI`*N9X.<MV0KLB,HY-#7JWU-],-'Y]TMW
M7W(1=Y04HMQ<FV^CO+:J'CO-.7.#SKI>W88/M<ZTWJ!;KM:Y#<NS38JEP9T&
M5WK2%NI*^1823RK1S:$=H/"OS6\Y^4^<^6N:W-).S<6E3='E27TLU\LO>%FJ
M[$CU-AU#3:%OAT@*\Y/#ASJ(YO\`&TK@6.679VW<T?=Z:+I.WJ;JUTE=K6BI
MO*G,?U:JV^`UZQS=B*WAT.8^!9_0\M97+>8S=%FI[$'IT\62\RC]43].N=K+
M*\N/BZ1+CRVNFQU>.-39*24<J+'SG.(^'VYCS';M>KI(1!QW$X"BJ\Y3>))#
M,&VQ&TDN)9,A:5.+`/*D$^"O:GI;Y-Y_YYYE;O3LW):>J=<J:I7VHI7;;FF=
M/>B#IUN>T>$3-P-P6T/;M;DR1*R-Y2?LF/PN4N0</:0?.2BU,(0AQ?\`G'&^
M;PU^G'E/RUI?+7(HZ-I+543I1ITPWLQI;+CJ(SW?8;SUW#MB@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@)D]OTJG#$A<P]Y,>P_1X:E/`A#O
M&OG5K^33O;^+F_?P>J<\?<=&&);O1+^2OM#_`!9</Y?NM:HX%.6+-I#V^[^R
M-7K>)ED#6R?=,$M:3(H!0"@%`3$`\2-21RZGM*2-"G7Q:5SM%J==IM3/B*MA
MR>QO93V5-L-3&?P=*,3;S;,[=[YX7.PC<NR-SK,\VE=GNS:9;5QL5_93R6V7
M;[E$3S6EQE!/(\5('-HDG0FMG.^3\OY_IE;OVX23K79%T6+[V)HU.CXD7/IH
M<C-PNF3J+V`<>8AVVX;[;:0&?21><>1".XUC&H[EB_V]12UD[S32B$*AAZ0M
M`*CQUKYT\]>C/+]1R?42Y=;BM3*-84C;BZU73T;#QZ>GE:OJ70FS"]NW4P:;
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MH==-B>G_`&VZ>L1%@P:S-H<E/(G91F$U?>W++[P1QE3;BHFX..)5J0A1Y!KI
M7T#H>4Z+RM8E'E]N$$EAEBNU1V%R&GC':L3-8!2GD(`&NI2$I2-3Q]ZCS15^
MW>>H@KS5')5+<51)$O*D*4OE'.H`*5IQ(&N@)]C6IF2:@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@':"#V*!"AX"#V@^P:VV;-G43X=^G#]E2QI9JW=S/<R
ME)BQIT6;"G,,RXER:>8N$:0VEYF8P^T&7V9+:P4O-NLCE4#J".%<^5[56]3P
M(QKI*TQ^HQK8QNQV(Y.[S=!>5X7=KKG/2E,LS\&ZR%N7?9?)Y[T+&UN.K+DJ
M=B$U"DKM.3:K);C**+:L\O-Q*Z\$\]^G')_-G+9N.GMQUJCL:A"LGOJ_K/'+
M^ER.L#3*XYXG!YSU@W8Q;,ML[U%<[IQS*;,]#AR2-`J6B\I:&.N1N^U0GNW2
M2$ZU\'>9_23SCY9UTM)I++E8E6:;N06+W)F;%_@1<9XU+A@Y;C-R0EZWY19+
MLVZGF8^*I39U2!J2ZX^I+2B@<3R$BO7&I\I^>E<HK#V?_=C]IN\9$^9<]R<!
ML7_IG.,5AZ:ZQY-VB,OCQZ\CNNHKL<O\E^>;L5_(_P#W8_:9\9$]>+/;I;NW
M*19]B]KLDRQ9:23F-ZMDRPX/;F5)'^N(F7%N,]D(2@\R?B_ON8=OAKW)Y:]`
MN;\]O6K_`#.#4-C=7:DL=JVO`RI9]IT9Z<>AVP;;7&V[J[I7%6Z.[#*3*MBY
M;4'XFP>2ZDMNQ;!&3]FBZ%1\]Y*7N.G97W#Y%\G^7_)/+EHM/:M*]&BG+AQ4
MH[.C*MM47K-B.R4NPZ#+2H.D2E_ZTXTB0H(\Y)4K0:K7X5`&NAKWJ]1SRW>T
MU?TV*:>VBZOA_H-G`R_&DD4ZZ)D4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4!,GM^E4X8D+F'O)CV'Z/#4IX$(=XU\ZM?R:=[?Q<W[^#U3GC
M[CHPQ+=Z(0?FM[4I>(;]&Q^XON-GWRGCD5X"$I5X`4@<-*U)41J=N-3:5U*V
MVU*>;7%4XDI86I/?(;=6-65O`%)[M2U:$=M;E=DL!PXE-:T)`#H7%"Y08#RD
M+>2TRB.VIR6ZVD!:6"\5<3H0GQUE:AY6[G=2KL'#C78&3S!*G^Z;22YS+#BB
MRE*`?1U)=#9*E3B`$`I'*5<:G*]9C!3=:.GSF5;BW0ASMA>@4/-*6W$.A;`"
MUD**6'.1?I#K39XI`"3IKS"I.=I;#&2),H+;U+[+K1?<;:BM!(<2C5U*2Y+?
M!"6BZSYZ$@'M'&F:!"5N5?@P)W4\R.[:')("9#ZE)^SMI8COJC\JDZ-*"UJ'
M-['9Q[:9H5ZB&2[U$B"G_5^8!:)S+C413:P5IFMGF)=:[>[[M)X:]OAK#:JL
MN'2,EWJ)E(*6%:%SF;4AJ1)=9[IJ+(6@NH2M!4>9MQ`Y4JU`YR!6^[J8W8*U
M-122HJ+::8Z24)NXN\V2N<C2VWG&>Z4`VEU;;KCTMAAU'O'(:4EEQE]1!)T4
MI!X>S5:,K<?@VT:^LNJYJ(QI\-"JD)BL!,=:FGVEK'?%*TK6PZ%*$"/H7"AU
MQ(U`6-=$\%#L.;D[3O0NS576B71[T5+UB=R+<DDS'F1[3[8YDUW.4X'C%V;D
M+BK4N=8(7QBXJ8RX\KTNY]RJ>VM!3H`EPA7ATK.K\-K'EO6[=&L5&/V'/>A3
MWF(7>B7I:<EKG/[+XWWWI<5*GELW5IE*Y3;SA<T^."PZ$J;``Y0-#7-CROEM
MNYFC:A7V1_U3'@5_I&5<4V9VOP4,/8WMWB&/.-%L)FP+%;_2%AS]H#$HLNR]
M0$G57.#XQ77T]W36(2A9MVJ-[?A6*-]G0XXF2FGEMEQR*$K8:G*CF9YOV4M\
M#$=0ZA)67@?-\Y/O:K78VIW>)W>GX=GT%B.DE':L2FB2E2U7)LNR/1#+9AR!
M'*WK@E`;#L<1%!MM26N8:+Y$E6O`\*DY6;E8MM[/F+$878+!4'HXB_8$A"0W
MP"6U*6@<WG:)4O51T*O#689<BR]VAAUK\6(J1@4`H!0"@%`*`4`H!0"@%`3H
M`U*E)<<0V"I3;2=7'!IH$I)("3S$'6HR;2V$X)-[3Q.7.T,H<4JZ6]Q+;C#"
MW#+8:#4N0A2U0EH+BE>EQ>4A2/?*T)`X5I5YM-[G]!/AH^B`PER(EQR.HSF7
M'(P;E`L.,M%(5(2Z6TR"ZHK&C/<^VH5%WWDS_P`-#/#6'24E=U'0'93P9C%]
MN.](DI$80UN)64)4.=Q#SSA3Q3S)Y3X34N++J,<-!34AQI24AF(^0&6'7W0M
MA;Y.JG'_`'@8[@#1;8*M"H<:<9I5W&>'$JN!CE<>"GH<=EEUV0]-;2TU&3'Y
M1(6\XIP!*DE0Y$_5Z]M9XK6.\QPXGG4MH\K)?9B2"VZ&B^XDMRT,A*O363S(
MXN!?FL#57#MJS!)5XF_93=UFEO<3N+80=2XAEE82M#TAQMEQ+:M`T5QEJ#Q>
ME+"@TVD%2B*SFL)J,G\3Z!M]Q3>*8;9?FK$="6T2RS)`BN(A$D$R7'%%J,\>
M4D!1X`@D<:Q<MV;T'!2::?0Z;40DY)5CB4PXM+JHY<C/2&THE/,,NI,EJ(]Q
M:48R2M9::2.9;I(24GS03PJP]5;4(Z:2662HG3;LZS$;E]1=*41ZGFG7_2D:
M.=TMXM.)CQ6Y<=EZ.RA\\\KO8P3RH4%`C0DG3MJAI+.FT-]:FW.3N?Z3JMN&
MPTRC<GBD?$ON,XME"'XN36.W7UMP,A<?(+9#N7HL<!*7%O>E(=4_YH)"&TCE
M3IQ)JXM4TEQ[=F4TGM<(OI>Q51&[H8ZIYY;**FS88(OW2#TN7UQ<B[[0X,)`
M>0V41_3[?$2\^H(AMJE19D*.'9;BD\J$I!YE<O;6B4=#-N5S3Z9R?_VX?8:'
MR:WOEVGW\=Z7^G["GBBQ[0X?`7$9"IA>LL:Z.J?=\QAAA-T=FE4@.$:HU.K?
MG:\=*W6]78MQR0T^F2>S9;AA[:5)+D]M;?BK[3-$6-:H;;-F8:C6=$9!DMV^
M*RS#9BQ6&N;NS"A]PZATE/#E0&DI/:3PJ=K72L7'P86XRR]$5AV%R.GA!4V[
M"OS]\%NE)1Z2V$EOS5)0WP[M34A`1WQ6@`DD:I/#CI7"YARJQS.YQ+\[L7_H
MRI7VHW+X<"!&O=\2.[1R:ZZE:?\`')U)KJZ=^%T:T5O;;72]LNTV.[)Q<-E&
M1K!J%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`3)[?I5.&)"
MYA[R8]A^CPU*>!"'>-?.K7\FG>W\7-^_@]4YX^XZ,,2TNB%PCI5VJ0YYSC]M
MEEY:@7%".G)+MJH%',G0:&M:P,/$P-O1N'U'8_O3=H&W+-WFX@W`S*_SDNV6
M9=(\QG$<53>K19(6C+K$9[(+DT8H=1I(1S:M^<!0P8\:ZI^JBZV?&[OC>.:9
M#DN*YIE66X1(Q'*#<\5FXGCTRXV+#H-[D0>ZN+N1S(+:`93AEI5(T'FA-:Y+
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MZ1KU8'AA[UQEV>);'8B6+I&@7%OT7XP0E<)83H5EX@4S2S=-:&W+`^?<^I_J
MRP.Q[@O7S'KEDD^S;;IN^-M8M@S2;J]?5Y5;+4XVTJ9"3'+WHLEQ?ZT5EN3W
MC+"AC'&>ICJH=O&593?8FX/<*FX")"[CA-W>MF$6V9CS0N<@XQ"A*@YH$3G`
MI](;?4Q(XI`2FHSCGIFKL=0E%;4;5[2;^=3N0;HJ1EN+2H>"LYM8<0LD5JPW
M.UO7VR7/%+K?T[JS+NY':?M7QE-MS3(AA:8D82^1Q*5A(J4JR65X,4@6P]NW
MU#Y[OCM5C+MQRK&\0D;W7,9_+Q_&78AL-MML6\-VG$;O-EQFQ>[)?4\KZ[@T
MIQ"5,I"5^<-2S1C2."(R4*'QYG65O_:]^Y^(+VTS*#M[;\OSA,[(Y6-3KPQ#
MLF)IEPFG<=^+XSZY-JR2:ZRXX9/V9)">Y\WFI6=:[352)B['NJ?JLQ^!>,AN
MD'*KM#O.$2-P+9CE\V_NCEN;OX2'+9MPE]%O,F!;[W%>=D>DZIFL^B!*2`I6
MIN;ICL9FD3Y&(]3?5IGMVL.:6%^_KLUOV4DYZ7(N"W%BS7;);W.M(N6"LQC`
M2)<JRIYDL20#<%)*BHUFLR45'I/O[A=='4+8\TW-L<K$[WA&&63)H=KL.79#
MB:[G9GU0=.>-:84>*\N])E+>T7(?2I]C0<Q&M0HZJ3[RK\YLI"E.@S9T]]0N
M^&<[B7^RYHFZ8Q87,X8E+](L&07?[N+)=D(].^*\A$5Y>-6JP!A"FWHCC<%K
MOR'5#A6'FC&D'1X(985VG4,J6H\SG/SGM[ULLN:?4\S:@%`\NG:./;X:ZEEU
MM1?4<^[3B.F%2%;#6*`4`H!0"@%`*`4`H!0"@*K82KF0L+(7R#1M:D.D]XD@
M-\A!)U'$?J=:UW.Z;+>)Q&R_IRZJI6XV5N6R!/<QJ\[V97O3;Y#.4>CIM3^&
M?&UBQBR\KDM(>M^1MY!Z4&&]>53"><:BM!N)<MQ7KBO.3Q<^5B>=_'MGV!CX
M/A>F7LV_T;>"<;<K(\@N$*U3$&1;)BHBP%OI+K?/JC3C47!2ADEW0FTZK$\E
MXVEZZ\WVVR>/<W,XLN0M0-JL)?QJ+E:6+1`QKDG/[AS(-PD2TJN5]D2XD7T>
MYJ4JY,IYDLKT6O4XQ<D_XD@9JW`G=1-QW]N>";2Q<\:A8=B6S=SC-7.=;KKC
MEMLE]MM\1N`F[KNKSGIN2W25$B+2']9#9:/=\"JD5',Y*M<'[@6#G^TG6E><
M$SS$;Q.W,RV]HQ7("UD,3)H-CM<R0\Y%<Q2WICVB6R\_D<0H=#KJ`8A20"JI
M&"S[3@GK"+Y$8MV:1KC`DHN>%L3KG:[O"?8CR&S*;R"_VUN0\56R0S&2QWD=
MD)CI4-4#4FHUD539G<?`NJ"Y;.;8V"Q2;Y]V]BW!C6R\7X.6JXY)"Q_O&5,7
M%^[35+D2)44J6IN0M1=&NFN@%-K5`8@RK$^NJ/=;AC5IM619/8Y.W=SMB6\B
MOD6<TS<+DB2P]D9$B0M%_N9"4EUN7S]TE*>Y&I--J5$;+5,^TQ')P;U@D2[B
M]6*T9*F\,X-9\=S]Z?DS$=RZY1:YLR1C$S&56*44IL=M4^A2V_\`S11YDROL
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M8F)6CO(_V%_3O$$I4#4+#G*+E+9M=$)*CH?8K<1%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`F3V_2J<,2%S#WDQ[#]'AJ4\"$.\:^=6OY
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MWV'66XWI(2IEN1&>?G-)6S.')H!H.`\WF/OJ0M6VMC3-=RY*#HDV>TB,M]+C
MC1T;2AAA(9CN+4T7DR'G7)(;1W`7)!5W?*HZ'7F\%8C9BKF5I4:K7KW$7?G3
M`K(2VXI*I2F4I;5*&K4>.XZY&6\IUMA?,UQ`<"5CV16S@VUN,<>>X\O*R"\X
MB.RX9"E*>6[%:2\7$,+;92TTG[&VR==5D\W,KP#P8X$,U:JE,!QY[@P&0F*E
M3;KCB$,H?*THC1W`J*M3K:T`.'N([@"$)!',=#J!4(04E\4:;7\O?B9=Z5=B
M*R7@TE.J2ZXZF,8Z4QHR4QHS39;=;DOI0%]_YP"$\2!KYU95F"N*"7P--UZ]
MQ&5Z;@Z)U*)8CK<=2$N-&2"P7F_1D);BH4%L)4I4=Q14TE'(K]7KJ>RMBL6U
MTJAHXM_<R4LQI#@C+@QC'>9EMMM266G(S29#91,5)>Y06W5)/*R`D@A1TY?#
MK=NW&>Q536U_0C/$O]9\S'L?L&+X[;\6L5MCVRQVZ)_J=L8B)4RU#6H*<M/>
M]XEQH.+T41J5)Y??'6LRM6W2BVU^3)V[UU5S)GR,[V\P;<>T/8_FF.6J^V55
MSMMV;8=AJ!>F02XL*DI9?96$I6H:\JAS]JM=*R[4$JJE39QY;F7?Z);RRVTF
M+;XB([32(S`MR)28R4I2AZ&AUAR$I<4(;3H.`<\(X57G:S1RN.W;1^S!^\RK
M\MQ4=7WCBE\[[FNGGR5A;ZN`&KBDI2">'BX#A5F$<D5'<0;S.N\IU(P*`4`H
M!0"@%`*`4`H!0"@)D(4XM#:3R%2D_9TMEQR.D$*6ZT`H:+Y`4]AU!T\.M:;R
MDX_#BF3MM)[3FKG?K!,AQ&=EF/6C9EN\W_#=Q;SA%]L<K*A8)<5B<[+N."7:
M(F5:GVG).:8Y:Y$YM(<*8Z6B@E1(-:8PN2BFTU+I7U&YRBNG85\#]8&_FL'$
M\FE;;VRR8IG.4*Q6&7<N4K)XS]JMESD7"Y7N*;<&;?;>_BI;:*UH,SO.=)')
MRG/#N9\VW+1[/EN&>%.LPQ?O699#)@;/WFV[2+BXYEF8S8\Z-'R!S(;X_`QG
MGBW*U"TI@07(0GRI3*K?+<4KOFDN*Y/-K/#;>:FTQFCO,B81U_9ED.28-:,@
MZ=D[=R-S,TN6'W#)KSFL"9#L;EO=919+G\:VR`\N\R;NR^X4,ALIC<A"U)YA
MJ<)]"VC-'>=1^5IMO5;3;<>+I;X4=U3UR?#:@DR$M*;>B)>:EG0A:M%)Y>RB
MA<HJXC/$@=0OF;+;*75-/N)"%+^RM\W*E0*]='/\Y]*K_"L8["L3I*>22L>=
MZ>EEJ4M:E-21YRM5I2"I.K8/;K3AV.H%-*&6O2FTH6\UW"$PN\D+"N]7S`-N
M.^^;9!&JE<=`>PUB4+*551[2,G)*L<2=(1R)*5".U&AN,1^X;/I*T.A7I5N*
M5+($-\$@J)*E:GLJ$K5AI;$ZLCQ;_64UGG0&^5`B/,H9]&0E2"TA2B`RI865
M)2R3S=X#S<?8J?"L--.E#'$OK>51HV$<X8*XB@]$D,A:G&5(``=#2E<CLA(3
MHE)X*T!U!-:KMFU3X:-4-MN]<2^).M3S,1F8BYQ;CPFWY_>37$16>2(_+=;[
MKTV6_P`W>+NJTI`5J#R@``D`"M,+$*IM4=,??@;7?G2E'0J+*'$K94VV4.Q0
MAV*MD+M[KZV^ZE%:5*.BI$75M:B#W@/+H.VLSL1S)1Z:U>[=\XX\J8'EMT&'
M;T0XL2VV^%8XI_U>TPQZ(B-'>>_UEA++8Y0VZ\M2^[U.@/,%:\*RX)JG\2P?
MNQ(YGCO/:5K6.9Y7.]WKZ>;7FTCH>4B$V%_5):BA*1X0!QUJ<(Y(J)$DJ0%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`F3V_2J<,2%S#WD
MQ[#]'AJ4\"$.\:^=6OY-.]OXN;]_!ZISQ]QT88EM=$7(OI8VA2M+8Y+9<3"E
M1%<P2K[H+KP)'9QK6L"F\3(F>]/^U>YE]E9+F>(6[(LHDVRS6MZ\/$194>#B
M=V>R&Q@3-4>A>B75Y3G>I(7Q[:&"V[=TH;#VR/(9CX-$*'82YK8=EJ_U;(1+
M=FG-(B6%EN+D[)4&V;BC2:I+2$A7`5BNS:;+3I.HM/2;L!978QM>W<!EF`Y*
MNKC"7PY#N5YN<=2;GD3C946G,CNC+JF94T_9WFR6EJ/$5F%)K-#`M.33HZ%$
M])^PK=L^+TX5*1!AW61=8C,:[WE,B!)N<=3<EFT25N\XL,YMY3,R"#Z&\E3B
M5))409.$NA#.;!Q+;'L\*#:X3,>-`M\&'"@1(S+$5N)%BQVV68J8,4)C0FV$
M("4(0D#E`UXULLQ<8M2QJ:+KJT5ZVFH4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@)DE*#WO(I;S8*HP2]*9Y7E`MI6512%J"0O7E/FJ[*C..:-#)8
M]\VRVYR-]Q63X-B622I\F`_>IMRLD)3[UVML=V+:[@Z_,9[U3D&(\ZTV2=6$
M.%'#FTK*==A@^2WLWM1&AS[<QMG@K,.9<8JI;$6QVU46>8:'4VY%R;2R?34Q
MV5K[E3>ICC5)TYJAQ/YG#:VM5,TV5/0UM-M1$ND>YC;K#67DAL>DV_&[8Q+0
MN(TXS!N:`B.E9%N:>6WR,#O.5TZU-U6U;3!2MFRNU5J58I4/;/`8TC&Y\^Z6
M-B#9H5JB625<%-+=?LL!#328"YBFPJ2ZA(5)4E)63RC3"BU)NN/S&3)R$)`+
M,AK5X/>F.>B'F2VGM"?#H!4C!2H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H
M!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"9/;]*IPQ(7,/>3'L/T>&I3P(0[
MQKYU:_DT[V_BYOW\'JG/'W'1AB6[T2`)Z5MH0D``6RX:`#0?^G[IX!6M%-XL
MVF7QU![%`A0\"AS'@KQBA@ET'9X-`G_R4G4#V@>RMMI)SHS#;BJH`:#0:@`:
M`#@`-==-/%KQ]NK62*V+`CQ)$>/#SE<!H.)X#7FT'B&O'VZSDB.)(E5VZZDD
M]I/$GVSX:A))/83C)RQ):B2%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H".NG9PH"!XZZ\=22=>.I)U).O:2>V@``&@```)(T&FA/:1XB:=?2!XCX4
MZ\OL<W%6GBUTXT`/G'4\3IIJ>)T'8-3X!0$02"2.!(T)'`D>(Z=HH"%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`3)[?I5.&)"YA[R8]A^CPU*>!"'>-?.K7\FG>W\7-^_@]4YX^XZ,,3"?2QF
M65X9T\[=8XYMQ?LF39[;-;;OV(W"U7ZSW93E]N;O>P+A;GI4*2A"5\I[M:@%
M`@\0:TJ6S!D7:M5[T>TV"5NWE`44C9?/U!.FBUMQ@5:@*)`2-.!.GMBLYNIC
MA6OQ1[2'RMY3^!7//K&/)4H3DG6*=?8':M-;91[4/E;RG\"N>?6,>2MO%O;I
M=C(\&Q^*':A\K>4_@5SSZQCR4XM[=+L8X-C\4.U$#NWE'AV5SSZUCR5%W+KQ
M4NPE&U:6$H]J'RMY/^!7//K6/)4<]S=+L)<*W^*/:/E;R?\``KGGUK'DIGN;
MI=@X5O\`%'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ78.
M%;_%'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ78.%;_%'
MM'RMY/\`@5SSZUCR4SW-TNP<*W^*/:/E;R?\"N>?6L>2F>YNEV#A6_Q1[1\K
M>3_@5SSZUCR4SW-TNP<*W^*/:/E;R?\``KGGUK'DIGN;I=@X5O\`%'M'RMY/
M^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ78.%;_%'M'RMY/^!7//
MK6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ78.%;_%'M'RMY/\`@5SSZUCR
M4SW-TNP<*W^*/:/E;R?\"N>?6L>2F>YNEV#A6_Q1[1\K>3_@5SSZUCR4SW-T
MNP<*W^*/:/E;R?\``KGGUK'DIGN;I=@X5O\`%'M'RMY/^!7//K6/)3/<W2[!
MPK?XH]H^5O)_P*YY]:QY*9[FZ78.%;_%'M'RMY/^!7//K6/)3/<W2[!PK?XH
M]H^5O)_P*YY]:QY*9[FZ78.%;_%'M'RMY/\`@5SSZUCR4SW-TNP<*W^*/:/E
M;R?\"N>?6L>2F>YNEV#A6_Q1[1\K>3_@5SSZUCR4SW-TNP<*W^*/:/E;R?\`
M`KGGUK'DIGN;I=@X5O\`%'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY
M]:QY*9[FZ78.%;_%'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*
M9[FZ78.%;_%'M'RMY/\`@5SSZUCR4SW-TNP<*W^*/:/E;R?\"N>?6L>2F>YN
MEV#A6_Q1[1\K>3_@5SSZUCR4SW-TNP<*W^*/:/E;R?\``KGGUK'DIGN;I=@X
M5O\`%'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ78.%;_%
M'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ78.%;_%'M'RM
MY/\`@5SSZUCR4SW-TNP<*W^*/:/E;R?\"N>?6L>2F>YNEV#A6_Q1[1\K>3_@
M5SSZUCR4SW-TNP<*W^*/:/E;R?\``KGGUK'DIGN;I=@X5O\`%'M'RMY/^!7/
M/K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ78.%;_%'M'RMY/^!7//K6/)
M3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ78.%;_%'M'RMY/\`@5SSZUCR4SW-
MTNP<*W^*/:/E;R?\"N>?6L>2F>YNEV#A6_Q1[1\K>3_@5SSZUCR4SW-TNP<*
MW^*/:/E;R?\``KGGUK'DIGN;I=@X5O\`%'M'RMY/^!7//K6/)3/<W2[!PK?X
MH]H^5O)_P*YY]:QY*9[FZ78.%;_%'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5
MO)_P*YY]:QY*9[FZ78.%;_%'M'RMY/\`@5SSZUCR4SW-TNP<*W^*/:/E;R?\
M"N>?6L>2F>YNEV#A6_Q1[1\K>3_@5SSZUCR4SW-TNP<*W^*/:/E;R?\``KGG
MUK'DIGN;I=@X5O\`%'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY
M*9[FZ78.%;_%'M'RMY/^!7//K6/)3/<W2[!PK?XH]H^5O)_P*YY]:QY*9[FZ
M78.%;_%'M'RMY/\`@5SSZUCR4SW-TNP<*W^*/:/E;R?\"N>?6L>2F>YNEV#A
M6_Q1[1\K>3_@5SSZUCR4SW-TNP<*W^*/:/E;R?\``KGGUK'DIGN;I=@X5O\`
M%'M`W;RCP;*YY]:QY*DKEU/8I=A&5JTUME&GM1'Y6\I\.RN>?6,>2LNY=:VJ
M7885FRGLE&OM1ASJ'SS)<GV-W4QYW:_)[$B\87=(*KSD,NVVFRVMN6T4F7<;
=G,<CPXD6+IJXXZM*4@\2*U.3;VIU]AN4-NQH_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tpg53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg53.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!6`);`P$1``(1`0,1`?_$`08``0`!!`,!`0``````
M```````!`@<("0,%!@0*`0$``@,!`0$!`````````````@,!!`4&!PD($```
M!0,"`@,&"1(/"@L%!0D!`@,$!0`&!Q$((1(Q$PE!82)2DA3P49'1,A486!EQ
M@:&Q0K+2(S-SD]-4E-06%Y=R4[,D-$3$A3:6UE>W.'AB@G1UE=6&QBB8P>'Q
M0[0F5G8G-]>B);9'=\)C-55(I$6EM49F9X<Y$0`!`@,$`PL$#P8$!@$#!0``
M`0(1`P0A,1(%49$306%QT3)2DA05!@>!(E,6\*&QX4)RTB,SD]-450@8P6*R
M<S07XJ,U5O&"0X,D=6.B1#?"LV1T)?_:``P#`0`"$0,1`#\`_9]<)C@_E@`Y
MP#KB?-&[W#IK\E^^M=,J9KVH]UDQR6*O.7?/H%&UJ>T=9SJ>$'.?YCYHWB%[
M]>#H)51+57XW])3JJK6I"PGK#Z>S-Y1O7JF;F+IM:E'4O>DE8VQ5+M]5-!'L
M?-1J0*>L/XQO*-Z];6SRWTTSZSWS8V;=`ZP_C&\HWKTV>6^FF?6>^-FW0.L/
MXQO*-Z]-GEOIIGUGOC9MT#K#^,;RC>O39Y;Z:9]9[XV;=`ZP_C&\HWKTV>6^
MFF?6>^-FW0.L/XQO*-Z]-GEOIIGUGOC9MT#K#^,;RC>O39Y;Z:9]9[XV;=`Z
MP_C&\HWKTV>6^FF?6>^-FW0.L/XQO*-Z]-GEOIIGUGOC9MT#K#^,;RC>O39Y
M;Z:9]9[XV;=`ZQ3QS?&,;I]6H.K9>7O:M',F.Q7^=BAJ6PFU6,14@EI/.IQ\
M,_>\(WKUM3<PFUDK`U[X\*\856JEB(.L4#7PS^4;UZJHYLVBF[5SWP3]Y>,A
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M$:W0A\QE%.97PS]!?FC>D'?J^DG3L7+?N?"7C$$T(=QSGY/9F_\`PWQA^Z/B
MUW=M.Y[[M*\9*":$)N`=7TO]>('R0]:J>]C5I:B8Y]D9COXE-.E:B-1=XL5G
MC--NX`Q^KD.ZHV<F&#FX;4LR'C+;:^>2KRY[NEV<'"-`0T-]*>R#U-,!TZ1K
MI=SLO;G:I(8F)RKN6VKP"JFX&+H+?KY_R8)AY-IVX$JI$BD60)9KLZ0K%/H8
MZ+D2\NHEXCKK7U)?R]9EGGG2Y;D:ZV.S>J>TX\^RM;*J$<JI"T^;\OV4_>D[
MA/XJ+?:JC^E;-M'^5,^4;_:\OG)K0?E^RG[TG<)_%1;[53]*V;:/\J9\H=KR
M^<FM!^7[*?O2=PG\5%OM5/TK9MH_RIGRAVO+YR:T'Y?LI^])W"?Q46^U4_2M
MFVC_`"IGRAVO+YR:T'Y?LI^])W"?Q46^U4_2MFVC_*F?*':\OG)K0?E^RG[T
MG<)_%1;[53]*V;:/\J9\H=KR^<FM!^7[*?O2=PG\5%OM5/TK9MH_RIGRAVO+
MYR:T'Y?LI^])W"?Q46^U4_2MFVC_`"IGRAVO+YR:T'Y?LI^])W"?Q46^U4_2
MMFVC_*F?*':\OG)K0?E^RG[TG<)_%1;[53]*V;:/\J9\H=KR^<FM"!W#Y):D
M77>;3\_H-V[5PY456M-P"29&Z1ECG4.!`Y2%(01&MV3^6C,\LHY\]S%<J,BD
M)<Q(0_YB*YDR:J(BHOE+N85RS;><<4V5EFUFTHPA[[@FDVRC[B1!D^8IG=O6
M9T02Y2F.X%5H8#%'7ET"OYUSN@?W<SAU#.AC:Z"^Q3<D3\<-Q"Z`]'J5C,$V
ME'CEZ#IL3%;N$5SZ9')(:CN5`+8HJ\P*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*MD_2("35"?<$/G-[)7XA?E!5])RM0.X^8_>W]T5WN(R5W!Q?R
MW<^GDZ/B@%3\27HB.>U$1=HO\2FK)=YB+#<,$M_9$QPY8PB0!$^Y?;"1741$
M#@&8;6%OX(\"BW6\,!#I'@/"O9>!LA'>(>7]W'+&35RW/5^ZU6M5T$2Y8PA:
M:5>Y48J[QN7Y!3.(B8QTRE5^E&XZG*8W$HZAQ,'`"]%?IU*V=!-E9?*8D%9'
M%NGBWNCPP0Q*E-[&$X;=O#[+9-X\;9FN/'Y\C6\Q.B!8^4A47IV+INBY$X",
M@U%(ZITP`=$2B:NG%2J*EMXWM'L'7/G3)^WJP(BZ,@W_`(>N*W8"_"6VW9C&
M1!+A8LGA9@7SUTV16C8X[XJ3@2&,=,Y3<-`I%1%3(3&&Y[".9,>N<JX]OVVY
M>P(V][MQ_+W$^<*0+-G<UD7`^M6XXP3S16.JT=/1ZJ//]26`O.D8Q1*(XBHB
MI>@L[$'02>`^C",%T2*H.CO$NJ636,7S9RFL4XHBS=)F`4S\VAN8--=:S%1%
M2S%D[DL:7WEO-V%HMPHTO3`DIC^(O-"1,@W;N'>2K64N^VB0JHK?K\RL0D)S
ME*',4>YPI%1%2ZKV];3C[@C[5>7!;S.Y)4IU(RWGDLT:S<NDG]5/$1RZY',B
M#<>"@I%,!!X#I2*B*G<#*,2K^:**-$GADE%DFAW"8.E$$SD3,X*@!^L\V(8X
M`8^G*`B''C2*B*EE\F;B\=XGNK%EF78HJG/9<OQKCRV4&AD%R)S;QF^?(+2!
M2K=:TCSH1Z@]:8H`'#6D5$5.TD\TP+3(%I6#%1#JYU+HBI&8=S=O/(Q_&6FR
M8BW!):Y>K>"X;)R0+B9N8A3`<J9Q[E(J(J>VA[]LVXO;`+=N.W9\\2Y\VED(
M25:RZ\:H(F#JGB3!9P=!<IBZ"!@"D5$5/KN,"N;=F3E,9`WM%,&.D4P")DE(
MYR!1.`".@&TU"L.<U[5I9C4=+FI!8Z($Y<]9;T;!%Q+JA::DNSWU3V:;>"ZB
M8B=F/^8AN/.NYN.;*9<1Z0Y03#E+T!7Y+>,M!+=XF9QEDOS)=!5.EM5$Y:01
M8JER7[A[/+)6W:BN6"*9G=(CWOD]->&F3%9)ER%M1]D=!VWKU=L$M@*IP)+\
MQ+D(H_&F.$(D4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`JV3](@)
M-4)]P0^<WLE?B%^4%7TG*U`[CYC][?W17>XC)5/_`+/E_KY/G@K'B3]&_P#F
MK_$IIR?H_)^PP4W]?^3EB_VF=KW],5K5[WP,_P#S-DG_`/6F?_MJ:68_1KP&
MY9<4PT%4PE+UIM!*`B(GZWP"Z%X^$;0*_3&I_P!6D_RU]P\6^Y.!/</S%=H4
MSO/'/:&79O%L&S)VZ;ZVO;=[<NJRXJ+A'L@G<:]PY!:6E==OIK(MS$=N#6I(
MN5.H+S"7V5=0K,*;;Q#>5A[C8=5TPO5LZS1D.P\IW2^:Q\ZS<NXK*LE%W@ZM
MF8?QK9N(L[;CYH8Y1!13Z65$=>(4!<C:I`8ML-KCUEG>UY)AMIAMSV\Z,R1'
M.X:_AC8?),EF'(3K'C^Y"QBJ:R\)(8W.4C0Q&ZR9U5$SB;G\*@/?X0BW<%+V
M\7>;'Y/8[25[0W.OMMT;*JWL1V29?9?=FQ/$E-;CL)EY.N\=*B-MI2!P0*QY
M`5`%-!`"N,P1:ES7+VH65%+)RLC,VIC38P7$)I][=T/=K1%MB6#=G*Z&->D)
M)73#ND"E>%*+I5(Y3HF4Y1,`@>/N,]P7'M\SE#Y/ALD3?:079-8ON#;[/,X^
MZ6MR3\8J_8/8!S9JS=7VCBD8>R`<DF$C';=:;7G*8^@@!V5HXHR+;FWG%V:(
M,<E#NFG^T0S);;Z\%I*^EG+R./&Y`2A(<L%(R#B*C;(;2"3<K1,Z(MBE`NIS
MCRB`'G8ZV+3=.=@;8(W(LCO%L:XKK>[K5UT;]DF\'D>0L"ZE;K>3BDF96%13
M?31`&/%F/4IEU`G+KH('SX!QP]P'ASLZ[_QWCC+-PY!R-LSS!>.4H9G<UZA<
M=TW7YU:A2GEUIM1^VCWL>F_7%%)<I>K2$Y4TQ$=0`OQV=#J?C-^6'!87):LI
MC^X=L]_C+0^.K"R#:-K6O/Q+F#]HX:\YNZYF33NF[$?.W!57AB(BJ<!$"Z4!
M^G6;3*G`W#R"8"FA)82IFY=2%]KG.G+IQZL=?!U&H?\`W$OA(?\`59PFI#L^
M_P"IIM]_[GK_`/Q+/5^4_C#_`/F#O1_[!W\+3Z!DO(3@,S@Z3>CTZ^:5%]/\
M8ZE7<!];Y59F<M>$KE_1IP$5`F*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*MD_2("35"?<$/G-[)7XA?E!5])RM0.X^8_>W]T5WN(R5SX#Y_+?7R?
M/!4/$9[9K7LE*CG;5;$M^$IIRD5)=NC]A@9V@;ILSPK9KIVNDV;,]R.V-V[7
M6.":39JAF"USK.%CFT*FBD0HB8P\``-1KWW@@Y)7BUD^835PT$NG>CIBV,:J
MRU1$<ZY%5=Q34KV/?+7"BJL-PVLO,L8L$"E/DBSD1,H=1$Q;DC2BH=(PK`0O
M(YYCE,!>(!TA7Z23<URV=FDE\JHDN8DM;4<B^X>1F4E4UL72WHB(FX?";*N,
M1$5?Q\L4KC34K@)^*4!5,P\XMN0ZPKD*`CJ`'\$#UU>T:#TTOI(4;"=S':B/
MRIXO-],4OVQQ,KX#C6XHU0Z1M=&ZJ!#+B@)D0Y1'0.`A3M'+_32ND@V$[FNU
M%+?)F+!1$CC(%C`8IE2E+[<P@E,<5.7ST!*IHDNJEKKITZZT[1H/32ND@V$[
MFNU!#)>,"'7UR%8@H#X"`%FX0AD#%**8J%(9;18IP'F-SZZFZ.%.T:#TTOI(
M-C.YCM1),GXN3,*(9"L4ADNI41<>W,0<RW*7E655*"W4I+&$="@&FA!X!3M&
M@]-*Z2#83N:[4<2^3\6*.51"_+'*H4H*).23,(8&Z@F*)"`1102KG$NNIP#P
M0U#7C3M&@]-+Z2#83N:[4?0&5,7$06(G?MF.`$5?I"EQ1/(9R<X"HJEYRL)"
MI%,'@AT:=%.T<O\`32ND@V$[FNU'S#E#''TQ`^0[%Y^0#@LG<,:'7B</IW,<
M%]"'*;0"EZ!*(T[1H/32ND@V,[FNU%:&4<7ZE2=7W9144DT!+YM<,45GYP4I
M@420;"MUQ6XF'4P&#D-PIVC0>FE])!L)W-=J(_*5BP2JMPR!CXZ!D6Y"\\I$
M-Q$I^<7@\S91,2F6$I>'0&E.T:#TTOI(-A.YKM15<&5<6EMZX3DR%98E2MZ6
M,H8MPQ6B2*<<Y#4P@XU`A->Z(UJ5&>9-239;ZJJD2V16UST3]H;2U+YC59+>
MJ)H1363V?)BGV9;>CD$#$/9BBI#!Q*9-6Y)TR9RCT"4Y1U`>[7Y>^+2+5>*G
M>/,*;SZ&?7.=+F-M8]L$M:Y+%3?0]WE$M\MB;1%:L-VPS/#I-Z/3KYM.ES'K
M(1K5546W>.C4^<EEH'IK$U%28J+?$KEHJ,1%O@159,4`HB1N`J>S?H4"JWJD
MI(S/-1=-@)JO;R>>W6@%-O)Y[=:`4V\GGMUH!3;R>>W6@%-O)Y[=:`4V\GGM
MUH!3;R>>W6@%2;-EO6#'(J[RBP5LLIY\RUC'*F\BF(H-*P^1.E_2-<WA2`BF
MDBJ45%N,BL@4!.E;'5*F$=F^'`IC$W2@TJM94U+VKJ&)J[J"JG*C$B^Q-\R*
MKV\GGMUH!3;R>>W6@%-O)Y[=:`4V\GGMUH!3;R>>W6@%-O)Y[=:`4V\GGMUH
M!6%J)"6J]L.%#*)%8)>166SI+^2YJ^407035J6VI<8(I!4O`H!0"@%`*`4`H
M!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`5;)^D0$FJ$^X(?.;V2OQ"_*"KZ3E:@
M=Q\Q^]O[HKO<1DY;@_9TMW-5R?\`!6_W\H9,A[WR[\;EN_>4UTY*<"'B+QLF
MULB6Z]LZ]X:.N6VYM1KSPTQX461Y&&(_;R"Q"%%4'"*A"BD8.A0H:<:\3W?[
MX5N3/A)5R-18IYT/V"%L4+(H[0]L1A'3#5JB)VX+&46)*""@$7%`R)557R9R
MN3*$%4="_4Q]*O;/\9.]56J9=E4R;+K7IYJLF><D+5O;"XB^7M6JS2<ON0ML
M7\RUI>5)_AU0]?O%G[[7?6-*.H#W(6V+^9:TO*D_PZGK]XL_?:[ZQHZ@/<A;
M8OYEK2\J3_#J>OWBS]]KOK&CJ`]R%MB_F6M+RI/\.IZ_>+/WVN^L:.H#W(6V
M+^9:TO*D_P`.IZ_>+/WVN^L:.H#W(6V+^9:TO*D_PZGK]XL_?:[ZQHZ@/<A;
M8OYEK2\J3_#J>OWBS]]KOK&CJ`]R%MB_F6M+RI/\.IZ_>+/WVN^L:.H#W(6V
M+^9:TO*D_P`.IZ_>+/WVN^L:.H#W(6V+^9:TO*D_PZGK]XL_?:[ZQHZ@0&T#
M;(!C*%PQ9R(%15*9PI[8'`"G#06W5GD0`X.0X::#T5NTO?\`[XI*F)WEGSYJ
M+#9[1Z+#3""<!L2*?81WR]5HVS`6?;$/:5G0#"V+4MUJ2.C(&+`&#:);MS'4
M39%;B)Q.0#*B;E`>.M>)SKO155;U1(VQ^%[QL'HJY=)F%6Y<<%U@BMMSW/7&
M[E*!6`*(D5AI!-3=\S:!\8/D57UV%D;0->]6>LR7V5$M)C=Q%W"R4Q'JJ$Z^
MC2FUR_[M++]@T:^C2FUR_P"[2QL&C7T:4VN7_=I8V#1KZ-*;7+_NTL;!HU]&
ME-KE_P!VEC8-&OHTIM<O^[2QL&C7T:4VN7_=I8V#1TUA9+:SYK+Y22YZ6Q;?
M#=O(/DM1(D:Z5':9S0>8BS-:%.S11J-21,WS'S5<_6@V:"I.HI]`NPJ%59E]
MNA3"I"PBL&!3@O!7\;Y(>M7%2?WM5\$6=@C9YR7;@ZHBE/&M^12Y_.6,U9B+
MPH924UM@XZUN=3J9";:M:KY*7HMV\38QKG0B3KZ-*QM<O^[2R_8-&OHTIM<O
M^[2QL&C7T:4VN7_=I8V#1KZ-*;7+_NTL;!HU]&E-KE_W:6-@T:^C2FUR_P"[
M2QL&C7T:4VN7_=I8V#1K5DEN6U$Q)+I#&-<M]\"+I;9;5?H(Z:VIE#EE-R,.
MHUMLU8P4=%:$V:UJX92V",;14):S'1QW;@@15@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!5LGZ1`2:H3[@A\YO9*_$+\H*OI.5J!W'S'[V_NBN]
MQ&3EN+]GRP?_`'Y?EA4^^$R;.J'MF<G:._B4UV\E.!#JS`&NH@'_`#8]'0($
M*(:?$&O/Y/EU(^*SDOWDXC-Y)A,?3G$3B4PF+S>%RF$O+S!J(Z&Y>&OI5.LH
MJ25,C0+"K2ZY.&U(*28L';Q&@]^M39YMSTZ?OE^-HT'OTV>;<].G[XQM&@]^
MFSS;GIT_?&-HT'OTV>;<].G[XQM&@]^FSS;GIT_?&-HT'OTV>;<].G[XQM&@
M]^FSS;GIT_?&-HT'OTV>;<].G[XQM&@]^FSS;GIT_?&-HT'OTV>;<].G[XQM
M*3%*8-#E`Q0$#:&`!#4.@0`>&H5!RU+%1*UT46ZW$1546X@0`QA,.@F,?G,8
M0U$Q^`<XCTB;0.GIK*2J9ZQ=N\!BXJ$/B=^NE3K1RKT]I`*TY[F.G.=+Y"K8
M"*I`J<OEIP@>E\6E9N^S<!Q*',!N5LCUBZ/(Z<HI&$RCEJF<!4('.)B)GY2C
MT`'"J*"B6IFHCKHC<LO/!S65<;6U)O8>X+ZMB(F6ZB:CR%>3T>1Y%@X2*NW1
M=)B`F25.W4*;0=!T'6O2U>0YE(D,F9=)2:]RVHJ*L$AO)I*)T_8M1VZJG5?E
MSP__`#D6?_&&/^AKF]F]Z/N<OHNXC7[0WU'Y<\/_`,Y%G_QAC_H:=F]Z/N<O
MHNXAVAOJ/RYX?_G(L_\`C#'_`$-.S>]'W.7T7<0[0WU'Y<\/_P`Y%G_QAC_H
M:=F]Z/N<OHNXAVAOJ/RYX?\`YR+/_C#'_0T[-[T?<Y?1=Q#M#?4?ESP__.19
M_P#&&/\`H:=F]Z/N<OHNXAVAOJ/RYX?_`)R+/_C#'_0T[-[T?<Y?1=Q#M#?4
M?ESP]W<DVA_&&/\`H:VZ/*>],R=@;2L8JI?!R>W`FRO1SH*H_+EAT/\`YDVA
M_&%A]!6_-[A=\:YN-DID?C+Q%O7&G:QF8,5S$M%P\9D"TI:7ES^;-8_V_8%<
M*G$-4VC=-+J^M=N=!Y"AJ8=!KR]?D/?#(XNF2FV+SG+Q#KC2X8CS@58#B8BX
M=:F02@!D$S"(`@/*`<PDY>GNZUJ4E575<K:YBB-J(JD$C<EU]I:R8DQ,2%-;
M1(4,DBH4$P5.F#H6Q'ATSB(I$Z\Z0`B10"Z<P`8.[496>U4Y=E*E,BEG)7W3
M:?.:C=\MS,9:QK;\F\AI[(-H,II@<B4C'GFF;95@X,DFJ#99)3F.50$U`$==
M.FNK)H.\U:O_`(\ID>%R'(GUK6+!#K_RY8?_`)R;/_C"PU^=K:G=UN^E/)ZU
M-D,=*2R$7.OWH&G+S/YS"1^7/#_\Y%G_`,88_P"AK1[-[T?<Y?1=Q&SVAOJ/
MRYX?_G(L_P#C#'_0T[-[T?<Y?1=Q#M#?4?ESP_\`SD6?_&&/^AIV;WH^YR^B
M[B':&^H_+GA_^<BS_P",,?\`0T[-[T?<Y?1=Q#M#?4?ESP__`#D6?_&&/^AI
MV;WH^YR^B[B':&^H_+GA_P#G(L_^,,?]#3LWO1]SE]%W$.T-]1^7/#_\Y%G_
M`,88_P"AIV;WH^YR^B[B':&^I4&<\/:ZCD2SU0#413_&2/)S``:CX7+PT`-:
MV:/N]WHS.I90]58S:+#$B.:J;MBJEA5-KXRU1%M@=E&Y>Q9.2;&)CLCV5(2$
MTX;HL62<\S&072,W56\SCT$1(#EX8Z8"```F$`&H9QW#S_+H[6-G[\?V&M)J
M%<L$+A`)C%*)@.!A#4P*%`AM?2,4-`*->;IY$VEF(VHO3RG9D*CTLN%=:=.D
MS439;E]A>Y("J"`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*MD_2
M("35"?<$/G-[)7XA?E!5])RM0.X^8_>W]T5WN(R<EQ<'\K]>(/RJVN]\QVVF
M?S'?QJ<V7->K$CH0ZP>D1_0!_P"P6O)47G(J*;;+52)&H@.G<KG3J64M;B6,
M;=TNP-5N+=&HU=U>7OZR.!HU&G5Y>_K&!HU&G5Y>_K&!HU&G5Y>_K&!HU&G5
MY>_K&!HU&G5Y>_K&!HU&G5Y>_K&!HU&G5Y>_K&!HU&G5Y>_K&!HU&G5Y>_K&
M!HUJ+J22_E1UF4:B7$5)M/*;""+9OF165D2UOCK`,!`\,%]$TR<ZQE"@1,#\
M=$2G`-1$=.GOU*CDK-GK)VTEK$L1%6U.$@KEB1R+E`"J=3UAPZXH)'$P@B;@
M3FY]`U$0&K*^DJ)$-C/D:XD<2D"54.YW.Z)?7K:RVAG3):SY\Z2_`D8-6U8;
MB;YE'+NW$<JW_"'L?7K5;F^53.L2ZFGJ-M+EJK;D\[<LC;P&TU9+DL1=9YE6
M\+28W-'V8]N:&0O&4(I*L8`)!K[?+1ATQ:`HG"F4!^Z:'73,`JE3%`O'4P"`
MU#+JK-64:9A12)R2\*NMEJMB1CO;AJU$ULM%P014TF+VSC"N(<I;ANT)>9%Q
MO9EW2$-G^RXYB,Y#-I=>+9FP_:"YFI'2Q54$^M74,H*:8^")N/&OTD_+A)RG
M,/#^D[Q;![<_GRWLGN?!6JC9CL.%EJ-L1([JGD,UK)[G-EXKHK9`V&&VA;72
ME,8<#8O`"E$1$;3C-```U$1^D]`5_0FSE<QG1;Q'(ZQ.YRF'>:)WL^<#9FPO
M@V_\+XY8WCG%1^6V#(6A#J1S!FS*Y(66EUQ*`M&+E\W!JD(AX;A0I0'40"FS
ME<QG1;Q#K$[G*91O-KNUIB5J"^#,1E.\4*DV!>VHEH=813%8132<E2,JH"11
M,)"<QN'139RN8SHMXAUB=SE.%OMFVI/44G;#"6'WC,57B2JZ5NPZI=6`*E="
M*C<JJ#<4%4A*IUIB=6;4!XTV<KF,Z+>(=8G<Y2IIMDVGO#1X-\,X77]L4%5D
M$D8.#77/RF#PT00$Y%FR6O*<Y1'CI39RN8SHMXAUB=SE.N:[>]GC^4EH-AB3
M",C-014#S4-&P\`]F(A)<@F17D(U(QG3=-R.@I<Q0YBCK39RN8SHMXAUB=SE
M.@O_``KM/L*S;DNX^W#'5Q&MAHS<OX&%MZW#3(&?ND&S9MYNLH44UU>OYP`V
MFI2CIK39RN8SHMXAMYW.4^LF#MG"3V$A97$6$8>ZKB;IN(>SI&)MYE<KTRA"
MG%!O&N3D<.E$P-Q,D4Q>_P!%45&745=+V-3+:LM%C8B):G`2943H\I3UR6U+
M;&8>57`F*3*`<VI$+6BB@=,.!C`*Y$SZH:Z'T`>(A6K2R94F9L)+&)+3<@B^
MZ9ZU4<Y3!7?CM[PACQ/:1<5AXQLJTIGW:.$6P/H")0BGSAH<+C'S)==L!5%F
M:@E#K$S:E/H&O17R7Q?R]M/E#JJE8U)T%W(^U`Z-%-F39F&8JJAF#JJH8Y]"
MD.<YS*I%+R$15U\)),AM.0A0`-`#A7YN]XLU;UE\W,94Q];%4Q,1&M@EUEAZ
MRDV<N2B+?'2`YRB'.*10-X!15.4A><W`OA!W1&O'4F>29TW`^1.5-Y#:QR]/
MMG,HDJ4G-]+YTM!.FFH13K`_N1$0$*V\PS6GD-392)Z+9>AG'+.$#F*L8">:
M*]8]$JR76*JE*<J:9B&%,0T`I1-X0=`UWLKJLRDU<M).%&.A>V/["NH:B,B8
M>;(\(X>RCDC?K)Y$Q_:-^2L1N^G89I(W%#-I-=C'I8XQ^Y3C6:CM,QD&**KH
MYBIET*!CB/37Z*>#.24.89-UJNE(Z>F&"W:=P\;F,Q[9V%JP0SFNK;1M(LZW
M)NZ9_".+(Z#MZ,>S$L_-9K%?S2/CT#N'3@$$&YUUS))$$0(4!,8>`!7WN734
MLA4ERY;42&A%]TXVVF),L4P\QODOLT<JR+V(M#$4(XDF44XG$6LMMVONW%)Z
M,0570.M:Q9VUV(W*9,[<QU`9=<)4O#]CQJ[9RN8SHMXBSK$[G*9@L]KFV)['
MHR2.!,6"@\;,WS4JMF-6RY6KLB9RE>(K(D.V<^'IU9@`Q!]GIQILY7,9T6\0
MZQ.YRE33;!M4DTC*QV$,1.$E#K)-U4+:B5B**(@9-9-)<I/-7#ANX()3$(8=
M-!UILY7,9T6\0ZQ.YRGAL4XAV79CM7\=K!P[B^X+9/.W';@27XAMXH49>T)E
MY;=PLS,I%LW>*&9S$<L7K"D%,X%U((E$!ILY7,9T6\0ZQ.YREQ@VH;8!%`!P
M+BQ,RXJ@5(]IQAQZM/G$%S*($5*F10I=0YM--=!XTV<KF,Z+>(=8G<Y3XG6U
M_:JS622=X4PVV.]5!M$H+VY%H.'[GJ3',B0BQ"<P%Y1,`DYA$H=%-G*YC.BW
MB'6)W.4Z"T<#[.[X;RSBVL-XBDTH&2=0$PHA:3-/S.=8+*-WK,2N&Z8\J*R1
MB@)M.80X:TV<KF,Z+>(=8G<Y3U+;:AM@<&*T<X"Q8DY,1144#VE'"*C4IN4B
MQ1!(4_#`0$0U'E$=*B^GIYK5EO8S`M_FHGN)$QMYW.4P6WM8"PMCB]MC,O8>
M,;.M&36W@VC'*O8"%:QSA5@I8E^*G9JJ-R$,HV,J@0W(.H:E`:^&>+&097(\
M/L\SZ5+AF5%(5TI8K!%Q-2UMSK%6\Z=#.F/FX7+%(&8*AC&,)C")C&$1,8>(
MB.O2(^G7YG3Y\S,7*^J@KMZSW#W%.Q$9%+R.X%:\B1+DJ[!&U=)9,55@F@BM
MDK%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!5LGZ1`2:H3[@A\YO9
M*_$+\H*OI.5J!W'S'[V_NBN]Q&2NXOV?*_74_E!5_>_Z:9_-=_&IRI7(\B'6
MC\U_>?.%KRM!NF\R]"D>FM:;_5^S0;*<@5:0%`*`4`H!0"@%`*`4`H!0"@`&
MZLG,4H'`BBBADE@ZQ(ZQD_I1Q('+X*9B:Z<==:Z614DN;7*KLIZPJN^DQ0Q;
MY4Z\TW[?)G?INCC\EWW![IK"QW!0V5+FM"&MEUAM:XEV<=#BD"'-*$NR-ZW4
M#]'5!I7M<PR_+]DCGY"Z*);\Y>NG>(VZ3(`<!]H1W-\..P^+M^<CZ7_]^5G)
M9N4T=0R9,R&,AKD5S5F6*D;4C#=,+'"MNX4_D#[0KW\6.O\`=]<_R[Z:TLU[
MZ]R^W*C8]UI6RCN3W:$WBIFUAYL3\]?:F=FSVK^X;>3M\EL39C4N^6MBRD".
M<W6K#O\`$%M6`);@?+HM)E=*>F5)1<AS`J"?**9RF`HA7]8^'/?CPM_MW/95
M]WZ2G<M',BUTUSEFP5WF(N'S5WT.3FC9[VQ;'&B_L/T0=B3CC.>)";VK"W(9
M>3SAEZ`SM8K6ZLAI0Z<.277'#%FJ($*FB<Q'8-&YRH]?H0RG5\P@&M?8?!;.
MLCSCN13NR#*FY712\:86S%F),B]RXHJB0A<>;J$>CO/Y1O4,8!*(!H(B`Z`;
M4"B.G`##RCH`]W@-?6S6/RK;S<-;K]X^3=WN<\16Q:+"R,-Q=G61C:5O9"5C
M[VD(;$-R0.:+S)9C`&PB1:6O"T5X]!5,PB[35!/@4]`8ZY;8S&X_'O:1[DYV
MULL(9!D[_P"S>)CY(7.0H9Y:C*^+8Q(EEB$M."8/$6S,A!DI!"1,W0,"9>LY
MC`;4P`7?SY@5.!WMGV\67:^1HS;U);H=O3Z0M.$F;_"VI!@G@^3=RBR$J64\
MY!@M+E*=\3SPJ)W'U3F/P$#QTC@FX<=82S3DK#$!D.'SI#[Y<N1&-Y1*7OQ\
M2VXP5KTBK601C9%VNU3M9P59$``$E6W$H@/`!H#MI>$=/</;8X/"]N9&AMX=
MEL[PF-];]K'7@U4=6XXLN?)E4LK)NWAFT@A+9(68.(DC4ZJJ:!/I12%U+0%N
MLOXRGL0;==I\KAZ'R/"SN1^S]DY')K^/>9"F;DG;G7OG$CDSQ^A+NI$4;E6!
M=P(]84C@B0*`0I0YJ`Z[=5/9'FR9(=1K1''U^VS<>)BPUN.;%R->F9[SAHIV
MFW"_+7R(UD8Z"L:#>MEC&*@#=RH5,X@J4PZ"$V1551-!)MY^PV"%)Y$14B19
M=<58N*YO-B`"VOF:(B;D<%*=(%#B/6`.HF$`]*N=3K"JBM\`:U^U>B+LG<5[
M=8*R;J867>DSO%PRQMR[7L0:;;VZ[5+<(HOCQ97+07PM^7B4%":Z]->%\5]@
MO=YV.^"^X=;+\6V2'(@AC_\`D'[0E83*#ODQX<3F-J8^W]R8W`>7B8+Y3UZ/
M2K\\,Q[S=T\K<^AK\C97U&-5VKIJM6W<@B;AZ)N*%AY._,1]H7:=E73<R>]?
M&KU6"@I&42;+;?G(%549MSK$`#?CV/(81+H`Z#I6<A[R]R)LZ/JI)A'TSN(S
MYY:K;!;O:&[@<"XMS(]WE8Z@'5]P;B=/$(8)=.08%0DWT<#477X[I^<:^8\W
M-R%]EIIPKI]Z.\7<>DFNDIW7DJB01';9V[NW;AAJO5$<7]_()V@ZB1B^[AQ^
MDH1!T"BJ.W]4AE%%"`!5/X;B("0*\U3SLD=6,=*D3&HKD5$VD<*:.3:=">C]
MG"*7)N%YNR9@+^M8F^.!R9>T=D*[8[>'<"4A=<;;XVTA*&-C7'2@*C%B]D!2
M.'/IKUIM0"OT+\''4[N[Z)):K7(C8Q6,5MM2Q()"%AXO,D7K/D-BFXF(E+BP
M3EZWX)FL_FIW'5W0\4U;Z`JK(2,,[:M`*8P"!-%E"CS:")>D`'HKZTZR<B+S
M3C1\\_.W:&(=P$I#64XL-ENGOF5MO%MZ61>(9W3B8^*QT=*-E5(TV&']O)Q3
MY>?DY1;S=0SD#E]K13$/#UJ9,]]9EA9VA<:D&]MONX&_=T1K-O>+RSD5>Y7S
M7&TG:4G:C^*M5JC&-YA(ET'AHA1L'F+8D:Z,^3,876HT!:+;;MLW!SFXK"EL
MY-QOD]CA=7+8Y)F'(6]<F,;2;0\#AA&(@!5BQR7=DDQ53O1@F8Z9G"B;M34Y
MRZG$*`Z*R=M.Y2S;*+;V#L,YOQ%F.'S%G&YMQ-P3CQ\:#RIMQN/+-US3.U+.
M,K<CZ--<D_`/D'+3J&[-<O,&JO<`#(RR,`7;DO)F,;5A<3YPL_9]<.X%F[>X
MYOR<N*+??B@RPC+)S;Z:=M[D7GTH)7("8$4(5\',_,4Q0`G"@,9,BX=W@2S%
MK;C'$V3E)#&UXY`8V`Y&VYR]Y5W8L!G!*9LMNPF4LA6VG:K:,L./(5NHY2DE
MW21`YC:'$M`=<IMOW&0K^_#V[C:_[/M>_KFN3(>0Q<V/=>0Y&X\L7DH\E+"N
MR)A6&4+0!@\BH9\=%P9-P5FU=&!,[=3V8`?I5VO1M\P6!,-P^37\E*W["V+;
M\5<K^3AO:22=R24:@#LTM&*2,F=I-(JD$KHI7"I`5UT$P<:RVU08P]H<8?QD
MV*".A0]V;9PCJ(ZZ?B!D'30`*(Z]ZOC_`(O?_B;O.G_\9?XV'4R[Z7R%Y3:"
M/`=0U'0=--0UZ=!XA7Y82+E/?2/HT'<"IMO7A,O%3("@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4`JV3](@)-4)]P0^<WLE?B%^4%7TG*U`[CYC][?
MW17>XC)7<7[/E?KJ?R@J_O?]-,_FN_C4Y4KD>1#K1^:_O/G"UY6@W3>9>A2/
M36M-_J_9H-E.0*M("@%`*`4`H!0"@%`*`4`H!0%!_J2GZ,/G#5T\A;-[07#/
MFM2-R*J(A6Z\UJ=ES_Y/Y;_M`7]\^VKT>?K5-I/-J)Z+;\)2)LPX<?6"OG<F
M;FJ3T5:B=LT6WSUNX(A$M0CAI71ETE$[K$V=-F;:9+7#9'SMRW<-M$E)=[A2
M($'5$X#^N.J*(+*<Z)P(J!P)U2XF3(41#Y@`&M*35YW34*4,F;,V.%4AC6Y;
M[(P-:JE,F,5&6N,%,-9?F=K6>]XREUX<RS<L5E_+%KWS9DA95M2<_$NX2.QS
M;EL.W"BZ:*Z[)P63C5$P1.8`$I0,4-!"O[N\#/%KP_[J>'E#D&:U4]N>RFO6
M<U)+W(BK,<K8/1(.\U4W;+CRN8Y94N>CV-1$X3)XW:'P0@(>YXW$\0$.&/IT
M!XAW!!IJ`U]A_OSX;?>Y_P!1,XCF]EUG-36A\ANT"MY8J)!V\[AD2$4,41_)
MS-"8@"0QP6$I&8)K`"VG@F`1$>(T_OSX:_>Y_P!1,XAV76<U-:'#[ORW14,N
M7;SN!+UW5HN$_P`F<J11PJ02F)(+*)L0#JB<O%,H@;7HI_?GPU^]S_J)G$.R
MZSFIK0J4[0*"5.H5QMZS^Z0$PZ@?&<N)@.4W,"C;G8CHDJ(:AUFIRC3^_/AK
M][G_`%$SB'9=9S4UH5?"#0W6"8NWK<%R_2CJ$5QO,J%61`H!YJC^LA$KDIQ`
MQE#^"/*.G33^_/AK][G_`%$SB'9=9S4UH2GV@-N@94Q-N^?D0ZSKP_\`#*7,
MLJMQ%10ZGF0Z*'$W@CW`$=:S_?GPU^]S_J)G$.RZSFIK0K-V@]N'`%#;=MQ1
MC<W6E3/CF34ZI4/!`Q3'9&`/!,/`/!`*?WY\-?O<_P"HF<0[+K.:FM#B5[0&
MWE=$UMO&X)9N`*%$@XTE^0Z6I1*D=(6/5B!A`!`=-2Z4_OYX9L\YU7/WOF)E
M^HLE937.=!K4C#2A67M"H<2I*#M\W#%\(A%6WY.)<YQ3*!@U%468E'AT:<0K
MG-\>O#9L_'UN?A_D3.(L[$S+FMZ2&,.Y;<)*[CY3;59%EX+S-"+6GN?Q5DB<
MD[IM20AF#*TK>"<"4?$>/FZ:2RZ/GI-$0'G/KP#A7@_$KQ@[G=X\I6DR>HF.
MG85OE/;;HML.A1Y55R7XYB)'A0SXY1*4"B<Z@EX&%0"@<HZB/(8"@`:EUK^"
M\ZD.G5KGSWO;,=;!%BD%/2T].K9*+,1(Q+89KXXBR1WK-G1__85>_7=[N-H*
M?Z>;,15NLB25LI%@ON&-/9K`/N&-MFH<?Q"?ZZ=S_K-/=^NUWHH95=5/23,?
MCLLN2Q$TDI4EDQ/,2)F^W**ISI%TZQ4JB:93"!1$YBAH7CT#K7C:9*Z55L<L
M-FU4^%[YB>U53"EY@M@+-\OMDR7O!C[KPMEZY6^2-Q<CD>U)2S;3D9N/?6X\
MLFSX,ICJM$%`1>)OH5;F2$>8"<IAX"%?W'X4^+O<ONUE75,[J)K)JHETI[[N
M`\M79=4S9FT8B0X4,G5NT%B3D<$#;QN-(=`G,*I,>3'TL>0#]<GUK04U11`>
M80'4/3KZE5?F`\+Y2[=U9/V:)?U>9N[T#BNRFN29%6I#A0^8G:`PPO%56>WG
M<8X6,VU?"3'DV8$%"I\R"[A$K3S=+K1TXE`##KZ5;,GQV\-Y\M)LJJGJQ?\`
MX)B?L+DRBN58(U(\*$#VA4.5#7W/6XQ1R;JDE=<>RP%.GU@'5$$Q9=07@(AP
M#F&J'^/_`(8RWX'5<_%_(F<1-,DS%?@MZ2'$X[0*$5<(*!MXW`G(8QBB(8ZG
MB*-BH$%9(51%IJL150H$*0O`IQYAX:U<OCOX;-A&KGV__!,XB#\GKY:P>U(\
M*%1.T&AM%Q6V^;C5C.#`H!1Q],)D0U+IU0BDT*=8H".IM1'T@X5'^_/AK][G
M_43.(AV76<U-:'&CV@4030B^WS<0<J93F`B./IP6XK=8(IG2,LT,Z2`4_!$`
M$"B%9_OSX:_>Y_U$SB'9=9S4UH<P=H'!.7`BOM[W$-R`0JW6IX[FB<RQ"ARI
MZ(-"JF.4>`";P-*Q_?GPU^]S_J)G$.RZSFIK0E3M"8,_5G-MWW'F$QQ`Y`L"
M52%'4!,*P]6S*FH&H:"`>%QUI_?GPU^]S_J)G$.RZSFIK0DW:"P6A#&V\[B5
M54S$$A$L=39D^)>!R@JS,HFJD'@B)=-=>'"K)?CSX:8TC5SX?R)G$93*:URX
M6M2*[Z&-.X//LON,R'M)B+9P3FNW$;`W(V[D:YIF[K1D8&,C[486C=<0Z?IN
MW[=-%RNF^ET"]241.)3";30!KYIXC^+?<?._#_/<ARZHFNS*NDX9+5E/:CEQ
M-6U52#;$6\ZM%E57)=B>U$\J&>2A!(<Q.;G$HB'/S%-S_P!US%\$VO>K\_TE
MOD1298IZN4J-8B+>4U7*>UZNP[BF7*BW"KB(H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`*MD_2("35"?<$/G-[)7XA?E!5])RM0.X^8_>W]T5WN(R
M5W%^SY7ZZG\H*O[W_33/YKOXU.5*Y'D0ZT?FO[SYPM>5H-TWF7H4CTUK3?ZO
MV:#93D"K2`H!0"@%`*`4`H!0"@%`*`4!0;ZDI]<#YP]=7(/]0\I4Z\UI]EQ_
MY/Y;_M`7]\^VKT7>#^E7RF#9@'=KP,OE*92].$BKRTD#!SE14Y`36#FYS%$X
MIB41`.7E`1*;NT!RG.H*0$*O("1-02E5742.B8-.!4DN<#DT],>Y64GS9'G2
M;U*IK5<B0.#Z9]TJ^03[94NT*WV(I1LW;P^F?=*OD$^V4[0K?8BC9NWA],^Z
M5?()]LIVA6^Q%&S=O#Z9]TJ^03[93M"M]B*-F[>'TS[I5\@GVRG:%;[$4;-V
M\/IGW2KY!/ME.T*WV(HV;MX?3/NE7R"?;*=H5OL11LW;P^F?=*OD%^CJ#\PK
M<-WM*62F*UT5T`>LT'5RJ(:=`$*`CW@'GX53VA7:/:-D^D#K&\T3\Y<HHF59
M"CHZ,N=/E!7F$3'3+R`&OQJ=?K?8A@^<-0YB&ZP3)Z@<RIBF,;POJAA*80`#
M]^K';2=(ZS-Y2+`N1R)+@NDMEFHAAQ#DDQ0$Q`LZ=*)BZB4!,Q5T`1TT`1TX
M5V^[E.^MF?-VP7W-9RYDU'.,:>S7`2[&MM?,&@C8CXN@\!YOQFG?!T$`\+O5
MUN^=1,RV>]]R.AN:41#>HYB;-(WHAF^LCUI%@.`K"+A(6ZZ)NJ42TY=?9"`A
MH/=KYW33JR9,NLC&Y2;[S%S,N><AP>2H+#6&;`89,R.O`/+KN)K<ESGM2VK1
MM51-1NQE)29CFTE*G>7*Z:*M&::;51,ZR>BATR^%7T7(\KJ*FGF5<U<,J4C;
M+8N<Y8(C4W8+RM"&C-=!((EJJ8_RN\K,KNY+%LBT\+8WM:Z9>P9.[;UA\WWN
M^L)*V_-).6B'+*-D8AA.H31G*49UZ)A$G,FJ43<HB(!Z.IR!S9;Z>H<L8(J*
MRU%5;4MLLW%--[E<B8?;/$0/:0RN3%V2&,,80\N2WXA64N*W;\OT+;O^YR1T
MP[A)P<56V=`2W^5L9@H+0SA1HDX0`A"FY^%=1F4U<J@=-?!%:B7(L%WH\!=+
M@CD;;:;2X625F(:(EP2?Q@2L6PD@C7[9-N^CP?-4G/F+QN5=0J#MIUO5J$`Q
M@*<H@`CI7QS.*JLD5BI"Q-Y=)OL1('9?3?NA4.'B%^CJ*9G6O:BPW-"D)[%<
MJ*D+A],^Z5?()]LK/:%;[$4HV;MX?3/NE7R"?;*=H5OL11LW;P^F?=*OD$^V
M4[0K?8BC9NWA],^Z5?()]LIVA6^Q%&S=O%:9U"&`W7"IH!O`5$4DS:E$/"43
MZPY=!'N%'C4Y>954MZ/?R$WB;):H]%6!**CGF:E,Z<N4S)*:I+.U%FZ>H!H!
M053*8`^-5TS.73$@MWLWS9.,`Y0`-`#E#30.CXW>KG3)FVMW#).M8DLPQWS`
MJX"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`JV3](@)-4)]P0^<WL
ME?B%^4%7TG*U`[CYC][?W17>XC)7<7[/E?KJ?R@J_O?]-,_FN_C4Y4KD>1#K
M1^:_O/G"UY6@W3>9>A2/36M-_J_9H-E.0*M("@%`*`4`H!0"@%(@5B*`5D"@
M%`4&^I*?7`^</75R!?\`_0\I6Z\UI]EQ_P"3^6_[0%_?/MJ]%W@_I5\I$V8!
MW:\#+5,2F4O0BKRT4B!PJ3)LN4L9ERB$1J'IU/KE-H36,&\.'H"L];I]":Q@
MWAJ'H"G6Z?0FL8-X:AZ`IUNGT)K&#>'#T!3K=/H36,&\-0IUNGT)K&#>&H4Z
MW3Z$UC!O$AWJFRIIG+!80X1A@3Q]*K=M1[VLP./I4VU'O:P2(<HI..7K$D@5
M%RD7P!$!Y>J$YM/#*`Z\*U\PF2^HJZ5##C0C,>K&V&M+M3=Z\)L:VTS.2+HQ
M==]_VA<+!Q:L].VDJ(!`O;B15:QA7K7J5TT6HG*;G7,'TL`UU"OJW@=D2]X<
MQ=2L5B/7%#$L$LW(Z5W$W3BSYN!8JIBIV$.^2$W;[4X.R[+QS>=N0^#89C:,
MYD"XEVXQMQR+R<F'[MA`D%FF55ZQ:O4^90HC[(-:[7C]W2F=W]DR8UJ/<C%7
M#;8JK9%8I&PWZ2=B9!%L-ZO#H`3"'S(F]D(=P3?W0ATU\/I:RDE*U$A8B;N@
MZ#[S"[+6,\UVQGA+<)@F'MF\9>Y<>QN,;WLBY9M"U#3$-;<E(S<"XB[G>H/6
MC$[*1E5#KI=1SKI@!2G*/$/=Y3GM/@;(5R)*15<B1^%HNO4TIB-1,6Z6@A=E
M]T9(RC9V5MT<S$Y3DF%E.XF98QZKAA",)U>6E'C=C'QL6LR7+&1,6Z004464
M4*L=(RFFAM`ZN9][J"GI'/EV-14L5R133N&JZ.[>>0W%[.L@Y"F+@MBW</8R
MNNT)F#5C<87W%3B6-LA[<II5EYFW?6\]:)C,7E`Q:NDB#4JZ0&<G.&NHUU,O
M[[4=1EV&<YJR&N1V#$GG;BP6&@L8BXK+X&S:QH*0M:Q[,MB7E%9N6MRU+>@9
M2:<<XKS$C$1#2/>RBPJG44ZV0<MS*FYC&-J<=1$:^5YQ7T557N>Q$1CG+!,4
M8)&[R&]+2P]3P^2-:DZ=325:VRU-)<]L1P]`55UNGT>V0P;PX>@*=;I]":Q@
MWAJ'H"G6Z?0FL8-X:AZ`IUNGT)K&#>%0F3I,]BR6)YSAAA;`GT=-:B4+FI;[
M@(&F#!890!5S5B@%2,"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`J
MV3](@)-4)]P0^<WLE?B%^4%7TG*U`[CYC][?W17>XC)7<7[/E?KJ?R@J_O?]
M-,_FN_C4Y4KD>1#K1^:_O/G"UY6@W3>9>A2/36M-_J_9H-E.0*M("@%`*`4`
MH!0$&3!4!((&,!OF2*BB8=!UX*@("3HJ+Z=U6WJS'.8]]B.2].`PKD:F);D,
M(+-A-Q>X?-^=K>MC=#*8>MC&*]ML8^&BL,6#=8+>W2<@H*GG\V05EC)^9``F
MU$>-?W3X5>!F29GW/94YBULVL<Q(.>R6YRK#2IP\PS!TIOS<8K'=@7N':!ND
M,8Y/=_W85%0Q`((;<\/BJJNES>"`F*!D4TM?"`-`4UXZZ5[3+?R[]WUF35G2
MV++2%\N5QG#3,ZB/+=?I4D=GFZ%0@#\(!=B3<RJJBQU=O&(".%78\H%,D735
M!L;3@D```>EQJQ_Y:>Z]34/2:NR1%3#@ERX*FZ6)FE1#E+'A4K]R'N@U*I\(
M!<A"(`MYQUFW?#X`*I@+KQ.``":(!KZ0:T7\K_<]G*J)EMJ?-RKO?)]IU'.7
M64)[0MTBI.9/M`+G12()DFQ/<\X7<'9*"`:HNUA,87ZRNNI>;42!1/RR=RH,
M3;3%5+_FY:8N*&\0[3J=QRZR@=G>YPP%3#M"+HZI<%4%SCMZP^*BCA0O*06Y
M@`03,D)A$=.%29^7+N]33(4UJ0BCMG+C!/*97,ZB%ZJO"69P?V:6;L"VW<MO
MV9O\OI&,N&Z9BX)5&0V^8C=N4YZ;!,JZK=8PGY4B\I3%Y1$`&MNJ_+YDM6YK
M6LPM5D8*UCHZ5M6R.@PF9STL556W27M)LZW0)JZF[06Z!*4J:>@[>,/F`%0Z
M2J<!T,8HAKKH-<UOY;^[DR+51K6[JI*E132OD,]J3T2-L>$@-G^Z$!:J&[02
MYRJ:N"$TVZ8?,@J14#)F!0!+RBJ0!^EB/$#::5?^F#N@U57;3%:B)?+E[H[4
MJ46Q55.%3Z4]G&Z8I`#X0"ZS::^$.W'#FHAKW=2ZU!?RQ=SH_33/JY8[3JN<
MNM23;.=T^G#?_=6O<`=N.&^/_L5KU/Y:^[%+)<^D^?FJG)=+EP3?0B[,:MUF
M-R)O*IULQM#W7Q4/+29-_5RJ*1T:^?)(J[<\/`DJHT;*+D34%,G6`0YB``B7
MB`#PJC*_`?(:63-6KHJ=ZHU53%+E+^TJ2OJHV3GKY5.JVH7Y<^2<*6U<5ZS;
M2;NLL[>$3*3(L6\='S)[<N*0@BJN&\2!PAU%@:@<$B@`:U_#/BGEM-D'>AU+
M3RF2I&TY+41$A'0AZ;+YTZ8B*][E5=)D8(:"(<QC:"(:F140TT'00(58I5#)
M!T%.(>&''NUY=$E3*M51B(Q4NA9<=E5LO*1U``$"<P`)>8XCH5(NO%0_IE#H
MTJBO8R6Y,"(G`4/<Y%L53&3>=D^Z\0[<LEWU8<DSC+UA5K/CXMXZCTGS1%O=
M-WP,"I(MFZY1;K.FB$H)R%-X)A#0>`C7T3N)E&7YK5R:2KE,<DZ:UBJK454Q
M*B12.@T)LZ:V6JHY;-\]6EM`W0\I$C=H%=!5!(1TD@7;IA]58B9R`;D7,)1,
M<H<^G'ITK^WV?E<[F.8BI->K4L5=G*2T\]VK51L<Z'"I4IM!W2EY0'M!+C)U
MH\QQ7VXX>1YQ-Q320/RE*F.G2`<1K*_E=[E)%5FO1+K)<I?*93-:G=<[65#L
M_P!TI%"`;?\`W4054Q`Q/<Y8<431Z.`J``F`YNX-&?E=[EJU<,UZPW=G+CJ,
M+FE5&&)T.$%V@[H$Q.4F_P`NE=`&RY#E-MYQ`+@5.8G5+(GTU`-->/=K'Z6^
MYRIAV[T<JI_TI5B:`F9U"VJY=:GUALZW3:!_M_W7T>]QPY]#4?TO]R_3/^KE
MF.TZKG>VIP+;/]TX$41+O^ND@"NT,JJMMVP\"?4@*G6$1)IR@H8.D>FK/TX=
MUZ>7U>4C9LF,8NER[_>':<]4\Y55>%2UV9.S<S%GK%M]XAR5OFN2X+%R'`/H
M*XXISMUPV"QV;Q$R*HMW*A?UFY3*?5,X"`D$=0&NKE/@?E^0SDJ,I<ZG<CD5
M=FUC%5>%JQ\I4ZO>Y(*U(\);C:KV2V1]G>([6P3@C>O<5JX^M(9`S5%UM]Q`
M_E)1Z[Y3)RSR1#G5DEE#>"<5S<W*0`#AI6_WB\(9/>JH=5YP]\YCE2#7HQZ-
M@EB)B7RB7F$R6U&MC!-\R?\`<<[I^[O_`+J$>Z(;<<-@`CW=/!Z*\M^E_N4M
MNT<BK_\`'++>U*OG+K4XS[--T*@+%/O[N@Y5T3-U@-MPPX(*H'`0.D<.7B0P
M#H(58S\LG<]G(GS$AHERR*YC4K>OMJ<2VSK=$@D7_;\NHI>=NF0H;;<.G)S$
M,`-P43*3PDB&`-=>`!TUEWY8>YTY,$V<]S+U19<O<,=?GWQ]L([.MT>HC[OV
M[!.B"J/,?;AA\A5`4`1``U*`"DFJ<1*'<J2?EA[GRD1LN>]K%N1&2[#+<PGQ
ML7VR@VS[=(DB<ANT`N<"`GRIN1V[X>X:&$QS'UX:IFUU'Q`TJO\`2[W+<_&Z
M=,C_`"I?NEB9E/1.4NLI3V?;IE03$N_ZY2F`H^<./<ZX@,11,X"0"IIF+U!"
MF(/.!RCS@(\*ULP_+EX?9=(<ZNJ)B(Y/-79,6"0THBK8I!<QJG.\V8^S<BMI
MX+9=?M^9*P1'71DZY$KPO6/O_*UA/I>.B&,`B[C;&R!/VW&3$G$M@3;(.WS.
M+3$1;@8-3^E7\6>)?AWW:R6L?V1F55@1;$V:-0]-039ST;C55TQ4RNT](*^=
M9/0.E.PVSX<^!V'N;>@T#T#4YE2K)CF]7E6*J&FKW16"V#0/0-0ZVOW>48QO
MTJ-`]`UE*QS5BVGE(HQ.TJ.'H_Y*L[2G[LEFLQ%1H'?]6H+73%OD2]8BHX=_
MU:)73$ND2]8BHX=_U:SU^;Z"7K$5'#O^K3K\WT$O6(J.'?\`5IU^;Z"7K$5'
M#O\`JTZ_-]!+UB*CAW_5IU^;Z"7K$5'#O^K3K\WT$O6(J.'?]6G7YOH)>L14
M<._6W2O?68T=+:W"V-A)JJ1Z=<EBO2JPN5<,2PFNQ7(Q*=7,1$=#<,"N72JY
M9#5?:[WP16P!0"@%`*`4`H!0"@%`*`4`JV3](@)-4)]P0^<WLE?B%^4%7TG*
MU`[CYC][?W17>XC)7<7[/E?KJ?R@J_O?]-,_FN_C4Y4KD>1#K1^:_O/G"UY6
M@W3>9>A2/36M-_J_9H-E.0*M("@%`*`4`H!0$@8Q1`2CH;H`?2UX#\@:BYLQ
MS5;)@DU;HZ2J?]"Z&@L/L>*G^7_>(CR%`S>?L=,BVIA54(HVG1'K#<PE$2B4
M--`#3C7Z3^`-%FB=Q)23W(KE8W=4\17*^%MT3K]P5LW1D_>-;&.RY3R;CZV6
MF';PN8$,>W&T@4WTM'DCS-7DD=S'R`NA:G.(B4I"\@#H(CKJ'W[*:"LIMI4S
M5:LN+4A%56V.X<%VT=.@TPDB.TNE\`1R*.1B25]33&1L'$-NW7/SCYI;UZ2E
MR.IMO&7L_96_;]Q/46RGF(@Y=-2.NLT#E3X"%9GY<]U;-6I?!$7S<+H6%K5>
MVU;R\F)=\N5=QFY?:=$V?'VM$6I./-S-MY39HOYQU$3KC',19#Q*4M=Q-0$!
M*G3:EFAY".F*`J"/26J5RZEAB68_ID\3XQ+PSL/>&XW.FXUI([A,FX'@,,QT
M7;UI0UAS,7#-8Z0U>+N,D7,T=QDD,@QE0$B:`<Z9`\V/X58?EM-#%M'>1YA5
M<Y8K$LM*]H[>EA9.M''Z,S8&883\IUD8)4F+?CY9F_DIF['2<8E?<C*BS5B(
M5^U.L4[F*`ZRAN0#@<`4``UG2,Q8Y6TZMV*7158PWU"N<I8ZR.TOW"XSVWV7
M=.3?Q"E;EC;*O?),^P05EIZ[[IMB-O\`O&$BTEFK*-*PM=JLA!]4E)JKJ@8Y
M1+U.I..$E9QN8/;,8G;Y[+'?:,Y?Q!;.7LTY;L2,N/!CB])EZA+,;O5?9`MY
MPCCBWKIBX9"T#P:+5PP?KR!6QU1>)]0&JNAM>6I,I\S5<,W"DM5MA&[=,HY4
M3=.VW-;Z,PJXU-:5T6Q'8HO]X\VLYFMESC^\W-Q)O,593S)&VI'1[IV\MZ)!
MG,2`)G(\3("I42G'03@`".SV=3N5$VCH+^\95SE2!ZK%G:<W8C<MOV3==D6Y
M:ULKS-P0<?=%^W]*R%P7LY:2#TB#FWG47:)[>%4[XOF@-)!W'K^!X!5/!`TN
MS*9%P[1UO[YA'N1('TPW:;;D):3FS.=M>/X^"A['D,KNU@RN^=2<?8$3DF0Q
MTH=5J%I(I.)M\M&&=@@!RE234`O,;3483FRLLDNJ):JY<*V1Q>T;$EZJJHN@
MVY'NA*\<4#="")V[:Z,>#.MVA3"==$DS`^?)I]8()E."2+CB/#HUTKF4>;NJ
MY$QSFJGF+\&&X3:D%1=PUH[(0`NW>,,B!4"JWQDHBB:)2E(<$[\F$^8P"`ZG
M/RZB.NHFXU^8GC:V54=\G8K/G>#=/6Y7N>S<,NC@4!$"%Y2@.@``F'H[NIC&
M'C\6OG,R6DNO5B703W#ONN.,YN4AM0`Q3`8ABC[$Q3!IH.F@\-=0[]:68\II
MK/O4PI[10YR[/LD\NA@2<8R(0@@'*/596LI,G,.@FU`!Z=>FOJ7AJW%FE(FX
MM0S^)#G3[)3H:%]PR[WS7O=MEX2C65H7"YLJ:O\`N6V;&4OMH*0&L9K+&*=W
M/NUU`\-'JT!;$'0`*LN0>.FE?J<V@IW^:LQZ6<\\(YSH<)C3DB;F]CK"Y%8_
M<_,Y&6N"!AFENX^S>Y&Z):!F.9NE^-$2O;L6$I)M''6&$S(C45%.8#%-RD,-
M2;EE-&&T=;^^117(BI:8\6SVE>=LX,K<LFQL:6W'RDLWW2,;^O(9IY$/SH;;
MINW+<4FK*@74>IR*W0XN,BQ$'2R)FR29M1$:SV;3(Y4VCK?WS.)T%WSLK#[1
M+-^/L.8KM[+-KX]A+[ONU+1D+$O-&\I&\FLTSE$GIID\I$,[>9/EYZ).FB5L
MR2$Q9'K3F*J0$AURW+*;TCK%YYC&Z"(?"CVO.8S69=LS"8`MB[%,6#E!?(<Y
M*WNXLLJ\=C9W;S/K+=MPT++N'$A-J3X"")UR=05,>81$:+EM.E[UA\8SM'%[
M77:8WMCB[6L;N&Q1;E@6Q!$"-O>YK8O!2ZXQM<MYM4%<1Q,89S$Q)G+BZ'*+
MM-8!`I4!1Z3:U%<KJG6T;FK*ANNMB,2K?>7,V-Y?RMEIMN+E<I(N(B<:3\H*
M-HJ.S/&=L:LUED&D<\%N@9T@+;J5.8"%Y3&T`!TUJIV6YE*Y;F07?4-5;56\
MT]8\R3NW=;/W6<;)D]V$$\98'SU<F6<GY@?VTGB^Y)1B^E&MF2&/T6!W<NX=
MQ1F9BM3&2;`0>)@-6.S<Q3S,<O$L+,2D8.2Z)LPA^T'SA`W=:NV^>Q%9#O<!
M<^,<0WU9Y"Y#>?B>^MR^#K0[V0FKB<6XBM[>QHQAW9FA&_T\50(4P::C?V;3
MVJY[HI?YQ/&_0=$/:KWJWOVT['N;$UG6"*#ZWX/(=QSU[2TC:25V2MSO8.0M
M2V9R'M9WSOV46@@]26>)-6JQW((BH42&-4NS*94^D7IF-H[0>5S?VCF7Y'"F
M6Y@F*(6SK,NBP,]P&.;VMC(1I^]&%U6!94C+Q\JZMWVA8ID1?*]7H";@W4ET
M4U,'"G9M/<DQ8_'&-V@^^*[0S-MEXQM2P\CVQCRRLQ&LC%LI$3+JXYJ^V%QP
MES0D(4C]C!15OMI:7N5TJX,9PU`$TVQAYCJ\@<U83+*94CM'=,8W%@H7M9<F
MI2;'<%==JQ4=AE[MWC#3%NN'[],T5DIUN6G\)1+Q=LQBY*1914\\CD5'(E06
M5:MUA`"J"30<+EU+;\X[IC&\VT;+-VA=UEOW\_/`Q$+,8UO-K9,PK`.[@D+7
ME'+J#:W"FM;[ZY;<M66>M&[5V5$YU62/TTAM-0T$=.O95TU&K<NP3&K:NT\X
MNE3%CA=<IIZVL[TV&*\?759+C;ON:O9Y'9MSYYU/X]QY$S=MNP7R[=;A`$Y!
MS<T?U:::)P+[#B8*_@KQ:ROOAF]7-;+[,EP55\[S+(PT'L,NF0:B(9)?")Q8
M?_I(WE#_`/ZNMWI_CL-?#\L\*>_68/BRMR5B1W:C#^P[*S(D?")QGO2=Y7YK
M;=_EM79=W-[T4[ED/J,G5S%PJNV:L52R^%I"(^$3B_>D[ROS6V[_`"VJ/JEW
MF]/D_P!:TQ$?")Q?O2=Y7YK;=_EM3U2[S>GR?ZUHB/A$XOWI.\K\UMN_RVIZ
MI=YO3Y/]:T1'PB<7[TG>5^:VW?Y;4]4N\WI\G^M:(CX1.+]Z3O*_-;;O\MJ>
MJ7>;T^3_`%K1$?")Q?O2=Y7YK;=_EM3U2[S>GR?ZUHB/A$XOWI.\K\UMN_RV
MIZI=YO3Y/]:T1'PB<7[TG>5^:VW?Y;4]4N\WI\G^M:(CX1.+]Z3O*_-;;O\`
M+:GJEWF]/D_UK1$?")Q?O2=Y7YK;=_EM3U2[S>GR?ZUHB/A$XOWI.\K\UMN_
MRVIZI=YO3Y/]:T1'PB<7[TG>5^:VW?Y;4]4N\WI\G^M:(G5R/:;8[MUU;*=[
M;?MT=@1=UWE:F/X^X[NQS#,(1K<E\S+:W;<*[<MKK>&*DI*O4P,'*&H=%='+
M^Z&=S%FLJGT4U$DO<B2'HYR(Q%<Y702Y$"O5K8I",4]LV4*F(W.HBHLV4`H)
MIIK@=8BRB^H=8!FB;=4B0!KIH*F@#W:^2U[%DUBIN8B[A'=]'>K=G^?30309
M(K0D-PRD0"K@*`4`H!0"@%`*`4`H!0"@%6R?I$!)JA/N"'SF]DK\0OR@J^DY
M6H'<?,?O;^Z*[W$9*[B_9\K]=3^4%7][_IIG\UW\:G*E<CR(=:/S7]Y\X6O*
MT&Z;S+T*1Z:UIO\`5^S0;*<@5:0%`*`4`H!0"@)TUX='_%QIAG/\VGCMUY,$
MC;P%%5,253OF*D41+C'C9=(L(O<)O$%^]8-E5IRPG":;F0:MP,F+:=U$AUE2
M`<2=W2OTL_+Q-S>?W/ET5:V8R:UC;59NPT(D3QE5.6H5,#7);PF1&:]J.W#<
M-=]NY"OUW.(7;;43)0L+/65EFY[$>(1,QYN,HP7"TK@C$7[:0!L0%2K@<#`7
M3H$:^[+/S2B1TES\;7K=!$A#A.:Z6C7Q^$ATLMLIVBSD6UAWEK0[%K$P4#;5
MOKP-[RD%)6[&6N+LUOKP,E&3#9Y"S,8H_6.F];'3<E,H(@?6J%IZN=/?45OS
MN-?-1$AAX;D4G<B01=2G<6OM+VTVBZQQ*1)%SSN*9>=F[/N21R7/2-RD?70F
MQ2N(;@GW<XM*76C+I1J!5R2*K@JH)@!@$`J?5)<?H70X??,8ECR5@=3EC9[M
MXS!>C_(=PR;^+NR8AXZWKA7M/)$U:<;=EN12[EPRM^Z8N`F6+.8CTU7:H\RI
M#*_3!#FK'4Y7H':_?$5YJGC_`(/;9J%S.;I1AUF#UW>MO9)68QN4[G96X-^V
MUYN$;<B=IH3Z=N(2296:13+D;@LH"8<YATJ]KJR6W9RFJDN$$2RX8EC%6K`Z
M9?LTMC#A*4;_`(OR;1I.0;^V)F/C\S7LRCY*VY%Z]DEH!PU0NE-,T*22DG#A
M-J``BDNN<Y2@)A$;6U%>VY'6W\DQ%W-74>CL[8!LVLNX'T^P@2202+%U'NX&
MY,EW%<UHKMGD0C`+@YM"<G7MO.W1HAN1('*K<S@@%#E,&@:0?.KIC59,:Y6+
M?<9BO-4^R.V%[.F%NW!;"L,O+QMR7-:=TO%KDRK=-T2K%W8TXVN*U(B`EI^X
M7TA;UJPDNT(LA%,U$6!#:Z)<1UUNIR_0NU^^8B[FJ?(7L_\`9F$PC+C!'%!&
M0/,#;`Y1N8;(>3AGIY%.X92S?Q@_%Z5N!F\."C=VX;J+('(42&+RET=4E^A=
MK]\RJKN-4N&AM4VQL#/E&D-&@:4L!QB^0$;R>&!S9+NZ75YN8M1(\KU(K*W"
M]56\XTZ_0W)S<@`%6,2CI8K4(DICD5/.=8OMA9BMMP*MGL6TO*\_%.U\</K>
MBYB&90\!9S^*C&IIEHX*V8,HE5LS3%RY=*KB"#4A2ZB;N5R:W,<CRZCF/;,E
M*N%;$>D;N$S*1[E2+5-;&QX#J;=H@I>J.?\`'W)A@!-<BI1:J7S,N4G95"")
M#I*)"`AH(CQK\Q/&O+IE=GS\UI)S-FCXHU$BNL]CEJ*VU?989="<J@F,77E$
MQM!,42#P$>X/'2OD\B?,LJ9K5BIVE<BW%)P`Q-!.F0=0T!0X$YAU]B77I-IW
M*IG5*5<YK$:K=]2MS8K$PD[10P'V=Y/5*8A40DL<->M5.5$HJERQ99AY>80$
M0`I!'4.@`UK[)X=R4DYK1HKD6-0SW4-.?3KLG6I<ON&S3*&.\89KL66QWD=Y
M$3-HW!&,F;^.3G$63DG4*-7A'+22;.DWS5RD[;$.0Y#E$-*_4=*25!/F7:_?
M/!QA\%5,;2;!MI2T1+1TR:<GY*5F82=+><GF"[5;^AW]MMW+.$4MR\PN,+@M
MPC-H[43$C-PB10IM#`(5E:27N27:_?#E7X+5.VLC8SM"QW+O9^UX?S>:D8:_
MX*0?O\D3LN9ZRRB\CI"_E5T)*<<M_;*YGD4@HX=`4%Q,GJ!N(UCJDN/T+H</
MOC$L>2L#RL=V<VR2+MI&UF<"]3CV,S;L_"O#Y=NUQ<%L2%J$?)V^6TKF<7(>
M=M=C')R*Q2-V*Z"(E/H)=`"G5)</H71X??&)>:IV<+V?>RF!:WNR86JU40R.
MWNAO>2DED>?E7,J6\5HYQ<1R*R$ZX%FO*+12!E%$N0^J?`>(TZG+]"[7[XBZ
M_"IYS<ML?Q7G=K'0T:]L.)A+@OS&]RY;]NI20DWUR6]C)1V>$A+:*E)^9P+[
ME?'`712%4Z/"JU.N4\O_`,1=FU(^:J1MW5CODD5/A(NI3*ZS\98DQTZNV3M5
M6/C7%XNO/K@.:YQ="^<%9IL2B7SU\H1D4&Z8!R(\I![H5735&:U[MF]RM2.A
M%]I+3*(BK!MYY5E@7!S3!RVVYN2-3PL[M61L]S9JET&<J!;TT[>/9)F2;5?G
MF1%ZX>J"*@J\Y`'0@AI6:R9F5(FU1ZO=BN1L%T;I)6HVR&YH4\;D'9SM:R@\
M=REWQ3-69<6E8UEHS<1?DM!3\;"8Y>NWUII0T_%3#68AG+%=X;G<-E4UU@T`
MYA``J*4K')B=)=B6V_WRJ-D,*Q/*/M@NSEX6T"^T9D$;(9L6<8S;93NEM'SQ
M(V1<R[(M^LT+A(C?@)R3I1032A71S\P@(B%.IR_0NU^^(KS5+782[-[;M8$+
M=Z5_O8J]9R[0OJ*4.C?5R!;L1;%^-G,9+L8"!D9U9C!22\,Y%L=RU324Y"E`
M#`!0K*T<K<DNU^^95;;&K`OC=^RC:7>TS;=R2T8HTN:TH"/MBWKEM_)<_;EQ
M1<-&1Z44V;M)J%G64@@<T>B5)0Y5`,L0.4XB`UCJ<OT+M?OD4<[FJ>'C.SFV
M21+-E&M+8(G'1T:XBFB)<GW*"Q6B\\ZNH"N'/M_U[Q9O=#Q23165,99!\;KB
M&`X`-.IR_0NCP^^9BL.2L3)7$6+L0X(C9""L.4<D1G9`DK)O[HR'(WI,2,BF
MD1JFJZF+IF)*5<F3:IE3*!E1`"``!6O6395%2N;MY=),=SU2W?M4FR6YZ8K4
M1-R"V^Z:Z-@3MJ_V_2"S(QEFJF;=PHF51Y^4529EN\@E>))F%$2:%U3,8!`0
MTT[E?G9XX9C5K5S&)62IT7+'"B6VGI:*6K6I$S0%,FGL"?8T_C?,U_-N6T<Z
MHF+%8VZ#O))=,1+41%)Y$_$)]B3^AKINH\G1RH^0Y7QM\Y;]8V:I9&XGD3\0
MGV)+Z&H]4R7[N[I+QC`ND<B?B$^Q)?0TZIDOW=W27C&!=(Y$_$)]B2^AIU3)
M?N[NDO&,"Z1R)^(3[$E]#3JF2_=W=)>,8%TCD3\0GV)+Z&G5,E^[NZ2\8P+I
M'(GXA/L27T-.J9+]W=TEXQ@72.1/Q"?8DOH:=4R7[N[I+QC`ND<B?B$^Q)?0
MTZIDOW=W27C&!=(Y$_$)]B2^AIU3)?N[NDO&,"Z1R)^(3[$E]#3JF2_=W=)>
M,8%TCD3\0GV)+Z&G5,E^[NZ2\8P+I'(GXA/L27T-.J9+]W=TEXQ@72:U.U6,
M1';?CE00'JB[Q-G@J$2`J9CF_+K:O5<2@`"4I^(@.O"OLO@Q1T+<TS*=1R]F
MK,JJ%6*JL466ZQ(W&G6S4IY:*Y(Q>GNFR]PHIYTX6,JH5<@*$Y41!%N(*/%.
M<3D3`ICFZHVG'NU\:G/3,\RF2I?F*Q=VTW9;DFMC<4=VH3ZALB>F7JBJ^*-C
MN6_\2QR0;$#TU;,D+3/62Y8JFZ118I$BH&10"@%`*`4`H!0"@%`*`4`JV3](
M@)-4)]P0^<WLE?B%^4%7TG*U`[CYC][?W17>XC)7<7[/E?KJ?R@J_O?]-,_F
MN_C4Y4KD>1#K1^:_O/G"UY6@W3>9>A2/36M-_J_9H-E.0*M("@%`*`4`H!0#
M0!Z0$0Z=`X#PXAQ[G$*UZN1F%33OD94Y[,Q<D):M5$<CMR"K8BD)LO:RUEK<
MJ&-5\[/ML^1+PF+ZO'"MES=XW$6,+,7"HT=IOG9&!%B$([DD'K958H`L/@=5
MIWZ^C]U.]WC%W5RM9+<PS!K[(?/(EW!$T%RR7\%((>;]P9L\`1`NWC'6G>9R
MA0'O@'MMPUK1K?%OQPGUV)F99EAQ7=8*ERB2JQ5(KP(4>X+V>=S;OCO7NCYI
M*\?_`.+5Z"K\4?%K82EJL[S*E>J+=-CBX>`P_*)>XGM(1[@O9[[WC'?WI*_Y
MWK0_NEXH?[FS7ZSWB'9,O0FH>X+V>^]XQW]Z2O\`G>G]TO%#_<V:_6>\.R9>
MA-0]P7L]][QCO[TE?\[T_NEXH?[FS7ZSWAV3+T)J'N"]GOO>,=_>DK_G>G]T
MO%#_`'-FOUGO#LF7H34/<%[/?>\8[^])7_.]/[I>*'^YLU^L]X=DR]":A[@O
M9[[WC'?WI*_YWI_=+Q0_W-FOUGO#LF7H34/<%[/?>\8[^])7_.]/[I>*'^YL
MU^L]X=DR]":B0V%[/!Z=O&.N`?<DK_G>J)WBUXD4Z(ZHSK,*UJK!&OFJB-WT
MLOW";,FEO6$/:*3["-G)RF*;;MCD0$!#PF$FH70>`ZIGEN4X=X>`]%;,OQ7[
MU5#,%7/G*U;XS%7]A>F42Y5L(^0R2LZQK.Q[:,18%CVW%VQ9D+UB;"#AV_FL
M>AYTJ9PX628]8<J1@6./_."->6S?O',S"*U"QCI55_86))V2>9>>L'73E$QS
M@G]+3,?344D_!3Z.@.0`T]*N9*;*G4B.2%L3;EQ5MMY60Q@'P#'((@;PTUS(
M&+X(B`@8I#\VH\-.'37)=+27,Q(2M/$W]C^SLHVG(61?]MP]VVE.-BMYN"N%
ML+Q%YR.$G1.82F*`@"Z13`/2`A7I\LSR=0)M)#E9/2"M<BP5KDN<F^A%[<;8
M;GNF.ON"]GOO=\=?>DK_`)WKU/\`=+Q0_P!S9K]9[QQNR9>A-0]P7L]][QCO
M[TE?\[T_NEXH?[FS7ZSWAV3+T)J'N"]GOO>,=_>DK_G>G]TO%#_<V:_6>\.R
M9>A-0]P7L]][QCO[TE?\[T_NEXH?[FS7ZSWAV3+T)J'N"]GOO>,=_>DK_G>G
M]TO%#_<V:_6>\.R9>A-14&PO9[J4`V\8Z$QC`0"@UE!,)C:Z!R^V^N@Z?$JI
MWBSXQJ_JU%G&95#%MQK.@MNY"&X8[+E)8K4U&(>^O;YM!P'M5RCD2'P)9#>[
MEHA:V,;$BB2S6;?9#FOUK;D?#*!*&42E'#D!ZDW+H)@X5[+NOWZ\9'ULM*W-
M<QE4SGIBF+-Q(QNZY4;%8)NV$%R^4Q%5C45Z)=`O+@'L]=L]MX;Q=%WWA&T;
MNO;\2X1.Z+IN,DQ*SDN\>IC(KC*R@RA!="U\\ZL2Z`(<E0SSQ/\`%^HFN;3Y
MA7HW$MK9]Z(M_EO+.SV*B8FI'@+K#L+V>@(@&W?'6@"(!HTE0#0/2#VWX!7E
M?[H^**6+WFS5%T;2[>'9,O0FHCW!>SWWO&._O25_SO3^Z7BA_N;-?K/>'9,O
M0FH>X+V>^]XQW]Z2O^=Z?W2\4/\`<V:_6>\.R9>A-0]P7L]][QCO[TE?\[T_
MNEXH?[FS7ZSWAV3+T)J'N"]GOO>,=_>DK_G>G]TO%#_<V:_6>\.R9>A-1R#L
M*V='(F4=OM@(G(L*J:A&DHH1-0J>J2BC4\L5-R4J@!X(F#6N97^+7B&QS:>L
MS.MKD6U'3)J^;N02RY3'4625@B6%_,98NQ]ANS8O'V+K1A;$LB(6D7;"W+=:
M^8QY927?KR4K('8"JJFU.]>N5%!$JB@B)^->6S'-<\[QSEJLS?,?,7=<[%==
MJ0W)$A&6(EA[X?\`AJ%-42LNY=CCHL6"045ASTF.68ESECK"WD5$P*`4`H!0
M"@%`*`4`H!0"@-:':O?U:,>_VQ-G/].UJU]M\$_Z[-__`%,_^!QR<W^B9\=/
M=0V8N?V2[_1#_P!)/7P_+/\`6:CA_:="DY&H=WXU:M?_`*W_`-QG[#8?R"!Z
M:[.8?U;O)[A6SDD5IDA0"@%`*`4`H!0"@%`*`4`JV3](@)-4)]P0^<WLE?B%
M^4%7TG*U`[CYC][?W17>XC)7<7[/E?KJ?R@J_O?]-,_FN_C4Y4KD>1#K1^:_
MO/G"UY6@W3>9>A2/36M-_J_9H-E.0*M("@%`*`4`H!0"I,F;)R3%54ANI?Y"
M3;QQ_P"6HS:QU4_9)-G(D=*E@[^E=-,DEI)VSITW%"/+&\3\BN5+?/VCV2U6
M8C5^&JK#@*WJB7D_']'J5?BJ^9+*\2#X_H]2F*KYDL8D'Q_1ZE,57S)8Q(/C
M^CU*8JOF2QB0?']'J4Q5?,EC$@^/Z/4IBJ^9+&)!\?T>I3%5\R6,2``^/ZOK
M5)L]\NVI8S"MT$C:%G[*U-TC3CTC6)E3)>GFI#R&&U&--X>I6NM%UF%L([\-
MPDC4>2.@]SU*J<KJ)>J7HWRWB"ML*>.M/I"0U],`K&S5MN^8)^/\G_BK<1]4
MMS92^4CB0G3O_+]:I1K.9+&)".'#P@XCH''I'T@X=-$6L6Q&2XC$A.G2&O$.
MD.Z'Q>'"L*ZK2]DH8D(^/\G_`(J8JOFRO9Y1B0\G>]\VEC*U;BOB^I^(M>UK
M?C%9.9GY5RFT8Q<>T(91PK).%CI\B*A/8`GJH80$``:QE^75-?GDO%M$BV$)
M:KALX(I$JF3&I>:H\8(75VD&=K1W$W!"R5K[,,'3II/`MOSK9=I*9NOIHJ7S
M/+UTPRY$O-[#@5T2G@^8G,X4,OS:@`5]ZSW*5[GY(^GG17-*F2BJJO5SI4MR
M6(W"J(CG6XD<BP1$@:R39<UV)JK@:NM3<.!BD3<->M,8B1P;@V9@`%:@'A><
M)FTT`CP#<H!W`+7\[)4375'G3:C6XOVC;[2KEY0[H``?-:ZZ=_ATZ5T8UM^"
M678VCE'@''4>(!QXAZ8<*QBJTO9+&-I`^#[(>7N<1TX_'"F.K6YLKV>4SC:I
M(AH.@CH/I#J`^IIK6%F5*7MDIY??&)!IW_1ZE$F53N2V4O`OOC$@XAZ/^2KF
MS&RT5U6QJ3-R"1L)M8V8F)=PC6M"=G,ML6RVV?%4RK$1(H!]&M4]57,$Q71W
MX>Z1%;2,V:)+YMFH$5D"@%`*`4`H!0"@%`*`4`H#6AVKW]6C'O\`;$V<_P!.
MUJU]M\$_Z[-__4S_`.!QR<W^B9\=/=0V8N?V2[_1#_TD]?#\L_UFHX?VG0I.
M1J'=^-6K7_ZW_P!QG[#8?R"!Z:[.8?U;O)[A6SDD5IDA0"@%`*`4`H!0"@%`
M*`4`JV3](@)-4)]P0^<WLE?B%^4%7TG*U`[CYC][?W17>XC)7<7[/E?KJ?R@
MJ_O?]-,_FN_C4Y4KD>1#K1^:_O/G"UY6@W3>9>A2/36M-_J_9H-E.0*M("@%
M`*`4`H!0"@%`*1`H!0"@%`*`4`H!0"@%`*`4`H":RC$F+LUN=9K`T[@5O+W?
MILL3$U45>%?VF<>[$CU:T:BOF*BRI2*OMC&NE"@P&,*:92@8RARD`HI&4$VH
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MO%P98@0P7'),U2+,)B8B[7EU9S)#N/U`02EDU2D$1Z@!YCU[[,V]QO#QK<G[
MOS)*S,:S%>LUKUN3#!7*JMMC%$L=8:$V,V?%Z*B8;C:)"K]J6JDLFQL38';D
M>Q.+)G$OIS/I31\<U12)&-S,X*-.Q9($#F*"(``$T\(``0KP+ZWPRJO/S";7
M=86UV!\E6QW88G1@319Z6-1L([Y];E[VKS4OMB>VNS_F&R>H&80%Q9Q;NA`.
M@.==BFQUX?\`.&UK4F.\+DE*M+,K>L;F)\C#Y8.B;K=O\+!#RG6!G;M';:<-
MTY_9;8>2")ZG=+XLS!!QZB*(<3';LLBR[`AS@&NA5@#O5HY;D&7YW7]3E54B
MFDK:CYSH)#0JIN\!K3(RVXL+E6.X?&':36=9J[K\OFW_`')X*,W6$DA*3&/+
MDO\`M=F<`*!U5;CQRPF(EJU*;74R:OFY0#FUZ:XU3W-;/J)TB1-IWMDQB[:(
MU'0W615,6\B6A+$15:ZW<M,LL/[H]O\`GAF5UB;+F.KY56\-"-B+FB)6X$3%
M#FY7D(NX-(Q2Z7S1'*9%"CPTUKS&;]S\VRR1M*65,;7*B*U%:Y55JK>C52U(
M;I?(1N/$W<+['27YA%1-0[W0#+&,H!G1$QX_26Q1Y--!X:!I7)I^[$FI2.>K
MA=NQ566^T;^-=*'+Z7LNYQ.&AA_1%[@^G551EN694W'E#D=,30Y7^TIC'O@0
MTK5I:S,:UBOS)KFS&K!L6X?-X()'A&+$16R!0"@%`*`4`H!0"@%`*`4`H!0"
M@-:':O?U:,>_VQ-G/].UJU]M\$_Z[-__`%,_^!QR<W^B9\=/=0V8N?V2[_1#
M_P!)/7P_+/\`6:CA_:="DY&H=WXU:M?_`*W_`-QG[#8?R"!Z:[.8?U;O)[A6
MSDD5IDA0"@%`*`4`H!0"@%`*`4`JV3](@)-4)]P0^<WLE?B%^4%7TG*U`[CY
MC][?W17>XC)7<7[/E?KJ?R@J_O?]-,_FN_C4Y4KD>1#K1^:_O/G"UY6@W3>9
M>A2/36M-_J_9H-E.0*M("@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`^,(]X``1'O``B`"/QZPKE:F)+TM"V)$X"J$2YD%1,J9V?\`6BB"P'62<\1%
ML\`Q"(,TB]`@!S_%I1S<SS9V!<2QWT7B-3:67&)6XS>UA#;9[7P-RRDE>&49
MPX-8'$N-V![RR#(OS:%;II6_%BHDV;NE#!RJO%VB`E\(3AIH/T;(NXM54HZ?
M-EJLJ4Q9CW*EC6(J(KE6-R*J1A%2#JAJ0WULWS&M&WNT2W6$=N;FNZ'V,XAD
MR@BG:4$U"Z=PTNR7XD7?W(B<L-CAVNWUYVZ99("&'@H/+Q]A5YOW/[ER4FRZ
M:1FU4JL2Q[I;&6+CO:N*"P@MG`9ES'S%M3"D%+V8E[.G:GA^7879^(SW)]_M
MM5I3*.8I=S?5V2SH1`55WZTPHM&.2F4'4"H1Z7+7E,P\4IU74+/RG,74<M'*
MLNF8L49B^"CE;;&ZTFDM,,%M0R]EI2T;!MJ9G7ZT3:MF0S%P[?N4$R1K5@2-
M*`JAY@@T21!CH<`4X#S#R\HC7B^JYIF+EG4U"LA[W12H145=]43?O)):Z$;M
MPQ.A=]&-[@<*QZU@9=MKS^WY2Y[!7N2SF\:WRA$P'(+EQC<Z4HY</N"Y13;/
MRQSE;F#E(/'3K)X?9S5R^LUF9/KIL$17JQ(LT,6U+4WHFA-=&H6-EFO?.JM;
M?YAJZ8K(MRJ6[DVVH#&;F89WC*W'``P287'#MVZTK`H,V3N0<+7&NDND"30G
M6BJ)@`HCQTO3PQK)CFL9,<KW0@F!+57_`)BQKD5MJ\)>7"^Y&T\S35P6PWLR
M^L?7O!0L9/O;'R+#>T$HO;,T*Y8FYXH[=5Y%NVSP&YS`EU_7%`/#*76N56=P
M:NCEI4.FN25B5$7"EKFWI?N&VBHJP1;3(CI`O@@`DX@;0H&#7TS!Q-\<1KS[
M,RK&.P+B7#9J\A:C="G$Z;MWK=1F]00>M%1$RK5XBFZ:J"8-!!1NN51$Y1`.
M("`A73DYS5(MZZ_>&#=,/<R;`]IV;E5).Z<71=LW9X!F%]XX%:QKOC'1#<Z*
M\<_MXS-DBY%33Z:N@L4H\1`0KULGQ'S>FJ4KLPFOGM;*27!SDY&XV.&Q$*5E
M-EMBU+8^V8ZJ8B[0/:J)W^"LH([N\3QYAZS$^?'R4/E>+9ID#JV-LYA8HK)W
M$)2AHFBK&(%Z`%7NUWJF;W>[_3'/EL3+7N17(J.68R#6(B2T:J-\Y[T5<4?A
M0A8:[9DQB07SO^-Y?7`6_?#>:IU7'-QH3N$<X,N5*X,)97:!;MW-W2?@*.+7
MD'1RP]TQ(K`(D.S76543XB0HCH'GJ[P]J^[\A,P:NWI'(BH]K8,MWXV07S;4
M2W232H:JX?A:#-\Y3%'0Y#`?0.9371%4!]@=!(P%52`":`8#@`B;4>BO(UU0
MZ?,3%+V:M2$(QCOFS)6+5X2BM(M%`*`4`H!0"@%`*`4`H!0"@%`*`UH=J]_5
MHQ[_`&Q-G/\`3M:M?;?!/^NS?_U,_P#@<<G-_HF?'3W4-F+G]DN_T0_])/7P
M_+/]9J.']IT*3D:AW?C5JU_^M_\`<9^PV'\@@>FNSF']6[R>X5LY)%:9(4`H
M!0"@%`*`4`H!0"@%`*MD_2("35"?<$/G-[)7XA?E!5])RM0.X^8_>W]T5WN(
MR5W%^SY7ZZG\H*O[W_33/YKOXU.5*Y'D0ZT?FO[SYPM>5H-TWF7H4CTUK3?Z
MOV:#93D"K2`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`D*UJE:M,*4C6N<KH+%
M86$7JY(0TBNVS*ZGJZ3IB(BPW%0(KEMW".]7$_\`-=/V;6LP\-I,G3T>@*ZS
M,FSF<F.4R5LX61>B+J"V+`XE5#I]6*:"KDPJ`7J$@T.IKP^K&^E(`4!U$Q@T
MX:=(UR*VA[ST\S#+E4RIN1??J6PJ5^%?.N,9MWVZW&^RO!-W[@<MJN2V99AV
M9Y%*.(!Y1Z1Y(-XX64.R/SJ2,@V%UUP@34#I)&T"O?=R_#WO1WJJ95*LN2DV
M8Y+&S&I9"*PC&TU)M6LMBJJ)<:_(3>UE;M(FZEL=G4LXLS%#QHT:9`W87A;Q
M0;1K9=#_`-X6SCBQGA##)7J!0,15RJ11)DH42G*)A`:^PU_<;)^X=&^MK-HM
M4YB[&4^7'&YJHBJ]6HF%NC=6]#E2ZF;.<B,AA1;5C[(F=&U_9IA7;(S>2UKL
M7UWY.GFXHWIE^\WJTODFX7PZ&=A(S2IS+Q1`6U_6+44FB'L2)E``"OD?>/Q.
MSFH>ZCE2)5-)24DO#+VC45N[&VW%!%=I6\Z]/1LF)YRK")EN(*`0"$5.D'5"
MD/5`5,3E'01%;E`.O/PX"?40KY]3LG5M1M'O>JN^"JKAMX3?=2,E,1R*JKQE
M!$BEZL!$#D3*(#UH%.<0-IKRKB`KH!^@$M=I^4++E;27*E*]-VR.LJ5EEA8?
M=+C:5S+MZS%B>WW<>VGK[Q\_@+?<.I<R9".V:[5TD[!8IRN6[(PI\AE>;4@F
M#4=*ZO=6NS2GS:2ZH:Q:1CTBU7*J0M^#&TUYV)$5K8(JH8DNIK(FY:XMO=D.
M\)9!Q0EB.]K6R)D:Y+P9*0`?C%8"::$5:-CR"::!<DPUTB9074A'B5BD4A.M
M*.H5]+G/9DB3%GSDVD^7YC$151S7Q\](+YKFPL1;;32F-=,F(Y4@J7^3C/'3
M&`,ODL7/LQ$6NH[GHG?TXW.6999WA(U2][/ME&#<#!G65_6AV4X*!R)=>4Y"
MF(.@<:TW9_3*^6C)KVJDG`JVQ1><EO*32AE);T1>$R\POE/).7;_`)N5<X=F
M<<XQAK/AT(I_D>W)&*R7-W@Z7>EG8V+82!NN+:L04J0HJ'`R;@IAZO2O,9C1
MTTURR)];51:Y?-1T4MW4W+=TO;,?>B(94<>@0$![H"'*(#WR_,CWNY7AG/:U
MRHC6JB+?`Z*+9<@K&U_=;J$>`J*;EUX`.I3%T'B40,&FAB]!R\>(#J`]VKZ=
M['3428QJMT*D2$Q,;<-Q'@`!.9,AU""(@=0.L`H>(FD?F11)_<E``K0K9U3)
M=&D<YB?NJK?<4HZLU=U3&_<'M6PON=A3Q66K0))2L(&EMWY%J&BK\LM^L',T
MF;4N9D*,Q#+1RIRG*DW5(B?ET.40$VOJ>[G>[-:5$IZF8Z;2V(K'N>YCD18V
MM58+!;;KS/4I3K45<6DP/B,M[A^SSDV%H;DWDYN)VJJOTXJ`W,0K165OG%2"
MQP\Q+GQ%J4Q$K;2(<J/MUR$31#051-RFU^J>JV6^(-.F8Y2U)-;(E0FRI:-8
MS%BLPXK7*J0W;U@5/>E)9&+%N5;[+S;%:]S0-ZPL9<UJ2\9<=M3[!M*P%P0;
MY"3AY%BZ3(JD=L];&,DY353/SD5*(%.300#C7QW/,BS'+*ATB2U%<U514<L%
M2&DM2;,5J.1$@IZ#D#V(\#?(K@2I>8J^$YC$;O*9VDS0A0/`1#T?*KJ)E69.
M3$C94%_?0VD:BHBK>1ZGR?6K/9.9\V5TT,X$WP'H]&E.R<SYLKIH8<V"12\J
MT]'H"H+E6;;C9/30JB[>&GH]`58S*,S=RFRNFG&(NWB*JJ:&IH\/6$:F*Z"H
MON&4CND5JF10"@%`*`4`H#6AVKW]6C'O]L39S_3M:M?;?!/^NS?_`-3/_@<<
MG-_HF?'3W4-F+G]DN_T0_P#23U\/RS_6:CA_:="DY&H=WXU:M?\`ZW_W&?L-
MA_(('IKLYA_5N\GN%;.216F2%`*`4`H!0"@%`*`4`H!0"K9/TB`DU0GW!#YS
M>R5^(7Y05?2<K4#N/F/WM_=%=[B,E=Q?L^5^NI_*"K^]_P!-,_FN_C4Y4KD>
M1#K1^:_O/G"UY6@W3>9>A2/36M-_J_9H-E.0*M("@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!KQ#7E(70XF54,5-!,2E$2@JL<2IIBJ8.4O,(`)ATJF<RM>K6T
M21F8K;%6SR&8M3E%K+GSKA&R9E6WKRS!C.T+@;IHJ+0MU7K;UN292KID43%-
MI,R#-9P4Q3@(&3`Q1#CKIQKU7JIWTS"B3JTIRQ3<E3%]QJE,R=+8=`;='MB*
M90A]QN"R'3*!CD-E6RM0'Q-?;H0YM:XU#X==_6U>*9(>G_9F_(-5U?*9>ON<
M9!MT.V8B?6'W%8,3,*95DR*96L<A54A4*F8Q5338(@)#&X@)@-IQZ*Z<WNGW
MBDYFZGJ<OKYLQ$2+I<J;@6*;GFEK:V4]E]GD.!UNDVO"S5,?<9@95(X*%4*.
M5+*73*FD;4ZITTYH1.0G+S%'H'3772MN;W+S-SHS,LS3ZJ;\DHG54MNZAH`W
M<7!BWMG)*9P:IN<QE@K9-B2]7"<Y?"URV6SO+-&1;9.XA7+&VDY*<9D;V=&\
MZY%%3&`RZH)J(E.GJ8/Z:\/NZ]?W+I)>;ORZN=F\RF5\A-FLQLI;(.F)N*J+
M8V^%\%.9,JY<]5EIR$6"[D>`S;[/#;9V>?9L6M=%J88W36W.QUVN&4G.,;JW
M#6E(6VJX:IG1-)-+8).*L6;]-1;I(?P]1$W&O)]\<^\5\]=MZJEC,1%2*4;T
MLW(^:2E;.4D$-DY-T^V$Y^K)N,P:)A.)4]<G60@*P!J/6#RS0IB;AQ'741&O
MB%3E?BA-GN=U-ZQ7[K,^0=.36RV-@5$W2[9#ZZ;B<'>`!05`^5;(3%)0P"(I
MF`\V41,7NZ:A5=?W:\2*VD;)G4KVLQ(L>K3&V\.`V)E>Q6PCN[Q(;I-LO3[H
MK!N@#J.F5K'$>''P0]NQ$1]+OUN^HG?EM%B?)?&'HIOR##:F4]8(OMH7AAIB
M+N=DVF[?FF,_$2#)*2MV=AG"3Y!_'/P$>K9/68K->0`2#F.4X]9J'I5\\J*;
MO9DM6U72W(]JK?+=#>O1#839OBGP3L13(LW3246<&335*8&J1CM"HIZCYPT.
MJ`&4626T#F+H`#6XE5FM9\_5Q2<K<-RI9P%<UC7.C#<*SAUH@=<J9PY2`@V*
M'(A'E((Z)("'A.!/W5#Z&[U1634;B^Z5;--"@X"X4.#P5'J0ID70%RNHJ#1V
M01^D(("`$*R.`!KQU[U-C47JJQ\HV2;Y'Q@#O!P`.\`>D%;'#>;(H":G+54=
M%#*)&Q"1J]J2WKA?>I%;+SP%YY-QKCA)@ZR3D6S,?I/SJ%B'UW75"6\$RND!
MC&0;>V;YLDH"!0X\PAH`5TJ?N_5UJIU5JK'0BK[B&L^IP_&+62^XO:M<#&1@
M[DSI@"=C+GCW43/0SO)]AKH.HI5$XN2*Q[>:<%D47#81(H42B'((UTI7=?OG
ME\[8T,J;LYB(L4ES%MCNJC=!5UIGPX1-0LAFS$'9@7PO=N%<Z8XR+L>R+<""
MM[8FC<HVE-W'MS=RKHB"MZ6,DE-KN):S'4NM^N8A`!5:%5.H5,>32OL#^Z/>
M7O)E/6,RIWMSR6C6HYDA[6/EM1&HCTA%7I#E0BI2V>R6Z#5^;6.[[F\;AXC=
MSM:F(2&FV>XW"2K*=CVLK'N39.LY`58Y\W*\9NED%I=-PU%=JH4_5J%*J370
MQ0,&E?).\7ASWUIGJDJ2Z/\`*F+_`/I+DJI2I8?8;=-MDY.<NXC""G%,-"Y0
MLT!'K5"D(8`-,@(@;FY@[U<%GA[GRL19F79DZ9"U6RIT%7=5/-NT%R5\J$.(
MDVZ3;(F"QE=P^$$TT5#IF4'*5F&*)B*]4;V$T82^%Z>E2_M[G?X9FGU4[Y(Z
M_*]D#E'<_MF!15,NXC!YQ3ZD0$F4[+$%"K)BH!BC[=<`*`:#KIQJ+_#[.VM5
M>S,TL_\`BG?)'7I:V1]PI]U%ME.8J:>XG!YUA-H*(93LHI@+W3B8\T4G(7N\
M:S)\/,]F-CV;FGU4[Y(ZU*T^X<A]S^V4G+_M&X)$HF6*=0<L6.FDF"!RD,8R
MBDV0ABF$W`0$=:KJ?#_/9#,29;FGU4[Y(ZU*T^X7!M#(5A9":NG]@WM:=[Q[
M)P+9=_:5PQ-PLR*?,B=Q$NW::950`1+S"',`<*Y:91794JMKJ>IIU==MFO;B
MA?AQ(D8;L"V7,;,BK3UU2+!0"@%`*`4`H#6AVKW]6C'O]L39S_3M:M?;?!/^
MNS?_`-3/_@<<G-_HF?'3W4-F+G]DN_T0_P#23U\/RS_6:CA_:="DY&H=WXU:
MM?\`ZW_W&?L-A_(('IKLYA_5N\GN%;.216F2%`*`4`H!0"@%`*`4`H!0"K9/
MTB`DU0GW!#YS>R5^(7Y05?2<K4#N/F/WM_=%=[B,G)<7[/E?KJ?_``4[W5-.
MZ=,@]+)KOXU.3*Y'D0ZP?FO[SYPM>-I,URZ4JMF3F-7?4WV7H1TC4'UE,^HV
MK7M67I-A%@RT:#WO5#UZLZ[2^D;K(8D&@][U0]>G7:7TC=8Q(-![WJAZ].NT
MOI&ZQB0:#WO5#UZ==I?2-UC$@T'O>J'KTZ[2^D;K&)!H/>]4/7IUVE](W6,2
M#0>]ZH>O3KM+Z1NL8D&@][U0]>G7:7TC=8Q(-![WJAZ].NTOI&ZQB0:#WO5#
MUZ==I?2-UC$@T'O>J'KTZ[2^D;K&)!H/>]4/7IUVE](W6,2#0>]ZH>O3KM+Z
M1NL8D&@][U0]>G7:7TC=8Q(-![WJAZ].NTOI&ZQB0:#WO5#UZ==I?2-UC$@T
M'O>J'KTZ[2^D;K&)!H/>]4/7IUVE](W6,2%10Y3`H)4C\H\IDUB]:D9-3Z6J
M)D1'JU#$3,(EY@'0P:U4O>A<DJI$VC;MGS)J,5&JB*B+NVHIJ5:37M:DE%58
MVPW##[9[BO&N0]R':"OKYQU8E[NX7-N-XJ#<7E:,+<QXM@IB&VG:B$6O/-9%
M9DW6.J)SII"0G6:\*_3[P2:F:]WVU5;2*UJHEKECN;T/8IYBOFSVNV;\20MX
M=PV%CMOV\:$*.W_"BYQ.J=<H8HL;K#IEYN3E`8/343@``/=K['699EC70E4Z
M.="Y%6/NG"F5$W%!L372V<R.1IJ[+PPOL:VUWKA*R[]+8;),]L6&G=V0G49+
MA`7T^9HJ6J=K;2=DR*;DID%"N#/#MM"G(!^$Z+)I2/VTV7L'7X5T;BQC<I;+
MG35EP?%'6^[>6L=[P-EUD7J%H9'VQ8C/;A[7RQ=4K?MMX?LEU#6ZWQ_EQGBI
M&TYYB2!Z]E*KNY$@',4ZA>O#J]..H6YCE6)B+(\Y;X)P7&5G38V8E1-\RI:7
MIL!3MZ['C'#&)(E"R@M,TK%S>%[*CR0[Z_88TW:`.XM.%#J/;6.'4%!#F#F\
M+4:V<JI\S8U9+T>U%;[2<14LV?N-=")A_B?=#@&[<IMK&O';7MPLN%5R@[L!
M.1/B^S3*/4&\%/3ZYT?_`'$;4Z;*#.H/`-2E$:IGY-/>D%FQ3XI>LV8JQ\[6
MIE%"Y_[,J>AYZ=;V9@EM#0=L)W@P?2.([,9-;JM<[IJR&;M(ZUND7EFB;YZ@
MDH*91Y%%B@(<=0U4[MOQHBS?-W?-N]L@L^>EJ(Z)D;A^U]E^<;>>W'8F'\'2
MZ<;+OH2::+8IL9*1@9IBH!'L3)-1@BG27;'X`;B4WS)AJ-=EU%2RD7,,+Y&)
M$2,42.F\-GS]W$U#W-Z;:]O"-G78LC@7"9%$K8GSIG2Q79":B9RQ3L2*$.2%
M`Q3$-H("&@^E5&945!*RV9,93H]J2U5(*NA;2<NH>YUCE2W28"]G\V(GLHVW
M((-RJ=3C"/\`-$$ESQB`J*/7P`?417.KR%)P#4```K\W/%GO*RGS.9)HZ5SY
MC56Q'<:'K*:JFX=U;#,43<PB`&.<$_I8'.``!@+^EF#ZHGJ/`W2-?%9.=3)K
M,>8RUD5$>2Y4C#<6ZY3L278F1>OG1'&K>UJ7GMUEOF:1QIVM2\]NL>9I)T^)
MZH>O6HM;2JL=HW61Q(-![WJAZ]8Z[2^D;K&)"=/1PK;HYLJIGI)DN1\Q46Q+
M["3%;BM6"#3Y8UR:V?4TM9A>BHU%*Y[_`#?-4PVR':=JWSO4VS1%XVU;-TQJ
MD7?*R]O79`1=RQZ@$MR4*FLW+(-5&)#D,7FT%$3`/=K^R/`2BR#-7RNT)DK%
MH6/[#SM=,2"I&#H&PI+;7@`ARG)@'"#=P03@FJMBJQC&,00$"@"R,(B9$3=`
M]P2\-*_MU_=S(Y.%:.F:]F%%BD4M\JG!G3U5_P`R[$D+8;F\:Y;M>C<+O,ES
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M+&BXQ[:`7'AFTUF3AS+6(_OHS.X')(,B+21.S8G633#7F1(81'AI4DHGQLB1
MVE0NXXOC`;@.SL;1MH-;GL7`IKEF;7Q]-W))Q>&K3"V[:99!B4).VY&<DAA#
MMXV/ETG!.H.8=!YR^G49^6SVR'/PKA@2294+8J.A&)>*P;HV`Y,O^6QG9V.L
M$2%U1+J:8LNMQ78Z;.><6V\)&W&A$N1M\A7WM.^5*DH)/!$3`)1,'&IT-',P
M(JM6"(3VDZ*\JW?4R15VU;>3]60FW[")P(D<.13%%CG2,4YB#R)J^T?(3@'=
M*/1TUIYK(<LE5E(JP0QMIR\I5APFN7`ML6]9NZ#>#;=IV];]K0#*5Q^LSAK<
MB&L*P;*.6LX*_(U8E19%`PE#0$TB:=^OX'_,\]E-6Y4D]<*JR=?PL/3Y'->]
M)FTW(&:&@][U0]>OY6Z[2^D;K.]B0:#WO5#UZ==I?2-UC$@T'O>J'KTZ[2^D
M;K&)!H/>]4/7IUVE](W6,2#0>]ZH>O3KM+Z1NL8D&@][U0]>G7:7TC=8Q(-!
M[WJAZ].NTOI&ZQB0UH=J\`^YHQ[_`&Q-G7].UJU]N\$JNF=F.;,:]JO7*9\$
M_P"V\Y.;JBRF?'3W4-E[D0\Y=?HA_P"DGKXE2U$BCS><ZJ<DMKELCNVG1I>0
MOD'=^1554Y)^:]8E>=(QM7$ET$A$V7\DD>/_`"A70KZVD6J="8W<W=XI:J(E
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M+AX/I;N_3R?_`&:]3GV9LFS9K>SZ1528_<_>4U)4IL$T0_8=6(\1^(7YPO>K
MYY,F-6=C7+Z2'`FDW&,1+1\OT=ZNFM8UE/'L^DAP(7OEHC(D<:U>TV?A])J-
M>"#C3M-GX?2:A!!QIVFS\/I-0@@XT[39^'TFH00<:=IL_#Z34((.-.TV?A])
MJ$$'&G:;/P^DU""#C3M-GX?2:A!!QIVFS\/I-0@@XT[39^'TFH00<:=IL_#Z
M34((.-.TV?A])J$$'&G:;/P^DU""#C3M-GX?2:A!!QIVFS\/I-0@@XT[39^'
MTFH00<:=IL_#Z34((.-.TV?A])J$$.0@\#?H1KG5N59AWIJ*:FRNCD2ILJ<C
MU5BHU53?58&M4J]C(RN5J,?MARR26?NT2ZQ1$FN=\;B`*K$3$1_(K:VFG.8.
MYK7Z=^"])G>7]V&T]2QJ6-^&B[F\IXO,UG.?YT<4#92=\4`,)%V?.04OI?GC
M?F,D)RB8?JG1RU]9ERLSZSM'M1&QYWOG"V=4Y+O.W+36:3;3N8L(]\XSQ'F/
M%MKX`O/(I\BMWYTIYOF&QUIFYR77>L1;SI@`6](H7+*'7`RKPPG;HK&Y!`P!
M7=F.J)RV(F*$+R:2*U$N6/"8U7-V6]YK,/:VW\P6AYM+.\AQ\Y+3Z3Y=W^+&
M0-Q,+GY((=:-`QC2K%2#3C55'8\C@JAE!$1$!KEJS-%<J2D;#??#]IG95+;_
M`'2_>8=DN1<DY<S-<UOY*L2VL;YQ=XNDKO9^9.#W='O\50J<#%1<8JL7VL)`
MR:1.M7.`^=%5*4I/`$U6),S>2Y&O1J-5+51]R+Y2*LJXV7<)9MEV6D['7[&7
MF?,=LF*TRM-9'6(<BXNE4Y&S+MM)"+1`P\@+M5KF*J!_F4TC%U\+2IND2X65
M,Y5X?9<81M3&WW3[\G=EBKDJQ]M5OJY/MY.=VW;=IC#[6053?1+&Y;K=REKO
M1FGB\9U;Y&WW/M$H"Z9/IHG4*8H:@(UC9L6^HFI#0J6\))6U*HD+X:3-W9=M
MNDMN=L74G=TQ:;^Z;SFS2<D%J/)%W!,&C43DC&+23N4XW%*%126,`*.A,8O<
M'C4)M/+6"(]9Z:'P5$WTWT,RV3E7YR*)PQ,K+V=-?Q.N\2O&YO\`JK<7@^<(
MZ:>U#OI\/N!Q^-6<UFNDY7-62QCG)+7S5L1;%L_8;[&HB(R&ZEL#5EV?X@.S
M3;((:#_X:Q71H(#^O9/TNY7Y6>+7K'V[,FT]#3P5Z_#1/VGLJ.0BM\B&6Z>O
M5)_H/_M#7SJES*N;*1N9Y?2K4II7$L-RTZ:-:B00JXUL=IL_#Z342@@XT[39
M^'TFH00<:=IL_#Z34((.-.TV?A])J$$)"LIFM4VW+\OI4JMR'FKOVF((3\?I
MX^CA7GIJ]Y:RK19M#3VKST7W5&!'-N,4IA1-/?CM>,H=,A?:"_\`3K#E('&W
MYCAJ80#XU?V]X!TM33S9/6*.F:MEL4UGF\VD86*^Y3:E(+MP%)0KYH"9^9)<
M.M;JJG)RB)2IIF,/,!#Z&'3N=ZO[8FRY<Q$7:.EN1MB-N/)36S$=\TD&[NX:
MV[JVT;E+9E<PVG@'(F$(/"N=//%YQK>S.XVUWXR2GHPT3=9\?H6L3\6I)>4,
MX7?E6D^90CQ7EU!,*K2GE0\^HFXN%"G#4[GNGC&_9VF@<=Y[L*#R-"(-\NW?
MMHGH>:.Q(9X@TP5&V5'22UQ-6I1CU92[U;7.KSH@)"&<<QM!`:QL6+?43=8A
M40NMX3CR/V?SJY\C7E=[;(\'&15R7))7`T8*M&Q3H.WMHRD&E&/2M@\T(F,H
M^(L99/Z89$HAKU@UNJRKF2H,6*(V]70539;+K%1%6Z&D\M%]G)>2V(7-BR^3
MK'+/24K"2"DK;HR0-VWM7BZ;Q^Z1*I(:/SE,O+=84H^Q2*).[I7)<F;->N%$
M547G^^1P545TIOGU1W9FO&FW[/&%7>4+=,IFW%NVC&@316PHMX1#`\!#P$FN
M1/E!<`N=&..=/E\)(3AKII5SES&;+=(J5P25O5'15-]+0K:I(Z$WSM-N79VR
M^"\Z,KZ<7K9LG9EA%G2V`DE*71+W>NA..T7#2(G&\^JI;T<SBVR0I%68:+JC
MH*@CQJVFE2Y284J)SDW;4")4WK=PFWA)TW%)'G7;(&Y"\R8.6QN0=.)=2'$@
MZ#Z7"M6LD2WRU1\][4WE,HL^-B6&I+%1RGW<[R1(<B@>V&.?#(<IP']:3WS1
M!$*_AO\`,TDK+:S*5;+96(]D[Z7X$%9R>'=/5=W&S$;.6:EZMANZ3+3C7\M=
MIL_#Z34>F@@XT[39^'TFH00<:=IL_#Z34((.-.TV?A])J$$'&G:;/P^DU""#
MC3M-GX?2:A!!QIVFS\/I-0@AK2[5S7W,^/O3]V)LY_IWM6OL?@S4T]5F^8-F
MTTB1#+*BUB6K&6Z*+P(<S,V-64SXZ>Z;+G'[)=#_`'7R?.#=-?(.\4G*>OK"
M$(\TZU*U%@A/#Y?HZ*J;-RN13I&%B6^:73Y<(D:U"5F<A&?,T=--E[CG)YR\
M)JHU$0CC5G:;/P^DU&8(.-.TV?A])J$$'&G:;/P^DU""#C3M-GX?2:A!!QIV
MFS\/I-0@@XT[39^'TFH00<:=IL_#Z34((.-.TV?A])J$$'&G:;/P^DU""#C3
MM-GX?2:A!!QIVFS\/I-0@@XT[39^'TFH00D-:G+S1J.BF7TFHQ!"0'T>@*HG
M9LV,.SZ34((?.(^$M\0OJ\*VJ/-4<Z/9])N;@@AW''DZ`_\`PS]T?%KM=K-_
M#Z/4(--.N8>VCV_XYR;>5ASN#=V<D\A9A<7$A;&)7+N/<=6S1\%)<7I0.01+
MJ&G2%??*W\KWB+5U<R8R91[-[W*GG3$L556[9J><9F"+YL2W8=O!ML$3'4V^
M;P^0_(*!?R+O%5")@0H:*B5]H501`1TK2_29XC.MVE'TYOV1N,S'45?#O[9]
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M/IS?LAVB/AW]L_O>]XGYDGOX?3](WB/Z2CZ<W[(=HE)NW@VUZ&!/`.\5`W*<
M15_(L^(0J8%$5`.`/#\X'(`@`<.-4S?R@^*\R"Y=.H6S&K%8S)R6>24;=)F$
MI5=M;L)C'>?:+=FGD>[IO(5Y;'-U\Y=UW.6*\Y.DQ+<K$'SB.CD8]HHX2C;P
MC"*J^U;<A`,8@F#HKV^3>!?CIE#$IDJ<N1J)#ES_`)"&G55]&JP6VW>/.I[[
M.RU$"G+L2W8\[U86:#0<7WUJ!2=.IOQ][@%Z=:]4[PC\<I3,:U670ASYWR37
MD5-`YT-WR&'4KOAV%WUO&@QMO:QN7A,!8CLEV2_;-MNR+W<S5V9/EEB#%PU\
MQX7JH0EOI6VY4<H)]:FH+I),_$H#7:IO#7QB[&MJ:!<RVMGG3L&S@L=SE8O:
M+G3Z-7P3D0WHQ,PDM]/95`F)4]A>ZU4PB`)/#XWR"X.5J0.5)JZ,I>C=(%B`
M`<H)@<N@>RKS51X5^.,U\6U67=.=\DGMZ%?8AR>[I[+/WB&ZD>]^3&^QX]/'
M_KWZ=99X.^.\Q(LJLNQ;D7SX1W(^;<8V]#[(%`[Z.RR'IV';J!T]/&-]#T]/
M_P#7G=JG^T7YH/O>0=*?\DSMJ#V0*O=U]EIT>X0W4Z?_`$ROO^7E/[1?F@^^
M9!TI_P`D;:@]D![NOLM.&NQ'=4`!_P#XROSU.%^5"9X4_F7IV[2JJ,GF2M$I
M9ZNU8;M)KU,VD67\URH[Q2IOG[+!5-1(^P_=0HFHF<BA#8ROP2G(<HE.0W_7
ML?!.41`>`]-5>H/C],383744%_=G_)-*7-9&Y#)6PNVFV@XOLRU\>8VVN;M;
M-M2U8H(6WK:AL)R9HF`ADN*B0.W<B=0Z@`/#41$*\IW@\`?&/-IKZR?U'&Y8
MV).1(\&S.A+K6RU@D<)ZLO;O[9N4#$V^[RS(&#F;'<86=JG40'@4Y3$?``)F
M,`Z!TA7G:/\`*MXG9E)ZS4.HFOBJ<J:EB;VR+ES!$6PJ^'?VS^][WB?F2>_A
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M6RWT:&M5U3)B>?<B>V6H]W9V6Y]#K;#]U!7&@"H4N,[_`#%(&FB0$,I?"8CJ
MCIKH%>XD>%?YEJF7BI:C*);$L5)NW18Z4\VXIR^=38';6_%O#W=?9:::>X0W
M4Z"&@A^3*^]!#TM/Q\Z*N_M%^:#[YD'2G_)-_;4'L@/=U]EH`:!L0W4@'#@&
M,K[`.'1P_'S3A3^T7YH/O>0=*?\`)&VH/9`PSR#O:V'67NNQWD)+:UNA+@&X
M[*?6+<V+;CM"_/-&U[.I="4C;XM=N>ZDFRLH1DU%F=$[D-$UC:<0KV*^&WC(
MS(MA/J,O[928V+D=.P8,,'(GFQCCM3>-9:NE298J;.&]>9GGWS]EF10XEV&[
MI4RF.<Q.KQ=?20&*(B.H$)?RI``?[DQM>[7D)GA1XXS)D6U67P^/.^22ZW1[
MWM%`[Z>RT$-!V([J1#TAQE?8]'Q;\JQW@WX_+*5U)598E3#S<3Y^&._YHZW2
M;W_T@=]799ZZ^X1W5?&QE?7\O:I3PD_,^U;:O((?&G_)'6J3>]HY"[Z>RQ)Y
MNN&PO=>Y(J=1NL7\G602=6`<!,4I;T,&A=.&@C\6L/\`"#\S\VSKF0P^-/\`
MD#K=&E\(>0N_B7M8]@^"6<NSQ+M&W5V@VGW2:\P:.PS/NW<DHTYRM?;!W)SC
MUPN+8JQ@)X7`##7EL_\`RU^./>-TI_>>?E3W2H[/9.G)#%RL49:Z$@6,KY+8
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MO.?F-<KY;$;N/1=1G`[[>?;,H=V53;UO%(*S@IEP0PF\=`<Y1`R:CQ0C\.K6
M$0#FTX<^M?.:_P#+%WGJ:Q8MMQ<Z;]F=2CS%%2V,3B^'>VS^]\WB:_\`T2??
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M9;$M@>'*<PB<X#RF.<1-R^"`B4>4!T#0->4H5T)?)+4\U8M.45#Z>S-Y0U?A
M:U,3>4%>Y;%6PIZP_CF\H:QC?I,0'6'\<WE#3&_2(#K#^.;RAIC?I$!UA_'-
MY0TQOTB`ZP_CF\H:8WZ1`=8?QS>4-,;](@.L/XYO*&F-^D0'6'\<WE#3&_2(
M#K#^.;RAIC?I$!UA_'-Y0TQOTB`ZP_CF\H:8WZ1`=8?QS>4-,;](@.L/XYO*
M&F-^D0'6'\<WE#3&_2(#K#^.;RAIC?I$!SG\<WE#3&_291$543?)YS^.;U1I
MB>E]Q9,:U$2!P/'S:-:BZDI!O%MTS%<>=2+I)LW<)JCYN@S3.H8I>95R&@:C
MJ(C5DNIIVK\["'":<USFW'5#<,(83@O<D(45N54K4LU&ZHI:`'*;F=CJ7G#H
M'C6*S.*6E8U:54:Y5@ML8H1ES%=R[4)"?M[73V^@S`(E'E-+Q'+J&G+I^N?!
M$-.D*UY4_*ZA%F3D17KNXC#I%._E-MX3#???<F8$-K&3Y?:]E>!L3-EI0$G>
M%M2/G5KROG$9!\[Z?9G;RI7C4%E8MNN"7@<PGTTKSF>9C2L8K)4$9PF&2*>7
MR6P\IIJ[!>^MY^5$LJ9USM<EJH8LOZ=3E).7N$D%&7GD*YXY/VN;KMV[868F
M;QS0HI%'D`O*7EZ*IRBLH7T+=LU%=%=W?,HR6Y5BV!^F4]Q00I@H%QP1VS@P
M*($&4C"+D`@<ATW3<[L46AD3>"0J92`8O$:W]KE.+$C$Q?&,[.3?A.+\8;?#
M_P#?T'_E6%_"*V&5]`VQJ03XPV<G1[91^,%O_P#Y_!?Y5AOPBMGK66[W2);.
M3S3F"=@!(`%GH(@FYE16>2T,U:""1@#S9!T9P*9U5]=!#34!IUK+?W=9C92;
M\/MG.C*QKU8P,W3`RR@"N=@C(QD@9J0VG*1+S0QSJ)$#I,.NG#6MNBS"5(FJ
M^@<C9V&%BQLW2;9<I%BU(*?;SCKKRI\/_NT_H:VUK:ESL:N\XLPH5%65*`E!
M0_(9<S@Q!,(D,J?3F$2"(E$HZ>QZ.]6)E;4S68'NBWR&2.L/H4H&$I2%`I"E
M\$I"AJ(%*4-`*4!'H"M5GS:866(".L/XYO*&IXWZ1`=8?QS>4-,;](@.L/XY
MO*&F-^D0'6'\<WE#3&_2(#G/XYO5&B3'HL8F%:BI!;AUA_'-Y0^O5[:VI9R7
M0AP&6^;R;"!,8W/S")NL,<QM1U\)1'S<XE\412#3A\7IK93.,Q2Z8NI.(.\]
M(.M0G4PE\)4H:@1/46ZCM<I$2!]3T-HB7JRZ<YM2AZ5:=3-FUSMK4+B<U(>3
MR&&4TA457(?([D&3(G7/'D:U27<@5JF=Y'HK),RH?3';T[@Z9%$CN0$@=64-
M#"%<.;.ERW6V(F^5ODR-Q#X!N*W^Y.P?^5(7\)K:D5>6_P#4@O\`S&J]DM%L
MN,*NT-M^*R%M:OTD3/1+*Y;#0ALF6N]:7'%"Z05LNX8V>F56*+1P0XO'4,P<
M-^IXE4(H.H"/&JIDW*G1BC;^<22EIU;'#;PJ9&X=RU;N3,3XSR$2?@$4[XL.
MU;N19"_CFSIDA<,0VDD47K99SH@YZM<.8I2E`![E11<G:L4:V/QC/5J7F>V7
M)_&&`_[00?\`E6&_"*V&UF7-2#8(G".JTG,]M2/Q@M__`+00?^58;\(K'6\M
MWM8ZM2\SVU)&XH,3$-^,L27J]0(!9N+*4-?[@KL"CZE22MR]+H:QU:EYGMJ4
MDN&!3+R$N&(Y>8QN$U%>R,.HB(B[UXUB9FE,V&%4APD'(V1]`F&-^Z<I+C@S
M&`H7%$ZCW/;F+-QTU`-"NP$=>]5DO,I#TL5-8;/FK>I]+>1([9%?MER+M5%Q
M2.Z;.D7*+95L/Z[;J`@=00,4#EU`1UJS;.=YTM;#:8YRPBI]PJ&'B501`>("
M`F`!`>Z`".H!5B/?"U;2V!'6'\<WE#6<;](@.L/XYO*&F-^D0'6'\<WE#3&_
M2(#K#^.;RAIC?I$#7OVF(B;;U8X"8WA[JMJ:`FU$#E37S/;::O(</"(8Q!TU
M`0$*UZBNJJ5J+(=A5UBV)=Y34JN2WA-B#DYNM<&*/5]48&P`CHD4R2:FI>M*
MGR@J?7I,;4P]T:G2*KWI-=RUW2<F:]%@BV'`"AQT\,W3Z8UT9]948<&+S?(;
MK55ZJC[0)S^.;RA]>M%LQ[FQ5;2MR(BP2XCK#^.;RAJ6-^DQ`=8?QS>4-,;]
M(@.L/XYO*&F-^D0'6'\<WE#3&_2(#K#^.;RAIC?I$!UA_'-Y0TQOTB`ZP_CF
M\H:8WZ1`=8?QS>4-,;](@.L/XYO*&F-^D0'6'\<WE#3&_2(#K#^.;RAIC?I$
M!UA_'-Y0TQOTB`YS^.;RA]>L*YRV*H'.?QC>J-5.EL=RD!6`CUP%U-H4YR%#
M4>!12`VFNNOLAJ3$27R+`=UYTOYCKU@Z_BKR]`='XQ\GI=/+PUZ:OZQ.T@[C
M(_\`#2<_QJ7Y2=<B3\'XJ>X8;N'A2=`_HC_/#6\R[RDE.3N5LNY!$BJ3(H!0
M"@%`*`4`H!0"@%`*`4`H!0"LI8IEO*3A)[E6.1'(63=PQ?W:1$=<..+/M^7:
M-W\+.9XP+#3<:X3$[27B)3*%O,I"/?)`8O7(.FJQB&#7V(Z5Y'.9TZ0U5;%/
M*:,]3;L?LR.SX:)'(GL_P=U9G!ECA^);(P"LKQ474,8VNHB/$:^<3<UJWO5C
MWN6"Z351RI;$QFW$;3=@V$&EFP\!L+PUD+)N3;@&UL:69%6G%,BSTPBV/(OW
M2\H\60;,HR$B4E';D1,"HI(F!,IC<H#;+S2J1%:V:]$X3*/=I4L4[QCL4M*#
MOE'.O9U8GQX\L2.N(^08L]NQ4PWNIA$6F_NP!QVJF[$]PQSUFS!-3F`O4J&$
M%@(`&$-2IKI\^QZJOE"O72IZS".-^Q0R3`VVC8>V[`%LR+BT+(NAY8[[&J<.
M[M)MD:.C9JWH26,BD2%93CYM*I*II$5.9=/Z:GS)^%4Y%9/ER4:URHB+=Y3&
M-VDM_G>"[,/#]Y3EK0NR7"-_&BK$)>LO(1EJLR(IOD,Q6KAY>$."RH\KM@[N
M;KCFTT,"(@`CK5RUU2OPEUC&NE2[,/B?LB6:CB/R)@':G:,V>];NM*/C0B8E
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M]?1C<%`*`4`H!0"@%`*`4!)2"(\Y%%$SE`PCRG$4E$RAS"DJC[$Y3]VMB7#8
MN4PKE2S<+-XFP9A[</VB;^S,WXZM?*5JP^SH+EAX"\X\LQ%1,XIEQO'&?Q[-
M8X(MUC,E!3$0`1Y1Z:^==XJF;+ALU5L5W#4FS%A8;0?@Q>SY#A[D'!>O_<EC
MZ]>*=F=2UV%'NUJ:RJJ[IKBNS$.S%S.9$=XK[,;$^4L*XBDY&(R%>[:'MQB:
M>7C6RZ5X+6%&/9!)O,,+(32<HRQ774B*R!TT2J'$H&FF9U"IRW:R2/="$5@7
M8MS&78H3$"A)-L/[8V<3%69:UR._.[,;1S.V[>N-BS7M./?E7*1&%?2#-VB#
M1BMU;A8!#D3&BYG/W'NUC:+"]3Q=_P!F=D?8T#)Y`;[5<!W;CJ#QS<U]RSJW
M[*;&NXBELWG!V9(1S:U78(2*@-)":*#@PD`4CEY1XCI3M*HY[M:C:.W%4\_@
M2)[(W.WMY'1^U#`5M7.W/,*6[`7#9B$:YEVC%D[D677F>$1*UDG;1J)P:#^N
M#D`QTR&*0P@[2J/2.UC&[2I=#'^)NQ[N\<=0C[!6U9K?&0XJ#<L;9B[?828(
M2<XS6>M(U5\ES-FR[I!NH9!)8Q%U"$,/+H4=':51SW:QC=I4N]9^TCLG[YNR
M:L6V-O6VB9NV#7=HNX9A;46JL=1@<$WS=HJ*@(OG4:H8I7)43'!$Q@`VFH5)
MM=5/2*/<J)OD7.5UZEV2]F;V?#DQ4%-G6#-%CJAU9K)9E-U:1B:'$#"77IXZ
M:U9+S"K:L$F.1>$RVQ#5)@6S;9Q_<^[:R;'A(^T[8MO=/EVW[?A8%$6$9$Q+
M48,&C)NT`ZA.I;@(@4-0#0:^EY#4+/DLVBQ<J)$W66HADHN;F5.;E*77EX%`
M`+P*`<`#@&M>@=!'+"XO.*H@4`H!0&OCM+_ZO=B?VL-IO]-=M5S\PY#>$U:K
MDMX38<X^J/?\)-^J5NT5R>S<,2N4<`=`?%]>MB>="7>O`!Z:UV<E"+^4HJ9`
M4`H!0"@%`*`4`H!0"@%`*`4!R%^KC]=-^HEH#L_VA_HO_K+0'H,C_P`-)S_&
MI?E)USI/P?BI[AANX>%)T#^B/\\-;S+O*24Y.Y6R[D$2*I,B@%`*`4`H!0"@
M%`*``&M85R-O)(U77$Z#4<:;Y+9KO#0:8TWQLUWAH-,:;XV:[PT&F--\;-=X
M:#6'/3"L(W#`J6K<A`\?C5933$1BXHA[D5+#'#<R<AK1QX7F#G#<7MV`2"!@
M,`?E8MH2G'4.7JSCX(#K[+A7GL_F25EKA1RNAH-6;+5RV'Z1GZ(NR&2*"A52
M<ZI4O"3,J0`%,4^L\(A"+"'*(Z"/*.H5\EF.;*F*YS7.BFXD325MB05#"W='
MA#+%Y2>!,J8A;VY*9!V[7W-7K"61<LJXA+<O)O<]LO[1DX5Q/$1?*PJS..E%
M%DW!DG!3*D`.0`'A!L]D8(R9T2,.`QFO#:ONXSO<3^_\N/;,@59"-R%$6[BY
MG/)W+!8]B[GQ=<-EI-$[A3AXI2XW,I-R972JQDD@1(<Q0*.FH[,N9*1(.8_H
MF(%K+%[/+/-L8JRFF:)QLUR+*O=L4C9T2A,"I'R?Y`\=VU9+]G)W&6+35BCS
MAH,YT5117!!,X%$IM*L6?*1<*->J6[@@>)DNS+W)WA,7Q>MQO\=1,YD6T)!L
M\MF/E7KN%MN8D-Q=FY;)&"\%NBK,^:0$$LB9X0&Y%77*/4E*;0&WE(B)@?'=
ML$$TGMK<[,G)[);-[F;&PI1S?[_+CJV7+_J))VT)?^:(7(\>#MPYCQ%L9K'1
MIB?2@`"*:`/,/&FWDP3S'QX!!-)3C?LULPV?GZT+@F)1M<%C6_E]QF-Y>$I>
M"#EXHN]:2B1+8C[10M]K,(+PYI/JT'JDNJB")#%*@4#:!7M)<(X'ZC$.`WDI
MF\U3`BA3CR\W,J!#"4`,(:&.81,.H]W36H;:7S7]$S`TF;_C<V__`&DCRG*(
M[>-QN@&(8.!;CQR&HCH)0U#B&H@(A7J^Y\QCLT5$1R+LG7I#=0V*9/G/(?%7
MTTWA0"@%`*`4`H!0"@%`2"A4P,)A$"B4Q3&`IS`F!PY2G4Y0'E3YATUJ>/#+
M<FZ:T_E)P'Q;0>8O:<W"($,=/W#R107(`"B8P9H:&Y2FU`=1*&NF@5\Y[QRG
MHULQ88<9JJCE2TWJCJ(@($-P'7333NUXY9*8L2PL4I5CHI!4UFIY[A#=QB:.
MRY@K#-DXUO7"N7;@OB1CL@7+>RUMW9BUMEIT_DLA(*6@2!?!?1E).8<+M!3>
M,.J+RE'G$-:1EL2$%LLN)(BPM+=VAV:-V6;B2Z<7(N+)F4I"[,+NF,@[CD`7
MG[?Q5%,HP5;@5<MG)^O<%9@=%$XG%(=``W"L8Y2K!&NMWC.$\])]FMEAQE#+
MMVMW-DA;]\8YRU;L#'(.%6QV$S>.4[<O^%;+)*I+H$9.$802NE2DT*L(&Y#:
M5:K9;6XK]Y$M$(:#EM?LY<KA8V.0G8C'<5?3#/;G*]X+,I)1\HA%N<?7S;)&
M*$X@Q8J2[AC(W(@"90302ZHIA`H:`%4K,EQY#]0@>?Q;V7F6+6Q+;5F7!)64
M6[8V0Q09[<T3YNFY39V3:5SV[).&;LD<F]*](I-D,B8#@8P%'40IM)<>0_4(
M+O'N=FW9[99P3G*V;HO<\5(VIC"SKJLR#NE>["3LU?B,V\C5XZ8&!:0D.I:;
MQNFP,#D7+J26<F.414#E'78E3Y3);HL?B6$+`B;YN=3;*`X(J8QQ*F7JTR'T
M,)"FTYA`_@CH/*'IU0K\;T6"HL=!*Z)^=C&0**90WF*BBHDBKO%S*FFLL!4T
MS"08+G,&IN82EUXCI7T3N\[`QL8V0-ICVHB1+UG-S&$=!#73@(:#T`'$.Y7L
M;[39145(I<4T,B@%`*`U\=I?_5[L3^UAM-_IKMJN?F'(;PFK5<EO";#G'U1[
M_A)OU2MVBN3V;AB5RC@#H#XOKUL3SH2[UX`/36NSDH1?RE%3("@%`*`4`H!0
M"@%`*`4`H!0"@.0OU<?KIOU$M`=G^T/]%_\`66@/09'_`(:3G^-2_*3KG2?@
M_%3W##=P\*3H']$?YX:WF7>4DIR=RMEW((D529%`*`4`H!0"@%`*`4``!$0`
M`$1,(%``[IAZ`#OC3&QG+,HY6W+`J,4Q.7F*)>;7EU`0YM.G3T]*QM9&E-9G
M:NT@I1.7G*43%Y^KY@XAS^+^BIM9.E-8VKM)(D.!N02&`X_,B`\WJ=--M(TI
MK&U=I($H@/*)1`V@CIH.N@<1'3O4VTC2FL;5VDI+X6@EXZCH&G'4?2#OT6;)
M5(1361=-=A6W<(*/.43D\(@'ZL3%X@"@?,:A\UWJG+F2$2$4UFKM-XMSE/&-
MF9DM`;-OD9@\",U;EQB[M>X9.$ET'=K3C:7B`;2,>X1>,7+:69E4'S<Q3`'&
MJ:BEIJE(136-HFZBGCDL"P[=,IB9=W-@9<SA<P!N6S*KU95'*ADTNO=W*8Y0
M*00T(`\H=P*X[>[66-<KIR)@6[SE2W605S?@H?27!<<)TTPRWN>$ZG$A?=*9
M:YC@'$1*'XR<=`"KE[JY2MK43#\92,5WC'[<[B^XK,P)E6[;$S5N=;71:%M3
M%TMU?=&9:<`5I`LE91T40"XQZ$&I@'T@K3G=W<JEI%42"?O*8B>FP)8">2,'
MXAR#)9DW-.9"]\:V;=KU9/<CEE(AG$]`LI)82IA<8`!0.X&DGN[ECY:/1$@O
M[REK6.<D4N+L_D-C>'_B[N=\(.8O^TKEKB7734/^LG$-1JWU:RS0G24ELW$_
MD+COYW-SW^\KEK^4E8]6\LT)TEXQLW^Q!^0N._G<W/?[RN6OY24]6\LT)TEX
MQLW^Q#Y5,`Q"JAN?+6YU052`<Q#[FLR]6(("``F*87-YL43:ZZ=)N[1.[66(
MY'(B8OC+QF-D[=/LMC`MGV]?,3DM6Y,L7A>$%`SUMPTED3*-V7JVB(*Z'+)W
M*QK*/N&3>)D.JM&I#UH%YB\O3QK=I,KIJ*8LV3#%"%ZDY<M6NBI>ZNB7B@%`
M*`4`H!0"@%`*`J#K=412=+-4DU14?@F?D\Z:<@@1L0"?3#GZWCI['2JYBK<E
MQ1-EN>L4+*WA@>S[TOMGE%W*9%M"^FMKK6/[:V#DFZ+(7>VNI+#-HMU3V=),
M$S"1SRB8%]1X>G6E/H&U<M9<Q(L7A*TEN0X`P5&A_P#-S<[_`+RN6OE?C+7/
M3NO3N6QMG"XS@>O_``,)M^MW--GVW"\<N6Y=6[Z_[J1:/V-EPD#N%SA)B$RJ
MW5,I*3B25Q*K-F$,J!E^9;1N8B7+T"%<NH[ML9%(6(N^162XU\=B%NFR3O2L
M.^[,W%Y:W1AEFUY-[+V]=),X94A6=U6S+J*R/*#-I-H,TBQ/.1N0Q0\(O$=1
MK4E=WVO?##!([Y%LI[HZ$-[YL%1RJ3!S^5O<X5$[81`J.Y;+0&\Y*)0.=4@7
M+P*/'IKORNZ]+AVDU+.%4)I*<@_(7'?SN;GO]Y7+7\I*GZMY9H3I+QDMF_V(
M/R%QW\[FY[_>5RU_*2GJWEFA.DO&-F_V(`P9'?SN;GO]Y3+7\I:+W6HIB?-(
MFM5,++<0K@>-73,D.7=S^AP`!Y=S.7$3<!`V@*DN8#DUTZ0K5=W4EHJK"S_F
M,;)QZ;%V([/Q1%S\;:HS[UM=EX3=\SCZ\+FF;MN!Q,SP-@E5E)>X'+QZHJMY
MJ00,)Q$:Z]-E[::$+-824[RERM3CQ4$QC]T3FYSCZ7,8.`CI71-EB0:B$T)"
M@%`*`U\=I?\`U>[$_M8;3?Z:[:KGYAR&\)JU7);PFPYQ]4>_X2;]4K=HKD]F
MX8E<HX`Z`^+Z];$\Z$N]>`#TUKLY*$7\I14R`H!0"@%`*`4`H!0"@%`*`4`H
M#D+]7'ZZ;]1+0'9_M#_1?_66@/09'_AI.?XU+\I.N=)^#\5/<,-W#PI.@?T1
M_GAK>9=Y22G)W*V7<@B15)D4`H!0"@%`*`4`H!0%BY6UKHS!NSP!@"/R+<>/
M;3O>P,R7?=+BV'?FDF_/8Z=M#&E2.**NID1E5-.)=.:O*]YLR7+TDP^%BW=$
M#7GN5L(&:A.S`;((G!KN@S^9-)0Z::"EQMR)D24T$551.V`W(&E>33O([3[?
MO&OM':2P*>UC#$OG*?V]DWKYT?YJA+2B+O"UQE!1E&D1*+O6[5RB_(P\R.DF
M=B<3$UYT0\(V@&"B=Y'0M6WA]XSC=>7]:]F='O47*C;=CGQ5=N<4GAPN%L`(
M*%(4RA!U:Z@)0'7Y-/61T;[.'WAC=OGR3'9QVU`DCB3F\?.,,$HZ39Q:CR](
MR-4DY!02E29M_.&X"Y.<Q@T(34W&L^LCKX^W[QC&[?/(WEL-QUCV)6G;XWGY
MIMR+2DF<0_</[L9\J$G(JD0CFZ9P:ZD5=**DTX=(T3O&]5@BV\/O!7N@?2\V
M"V$P0E'K_>5EQ$UL6P6YYHK>\6!G$?"(=:^),N6P-^<J2C,`U,8`UJ,_O)-E
M)%55%X2I%=I.TM;L\+5O6%AKH@-X^<YV"N%OYY$23&=:`WD43&-X:0E:\H@0
M0$H]\*U9??1R/@K_`&UXA%QZ/X,--0BH^ZLW$M2',*)RI7"U("A!'0@&`68\
MQ><0'AI6[5]ZIU1+8R4Y;%C&*\1E(QM,';!@[HQ_FS=OB.<R%<-_0^+,AV%!
M6BZN$4GLRFUF\<04^ZYU"=6)>9P],(B%>KR2OJJIB*KG07?)QC:A<^^[?3O2
MQKTLYPB!8^[K/G;=43T^GKHS44YAG!/3-S'=#74K*>H<V]8>\%,,NS<NM25V
MM1]M/UA]ML/WE?&*'L(J(C(,(2R;I?VU`BJ0?"*FI&,$S$[G*(5FCIJA:=MJ
M[IT:=GS2*9\%2*!E!3-])()2ID-IUA2J%Y]![W"MKJU1I4MV>^5Z!Z/^2L]5
MJ-*^UQF=GOC0/1_R5CJU1I7VN,;/?&@>C_DIU:HTK[7&-GOD"%62Y,V6[$]5
M5"+F84B*N*Q0"@%`*`4`H!0"@%`-*DC$=>3:W$34E5)?`3V2:2-*PE8UMAG9
MII,4M[=_Q>--KN8;B=D9J/G=NJV^U!PS3<MTGUY@2R(H$2K^`#D7\VDIP^:"
MM*HJFN1=!'9(EZG?[3L3M,0;?L.6PM"Q3&Z8/%5JP$[-)0K)I.O9<L2S&7YE
MFI>M.59XF8?"'6M254MQ06Z)G9;]AD@;P46AE2E,!4O-$D@T*LB?@85EB=(:
M@3Y-=S:[6F=+EWJ-D1H'H_Y*YW5JC2OM<8V>^-`]`?\`%3JM1I7VN,;/?($*
MPM2_+G(DY>7='>UA)::2=`KJR:MLYD4&S0C3IXUK54Y&W)I&S05!CL3$=I0J
M<D%@*D8%`*`4!KX[2_\`J]V)_:PVF_TUVU7/S#D-X35JN2WA-ASCZH]_PDWZ
MI6[17)[-PQ*Y1P!T!\7UZV)YT)=Z\`'IK79R4(OY2BID!0"@%`*`4`H!0"@%
M`*`4`H!0'(7ZN/UTWZB6@.S_`&A_HO\`ZRT!Z#(_\-)S_&I?E)USI/P?BI[A
MANX>%)T#^B/\\-;S+O*24Y.Y6R[D$2*I,B@%`*`4`H!0"@%`*`\5B#__`*9;
M4O\`Z&;F_B^PL2O#=])C6-D-<E^+<T0-.JO:;]7@@FW<J@B+@Q&[@_4%#4[@
M4TQ.1$O#B8Y@T#OC7@DGRMQ$U&K:MA^=:/V_;Q87,5I[VD+7C'BF0,WWLW<X
MF4M.?C<\6;BO-",59\VK=ER+S*T"E"6"SMSVP:MQ8\J`.Q,40$XZSZW*@B84
MLA\$6F&=V-,WXJLB1C+QQGN.=XX=[GMJD&O=KQMF*P<LWPR?9?GE).TTTI&]
MWL=?#MRT<%355@T(U!RU.D10A@``K6F9@S&JX&P3]TQ:>_S[B+=E*0.3K>L'
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MBV\_580RZK)NV,_$'B2;<72I0(5P\422(=8Y2J%%%`KE0HB8>70"#PTK.-:Q
M48Q(*BQL2!8R)^7O->&<JY(WT;XYRPMS&4\*+1V1,9H+0%CPEA2MM2(ABBVS
M%>3J5RVS+39G?5>!S-W21`2\+EKZ7W9E*U&N5?--EC41J'AGKCM#<*+-YAH^
MQQNJM%BN<CZWFT:XL?,?M4`F.JZCI-9RM:\LJ4OA@W28IK*C[$Y1$-/:SW8D
M@G),P\ZY,)B]LIW*X^<;XL_8OMYK*6LRSC#1^13XYO"/<PEP63D*W"-+9FK1
M?(*G(M&+S;@5I8%/I@."%YQZ:Y"/<V?A1SD2%T;":.5%PH;M"JE254$5U'3B
M*,BDY.91NF05#-S`JW:N`1%!^":>HAX(FU`!UKTDF8W9)'0,3M*ED<S;BL5X
M"5QVVR'+24<?)-V-K2@$D8Y20*NXE6[AVQ4GET3)^U4*55`I#N@Y.5P8B>OA
M:#ISW*BQ15@,3HWJ>3R!NQQKCFZYNQWL?DN=EK="WU[SE[&LM>Y(*P27"D5:
M.+<4JGJWBCR?.!D@5(I]*`P]RM=E8D;#,5TJ9+,W:$BT:R+4W,WD&Z3U$VNO
M,FX*"A1UT`!U`>X`!WJW&5#7(8Q.TJ?2-63)K7M@FDDU55;54BM<F*`4`H!0
M"@%`0/,.G*!Q'F+[`O,(!J&HB&@^"`=-29R@5"LW;%6.HH@H`%UD#NU0:I,6
M(>S7,<1*5,"EU'F[U:T]51+!N%(<OZT%HHB#.0**C!V50KA%<J8#H*:NI@,4
MY2_'J,A56]0003'%10Q#$,<X\W3RF$G@<Q"]!2^#T!6V^R$-!6Y51;"L:-<U
M$\XQB=I4:#Z=31TK=1-0QKI4UE[S7:F:,_[6=I$<(*Q\Q<CG,N7M`!=JSQM9
MRCEO&*R20@9(#EO4K`Y"*!Q*',`=`UP9L%F.1+HJ85RK8JFS),X`!2E(9,R(
MB0%-1`'`%\$CU'Q$790YR`'`"CPK9E,;AN0EB=I4K$#'/S!RBH8P:G4[O$-1
M,8>/16^UVS2.X2EN59B158%2HB!790%1)LDLG]-(F4XF-QU(F8P".FO<`:V&
M53$2TO>^R"%EKLO_`"8OF"RL)X9P\RRID&ZK&O6_&L=-W]'X[CTK=M>5A8Z6
M7,^DF;U-9V1S+H@0```#4=``*XF:9I*IY<5=AMW]VXTYDQ=*Q4]Z;&/:'%,)
M"[/+(.0-#$.;<_9":NAN/5J%&VC`()]`#W:\W*[S2):KM$1^C$U5AP1*&SGM
M6Q5(_)KVAB?AJ;.K'ZLO$_-NDL8I>4`XB)AM@```K:3OA);8UK43XJ\9+K#]
M)\I,==H.L=EIL\L0B``H0XANHL4XR#4--%FX_BV/$H](AKTUA>]\E>4UO17C
M&W>?2&,>T/[NSBR"]X=T5CB(!W-?^J_3I64[X2DL1K8?%7C,;=X_)CVAWO.K
M(_WHK'_DO6?7&5S4Z*\8V[BD^,NT,`IA/LXL@Q`#4P>ZDL<FI>Z'-^*_@ZAW
M:RWOA)5R(Y$A'FKQC;.6PZB9M#?_``D+(3<EL^M&/;QZ"[Q\[0W,V.X,VC6:
M8JKG;L36R8[]7JP'0""43#6M5=X)3Y_S3EPKPH81SD<B1)Q7?H9/L"W;Y"*6
M@S3B+HRT2X<I/%6+AB^<QSE$SI`B:*X`NT,(&*4`$!KZ#E$Z5/H\2HBNAH-Y
MBVIPF'?:8?U>[$_M8;3?Z:K:KBYJU6S$T1*J](-;PFPUQ]4>_P"$F_5*VZ*Y
M/9N%,KE'`'0'Q?7K8GG0EWKP`>FM=G)0B_E**F0%`*`4`H!0"@%`*`4`H!0"
M@%`<A?JX_73?J):`[/\`:'^B_P#K+0'H,C_PTG/\:E^4G7.D_!^*GN&&[AX4
MG0/Z(_SPUO,N\I)3D[E;+N01(JDR*`4`H!0"@%`*`4`H"S=SVCDEEFO%F=L3
MWQ$V;=^,[7R!;!23,$WN!K*Q5^%AP?HE9NBF2353&()RJ=)=>%<O,LHEYHC$
MF?`CNJE_!P%,YF.!=H,^;^%"%*ME_&J!U2**%(?'L-SF2]+EY.`B%<KU1ITT
M:U*-BN\<*.<M]Z!SG3S!C4#'*!!$<>Q!N4@<03)JF/*0!'H"GJC3[VM1LCSU
MSY$WC7LVC&=WY!Q#<C.%GX6ZHAI,XSA'K>,N2W'8/H*<9)*IB5O)Q3P`515#
MPB'#4*UW]T)"NWN%3&Q4],.=]^)DP2-F/&QR@8#:FQ]$"83`;F`3&Y-1T&H^
MJ$CV*X;%2#9VWY&-S#F7'`&Y0(`EQ_$%T`!$?!T3X".O'TPIZH2+]WA4;%2D
MF<]]Y#`<,Q8W,H!!3%53'\0=4Z8F$_(<YB>&4#&X:T]3Z?V*O$-BI)LZ;[CF
M`Y\O8S,<I1(!QQ[$<P$-J!B:\GL#`/$*>I]/[%7B&Q4X3YNWW`V/S9@QNNDD
M4Q3D/CZ%45%%?Z4<"BH4!%-(I]=/%#2IL[IR92XF^ZI-DO"MI:S'-BY"A;]S
M-DO)MX1E]W!FRZ;<N=1&(@FL5$L#VU:<?:J!PCFOTA)=-M'`(&Z=`UKMT=`R
MB1&M2Q%B6V%Y0#0@D`QP`3&,;PS<Q@/KSIB;744SZ\0Z!K><[$D`:S-^FTQ"
MYSVON[PK$E@-S.W)V2\X.8M[S=DXNBRV("6\;:G#HF(Z6(XMP[KJ$R%4.HJ!
M"Z:#7/G,POQH85+<6Z9%8,WJ;>,]JV)$XYR7!.[^NRST[T+CJ/>,UY2W4Q,B
MG--)M@S45<6](1CUP*;A!V"2IU2B(%$.-8EU:M6$3,46TQMW4[7<K;F\H7N[
M:7:ZLBSL?XV/;=IHKVI%7:7+#^1DXS(;A=BO)'!2`5B;CM]%@"J6ARD5'0=*
MZC/G9:JE\!`L9?\`:>7[HD#W2^QOF;'>?)^R\1K1LYC*=4=V'D&X6$.@G.0>
M2;+=+I6VF-IJ\S9-P_,F"C<3F3$PZ:\EDIZJ+S<?::<\G:UMIW42,1N8D)'%
MGT88ATXI*6!N0'J<>!R$$6I5M>4=-!#HK<E2'JW_`(F;CT%;;9;FK%3++Q4R
MP4`H!0"@%`*`J(/A`7Z;],^E!U)P(?53P>!A$-`X\:FSE`PKWX7K*P>&E+-M
MJ+G)VZ,KSL'8*,9:6A+N>03J10)>2T<"ADO-%X>W5E'!5R#S:EX5JU%PW#H^
MS_O6Y9+`Z>.K^2D6E]8.NV;LR[TYQ51S*L"*F7?V2DL)Q-YPLXMEVR%<X"(=
M:8VHU"1>-PSNYS&32U(/(!/`6'H7$WA*&*4.!2E4$0^-73:GFD'7DB*@`<4D
M2KF*0YNK,IU0<I2B)C@;4-1(`:@'=TTK2FO1D2M#S-XW?;U@VM=%ZW(]%O:]
ML0;JY7DBKR("5C%QIWDDT`J@E(*_TDXIZ\3F`"ATUS9E2J+8MADTU;6-T^#X
M.Y\K[N,W7Q'*9*ST]%M:>/X%C(7O>%G88B!]JK.;HV=:C>6G67XY1B+63<E(
M@`=>?F'C5,8VZ3!ENV[0&UYD@J61@C<?>C<OZU9OOR:RMI,W2#7Z2V39HW>T
MB'YTT4R@43F3#CT\:WI7))'WCO(R4LB<Z>R?<,H3D,9/5_CQF94"AS<"O[A0
M,4=`UX@%;$Q%64J)>J&$6"Q,,^T'WX[M<5[3+]R-96T#,F'9*!C(^?A,CWM<
M>)9VWH=CYTV24D9&WK?NJ2D7P.S+E("1T=2"?HX5S'[5&.LNWBF9/7"Z%Z';
M]@MOAW,[SM\.*KEW#X0=8X/`;4,SI0]\)1DU'QM_I.[ML%1229,'C1!N@)^J
M`YS(<Q3"(<:\9G<QRMMTFHLU7);>?MCCB#S+*'((F.5$!<"8A^OY0,`"4X&%
M02%UX`8`TKR3/GHX[D(HXMYG15XAAS)2\<H[1>H6?,K-EF0'%TDHDU.IUJ/5
MZG`R8%$=0X@`:U<V0QRX=)G%8:7[MSW?EG87V19(LJ<&Y'Q,$Y'O)T5.3=R+
M.>4AC016[YV5+K?/VK=1R/6**!R``Z:U<VCEN5=Y87J8QG77SVD^YG&<HK:\
MA"VW=UQV1B&Q<Y7@O'6X^8V]-QM_.I9%M9WXPJLTXFWV$4E"G,:04536$5/"
MZ`K/4F6P7VQM"X&)]_>9;PWAV99REPL;EPKEF=O2W[<:LK*815O6XYMB"MZ2
M(RC[I6*C>5U3:#J9.5VH5`\8FF5,P*^$;0M'+1%BMB;XQF[!-ZH=99(Y`%$#
M@7K#BF8#`IX!")%1,<QB\Y1U,8`#C52T[&0<E_E)-=%8'C\FD!/&=]&#7P;1
MGM"B(F(`>U[@?8CP'HK05TWK$5YR%R<ORGY\-J!2DP)8Y2`!2];=(@4.`!K=
MTX(Z!W.(U]R[LS%2@MN@=&7N<)8+M+_ZO5B?VL-IO]-=M4S5Z.F)`JK^2WA-
MAKCZH]_PDWZI6W17)[-PIE<HX`Z`^+Z];$\Z$N]>`#TUKLY*$7\I14R`H!0"
M@%`*`4`H!0"@%`*`4`H#D+]7'ZZ;]1+0'9_M#_1?_66@/09'_AI.?XU+\I.N
M=)^#\5/<,-W#PI.@?T1_GAK>9=Y22G)W*V7<@B15)D4`H!0"@%`*`4`H!0`@
M%!0%#"H&B:A``@E#B<`T,/,0_L=*1=\%8""+><92G*<J@J&45!,R1CJE(<13
M-W"^"'((?'I&9SC$&Z"K0?&'U"^M2,SG&8)H&@^,/J%]:D9G.$$T#0?&'U"^
MM2,SG"":!H/C#ZA?6I&9SA!-`T'QA]0OK4C,YP@F@:#XP^H7UJ1F<X030<B9
MBH@JL8S<3$06(0C@-><5DQ2$$R%#4YP`^NE7R'JU5Q^<D"+D2!PI$5`I6Y?U
ML\6!$G4G(LW!N;4FA^*2@"5PW[G#V54S9LK%"*(4N7#:<H$6$IAZDY!.Z.BV
MZT!3(NB@4WG2W/H($,10A@(7CU@:#J&M5-;(<L-HFHJ6?!80+7YOQ2&9L7W?
MC-2[;SL5O=\0M$&N2QGJ,1<#(KLH:+IO'#-Z!4Q(/(H3EU,F(E`0Z0JGR:1T
M6NGM1>`FV8CFQN4_-+M8[/.>[)'?Y#9+R%>;Z^\'YC9OL>0^2"L@:N8>Z9E<
MDRR1NY91=1NT9JD9"4[PQB`=40+RZFKFIEU*C\?66QX%,-5$6*K%3]5C=,''
M(9$!?,A1272\U!43*E4*!SN(LR:@IG8KB.IC`;0VH"%=:G=1R4@Z<U;-!/&F
MDY]'0B(F374TYBI`H4X@BB(CU:`<HE,HDGP]F)C<.G2K$F4*7S6KK,8VZ3B%
M!70H]4Y,<2@*IE`YN94?JAB`!2@1,1Z"]P*M2IH4_P"HWVS.-I`I*AH)D%@+
MKX1@3,/*7NF$/2"I3*JB>V"3&IK,MF-12.J5`1$4SBD/U-0A1,)_[S3P?5JG
M:T?I6DMLTGJ%OTE7R!IM:+TS1MFCJ%_TA;[&-5.J*9'0;,14*W5*-6$(D'1<
M`0XE04$Q2B8I3$.`&$/F=2E.("/Q-*M:Z2ZYZ!*F*7>V#$$.M'003ZHAVJPB
M7JG1S:@9,!`PF()1#3H&K,#56"+$O1T3C#70->`]T.G0?B\-:K)$T!TMR3C&
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M8=O&XDQ3CS$`EA-Q-JD/.?K-)D0*40*(%#7PC:`.FNH:,W/:68BI8GE]XKV^
M\:X-]T/N,W>/;.VTP6!MR=A[;[C=MKIS;D-E9[9M<$Q'L%`.TQW;;=M-CU;E
M^[325<+"J!2(\Y.4P]/.FYA3S%@CVH86<JW(9.X)Q9BC;I:\;:F+-DV6XI.$
M:)MVSZ1Q>TF;PD7'5E2$PS#N=.]5D#D$54B`N1`I0X$*`<M;K:^D1J)C;<.L
M;QD2&8I],"'/M\W+$*4A&Q5#8];&<@LD`$*@J4DT*22J.G*KR!H4X=)NFMEN
M;4C$@KFZQUC]T^H<Q7-H!1V\[D%G*0@93K;`:+-42";E`RB@S!!'41#4NG=J
M;\^I93%>D'.1+HW^T86?%(0/`W-DJQ[B"%QME_#F4H"&RK=R=G-&>1;/;)VY
M+2)RKRJ$;RN'[A`C98\;UA4^4>4"5;3YK)KVP1B)%-,2I5QV'H6EV/-N^\["
MV7&6&,B7MC^W\"Y9QVHUP];<?,(6S+3UP6B]8,DXXTQ"M.1VWBE!*`!]+`F@
M"-<;.,G=/EK,EN\Y+80O]LRRFQQM@9ZL.U&L%`JA4=KF\</"`ARJ8MMWK2G)
MJ`@H`WWRAWM*\=+R:M;'"QRV[W&8ZILT3SE/I<]J+83MNNU<;6=X:B#E%1NN
MF?%=M&(HBL04U4SE-?0@8BA#"`@(<0&K$RFO18X'^UQF-A^\8L6GG#9+8\G/
MR]K=G_NEBW=R,7D9)`7'*+EF$;(G!1_&1T:[R@O&PT8[.4!.@S103,(<0Z*E
MV7F2)!&O]HCU=><>AOC<[M(R+)VW,7AL0W23<C9[--C;:SG%T>BDT9I:=7'O
MVC');1I.1B7*'(W>D<)$U'E`.8:RF5YDES7^T9ZO^\=:RW"[-8N]%LAQ>P;=
M&QO%Q*MIDTPAC)FD+5^W`A>NBF2632,(<RI$R@H#9)(JH%`%`.```8[*S%?@
MOMX!L/WC)`.U"L0BA%QVN;QQ%%,4TTT\5VWR%3TTT`@7T)C'T[]17*J]OG.8
MZ">S29;)5'(N(Z*^.TSMB?M*Y+:B]JN\([Z<MZ3CV3AUC"W$(]-P]:JH)@\=
M!?*AFY2G/X0\AM`I)RN?/G(JM5$C?#WS826L8F%NVB%G(#"5D1=QPLE;LRBG
M-.'D),))(R<<+ZX91\D@\206<)$6ZAP41`IS!QZ:^H9.U)$G8P\IMM?A,<.T
MP_J]V)_:PVF_TUVU4LTDX,,R,8J4U<S&UJ0A:;#7'U1[_A)OU2MJBN3V;A&5
MRC@#H#XOKUL3SH2[UX`/36NSDH1?RE%3("@%`*`4`H!0"@%`*`4`H!0"@.0O
MU<?KIOU$M`=G^T/]%_\`66@/09'_`(:3G^-2_*3KG2?@_%3W##=P\*3H']$?
MYX:WF7>4DIR=RMEW((D529%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%.H`8!%
M,#Z%4Y3"!=2*<@@F)1'PBB)].)>(46.%53086XM1MKVRX]W1;B]S*67)G*+M
MG9;VU$(6+MS+^1+58I).K7B3K!U,%/,$2`*ZQN`:!W:\!GN93J951BJBQO-6
M:L&V%T]TFUG8/M2L6#N_(;?<-((7%?-O6I!Q47GO-,D]6EI19LU64(BUNDZA
M&,/%*J.W"@@)"I(F.(Z!K7E&]XJI7P:]47RFJM\5+T);!NS\!W#M!O3(Y'MP
MM`?PK)7<_EGSB5:+,#2A'#9N:]>=0IXXHK!H&G5AK4WYC7SE69C<L=W$J!'0
ML+;WIV='9PWHQM*W9!E?>3[7O.]@M]RFON,R-<D!$2D?&/Y\CB;CI&ZWC)0B
M!8L?`4)J0VA_F=:CUVOW'.Z2C&I[J'[/GL^'D-*NK?O3(!82TE",I5Q$[J<H
MHQ]LHF**B+(YF]YE:,&`II_2T2Z)E*'@@`!3KM?%/.=TE,XU.U7V";`&H6T+
MF^LAH%O(2EM,RNZ?*I"W()R\Q0A3&O<`D#"'<)KH/"G7:ZZ*])1C.T:]G3L8
M>B<&ES93<&3D'D0J5+<YELPHRL><4W\:L`7K]+>LE`$JJ8^$0>`@%.NUVE>D
MHQJ?`.P#8,2*E)D;VR+[3Q2ZL?,2`[I<K>:1[@AP25;NU0O82HJ`IPT'0=>B
MG7:^,$5T?C*8QKO'DVNQ;8>U<W`E,R.6K:B(!%@Z"XI3<_EE&'>M)0JAF+EB
M]4O,J*Z;DJ0B7E,;4`K"5N8<YT/C*9QJ<L[LQ[-JV)*U8:X\JWG!RM\\;-CI
M3=?E)H\N@@\O(K!(*WP!Y%%3F#E.GJ`TZ[6Z5C\91C/+V!M=[,S)B=]+VID;
M*2[?'.1IC%-TN7^Y/,48W:7I"`U%Y'MU7EY)E>H'\\("*Z?,FJ.H%$=!JB9G
M-5(>C'.<BPCRE$8E]E>RZVEN&*KR/5SJ044%':"Z.XS,9`,!4%#I*!K>!B+H
M'$`X:"4W=K>HN\%6YR8'JN\L5,M5?(:S=J+8\?C%S%*OYN12B+FGH]DI-3#N
M=DP;-9%=)N166E5G+Q4P$*`:F.(U]/RRK=4,BJVP-]MYDY\CXHZC\<>[74+"
M:`MEFE-%7$&3DG"9E4U;&N1,2DTYM3QBX%,'-P'E$>BN1GK9CLL>DOEQ3W2F
M>L):J;O\2HB3%.-")@10$\=6("3(Y"%!`J=N18F/H0`,<P]/R*^1U#:A7Q15
MCP[YHXEA:>EN6XH.SK;G[MN-X5C`6Q$2DU//EA**#.)C&BK^17=@MJ5))NT3
M,?0W<"M27)JL48K?I,8MPT([2.U.N":A-T$QE>?M7.<Y:TR;(N'K%QNX@&$K
M'X>E+J)85IPSZ4(D1HWFY6;.FJ!G`B/5*@%;,R55HJ)%;M(5R+>98W-VE3BU
M(>^Y.:V\WA%PV-9#'-IY5F8Z\+)6-C>\<OM8%W:,(:&<E.ZN%\#2Z&BBZZ)3
M-P.82#QJG9U2K&*ZS$3P]F]IA&146X;/\/Y+O2VK0OYC:^1<BRTQ8L&%L/;H
MO=M:=MJ#:\2W:H3J"TE*-R<C),5DB&ZQ7B4PTV-5&*JNL8BF.[29];NEJQ6*
M,EYGN'SS.=VW3.2\]CVTR6+86-LUN<8O%DV[!LS:SYX]RH0D>V:E&1<-@`ZX
MG4YAK."JTK:FD1+@8_[63;SD++5DXSM55NO$7Q+)6?`W0ZO&VV=PH7>#%=\_
MB)?&:NET1R+0S-5(SU8@(G5``*/A!19=6JVQCPB.@VN<J8`D4R0&,<W-IH`F
M$-!'K5BET`2"/I]T0J$Q:B6U7N58-WPD-R\U&=K+R`SV3&<'ZQ(-Z-F"8.1`
M#B@:P+]`R(IF((F3%42B(=/`.]7IN[<]75*.W%;:FY?821;8;Y;;E%$/!`ID
MT3B0C5HX79]898!$[LYT#$2,=ORZ`'S7-7UALADR4F*]4-F5NE(&%/E(0A02
M*F33F(DHH90VHJB=10#'..NG$1&JY=/3R%=C1%BN@N?+VB)O%76&\4GV%O\`
M05;_`.)S4U%>P'6&\4GV%O\`04_\3FIJ&P'6&\4GV%O]!3_Q.:FH;`=8;Q2?
M86_T%/\`Q.:FH;`CK5`XE\$P<0,1-`AP$.Z4P%U*/?I@I9OS:-2+K+C*2(6@
M@',`I&%)%$WAF60.Y%PJ;NE6*H843`.G'AI44RJ3+N1$AO(2)U#N$*0.@"E*
M4H``<.!2`!0UZ>`=-3;);*2+;T!KY[3#^KW8G]K#:;_37;5<[,GJYC8\XUY_
M)3A-AKCZH]_PDWZI6W17)[-PG*Y1P!T!\7UZV)YT)=Z\`'IK79R4(OY2BID!
M0"@%`*`4`H!0"@%`*`4`H!0'(7ZN/UTWZB6@.S_:'^B_^LM`>@R/_#2<_P`:
ME^4G7.D_!^*GN&&[AX4G0/Z(_P`\-;S+O*24Y.Y6R[D$2*I,B@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H"!`1X%`1'4O0&O="K9:,6.-41($7*B):>M[.CD'<;
MO(*;00&2LT@E'EX\ULPO@#J(!J;7HUKY5WHD*LQ8(JH:LRY"Y6\3:'EG=KER
MS+;_`!N4QWAZQ\:WE,QEP(1+&;>*Y5N=M)665LA&KO6Y6!6UG3*RB;D#*"58
MH"!=:\O24TN6B/F6)$UU154P5E=GN;&6-[AG\NQ[>UI?&V`XK"]NY-F9$`EG
M]J8\R;;2[!CYU$KO!9&R7:5OB5RN<A>K\\,"BA"\U;T^=)DS5ER?.EI<NX4/
M54<J04LMB;&5X[D<LYRNG!.'_P`G5BP6:;`>GMN$O&)E8?VH/LYOW'SM=!Y`
M3,I`28!=DR@@!$7/6D4.!UBD,4=*$J45+44@BQN12]Z.P3,N.V&VB4M7$*LW
M96*\*X]-FK#,9-MFZ^8KF@H2.B96SI5)W))QKF<2D5!?E64<"@H+42BIX6@R
MZU>D%CP!(Z%+?W7LEW+F>VO=EOX'FH^4E;KR#+VI:JLI$7Q96/K:N_)$+=K>
MWLDV-+3\*RB7ZS)@"H/(EX^&/51!),IR'$:RM4B):UVH16^"EW@VG;O;H"0Q
MU^(KRTUHW</F',\AE%W-L6]OR<'D:2=2<;;=G-F$@YE'"@-#F;/2O$6Y$U#E
M%,3`&M12J:VU$6`BNA3D2VVY09.;2OQ'9"\:6;C]M9UNSF%VMT1;Z\<K35O0
MTK$M;T,5Q.(V^:)M0SPZ;4SEVFN[;/%#J$!0A2C+K:0Y*QX!%="E5G[$<PR5
MWV<M>&%[=@+)0N3'<P\QY$W"[=VU:C*%AKG;N&5OG<K@K*,K?6DTB%\X*F8X
MJ:@40#@ZWH:L>`170XL7?NR;>,K8UUXOMO%LLU:/,1V];-F7%9DG!,7+F3MJ
M46<2%OY,GI62-+I-&[=R4(E*.2.1<#+=<JGH74M4BWM=?H$5T./DN39!N@8W
M]<USL<-7F]MF4RQFF>;VJP:6;++KLLH0MDQT5)I)/;MAV;=DV=6\L=^X.H9T
MU+R&;I*F,8`P^GDU<M9SU@]%1-!:Q%5L80/T#[=K$N/&VWW'5CW@]6D;DL^Q
MC1DQ*O)%::7>NQ3<J'$TP[3:NW0MR'*F)U$B#X.@<``1UI$ALI\8HJES8V<)
MHQVS`/XC31P]A^.EQ!S:>"(FEG.@<W1J;N5]>[O[/9(BN:GF[JH;Z0BADA7;
M5%B610``CJ(`(@'3H'1\7TJ0410MKF?K"8@R<N5-P<$+$N9QHU*L9<Q48MPH
M;J"()+*K*:%X$*41,/`*YV:[1*)RRVN<Z*6(D5OT&M5K\RL+5,^\<=H'M%B\
M<V!#R>76;.5BK'L]K)M7D!=8N6JK>WXY)P413@S@8R2I!*;0=`$!UKY5.EU$
MEZJ^7,2U?@KI.;B5UD':CSF7][^Q"],>W=;-Y9_CX"S[GAY"*NZ4+'W%$B>%
MDFJC&3ZY\K$]01L[C%#(*&,(%`@CQYN%:TM\Q70;+>JQYJF+8Q@[48U7A>O9
M99)9XZDH7-L;$PMCVG`VNQ6L*,FF;"Y[/MY1N[AFDK(PEN*IS!F+QN1TFIS'
M'KR@(AKK6XKJQBQ23-6-O)5?V>T38CG)&"ZC#;<Q<6"LM9BGK1M/)H6]B+)E
MUXHNZZ[QC;LOA*&DC8Z;V]YO+7E:1[,`TA>"C6#*R;)E.*!$1*N90J@"G4$?
M5HL=C-Q0YB\1/"[0NHRM8)=F#&VGD2T$<X32[')=XVI<]PKJH7@832MD7;%7
M9#^9`-O?K?E?PJ0K&Z%`YO3HY]6ZQ9,VS]Q>(S@?=!3M;5D.S5LZ5GGD1GV9
M26N.U\LVZN+AG=JJS1AES))\E78X:K_B\8H+J7"H)4!'PDT!Y0#AK6NCZQJP
M23.Z"\1G`Y=PZG'!NS3Q)=EI7/8FX2X8BW;1?(S3"PDV,^YLQ6X2M%8V1N&3
MBU[0\^=+RZKM15RGUX`JZ4!?4.7EK*S:Q?\`H3N@O$,#M"F>K?M#]FS55P"N
M:F"9$S&;D2&`NYPGRG'Z5U:@07,4J10`--!`OICTU4]M7.EK)63.@O[B^[`8
M7);!37WV@&Z'!N>G^SJV,0Y`2N^;@=W5F3DXT:05SMBM(1K8=\-7+QPZ=PJ*
M#9J"[E,HJF,!`,8`UU$-?1]WJ*HDSVXV.1,*I:BIN\!EK7*MRGM#<O,8"E,0
MH".A#&$YBAW`$X@43:>F(!7T]DQ9<F"WP-J6CH7$!IZ/0%4-E.JW+B7"B+NV
M&Y+:BI:3X/?]'QZGV=^^W63P-'@]_P!'QZ=G?OMUC`T>#W_1\>G9W[[=8P-'
M@]_T?'IV=^^W6,#1P[FOH^/6%HMC\ZCD56VWZ##F-1JJE\".\.M3;5N<EJ+;
MO&K!=`X5))CG6""Z#7SVF']7NQ/[6&TW^FJVJT,R:C9;-.(UZA(-3A-AKCZH
M]_PDWZI6W17)[-PE*Y1P!T!\7UZV)YT)=Z\`'IK79R4(OY2BID!0"@%`*`4`
MH!0"@%`*`4`H!0'(7ZN/UTWZB6@.S_:'^B_^LM`>@R/_``TG/\:E^4G7.D_!
M^*GN&&[AX4G0/Z(_SPUO,N\I)3D[E;+N01(JDR*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@*?I@G3*@(><&$13*74RYP(`F5*@GJ!5#"F`Z@/0'&I-DRYWFS(0
M324SD542!9!7%5[0=ZW=D'$FY#*^"G%]K,CW9&V$VL=ZU?R4<U19-#O3WG:U
MQK(K&1;ET*F)2UHUF0TE4B8D:L.'C-?"[18=Y[5;L??^[EQ_>7!__IC7$F]S
MY+[9:HB<"\9'`N@^-[;FZ"38OF$IOSW"R*,@`,#1\C`X/>-'+-<H%<INX]7&
M0MG29^("4Y1`0X56G<V5""P5>!W&9P+H.CM/&N>+"CW,!8N]#.%C1R#PRAX2
MU\?;?[79.5UP%1:1%C&XL1;'.H?I/RZB(\:RG<Z2ET-2\9A6*NX>H]J]V/O_
M`'<O_D3!W_IC64[G2H^\O&-FN@>U>[#W_P!N7_R+@_\`],:V'=S9")9#4O&8
MP.YI93.5J]I,^M4LG@'M(,QP-WPBWG'M?D*Q\23EK70F/A>UCA6%L:(>Q"Q@
M#E*N*ADRB.IBC6K,[GR4LL7I<9G`M\#%>VM\VZ&Q)A"R-W^ZG=WMNO=PLBU2
MN63AL.S>'[I="/(5Q;5[HXN,U9D=CJ=-JJGS\O2IPK73NG+E^=IWEXR3)=OG
M)8;`;<E=PUV,&DO:/:,;@+KBGB)5D)6#CL%2<."9R\Q>MD&N.U.0^G<,4!K/
MJS*T)J7C+-DS>.T&*W8<?]OW<O\`Y&P=I_1C3U9E:$U+QC9,*?:G=AT^[_W+
MA^\V#_\`TQKH4W<^1.DXE1(QT+QC9,T'&I";IW"2B3S?]N:.W.0Y54B16#TN
MO3,42F0.<,8<X)JE,(#RB!O2$*J]3I+)EMB>7C,[)J+%$.PQ/C%GB*TV-J)S
M\Y=CA41?/KCN<6@OG$JLY6<***IQ+=C'E4,90!$"HE#4:[U)D=-(2'FQ\O&2
MX"Y0Z:CKQ'4=1#H'OA5W6,-D;C-I68XBW.GS`5(ANL7`GU8R8AIH`](%'2G6
M=\6G63,G"0[$'T[(QD!#`D8RAY^309LEF12B+LKL7*B1?,U$@$%-!`PEUT'6
MIRJQ6/Q(MHM-%':0[O[FD\<REN=G7(3=WYCQP]6F[M=6%C*-NRSTK>:$!U)P
M=TW<]8K,6J3=D4ZS0B)146.8I!..M<#-9BU"KAM4PY5PJJ6J6;[-W`^XKM!\
M6Q>;NT-N:6D<?C<1S8UPPTBHBR[>NOVH==6\E;Y9PL7&3SQ@Q=MU"%9><IHK
M"EX93<PZZ^6T+GNQ.3=,-M2T_0S&6%8=OQS*#A;'M>(B(ENDQC8N/M9A&-F3
M1`H)HI(M&R)4DTN0H"0=.82Z"81-J(^J=*62B,W(%K$@A]WXLVM_V8A/\C-_
MM=1BI,?BS:W_`&8A/\C-_M=(J!^+-K?]F(3_`",W^UTBH'XLVM_V8A/\C-_M
M=(J!^+-J]VW81$/TSVD;FY?2'EZOCJ-(J#LFT%$(*$=MH2';+)`'5N6D0U17
M$`Z-`*374=*1!V1SG.83GYN<P\QN8O*;4>(\Q0```>]6`10"@%`*`4`H!0"@
M-?':7_U>[$_M8;3?Z:[:KGYAR&\)JU7);PFPYQ]4>_X2;]4K=HKD]FX8E<HX
M`Z`^+Z];$\Z$N]>`#TUKLY*$7\I14R`H!0"@%`*`4`H!0"@%`*`4`H#D+]7'
MZZ;]1+0'9_M#_1?_`%EH#T&1_P"&DY_C4ORDZYTGX/Q4]PPW</"DZ!_1'^>&
MMYEWE)*<G<K9=R")%4F10"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!'_&'J\!]4
M*IG)-5$V5\=,#*-5UB$D$2'%0G@J&#03AP,(<O)Q'N^`.GQ*H1U6R]5UF=DN
M@@"=X/4JYM3/2Q4]LQLET`Q.8@IF`!(;I*(:E'XH5E:NHC8EG"9V:Z`4G(0$
MB@`)@.H$#H`>C73T]*QUJIT>V-FN@<G>#U*)55$;O;,;+>(`I?%#Y=;3JF>J
M71\IG9.T'A+WR78F-C6P:^[C9VVG=-SL;7MTSKE*26G7K=TX;QH\PAJHHFU.
M8H]P"Z=VM&94SX^^$EKH#F0Q]?\`)WICA[[4WC*1T7#*W=!24:C)L7$?>3==
MW;B8HN$E$$6RK1HKU@GY2:Z:C6HZ=4/2"*L>$B^6K6Q5+##Z<[.[$\2_5N'!
MMR7]MDN=)4Z\@7$UT.XNS5USFY^L?V''.?Q5EAYPU'K`'7N]-0QU6_K*8'02
MMM]I;BDHO;+OK!^Z&$:HF6;0U^0Z^,KX>))AKR)/+8:!;!W`E#0#N5RHB/2-
M85]7=;K$#&B'[5[+=JY(;XHSIL6R=8]]2;KJ8AZVO*QV=J3:ZA^K1:VS,W#-
MM8:Y)`Y@\%JS555/J'(41UHF<3Z5W5W115MO7=,1W%,NVN^&8*9PC(;6-Q$5
M()_LIJ>`A)5(JF@&*49"&<.X\%E`]DD@<Q"AH(]-;R5U1.2*>Z9*EM[\D5L9
MRRVI;AW<@4_,1LE;Y$4SG[AN74I=>CB-:LZJJVV)[H4&W/[J+@T)8VQ#*#-!
M<H"G,Y`OK&$7#(F.`:*NF[:XQGNJXZB!$A.`<--:VTDJJ(JWB)U;B%[2?(17
M)GET[>MOL*=`@J+VDQNF_KK30.8VHJ)W=&$M\7`$X:)JBGJ&H#6$DNW3".6V
M)R,NSSLBZ7R$WN3RKE'<S)K$3<$CKLN4\1CMN)=#*H#C*%=FMEV0W0F*A-4A
MXAQ"CI#E2"7F8F;MIX^LC'\`E:-G6;;EH6@9B2-:VW`QK1JR!H0PG*F=N@0"
MG+UAA,(&UXC5?47\IUWD%R6'H6+%G$LPC8UJWCV*9A$K-HB1!N4=1$P@BF!2
M%,8W$>'$:VI"-IDM!]0F$=-1$0#@'>#T@K:F3DGJCDW$+&7$562%`*`4!(")
M1U`1`0Z!#U*`@WA&YS<3!\T/30`1$1$1'41Z1H!0"@%`*`4`H!0"@-?':7_U
M>[$_M8;3?Z:[:KGYAR&\)JU7);PFPYQ]4>_X2;]4K=HKD]FX8E<HX`Z`^+Z]
M;$\Z$N]>`#TUKLY*$7\I14R`H!0"@%`*`4`H!0"@%`*`4`H#D+]7'ZZ;]1+0
M'9_M#_1?_66@/09&_AI.`/\`^:%^4G6A2X7HBZ$3W"I'+")X8O0(!K[(_P`^
M:MYS'L9%IG&N\5Z]ZM:543UJ$ESD38K?!+2<OSG06XCXP?)KHQIM+C8P,'Q@
M^32--I<,#!\8/DTC3:7#`P?&#Y-(TVEPP,'Q@^32--I<,#!\8/DTC3:7#`P?
M&#Y-(TVEPP,'Q@^32--I<,#!\8/DTC3:7#`P?&#Y-(TVEPP,'<]'_#47,:](
MR=S2538,AA%<Z;,J9;\*(D(E.)0%;U(B3OI+MX*]169B-:]4;R8DTM2(J!D4
M`H!0`!T]+X]6RISI*JK41572D22.5MPU[P58ZI>^]&ZB6T<-:J68JK&"#:.W
MAK6,:Z$&T=O#6F-="#:.WAK3:*EL$&T=O$`.G<K76LG.L5&ZBO;/WC4SO?Q5
MF+<ADB0M?'\1')VSAJQ/;-[*7&Y=,D"7S-N&-SVY<%IG1;*]=,Q<9#.V)M.?
M0'8@.FM5K43%6Y-0VS]XY,#;AK8M7-F3+IS'Y]CF<S+BC;<ZAX-W;MSN4SRC
M2W)MO-13=>+BGS)!*.<+$*8JRZ1]3!PJ<F8N*Y+M`5ZS$PN-KK59NZ%JL@8I
MXX[59Q'.BD,4HD*"8IZM1$.!@/QYSZUM8]Y-1'"AS"8PB7PQY4QU13`"@FB/
MIIE`OR!YB]ZL8]Y-0PH6]RAB;&^9;1E;5RC:4+>D`Z14%S&RB!2*IB<H@,FQ
ME6_4R$'(L1\)!9JHF<#=`#7)K<OE54[K#XXT1$LL2PK<U+C`"T;TR9L3R%9V
M&LLW++Y!VQ9(?A"85S+.K"YN3'UP/U"IP>.,C.1`@.;<<J'!.*F%.114Q504
M('(`C&543*?S6(WRH-PV@MG)CILUVYQ<(N4OI+TJPD.]T#F4<)M]=6_(4P:)
MB)N8-!`>-=22_;LC,1L8#A(.`F**?.IU6HCU8G,)1$1XB(&$PZC\6K,:W6%F
M%```4#%)J0#E*0P`)C`(%$1`-%!.'2-,:[PPH5"8QC"*ANL#0@`0Q2`0`(.H
M:`0I!#CT\>-,:[PPH5$/U:PKD*0J@AH`Z"($T[I`,(\HU+:NWAA0I$PF$3#Q
M$1$1'TQ'I&M=\MLQ(.&!"*Q+E-E(J-C!3*)`589%`*`4!%0F.P,5R;AA5@D2
M:2G+,:BZ2&-1ZM8G;5B19"(Q+O$]_P"14*.:KU>E39!4A#]I=*1'1Q$?&#Y-
M;T:;2XMP,'Q@^32--I<,#!\8/DTC3:7#`P?&#Y-(TVEPP,)]3Y-85:9$C%PP
M,)T#O53M)&^8P-*>0Q^8B:K?K].9%`IS*+*%`./.7E*"8CIZ8UC:R-\8&F`/
M:0IBYP!88*MU4REW6[40632415<$6#--M>;E!(5"B)'"NA=0]AKJ-:E6^D<U
M,:NO-6JEMPIIB;`5E!%9P0X(`JNX<%411<E7"-.@X4XKJD+HL*Y"`4"@`<AA
M[M=.FZFC45BNCY"+6M;:D2CH^)W*KJIDM+HP]XN;,PW7CU/D_P#!49#J=TI%
M=BB6M1KTQ+>H^,'R:NC3:7$L#!\8/DTC3:7#`P?&#Y-(TVEPP,'Q@^32--I<
M,#!Z/1K54U68?F>5OE<Q&M;%!H-4IMMV$"C&!X5L-:BI%;PCE(J+D1%@EQ-%
MBA-1,B@%`*`4`H#D+]7'ZZ;]1+0'9_M#_1?_`%EH#T&1^-ZSG^-"_.IUS:)%
M145;H(4I<>'(53JG"PH.!10$@"LDB=9,%EUQ2336,3]CD$PAJ<W@@%=_:2VI
MYUX),!PT\$3`("8%">$W,4!Y#"1QIR',50!`0#CPUK0<^GFOV<4BN^9142TI
MU-Z1?++3J\G2FLSM&[PU-Z1?++3J\G2FL;1N\-3>D7RRTZO)TIK&T;O#4WI%
M\LM.KR=*:QM&[PU-Z1?++3J\G2FL;1N\-3>D7RRTZO)TIK&T;O#4WI%\LM.K
MR=*:QM&[PU-Z1?++3J\G2FL;1N\-3>D7RRTZO)TIK&T;O#4WI%\LM.KR=*:Q
MM&[Q!A,1-1PH4"-D2ZJK\Y3`0YA`$R<A?",*@]&GI5LT\RGI8HY4@[?,*Y'7
M',<@E364X@5$[1(XG**?,NY$W.DGS>S%```3"'`0-5CUDSK6PAPF"GI^-6NJ
M++7S;A<0/34(JMJWEK;A0R*`4`H!0"@%`*`4!%`5:53@4IB24"`4Y!+X*ITU
M%1`?#,9(IBI@4W20-#<=--:8%TB)0HBU.18.IZGK"%*5)(?UH*H&`P.%VQ]4
MG"J0!H3G`=-1J3&X5B29>2<3G%43JBN)R+D(`HH-4B`J)!#];LR)(&TY.Z76
MK"P@/1I0$B.G(!2D,4QP,X!0-0,!/J?*4/`,<!$?",`B7YG34:LV6.7'?*WW
MF-6\:V[)NO;+G1OD=(5;91Q_.2\A($)J[@?:AJHX92D6J&@LUXA7PT%`$!1,
M8P@(:UPZAN%Y$U+]DCVP&/-T4/![>LGJOH'.EL$5CHF8>H*+1^0HF(74:L)=
MD\03!!M,@R1(55)0=5="Z`-9IZFYJV$&O1UERF_T1U$1U$=1$=1#01U[HAW!
M&NNEQLB@%`*`4`H!0"@%`*`55/\`HG<!AUPK%#%J6V?\2HJ$IR$0,JFH@+CS
M@R9UR&3;&0;G*F90CHWTHZAC'``3#PN-=";-DM:N*SR@I,"A1$#)G()3"0P*
MEZHP'+[("@?B8@=PP<!K13J\^,%1(;YE'(V\IU-Z1?++4NKR=*:S.T;O#4WI
M%\LM.KR=*:QM&[PU-Z1?++3J\G2FL;1N\-3>D7RRTZO)TIK&T;O#4WI%\LM8
M6GDPO36-HW>*=3>D7RRU3U63I369VC2KD#E3(9=1%1=14Q2I))%4,FBF!S%*
MYY.;0X:AT]-9ZO(YS=8VK3\W_;M;O]P&VQEC2WF>'K6N'#4O?^,LC0>1&2LF
MI*H79C.\F5U(6[)%36%,3O5(XA1-IRZ'X<:Y.:T\O`S`Y.5^PHGSD1$AI-S6
MR[+F:,ZX$M7+6<L;06*;KOUJ$DPL^VV[G1C%.!-),EGZCLRHJ.Y)JH5P<Y?!
M`JNG2%=#+)#%@JJA4DU52*K>93:G\4OEEKN/I9,+7-,[1=(U-Z0>66M%]-(1
MT$<V'";#)B84C>-3>D7RRU'J\G2FLEM&[PU-Z1?++3J\G2FL;1N\-3>D7RRT
MZO)TIK&T;O#4WI%\LM.KR=*:QM&[PU-XH#_?EJR6DB0N-52Z%YA7(ZQ"?"](
MH!W1YR\`].LNJY+KE368*B"0X\J:I#CUR:9@`P<P$4*<P*E*/$Y0Y.YZ=4S)
MJ.7S01X6A3"10@'*!B@JF*9C$'70X%-QY1TX#66*JI:6-N%2)"@%`*`4`H#D
M+]7'ZZ;]1+0'9_M#_1?_`%EH#T.1M`O6<_QH7Y1*ID,3`F&^">X5[-Z)%4L,
M+]U<E-1^-+8:P$].VVZNG.&$;#DY2W)-6)F$[?O?)4);LT$:^3(<63PK!\H)
M%0`P@;3A7+S6IJ)$I7)&"(NZ17S4BIL3)V36&5%E1/GG>>4Q5S&!4-P\N4ZP
MF+H`]86)$11(7@!1`-!#6OGC\[K6O1S'KM(7&L^:JI!#ZO@FL,?S_;T/]XN9
M_P`S4]8,UYRZRK$=#*]F'MR@CMDIS<_NUAE'BG5,R2NY]Y''=JZ\O5M2NXQ$
M7*G-PT)S#KPIV_FO.76,1VR?92X/5YNKW"[S#\A"G,)=QLP(`0Y0,0_-[3:<
MIBCJ`]%/6#-><HQ%2G90X33*!C;@-Z/*(E`#%W$3AP'FZ!`2P@ZE[_13U@S7
MG*,2E/P4N$-5`]T%O0#JC%*<1W$S8!J<-2@41A-#ZAXNM/6#-><HQ*<9^RJP
M6FN5L?</O+*X.B=P1`=QLSUID$SE246*G[2\QDR*'`!$`TU&GK!FW.76,1R$
M[*7"!P,)=P>\_P``XIFUW%31>4P#IQYH4-"CW!Z![@T]8,UYRC$I2'93X/$=
M!W!;T2_3%$@Y]Q$Z3F.F8"F*7F@PYAU'AIKKW*>L&:\Y1B4D_938.3`3'W";
MS2@!N41-N,F@Y>^.L+P)_=>Q[]/6#-><NL8E.<O9.85.4#DW`;SSE,&I3%W&
M3!BF`>@0$(80$!IZP9KSEUC$=1.]E'A]A&24DSSYO*!\PBI1RS67W"RZY$7"
M+-55(QBFB``2]8F&H:#K1N?5[GM;.<L56S]I9+F83`C:9+34]MRP_<%QRTK<
M<T[MMVWE)BXI9Q+W'+N4IB29DE)&3512\Z,"3<NNH`(U]%RF;5OE),F(N"&D
MV6JCEL,BPKM[65,7`BQ>68'+<@'I]3Y50@J6+>21%1(+>*&10"@%`*`4`H!0
M"@%`./?]6KF[-W)@05CD2*I8>'R%D:S\5VJ_O2^)8\5;T8LV;O'+=A(2[HBS
MPX)MDTXR);O))P=8XZ`":1JUY]524R1G.1J>4@Y4;RBT!MVN("JJ(BUS`8R2
M_FYS)[?\VJ(];T^"N2Q3(G)I\V`B7OUR7]X\C1V!)S<:;SN(PDV6EJJ5FW98
MA*F14S3+X%4<':E#W/\`FP5.N)[+F1"Q>M*D'CB`$'TZCZQ9/Z9-2\1+;RM)
MQFW;X=*8Q3-LO>"@5P8P8`S69,$SZ@`"H%BBF"NH<2:\X=T*>L63^F34[B,;
M>5I*@W:X?,94@-,PB9'E!0/<^YNX";B73_J)H81[VM;LKO+D*4ZM=4-29'0[
MB(.G2U6Q3PV2LY[=<MX_O'&5\0^9)*S;X@W]LW1'(X!S<B\>PT@F";YJQ4_$
M8O5O%$N!!UT#NUPZK.\JF3%67-16\"\1A9LO2:^=F<9MPVL;A=P4?CW#.1;4
MQ*_BK/D\?SQMN&8TC#(JN'Z,HDASV"JY</6":21UA5%!,_.&@CQK4EYOEK5C
MM$C'0O$8QR46*0B;0/=:8@^:;Y=`14(GJ?`&:4@.HJ.B8%`;&`-5#=``(UV4
M[Q9/#Z9-3N(NVTK25>ZPQ'S*D\RS%S(B4J@>Y]S;P$W0`?\`43PA^)KI6?6+
M)_3)J=Q#;RM)2.[+$(?M3,&O,)0#W/V;-3"``(@4/Q%U-H`\=.BGK%D_IDU.
MXAMY6D>ZRQ%]PYD_W>\W_P`@ZRG>')U6"3DCP.X@D^4JP12Z&-\K6-EN(=S=
MARCR58L),\._*]A)J"?,9)-$JZC5Y&3;%A(-E")&`1YTR@'1TUO2:ZEJ/H7H
M[631[5N4N*8.4YB"("8F@&Y1`P<0`P:&#4H\![E;BHJ7DA6`*`4`H!47(BM@
MMQA454@EY/<HB*C8L(*QZ7H6'+CD,[[U<08%G+_RE9-B7!@++N07Q,77LZLR
M>7N*TKFLZ+CSKR#=LZ4\R5;S"W@"0I3#IH(Z5Y+/*^IIV12RW3N1*WNP7WF=
MC;LH\'F(0Y<^[SD3'(B`H$W#S)#)@(&ZL%$B1"@@J8`'4P^RKQZ9Y7L<NQ>J
MZ36>]57>/J^"BPCQ_P!H/>=X)3&,/NBYG0H$TYN<?:70@AKT#H-2]8,UYRD,
M127LI<('3!4-P>\_JQT\(=Q4V4"Z^/S0@"G_`'VFE/6#-><HQ%7P46$A'0-P
M6\\?"`H"7<5-"43#KH4#!"B77AZ=/6#-><HQ*![*'"0``CN"WG``B)=1W&3(
M`!B])1$870IN/0/$:>L&:\Y1B!>RBPD<I3!N!WH`!@#E$VXJ;)KJ.@`'/"!Q
M$0K"]X,VARE&(XR]E)A`_+IN"WG^$;D#7<7-%'GUTY>,(&AN]TU5V]F_[VLS
MBX`?LK,+)'(?W0F]`H,P.L0QMQ<N=,Q#`)%$R_\`N<1$!Y>@.[3M_-T3X2^4
M8BU.6>Q`VA9FM=&ULI9#W;WY;K22:S;6*F,_R;Q-B\263<%>M@6B`!'E$H&.
M`#J)0Z!JM^=9K-2#\4$728545+2Y47V4&!T&K:/BL[[Q4H^+8,HJ.2:;@)<C
M9FQ9I)HH-&VD1H8442`43%#@7AW*VY6?YG*2#55+-)&P^M3LI\()`J8^X'>D
M!4`$5!]T1.B`:%YA`HA!B!QT[@:B(\.FJYO>7/%L:KE\L#*(FD%[*C!QA*'N
M@]YX"9(BWA;BILH%(H(`0#B:$`"*&U#0@Z&[U&=X,WP)C5R+PQ,QA8ARAV46
M$1$2AN"WG"(&Y3`&XN9'E-IS:&TA?!X>GI4_6#-><HQ$?!1X0'73<)O,'EXC
MR[C9@W#F`NH:0PZ@!AT'3H&GK!FO.48BL.R?PF83%#<#O.YBCH8ONC)CF*/<
MU*,-J&O<].GK!FO.48CC-V4F$"<W-N"WH`!=>81W$SF@<HZ&X^TF@B'=[U/6
M#-N<NL8BGX*;!P@4P;A-YI@.`&3$NXN:,"@#T&3$L+HH4?3+J%87/LR?8]RH
MA)LQ6K%('E[R[+S#,1:EWR4;N%WD'D8:V+ADV@*;B)E=OYY&Q+MVB54OM.!%
M2D61#G)KT<!J^5G%?%%Q(J10L2<JWP]LPQVLS$O/;=<'3MR2CNYIB4QW#/YN
M5FES/7;QX=$Q0,<3%)SJ"`<1$>(U]"H7K/1(6JL"]'(Y(H7X(GU1"DY@'P0'
MD!$J`(Z\>I`A3J`($]/7C77=+=+7"Y(*6MN*ZB2%`*`4`H!0'(7ZN/UTWZB6
M@.S_`&A_HO\`ZRT!Z'(_\-IO_&A/G2572\E.!/<+W_1ZC";==_`;&G]J#;'_
M`$T6S7'S_P#I7?%4TIW)/TVE]D/Z(U?)'_3M^*:*W>0Y*N(&A_$F`<8;R,V[
MZ,E;BR7!<[VT\A)8RLN"E+HN*-98;M%G9B8N5H!A"2\.T8NI)XF,R#Q9-14@
MJ>R$G"@.K=;WKMVL1=]X5MNYX;-D1;%AV+,;6[Q>K'EY^^;95OFV\3ST3>$D
M@9!.X#VA=$P<@*()IK`Q;"=4RA@$X@8]XEW/[U<=9_S]BZ?OW%MPY!W`;J,:
MX2QS(.[5O%;'V+I)QA>;OZ<=D8J7895>(1CK?<MB`BH@#A^=)73EU3$"[[O?
MUO(@MQ<9L>(.$Y#-L7G"S\9SF6GUMW$C8"]EWYC6X\C6_)1=H_C$:3D;ACF,
M,DWD='I047,82%3+X(`8]7AOLR>ANXM^;R7<%CVA?VW/$&?[.O*0\\F[;P[/
M2C7)UMP]G7,:&7E'QU473,1,9DHJHY26.5#K0,;6@+N6-VD.[9^EN)L:/M$V
M6+RL;$]LY+L28B,23MBO9!S)NXQ*XR6_9DY=$E(7JPCDWYE&+<J[90J)!YC'
M'C0'<P?:2Y[N4N-<:8VN["]\9,O?/4'BV;D[SL:[[7G<=L;BA;AF8^1OK&"]
MR%E6KMF$(9$%$7I$G?.)R`4"Z"!Z'$W:![O'JN&+NR^QP1+V9DW>X[V-*P5C
M6Q=#"=8W.D$KU>123TC<LA'E@E2PYQ+&':G6+S!JL.@Z@;_F)`3:-TP5.N!$
MREZT_)SJ:?-&!,B9`'XA0"@.LN;^#L]_B26_Z`XJEW]1+X5]PDT_-GL[_JOX
M:_[OO_\`XBF*^SY3_IZ<!N2+S)D/6JRF_JEX3>E[H'I]'I5O/Y2D'<I142(H
M!0"@%`*`4`H!0"L+<92\GNC69%Q;-Y"<)CAN<!0MEVPH0RI4_P`?;5!?JTTN
M4P>VK?E!4>7K#E#TA'A7GL]^B\AHS[C]'R93"R:&7U4#S9N*0I'<(()E%%/3
MK^1<"#Q[NGQJ^4JL:E=$#36$+#"??!NTO#:39^*)FS<4-\S7AFC.ECX!LZT)
M3(D;BUBVN&^&TR[;R<G><K$S+)O%H%A3<3(:\0XU<0*</;D,P2[F09[G<5XS
MVWR4U/0-JXC8P>X2#S@%_7'(`\%S&HLH"VK64BI5,R9`336.N*XF'3EY1U`N
MU/;J=OMBA,L[PS/9T:\M20E8.90?S0!+(S,$5!2:CU6*29E5Y")*[3%1-,HC
MH<.%`46/N]VT9&F/Q8L3-]@W9.I0"ET`A'SA=584@*&</TW2A2M%`:E2$5DP
M,*B0:<Q0UH#R%M[[=I=ZL[TFK7S_`(_FHO&L++7+=SQK+/$48"!BP.65>R"3
MM%%.0:L/-SBHJD8Y"`&O"@.E<=HOLA31;BON@QH!)5_YDT=I2+ATB@Y!!LX*
M0546"B#5/JW)#).%!!$QA$`,(E$``Z>TNT&P!<6>,R[>$[O;#=6$["@[]N>4
M<2ATH((R:4<J-VA9D4$4%)!)DD5R?D.8HI*E`-1X4!D[B/-F-,W0ZMQXJOJ`
MOR#:N5&KJ1@GAW2;20(4"K1J[=P"3M)5`-#<QB@4P#J%`7>$ZO?^Q#]%66PC
M;<9;?;<?G*QTLX/F7=Z!55`*IFLL<U>D2(DTY%+?C%'")$2%`"*")S`)M-1'
MCK7T#(_@FY+N4O<)BZ]6F4A4T`!$H%UYA$@:&$XCTB)M1KV;]S@-E+A4#(H!
M0"@`=-1?R5)-Y2$^G5C/H_(3F[AY+`1^?M/,'B(%,<^UK.Y7`Z:.D2(7CC\K
M8K@WL?-%B&$4P#CP#6O"]Z%7!9?$Y]1O&:[+.6XS)_Y:KWQ$QQ<G9V'LB7MC
MPMO7JPF$KAO"8QVY%&XT6UQ,9-HR@$DDA'S<Z[9P"@CPTKP$KEOX35<D#S%@
M]IYA6_VJ!(:R<G*'=PN.UF+4+8.5M(WID5.7-;=B0LB=S_[ZN5X:%<B=+E#J
M@3#774-+B)$IVD%DL<O6IB9CC+)DLM)1>8EKW3&WN6Y+2N3$Q+;,]05@SO$$
MY:.?C<``+@%DDT>JXE'72@/+7OVIV*H-S$0MN6?=%RW*?+6)<<W\Q9LS"G9=
MM93>R[2*NIXX*LDW<&2]IUQ%-("CJ33F&@,GL,[S<6YLN:#MNVXNX6Y;S@7]
MRX^E9MF@WCKT8PRRR$EYBH@Y<>:.8TZ&JA%B\VAPXT!A[+[]LHHY"SU;-N26
M-I61PWN$-AJ(Q&I:-SN\C7XS;1D#)FE(R?;S'M*DX<A-&32`S8"E%(1-IJ&H
M'>PO:3VY)P^3((B%Q2%W6'A:7S?-7JPQ5+#CFQH-DO+M$FESLS7&,HM+LY"%
M72\V(N0[\Q.4AD]=0`]@Q[3#'JMW*XZ8XORO=EQMKOB\<)3EM6<)[5GKR>V-
M;=\N"-UEW9SQ+)**N9!;D4%0R8F$HF$2B-`?+9O:4XNNN^V%N6FI<5ZO+];/
M5<>X]M^Q'X7A+.[9E'D1?*QI5>7482:<$,4X`R*;=$2@ES"80'2@+*XM[4YJ
M[L.+R1DFTYELZDH=F[0P];=F2"EZ,I"Y=R4_@"V90DZ$N6+*W>/(Y'KXT6HK
M)*"=;KA*($`#)@_:0X9%K,L(ZV[Z=7Y:+:5EKSQT:.10G+-M^!>.?;>9GDW3
MHI43+$:*`S3*!S.EA(F7E$P&`#U>X;=-,6-B?&>3<=V\61M3)[MD]E[YDX-_
M-L<3VF\A_;EM=-V63'.VLU.G<*<C%5!NX2.R54ZP1.5,0$#PN(-_..G]K(2>
M0;VM*ZTY,EV/[=O[&39Z-AW$WM2/DI22@"L))5.7@+R:0T:L;VK<'757%,5"
MG`H@%`<'PF>'2S%S-&-BY7<6U:!+`3EKK/9OF\,"N4[';W_9C!)4SGK0.\BG
MJ*:QATZET;JQU'C0%E<>]JLI=%TN_P`8\(7M!68QAKAD99\$0H,A'EA\A1MA
MQJ[L1<B!BJ+2*9S#Z5`7YG.TFV_)$5=$2NR5M!:Z+AQ\E>,?"GD(Y:^;55=^
MW=LA&,78OQE&@QJY0'0I#<@Z^D('07%VBF+D;`Q[DR-&>@;,N/*D)9:R4G8[
MZ>D[FC9*VYZ<)&P)8J79K6Y,MPB`%RJX0.FT$HI"FH8X'+!]WE!>JQ-QUI;D
M,/Y.N6QX*X8V':V5<8M7DK$IH1CX\O;$NX2?LUDG?G)Q2(@)72:B:9D53E+X
M0CJ&S)6#DX4)-O-0NT/^JW@CN_\`AM`_J9Z^IY-<AMR^3Y3)%3V9OB_\`5Z*
MK^E\B&TEQ36J!0"@%`*`4!R%^KC]=-^HEH#L_P!H?Z+_`.LM`>AR/_#:;_QH
M3YTE5TO)3@3W"]_T>HPFW7?P&QI_:@VQ_P!-%LUQ\_\`Z5WQ5-*=R3]-I?9#
M^B-7R1_T[?BFBMWD.2KB!K6S?V>^,\MW[?E_QV0<N8GE<HD9Q>6H?%%XRUK0
MV3FK9@E$E<R+9HY;)FG/Q>2!DL]3`7!6O,F`Z4!:N]MA\!=&X_:`>W,7JV#B
MC:`Q=.8*ZS3L,Z)>K/VD>Q;2Q9:-!T>9D&@/'1)5PZ=IBJJ[0YQ$1'6@+T75
MV=NWJ[)_+%Z2[>\@D,MW3;-^S*L3>LZP7M2]K2AO:6'N>PW4>X`]O/C,N8JB
MB0I\R2ABF'E,-`8BYK[+*"E\@;7GV,3Y!;QEKYN6RKFG+*V5[A;Y;4$]K7'$
MLWS.\&SX)UZLFXEB)HIHJ&*@W,9(NB8B%`9$3/96[2[IC1A[FM*8G44X*[H1
MX[F[ED'<S<BU\79%WO-7!<$MUQWSB<"YH=!VV4.83IF)W*`^A'LS]O<;<5RW
M4\E\SW%>MZ6$UQW<%VRV9;S?78:$9.&+J*D6BJC\58ATP-')D(HW$%`(82^Q
M$:`]%:?9R[<[?OR"R>JA?L[DJ%O>V[Z>WQ=]XSESW#+S]LQ$O$6^A)R+I99)
M:&AV$PX31;<PI(`?E``H#T3#8E@F-AK"@DHRY09X[W1'W=0!0EUE$RY8#VQ*
M>:5<@J(*0"@2RG+'B/(74/!X4!GPD)13()!U*)0$H^F`\?C4!TMS?P=GO\22
MW_0'%4N_J)?"ON$FGYL]G?\`5?PU_P!WW_\`\13%?9\I_P!/3@-R1>9,AZU6
M4W]4O";TO=`]/H]*MY_*4@[E**B1%`*`4`H!0"@%`*`5A;C*7D]T:S(N+9O(
M3A,<=SG\";;_`._MJ?\`\U0KSN>_1KP&A/N4_2*3]B,>(@`MD==$@5X=2ETE
M$!X:]VOE/_W*_%-1>2:NNU)V_2NY2V=FEE-;5DKPMB+WR89NG)36*>'BEF%B
M1$9>2<Y)*N$SI*($;*.D?#`0$NM7D"T6Y+9U#X8:[9[RVY8]NN;MW$>YNQLG
M9#MUG)OIVX'T%&#(C*S;=6565<S#F.%4@)HM1476ZS@`\HT!AEB+:ON`O?>[
M&YSR1M\EX&Q9[.NZ;)5M(W$LPDU;;B+JA[-2LRY9=)HJNW2F999DN#5`P<R`
MIFU`!&@/AA-EFXNQML>T&-Q?@R"9Y5L^\\K71<%N3B#5"-<.KG?M1%Q>BZP@
M5PVGV[0H.$CB(&(F4-.F@,;\L[0]W5^P=R2)L7Y6N)Y/[+-T^*@B9&`M6RK2
M@+VN&W$$(2R+:LFSC)1[)F_=KF*T>=6";@!]D)@-H!E'NJVI[B%(*[<1XFQ'
M(VA9ER;'++QS9#+"]IV!#IW5D1K`O"W'9^3KN>`VG[>@[?<N`<(D$Q$5EG"G
M5"93F"@+<WALRW97H6Y[=MZQ+OL"3E<&;2WYI+S6V)M246PYD.6F<AX\(]DE
M3PKZ8F81$I$&\BH#=SUQ2J>`-`;/>SQQ)EF,SUF/-U_*9."#NG'-H8\ACY!L
M?'V+4I5_;$LY?N9%O8UB]2*DDT;N"LCR+M$IW"#<@$,9,"4!N*-T#64O,I>?
MF_QS_P"<6[[_`.O*O_PC%5]!R3X/`AN2KE+Z&Z$_K9/G0KV3]S@-K<**@!0"
M@%``Z:B_DJ2;RD)].K&?1^0G-W#QF!5$C=IMADY2F41)M9SF1<"AUJ*7+=]@
MBHL?4!$%DS@``7TA&O#=YHX;%A;KWCGU%YL3G]HD<\E,@)VMDK(%BV7EN6<R
M.3K`@Y1IYG//Y!?SF1GH.<,O[<68]N`Y=7!V(D.L4-#U\_E<M_":SE.1+9#A
M`K:YFL9#2\4U=R-E34$[8OG$6ZM&X[&2D4[<G;2\T,1[&R,6,FKH<H%`P*&Y
M1T$:N(%O+K[.3#]Y$?.+@F;N&\YYGDJ*O.[FLDL[?7/'Y:"$"]0\V75Y(09$
M+>:\H-0#S42#R:<YJ`Z2/[,#!S=64EG4U/R<W*26+YU9RLW9MX\DEB!>86LY
M1"V3"6*2;-!FU^N:B4$C";F$-1&@+H[=]A6(]M]UM[JL87J:$1%OHNV&A&S.
M*3A6,JLJXDR/7#0Q7$XHX65,;K7&J@!H7H`*`OQC##%J8PF,JS=O%<$5S+DR
M:RK<IEFY%>:?FHB*AEA1<"43MRE0AR"`@(::T!C=!]GIABW4,SMHU[/A^7'%
M#K#UU+F?JG<^T"LG-S)WHCSZ>W!'%P+%2./04I:`]3:.QK$]FW*QNV,<W`[D
M&N05,D(MG$@8$3S:E@VWCPQ70=9HH@2(MA!0@#T+"8>[0%K;:[,?">/W$'-V
M5<5V6Q>]IJRY+.O9G(B><M\MSW7*W5<(('44Z@5II6:69*@80YVO*7O4!\<3
MV9N!H1K"LFKZ^ER03"U(HRDC,++/'(6CFMYGMBX<+K*BLH=U?K]03B75,K8P
M)CX(:4!]&0>S.P%?>1;NR<Z4F6=\7T=VG<TH+9*2:JVQ(MA0?VU&B[U0BG*A
MU#JH/F^CINX,!B"'*`T!DC>NV^WY^Q\76G:MR7;8KS$8-C8_E(646?.V*C6)
M"#26N)!\<65T%-%\%4G_`#D54U,;4PT!AGG+LVH&_8RU(:-EWZ\Z^SA;V9<F
M9%6?#"S2[^`A/:EPXM^$8'2A(9G+Q!#,';5F`)*(K'$P"(T!DE/;*,/W0]R<
M]>!+$C<M7#CZXIR-8.U(QJV<XX@&=MVNE&F3,F4C`(9B0IRAP$]`>,ANSVQ/
M&FO)N>=NUZ%Y(O(LP>=^:!"PKNZ6=XF9MDN<I9!/VRCDB\XZF[M`>;MSLP=N
MMJ3JTU:Y[GMYHVNBX;^91=ON@BI<M_W*X<JR]P2%UQZA9J98.G#Y4YHU<YFI
M1,&I=2A0%<7V:&$V#[VV7N2[1NQSE&W<NR%RP+E*WUGUV6;;D[:<.FM'1JB:
M(I)QEQK@Y/RZNU=#K:FXU!]P/>6#M9L+;O;&XFY;9>2#RX,KVE*&NR06;)P[
M9S^)]J3C"((C$M.6':O@0?'\X=)`"SX_AJ"(AK6U(BKT:FE/=)--3VT/^JW@
MC_Z;0/ZF>OJ637(;<OD^4R24]F;XO_`%>BJ_I?(AM)<4UJ@4`H!0"@%`<A?J
MX_73?J):`[/]H?Z+_P"LM`=_D;7\=9S7I]M"_.IUHR)JX41J[B>X5XW*VU;#
M$S<?8UY7WC:-:V`PBY:ZK:RKB7($=&3DHI!1;TM@W_%70Z;+2Z#2270!=!@)
M1`&YM`'6M:OI9M3*5JQ6PBOG7VF6YM^6]!%0IS;5\&K@83<&VY&=-R$X\AU4
ME<4$(F8X=S4=*\-ZNSWS,+457Z8)QE#I<&P.3W?6\SWJ.%O]XR5_]+:L]5Z[
M?U?XBG`?.IOQWB*F`ZFTS"AC@7D`P[C)74I>;F\'3%W@B)NZ'&L^J]=OZD^4
M,!`[\-X8AH.TO"8ARB3CN+E1\$W2''%NO'T^G2L>J]=OZO\`$,!)=^.\4H@)
M=I>$RZ)@D`!N+E0#JPTT)RABWETX>E3U7KM_5_B&`K#?IO'*(B7:;A0!'EZ-
MQ<H`>"'*70`Q;H``%9]5Z[?U)\H8`7?IO'*(F+M,PF!A$1$0W%RFHB(ZB(_^
M%O$:QZKUV_J_Q#`4J;\MXJW,*FTS"9A,7D$WNBY0#B74!Y><,6@;34/3IZKU
MV_J_Q#`5!OTWC@<3AM-PJ!A*)!$-QDK[$>D-/R6Z<:SZKUV_J3Y0P$!OSWC`
M*8AM-PH'5%$J>FXR5`"E-H(@`?DMTT'2L>J]=OZO\0P'+[OK>9[U#"W^\9*_
M^EM/5>NW]7^(8#X9+?;O-E&;R-':OA-HF_8O6BKQ7<3+J$;E<-E$>?JT\8%4
M.8!/P`.GO56_NY427M=-C&-EB<:DV2XF+NV>QKMQK@C'EAWNUCV%UVU`I)RC
M>,D/QABRJ/Y:3>*$:RIT8YR84RK@`&.W+7O<H9,;+26]5P:#9:B-NO+Z?&^5
M7:_\:6[$C41^DFCW)<I`U4Y4<L4N+$6*145$"@%`*`4`H!0"@%`*REX)Z:NF
MHQK?FT@I6KWJD%4L?N%LB^+WQZDRQXQAIFY6$[$S#6*FY,]OM#C&/$W6GMNF
MV?F+UA4A`?I(\NM>8S"EGU"*U8D51'7VF4*6_+>6W*U05VJ845,#9/JC^Z)F
MDC*%3(0@J"G^2]5(@CIQ#G$:\DO=JH<[S(XN!.,UYDJ"12Z)RGWY;Q5"&3/M
M,PF8AC"82CN+E=.8>DP?^%O`W?"I>J]=OZD^458`??EO&4(*1]IF%!3$`+R^
MZ,E0``#HY>7%H"40],-!IZKUV_J3Y0P%1=^F\<IBF+M.PL`EYN73<;+:!S@`
M&X?DNTXZ!3U7KM_5_B&`DV_;>28IBFVG85$#Z\P#N,E1UUX#_P#*W7HK'JO7
M;^K_`!#``WZ[R0,!PVGX6`P%`FONCI?V(:Z!I^2[3AK3U7KM_4GRA@`;]=Y!
M0$H;3L*``](>Z+E?"XZ^%_X6ZFXCW:>J]=OZO\0P'&??AO$4+RGVF84,7F(?
ME'<;+:<Q#<Q#:!B[V13=VL^J]=^]J_Q#`<H;]MY0"`AM0PMS`&@";<;+&$`]
M(!-BX1JN9W;K93<:HL.!.,RV7B6!6._C>:/_`.E'"O\`O&2O_I>%1EY#.<L'
M*J)P)QEJ243=,4,*0&16\OF.]LI0=M6W<F3,@+WR$#9DZ[NR%CV!HAM#D07D
M7T7!N^L3,UYA$$!`1XU[2@I6T[42$%1$\I>B(EQ?+F3$B9"&$XD+H=3GY@.)
MO"+RZE*8H%*(!H(`-=Q'8BQJJJ6D5DD*`4`H!4F(BN1'6H8551(I>/3_`.*L
MU"860EV1(*]RWJ65DELTXUW0XIW!8CL:RL@?BUB/)>.YF%O2^'E@-NONR=MJ
M2CW)'4=;MS"N*",.<I3&3+J!N(5Y#-<NG5K<+E6,;"#FH]+3)XN^W>0D*J9]
MJ&#E@.(&,JCN/FE4CF'B($.MBHAA`@^D&@5YY.[-4Y55B+OV)QFO,EP.4=^N
M\@3"?W)V%>8>74WNC)77P->7_P"5O<YAK/JO7;^K_$5X"`WY[QBZ\NTS"@:@
M!1$-Q<J`B`=_\ENM/5>NW]7^(8`??GO&4`Y3[3,*&`Y>4^NXN5\(/2U_);K3
MU7KM_5_B&`J'?MO('@.T["@AR\N@[BY73ETTTT_);III6?5>NW]7^(8`7?MO
M)*83%VG85`1``'3<9*Z:!T!I^2W0*>J]=OZD^4,!'N]=X^AP]R;A30XZG_VB
MY0.8=--1_P#"WIT"L>J]=OZO\0P`=^F\<=`]R;A3@8#!IN,E0T,&F@\,6]S2
ML^J]=OZD^4,!27?EO%+RZ;3,*>"(B77<7*CH(B)M>.+1U'4>FL>J]=OZD^4,
M!'N\=XH'*I[DS"G.4QC%,.XR6$0$X<ING%W=#N=%9]5Z[?U)\H8"KW>>\83&
M,.TW"@B<.4W^T9*Z"&FFFGY+=`IZKUV_J_Q#`2._3>.(:>Y-PKH`%#^L9*AP
M*("'1BWCH(5CU7KM_4GRA@*#;\-XAM.;:7A,VFH!KN,E1T`QN80XXMZ!-6?5
M>NW]2?*&`@N^_>&0RAB[2L)@*H`!_P#:+E1`0*````4<6B4H``=P`K'JM6[^
MK_$,!)M^.\4P:&VF84'@!0_VC);4``0,``/Y+M0X@'16?5>NW]2?*&`K'?IO
M'$2F':;A3F*;G*(;C)4!`V@@(\,6AQ'6L>J]=OZO\0P`-^>\<!\':9A,!$3#
MJ&XJ4U\+V7'\EH#QJN;W;K)3<3D54CH3C4DV7B4Z&Z-[6\B?MJXX$-J>%$!F
MX"7ARKCN*EE`0-(QKI@1;JQQ@'-U7G&H@`@(APU#IJ4G(YR/2*JVW0A8DE$W
M2P6WJQKIQOA+$&/;U+$HW9:-CPL1+HVVHM,PBSPB)C')[8J),US&(("`:HEK
MW-$Q9"(B6*A>B0L2XO*<#ZZG(JF8P`82JD1(/'Q"H+N"]7PX:B!O3`*ZRO69
MYSEBI8VXHK!(4`H!0"@%`<A?JX_73?J):`[/]H?Z+_ZRT!Z/(R2PWK-B"*PA
M[:EX@DH(="?=Y:X=&^*I;N(4I8AX@B"X&`_4N`$@K@``FJ7ZKS$$=0+KP`>%
M>H8DIS,2PAY#!6"2Q2<@(N!$3<QCG*N<3@!>4"F`Q3%T#3TJHF]7D?/)ALX-
MTRB(Y;1U2WW.?[V-]JJGM*1H342V;1U2WW.?[V-]JIVE(T)J&S:.J6^YS_>Q
MOM5.TI&A-0V;1U2WW.?[V-]JIVE(T)J&S:.J6^YS_>QOM5.TI&A-0V;1U2WW
M.?[V-]JIVE(T)J&S:.J6^YS_`'L;[53M*1H34-FT=4M]SG^]C?:J=I2-":AL
MVCJEON<_WL;[53M*1H34-FT=4M]SG^]C?:J=I2-":ALVE14S]"C,RA.D2]0H
MF8?B*)E(H7XPU)KI%=;YOF<&[PF%1&W%":+A),J0(J<I0,43^:_3U"CQ*55P
M"76J`37@`B-5O65)L8J1(D=2N/\`S"WV)3Z&J%5TU?-5-9FP=2O^DK?8E/H:
MV&^:U&N5(IOEJ7#J5_TA;[$I]#68II369'4K_I"WV)3Z&D4TIK`ZE?\`2%OL
M2GT-(II36!U*_P"D+?8E/H:132FL#J5_TA;[$I]#2*:4U@=2O^D+?8E/H:13
M2FL#J5_TA;[$I]#2*:4U@=2O^D+?8E/H:132FL#J5_TA;[$I]#2*:4U@=2O^
MD+?8E/H:132FL$BBM^D+?8E/H:LEN15M5%LTE"$"@MT@BN4_*)0.*2AP`!$!
MU!,Y#)@.@:=%7M;*5?.A[1G@.0Q%S@GSH+&%+G`GTE4"%*<0$2@B!>J``$.`
MZ:U&=,IJ=FTLQ1AN&41'6*4]4M]SG^]C?:JUNTI&A-1G9M'5+?<Y_O8WVJG:
M4C0FH;-HZI;[G/\`>QOM5.TI&A-0V;1U2WW.?[V-]JIVE(T)J&S:.J6^YS_>
MQOM5.TI&A-0V;1U2WW.?[V-]JIVE(T)J&S:.J6^YS_>QOM5.TI&A-0V;1U2W
MW.?XS8WVNIRZNGJ';)4;!=[0%:C4BEXZM?[G/][&^@J;J>G2U(>T1(ZAQRK@
M0CHGG!.J4.!5C+]2(<42N#%%8B>HZZ`(`%:\R6QJ^:J1\AB,`9!43"8&RA`$
MJ90*5`_`$TRIZF/R<ZAC<NHB81&L,@B054UEC%L(ZE?](6^Q*?0U.*:4UDQU
M*_Z0M]B4^AI%-*:P.I7_`$A;[$I]#2*:4U@=2O\`I"WV)3Z&D4TIK`!!;](6
M^PJ?0TQ)I361<OFDBBN'0@M]B4^AJV6J+&*HOE*D(!!<.LT2<@*ADS&$I%BC
M]+*)2@'*`<!`U7-;)7E0CY#)6*:W@@#=4"E(4H%,DJH`:!Q-X9#"!C=VJY\^
MGI8(V%IE$1UY'5+?<Y_O8WVJJ.TI&A-1G9M'5+?<Y_O8WVJG:4C0FH;-HZI;
M[G/][&^U4[2D:$U#9M'5+?<Y_O8WVJG:4C0FH;-HZI;[G/\`>QOM5.TI&A-0
MV;1U2WW.?[V-]JIVE(T)J&S:.J6^YS_>QOM5.TI&A-0V;1U2WW.?[V-]JIVE
M(T)J&S:.J6^YS_>QOM5.TI&A-0V;1U2WW.?[V-]JIVE(T)J&S:.J6^YS_>QO
MM5.TI&A-0V;1U2WW.?[V-]JIVE(T)J&S:.J6^YS_`'L;[53M*1H34-FT=4M]
MSG^]C?:J=I2-":ALVCJEON<_WL;[53M*1H34-FT=4M]SG^]C?:PJR744]4NS
M5&P1(W&%:C;4)ZM?[G.(?X.8/E$UK+J>G2Z'M&"@J#C0Q1(\`@NTW6B77MSC
MU93E*B=5`$U3HB!^("-:\QC$7S53VC$2`;')J";4Z9=1'E(@<H:B.HB.A`$Q
MA[HCQ&LL@B054UEK%L)ZE?\`2%OL2GT-2BFE-9(=2O\`I"WV)3Z&D4TIK`ZE
M?](6^Q*?0TBFE-8'4K_I"WV)3Z&D4TIK`ZE?](6^Q*?0TBFE-8'4K_I"WV)3
MZ&D4TIK!RE17Z\?I"WU4W_-*?I)?[FD4TIK!V?4K>8?45OX+_I2G_:3]#2*:
%4U@__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tpg55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg55.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!NP)I`P$1``(1`0,1`?_$`1@```$$`P$!`0$`````
M```````&!P@)!`4*`P$""P$!```'`0$!``````````````$"`P0%!@<("0H0
M```&`0,!!`()"@T,#`<'%0$"`P0%!@<`$0@2(3$3"4$442(5E=46%Q@X87&!
M,E2U5K9W>)$C,[/3--1VEM8WE[>AL4)2)'2D52=76+C!T>%B4W,E-39HJ!F"
M0[1%)D>'\/%RDJ*R8Y.4A6<HTF5UQ<9(.<*#1,1FAJ99J1$``0,"`P0$!PD+
M!PH$`P@#`0`"`Q$$(1(%,4$3!E%Q(@=AD;$R<Q0(@:'10G*R,S0U\,%28J(C
MLW05=3;ADL)#H[06@M)38Y,D5!<W"?'39!CBE"6#PT34155EE=4F1O_:``P#
M`0`"$0,1`#\`O>P;QYP+.8&Q%9G^',93,M)X]K#^>D)*E0#V2>RCJ.24>2#U
MVX8J.'3AVL83J*'$QC&'<>W6VPVD/J\;RQN+!C0="Q[Y2'D8TJEPMQ]XZ%#L
MP3B7V!VH-:[/KA[G]NI_5("*Y&^()Q#MJ5X$P+QQ+N!L%XC,(;]GQ!K(CZ-O
M_-X#V;:F%I"=C&>(*0R/)P)0;!7',@A_D(Q"(=HCOC^L?5__``=JHVR@!JYC
M/$/@4`]_X1\:QE<'<=5`Z0P3B(NWI"@5@/2(>B.`>X-]3^K6U*<-G\T*.=_2
M5C?()QV'_P!1V)?X!5GX/U*;2W-*1L\04#(^FTH^03CM_F.Q+_`*M?!^I39V
MV^-M>I3ME=DVFO6CY!..W^8_$H__`-A5K]P!J`LK?>QOB".D<1@3XT?('QV[
M_D/Q-_`.L_UO4-3&SMOP&>(()'4VE9#?C]QW74(3Y#<3;"([C\0JUVAWCW,-
M2FQ@.#6,KU!0XSQM)2]CN/G&-[U1RF!</%=I)B8AOD^JX'7(&W4(&".[5$]^
MWT[=OLZFBM;>I8]C#[@^!2F1YWGQK.9\>.-K5<J3C`.&U!W-X9E<<U42+E`0
M*<A@&-V!0O<(>CO#OU5]2M:T,;*=03.^FT^-:NP\6>.[,AIF(P7B96-*.[IK
M\0JVJK&G'??J`8\14:&-W&[>GN'LV'5"2PB9BV-I'4%'BOI0$K6L<"\99-(6
MRV",0H.!``*8E`K"8B/;[<A@C^WL[PU`6D(P=&VI\`4!(\;SXUIY#C;Q_CU.
MD^#<3F2'M36"@UOI,&WL^Y^AL[=K@"QF/@"G$I.\K(C./G'4?M\%8C4W'<>N
M@5@=@[?0:.V#?;5-UI;@U#6^()QCTE*)+`'&MJ455L!X</N([`?'M6-L`=G=
M[G#W;[Z-MX2:9&>()Q3TE:&4P7QO6,86^!L/)?;;>%CVKE#V>\(X/L:JQVD!
M-71MRTZ`H&1Q&!*3PX#X[]XX.Q-_`&M?!^JGJ5M_HV^)2YW])\:_1<`<>#&`
MI<&8G,81`"E"A5H1,(B'9MZA]74OJ=OEID97J"9W[B?&E[%<9^."*'4ZP7B(
MQS%!58ZE`K)BHI%#<2EZH\0ZA]GV=0;90$9G,;X@I3(_#$[>E)B8P3QP6<=3
M?`^(440]JF1.@5@@B0.XYNF.#J$VWIU#U.$GS&>(*J^4T`!(]U:;Y`N.W^8_
M$W\`ZU^X-5A:6]/HV?S0J1E=MJ?_`!6XCN/7'4^YE,&8E,4.T=Z%6AV`.[OC
MAW^KJF^SMP?,9X@IP]U<2:+'>8#XZ"<2DP7B,NP[;%H-9`=@W`.Z/](Z@RRM
MG"I8WQ!1<]]<'&BPOD!X[_YC<3?P#K.WV/[AU/ZG;$4X;:]04N=_2?&OGR`\
M>/\`,;B7^`=9_<.GJ-O2N1OB"9W])\:^_(#QW_S'8F_@#6?@_57U&U_`;X@G
M$?TE'R`\>/\`,=B7^`=9_<&I'65O7!C=VX)G?TE'R`\>/\QF)OX!5H/_`.0U
M`6$+L!&WQ!,[NDIQJ[QSXVNH>3,I@7#ZBK<S14BA\>U<Q@+XO2<"G&-$=A`>
MW5%]C"P^8WQ!3-D?7::+&DN-7'!&2<[8*Q$1(PD.4H4"L@0H'(`^U`([8`^Q
MJ0V]N!YC/$%%TA&TE?DG'7C<&P!@;$!MA`!,./JP/;W=F\<.X#J0V\!'F-\0
M4PD<1@2MBWXU\;C`)CX%P^4H[#VX^J_9V]P?\F[ZIFUC_!;X@H9G])IUK8AQ
MRXR$#8,!X<,(>D<>58=]O_L=J#;2(GM,;XE$.?TE?`XY\:CFV#`.&]NX-L=5
M7LW[.W_DWMVU,;2&M0UM.I,SNDK;QW&+C4Z632^;_AT>H>W_`"=581V[`$=_
M<WOU+ZM$[8QOB"9GG>4XZ/%CBVF0B`<=L***"`")QQK4SF](>F+$0'51EK"!
MBQI]P('/Z2MF7BKQ932$1XZ804,4-U-L:U$QBAL'MA+[E[B`".J4D,#FY6M:
M#U!"]W25@J<3N,!MU4>/&%C%'M,D&-JD(@&^_40/<SVQ=O1Z-6IAC&!:WQ!7
M#'YAX5\2XL\7.S_[G7"1NWO'&E2'T^S[E[:E,$1^*%-BMFCQ3XL^GCEA`0V#
M_P!6=2_J[Q>J'#8*@M%5"I6X;\4.*I^PW&_!P]W_`*L:A]3MW]RN[?4#&S90
M>)*E9_S2>*FWT;L&B/Y,*?\`U?\`DH=N[4O#'0$J5F(<1^*8CN;C9@PW9W_)
M?4.W;?T>Y/I_1U#(T;@E2LH>(G%$!V'C7@WN#_U84\>\/1_R5[`Z9&?@CQ)4
MK*;\1.)PCL/&G!8^GMQ=3Q$=O1_S3L'9J&1O0$J5^7'$/B>4WM>-6"P^H&+Z
M?OZ.[_DG4<K.@)4K&^:+Q0_T:\'?S84_X*TR,_!'B2IZ5^B\1N*`#V\:L&[?
M5Q?3_L=T5OID9T!1!-<5G)<0N):@#_\`<U8+`=O\V%.[![.SMBNWLTRLZ`HN
M.."\U.('$XH_1KP9]8,7T_L[^W;W*W`-,K>@*6I7J3B%Q,`H&-QIP4/?OOB^
MG_8_\U=O9IE;T!*E?#<2.)?44J?&?!)C#V?R6T[IV#M$P_\`).^P!VZAD;T!
M*E?3\1>)9"B<>-."NE/??_);3@ZSCOL4O_)/;N(?H:CE;T!*E8(<1^)XF$3<
M:L%]OH+B^G@4!]'_`)I`0TR-Z`E2O8.(/$\P=G&O!GU?\F%/W#Z__)79IE;T
M!*E?`X>\4^_YMF#1_P#9=4-NSV?^2M,C.@>)*GI7X-Q#XH@`_P#W-6#`V[!V
MQA4._P"I_P`D_4TRLZ`E2O#YHW%+_1LP6'U\84_X*U#(SH'B4<Q1\T;BEW_-
MLP7M^3"G_!6F1G0$S%?/FC<4O]&S!?\`-A3_`(*TR,Z`F8K[\T;BCZ>-F"_L
M8QIX?_DK3(SH"A4K]!Q(XHAV!QJP5W=XXPIX_P!>*^IID9T!*E>Z/$?B><0(
M;C5@K?T"&+J=]3_\$^G?4<K>@)4K+'B-Q*1*('XTX*$QNP-\74X=@#<1$?\`
MDK?T:9&=`2I6)\T7B8(_1MP5N/;_`"84\/9[O^2MMM,K>@)4KZ/$/B>'9\VK
M!@_6Q?3_`(*TRLZ`E2LU+B!Q-\#J'C3@H>Q3[;%U.`=P[0V'W)WWVTR-IL"9
MCL6%\T3BA_HU8,_FNIWP3J&1G0$J5Z%XB<3]OHTX*'?V<7T\!#T^B*U'(WH"
M5/2MHTX=<3A**A^,^"1)_8]6+J<(^@?\4]VI7,:1@!53APICM7D?B!Q,%<-^
M,^"@)N'8&+:<`=FW9O[D^G?46L;38%)4KS6XA<3Q.)2\9\$@`B'8&+:=V!V^
MGW(W#ZVF1G0$J4!P[XH%,'5QIP5]4!Q=3^X?_L3J.5O0$J5G$X=<3-NLW&?!
M!0`OM0'%M.'J[AZO^:>W?0,;T!*E>8</^)9U"E'C/@@2F,`;#BRG```(]W_-
M'=L.HF-@V`52I7*3\2J?^#,#[VM/V/5G0="J8JZ7CA*^J\?\,.6BGB$3QQ56
M[I$WVO46,2`Y3E]@>W81[];[8-$EI&QPV1CR+&28/=CO*=":%NJR4D8T.M+;
MJ71+]NW,/?[`B01^IJX?%EP([*D#@[84WJ;U=0X[IN`*;N,0@G$!#?[8.P!#
ML[]4AD8,#BIJ$K8`@_6*4S</6-P]L4NY%`[/[13MWU',W+4T2A6H<K/6HCZP
M@JE[;^R3.`=_LCV?U=2@-=B$Q"\P>+[=7AJ"7V0*.WZ.XZ4:#M4I-!4[%X^Z
MH=73N;J]C;MT+`:&I4006X+(!=V;N15[>X>@=A_KZIG;04HHH%RZ+]LDJ'L^
MT-_MZKMC!-2:J4NQI1;..D!0*HY4$2@`"!0'L'N'M[=MM]M'MQHU0+P!O6O3
ML#@KPCILHIZPFJ"B8D[>DQ1';L[0$#`/;[(:G;$/=_D4HD!.]/&WE23425^"
M9R&*&SU'IZ56SE,`_NIN.P;"0H@(]FQB#]0=7$3(\N4TJDA(&&U>\/954%A3
M$Y3*%ZDU2B.Y'"9@Z3$.00$-C%^V`=_T-0R-S4.Q18>S4I/6.$9.EY)W47K1
MR^BT&KZ>J[1VBM*0C=^"IV;T&::AW2#-YX*@I@<H=0$,)!,`#M)-;RQQB4L=
MP75RFAH2VF8`[#2HK394*FRXC=(Z(.:9F@$M!%0'5H2-HK0TZ:+0P]N(Y3]S
MI9(5$C^T*L8!`WL!U"`;@/U>_5NUH-,P%57KT+;N">H(G<-CBLV^WV[?$2+W
MAU!MN(`(:E?;/+\S3@I<[>E()[9%%CB`J&`O=MV@&X^@!U.RW:UU*54001@L
M,)D=M@$WI]!OJ_5U7,3!LPP1?D9?_?'#[`@'L?8#4N0=*):0)#%Z'C@!ZU`_
MN=(P]I2#L'B&#<!ZC>CNU2$7;'X)4:K/LEE*@5"%04_3%A*H].!NXH_:)"(=
MO=VCI(VN$8[*8;TA'LP4%A(!^P@`'8/]?46Q.J#3"BE=(W<L8DMU&`"J#V]F
M^_I'8=_K]FIBTC:@<"$HRROJ[3[<0.8-@_\`@@`#[/;OJCE[8`4Q(`J2DZ>9
M`YQ,*@_;"/>'U?J]O:.K@QE0!!%0OGNP'_"#_P#&#_;T#-Y2J/=@O_"#_P#&
M#_;U'($JOGNR7_A!_1_W=.$?"I<[5^RRW7MT',81[-@'_=U`QTWJ8$'8MLR,
MLX,`[])>[8=P``[?J"'8'=J1SZ8544[-9<)IM)9L50#J'C!4$-^X4CE-[(;@
M&J/T@Z5'8L"<?*'>(G`^Q%&C<_>&VPD]L.X#V]H=FXZMG,[5&H:G%8*4NBB8
MH"<!-OO[;[';WCJXCLWR$`C:I"YHV[5N0FBJ$WZA*4O:/:'M@#ZW<.LB+.*-
MM".TI6OJZE%B>ZVYA]N/VPCWA^AV"&X:Q[F`G$*J"0MHV?B<2`3<3"/=OOOZ
M>\.S?LU;O80<`IPZNU.I"`#%L54_ZLJ```;;]("`>P/8.W9JB&.+J`8*->A*
MM-\1HB9TL?81#8H&'M'8!$!]GL#26L;2!B4!)ZEHTIY=1UXY51*8IMR=O9MV
M;@)?24P!VAJVRC)F.U12T8R!'9050$$UTP$RJ!1``-MVBHB(B.Y1$.T/1JG0
M5J5!9YBD<CU(]!%Q[3)A[4BINP1``[`35$>SZNJ+A0X;%=,=F'A2?^.-7:K*
MM7=JK#1RW4,DNV<6*%0704(;8Z*R"KTBB2I#!L8I@`0'L'5$OBKBYN;K"RT>
MB:Y*P2Q6-Z^)PJ'-MYB"#L((800=Q!H4K8N98/&GKK&08/V)NL?7F3UJ\9?I
M&_BB#QLJHW_2=AZ_;>UV[=M"&/[0(ITA64]K=6TWJ]S%+%<X=A[',?CL[+@'
M8[L,=RV<7-1\F@#J+DH^3:F.8@.HU\TD&PJ$$!43]8:++H^(7J]L7JW#?MVU
M1J">SB/!BH7-K=6<O!O(I89J5RR,<QU#L.5X!H=QIBMPM,QL8W!S*R4=%-C'
M!$'$H_9QK8RINHQ4@7>KH)&4,4HB!0-U"`#[`ZE=E&+C0>'!1MK2[O).%90R
MS2@5RQL=(ZG31@)IX:46*-UIQC%`MRJ!A,8"E*%I@3G,8P[%(4I9$3&,81``
M``W$=29XOPF^,*].A:\`2;"^`'_IYO\`,2G;.-C[;B`#_6[![.WTZF=@L4LA
M\H`#O]G^L`;!J-`BUX+_`&/T0_K;Z@1T(O0%=^P-Q$=@``'<1$?1MW[Z4P2J
MS&RO:._8(=A@WV'L';8!'T]NI4VXKV5,&_M1[>W<!V';L#;M`-M$7@=80+TC
MV]VVW;['HW[Q#1%ZIE%,.G</%,`"8W9^EI]/8`=O?MWZF`)18CAQXA]B#^ED
MW`@!MTCV]INP.T3;:@BQ05,(CL`CMOOT[=WL[]O9MJ(:2A(&U93=QN8-]P[@
MV]D!^IVCOJ+FY46O4NU/3,*!KA4B*E.*9T3VB!*L14#=(I&2-(`<BI3AL)1#
MJ`>S;5+B1_A-\864&A:ZYHD;87QC(K46\Q%-M:Y*4IC791;%W)1;!N#R4DHZ
M,9B9,I7DD_9L&9CK[>"4KIVLDV,9;?V@`;<WHWU$D`5)`"LK>UNKN7@6D4LL
M]#V6,<]V&WLM!=AOPPWKV440V*)3)F`P`(&`2F*8@@!@'?<0$![P$-15$@@T
M.U89UR;]X?8^KV!N/V-1H5!>(K[]VX!]3;^OOJ"+6^[D/UODO=F*\6+)XDJE
M[J,/$BD]NKQ)1/UGKCD^GMZE@(&W;J&9N.(PVX[.M77J-_EC?P)\DQI&>&^D
MAZ(SEH\^!E5E-7S5Z@DZ9.V[UHN7K0=LG*+MHN3<0ZT7+=15!8FX"&Y3"&X:
MB""*C$*E-#-;RF"X8^.=IH6O:6N!Z"UP!!\!"V:!BIE%90>SN*41[Q_L3`'I
M#?14E^G2O4!3@;VIB[]_;V[]GL=NVIJ8(L$%O_A?9V'^N.C!F-"B_8.#!_9'
M_1[/T-34;3PHMPBN/J)3B)A$17[/K$[-_J;ZA0C8BUP.P$`Z@$N^VWMMQ[.S
MM#?8.[ZNI:%%GH*)*"4`.`F-V;#MN'L]O9Z-3E$H3.`(W`A0`.D`+N'<'8`"
M`_5';4@:3U(M698#'$!'N`PB._M0_K!OJ>E$7QDH"JPF,(B4`$>WM[@]J`@.
M_=W]FJ:+-35(HL8QS`4H#V%$0#?8>SZ@`.HHO8[]MOTF.GL`[?;`.P;;]W5L
M(;Z'!%]368K*$`JJ8>V`-P.4.W<-AV'1%QR=)/[;^J&K6H5960\>K`:,PMBC
MVP'0-0JZDX1-L(')Z@GN(!Z#%#N'OUT#3XRVSB?7`QM\BP<WTSOE%2#1DSM$
MGKY@N51HK$2BR`CL<A5$F#A5,JI#=0>(DJ0!V$-AVU>71!MGN97.UI/O55WI
M4,=QJEK;S#-#)<Q,<.EKI&M</=!(Z<5R84WS"?,GR3;ST?&.0[7=+*J:5795
MVK8]J4O*JLHP%5WBR3)I6EES(,VJ8G4-L(%*&XCKS=#S/S9<O$<%Q++.:D-9
M'&YQ`VT`97`;5^ECF3V+_88Y(Y?_`,3<Z\O:3I6A-X37W%UJ-]!"U\A#6-,C
M[UK0Y[C1HKB30)[?EX\[,H[A`YT*;T"&&(4HAV#W?^B>X;;ZO?VOS_\`@WW_
M`,NW_,7,/^3O_:S_`.(Y,_\`[Z?_`/R"M;X)9CY--<`\D,I\]4+C'$Q>HWL4
M":\5%A5'BU;C:R^D)9M$((1\060,X?H))EW`WZ<H4H"`FVUM/+>KZ]%:WMYS
M$)A'"T.9Q(Q'4!I)I1HK5U!7I7@OVLNZ/N`U7O/Y)Y!]D_\`9,TFN/?;W/[/
MO9+YHGDN88XG3.=//P\D;I'T!;V&N<0:55$K'S:>9"-Y:3[S(I'50);$9EW1
M?BU5$HYQ7`E0=+U;UQ.#"03:J1N[8%@4\8H>W`W5K1QSCS-43NN3ES9BS(RF
M7-4L\W-@WLUK5?4VZ_[=/LL2\L2:/;\N1,UYU@Z%E]ZS>F1MP8LC;OAFY,6<
M24ERY.'7#+EP72YR#MON5Q6R;R$Q'.`V*K@M[E#'TP#=L\%BI(0K>4AW0H.2
M+M%U68N0`Q%2&+U%$!#T:[+?:F7\N3:C9.I)ZLY['"F!RY@<:C#Q+X)]T_=K
M`/:7T#NC[PK436_^+(=,U"W<7L$C6W!AF9F86O:'TJ'-<UU"""%SA8TYY^:)
MF&0D8C%%RO.0I*$8$E)9A4<;U2;=1T<HY29)OGB+*L*G0;'=JD3`X@!>LP!W
MCKCUOS+S?=.,=I//-,&AQ#(F.(&RI`9@*X+[L<Z^R![`O=Q:0ZAS]HNB:-87
M,QBBDO-3O;=DD@:7F-CI;YH<X,!=E!K0$IS9;E)YR5&9.;/:(/,",)$MUGTF
MZF\&QKF&:,T""=P[E#(U$"MVB"?MCJ*&(0@!N(AMJXEUOGR*,RRNO(XFXDNM
MV@#K[&SI6D:?[/O_`&RN9[MFA:#)RG)J]R[AQ,@UZ7CO>[!K8FF_=F>3YK0U
MQ)V`E3G\OKS*9OE-9E\$9JAZ_$Y,?13J3H=OJ[/W(B[8K$-C.I2!F8<5U464
MV=DD9PW5;=**_AJ$%,@]&^W\H<Z7>H7HTW5<AE>"YDC1E#J;6EN-#3$$;1X5
MXS]M_P!@G0NY#E+_`)K]TDUY)RA!.R*^L[A_&DM1*[)'<Q34#G0\0MCE9)5S
M"]C@\MS`+;S(^4ENXK8@JR.-YY.!RUD2W';0S_U1C(.(BIUM`'-CE$V4DV>,
MS"[>NFC,@G3']54$O:41#+<_<Q7.D6L%MI<ACOYWUS``Y6-%7&A!':-&A<P_
M[>/LT\M=_O>+JNI=XMCZ_P!W>B6`XD+G2QLGO;EV6WC,D3XWCA1LEF(:\8B,
M.P<F'\JGS'<P99Y!2F'>1=]):V-_JKGX@NW<3!1!XVXP!S2'N<B:(CF'K/N[
M#'<E`BG7NJW(!1+U&WU?E'FS59M9%GJL_%AE9V*M:*/::T[(%<S:[>A>I/;W
M]B;NM[N^YN/O'[E=$;IESI%\TZ@R.6YF$ME..'Q'>L32Y3;S<(@LR]B23-7`
MB]FQ)'C'R;IF?I(*A=A#M```-R]H".Z8A]J/L;:[@69HA*.@+XI;#3<FTP))
MI?/!Y2O5"@F5?&?&%-;[4.H"M\BD,'4';TAN.WL;ZSFJR/;R;I)&-;J^\L"U
M?3&@\XZI^K6?DF4:<)6_EG/PE2N-PJ[2S+YHR+?X2N_'-S5*Q7ZY4Z&GE&Q2
MEF@HC'=85M+=^YB*BSCVK2PF(#ERL50%/;;&VCF7E[DQDL\.GR.A]1MH9).$
M)'R223<!K8W&:41%H=(Y[GP#LM!!%1AB]'UCF=[VONF-DANKA[(B\M8QL<9D
MS/`C89`X!@:&R^><00"D+6?,"OP1LVWD<!JLCUFDX\DEYZ[S\A">$[N3G';1
MS>;7$Q574>M\6LRWI<YGS%F)TSPKDJI4P-NG?W/=CIL4\9BU*L<UQ,T,B8U^
M$8G(BC<Z6AG/!`R2.`/$;0FF-E9<\7SX'MDLR98HF',]Q:YQ<8@9'-$8`B`E
MKF94]D]E)QER[S5&8'J>6[)A"I6="4FJC2%)AI.62L!(6F9QNIDJ3G)MLZK+
M:'J]5D-TH2&6`YS.I)8@JD3'=(9KCN[Y=GYBETFTU">`Y)9@W)'(&1MN/5VL
M:>+FDD&,L@H*,!I7`JJWG#6;;26W\MK'(T.9&7%[V%SS%Q2XM$;FL9L:#7$G
M=O5]SY(Y&2B;77ZC2J_7;\S26>U5C=U;2]LUB.?-4M3^B"B86DK5I]5:W!1:
M;:8>G=>L(>MD63(<P)F6MK;D31&W-O<W=Q)/IKRULAA$8CC'J[9#Q'OF$C9)
M'.S1M:TM.4M.4$Y9IN;=3=!/!;QLCOFM>Z/B%V9_YP@<-K8BQS6@!KRYP..8
M5(Q79<_V6#LN`OC/CY%%MGBTW"L2=>3+.R3F@S-!R>MB!0M-:L*\UGK9!6UT
MQ5L'K<BF!HV/#=8A$/T\,4.3-.NK34C:W+B[3(8Y&O.1HN&RP"Y!E+I"R)T8
M<(<C*\1VPEW95X_FB^M[JR;-%FCOWD%HS$P%D@A(:&LS2!YJ_,ZF08&C<5,Z
M:D48`)%VLL51-B)TD=C`!'#H1$J9""`@`D`P``;>C6@LHZ(.V5&Q;LXN!I5,
MRTFE7SYP\76$ZAQ.LH81[C&W]/<``'<&IVL&0#>I:G>M6M.`=90XJA[8YA[#
M![(@'I]C4[6!C13:H+U:2H*K``*]@;"/;O\`U=_JZD+*XE16SDI\"@")%`["
MAZ?9+['HU*VW[55,9#A4="T83`?\(/Z.W^SJIPB-N*@3T8+[[L`'_C#?_&#^
MKVZF$0(QH"@<1L7SW8`?_&"/_A!_MZDR4-`H$UQ*RVSQ1QL'B;=W;O\`4W'T
M]@[:E)HB439VV:`!U5`,?L[!'M';V=]NSTZMI'.<*@*JQS0,5G&LO4'0W$`+
M]?I[_P!'L#Z^K81N)Q&*G,C!O2XI$R4THJBHN!S.&#M'[<.\4C"'9[.X=_9J
M<0.9VL0H<1OA69973@(^-=I&$0%MX1A#_P"C,(!Z=NP1U7AAC+@[?_*J;G/I
MCL3?MI50Z@]9S"(B(")A#??V1`#=VLB<C`**GM*4!9SI*!`4[^\-]^_L^MJU
M>ZN.Y5&><LYO*`.P]8#MW`(^VV[_`&=6I`K4*JYV453FU5`5MGCD0\$@]1`'
ML`>W<`^V[=]47M<[9X%,#453HLG/BCXQS`1%,`V]L```%_WP"/8&H\,AA)I5
M*K1S%A%TN**1P*@38H%`V_:'I`0'MW'5B6%[JG<JM:!?EL_#<H^('H[A`-MQ
M#T`(=P:E,=,"@-0E,TD#I&(HF<2G*("4Q3=H"`[CV[]N^_Z&J;XP5&B<*)E"
MO%$C$V(X(H05$P#L.'67=5+V>S[8OHU0<RAH5))4,=3H*X[:L3R[GG)CG$/.
M*'R_,3Y>2%S#'JN.$KZY:-88;#81F4Y,M24!N191[X7A@M[?H`>GLWUR&-VB
M-U*^_;`F<_UDY,@>X4WUR5ICTK]#&KR>U=%W-]VW_MPN-!M],=RA:&^]?-DU
MSI>!!PC'ZT*D!N;-DPJ17%6P<A\K8;XE>5+',N(#6U0T!R)*YI&!XRQN9M6Y
M+2.69.2):)(2SZAIEL^:1:+TZ*2@AX*JB6P=(AOL=]>6NG<LA^E!P9<`-B#J
MAU9#O#NT.HXCH7AWNGY*[PN_3VWI;CO\?8W&J<IY;S6I+=L0M!'ID<?JT=81
MPG,=(Z$/<WSFMDKB,-%Y3;2W\-^0><O+ORC-#).7=1I?(+%\BHH8K:1-*5J'
M;Y"CHU)0Y@+ZLY.0AB%$1$T6N8=A`V]/EILNDWTV@W!)[#96'IJ`'@=-#M6:
M]M^[T#O_`.ZOEOVKN2[<0P,O[O0]1C`&:/AW$KK%\A%*YF@D$C9<1`5!"N1Y
M#\8<,\NZ`PQ?G.%E[#3F%GCK6V90EDE*N[+-1K5^P:KFD8A9%V9`C:36`4A'
MH,)@$>T`UL>I6%MJ$0@N@3&'5P)&(\(7@[NE[Y>?NXSF:3G'NXN(+77I;-]L
MY\T$=PW@R.8]PX<H+02Z-I#J5%"-Y7/GY>_EM\3,S<D^>52OU2MLE"<<>0\7
M4\2-VF0[/&J0D(VFK6**,BNU=E4G52C!MMU'`F,/0/\`;#K1]%T>PO+Z^BG:
MXQV]P&L[1%``#CTX]*^IOM1>UKWV\@=TO=KKG+-]8Q:AS7RM)<ZDYUC;R":5
MT-M4QAS:0C\])V64&(Z`IV<?/-4SKG_-UPH%6XAMFV*L/9;LE)S=FT+\]<5K
M'M"KYIHC>U.VRT,T75G'+>N.USLR>*F4A2%Z_P!,$Q<M:Z]>7EV8([8>KQRE
MLDF;!C0#1VS$FFS=TKS=WG>QAW;]U_=[8<T:QST]_.FO:'!=Z3I/J3&W%[>3
M\(NMFN;*X"%KIXV"4Y7$EQIV:'0O/.0RB_I<ER<B>*$4\X21-W5J1[^KF*O-
M<X/(!M-I0+B_M,2J$]:-$DD5@(#<1^NML!C!0=S-.8CJ+;<'1P?.SCB4!IG#
M*8MW[:TW+-CV#>3XM=A[H;WG6:/VA)].%R+,:7.[26S.B,S;)VI`Y1)PQ7/X
MHZD-,N,_\Q,\0DSCN*XK<<8_,5=O.-6N57&9\G7UEB;"\5`2+=)Y%P;:V2A0
M:/;:[9K)J*-5%D12!4NP'Z5!)E[[4KUAC;IMN)6.9G,CW9(P,*#-0DN.VBX%
MW8]Q/=KJ-AJM[WT<V2Z#JNFZN[36Z5I]F_4M6DGC<623.MH^TRV:\.:V1K7Y
MBTURU8'5ZYU\RK-G(;ROLTYNPECI7&%UIM]D,.YIEX7)C=)UBYJV"%<*6[',
MXDU0=VTDW[LMV'AH`BN@1PHLFH8I"G'"7FN75[R[->6S#%*QSF2$.\RFUS,.
MUX!@O4G=O[)/=]W6>V-R_P!W?>'JPUCEZ_TQFJ:3%+I[BW47.XS1;7T)<6VQ
MAX3YLS\S'EC&.8"XM"YK_F.\BN,_'/@9$7[BU'VNU9Z-"8[IL5!9>),V2UUA
MA6*8G5+J#T8UPR;6:ZOIX_K#)^NF#(2=:J@@8=JC=9OK&TLV3V[723NR`!]2
M6AM6NV><[>TTICB:+`ZG[*G=7WN=ZW>5?<L<YRV6B\LB:^NI)M,,4%M</N+L
MW-IDXC7NM[1D(R2PL=Q:Y6-%!5>5OS/>8LQG#*7$8W!BNK\I:7%M[=$P$=G"
M*/C%K1?<]O*R$Q;+HY8HCZV@VD6B+--B4X/7:_AF!'H$1JLUO4W74NF^JM_:
M+!F`XG8R]+G4P/@`-3O6NZI[(O</I_=SHW?D.\>Z;W,ZA,ZVDFDTB0:@Z\SN
MC9%;6C7GLET<KI73$<*-F<<3-0+>J><)1W?!27Y=W+%$M"7V%RDYP.3"D5-I
MOCSN8`!)2.C(FQN6:(H0+EDJ9RX750,JV*@H0"JG%/KGBYDA.D'4Y8W"42F+
M(#6LE<H`/03O.S>L'K7L+<P0>T=!W'Z#K4%QRY<:,W6/VK)$6"'3*D/DE@:X
MUF:\"-C&O#9"]CB6-SY5;A+S$\L.^1>-.,O+;`M/PE;,[0LA,8@M&.,N0F6*
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M<M8[+(\2F&.U:Z1L;)9'-?+(2W*QK2Y,1YB?.;.V5>-G`?*^`ZG)U#&G(/)]
M)?V$$<C)04S.Y!BYV031P-/(M46[I:F2#N'!VI,`8C8_04BJ?>75GK6K7=U8
MV5S9`QVL[V$]NA+JC+$0!YKL:NKA08&JZ3[*_LZ=VW)G>UWF<E=YE[#?<W<K
M:/=L@K8F:*&RDA83K,)<7-%TQLIC%K0R"I<Q^]=%>+IN^S]+J<WE6G1>.LD2
M4:D\NM%A[$WMT559T[A<KF'869FDBUG&Z!"D$'"92D,)A``[-;K`Z>6"-]TP
M1W):"]H.8!V\!U!4#IH.I?*[FVQY8TSF&]T_DO4)=5Y3AE+;2\E@=;27,(:,
MLK[=Q+H237L.)(I4[5QB\<ZQY5\^CRQD^=E^LE7RLRY!922I"5=L=]9S05(C
MQVJV=Q$37F#Z$D)!.=%;PBN@'K.`%,'1KFEH[EZEP-9EX=SQGT&<M=EJ:$`>
M%??GO6UKVS=,DY)L_9PTVTO.2Y>6-/-V9X+)T7K):T.;)).]DK&&'+F,>P$D
M=I26J&1).`\E)K-\G,:7#..-&O*B+B<+P%TOMEQS9)'')GO55YP]EB6<A,&B
M8F;!\5JCT"W5*8Q2"")$M7D<[X^5A)?QOFA]::(PYSF$L+P&&HJ<-H&_8N1:
M]RQ::I_W!GZ;W0:O8\N\W/Y,DEU6:ULK>^@COLO^\0BWD<R+BR0\$R.KG:0"
MX<1SU;+F7S",P8]Y<5#A;A3C(PS);;3@.N9+JL@ODDE1;Q[M]'/U%&UJ=2<8
M>/CJC`1\.8[A\"QG2QQ(F1+J/V;+<ZO<0:BW3+6`22.ASM[5,?#A0-&\[?`O
M$7(/LO\`(O-'<;?>T#WA\XRZ!H=ES-/87+!8&Y<]K'L`=;-CD#WW,SY0&0E@
MC:`YSGY6K6XW\UF(9XTY827)_$[["V9.&RK%/*&+X2<0M#6QEL3SW,IIZ5-K
M%:I.%+!+'20$%!,DDFNFN"ATC=DD',3&V]R_48S#=6GGL!S5KL+3O!V;%<\V
M^Q9?S\W<DVG<[K<?,/('/S7G3]0FA=;N@X#.)=>MPC,6B"(.?V:.<YCHRUKQ
MBE,>^:5E>)O>`F'*7C=5,.XPY0RC&$Q1>Z7E^$R-*5^=G4F3BKPV3ZPS(1]7
MEIE*1;@8X@D9`RO:F()J@2G!KUT)H6ZE;MB@N#1CFO#R"<0'BG9)]T56:YI]
MC;DJ]Y:YGN>YGFV]U[G'DV%\NI6=WI<UC'/#"7-N)=/N'$LG$18^@!<'AN#J
MO9FBC49F&@^2_G[2MLKJETK,3C-@\G*?[NOZZ%ABVT#)'?0J<_'I.'T$+]$H
MI^M()F42WZB@(AMJQ@+6W^KF0%S`T5%2*C*,*[JKMFN65_J/=%[,EGH=V-/U
M>XUA[(;K@LGX$CIHPR4PO+639#VN&]P:[83BGHKGF#M.*O#KRWU<1\9U;#7>
M1B[BD5S%[;),G(S]3(6PF:L(J"LLY$@:TRDH_DA*0\@+1-,QP`QN@!$*L>LB
MPTS3_5[>K+CLAF<DMP)%"1VC7IIT[EH&J>R_-WT]_7>PSGGF\6NJ\IM;=SZ@
MZPCCAN:P9GR36\,E+:.-D>(@XCB`:#,:*3F#O,.R9.\HLG\5.5>!8;CW=:)B
M=]FZ(DJ]D-#(=?<8_BT6SV1"7DFS-JW*_;QKH504;B9,RC=9,Q""4@FR-EJ\
M[[^73]0A$,K(^("'9@6^$T&(\%5R#O)]E[E'3^YO1N^GN5YFN.:.7=1UQFD2
M1SV3K&9M[(7,9PHW.<XL=(W*6O`<`^-P<X%P$:_^^0RJXH<AR:8<3HAUPJC+
MN-64O)\Q5]OF]:OIS"4"K?T,3*)^M&BR2"Q2>!OT@(["OL!SEL#S/<"$ZCZL
M/V.#YV<<3+6A?D_!W[:TW+KO_L-Y,CYAB[G[KG:=GM!2Z=ZP+,:7,[2!.8C,
M+)VI`Y>)PP3GVTV1U+6F\"MVB&MU<K]LKKU*1K]IA(BR04@FF)2/H:<8-Y2,
M=E*;VQ/'9NB&$H]I1'8>T-;='(U[1(S%CA4=1&"^<NK:7?Z%JMUH>JQF+5+*
MYE@F8=K)87NCD;7?E>TBHP.T8+<^/]4@?8`/T.[45CUNVZV[%/?<?TQSOMZ1
M%/L[-PV].B+3>,`#V#MW;]O^Q]31%^P<"7VP"(=H;&[NW</2&_HT1*@%3`W`
MYC?;%3,._=Z!]/9V:J1M.8'<HA8@*&.FH("`=0AN(^Q[&VX!W:GE\WW4*]$7
M)&20N5C;[^U33WV$PB`!V]HCTZMLJ@D^L]47.8QC]YA,!>XI0]`!W>C4R+Q\
M7ZI?T?\`=U%%Z)*[*$[2_;!W;_[`ZE(JBY%>KZNK&A53M*<.%9<"8>QDAU_:
M4R#+MZ/:LR%V'M[._74]+BKI\).-8F^0+`S.I,[HS%/A7[09F$DT6'QF#J(E
MB*)[[^&H:-=`10F^^QBCW[:I7S'Q6\KAYN1WD*R6AN!UJR'_`*R#]*Q<N_EB
M<AL9<7.:L#F#+DR_@:5#0&3(IY(1D6]F'97T_`2,7&HD9,"F<&*LZ7`IC?:D
M#M'7F#EZ\MM/U6*]NR1;-;(#05/:P&`Q7ZD/;,[JN=.^?V=KWD'D&WBNN9;F
MYL)&1R2LA860SQR2$OD(:*-:2`=NP*^VQ>;EP\>RKEU"YVMB+)8XJ)H.Z);B
M'2$VXB0!(U5`Y`$=M=79SWRNT#&7_9N7Q6/_`&UO:R/_`.C:9_\`V-K_`)RB
M'YI'+^/L/$'&</0[>\GH_DZ^5GV;Y0KN.=GQK2)1=I(^M1KTB;UN28MS=)N`
M*`4#$9J_;`.X8+G?F*SU'1+6#32>#=NSDD4/#C)W;:.>`.I>CO\`MX^S!S+R
MK[1_,6K=XMK%%J'(\#+8,:]LL8U&_A;(PMD;5CN#9N<^K:Y73,.!&,([/P0C
M(;RH:5RC!J8,KO\`)[N[RJ*:?B+#A*<,6E0R:QBG'P0:34822#<OZB],(^C6
MH.T68<KLUP#M<<N=M^A=V&^(T=[NU>UM(]JIM][=FH=PKIQ_A1FB-M(149?V
MO`#>3&NW,Z![K>E?/A`I52\X<YU-E;RG>7F*IEX9Q:./.*K8SCP.<QEU\<6T
M3NH/Q1'M,G$3:CIJGW]*7AD[``H:V'E_41)RE?:6\_G8(9:#\1S2YON`U'B7
MESVG.YX\E>W]W==YVFQ9=#YJY@T\REHHUM_:R,CF!.S--#P9?QG"0]*BQY-_
M)O%'&+)N=9[*V0&./F5NQ1&5R"?/D)59.0E$+G$2BK,@Q31XJD8C-L=3<Y0+
MV>SK!<G:A8:7J\EWJ3Q';NM0T$UQ=GK3"N[%>B/^Y!W,=YG?5W=\NZ+W8Z5+
MJVIV>NOGF8Q\3#'$;2:,/)E>P$%[@V@)..RBNOE/-HX@5MG(R;_.A[;X$>^5
M+68*MV.77GO[F4`(<IW48V8)FD1'PMW!RHAU;G$"[ZZ5=<Z\JLMW&*7BR`&C
M6M<2XTV;*8[*DA?)[EW_`+>?M9:MJ]M:S<N#3H'SL#KF>[M6L@&8$RD,E=(>
M'YP$;7.)`#14JB'RI<>6#,WF&TZZ5*!4C:E2+%;LGV<Z2&\?5JV[0F6\9%BX
M133:(.W#N61:M4]@\02&$A>DAMN8<I6\USK\#HFD")SI'`;&`URM)_R@T=-%
M]AO;TYLT?N]]D+5.6>8KQL^NZI96NFV^<CBW5PUT+I9@PG,<K(GS2.%0RHJ:
MN%=USLGY;FUYD;+"F/EQD(2-NT!@:E"U434;=3>5!.Z6(A@-X`(C-+OES*"(
M`#5J3J'VHCJMS)>2Z[S*88#5HD9;Q[=@(XCO'F/^3[JP?LD<M:=[+GL7R=X7
M,T7"U2XTZYU^]#L''/%FL[>NVO`;!&`<>+*^@QHM/YA>&1\O[GA!67#!QC:F
MW/1LLXL7:I`U2:J1(MF,[#G*454MRS\,Y\4@"<!;NR[[]0ZM^8;&30]</JP+
M(P630[3@V@<*GP@^XY9_V1^\B+VL?9:NM'[PY!=Z\\7VDZKF`)=QL[X9:;/J
M\T>0_P"DB<1LJNGRHY'A<I4ZG7:OB56$OU2A;U7"B<%`-%SC-!V\BC&+N!EX
M9Z<Z0@':`D'^UUZ-T#4X]3TV*YCH8I&`BGA'WC@OSC]XW)>J]V_/.K<A:T"-
M5TC4)K62H\XQ/+6OZI&97CI#A1-KC98S?E'R@6;G$A`QKQL%0P]@^&+;(H&(
MIL&XF(4!`-@W[.S6XZLW+REI(&-+J]_^X7)M+=__`+=JI.SU:S\DR9^F<G.9
M!KP]4<T;(\7CR]9KH]AI)9O$C^7;1&!&,Y9J%::LBZ@?$D&4O/&CX*>!Q*$:
MO6YI94"E]704,GN=QR[R:W3VLM[BUEU.VL)&39;@-S7CF,FC?VP&.8RLT)$9
M<TB,$G,X`X.+7.:/7#))%.VTGNVOC!A+LMJTN8YII4M+Z1O`=E>'//Q159D%
MSAY1WQI6D7&!I]@TG;+=:[/WIEBS,L(ZJ-:8U6MV"KV)>&=-)LRBTO.V!6M>
M&*ZWJ\J7UPQ1:(.2!2U+N^Y3A=),R^B=)%%%(V/CVSN(XOD9)'F!9@UK!.3E
M&:(Y!VW-*C:<W\PSMCBGMBQTCW-+A#/^;%&%KCYP!)<8Z9C23M'LAP2NP%RM
MS[?K99:S?,:V^I0U:QG2K`WDK-2+G6WWQG<IQ+2<@)22L1/<BPNG+ATH]:+M
M$VA_5TQ$Z(=Y=>YKY.Y>T;38M0TRZBGNIKR1ACCEBD;PZO+'L:SM,``#'-<7
M@.PS=.5Y;YBUG4KY]G?6\D=NR`%KW,>QV=N4.#R[LNS$ES",M6BN52Q)D":E
M3%<+O'!79";@B*YR&-U%`03<%`=]A$H;AV`/IUJT>CVLC0X-`-%M[IY*T!P6
MC/=K08SCUIZ<[A4P)@43B`(I&#HV2$>P#F*/2&W<&IOV3"QP+FBBD$\@WIEL
MG6CJ?MX-)4#>H$*L^,4P;'?+E*;H$?[(6Y#;?7U6CA8Y^6G85/,3UI)1\AZO
M%.G0F`/$`Q"B8VP^@`V[0#MU!UL21DZ5`.-4F#2H`(]1^T=]]Q#?MW'<.WMU
M7=`Z@``H%$2`A;J-DP3*=8P[AL.VX[>C?ZVW9JW?&[-0*.=:IS.>*L8WB=PB
M`;"`]W?Z0'?MU/PB&T(P0.&]8XS'LG]G81$/_OA'[/=J5L-`.CPJ)>%[IR*B
MP@4IQ'M[_0'U?MA]G4,C68G'!&NJ<5O&JR:>QUU0[]]MPW[/1MVAZ-6SGBO9
M4RV83J9"@5#;^UZ@'ZP`/8/=JWH7%35HO$TN4/TQ9?NW`2B8`W]D1^P.IH[-
M[CX%)F;L*UKFTE((HH&#L[-P,&^QN[N'MVWU>QVC6BAVJ4O%,$L\;3RA[-&B
M941`[DB8AU=FQP.3M[1#O'4DL(I4*+78XI[92:12AF;57I'9R_2#N'<"K&``
M](@(!Z-6.0B09=E%5+R13<D61`/#5<E#8O:._I+VCL'?[&J_#=@H5%/"DT:6
M'QS@`@/0(E'<W9N&P;&V,`=XZD,+F]*---B6]525F7A"$_4DQ`ZIA^U`H#W"
M(]FW9JV<QQ-`-ZJ<0'!P3]-%2;HL&H_I*>Q3&+M[80VZA[_9#5<09!F=MHJ;
M'D4:-E5L9^>2CFI&:*@>(H`=0`.VX@&P]XCV!JSD)<Z@V*Y2)1D>LVXJ>GT^
MG?M]!A$>_4F6C:#:I<IS9JX)0-7O8':40';T[!Z`W`-PWU2<RHQV*J'$;$KF
M3P#%[!W[`#O#L[@]D?K:MW-+>R14J<)11TB9!9%0#=(I*D,!P[1+TF#<2]OH
MV]`:I.8":E0>,S"!M(*@KY??'/)^&,F<V[1E*NPC"/S5GMYD#'JJ,M!3RLK6
M5G5A6%XNV9+.5HA;HD$A,@X!-4!,(=/M1UJ6AZ7=Z?=W\UVQHCGN<\>(=5N6
ME3T&NXKV9[4??-R/WF<F=VVB\CWMQ-?\N<JLL;]IBF@$=R&6X+&N>&ME%8WT
M?&7-H!CBDIS(X3Y(YN\M\&0V18QU"\+<0TRP2TC*UJYP\19[#DN>24,9K&1+
M55:=B09J,X],CP6_0":*W2(=8"-GK.BW6KZI"V<4T>*-Q):_*XR'8`!B*#>M
MP]G7VC^4/9S[AN9+_E2=ES[0VO:C!$R*XM)9;>#3X2.U)*X"&7.'SN,0?F+G
M1U!RD!IK]Y5L[QQSCQHY(\'"W:[62@9&*AEFO9,RJU>.)/&$FW%K*!&2MF58
M)@";%P\0.U(=05%'*:A2;IF'5A)RT_3KNVOM&$CY62?G!)*7$QD4-"\GQ;UT
M+EGVUM.[VN[7G'NE]H\Z=I^AZII.;3)].TUS1%J,;LT?%BMQ(<7MA>)2&AHB
M<QSJ/"OM8."E4*8H_I?6!@Z@#J`G5N'4`"(=0!W[#K<RT.VKYED$LH?.HJXN
M`W&W+V!^07/W(&3(*.AZQGO/+:^XT>L;!$3*\S6DY*WN3O'K&,=.'4*L"$NW
M'P714U-S&#;VHZUS1M,NK.]OY[AH$<]P'1T<#5N4"I`V&NXKV%[37>[R)WE]
MUW=ERQRA<RSZSRSRTZSU!CX)8FQ3F.U:&L?(UK916)_:C+FX`UQ";WR^.'>5
M,,T_G)3<YP3&NQW(O->0)^M+0]AA+`N]HMPBIF*))+>XSUS[GN4TI/K*W<"F
MJ`CVE#MU1T?3+JTCNXKQH:)IG$4(-6D4J:;#CL6Q^U-W^\E\_:]W<<P=V]S+
M=77*G+UE#<"6":`,O+62*3(.*QN=I,="]F9I&PG!5ST?RN^36+JB&!6?!GAQ
MEN0:7ARO"\T<C6@CU!3'[N7,\.A:L8IO&5A>3+9@844@2V.B40(4JG2"PZ_#
MH&H6\?J8M;65P=03O/Q/QFTKF`PVT7KOF+VQ^Z'G/5?^9LW>+S[H=H_3FB7E
M:PM\CA>MBR@V^H%CX&Q.>,[BZH<:N)94QB0O*3@IR'F.4&.[=!X"QKRWXWUO
M"E0QE3<'VS*\EB+&.);A78]FP7L:E13DS^Z%=*Z;JN4T2@].L@X%)0?$12$V
M2U'1[YVH1S-BCN=/$#6-C<\L:QPVNRX@@X=-`%R#N8]I7NJL>YO5="U+F?5^
M1>]J[YANM0NM7MM-CU/4-3M9WN>(!<F,9)RUS8W/)B#7Q\1@RR/II,)^7/R9
MJ7EW<Z>)UGK%&@+_`)8RB\O&*UJ]:XMU1K&Q*C53H1D>H#@[ZK,?$JPHMRR:
M:*B::Z76`=)Q"C!H6H-T*]TQX:)I7N+"",I!I0=+0-@KNHLCWB>UEW/:Y[5/
M=MWW:/>ZE=<L:)HS;/4A/;2-O('DW(=(\90RX?2YS2&W<]I+'Y2:M!4CSC/S
M2R['>68O=\%5O&[OA]E"*87AFWRK5)\[G'M9BJ.Q97=,4W2`JOY96'=B,:V]
M862!,H[B!P'5>33M7N?V:Z6%C/59JO&<'LAE,WAJ=W1BL/#WR>SSR)=]\$?+
MW,MWJT'/FC2/LWNTVYA#;ZXDO'OLS5IHR(2Q?[Q)D:[,<`6D*8N,>,&8J[YJ
M7('E=-5^.1PGD'!D11ZG8"6*&6DY"SLD*B15HXK23LTXR;IGB7'Z<JB1(W0&
MQAZ@U?0Z?=Q\RW&HO:/5'P-:#45+@37#:!T'[CPWFOOAY"U7V*^5NY>RNI7=
MX6E\R2WEQ`8)1&R!SKHAPG+1"\TE9V6N+L348*ON)\I_D)</+^RM@VX,*A4<
MRMN7D]R*Q9$3%BBK!4[9$&C$8P(.PR,"Y>MXI&PLEUR!XGMDE$B`J4A#F,7#
M1<N7\NBR6<@:R[%VZ5F(+2,Q(!(V9A@>A>I+WVV.ZW0?:<T7O(T.6_ON07\C
M0Z'J,D4$D-S;2\0R<:".9K'2&!X8>S@YKG9"YS0"]'$CA_E)AR7QQDR[<`^)
M/$B@XO9^OR;^KS1<D9)M5_;)K)L)RAR<7+BA4(U-=0#G*Z*L!42B4HJG/NGD
M-,TBZ%\R>:SM;:&,5.4YW%_2TBE!UXT7->_7OZY+N.Z'5N3^7>\_GCGGF?69
M,D;+B+U"PMK)Q!?#>QR15NI"T4!C+"7D$AC6T<H^,_#;D#C7CIYEV.[96(EA
M:^2F4LPVG$C%"V5]^WG8>X0<FQ@EY!^R?KM(!1TX<D*8CPR2B0#N<H`&HZ9H
M^H6UGJ$4[6B2>>1T='`U:X4!/0?`=BP_>][0/==S=WL=T'->AWL\FB<HZ-I=
MOJ;S;3L=#+:S1OF:QCV!TP:UI(,0<UVQI-4R>2N!7*EWY<G!W$U:I==E\X<6
M<RQ.4;+CIQ=(%HUFFD=+65R6.C+85VI`G<"20;G/TK&_2S'Z.HY>D;*;0M3_
M`,/V5JUC?7;:1CW-S"ARG$!VQ=$Y0]ISN6@]K'O'YWUC4;J#NXYSY?DTZWOF
MVDSG0N?%;MXDEME$P;5D@%6#M!N:C347TXLM-]LE%JECRG3&&.,AS$820N-%
MB[`VML?5IA9PN92):6-HFFWF4D4>@16(4H"81+MV:V^!\SX6ON&!DY'::#F`
M/17?UKYI\XZ9RSH_,M]I/)>H2ZMRK!,66MY)`ZV?<Q`"DKH'$NB)->R2<`#7
M%5A^7!PFFL'P'(@O)#$&-7ECO7(ZWY!HKZ59T?(+TU+EBIGCEP?E1E3Q/4ZZ
MS>J'.0Y1'J,4!'6%T+2);:*;UZ./B/G>YNQW9)J,:8=6Y>Q?:S]HS3N\34^5
M3W2Z]J\>DZ;RG:V5XR-]W9,%W&2'C(3&):-H.(`01@'$!.+YJ_'/*?*/B0&(
M,&UZ)F;<EDO'E@:PSN:A:I&H0-:7?B]%!Y*N&48@1HDL0"(E$!$O80H[;:GY
MCTV\U#31;6;0Z7C1NH2&C*UP)Q.&`V#>M3]BKO<Y+[F^_+_'?>/=SV^A.TB^
M@=*V*6YD=-.&9*MC#Y"7$$EY!%?.(K55\9UDL]53SJ*!+<?:=3\A9%K'"""-
M)8\N-F&HQMQKS-I88^QP,7;`:O&L-/E.<B[)=8GJQU$.@X@!]]8F\-W'S0QU
MHUKYVVF+":!PWBNX]&Y>IN[:V[LM;_[>^J67>CJ%_I7*=YWBS".^M;?UJ2UG
M<Z"2":2VS,=+#0%DK&'B`/S-!+4L&'EH\@N2=#Y^Y)Y'EIN(\X\R#TLU%H$%
M-C:*_CE+&4DTFJPE9I^.]83=A-.8UNT7%#QE$42F7$H'-X)3=!OKZ&]GOLD5
MY=`!K0<P8&8MJ=Y)VK!7'M>]UW=)S)W8\I=TQO\`7>[GD(70O+V:'U>>_.H1
MOAN#;POREO";(^5F?('.(C!+6\0I?CQP&S>?(V"(>^^7WPSPG6L4N(EQEK-1
MIE/(]CRH\KGJ)X^:QY`1,PV6JD_(/&`./%7ZT$EES'/MX94#2V6D7?'B$UG:
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M]0`7;<=]6IT;4/5=*CR-XEK(#+VA@*$8'XV)"V2V]ICN?CY^[\M>??W'[,YX
MTET&D.]4N*SRFV?'21N3-;C.0,TP8*8[E(R\\-\HWWS.,@YYEX=FCQ[OO#>P
M8$>VI"P0QII*P6*.&+=MDJR+T)P"(MUSF*N*((")0]OVZR4NG7,VO/NW`>HO
MM3'FJ*YCA3+T>%<CY<[^^3>6?8\TONTL;B1W>EIG/\&M,MW0R\(P0/XC7&XR
M<&I<`"S/GQ\U5B43RQ>3.+ZR3`*?!SAOE:7;7=96'YEY%LX2+(V/G$MZV="S
M8U2>L;`]F$F`F23\,`52*<"%*IT%6'7X=`U"WC]3]4M)7!]!.XU[%?C-VEP&
M%%[$YE]L;N>YQU@]YS^\?GW1+%^G-$O*MC;Y'^NMBR@V]^6/@9$7T<[-V7$%
MQ+<QC'3C4:\QI=3J]/B6T>QC*K786O,640T-'1+9M$1R#$B,3'F7<F81J?@?
MI"(J*"DGL43F$.H=]C8(XVQMH&M:!A@,.A?'77]7NN8-=O=>O7RR7=[=RSO?
M*[/*YTKW/)D>`T/D->V\-:'.J<HK1*$JW:("/9W=_=]<=7$;#YVY8H+>LU?[
MD``]"J^WV4Q[M^_M#4C_`#E`K0^/V_;`&_HW[?J^D-2J%=RS&?Z>LF3?L`>H
MX[=P%[1ZMAVU,T%QP44H%7767H((`4?:AN'88">G;O'ZG=JY4R\"N`.81$VR
M"0=I1-MN("7J,(AMN`B/V-49#CE4"M*]?BX6[#`!"`!4PW[-O9#8>W5)2UW+
M#\81[Q#]'_=T45\\7ZI?_=]G1%ZHJ[*DV$OVP>G_`'=$7)+U?6U8U*J5*DQB
M.5!+%^/TQ/T]%4B`[Q`/:MP#_8UV#1F#]G0'_5-\@6O3D"9Y_&*>6)DP6]:`
M#[C[FR(;[#V?W`Y[^WM$1U'58@;64[#PW>0J^T)U=;LOUR#],Q<V/EW<<L9\
MJN7L7A[+CNQ,:/*0>1YN1=5:1;1<PBYKD*_E8\47;MF_0*D+I$H*%,F/441[
M0UY+Y>L(=4U.+3[C,(GM>>R:&K<1CY5^J7VNN^#FWN*[@+OO'Y);:.U^UN+&
M-HN8W21%D\T<3ZM:]AKE<<IS8'I5WYO*#X!)V(8%21SL"GK)42F"[06YR',`
M%4(8:GTB&W;OMMKL#>ZC2W1"3B7&(KYY7QX=_P!U;VDF'&WY:H/_`$<O_P"9
M7/\`\V;947^;7>,\:OI>2PUQ\8GPOBP9E\1Y(N:Y6YV8DIJ2=NT$DFRKJ;MT
MS(K^*DF4HHF2``V*&N+:HVV;>26UJYQT^"L,>8U.5I.8UP\YY<:]2^U_LTZ-
MS)'W8V_.O.\-M#WD<V.;K&I\",QQB>X@B9!&UCG.<!#9Q6T1:YQ[;7G"JG%8
M?.*EK'A]?![OC'CE&B*XP-BA*/0MUF+ZO7"P7N&T63*+04QD&9"$7(IMVN"`
M80[];,[GESM,=I'JUN+-T62F=V`I2H\(V]:\FZ9_VU[#2^]6'OCBYYUQW.<6
MN?M0R&SM:/F,_'>P]KZ-X)B(&/#/2JU<%9JD\/'RJP14=J0&6L/7G%5FCT%E
M"I.4+"P*M"NUD"G*DN>)L#)LL43@/07KVV$=:UI]XZR=(Z/M,FMI(7>$.&!_
MR78^->VN]KNML>\R+0)ILD>J\O<S:?J]M(1BUUI+^=8#M`FMWRQD;"2TG8%+
M?RSN)&&^6UWR[!YGG[G`0E!QXPMD4M2W,:U>.9)U:(V%40>GDV+],6H-'AC`
M!2@;K`.W;65Y5T2+F#5)-.G+VL9;AX+#0YLV7&H-1X,%YU]NKVD^>O9HY)T+
MF;D2WTVXO-2UEUK,V\CED9PFVTLW8X4L1:\N8!F)<`*X56CYN\*"\/[A4[94
MI57*N$+1()>XLM/LE&#IM,QIBNY"B7,L.Y;="SQFF91!PV4;BZ:B<2>&HD;:
M?F?EF\Y;N6QRDOLI?,>13$;6/I@#3$$;1X5<>R'[7FD>U5RM?Z;=Q1Z+WF:=
M'_O-O#('@PR=F.^L^*UQ,;7D,>R1K^%+E#B]KVUN1PKS9X]TWR_LAY6X\X_J
MN";'C.%)$7+&D$*BSQ7+-D!U&4B:4GI)5]/VR`D'SD5V:\BLNLBFW5;GW%,1
M-MFEZ[HUERG=7.G0LMK^-N0L!J>*\96.!)S/!/:!)J-AI1?.+O;]E_OQYM]L
MSEON^[VM;U#FCE+5KEUS;:C,`UG[*M7-FO;<PPM9;6L\;&MAECA8QLIDCE;Y
M_9H#XF<H9#BWGJ/Y`&HT'E*SQ3.Q^H,+7(/V31"=LJ"C5U9!<,"'<'DD$'3C
MP^X`.L)]P,4-<\TF_&CWC+TM;+,QKJ!SBT9G;7X;]OC*^PO?[W'P]^O=7-W4
M1ZI<Z%HEQ+;\5]K%'(YT%NX/;:Y9"&MC<YL9)&(#`!@2GEYO<_Y#FY$4%M9<
M/5:ASN/I&:7C;)`6"8E'3R'GT4!D()XWDFY""V]>9H.$C@?=,Q#@`?IAA#(Z
M]S([F%T+IHXHI(JT+7$EP<!V37<#B*+EOLL>Q_9>RS>:P_0N8M1U;2-8BAXE
MM<6\,3(YH"_).QT9+LQC>Z-S3@1E.UH5M'DYYJ)D#`<_AZ563<6?`5H1GJZ5
M18H/W&.;P\64=M$$^KQW36$L)'(&'M*B1ZD7<`Z`UT;NKU5I9+H\I[<+L[!^
M(\[N@-=4>ZOF/_W6.YX<L]YVF=[VF19=+YCMO5[HM%&B^LV`-<:8!TUKDZ"X
MP/.)S%6<8T9I'Y9<J$@<-!0#&W&82K.3>$D=%1KD,3=I/U0W1W[[#OKT-JL6
M;E?3&LI]9O??X"^/6F$?XNU3]6L_),H58_Y'<]</Q,G8K-1KMD!"QH(FKK.R
MQDO9XMN@]R#DYBA8#1E-HU!D:(#*.K\/"N859Y++^%,-98JBB152'WVZY5[O
M-0F;#:W$-J8O/<QS&.+N#`3&#-/(V8.+Y)6RM;$`8WPY<U"-29S)SG9%\TT$
MD\4A=PVECW-#!)*!(YL<+7QN&1L98725#V2AU*A25M'.3EA%M\M;<?9(\M1[
M'2XV/1:U+(<K7HF%L2TBU7DI*8,\A)"WOF[ALBFJVCF#9!BDZ*X\=REL!]=M
M.3>3KH69DU)K6W$4KG5DMVO+HPTAK65<(PX$D&5]792W*UVS+3\V\R1-N1ZB
M>)$]@:`R=S:.)!<7909-@KD;1I-22VA.;"\G.464\BR^+T,.)U06#^B,WD[?
MJ1D`E:KKN5-/)W-D63;SZ+*W-$C1":D7*IGC$#HO$E%T2@8`&RN.5>4-)TMN
MK/OC-(8I7\.&6`O>&Y.%V2"8W'.<\;LY!8X-)HKVWYBY@O[MUFRUX;.)&T/D
MCF#07!Y>2<`]HRC*X$5S#,&[$S3W-?)1S6J]DJO8CC5).N+9,/E##Z6+\PQT
MBD2(>X\915+/8)5D+>8NZ"<L^<1\O$G<0JY"K@=%;PR"&:AT+E2.YET^>Z(;
M)P!!<>LVK@<PF<Z7*QW8B.5K7QR@3-);BVI6)GYAYE%HW48[;,Z)KS);B"X:
M<"QN0N<SM/&8N:Z.L9`=@:!3'M[IG"3RK7Q"/$&SGJ16*)3&(!#[E`X`.QP#
MLW$!VUH\$INK9I<TAY`KXET*4<-Y:#454/;DI*-)Y\Y?=:I))VLY0=E*)DUB
MK*"8`*8-P`Q`$`Z>S;5)K>$'%`5D2\T#&$9-A/LHN!3B'I$.T0`>X!V^OOJC
M$TF3-O4#6F"1J<V0Y@*)P,(CV=^_H^KML`:R((+,!B%(T@)1.)Q)NR`H']N8
MO2`;[#N(;[AW:IQQ!\N*F+AN6B))>,;V@B(CV;@(CL`[=^PAOOO]75PZ)M.B
MBE)<=E*K:(F```ZRNP;?:]O?VCOWZQDSF@`-W%5,2,=JSTYI%(2D1]L("`;]
M^VWZ/?JPD-3X%,U9AWP]/C*J^UWW[Q'L[]O0';J2*%\IH`IB_P`"URUF00`2
M)F`P]H]@?6[Q`>S68M]+)`.]4\X(6G7GSN!'J5';?L+V[!V@([>SWZR3=/<U
MO95'/EQW+#]TA$>DI^KV`V$.WV=QVU2=9N;B=J,E:1AM4@,3(HG?Q;U90`$'
MS?8HAV["H0H=VW;N/I].K*>`-8:[54#NG:H]Y#Y5V9ER7J^#:_4<?2E'F9^-
M2+=GF36:-NDVTY7VEL>3U9IK)JZ26KC*,DB)-%G;A$\L\:.DFH&Z4Q-K/K!%
MZV!K6F,TQS8FN-0.KQXT5V&CAEY)J/`IX0!4'\0J!E"@<Q#;;C]3N#M[]OZF
MLL9<AI3!4ZAVY-FE".W<N9LW$PE.N("?M'8-]C&#MV[M2/D;12AO:S;D_,6D
MVKT>DQ:"`NE"!XRW8`F$>T0``[0Z=0BMR3Q#L4<_B2J0DV\)'*OW*H%';<NY
MO;&,(;@4H;CN(C_4U3NL.R%,P@TZ4UKNTJ2CU1<Y]P.<.DN^Q2D`>D"AN(=N
MVK`0FAPQ*N#(T&B4"+TOAD.`CV[!OOZ=N[Z_9]?5!S2TT*!X)H-JW[*0*(;;
MAOL'9N/>&V_I[NS4C]BG2QC'Q0$"_P!L7?O[^T!]@>T-6[FEV-<5%*I!QL<O
M]J.PAOOZ1W]GT:H$4&/2HM<!AO2I9/\`PS$,0YB'`2B4P&[M@VZ@'<1#MU3<
MS-V54*<B,D"O4A4#I\<"_II.WI4#_A";?:C[.W<.J;XMA`V)U)1MEP``.F;<
M0$`.0^^Y?9!0@CVD_P!^'V0U;NHZH"F8ZA\"V0(D,`'3V1/W"41V3.80WV*8
M-P+OO_N!JFYA:`>E5\[:H\8R9A(H`D-ML(#W[^CLW$-MOL:I@$BNZJFJO%18
M!#L^N`F'V=OJAZ-3EE1X$6Y-.P\3!*.IZ8BH5B51-'UV8DF<6R!90#>&EZT^
M7;H>*H)1Z2]6YMAVWU0?E:PE]!COH%=6=A?ZE-ZMIT$UQ<T)R11OD?0;3E8'
M&@WFE`D[&S<---Q>PLQ%S;+Q#I>NQ$BSE&?BD'VZ0.6*[A#Q"[]I1-N'UM21
MMX@JP@TZ,5"\L+[3IO5M1@FM[FE<DL;XW4.PY7AIIX:46090`#O$1^OV"(^C
M8-71:`*':K9;%DU*<I73H!*W`=R$'VIEQ`=M@`=A`N_;OMJFYN;:I7-S+8`N
M#A43_:I)AT@&X%*7;VP[;#W$V^L.F5O0%,``*+3/)ELCZR]>.FS-@S144.Z=
MN$FS1HU3*8RCAPX7.1%!$I0$QCG$`#OWV#4P``)P`56&&:XE;;V['R3O<`UK
M07.<3L#6@$N)W``DKQ*Z0>)).6[A%RV<)D<-W#=5-9NNBJ7K26061,9)9%4A
M@$IBB)3`.X"(:G#`14'!2R1R0R.AF:YDS'$.:X$.:1@00:$$'`@X@[5^!.4-
M^W?;4>'X5)5?@RR9"B<YRD*4HG.<YBD(0I2B8YSG.8"D(4H;B)A``#OT+.A1
M`+B&M!+B:`#$DG8`-Y.X+!2L4&M%JS#><AEX9(%#*RZ$JP6B4B-QZ5S*R23@
MS%,$##L<3*`!1'MU1SLRY@X%@WUP\:O'Z=J,5V-/EMKANH.(`B,3Q*<WFTC+
M<YKNHW'<OV:8CQ8#*^Z+`8D&OKPRGKK88P&)2>*+T9`%?4@9E2#J%7KZ`*&^
M^VHYFY<U1EI6NZG6J7JMUZUZCPI?7L^3AY'<3/6F3)3/GKAEI6N%%Z>NM_5@
M>BY:E8BD1?UX[A%-EX"O3X2WKBBA6W@J]8=)NKI-N&P]H:5%*U%%*()W3>KM
MC>;G,1D#27U&T90,U10U%*BAJFU'!&*%<S-N1*E(BOEH:U$U$:Y"]9D?=9.G
MJBL8T(1N5_[E&:#ZR<>H6XJ>W[#ZMC8VAN_7C&WUP,RY]^7HZ*+<V]Y7/4?=
M\_NI;J4P[O'WXO76.6/A&Z%/SV;)Q0X91AGRX>:GE34*"8]2X;AN`[#V#N("
M&W:.P[_8U,_`TW+12O`'J8'Z`,8PB/8`"/=[`!V]P#J&4AN8["BS5'Y&Y-M@
M`Y@`3"(CN`#OV#[`[Z@`2:!%B^Z`#W[>CT=HAZ-AW[>S42T@T3?BOT#HI@^V
M#O``#?81'M]C4*4VIU+]@L0P[@/I]([]P;[#W>QI0E$"*8]O9V]OI`/]K40T
MN."+\B4@]PAO[&^^_P#5[-507M;DHHK9,MBH[%VV\53M#M`H"00-W#V[B.HM
M87M.;:%"H)R[UHC(&$WM#"81'N`!V]GL[0]&J65PW8*0L)-=ZW#=,Z"?A@;9
M57;Q#AOL4O?T%VW[1VU69'39B5,W-\9>ZBHD*/3ON(`1/L$0#;ZF_>.IB*8%
M3K7/'G@I`U)WCL=00'V=O:[_`&=4I&$FH4"M,*P=7VP!]3<HC_5VU)E=T*0L
MJ:H\<O\`;#^C_NZAD=T*:B^>.7^V']$/]O4PC<4HO1)<OB$]L/VP>D/]O3AN
M\"C1<FG6'U?_`'?9U892JB=;&$QTXZI90$!\*O1Z0^P`$3$/JB&VNPZ(?_I]
MN#C^:;Y`M:N3^??\HIZ:M+>([53#VXJ,7Y$R%ZE#J'49KID(4H=HG.<0``[Q
M'LUD-6AK8R%HJ[AN\A5YHKVQZU9R/(:QMW`22:``2L)))P``Q).P;54?Y76*
M,L8YYDI6Z\XPR+3:VA0,PH'L%GI5C@H<CE]6)!NQ0&3DXULR!=VNH4B1>O=0
MP[%WUY5Y+TW48^8[9T]M.R(-DJYT;FM%1AB0!CN7Z&_^X-WI=V/,OLJ:GHW+
M7,>@ZCK#KS3"V"UU"TN)G!MU$7$10S/>0T`EQRT:!4T5L>1\U3]?Q3F&>J\'
M.VO)%<K<BTQS'5N'>6*8?6&<,$-$J!%,4'+EVWA'#X'BH@F8"IH")@VWUWKF
MO4+O3.69YK-DDEVYF1C6`EV9_9J`VI[-:UW47Q']F[DKESO![\N7N7><;VRT
M_E`W[+B^FNIXK:$6MK^?EC,LSF,#IA&(6@NJXR4;BJZ_*&XMS<#F7(><^0N+
MIN/BL=T]Q'U2O93IDBR;6JZ78ZS->138V9D@23]P(5!RH<PIJE!=TF([&`!#
MB_=[RK>7^LEU]!(VVAAPXC",SW';1PQH`37I*^P'_<E]IGERR[I=+Y$[I^8+
M&YU35]2#[B32[Z*1T%I9MS\-S[24F+C3NA#6YFYF1O;0M)5N-\N5:@7(RT3B
MS&CB!44]L!:!51/'G'VO@K%"*W*0?[$?8UW,\H:7'V7V\7\QOP+XC?\`-/O&
M/_\`T&M__/W7_FJBCS)>/5EO>7Z_F3"F+IF<B\E5=M\:X/&M/DY-K`V^L%1B
M'+EU&5Z.60BDIR*!JJ3I(0AU4U1^VWWX9SYRQ=:=KO&TZWE?8SQ`TC82&O;@
M[!HPS"A\*^Z'_;D]J#EG4NY>XY+[T^8["TY@T+4'MADU.^AADGL[FLT>62ZE
M:Z4PR&6-W:<6MX8-!1.1Y56.\E8JM/(.0R+CN]4-E,8GBHZ,>7"ISU::OWQ+
MI$NC,V:\PP9I.7)6Z1CB0@F,!"B(AMJ_[K=/OXN:)I;BWFCB-H`"]CF@GB`T
M!(`K3&BYY_W4^\7N^YQ[J^5[3D_7=&U:[AYBD?(RRO;:Z>QGJ4S<[VP2O<QF
M8AN9P`)(%:JPBQ5^G9IHEPPSD(!5JUV9G01>%V.ZKTZW$ZL#9XX3@($?PLAT
M*`'<HGUIC[4XAKMO-O+=MKNDR64H`<X5:=[7#%KAU'Q[%\C>Y#O@YG[C>\K3
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ML:.34H6^M2DO(>T$MS'!IJ*BC:"F&-5\#O;A]H_7^?\`VA]8GY)UN\9R;I;8
M]/M#9W<K()6P-K/<,,+PR037#Y2V05#HVQT)`J76#(>,[\PFZ-;,78W-`7&%
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MW[2F(4@]H>GT=NO7DTSCRII3OC&YO/+`OS*:<6GFW5"=GJUF?>FW*,M)Y`<M
MW$[*@Z@<OU>MWC+5-M&-E%J#$G2B<2.I>VT26J9'44C+O&[5<[>OS;A>;(RD
MD5)58";-4#"3<[[0>3^%''Q+&6YMK*2.X`F(+KD"*42#,6M)`X\0$1?&0QA\
M]PKKK->YG,Y)9=L@GNVOA_,[+<\2/*2`Z@S&%QSAKP2[#("0K9#E3R*KBN)H
M\M#R!<Y"YS.&HN8EI>D6<\6WC;!3,7HY"<*23,U?/4;'!6.U/W:S8[!X@H#)
M?<R14SE+BQR9RQ<QWTTMS:P.MV73F,9/'F<637!@%'9Q*QT<<;06O:X9F[20
M3>GFC68KBS@BBGECN'P-<]\,M&@QQ<6I`;PW![G$5:6D@X@`A9U?Y2<KY%_0
M(*\8WB8QO:QB)$TG&4/+,LU.[GJ]!R\7B,S)!\NK6;:X>.GS=2P21TX1J9F`
M+D3.;IU2O.4^4(8[B:PN7220YFY#/;-(#)'L=<YG`"2,`,<((P9G!]6D@556
MWYEYAE="V>`,CD+37@S.J7L:YL&5I.1QJX&5WYL%H#J$I2XAS_FG).*9*UY3
MJ2N,9YM9W,$SKAT)V(>IMFD9&.)%O(14XLZ<$7@YQVYC_64%E6KTC8%T^CK$
M@8OF?E[E[1M7CL]$N/7+8PM<Y_8<,Q+@,KF84<T-?E(#F%Q::T!.5Y7UO6-8
MT^2ZU:W=:S,G+&M(<TD``FK75.#B6AP-'`5'0LVKR!;%.J#*NMVQ3@*AE%>@
M!,L4Q@2*<WM2B<"@'V=6+HQ$T<,%9QQS&J6]UIC9LR(NT1)(,5$_&<QHJ>,J
MV`H`(N&1^TPJ)CVF+[&D8$KJ.V%2J)F2&;I(C:2CC'=Q21?"4,3?K:'+V`1P
M0`ZB!]7;;4SX.":@=DJ+7UV8IIV$L91P7MWZ=Q+W]FP#V`&_9OJ);V,*4"@M
MNX>+K*%*8YBD*'5MO_7[!'TZHDT\W:BS4I9)H4"E$#*=W9N(;AMM^CMJD^5]
M<#4*IE:TX+W"376'K6.*2>^X$$1[=O3MV]H:LRPO.&VJFJ!@O!6S,V?84Q3J
M`&_?WB'U0].KZ"RS4J%3S.*]4;-[HIBD!]A#L#M'M`>[M'N#<=9:&"*(X#;1
M4:NDQK0+3J2'0H<HB'4)A`=Q'^OMWCK-0Q0N:**EB.M?CW24#NZ1#L[C"'9Z
M1VV]&KX0-H`T*!)V+8L'YE3E,??;J[-P'<=]]]]QVVU:7=NR.,D;5,T]H="=
M.)MJ\8+06RIDC)+-U"])A#M*J4>H/]\76GW.;$%7<>)59UHEL'1WF%FC*1>H
M&L*T[(U&AV-,I==+-PLG.S>/F]@FXJ6L+**FE4+NZL3F1:RX.WT>VAF*K$R9
ME715VR>I6\-N_6!%&X!P>!0"M32I%<<:UK4@`4WX*_=G%N7.&%#XO@5O<5<)
M$K<I6X&*4>P!)OZ0W#N#?;6VW>AW`CXQ%&*Q9,T&C=J=:L/%F+4TD[V!PL'Z
M64P!U`4?L>R.L;!:=NIK15G'#'>EE&OQ74.Y<&`B2>YSJ&$=N@-]P[0V#ZFK
MV3)''C@%3%",$V]KNYY=^+5N<09-3="92CL!AW$!/L'?W:Q08Z1Q<[9_*JC:
M#LA8#"3[2]HCL'</4(#ML/L[;:E+"[9LK3WU,G$CG_BM0#<1-L(=HAL'Z.X]
MVK62.CJ%3`D&HVK?L7XFZ=A[M@[.[?T[[;]VK:2.G4J['9@E@P>["4>HP;#M
MW[;#V=X[:M7-IB%/5+]JZZDB*;AN/8(=P[=G?[;NWU3X;:8]*8+>M7>X[[_4
M[=^X!^OV:H.[+Z!3!V-"G"K;\"KD`3``=FPB(=/H[_T>T.[5S"UCFT<CB0:I
MR3)"/2L@(%W[QW$H=0CL!1_WAMMM_1JRN;<,>2.A3`U%0LEJ[4)NBN&Z6^QP
MW]L0=]Q#T;]NK,`@97[5%;@RA3$*FN0%4A[$C;AUA]0I]QV$/[7TZI/[)PV%
M73?-'4L%=KM[9%8IB_VI_:&^L`B&VX!H'D"BC15A>:^UKLAQ\PS%79"'7I[[
MF9QH:6AM8Q:?%]Q7'5Q51G$)P7IRL1AU8PZH.?&$$O`$W7[7?6M\RB)]G$)P
MW@FZBKFI2F;?7!>T?87N=5M>]#F&XT!UPW78N0=>=;N@S<9L[;4&$PY*OXHD
M#3'E&;/3+C10$SKE:J<-<]\G[9Y?$7C\,=P/$JMS>383%RT;8<,TG+LWF.(J
M-(NCV'A'RM386!A2Y)VY<($41*J@BF9QTD$PCB)[B+2;NXFT-K!`+8%P;C&U
MY?1KBT'*#E))V5PJO37=QR-KGM`=VO)V@^U/-JO^*KGGRXATZ;41)!JMWI4.
ME2W5Y:,EE8+E\#[N.*.-Y:\M>YPBJX`)?NN9G+2BX_O=?E;Y%RJ;OD3QIQ%6
M.1%O8X9D;-BNNYH;NUKY+WZHXQL<_0V[F!49HF@7+\44C(2"8K`<Q-]7+M3U
M.*W>Q\@(-Q#&)7".K!)YQ<UA+:CXI/2*U6LVOL]]Q?,?-6F:M::7-#+'RIK^
MJ7&A6K]69;:C/I+FBSCLKG4;>"]<)@YPO(X<S@^!_#RAR6V8^76>J?\`(QA&
MF<HH3,CRVYTSECNX\C\64G&C.V0S+&%90L<'C)VTO,A"89^4HXO`&2?(*E;+
MM$C%;)BKV#->:A=Q<*TAN!+GFD:Z5K6AU&-S!E'$,S])Z`:!8#D7N/[MN8CS
M#WB\Q<F7/+]O8<M:/?6F@ZE=Z@ZVF?J-PZ";4&NLHYM5]0`81;PO:7LE<#*X
M,Q2)CN6O-7(XXEIZN7:YB>8F^$G(K-UML5(K&.;\UMUAP_<9>-JEH@'9'<_7
MH<+7$1[8'R+=PX0;&%T1,H'$AT[=NI:K/+#;"5L1=932N+0UU3&X!I&T"H.(
MQ"S]_P!R'L\\FQZYKL>@W>N:?!WBZ%H]M!>7%_9.M8-5M8I+FWF;E@GE]6D?
M(87O9&^0"%SB6YFO:J?Y*\D[OA:9ALMY0B[_`%7D]Y568^0[^KM*+7ZHUH%I
M@E$X1G'U=_%%]T7C&1BG8F>^NJ+BH[$QT_#(!2!09JNH7%HQEU(U\5YI,D]`
MT#(YN0=FF)!S8U)Q'A6U:3W1=T'+?>);ZAR'HL^EZWR9WW:5H++EUY/<NOK:
M8&9[[EDOYMCXY&TAX+698Z-?G<2XXL;S8Y!\:,2UV.I67:GR-A77ETU[-D'#
MMJA6TV^`;97I.I4:+;.CU97UN2JJ,9)J*+(3)Q=*N6*AS'*01`*@UB^TZW:V
M*5EQ&=/X@[(I$YI:T;-K:$FCC\4XJ[O/9V[J^^'GF[N>8M!ON4=09WM3Z1-*
MZZN"[6[:>.ZO)'-%R,L=RZ2,-8^T;PVQS-:&DXE8V?F1S3IN$<X.HS(T?8I2
ML7;BQ'X]RC;XO"SRRQK[,TVC'6VIW*I8NL%C@"5YPFNF\AG*I$7@QYS%$QE"
M]05)M8U6"SEI(USFOA#'N$=:R&CFN:PD4Q!:<#0T6!T3V>_9[YD[QN6X[O2)
MK2PO-.YC??Z=:R:NRW>S2H2^UN;6ZU*"WG,X(=%=QM+XA.&D`,-%;#E.@P%1
MX9Y`KW-[.,A;JI'U":=9ARA644\83DY!#+>ZB,1#QU766"/6=)F;Q"39`YSR
M!3`D81%8VL_=LCCTB1FKS%T(83(\?FR1MPH<.C`XKQ-R5KFIZU[0>EZO[._+
MUOI^M2W\3=*TVX<=2BAFX7#,LK[@#B!ISW3I'@-@(SB@C"HC@X[%TEB"KVN&
M7Q]3^,O)/S$N.+[(?'&IW6)EJIA_`*#$\57XS+)(:15BZO.Y-?1Z<A-L1.1N
M0_2FKN8I@+IK(K;U0/9PV:;<7L>:)KAE9'L`>`:`OVN&`QH5]*M3O>;K'GV]
MT34&ZMJ'?)RAW4:^RQUZYM)8KG5=:+Q+/)IAEC$ES#I['N@M)@'/(JYF!!+C
M3E(?7;RO>9[.L9%ME,PIA[/_`"X?8SJU&?-$ZSD#&4%+L0I=/5G#E=/#XRKE
MK5?*I-&2A$'@)%1.842[#<R0<3EJ[R2.99PRSY0T]ES1L;7\!IK0##=L6GZ?
MS59\N>VAW>2:OH]AJ'>+S!RORPW4+F\8XW-CJ$\3S=W0A[+1J$]L(6NEF:7Q
M%QD:!(:CQ\TS-%]D^+="P<A`Y0KV*JYQPPYDVSWBNT>9DZ9?[LY7I<53L<SE
MM:M%(>NU>OL?7)21.X5(=U)>Y[<@=HB,_,-S*[3V6@$K;9L$;RX`T<ZK<K2X
M8!HQ+J[30*?V*>0^6[?OIU3O'FN]%NN=KOF[5=.M[*>\BBN[&S8V[ENK^&U<
MX2W%S._A6T`8TB.#UJ5QP"Z$,:6YM<L<T*TL6<Y',IVGUV0:L+)%.X*>:(JQ
M34H(RL,^`CN->%Z/;)*`!@#;V=;M!()8&2-!`+0:$4.S>-R^4G.6CS\O\W:I
MHEU+;37-KJ$\;GV\K9X'$2.QBF95DC,<'--#BG`;KB8#%W,&X>SW]WU=]5"`
M=JUM9*0^K$,J?;K'<$M^\=]A[0W$>S[';J8,SBFY0-`%@J+F,8QCCN)C;[C]
MG8`V$>S4[80&^%4>+X%\*IN(;"&X`&X?5'?T^CL#4^2@QVJ'$)/0OHKB7M`1
MWW]GM_K]FH&-A&*J!M#4KX#PX#ON/I[1W]C_`.%JD0`:#8JB]0D%`]GT=_;M
M_5U#9L1>I9(0'TB/9V`';];M'LWT1;^/=@JCU!V`"PE#T#OT[;[;[#OJH&]F
MH4M!6N]?6ZY1$5#;%VW`-Q^U#?;J[]NW4&4WJ)K3!9B;E-7J,4P"0GM`V[`,
M<0[1[^T2EU4%*8;%;B5V]?DZI`ZC!L'0'M=M@]MW]FX_4U!S0>M5FDD56E4(
M"AA$PB(B.XB([CW=W?JD!7`*=8QVH[`(!N';L/=OMWAW^SJ):0B\#(G`1V#N
M]'U]OT=]2T-*HL<Q5"B._9^A_6'<=!CBB^)G."A``!ZMPVWV[1[@`.SO$=$7
M*)[?^T']'6*H>E3K[C&=$*?7FP&^UC$40#L[!()PV[^X=M=AT<`:?;G_`%3/
M(%K-Q]._Y1\J=B/GUV3@JB:O2H0=R"`]H#OON';W[ZV81-FC\"LL[@ZI\2VE
MPS;=E([W*5F7AV/2!?",X5,3I[0#<AC"7L]'L:Q3]-A9(7T[2J1O97LM:#X`
M$TT!DF<K<FG,13Y5J^14!5-=)0Q%`.`[B("40'<0#[.IS;,D'"D&*GP.#@"/
M#BI;-,Z3^689,'LHN-BB4P!PV.N8P/FY`#==`HCL*@?V0!WZKVD$$#O-H5)+
M0-HP``G=AY%A-+8W7!1H\(4Q'!!0<H*ALDN40'<BA1[`'ZO>&VLU+!%*RAV'
M8J37AO6D1)2%OQNJI-4>2>$A%A`RJ2"R@*QYCF$>A4"&W.B`_:F]'IU@IK-@
M<8YFU;TJL'-<*D`TZ0#3QI&V/-5SM;,&\W-.G:0"(@59PHH4OH$0`PB`#]75
M6WM8(2#$W%4W/93L-`/@`"2$9;O!4*45``Q1Z@,`]P]_;W;".^KY\&8X[%)F
M<-AHGNC,U7B,C2-(J<>I-^G8J:+I4I2AV=@`!]P`=8^72;=[LS@%.P@GM-!/
M4"F+MMOG9I^J\F'2KA50XF$RIS',(B8=]S"(CN.^IHK:.$96;%5,F&PT"22<
MZHBH!RGV,0=P$H@`@(#[.X>QJH]@`H1M^!4^+X%.WCCD6SQC-6VV66?EK$65
M1I`Q?K!RFF),2=!E$4CG*063`ANTVPE,H8`#?8=8Z338IGX@YE.'1FKLK<W4
M*I5VJWM'MHM%P8Q@-++;F$`SFY<IUU'4I%5Q)X2O,UCG-X`#$IR2X)]!"=0*
M"!A'8-9/U.4V\-F]Q-I"Y[F-H.R9*9SLKCE&TFE,%;116T5W+?L92[G:QKW5
M/:$>;(*5H*9CL`K7&N"T,9D^X%.+-C*.E"";I\/Q%0#J$.D-PZM@[![>WTZD
M_9<,A`R@N&S!71NLN\K<N\EY)BT%CE<NBHG*!E3%654$`'L$3E\3?I`P[ZC+
MHD48!>QO@-`H^N'I.*;Y/.%S9.5_^6'6[H1`0*N?8.LP";J$#;;&'T=NK9^G
M6VQS1XE+ZT_-5I-"L.:RC-6-1%"0D%''B"1/K44,H(%'8IND1$?M2AV>CMTC
MLXHR.'08J+YG.;F-2E;5'[=&(<R,F"R#8[Q)8BA"[^(!-^D"%'L,!0[O1K)B
M/\T[$%4#(2I(H6.$O4&F2J3+5*RL42E*Q>&*R,]*4G3X1@./0H8Q0[#%[0].
ML-E,4@#@:55<$'9BHX61^JQ>KLYF'=04N83).4E$?&CGO>!DW10#8`5+]HH&
MY1WUFV/BN&!@&(5#%CL$T4C545U%GM=*FB[#<Z\0J<J>YAW`3LE3>T,4P]Q1
M$-M65Q92#MLV*<2"E3M37OG4PBX,B]:KL#`;I,#@AD]^W;L./M3AV>@=M8YS
M'-P((*J`U%1L6O5GVD>`F.IXRH![/>(!N'=N`]VJ\=HZ6C]@4"X-P*3KVXN'
M(B5,YDR;CT@'9N`[[`(!W?7UD66D;""14J4RU*U(SAS"(]0B;MWW]&_I^KJ<
MQ5.'FJ'%\"SXRQG0=$,)]BB8"CV]F^_U?3V[:FX8`PK52YW)134JHF";H@[D
M4*4!$-_:]G>'Z.EO.^-V4[5![@YU1L6%'V0%%`(8W;V!V^WW#;M^H.LLRZ`Q
M-=BD.(HETSD2J`'2<``-N_O';^MWZM9'NG=V<2@[-%[R4T+9$IRJ``]FP[[#
MN';W>QJRGL0&9W="F8^A`JHP9EL\*KS!Q]'-5E)%S9G^*;Q(,(F:MS1>'<U7
M'%F@U+'(-(:D+5-_"@\;IQ[I.0FB)D7562+TN'2C<VHPF*+7XF'_`$C20"12
MC2*FC:$;C5W3O-%E!4VI.^A\O6K3*6"#R,2>G]H@4H&$P^U#L`/:@.^P]6N@
M:G?QRVX@BQ*QD,;FOSG8EVC)GD'1$$OU,@])``>P"@.V_H';6N,B$3:GW%<!
MV;'<L*]7-.&9I1#54?67``*PE,`"4NW>(@/_`+^L=.PRC+3!3L-$US.5!80,
M)P[1[1[-^\0$1'?M'5N&&,Y2%/7>E2Q?F`2>V[-O9[>WN]GMU(8SC3I4^>FU
M.57I'K*=(P]@CV``CV]@;]N_LCJTF:!U_P`JG2C:O3$4$O<!3"'MA#V0'N[_
M`/9U;Y2153`T2S8/A]H`]G=V=O;V_5-L/;JV<P@>%5FN!PWIR(IT95OMU;B!
M=P[/8W[-@'L#LU:.!;CX546\:N3`/2/>/;W!MMO]?T#JBYN8DCSE$4!JE_`K
MB9PD0![3"`#V]G:(>C?56!KJ$HXU4A&I$DV("80$?#$1[MNT!$0`-]NW5*0D
MOR4-%,"`/"M2F=%UUF0.`F(;8Y=_;!Z-N\!$-@[-6$H[5';E,LA!R9$PIJ;^
M&81`=Q`.T`]J<H]NQB[ZMMU/BJ-2%M4#D7*8!V`R?6`G#LZ@`.S<-^T!VV']
M'3AYO-4<[^E)N?Q]C[)D8K4<E4ZK9!KJZZ,@:O6Z&8S\+ZZQ!06CLS"21<-C
M.FWB&Z#]/47J'M[=4IK:&5ACN&-?'6M'`$8>`K.\N<U\S\G:G^V>4M0O-,U@
M,<SCVLKX9<CJ9FYXR'974%16AHM;%8=Q'CZ%EZ11L4X]J=+LJ*GQ@JM<IL#$
MP%@!TB=LX2FXIFP2:2Q54#"02N"J!T"(;;:K6MK:Q0&**.-L;JY@&@`]8W^Z
MLAK7>!SYS+J\',/,.M:K?:]:$&"XGNII)H"TAS3#(YY=$0X`U86XX[5I*_Q]
MPM7:',8OKF%<:0F-K&HX<S]%8TV!:U2<7<=`JN):&]3]3D')Q3)TG5*<Y.DO
M2(=(;3LL;*.`VT<48MW;6AHRGK&]7NI=Z/>5K',MOSGJNOZQ<<W6@`@O)+N9
MUS"UM:-BESYF-Q-6M(!J:@U*\7'&O!K_`!\RQ&^P?BYUBN.<E>L<>JTROJ5%
MD_*H8_N@UA19@V;R(G.(F<%`%C`(@8P@.VI':=8.MQ:&&+U<&H;E&4'II3:J
MD'>OWH6W-DG/=OS%K3.=9F9'WPO)A=/92F1TN?,8]E&'L#:&@K>R.%\<(A`J
MQ6.:0V=P51D,=Q0M*]#MCQ%`DR$+(4Y@*#8A6E6>](>,Q3V04_LBCJ@^T@:Z
ML<;,S6EHP&#3M:.@'HV+$OYYYTF9-%-JVHR1W.H,OY0ZXE=Q;V/Z.[DJXYKA
MGQ)C5[=Q"U;?COB?U2.9O<=4+U*(I;[&\7')UF),A&X\DCD4D:.S3%MT-ZJ_
M.F456)`!NH)=Q+JEZG;T#1&RC69!V1@P[6C\7#9L60;WA\]F66Z&LZGZS<:B
MS4)7>L2YI+^,$1WCSFJZY8"0V8]L5P*_,#AS`.,E+,:D8>QK77MTCD(FWC!4
MV`9#9HIJU]3;Q<_X#$J<C&IM?:>KJ@9(P=Y1'MT98VL)<Z*-C2X4=1H%0-QZ
M5/K?>9WA<Q,LXN8==UB]9ITKI;437<\GJ\KG9W20YGDQR%V.=M'#<0$AHO">
M#8"IO*'6\,XNKU'D)]G:WU1AJ1`L8%Y9HUP1U&SSN/19E1=2L:Y2(=NL<#'1
M$H=`EVU!MA:1Q<%D48BS5(#12HV'K&Y7.H][?>;K&MLYEU;F'6KGF&.U?;,N
M9+N9TS+>1I;)"UY?5L<C20]H(#P3FJEK;:O5;_7WU5O=;A;A69/U<9*OV6-:
MS$._]572=M?7(Y\15LX%N[1(H3J*/2<H&#M`-5GV[+AABF:'1G:"*@^XM7T/
MF36^5]3CUOEF\NM/UJ'-PY[>1T4K,S2UV21A#FYFDM-#B"0<"FVC./.`(2L6
M:DP^$L5Q-/NQ6Y+?5F%'K[6!M`,]Q:#.1B+,K61.S$PBD90HF2$=RB`]NI&:
M;9-8Z%D48C?YPRBCNL46RWO>[WK:EK5ES)J',FN3\PZ:7>J7+[R=T]MG\_@R
M%Y=&'_&#2`X8$$)8M<;8]9T7Y+F5"J33&P12D$-!;0$:C4!AEMS+1AH!-$L>
M=DN8PBH04Q`YA$3;B(CJY&GQ<'U=L;?5Z4RT[-.BFRBP$W.7-UQS1_C:XU2_
MDYQXXF]>=/(;KC#9)QR[B!XV`@X#`4"W4S2ZI9*FM1+%6H&;I+IDRC7-0E(Q
MJ_KB\='*-5H]BM$."'8J-62K)$R1!()4S)%$`#I#5R=/CDCX4K08B*4(PH/!
MX%::?S'K^DZZSFC2KVZMN9(Y'R-NHI',N&R2!PD>)6D/#GA[PYP-7!S@=I2D
M(F1(A"%`"D3(1-,H``%333*4B1"E[BD(0H`7T``;:O#:M;NP6(=*XN)<:N))
M/A)-23X2<2MDT$``5#;`4O8/^^$?L^C5A<-:T5"F8^A.8E8;M[U'[=]AWV+Z
M`#?O^N'Z.IH15BE<:DD+",Y'LVWV^P/^SJ1Q)=V=BE7H181*(B(_6`.WL'??
MM'TZI2/S$-WJ(.-2O(RXB.X#_5V^R.XAWZ.!(5;B-7X%;V>_]'^KOJ7(:)Q6
MKYXWU/Z@_P"WJ#FY5'BM7T%Q]'I^Q_LZF%`VI4.(U*>&5,+<1'?8SL-N\`^T
M*'L]WV=09L)W*5\E<&U!6M>OS&4.W1$0*"@E-MWG/U;=(=OV@#J6BJ-/8J=N
M*W:*HMFY"#MXA"!OL(CU+*;_`*'2`:J^:W%6JUCV6.!@23.(E3`.L=P]L8>\
M-Q]C?4ADV*YC'9"QB2ABA]M]4>[;M#;M[-]P'[&E"W$*9S@-JRDY<.P!$.S_
M`'-_3W=NF<J3B-/2LDLDD<`ZMN_;M[@`>[T]VVJF=IQ.RGWE3I)X5[>L-E-M
MMNW?;[&W:'?V:=DXCH4IK7':LQJ1'Q"J='4(=(@/L"(@(#Z.S3*U31N`-3T+
MDP[/9#^K_M:PBN\P3,T.61B4H]B]D&2!V[!LN8BKYN02IN2"Y2ZBBK[7=)4.
M_;;7:-,C'[)MJ$8PL.T;VA:K<2'UB04^.4YX6N),MUEEX_8P`&_NBU[-A[=O
MT[OULMGE(`);XPK)Y.W>M3:;#%F0`X2L=L)=Q$'[8?L?JVHSL`QJ*]84S7$U
MQ(_\$U/QHCA[`DV([#V?W<W[M_\`C=NS?5JYK0^M10#I'W;5.'N&W%*>MW4T
M))M9./F62"S50#@(/VP=8=0"*:GZ?L)#@&VWU=2ES,M01F"B9'5PV*5:MF@+
M5!DM,-*Q952=)9F/+(LP5:.@#VZI2@N`^$H/;K)VT[7L#21G'A5.E75WK\0>
M18E$/4G\K%JH*@*1O%D&@D.4W8*:H"L(&*8.X=7,D4<L=.SXPJ;JAYIL33Y+
MAFD3UST#*L',(L;J<()2#0RL<H?J$0.4JXB*`]X"'H[]6L;&0NRRD9>L*=N(
M3)C;(\@]999A]4WK[41'N[/U75W2/SJ@C=B%#.=@"5$/DA@WZ2JRK`4P$-P%
M^VV[-N[=;NU0RM<:5%>L*!!`WI4.[!"2R(G2E8WJ$-]@?M-_;`&^P>-U:MWQ
MM:ZM17K"`C+2I6=2ZDUL#HTE,349&U=D?K=.E)-HD=\*8]K1L(J]A!VV.H`#
MMW%`3=@2Y2\4!!/N*=V`3[RV3JZR0;MX^5C&C!F@FU8$3>LR'(T1#8B4:V%8
M2M"'$!ZE3[G,(B(B`CMJL&QQGSA6G2%`5W5HD=\HON@OZP:?CVO1N8ISRS8I
M4DP``*F0/&,97I`/2':(CJ5KG2/S-<$)I@$[U3NK%_'@]-,035YXJR*?K#IB
MBM)"0@#ZTA^G[;D.(`/]MOV#K)0.:T"F7B>XJ9V5=YJUJ62T%94K5PY8"Z\4
M2;)R#8Q!$1[>LOC`44Q(';OZ-0CGXDV26E%`,HT$5(2`R+-5^-DO[BF(DA'A
M/6%&Z<FS$4%-]QV`%A`I#F[M6.H11LD!86X^$*H*G<M9C61C[;<("OA-1Q$Y
M"30;*JFD&GM$#GW<J`(K``&(@0XAV]X:QV=K!F/WE'&HVJ3]]ML<BX&/@S1R
MD<S,=FP9H/V"[<"([(HBZ`BH*"NJ4O68QNP-^_5Q9RP\/MFKSX4+7-)%.I,M
M+O9-HLFZ56BXM90Q2H%9S+0A^LW:7I*B[ZBB.WHW#V=7S(X+KLC+F'A"E#LI
MJO:5R)+(MFY9&UF4,B0J0-99PBY3!,/0BZ.H?8OU!'5,6L<,E6N;7K'PJ8.#
MMH*\4LD5Q2/147D8])\FIVKM9!INF41#8PD!?<Q!]C5S%)`&Y7D%W6%3((.%
M5N#6RO3+02+R<,X,8@[",BS]77`.S8Z2BIRD-]C?ZNHOM+:=F8%N;K"B'O;T
MIGK#"T9ZL<$I=&$>`!MTRR;,Z`F[-A*FJX,0Q1W_`+$Q?K:L'P.B%&.%.M3Y
MR_%-S(59XW`3QL]794G;TI!,-&;TP!_:HNERI*"(>@BAM&NRFCR*^XH^#>D!
M(2PQ2O@2:B3!;<=BNG**8FV_M#&5!-0.P>THB&HYV4VCQA*%87QKC"CN648`
M(&`0_NYMV^D!W\7L'LU,&M/FD'W0F/0G+A[7$3$6HS/+1P+%(/AF&0:[@8H"
M&P?IW;OMJWE9D=F)&'A"@*D5WK0%FHN.5.*LM'AT#N`>O-0V[=]A$%@U5#P]
MOG#QJ-$DIWDAC2F22<38[O'1+Q1J1ZF@9*4?=3,ZBB8+BK&,'R)2^(B8!`3`
M8-MQ`-PWJ17=G:2!MS*&N(K3$X>X"$R2/'8:2*I6UK*D7>:E6+:BL,.E882,
MG4(J6=-D)2-))-2.TVDBW,H`I/$"J`50@@`@;L$-5)+AMU:MF9V0]H-#2HJ-
M_A4N3(\L.)!HEM4\0XHQBG%Y?IMKLE1;V*M?%Z_UF)3"^UV<C9JYEDI&07C#
M,Y6UUDJ4RU;.7,DU=`R8,V9@.@4AE%`TQNGPVUT9HG.:#@X#M`AQKLQ(QI4@
MT`&S>KTSND9PZ5.[=_(5-Q2U0D<V:P4?+QH$:D*DH8DDS$%5`$`-L8KC81$V
MMEBM8V=HD5ZPJ`<XD#'<EFA=*U58D7[^9BCNUTA\%$)-EU[[>U#8%Q$-QU;2
MQ\601M(R^XIFFC2.A1_EKHRE7ZK]U,1G6LH<W1[I--BD#<"EV!;NVVU2FBCC
MHQI%>G!182ZM5E,+/%]@A+1O:8.SW2:=H#_^_'OU9R<-QI@JP))IN2ZC;/%;
MEWEXO?ZLFS[=S!_]/Z-6SFM:VM1M4Y%$Y5=M,,5R0ONU%`!@V[9-CV#W^E;5
MG-0[*54X<30)<GGX=)R&TS$""G2/_.K+O$1WW_3AWV#5H:$4JIQ4FB4S"R0X
M"40F8@=M_P#SJQ^IV?MCLU;.H5.*M/A3GUZSPPF!,9N(`1V[Y5@/8(=F_P#=
M'?JVF`R8*</)=CL2M+/0I#[A-0W>':$JP].X]O\`='H$-4"!EW559.!5)^%,
M\2,,W#"!!`W;+1P!Z.\1<^C;5:V;F)%0%`IVY*\0:+04R3L-UF`"!M+Q_IW$
M=O[H[PU/(QD8)J$H5I(RXQ#9T1<)R'-[8`5)[L1VRA!'<2B'K.WH[/8'6$GR
MNJY5AL3F>[-?<IIJ$G8006("J9PEXX!Z!`>P=G(=P#]?<-6P%=B@@)R"32':
M=B/$,(`HH:6CB@(%#^Q)ZUO]GV=5!0,K\91W+*B)^"(^04]W8783F)_SQ';>
MV*)>[UGM$1#MT)8UM78DHE=(SD.+=-=O.P1E4P,(E"6C#'%,0[1('K0;G*(]
MWL:H,-*BN%423^-,,YZMIN*/T[=1CSD84"B(]@@F5R80V^OJZ#F@&IWE160:
MTP[=$"!8(43#L!B^[,=V!L/;N+D1`!]CV-1X@(P\Y%G04Y`N%3*+S\)[;<"C
M[M1OVH=FP[N0VW,&J,E0S,W?M4%ARMGB4UG#8ME@2%$1`#%EHX%"%-W!OZP(
M;;:I-S''<5.QQ:<$E%5H@_Z8E8(18/[(P3$;N(B`[]0"[$1V$-7`<,6[=JE)
MJ<5KS/8TH]LU#"7<=]IB.[-M^SM<[ZD>1T44"O!67BR_^=X<1[]PEHXVX!]9
MUV:DJ%!8HS\.0?;S,.`]FV\K'_N@!U7!:XBA`HIEDI6>!)_Y^A>W;NEX\._O
M#]L[AK(Q3L#2'$*1P<<`OV-L@>T`FX8?1O[L1^P;>C]LZDENFD8(UI`Q7FG9
M(58X![O0I2@`"<WNO';``#O]TAN.K-URXN)W*;!9);1!'.4A)Z%Z"CZ)B/[>
MT.W]L@'?JV?V\246,ZL,("F_N["^D/\`G>.`-MO[X_LM!@VE<%!8Y+!!F'8)
MR$#V=I>-[A]/[8T1>RMB@R@`!/0VX]G_`#M';]W;V@YWU`AO@JBQC6*#[/\`
MER&^S+1X_P!9SJ*+X%@@A#?W<A??6/\`W4&E0B^_&""],["^^L?^Z]0P*+U1
MG(-4X$+.0H^D1]UH\`V#?M_;/9OMJ5Y#10;%%+!C8(`B0)DG(,0(X2*8`F8X
M-MP`1[G/?MHVF2F\HD^TFX-1ZL<TY"B5!50YMY:.[_$-T``BY[=0%:92*J</
M(;E6UD+1!H$[9V$ZR`([%F([M64](_W0(^U#47FH"D26&R0@CN,["B(]HB,Q
M'[[_`/USH`0=U%.'N`H%\&Q08_\`GR%]^(_]TZBZKA]W0H%SB,5\"Q06_P#S
MY#=NW_GB/'^IZQJ0-'W=2EQ7[+8X81Z"SD-V[=GNO'!V[_WQ]740T.-:8*IQ
M'I3,92$*3QG$_!@'?TC+1P=FP=_]U!OWZK-A:!4X%2DEQJ=J^.;M!)J%10G8
M0`*8`$P2\=MV#OV;.=NW5*A![)4JY4?=)O\`=3?_`.N$OV76$Q\*O%U,<1..
MG'R=XM\>YJ;P1AF8F)3#]!?2<K)XOI#^2D7SFN,%7+U^^=0:KEX[<K'$ZBJA
MC'.<1,81$1'5MF=TE5:!2*^:]QH_T=\%_P`TE`_B_J.9W25"@1\U_C1_H[X+
M_FDH'\7],SNDI0+Y\UWC/_H[8*_FCH'\7],SNDI0+[\U[C/_`*.^"_YI*!_%
M_4,SNDI0+Z'&#C27?IX\8,#?OVQ+00W^OM7]1S.Z2E`CYL'&G_1XP9_-+0?X
MOZ9W])\:4"^_-AXU;"'S><&[#WA\DM!V'Z__`"!IF=TE*!?CYKO&;_1VP5_-
M'0/XOZ9W])\:4"/FN\9O]';!7\T=`_B_IG?TGQI0+[\U_C0'=QWP7_-)0/XO
MZ9G=)2@7Z^;#QJVZ?F\X-Z?8^26@[?H>X&VF=W24H%\^:_QI'OX\8,'_`-DM
M!_B_IF=TE*!'S7^-/^CQ@S^:6@_Q?TS.Z2E`OOS8>-79_P#<\X-[.[_)+0>S
MZW_('9IG?TGQI0(^;#QKWW^;S@W?V?DFH6_W@TSOZ3XTH%\'B_QI'M'CQ@P1
M^KB6@C_^;^F=W25&@7TO&#C24=R\>,&E$.X2XEH("'V0K^^F9W25"@7Z^;'Q
ML_T>\'_S3T+X`TS.Z2E`O@\8N-@]_'K!P_7Q-0O@#3.[I*4"!XQ<:S=_'K!P
M_7Q-0A_KP&F9W24H%^?FP<:?]'C!G\TM!_B_IF=TE*!??FP<:@[N/&#0_P#9
M+0?XOZ9W])\:4"!XP<:A[^/.#1^OB6@_Q?TSOZ3XTH%\^;!QI_T>,&?S2T'^
M+^F9W24H$&XP<:3;=7'C!AMN[JQ+01V^MO7^S3,[I*4"_/S7>,W^CM@K^:.@
M?Q?TSOZ3XTH%]#B]QG#NX[X+#ZV)*`'_`.;^F9W24H$?->XSCW\=\%C_`.R2
M@?Q?TS.Z2E`H69F\KS'>0<K)9.QS8*1AE`?DR=O:;$\=<,VNO/IC%KK("T2]
M.$U"(.$F$XWR"JE*,P$4W8,6INH@I]K.\;''QE*#H"D=BC"/$R]T2#FH3%_'
M[(P-D5(*:MS/"F/88TI9Z^H:(LBCZ`+74S5Z1&8:*BLQ,0@MC&Z0#IZ1%G?T
MGQI0*B6W<?JM&^<!$LIB!XH2-,GLKX]@`H6.:1`I.X"KQN*W]NK#')U.FY58
MT'=%9%FB074.N#200<MUE8DJ3ER(0S.Z3XTH%T1?-BXU_P"CU@[^::A?`&HY
MW=)4:!`\8N-8]_'K!P_7Q-0A_P#R!IF=TE0H%\^;#QJ_T><&_P`TM!^`-0S.
MZ2E`CYL/&K_1YP;_`#34'X`TS.Z2HT"^_-BXU_Z/6#OYIJ%\`:9G=)2@7WYL
M?&S_`$>\'_S3T+X`TS.Z2B/FR<;?]'S!_P#-/0_@#2IZ2B^_-EXW?Z/F$/YJ
M*'\`:5/2E`OOS9N-X=W'W"(?^RBA_`.E3THCYL_'#_1^PC_-31/@'2IZ2B^_
M-HXX!W<?\)!_[*:)\`Z9CTE$?-HXX_Z/^$OYJJ)\`Z5/2B/FT<<?]'_"7\U5
M$^`=*E%^OFU<<P[L`X4_FKHOP#J%2B/FU<<_\P.%/YJZ+\`Z5*(^;5QS_P`P
M.%/YJZ+\`Z5*41\VOCG_`)@<*?S5T7X"U&I1'S:N.?\`F!PI_-71?@'2I1'S
M:N.8]^`<*?S5T7X!U"I1'S:N.?\`F!PI_-71?@'4:E%\^;5QR_S`83_FJHOP
M#I4HOOS:N.8=V`<*?S5T7X!U"I1'S:^.?^8'"G\U=%^`M1J47SYM7'+_`#`8
M3_FJHOP#J%2B/FU<<O\`,!A/^:JB_`.E2B/FT\<O\P&$_P":JB_`.HU*(^;3
MQR_S`83_`)JJ+\`Z5*(^;3QR_P`P&$_YJJ+\`Z5*(^;3QR_S`83_`)JJ+\`Z
MA5$?-IXY?Y@,)_S547X!TJ41\VGCE_F`PG_-51?@'2J(^;3QR_S`83_FJHOP
M#J-2B/FT\<O\P&$_YJJ+\`Z5*(^;3QR_S`83_FJHOP#I4HCYM/'+_,!A/^:J
MB_`.E2B/FT\<O\P&$_YJJ+\`Z5*(^;5QR_S`83_FJHOP#J%2B/FT\<O\P&$_
MYJJ+\`Z5*(^;3QR_S`83_FJHOP#I4HCYM/'+_,!A/^:JB_`.HU*(^;3QR_S`
M83_FJHOP#I4HCYM/'+_,!A/^:JB_`.E2B/FT\<O\P&$_YJJ+\`Z5*(^;5QR_
MS`X3_FJHOP#I4HCYM/'+_,!A/^:JB_`.H5*+D'^)M/\`P3K/O#%?N31%UE<+
MOHD<;?R*XZ_%B.T12:T1&B(T15+4KS<<-2V<N2.,+[6'5"H.%[I7*AC_`"^V
ML3:XQ67$_EAB^.>4+$O7(B*0D<?U_$V>9UC"R+QTL\:&9.R21UD&W5L1.8\\
MU+B,A=<.T5M9K0ZD,_6:ZTK$D^:H3#>FVRU4NS7NG*Q[><.D*YF,W8L;2R+%
M^BV79*IH$5,H1-=`RI%'&K>=SQZ;8MN>9\P5J<H^-*H;`I6UOIAY;(D9,MLV
MX(A,YFFA;.:Q39>)A*M&2YF@^,W%^_,EUHM0.;P"D7V[^=/BJBUCE@\E<3W1
M*V\?;=R%JN-8YV>594'D*XX^U.JWF9C:KE0]35@(*Y2E2LPR(PZB+Q9LS:+'
M\14Y#ID(IDX"\Q#BUR4S5>\`8IO2DYDC'S2R.Y1J,<NC"S*='LC2F7X:M,&'
MPY<M*M[Y*.>]9$#&5-UH`LB!E0(IPZ(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:
M(C1$:(C1$:(C1$:(C1%4]YOMHC:IQ]H;J7LER@&#[+4<S(E6+3;JI#R4LSJ-
MNL,$6_+X^@K!>)NG,9>"266BF"*:<FL5-LZ7;M5%5DR*97#FP5ZS<8<(2=8;
MY$1APQO4&#=7*[.P(W]^,9`1[`TC8I.RQL7)6MV]]7`X30$4;RQ1!RBJJFH4
MXD5(#[BD?%/FP1%P;V1JYEKIR&QID&+A`:XGHS^=HKO#EA@IFR+FE)^PVC)M
MB9S%84)-2XQS":E7:#I=9RBX7CRR9%TK:(C1$:(D3%9)Q].6J>HL1=:O(7:K
MG1+8J>WFX\]HABN$$7#9>0@?6`E6S1TBX(9)8R7@J[^U,(@.Q$MM$1HB-$1H
MB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1H
MB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$7%_HBZIN%WT2.-OY%<=?BQ':(I-
M:(C1$B;GD6A4%:H,KQ<J_4761;?'X[HJ$Y+-(MS;+S,L9*0C*I7$W2A%)2P/
M8^(=KI-D0.J9)LH?;I(80(JZFGE8^6S6Z;/&B</U")C(+&^>L690N,#-.T[7
M;Z=F!@J\S-&9@ML4Z-8+K+K/RIS!5I-59]%RS9%VV%%9,@Z(HV8#P]Y-G)FY
MXVON`K:HZF^+N*\`+5-@E:LP8MB&>,L9EN$)@J_O:MD!M4F-Z@V?QMFV;>P%
M0>-'CA^L"ZRC@2&*1*&W>6MY3CP6V!I-"8]V(5?%6)WM2JF6<GNK-%-K=@\V
M*L=U:U_%65=OX:$N>):0!1=2`MV[@&@+'7*97=4B?.9\KG@%9E<F66?C)N<B
M,KKY-&Q,Y'-US=4B.MV4H&$QWDVWTZ!-9_BU3<@6"M5YK"NY".10=$;E,B'0
M957K(G.X[<?.$&#<QYRN^"I2`B+Z>U+4C)]=;Y+D).NX\N5]?I95EZQ'4V0F
MEH.EV.]RE@2FG3=)$CIR9P42`5(>C1%/S1$:(C1$:(C1$:(C1$:(C1$:(C1$
M:(C1$:(C1$:(C1$:(C1$:(JG/-G>3RN)\6#CZ%D;A>J;FVMV]6#K[29*\AZZ
MC3;\E-V&PWBK7K'D[B*M1D`#U\[F1DTT'#!@Z:G0=IJJ(Z(I^<<I68G>/^$I
MFPU^=JD])XIH+V:K%G]T?C%7Y5Q5XQ20AYLTO*SLH>3CG1CI+&</7BQCE$3K
M*F$3B15^,L)PE6YV0U[NW.#W1S#95X%S)8/AJPM5V%NA(>#LD?3HZ7@XF\24
M*T>LXEVJ?UM5D1R^3;IF4`Q"H]!%;5HB-$7FL50Z*I$5016.DH5)84P5!)0Q
M1`BHI")04!,P@/2(@`[;:(N<S%US:7_S.6U+O4U@SD.V"\2M'/E&0:U-MDUO
M=,88LF\@.0QQ#0D_<&N.8?'\M&QB1DFDA%S$O[I.E2-G#=G+^K$71OHB-$1H
MB-$1HB-$1HB-$1HB-$1HB-$3=/,O8LCX]*5?Y#IK*/7NJF-D'+NPQC<KC(2<
MBO$GI#<BKDBB]K"0:J)@P(4SH>@Q@()0$=$3BZ(C1$:(C1$:(C1$:(C1$:(C
M1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%Q?Z(NJ;A=]$CC
M;^17'7XL1VB*36B(T10*YY</9+ENPXRKU]_1(JQ<=^4%.STT>7F`<3!%8R)I
M&1*)+MJV^9$5=UZWQH7Q&;B'G0HB26AFOBE`NRB9%&OA;Y:M_P",\)EIA9+Y
MB[QKCQ@H/&*-88FJ%AJU>OS_`!ZCD0H\FLW,IV8F'5BS_D,U[(G-.4550!NS
M`@NG/644B)B9SR2TX;B!CW#6-,D-)/.J-/X_8QS-D[.EBR;F*#N&(L/MI%])
MXJQFWN<]8'N$Z8YO,@6=CF\`W:E;K-BHB!/$!=(B;.H>1WERM,JY#-\\XZ@'
MIJSPZ:7/,-2JMHC\TNK%QDX^9$P%,KQDZI(A[HQ=C3MK&>8"^<^,UD(\I%@5
M`B:H$6LHOD*6B)Q!!XVN^5,=6L\:SY$@XC7\/;)NE!9LC\3&/'#&N0HNO3"X
M,8JX0UFC4[5*JH-TA]=$AD5%7B(/E2+79.\B'*MM;WE*M94P;%6"RY5QUER&
MR<\I=K-=V5JBN-E/P?=%;A$N7$W1LEQ?QEJ"DZT934>Z,^"9?)F<1[DPO%"+
MI8@&+^,@82-E9$DQ*1\1&L9*628I1B<H_:,T4'DBG&H**H1Y'KA,RH($,8B(
M&Z`$0#?1%M]$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$4,,
MS\:N+;F_6KD9FZ?DZO(3M6Q_092PR><;CB"G1\72I:XOZP@"M7N%'8*2CR3O
M3P#*/5W*AQ!(B/A])@.1/UA2T5NVXRJLE4(2UU^LM8Y*&@XZY`Z<3`Q$,0L?
M%OR3;B7L2-LBI6-12=,Y=O)2*$DV6(L#E0QC"!%4(A!X_P`1^9LWQK7&B6/)
MRSSF,KC#6"QVCDW+O<F5,U$OI)NGLH@4+'CF\.4+2[?JDF):S1+6O>`V:MXE
M?PW0OR*]#1$:(L9X3Q&;M/P3N>MLN3U=-;U=1?J2,7P4U^M+P#J[]('ZB](C
MON&V^B*DKBU&\;,<<SF^-:KP%R'@+-*BMLFYJ]R&7(B[,D"OJ$A(OK?-Q,;E
MJTR4W#V=B]2ATYM6.6:C*E%N*Y54TQ$BN^T1&B(T1&B(T1&B(T1&B(T1&B(T
M1&B*A&9H>-6G/U_F*"O%9RCG`^3!I+FC8NR!R!B\X,Z>:XLADH60+(7*5Q6>
MMT!E'D=S31PQ81YH6.<-$%VY#)I&(K[M$1HB-$1HB-$1HB-$1HB-$1HB-$1H
MB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HBXO]$75-PN^B1QM_(KCK
M\6([1%)K1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$
M:(C1$:(C1$:(C1$:(J4?-WAKO-P^,!AK'%RT<SOD%'UC%@\<K[E&Z+Y%DJ?E
M"0C;UCJQ5W(='B9*U5IK"E=MVBP@6&49>O`J9X9BW5(K/>,E?4JG'+`]96B8
MJ!7@<08ZB7$+!04Y5X:+<L:E$MW+&*K5G(G8Z\P;+D,5)B_`'C4@`DM^F%-H
MBJ9RW'UF.\V&H3,S5,)/(R8M6((YM;E[-9G^0F^3E*&Z%A7;A#M)9RK%+L(&
M&B']::I0XU]@_<-7#Q\B\L(`0BO7T1&B(T14_P!7PKR(8>9[8,QFQ>0,'S\K
M)E&Y6DV);%,QS2*Q`YJ[R7I]A-CLV3:-`2=F5B$&<`C/#[HB]EG1Q20:G;N2
M*X#1$:(C1$:(C1$:(C1$:(C1$:(C1$:(H*\E^7"&-,G5#C;4SIP67,H04/*5
M>[V(U)/3JRG.W`E1C72U?M5]HDC?WGKZ"_CQ,4X]T`0Z3I`<QBET13?CP?@P
M9!*&:&DP:-@D31Y5B,#/_!)ZX9D1P=1P1H+CJ\,%#&.!-NH1'<=$67HB-$1H
MB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1H
MBXO]$73_`,-J53W?$_CDY=5>!<.%\,X]6676BF2JJJJE:CSJ***'1,8YU#F$
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M(4BL]PKB6(K&'\6UNUU"!+9H#'U/A[`1:LU"-52F8Z!8-9)%2/J9GM79F1=I
M'**<>LJR*(;(G,3I$2*EC&V38+DKYAM3N.)K#BQKC&8KF+K)(T&U)8!3L+*F
ME899CZ78Z\M`V^Q62>MN0RL9U!W7I")3M=51!(SPT<CZB!R*_3XA4C\$:Y[S
ML/V#1$?$*D?@C7/>=A^P:(O)>ATXJ"QFU-K"S@J2AFZ*T8R;I*K`012257*R
M<&034/L!C@F<2@._2.VPD5`6([?B#(WFS3T4ODE@\F("[SU+94=AF'(UCI,W
M,1''56SJTND4VO8L:8+=P5.2L$TI,I2,L6;<R<2R=F,T6CS,79%T!?$*D?@C
M7/>=A^P:(CXA4C\$:Y[SL/V#1$?$*D?@C7/>=A^P:(CXA4C\$:Y[SL/V#1$?
M$*D?@C7/>=A^P:(CXA4C\$:Y[SL/V#1$?$*D?@C7/>=A^P:(CXA4C\$:Y[SL
M/V#1$?$*D?@C7/>=A^P:(CXA4C\$:Y[SL/V#1$?$*D?@C7/>=A^P:(CXA4C\
M$:Y[SL/V#1%0WS'KU[A>=W'Z*L49A1*KVZUX^:U=G73+QMA6J49F`#@U?2,T
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MUHB-$1HBIQL?G5\>*;=,KU:VXGSK"0V,;3RUHK2\BTQ3)P=\NG#&#L]ER[`U
MN#B,J/K[$D<0=.D%XA_.1$3&/!1`AW")U$RF(I41WF4<(WN+H+,3GD!3H:B3
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MF&''4D^Q%BM[,H&:R[S'%'=2K4[Y])F;23BL1:KY`TE)R4S)2!D71S%%=P\=
MKJB'4HLJ81.8B<?1$:(C1%3QYD>4.`N+;WC<O(3CQAC-.?;][E5^F?*GCJ:6
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M?B_5`>2+OQ3$*M(/FT7&LVZ#=-9V^D924>HM6C9!-1PZ=+)HI$.H<I1(F6Q#
MRTX^YV+,J8SR`$LA!QB\ZX=SE6NM$8R-=:.%VKVSUE]?JY6&=QJL>X0Z7,I$
MG>Q[85$O%6("R/610(3X?^7M$/\`D;Q\9S58<YVYVLN3>4;;D^%J=;G,NPU!
MY..;5:K,),HPE1>L*G1",5GA*T6>>I(RB$:<B`O#-U0*1,)RK\L#A-D5M--<
MF<J,G46$S??F+I=C'2]+DJ3:++)XTP9Q5@X6+;RU+GZ[\=&;K$$06,=IG";8
M/7LD1N=-!10$2)5V_P`GWAQD)?.>5K3G+(#2'Y%HP5S5(61QO0J=!3T9EVKY
M8KMZF:FVID#"7:RPN0(UFP3<6EH]>%8.%(YT91945`(G4R7B+AGQAQ;PUXL9
M`O64ZTWP[G2FYWQ8YJ&&+C9%LCY.J\W?KJ\CID</XAEJ2S<663E9J2=QC1)B
M]!J@=<I02(=4Q$[_`!*XI<<^&$S(N:7EB;EU*WQCX[8%F'=WE8-*#C*)AJTY
M><T6;?3C2+BH=O:9^6RC((O41<`/2BU$J"0*`94BFM!9BQG9L@6G%<';HY_D
M&EE4/9*N5-Z@_8%;LZS(/!3.Y:HM)'W-976'4=^JJ+>J%E6GC=`N$>LB<O1$
M:(C1%C/'C6/:.G[YRBS8L6R[QX[<JD1;M6K9(RSARX64$J:2*")!,<QA`"E`
M1'1$U.(,ZXVSM%R<WC.0LLK$12[-%23GL=9'H3&0+(('=,GM=<W^IU=*U1+I
MN3K(]C!=LS%,4?%]L7<B=_1$:(C1$:(C1$:(C1$:(C1%1SYR*3F0KN):Q+UB
MD1\!:LH0414[7)9/N]7D+3D"QUFUTAK`V*O4>JP[Q&,@6]D1<QTFXMB#="3,
M@91FJ1(0$BLQX@U-.F\<L61K*\3M_@)"L,+/4)BPO'4G(1M+MB"=BJ=53EY%
MA%2TS&U."DD(]H[>-&CM=LW(95!$VZ1"*2NB(T1&B*I'S=ZG0[%ABE2$_3:!
M.V.M7-618W&Y0F0Y(V,*[(U>R5R9M:DIAF89Y9K,2\=3C>,*]9,):."3?-$W
MB"15$W;<BL(XYQ@0N`,)0P1MIAPB,48_BRQ5X]4&Y1Y8^JQ;0K2TBQ<.FAI]
M`J(%=B10X"N!AZAT153VLTW,><&=)I77,_'U2M8:.L_EWN%I-K6`D*M=Q>*U
MY>VU);)]$2>MY`'`-(9^8LTX8.^@Z2ACE`BN^T1&B+R71(X16;J]?AKI*(J>
M&JJ@IT*D$A_#60.FLB?I-V&(8IBCV@(#VZ(JY<:\4L3\(,K*Y6IV2[-!5'+S
MNL8NME5N-):W\'LD>6O\[1S-<HP4"QNE+(:W7AWZW)69[*Q;DHMVACMW!VZH
MD5C^B(T1&B(T1&B(T1&B(T1&B(T1&B(T10=Y(<PX7$V4J;QRBV5KB\LY9J_N
MSCVYJ8_+=J&WD#7.O5(D6I!)7*G6*\2S;W9.^?L(4ZKB/B4%':PD#PB*D4UX
M_P!?]09>ZGJGNGZHV]T?<_QO4/7_``2>N>I>L?W1ZIZQU>'XGM^C;J[=]$67
MHB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1
MHB-$1HBXO]$75-PN^B1QM_(KCK\6([1%)K1%'CDMCRT9`IE15IS9.6GL>9>Q
M7E9"JKOVT6WN;2A6YA+RM9/(O3DCVCQU%@LNQ,YV;#(MVX*G2()EDR*`+?R\
MLVVG`E9PMD3)^/89;#>'9[$F(+%C=G:2N[(WG[9CVR24MD8UF2<$A2R##%S&
M-.TCD7Z)4Y)XHIZPFFFU4(M&\\JJ6>5MXQ;W2C14W8,2V"A6-\:`DIEVK)6S
M'_F"5B4:C8CC$R4I58N7YHQWJ3;U=BW2CZX9%NT9I':H-2)6WWRTI"6L#N2I
MTKB2/K4;D&-MU#H,S1G'Q5I\6VO7'"SKQL2Q8F4:1#Q%IAV9.BJS03ZG\R54
M_P!LY,H1(2;\I^P'HK:%B,J1SR8K1\3%I<,^;+Q51BHR"QW-U[,U=9G/$6E6
M`A<M9+L9KD](BQ=>M2T2P,N`.2>NID5C#K`+I.O<2ZW%64I6?&BW5>;=NI(D
MH_?6N*K.#,C8?(U([>R;^03D7CBZHO5%W;AVH<B"A5#J*'\31%`UUY8]JB\:
M2-*H]ZQK`R$K2ZA7Y5=;'R#IC*6..R]G?(]EN"P2*$R1M,ORYC;*D<>K+.UU
MHE1J*J"+SQVQ$Z/'+AKDO#.2\5N+':V5JA,=P#F>F;\V%5G(V^V.^-G'?C<-
M47BGDE(2ZC!VXPW(VIZ[<*^&59>,0(#A8KA9N16<:(C1$:(DE?@,-$NH$471
M,-2L8%6:UU6WN4C##O-E&U30_3[0N0>TD<3V[TP`B':?1%57Y2%2:T*L9BJD
M37)6!KZ)\2SD*H>E?%VL2+>PTY^[,>M2SAI"R)P:$2(FO!C'(L(1+P%F#E\S
MD4G`D5P.B(T1&B(T1&B(T1&B(T1&B*JWF!PWY$<A,JFF8JX8QLF%S)TT38KR
M3<LW5B,!K"0MR;V2#-%XSD6L"=2>M4K"S:,^*83S$T.9@DL#)TN0Q%85AQK/
ML<28OC[7=HW)5KC<?4Z,M>1(?P/<J]6B-KT>QL5NCRM3';IM+%,MUW9"$$2D
M*KTAW:(G(T1&B(T14^<WW/#^L9_AYG/^4,K8UL=JI];A6@$P58<CXFFW5>:9
M/GJ&Z<VUSB&]U-,:O*)R#^1K2D@FQF'B44>28K@FT$2*S3"=>J=2P]BVLT-[
M.R-)@<?U**J4A:`E"V-]7&<$Q1AG<X2;9QTNE*N(\J9UR.6Z"Q%!$ITR"`E`
MBY\8:N(0GFM817M&-+5C^P6&1A;7',[+GS)V6K`W;K4C(C:/3![=G:+1G!2K
M>5\61@GD<[=1L@R139OT$$"):(NEW1$:(C1%0R]S35HKS9D\>2T#E:RR\3D&
M4E*RRAKG*6`8N9L&`J_7Y.T-Z:W,@W7QHV@["HW?LCD55BG#;W0%1-JDF1<B
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MP=><3UTMLG$U+'K.)L;QLY*]?*+`42&<%;.BLU$3$4HN-E8B*C@/$,1"@LH@
M;'M2E'TB\H[;&<I/SDU!L9:P6>=QZT81;>E6*SS+Q=_(QA6R'J3UPJD*91*(
M`1/?HB-$1HB@[SU'!+7%=6F>0*]ZB:?$9"B!C+30R0DC(UBQRT9,03)X\K4Z
MA,M;(QD6DFNQ\%.&F%T%')5R(HBGZRB12$P/*8OD,3TMGAM^N^QY6(=K3:^1
M^2PHS$8VJ:1(,(B=9VY!K:V,S'E9@1=*123=[[&.7VP")%5AA#!E]KF:\:V!
MO6.1<?R!1R*ZG.4$_<+9FPW&VR40C>>;MXNI6>9O\A6K['T!.?(C26Y4WDFX
M07($RB7U5SZH176Z(C1$:(J4ZC;1FO-?M\1.7`4I"GS<I#P%/N,WE![6_<.7
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M-OL(AL.B*2?BY#^XJ9[Z3GP/HB/%R']Q4SWTG/@?1$>+D/[BIGOI.?`^B(\7
M(?W%3/?2<^!]$1XN0_N*F>^DY\#Z(CQ<A_<5,]])SX'T1'BY#^XJ9[Z3GP/H
MB/%R']Q4SWTG/@?1$>+D/[BIGOI.?`^B(\7(?W%3/?2<^!]$1XN0_N*F>^DY
M\#Z(CQ<A_<5,]])SX'T15V2F6.0N?@RG6S8/X>VK&U+S)>\8)0>8[?D:=6FW
MV,9I.,&PR-?0PK8JZV,Y>[K-DRJKG0``'KZNXB2$UD7D+Q2Q?D3(M4XY\%*M
M6*Q$FMMKK^*[1DFF2%B;Q(IHF!,K'`<7%NI5-LX,5`[H>DN^PF*`CHBM#%7(
M.X]+*F[;CMO*3>^WHWVB-M]M$7SQ<A_<5,]])SX'T1'BY#^XJ9[Z3GP/HB/%
MR']Q4SWTG/@?1$>+D/[BIGOI.?`^B(\7(?W%3/?2<^!]$1XN0_N*F>^DY\#Z
M(CQ<A_<5,]])SX'T1'BY#^XJ9[Z3GP/HBI/\U;C;8+5+XWR^PBX^3MD]88&@
MVM@&6ZG2H9ICF!;3D_-2E=:Y*BJ957EL8QJKMSTO[6R!9-J":#5<QSF2(K9<
M+%R(VPYB9L:-I")F^,Z&@9%&QV:511,E5HI,R24F^I]=?2229B[%<+1[%58`
M`YVZ!A%(I$Y?BY#^XJ9[Z3GP/HB/%R']Q4SWTG/@?1$>+D/[BIGOI.?`^B*I
M7S.\:W6QON.=R^4&X42YL,L.JWC1WC?.4UBF)B9F9Q/E9*7),`X)'QLXM:&1
MRH`N!32S(C<2,O%*NX9.R*?G&6/RU"<=L$PUD@ZM%ST5B3'<=.L'=WG+B]:R
MC*JQ3:02=6LT:N-D=`X3-UO3*'%R?=03#U;Z(H+*Y?Y--.<,33LCY+H<9&_&
M"CU>"PECVVV]JFX:SE2N-A=6]W69C#BEJR54!\%@G)3K)PTAH*24%JJ]4!J]
M*P(K5_%R']Q4SWTG/@?1$>+D/[BIGOI.?`^B(\7(?W%3/?2<^!]$5-L]CWB;
ME?S!KS3)S'5O2Y*,I&F6V1F""C!UX9].JM9J*OM:GV]5',:,,S@,5-H=W(JN
M2T\KAPU9IE]:?M3F(KDO%R']Q4SWTG/@?1$>+D/[BIGOI.?`^B(\7(?W%3/?
M2<^!]$1XN0_N*F>^DY\#Z(CQ<A_<5,]])SX'T1'BY#^XJ9[Z3GP/HB/%R']Q
M4SWTG/@?1$>+D/[BIGOI.?`^B(\7(?W%3/?2<^!]$1XN0_N*F>^DY\#Z(CQ<
MA_<5,]])SX'T1'BY#^XJ9[Z3GP/HBIOS=R)K>#^:E+CK[PDPN]RS;[#7EHC,
MM;R7;;/8(:IV*WL\6US)US@H3CF_955_(J/#$:H.I07ATFBY2N@2;*+D(KD/
M%R']Q4SWTG/@?1%#7C9S(M_)*^96I<5C2KTXF+)>9A7QYRU9&&UJ.H>U2E7*
M,_5);"M7A*V65]R5'C/U2?FBN6IB*)F.D/BZ(IE>+D/[BIGOI.?`^B(\7(?W
M%3/?2<^!]$1XN0_N*F>^DY\#Z(CQ<A_<5,]])SX'T1'BY#^XJ9[Z3GP/HB/%
MR']Q4SWTG/@?1$>+D/[BIGOI.?`^B(\7(?W%3/?2<^!]$1XN0_N*F>^DY\#Z
M(CQ<A_<5,]])SX'T1'BY#^XJ9[Z3GP/HB/%R']Q4SWTG/@?1$>+D/[BIGOI.
M?`^B(\7(?W%3/?2<^!]$1XN0_N*F>^DY\#Z(CQ<A_<5,]])SX'T1'BY#^XJ9
M[Z3GP/HB/%R']Q4SWTG/@?1$>+D/[BIGOI.?`^B(\7(?W%3/?2<^!]$1XN0_
MN*F>^DY\#Z(CQ<A_<5,]])SX'T1'BY#^XJ9[Z3GP/HB/%R']Q4SWTG/@?1$>
M+D/[BIGOI.?`^B(\7(7W%3/?2<^!]$7'%U2W_!1?_P!7>?N?1%U;<+OHD<;?
MR*XZ_%B.T12:T1&B(T1:Q2:AD9%*(5EHQ*66*!D8Q1^U)(JE$HG`R3(RH.5"
MB0HCN!1[`WT19R"Z#E(J[99)PB??H604(JD?I,)#=*B8F(;I,40'8>P0T1>N
MB+R671;)*.'"R3=!(HG5664(DDD0O>=1102D(4/2(B`:(OB+ANX\7U==%?P%
M3(+>"J17P5R`43HJ]!C>&J0#`(E'80W#1%[:(C1$:(C1%6=QT_4^1'YXO)?\
M=R:(M9S3^B1R*_);/_\`SFNB*T31$:(C1$:(C1$:(C1$:(C1%5'YKUV:5G&N
M*XD_J!GECO4XT:.+)`0-VQW7WB5`M2\39<FTJ=K]M0?5AI*HIHMWON>46DFN
MW(F\9N%T5!(K&<1(OV^)\8(2DJ2=DT,>4I&1G$QF1),OTZW&$=RI!L:3>PB2
M1<%,L'KZ9'FQ_P!/*"O4`$3AZ(C1$:(JO?->K1K%@6@*^Z31%&N9MI%I<U]>
MNUR[N[FV@$):2<U6)QY+6B@SM_>S#9N=!>,A;!$OACE'2YU%6Z"R"A%.[!D.
M6O87Q/`D<3[M.&QU38Q-Q:JPTI5E538U]@V3-/4]BU8LZM+`1,`7CTTDR-%`
M%(`]KHBIL6-GBS^:G74+16ZT`U&4H[FU/*!D6Y2[FL5"2H%Z=PGJ-BL&)X!O
M6Z/*K1;,)6G!+()STH_?O$"+"FL"Q%?/HB-$6(_\/U%YXK<[Q+U1QXC1,42G
M=)^"?K;D%PLW0`ZY=R@)U"$W'M,`;B!%RY\=,HTF4\UE.%XI5.HGI<7=;%C,
MC5Q&S<16ZO&Q.%(BRY$9+#%5.?>,+9"2A95)*:,^/$R;Q5O'$.1%4KPY%U+Z
M(C1$:(C1$:(C1$:(C1$:(C1$:(C1%1[S!,^J?F'\8XM!GD2<@K9`UJ<B(IVW
MSK/0"MZJ.:9)^\?4Z7I>=Z+7E+G$U3)\HHLVL$:_CHNO-_!2*HU/ZCHBNRE)
M5C"LCR$BJ=%H1=FW,HFW<NS@L_>-X]J4$&:*ZY@4=NB%$0*)2`/480*`B!%2
MEY9H%4S=>Y!C6F;D)?'-PEK5=*[*S+NC5^==YE5)$8KK#F1K<#)7"5A&K=\,
MU,3$I<W"BS5N=A+-TG3U@0BN]T1&B(T1&B(T1&B(T15D\H>?UFP%FLV(H3#R
MUC03AZ*LI:Y=OE4L1ZUD<]O29V0'=`Q)D*-3HV.U*>;XR&4<)RA1D&A&C54R
M@")%8919ES8Z33["\?1TFZG:Q`S+B1AXN7@XE^M)Q;5ZH\C(:P*+3L2P<F7$
MZ+9Z8SM%,0(J/B`;1$JM$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-
M$7%_HBZIN%WT2.-OY%<=?BQ':(I-:(C1$:(J!,L^5;>N3'F2\@>05VF*_C'%
M:$WP6M^-;U'XVJ5FS59)7`2$_8K1#8OR\XLJ5HP=%*3J#.-FP1C%C3#%VJ0A
M@#<Q2*,...-'FK<?<!.<88XCLU2$';\8TMQ+P,;F*CMIO#F29?F#FF9OCS#Y
M"VBH+E;-<&R%>7<1",]%MWY')SB^!TDLFH1*G'=$\])E=,-S$G-WJ9L#WAW%
M5&^(9'N6,(G$5%SZSP);XA[>%D*9:Y8M_GW6;2Q:SEF_K1C'.<'+>5]0*J@)
M$[U7X^^8MDCRF>;F%N0JEUOV?<HTZUUW#M.OLK3D[BD=[CVJQTS&J6Z/R1>H
MYU"S>2&\NZC%'\H@=!JJ!2(MF@MD4R*PW@#AC)N&S\UAR775*\&5.>.:\OT`
M5)*.DO=S'%KJ>+HZ`GT_<]X[]03?/8!X0&Z_A.$Q2$3)E`Q1$BL%T1&B(T1&
MB*L[CI^I\B/SQ>2_X[DT1:SFG]$CD5^2V?\`_G-=$5HFB(T1&B(T1&B(T1&B
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MM&%K$81G(-I63@:M)22+M`I3E7<1D>NJ`]1VR)A%,I%1LO/6K('FXXI?Y9XX
MM\!75A9'SBLR:F3F=]M.2:74:=>*G#6@_P`1,A6RBLJ+/+)KN&T?(UZ"L3-5
ML4SH41'=8BZ+=$1HB\'1/$:N2>KIN^M!8GJJPE!%SU)F#U=43D4(":V_2;<I
M@V'M`>[1%SE\7T#NO-,B4)_BS7N(-DAH&^S+;&U8N\+95WL,M025=K+S#?&5
MZM^'"PTN=LL\9D81->DFYU0]=`7`J%7(NCO1$:(C1$:(C1$:(C1$:(C1$:(C
M1$:(J#/,$KK*Y^8CQZJ;S+#K&ZKW'F+9"-"N2>'(VY^ML<[2I4WT,KF+)E%=
M-G3ITJBF@M5XZRO51;*MWT>X25;-G!%>1.24A3J<[D&,%:\C24!$)"A!P:E8
M"X6MPU221%-HK89>FU3W7?"`J'%P\8-NH3;"0-BZ(JBO*_QW?(?)_(7(DCC&
MVX[I%IL^2H1)S9&V/FC.R9`KF;+C%7M>&K=-N,ZIC8T9:(V11>1X'L#26<B+
MTDN(I@5T170:(C1$:(C1$:(C1$:(H*9;X<W2]9LD,U8[Y/Y)PL_F1Q6ZFJQ7
M*K0[%!2LIB-OD)E7EG9['$N)!6*DF61G19"/,J9LY.V;J`!#)CU$4IL47&#O
M%"@)F"N9+^1LV&!E[2,5\7WDG9*\88BQ*RM;%I'J5N5/+M%3+L#-T/5C&Z2D
M`G3N1.+HB-$1HB-$1HB-$1HB\EUT&J"SERLDW;-TE%W#A=0B*""")!456654
M$J:22291,8QA`"@&X]FB),UF^4:ZK3+>FW.J6U>NKQK6P(5FQ1$\M!.IF%C[
M)#MIE.*>.CQB\K799J_;$7`AEV3E)<@&24(82)5Z(C1$:(C1$:(C1$:(C1%Q
M?Z(NJ;A=]$CC;^17'7XL1VB*36B)G.1%MN%"P)FB[X^CQEKS4<77JQU".!OZ
MT+NQ0U:DI"(2!KTF]9$7J!!\/80/MML.^B*JV/O7,V-B)!&@RCC(^(6',?%,
M-3,IRMXODYEJ[8O=47%,D+AO6V^.SU*<QC;[`^<JNWQ+$DT]6>.1*"8D!$"+
M6EYH\R;[7YF:QG'Q+7X@8YO%PLZ<E@>^OAG\@XGXP82R;.8B9)NY&%68.;'F
MJUS4$JNW*[6!HBLU9;O6X+ID2UR;RPY>XODZ96#5N3ODW'<DTL<3,I7<+RL?
M!9%HLG*X+,]EA-[HSKFO,JE$Y8FE2>YY5CK1]94>N'I/5GJ:I$[F%<M\K+MC
M7.+?)SAY'6ISQR;Y4QU8J1AJ4C9RF6JUS6?:@SI<)4)N8>(W^TU-CC&#EP:K
MN$%WTA,"F8B#19H0A%#)SRJY$8=X]W>Z8J:94R?(1F0/_1IN<<H<A*S<W4'B
MY6SO:95;UEVI5#,#`MIL3,&L@P6BGIF[TQV\.NALH($2HKN8^<]8S0TI8R]F
ML;',>7<Q*IV>Y5-^VC8RNQ6<+YBEC5*'5"-I%G%M<0X6J45:V*C$C!&=>R0.
M9==9!8ZXD4A_+:S=R1R?`P%'S3,)6LN+L#8GEK/DJ6K8UFXY.MV7ZU7;C7%;
M!6UGA7M-G\;Q#"5AIM)=`RLW('*_$C'8&RA%:IHB-$1HBK.XZ?J?(C\\7DO^
M.Y-$6LYI_1(Y%?DMG_\`YS71%:)HB-$1HB-$1HB-$1HB-$1HBJK\S'BQ(9^K
M5+?#R!@\<,8ZX1`1M4R?9L:4FAC9VT/9#5N=IMRGL,Y&M\-D-C85F<B"""BJ
M4BA%^`!6X&.MHBL>QI`*53'&/ZLM(QDNK6Z35(!66A8YA#P\HI#P3"./(Q,1
M%)(Q<7&/3-A50;-B$;H)&*1,H$*`:(EMHB-$3.<A,Q1_'S!^5<W2L#)VB/Q;
M1Y^ZN:Y#.&+25G"0;%1V$4P=R:S>.:N7QR`F51<Y4B";J,.P:F8PR/;&WSG.
M`'630*+6ES@P;20/'@J=\H<F:QF"RMK/DWR]+#:IZ.CT(1%PZY*TAHT&,9/'
M;Q)BYBHNQL8E\V%R]5$X+H*>*4XD/U$V+K;#R3K8-/S/\_\`^%9W_#FH_P"K
M_G?R)QC^:Y:*_:*AC9'A-;&4A8*S:9FNLV&:L.(P[2#H"U3CI1L8R+M-)@*`
MV]B5LB1,2F(!]ND"``TSR=K(E;$>#G<"1V]S:5^+^,%(=`OP\1GAYB"?.Z*5
MW>$*..-;]@;#M_=Y2Q=Y6K:BY`D;;-WR5L]<SWCR/D)BZ64BR=@L\T5.?]5F
M9J:(X,#EPZ3646[.H1Z2[3_X*UO_`%/\_P#^%3?X=U'_`%?\[^17+\3^22?*
M+&\W>S4&9QI)UG(UUQG/52;FX*QKM9NDOTF;MTTFJXNXBW\>^3<)J)&*)3@`
MB4Q0$-:W>6DUA=/LYZ<:,T-#4;`<#[JQ%Q!):SNMY:<1IH:8CI4G-6RHJ$/)
MKEQ+81R)3,2UC",YE^>NV/[A?GJC&]U"B1D)7JQ8*G5ET5WEG<$6?/Y%_<$A
M3(@79--(YC&`1*`\U[S.]?E/NFT^UU+FSUKU:\G=%'P(A*<[&9SF!>R@R[#C
MCN6Q<N<KZIS3<26VE<+B1,#G9W%HH304(:=_4JX,*/<4<<K*C;L%^5S$XOL*
M+F=>%?5/D)CN/(J]LZ:J=A>NV'NRI'/7LSXQC.%ED5%%%!ZQ-U@!@X]_[R>Y
MO_\`F/\`Y0?^<MN_Y0\W_P#I/]J?\Q7`\9\Z$Y&8DCLGC393'[Q:U9&ILO49
M>6B)UW$3F,\A6?'4T0LS`K+Q4DS=2=757;JI"'4@J3J*4W44/2'+7,&G\U\O
MV7,VD\3]F7]NR>+.W*_(\5;F;4Y74VBIITKG>HV$^EW\VFW67UF"0L=E-1F;
M@:'"H\-$_FLVK-&B(T1&B(T1&B(T1&B(T1&B*(7,+E@7B?6,<3*&,IW*LSDW
M(PXZ@Z[!V*MU86KI&B7:_O):1F+.Y;L$F3>*H[A("$ZU5%UDP`.GJ,&8T'0K
M[F/4V:3IN3UM[7.&=V5M&#,:FAW;,%2FF9;QF62N4$;/"JB)#DAAR6R&7*\G
MY;<^_P`@DM*5T2LKKD=35G2-F0E`FD9-!J>UC'-Q2E`\8J)$2H`;L`G2(AK?
M?^3?.7_H_P#;?_`K+]JVOXWB_E3JS'FN!EI#)V*)[A!?9:.A#P]:N\<OG7%T
M6V>$LU<C+8R18249,MGYTC1<BCXBB1T3D5ZB`([;C0B[H^;I9I8&>J9X7-#O
MSN]S0\4[&.!%?"ICJ=L`"<U#X/Y4W^+N9N-^,[>V63$WEVV:C%>1LQ*6,(CD
M+0GQ9!(KM]:9ASZA+V5\S]TY*457=+K%*19RY5,=0YC',(UG=SO.+&EY]3H`
M3]-T"OX"@-4M2:=KQ?RJ^?&-Z8Y0QKCW)D8Q>1D;D2CU.]1\;(&0,_CV-M@8
M^?:,7QFJBK8SQHA(%35%,YB"<H](B&PZY6LBEQHB-$1HB-$1HB-$54WFXQ5B
MD,&XR>0M7OMMBX+,*4O<(_'7QM4GV=63QID9J]F2LJ@DH\E21CAVB<C9P9)N
M9<4U`."Z2("12TX84V$IO'#&85>R7JQ56W5R(R)6"9%F0L-FKD'>X>.L;*J.
M)HS)@YD4H0'QB`JND58QS&Z@+V%*12ET1&B(T1&B(T1&B(T1-)G6%6G\29$C
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M`:G*H1*JW\L\S1G)3-F,Z]7HI_2\-)U8S:(;X%SG:7]Z<S.(VF27,=)<A*_,
M(X1PZX<2#XC%(\\T6*T1Z'*X&(NF&B*-W'+S-N0%W:23W-W'^KU^;G&E88XJ
MQMCJR1LG*VJRW*1P*2MH2]_E;JYK<&T?H\B8AJ8BS%$$%(YRZ47*"R;-$BE-
MD+S%J%C;*]MQ-/T2?">@\=.+G!-FMFIK^9GIYDVIBKRG2L'%2TD:FJH.L@1;
M;UU^X!(5E%#='@E356(G,I_+`]^RE+\?6>/;#0\VQ56FK'.0UN4@9V(H\8WJ
M=*D8.U3JU8LA6MCKDM;[J6(10C7X/EC,%E3E;(G35T11=0YQ9UQK2K#/9BJU
M#R'+/;ORPIU2)A:H3%1BZI'\1ARBO=+MD(<AY>FG$Q%V.,H**C)A%&1=).W)
M6IE%"J>M($2CG^?,,QR;:\.8]HU9BLIR-JPIX$W*OHB9AK(UOV6<-8'M]IMD
M12Y<DU#RM/=9+BTV+1^]]<?MFHIG%KZL9(I%.7`.50S9B"DY*5BBP4E/,'K.
MQP23@[UK"7&LS$C5+M#Q\@HBW/*1<7;H-Z@T>"FD+MLF1;H)U]($3PZ(C1%6
M=QT_4^1'YXO)?\=R:(M9S3^B1R*_);/_`/SFNB*T31$:(JM+7YDC5CS4BN*M
M*JV,;7`(9&J^(K?<U<VQ36X1N0YRO1ELF(2*QY$UR>(`5BOS21E!EY.(4>/F
MCQBV(HZ2335(K2]$1HB-$1HB-$1HBHT\Y?)&-VD/@ZN'FH5YD_'>4F.4$*D_
M2R%&J)PC&G7.4CY4;OC>WT.S4YVC.UQNXCS-'ZII&0:HL3MS^LDT16]X0]Q_
MD6Q!\7HME"0'R7T#W#A8V*<0,=$0_P`4XGW,BV$&[E)MU#,F#+H22:*/7BC<
MA`3,NJ)14,1.AHB-$4)O,B^@9RS_`"(7C[UJ:KVOUJ+TK/G!58?IV?+;Y0JI
M'7[9<?\`'J_KAM>@W><>M=3.U1_M?TE\&_DDY&??[`&K-_UZ+T<GEC5L_P"M
M1_(?Y6)^=7:N%85Y6?\`(QFO\[;/7WUB-<2YE^WKKT@^:U<[UG[4F^5]X*S'
M6#6,527,;Z9F)OS5\N?TQ84UX@]N/^$>7_WI/_=UVGN4^UK_`/5F?I$@0[P^
MN&OFZ=B]$J77EP?1I=?G"<MO]:++FOMAW(_]'N6?W-;?,7C/G/\`B[4OUR3R
MJ>.NHK64:(C1$:(C1$:(C1$:(C1$:(JDO-E_YCXB?G,S/^K1R"UTGND_CBW]
M#/\`HRL?J?U-W6WRJL[7K=:TF.QM_*]R:_?CBK^A.FZQ5C]HW_I8OT#%4?YC
M.H^4IR[O_P!"+K^\ZU?>"0UD)_H'_(=Y"I&^<.M='_$?Z*/&/\WK"_\`1O6M
M>!3M6Z*0NH(C1$:(C1$:(C1%3-YP&1L9?)Q2<8RZL1:;RVN\1<4L9SD'87$#
M*0AZW=VJ<S8[56'$):*>R8G9KF9KQ,FW<O)(K=BN11L[4(8BL[X^R(3&!\+2
MY9:;GBRF*,>R1)RR0\97;#,)OJG$NDY.<@(4B<1"2SXBH*N&C8H(-U3&(0.D
MH:(G>T1&B(T1&B(T1&B(T112YE6ZU5S"TC`5*L7:;>94>NL425CHM+R+D&1Q
M?!6VK6<93)+RK8E:NLBOV\.G'@S:FB_!52EG[,ZB[=`%5TR*.'ED8JJ>(:EF
M:L53$]EQ\@.08IVI9I+$N1<'U:_M7%78KQ8TK&^5(N-O$8QI+5<8ATZ?K2[E
M^Y1%4\FYW!%J16>:(C1$:(C1$:(C1$:(C1%Q?Z(NJ;A=]$CC;^17'7XL1VB*
M36B)A;MQ>X^9(M[R^WK$E.M%ND(.4KKV;EHX5W#F*FZK,46:352!4K4SR7I,
M\YAW3OP_6UXLQ&IU#((HD3(L2X<4>.U^F&4_;<45J7F6-Y)DE.0'W09+N;H1
MY5I(LQ*#'/F99HONE1X=R+5X"[,7,8V5%(5$B&`BR9GB_@J?R>[S+)T1)3(\
MB$:$M8&M@M<8C.>X\0:OQHV"!C)UG7)\S2$-ZH47K-<1;E*0=RD*`$6"YXD\
M;'40\@E,.4TD6_B$8-=!JR78JEC&R=&2:H-'K)RW?1ZK0F,X#P5D%$UD1B6X
MD.42;Z(OLKQ*XUS=BE;;*88HSJPS-;?U)[)>Y0(J%KTK#15?E(^/1;JI-8?W
M2AX".0<*LR(+K%C&0G.)F;84B)54;!N/,<6R1N%2BU8Q\]H%'Q@T8)JI!$PE
M)Q\]L\I`Q$4V3037%166N+]T[=.E7+MTLJ'6KTID*4B)3`.&)MBK&2V-ZL_8
M+NLHO5FCB/`Z*CO-A9<F67!B]8;J7XD^]"1'_P`?ZR?NWT1)![Q)X]N+#.W-
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M,9,LD7[/UV-?)(NV3D$%PZTSE`2FW[P[1(J*,B1F*WWFVTJRQ\1>7K^1NE1C
M8^^42XPP4.4O%7KI6EMQLNUJ#7W!C+)15F7NI96]ED!L\C&R#QH1DDU+$J/"
M+H$T1&B(T1&B(T1&B*O'F;CRLS+N&=9'SE@;&U'N4Q`UNOU/+O'7'.65K#DK
MU*8CHYY#/[A,-W4A85HA^=JT13:J*()B8A#[+"02*76"JA!8^PCAR@U>SC=Z
MU1\5X]J%=N8KLG0VZ"K51B(6)LXN8PQXYP,^P9)N_$;F%`_B[D$2B&B)U-$1
MHBA-YD7T#.6?Y$+Q]ZU-5[7ZU%Z5GS@JL/T[/EM\H54CK]LN/^/5_7#:]!N\
MX]:ZF=JC_:_I+X-_))R,^_V`-6;_`*]%Z.3RQJV?]:C^0_RL3\ZNU<*PKRL_
MY&,U_G;9Z^^L1KB7,OV]=>D'S6KG>L_:DWROO!68ZP:QBJ2YC?3,Q-^:OES^
MF+"FO$'MQ_PCR_\`O2?^[KM/<I]K7_ZLS](D"'>'UPU\W3L7HE2Z\N#Z-+K\
MX3EM_K19<U]L.Y'_`*/<L_N:V^8O&?.?\7:E^N2>53QUU%:RC1$:(C1$:(C1
M$:(C1$:(C1%4EYLO_,?$3\YF9_U:.06ND]TG\<6_H9_T96/U/ZF[K;Y56=KU
MNM:3'8V_E>Y-?OQQ5_0G3=8JQ^T;_P!+%^@8JC_,9U'RE.7=_P#H1=?WG6K[
MP2&LA/\`0/\`D.\A4C?.'6NC_B/]%'C'^;UA?^C>M:\"G:MT4A=01&B(T1&B
M(T1&B*KOS3+8]J^.<)I1AJXSD[!F@8=A+7?)"F/J4B`XUR`]G8:1;J6JD15V
ML-FIC24:0<,]EXUN_E#)HJ.4DE%#:(IF<680]:XS\>ZZI'5N(4@L*8OB#Q=-
MLIKG48\T=2H5H+.K6T[EZ:RUQOX72R?>,J#IL!%`.8#=0D3\:(C1$:(C1$:(
MC1$:(D'DV_1N,:):[M(-S21ZY6;1/L*\V>Q[*6M3RLUF8M2E=@1DW+5JO,OX
MZ#<"D4QP*4J9E#B5,AS%(H:\'>0V4.4#S)^1[G'0U'@Z](1E`;XZJ.3*CF*D
M(V&.9H2LE8(.YQ6/:)8T9`"R)FKPJBLQ"2*8-G,8Y*4JX*$5@VB(T1&B(T1&
MB(T1&B(T1<7^B+I_X;VZ*:\3^.3=1K93*(X9QZD<R%.MKI$3)UJ/(84G#:$5
M;KIB)?:G(8Q#!V@(@.^B*2?QVA_N.U?P'N?P#HB/CM#_`'':OX#W/X!T1'QV
MA_N.U?P'N?P#HB/CM#_<=J_@/<_@'1$?':'^X[5_`>Y_`.B(^.T/]QVK^`]S
M^`=$1\=H?[CM7\![G\`Z(CX[0_W':OX#W/X!T1'QVA_N.U?P'N?P#HB/CM#_
M`'':OX#W/X!T1'QVA_N.U?P'N?P#HB/CM#_<=J_@/<_@'1%7KQJ<INV?(-RD
M5<B:W,/DN8A7+9RS<``7D"[*M7:2#E`VY>XY"CMV[;"&B+!YK&`G$7D8<0,)
M28JL)S`0ICG$">K&$"$(!CG.(!V%*`F$>P`$=$3'>;%DMA(U:ET:%O.1J;=(
MFXU#*T'*1V*,\QL'CVMP3.[5&TWZY9!H%0EWJ=05?VZ-CW21&CTK1TNU(X0%
M%\"J9%-6H\HL>X<Q'QVKV8++DRQ9#N6+8MRW5@L)\C,B62YNJA7*K\=K0>.C
M,6/KLFT0>6%HHX<R[%DN)WJ8*D*J8Q`(H28/AN)N`<D1N2:5E'GT]>QU0K&/
M/<*R<*,C2,6\H%-E+M,URHNYEGP6C;\#%I)7^047=I324I(B"`/'3@$$P`BM
M*QER-Q7F"#E+!0'=UE&$'99>G3B$GB?*]4F8.TP16AY:#F*[;J5!3\8^:)OD
M3B59L0#D5*8HF`=]$3B_':'^X[5_`>Y_`.B(^.T/]QVK^`]S^`=$1\=H?[CM
M7\![G\`Z(CX[0_W':OX#W/X!T1'QVA_N.U?P'N?P#HBI4\W"A3F7!P8X97S)
M<='PMOL\C5\8US"<Q-M;%.5K&]HMH3SZPKP\;::Y;H24AFRL6[:2",4V1(HX
M>I$!L+M$BM&XY69E$\>L#Q<A7,B5]_&X8Q<Q>P%DQ]:&=B@W;2CP2#B'GVD?
M!G8-9N,63%%VDB(I)KD,4@](!HB=&0RE2XAW$1\N_D(F0L+U6,KT?*5VQQS^
MP22+)U)K1L"R>1*#F9D$8QBNY.@V(JJ5N@HJ)0(F<P$6T^.T/]QVK^`]S^`=
M$4+?,9ML6[X)\K6R36QE46PG=4R&<T^V-$`,I'&(457+J%1;H)@)NTYS%*4.
MT1``WU7M?K47I6?."JP_3L^6WRA5F.OVRX_X];]<-KT&[:>M=3.U1^M?TE\&
M_DDY&??[`&K-_P!>B]')Y8U;/^M1_(?Y6)^=7:N%.ORQ+)'Q>(,V-7+><44#
MEKG@PFCZS8Y5OL:2A3ALZC(MVU,(`<-P`XB`[@.P@(:XES+]O77I!\UJYWK/
MVI-\K^B%9%\=H?[CM7\![G\`ZP:QBJKY93+27YE8K,T1E$@1XKY9Z_=*%F(8
M1\3,6%^GPBR[%D*^WACU='5T]F^VX;^(/;C_`(1Y?_>D_P#=UVGN4^UK_P#5
MF?I$E@[P^N&OFZ=B]$J3'EWVB-CN.3YHX;6!15+D+RU`QV54L\BV'JY/Y:.'
MA/(^(<M%@Z3AN)#F`!W`>T!#7VP[D?\`H]RS^YK;YB\9\Y_Q=J7ZY)Y5.7X[
M0_W':OX#W/X!UU%:RCX[0_W':OX#W/X!T1'QVA_N.U?P'N?P#HB/CM#_`'':
MOX#W/X!T1'QVA_N.U?P'N?P#HB/CM#_<=J_@/<_@'1$?':'^X[5_`>Y_`.B(
M^.T/]QVK^`]S^`=$1\=H?[CM7\![G\`Z(CX[0_W':OX#W/X!T152>:E86$M$
M\1F[5":24+R5FU1-(URP1"`E)QIS^40*YE8QFV,H(G#8@'$XAN(!L`[=)[I/
MXXM_0S_HRL?J?U-W6WRJNK7K=:TF.QM_*]R:_?CBK^A.FZQ5C]HW_I8OT#%4
M?YC.H^4IR[MVTFZA[-.M/>.W_F&0](]@:R$_T#_D.\A4C?.'6NA7B9<8E'BM
MQF2.TLXF3X^88*84J7;UDQ$,;UK<2*HP9TE"^P)1$!]`Z\"G:MT4@?CM#_<=
MJ_@/<_@'4$1\=H?[CM7\![G\`Z(CX[0_W':OX#W/X!T1'QVA_N.U?P'N?P#H
MB/CM#_<=J_@/<_@'1$?':'^X[5_`>Y_`.B*G_G9Q=O/*K.%5L$K1K3<,98_K
M!5L?KUI[(TJP5:6>15N2R6V)%6R%&+E<F7M)6(AZQ)O4'=;AX]U*GD2)K':N
M$B*R+C\D3%^"<,XUG:^G!S6/\64&ERL+0,>WEC1HE_6*O%PSJ-J#-Q`BNVK3
M%9D*3(A_;%;E(`Z(G>^.T/\`<=J_@/<_@'1$?':'^X[5_`>Y_`.B(^.T/]QV
MK^`]S^`=$1\=H?[CM7\![G\`Z(CX[0_W':OX#W/X!T1'QVA_N.U?P'N?P#HB
M/CM#_<=J_@/<_@'1$SW(2[LTL#YI>1;R4K<Q'8ER6^A;1.TZULXFKRJ-(G@9
MV&0?NV,0A'L8E0_BKKF>-"IH`<3+)EW.!%`KRF95A4,*7"K3]9ME9O,78ZRK
M=(&1Q3.UBQ)RCVAUXY)J7B(^1LCI1O8`2.NS?+M(4C]'=1%DFF&P$5JWQVA_
MN.U?P'N?P#HB/CM#_<=J_@/<_@'1$?':'^X[5_`>Y_`.B(^.T/\`<=J_@/<_
M@'1$?':'^X[5_`>Y_`.B(^.T/]QVK^`]S^`=$1\=H?[CM7\![G\`Z(CX[0_W
M':OX#W/X!T1<;_N@W_X-][V27[DT1=6G"[Z)'&W\BN.OQ8CM$4FM$1HB-$1H
MB-$1HB-$1HB-$1HB-$1HBK.XZ?J?(C\\7DO^.Y-$6CYOND6'#SDJ_<`L+=AB
M*T/G`-FSAZY%!FDBY6!LR9I+O'K@4DAZ$42'55/L4A3&$`$B2V7K+Q$R_D@N
M39F0YBUZQ%AJ[%NF4)PQY$/X5Y)T1:VO<=6%Y'W7BG;E!?T2:NSY\BQ(H2$E
M70(>Z[&12;()$(M)7[UAU[R!X;8EPTQRXRKN(^-_)2O,!REA[-F-7"D+'N>-
MD3'>#-9;H%*0LTETM0,X*R,LHEU`8Y$R"71%.K<?9']$=$2(X3#N7E@(]H_/
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M7I6?."JP_3L^6WRA52.OVRX_X]7]<-KT&[SCUKJ9VJ/]K^DO@W\DG(S[_8`U
M9O\`KT7HY/+&K9_UJ/Y#_*Q/SJ[5PK"O*S_D8S7^=MGK[ZQ&N)<R_;UUZ0?-
M:N=ZS]J3?*^\%9CK!K&*I+F-],S$WYJ^7/Z8L*:\0>W'_"/+_P"])_[NNT]R
MGVM?_JS/TB0(=X?7#7S=.Q>B5+KRX/HTNOSA.6W^M%ES7VP[D?\`H]RS^YK;
MYB\9\Y_Q=J7ZY)Y5/'745K*-$1HB-$1HB-$1HB-$1HB-$527FR_\Q\1/SF9G
M_5HY!:Z3W2?QQ;^AG_1E8_4_J;NMOE59VO6ZUI,=C;^5[DU^_'%7]"=-UBK'
M[1O_`$L7Z!BJ/\QG4?*4Y=W_`.A%U_>=:OO!(:R$_P!`_P"0[R%2-\X=:Z/^
M(_T4>,?YO6%_Z-ZUKP*=JW12%U!$:(C1$:(C1$:(H49?S%E['^4+K$2$5:XC
M&,EBALTPW9,;X!R+R!EI/,$D[>EF'UT0H17:-28TU)NP(Q82I(R/G`DEE!DT
MO4U"%(GLXZU.<IN%\>Q-IAG-9MSBMQ<U<JHI=;)D%C5+C.,T)2UUN!M%LF;!
M-/:Y#S[EPBQ(H\731;E*1,WA@71$]>B(T1&B(T1&B(T1&B*#WF&8ZLV1N,EU
M:UNY2E`+68RVVNR6Z'S#D'";Z`J;7&=]AYR<3M..*C>Y>6"O(S99'W'<Q+MC
M)"S`AP34!)4A%#3R0W#EM@C*U9<LYJ,-`Y-9J$C)>+DHLS(DI488QR'0?-&I
M6LJ9PT/ZZT,4CMJL``X22,8H"176:(C1$:(C1$:(C1$:(C1%Q?Z(NJ;A=]$C
MC;^17'7XL1VB*36B(T1&B*)/)[F7C/BI+8FK5SJ68K];\VR5UC,>4O"F,9[*
M-KF%,>552Z6]RI$06RK1E$5Q$RYE#C[?IZ2`8VP"1(_`OF0\-^2-G1IF,<S5
MY:T2%.Q[>X"!M"A:;,VJNY*ICV^0CBKP]E/'2TVYBZ_&N32J"*`JQBS=1-<"
MB0VQ$ZY.8?$Y2LL;H3DM@DU1D[8I1(^S?*M2`@GER121<*UA"4&:!FI-I-7"
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MSF%LK;.0GI'%KZ/Q^Q"=KKZZ3U;)D>`8J2$1<UZ(D1UZTBPDH]B>18D?BF#U
M/1%8QHBA-YD7T#.6?Y$+Q]ZU-5[7ZU%Z5GS@JL/T[/EM\H54CK]LN/\`CU?U
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M9VO6ZUI,=C;^5[DU^_'%7]"=-UBK'[1O_2Q?H&*H_P`QG4?*4Y=W_P"A%U_>
M=:OO!(:R$_T#_D.\A4C?.'6NC_B/]%'C'^;UA?\`HWK6O`IVK=%(74$1HB-$
M1HB-$1HBYT/-NPS4LS\B:2G'XTXQ/KW7\;1D&YRW93\DK+R"A%K%.3LC5\=0
M=(P]@[(>/GS*VM8J24CVLT_5G7R1)!6,9@1HNJ)%>CQ^)%IX(PNE!OX"4AD<
M58^1BI&J.(YW5WL>C5(I)FYKCJ(KU2BW$&J@0HM#MXJ-1,ATB1JW+LD0B=[1
M$:(C1$:(C1$:(C1%''DY59^TTRL&KUDA(QS5K]$71Y3[3>)G&U4RQ'UJ&L+U
M;'MGN]<;OYZ`AR+>'/&409OT558--)ZU<1RCQ(Q%C\=<<7ZFKY5MU]/#03S+
M-Z&\I8RJERG<AU"AO%HQLQFG,/=+-`U65EG5UD6XR;M).+CF#,ZA4&Z&Q%%E
MB*2VB(T1&B(T1&B(T1&B(T1<7^B+JFX7?1(XV_D5QU^+$=HBD;)24=#1S^7E
MW[.+BHMFYD9.3D7*+*/CH]DB=R\?/GCDZ;=HS:-TS****&*0A"B8P@`".B),
M1&1\?S[.LR$)=:M+,;I*R\#4'<?.QKMO9YNOH3KF>AX)5%R<LI*0K>KR1W;=
M'K5;ECW`J%+X*G21+31%!GEMP)Q%S0R-QJMV:2#8*?QXF\JSI\;.&[LL1?'6
M3,>K4-,LK+QDM$RL62N`MZXF"(J%<G#PU"]`[Z(HMY8\K+"D9;++F6$RLSXZ
M52M7OC_E"O?%:FTN`B,.UOC3QXRM@J#K]=F9%0L?$PAF>3CS`'50%!JY8$3%
M%4BJ@Z(H08[\CC%64L)N%\?<V6=^=V7,`96C\^4W'K5[882T,<+4K`E@=TVS
MQN675AAK2]94!"0>G<2SR+=/G"Z#N*69^`W1(IN\4/+^P#QYY*YVYJ0'(DF3
M(D)'.)IIY9GK1TIC6U7J3IUESHI:L@DM2U>4:,'=%054;)Q$2+$AS>N*N100
M,D13*P+C3'/!#CE(P%MRK'&H,/D;,>3Y3(MQ&-JL7'_+OF^Y92+'NUO7%F"+
M2)E<AEC&ZQE0%R5(AQ`ICB4")\:#F[#^5*BTO^-<ETJ^4=_,M*ZQMM3L4;.U
MU[.2#B/:,8QI+QSA=DY=O'$LV(D4AS>(*Z?3OU!N1*2T7ZCTA6$0N-OK=66L
MLB6(KR5@FH^(4FY0PI@#"+(^<(&?._TXNY$^HP`8!'1$K=$1HBK.XZ?J?(C\
M\7DO^.Y-$6EYN_0]Y*_DBM'ZTCHBE6[_`&TY_OA;]<-HBBY>_I=\8_R-<M?O
MKQIT12;T1(GA+]KRP_/*R[^+^/\`1%-[1$:(C1$:(FNS9E^H8"Q/?<S7[W7&
MG8YKSRRSY*_%KS<XLR9]!?5XF(;F*M(R#E94J:211+U',`"(!VZF8UTCQ&P5
M>X@`=))H!XU%K2YP:W%Q-!UE5.Y/YB8-R;:`G9FL^9=6$",6L0_J%!93U*I\
MBV9KN3N2/X:"N3<QG$DFY,BZ6263642`H`<HE`0SG^&-?&'JS_&W_.63_8NJ
M?Z%WC'PJ8?&?FC@W+EQC>/&.<;Y8Q1)UO%3ZUU.NWC&:=%K:6/*#*4VCN&58
M59R4C&HEKCBWQ*";/9+I04`4P$B9NFPO=+O]-R^O1&//7+4@UI2NPG94*UN;
M*ZLZ>LL+,U:5IC3;L*K4XLU4]_YW0N3,/L^1"&$\:S4C4Y.2OLX7($/*W4<:
M/(:^O)F;9Y'GEJ8N_G&S,RK-RV7;N3D;F:B1MX+9E8*U70WHBA-YD7T#.6?Y
M$+Q]ZU-5[7ZU%Z5GS@JL/T[/EM\H54CK]LN/^/5_7#:]!N\X]:ZF=JC_`&OZ
M2^#?R2<C/O\`8`U9O^O1>CD\L:MG_6H_D/\`*Q/SJ[5PK"O*S_D8S7^=MGK[
MZQ&N)<R_;UUZ0?-:N=ZS]J3?*^\%9CK!K&*I+F-],S$WYJ^7/Z8L*:\0>W'_
M``CR_P#O2?\`NZ[3W*?:U_\`JS/TB0(=X?7#7S=.Q>B5+KRX/HTNOSA.6W^M
M%ES7VP[D?^CW+/[FMOF+QGSG_%VI?KDGE4\==16LHT1&B(T1&B(T1&B(T1&B
M(T15)>;+_P`Q\1/SF9G_`%:.06ND]TG\<6_H9_T96/U/ZF[K;Y56=KUNM:3'
M8V_E>Y-?OQQ5_0G3=8JQ^T;_`-+%^@8JC_,9U'RE.7=_^A%U_>=:OO!(:R$_
MT#_D.\A4C?.'6NC_`(C_`$4>,?YO6%_Z-ZUKP*=JW12%U!$:(C1$:(C1$:(J
M2^>&("S_`"&);)?'*,$C*16)$ZCE6NXPY<9DL-HEJB_O1I@KJ$XTWZKQ%5N>
M/6=B(RK:M@3CVKI&ROEPE`!D=MHBM4X]UR0I^!L+U.5HT)C*3K.+*%`2&.:U
M(N)BO41Y$5>+8.*A"2SMT^=2<7756XM$%U5UU%DT@,910PB<2)X-$1HB-$1H
MB-$1HB-$3`<G\)8FY`80R!CO,\!1)FGO*M:'(261*I`7&!I$DI59V(3OA(FQ
MIC'%>UF/EG*H*B=$W@&53%0I%#Z(F'\OCC<RXX8HL$9"V['%LK=TLQ+'!*XM
M2,^K#=%C%,Z\[53N#YY)3EJ<OG<48Y_6'"B+`2^KMP*0HAHBGOHB-$1HB-$1
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MT>WCF+I9`CUR0IVJXMFRBG6118-Y?W*>OUK*KFQ.,=7,MFD+NC3*)2'RI&T=
M.Y1P9;\(2=P32D:C5V3('>0+2PM+]Y).I2=2B&!?7Y65D6@.%B*]Z`8O(N"A
M8R0?J2K^.B8UB^DU>OQ9%XT9HMW+]3Q3JJ>(\63,H/48QMS=HB/;HBVVB*L[
MCI^I\B/SQ>2_X[DT1:7F[]#WDK^2*T?K2.B*5;O]M.?[X6_7#:(HN7OZ7?&/
M\C7+7[Z\:=$4F]$2)X2_:\L/SRLN_B_C_1%-[1%!#D;R2R-QYR4^LMA7PU%\
M<X/'=+DG"-\N,+CW(-ZO,];[O!V>*QI9[1;HZJO9&GQ[>LJ&BY!DU2?'FBID
MD4U3D3`B??C!DBZYAX_XIRCD.H2E!N-\JC2S3-,G*S.4N<K@R:SA=A&3=2LQ
MSV"N3",89'UIF\'QVZXG(8`$-@(GXT103\S;Z!/*#\FKG[[16KFR^NP^F9\X
M*M;_`%B/TC?*%5V__;SW^^W/Z\?7H%WG'K74CM3E<,DR+<_:NDH7J35X;\AD
MU"CW&(?-/%@IBCMV]I1USOG[S;3KD_H+4^:-D'^7_14NJ;Q]X^\-[[59&L9<
MY$2]A<1V/*&WQ,&5'60S.*!58J9J%&5D\9@@I99&B8ZB7[HXN6B*RK9-$5U?
M&\$YB\Y6IJRS1%";S(OH&<L_R(7C[UJ:KVOUJ+TK/G!58?IV?+;Y0JI'7[9<
M?\>K^N&UZ#=YQZUU,[5'^U_27P;^23D9]_L`:LW_`%Z+T<GEC5L_ZU'\A_E8
MGYU=JX5A7E9_R,9K_.VSU]]8C7$N9?MZZ](/FM7.]9^U)OE?>"LQU@UC%4ES
M&^F9B;\U?+G],6%->(/;C_A'E_\`>D_]W7:>Y3[6O_U9GZ1($.\/KAKYNG8O
M1*EUY<'T:77YPG+;_6BRYK[8=R/_`$>Y9_<UM\Q>,^<_XNU+]<D\JGCKJ*UE
M>:QQ3254#HW33.</$/X2>Y2B8/$4Z3^&3L[3=([!V[#HBBCQ_P"5C?.CL8QS
MAO,N.G.\LFRL-GIDBKC.RFAE$BK.:?D)L@1A+14H@<SF,<NF[`)!H7K3+UCX
M8$4LM$1HB-$1HB-$1HB-$527FR_\Q\1/SF9G_5HY!:Z3W2?QQ;^AG_1E8_4_
MJ;NMOE59VO6ZUI,=C;^5[DU^_'%7]"=-UBK'[1O_`$L7Z!BJ/\QG4?*4Y=W_
M`.A%U_>=:OO!(:R$_P!`_P"0[R%2-\X=:Z/^(_T4>,?YO6%_Z-ZUKP*=JW12
M%U!$:(C1$:(C1$:(HC<C:!PQ-)0U[Y-4C$<C,S"9ZC!3]]K+&9F)%&%BYZU&
M@H\YF+Q^X28QK1^Y!(A1*`B8`]NH4IB)S..-RC[_`(1QM;8*IP=,J4S5(9W0
MXBKS)9VK*X]58-ST25K3T\)6)!&#E:H9HN@U>Q<:^9E/X"[9,Z8@)$]NB(T1
M&B(T1&B(T1&B*.'+E;*J''',*V&;K7,9WM#'5Y>1N2[1$REAC:`$93IZ4)9B
MUV&(:2FG3=ZR11(5'J.U!<7947AFX,71%7UY14!&,X/,[EU7,=P=KKLU3JTJ
MYQ9"76,J\O7IRE05V:NW5FN+EU)9.D1EI9UTR3IP_P#<[=5JR539G`%2*Y31
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ML/IF?."K6_UB/TC?*%5V_P#V\]_OMS^O'UZ!=YQZUU([4YG"_<?,`JH%$"F'
MASR$Z1$.H`'Y:N*^PB7<NX`/HW#7.^?O-M.N3^@M3YHV0?Y?]%#NK5HWF^UT
M)YG15[O'_%6Q2L[8Z'D:"M=SG0P$[BF,KC:<*I:*:[JE5*Q>F;M?=-B6,=RD
MH@NBY64375YRM35\FB*$WF1?0,Y9_D0O'WK4U7M?K47I6?."JP_3L^6WRA52
M.OVRX_X]7]<-KT&[SCUKJ9VJ/]K^DO@W\DG(S[_8`U9O^O1>CD\L:MG_`%J/
MY#_*Q/SJ[5PK"O*S_D8S7^=MGK[ZQ&N)<R_;UUZ0?-:N=ZS]J3?*^\%9CK!K
M&*I+F-],S$WYJ^7/Z8L*:\0>W'_"/+_[TG_NZ[3W*?:U_P#JS/TB0(=X?7#7
MS=.Q>B5+KRX/HTNOSA.6W^M%ES7VP[D?^CW+/[FMOF+QGSG_`!=J7ZY)Y5/'
M745K*CYRJDJ)#<?LF2V2,;O<NU2-@TWKG&T=4#WR0MTHWD62M<BF56*DJ22<
MGL16IB"KX:"!B^*JHFF0QRD50WDFUZYL)7-]BL="RSCYO::%A.8D(K*%!B\=
MJ)W:74OU@ML'%5MC$L@BF='?S`PS-!%8Z(Q+1FHLDD^4=`)%?JY=-F2"CEXX
M0:-D@**KARLF@@F!C%(45%53%3(!CF``W'M$0#1%5AQ*MK:T\JLBL#94SY<K
M#2Z_FV%LM(O<LLG5,>@_SK'N:ZQLD&@DSJK^SOH9B5:NOH@9$[2(4?-':S4`
M:M1(K5M$1HB-$1HB-$527FR_\Q\1/SF9G_5HY!:Z3W2?QQ;^AG_1E8_4_J;N
MMOE59VO6ZUI,=C;^5[DU^_'%7]"=-UBK'[1O_2Q?H&*H_P`QG4?*4Y=W_P"A
M%U_>=:OO!(:R$_T#_D.\A4C?.'6NC_B/]%'C'^;UA?\`HWK6O`IVK=%(74$1
MHB-$1HB-$1HBI(\VU?-=7@ZS9JY;GZ=/E[[2XFHT^M5.2L5R2N,31LMS%@LT
M9-L%W9ZY%H0*!4EFQ8U0[MQX2@/$CID;KD5BO##)M9RKQFQ#.5I^Z>&@Z36Z
M59D)"+<PDI$W&I0,9$62*DXEVV9K,7;9^B)NGPRE,FH0Q0`#`&B*46B(T1&B
M(T1&B(T1&B)L<V,SR.&LMQZ;0C]1]C&^LR,5%YAJF].YJLJ@5H=S78N<L#<C
M@Q^@3L63QX0!W1054`J9B*!/E/R.2)'CPZ^4>?//2$=)5^#3]T,IP>3)^'>U
M^FP4'+PDN$%8;@:KD9+QR8MF4G)JSA$C]#Y%!1(/$(K1-$1HB-$1HB-$1HB-
M$1HBXO\`1%T_\-IR81XG\<DDJ7/.DT\,X](1RB_JA$EREK4>4JR97-B;KE(J
M`=0`<A3``]H`.X:(I*?&&<_`2Q^^--_C1HB/C#.?@)8_?&F_QHT1'QAG/P$L
M?OC3?XT:(CXPSGX"6/WQIO\`&C1$?&&<_`2Q^^--_C1HB/C#.?@)8_?&F_QH
MT1'QAG/P$L?OC3?XT:(CXPSGX"6/WQIO\:-$1\89S\!+'[XTW^-&B(^,,Y^`
MEC]\:;_&C1$?&&<_`2Q^^--_C1HB/C#.?@)8_?&F_P`:-$5>G&M51=GR#56;
M+,U#\P^2XG:KG;J+(B%Y*'2H=JLX;F$0#?VAS!L/?OOHBUG-WZ'O)7\D5H_6
MD=$4JW?[:<_WPM^N&T11<O?TN^,?Y&N6OWUXTZ(I-Z(FLX;2TDS5Y8)-*Q+R
MR?SR<N#ZTR=UY%$1&NX]-L!).:8.-RB82C[3;<H["(;#HBF=\89S\!+'[XTW
M^-&B*KSS;7HS_&6IUZ5QU>%Y&:SWB]&J.JV,7.VZ&M$2,]9V$W4:M!WV%+;+
M`P;P*PIL7;@K8R9E%0_3TD1`BE/PULMO'C%AI"6P->L:O6-)A&2M6FIJJN':
M1DX]LJL_2!_>)&9:,G[I90R3>0]7?(``D4;H@!"Z(I.?&&<_`2Q^^--_C1HB
M@YYE<W+N."/)M%>GSK%)3'"Y3NG#ZKJ(HE-,Q!3**$9V!TY,1,HB80(F8P@'
M8`CL&KFR^NP^F9\X*M;_`%B/TC?*%6^__;SW^^W/Z\?7H%WG'K74CM2\X@/7
M;'GW4%6<0^F5#\/N0A#-V"\6@HD3Y:.+)O&.:5D(Y`R>X=.Q3F-N/=MN.N=\
M_>;:=<G]!:GS1L@_R_Z*R:Y;>/V4?,V97VD5S&V59]Q+-Y1*[$ROCZ&N$)98
M'$2<!&0]&9JY0LRV8(>OL$)57U>&8032'>2\F5YZVL05-<Y6IJW_`"C=G$70
M;:$G6)^*&1K-F81Y_C[1J*\=R'Q:EWI&D5;W-L22K4F+5DJHG("8`8`D+DP@
M5(P@14)U6^4.[\`/,2L>/(R^S2CO!M%K]ML=MR;4;2_4E*[B3W,7`:HRGA<P
M,)&/!=%CI-!LFUG8L&Y&B8%8"F2O:_6HO2L^<%5@^G9\MOE"4CK]LN/^/6_7
M#:]!NVGK74SM4?[7])?!OY).1GW^P!JS?]>B]')Y8U;/^M1_(?Y6)^=7:N%.
MSRQ):29X?S8DTJ\Q+)ARUSP/K3)W7D41WDH4P@!)*;8.=RF,)1W3#M*.VX;"
M/$N9?MZZ](/FM7.]9^U)OE?T0K(OC#.?@)8_?&F_QHU@UC%57RS?O7W,K%8O
M(20A13XKY9Z"OW$0N*_5F/"X&\,8J3D2E\,"`(]8EWZ@VWV';Q![<?\`"/+_
M`.])_P"[KM/<I]K7_P"K,_2)*AWA]<-?-T[%Z)4F/+NF95KQR?(-JE-22*?(
M7EJ!'K1[6DD%@'D_EHPF33?SS)T4"F,)1ZTRCN4=NS81^V'<C_T>Y9_<UM\Q
M>,^=/XNU+]<D\JG-\89S\!+'[XTW^-&NHK64TN<<PY)Q;C&Q7BC\=[]F&SPR
MD*2.QY79NKLYB>+)SL;%/3M7#-[87"81+%ZH\4Z6BNZ;<P#T`(G*1(^@\@*Q
MF7)#]QA[+5:R!%T.'=0.3,2TJRX6NZT-/NY9^UC9Z3G8*\FLU6F&$G`OHT[=
MQXS%QZLX)X)'"0J$(GTG5%[-#2=?G,<V)[$3#->/D&WNM56YE&S@@IG%%RTM
MJ#MHX3WZDED5$UD5`*=,Q3E*8"+GY\K.D8RH7-;D<;%D);Y!I4F&<,=Q[2Z9
M"@\BWQT_=9IIU]O4FVM+Z+J<@E`)FL,$58LNXD9!ZNLD<KQZ=%VJ4BZ'/C#.
M?@)8_?&F_P`:-$1\89S\!+'[XTW^-&B(^,,Y^`EC]\:;_&C1$?&&<_`2Q^^-
M-_C1HB/C#.?@)8_?&F_QHT151^:G*23V*XC)/*U+0Z8<E9LX.7SN`72,<O&G
MD``(@2+F9%QXAP,(@(D`H`4=Q`=M^D]TG\<6_H9_T96/U/ZF[K;Y575KUNM:
M3'8V_E>Y-?OQQ5_0G3=8JQ^T;_TL7Z!BJ/\`,9U'RE.7=O\`H3=?WG6K[PR&
MLA/]`_Y#O(5(WSAUKH6XF3TTGQ6XS$)2;`N0O'S"X%63?U(J:@?)O6O;$*M9
M$E0*/^^*`_4UX$.U;HI`_&&<_`2Q^^--_C1HB/C#.?@)8_?&F_QHT1'QAG/P
M$L?OC3?XT:(CXPSGX"6/WQIO\:-$1\89S\!+'[XTW^-&B(^,,Y^`EC]\:;_&
MC1%7)SIXL9UY3IQ#:NSRZV.V#FDNK+QUR$:*B\<9`)5K_!VV=2E+C1;@6SI+
M6^M1;F!4;O64DP32>BKTDV.4Y%-7$;]&*QK26=6P^SI\0C6H5%*L4*PX^F*E
M`K-(QJQ<0L'-QDS%M)MA#*-1:).RMD!7(@!A33'VA2)QOC#.?@)8_?&F_P`:
M-$1\89S\!+'[XTW^-&B(^,,Y^`EC]\:;_&C1$?&&<_`2Q^^--_C1HB/C#.?@
M)8_?&F_QHT1'QAG/P$L?OC3?XT:(CXPSGX"6/WQIO\:-$4>>4F866,\*W6TV
MY[.XSCDJ]:F#)^:Y8VJ;ZR3TC2[,V@:G`V.6L:JD19G\F9-S'+,^EV5XT3Z>
MI,5"&(H9>4A:KA+<>[#9'M0?2K.R74TG'S,;3:#2'4FM[AQC><//RS1U#J9`
MLC6>2<(OI=9>055<D.47!P+HBM3^,,Y^`EC]\:;_`!HT1'QAG/P$L?OC3?XT
M:(CXPSGX"6/WQIO\:-$1\89S\!+'[XTW^-&B(^,,Y^`EC]\:;_&C1$?&&<_`
M2Q^^--_C1HB/C#.?@)8_?&F_QHT1'QAG/P$L?OC3OXT:(N-SUQU_BIY_]6CO
MW=HBZMN%WT2.-OY%<=?BQ':(I-:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%6=QT
M_4^1'YXO)?\`'<FB+2\W?H>\E?R16C]:1T12K=_MIS_?"WZX;1%%R]_2[XQ_
MD:Y:_?7C3HBDWHB1/"7[7EA^>5EW\7\?Z(IO:(JJ_-/FFMGP]'XOJ937#(E;
MR7@S)]CQK#&H4S/!C1W<;'&$MLCCV_0=D:7^N-9*LO3D8LF*[TKY@FX*HU*W
M%RD13@XR-Y%IQ\PZTEH5.O2+6@5ULZAD4JTW19*(,4T@*@TIR#6M,4%2$!0C
M=HDDFW*<$Q(4Y3%`B?31%!/S-OH$\H/R:N?OM%:N;+Z[#Z9GS@JUO]8C](WR
MA5=O_P!O/?[[<_KQ]>@7><>M=2.U.=PM_P#U@-4_,ZY!_P!-?%?7.^?O-M.N
M3^@M3YHV0?Y?]%/=D->RJ\^&T/7[!R4I;NQVNF5]9I0).I5;%3N#9XQ>W0,F
M6>N7/XX(938O):KC6I!2-9Q3E-%OX*IT!:(*2/.5J:L5Y`4&CY1PAE>@9*K:
M=OHEHH5EC[-6SM9=Z,M&A%N')VZ#2OLI*>7>`J@4Z!6+9P\\8I?`345Z2B1<
MYW&ZLX\B/*Z\Q6>QZ>12CK/C4W1!R'J=A7J<;6*._J[*LOLDL:Q5QLDTTD8M
M^NYBWB2LC"IN45#J&:OV8ZKVOUJ+TK/G!58?IV?+;Y0G<=?MEQ_QZOZX;7H-
MWG'K74SM4?[7])?!OY).1GW^P!JS?]>B]')Y8U;/^M1_(?Y6)^=7:N%85Y6?
M\C&:_P`[;/7WUB-<2YE^WKKT@^:U<[UG[4F^5]X*S'6#6,527,;Z9F)OS5\N
M?TQ84UX@]N/^$>7_`-Z3_P!W7:>Y3[6O_P!69^D2!#O#ZX:^;IV+T2I=>7!]
M&EU^<)RV_P!:++FOMAW(_P#1[EG]S6WS%XSYS_B[4OUR3RJ>.NHK64C,BQ$Q
M/T*X0M?L#ZJ3<I7)=E&6.,BH2<D8=XNR6(D]90]D0<P,DY2$?:(O"&;G$=CA
MMHBH0\D23<-[9EJMV'(6+;5-1.(<+UV)C*1D7$T^_8L*LYN)GBKJI8^B&B49
M+RS*<CI6RKQ;U_#IV>2>MW)C3*<BY<D71%HBH9X$-^0$KSGS[=D(^2B\-71_
ME24FKK:,8VI!UE%C`9-5AJ(F[FS9AE*C7K'!+OI.'B%6,>H96/K$I[H1K55V
MR<F(KYM$1HB-$1HB-$527FR_\Q\1/SF9G_5HY!:Z3W2?QQ;^AG_1E8_4_J;N
MMOE59VO6ZUI,=C;^5[DU^_'%7]"=-UBK'[1O_2Q?H&*H_P`QG4?*4Y=W_P"A
M%U_>=:OO!(:R$_T#_D.\A4C?.'6NC_B/]%'C'^;UA?\`HWK6O`IVK=%(74$1
MHB-$1HB-$1HBK`\U#-]SX^8HPYD:F9&FL6K-<_5"'G[1%3V/6C;XJ3L-8XRS
M-YBI9"AK"WR(PCH1RO+!%Q[0TB"T61=-5$J1E`(I<\47E1E>/6*I^G-*:S9V
M6H0UBFTZ$\HC^N*7.68-W5U<(O<9%3H+J07LYG1GBD20C,SL5!3*`#MHBD-H
MB-$1HB-$1HB-$1HB8#DA9FM6H+%VXSHOQ]5D+7#1+&Z,ZO6KE(2#MVB_4-7F
ME?M$%9&;A-1FW6?O'";431\?'N':RB+1!RJ0B:'A-9L5W:&R];*-D:Z93O#S
M)[R#R[=+Y2ODVEIRQU&)CZY`R,)2V==JE<-1G-78-@B)V(9JQUB1(9VD\=]I
MRD4W=$3;98RA#8?I<A>K!!7:?AXHY/=!K0:A,W:;:-/"67<2BT-!-W+U.)CT
M$#'<N!+X:!.TP@&B)N>./*C%?*:%L<[BY.\-VM5>P3*6;7V@6K'DH4UEKD?;
M(1RUBK;&QC]VQ?04H@J"Q$Q(103HG$JZ2J9"*1^B))7"_47'L>G+WZYU2DQ2
MR[=JC)6VPQ%<8*NG;QI'M6R3N8=LT%'#E^_003(4PF.LLF0`$QR@)$K=$1HB
M-$7%_HBZIN%WT2.-OY%<=?BQ':(I-:(C1$:(HVM>87&![EE'!+?-]!-F!U-9
M&K;3'AY<$;*]G\15ZK6W)<,Q9+I)^O2=,K%UBW[Y%(QU$VCLJH`)"G$I$U*/
MF9<#%[Y3<:$Y/XT+<L@,:!)5*-6=RC=E*M,JL1D<:F&P.(M*N1RUZ:;#%I.G
M:"SPQBD3*8YBE$B<')_-CBUAG+]9P%DG+\'6\QW".KTQ7L?C%V:7G7L3:["Z
MJE=E%B0,'*-8V.EK$Q6:)+NE$4A52-N8``1T1+['W(G">5)VRUB@9%@+%8:;
M"5NR6F&1,\92,#!7":MM=JTI)-I-JR4;M)Z:HDNW:F$/TT[!3;LZ1,1*FV95
MQU1;/CJEVZWPT!:\MV-]4<;0+]P))&X62-JUBNKZ(AT"$.*KIM5*E)/C=707
MP62H@(B&VB)P-$1HB-$1HBK.XZ?J?(C\\7DO^.Y-$6EYN_0]Y*_DBM'ZTCHB
ME6[_`&TY_OA;]<-HBBY>_I=\8_R-<M?OKQIT12;T1(GA+]KRP_/*R[^+^/\`
M1%-[1%%S.>/^($9,!FCDC3L*&>R$;6,9_*'F:"K4G#QD7&2-LG:S`'F;FV=U
M^J-5YBS2(E6$S0'KMTD@=157U1,")T<./S/:,R;I8_@<:Q4*^DX"MUVI3=9G
MZ>I5XAXHUK\K5'M429QS>'?QA4Q]4.T9K,G!54!3,1,BZQ$Z6B*"?F;?0)Y0
M?DU<_?:*U<V7UV'TS/G!5K?ZQ'Z1OE"J[?\`[>>_WVY_7CZ]`N\X]:ZD=J<[
MA;_^L!JGYG7(/^FOBOKG?/WFVG7)_06I\T;(/\O^BE"KZF7SA;`N647C2MOD
MW1?-QCL+7&&DW\WA*UI0S<UDG\D1&4,1S3PM?=`2(BX%^XE?4_6CCZLY*=/G
M*U-7"95EE('%^2)Q)"?<JPM"N$LFVJAS)VEPI'5Z1>$0K2A?;$GU3(]+,0[0
M<"0=$7-KA6C9SKOEQ\_9[(5J6=X^G<&.GU-A8Z:QY9:K89*1IK4BM]CI>G4*
MDG>2<G6X>/>/I-L"\;-/IEP'69>/%-O7M?K47I6?."JP?3L^6WRA.FZ_;+C_
M`(]7]<-KT&[SCUKJ9VJ/]K^DO@W\DG(S[_8`U9O^O1>CD\L:MG_6H_D/\K$_
M.KM7"L*\K/\`D8S7^=MGK[ZQ&N)<R_;UUZ0?-:N=ZS]J3?*^\%9CK!K&*I+F
M-],S$WYJ^7/Z8L*:\0>W'_"/+_[TG_NZ[3W*?:U_^K,_2)`AWA]<-?-T[%Z)
M4NO+@^C2Z_.$Y;?ZT67-?;#N1_Z/<L_N:V^8O&?.?\7:E^N2>53QUU%:RDA>
M[;4J1592PW>R0E3KJ0-(UQ-6&8BX*.(_GGS:"A8\)&9>,(XLC-34DW9LTCJE
M%P[732)N<Y0$BI?\IB@MYH\M;+WC&P(6S&9%(JC9#MF.LOT*;:IH3.2L>O(!
M1S?,QY!J+]%Q3FK:2:QU69H5I@SFRJ(*J+*F!(BNPM-KJ]&KDU<+M9("GU*M
MQ[B7L5IM,Q'5^N0,4S(*CN3F9N6<-(R+CVJ8=2BRZI$R%[1$`T146^5[,TRR
M<P.6]@Q_?<-7JKSEFRW8HV>QP\PRVG+`C-9"IY9!29I=0R!*9`KC**LT>_<)
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M"'L!46%1BWLP]?L(YNDJ_5D4(UNN4A6P>.L10Z(=153$,11BX`7#!5OJ.1#8
M0P7E_!S:O6>&K%FA\RKMY*Q"[A*ZT8PE692"&3LJFA8O'<(BE%(UD[UB:LID
M*V+'M4S)@<BL`T1-MF*SMJ;BK(ED<R[V#-%4FU/&4C%,V\I.(R#:!D'#+XO0
MSE[')SMA\=$!9,?'2%VX`J0'+U;@15A^3J6Z1N)<IU>XXW+07M=NT.@]<-'5
MS,QL=F6@02LL@\C;7E')<;$VI8[)L\D$X(S6&%-^W!$RQBJ%0(KA=$7//8K;
MQ.G_`#(Y6Z$SU4,&YQH5ZO?Q<5SM>,1Y%K4]:*'&UO"=YK+W'MJDZIEO#Q;%
M%9.%:F(Q5J02L2:"CXK8C2.!@N1=#&B(T1&B+B_T1=4W"[Z)'&W\BN.OQ8CM
M$4FM$1HB-$5!N2_)_P`A9(SMFG-ORI4NL6>4OW(W,O'&W1;.P*VS#N9LAQ/%
MYOB>X.0\!!I(1\*O@Z88V1@144I6#G#M`ZBJJ])$W-/\IKE]#XRO?'.7R'QR
M'$N?<.\)\<9IR#'&R..2*F]XR5F(AKL\Q-4U8%"NO%K8ZCSFA'<E*-3Q0G*L
MHDL=,$C$5DMCX+GNGF#.N9%BO5IC:W%X#Q9C*J5&B9&R'17CNUT/)=\O$B]R
M!%U>3B:[>*>]9V=JBBPD?6T_$36ZTND^XD51=P\COE18ZU*M0Y%T-T_>ML6(
MRE<<R-O9U[()*)-\PGQ&5XFI"HW%T6.K9^14+(Q)"QCLPOH14@&:&]5=HD4E
M,5>4QF?&W,+`><Y7)>.<EUC#^7FV4W^3[S(Y&E.1\I7B\+Y7BZCA%!9V5[4G
M-!KEJ=?&-B]<.@>*^MN"K(BZ$[I<BOST1&B(T1&B*L[CI^I\B/SQ>2_X[DT1
M:7F[]#WDK^2*T?K2.B*5;O\`;3G^^%OUPVB*+E[^EWQC_(URU^^O&G1%)O1$
MWW#1T+&/Y>/0:NWPL^7^9G0,F"15GSL6]:H2H-6:)U$B*NW'1T)E$Q0,<0`1
M#OT1*/A]S`C>74#<)N,Q=?\`&IJ5..*Y,-+JQ.W%"?:3]GAGM;564:L@"RQ;
M.OMI)VW2*L@C'S4><JYSK'(D11I\U*M99L=%Q.A4<FUFG4M7+5:BI^@V6D2E
MX@<Q/Y*N7Y=M7;>WBJQ8'L?&UN0C(Z4BDB)N$9251*@HCZR1@"I%*#@=',FO
M$S"DJA7T:U)VVF1-MM#!&FUK'Q5[7,-$33DB-.ID)6ZC">O.4.LI(UBV9K$$
M%B%-X@J'(I>:(H)^9M]`GE!^35S]]HK5S9?78?3,^<%6M_K$?I&^4*KM_P#M
MY[_?;G]>/KT"[SCUKJ1VIRN&7B?/\K'A&(57YFW(;PC*`(D*I\M/%CH,<`V$
M2`;;?ZFN=\_>;:=<G]!:GS1L@_R_Z*?#BM@[D3&Y_-E_DOQVQ3;K[-0E6:NN
M13;)=%G;O59AK5Y@+6RAX>NXPIIGN/5Y9V@C56K@[F8AXQXN1=ZJ02D#G*U-
M6%<@\H8^Q5C&<E<C6AS58RR).*1"NHV""TSTC9[)&2*$1$5NL'BIMO89YSX"
MBB#1PU7:J>$;U@O@`IHBH(P?4Y>J^5'SL2EV[=F=WBJ559MT\?R>.I-://6I
M5['/;A!V&L0UA1O:<=((L)),SMTQ2"/2\!%NL9V=S7M?K47I6?."JP_3L^6W
MRA*]U^V7'_'J_KAM>@W><>M=3.U1_M?TE\&_DDY&??[`&K-_UZ+T<GEC5L_Z
MU'\A_E8GYU=JX5A7E9_R,9K_`#ML]??6(UQ+F7[>NO2#YK5SO6?M2;Y7W@K,
M=8-8Q5)<QOIF8F_-7RY_3%A37B#VX_X1Y?\`WI/_`'==I[E/M:__`%9GZ1($
M.\/KAKYNG8O1*EUY<'T:77YPG+;_`%HLN:^V'<C_`-'N6?W-;?,7C/G/^+M2
M_7)/*IXZZBM93?Y3K\_:Z!9:Y6I2KPTG-,2QZDC<:7\H<`A$N7"*<^5S3C3=
M?;3;I>#%PFU3<.#-"NC)G<(.42G;JD4->`,!QC85FV67CKGUCFI6])UNQW%E
M#S]0CH.H.!;OV+!O%X7HS""A,1(/%FKE,6:D>FY$6PHBH8B!2D(I'<H\>5C*
M_'S*^/;F:]$JMFJCII.CC&.DI7(1H]LNVD%DZ='PS1],N;`KZH!6P,TC.RJ"
M!D=E`*8"*+/$3*7%2Q9FR!CS#UMY#N\KU.JN3W>E9ROF?YQ>N1;:;@T')%*K
MF2U3+>$GFK^19E.)&R+U-%?I$P)J"!B*4/*/-,CQ[P;=<KP];A;9,P!JW&PT
M)9KQ!8UJZ\Q;[7!TZ)<VF^60?<BK5F-D9])Q(.SE543:)*>$FJJ)$S$2=X=9
M[L7);!<%ENS5NHU=[-S5HCVS*CW0U[KSN.@IMW$M))M+KP\!(-7#OU4P+,W;
M-!PW5*("`E$AC$4H]$1HB-$527FR_P#,?$3\YF9_U:.06ND]TG\<6_H9_P!&
M5C]3^INZV^55G:];K6DQV-OY7N37[\<5?T)TW6*L?M&_]+%^@8JC_,9U'RE.
M7=_^A%U_>=:OO!(:R$_T#_D.\A4C?.'6NC_B/]%'C'^;UA?^C>M:\"G:MT4A
M=01&B(T1&B(T1&B*JCS-[);8JI5==[5HZ+QE3;#%7:4RA(R6.7[5FY386"#7
MCE8.U5F_VNOOHJ3EHMRTD(2I6QP[\15`Z<80!?E(K!L*(E#%%`?J2T+9)*>J
M5>L4];X&HA0X^[6&:AV3Z9N9:D9%!Q!*V9ZJ9V9LN4%T?%Z%/;%'1$Z.B(T1
M&B(T1&B(T1&B)FN0:$07"^4)N6-'(%JF.LBV-G)2K&2E(Z'<MJ!9V*\H]BHA
MN]D95HWBY!R55LBW<*K)',5-,Z@D#1%6UY,[Q0^%LIQ3^DW:E6&(R-')6IK<
M)U"=!W95*;")S`L2MX.(/6731\U.1W!O#N92+/T$=F`QR[D5Q6B)G\]TZA7G
M$MY@\C5J,M5>+6YZ2)&OZW"VQVA)1T)).6<G7(6>3.P<VJ-Z3*QX[IG*X`-C
MD[3`15*>35B=W68"Y7V'MTK&UJ9CXV-F,7K?*`HR?/G==H+FFW:48Y.Z;'4+
MPPCXF8++M6XJM'KR;4V%%-DW0(17EZ(H'<NN8M,XY2D92$L?9`N.2KE`*R<'
M+5'%L?D&LT]X]5E(RH/;FSD,@8P>6-Q/S$.[1C8&$DE9Z65:';-4RKK-@5(I
MMP(SHPD0-H+$DL@QK+W>+`G>*0A9CU=/W1"(4D$TGYHWUOK\`5B@KX>W5V[Z
M(MMHB-$7%_HBZIN%WT2.-OY%<=?BQ':(I-:(C1$:(C1$:(C1$:(C1$:(C1$:
M(C1%6=QT_4^1'YXO)?\`'<FB+2\W?H>\E?R16C]:1T12K=_MIS_?"WZX;1%%
MR]_2[XQ_D:Y:_?7C3HBDWHB8GCY<J]CW&7.J[6QZG'URM<H<[2DN\5))*)(,
MT*E10.94L/%SDH"9C&`#&09NE"`/4"1]ND2*$ODH(0<\KEVVU&\Y3F*^C5L3
ME486"&AJW3I%S8(N?59-O56<&_5MT]3H^$+M9#2\=*RY98YY6#9'*U5<$4T?
M-1CKBXXUP,U1DE2S=+S5C*ZK2S:R9/I#JNPE?>R"]AFT;[BP?=&C`A"*+I*2
M<D4\0BBL8BH"LHWT12YXUK23G`.('$Q9(BX2*]!KJKFT05IG+O%SHJ,$C)R*
M%OLC^3G+&HX1$HK/'*YSKK=9O:@(%`B>[1%!/S-OH$\H/R:N?OM%:N;+Z[#Z
M9GS@JUO]8C](WRA5=O\`]O/?[[<_KQ]>@7><>M=2.U.;PO*!O,`JI3`!BFX<
M\A"F*8`$#`.:N*X"`@/8("&N=\_>;:=<G]!:GS1L@_R_Z*>W%OEYU+$G-5WE
MG!KS%E,QY"3;.7FL?5Z=EG,E7E#XFAZ4I5QQHI'/HZ)E'R:3*10G@GF:;>-6
M3:)PA@V>+<Y6IJ:'+O'^.KYC&)6R?C"\9>K="O=?R(2FT.8K4'(*2->:RS="
M8EWMLNN/H7XN0;:36<NRJ2B`[)E-L<"B42*M^ZY`XZ9$\MGG!-<<\:6+&M=7
MQ#/O)%O996LR#FQ`[K[].,G8]*OY)R*HE%"#-PW(JL=H55=!4A"G,BKT5[7Z
MU%Z5GS@JL/T[/EM\H3(NOVRX_P"/5_7#:]!N\X]:ZF=JC_:_I+X-_))R,^_V
M`-6;_KT7HY/+&K9_UJ/Y#_*Q/SJ[5PK"O*S_`)&,U_G;9Z^^L1KB7,OV]=>D
M'S6KG>L_:DWROO!68ZP:QBJ2YC?3,Q-^:OES^F+"FO$'MQ_PCR_^])_[NNT]
MRGVM?_JS/TB0(=X?7#7S=.Q>B5+KRX/HTNOSA.6W^M%ES7VP[D?^CW+/[FMO
MF+QGSG_%VI?KDGE4\==16LJ-/+7+UQP;AA[D*CUBOVV6:W;%M>?Q5HN<;CJ%
M0J]TR15J?;9IS>9EPWAZLM7ZW-N7J#MT)T"+H$`R:F_0)%'#@'@#(6%7^57U
MYI%LI1+22K^YONYD^@7U"QF8*SZKJ<FDZ)78+W3R`J5ZF$K8I`3NYDID0Z$_
M`-UD4][[+*P--L4VBK8$3Q$:M(B:J55[>+(9-F)7"R,)48UC)R-@D7**9DTV
MR#=990QO:%$VVB*C#RNK'%3W+;D`5:@6"JO099O?U"0D*#)TBOOZH;/K.*>/
M(YE9*9!V)"^/DHR+8V@5I!^X<+0C--PHHFS9`B16!^:$L_:\$>03V-<Q#->.
M@JQ)KNYI:/;-VL7&WVJOIMRR<R5UQPFVGD(9NN>-51GX=ZG(%1,T=HN02.!$
MH/+VOT+DCC#5;)!6.7M#;XPW:-<2,\>V&FDGT?:)%%PQDDKQF?/MG;+M0$H%
M3<V9WLD)1(DV3$J)"*;6B(T1-KEG+=&PE2W=^R%(O(ZO-9&%AB#&PTM8)20F
MK'*M82!AXJ%@V4A*24G+RSU)N@BBD8QU5``._1%5AYEERBL@XWX57*$:3["+
MG>2,ZY9M+37)JI3Z":7''D2T,62KEB91TU%K"HW,($<()F,02F`.DP"/2>Z3
M^.+?T,_Z,K'ZG]3=UM\JKZUZW6M)CL;?RO<FOWXXJ_H3INL58_:-_P"EB_0,
M51_F,ZCY2G+N_P#T(NO[SK5]X)#60G^@?\AWD*D;YPZUT?\`$?Z*/&/\WK"_
M]&]:UX%.U;HI"Z@B-$1HB-$1HB-$43\]SG%+#%JI&:<XP-42O=GLU3Q)CRV2
M5+>72U?&*<>R#&OP=7*SB9M[7SNUYUP1P[;D:D%)79RKT`0`(G:PG>IO)F,Z
MO?)MG5&_QK8)SL&]H]BD;/5;!5)4A9"JV:&D9B`K$PDWGH)R@X,V=L45VJAS
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MF9.42`C),AS$(X(K^]$1HB-$7%_HBZ>^'%WJ[/BAQS:N)3H7;X:Q\BL3U*1/
MT*I5J/(H3J(S,0W2<HAN`B`[=@B&B*2?R@5'_&_^`2?[BT1'R@5'_&_^`2?[
MBT1'R@5'_&_^`2?[BT1'R@5'_&_^`2?[BT1'R@5'_&_^`2?[BT1'R@5'_&_^
M`2?[BT1'R@5'_&_^`2?[BT1'R@5'_&_^`2?[BT1'R@5'_&_^`2?[BT1'R@5'
M_&_^`2?[BT1'R@5'_&_^`2?[BT1'R@5'_&_^`2?[BT15\\:G*#UGR"=-E/%;
MK\P^2YTE.DY.HH7D""/0H4AR[&*(=H!W:(M9S=^A[R5_)%:/UI'1%*MW^VG/
M]\+?KAM$47+W]+OC'^1KEK]]>-.B*3>B*-&$,C1M!QQSNE!A[+:Y6)Y-YY?-
MZE3BMTK1-'+3*(H5E"/922@(=K(*)J@8BBT@U*GMU>(!@VT112\E;*C.7QS>
MWUGI*-#E'U2PT_4EFMWJM@9V=84LAP\FT;T.B4FIA7UJG-P3EH[G98LI,3[P
MZK9Q).?<DI$")X_-.RQ3!Q;`U.+LELD[7*W?'LRG6X6DQ%PC8"L1#NW-9Z\O
MJI=(J*JES8E2DO`?1,C,()K$0;JI)B9(Z;DBGAQTO40WP-A]&?LJDG,)X[JA
M7T@I6HB",]5]QVH@Y"&HSJ>IT8FJF)1(C%O73$A=@15.38PD3S_*!4?\;_X!
M)_N+1%!WS*KG6I#@ER;:-)+Q7"V.%TTD_4Y!/J.I,Q"9"]:C0A"]1S@&XB`!
MOV]FKFR^NP^F9\X*M;_6(_2-\H5<;_\`;SW^^W/Z\?7H%WG'K74CM2ZXAS,=
M"<^JBYDG(-DE>'W(1%(12<*^(J&9^+*G1LW17,7VI1'<0`/LZYWS]YMIUR?T
M%J?-&R#_`"_Z*;%[9[/8?,V;#G5YA1\E8<G5.GUBPX]',,?DK&]3;81^4ZIX
MU>?%:^L86+L,==XITY<V5XS?-I('144111=(,F?.5J:NWSIDE\UQ9<5L=)4>
MPSQ823]9C<A(W5.MG@@CG9IM55A5<>Y!F;"\18`848M.+7]T3_I`B'6&Y%0U
MB5;'E5\L'GC6*_.T66DG&)TI68?XVL!+K3#3ULH1IZ1AHJ;C,0X]9UQQ%3DH
MZ3>5E5_,N8!XHKXQT2N2+.Z]K]:B]*SYP56'Z=GRV^4)?NOVRX_X];]<-KT&
M=IZUU,[5'ZU_27P;^23D9]_L`:LW_7HO1R>6-6S_`*U'\A_E8GYU=JX4Z?+&
MM4!#X@S8TD7_`*NX#EKG@13]5>K;`:2A%"^W0;*D[2*%'O\`3[.^N)<R_;UU
MZ0?-:N=ZS]J3?*^\%9!\H%1_QO\`X!)_N+6#6,55W+&=BISF3BP\6[]:!#BO
MEGQOTARAT>+F/"X)C_="*/5U"D;NWVV[=NS?Q![<?\(\O_O2?^[KM/<I]K7_
M`.K,_2)+AWA]<-?-T[%Z)3X\(LF15$XB7J71:KV"=J^8.:4VTJK4XL',Z_B^
M1>9)-E!-Y9\B6(8+RZB1$2+KJ`@B94#*&`I3;?;#N1_Z/<L_N:V^8O&?.G\7
M:E^N2>5/CQNY7.\W,[S+6RBH8XB(&8JS&I."V!S9GMGCYW']7N+Q[*1S>`CS
MUETR<V(I$VYCN?$:G14,H185D$>HK64[63BX;RG1YRCY#9-;;495-HXE*^\2
MFF3>0/#OVLU'E4=-P8*("C)QZ*A3>,0H&('4/3OHBAQP7\R.H<R$LA)EJD91
MEL=NBL9!O&W`+L5)9S;+M#1#4ZS2"BP?H2-6K3"61DX\'T*Y"2,W0=JJ-51$
MBL$^4"H_XW_P"3_<6B*FC@=:FT7S0Y8OK,5O[IVF0R#*+V!*M7^`M(QT?E!J
MUJ\-E&K*W>9I-9EV<$Z(6"6;PK=U.1J:[SQ&_P"G(KD3O>9SR3:5G&,-C*JI
M8TDGEX;O;O.V#)B<D,/BZK8FN6-Y97+"L&[H5PCK`RI]EFXP3D(V>R31RNV<
MM8Y^"2Q$R*4'$2(@<*X,KF/96<@',A$R=E<.7-<L"E]8.#2,\^>D44ML?BG$
MY)EX5)8I%3J0R*J8E\,RJW0"AB*3/R@5'_&_^`2?[BT1'R@5'_&_^`2?[BT1
M5F>:U)UBT\5+,RAAG[C:'=FQM[DXZC8JQ3L=<DZ]=XZVO(>4KK>T4=./92C*
M'6;+32;YJNQ$Z>RHB)4SD4&,L3\.^X8>7!%,:TTI*['/]^13JD?\8'$4W8,,
M0<IF;67@Y&Q3-FDW]?L;8$I)@NXD%EEV3U)02I]7A)])[I/XYM_0S_HRL?J?
MU-W6/*FMUZW6M)CL;?RO<FOWXXJ_H3INL58_:-_Z6+]`Q5'^8SJ/E*<N[!O2
M;J`=XTZT@'V8&0UD)_H'_(=Y"I&^<.M="7$V]55OQ7XS(+2O2HEQ\PN4Y?49
M(VPAC>M>DK,2CKP*=JW12`^4"H_XW_P"3_<6H(CY0*C_`(W_`,`D_P!Q:(CY
M0*C_`(W_`,`D_P!Q:(CY0*C_`(W_`,`D_P!Q:(CY0*C_`(W_`,`D_P!Q:(CY
M0*C_`(W_`,`D_P!Q:(J*?,IK&`<SYPK-+LETY,M[F^9TRSPU7H-BH9<3W!O"
M0>4X$D.;%V8<XXUKMPN4<-D/)G>QD8:1CBM&HG7.D;I(16V<;KA)Q/'G!45E
MEP,7E&,P_C>/R)&F3?OU(^[,J?#MK.R6>I.9Y%VNVF4UB**$?/2'.41*NL`@
MH8B>KY0*C_C?_`)/]Q:(CY0*C_C?_`)/]Q:(CY0*C_C?_`)/]Q:(CY0*C_C?
M_`)/]Q:(CY0*C_C?_`)/]Q:(CY0*C_C?_`)/]Q:(CY0*C_C?_`)/]Q:(FTS1
MD2FHX=RRLM;&4"BCC.^++3LC6YR>CX5%*JRJBLL_@V9&+N991I"BLJT2614<
M$(*93D,8#`10/\LS*=+N5$NEV2LM)?0A9*N0U"BJ=1<*0L91J\]I-6FK'#P;
M[!TG9!"&M5K,>55;3*R4@9T(N3HHE6(V;$5G?R@5'_&_^`2?[BT1,=R1#$N2
M,*9#AKD[:N(J+JM@M#=P^?6:ML(B5K\')/8V<?S44,>NP9Q*X>,JH=3PB$*)
MCE,`;:(J_O*&L]1AL17]I+'O$%=4YRDJVJ`O<O:)QRP57Q[`L&4I6V%CBD;(
MPK%G2A#.$W[D2^[KE-5Z*2:QENHBMR^4"H_XW_P"3_<6B*GGF;FB=9\C,6/9
MMVUP'2:V^;.(C,J.:XO'+K),%$V.-DW]7E9JWJ)8OBZJF<P.7T--1SV4.Z(S
M.B<J:OA+$5O[7)5'?-F[UC8&[UD\02=-'C1N^<M';5PF55!RU<H-5$7#==(X
M&(<AA*<H@("(#HB]_E`J/^-_\`D_W%HB/E`J/^-O\`D_W%HBXX/=:.^Z0_\`
MJ+C]AT1=6_"\=^)'&W?M_P`BN.@_0J\<`?H!HBDUHB-$1HB-$1HB-$1HB-$1
MHB-$1HB-$59W'3]3Y$?GB\EOQW)HBTO-WZ'O)7\D5H_6D=$4JW?[:<_WPM^N
M&T11<O?TN^,?Y&N6OWUXTZ(I-Z(H?TMEF^0Q%RY88$;*NKB^YWV]I+MV,K48
M.PK8\<&QFAD`*A+9`B)^D,K4%:,X%D:39.6@J@)3$ZA`0(EQY:?'.[<?Z/?"
M9,Q&GBW(=SDX:4LX0EJHDQ099TBXLSOU:@UNC)HH5*+CW$PJZ>^M%!62E9)R
MZ(5(AP01(GJY9RM.HD;7,@Y#Y1YIX^U=_-UW&K"+Q@UI$@SL]MMLLLA#)'8R
M^'LEVL\NY`YP46:+-FS5DV.NH"94E%@(GSPBCC%MB6@-\,F:'Q<C7&:5+,S.
M^42&(3ZRE%4TI_RH+[U@%/6?6MG(.>L%0!3J#1$Z>B*"?F;?0)Y0?DU=??:*
MU<V7UV'TS/G!5K?ZQ'Z1OE"J[?\`[>>_WVY_7CZ]`N\X]:ZD=J<[A:(_]X#5
M.WOX=<@]_J_Y:^*_?KG?/WFVG7)_06I\T;(/\O\`HIV&$ED1OYL%\@H-.0"E
MOV6-+--LSY%P\:(=+L\/V*O34NG5;#`'R[&RD6R=0I$V<$"C5TDX76<R*1#"
MS)SE:FK.LQREWBL?3Q\>X['*-F?-SQ+:I_&>)J*2Z$FBLT</74S+R$6@1HQ*
MH!U4TG"3E0FX)&*?80(JELC8\S)C_P`NWG8TR]"VR/?O\-O1AGEUN-1N-A=M
M8JB>YLFU0<422<0#*LQSML)V!%FY982N%1D'<BON[/7M?K47I6?."JP_3L^6
MWRA,(Z_;+C_CU?UPVO0;O./6NIG:H_VOZ2^#?R2<C/O]@#5F_P"O1>CD\L:M
MG_6H_D/\K$_.KM7"L*\K/^1C-?YVV>OOK$:XES+]O77I!\UJYWK/VI-\K[P5
MF.L&L8JD^8P__=EXF#T?-7RZ.WU\Q83W_1VUX@]N/^$>7_WI/_=UVGN4^UK_
M`/5F?I$@`[P^N&OFZ=B]$IV.,$%.67@-E*(@T&<LL\R)SY9N*I(QC*38W=&2
MS'R%BVM1=ED%4F[1K)S#]J=50=P.FD9$P`14Y@^V'<C_`-'N6?W-;?,7C/G/
M^+M2_7)/*FF\H&UYD>P-_:90K<M;&EU6:7&)Y`FF+=8F]A/7ZOCR'+1+%+7^
MLU6UBZAFEB*2!.9%5H[CH]THV,#4K=1?J*UE702*B:4>^56W\))FZ45Z2$5-
MX9$#F/LDI^EJ#T@/M3>U'N'LT14R>4--S;1IEC&MA<"H^I</17#1JA(Y%!*-
MB964O!F<?,TBWY6R#7\26AJ5#PW-9B&<8A'$(0@`*(((MR*T#D3(7V*P;E*0
MQ='3\ID)M3I8U2:U96.2L19@R/AMWL.65B)YD[>Q@'%R1L+)R=WX/@IIF44)
MHBKJX'4JI5K.]HF\9Y+F>0,#:\734ME3*DQ3*S`OZSF:5NM>G)BO.;..+JE<
M)Z(O(R#QW#0ZDH[^+;2&43=E4!U'&0(I$>86=K7L+QV2#\>>.7(1:EW2FQTA
M%<BT%!AZS3[U<ZO5[=+UIVWQ?D]9O*BV<H'4\5%@Q(F@#ATN*;?PS$2SX/71
M&\8/6?M<34;"3.&R5E&ILL?8YK<Q6*C'M:S=)6*2DHUG-U&AO'AI[P!>+.?<
MB/\`%66,!T4U2J$*13!T1&B*F_S><"/,N53$MD1Q]Q5E4:?-2\.UR9FJ.RW/
M9MHU@NIXB.@8OC;7,28\O$G-VNS.&9B.D'!5"G23*)&YNDZA"*.&?&#2(X7>
M6O"LY>'G"P><K'!/9"!3?MF!YF#P/R<BIYJJQEZ3CN:C):-FVCAL_9R$.TD6
M3])9!T*[A-5PKTGND_CBW]#/^C*Q^I_4W=;?*F`UZW6M)CL;?RO<FOWXXJ_H
M3INL58_:-_Z6+]`Q5'^8SJ/E*<N[_P#0BZ_O.M7W@D-9"?Z!_P`AWD*D;YPZ
MUT?\1_HI<8_S>L+_`-&]:UX%.U;HI"Z@B-$1HB-$1HB-$5-/F8W>Q1L[&TFV
M4_)]OP?:X_'\-,I*M6U&X^1C^T9'C:K+3&2<P57'63LH@%:0EFDZO',U:DDB
MPA5C#(K)KJE0(K5<3-XYIBS&K6'E*O-Q+:@T]"+F:0Z>/J7+1R-?CTV4E47L
MA-61^[K#YL4JK!5:1?JG:F()W"QA%0Q$X.B(T1&B(T1&B(T1&B)G.0EDBJK@
M_*LM+69"H)C0[1&Q\ZK8*[5G#>>F(9Y%5Y"(G+;,0%;8V!]-/$$(\7CUJ@9Z
MHF4RA`'J`B@;Y2-4OE3X_33?(..K;CZ<D)V"?NB7'&KO%\M+R1:=!L)Q=S#R
MS>'F)AZUEV2I5I7W+CV#X#D.T*8G61(BM5T11=YDT['-RX\Y":Y1OU\QA6HJ
M"F)-&\XUR#9<<7*"F'$#+U^,5A):L6"MN)B0<J3ID&T2Y7.SDG2B22B1Q$FQ
M%&+RLJ9"4W#]P;U-K"Q]3>V.!4CV-3OL]D2L!+-*A$,[(_-,6N1&RQEQD))+
MJEXQ>.9-V1BH>J+R;8Z<DY(K/]$5.OF'W![!Y\PU7:O?:73\B6;'TF-+DY*@
MX<LEUI(M<DT^,G;C793.EI@:TO'2,9/^Y[QE$)J2QT`4;F*'N@V?19%;['1L
M=#Q[*)B&#**BHQHW81T9'-4&,?'L6B14&K-DS;)I-FK1LB0I$TTRE(0H````
M!HBS=$1HBXP-Q]D?T1T1=4O"[Z)'&W\BN.OQ8CM$4FM$1HBI@\S#EWRUPAGO
MCQA+BRU<OY3*>$.3.3'<;7^.,OR/M<S:\12N%8FC02L'&Y2Q<E3Z-+/LE+I2
M\VLY6*S,+?L+UB.B)L[IYS.1<2M;/#9)X;RYKE0\H8]XVV!6M92:RL#,\E)/
MC+6^4&4:M#QU;IMTLT52:'2YP6S:671<^Z4F`(D3*@19XF1.QE?S')#(S[B-
MBK`,VKQ_N?)RR0[2^9)SQB>R.(K`T7*\?K#GZ#K#="?5J6-[UDB[H0J<*R(T
MGGC)JX%<3$66(FB8BCZY\S[,],S'A+&DKE#`6<JC:\;X!?3&5\#U9TM6+W<K
M]S/REQXL;^OJ3%W=MH2)-5Z*BB\;HJR'N=.INC-U7*($3`BRT//!:SE+H^09
M?"%NQ/`R+SBIDIRQ1EZIEB;MF"^2^+N2&0(A)!I%NZZ2M79DMQXD$5VQ#R!B
ME6;"D*AEE2H$2TS)YUK'!?&^N9YNV!:^]GK(V<7AEB"C\AZI?KJ;"K+%E<R]
M(WQ9.JTZ24A)N'K%I9D>QDRWBF+=14BWND9LL@LJ13^X4<@[OR$:<I'=U)`D
M)B+F3G#!E,]P8]>/$U!H(5=2M&G`7D)`'MA\*:4!TX3%%)40+TI$V[2*;&B(
MT1&B*L[CI^I\B/SQ>2_X[DT1:7F[]#WDK^2*T?K2.B*5;O\`;3G^^%OUPVB*
M+E[^EWQC_(URU^^O&G1%)O1%7SA_CMAW)%QY96RZ5>7EI]SS"RI'K/&>1LIU
ME`S2-I^+DF:8151N\!#D,DFH("<K<#G'M.)C;B)%Y\G^,F%*1QLS_=*A7;=7
MK94<-9)LM9GX[-.=B2$)/P=2E9*(E61E<G*I%=Q[]LFJGU$,7J*&X"'9HBT'
MG8K4N<QMQ^H\W:;Q%VJ;O<U:4(R*8Y,LN.CTJDT"Q3MML.4*7245*U,-&DF2
M+C8I[/&09P\K+(O15*FBL`D5CO`]A)Q?#;C8PF&DFQ?ML1U$BC6993\=+(H#
M'D.R"18VB5FYUL\,Q,F*A5W:^QA]H84^C1%+31%!/S-OH$\H/R:N?OM%:N;+
MZ[#Z9GS@JUO]8C](WRA5=O\`]O/?[[<_KQ]>@7><>M=2.U.9POW^?_5=C=(_
M,XY"[&$-P*/RU<6-C"`B&^PZYWS]YMIUR?T%J?-&R#_+_HK94C(C7*OFELDJ
MSD&CYFB:!6X!->?"`NU]1B".L4^I6B9Q+/TR,N>(<;0[JVIHDESOY.*=)R;E
M9H4RAUTRK\Y6IJ(,Q4HZ^YDY5S=OF<BS$DUY:YWK[)0N8LPQ#2/@H&QMV,+#
M1L3`WR+AXR,BVA0311;MTTR%]&XB.NH\L:1I=WHT<]U;QR3%SZN(QP<0/$%N
MFC6%E/I[)9HF.D)=B1CM*8[E!BJFQG'?,,DT->O6V%+=NVWKN8LS2S0%DGC$
M2>LQ<OD%_%2"`]QD7""J*A1$#D,`B&LO>:'H\-J^:&VB;*T5!`Q!&PC%7UQI
MMA'"Z2.%@>T5!`V%9?,CFIC;ADCCN5R7!STE&Y-NKVK-Y:/DZK`058(T,P];
MF+%-6Z9A6())&E43$:-17>JMR.7!4_`:.#DO]3U2#3,CIP2V1]*U``\))(Z=
M@QVG8"KJ\O8[/*90:.-*X`#K)\FW:=RV<3<X_(^6N*^0HAC+Q<5>N/&:[?&Q
MM@9>YT['L;&XX[2[5E,,?$5*TDFJ+L"+$*<Y0.`])C!L(SLE$]Q!,T$-?`\@
M'`BO#./A0/$DT4@J`Z-QQVXY%*C5^KM6%>5G_(QFO\[;/7WUB-<2YE^WKKT@
M^:U<[UG[4F^5]X*S'6#6,527,;Z9F)OS5\N?TQ84UX@]N/\`A'E_]Z3_`-W7
M:>Y3[6O_`-69^D2!#O#ZX:^;IV+T2OM6G$JWY3O)^;7R57\2MF%BYY+.KM9H
M&O6>)9M/G`YK*ZBCU^U3==@I=Y9&YC1S9!=XD"CAT0`ZC"!1^V'<C_T>Y9_<
MUM\Q>,^<_P"+M2_7)/*M3Y'K)[#8ESC69*6@IA_5,BU*OJ&K]\9Y%CX=LQQU
M!>IUQK908MY*181B:@J-5O69",6;N"#'.#-P$I.HK658-SDAZ--\<[*TR1D-
M7&%,0M>+Y.9M2E#=9/@A)%9+J<BVKMUH+=D_1L^/[>[;)Q<XW=$*R]S'BQG*
MB:)3G*11U\L5MAEC0;$VPQR2JG)&"=Q]6GU;/&XB2QU;TVMC-.S$(M<9Q4_N
MO8T_<EVFQB63I-`(&+CT6*"2*"::1")+9ZSWR?\`G/9;QCC++5-QO2,;5##K
MYBR?X;:9`EY66O["Z2,P]>S#^\U\J""`02":"";?8H`8QCF$WM?*_M`^T#KO
M<YKNG:1I&G65[%>V3YW.F?*TM+93'E;PR`105QQJNG<A\A6?-]E/=75Q+"89
M@P!@::U:'5.8'I.]-XYR]S;1;.5B\H:*)D6ZZQ0-QA@^D3))'4`!VRJ`[")>
MW7`?_?#SI_\`L.D_[6Y_SEO?_)72/^.NOYL?P+YRCY/7ZV\$^/!9)H9>P\CN
M.M1S#G&:H5[G\13%5QS"QF(I_+<Y7G\94;X\C:C.N[RE7WP-5SS3!K.)G9).
MC$55;_2"WD,UM'.X4<^-KB.C,T&GOKSS(W)(Y@V-<1XB0I9>6A'+P?%F)KTH
MM-$M-=R!DV%N\%/6R=N3^H7%G<)()NJFEIYLFLD$8J<IC-VZ[YFDJJ?P7*I1
MW"LI%/\`T1&B*J#S**SR,R(E$XRQIB[(E]Q1<*K'M[Z>@)U&7.Z?(9)J_K<;
M)1MOR_BY*%4@*BJ\G&:[4CL9IRP+%N3HH*CUD43N2=9ME+XC^7A3KK5YVFS5
M3Y%WJM-X&T+,%+(G6(/#/*6,I$I.MXFSW.)AY:Q4IK'R+B,:2KYK%*NA9HJB
MF@4`Z3W2?QQ;^AG_`$96/U/ZF[K;Y5''7K=:TF.QM_*]R:_?CBK^A.FZQ5C]
MHW_I8OT#%4?YC.H^4IR[O_T(NO[SK5]X)#60G^@?\AWD*D;YPZUT?\1_HH\8
M_P`WK"_]&]:UX%.U;HI"Z@B-$4,GW*JR$Y2QG&N-Q*BY$TZ4)RT/\E5=A+-,
M>JXVD+8ADF%H2+=_.S,(%T;I5Y8BAV8(JG\;Q#&$C<Q%,W1$:(L9P]9M1*#I
MVV;"?<2`X721$P!WB7Q#%ZMM_1HE*JO7F/Q9O7(V3@Y>F\CE:S!PXU'W6PI9
MI"S$Q#>D*W?8.WR[*QACBZ4:?42NL'%+P,A[H#-M/<YZH!6@E%1)6-"HT*FM
M0482L4:F5EO%4*CHU^JUZ#0I-!>M/B/44XJ):,$ZO3`3AZP3XJP)4`:QVT;'
MAZHDGLV0_4BJ%*%*J9F(ROQ$E.S#Q%A$Q#%S(R#U8VR39FT1,NNL80W$>E,@
M[``")A[``1$-04%4/PUYUW[DIR+OU$K-OA)V@Q=JRBY&BY%Q1D:B9GQ]4<?7
M=?'\@WLUA4J]1I\9.J6Q=,\9"+Q\D_6B$S%?/6;U!4%2*X1T9R5LY,R306>%
M06,T1=+*-FRKD$S"@FY<)-W:K=`ZNP'.5)0Q"B(@0PAL)%1%C7(UR6\W>T5Z
M4<O;-6I28F(EM)"%W?Q=,F(_!<DM,4NKNY`*_'/*W!S]5>^O/?<QXR9OY%JB
M=TW7D6+<Q%?)HB-$1HB@]S[8X^^1R#M.2!Y#MX3'=U>7AO*<:<:H99O$.Z88
MOR9$OWDQ2G>/LH,W]4=5J:D&9U5H=8C:2=,E/$;F*5=,B^<`;5B>R8,8LL)Y
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MCI+%]ALD3"+MHZ:M"\'6CIO"&.X732<JQY%=YHB-$1HBXO\`1%U3<+OHD<;?
MR*XZ_%B.T12:T1&B*GG$/FB\6,P6W'&6<D8/R#@"'LU/Y$M<!\F,Y0F+&U3M
M-3Q%*KN<\UZ`M]5OEMLU$3.UQD6848S36*3EV<."B?BJMBI@1/;)Y9\K_-./
M;\O997C%>\>WAS%YCR?&7*M5EXRL$XPM,5A*,N=YK=GA2/5KC%VV`85D!?M@
ME6KE%JS,4G4B0Q$F\O<O_+KR%5:SA&Q$Q-R(H4]G?&W&^5QRVKM/M]*HUCGS
M71M4[%/0-H(T@6]`K;_&<HT)+QY'+=H[8*)(&\1!4$R+!:<A?*,-3(;(#"Q\
M54*CCM_CS$-3>LZ;`LCUY:+"=R7B&F4>`0K:,N:)6]1D9NJ)Q34[)Z9-=S&B
MJ('-HBU<URJ\G?&KRJ,WM_XFP[J*JN,+'2R0E<@90K"LU"E62UX</7U*[`2"
M*`P-!M\T]KK1`P.$HYW(':)`GZUL1>,FY\EQNT5Q%)UG@LG"0E9D^2BM36QW
MC`:G'0LU04;3*Y'`Y:X-:1EI'%@HR:A05]TCUTB3GPO4B)G*1.MC'G'P!9Y"
MQIA["%ZHCNR<E\BY7)!-L:UY0D5.9+H=7K5KO[ZYO64>T(QL<K7)J*<H.GH"
MK+-W""R1U$!*KHBL/T1&B(T15G<=/U/D1^>+R7_'<FB+2\W?H>\E?R16C]:1
MT12K=_MIS_?"WZX;1%%R]_2[XQ_D:Y:_?7C3HBK"0YG\IZ_YH$QQZ)D.HS?%
M&8Y)L\<K*3^*,9OKW6K38L>5V3)AZNV%/F%%Y@1KS>Q*D%I/_)*ZBFOKRO6J
MJW(9T4BL\XS_`+>Y5_GG9B_%+%>B++YD?1&Y0_F_9=_$6<T1*OF#2.-]7&N\
M@<\90O>-V2I<:XZ(QJ,`SNP7FTUJR6&XX:9MJ6CC+)=RFINEW6=?3*+&(138
M28(;3K:1C6@(I$4E>,"&*VW'_%*&$9>7G\5)U-H6F3,^UEF$[)1OC+BL[FHZ
M=B*_*Q<LK("L+AHLP8BU6ZDBMT"D*D4B?G1%!/S-OH$\H/R:N?OM%:N;+Z[#
MZ9GS@JUO]8C](WRA5=O_`-O/?[[<_KQ]>@7><>M=2.U8F#<[8<X_\XJ#:<U9
M(JF,J]-<4>0<!$S%NDTXMC(30Y>XOR'N:U65`2J._46BJO3_`&A!'T:Y]SW'
M)+ZJV)KG.'$V`G\#H6J\S,>_@!@)/;V`G\'H4C*?R*X=(Y'J-\R=YA7&FV-\
M?R\E9*?#8[HE7PV]3GY&*D8`36:T15LLTQ8Z\2%F7(*Q1?5&KMUX*SCQ00(G
MKGOJEW_HI?YCO@6J\&;\!_\`-/P*#^-+I5,BV/DE>J+/QEJIUJY=\B9:NV.&
M<`ZBIB-5N)$B/&+DH`59`543EZ@[-RCKKO*+7,T*-KP0X/DP.!';.Y;YH0+=
M-8'`@ASMORBDERO^C3FW]X<A_P"5L=9C4?J,OR"K^[^K/^2J]O-*LN0[1,4:
MA8^Q3G;(32H6&T.K96JA'\IJC`VUY,5ZK2%9M=<N?&$/C5:6=&;O'S!\DN<L
M8U?28I*@9P1,2X?7WS2.;%#'*\-<:@<4`U`H0Z+$Y<0=P)Z58:HZ1Y;'&R1U
M":@9P#4"A!9B:;#NJ5+3%+E=[/\`"1VZ:/8]TYXH9/6<L)*3M4U(L7!VW&X5
MF4A,7I5>[2CUJINFJXF#GE%3E$SH16$^LC;$E]J2"#ZN[:23_5[W=H^[CTJZ
MB)+H"=O!=TG\#><?'CTJ:VLHKU6%>5G_`",9K_.VSU]]8C7$N9?MZZ](/FM7
M.]9^U)OE?>"LQU@UC%4ES&^F9B;\U?+G],6%->(/;C_A'E_]Z3_W==I[E/M:
M_P#U9GZ1($.\/KAKYNG8O1*0.-Y/#V1^'2V()KDAQXH%C@^67)NQVC'68+Q`
MC6K?%H<C,XI-JCDZGL;Y3[2I!INYAE8&[0RZ2+Q]%,B.TG$>LNBM]L.Y'_H]
MRS^YK;YB\9\Y_P`7:E^N2>52]X=R''SCY&VFCI<RL'9%"Y6V&6JL(QRI4577
MKQ(6,K[J3,V?7F??/;ODB:;C(RB##U:+(^7!)@S;I!TFZC0K659([("C5R0P
M.!*=NL00:*G1="!DS`(-EDU$E$G`@/M#%.42FV$!`>W1%6-P(;\-Z=9+Y6,!
M98L4S?)5-.)L^-KU&UJDVBO#0';MO(M9"MUN@8]3OEMAWLR=O+6R3-8Y^5\,
MGK,P[32(8")E<L?39Y1_O+XR?B[DW7S9]N+^--!_=$O]Y<O1?<K]CWWZTW]&
M%B/_`-H/_P"\7G_DRNO$F_W5V<[$G\GNL'(>6%P_)DRC8?MV05.+&&@Q`OE?
M&V)\CJHO#T_$J5UK],2RM'3T-6K%9:R<?#E7,9)Q,:HT3>/F3\&R,<\^^]C]
M0M_01_,:O",WT\GI'?.*G#Y:;MC(<1Z-(1<#4JQ&/IV\.H^OU"HX\IK:+:J6
MN4Z4)J/Q77Z;1Y*SG.4RC^09P%?%\L?Q%(]!43]5TJ:GKHB:W.4S*US">8;#
M!/EHR;@<6Y!F8>2;='K$?*Q=2EWT>^0\0BB?C-':!%"]13!U%#<!#4":`GP(
MN86AV[.<W0Z).27++ELO)3='I\U)+ESO8D2KR,M7(R0?K%12;%21*J[<G,!"
M`!2`.P````:];6_=7R/);1R/M9,[HVD_GI=I:"?C=*UEVHW@<0'"E>@?`F\R
M?)Y#<Y+XRH6G-^=<CQA\JW-4L#DS)TS<J^B]1P#EXK>4;Q4@F1!*5;)+JIIK
MA[8B:RA0[##JZLN2.6N6]9LK[1X'1W3I)&$F1[^R8)211SB-H&.U0?=SW$+V
M2FK0`=@&\="?'7058ICL;?RO<FOWXXJ_H3INL58_:-_Z6+]`Q5'^8SJ/E*<N
M[_\`0BZ_O.M7W@D-9"?Z!_R'>0J1OG#K71_Q'^BCQC_-ZPO_`$;UK7@4[5NB
MD+J"(T14)W7&"%L\V*.DVE]R?6:L6^M'UA4CI^YU?'[[)4;QX:(1E,IUOJE]
M<UM+*[RMHE=RE?DX5L[?UKUE3<J1TUER*^S1$:(J4N:>*<7Y6YPL&64,<T7(
M[.#XD5YW"L[W5(.V-8AV^S3;D'SJ,;3K%\BP<O$&Z9%5$BE.H1,I3"(%``Y_
MSY=7-M':FVDDC)=)7*XMK0-I6A%5R[O,O;RSBLS:2RQ%SI*Y'.;6@92N4BM-
MU4T/S0.)O^C#Q]_F=Q]_%_7.OVKJG_$W'^T?\*Y1^V]9_P"+NO\`:O\`\Y-G
MFSB9Q8CL)YJD8_C7@9C(1^',J/V#YGB2AM7C%\RH-A<LWK-TA!)KM7;1RD51
M)0ABG34*!BB`@`ZK6^J:F;F,&YG(,C?ZQ_X0\*KVFLZPZ[A:Z[N2TRL!_.OQ
M&88><N@G#Q"O,,XL(\*5V5SC*C>LE<@#@''B5:+%3QP5Z_&\01'JZM]]^W7H
M!WG'K7J-WG'K54W"6QP]MYHYL6EYZYR-RI%FY14>*E`R369C'=LA%LIXXM;I
MDVK4>1A+25DI4/-0B:BRB+P8<KL[0SP"F3:(P4JN1GI12$@IJ:2C)*;5B(F1
ME$H:&0*YEY=1@S6=DC(IL<Z1'$D_,D"2!!,4#JG*`B&^^B*A'"T[F;+_`#CH
M^;ZYD*<J,%D:7F6KZF%B[1?6T+#,<;5J?OE)*:8&DPBN(:L\A64-*3PM64C$
M93EB1Y8^09M6[X"+H$T1&B(T1(C)C.!D<;Y!C[5$-K#6'U(M;.QP#R49PC.<
M@74"_0F(AW-2+^+CXAM)1YU$5'2[ILBW*<5#JIE*)P(H9\#;7QPFZS-N<'QF
M:HR5N14;78'6<X>_&LMB8P"OQ,CUXF]6()*E76)KJ3--J(5Z7DDH_P`9--R*
M2Z@DT16!Z(DE?F<-(42ZL+%%-IVOOJE8V<["/'[6*:3$,YAWB,G%.I1ZZ8LH
MUM(,CG1.X67121*<3G.0H"8"*#O`BU<:IB"GE<&Q&:XF6MJ"4S,.LW1-Z=R\
MY#4MVI3XY"O9#F#S5`N,'53K@B"-?FI$(_UT@.@255Z=$5A^B*CJ9F^,V)^9
MLA'J\@^<N%,P6.V9-5KU4^;C$26.;RMF?)-.?7:"H%REN)=V>9%@[!:,?Q*[
M%1*?D%(ADL*;9=H5PHD!%>+HB-$1HBXO]$75-PN^B1QM_(KCK\6([1$[URRG
MC#'*L>AD+(]#HB\LFY6BT;E;Z]6%9))D*)7BL>G-R+$[Q-H9PF"IDP,"8G+U
M;;AN1*V*E8N=C(^:A))A,0\LS;R,7+13QO(1DE'O$BKM'T>_:*+-7C-T@<IT
MU4SF(<@@)1$!T14DL?)6X]3F.@XYYAY&9DS-BZJUG.57PUBJ8?XLJA,-K9XD
M'MDO]GB%Z52(:TW&WLFUH,G'N+"YDT&,>_4(*!R.`$")UX+R;N,L67C`Y?S=
MUDI?C9E^\9H<O&+>F5.,S18[W886[/(/*U7JE6B:[*TZ%R!3Z]-QS%!N@+=]
M7V9Q4.)3F.1-M1_(UX=5Z+GZNPM-WGZX7*]9M9HHZM$1DH>$J_RG2(XFE[-`
M56.M$Q"R1\TR2KE:1=*R@)@S$BI3)F46(M7;?*,>#-88E\3<J+V&4<1Y?X]/
M)K*MO#'+F^4?`W';%66Z5BC&=,J\'C)2@/YMH.4CNG;J?BCJS2:RZBRY1!$H
M$3AT/R<.,N,DX"JU3(V3VQ(>5A;BPC9&=K3Z8?.JSQSO'&1],.S#!MW#HLC$
M93>2CM5-)-)*752*F"2`@@)$C&WD.<2F4A:G[*SY'3^..##8AER.24B1=HV-
M3`$=QG5RO$3DA4G%AA;(KBJ.*@:.:NTH87JBCCU;],.02*3-:\NK%E!Y`U#/
ME>RMD&'R'&96F,D-8U=U474596$MQ\QYQ_M=%<14E`KN581[4<81;\7+0Z4@
MR=E4,FL5$_0!%9%HBQ6;YE(MRNX]XU?M3G63(Y9N$G3<ZC=91LX(59`YTS'0
M<(G3.`#N4Y1*.P@(:(LK1%6=QT_4^1'YXO)?\=R:(M+S=^A[R5_)%:/UI'1%
M*MW^VG/]\+?KAM$47;R(!R]XPB)0.`8;Y:")!$0`P!+<:!$HB42F`#!V=@@.
MB*@:$C^25%\[.O-;S"9!R[2K#R.LE9K.=Y#C?QGI=U9U5GBJM68*@]S#5>,,
MEEB0Q#0:G=&Q#JENL$SL$2V=)E!%5-VU$BOWXS_M[E7^>=F+\4L5Z(LOF1]$
M;E#^;]EW\19S1%F^9^I/)\8J\-?6B6RZF2:BSE5[$W!E6SUF2KUHC;1%V"_?
M&:F*8JC+)!/%XL9HLFV\91Z2+,5P22,U6(I6<4W'K/&S!RON9(PP?)G4TRQ<
MJSFF#QB1"*003;BWL4E,30MB$3#P%'#IP==#H4!0Q3@(D4@-$4$_,V^@3R@_
M)JY^^T5JYLOKL/IF?."K6_UB/TC?*%5V_P#V\]_OMS^O'UZ!=YQZUU([5&^=
M660Y;XB,BJHB8>.?(4!,D<R8B7Y2>-H[")!`1#LU9/)&HQT_T$GSHE;N^ML]
M&_YS$@JCS>CK]G=QAFEX[O%BKK2VV*E.,W,,EX)/0AFJHP>+3IF53+EH^7Y2
M.:RS$\>FX;5Y0JZOZ>3=KNL%&/56S7?JT3'N9F+<^:/+4;:#/G(KAYOAV8JF
MR^$D_!8UQ;4C-5M*C;AFS>#9[R7?'`YCQ>;CG,8YS<K>1HF,<1,8P_'Y?M,8
M1$1'56R\V7]8D^<I[;8_TK_*O;E?]&G-O[PY#_RMCIJ/U&7Y!2[^K/\`DJGK
MSF\+4V5R'BW(=NON.6EILIKE`49++TS@+$E(J=*J\;4E;371R1E"&EE[=-S5
MHED92/9+H*N&Q5GQ454D">&IKG,UK$Z:.:1[.([,&YS&QH:`*C,\&I)-0-NV
MAHL1K$+#(R1[FYC4#-E:`!2HJX8DG$#K5E&'B@63X,D*YKCPI.(V1R%=T]S6
M7E2=%(PXUE*XK#RE1\53G<`L`=316*:MXY1`2F;ID2$I0S=KYUKYI_W9WFTI
M_5[,H#:=%`!T+(P[8-GT)V4I\393"G5@IO:RJOE85Y6?\C&:_P`[;/7WUB-<
M2YE^WKKT@^:U<[UG[4F^5]X*S'6#6,527,;Z9F)OS5\N?TQ84UX@]N/^$>7_
M`-Z3_P!W7:>Y3[6O_P!69^D2!#O#ZX:^;IV+T2HJ\<Z;396GWU_*TZHRK]?D
M;RB%=_)U>!D7RXDY`Y#3(*[QY'KN5A(F4"AU&'8H``=@!K<N;KJ[CU&V9'-*
MU@TC3J!KW`#_`'&#<"`L/I,43K>1SF-+O6[C:`?ZY_@6PY%4:C,L.V1VRH]+
M9/&U@Q8LV=LJE7FCMLL3,%`Z%F[EO')+HJD$>PQ3`(#W:VSN,N[Q_?)RRQ\T
MSF'6+<$&1Y![6\$T*Q/.\,(Y1U%P8T.%I)L`&[P+H&RA5W5TH=CK#:QV&JDF
M&)FLA-5)\O$VI&($Y#R[>M3C5]'.:_.OXXJB#60(J!F2RA5@*;HZ1^T:\=JI
M#RBL>9)I$5*-[)+YHNV+`PC@LV([?EF8?*LVHMRWN+G86#KR=BG:BA-DCT&2
MC^8BP35E$U$@7*FB1H0Q%^\L?39Y1_O+XR?B[DW7S9]N+^--!_=$O]Y<O1?<
MK]CWWZTW]&%C/0ZF3TH"`"9D[`!'L`-VZ@;B.P[!KQ*`20!MJ%V<[%'.BY3X
M_9RXF<3JUDK`//11S2^*=4Q0O/8?6/C]A::?<*1C,MUA'$A5LPP+NP5.PR./
MXUPCZRF10"MRF*"?B*%'[%GVB^Y?2J:7J&NP17]L!%(PPW1+9(P&/:2(""0X
M$5!(Z"1BO(@[ON<;K_>;>R>Z"0ES3GBQ:XU!Q?7$'?BIT<:N5&",925)P?7L
M0<NJ@.8<K3R32\YQBB6<9S)UX;3]R?.+7='>1;98`6ETX%P1$YTA;H^&FB'A
MDZ=;'RGWU=U_/.LMY?Y4U:*\UA\;WB)L5PTED8S/.:2)C>R,:9JG<"L=JO)W
M,NB6AOM4M70VH(!<71G$F@P:\G$^#K5K&NI+64S7(WZ/>=_R-90_$B<U*[S3
MU(N8W%O\EN+OR9X^_$^%U[ZL_J</H6?-"TQ_GGK*0^4?Y3>,7Y5+O_0%EK5E
MJ'UZP_6'_P!WF4[/,?\`)'S@GQUE523'8V_E>Y-?OQQ5_0G3=8JQ^T;_`-+%
M^@8JC_,9U'RE.7=_^A%U_>=:OO!(:R$_T#_D.\A4C?.'6NC_`(C_`$4>,?YO
M6%_Z-ZUKP*=JW12%U!%CNU5D&CI=NW,\<(MUE4&A5")&=+)IF.DW*JI[1(RY
MP`H&-V%WW'1%0OQU?WVZ\_F&:'JE"=6N^M(QCEW#E:KU7D\C8)58XTG8NQEN
M=HN&+'>0*#5Z7/PD'!/6#2R-R6FQOC2+$$HWJ9&(K\-$1HBJ0Y*_3J5_-`JG
M]-MTUSCO#^CM/E2>1BY+WJ?0V/RY?(Q:W7,EQU-5GC^0?.WY$LN_T=635:V^
MM1>E9\X*YL_KD/IF?/"MYQ8_/%8(QI))QTC+J,L4TER2+B$VZTF_,E4XLP-6
M"3IRS;*.EMMB`=5,HCWF#7H]WG'K7K5WG'K5:G#>>KJO/7EK$Q3%A7I5^\M[
MV:B`IV.+',S"T!=6<46T2&?8PT3DB4:2*#]$[.LR#-ZR@VR@,TG)`9$!:"E5
MP+I15%LX6;MS.UTD%5$6A%$DCNE2)F,FW(JN8B*1EC@!0,<P%*([B(!HBK5@
MN:N4LD<A('C6QPA;<&WV,LBDC<)&\/L6Y*@UJ9"5-O:)%%S#4?*+:Y04':D)
M=%E%6A-HYC4YMN+4Y%`.7Q"*S'1$:(C1%%[FECJJ92XM9UJ5Z"?=4Q?%617M
MD@Z[:G-(=V2/8T:Q*DAU[;'QLK+0+4'PHNO';)''QFJ95TG30SEFY(HB>5+5
M'-?H&69=&PLKI6;C9<>V&IW1;,M2S3;9N+7Q35`5;6R<IQ3Q<6K$NQ.FS9^,
MN*+8X)@HN5,'3@BM<T11TY:8[K.4^..9*9=23SVG2..;LK98"O69Q3'EHC&M
M4F5O<%6V1T;*3-?;+/`26]89IBH"B!"JD<-C+M'!%!3RDJF>!HN3YQC8&=RJ
M5O+AZ6J%O=YGJ>9[G(QH8T9J+1=HE:BEZA"MH9=W_P`GM#*K&117.CUJB@9R
MX(K=M$59_-0.+?RO8EC<_P!(RY892WU^3B8U7$XV:UDL5>KTI\8'M2O>*<;R
M3_)ULKJ3X2K)&CH"22_NA<%5$DDU3`16-0$[$VB#A[)`O"R$)/1C*8B7Q$UT
M2NXZ1;INV;D$7*2+E'QFZI3="A"'+OL8H"`AHBVVB(T1<7^B+JFX7?1(XV_D
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MV[:22=-4`D%2^$)WA#$(GDD*]R!IN=.4ZU-PL_LU?SZQHRU+RFSR73*K`U69
M@,/HT@WQN9'G6N3(Q-A8X],XNX:-D'!&RI54"F5()-$4"*3Q&YX(V+&UCL[%
M^A)U><RM"TR989WE(U[BFG7*_P#%6Y5ES;8I:Y7F0R)$H(8]NI7\0XL-@1:N
MI!/P$W:*J0-")^:/QCY:.;]#GN-@OT/3F>9Z79LD+M<_V#HRHM6B<BY&9NT(
MVB)]P_K>/+.G:*%%.JR4D2"Y8=43QY$TBJK$4<$.&G/*:GS6ZTL5D['6[7E%
MWBM[&YYLHN:*WR-@E>MY`DR/9F_61_(DO=XBC,&"ZBXKMT9%I)`PA%/7D&I$
MZ,[Q\YF5BL2>3*Y/Y6K%OH=:9FXY8W^5NQY-95JPVKD;D9-K2<FU-M99:JY,
M=P6`[M'PYYB;=RT7&&+ZV+DWN>FZ2(I^<,<>3&-:=E&$696>+ISC,T\OC9A<
MSR9[,O7HBF4.HVVWRONTN[F!-E;,59M%P15=+*.'3>P)N%.@ZPI)D4P]$59W
M'3]3Y$?GB\E_QW)HBTO-WZ'O)7\D5H_6D=$4JW?[:<_WPM^N&T115R*9T3EC
MQN.P:>OOT\'\OE&$?XY&H2#Y-]QM.S8"[4*=-H#UR4J7BF*8J77U"`@&VB+G
M'P5E:#R=YQJ>2"7NAUNRY%S;0XFWXHPASRPDXM41?J?C)&*O&.<K8GJ-.=9,
MY&XVI=H!XW=)*$B(H'D<61]:330\,"+H^XS_`+>Y5_GG9B_%+%>B++YD?1&Y
M0_F_9=_$6<T1)?S2<A-,:XKQ!<9EQ5E6E.S#0;9"LG-J?UZUP[P]8R+0Y*_L
M(R,N%,F;6E2Y.^P:[%I&O$724D8BI@<[)-%B*8G"Z+6A^*6!&3E:^.'@XW@'
ML@XRA59ZC9#7DI1`TI)+W"FV=G'6"K3JSYXH9>/=MT5FAA\,2%Z0`"*3NB*"
M?F;?0)Y0?DU<_?:*U<V7UV'TS/G!5K?ZQ'Z1OE"J[?\`[>>_WVY_7CZ]`N\X
M]:ZD=JC78OI:XA^KQTY"@/UAR1QM`0^L(:L7_:$?H)/G1*V=];9Z-_SF*G?'
M$ABFB>:+$89IN+N/=6;Q.>,@R=<R52.-R]?N)FKG%$]#.,$M[6TQ;$TV*9U.
M78.CN)ME/*OU9-%P503D=BW)K4!MX=>%M%'"T"5Q#FQ4=YA'#KD#10U[0=6M
M>FBQ$1BCU00L;&*2&A#*'S3V:Y0,.D&M>NBN(XW?\TYL_.LY&_C\XULMEYLO
MZQ)\Y9>VV/\`2O\`*LCE?]&G-O[PY#_RMCIJ/U&7Y!2[^K/^2H5^:Q<,U8^B
M<4W/!Z5P7G(=?*Q[*G$4#'U^J2-0395&1F92RL\B4^]1K68A$8[UM@#6/%ZI
M'HRATU-D116QG,$EU"V.6TS9QGK1K7"F%2<P<*BE105IFZ*&SU5\T;6/AKF&
M:N`(IAMJ#[F&RJD%BV7L=@L7">>N#&0C+9-<4LGRMFCY:&CJ[)LIV0;<;G4H
MVD*_#L(J)A':3Q4X':-FK9N@;VB:290`H7ENY[WVKY`1(;=Q((`-?S=:@4`Z
M@`%7B+G.@<_SS$ZN['L;MRFGK**]5A7E9_R,9K_.VSU]]8C7$N9?MZZ](/FM
M7.]9^U)OE?>"LQU@UC%4ES&^F9B;\U?+G],6%->(/;C_`(1Y?_>D_P#=UVGN
M4^UK_P#5F?I$@0[P^N&OFZ=B]$J/'&7_`*"7C\XWE+_K!Y%UM?./VG;?NC3?
M[C`L7I'U:3];N/T[UM>2?\BMK_\`QWB[^F#'^ML[BO\`K-RQ^^;?YQ6*YX_A
M#4OU23R+H5=E.=HZ(FIX*AVZQ2*]"2GA',F8"J>&N(('Z!'?8_M!VV'LU]JE
MXV5+/D^T:*I26>XYI*UQU,1D^SAK"UJ&):A3X)19>V9`MT2\&_8^FK-C^XR$
M=$VLD2+:#>IQ[9M&HKE;E,Y%0Y%^\L?39Y1_O+XR?B[DW7S9]N+^--!_=$O]
MY<O1?<K]CWWZTW]&%C//VF\_O-U_Y.IKQ/'](WY0\J[,[S3U*J/-68<M<??*
MUP[FO#U]H>/YW'N+N.#^:>Y#HR5YA9VMS*5+K+JLMF[NZ4*+@9*7?3*"99!]
M)-62*0J`JX9`8'K?M_+N@:%S3WT7_+NOVMU=6UU>WX8()N"]DC#+()"1#.Y[
M6ACCD9&YY-,K)*<-^E7]]?:9R;!J%A+%%)%#`27LS@M.1N7%[`"21VBX`"M2
MWS@\7!'.]KY*XXX%YEN]@A[+:+1S/\"4D*Y&4:(KC<\+!9JBD(JOL<>9*R_`
M%B8ULV(FF=2Q2,@H/49T9-0?#+VWN3Y9L>4/:B'+^G120V4.DSEK9'3.D.>U
M:XN>9[>U?F<220((V#`,!&)TSG/4I]6[LS?W#FOF?=,J6A@;A(10!DDK:"F'
M;<[IH<%U7:^D2\[)FN1OT>\[_D:RA^)$YJ5WFGJ1<QN+?Y+<7?DSQ]^)\+KW
MU9_4X?0L^:%IC_//64A\H_RF\8ORJ7?^@++6K+4/KUA^L/\`[O,IV>8_Y(^<
M$^.LJJ28[&H".7^30``B(W+%0``!N(B.%*;L`!Z1'6*L?M&_]+%^@8JC_,9U
M'RE*JP6ZHV&J9#CZ];JI8)",IUK]TX^!LL)-/XSIAY)L;W191CYTY8=+D@IC
MXI2;*`)?M@VU=.N;::*5D,D;WM8ZH:YKB,",0"2,<,=^"@&N!!((%5TF\89(
M8;ASQYERQTG,&BN,^)9(L3"MR/)B4%CBV`=!'1+159NFZDWHI>$@F91,IU3%
M*)B@.X>"SM6Y)B>+G-BS<F<R9`H3O&K#",7C>'AG#ZE9.F)EKGNR/+1#QLPQ
M?DH+NOU]C5(2L%%9)^)7,V+GUQFH"C3<4U8(K#3&`I3&'?8I1,/24QS;`&X[
M%*`F,/U``1'1%5!1><V4[]SW5X^PT##I89E8*)GZT]L>+\T4/("<1'5BX.+F
MYGF5[KE=D8]^K:D(E.,64BDH%9D5R3W0.\4;HB16P:(C1%4AR5^G4K^:!5/Z
M;;IKG'>']':?*D\C%R7O4^AL?ER^1BUNN9+CJ:K/'\@^=OR)9=_HZLFJUM]:
MB]*SYP5S9_7(?3,^>%:W55Y!KQAJSF)6M+>4;X,KZT<XHT9!3-S1>IT1D=LK
M4XBT-7U;D[$18`%FW?HJLU7`$*L0R8F`?1[O./6O6KO./6H5<)L-6"AYER!<
MXF!Y(MZI=V5ML5^E>3AX&HRA\FVNS1$Z9UC/'N,9AOCM9A93>Z+F=<N8-HNR
M<(M",7!DW+M`D%*K0I1KZ]&2++P63GUQB[:^KR*0KQZ_K#=1'P7Z!1`RS)7K
MZ52!VF((AHBYXN.Y+;2?-PL5-O$OQZ3MD^^GYZ:KM+B*`$A'M3X`CH^NC09Z
MPQ,CEF#&33K#TSFM%E_%39QSMZ5,61ET6Y%T5Z(C1$:(F]RVD"V*<FHFE48$
MJN/;HD:<<2B$&WA@4K<D495>;=0=G;0Z,<`^,9TI&R*;<I!4,V7`HI'(J_O*
MAI3ZDX`FHV0/DQPNG:&L:64OE.;5&$LS:"KT5%LK=05COI&:N-?L#%%(XSSP
MZ`RHIE6*V0$5.LBM#T1(O)"8*X[OJ0R984%*7:4QF#R+>(+$@>#?%&3-+.X:
MQM8LK#?Q1<*QS]-`"=9FZX%%(Q%7%Y3E*>TK!]J8/G&2GZB=I:1R,Y=*BVK-
M6MK.,BD_4;CCB4.Y=3>0*]-,GB:9+$[!F65:-FJA&3=3QQ5(K4=$7/AYCF%(
MEYRL@Y>L6>?^6'(N'FCI:&MG).`Q3CC)%8J.9ZXV8T26IDVQ(U<Q-98V8S<1
MBBF5=>OD<OP,H@LH_(N@_1$:(C1%Q?Z(NJ;A=]$CC;^17'7XL1VB*36B(T1&
MB(T1&B(T1&B(T1&B(T1&B(T15G<=/U/D1^>+R7_'<FB+2\W?H>\E?R16C]:1
MT12K=_MIS_?"WZX;1%&"[)G6Y@<7T4]O$5P]RR3)U&`A>L\OQH*7J,/84-Q[
M1'NT1<[^`N9$QR'\W];&W&&R1*6&97D=-\CLI)W*J8^PQG%G"57&I<#9$J<>
MH_SJK<;-CN<NWJJBM3D,=Q\_.(NE9\BYS(MGJI%T-\9_V]RK_/.S%^*6*]$7
MOS.5(AQ`Y3KJB8$F_'C,:ZHD(=4X)(4">54$B213JJG`A!V*0ICF'L*`B(!H
MB16>+GY>W)8L%+9'3SVVN$!$,HNO7^CX-YCT>Y0T<VFHZR$9-96OXK9HO60R
ML>4X(O4'212JJ@0I?%4ZB*7N%>5>$[M,U+#T3DK(5NR0[K,J_92&2\+Y&Q9,
MWAO44XLMEFB+3N*<:T=S)M0EVRKEM&(H`0JP&(@4@#L12UT103\S;Z!/*#\F
MKG[[16KFR^NP^F9\X*M;_6(_2-\H7/OS%Y:J<7%ZBBSQ%;,K3>19"RLJXSAI
M$*_"#-0LC7"!`R=G4A)YG$R<A$SCN31]8231%C#/#=8J%(F;M^IZCZ@6@1ND
M>\FE#05!&!-#0D$GJ:5T:\N_5:487N<33<*BF%:'IKU`K8,Y\;9R(XZVSW'F
M:\%KXF9DLY8"QLS1U@@R6&X\89<D/.L#"864S&%>>`Z2W'PUTS%]&HA_$O(9
M*%N:W>:'`BKHC0^$;U,'9[B-]"*Q.-#M%2PXJMFBVY2P^:/*-PR/1C35<S9E
MN`+797-'&Y-4M7+1U(65K50X\!C%KR/89)?M*W$^NSPSQFLBWBE7)CJM#)$#
M"0R9]?(SLSME>*%\6S+0@1Y>('8"KLU"!78L;&_-J9[3<P>X4S,V4V!F7/7`
M8UQHK1N-W_-.;/SK.1OX_.-9ZR\V7]8D^<LG;;'^E?Y5D<K_`*-.;?WAR'_E
M;'34?J,OR"EW]6?\E1:\Q"^XP@#P9G'-.F<9LST"!OT]7:1-3V(W$CDJK9$A
M75/DH\](RQ,1L.*\@A'N6L;,B`F9=;Q-(0,J8Y+#6IH&4K=-@N6!Q#265<'"
MA&5Y`QI0'=BK;4'Q-I6=L4S02`2WM`BFQV'4=V*>FEQE=A+]P_AJ?<U\CU.(
MXR9<C*SD)U,(6%Q>8!@'')K$6Y6=:G4;3!K"Q2(Z]83,9-4%0,41`0'5W$UC
M9K9L;L\8MW@.K7,/S=#7?7;556!HDA#'9F")U#MJ.QC7?52]UD5>*PKRL_Y&
M,U_G;9Z^^L1KB7,OV]=>D'S6KG>L_:DWROO!68ZP:QBJ2YC?3,Q-^:OES^F+
M"FO$'MQ_PCR_^])_[NNT]RGVM?\`ZLS](D"'>'UPU\W3L7HE1XXR_P#02\?G
M&\I?]8/(NMKYQ^T[;]T:;_<8%B](^K2?K=Q^G>MKR3_D5M?_`..\7?TP8_UM
MG<5_UFY8_?-O\XK%<\?PAJ7ZI)Y%>QE69:5RDR-@>56[W0D*\A))"MXZCWLM
M;'[YM-,#,#,(EC*0ZDHV9N^A=TW47!!5HFH54ITQ,0WVJ7C95?\`E3UF\TM+
M*M<RC#7['UY+%TI^;%-[R3.V1K7JZI*79"+G,=T.PXXJ3RF8^E%DE6K=0LO/
MBJX8JME5B*M1.N1)G+'TV>4?[R^,GXNY-U\V?;B_C30?W1+_`'ER]%]ROV/?
M?K3?T86,\_:;S^\W7_DZFO$\?TC?E#RKLSO-/4JL\US*$#Y0+:16FK97A^:U
MB!@TF*2_JT98V<E+1E,BHL6CVXH.H1)HK(/$TW8`DJ].T,H5D0SP4`'M7+MN
MZY[^3$V."7_ZU=.+)FR.C+6NE<ZHB(?4-!+<0P.H9"(\RTW4'B/D;,7/9_N<
M0JPM#@2&`4+\*5..%:5R]JB4?EJVN4NN#?+UL,W)S4Q+N>9CA"1DIY6NG>.G
M32,S@BHH@A5:M3H6/CAV_2&R;,3HEW`RRHCU!Z![I[*'3O:P=:VS(XX&Z3,6
MM8)*`&T8<3))*]SNEQ?0[FMV+0N:9GW'=:)9'.<\W3*EV6OTI_!:T`=`IATE
M=;NOHFO/J9KD;]'O._Y&LH?B1.:E=YIZD7'[D_D9'\9.-N&KR_ID]>3359QS
M4HV'@5?53>[#S&"LO$)/GI6$H=FE-2,,E&(*`W4(5X^2%44T@.<OM_4M:9H6
MD6]V^)\N=K&!K<.T8R14T-,Q:&C#:X5H*E:C'"9I7-!`I4^^LN+R*ZRT3AED
M5]3YF@OK/D7(+A]3YY9-U(P;UAA;-,.[;@_10:HRL:X<1QEV+TB21'K%5%<I
M"`H!0@R]=J(TR]=&Z%\D\E6.Q+2()P<<*@TJUU!F:0:"JCDX?$94&@&/NA2^
MULBMU'RH&3)D/EJ=4I#I$EZ"=4BCA1FF=(N`ZL90BCQ(2JLTSD`0,J00,D`]
M0=H!K#VM!>:B3LSQ[Z?_`(=N_=U[E5/FL]WYQ5-'E9L*T>?Y,V"$Q16L>*R'
M'%@T]>K`9$/'RZ+5J1LY>A(V_$^.XZ?=V/U%H\=/4G<B9PX1%PB1$KER=;FO
M=\R`W-[-%;LA+K-HJWB4--IJ^*,.+J`EP+JD5``<XG(7N:C`7$]O?3[Q/WE_
M00X\,',IPCP9&,H].7>2/%?&3!I%+3TE549-R\Q)"-T(]6T0J+F8K:;U50$S
M/VB:CEF!O%2*8Y"@/F([5L"J\X`*1<-S!L=:RU)T]WR/KE+N-`>U_''*3EIF
M3$>-U8YQ5K#;*)2:_F?'R%&FKF011/.3BMB&?`C4C46#8B"R2<$5\RPG!%44
MQZ5`24%,P)^+L?H'H'PNHGB;&_L>H-^[<-$7*]CFR99S1YM\6TR7&W'!$B_R
MDN_:5<][L]/M5FJE(XQH,VMW85:/F5FD),W=VQ!1]$*MU&J$$X61.==0R;]8
MBZIM$1HBJ0Y*_3J5_-`JG]-MTUSCO#^CM/E2>1BY+WJ?0V/RY?(Q:W7,EQU-
M5GC^0?.WY$LN_P!'5DU6MOK47I6?."N;/ZY#Z9GSPK<<;PQ;%Q]Q_`'DIF&)
M-8>J44:7KLBK$3\85_3(YJ+^%E4`%>-E&@*]:"Y/;)*E*8.T->CW><>M>M7>
M<>M5I<&+%G%3EWR'HURM.3[EC6C260J]3[#9[QDF^T-]#1$Q0&,`A"V:99&J
MTQD2'E4YQM82K#'+LC>$BS2<%*\.G!2JX:1."4>^4%PY:`FS<G%TS;@[=M@(
MB<PN&K46ST'+E';J(GX*O68`#H-OTB1<X/`4F4+%SL:VBT+YTR%3W8Y4L(93
MS;PO5XDSTY=7L1(L0?S=9)B.);/WC"+<NFT3,KK0Z[AH\=@U6(D]=1\@1=)6
MB(T1&B)A.2K:U/,2V5I1,6+Y9NKZ-G8>K0Z*N/$@@)BQ52Q5M*V.PR;/UVN.
M(R-0EU$':`+*.'#5THD5%0AU"Z(H8>5=C.8PWC')V-KM6J[2LJU^\0BN2ZE7
MWTO*)QDW)4>ONF$@Y?N)ZV5TP6.)\)^BWB91X@S07*@L)5R'#1%:5HB9+D&G
M8U,8S@4W%KG+5O.WD&=9K[5?'S=6*EIB#EX-*S*'R9.5^L*,XI"34*Y2,L=9
M=LLHF5)4#F*)%!/RJL6SV%J)E?&^0:O6Z1EV%LM0=Y)JM=>RDD1N_DZ@V6BI
MU=T-@MM511M+),7C=G$R;DC!(_@+@10@=1%:SHBIV\PJB*VKDUQ8D4[#D]0K
M)K+0KJGX@@H/(=S;-;!8XE`+^-'DV\82K0E:>((J'MSMW,M8^128MPB#D5<B
MN17$Z(C1$:(N+_1%T_<-X.<6XG\<E4;I,M$E,,X].FV2C*P=-`AJU'F*D0[B
M#67,1,H@4!.8QA`-Q$1W'1%)/XOV#\/)WWJJ7\7]$1\7[!^'D[[U5+^+^B(^
M+]@_#R=]ZJE_%_1$?%^P?AY.^]52_B_HB/B_8/P\G?>JI?Q?T1'Q?L'X>3OO
M54OXOZ(CXOV#\/)WWJJ7\7]$1\7[!^'D[[U5+^+^B(^+]@_#R=]ZJE_%_1$?
M%^P?AY.^]52_B_HB/B_8/P\G?>JI?Q?T1'Q?L'X>3OO54OXOZ(J]N-22J+/D
M&DLY5>*DYA\EP.Z6(@FJL/QY`0,=-JD@W*(%$`]J0H;!OW[Z(M9S=^A[R5_)
M%:/UI'1%D\B>2L[A>;;U^D\6>4_*&U/&Q)Q_"<>L?U^0CJ]`NWTDP0?S5YR/
M<,=T#W0.^CQ)[E-9-U+%2.5<[8B`@H)$U%-RNAFGDEQAL*^.\L8?F&.,N6E=
MM6/LTTIQ3;O4YY)QQ7?O&+A)%U*UVS,&Z$FF"<I!R,G%.3E.1)P8Z:A2D42*
M7R#S[D?/&%)C-OE54Q6L9'Y!-$L0\FZ`$1E"=X_R-5F,CTJQV/DO(2=.@+;B
M[)+"BPQ',!-0QY:LR;*7(D61(DN@8Y%89QG_`&]RK_/.S%^*6*]$61S,^B#R
MF_-YS%^(,[HBDFV77]6:_IRO[5;?^,/_`,`G]71$Q%J1?/\`EOQ!1;2SR,5"
MO<I3@Z;I,G2O3\5,7%%/PY%L\;@43&`V_1U;E`-]A$!(IX_%^P?AY.^]52_B
M_HB@YYE4+--^"/)M9Q<)=\B3'"YCM5XZMI)+%+,Q!C)G.TA6[@I5"@)1$IRF
M`!W`0'8=7-E]=A],SYP5:W^L1^D;Y0N4/S?Z\M8)O""<%3VN3;:U99F52H$W
M&3+NOHU4SW'(3E]%W$<C>-P(6"O2A8]DU14D9/QD)-<P-2^&*H=;YD9G?%E;
MQ).WV2#2G9J["2/$&@&)VG!;UJ[:N909GT=@=E,*GSV8C#>=NQ.7P[P]"86N
M''F#J=P?7&CV[CIG+)%#<OT+$U7C:E;Y;A^M'-EVUILEJE4)2=79K3LH0'16
MQ)B7=E0232`@:KZ;;-M9(61N+HG0R.;MP!,--I)J?..-*DTP52SA;`^-K#F8
M8W$;=AX?23MVGPDJ%4VXY`M?,>M$YB"H0ECMQLYW*#K5]R7<N4=9P1:XY&IS
M:*N$5QB,$3F$(F\P,8V.F9W'22\@H^B%0%<ZRBV^*<;P:VY]LT.DXK@'.=*(
MS@>QA&6!P&\$FHVUJK)W'&HET307YS0N+PTX'L^;EJ/`:U"LA-;+)1.+/->[
M5V6/6K=5LJ<N)V*G&$4K8S0$ZRL;Q5.39Q`-'2\J2,=;J$*#9=02$ZP05,'A
M&S9D?#I]U*PY9&R3$&E:&NVF^G5[BR(>YEK,]IHX/D-=M#51@PIDZ[91X;\P
MIFZ\B(S/SDC9!VW3C(RW(M,:.)IOZ_)4^(F[EBC$4K.51,X))Q8'8.5T4VBB
MJRX'=>"E86L\L^FW+I9A,:;@>S7:T%S&$CHP.S$XT5M#(^6SF<^3B'W<*[JE
MK:CHP\J<WS(\NW[&$M#0;7%7'>6HF4J[8:X7+^2G>36UTH4S"$>2<ZNM)T+"
M>46]2K<?%NFRC!^NKU*O%ER>"4"=9KC6[B:!P8(X3#(",[LV9I&)Q:Q]`!2A
MZ:X*IJ,LD1#0V,L<",QS5'3L:Z@Z"GPQ3EBFYLN_%+(5'L6-+'%R^`<Y^OJ8
MBF5)N@0\X*_')S)UZO.'4="RK:-B5'12-T7S!@\(V%,56Z0FZ`N[:XBNI;>:
M)S'-,,GF&K0?S=0,`</"`:;@JT4K)I(I&%I!C=YNRO8P'\H!\"F]K**^4Z_+
M%BI5YB#-BK.T2<2D/+7/``U:,8%PD`A)0I1$%)"*>.!$QBB;M/WF$`[```XE
MS+]O77I!\UJYWK/VI-\K[P5D/Q?L'X>3OO54OXOZP:QBJLY9,'['F3BL'TV]
MFC*<5\L]!GK6*;"ATYCPOU=`1C!B!O$Z@WZP-MTAMMN._B#VX_X1Y?\`WI/_
M`'==I[E/M:__`%9GZ1)8.\/KAKYNG8O1*BIA2WUC'^',JW:ZSC"M5.L9]Y4R
ML]/2BADF,8P2Y"Y!3%=<R9%%3F465(FFFF4ZJJIRD(4QS%*.[<Q6%[JG,%EI
MVG1NFOIM+TUK&-VN<;&#`;ME222``"20`2L-I\\-K837%PX,@9=7)).P#CO^
M[P[`D'E?D5B3,G%W.%TPO<6V2F>-[36ZY8VU<16CIAA<*KD^D.W=;]4N#6#2
M;R+DR(%:.'($C7`F`X+&1`Y@W+NYT?5N0^]WEJ[YKMI;2$7<-X*Y7YK=H<\O
M9D<X..5I[-<P.!`)6'YBN[77.5-1BTJ1LKS$^+>*2&C0TY@",2,=F\&BL8OO
M+><R!7YBF6GC1R^"$DU$"/DJWE+B]298OJ#]!\@1E::3G"O6F.`KIH3K%N]2
M%9,#)J=29SE-]`A[77<<147]]0_^BG^!<$_Y4\Z_Z"'_`&S/A23QER%C\/HR
MR=!XG<LV3J>6;K3<Y8LH\8[_`&N6!D0Z<>TD+CD'.MIM;J+C"JJ>J,SO!:M1
M65%),AE5!-'_`-W/<=_Q]]_\E/\``G_*GG7_`$$/^V9\*8RL9.E,M<G.4MKF
M*9=J(\+#<<(OW"O[W';^>%%M4+VY3?@XQA.V*L^HN_71\,HN/62F*?K(4O1O
MX\]J;G_ECO)U?0N8^4I99M*%A<0YI(G1.XD=Q5PROQH`]M#L./0NN=V&A:ER
M[:7NGZJUK+HSL?1K@X97,H,1U%/*\_:;S^\W7_DZFO+4?TC?E#RKI[O-/4JK
MLWQD+,>4'&1\_)XXA6*W&O!IF\OEL;&CCR,FT$Z&O7']CD*HJE,0:36?2;'0
MDO;M8UR5-RZ(HV25(;M?+DUQ;]_+Y;5EW)(-8O*MM>&9W,/&$C8VR`L>2S,#
M'@Z1M6,(>YI&F:@R-_(P;*8FM]4AQDS9`>QE+BW$4=2CMC30N!`*5WEZL(A/
M"O`9A5)W&"S-/FJ^1++8-L%IO6.$7S=MG).02JMRR*#R2NC3QD3![IE3(R<E
M.`MR%`O4/>^Z!]S)[5>>[9>LF.D2FEW'%#<4-HPM,D,(R1&G]6:O;\8U*T7F
MP1CNOI$82P7;<8G/?'7BFN5[\7C\;`'<NJCXOV#\/)WWJJ7\7]?1A>>TSW(>
M!GB<?\ZG/=YM8A<-90$4CQ=6*4__`*#SH;"*<"0_8/;V"&I7>:>I%Q7<TH&U
M3G$GCF:F%R#'SL:\Q>\;V_%\?F2?N-*06PU-L'4DQJF!+%5\FVAK,(.QBW"+
M1V"#9)Z+IP4R2(Z]C\UPW$N@VGJW&$S7QG/$)G/9^9<"0RW<V5X-<I`-`'9G
M8!:M;%HF=FI3'`TH<1O=4#I2^P=\90QIP')<"6@+(C><EMY-:[/KB^MD@+?%
M.=T&DO.AD.3FKW%OII@FD[&,F':\A$$6*R6-UMQ`+K2N/ZAI`N>)QQ-)7.7E
MYI%/0NXA=("X4.5Y+F5RG8H29<TN6F6@V4IM'1A[HV[5/567B$)!"(7EXE"7
M<HE<MHA>38HRKEL=86Q'+>-4<%?+MSN0\,#E3$HJ>U`>KLUMQDC#Q&7-$A%0
M*BI&RH&VE<.O!6M#2NY,;3RJ'R+RT(DFLLJ>9Q^1)%NDFNX65-@2JE31;H*@
M*2ZZIQ`I"&`2G,(`/8.L5:_7-1I6N>/^[M50^:SW?G%4M^5#7G,'*\GS/*H_
MK+L^!G*#M*5H;>ER17:;MP+EC(D9<=L,LQ?MUBF!9NC)2R22A3=!1*`+:YEW
M=0NBGO<T9C=ZKC6,,-:X@TMH14;P'/`.SI60OB"&4-1FZ:_TC]Y=\&%ZUEA]
MP1Q,ABK(7N-DIWQ&H:&.'5BB:XK6HN]KX9BDJ@[G2EK$B[4A6=A,W4=`"2YQ
M0*8`(<?:CYD.U;`HY<0^(?(+'&:K'DC,R#!)P6,ML)0+I%YFK.0++#5FW2D)
M<K%$W2+;<8,4%OUPL^2WD_*.+"^?*G;,W3=HDVZB*+&(K0#P%@*0YAOL\``0
MP[EB:F8Q=BC[8I0KQNH2]X!L._L:(N>SBK(YWR1S_B+%<,C\K<HT]M*9&3B,
M@9OXJ7+C7!P+V.KLO`QC*KX\L]#>T<&Y:XV320M#1I7#3WK*QO$*<YV[LBZ%
M?B_8/P\G?>JI?Q?T1'Q?L'X>3OO54OXOZ(JK>0+)ZRYRN$WLP\F5#<0JF)5G
MC:-;'2`,VW;<I2QC)DF8#;A]L41#I[.\=<X[P_H[3Y4GD8N2]ZGT-C\N7R,1
MKF2XZFKSQ_(/G7\B67?Z.K)JM;?6HO2L^<%<V?UR'TS/GA6G8M:O(;!F-IN7
MR2^A8:+Q/2Y&2D9!K3F4;&L&=0C%W;UZ]>0A46K1NBF8ZBBAP(0H"(B`!KT>
M[SCUKUJ[SCUJG?R[8.K6OG/R=R)3+Q)P<A.!EI\>,KK&EV:I7Z!LV7V4C!Y=
M;6\L,S%%U:HV-;K),TVQ]R+*E6Z!;HJN8*52^Y1Y!Y"P?)"EXHQ]R$LN.ZPY
MP/9LCRJD5CS#]CDY:PLLC5BK,B+.;C1IQ)I'MHR46_2VZ:1CJ"!C&$`VUJO-
M6N7>B00R6K8W.D>X',"=@!PH0M*YTYCO>7+>WFLFQN=+(YIS@G`-!%*$=*9?
MY1^1A9Y.K'Y\V@EH52*Y)6#8[XG%LIVHHBX]93KYL6A+G;BV**GB`B)/#`3;
M](;ZT[_'6MY.)P8>'TY7T\>:BT'_`)D\Q9.+P+?A?A9)*>//13>X5VK*^6>/
M<'<,BY6F+';4[_G2H/IU.J4&$-*L<=9UR1CV`=N8R'K+:+;/CUZKM?6!;I))
MJ+@<X$+U;!T[3;A]YI\%W*`))(FN--E2*FG@78])NY+_`$NVO9@!+-"QY`V5
M<`32M33W2I6?%^P?AY.^]52_B_J]6059_+#G1D/CAG!MA*JXYELK/`Q15,J2
MECD<FTC&S-DUN%OR%48Z$:1Q\-W9Q(N4%<=N%UEQ40(!'"92E,(&'6*U+6+;
M2BP7#7DOK3*!NI6M2.E=/[N^Z?F'O+CNY-"FM(FV9C#^.Y[:\7.6Y<D;ZTR&
MM:;J54/\B<^;CEVOA4\I\-*ID*L%D&LJ6`MV?J!-119-D58C-^#-WQA.D#ML
M1PH!#[;E`X^SK%_XNT[\";Q-_P`Y=)_]J_>!_P`9I/\`M)O_`"%DT+S!;WBR
MMM:=C3AU5J%5&2SIRTKE3S[CV$B$'+Y8SAZY(R9<7TDA<.ESB=0X[F,/>/8&
MG^+M._`F\3?\Y/\`VK]X'_&:3_M)O_(61;_-XS/2X^+DI3C,Y70EK;3::W(Q
MY(T114DG=[+&U:*75!;C2B4K)O(2B9US`(G*B!A*4P@!1J1\U:?*2UK):AI.
MP;&@D_&\"LK_`-F7GO3XF2S7>EEKYXHA22;SII&QM)K",`YP)WTK0'8L+(7/
MVZY9KIZAE#AM5L@58[UK(J5ZV9_H$S$'?L#',R>"R=<8CI"X:F.84S;;E$1U
M3_Q=IWX$WB;_`)RO?_:OW@?\9I/^TF_\A?J@>8#=\45Q&GXQX;U2@55NZ=/4
M:]4<]X\@XDCU\IXKUX+1EQ?23.Z=*``G4-N<P``;[```_P`7:=^!-XF_YR?^
MU?O`_P",TG_:3?\`D*R7A=R/MW+:DY&LTM%SV)YK&N57>+96O)V2E9"9OUT<
M?X\R&VG&%@;XYJ0@W<QV0T4#(*,RG26;''K,4Q1UGK&\BU"V;=0APC<3MVX&
MAV57$.=.4=2Y%YBFY9U9\,E]`V-SG1%Q81(P2-H7-:<`X5JT8]*@-SUPAE&U
MYGQYD":H$E3N.V&Y&4<73+$R[Q$@5W.6N\525;7Z/C,?2$SE"0@SOR*MG48X
M@E'*KMV#H$TRIJ"M=K5E=]\7[!^'<[[U5/\`B_HB/B_8/P\G?>JI?Q?T1'Q?
ML'X=SOO54_XOZ(N-_P!4=?XU=_\`UO'_`+ET1=6O"[Z)'&W\BN.OQ8CM$4FM
M$1HB9[.V?L/\9L=/LLYSN\?C['T=,UBNN;%(LY>13&>NEACJI5(=M'P4?*RS
MZ2G['+MF;9%!NH=1=8I0#MT1)+%7+KC?F^.K,KBK*]?N3"VA?`B5X]O,MQ;N
M,8JQ:-]CK&C)1C)Q3IBL&FVAG#*7*Q=^&X(H1,Q!ZM$3]IS<,K[E^%+QBGNV
M0ZD+X;]J?W7321]94/%]*H^OD3;CXAA2ZP`GMA[.W1%^T):+='72;24>X4:O
MC1CE-!XW6.WDB)>,>/7(FH8R3XB(]8I&V4`O;MMHB^!+Q(N"M`E(X71VJ[XK
M8'K87!F+9;U=R\*B"OB"U;N!Z#J;=!#^U$0'LT1#67B7R9U64I'/$DG7J*JC
M5ZV<)IO>H">IG.BJ<I'768`\,1Z]QVVT1;'1$:(C1$:(JSN.GZGR(_/%Y+_C
MN31%I>;OT/>2OY(K1^M(Z(J4O.$Q=&6[FQ1[H;A!E?G>-.XQ3Y;+CS$5[Y,4
M6/I#1U;K&>KW;-2N,:Y*UJ<K$4^([7BV=3>IY$<E*]2+$3+4R(LR*T/!R4:A
M:/+8;5\T`UB$.&^:$84E63OJ%9CF1(SBH#1I`I9.5=9-1BHTNR203YC30%3_
M`+K`''64"+G,XESN'5_.L<5+"7%1O68M7E#=+V_EW=/R;(6#"WK\/.L;#'3M
MKQ=S>L''"GD/::C+KQ<;*4=5\5JX*B,>8Q4`(1=4G&?]O<J_SSLQ?BEBO1%D
M<S?H@\IOS><Q?B#.Z(I'-OVLU_O5M^L)Z(F9E_I?\0?WM\IOQ7Q5HBL4T103
M\S;Z!/*#\FKG[[16KFR^NP^F9\X*M;_6(_2-\H7'/YS^*LB6AS2+1`-[ED&J
MM$K-(OZ-)16(Y7&5(<U9>):OYVOM+5QKSO=Y#)-JBK*L[,S;'1(ZC(!R5LDJ
MY*FBIU;F>WFD+9&9GQBO9(86MI2I%8I'9B#6@VAIIC@=VUF*1Q:]M7-QP[.4
M4WBK'',:^(&F*GQCQ2:5RIQ%5LC1S'V-7A%D%2P,'JL:N\8SAYGBH:79NUH5
MA%0RKIK("H10S1JU:F.412123Z4RY>',;BWSBC_575V;:PUV`#;T`#H5_&7&
M6$N\[@&OCCZ%7Y?_`"QLA93YY265\EXNQ[,<:KGDRYV>XLV5DN,%,DC&]8Z:
M[91?162&$\E;KC.R2(JA'L&J35TS?$4Z&BS8ZV&FT*:XU<W$\;#8OD<78D&E
M,#@X&KCT#`@[B*X^33));[BR-:;8N).)!V8';M)Z!T[J*55WLT90^'?-9^]5
MR%'1H9HY/U@DIB^I66]W"O$FKDM!,I=M`U61B[,XC8\RY`?.&SQLN@U,=3QT
MA#Q"Y"61L.FW1.<-XLHJT%Q%74K0$&@WT(PWJZ>X1V<Q.:F=X[()(QI6@QZU
M$SBC&1S'A7S3<0/B,Z\\3B2,8.*Q]R`QM1XR09Q"995U68#DQD*_9/7EI0JS
M<)5SNSBC^KM2MBJJ$<F)CM/:T:7=9,&88!LC6C#&@E<YU3A4X#`4WJUM0!93
M%OFX84>![@>2[KV#93>EWYN5NN>*KUQGR>SMU<C*>A9+E5NBW<;<79LB,?6>
M76KJ1LA,9Z]ME9"&E',,L=`\<UW4<L6CE=,0!!8HUN8Y);>:"X#FB/,X8Q,>
M&DT[578@TW#<"=Q535GOB?%*"`RI&+&NH<,:GR=:F+B9E%JWGB/8F$,_B):]
M\:\G6BTN;'6:_3KE-V!W$<86!I6^Q%:8QD*TM*<>R;MER(I$1;IMR(I@5),A
M0R=L&F6W>`0Y\#B:@-<32+%P%!6@`]RBNH@.)"X"A=$XFH`)/8VTPJMI2>=F
M$K[E>*PM#UGD3&WJ8DW<6U3M_&G,5.KJ)V2+MRM(R%IL-78PL;!'09'.D_65
M(U5*)!*<0.41C%JUK-<"U:V82DTQB>![I(H!X=BF9?0OE$($@D)WL<!XR*45
MZ?E9_P`C&:_SML]??6(UR7F7[>NO2#YK5H^L_:DWROO!68ZP:QBJ2YC?3,Q-
M^:OES^F+"FO$'MQ_PCR_^])_[NNT]RGVM?\`ZLS](D"'>'UPU\W3L7HE529E
MR-2Z5PCY(UVS2%&).9%R/SEAZ77<C1\^^JEK?5[+^2[/8&+X\"S7.Q7C:VP<
M/&JZRS5--ZD@;Q2](B';^7])U'4>\;2+NS9<^K6EIH[II+=S!+&)+6WC86YR
M*ATCFM<`'$L+AE-5I5_=V]OR_=PRF/B2RW8:V0$M=261Q!H,*-!(-10TQ4<.
M*^0*%DG@9RSG<78XIF*,>LLB8KK=1HU?L[^]6J"A:Q'X3KS5A?[V[)X%J=I>
MY8GBU$U#J(1ZOA+_`*:`G4VWG72]3TCO-T.UUF[N+[576ES)+,^-L,;WR.NY
M"Z"$8Q@YJ2`@!SQ5O9P&*T:ZMKOEN]ELXHX;431M:QKB]P#1$VCWGSCAV>AN
M!QVWZ/OVZ\_OIQ^O'UY@C^C;\D>1=+.U4]>8;RYSI@_,&.\7X?R_QMQ"WL.,
MEK])S6>;GBJH`:196:QL6$<5OE:SU@;%`VQQ7V\0<U?,O(0I73I\Y*'2Q(KW
MSNIY$Y:YCT&[UK7K#5[]\5X(&LLHKF7LF.,N=6VCDX;X@]THX]&2EK(V'&0M
MT7FC7-1TZ_BL[&>T@#H<Y,SXVXAS@!^<<W,'90WL5<VI<?BUERRR+5,9Y9Y4
MWF_V"*KL&WBN);!S-"A*2$.2<ME:GZY7T$$V#5[(K,96S3+5NB<4]@(L4ZAB
M$`QPT272;[6-#T33=+BDEN2_4W!E6M?DBD9)(3F(:"V-CG$5W4`)H%F67D-I
M>WMQ=/:U@%N*XD5<"UNRIQ<0/=5:7E8\N<C<@\P9*K>2,RY<R%.-,/S-I?P-
MHR9@*T8H;3*=EKC&6E,753&>'*'=H>#:N);P8\\C,RJ+:.7(DMXJYTU@[!WU
M<B:3RMH-G>:1I]A:6SK]D;7QV]['<EG#D+6W,MQ=30O>0VK^'%&72`N;E:"U
M:IR;KEUJE]-#=W$\L@@+BUTD+HP<S03&V.)CP,:-S/=1IH:G%/!R&ON0*9Y8
MF'V5:HUJE:'9>.V,H_+V2Z;FS&6%;!C.ED@J(F^91,ED9!X>3E\E1[MU"-#1
M;=R_:++`9))18Z)#8#E72]*U#ODOY+RY@9J<.K7#K6WEL[B[9<2YYJ%S8",K
M;=P;,[B.:QP%'.#0XB_U2YNK?E"!L,;W6S[6,2R-ECB=&RC*@&2M3("6#*"X
M$X`FB<;RN3.%>/GEYN%9VQ6!HYYJR2L.XM5_:9-FXV&!AG!-C7W=L9RDQXHP
MQ2&(#194CEGU>&HBCL4@=W[L`QOM;.8V**)XTB4/$<!MV.?ZHS,\1%K//VY@
M"U^T.=B5H_,I)[J@<SGCUIM,SQ(0.*:`N!.SH)J-E!L77IKZ%K@*9KD;]'O.
M_P"1K*'XD3FI7>:>I%_/;\RJGTV>Q3Q->V?*5%A[C\2Z`SQ'CRTS>.,=KB9/
M&\LMDRURF1+YE/&R!JJ]B3QK8C=0RA&TJT;IHB)WZI=>J>?+:UFL[!\\\+;G
M(P0QO=''_5NXKS))+'V",HH<`\-IB\K7;)S@]]&DMJ:D5._`4`/A]SJ4P>+K
MF,<X.\N_W)7BW+)G<,G11G$&WK:40L^A<99^B)92-<5"P6FMS;095BOT2K61
M=EF`_NXZ@J.#@&PZ"Z-VDZ-PRTL$LHJW+2K8K@&A8Y[7"H/;#CG\\FI5":O$
MEKT#RMZ:>+=L4"N2T';WWF2U^P7*L5*!GV]VPU`5^H5_(MR7MF9L:DN=5DZY
M9X-J?B[/G8G@/<9L\EXMI<XI@VD(=ULJ45%UU]1UR*Y?SNR:ZCC9,)86M8V1
M^>:+.PM<T>JNIER@O:)FM#F.QQ)-S"6BT(:210U-!0&GRO$:':KH:IU#DOEQ
MTH+/S#.T+I:,SJ(N7QAP-5]FK-5N/BHN'8^T2,G[<AS`)>T`UT^V^NZE0$]N
M/`;3_N[<!3>=U%CCYK.H^4JAW@K:6>-,I65SCW$>+UH_*./8+&.2GM`O5^EK
M'C68>PSK](LD3)<8,6LY*\O'E9-*6$KZ67;-$(>2<-E$U5E2N>2<IW#;#4'N
ML[:#)<0MBE,<DA=$X@^<#:Q`R$MS29GD`,>YI!)#LI<MSL&=SJ@U%0*'\HX8
MX8;PK!*UGGRW<75#'>/LH6K%]9R'7\3XG<6N"DJO>73Z-7FL>5R70=2+N+KS
MZ-*F^;NP6\8%A3[3`)@,4X%V.&3NVLH(;748M/9?MMXB\.MZD%T;75<1&1C6
MM:_?5`B_>XN87EE33M>'K4_RX$PF8I3%QC41*<I3E,#%38Q3`!BF#^Z.X0'?
M6W_X3Y6__;K'_8Q_YJM?6;C_`$C_`!E:*DNKC@/DW6%N-=P3P0^LN`<H%M3F
MO4^JVMM8VL7D;#WN8@]B+JQF(I%>/5?*F2<I)%<%*H<G5T',`ZCS!W>\MZWJ
M-M9-B%G&V"9Y-NR-A<0^%H#NP00`XTZ"5<P7T\+'/KF-0.T2=Q\*F5\YOG/M
MO\[J:VV`V_R$X'VZ1$2@;?XF]PF#;?V=8O\`Y)\M?\3?>.+_`,M5/VM<?@L]
M_P"%6S^7=ES)V:>-Z=LR]:4;K=HO+.<*,YM"->AJL>6B:%E:UU2OKNX6O(-8
M9L^)"Q:!%C-TDR*G*)^D!,.O/O,VF0:+S!>:3;.<ZWMYRQI=3,0*;:`"N.X!
M9NWD,L#)74S.%5.?6#594K<V\HXSP[S#=7?+F1*/BZF-^)U'C%[;D.TPE-K2
M,E)9PO!(Z/5F[`]81J;U^=(P(I"H!U1*/2`[#KGO/D$]R+2*W8Z27-(:-!)H
M`S<,5RSO,MKF[%C#:QOEF+I3E:TN-`&5-!4T"2N)LZ80STRE)7".8\7YAB8%
M^SC)^4Q=?*Q?(^#?OTE'#-E+/*S)R3>/>.FR)U$TUC$,<A!$`V`1US2XM;JT
M(;=1R1N(J`YI;7JJ!5<@NK*]L2&WD,L+G"H#VN:2!T5`JJY\=<SLR<E('EI2
M+EQBF,04RH<?,]($M<M(6T):,O\`4JJ6&LE&M499*16H=4BRUF53BY*(>OF[
M]6#DCE+ZJ#5POF)],MK)UO)%.))731X"E"TFH<"'$[L00*9F[Z@9^YT>TT]]
MK-#<B:9\\?9`;0M<ZH<TAQ.[$.`(S-WU`MJ)S`P5E3B[&89NV&^8:M7O>#H.
MCV%>`P!D&/D#1,Y2&,:Z=PLPU:J&:.P07\1LX)U=!P*8-P[^M/YFT`/(-U%4
M$_A?`NX2<X<L->YKKV$.#B#YVT'Y*;C"U_XT82R6ZRO'5KS(KY:G">1A(&3<
M57FRQ+*1RS*4F7R!-LHQI68=)&5L#K'L4!C")D4$VXE133\0XFE_Q/R__P`7
M%^5\"E_QERO_`,;#^5_FK59$SM7>0G,!JO5JUERA##\1K3&JN<CX[E\?2?BS
M68*NFTE*VA8T#)RJD:JT.<QO#.DDJ"8'`P'Z=:9SIJ=AJ-I;OL962M9,[-2N
M%6@@'`;:+G_>%K&F:K8VC].F9.V.X=FI6@JP$`U`VT.Q48<=L1T7$OF^/*O8
M\B9CR[GY$UXLDKDK,<QP8>2%OJ\UAAD6.FD7E(I5<Y'HRX%55:EKC-NP:,8]
M`KDYCM0<D4QEY<2W'+HD8R..T[(#6">C2'XCM.,=-^8U).&VBP]_=3W7*@EC
MCABL>R`R,7-&D28CM.,5-^<DDDTVT76/Y<_T6HS\M?+'_6MS3KIVA_8MI^KL
M^:%V/EO^'K']5C^:%.7656:7+=YT2N0&G)ZURV-<G)XKLM?X@8:L?NN&/:WD
M^1L<?!Y+Y:R+JDP-3M,Y7HQS/V!1!/U50'`*%.CT@7H.<Q=/YF$1NK9LS,["
M'BF8MI4LQ)`.`WKU?[.AU1G+?,4^D7@LKN)]J_-P([ATC61W;C$R.1[&E[Z#
M*<U:BFPFE9_`3*^?<ITG)QN1`R)KE4<@MJ^R]=K>/X!%*.4KS1ZLV9+XVDI:
MN394'YS^(X*NH)1,!0,)=AUJVJP6D$C/5*<-S*[7'?\`C4(7IKNRUOF;6M.O
M#S5F]?@N@P5C@8,N0$@&W<Z-]#6IS'HV*>>L4NE)D,_?]$Z5^7CCU_3'3]75
MIY[_`$4GS"M=YF^I6_[RLO[U$F8RMRZD,8<J\4\<G./HA[%9580:T7>'>2Z%
M!NTI"5GE8MVU"J35CC[(L1BV;JF0(@Q=+2+HA$$`$5@,G<06`GL9+P/.:,FK
M<KCNKM`I[^`Q*P&M<\RZ/SI9<J/M6.@O6,+9C<0L(<Y^4CAO>V3``Y0&.+W`
M-;YU1-<=8U=!3A\.^=-XXUO>3^/ZUQ[:938N^0L?9U+*XS)&T$R+F4XZ<?V9
MXDL&[HMD54*T)%%/ZQZP!5/&Z0(7H$3;MI6NV>FZ=%;W#9"\YG=D`BA>[I(Z
M%XZ[SNY3FOO#[P-2U[0Y;%EFQUO"1-(]CLS+6!Q(#8GBE'BAKTX=+O\`STZK
M\I'RPF\LK$:F4O=?W?\`C^KFREJVH)P$/5BRX3"N'3NPDDT0`"+`;Q";`)1`
M0`0R'^+=,_!F_FC_`#EHG_M9[Q/^(TG_`&TO_D*04!YM-[=V_'T#9^)*=?A+
MOD[&.-7<_&\@(.Q.X)7)U^KN/V$R$%\G,.:50BY"R)+K(E<HG.B0W2;JV`;B
MTYCL+VY9:Q-E$CS05`IL)Q[1Z%K_`#5[/O.W*'+UUS+JD^G.L+1@<\1RR.>0
M7M8,H,+035PVN&%5=3K8%PQ&B+B_T1=4W"[Z)'&W\BN.OQ8CM$4FM$1HBA7S
MVX\Y*Y+8,@Z3B&?H]<R'3L]<<,XUQWD=*P*4Q^ZP+F^C9<4@9HU736G6R%@;
MU$S,JS<AS(G6`^P@`AHBJYRKY/6=LV/\K9!R!F'%I+_R!<Y]LF6J74?E6J.,
M6<]D.F<8\<XXA:=+P,Y'7)9C6ZEQS(I*RS\IEGLG)G4]0.U`[-0B4>#O*@Y"
MXGL/'6QV/*?'[*;_`!=34J$LXNN.ITCC!D7&9UN.6(ZU<<$J2-$ACY)E:Q;@
M@967?,H8KQ9@V>JH+(E/'*$2"I_DR<A:?0K>6K<AL<XYS34\8XEKF"<CT:!N
M:C.VYTP[D^PW^+Y9\E(J:?*!;,NW6$L+JO3B2`/4UXV1>[N5"J((MR+\R7D<
M7V+RC)6&D\B5_B>3C3(XCJ;FQR]Q)=JS;G'%^XX&72!S%%ZI.B6^\7%U=)HB
MTB(J2#E8A61UP;O4")P,+>6S8\.<T>-58Q_5UJ;Q/PIQ_P`7Y"S@G$-D(?'6
M6^8F*(:WT'%]GJ#8D\XGGLPHTR+.V"U*OF*7K<A&0JRSEPOU@!%?MHB-$1HB
M-$59W'3]3Y$?GB\E_P`=R:(M+S=^A[R5_)%:/UI'1%3WYS&&;?8\]T_)+^B2
M^0<:EQM$56,-+X,YX9YJE3NC*UW21DV-7@>!G(''UIK\U:HEZW<2[JR5U5HH
ME',B,Y$3^*W*13EXQV.8E[3P,:241FABK2>-7(:E,+?G:GR6.K_E%"MQ/$Q(
M<G&H]FL-@R'5HJ>>'4(W;V<S:?W;F,Y2'<JRI$Z4%P6X=8MY!8TR!B[@5QMK
MEI64R3>Y;/\`5<3TJOW/'=\BAK1ZTZ;3#"'2E%)O()[/,"+LJI5$QCU-Q'Q=
M$3J<9_V]RK_/.S%^*6*]$61S-^B#RF_-YS%^(,[HBD<V_:S7^]6WZPGHB9F7
M^E_Q!_>WRF_%?%6B*Q31%!/S-OH$\H/R:N?OM%:N;+Z[#Z9GS@JUO]8C](WR
MA<??G4M7J'R,V9E18S(2=999D?343=,-XOR]CN$KGNKB\LM<9!#*SPD-!62O
M&,B9-5HW6>!"*2:YCIMVZP&ZOS0".%(&!X:'U#F->T"K*GMX`CP"N7,=@*W?
M6@>P\-#J9L"T.`&&/:V$>#&E5-W&)UU<D\.U'4.:NN5>#%[.YKQH-G5S0*ZD
MGQ2%>$&LQP%CZV,4<PM_<]N`(,O#\%/8A`UE8*F>V)&4^JNPI2F,.%!LIT;M
MBO8_I8:BGY@X4I3&/=NZMRJ/Q=CRD8O\W&J4JA7K$D7&P^2<A,D\5Q]ORC:;
MA`Q++&LF_CB/I>RW.QM9"W6)*8,JX9G2!*+=L'J2A44A9&/KEO#%;\QMBA?&
M&A[NQ5Y(&4D8EQJ37$;B#LP6)CC9%JX9&Y@`<>S5Q(PZ23B>C=0^!6>6`&JO
M$SG6R=-%I/W1R;S,9(PK-],,)*;54FI81C(Q6N05IL:KQ=,IOTMA%2;DY`,`
M-5RB9,<\^ATZ[:<:OFPQ!.)P%`3X@3X"LF:>J3@XU=)[N/@!/B!ZE"#B'0J[
M3N$O-"7KN!K+@Q"]MH>S*-Y%U&IT^Q$68+J%0QS7CX[Q9>*_7JJ^=NFZA;-$
M)RJBK@")J*,4&H%Q6G0LBTNZ<R%T0?0XTH</BC*QP`Q':%?<`5E:1M993.;&
M6!U#X#U"C2`/QA7W`I)>;!D;*6*H#%-TQ`_OS&T1;O,@2YX"&K$[1$:"^I[&
M+ODK=H^VRL5%C+PL!('7C5R&4<LHP)=TD4HH"H2^YAGN+=D<ML7B0%]:`%N6
ME'%P)`J`<-X&8[E<:K)+$UCX<V89JTH12F-:[P-G0*E/MA==TZ?<%'#Q.X).
MW'$'(2KA+(+OW0O9%E([C48Q;>^!)#UVQ;C_`'4KT%\17<=NW5W:U)M"<U?5
MG>=YW]5M\/2J\-28*UKP3MV_$V^%00C*8QD?,SD,A25.M7N7\Y)8D!E&$Q#Q
MUFHV1FTJ"RC8F`><GU,I-LX,:@Y<>(V<U%&MK^%T^J$.=$XJ%Q#8FNUPS%KL
MO'P>&1FIRX#BYL]-V3+X-BL@P'4^(6G+Q<'!K-M-F>N:GXN7P+K<\K/^1C-?
MYVV>OOK$:Y]S+]O77I!\UJU;6?M2;Y7W@K,=8-8Q5)<QOIF8F_-7RY_3%A37
MB#VX_P"$>7_WI/\`W==I[E/M:_\`U9GZ1($.\/KAKYNG8O1*J@S]6E++Y>'+
M,[:SVBGR=5S!RBO4)/U/+3["CYG,5'DM=Y9GZ_>V<_6$$(93PC`X9.GS5N_]
MJB"S=8R+A+N'*]X+/O6T,/AAN(9[#3H7LEM6W8+)=/A:<L)9(2_\%[6.<S%V
M5S0YCM*U.$R\K7M'OC>RXN'AS93$06SO(J_,W#I!(#ME0:$11X3Y)?Y4\N+D
MM9YF2F[!.A?,<Q\[9K9GQUGRW3$PU7Q($JC)R+S*V8%ZA!1DJ9P$(P-)IJ+1
MJQ%5$?%`ZRN\=XND1:)WMZ/96[(XK;U6=S(XK(643&$767*T6UJ)7N;EXSQ&
M0)`6AV6C6X3E^[=>\JW<SRY\G%8'.=,9G$CAUJ3)+E`-<@S8M-2*XFUZ=Y=1
MJ?(^0P!`8,SU<O<VZQ-)M68*["T!/$--L<W#PUG59SDA/9$A;JX1@H*RL%WJ
MS"$>)AZR!$A5.0Y2\/MN1)CRDWFBZU+3+?/;NFCM9'S^M2QL>^,%C60/A!>^
M-X8'S-/9J[*""=T=KK/VG^S8K:YD`>&NE:&<)KBT.H2YX?@US2:,.W"M"JA/
M-GR%CF?Y)4;&QLM5.&O](Q>R.WI%AMV?<:SM8LUQL4A(5>\5R-QE@#*<1R)/
M--TFR:%7>/&C$5X_P`.)W[CP^\=QNE:M:\H7.K^HSR:7<WIK,R*RN&21Q1M;
M)#(ZXO;9UAD.8NN&,<_*_-2D3*Z/SK=6DNKQVG'C;<QP^8YTS"USG$M>T1PR
M">N`$9(%6T^,:7+8K!RGGODP58ZCAV6J<92+G/&^K*N5_DXMY5C'AA\/P%'"
MF^[0>GI$WA#MKS]K>0\L:.6@"/CZA3M5H./%3M[Z?A>ZM[L,W[1O*XNR0;J?
M$?N^\J4_*0A(>O<H<R,(FB\F:^NOQZEY9T]SO8*3-U2/A)_**5BKB6*Z+6H)
MBMQM@)U]+RC0:@B]>,RK5Y5HJ(NX=553T1WZ7%Q=<F:?+/<Z/*T:JUH;9,F9
M*Y[+8QR&YFD>1J#V-9&[UHL8^D[7BC+@-&A<D1QQ:Q<,9'=M/JI-9G,+0'29
MF\-C0.`TDN'"!(JPM/:82I.\G<AX]A/*WQ1B^VJL/C#E'C=C5]5CV&DYAM=!
MK"6.X?'MCDLCY1G<+0\O8\8T*DR"D>JI9')?48Y^LU,LFNF)T3:;R;I6JW/?
M1?:S8!WJMEJ]P).'-:Q3R&=\\;;>V9=O;'<33-S@6[>W(P/REIHX9?5[JVCY
M.ALYJ<6:TC+<S)7,;D#'&20Q`NC8PY?SAP:XBH(J$Y7EBXCA\<4#AK:2X@5P
MS<<K\V8>T7&`.YS+X4T2.J6;HRJV=O'9R>%NS9&:@1*L1TO&0BLBD<BZK,!$
MJJG=NZS7;C5O:@M[(WXU#3['1[J.)]+3L9K=KI(RZS'!)8_`M;),&&K1)M`T
M;F>PBM>[:2XX'J]S-=1EPK+B.)1KJ3'-B`#4M:2,<N\]@FOH,N"IFN1OT>\[
M_D:RA^)$YJ5WFGJ1<!_/J!KCK$/'39MF0+E;,;XPCOC;6:CGN_8UQS3JC3GD
MDZ?R4/A%EZ_'6:X6"=:1QDO7F:C](&ZZI54HXI0]9<YPP.L;3"Y]:DBC&=K+
MB2*-C&DDEL`J'O<X-\X9A0FH8M;M"0]WFY03A5H))/AZ/NVJ4G'=D,3B7R^6
M19-_,"SN>2"EE)2`O57?NQ#%6>%"J.:]D]5Q?(PY.KI!.3.94Q2@8OZ49,-9
MW1F\/3=&:'%U)9,2V1I/YJ?:V6L@ZG8^Y14935\I\`Z#O'1AXE6/R5A*ECKS
M(L6T"IJ&@X&%MF`58^%=S4XHHFXLMC9V.4\*0LF2Q>V`KR5EU5=TV9TT!5]6
M`B@)`&M$UR*WLN=K>SM^Q$V2WHTN=\9P<<72U=4DG905RT-%>0ES[1SW8DAW
MDZE>I2E':.5.5RS!`KJ01LV.EF#503%(Z?(X,J:C-LH)1(8I'#DI2"("`@!N
M\-=8M2X7^HE@J\21T'2>`V@]TK&.ID9T4/E*@7PCY1Y8Y$-^0#+(N1;!;E*A
MC)Z,Q6G6+L$TJ!H=QD4))"2@&-DQ1FW*EDG5&AFCILBG,M(\RK=N*QC"L!D]
M:ERMKVH:T+QM[,^0Q0&K3%`QL;S6K0Z*>5SJ4(&<-P%=N"N[B%D63(`*NVU<
M:CJ('O*,?,=[=(97AHI"52?>56Z\9,7T6UN:UGB5Q4SR(\?POJ50QUDV,:9<
MQW'GH*-BGDVQEEV,HJ\;6.1(B)3M!17P/,K[J(Z88HWFWEL(HWELYB$A+:,C
ME`FC'#S.I4M<7"1X&+:&K;AIXE2,P>2*MK3I(P./BV!6'\T><%=XHO*!2F#G
M%),BW5L_F@C<M6J_4ZE5VEQ"2[/W3=3]"QKD:17>RTZ@+"/0*T(4YT%3*F(7
MHZ]SYGYJAY>=#:L-N+V4%U)GR,8U@J*ET<<AJ7#*T4W&M,%:V]L9P7=K(.@`
MFOND)64S(DO?;3A7*C*+K=BGK/P[RS<64'1[$^5JD[+K73#3UI#UBUW"$K+\
M(F4>)%00?2<<Q,F"GB+(D*40U7MKV2[N+74&M8^:339GAK''(XYX2`Q[VM-"
M<`YS6TVD!2N:&M<RI`$@&.W8=PJJ\<`YWLN2N=4%'M<K5V3Q;+9:RA<X>A5_
MD'Q\O=HC+U,XSEHNR04JTI]M?Y.LV-X`T.HU:1XQ"$8T]2:.$UNE/Q7&FZ1J
MT]]S6QC;ACK!UQ*\1MN+>1PD=$0YI#'F5T;:$!N0-&5K@<*F[EB:RV)RG.&@
M5RN`I7#:*`^[TKM/\J3Z*LI^<9RC_IXO6N#<^_QIJ?ZV[R!9FR^J1_)5E.M1
M5RN?[S6:G&7;(G(&`D\>265`4\NY5]&46"3CS669G8S*E_>PIJJXDH2RH,+*
MQ?HD7:KECWJI#$$"(+&-X1]%YQD=%=Z>]KQ'^>=5QV`')6M",.G$=87->?I7
M0WNE2-D$7Y]X+C6@!X=<U"*@C:*CK&U5E>4]>D*?@;DAG[.$/E>@DBGU4F<H
MY2S+465,9/8K&U/G'DZRK5&J^!<#.TH3&7N@[56?!7%7<HC+-P,J*R"C5MIG
M,$1DNX;2U,;Z@AK6'-BXBA+C))B[##-04.XU//\`FB`S7UO861BDJ'!C(W9L
M7N%"7&645?04&>@RG"AJ:]?+&^2Z0L_-BR8XOM*F(2T\3>25SJ^.F.5+%:,B
MX[B;DRK:\BWOM;/Q6PK"O;"[80D,E,2+NT65Z24;&43%PH^?/E,QKG'#+5DS
M'!S;B-I=D`:XMKYIXKS2I=0!K10[J`+/<Q^LMCLX[ACP]MU"USRP!CRTFF4\
M:0TJ790&,%#N#6M5K-V\S[&_&67Q+AC)V"<]1[Z;IN,XNFW95_Q\KM*R`T=U
MFJ,#V*D?'G.]3ML[7V4E)%;+*EBBJ`X3.0J9C=/5@(M#GOFR7,$L1`<XN;^<
M+FXG!V6,@&@KM6L0\MW&I-EO+:>`M:]Y<VDI<S%QH[+&YH-!7SMB5'/WS(*S
MPWN-#Q3"R6#ELIVR'E;E,M<\77*F/:76Z,R<HQ,,\]W,:8>RQ(OK!<)XSE*/
M:F;(IE1BW9UCD-X!5*>D:*_4HWW#Q+P&D-'#:QSB[:<'/9@!2IKO%-ZIZ%R]
M)J\3[IXF]680T<)K'.+CB11\C``T4J:_&%-Z>O#MZ7RCF7$>2G)ZNHYOW!*-
MM[@](E)F;IAEI_+5:D5#529L<%5[!*U\3+_W(X?1K!TJCTF5;I'$2!;7,0@M
MI(!FHR[([0`.#",0"0#TT)'A5E=PBVLY;<9J1WI;V@`[!A':`+@#T@$CH)5;
MV,W2=@\Z:])H*<5VT;3+7DA#W+;6S&T1R`>6)3#K0'DVI4$;PGG.VW$I)UR4
MZTE`JU)I7EWIX]9,P$,.9G!9RRVOK!<YK<:.,=,^RN7(!@-CLY=2JV&X!9R>
MROK1<]K,<KS%3B'#-EX;6X#8[.7!N8+J0\N?Z+49^6OEC_K6YIUU/0_L6T_5
MV?-"[3RW_#UC^JQ_-"G+K*K-+DK\_6&?369\D(1>#E,\2C?A;C)>/@F3^IL9
MZDK.+9S+BELG51.X$,SE[/5F4DJFU8-=G[T7ADDAV,?6JZ^X-OK4NEX3>UCC
M0]J/LFFP'>3@*+TUW'6\EQR7S,V'3OVE,.`6L#H@^(F"]:;B,2X.DC#B&L;V
MWY\K=I5%O"7)6<J]Q+R1:..&`L>W"WI9YI\2A7*=C7'>+ZI8*TXK$>:Q2K)O
MCB9J\'8I6.7!O&NY!9UXT,1T9RHDY2:"W5P>I0VKK]D=Y*]L?")J7.<0:F@[
M0)`W@4QI3"M5VGN\U;F*TY(N[WE33+6>^&IQ-$<5O!;QOC,;<[@('QL>YIRL
M<\NK$'%Y:\,R.L*X49;SSF6GY"LF=:5(T5VVOQF%,KTS19RCSL+"FB6JDG4I
M@TT@Q2N[^I3/6W/8HYJWBI4R@F:@9,@"&(U*WM;>1C+5P<,F)#@X$UVBGFU'
MQ221O74>[W7.9=?L+J[YDMWVT@NJ1,?"^%[&91FB=G`$SHG]DSQM;')6K*@)
MV,[.FCNI5`6CQH\!OG[CZV<"S=-W0-W*>8Z?XC9P+=13P'!/[),^QP](:HV@
M(D=7_0R?,*S?,CV/LK?(YKJ:G9`T(-#ZU%@:;#X#BJL^6][Q3C;S)<3V.\S$
M#6FR4'B>3LMF?9IM%3:09XN?D"P;FUT)C$.XN4:KQ8N$FA"`J1XL9+UE9NCX
MHIYNPBGFT>1D0)-74&0&M0*T=6HQV]&X%<9YXU+1=)[V;&[U*2.%@CMG22&[
MDC#,KSD,D+6EK@6Y@T"H>2W.YC<U)O<G>5F1L)92P[CVB89/D.*R65DYEKFN
MTRH^B(I-_9FT$6.AU,9XUOS`\NU8J&?JC*.8YMZNJ@8J@D%0Y<996,-S!)++
M)D<S8.S4X5J<SFX;L`3M71.<.==6Y=UFPTK3=/\`6H;P`NE(N2UM9`S*WU>W
MF;F`[9XCF-REM#2I#]8O*!,A\FR%-U%)FJ!*4WM1Z@+Q_P`)`!MRB8O:`>@1
M#5K-]%#Z,_/>MFT84U/5Q_\`R#/[E:)ZM6RV!:]4/_2["'YT7$W_`%E<5ZS&
M@?;$'RS\TKD_?G_TFUO]7C_3Q+K>UU9?,1&B+B_T1=4W"[Z)'&W\BN.OQ8CM
M$4FM$5/'([#E]S_RQ:4F3:14BP@LJ8SGV$=?J]9[GBM#C83C/GAN_F)&FU[(
M>-B2TW(<E'R[%TX)(F<,G*5>6=M5&Y&7BD6PGH;FK!YBMR]!'(%>QA6LF2$M
M7*Q`UR@*5R]P:V1N*=/C49MY(1+RQN82%Q.ZO+A)%LY9K+&:BLJH8[1L02*/
MGJ'/UQ9,G7.+99X>Y*;4-DP5<6BF4].KU3+<#@+S)EQ8X23=Q36!L]"993MN
M/0CW_3(%<GD&;-9ZY:@J1,BVO(',_+7!MDIN.7^6<I>N2>8%JSA^03A\,O[_
M`)H;N+UQD5E5;?7UX)H23H+.G72_(^/"QS)U'F;-$T!6>(-@7(I.R_%;*-XY
MHYCSG[J1]1A:I.X8E<:3"M8GW-_LA:GCEFO-U6F7\,H,:K5<<62R&4C++&N*
MJ^5D6R[TA7*)G!%D"*'4TS\Q.79T>]QIN1SJ_P!-@<IL8=E/Q-<A($^3K1@V
MK+Y*1M4)$U8`DL;UZ]Q<PACY]ZLZ(9X*!6II#QD2J$3[UIAY@,['4U].7/+B
M#!I6,6QIH1A6:=!A/,\B<H<D4RZS%Q>VBG1]Z&XXVXM/(F0$YV\&)94B,DXC
MBKD.Q$B8.AJ>87C7`.%(FBTGD%)6IG<<2MY`;BC4TY]_#P>#>)];MZ>5&SFI
MOIB>3:3"%[.5P[?PK=U[D'1%VN]4BDER*X/B97;C5,&5^"OK2<8V9I;<N+.&
M]C=JOI<(N1S!?).MJN'2SEVHH@YK3QHHW`5!Z&QTR@!0#I`BD?HB-$5(,[<L
M[4?$'(F3XX5_'<[E&5Y_97J;1YEA:1^3VEUZTY;91-ER':8N%L=2G['$4Z/6
M]9<,(Z0;O3("==,%?`,@H1-)/Y/Y.9!XB<_X;DM%<=SOJ#55X>H7'C/99N?Q
M_-IR]5;S-IJ#@UHGIBQ.[#C&551CGTJLVAV\D[65(@P2!H=14BU7/3E[R*PA
MRWQKB[#?)'AKCEU9:E3IW'_''D0I[BS/*^ZS.0[)`VS&3O,+.17F..[MS6XY
MH-.E@B7S"9EQ<ME]Q2Z=$3_X0O%VRG=O+BR+DM.MJY%O_$K.]JOC:I2;"3J9
M;?/$XMOK"PK\U%'5BY*$;2:ZB"#ML84%TB`H3VI@T14`<,^7^1;GYD6)<:2?
M-K/-UK;OE#F]JHE/RSYY6LIPDVR595*E26(C\CK2]HT=..JVX340>4MK%TPO
MAN(QO%++OE!(NC?%]T0QM2.=61G4%8;0VQ_R8Y&W9Q6:DP"4M5B0JN-<=3JL
M'6HT5$@?SLJ1@*#1(3%`ZYR@(@';HBB9%\ZX+G!PPYWS-;Q'><<P-'P5D4*U
M9[#*PEBJV4:Q8J5D:/C[/5)F$3;^I+$D:<]\>,>(IO$F*K%[VH/D=$5OC8-V
MS7;[E;?K">B)F9?Z7_$'][?*;\5\5:(K%-$4$_,V^@3R@_)JY^^T5JYLOKL/
MIF?."K6_UB/TC?*%RN>9#S8L7'RSTFL8TS#!411U(WI#(\E7Z1A3,]P@+)&-
MJ+*U*GSM*RMGS"3&J-IVLV]Q*^LE5=O5$TVVR1$%_$/V'6]4?9R-C@E#,79J
M-8\@C*0"U\C*5!K7$[-Q6^ZC>FW>UL;PTXUH&N(.%`0YS:5!KT[%).KSZ]ES
M3Q=M<C)C)N;%PTRI9'\VY814&,DO,6/BW*NY9Q%0\O.P<*+U1R98[9I(/6;;
MJ$B3E=(I537L;S)=02$U)MGFN`VF(UH"0/<)`Z2KEKLTT3R:UA<:[-I8?"!X
MU7KC]]?H[S/YN)B+5F!O1I;,.0IA_B!I/<G28T)%3=0FI97,+B;70^:O.UZR
MR9D'Z<"T-[H)+OTMCF=-E!'#0F9NO%K72<(R..2LN6A:3GK]$03CE&-2-X6/
MC,@U,@%^0O)RU?EQ%<U?,(.VFW'I"?3-N-T\A<0>8+MFQ@'%LQ]R`Y9WFGO9
MS$M=S6HR=M)F=B;(QB*+9S)L'3ZU4N4D8E18ITU$FSQ01$R?B$-=W<'&TVY(
M`XC)IG"K`_>0:-/2TD5\*KS1\2TF(IG;)(1V0[IK@>D5'NJ/?%]EB..XC\ZF
M&(K/C2[Q;1O3B2UMPO@"E<?,7R+UW3H^6+&1E;JCN0D96U5US).6DLXDUQ-T
MD:*-2%;KE.K96`MFZ==BV=&YHI4LC;&P]FM`!4DBI!)/13`JWM1$+2<1%CAA
MBUH8-G0-XWU\%,%,SF!YDF/>(.3`QY8Z$]N,FXKL)/#ZGF#!V/9!66NTC:HR
MCPL?6<G7JKV&7A9!]4W02\^V14BZ\D)#N1.8X)ZRFI:W#IT_`>S,[*#Y\;35
MQ(:*.<"0:&KMC=ZO+O48[23AN;4T!\YHVUI@X@TPQ.P;TX&-I.\3%[XF6#(E
MLJ-UN-@X_P"=K)*6:@>YAZ@]/.R7'J613KLG!NG4+8(M@1UX+:49^$WD4$R+
MD3#K$35H'2NEMWS.:Z0PR$EM*8F,X$8$#<1@=JGC+W20ND(<\QN-1LQR;*8'
MKWJJ.G8FQ#4O-N//X^R+Q[QO9TN1%Y93F%D<85F$R'),'^/(*64?5:6+@N:F
MW4AD"6F90KA9"ZQ39`$RO$B%*LI'AKT5O;1\Q9X7PLDXSJLR`.IE!P/#)[1)
MKVP-XVT6,9%"S5LT;HVOXA[.4`[!L.6N./QAT^!=FOE9_P`C&:_SML]??6(U
MHW,OV]=>D'S6K6]9^U)OE?>"LQU@UC%4ES&^F9B;\U?+G],6%->(/;C_`(1Y
M?_>D_P#=UVGN4^UK_P#5F?I$@0[P^N&OFZ=B]$JH?D597D3P(Y/5QK6;1)$N
MN2^:K!Q;XNOUN=J&.TX'.5_LI9C(:EFMM/:Q$7-GCO<Z.<IN/%)*KHB!VYBE
M7)WCE.SCG[SM&O'S0L-M9Z0X1.?(R6?/9P1Y8.'%*7.9FXDC2VAC#L'5+3HN
MK3F/EN[A#'GB378S!K2UE)9'5?F>RE:4!!K4C9M$-/+XE`E/+?Y?.%)DS\I,
MLTX#/0G?C&9F3UW%ZAC%<&RGEKPS(E'Q`3%ZVW$-Q0'?K-T'O4AX/>YH+!'E
M)L9<,G#KA<;O5K7;LKD=\K<,#RR_/RI?.+J_GVXUS4^C_P!9+Y1U;U&O'%CQ
M)DWS3<;6F6<V&XY,3S9BE"IYONTIPL=MLQU6#J%//5<H*+0?%N)SR,WD*`3(
M=@VC7T65H[42:BXCTT5O5]OU>TUW1^Y:\LH&Q6^CG3KDRV<+=6!M97RR\2WH
M_47662!]0]TC)"Y@+\DI<W/A[*6PN^;H)7YG78GB#97FTI(UK&97]FW$U7MV
M!I:`:-JT`T<KS3XFHX@Y;P;*W.<(P='R[3+'D&$L5IF.5R60ZQ8'DI9YR_K+
M*TKEKB.M6M>;E8%92L0+%FYCTGOALQCV8NRK/\/W*3W^O<BR2V`U&34K"XC@
M?'&W33!(P-C9``)M,NI(@QKP+B9[FO+*R<63(6Q7O.4<%CKC63FW;;SQN>'.
M-SG:XEQ?YES$UU2/S;`"T'LY6Y@77K5FOQ]LR=R[K#F7L#*+L&-^.T0I/UJ;
MEJ3:6C)]BVYH%F(.P1JR,U5IM%,X+(.$C^,U5`!'JZ1`?-5[=2V.C:#>,CB=
M/%=WSLDC&S1DBXA.1['#)(P["TBCAT+HMM$R>[OH2YX8Z*$9FDL<`6/Q#ABT
M]!VA5:^4O3N4T!D.Q2.8)*]W?$,AQLC)'%=UO?('(68O<MG/R%8<Q-<AVUER
MG8:R:9>1\<Y]V'+&NQQ2I1\>X;J(-I(K4>T]^6H<E76E0PZ`RUMM>9J[FW,,
M-C!:YBQL@=(XQVS),@<YO":^>3%\K'!SX2]:AR3!K,=TY]\9)+$V@,;WS/EH
M'%I#1FD<VI`.8B-N#6D$!]$_.=<><7Y#RWL&9NY.XBM&8('"7'K&*,+7JGD:
M\XT?.CY*B\<UE>(DIRGW.G,"5R4F$8U1^M+'=,V+=J9P"0BF(&UCEK5N<XN]
MS4N7.3;^&PN=1U6X+WRV\-PT>KNGD#FLEBE=Q&L,@8(@USW.#,V.&2U*UT=_
M*=OJ&KP/G9;VL>5K7OC)X@C;0EKV#*3ES%U0`*T3[\`+;C"\8MX#V3#N/I?%
MU`>\T#)1=,G<NR6=)./>-(3-;>6=+Y+EYRQOYHDE($.L1$[M0&93>"4"@7I#
ML_<S8ZSIOM3"SU^ZCO=4;I,^:5EJVS:X&U:6@6[61M9E;0$Y1F\XUK5:=S?/
M:7'=CQ;*(PVYNF4:9#*01*:G.7.)J<:5--BZO-?1U>>4S7(WZ/>=_P`C64/Q
M(G-2N\T]2+AMYEXYS=F#CQQIH6(\&M,OLF4!0[O8U+&&%K'1$%([&8UR/KUH
MQKF2Y4V/M"CD;$,BR=I*K%CW3`ANCQ!(8OL3FJRU34M*L[/3K07+0&/=FX#H
M\(\H:Z*9[`^N;,T@G*6C?1:O;/CCE>Y[LNT;Z[:[0#38GAP_4+30:#P.IUVI
MD#CRU0-YR.UF:76(&EUB!K[A7$F<WB36,@<=S$_2HU%9JY36,2/>+I&45,<Q
M@4,<I;_3K:>SLM(MKJ)D-PR:0.8UK&M:>#.:!L9<P8&O9<1CTU4CW-<Z5S22
MT@8FO2.G%0DY=-:U9O,'QTR"V69"PU6Z<>?=!H\Y+XCQ;'Q4:Y6:31ZY3L47
M/+-7M-V0G%%X]\JZ9P,B=1VK(,4DW:CE,&VK\QM@GYQA;Q)!-'+;U!N88@`:
M.RLB?,U[\W9<2V-V)>P!Q<,MQ`2VU.`H0[XI/ND@4'C\*M2JZ0N<C<NVX)H*
M"YF:*@"3A8S)LH*^!*NF";ASXB)F;<XGV.IUD%(@B;J#;<-_MQFO-2;AB^/P
M#ZNWQ#P[E9'S8^K[ZJX\MMY$3#'+L@#*=]UH7CX]J<;(/[]Q<L4`WA8EV>.G
MH:KQ>`*74;1,QJ-AA4BDF[(K*J^"W3(#D571SK:%R0Z.5ER^C^(VS+`3):N:
M&@T<UHMV,<X9FCMR%YH`,U75-[=U!;T%]=CO?S$CW`FBYRP$LX:\/I.(J&*)
M5U,\8L4U`C'(N6%:LYRNO.1"E4:5.*I!<HXZ3D'./EKQXY)$`6<-4+,Z=HG`
MT:9,^-YJAD+=-DCCMW.=81,I)+D,N9N0,#.+'4Q\2N;$@2N</,H9[8CM@EWG
MDX"M/#6AVT]ZF]6#>9'?,GXNH&([EB%2\M[Y6[E;9%O'U6NP%LJ!X-GB^Q$N
M3B]P]GLM7AWR%?JYWCJ+\1PJHF*3IPFD=1`JB>Y<[7=_86EO<Z;Q1=QRO-&-
M:]F41.SF1KG,:0UE2W$['$"HJ+6T:Q[G-DIE('@.W"FU*OB^]=OTN(#]XI<%
M';KA1;EUE;\Z*]N:AAN^$`(M//$U%B.7"B92F14!14#-12'Q%?U0U?0G.>--
M>[B9CI;_`*0U?])!YQZ>C$X4Q.U0F%.(,/I!LV;'*&N$JAD&`\R_(DQ3VEK+
MA2:R?D8).PPV)HN%J:<['PMR;V6E*SZM_;HL*\G;I`$7KUC717EI:%:.1$3.
M'+@VLZ7;7D//$TEJ)/V6Z>2KFPAK,P:_,S-Q,&YS1SFQU>]C7;W.5Q(YAM`'
M4XE!OQW4.SH\.PE=F?E2?15E/SC.4?\`3Q>M<!Y]_C34_P!;=Y`LU9?5(_DJ
MRG6HJY5!GFEQ0SN1>1T,%7MUU&3\MJ69EJ-"D/<JYV$RN2\A`6,K<A[E3WJ\
MBJ8-P_N!_P!:93$]5<=7@GT3G-V6ZTYV9K:3NQ=BT>9B<1Y1UC:N:=X#LE[I
M3\S&4N']IPJT?1XD5&'NCK&U5H^2U3KE3JGR5;7;#TUB^?/E^M-)^Q.[*K/U
M_*]SCHN>6MUUB"H85P=`*S$B[E$)&3E(R,>-)(DNT2*X(#$K)KI?,TD<DD!B
MD#V<,T%*%C211I[;S3"@!((H<,:GGW.$T,TML891(SA&@I0L:2,K3^<D-!0@
M`N!&4FF-3$SAGE;-MQOW*G'^27O()[2*%P;Y)'P\YRA`U>N!)X]LMC7FXNPY
M;/"W2VRMMR7*2[J008OY)&-<,'S.Q1_A@*!FS7(ZE!;1PV\L(A$KKJ//D)-'
M`4(;V6T:,*@5J"PUV$Y75[:SBM[6>W%N)GWL6?(2:.`H0RK6@,`I4`NJ#&:[
M"4+RUN5*R1G?!J`\4K-G./?8BX[5=.7D:YS.QI;ZU,8=M&1ZU<4FY<8\7\IP
M5IQW9&TZX)ZX>3BVDK#',L506RC1\2II\4L%K*?6&Q$22&E87`AX:1YTK2'"
MFRA(=AMJ%5TN&:WLISZTV%PEE=0&W>TB0,<WSYF%KQ084<6NPVU:K%?-NRUD
M7$J7'N9Q)DUC0,BO9_,3)B%UN."J7B.=K$C3X2O6\UJ>9]R]AVD/[DR:6%!.
MOHHR+M\BB\DG""`&2!=+#\O00SF9MPS/"&LV->YX-2101L>ZF':P`P;CN6!Y
M5MH+DW#+J,R6X:RN5LCG@YB6Y1%'(X-P.8T`J&@G<7NXHR3&8G^,\K&3MNL\
M>_\`+CISAG8[^Z9/[M.(CDBI%"3L[^-D):.?RSH2B8Z[=V[16#8Y%E2F!0UK
MJ#2UD[7!K2+TX-\T=DX"M#3W!U*RU1I9'<M<UC7#4'8-J&CL.P:"`0/`0.H*
MI28RQ,5GSOK&VA.1N#:@[=9/9T16+S!#OF-?DXZ2QY7$Y3"4*DPR-%+,\O.H
M]91>`L9H!!*2E/!8*/WA'!FKG8&V[7\KM+H97#AYJL.(.8T>>R>Q^$W-@*F@
MI4;2RU9)R8TOMYW@1%U8S4@AYI(:L/8K@YF8T%7912H[%/+J``XNQP`!B@&;
M>60`4_VY0#E=FH``^P![8/3]771]"^Q;3]79\T+K7+?\/6/ZK'\T*<6LJLTN
M9?S?S.R<CLUG82%EB'Y/+TIQV4K3&"DI<(QV6\\M#-I&IQB+R.5D;*R6`%&*
M!7#<RKHI"@HF(]0:9S33UNSJ&D9C@<`>TS:>CI\"]=^S47CE;FLQ/F9)ZM%1
MT3<TK3P;NCHV@M+I`<6#,VKJ"HVJ@+RV9^3A^'G)"U0M@&.F85_<9B(M-R3?
M.J5$RL-B]-_'2ON^:_Y81G8:&>)$5EBMC)BS$ADS-E3B`FPVL-:Z_AC<*M(`
M('G$%V.&5M"=U=O2NN]TMS-!R'JU[;RY;B-TKV22U,37,M\S79^-<A[&FADR
MTRX@L)VOUY;>4\K99Q)DB5R_D2=R!:8J[IQK;XV++(3L!%.*FP?-6CJ.>X#X
MZ/8F,E%5CN6IE8UZ59(1.5YT@)"6NL0P07#&V[`QA;NV'$[\\E2-FT=2V7NF
MUG6M;T.[FUVZENKQEQE'$)#V-,;2`6FRL2UKB2YM8W@C$2;A`K@T$-#5JPPM
M84PY;'3WD5QT<9%M%`OLE/9'C)$F;VKZ-=YA8]4I0YN1D;*XEHMB]KTQ,&28
MLFR:JW@IAME=3S.>'/XC1P9,H<VC3V,<GQA04)#@,2:+F?=SZO;VDMO9FPG>
M[5;$SR0S.?.UWK8<TW0[4+W.D,L;'P2RT8Q@<[*%+#E//<5+#S/QSA/+''9[
MD/(5RC<?PKVYOLJ/:)6TXRTR,FVK9'V/F]CCT<HK5Y,5%"*J,U%VASD21.!B
ME$+"Q9?LTY]S!,&0M+C3+F.&WM4[->O%;KSE=<E77/\`:<O:UI3KK5+AD##*
M;DPQY9'.#*P"1HN"S$U+2YIHUIJ`F0\P)JM(\H^,*%\@J'#*QEJ,QH[>)R'/
M.)5?&,3>(!S$W%]'->,F2'F*'I7@.$7LC$S$*"!$4&ZTCT>`9.YTHTL9S$7$
M%N-6BF8M-17B-S^`$'>0W:M>[SV&7G+1VZG%;1EDV6$-G>7&W;,PME+1I\YM
MC7,'OBEBH`UKI:92++EL@1^)V_.#*<U&RDM$8YOGQRE8R&01-*/6D'QSPN\5
M:,DUE2-45W)B`0#*'!-/?J$=@UA1$9S;0-(#GMH"=F,CUUUVJ1:(SF+6;ACW
MP6ESQ7-:!F(98VA(%30$[,30;=RR^*G)F'Y08R>Y/;5A*AL(^Y2-04CGEYK-
MQ1.M',81Z#TU@@`;Q*(.S39$BH&_32F*`CN!RAI?63K*80%V9Q;7S2.G<<=R
MGY+YO@YQT=VLLA%M$VX=$6F:.45:&&N=E&BN<"AQ\849^"U@F9K+:R4ODKDS
MD%XARUXDN9EOG6L2U9K=3FE^8M>11K=+:3"8,!D(RNMV2;Q2N'/7'7ZLGT'$
MA"[':,:W5;/*R%@S&F0@DC)M-.DUIF[07G[FJZN+CNSYM$]WJ]U((HR\7D;H
MXXGF\H(X@[#,V,,#S`3`[SA0T`[_`+6_+PVC1%Q?Z(NJ;A=]$CC;^17'7XL1
MVB*36B*IGEME/DOA_*&<9FC9X5"IT'AQE7DI6<62>-\:+1JMJI"S>OPU6>W%
MS$%LQ:S(2*@.EU3K>LD5'8%O!+X0D7[EO,7R%7,ET;#\O@QC)7ASE&>Q_D92
MGV*S3]6B4(JYX4JOK5<L:E*8-FZ[)IG1B^<J6`L,U5)$/4FQU3J-NHB3Q/,_
MLD6'&ES<<5TR''D/(UUHTK=?O5KMD_$,LE6N\U7%LHO*HXXBZ@P++)X\?R3E
ML]?(.ED2.&S(CA=@L94B1T;YJ-L?X^K^3)#%M9,NOC=7('Q:QU?5,E04BG<<
M;86O5,B$K&RH;6:F)6L*99!M,EB6P]1FBGJY'(G33*1/+'>8;:DS8F?7+&55
MH%8M+"T%NU@MELLD6@SEH/(-^QPP/%I#2UU*-&S+NB$E&07<*\J_;RJ;)#=^
MS?)HD36X9Y4<C7+$V3,A94AK'(_+3A[%C_C82@5:L/(R!RGB3"^0Y^;2=M"K
MY);V3&(Y)?NWAW)E6*L9#KBLU;`87#8B6</YFT\THU=M5]PW7X>;G*=C>_FI
MM9R8:P2(U[(/&',O)7U.%=OZC!>[\I"LL6H1*BB2!&BCB0.H!RE0`JI%ZQWF
M+WX10;3V.L0MB0F;Y?$UWM]7R_-W2CHLHJI8)L2<E%/8/';F<AI!^MFWP%SR
M[!"'A742+-^]3=/6Q!(IR\9LDVC)>.Y9Q=C,75MHF3,IXDGYN+9^YT7:7N+;
MY.4LMK8QWC+E8%L#6)3<K(E-X2;DZA4RE3`A0(I"Z(C1%SZ9WPW(<A.._(/"
MS3!.'.1,=D/S$LM0=KH&>4K>3&[*G!>I1]/V]]-T%VUN%+G81%H1"*GV`+K0
MK]ZFZ\!8$Q()%%[CEA:DX'\NOGS0:?PEAN'3Z#"[P=\<0>6<4YCC<L7^";N&
MUC<0]FQI!5.1:U?'CA<&,2TGXB,DTV3TAC-R*&7`")F?.KR_EV%Y.M>-V)^+
M51SRWY48>PUC>^VEYABO9>AZNR^5_)RE*KV:@RE;*=A2KJ6F^.XYM1)"7?,G
M#19684;N`<F;$`BM<PIC^8Q!9_+<Q;9:;6*%/XSX:9II$]0*>_E9*H4^5JL1
MQ3B)&JUZ1EY27F'D+#.6AFR*J[UTJ8A-_'5[%#$4-:UQ$RC@#S,L+WZ]\[GM
MNH>3)'.LI`5"8Q/Q+QK=9B^+QU%?L,)WBQ5/"D':[XO<XB8F'S)^C,,[*^;,
M%DDFQ2(R#QZ12'RQDV0P[Q)\S7(C"LY5LR<!GKDG[M#A"2KD5E:H5N0QKCN.
MG\ETIS:I*(B#2F-8YR>:$@N$UO"9G.GN8FPD58/E[)8!5X:^:O+8!NW(FS0$
MGAYVJ[@L[N(%TWIZ)L5Y3>MV%5>Q/(GD.]DU'4P_DO%7=.(@48A&*9^"[6:K
MOUR*9_F[9TRI7HW&6)L#3/*N+LT1$?*EG);C)C>QVF098(L;6<IYG:MMJ.1L
M>VFLY!(>MS:]638A*H"^:F<.F_6W9`H12-X%Y%M.7*WY3>2KJ^M$M9;AQ[Y!
MR<A.7A1`UTL!"5C&C%C/VY%`ZPL+)+L&B2SQJLJX=MES&3<K+.2JJ&(KV]$4
M$_,V^@3R@_)JY^^T5JYLOKL/IF?."K6_UB/TC?*%QX^;-$7"J9APY<:*OEA=
MA>FEZA[[7<8XDQQDUNR/#R-(9-K^YAI+C-R$MCNPK,GS9DNZ7;-VZ$;'@FW>
M)+=#%]U;F)LD=S'+%Q*/S!P8QKMA;VJ<*0UV`G#`8&N!W?5@]LS'LST=4$-:
M#O&/F/-?O#;N,VF;$3W;CS%O\?S;H3\!\U1[[$]P?QB]D=BHXXR-G6-;7*/4
M6<*K.NQ,:)?N%TD6AG!E#G(1+<H91HK+"US#]4?V#2O]5V2=E=QW55[2KXP6
MGZN[LG;\3LG=7<53]PYK$Y'>8-!1]PQUQU@)&HY4R'#MG%<JW!>D9MJ*D'29
MV,BJ3((5C(3_`#A)QU.B5"PZXP=>2*_1:%<(.O<WK,;7--8X:R!*R$.:]PP$
M#7BC2`TT=G(`P[+<:5!RK$6;7#4`'MC!#R,!$'"@.&!S8;,!CTT5GEWQW"91
MXS<G:I9,^/\`C5`GY:9UD93*C>QLZO$-&[3)#E$M:ND@]GJH#NB6IP[(TE&2
M4K%N7J1@21=(G,!PSLL+9[&>-\Q@9ZQ(2^M!YVQV([)V$5!.XA9)T8EMI6ND
MX;>*[M5H-NPXC`[Q4=:;'&/&Y'C'PJY-4Y#(^)\PM[+5(^\1F5:-#3,;?;S`
M6`J[N%DLI2$OD'))+$TCTE#L*H\:R)V_N$T!,.HQ#;6\%EZCI<\8?'('-S![
M00YP.S-5SJ]#"#3*%3CMA;64K`YCP17,!B0?PL37H;CL2,\SVN9KL^6B%Q9E
M'CS%0M*PO)Y/R+0K,&*JUF6*QI4[0X)?KR\NN1,`9O<.*3)1+P(Z%0:KP)XF
M8\9[XCDAC$)3UV.ZDN?]WDA#&1%SFG('AH/:=F=&_LD8"F6AQQ4FIMG=+^:=
M&&M9F(.4.R@XFI:[#<-E#BIM8P-$FLO"D\`QDHR"/Q2R>I"QTQ;(>^R[")4;
M<;CQS.4O->46@;C(MFAB$6E&1S-7R@"LD(D.&LK;Y>):Y`0SU=U`2'&GYO:X
M8.ZQ@5>1TSP9:AO"=OK^!O&!Z]ZKGAYUXZ\X"]L2Y!SN>+99'I;!W4JFA%7Z
MJ%DT,<S!8EK?9"(R,62PUB%NC(.D#%?UH4WRJZ;<ZIE_`=)X1CR>8WC/-E#Q
M@*.%<IIFHZK&8G:W'9MH5CVN)U=PS/IF&`H1LWX]EO6W'8NO/RL_Y&,U_G;9
MZ^^L1K0.9?MZZ](/FM6L:S]J3?*^\%9CK!K&*I/F,`CS,Q,`=X\5\N?TQ84U
MX@]N/^$>7_WI/_=UVGN4^UK_`/5F?I%&.F\@L!9%M+ND8]SIAF^W6.3?KR%.
MI64J-:[4Q0B7!&LJN[KL#.OY=NC&.E"IN#'1`$#F`I^D1U\^M0Y6YHTFR;J6
MJZ9J%KISRT-EFMIHHR7"K0)'L:TEPQ;0XC$+O=OJFF7<QM[6YMY;@5JUDC'.
M%,#5K23AOPP4,KY!0]MX,\I:9-9-QCAUM=,O<I:LUR+F.3C8C'-=DY7DQ<RQ
MRMB?2CEFBD1VX2!%`4E"NB.3IJ-Q!8A#!T+3+FXL>\K1=0M[.\OWV]AILA@M
M&N=/(UNGQ9A&&@DT!JZHREH(=V20L!=1,GY<O('S0P!\]PW/*0&`F=]*DD#'
M8,:UQ&*C+QUPHIA7R_>2+(N<\+<@(^UY!JDU'W/!=_M62*BR%C9\:Q3V">S]
MJL%C73FFKA'Q%&Z"Y4R)JD,8@',(CN/-?,0YB[TM(D.FZAI<L%K(QT5Y!';R
MFL=PX/#(V1C(0:!Q%200#0+#:38&PY9NF^L07+7S-(="]TC10L!!<YSL?`#[
MB8+E79Y&L>9I.Y22P7E6V5#&W('"4;*7W"M.Y#6V\6&[-ZUC62A\71L>]Y8U
M;CN]=7!Y/1L.Z*-)*0C)^)A*J]`S@^T<DV45[W/1Z*[4K*"_O-+O'-@NY;&*
M%D)DN&ON'.&F27P$09)*W_>R2]@\V.C1B]7G,'-)O?5IG6T,\(+XFSN<7!D9
M$8!N6P=JK6G\U@#7%V*RO-_R7;PR;Q_7AJUD55RM@LN0*)6VMDS51)[$V2IN
MTOCHV>]0F(.-O(.+L[MDI&1;5S#2D@P02<1"R9/$(L=89.X71[#]C:HRXFM`
MP:EP)I#':3,NK=D8K'"^ZO[%T8.:1S98V/);*TFA:&JISS>3^N6Q8R6OJV=C
M<TK'12%Q[3Q%!.'4HT%CG`5:1C6JL+Q])<K;3!<P9"0K6,\=\KG^/>/YX2!A
M<BNK)C5.R-JW;S0(O,@3-"B'#1E;(1`HOC'@3^YJKQ1,B:WA%.;E6JP\D65S
MH$44UY=\CMNKW.]\`CN.&9(L](&3O!,;SV`)AQ`T$EM2!LMD_6IH;][FQ1ZT
M8XJ`/)9F`?E[9C;@X8$Y#2N&;:4_P@XV7["UZR99;OP,X.<7!L-?MJ$9D+B[
M<_=ZYRD5)6&/E(?&UEC0Q)0O682.8MA6<2AGASNWC-$QFI1.(DNN\?F_2^8M
M-L[/3>9N9-:X4L1=!J,62)KFQN:^XC=ZU/1[B:-CR`-8]PSFF,G+>CW>FSRR
MW>GZ?:.=&X<2W<"YV((8X")F&\NK0D#LA(#D)CK']F\L'$E\N4NXJ\CCWCWA
ME"(M?QQRO6V$7$6=YB0]HC'L+B1&5LMR/96\`W9)1[*.7F7@J&9QSE@L[,Z)
ME.5=6U6S[Y;[3-/C$T-UJMV71<*VD<YT8NN&X/NBV.+AE[GE[Y!$V@DE9*U@
M8:&J6MK-R?!<W#BQT5K%1V:1H`<8LP(BJY^8-`#0TN/FL+2:IR/+(+5D\-<&
MD:7;9*\5M#GO8DHVR2K/)D0Z>E"-S0=4B=;S$R:Y(J+)%4X@A$2BTBJP2$"%
M?O4^E<W=NZLWI]JR-VH0,MKPZ%(71M-NX#_=&T_.6I-O*2/.EC$8><3%&:M&
MC\S\'_E<X0/,D0O6T<1(*_G3\64"1HZ&N+J?A.&*Z[M?0U<`3-<C?H]YW_(U
ME#\2)S4KO-/4BX;>2V:+/@*O\5<B,,B8FBJX7!I*Z\QSE3D38<"1DK,S]*KC
M,E[.UJ^/LA2%[2@(<RR+47"#=K!2/A.BJ"LH4NO8FOZI/I#+&\9-;M@]6+3'
M+<NMP7.8T<2C(Y#(&MJ!4`1NHZM2M7AC$I>RCJYMH;FW[,2*5]].M@R6L4SC
M7@%,6J<F[+./;KD1RXE;.M:Y"<4:?)-G0L1'RDQ>ZU3K?:EH:&(W9>[,A%LE
MYLC<'PI]+@IC7NE232V&CRW#W22F60DNSEU.#/E!,C6/?1M!G<QI?3/3%2R`
M!\H``%!LITCHJ!U;MBKGRC69NO\`/:`J=NA+8\C*QDG$@5W-,QGGD)<HB,K<
MO.QUD@BY18PN#)NEM;)(N9(8YK&RUJA$DD561.I1IX2JVEW\$L/-S+>Y;(61
MSPY9W7%P\!KG!S>*&P.8'$G*&OE8`"T8MH3<L(-L7-(J0<,K1XL:^(%6ZN6U
MS>3O-9OCR0A(>]J/:(:JO+/7SVFO$F4<%U%=NRG:XB[8*RT9)@D9HNDFL10"
M+"8FYB@4>C%MTZ75&V1:V[S1Y"YN=N;@,P<VHJ#L(!WX*Q&7\WGQ;C7=O*KA
M\M=A!-X_.SYE3\>UJ?E,*@\LI*GAGF3CF5C9=5D)).`7F>34[-TH8]H]0\)2
M,J@-4_%9HFZ!:MD03TKD=D09=O9'#',ZUJ[)#>1D.IBW-=.<R@.!;%3%HPRM
M%+R\K5M22,V\L/S<?&FTS[5\!NV>-7-KYKVJ-R3>\2<8L=3?'RO4#".4[%`8
MF7KD,A98/'T&[PK>\CLK6$)9IB::M47@33A9T"J93HD;`2QU>WTAS('7&J2-
MOI;:UC=;MC@E<V'*`YL;3!)('Y7/>`'9R348!M)HG2XY8QD#G'-5P%?#B!3`
M#H4T/,Z.1&@82:/5'A:N>[V'W:;/JOR8M=+<JLZ<7XOA<6/%*QUC*S=ZFN=7
MW+5,X-&`L9<').KPA#9^>R!9VK75]7XKLU67+V&C.SG%HYLH.W(:Y:US8T5O
M9^<XCSJ=+0=N[-A]]/%@!`[67XLMU+%-6TR/#B\D"R6*%MM;FI=/X]X1,BN^
M@;\LXO42""(E011F5%),&Z28N3&5$PCD=(!;+I[2]TE-,D[3FO:X_G(-K9*R
M#H`?VJ`9L5)+L?A3\X.CH=T8>+!54-;E3,.^9UDC+]\K-,9T-#+]S:?*U!\8
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M2N;"YMU92,@=</897!C20<`PYJ@$]G;0#%<\YX+V7FG31V[[I\;IGAC'%IJT
M,.:H#B<NV@!)4;?*GP3%8AI6;K'7<C8'OM4R%E]>)JOS:,68]Q!AP(#%3VQU
M9A=(2L8TN]XJ*\SD5&0!P_=%636V8HHJ>(")1+SW7[MUQ+$Q[)62,CJ>(]SW
MU?0Y27-::-W#PD[URSF>]==S0QR1SLECBJ[C/=))5]'%I+VM=1E*`>$G>J\>
M!1!=O.7TJ]M]K+9E^(N>3WNL2^+N>%9G;38G[4%W%HS1:N3-RLN"'&2ZP]1=
M)H-J"W9-W:TQ)JH`+!%,I<QJV`MFAK<GK$>4AT!`'0P1`293AC)4BC:XE9_6
MS06C0QO#];CRD/MB&@?%C;"T2Y#AC+4C*T'M%1ZY76V%R1RQPXWR&M@R-R)C
M/#N',:/,=5SD78\>9CD(-_-2DOBIS4[76>%-QS,[LEMJ3Q@_>UZOW!O&&7>'
MC#`LBJJNYO=/C?#I\IAXIA?(]V8QAS`:`/J#,UE`:@.<PG#-AL%_I<3[?2YC
M;\<V\DTC\YB#XP0`'YFFX;'1KJ@/=&309L#0"T3SG&#"R5'#%2M&2<K8OILE
M*Y6G#6'&^(\J94BELBUR&J?R=QUV9X6A9VYPT/(EE95L82@D@=BN]53/ZZU9
M@."Y:)9++)&R.24!@HY[&'*2<Q;G(:2*`]=-Q*UKE%QCFFEBCBEF`8*/>QAR
M$NSEID(:2*-/36@/9)4F^-R8PUKX_)R5SL%V")\NBM>OY`O4+8:A9;(BQR-5
MCN+-:8"[`E:JT^<H)"LX;RP$?-@#9SLH!]K&][4<Q#0VMZ>RT@@=DX`MP/N8
M'<L;J)SQ3EK&LKJ!HUI#@*L=V6EO9(Z"W`[DT%2XJT3*7/*$YAU+,:^9*'+U
M^>R(<L(GCJ\X!449$^32F4F"=UR3<-RW&!?."V+W<=(R+M9W#D\)9HJ!^JXD
MOY8-*.FR1<.4$-QS-D_"<XU&P^;E%!0["KN74Y[;1':3+#P9PX,QS-EQ[;G&
MH\TCL9104=B"%?WY=`B/%N,$1$1'-G+$1$>T1$>5N:=Q$?9UV#0_L6T_5V?-
M"[URW_#UC^JQ_-"G)K*K-+EJ\ZNN90M'([(,9B3)$GBZT%X5XI=.9^OX^:9)
MMDC!)9$Y;DD*Y2X-W8ZKZA<I555$8Q^D[*NV=)$`A1$_474.97P,N[5UPP/9
MVL"[**U9B30X#>*;%ZM]G>TUF\Y6YEAT.[?9WG^[DO9`)Y',$5WF9$PR1TE=
M4<-X=5K@*#'"@KCK4;]"<'N0DMA/(EM6G8:??W*-ELBX_M.(Z[<F4+BQ(MOI
M,FUSLIEV7<U9BH_7]:=)LX]NZ>QR28'*@LN<,+=R1.U*)MRQN4BE&N#R*NP=
MV,@J=PJ:`]("Z_RK8ZG;]W6J3\NW4YN8Y72M=/!);,E#+8<6%PO/6G&,5.9P
M:QKGL:`0USBGP\JBJJ5?!F2X$UKQ79TE;ZW>)PF)9''EDB*T:9H,"]5:2MBQ
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MMI9Y=+D<YH+<KP74C&QM!@:.)`&UM*8DYBJ_,&FZ)I?>780PW$D4QGM7LBSW
MTA+GSESJO`?;PM>^0DLF+S(,C&&!A%7ZYIR$D/)SBQ%Q\OR/;F;(2$J2/P=2
M%++#IR;J[UQK%NK=*Q["1-&L9`L>X*X;31203@&;8XG*9)?>UTX#U*=Q$.T#
MMFAIE-:#R$8XGP+9>\"67_%^C0Q/U84!=EM(N(W,98PTRN:UV4.RNS-EI"[(
MPU!:Y+G-]$J=UHG.!W9G;B)-3+Q+V*OV!C;[93T:Y)/.)^+:RZE5)"J(R3]X
MB2#G'222*D=*#XJA#H-C.BHG)2M99(Y;8,QS-`(H#7\ZXTH?"!O'A-*K)\Q:
M;8ZAIO,3[QQ8;>X<]CQ++%D<=-MXR[-&'.(R/<`"R3$@M9G#2&ZX(8\QAE?B
MKEG':5A7O='L^5Y,IY-W7\BQY827^*&,K%#N:W3.1$1,6N!"HS:+1_%IRAYM
M!9RBF^\817.V0JZI-/!?,FIED:S95IJ*N!J8R`:BH-*=&ZJQ/=MI6CZWR7?:
M6)3<Z=->N[19.W([A6[VF.*^:Z1G">&OC$AF!<!)F.8L:Q7E-42I47+U@AVL
M38$,AUWE)PVIEWF9U_@=`\B$#S$K2+8WN)AJ/824B\?K$%VYE9DSQ0JYSM4W
M*FPF-L(EDEU6R<2WA%Y(`S[V=+\/``*=-%PF73;'3N[3G&!C)1JL5O#%,][K
M,9LEX*=BU:USB3VG22YC6K`\[_Z1VMR7D=&B+B_T1=4W"[Z)'&W\BN.OQ8CM
M$4FM$6DDJU7)D[M27@(254?Q#FO/E)**8OCO8!XH"KR#=G=(*F<1#I4H&4;'
MW1.8-S%$=$6G?XXQY*R<5-RE#IDE,P5@7MD)+OZO!O).'M3IFA'N;-%/W#%1
MU'V!PP;)H'>HG(Y.BF4@G$I0`"+`E,2XNFB1)9/'=)=GK\6]A:ZY/6(8KVMQ
M4@LU<O&-;?ILR/:^@X=,4%A!FHA^G()J![=,A@(M94L&X<HM.C*!5<94B)I\
M3#.Z^U@TZY%N&RD5)0[*`F$)$[QLX<2RL_#QJ#>16='66D4TB^LG5VT19AL,
MX?.G6$3XIQL9&DPDI6J8D:BU<R=1KDVP&*FJ_6"#%B6`A)>,,+9TT:`D@X0'
MPU"F)V:(LE#$^+&MTD,D-<:8_;9$EV(QDK?4*;7$;I)QHLVL>,?(6E.-+./6
M(L&*"`I*+F3\%$A-NDA0`BQY?#V+9M]#R[[']1+8:S77M3J-K8P$9&W"E5Z0
MC740XBZ1;&#9M8:<W".>JI)A&N6HI%./1TZ(D%C'BGQ\Q#58"G4O&%<")JUL
M5OE?<65%:[3T3=5&#*();&-EN"TY/M;"TA8QJQ;NTW!5F[)JB@D8J29"@1.Q
M1:-5<:U2(I-*B4H2M0:3@D?'IK.71P4>O7,G(O7;U\LY?R,G*RCU9T[=.%57
M#ITLHJJ<RAS&$B5NB(T1<V/,[-%SP-PVY37C'N77&"+B\\P[)-0A<JFL-,J,
M#55;+E)5)PO=K3?,39QA*_3';1JHB[<IUB2>>,=`B()=9E2$3%\4,MUC,OEA
M<S+E&<O9_E+=YBLVJ:S#"S;#$Q$\/9.D3S#"P-(FP8GP]A=E=(K)AX,)MI*R
M$9ZX[8`V4,1L8RB.B)J/.ZKD<]Y041P7$T7D->QT/'-?L;E3'/FUV=:/A(Z_
M9!E8VPS$EP-L,+A^7CZ+(=3QK&ODU[<BNN*R8>"+80(K:\$(E3N7EJ-TDTFI
M2</\RHII&C\G,46X%C^*9"IFB\WN'&9&B26VPH6Q4]B(`=,@87/B#HBI(X$<
M:J=7>;>*>4F,N/\`YAE5E<EV28:W*V<D^)&!LNX0;5&W2,C/RDQ5^7KZ:K&?
M63UU9(YJ6N7:01DI!E`*>Y"3$&JB0-R*T3D#DO(6*^)/F#3N+(LKZ[6/F+DC
M&4=++8LO6<&-$:9/B,24N5R7*8>QM4+Y<<E1E"CI9205B&\2]0=^&!71!:@L
M`D4'^!U=BFGEX\^[18Y[+%DY`RN!+M5LQ25XX>&X;T!2*I-=S2UQR]Q'3T./
M7'MM:(*SQ\F]FW#AVTE)R,"30CWS@O@(E,1;3SIZIDZY98Q"2H\&<;\J6E9P
M^Q"OSE_X8PO)B-:3=UM\Y$6QO+WM3-V+;30$,70D1'V*,A6#"40LC]T9NZ6:
MI"8PD5K'&:.-#V'RP8D\=8H@\9@'.3`\3;,?U3$]DBSM:!B1$T=+XPHKN0IV
M/EV1BBF2(CG+ELQ1*1,%EC`94Y%<KHB@GYFWT">4'Y-7/WVBM7-E]=A],SYP
M5:W^L1^D;Y0N23S@++C>BO<+V_)M89V.).PSQ484(K/DK@J^Q]LL$;4'=9DV
M;AADS&R%IQ]#RD.1[-LSJ.E%7#=B@06Y5SJZZWS(^&(Q23M#FTD:*2&-P)#:
M'SFU:"*N&.-!A5;UJ[HXRQ\HJWM#S\IJ:4WBH&T^X%+C&RHK9/X?K'4B'`J\
M'K\J=:ORLO.0"XJ2_%,YE8*<GUW4_,PZHFZFKM\JJ\<H"518YE3&,.1@/Y^V
M.'U5VPDC;#L)Q(Z"<3O5W%]+#L^@.RI&V/><?=57^(V]WI_FA'I-ER_3,U@A
MG;):GN>UE,6(YOJ\<_J=NDHN7R/&5OB=7[F:)JC51-@^3&^E8"=9L<2F#I;C
M@;<2QZ]PGRME_.NWLSC`D%P$(=0;#^<ILZEBX<[-3R.>'_G'?@YA@=M&`X;#
MVJ;%+O-T?(?-*Y-W.,H=!R4XPYS'S'FQ6G9,DYJ*J$G'XWR@YEI0TDM"Q<X+
MM)M'**F69NV3IB]:>,@H0#'343R5T#^SIY6L8\Q7+WY7$@'*ZIK0'=N(((J%
M=S`^J2O#6NR3.=1VS`^[Y**/G&!'$JW$OG=/XCJN(J1%3A8$7]4PCR`O&><?
MP)FC!\JSCH$MYQOCI?&\8"L@Y60AF";J/`5CF1!L0I4=65B+<Z==OMVQL::8
M,D=(T8;LS6Y1B<!4=%-BH6O"]4G=$&-!I@UY<!U5`IU;.I2EYI...D1F4C^_
MY)Y]8NO<A2(@DP]X?P'(EU5K)5HR9M`UP;G)8IQQ=ZLM-P3E[)%33460=HMW
M.ZI!(=(VLAJ?J3;K-,^\CE+17@B2A`)I4L:X5&/AH5<WOJPFK(Z=KRT5X8?0
MBII7*",,4[.'EHES+<'W$!6)&EP3CB=E!:&J,PYDWDQ6XI5'C@=A#R[N;;M)
MES*LFIBD<G=I).3+`85"%/N`7-J6EUJ6-+6>K.H#6H'YO`UQKTUQ56(@N@+1
M1O"=0;QYF!KCXU7Z:^1!O-[?TB5R/G-M-Q62:\O3Z<43,H-TSM.+'I;M&+1K
M:]E)-8:.>NPOA.7T%NU:BLLS`XK.WA,-Q6_XC,3GS!X>,HW8L[0IFQ9@W$MP
M%2-I*L>(/VOD+GAP<*#=BW$;<6X#:.K>5UU>5G_(QFO\[;/7WUB-<_YE^WKK
MT@^:U:OK/VI-\K[P5F.L&L8J>N=(LR\J*6:10=.HXO#//9I%JQ/X3YU'ADO$
M`OFS%7J+X3UPU`Y$C;ATJ&`?1KQ1[;'$/+G+(B+6R_MJ3*3B`[@MH2-X!H2-
MX79NYG+^T-2S5+?4Q6FTC.:@>'H7*_Y3UBP%>>1=6:3.?Z<\R%1H4+'QYP]2
MFO'R6)+5Z?H=QK[MA<<A8YXI8-R,YR/BVDMW9)V(>RDBP64>-W:CAVX)N7CW
M?A:<T:;RG.^WTNX;I5S)P[ZZF-\W*]DT3PZ*"?4KR`07,Q:8961QO`8^,,8T
MX[9R5-IMSJK&R7,9NHVYH(F"`U:6.;1SX[:&0OC97.TN<,0ZKCLE1S?EX2$X
M1OGLE.5JI3(\_P#."%+NE[F*7#8[J5F5RWR!%:4OJV0<0YVJSJ#>58DFP017
MJ[\_NH\:*)F0.F"Q-*[N;>XN>\9L<4<T]O\`X6LS+%"R9\\L?JMC1L(@NK*0
M/$G#>XBX8.&QX(<#E.:YBDCBY=+GN8R3]IS9'/+`QKN)/B_/%,T@MS-`,9[1
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MB\;%&;YUE#$Y[Y6,=*[4RT2N8P.CC=:2,=GAXI<7R.&`9+:2<YP3BXCFFBGC
MA)(@$SGAH8XAHM@2P.):YPE:1E=E``:$ZWG?5&K6+.&!7=EDH&/.QQ+,J,(V
M^RF/&T=<R(7F0<.JSA2"R!QOSVA:<SK=)4W+1!Q!%51<Q*:JAP4`Z6$]G&_O
M;3EO4V6;)7AU\S,Z%LY=%6%H$EV^"_LC':#$M<6S4+9RT"E'7_>'!#+J-LZ8
MM%(#0/+*.[9JV(/@FS2](!9@6`G'"R#.,?%RU*\Q)C+AD]C#JX*X[+R!,5UQ
M6?S&T8L*!8)%5*AUF.=1ZSN_(IM.EFDBJEX#L`.7L3Z1Y)RY+-!J7*<L'J3K
M@:G?!OK,F2U)=-&T<:1P=2$U[9(-6X';5;3?M8^VU5K^,(S;Q5X;<TH`:X]A
MHI5^&%",<5$SRKL_UK/64,S/*3?.1\Y`U2A/HB5@.37.ZN<C;0K-O7]>E6E@
MIV)*U"BV95AM&NA:.[0>2`S63%2,]7,8YU";SWU\K7?+&C:>S4+728KF>Z#F
MOT_1I+"/(&R-+);J1]3(7#,VW$='1TFS@``X+DC4FZA=3ADMR]K(B")KH2FM
M6D%L0S`-QH9,^!JS*<2G.Y.5GXP>4[A1VVR',XMG*U4^'\Q5;JRRU+88K4);
M'5FQG`UR4R/<XE)P=K0828ED7[PQB`HV,U3<(*H+I$5+A>3;SU3OPU%C[2.]
MMYI]4;)";5MW(^(1W#Y&V\+B*SO8TL9C1P<6N#FN+3D=7AXO)5NX2NAD8RU+
M7B4Q-#BZ-K3(\;&`D./12H((!3J^6?#2<#A;@;'32M#?RX<Z)IU)3^.,EM,N
MUNW/7C#-KA>VGO3&U7-K(S4T<XF>HD??W,J3H%%`VZ8=R[J+B&Z]JULMN+IL
M'[%D#67%N;62("T:!%P3'$6L9\0EG:!KF=M6D\T1OB[KBR3A%_KC:F.02M<3
M*>UG#G@D[Q7`[AL77-KZ(+S^F:Y&_1[SO^1K*'XD3FI7>:>I%P'\[HV#L--X
MK5Z8Q#6K6"^!XQT?(4YC;F#>W3&/5AZ@Q>8V:ON'J;:RQ$7-]82+UM,NPCW_
M`*LET('51ZR^LN<&0S16,,MM')6UKQ'17DA`HP&(&SHX!WG.#W974%!456MV
MM07D.([6RK1TX]O[RE?@>0GYG&?`5S9`MYYWX^Y.CW2UZ7O:UG?%B\79YB6$
M@[#*,=%9%:,)-@S17CVTV@61:1RB""QE#)^*?/:2^:6PTATW$XW&E!XG$SFD
M5P`3Q0)`"`"T/&8-(!)I4T9``^6E*4&RG2.C#Q*$V>LT82M/-NBC#0^.KS+7
M&T\=BT&]ER[8ZU400K]T=PMT0RGBPES@4L@VL7S#U*MN20;\C%2/9B<RP=9$
M-7U?5-+GYIAX;899))+?AR<9S6=EY#^+%G;Q'U&6(Y'!N5M:[!<11R-MS6H`
M#JBE3LPH:8>'%6D-I*9AK7S.EJ]67MUG(U]1WD74F<\QJTC9':&!:J<D0SLD
MD/N=!R#P`$J3I82II*[")BA[8-]:^6*?5)(6&65KF$,#@PN/J[<`XX-)W$X`
MJQH"(P30=.W>54MY5DGCI^KR,;T=[=$EF.&)%=_6;EE#"UQ4KRDT_=R$FTBX
MG#%8BB/T"3!3BYF)YT>0,Z5/X20F>O5=<\[OWV3S>MM3+46IJU\L+\N8DD`0
MM%<=KY#FJ<!VG%7]Z'C)FIYVX$>4^\/O*+>?9BWL,R8[)C[`GN?+,L?8'EC\
MB:C1>==4D:]+H88HB0W%>V81D)/'^0,BPT.^68IODJ^N@E&)`S6=?I9R!@-7
MEN6:G`+.TI((8#ZRR._86G@Q]LO@)CDD:TEN81D!HREV!"KQ!IC.=V%3V26&
MN)PH<0/=VJT?S74D'5$P(R*GCJ;DG.0;4I&5/,,?B1YC&R%;TLAG[ZP'S?E3
M$](:3,`BJ12,ZGKE\<[E<$D@`%3ZWWO"#76EHS\R]YF?1DPA,3J,Q+N/+$P%
MOQ>T78F@VJRL?.<>U2@Q%:C'P`E:K@K*SUEC<7,H/D=C_+3AGQ;RM"4>2KE*
MJ;1SA!;XUX91C:1D"$JF3+Y&VB4JLN(*IE/)-2NHU%)-(01,175/E226=ENV
M&]AN7#3Y6QEK&#@=N&C)&LED#BPXCM"K0`,#51N0&EU6%O;%<3VMN(J!2JAH
MS/CU+GM;V_(/).,1Q;.WC(^-KN]FK70<<P\M?OB7/1%N=+8X1Y8N[/BTEFFX
MV2*>?&H-C/R.C(F.!),53ZRWU,<VRC6)X/4'RR1/+GQQ@R9'!YX7K9=%F<'?
MG.",U:;)*FX[?JHX379P`1@3A7#'+0TPPKY%W7^4Z5`G$YZ1J5$C4G(7DZ1H
M1N!`;D:ESG=RMBMP3_2P;E0`H$Z?:].VW9KC'/E/\9ZEE\WUIU.J@HLK9_5(
M_D_?*LNUJ2N5S+^>.]NC.W7Y.DU3,MV7E.+6,8:TUO!J<8-LD*%)9QR$C;BS
MSQUCW*T[$8]"/``FGM>KTI9FS<Q31J!U_:CIW,XB-Y9<5T;0#*07UH'`,I3M
M,!=^"'.#3\8T6@\Y-A.H:<9G0L`,Q!DKE#@(\M.VP%]?-#W-83YQHH<^2+%4
M9EC;.\E7:;$8TN<SDBG&R1C67M&8K/GBINXN%FXVHJYW6RMCW$B#)U9ZTD62
MJI(6JQ")ZZX2%WZTY`5S:%S0Z4SQ->XOB##E<`P1FI!/#R.?L.#\SSVME`N9
M<Y.F-S`V1YDA$;LCPV,1.J07</(Y]:'!^9[NV#2@P51W%&;&#R)DI2N<BN-.
M%$+EQ]SF@P<GH?%USD/F%3E@A%9.LY.<X]Y;7#(-<Y`3OK+)>*6L<,::(ZD9
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M.-:@"H'@6*Y-):ZY=65K,L=71&4/!JZ@_-1R.RG$FH`JUM36BW?EY69W.0%7
M>_.+JG*.-A^!TLQK3_'%,IL'9J#!L+55%&.'K;"5[(F6H.<R;`&Z@$SIZ)70
M.$$S('0Z3J2ZPP->X<%T#C=BN9Q(<:'M@EK"&GJPH<:J37XPQ[F^KNMG&^%<
M[G$.)#JR`EC"&'JPH<:[(+^5TIBB4YJ43);?#=TD,HW*EVK&LMG,^56-8K4S
M8Z'37EALKFG\<\08*PGBF>QK0:U,1%6G[))-6HL[W(>K-6:[A-1]K*:[ZPW3
M'P&1H@:X.#,E2`XT%9'R/>'.(+FM!-8Q4D#!9KF3UINCOMS,P6S'M>(\F8@.
M<`,TLDDCP]Q#GM8":QBI(%`NR[RY_HM1GY:^6/\`K6YIUT70_L6T_5V?-"ZO
MRW_#UC^JQ_-"G+K*K-+D]\^2_2%!S+EA2"A'%DM%OX08PHM6@D#V]D$G+3]\
MY>JKH#/4J`L<I6'186/=G9/54$VHR!&[<ZZ1UTS:U/F&)LM]:9S1C2YQ.&P%
MFXD`XTJ-M*G<O4'<3J<NF<E<TFVC,MY.VWAC8.*,SGPWA(SQ,D=&<C7%CR`W
M/E:7-+@52?Y<+*3I_#+E!(0:SFI3K=:ZRL456IRD&G6I:.Q*0T?+MX"?Q%@B
MKNS"]0*X4]3ABHKG3Z7CM53M)@-8<V348`ZCF]FN(-1FV5#WGP8GJ"[GW3QS
M6'(&LRVQ,%R#*YM8W,X;FVPRN#'VUG&<1F.2*A(I(]QV:?R\8"QYAX<\D,<5
M[)%MJ-E&Z%3K]L@;+9HA>LS2]0A9]JHSF8.R3SYI#RSIJ4LHE%N4U5&RJA#%
MZQ#JFU9S+?4(9GL:YF7$$`U%2-A`Q&ZJH=UMK=Z]R%JVDVMW/!=^L=B1DDC3
M&\Q->*.9(\AKB/S@C<"6DBE4QGEVPDG6:M?JY85[6WL,7E7@ZBYAI^KS\)'*
M1Y<P@FRM,2_M3\]@=DL(E,9-)5DR2%D1!R0H^L"!;K5G![VO9ER&.?$$'XFP
M@88=9QJ-RUSNKMYK.SN;2Z,XNF7ND5:^-[&EOK6$C3(<YS[@6,&0->!VD_\`
MFNE23?S(:N\B<@04Q`.,C\?[79\29-Y%.HB2-/N$5215LQEBB1GZ\C*1-:CV
MZJK-!N,HK[K(>K)MA;KBD6TMI&G1W!S"'ACP'MCJ*;PYU#0G?LPQK4+9N8;"
M5O>Q"^"ZBDMC=V4DEM<7Q:[.?-DM[9SV!S8V@E@;Q#Q1D#,KLHP/,]F+77^1
MG'J=J6/GMOD(FL1+M)E%6Z<J<ID5X3)KA9GC)N9AEW'",D9`C=9Z!6L?..FQ
M7:BSE(C,O;'16QNLYFR/#07':`0WL^=YCNK$MV88JEWPSWMKS5I=S8VKIY60
MM-&ROB=.?6"1;C+<P!U*%_99,YN8N>`P*3N<6)KCQYY\NK,O:<9/?=R!MDBE
M$7Q*JR]0FF''C`TL>)G;I6P?Q:D+$2&Z$LH@5PR<M4E3)[AX:A;*V/#N[4,R
MO%",6U!'$>*@'&I&S?5;CS'&;_E7F5]X9K.7B,D=EF$;HGML;-V5\L>9N1KL
M)",S'-#B-Q6/P*?V+&O'3(D[9&3#,5D)G29<RTS@3(+7D!+9)?3;6@1#FT'G
MEKE)@\?QAW)O62+N&+DL+'D>*M2JJB"L=4#)KMC6$QLX0H'MX8;3,:4IOW;1
MF-*J3NTEN])Y4NKF[:V_N_VDXN=9SB]=.7B%IDSF5U7-KV@XL<(F"0L#CC&/
MRHV;^)S[<X244`9*&Y0<+8^0;%;H196KQKS`JR#E(M?:V6;;0)2+$$H-DT&A
M$=N@`V+TEV-I#M2L7-V%[O#\3IH*]>*\^SQRP]WW.=O,?ST=M`UPH&T(O`#V
M!(\,Q^*`T#9NH/Z2FMR7DE&B+B_T1=1O#.QUU'B9QO25GX1-1/"^.R'(:68`
M8ARUB.`Q#!ZQN4Y1[!`>T![![=0J.E*%26^-%9_"*"]]X_\`=&E1TA1H4?&B
ML_A%!>^\?^Z-*CI"@OOQGK7X0P?OLP_=&E1THOGQHK7X107OLP_=&E0E"O@V
MFL!WV.!#Z\O'_NC2HZ4H5]^--9_"*"]]X_\`=&E1TA%\^--8_".!]]X_]T:5
M'2$H5^OC/6OPA@_?9A^Z-*CI1'QGK7X0P?OLP_=&E1THOGQHK/X107OO'_NC
M3,WI"4*^?&FL;[?&.!W]CW7C]_\`RC2HZ0B^_&FL_A'!>^\?^Z-*CI"*E!\C
MF:R8YS6/&#(F%*UEBN^85F.X-4<T3=@3QC:ZK$WB02L=/N"="6/:EHN;:OR*
M$(W`"F<-D^LP%`=*CI1,8XJO+#'_``EY>)<RLU\>\B6(^`*G4:2&$K#=G$49
M"C0UB;VJYVLN25$9`]]R#(3;51\=D`ME"L$^PIB]K,WI"4*V/F`\*LY<J<[0
M5RQIRDJ%#Q"ECPM5O^-W68\X8_D+J>LRENM\?C8DAAZ\PT7"8RS!D%:K.+I.
M,T&UT;1=6*RC'GJ[URB9F'2$H5(VAQRN-,N\!J+>\F1&1K50>+N?ZM<+NXG@
M<*6Z<@$^+;"5F57,[,RLRO[J.6JADSOW3AXL38RZAU1.868=(2BKAXU^77RO
MQ;S`H6=,P9LXSY,Q95+A-7)_5G')#F':Y$^0)Y>P$F.0\;CG(%KD,3)YXEX=
MY&L4D^A"L0:+$3QK!%=3Q@5'2BG')8AH_)_!?/C!LQ?0JIKURIS8E7K37,BV
M"F2M9M[*GXN?4NT)3./[?4+4LP@[*W;N7#1"012?H)'05ZTSF*+,.D)0J)V*
MN)]XXF</_,(>91N^%BN<D\>Y]C"4G$6<>2V8:I%EI6/<FG?6EQ/\L,DWJX,+
M-:U;8FV78Q7JT:5O%-U!!190W0S#I"+)\V+R[;CS_E\3/\90WETG<T:+K)G>
M4^2T3>K/F5BE#R\_)NJ!45ZH:2I2>.9M":*JNC*L9`0>F6/ZN;]*.1F'2$H5
M.?CY3V&$+GY:V(9F3Q='26+\)9^I<FQQO*-TJ`P=PU+Q4U.VIZ#QM#O4*\0Q
M1!J59HV4Z`[4R]H:5'2BM_\`C36/PC@??>/_`'1IF'2%&A4%_,QLE<6X&<GD
MTK!!J*&QLZ`I"2T>8QA]U8H=@`'&XCJYLG-]=AQ'TS/G!5;?ZQ'Z1OS@N9/G
M-@'DMGO*58L&#<S8EQ=`4FO6*$83:&:,QXQR/(N+A*0S^V14X[QDWD(66J@N
MJC%+,4S]"R2R:IC[[EV['JUI>W=PU]I+'&QK2*YWM=B02#EJ",!3>N@7UM=7
M$H=`]K6M!'G.:<:5KEVC`43YPBA8'/G&V$L=IA9F?@N(N7H2Q2Y;+[JIRD_&
MVSC"QEGXS$JLG*R(R4@V55!PZ`KM<#"HH`*";:[8<EW`V1P+Q;/!-:XAT5<3
MCMZ<56:"V>-KC5PA<#XV*N[BEY>6><)\KXC/61<OX.L5-CYFQNVM0J&;^3;@
MM=C9>&L<<U*PJU[M,Q6K;,$5ET"J*S+E5L1-(5$T/'*F8,+IVCW=KJ`NYY8C
M$"<!)+A4$;'$@G'XQ]RJQ]KIUQ!=BXD<PLJ<`Y^%:[B2">M2'R9B>T<B.,?(
M[%>,+CC.O768YD9CE(R:R!;+U"5V/:Q&4%W;YR=QBBR5ZVN7:S+J3;H^L>HJ
M&4$RQ#@0H:OIX'WMA/;V[HQ*;EY!<YP&#OQ"#U8TZ5<20R7%M)%$6AYF=B20
M,#^*0?O)JL(\8KQQ#X.\GZ5E;(U!O=DLD&QET[/7,IY/OB\K[G1K*,>F?DRP
M_54KQ3/`%5NSBR>"`+'\8ZABIB6VM;&73M*GBN'L>]PK4/<ZM!3XYPZ@J4-I
M):64K)7!SB-H+C\[9[B>GG7PFMO*^]05NJ'+5;',77HMM%KXHG7=HE\82CF,
MFW$PYDDF%!ROC=VT?WILJ6'L"KTLJFO#I)D;HI*E$YKK5M+DU"8217.1K13(
M22TT-:]E[<7;'5KAL"K7UC)=2![)2T`4RFN7WG#;L.W!/_6DHNG97XF5E^7&
ME>6JO'G,<$^KF.7P-L>P2T2YXZLUH.D-IAP$DVJ3$6QD8U-WLN#0A`4#J`VK
MR/)%<6\9X;<L#Q1I[(IP\&UQH-U=RKM&2:)I#1EC<*#8,68#P="@I@+A1R%Q
MUR6IN7,H95P'?:-7)N5G7<(KG#DM99,+E-$F$9K-$93KQ87U`)EN=8KLFO0/
MA042@V.,>T15/XFL39Z9>0WS;F>2%\3233B2G$UJ\-<<N<X#\$4P`*LH+"XC
MN1-*YCHP:TS/./X0!-,QV=`W!=2WE<62NH8:S456P0:8FY:9Y.4#2\>'4096
M(V,']T=I1]`^G7.>97-.O75"/I!\UJU/6?M2;Y7]$*RSXU5<>ZR0`_\`V8CO
MW1K!U'2%C*%5%<VIB(DN66/FL;:H5D[>\0LWQ[&2),L"C'R+S*6'$&+PIRN.
MHBC1P<JI=O;>TW#<0UXG]MIP'+'+DA89(V:Q*YS0*U:(`2#UBH]U=F[F?M+4
M&URN=:-`/02\T/N;55;@6C<_X/)M)?\`('.W$69Q7"/(5]966*Y_+'QZGC5K
M#LMCAG'%^.@IUP\9;+:\;VB;!00.>50\1';8"Z\<<SZOW4W.CW,7*VG:Y'K4
MC7MC-RRUX+.)=-G+OS59,T<0=;PTP$9HY=<TJSYHANXSJES9/LVNJ[AF3.:1
MN8!VJ-H7$/=7&H6X2:YGLF%)(>-.1<,UG(<'S`Y03+U'+\W8$Z'8JF\REG6N
MOHF5)15E+`JY:R=@8RK$"[(>MQR1CCL``-NZXY:L^8F?XOMKZ;2I-`TY@-JV
M/C1RBVLY&N;QNP`6L?&_?ED("K"/4IM//[(D@9=-O[@GBEV1S3),T@Y.UM<'
M#=5H21<PW(.C\2,[$Y599PK>+>Z3PC&UH<0SEE<5YI!4R1QQ7)29D4\@&3DA
MN5VG6B\K*&1`6BBZO4&P[AJ_9?<HZESUIAY)L[^VL&F[=)ZTV(/+Y6SR-:W@
M5;PH6$1QU[0`ZE:\#5K31+@:U/#+.3$&\,N(`:6`DYZ',XU)W;-Z:2G<$\IU
MKEM'YL&Q<8J168S-\ID1]8:-R+YIVK)<I5E;-)3#VKJT+(N57N#"J7J+<C&2
MR0QYF#%N\7.Q2`R2!0SNH=Z&@7G(K^7`S5[F\?IK8`R:QTB.W;((VL$@G@MA
M>?F7#B1'/G>YK1(ZCG*SMN6;^/6FZC6TCA%P9"637;I"W,26ECY##VQV7#+1
MH)RC`)P>0O&SDO?\B<@%L9Y5XS#CGD&&-R.K!DG*7)2&RSBAOCR-ARUYIC".
MQE?8V@PA:E;X]S8&BS,L8M-.WQVLN+AL0H#BN5>=.2]+TK2VZQ9ZO^UM*]8H
MRWM]/?:W)G<_.;AUQ"Z=_%B<V!P?Q!"U@?!E>2KO5-&UFYNKHVDMIZI=<.KI
M)+@21Y`,O#$;PP97`O!&4O)H^H3UVVNR&2IOG'C.G9?8T6\6S'7&NO5_*"$Q
M')2=<G4Z?83C;VI4UG"9Y1J=J=<B0E51,L8"*E.D8X#KMCJ%KI%ORWK&H67K
M.FP7>H/?;%I+9&<6/\T=G9-0"<"!B"'`*]EMY;N34;."?AW+XH0V3>TY7=H>
M$;1N/11*/"F"K;BJ[V3(.3.;=NY,.W]&E:A%LLDT+C/37->:O)1G.*NHZS8I
MHE2M"J2BS#I/'K.CQQS*BJ9$5B)G+:<Q<U:9K>G0Z5H_+]MH\;+ELKC;SW\H
MD(:64='<SRQC!V#PT2`#+FRD@W&G:7=64[KJ]OY+MQB+0'L@;EJ0<'1L8X[-
MA.4UK2M%&6T8^S_E_A_Q@KG'K(W&B-B9?BW#4S(]:Y"O+'+5ETI/5[%DM4K=
M!0E23?M'=LI[FKO4T1DDC(HIR!Q(7K[0W"SUKE'0>?=9N^:[;5GSQZT^6WDL
M>$V09)+ELL3WREI$4HD83PR"2P5-%B);/5;_`$*SBTN2T#'689(V?,6XMC+7
M-#:@N;E-,PIVE,/";>6I+OA37LC-N,U*MC'E_"NY&N<94UZWAR/:/*?F)RP6
MK\//E8RK9\Y:JD/('42*51X8QBB("&NG>S9=6-_[0\-[I<NJSZ>[2[H-DU%S
M7W1(@`(D>PEA`.$8!P;0'%:UWB0S6W=^ZWN6VS+@7$51`"(_/P(!H:G:[#$U
MHNC[XW53\)Z][]1O[IU]/ZA>:4S7(JVU4_'W.Q"V:O&.;#>3RE*$U&B(B-)G
M```#UGOWU!WFGJ1<1W);CQ=>26,N.(XSM.&8M6LXJI"4E*WG-/(''\FVZV-)
MEU8Z(88(NE>AY=E-QT8NR>*RR2[MLFX$6ADS=H>QN8-#O=;M+3U%]LTQPLJ9
M)KB,_$-`('M:0X`M)>"0#V:+5H9F0N=G#C4G8&GI_"'D3Z5*#3QC%<)Z)8Y>
M@-INL9!R"UDT*C>[;;JVW47PWFM\F$99,J3LUD"3;^"\)NI*NEE@5$Q"B"14
MRAD[>!UC%I=I.8A+'-(#D>][?H9S@Z5SI",=KR37#912%V?B.%:$#:`-XZ,/
M$H22_`G,\IS-7Y#J9;P9\F!,O-[[&X]9YKY&PLB$2E;6<\H[G8UK:'E5FI\6
MK<YB1J7J4"5PJ*0I&:_I>M7EY.U:3F8ZT9[7U#UGB",37+33.'5<`XM+J#S1
MECJ:4RX*X%W&+?A979\M*T;T>/[ZL*+*R$C9>93+'\[C8USDY3';&LA?IE8E
M-5?/<(TYJ<+":MN?=L(X6JJH&%GNJ53IV[`'6X`RR3:FRS=#ZRY\8;Q"<E3`
MP=K+VJ4KLQ5I@!&7URT.S;M*C=Q2P-FWC["Y63S+G:IWRIK8@=5BDU^.SED_
M(;6MGAF"P(%:1>3&[&/AFJ$.W*V2.S$RPD`$Q#HUA>7M&U?1HK@:G=,FMS;E
MK&B>60-RC"@E`#13`4QW;%6FFBE+>&TAV;'`#R*-\GQ&Y!92=X_O]=RS@QWC
M:>I&&9!]2;OG3DI`%N%*B,68X3C,77ZF42R)8\/2H.TPKN0*VCVS5:2%X9-\
MLJ03)CA'\M:W?NAO()[4V+XH26/GNFYV-BCI%(QCN'D:]I=1H!=6CR1@JPN(
MHZL+79P3B`W`U.()QK13QYL\?U^5./JM2ZUEFGT0U=F9JP+J.'D8(2,C\57[
M*KMT9-JD_D8J+:V$42OTFY2"XCUU3`(K-T"&VWFG19.8+..U@G9$6.<[&F)R
M$-%:$@!U,U-K2=X"M;>80/+B":C[ZU&$,;5?!]OPACA.?Q^:TQ?%+)D9<[E6
M4H"""VW!"[85:KV626;`V>R[\@B":;M[UO5D42F/L81*%+2]/BTJYM;(.B]8
M;I\H>]H#<[\\`S&E"3N#G=H@8J:20RM<_'+G%`=PH4S6-^-&<'64:S8>0CS@
M)=:<A)5F0O,G7JM+3.4+@I4\=6.H>)(2=YAEHJ2<WNRRC2=GSNE#&5?,B'2$
M!``UC++E_5W7[)]9_9,ML'-+RUCG2OR1N9B7MH3(XB22IQ<*A3OGBR$1<4.W
M8X"IKNZ!@%U<^5/9ZLUXJR2)[%7D`+R(Y0`FE[L1A`(D&=KR"0$(#D`*F!`#
MI`.SIVV[-M>;>?"#SGJ=*4]:=Y`L_9?5(_DJR;XW5/\`">O>_4;^Z=:DKE<_
MWFFXF-R?SK9L3T[D5(X)EI?BICZ03O%.G"]4@C$9OOBKJDVI"&M-2GI&AVHC
M@$9=M'2T6_6;E`$72!_;AHW.-VRRFL[A\39F@RC*=U0SM"H(#AN)!%=H*YOS
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M%E:92:U=6M#7`Y0=I-,S<<PB_9;6=M%+"X7,=2"<6`TRN-:NK6CLV!#0[:X@
M/[D''W+S+$13DJ8OY;#>D,\>X]8XOR9D5AD>9Y*XUBEZE5G3N>KD\W:OZW7;
MO'2B"CEDHP.FW(LFB<_MRF$+.&XTRW<[B^N\7.[,UI:(W&IP(VEI&VOA5A;W
M.D6KW\;]H<8R/SL86"%YS.P(P):1@:X[4Y7F+\49'FM3J36:7FVE8Z&E/KE8
M2$DWT<`S5A?1D22I(.9^.;RDW&5X%XURQE4&H%,JVD_7">(YCVJ1Z.C:DS3)
M7R2QN?F`&&X8UPP!.((KO%-A)5OR_JK-'F?+-"Z3.&C#<`3FP-`3B"TG>*;'
M$HP+BJGX*O=%Q"PFL9N;'%<"EJ]<[7`IPE/89`OZ.1*["2EQGU*^HPE',C,N
M$"BL^.<94Z!`/X@*@7I7=T^[A=<NSY#=U:"2<K<I(:*X8=&Q+Z[DO8'W;A((
MS?5:TDN+6Y"0T5PH-P\WW%&#A1P-RQQWY(,LN7V=XKFJ299<K5G0.37-Z]6*
MHHR%(-6SQ=:KN<<HS^/9MA-SO5(/E9ELZ<MSN53-#)G30Z+[4]8M;RR]7A$_
M$P\Z.!H/:K4EC0X4&`RD##'>LEK&NV>H:>;2`7/%PQ=#;M#J.K4F-@>"!@,I
M`-,=I72+Y=EIK"/%V,(K9:^0_P`M7*\W2,U&[])N5F:3%';UKN,40$/9`0'N
M'76-#PT6TK_P[/FA=OY<_A^R_58_FA3A^-U4_">O>_4;^Z=92H6:7*'Y[&-$
M.17(.Q8XK+/C?<I"2XM8+411Y`+STI2(4WRE\N([XR1*%(D&LV2YPBLLF=BH
M"J:9"'5W,4PD,&J\P7+;6\MIG.E#0U_T=*G%F!KA0TQ7IWN(Y?FYFY4Y@TBW
MBTR:9\UF0+X2&)OYN[;Q&B(A_%87#(:@"KL0:%5-X%XJYVX^<=WN-J1=N(;'
M(+O)36PRQ69K1'XHOE*6QS.T>8B;Q$1<5&SCN4.ZDVSI%(P.T%18IBX5.83`
M.M76H6EW=B:5LYAR4&S,UV8.!:3A3"F[;@%Z)Y9Y&YHY6Y6=I.G3:(W5'78>
MZ@E;;31&!\+VS-:UKRZKFN`[0.09G'%.NSPUFMYQ*LF"YBQ\4*O>%7E):1#K
M$DUD3'=#M]<A'=86N8Y%D:NYK]ZC['?VL0Z1?.X,[=0Y'`?IA>W:W-U:B_%T
MT3NBH:YLKG`FM,H-6T;44#EFF<M\RR<D2\MSOT:'42Z$--LZX@AEC88S+QW1
MEDS9)@UP>Z$M)#MNU:?'U4R[B'$M8H>:+?@>9KL'R&X_+8Z^3>Y9(L\Y&P;W
M/4+)N:U9[!EN5D9R6B:RR<MF<2J=RNX*V2,"YQV+JI++;7$[I;82!YADS9@T
M`G(<0&@`$[3NZ%0TS3>8="T2'3=?ET^2UCU2R,'`DN)'M8;QCC'(^Y<Y[FQ@
MM;$2XNR@YCL654,3\EF.<H6^9!L/!W(E2B%&%?;V"P,K?+YGCJG%7RTV=A9H
M6P2;,[!CDI&"L*,<4Y5R,$B1Z`$`H`(C"2YL3;&*$7+)#C0$!A)`%"*^;45Z
M<5-8<O\`.<7,;-3U1_+]W8L+6![VRNNVQ-FDD:]CW-H)PQX96N09&TH$Y/(K
M$U]R=E'&=KQY>N.<?4(V*-6<GQV3JK'6NSR<$6U1]D:GJDJD#@^[11L<R;%1
MQ'H`Y$53JJ"</!H6ES##`^.9LID)JW*:`&A&(^_CAAUY?FKE_5]8UFSO=+GT
MMMBQG#N&W$0DD<SB-D'#=CLH:,+F#-B7&HRHW)T)E/(4AR'B\%WW#,/*.\UR
M$5;(W+\G+/:98:E;^(V,JM^G,ZOZRXDYBNS4DVD61')#,Q<-MU`$0`-5()+:
M$1.NFO+>'AEI4$2N._<1@5C]:L=?U:35(.6[BRBF=J);(VY+S$^*33;>.A$8
M)<YCG->W,,M1CC12'XWQ,]CO':%=R23C76[$UECJ`WX\(K5RE23!.+B6:4U*
ML)TC!VK<)%RS5,]6*3PCI@B!1]J(!:7DD<TV>$REE/ZS$C$X"F[H6U<IV=]I
M6E"UU9NE178?LL6F.)S<K1G<'AIXKB#G-*$9:**'![C+;^,N3XB6R%?L0SC>
M\<EN&J44:BVN94(@:,Y5T21=JNX*<B(2&KK4R$@3PT8\RB2728G80I1'9+._
MBO=5M!$UXRO=7,!O:=X)KLWKSQS9R5JG*/=CS1-J<]G*+FUA#>`]YQ;=,<:L
M<QC6"CA0,J!LV`+OG^-]3_"BN^_<;^Z=;^O#2^_&ZJ?A/7O?J-_=.E0BXTO=
M2*_QK%^^3+]GT10VI6*,:SA63]]C/'ZYG3)LDH*E,KHBH*!!0\8^\=[=544Q
M.<X^V.81$1$==MTZWLG:7;.,,1<865)8VI.45K@M4N#,)WT>X#,=Y3CA@G$I
M5/##%F.Q`H`(_P#H571[-^WOC=]PUL-II^G&A=;P?[-GP*S?+-LSO\9^%:NS
M84Q,B@!4\78\(.VPBG2ZV4=_0.Y8T#>C4TUEI],+>`'T;/@4S9)ACF?XS\*:
M_P"1C&0#N&.*)]3_`-$8#M#?M[!8?4U;.LM.SY>!!0C_`$;/@Z5.'W#OC.IU
ME*"#P?CZ5?MH]IBRAN5W2@)ID+3*Z<>H1`-Q#W.'H`N^XC[&I#I]AE-((<WR
M&_`HEUQ7!SZ?*/PJ4IL`X3J<"2`;XFQB^EW/2I+R2]$JSA1)4P=K5L9:+4,F
M5(>P1+MW:R5MI-@&YW6\!=Z-GP*033`TSO\`&?A6/!\:<1/3%<.<38V(W+^F
M"!Z-6"`)0#<3'$8S8J90[1]G5T^RTN.,N-O;?[-G^:J;IIR\T>^G6?A3=9*H
MF&SE/7JQB'&"#5,>E]+)8_J95W*A1$!2;JEB>M)(O=N`@)N_5HRRTR9]7V\`
M9Z-G^:IQ+-3SWUZRF0-A3&)QZ28THNWI`*C`=0#V!]P@.PZN_P!G:7YHM[<?
M_9L^!2Y[C:'O\9^%*&)X\XV="`GQK1.D=O;#3X'LWVWW$6&J'J&F`U-O`*;N
M&SX$=/+3SW^,_"E8OA+$$4B(#B['AS@&PF-2ZX8>P-AV$8T=QU0DL]-<Z@MX
M/]FSX$$DM*A[_&?A6VI=7PM'N1A;-AO%SV`>G\,'AL?U<SR+4.8=EO&+$^.=
MJ`FW'8W4GWAV=FI/4;!@KZM![L;/@4YFF/QW^,_"GAF>+F&SE(9EBK'"[51$
MCAJNA1ZP9<K18`.DN3P8P$I)H(&WZB>VV[P`0VU6%AI<FRV@_P!FSX%`33`8
M/=XRD63CCBMBL*#C#.,W'B&,'22A5DIE3&[?&243B0$YE`V'J'?<>_4K=/L8
MW9?5H"?1L^!#+-N>_P#G'X4[U7XVX;2C`;R.#\4R3L3K*H>MX_IBAF:!R!LW
M<HC%F!R<Q]NGK`0*'?K(PZ7ISJ'U:WS^C9\"IF::E'/?3Y13373'/'G&]BKK
M:XXNH;5Y9@G7[%O#87961JTB*Q[EFL<W/GA*K(MJ_6X-*;:G=/GGA()%5ZA-
ML!A"S?::5:7#?6K>$!U2*0M<*-IF)HTY6BHJ30*=DD\C>PY^%/C'?NQ.*TV0
M:%Q3<R[E.(J?'P585W%P4HJPB,<_W+,6+PQ@XI<$$!!N^F@,3U5(>E1V`E\,
M#]FJ-_%HADI%%:=D@&C8]IV#`;3NZ=RF:^Y&UTGC/NK78OJ?&"&O-4=.ZC@*
M617?NW:<8M"XY?FDXZ&*"EB.U9JME0?)PS)45'(D*<K<NPGV[]8[U;2I*,#+
M:I!IV8\:;=V[?T*/$N?PI*`])4BKCC/BH)T)2J5[C&M#347-6Z"E(VNXG6C)
MNM0RQ4Y:Q(OBM54'$1"G,"3]<FZ+94.E0Y1[-5K.ST5\8<YEM6A([,="!M.S
M8-YV!1,MT7$5DJ#3:?<"0+K&6'9]@P?,L3X%F8U\W1>1LK7<?T*1C)1FL7=%
M=L[CXQPR?M%R#V&()R']G63ALM'B;Q6PVSVN%1V&$$=(P5+B7!.4O>'=9^%9
M;_CSC9^V04/A"BF,J4#@K\F]0CF)2#_P8A!)F5V]GJVU+ZOI,KR&VUO7T;/@
M46R3-\Z1_C/PH2XOX5(P16=8JQBF].H8H)(T*JJ.>DVP&32/[E"*?5V`80[!
M`.W5Q%I.E/;G=;P`^C9\"D,\Q.#W^,K>I\=L(QS;K7Q#BPARICTI*T.KJB4.
M_K<*C$FVV^J(!J9UKHL+*&WM\WHV?YJ"2X=L>_QGX4U=BQMQO9**`ZQAC*57
M,42F:,L=U15N'=LD)`BBMA*&W]D8WUM6$EOI[Q^;MH-O^C9\"J9YF8%[Z_*/
MPIN)"IXA.`DB,!X>0[^EU(8_J;M8`$?:B1L6(2;%,`=OMNO1MA9/-3!"#\AO
MP*/&GVYWU^4?A4>KZ7CC796=:WNO8CA9.J8ZD<K3+5?'U99&C,<QLDI$2ED(
MFPKY4U(YE*)%0533$RI5#I;D]N3>VF9HELYS9V0-<R(R.JQOF`T+O-V`X'?L
M55KKMX!:YY!=E':.WHVKZ_JW&F-B):<=P.&$HV"`ONPI[ATPZ\:X/'J2B,8\
M9IM3/$IMPP2,=)D)/6E>G8B8F[-5"W18V.EX=L&M\[LL-,*TI2M:;!M\"@'W
M9(`=)4^$_=[J<!A4.+M<C8-_+57"Z!;4QDI:$6<56G`T<LHR.D)>3E'3H\?Z
MK'L6C6,<>(X<F33!=$Z(F\4!)JC.-)[(,=LW."0<C`*`$DDTPP!Q/13:I6ON
ML1FDJ#CB>KI219$XCV65LD.TB,$J+UIS#,IU0T!1$(MJ\L;5H]@F?NDJS3CG
M*\LV>IF0(F<_BB(E+N8I@"$?[#+G,#;8EF4'LLH"X5`K2AJ"**<NO``2Z2A\
M+MVU+B,PO@626EO<RGX>D?<$1]W2LH*E/!@Q`'`F"9\!LI[F"4&JHCX_1MX1
M]_M1VRUE;Z3.XMX-L2SSNPS#KPPV;U0?)="ASR4.S%WPK!@ZEQAM-BEJM4ZE
MAVS34!7X"S29H*GU&78M86TN95K"N"3+*-7CEE)!6#7'P4U3*%(F4YR@4Q!&
MC-'HLKWPVT=L][6-<<K&$!KB0W$"F.4X54V>Z:,SW2`$D"KG;MN]3RK6!<%0
ME)@'KW".(G0DK9'SI1SC6F*JG,XE1`ACJ*PIE#&!,1`!'?L[-8,16;9<_`BI
M\AOP*J7S@5$DG\X_"EDIQPP0=NVEHO"V)09NP!<4D,;4TA"*'Z1.)B$A0*)A
M$-A'81';63C@TN3#U>#-Z-GP*423Y@2Y_C/PI8EXR8!M,2*'R+8F9R+=,>A5
M#'-02,<VWM>OPH<N_:&K:2UL(I`[U>'(?]6SX%.U\I!.=V/A/PIA)/CGAIB^
M49O<,8J!RW.HB)SX\J1C=`CU``'&(,)2&V`1`!V$=AU1GLM*EH_U>W<.@QL/
M]%1CEN&U.=X_RBD*[IO&*"N`4>1PS1C3"$+'667?M<'Q[^J5BO2CF;:,)FXW
M)O5U*Q5(]=>MOOTQ^Z0*4K<QC;%V$<5-::-%+PC;6^:@/T+*-!KM=EH-AVE7
M+9+H]KB/R_+/DKBE.^@N$U5-&$GH#C&P4EY>K0S!L-=Q@JX7D+Q+$AZP<S5N
MR46393<F?H([.4&X[&.8X%`Q@MY8=#`HZ&TS$@#\W'OP'Q=G0IQ)=$8.DW[W
M>[O3O06..'+B&<6E.A<;9JMLXXTJM(1E0QA-LW#,KEZS3,S%FP<IOU',E&.&
MR!$NLRSM$R1`%0HE"VEM=)#>(R&UI3:(X_O#W%,'W-:%\G\YWPI?%QIPY>15
MDLK+'7&E[7Z5'.92X2T;2L92;.L,8^+5G'R\^>-BG0Q8MH9([DY%@*?PBB;8
M=6IM-*R.>(+;*W$TCCPWX]G!3"6XS#MOQ_&/PI*TQ[Y?-HL;^G$I/':MW.';
M0;J:IF1,54G'-LA2VA^9A6F\M7[Q78218OK`<$UF2!R>*Y:N6ZY"BDND8UF(
MM)<XLX-N'C:#&P$5V8%HV[E4SW6W,^A_&/PIR(__`+O*/K[*WN<=\='<0_L/
MQ4$\?AVCRDFRL24B,.C$S\,TK*TO!NW#[VJ(/44042,"I1\$0/JC+'I8CJ(H
M*5I]&S#W,N"F:;D.IF?3Y1^%/&QHW`:453084SAPY<+6%K4`:(US"*CPMN>(
MK+-JDJT*S%=*TKI(*"6.,4'8@F?9/VH[4O5]-RU$5O6M/,9MZ-BJ\2?\)_C/
MPIV<>82X2V.6CXB!Q'Q,L+V0C74K'Q<-0,-S#IY#Q[Q.-?2C)FPBG"SB*8OU
M2MU7"91126,!#&`P@&KBVM]/+B3#;N.WS&$^10,LP^,^G6?A3_27#CBZ9MXR
M7&?CV51(05()<+8V*)#``@)B"%9`2F`!'80[M]57VNGG&.&%KO`Q@/C`4#+*
M<"YU.L_"M3'<2.-#ERFW+QMP%U&$.L38;QX($`!]L<P?%S8``!WUB9H86@C*
MW;A@%4S.IM*<L>*/%1!(B9N,?'DQ4R>"(*84QJ<5``HE$5`&LCU=1=]]]]]]
MM6P9&/BM\03,[I*\`XD\3C)>UXN<<0$NW4E\A6+@,F40V#I$M5VZ0V[O1W:J
MAK2S\9*FFU947Q$XF+/6Z9^+7&\_2H)RB?!6+C;;$$1$!-53;")3;#]0?8U'
M(QS>@A*GI*]LB<<^%F.:/9;S9N,?&N*K=/K\O9[+*EX_8U>GC("#9*R$K($9
M,Z<Y>/%&S1`Q@323.H;;8I1$0#5`4H7'8$J:T&U-FRP[Y>JJ(/&&-.$3QNZG
MVE5\=&AX$6*K;'<9[LLJP5PA'*I*6)S#!ZTFRW]:,U#Q"D\,-]5P(B#LVT4>
MT>E>WR0^7B]`I4,9<(5%C5F3NGAI4O`2@J4J%<+LYFVD(2-$3U>(=MU$G4@`
M"S043,510IBB`1RQ-%016AWIVO"MA"XG\NANQ4DGN+^#R<0C4$<@>Z2M(P"6
M-)CYP[%@UO(O#1GJI::L^_N=.2`P,3+?I8*=79JE(Y@8`TMV>!.UX4KU^)O$
M.4;HS<1Q?XSR,-(-6\A'2,5A?%#V/DH]V@1PS?1SEG6E6KID[;J%4253,8BA
M#`8HB`ZD83X"!O46ASC@5I%.+W$TG8CQ5XW%-MTB<^"L6'4`![3E!0:J)BE,
M8`W#?O#5P(VDEPIO4N(.U81N+G%<X]G%SC>4N_;M@O&`]_L?^BWL^QJ1S:;:
M%"3TKR'BQQ@(`%1XS<=T2B8PF(CA'&21=S#N8XE+6``3&$=Q'O$>T=4S'&3Y
MH\03,[I*\#<5.,1QW'C9Q_\`J;87QOW_`/@UL._5800M^*T^X$J[I*_9.)'%
MA4W6?C-Q[,?I`O6?"N-CGZ`$3"7K-6A'HZA$=N[<=7T=E;O:2Z-M>H*1[G8;
MU^QXA<6N\O&?CSM[`X4QMV[]FX#\6>S5.73H0/,9_-'P*#348A>9.)/%I,P@
MIQBX\'2.'2H4V%,9F#I-V#V#61#VP#L(:M'6+`ZF1F'XH^!3X>"J:Z<QMP+J
MM\8X]E\`X";S+I5@S=O4^.U0<T^LR<O'/)BOU^Y7=M2E:E3;!9(B-6=1S&1=
MMG#MLGXA"^&8AC6KV6\;LCF,S=0^!,IVTP6P:8K\OV=6B$8/'/"V74L$6\G8
M!*(J."I`\Y!L$GRSZ:AR,F"II*)8HQ;HZSE$#HIE;*B8P`F?IB([=PJ&LQ\`
M2AZ/>6_K/'/AE<(B/M-/P+Q9MM=E4E#QECK&*L1V&$DFZ2ZB"HL)F)@GK%XD
MDZ1.0WAJ&`JA!`>T!#41%`1@UA'4/@4*;BE"KQ,XLF`#%XR\>@V_M<)XT](=
MO9\6>[4>#!^`SQ#X$H%CAQ/XN$*!4^-/'PA=S#T)X6QLD4!,(F,;I)6BEW.8
M1$1[Q$=Q[=1X<8V-;X@ILSAL)7Z#BGQ?_P!&O`'\S.-Q_JC7-1X<?X+?$$SN
MZ3XUYFXF\5SFZU.,G'E0_2!>M3"6,3GZ0$PE+UFK0FZ"F,(@&^P"(^R.I3%%
MO:WQ!3"65OFN<.HD>1:"P<>^&E)1A7]CXW\=V3:?MM3HL5_D%QV]%Y:+S.LZ
MS5HP$V=2<*)C)S4@DCXI@*DEU=2ABE`1U(^*&E0UOB'P*83S_AO_`)Q^%::'
MIWEOO365-;$W$:$4J]XGJ#+IVS$.)JHH>X5%>5:V2!AD[)6XY:=>1:L(Z\0K
M,JH&*EUDZB&*88-9;Y:EK*CP#X$XUQ^')_.=\*R<?8@X)9,J89`Q_@#C+?:F
M]CBRJ"U6P9C*P21#'BFU@;1)H%C57$RTM1XYZ@8(E5!.2(JL1,404,!=&QQN
M&8!E/DCX%-GN"*E[_P"<?A3;T17RS,LF9-Z[A;CQ6)*7KKBV0T5D_C74<12L
MW`,9BW0#R6@X[(E&K;J6:-9.A31%A;E4,BG&.%3@5),3ZD/JSO-:VO4!]Y0,
MMR-KY/YQ^%+QEAS@+(R2$+'8MX9R$RZ81DJUB65'P8[DW47-S!*]"R39@VC%
M'2\?,6!4C%HL0ADW+PY44Q,H(%&<-A)H&L\0^[:HB2Y(J'R4^4?A2:M='\N6
MCI%6LV..&<8=9]66?JJ>.\+.Y,5+=:24B!>KQK.%7D$XE:R=;99\=,&K0K9=
M1=1-)LL9,]L#1BUGB"AGN1\=_P#./PI1,</<`I-\VC(S&/#*2DGC&)E&D='T
MC!3U^ZC)]:$;P,BV9MHQ5PX8SCBS1I&:I"BFZ/(M2I"87"0'@UL'X+-VX="A
MQKC\.3^<[X5X43$O`K)<WD.!Q[ACBG<I?$=L;4G(K2!Q'B>4&I6]>&CK$E"2
M*K.N+(IR*$?(IBH!3"*#E-5`_2N@L0D6-BS$`1X'H'1U*8NN"*%SR/E'X4^+
M'BUQ85("*_&/CWU=W4.%L:AV;!V[_%D!U<--N1BUM?DA4B7#`DU7DZX><7O%
M!1#C5Q_,0Q@W(&&L<]@#N'X-[:HEL?Q6CQ!0S.Z2N8'Y(<6_YLL>?P)K/P9K
M$4'1]WB5W4IP\8P8C4J^Y`@B(QJ*VX[#]N)Q]@>SMUV'2#FTZW;_`*IGS0M<
MN,9W_*/E3IH1)CJ"<2=P;]W?L/;WAW!K:(WMC8K&CBZA&*1UJCS'/T@7L[OL
M;COV`&VK228N-`<558PM-24CDX%58Y$DTA4.H8I$RE`!,8QAV`"E`.T1WU(U
M^.=YQV44ZDY3J*G18Y)XX0!2U2B0"DF)0$8MJJ'?Z1*L<!^QJ[AC+SF<<%2E
M)`%$KV=0!13UAX?J$H"NJ=4Q?#3``W,HL<1["^SK)22QQ,J3@/?5-K,U:;4T
MU[NAG`*P%9V)'%_2GL@3VJCT2[@9-(0V$C?</LZQ+I'W+BXFD:K!@:VE$TA8
M\IB`!TA`>T.WMW`1[>WM]G5PQI`&4JF]N48+;,*H"QO&.0`+Z`[]PV[-]_J!
M]355TV4T*DQW52G5:DCVX%(0"](;"8`W`1[PW[^S[&J3IP30*=C:GH3?/T5W
MBI@$O8`CMV=_;VB/U-4"\$U57(>G#J6J]Q1'?<@=OU-^_P!&V^VHO>7?=X%3
MX3NE2TX]/FEC/\F=D7%$QTUG-0EC["JP=)@*KB)$W641;."`)T@W]H<#`'VV
MJ)G,9+R33!3B,`4.U.?<JZ]@)$[=<IQ$A01;J^&8"J)I`!3."=9?%-UF[NW8
M1[=7C;QL@%#L4@CZ4CXYD_1<&=M2K[`H`F44$3$\3;J`#&'VO4(!OW]NJC;A
MS#G%:U0PM=@4T>9L<9%R'.52:JECKM>+&57)M`L(2=>>3;N0KF4FU3:3*\"H
MQFXA-A8HU"L`#<[DKEL87'MTQ`NQK:]?<WKV2,<UN5CV&H)JUX;6E",1EPK4
M>!5(V1L!#@3B#T;*_"H<5'@:XJ5D8R\);F<DVI\O)DK+"ZP<Y<F)*A8U[>>=
MA)Z&D;02M'>,R7%88\6#-DU,LU24=)J@)R:PD>D<&02,>"&$Y0X%PRNS5!!=
M2HS84`%0*JJZ8OJRE*[:&F(I2F%=RS1X#%8?$9*+N;:,85>A0-7DD&\`\!BY
ML-5=W^6B+BUJJ4XC3Y1Z\F,A.7#].:9R0*"@42>V44$:?[+8TQM:Z@#`-AI4
M9R'9:Y3B\DY@5.9<#A5Q=7QTJ*[=VY*BL\!+#,U:RQ=ARVW;.+)-3<K+2\5"
M6]])N),T@24J,=[N6.[2TJ:*@G9ECF?%43G$$UUT6;Q%!RNF:NW1WF%^:0!S
MB22`ZM:U:*EQ-!T^<,0"`2I#/E([&`P&SW=@_D\"M.PQ@JM<=<3P4"@U:W.Z
MBK.R[B2>!+NF)YBTSTK:)9XB2PS%AFP:A(3"@%.\>+KG*&XB&_26-NQ[&-A+
MB14DG':XDG:2=IWE2NRN>7`4V>\*))6I&:EGHNI^94>R`[F)%Q_2W8MD_0"X
M@8$VK1`NVQ"@`CMVZS\<3+=N>N)"M3VG8!-+)6)I&JJMH<&\C+``D4>*>W9-
M!#<>ANF4P>*8H]XCV?7U;SWSAV&>-3B,4QP*:F3<6!XL<91TL]3,81%+]30`
M-_[%%/I3``W](:QCI7O-7&JJ@`8!:)>LM)$!Z"`DH(=A=MMAVV`-N[MZM]7$
M5Z8P&'%2E@<:I.O*<]:!X@H*&0$P@14$QZ#;;A]ML!>\.[?619<1OI0T4IBZ
M%$?.'$TN9K,>Q&M1J\)Z*WH+]FG"$?EDX0)6RS,A'2BIGC?UN&E'\LS%9D<H
MHJ`S$3`8XIBGB=1TYM]-Q<^4&/(<*U%7$@XX@DC#9AXJ\,CHFY:5[5?)]WNI
M)$X134DS0BTKM6C'BZ99\=PZDK0E9ADXK%Q2O)IB7M$8O/I(R]OCW-X5,Q53
M,BT33:I^(F8VXZH.TDNCRB1A(C<P594%KL]2X5Q<,YIL&`J%-QR#7*<2#MWB
MFSH&"WDIPNMB;ZH%:9/BB-,>UA_6*@V)2G";X6;^=M=D.ZG)4MA,X/).9*V*
M)"X8$:+-$4"*M3IN?TTJ'0;E[F.$HI&W*WLXXEQQ-=M7;10BE10XJ#[AK21E
M.)J<>H8>+[@D;2.`%GJTQ,S)\CUM_(RL/-0PI/Z9-.$R)7&!L-<M3Q\Y>VM:
M3DI!DQGQ6B555.M)TD!G(K`80"\M^59HGEYF:7EI%"PGS@YKB>U4FAJTUP.V
MJ@^\:6TRFE1OZ*$;O&I)U'B#%5BDSM*9V,B;*P8KN&-G$FTK[=D]</;1D:P7
MPMKDBI.?!D)%%*83:.`-[=<4A."A0.!"UAHWJ<+K>-^#X7,K2A[3R_,>DXT/
M314C<E[@\C8X'Q`"B<+&N`7]`G\GW.5E8:7F\KRD1.3+6OU]>#A(:58OK4Z=
M-(,CN1DWQH=5.PIE2375,JF*!A$Q@.4"0A`MG32R.:9)B":"@!!<:#$FG:V'
MH4'.;(UK0#1NRON;58)9(/U2G@Q$G21O6JLP'L'8IUA,X.7Z@[C_`%-4;1K)
MKD-=L)54CL$[PE/2B(-XE*/7$#I"4"[&[>D1_LB^D`W'MUL.HZ:RVA%Q$K>*
M4O>6%+=K'*Q;LJA"AX9AW+L&Q1(8=]M]MQ[-8`2ME:JX%!1:F_TLDDBE.,T_
MTTA0!<I2?;%V#O`/3[&L=-(8L=RG:`0H0Y(XMPF39;*L[(/R-9C(>"5,)PSI
M1&470JZ+QODEI*S3J+;S3*)LB3]OD`I?5G*`F2!J/0J45-RXR>W%V]\CCVGQ
M9!MPKFQI6A\[?T*NR0M#0-SJ^3X$VN3^"UDR-?(6RP&2JS4Z]6W$:]K59<X_
M5F(R'79M*'&&:EJR4\PH;UNUCZ8<6SA>-4?J&=%0=*K-$"(#:7-B^64/8]K6
M-(H,M:>:-E<N[HKN.`HJS)*-((QZ^O?[J6M:\OBRJ1\L>RY1BG,X\<9/68NE
M:G89IN5'*]$:X[FDY)_;[=+V61&`AV)'<2(.R%:R"BO9X)@(%K)8NH<SP7]K
M<3YPH=I)P`P\*GXPW###WL5(O#G$AMBJM3=8CK%$BG.82'$;QTRI,2B@>94O
M68KI(7I_!R2DA#SCI^OECPW#1\DN1T9B85SJ$7$A816_!C+`1BS+L&VKC6F_
MSMZE<\N-?#7WA\"9V8\NS(TZA,#'9IJ4`I8J'*T9Q&1]2OHL*VPD`LC-!G3;
M0KDI?(T;6T$[.YD5XU:562?2BZB2PC&^&T3L'VCW`T>`<M*4.&W8:UIC6E=O
M@5RQ[10D8UJMH\\J63L56K,"^S+6(\*A$S-=B'4!BCW'&6AIZ[W?(#M_:&Z5
MM43D[?[M7MRV4D""F#IFW2,JGXPJ&&U?9EP#2X85&SPDXX[<5/Q/`GCD_+VM
MET?-9.Y9/J+B3&>N#2?DZQ6;_47%NQW:Y*CNV$%9DX/)3(TI)45ACR/CX=NH
ML:#(V5<G5:G65ZM2OMS7M.&;'<14&F!QW4PW('BM`I$XRXF6K!\AC*S8@<X_
MD9C&N$:MB9.KN:RI4H:XV**;C7PNE@?M9-^UA(B+8S,A**!%L23[A05&?K:Z
M#E1(UQ;1O90QTJUH&RE?#_X8[E!Y!P-:$JWA$&RS02E`1*)3`7K`.KI#?I$P
M![7<"]^PZJ29FOS5(8I<H('2M*B@@R%3P2AXB@^W/]3[8`#T`4`'5C*075=L
M*G\"R4FYW"@F/]H7<QA[M@V["]^XF./=WZM:[_BI0K:H)$1*<3=/Z9N($'M,
M`;;E*(^CM[>WL`-1$@;B%&A6="))J.S*E+TF2(?<O:)#=8"'6'?MOO\`9U`O
MS5\*AO2`SQCUQEW&62\6-Y<8(V0:!9:,G,^J'D2Q"UEB'<7[HF8)K-!>>J&=
M=?A`JF*G3T]0;[ZKQLS0EO2IA@:JO6O>6P[HLCCYY6;Q06_Q-P4QP9-0T]AM
M"2K\PP>SUVL=NR*U@TK%'-F^09.8LK11@Z=>LD;+).%EO'541%*0VP-*'8`-
MG0:^7[ZFS+5J>6D9A)U\]3RE'5B*K.(L74^$B$*W82P4'?L5X75PG&V>%I+"
MXQV/FT58(%XZ<N%EXQS/QSMT92/>H+I(.$9!;<-M0_97Q^/8*T&\*)?7&B2!
MO+*M\17V:89TBD+":RN<C/I>&@LC-GT_D9KG4<RU_P!V[?*Y-EKTU@X>/31A
M3RD8]86AZT**3E\JV(D@2VDA)!`-:UKX_N\*-<2<`K,,%56,PYB#'.)$5/7&
M]"K#.ODDTS2BB;Y=-1P[?.RFG9>?FSD</WBI@,[>NW!@$!44,81'51F:,90J
MP`'6G.>PS&3W68K)$6,!MP((=)A^J00`0$!^IWZG,E>SBI#&":I+.89ZTW!5
M!0"AV=8%W+V>DHAZ!U#,:54O"'2L8$-P$3!V_5#8>[O[=NW?1KR#BAB`%5YB
MCV@(]X=H=@!_^SJH)`#7$JBOV4#D'<#``_4[/T-@U6]:>W`'!*5P"]_$'LZB
M^QV@/8(=FVV^K@7E:5*B6Y=HHO0A15,!")F.H8=@(4@F.;8-]@*`")M@#T:K
MFX:[:H9:XJ!'(W@>OR`F+JU3R:_Q_5\E29K=;3QC.R)WAA<6F)&>&44JY)Q5
MK@ZZM29^K0D6,JPEHV1<IN&(K,7#=1;=/#W<0>XN:Z@_D`5:/':-B8V3\JMA
M-53*<1/9,9-;=E^5I,K:;S#5^T2]C8#65<W+3+"&MM\N]FN[AI/K9=16)ZS(
M=#=:-$Q4A\4GA0BM@Z,U.)_E\/A4"[*:="G'QSPB[P7CIQ49*=1LL]-7&SWJ
MRS;9Q;W;=[.V=9IZP*+N]V>Y6ER1)I'H$ZW+X^Y@$"$3(`%U4##'V1]WCJJ1
M-35/\5$>D0'?<?[(.T=A[/8`=2/86D.*B!4T7B=N(=@!U!]8!_KAV:F<2`JO
M""_'@>R78?K%#^IJ&<4\*<(=*^"W#V`']#_9#4KG54>$.E,QGC",/GJD1%!L
M+GU>!:Y,Q5?9AN!I-$TS'XVOD)=7%=3>PDK"R\6I/%A_5@=MW)%&PGZP`VPE
M$6A\>7=7[Z",`U56&1O+'N]15R:RPLU)>XW/]CG(<S&3I<99(##U:E,T47+\
M<XDK!=<F(6*.F8AS6`31M)6\TLW115`C0':C=5.T,)^+O/W;_NVJ+A2A5B."
M.'L+Q]L$/-PMNFE&%<IF&:C&5NFJR>/Z5(.\5XY4H4K-6VF1$HI`6HUH<G-)
MMB/$5#QCDYC`=1014U6:S*=N&'O*9I)9CX4Q]S\M%E?<=S-67R)"(SDKA.I8
M=C;:YQ\D^DH-M7>2V0.0<V[9G4FR/4V%I2NB$2X9I+IE.,>5=0R@&*B1P`YI
MQQ*H9RLZW^7E)+6VKS],O%*JL%0+QCO,>.H,,:N?[BR7CBB8@Q[&5R=/%66)
M9JX6&,PVT=$C(]%G)H/7JW0[`A"!H8'`@@[#4=8^]@JS#5F*BE%>6ID97,6)
M*38DX:ZXYH&7AY%WO*T_B6GIQ5OE5V=#<S-(KZOQ_FYR.@IV5QVP:JUU:)*@
MW46<2B[UVDBR:!3X1<0W:`:[.K[J>ZISB$OZ#Y9F08^[Y&DW=TI<$QJ_*)CR
M&Q),KXV25EKK9XVL8QFJZA=I6)N",H^Q-"3K*1AU8L0:2J3B/%RR710<`48B
MW?7W:J0@4VG8IL\/>*%AXQ166HZRWZMY#<92R@^RHO+P=&6HSE";G6*+>Q-7
MS,UAGVKEFJ\:D69^&8AT2G4*H*@B4P5XX,@HX@UQ]Y4S(\[%,D&3=/NV[Q].
MX]O=V`&JN5K<!T*D22:G:M@U!,3`GU@':78!]/;W`&W9I5HZ%,QH<:'H7)=L
M'U?T?]S6$Q5WE3FXQA]\=TPP%_5H!@H;L[P.F(]H@'I$?L:Z_H@KI]N3_HF^
M0+7+GZ=_RCY4Y"41TIF'I```NV_U/9'<![=]9Z:0!E!M5#&J;>8BS*NA#IWV
MW'8`$=PW[.X``!U8!X()\*FR%.U0:$A#M26J9;E5<J;>XK!0O>IOT^N*D,'V
M@=X=G:.JD8S.H[S5+2AH4X[*#<OEU'[@Q/%.`J*KJB()MD@W$QA,(;%`@#MK
M+":.!F&."D<PO.":J^6<SX#P$`J8L83=-\])N"L@J7O#J#M*@40VV].L9),^
M4U/F]"F$9:$TQ(/8`]H/V2]O?_\`!U<,(:W:IEM&M;ZA`ZI`Z=_0'Z`B`@(A
MW:K"2AP*D<W,MBJU*W)T)`'44!#VN_U=_:_7'V![-4)Y`[9B5$#**+1K,EE]
M_$*(%'LV`.X-^ST=_LZD8YNSXRF6",+VEV+W]Y0+Z.\>T`W`0']'4DI(*`5*
M^>XH;[`01,;8`*!1W-N(;```7VPB(]VJ7&H:$XJ.4[%(K$F(I-HY1N\LV49M
MHX?%CTQZB&!R8H^"NN/M>D0W]J3O'TAJEQ.(:8J%"!52,M!$[@8KF4V3=1T:
M@U;%22$Y5E>CJ`%"!L(BN.VX]7M0U>VT!RYCBH55?&0J[D^'R1:)R/CLG&L;
M*582U)GJE"R%AI<=@IEC!1&Y5HT*8BM+DLA2.8@(LVCGB!IAV4[91!4C-)51
MO9W3+L7)>,^84+2T$M$>3M"GFEV?<1F.!!I6E=A9E`-*;Z[:UP/53W%$?)5A
MYB6%G>X^2KF4H"1L..W+-XCC3&3=V9/*;6=OK:NTB&=,O=!-MCT]25!TO.-G
MY%R+D:*"^(X53CU<7//J='!W$:YT=#E;\>KJ-&WLY<<P/1C7LJJT0"E*4!WG
M=ACUUW)+R[7FI<L_4]!DVSM6X&.L-FCF3U?'135:-F[`@Y<N"VM[(8KJM.&*
MK`UUG[F.4W\S#(JN#D3F7X.3%U0DN-4EO6Y3*(P33LX5/3V`*"@IBX8^<:J9
MK8&L/FEQIOQP]T^[L/@4CJG/\PYS*6*%K?5I&HTZZ"WL4[6#5E^M%5^'<6>_
MQUIJDM(,Z-+ECWD+3H2O2,6XF;%`/2NI==,K>6$O@-[F*YU&2>/C`MC<:D4P
M`JX$'LG8`TC,YIQ.#M@D='$&FAJX;_%X>O<?<3*<D(/D+7[[?;!B-MR`2GXF
M^L+,SG*56+%-MO<R/^(Z5*@W<$[86['N5,<J2YG2K6/BFC":A2H/C3ACMETQ
M+;ZFZ]$KGVAFSA]<`3AV:"F+7-K6@`#ACFP*GCX=`U^6E/!X:^$'WNA2AROE
M7F1!6[*L!"3%C<5&GQK9K&6EACY65>V.NILL;#&SU3+"X?D*]&76Q3+RPH/A
M:O[<JT;D2$T`R31%R>J9-1AF>.UPV[#EK4=FA%&$`DYJXOI^`-JI!L)`K2I\
M/7X>KHZUA4ZY9ADYC)4)>$+6SCR2D.XC'<[6HZN-P)(MGBZ]?BC,&9?7S13$
M&OKJ[23L,6X<*"J@_2446C&.2@NKF=[V3%V1I%*@`=0IMIA4@N%<0=K13,;`
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MNO0D!!1[]LI$A<A17>%,FJZ?+H1Y7[0U$W(-9N$TG8-Y#AC^;(H``13/0G"I
MH%,&1-9\7,?#U>'RT\6*WKN?Y?NL<EED:K?"2HUV$DXI`N,SIR"M_CKA`$48
M/6LA"PLX,(G1T?=8JKF(CTW,HJY0/X0)%9!DA>:G-!5@?GR@CL8YPX8'`&F7
MM8M%75&%,JI9(6.H:9:].ZGPX;=GC4A?<W-#O&V1(B;>V>P3D1:Z!X$T$1'U
MRSV:A/X3&MGRLUKR$&UBVQGZ*<G8HJ-*T`CQ(Z";<JQW2?C&V>$W+;.2-Q>Y
MX>S&@:YS"&.D#:4%<7M;3$4I6HJK0F,R!PI0@^$`U('WBF*M4MG6!83+'`\%
MF."A1_3L7PMHH3NQ-#UI\>[FN,]*'M,,O8H1Q7)5K#C7(*8?L)%5FY4*=JZ`
MW6G3EN[^)A&F-G:S^K#F9AE.?,3F!<,IR\-CG-=0FK3NJ-;$<9<I.^AWX4V8
M8XU(%%BQY.7,1GK-K2-G\J3,#!X\MJU*4G*#`'IMVD*6_=Q]$]0F"5J/AFU@
MEAFG+I9NQ7(M))()`9,2$(<+&XFU;]H7`:^5T;8W9:L;E<6$AE#E`!-22`:N
M`&&]3M;;F-A(:'5QH345V[]GD7M)I<O3Y2=6VGQ68YJCBS0KT=:)VHSL-+N<
M9#>D$1M3RH1F-K%ZADP8P!#PT:4[D?5=S^YO2(JEU>Y?J?K#IF\4PTH"00<F
M;:1E-'4_$K3XJNHQ#E#3ES??IU[/=]U3CH!.2UGS%5/EK1OC8(FAW^/M#)K0
MU:UAUF[7A,!JX^D8R>%!JYEK?8O#L!W,>Z,Z/'*MU2]$<H)VAY]-N;MM\U\Q
M=4-=7"C?B93X2>UANQV;%+*V+AEK:4J.O?7W-BG-%UF430(*'7T%[0Z0-W``
M!W@'I']'6T7?,$SHN`[$45JR!H=F;M3O5QLM)L_4G1?[J;AL0PAVF*']4>T-
M8>"[[=*X>15G-!;CM2OCF(E%1F[)XB*NZ9RCZ"CV`80$.\-7<H9+'CL5,``8
M)KK/2UH21,9,@BT<&\1$X`(@`=HB0![0W#?6+;(8W9';/Y54%#VEIGL6Y/!S
M1&15Q>G@Y<K$K<>EP+P\:Y*U*W$``2N/'$O0/>!]M4WO(!`QJJ@VX[*JL3##
M?DO6</10X]8WN#?5K"J-FN%7#"68X23R!F5K)X5KGQ9M$AR&=6:TR;\:[,V)
MT\7JJS%B^.V.HB9$[<YAU]CKEL0R5!#*D978NJT8YZGI\VBN2&.=CO/2-F/1
M]]*E>V<WL34"@UR%89>ODM#U#!#QA+/L<A(C,V2PTF@A?*!;"UO&EVFGC6K/
M%Y+8[]>`(DNV<&D;'ZSX#9:D^:[C8U@S$@-QIOH*@T!V8]'A=556MCQ)IB3]
MWW>)/%5[7SFB9*.@I<^2+*H?"E:N=:G/D<JR;6T\B[1BJOSSW$U[%I&1,14,
M6UZ>"736=&<1[J/D$$D%9!PLH@P7I<2Z!R]H]D&N48NIL/0*UZ,=^Y349MPV
M].Y;['MNYURM+R/8;'8,BQ4=7<:5Z3I+(F&W[JS6"=D[ZK&W1-VO,8)J5V<V
M2N0L>](P*QHJY6S-RS>!'3140/(4VRW!:XN)H!AAOKC\4'#Y/N'>.2HI3[O=
M5I.';<2\55L+OUY*X5IO`U_)$5),&;.0KU^6J5=L<[7I(8A5W6UY:*+/HD>!
M%N73)L[\1N"GB)'(6J'<0UQS;^NF*E#2'5W*1U;8`=<G47<O9L40'8>X0[=N
M_LU=P%H;5RE?6H"<XROAE*BF'4'<(;]@B`]W9V`0/3W;ZM+FX#GT;NV*<#*O
M9JV66,913VI-]SFZ=M_1V`(!V;ZL<V?MNVJ*W(I>TZCF*B@4>HHB7IZA_MNG
ML%0X^CO`-4GX[-BNFTRA8:SI/82HHB81V]NH(]OU=BEW'?V!V#4`TD5"BM[7
M0.(N%#[;``=@%``$`'<0[`'LV#4,1@I#&":J-/+)*]3'&[DC%X^)-.;O,88R
MA&4YI7/=,)]>ROJC+-8-&$-#+M9DLJ>053!`S15)R"@AX1RGZ3!+FDRN8PG9
M[JB6@D5W*$F0Z#R>H+K"41@^J1B=>XX1ORX98CJG;\R0->RU8;)D",;R>/\`
M',%<%,N67*,JUP_5K`16!?S['PI*9:E37*+U`$8`S,H`3AM-?)AB=U.I0R`D
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MD'<AC%$!V*)0VVW^ML/>/HU`M"+-3E)%$.D506)O]JL7Q"AV^@1#JV$/J[:E
MR'9N1>X/&;G8KJ.2`WI.W$4S#L'5OM]7;4A%#1%CJ,8M4>I-=5OOML"Q=P#[
M/?VZI%QKE;M4*#H6.:'$0W1626#MVV$`'N]C50$D=I1H.A89X]PF.QDA^P7<
M/8[PT2@.U,OR&IQ[K@3-=72CI:4D);%&0"04?!/IJ*GG5H:5:4D*F2$?5U_&
MSB$P6S-&AFH-EB*'7`I/;%,)1@^I814[%$8*KJ7A>:&"(&T.,",\I.X%[,8>
MJJ6/Y:`E;<QJM/0XFXOL.5LGU^Q3E<R;?U+@QR)&RS)N1%I--@FQ=-PAI1^X
M31"B<[=A-/Y/N_\`%1P*VRV2O,"98)R+=K"XRY+6YO<:O"8X@ZCB`6CE&HI8
MA^-K&S3+-#CQ=LL6)U<+NX9P\L9*BLQ;R95D5FU?046581$LK6$U/W#J^]XE
M*6M/0D#1>3'.>7Q?,Y55>S;M_$S<I6;?7\C8RKN.Z!$Y`M.>[?Q^H]+QU/M(
MA20LL;4C3<;*2:GK<@[1DX8&\CZJ4RS9W,R>4MK7[C@J?"&Q7DQD>[C8Z-CI
M"25FY&/CF#&1F7+=JU7F'[)JDW>R[AFP328M7$FZ3.N=)`I$$S*"5,H%``"[
MSU`S;:*GD+34K,%#?N#T^QV_UAWU`N9OHJP=4T7X!H8P]A=_]P/JAJD:5PV*
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MEDO1GU-6H%4M>*:M&57*\@]ML)C2;M%PL,E&12C:&A<=1II^2-%NH2.;N_\`
ME!0[=DDJV49Y16NZF[;]P51H`%%@W.X\L,Q8&L+['-NSS;+_`(4YR8KD*JC(
M8XK>/KS*T"(XJ5+*#F.R-3(VMQ0R]/0R/;%'3;UQE&+RPJL4UVO2=%`U+-(6
MU%:AWWJXJ;!3:XDV;D?:L@9LD,LV')+K$%>+7X;CXCDC&,)CVRWJL25KR2HK
MDB[`6GT^PDO)JY!PJ#F+/'0R3$KCQ56)%').FI%),1^<VT&Y0(&Y3H,X.(CZ
M0_J=P=@=GZ.JI+B*$J"QC**&$=P_W/T.P=02@7Q,5?$((".X&`0[#`("';Z.
MP=-Z4`V+E$ZU/9+^A_N:Q/C512>Q+%`KC&@*"01ZZI$CV!V>V0`0'NWW[==>
MT9P.G0`[>$WR!:[<"LS@?PBG)<Q0)M#^U$`$H;!L&YO9V'8>T`#5[/*&UKB5
M1:T@XK\U"A(OW*D]+IG+$LU.I)(P;#(.BC[1$@#MNF4W:;V-4(SG?E![.]3)
MV&L(K,O%%UB@@W1+VF-[1LQ:IAW=H`0O07]$=9`3-8`X^:`I2VIJFUO%A(^*
MI`5[K2B41$CIT`=*TBH7<.TW3N5N`]P>G5DZ<RNJ*@>5`VB:DD&`;;%-U`'8
M`@/:`[AN/8(CMZ-7#75"GIN6R0KZ8>W,0>X-MPV]D`'M#;?4SY1L)5(M.S<O
MJS'8!(0H@(#_`&/8'U>W8>W5`W!S8?=@HAN\K7^XAE1$XE$=N_L[0'O]`>P/
MV=3B49<=J%H.*_)841-T@0QC#L`%*`F,(B(=@%*7<1U`W#:U\*9`M\TH#]ST
MJK)%8(B(!XKS8AA#;M$B`!XJ@B4?8`!U++<YQ@IZ)P(2I0\-T+-6PR,CL'2]
M>)AT-O9%N@.X`(>@1[M4FF/:\]K^10QKX$LVYWLA(1<.,HJH+E^@44O6!*1(
M@G**QDFY!`A>E$#")A]`=^IH9&"3;VE'K3T2;ABV441:QC50I$P*FFJZ,DH8
M@=@&$A!#PQ`@=6YAW'TZRS;N@#0!0*F6%0=RUS`H&-<F-<3OJ/<9FVS*U;BZ
MTSI\S3)-U-V6U/XEI'0K>'DK#'2$2BFVEBK'?R`M&@BF8A.H13,I2FUNVCE%
MLYCG/-`*9:DFE!2HIMK4T"J"W>YN8$`>%)B3YBUQ---_"8MLPQ\%(98J60+-
M8'$,6-K>1,48AO\`DB3H;9"#F7<E,O1DZDU;EE$D%(IZS<+G;K>*B4#8Z[U.
M-])(XW!H+@XFF#FL<XMP..P8["":;%,+<TQ..%.HD"OOIS<8<L87)]CQCC5?
M$E^A;MD+'S/)Q5TI:EO:E%8]7CFZJ-V?2:<^:00BY66*Z:,XX6ZLN0R!/'13
M!8I@MX]3%PYD!8X2O;7=0-IMK78<0!MZ5%\!9VP1E!IX:]";RP<VZ'1K;FVN
MWO'EN&#PK=R5F;N]:4A)."283S*;-1D%V#Z;9V%_9Y^4JL@BX3:,SLF2`H+'
M5`HJ`60:BV*21DC#DC<`2*$8@TWUJ2#LP&U3<%Q:TM(JX;#[Z^7OEM7J"M8F
M]UQ'D&H2-8M-3HKR.F)G'Z#9[>;7CR0RHI6(F<:6=ZP='B:/"N71G0E3;O%3
M-D&XG6<E*2[FU%EM7.QS7M+6FN7SBW-0&NYH)KL.%-JIB%S\00?'LK3RJ/5L
MYNU&7M[VKMZM<0+'G@'D:T*ZJS0J$%-/6[!6:M_K,ZFWH+QB\=(H`RF56SI=
MVLFW`$UC"0MF-5BD+H\KB<.C8<*G'L]1H2<-JJ"W-*X?=Y?<3AXJSI3.13&>
M-4HR;;$IY(M8K]_ZDNSEHB8D+#&1SHBL>NX)%2QG-9<BXBW)BO6B)D%%``JQ
M-1L+UER]PCJ,M/=&(]PX;-HP4LD;H\2G/2@^DY3=(@).[?['9L)=9JE&=:H-
M;5*!S`IKLP4`OMBAU[]/L!MM]KZ=21/:V4!RF+1N6F2C3-S>T[-O0`=@AN'L
MAW=GU]7#I&Y<:&JD(+?-`JH(Y-YSL\77G(E&L%`265HN:L54Y%XA++J.);#]
MMH\);LBY33CRLQ)[HX]?.W4:G&>.1216%!4@`F"N^J7FHMAE?&6XME:-NUI:
M"YW^2:BF]7C("YH=7:T^,;![J_3'G76E)BR/7&-9N/H%7J$%8)"SJW"C%4/*
M/7-G?2K*)!:<10LS!G4X--P@>-(NHK(@Y9GZ#(]06AU-N8G(1$UHQJ/"3OQP
MZ-]0IA;GIQ)2[J_,F+FH2']W,67!O/3D)>+Q",(YY7$V4[BZ@RV1&UDOD>YD
MYLBK`D9%XX=JA'/`1?O5M@03Z3EU4MM7?&*N:ZI!(&&+075.WH:<#B=R@ZW-
M2*BFSW3N]]>N!N1+7.LV\@(VD2HR3%R^=R\C$`Q2@ZW6%E4T:O,R@S$R$O)&
MGG)C)*@T;=;)4-E$Q3$%39O3N8#<'AEIS#;38!N.)J:[Z#!4WVS6#-U>ZDZI
MR(M,)9LKDGJ"B]H]"NMJH[&:CTY2G$0F*_8X:$B&TO=;^ZCJ%9W5J:OGCH$H
M)15:*&.,DY3,==(2WC>8)FNDS,!@8X@$5&((`JYU&FN)[.RE#M5,V[7-`!H3
M0_=3'QIIZ)S\:6%+(UJGL16:)QC6)>N,JG;8N5K\BZF6EN:7%Y6/=J+6FR+L
MY2<0J9MDT"&2:=0F7.4HD#5BSF8S"1[XG"!I&4@C$'-2HKOI[F]3"QR4HX%Y
M_DJI:T'S"L(1C-646B+'(05=F(TMBEC/JQ&>IPZ\G9D%).,C)68;3-E>$C:R
M#]-@R;J.%6[U$@BFN!T@HSZW:O82`:#::@85.RIJ<!6@&PJ<6SP<:5W*0,GR
MWI5FF(N#CZ7>04E,J)X_L$@]-66,/2;^8SQM-42<DGDX@R=6RKJIM.MLS.NG
M)).S'CE79FKA,F-;>QNF``=BX-.S`UQ!QVCW]U:%3\$@5KN]Y39KJ31E$JG5
M3*90A3`&Y0W#8!#<-PW^QK).B+SX*J4#+C7!-VVGUV$P9=`!\,BP]1>D.TFX
MB)>X/9U(Z(#$8%2!QS92GT8@UFF*,FQVZ^G].2_LR#_9[[!VAJ:*Y/T93)XD
MG<L6Z%H^,IFVS48,JE%K1;1!B69KU>%5[+R+:,:`>:M$A&Q#!`J[D!.8RAU!
M*&R::AQ`HVU](&,X@W=0WTWJI$W$`*O6G\X\?W`U;7K.,<GR,??+>PQSC1Z=
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M%",CGJ_A@HHD`G+0]>8`"X'&M/?IAMQIU*/#-:)W+-Y@5(IN0)#%\GB/*[G(
M4+.5"D2].BEJ*_G8O(UK&@')4Y,$[26)81;)EDB.6).JO"Q;[I52;&.L0$QI
MNN6U+"TYLVS#;AA[^U&Q5[55J$_-)X_M&[)9O0LJ`9>ML[Y(0RL16&%D;5:V
MPL+9Z5/-:^C/.UK`K<6%F:.7)&Z@JPK=4[B2%(B:G33-Y&.T`=E=WW8^]O57
M(?`I8<<>5,OF?.=]Q&&%[-CR.H6(*+?YF:M]AJ#N<962_/B2<+5'$35IZ=:@
MDXQ[+Q<F=9-0_JKU=PR5-XB.XO62]_#`I@/?ZO`I2V@JI^MD0["IAU*&$HF4
M'L,<NP]@>@B7_P`H?J!JFZC27*#15U-RV8*IIE!/L5,':)2]B1!#<`ZND-S!
MN'=WZD<_,`-P5?AM7P4U%S"90PF';N[@#;L`H%[BEV]C5)I(%/"IZ+Q.AT]V
MPAW!N`!W;;>CV/KZJ9Z"@V(E5%I`C&JG$-M_9[`[C>D0^KJB7&A.]%`K('(C
M(5;Y-R>':]4F,Q4JSB2EY0F/4\9YAMMJLCJVRF76BU<C<@5;P<.8H401QDD#
M1S;ET4'BSPP`8")[ZI-F<QYZ:?=X$W5313_F:XMB*O-Y!;XAS1+8S@*=7[RY
MO+5M1FB*\5=;%DREX_9LZ[(W!M8U9RY7+%4BS1;F0*FS040=N54T3&Z:SIVD
M9B#TU\?P*-%CFYY<?:IE3)1U^.]C:YK@8!A"WRPQL-C0+LQ<QT;C>>>U/*%W
M82BA*I4ZM#Y(B53S4M(#!'.@X215-ZJ)M43*QKZ%IS4QV(<!X$OIGS":A$Y"
M@,>QV+[Z_F;3>U\;5JOO5Z,QG+A:I=.ML:0FU,:\BG282T3=AW;R,J@K&R$4
M*+]FX405`P1,[&BNX(!48)1X!YK43D#=6E6K6.LCUN,EY"YUVNVZU$J986>N
M6-Z91;W?JNR8PUCE)U(M9AK\V2&17;(L7;UNLD@8X`0YIV3@NRMK5"%-11,"
MF'J+V;]N_8'5N.W9W#VAJYSA0HL<4BCOMV;_`/N[/8TSCPI1?/!+V=O:'U-P
M'Z^_?J&<;ABB]!0ZRB/MO1^AVCVAML(#JGAN45Y>KB7NW*`;;;=GL;>C1%^R
MBL3;90PA[`B`A_\`*#1%[=9C;>(F0_=MV;#]7T#OOJ%0BR4TDQ3']+,4>\0#
M^QV'<-Q`!W#ZFJ,A-?`I2O$K0"J`HF<Z9BCN`@(AMV]X;!V]V^H9B6Y-P1)]
MYC*B2#>$27IE1<(UFS.+K7FR]=ASHP5S>.)1X\M\,@9F9.+L[MY-O5E7R)2.
MCJNUCB<3*G$91@:HE#[F[=H]G;W]G9];L`1[-39W5JF]?L&A2A]KW#WC_L^U
M].I22=J;UZ`W(4>X!'T=FW:(=_:'U=1#G!%]$A`'81[O1N&C7%O4B^;D#N#M
M#N'_`&Q[.S54"1S<PI11Q6YBD2KF01W$I5G94C"0-QZ3[`82[CMN7^KJ9KRU
MI+MI4H&.;>J78WS:(J&3IB&2\6I5BU6=3,K(E/C;<R1>OEZ5E"-K>+[/#SMJ
M]QHA"B9+QQ[I22CMQU@UL$8O#)*++HG-JVX[CM4V.Y2/Q5YEV"<OY"I.-:Q!
M9$:62]6%.N1C6?AV40HS>>LW%-R>9CW$@+Z-4CHZL-';E`Y!733G&B?2*Z3Q
M-M79<-)HVM5!H?\`&6ILG-:YT6Q*HY`Q=%7:DY"Y*9,XNX;KF*_%'([ZU4;(
MC+'3=Q?OC_8&-'E(:X!)>.HHR48EC"I&(HD[*H)T9>,<Y#A7[B/O*>B3)^:>
M`\+U.KU[%O'FU1K69QQE#-$=C/%L%C"JM4*WC*?R\VRD^;-RV"O5E6P,T,+R
MTBDB10II4BS=-)05C&(2DZX:VK6BE"E"K"X20;S\)!SS5)1-K/PL1.M$U@`5
MDFLU&M9-NDMT&,F"R:+HH'Z1$O4`["(=NJF=YQ5(OH:+9>`4/_>$?]G4.(Y3
M51X)?J?H!J;B%*KT21+XA.[[8/0&G%/0E5R;=`>R.L?F57%3JPM#E/B#&:W1
M]O3(,V^W8(F:%-N/9W]G?KJ&E2__`$^$`T(C;Y`L!.VLSJ?A%.VQJ1I93],+
MX+!#I.[<;;`!0[?#*.P;JG#N#54ROE?D'2I,H`2S3A?=%5-HT239QK)/VF_M
M4&R).PZZI^PHF,`;CW[ZO<S8F8>>I`"4@KA,I+I&KT!NG%)C_=;HH""DDJ7?
M?<W?X`&[@](:M9+ATQRG8IPWI3;$A"[=B?U_:_7V`/J:G:2`#L4A`S++3A2$
M`!%(-PV'[4=N_LW[.X-5#,6C$J8MKL7X/&&4,*:2(J''L`"$$X]^P`!0*(]H
M!^CJW-P2[;]U%$,"SF]&D%]CJH)M2&[>IR/28=_83+NH(C];4AF3(E$TID6S
M#=V91V8W<F79JCZ-Q$QA\00[/1J`G/3@ILH7N9.+C1$B"+=L80W`K)`3+#V`
M':Y4_3!,(?[[4`\N.!*@6A:M5^3J$4&1CFWV\5P83#V>R!1ZA`/KZN&M>X;A
M_P""9%J'2DDY`2F5%-(0^T0+X!0#<.SVGMC>QVCJ1S7-!\"C0)T,:T\[5%>R
MKH_W6Y`S.)\7<>A(1*5V]$3^@Y@\,@[]H;[>C4T3'4#C3+AY%*YN&"9:T<J.
M.\;$14NXR]4&T-/3&3X*-D3N':AWLQAE^[C,N(+()-3NVH8Z?LE$Y452$(U-
MT@8?;I]5.34+6GG@`EP]UOG>+>HB&0U%.CW]GC2[KF(^*E\G(/+SQ/&MOGV3
MZER["T_',#-DK1*LHM]CM\YA&MC0@RW61BT&98M5VR&8<-2(H)B=$I$PREC%
M9R2-F=D<[LFI=L/Q<*TS;*5%:4"@>(T9,:8_=LV>\M%\2>"+N'JF6&=5Q!-/
MI>?;2U'E4Y4&KQW=+2Y6N395K%O9EJ5G<[&K."Y42<-22CMJHBDH0[9)NDG"
MZ.F]F5C8W$FH/A..RNTUZ*TINHI0Z<#*<P^#9XDT"+3`^/UI[+$0ICO'T;7?
MC&66M$5/FD3PK5]'M+'/5IATRLL\20]QXE)ZA7HY(B#9N0RK1FF110Q\.XVD
M1-PPM:037'W2!B>N@V#8%6&=X#34IW%*-Q1=S5GC[%%XGD;+D*P4J2M:TL^C
MU&5WNJBMF;48KUVY?A"2]D.NK)@W8H',XV5,)T=CIB-XV2Q;5KPPO<03^,<:
M>"NW!2'B#96@'_BFRDC<1HNG4>."KJO8/,+HMPHS>D5?,5JLEM/2X",@W5S1
M?T1G*7]@K%UJ7;M9&2=KMS/&KTZ;Q58'"P'HFXL7-:QP_-O-10.)-!2M15V`
M-"3MWUJ5&DQ)Z1U??P7CE/COQ=)8B6X]8QPV5N[=B4Z!K29G'+K.Y<A_5(*#
M)8D(5A&VN<*(.FT<V1;3;A15)T1R*RQ#FQ63927!M#X?(*TQ.VFW?7%0#Y:;
M_%]W\BUE4?\`';'4X]QS7YNE5VZVUM8;"I7&L^N]6+&TQPZ&Q&!!>0D(VF5^
MJ/'2_C,$_<]@Q654$$2&,<1@+BUMY<D64/<:[=PV]0'1@!T*7+*X5-<H2V92
M%7EEF;>+L5<E',BP&5CVT9.1$@XD(H"-U/=2/19NUE7L;X3Q$WK"13H]*I!Z
MMCE$;XW5:92W$5P(^ZB@(B`EK'1?BD.B)0#L$``0]&VVVVV^J+YG9LP*CE*U
M#B#!)8Y?"V[1$-B^R/;VB'U-3\9Y;4G"B@&].RJ:6:XZX<LDV^LMAQC49N>D
MWB,A)2LI$)O7;]XV"!*@LZ,L)R+`D2L,"`0Q?#\-`2;="JY5;8LMI'9W-:YY
M.TCJ^`?=55*N`HTD)/.>)>`GHI&?8S:.UTH9Y7`D%;)>?=I2`D57:C^'<SY+
M02<>,79'ZZ!R+.%-V2IFG[5'P=4C:V<F!9C2E:FM.NM?Y,-BBU\H.W#W$I(K
MBQQU;,U8QIB*L1S1P^,_428FF61BN%3RBCQ)LLUE$G#*+EE9QZ>08H'38R9W
MBYG:*XJG$UN;&W:*-:*''"OA^'$;ZXJ8R/KB4K:_QJPS5)EC9JGC:LP<W'/7
MTBR?Q;=RU42>2+=)JX7,@1SZFX,5NB`(`JF<C,1,9N"1SG,:DV&.-^9C0'#[
MON]Y1+GD4)P6YF,-8\GH:3K<O4F9XJ7L[N\/DFKF5BW(W%\Y%X]M#.7B7["9
MB9Y=P<PF<LW""G2H<@"!#G*-9L[<I8X=C-7>,>FH-0?"%(,#FKBFRCN'O'^N
M1,O"U_$M49P4^^@9.8BQ3DGS*1?U6*?P=>>+H2,B\`%HF+E7*28DZ0,+A10X
M&5,*FJ\+++*6M8VCJ&F-*BH&_H)_\5!SGG&IJEG3>)''Z=EFT1*X?JWN:]<(
M%DV\265K9I1BE%MXI2)DG=:D8EW(03R-8I)N8]911B\.F"JZ*BNYQDFAM2W*
M&-H>BH\&[=3=L/0C725Q)3Y1_&>EMZ\D^NZ++(%A=Y?NN:59Z0AR0+9&ZV62
MCG1E6%?C7J[-.(CBP4>=)D[5?(&>LDGA@\=-`4+)L;>(`[M',7'#>?!T"GAQ
M%55=F&S!M*)Q2+;(K-P'</;`(]XF$1V`?9[0U?<9XH:E4\H/0DB:)'QSB!`W
M.(F[MNT=A](=F^I'3EV]`VIP3@5!PK#NR%^V;J[$43[1+L([;[=@!MOJV=(\
M.J#O501])3H66C56\0PPUGATINNO'4=)`V]:D(YTSDHQXB_C)2+F(9W'3<',
MQ3Y$JK9XR<MW3=0-TU"COJLZ1D[>')C]WW;%(P.%'#I39R7#CCBWI\16(;$%
M895R#?2,O$Q[=>=!Q%S4PPK\9*33*:&8//MIYZPJD:0S\KH'F[,AP5!03&-C
MGV\3.R&C)7X!UUP5WF=6M<5DUK"N,JJQH437J'78B*Q=$3]>QU%LV'AQU.@K
M2Q+%V.&AF1C';)1DS&D!NN@H11,R(=``!>S0-C:T90.R#3P;BI,Y+\N-3M38
MS?!OCQ82U)LA0V4#$UN^,[TZA8Q_8_<^6595FZP!(I@12>*-'36?W0959U`^
MY[MQ(L6ZBISG*!RVSX8B!44`-?*/<VUPWJJ"ZB=(G#;C&Z61<J82IJ7@+R#T
MK)@69B819])(6%JO)/*Y$RS&O2,JS:VV328.W#55U$IO#E8J-B@0"T'Q1N.8
M`#P*<$^ZEU%<6\#-7S!^UQ;`D=1QJZJP(+N?<-$9"JO89_`3A8IQ,*QBMM:N
MZ^Q%2:40/,/"M4TW3E9,.G4CFQ`XC'X/O^':HU*6$9PWXT,FS9`V&*DB"4,V
MKIV+1:>91SF`952'H\=!ST>SFF["SQL15(%DU8MY)-VE'BV(NV*DY$RQK=S&
M.P#0`H9B4[U5P=B>H7J8RE6J-#UZ^3]>CJI8+6P5DT7DQ78MK",HN*D6QWYX
MMVE&-*TQ2;J';BN@FW`I#E`ZO71=E%<H[?2JL6((.Q.J=R(AX38!(E_9*;=)
MU.T0[^T2%[/KCJ6IICM54`#8L]DAOL`!V!Z?8_1[=QU`N`VI5;PJ.P&W+V["
M&P>CL]C;V`U*7MIAM2JQ#I`8P%`._LW$.T0[-MNSL^OJB7..U02E4*",84@!
MMOOOOW?7[M2HHZ7#COAJ_70V0[=232ET4K*-+=3;:UWN`]TZDV&P&:UZ=BJU
M:(>"L4<T&V2?@E?M7(I>O*]`AU=D[F`M#AN"CN33+<"^,3[(=KOLIBVJ23.T
M4BOTA.BFBU(^G0;2+DLD2<T\CXB,?-&"P6ASDEPJHU40%JP>M2/F9$7JBB^J
M>4>XE2G1L?&G!MJDK++V''$7(R5P010L+D)6SQY'AVY(A()-FUBYQDS@;*NA
M`,47$O')M)9V@T227<J)$*0*A;G[64)B5@'XA\7I1PNX>X0I"<DL!/4Y5BE+
M0\C"@B1N5HUJ;^'E&#NBM8]=J#EFE"'CDV4@HL\0*F[<N%U:;F-)-0$J4X%+
MP#AC'J\,K2<9U:HO:T]GI.!7B&2Z"D;)6FL5RFV1ZAU.%`.]GZO4(QD[5.!S
MKD9D.<15,=0\6@--6C%*E+Y=(>K80[.KM[OJCOM]0!U6XN&S%*KQ\'V`W]GL
M#LU#BGH4*KZ#<1';I#]`?]H-2E[DJLI)J([ATCMM['8`^@![-MN_4,SNDHOT
M9E[)=OL#L/Z``&IA(X"B5*_'J90[R^QZ/K]^^H9W=*57J5`@``=)>S^K];8`
MVV#4I-34HO4J8=.W9L'?^CZ-@$>WZ^H(O@$*`=O^T&B+]D4(F8!^P.W]K_MA
MHB^N"].RA`#H,'5N(`(>GL'L[/J:C@BQ#*;AL)`V_K_HAJ"+ZFF"HB.VVWHV
M[-_1V@&B+&.3M'8``/1OV=G;^B`Z(OP5'MW[.SO[_P"IV=G?JM&\^8=BB$HH
MQ$X))"@'Z=ZP<$>C8#>+TCT"0>P-^L0VWU(XG,H%5O049Y?.85(OW*JU/6?5
M%C8,>UBPN:SDC%UCBZL%QM%RLXTF^/FE+LJF.T[U69A=U.14@>%3>`Z;F=E*
M[417HC(=FU*&J?J$QKQ%HE@1R,PKF`ZM,UE5ID$UQ(^I<0I727F'0JL5<EY1
M201;1,5:XID5NP=J"1F\5*95L)G!U%#3MRM-<%$$[%MGF$.)M.F+7DR1@<90
MTC/6TF0K/:K)=SIQK:Y0%^@+6XL[0;%:E*[3I)MDUM%.Y`\<E'D<RQ&A7I55
M/!+JOE8VKCL^[[ZBF%S3P:XF9887J)@ODIQU9;6G+%R99V;*OV^5<U"03M<9
M8Z\^C96U,%*;#-9'($DX32:*LX=M)2*WKC!XD[<-5Z$T;2:MW[4J0IPLZXWK
M,=$P#,%Q80<3%PD>9X<%G9F4.P;QK07:P))`L[%NV+XI^@O4?<>D.X`V*0@$
MU.U>_A?4#^J/]?117SP?K?HCHB]$D0\0G=]L'I'1%R3]`?\`NWU8XJIBK-^/
MT`>3POB=-,@`4U#KRJRH@(%23]13ZC"/=OL/9KH>GR5LXF8X1M\@6%F^F=\H
MI_PB`<>%%1R70S0]L93L*!Q+VJ.%S^GM`1`/1K)@MB[5<2J1Q"15I?)BD:!A
MQZ&1!Z7KHOV[Y4N^Y>HO;X`"'9[.K66;,2:XJH(\HJ.A-Z6$+N79,>K<=O9W
M'V-^SN'46.`IF4H:2,%NFU1<+>V!`$TP#]45_2R@`CZ0'M,'V-3R7#2</NP4
M<1A3WEFFKD.VV%ZY\8P`&Z*0B4H[#W!T=1Q'?ZVJ)GJ,=B@6EHJ5^O$9M"^'
M'QY4Q_M]BI";LVW,8O4L;?ZHZAGKCN51K0YJU:XR"^_2()`/9LF78^P]O:<=
MU-_LAJ(>%`LZ%KR1:@*%4."AS@/VQC&,(_\`QO1JH'-`QVJ6AV46V?P)%D$W
M)4@'VH%-L`;^CV`[.W46R"N%$+''8%I@ARCV>'M]@.SV>XO9JNV3'`XJ38MW
M`4H9Z13:E3$J!#%5>+`':F@!NPA1#L%58WM2_5[1[M2R29NR-BBGCE")(>IQ
ML<@`I-11*5)(``HII;>&D7O_`$LH%#81[]M_3J=\M&",;*(JBI;R?Y2YKKHC
MF"&]44N-\M\9"R=#<2$'!.\GV!_8KT#!G[M`D@XL<@1@L]6(0II!RFLHXZQ\
M+IPXTET@)S@"I.(PQ-3X\.M5_6*;ON"=6O\`!J:Q,[Q2W5NN&K-8L31#FL)1
M26,)5W2K%%65]?I.S3]^B'T^'NK>:LYR"HC5P(<6[5M'M0<&`P&VJ,8^V+<K
MF.+12F6H-0:U%=HK@H%V:NT`^'[NC%-R'EG2)BUM"O7"D1K!MA6`PQ8$EZ,[
M(@)_^4SW'*];1822!&N37"RZ"D8Y<`<$S"MZPJ<!3VI-MG/I1P`#`TX>-P_&
MZ/?3BC>,:U_DZEI+EY=*;*K(4^E6_&C<Q\"QN$IA&7QBM*5U*3%Q*R-DRM%1
M32<8$'([J2.S]1=JF,=L07!U%%#@B4(/L:#*PM\S*<,/"ZG3T*(FQJ0?.KM]
M[J2/L_EVV)U4HRMT[(-2K:B&-*MC^462J#Z+];DHF1R9*S-V:R4(\3F6TE(R
M&0?&%H50B3Y5,QG:IQ*AT3.LZ1B.-S1V`-GRJGI^-LW[]R"85J1O^!2_H7&A
MH@OQ,9VNPGE2\8*U=8F.4C'5GJREHF[(E2B0[U1U`6".62BHA2J*"M'O#/&C
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M3&E*>3'WE.%E%%26#9,0`>P>SZO;^CJ\+SL*I+825>`=EB);[E#MV[Q`OL^Q
M];4C;@9LJB6.PKTA:7W&+_P?Z)0_VM5.)7H"@13PK[[C@/\`XL?_`(H?[6IA
M(T#M4*`5P"^>XQ0WV3$/L?[G9J3/C4%*;BM@U;'0VW3-MV!ML(]G<.X]OH^I
MJ1P!4:I0H1[1Z``8@%./]<?9#8-M@[-6KVN:,%.QC2,5D&K1T0ZTB@<FP?5#
MLW]CNWU1$K@IS$W=M2XHT(B66,N*'AF;LW3C[40$!(D?80[MNT=3BY+^SO4.
M$.E;2R)+DC(UHD0=O5S*&V]'B&W[?J[[_7U6A?'FI\92.STH=B;QK&G`X]1#
M;[B/:78>_?;N'NU?D,<!2F*IK?!"=0%/X?<`;B`#M[/:/HU:N;3!5&><L]O%
M%#;V@;CML.P=@=WV?T-6[B*X*H]N9M-Z=6JJE`@,'(!TB/203;;![`_4VWU0
M>\L."G`H*!.:R;`4!;+%`R*@!MV;@(#W=^PC]34W$+FG-M1)R6KXLW`G(F`H
MGV,!BA[78=]@#L[1'5D9"PY3O57*"%^FK`OM0\/;M`!`0[>\`WVV]C4I?FVJ
M+00$IFS`3=!2$W,;8`*7<1-OV``!L/L?H:I/D`44O(Z)!D!1,4#NC!MN``(-
MRCL`E3$`_5=N\?1Z-6[WYCX%#:4H2)(H%!1<1]MMT$`-SJ#O]7O*`]XCZ!U1
M<_<%6;'ACM7[/XCCIZMP('VJ8;]!1]MVB/9N;;TCJFJC6ANQ9C=N'9V?7[/T
M-NSL[=%,M\S1[.PO3N/U.X1$.\/8U1EVA0*W(I@`"78`W^OM_4U2KN4%X)H`
M94OI#LW[>_Z_9M_[VB+;R!-D$B%[/:"/U>TVP_9#4*@(M%X(>G<>ST=/?]D`
MU4K1E!O1?02V'[/V>WZP;:D1>_JPF`-B]H^D.T?J[[!J&8!%ZI1XB(B8!`O9
MZ-@W`._<`'OT+O&BV9D2*`7M_3"E`-_[?;;8!'8=C!MV:`]*+"<LRF#QB@'I
M\0.GMZMOMQ[/3Z?JZ%%A>`7V"C_[OJ!IF"+]@D`!Z/T/]G3!%D()%ZN[O[/1
M['H[-A[=1=V?"$7LHCL(>UW`?L[=W=V=_LZES(L8Z/<.VX?6[]_LAW:`UVHL
M8Q#=P%`/JB'=ML/;W;:F1?GH-W;AL/\`L?8T1?@43".^QA^MW?8WTJB^>`/]
MJ;^I_M:A4(LA`G2(E4`13/V"`]NQO0/U._3#:B^*M!(;M*!BCN)#"&Y1*.X]
M@=/9MH"B]BM^A`3=(;G]`=W:4=@#8`VWU%%AB@8?[$V^_P!3;M^Q[.H@5-$1
MX`^DHC]?_<TV;$2@CP\!%HL(!LBZ45$H=YO"`#]/5L(!U;;:;=J*GV<\MZ[7
MNNXSA,@9-QS)!@]WDZ,QJTB:?=&\5+TS)LE<[%)DR`8;:UF0MB4_+0P)+Q#E
MJU:H1S@Y2*J.4R(4>$=Y&U39NA;V&\ON^U^,;E2NV#+?.1-YJN4X][=<-NP3
MG[0RQY&XUL-`MZ\#+LQ/AUI'1:<M%LFK8'3B?V>/.DY1$\<A'0H56KE/*F>D
MKWJ->S:X<N:ZAAA2@QTY$RT-$14C2J2E5,K*R#ZM2IY:-0S3,-6U@EACBD5>
M2S1([L5Q*54L[6NV`U405^HGR[HO%L%@/%-=B7]K1-R@NV2LL7VNQ36!AY+!
M\JE%3<SCW+TE/RLY/7-.?>TNJQY&+I:0)-)QI_&`!034+!\1813%I^[[^/4%
M$G!6^^`$H4Y%A_3Q,*I5AW,)C"/4;J';<>H1[1'MWTKT;%(DZHT.B<Q%"#N4
MPEW,'M1V]CL[]3(O+P@_M"C]@NB+T22_3";%`/;!W=(:$T1<BW1]?^IJPS*K
MBK`,$?*%\B5!]SOEQ]SOBE!^J?%WYL'N3ZOZJ7P?4_C5_P"E/N;T;>#Z]_=7
M1^J^WWUNMAQ_5X\O&IPQLX5-GAQIUXK&2Y>(ZN3:?PJ^\G12^4[W&D_I%^'X
M0]?J_P`T/K]'ZOO_`'1X/L]&KR;UB@KZQ_8_>5)F3'S/RDTG^43K_P#7K_9?
MZ+6_</?OV=.K7\__`*[^R5?L_B_E+=Q/RC^)[3Y</^RGX_?_`&/K'9O[&VHN
MX]/Z[^Q4.S^+^4O>4^4?I'K^<5Z/U;YJGA^C_@?['_8U*WCT_KO[)1[/XOY2
M3H_*)N/\NO\`V6^KO'OU'\]_KO[)4Y,M/B_E+\&^43?_`->F^W_5<W^QMV;^
MQI^>_P!=_9*+,N7XOY2_8?*)V?R[?]EO?_W]0'&K_7?V2F[-/B_E(_RB;_\`
MKW[_`/JM^Q_7U<#UB@^G_L53[&;XOY70MXC\H_N>;;Y?.G8>_P":GX?</L_I
MFVI#QZ_U_P#8J)R>#\I:+_*)O_Z]O_!^:UO_`._JLSUBN'K']BJ?8K\3\I.9
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MIHC_`"B;G_EX[_3\UOV1[]O[+V?JZA_O&;^O_L569EI\7\I??\HG_P!O;_LM
MZE_WC_7_`-BINS^+^4OI?E$W#^7;[8/M?FM[_8_WVH.X]/Z_W>"G9_%_*3J,
M_E-Z&NWSC=O#2Z>KYHOB[;%VZNOMW]CJ[=N_0<?+_7[/]31.S^+^4D?-_*3[
MO*^)\O/7N3_10\?[3_QOJW]S^)[.C./E_K]O^I4KLM?B;/QEH7?RB^.KO\N^
M^_;O\UGV?[+H]KO];TZG;ZQE_K_<X*H]C\3\I>2/RB=9=OEW^V#N^:UOZ.[J
MU*_CU_K_`.Q4[<GXGY2W[GY2/5B;_+YML/V_S4MNX>[I]MO]?5%O'XH^FKA_
MHE._+E^+M_&2>#Y1-O\`U[?]EK;O]'U-5W>L5_K_`.Q4&9:?%_*1_E$_^WM_
MV6]2_G_]?_8J?L_B_E(_RB?_`&]?^RWJ/Y__`%_]BI3E_$_*7X_RB?\`V]?^
MRWJI_O'_`*C^Q5'L?B?E+*:_*+UAM\O7>'ZG\UG?O#OZNS_=U3D]8_UWN\%5
MF9:?%_*2Q8?*5T^U^<-]GYIG1Z>[Q=6;N-7^L_LE4[/XOY265=^5#QY#P_G#
M[^YCCJ]7^9]XG3TAOU>L^UZ/9Z?;[=VHQ<:G];[G"4#E_%_*7C+?*?NUZOG$
M?M%#;QOF@='3MV='A?V/L;^VW[]4_P`]Q1]-7P<).S7XOY23)_E+\4O\OWI_
MT2=_L[=F^LM!ZQ44]8_L>GPJ@_)F^)^4MTG\IW@FV^<-ML/^B'T=WU>W?V?J
M:JR^LU_K_P"P48\F;XOY2_)/E.W#Z0W_`(/S0_ZF^L8[C9OZ[^R5;L_B_E+>
ML/E1\9+I^<?]L/ZE\SSJ^QXG9^CJE)QJX\7=_HNE1&7\7WTZZ7RM>&A]*#;8
MNVWS)?$_J^V^MOJF.-7^M_LE$Y<?-]]9LG\KGJ).KYT&W;^V/F0[?:^CPO;_
M`*.J%QQ=^?W>']Y1;E_%]])]K\K'4&WSFO3]K\RK?N'NZ]43Q.'_`%GY'2IN
MSX/?2R@_E>\<W1\Z'?H/OX?S'/%VW-^I>L>UZO9V[=2'B?C_`)"AV?![Z4;7
MY8O$[/G5?;_]1/?T?;=?9O[.J3\]?C_D*I'2N&7WZK\K?+%ZP??YUV_4&_B_
M,3ZN[T;>TZ/8V[-M2=O\?\E5UL$OED\,NWSK>X/]`_;['5Z-.W^/^2BSTOEE
M]K]+#N_L?F%_[.J?:J?I/R5#"JVS?Y:/:[?.T]/VOS!-^_\`L>K4CLWX_NY5
M##[JK8F^6G_K=?\`8!ZNX?ZFI.U^-^2F"_"/RT^('TM_L?,!W]'=OV:'-^-[
MR8>#WUG/?EJ[-_G>?:_V?_=_;>C^T[-M.UX?>3#P>^M9_EI_ZVW_`&`=1[7X
MWO)AX/?7T/EIW#Z6W>'^@%_4T.:GQOR4P\"S4/EJ]'SN.X>_Y@'L^CKU)VO#
M[R8++-\M>X_2\_\`!_[OS;N]&W9ICX?>4</![ZQQ^6K</I=_;!W?]W]_\G;T
MZ=KP^\F'@]]91_EKZE/I>_J?;O\`]WWM]K_9^CZ^W;OJ89J?&_)4,/![ZU?^
M6G8?I;]__4!V]/L_U-2]KP^\B_'^6G_K=?\`8!U/VO#L\"8>#WUZH?+3U!M\
M[KT=WS`-_L;]FCLWA_)3"N[WUFG^6OL^EYW>G_N_?ZGU=28^'WDP\'OK\$^6
MO;_]+C__`)^[?8WT[7A]Y,/NJL57Y:NS?YVO<'?\P#?N'V/ZNHC-X?>3#[JK
M%_RT;_\`Z6__`&`]OZG9J;M?C?DIAX/?0'RT[?\`Z6OV/F!;:E-?QO>4</![
MZ/\`+3_UMO\`L!:ACX?>3#P>^C_+3_UMO^P%ICX?>3#P>^LY3Y:O5R?2[V_W
M_P`P#;^R^UV]MTZ=KP^\H8?=5?A3Y:O`3^ESM[7;Z`'3Z?8]M^CJ?M4^-^2F
M'@]]8O\`EI_ZVW_8"T9FS'SO>4</![Z/\M/_`%MO^P#IVOQO>4,/![ZVZ/RU
M^HE^EYT]:WVO_=^]'VH[]_Z9]?\`J:=K\;\E,/![ZU8?+3V?2V]/VOS`M^_T
M^G;3M?C?DIAX/?64U^6KQ2=/SM]]_P"R_P"[_P!_L>)[70YJ;_R4P\'OK?&^
M6WPA^E[MU%__`->^WH[]NWZWHT;F_&]RB8>!8`_+9NK]+ON]/_=][=P=_P!7
M4[\V7X_Y*84_\5^V/RV;GZ?G>?:?V/\`W?6_=_\`2>C5#M>'WE'#P>^@WRV>
MVV^=MW__`,3_`-WSMWCW=6HC-7XWO*&'@]]8!_EKW[?G7?\`@?\`=_;?U.S0
MYJ_&]Y,/![Z_3;Y:_$)M\ZW?K+MM_P!WYOO_`.'[7]'LU'M?C>\AIX/?7,A_
2RQ__`%/_`/X+JSQ\*J>)?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tpg56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpg56.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!<@)D`P$1``(1`0,1`?_$`2$``0`!!0$!`0$!````
M```````&`P0%!P@)`@$*"P$!``(#`0$!`0$```````````,$`0(%!@<("0H0
M```&`0$#`PH($!(3#04(`P$"`P0%!@<`$1(((1,4,4'3E-055187"5%AD=$B
MTE36<3)"4I(CDR65U396EI<8&8&QP3-3)$1D=*0U129&)S=76/!R0V-S-&5U
MA;6&MD<X2'C("AJA8N*$9G9WA[<HB)BXHK+%9SF"PH/#Q.3&:+.E21$``0(#
M!`,)!PT+!PL#!`,!`0`"$0,$(1(%!C$3!T%1D=$B4M*3%&&AX3*2%0AQ@;%"
M(S-3TU245187\,%B<K)#<S1$-46"HL*C=(08\8.S)+3$U"5U-E9D1D=CPX8)
MQ28WI/_:``P#`0`"$0,1`#\`_OXT1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$7@/YUZSW*/XBL(5NN72T59C8*1',WA8&9D(Y(59&]R<>=Z=LT<H)+N$D3!
ML$W*(%`-NS7[Y]%+#,&G[.\<Q+$:*EJI]/7/<W6RV/,&4K'W8N:2`3O;\5_'
M/_\`8GCF9Z3;9E3`L$Q3$,/I*S"9;']GGS98C,KYTLO+6/:US@(0)W`!&"Y2
MA\2Y9G\>RN08G/\`D!XA5S9N-<(%.R2P3D%%XW96$:C:>C#*[75:LTY!=[7J
MQ0`6+I=(/9`J79]5K,VY3H,P2LOU>7\/9,JO-O9YIDR]5-?6.E=HD7KG)G29
M<W72VGWUC7FRX5^><-V:[0\7R949QP[.6,S9=!Y[-93BJG:^1*PV7/-'57-=
MRZ:JJ)'9ITP>\37RQRM8V&ML^%MF-6RCBH9OS)+DB[W:L:6)"RSKIF;O[6H>
MOS7?6%=14TN5:)?M+`!>:6337042Y1.4X"'I,A'"<R3!+Q?`\&DNFT$BLDF3
M*:[W*=,FR[DQLR6")C'2HWFDM<':`08^'VP2LPY&DZ_+6:\SU+*?&*K#*EM5
M43&>[TTJFG:V0^5/<'2IC*@"Z\-?+<S2X.!']3^$G+AYAC$3MVNJY=.L84%R
MY<N%#K+N'"]4B55EUE5!,=5550PF,8PB)A$1'7\M,[2Y<G.>+RI30V4W$ZH-
M`$``)\P``"P`"P`:%_H.V5SIU3LPRW45#W3*B9@.'N<YQ)<YSJ227.<3:222
M23:3:5L_7F%[Q-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%
MJ_-[EPSPOEYVT76:NVN+[^Y:N6ZAT5V[A"J2RJ*Z"J8E.DLBH4#%,`@)3``A
MKU&2)<N=G3"),YH=*?BE*'-(B"#/E@@@V$$6$;H7@-K$^=2[+,RU-,]TNHEY
M?Q%S'-)#FN;23BUS2+000""+01$+^9&*QKE^7X?(7.T5G;(#YLG1\A6FZUQ.
MSRW?.K>+<S.PM.D.;-*<\]K-J>UYPU6=`&\T>%*0P""I!U_3*JS+E"DV@3\B
MU>!8>R8:ZDD4TXR)=R?KI<J94-C<@V=(;-8]K(PF2R2#%K@OX.8;L_VDXKL=
MI-K&'9NQF;3^;<1J:VF%5.UM)V:?/IZ*9`SKTRFJGT\R4^:!&3.#6N!$QI4N
MEL67!QDV"H-4X@<S=%99#5I&1YBPR+\$(.)BZ.SR-8;K"GAY=T+F,BZP#P3M
MG"2:I%6Z8B<Q5?8<FDS3@\O+,_'L5R_@VM?AXJ:.7*8R,V8^I=22J:9K)8@]
M\[5P>PEI:YW)!9RO1XGLXS)-SY19/R]G/,_9Y>,FBQ*=439MV1)E43,1J:V0
M9,YUZ7*I1/+I<QK7!TMG+<)G(ZN\V>;(M=XNL]8UO%QM5F)3:%+LVH3\Q(/D
M5TD;M5@BII)FZ>NT6JLE#NDU@`!$Y"+;HCU0U\I])89=Q'9'@.9,#HZ6F=65
M\MSM5+8T@FFGWY9<UK2X,F-+=XEL0OT3Z"+<ZX'Z1V<,C9LQ/$*\89A,YC.T
M3YDP.:VNI=5.#'S'M89LEP>(<H-?=)TA>\6OPBOZ[)HB:(FB)HB:(FB)HBT+
MGG.K/!<37Y5Y6W=C+/R3J.(BTD$(\S8S9ITH53G7;N`4*</8[``!`==O!<%?
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M<0`=@#M#9F1)KGAKJIC6DZ;A,.[I04I)M<(>HN%V7G^J4[6.W4X8[HT63.9-
M1)?(L`"B:B9A(HFH0:Z4Q#IG`0$!Y0$-=Z7LHJ'_`+=+'^;=TE9&&D^W'`5G
M/O[]-_BV6_[8D#[W]3_9!4_+Y75.Z2V\UOYXX$^_OTW^+9;_`+8D#[WM/L@J
M?E\KJG=)/-;^>.!/O[]-_BV6_P"V)`^][3[(*GY?*ZIW23S6_GC@3[^_3?XM
MEO\`MB0/O>T^R"I^7RNJ=TD\UOYXX$^_OTW^+9;_`+8D#[WM/L@J?E\KJG=)
M/-;^>.!/O[]-_BV6_P"V)`^][3[(*GY?*ZIW23S6_GC@3[^_3?XMEO\`MB0/
MO>T^R"I^7RNJ=TD\UOYXX$^_OTW^+9;_`+8D#[WM/L@J?E\KJG=)/-;^>.!/
MO[]-_BV6_P"V)`^][3[(*GY?*ZIW23S6_GC@3[^_3?XMEO\`MB0/O>T^R"I^
M7RNJ=TD\UOYXX$^_OTW^+9;_`+8D#[WM/L@J?E\KJG=)/-;^>.!/O[]-_BV6
M_P"V)`^][3[(*GY?*ZIW23S6_GC@3[^_3?XMEO\`MB0/O>T^R"I^7RNJ=TD\
MUOYXX$^_OTW^+9;_`+8D#[WM/L@J?E\KJG=)/-;^>.!/O[]-_BV6_P"V)`^]
M[3[(*GY?*ZIW23S6_GC@3[^_3?XMEO\`MB0/O>T^R"I^7RNJ=TD\UOYXX$^_
MOTW^+9;_`+8D#[WM/L@J?E\KJG=)/-;^>.!/O[]-_BV6_P"V)`^][3[(*GY?
M*ZIW23S6_GC@3[^_3?XMEO\`MB0/O>T^R"I^7RNJ=TD\UOYXX$^_OTW^+9;_
M`+8D#[WM/L@J?E\KJG=)/-;^>.!/O[]-_BV6_P"V)`^][3[(*GY?*ZIW23S6
M_GC@3[^_3?XMEO\`MB0/O>T^R"I^7RNJ=TD\UOYXX$^_OTW^+9;_`+8D#[WM
M/L@J?E\KJG=)/-;^>.!:,R=Q)\-7G#+/7929M\YPI9PJ34(3'KJ_O6$[BJS(
MIOCS,:WF;5',68U&5+-.5`*X7`$2)@'L53"4H?9=F&:,P;&:2HPF;12L9RC6
MS;]0)4654LE@EN+&N);-:6`1982?;MMC^*_2N]#D;?:BBSA@.+3<-S]A--JZ
M9SFWZ68&S'3F-F-`ULMPF.)$Z69ET&V2^`ARQD['G%A@"8[TVI"WL&MGC+'5
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M6RY+A+M)#P8K]>;+_0P](7TAQ0XQM[Q*LPK)U.73)4A[9?;YFN#+\P2`T2Z=
M\P,8'SJH.J.0T.D/:`1E8_\`UE?"U'CXZETKA.RI-4^HQT?6*O+SN2JC$S4G
M`0+)"+BGTK&(0,DBP?N6;4AE4BKJ@4XC[+K!^7<0V,XSC-?/Q?$,0IF5]5.?
M.F-9*>6"9-<7O#27`W0YQAW%_:O+^2)&6\`H<O4$TFAH*.332[_*?JY$MLIE
MYP#0YUUHO$-`)B8#0KO_`&G_`!Y_$[O_`-MJK^]35/[!ZWZ2D]2[IKL>8G_"
M#@/&G^T_X\_B=W_[;57]ZFGV#UOTE)ZEW33S$_X0<!XT_P!I_P`>?Q.[_P#;
M:J_O4T^P>M^DI/4NZ:>8G_"#@/&G^T_X\_B=W_[;57]ZFGV#UOTE)ZEW33S$
M_P"$'`>-/]I_QY_$[O\`]MJK^]33[!ZWZ2D]2[IIYB?\(.`\:?[3_CS^)W?_
M`+;57]ZFGV#UOTE)ZEW33S$_X0<!XT_VG_'G\3N__;:J_O4T^P>M^DI/4NZ:
M>8G_``@X#QI_M/\`CS^)W?\`[;57]ZFGV#UOTE)ZEW33S$_X0<!XT_VG_'G\
M3N__`&VJO[U-/L'K?I*3U+NFGF)_P@X#QI_M/^//XG=_^VU5_>II]@];])2>
MI=TT\Q/^$'`>-/\`:?\`'G\3N_\`VVJO[U-/L'K?I*3U+NFGF)_P@X#QI_M/
M^//XG=_^VU5_>II]@];])2>I=TT\Q/\`A!P'C3_:?\>?Q.[_`/;:J_O4T^P>
MM^DI/4NZ:>8G_"#@/&G^T_X\_B=W_P"VU5_>II]@];])2>I=TT\Q/^$'`>-/
M]I_QY_$[O_VVJO[U-/L'K?I*3U+NFGF)_P`(.`\:?[3_`(\_B=W_`.VU5_>I
MI]@];])2>I=TT\Q/^$'`>-/]I_QY_$[O_P!MJK^]33[!ZWZ2D]2[IIYB?\(.
M`\:?[3_CS^)W?_MM5?WJ:?8/6_24GJ7=-/,3_A!P'C3_`&G_`!Y_$[O_`-MJ
MK^]33[!ZWZ2D]2[IIYB?\(.`\:?[3_CS^)W?_MM5?WJ:?8/6_24GJ7=-/,3_
M`(0<!XT_VG_'G\3N_P#VVJO[U-/L'K?I*3U+NFGF)_P@X#QJQE/]97PU=XR1
MI=OX2LGQ52M[!Y5[1*1&3ZJ_E8VO3[=2)FG\:Q-7&8/'[..=J*(I<ZGSBA0+
MO!MVZN8?L9QC!J^1B^'XC3.KZ2<R=+#Y3[IF2G![`[E>*7-`/<7'S#D>FS+@
M%=ES$9A\WXA1SJ:;<Y+M7/ENE/NNMNNNN,'0,#`P*BT=CP,Q8_=7;@+X@U.(
MC%T=3)ZG3>,$5$Z]G.@TN?FS3L[4[5C)TDTE)F&=3;P7!G39`"N7&\=!,2E`
MVOU5E?;!E*KQ)E#M2PN3@N9WUDJH;4F+Z*=4RI8E2Y[)\3J9C9;;@;,)`;`.
M>28+^)FW;T(MONRFAF5.R?$J['\BR\.J*/LK`&UTFAJ9YJ9],9+!<JY3YSC-
M<9`$PS.4*=D`588T3XY>("V+0M+ELAKRE>;3<).3[M4E*B*BWDT8V)L8V*Q'
M:Q*,;+*LHAN@N8QSRQT&W-D`Q2B77M<UU&PC9O@AQ3,+,,E8?-,N<QGO[IVK
M+YDHRY9<^]*:Y[WMT4X<^\X@D%?F[9[3>EYMNS1YCR?-QR;BU,)U--G?JDNE
MUPE2:@3Y]V4&3W,DRI;[75;F2[C0X-+5Z-8?L^.^$JVS.0K/E"Q<3^?;166-
M%N$G!.F["E5^#@E(LC:,0GI)FJ^LTFU&$;H@],8XJ)HCO$3$=IOXO>E!_P#L
M>V5S),C(6SS"F5.7Z*OFSM52O#0R:=8'N?/<#(%YTQY$FG;,:TDQFB`"_P!"
MGH<__K,VG9/KZK:AM3S!/J,_XIA4BDF3ZEI<PR)8DF6R7*LJ9A:V3*::FI?+
M<YK1"2"7%='_`'RRO_P1SWV51GTKU^.O\>>#?^-5GSR5\2OWS_@XQ7Z?I?FT
MSXQ/OEE?_@CGOLJC/I7I_CSP;_QJL^>2OB4_P<8K]/TOS:9\8GWRRO\`\$<]
M]E49]*]/\>>#?^-5GSR5\2G^#C%?I^E^;3/C$^^65_\`@CGOLJC/I7I_CSP;
M_P`:K/GDKXE/\'&*_3]+\VF?&)]\LK_\$<]]E49]*]/\>>#?^-5GSR5\2G^#
MC%?I^E^;3/C$^^65_P#@CGOLJC/I7I_CSP;_`,:K/GDKXE/\'&*_3]+\VF?&
M*<?=[0ODU\H_DTF>8\=_$OO3XQ1_/\[WD[]=\.E=[^:YK<^5\WN[VWEV[->M
M_P`9&%_4/Z\^8*K4^=NPZGM,N]'4:_67]5"$.3=A&-L=Q>9_PN8C]<?JAYYI
M];YM[9K>SS+L-=J=7=UD8QY5Z,(607H#K]HK\JKSZ\X']2..O^<\K_:C7N<C
M?K51^C;^4K--XQ]1>$W$_=+72*=2'5/EY2%?V#+M$J3]Q"#5"3#B$G#2A9%C
M&N;NDI6&3QR#8FXLZ$B:8EY3``CK[#@E-(J:B:VH:US&4[W"-Z$6P@3<Y1`W
M@NG3L8]Y#P"`TFV.D>I:N5;%Q09+@,8586ED0>7YGD_+,A/=\8B*G)1]BG#4
MNJ5_79$:.R=UN0G+'TEM&!)1@I,S.3"*:Q=Q0Y>Y*P2CFUK[S(4ID2@V!+0)
MLX6.%\AP#8%UUT3#2+0%9;32S,,1R+K8:1:[=MM@-,"MT.,UV)OF^(2?V<7N
M+;G.U&&QPA0)''TZW,6UTHTZQC\GUMX!\EP\NZ=F%X,@Q$\>BP%OO$(4ZBH<
MT8;*.&N+&0KI;7F9?$QIY+[I,MP]S(`LNGE%T=-@46I;J#`>Z@$F,1H,+#H]
M;3%1.A9FN-G:8\=7'-,;CA!#"&&+\N\D(*L.$LF6J_VF=AIUH[:.T&SMRT1+
M$M&:;>%%NH@YDB*'-\(0UBJPZGD.G"GIG3CVF<R`<[W-K&M(,18#:3%\8AL.
MZMIDEC2X-87<MPTGD@`$?<=Y9+B4RQDND9/&'J4_/0T*RQI6)P3LF](&I0EC
MLF4$Z6SL&37-ECW<^6C)D<)HN>](@X2V[PBF`\X73!Z"CJ:+65#&NF&<YMM^
M\YK95\MEW2&W]T7K#W="Q3RI;Y=YX!-X[\2`(P$+(^JOBBY'RI8IGB'='O3A
MJYHELS;`4@MKDL5QN)6)JL?HM:;SS)LDCDXB<**W25GBQ@8BD@(JJF#:`JJC
MH9,ND&J!$V7)<^Z)IFF]:ZZ?>[=``Y5M@67RI31+L\8-)A>O6Z?P?6TK7Z^>
M<D&@*?6O&G(C:_#E^E5F_&1=8(>"M$6?&-QLZ3&A75LV+C5RP>R4`5R;IQDG
M[0A02/L`Z8J6QA5'KIDZY)-)V=[F>_BULQC8O9[X"`Z')BTZ1H,-]1+O.=!M
MRZ2/&W"!:-.[N6*=Y?XA+)B^6PC#1MF.]91<4SR-FYQ8&D7/V*3H3^<8U0D(
MH^HD8ZJ<?.(*RCV1Z2W,V:'2@C[BIP$2+5</PF372ZF8]D'%QER;I+6AX:77
MH/(<6V-;`Q,7BS=&DJ0V:'DBTF#=R!A'=M[GKJFVRYE0,^R\&C89I2J%S!DV
MK1;.89TDV.Y>MTO%[.THU.O.(UF6_CD091ZBZ0%PN5JZ9%7W!4%/<#+L/H?-
M39I8W7]GEN)!?K`Y\PMONB=7JX"!@(@PT10RI6H#H"]=!W8@DPB=R'L+"N\U
MWR*PY3[O%9D;W^ZVR3X=IF:H\;$4=&4JJ&1;,1E8JRS>(%08-(^<$58UJA);
MKUHJU.H9R&\82R-PVE?B$RFF4YE4TMM0&O)?!VK;%KB-)+;'$MY)!`@LZEAG
M.8676`.@;;8"P^MIL73."+U:KV;,:UK;/HM>M9MMU3AZ])]Y#R%8@HR,KSAG
M`O'5?6=QK]9HJ^4,*Q5W!C`IL%0=@`'&Q2ED4O9Q((<'TS'%PO0<XET7`.@1
M&`L@/45><QK+EVV+`8[^FVU;ZURE"FB)HB_0'9RAR"'*`AUM$7EAQF87\4I]
M'+=79<S`6)V5O:VS5/8C%6-7E2E-P@;J32>`!WQY`!V`]=4->CPBL+F]G>>6
MW1W1O>M["MR)D1=.XN68QZ1X@4P#[,`]D&T!UZN4\/:K@T+):E64T1-$6Q,=
M8DR;EU[*QN,:1.W=]!1Z4K,MH)%!4\9'+NB,4'CLSAPW3217>JE1)[(1.H8"
M@`B(!JC6XE08:QKZ^<R4QY@TNC:81@(`[EOJ+1\QDL1>0`5G6/#WG.2JT]=F
M&);VZJ]7?3D98I1."<@>%D*P5N>RLY"+/N32"U>3=)G?`+;8T3-OJ[I0$0B?
MC6$2ZAE(^IDBHF!I:+PY0?XI!\7E0Y-MIL$5C6R@X-O"\>[OZ%^2_#]FV!K,
M#<9?&5I9UNT^+GBW)=&:N3SHW!)%>JEBXQD[<S#P]A1<IF:%(W$RP*%V!RAI
M+QG"9U0^EE5$LU$N]>%HNW/'B2`T78&-MB";+<2T.$1][3P+#6##V5:HXLC6
MSX\ME?<4^%C[)9DIB(<,!AZ]+2K."C9MP9P!$UHM[-OT69%D14)TD_-B('*8
M"RR<3PZI:QU//EO;->6MNF-YP!<6B&Z&@N@866Z%ELR6Z!:08JU9XLR1(QL?
M,,*18GL9*U&S7Z,>M&!G"3^E4Q^K%6RSM02,916)KTB@=%TH!=J9R#R"`".L
MNQ"A9,,I\U@F-F,ED$P@]XBQA[KA:-]#,8#`D1!`]<Z`JCW$^3(Z*"<>T6R(
M1)F%)E$WW>\RJ2L?DD[]+'[E`B!E5UR7%2+<%8`0ACKF1,`!MV;3,1H)DS4L
MG2S-B\0CNRH:P6\R(O;T4$QA,`1&WO:>#=5U(88RY$W&OX\E,9W>/O5LZ(%8
MJ3NN22$[81?;P-RP[$Z`*/S\X0Z:I4]XS=9-1-4"*)J%+JS%,-F4KZV74274
M<N-]X<+K8:;QW-\;X((B"$$R66EX<+HTF*B1ZM8TZ\XMBD+($K32QEJ#J;.C
MNL&]H.P<RA8%503`8DD,>S56YO=Y")FVCR;-6>T2#.%,'MUY9?#=VY$"]ZD2
M`MKS8W8\J$?65_1J%=,F61I3\?UJ3MMH?-Y!XT@X=-)5\NTBF:TC)N2E6502
M*@P8-SK*F,8`(F01'J:TJZREH)!JJV8V53@@%SM`),`/7-@6'/:P7GF`6?FL
M+Y;K;BU-9_&]OAW-(-72VM%_#N$%(8+>_P"]=365`0'I;6S2/RE@LVYY%T<?
ME9C`.W4,K%,-GB6Z3/E.;-O7(.\:X(O]0M%K@8$;JP)DLP(((.CUM/`OM[A/
M,4;9H*ER&+KXQMUF;*/*_6W=8E6\S*M6Y!4>+M6*K8BVY&$*(O-\"BQW3`XY
MH2F`,-Q7"WT[ZIE1)--+,'.#P6@[@)CN^UYWM8IK)=TNO"Z.ZJ4?AG+TL]ML
M9&8OO[V3H2(KW2-0JDT:1K!-TQP3EV`M"NVSI1$AE2(;@KJ()G5*04TSG+E^
M*8;+9+F3*B2)<XP8;[8/_%,8$;D=`,!&)`0S)8A%P@=%J_6F&LK/WR\8QQ_9
M7CYM7ZC:UT6K(JY4JW?GD7'TB:,X35,V%C;'\TU18&`XBX46`I0V@;=.Q3#F
M,$Q\Z6&%[V1)]M+!,QN_%@:2[>`362P(DB$2.#3P*:+<*O$:WL2516Q!;"69
M6(DY\L+MAS/"0T,^8Q<K(K[DJ9!JW824FW04YTY#`JL4H`(CJJ,Q8&Z0:D54
MO4!P;>Y4+S@2`+(DD`D0W`M=?)NWKPNJ%DPSEI1^RBPQQ<"2<A8Y^HMH]Q"N
MFKT+/58A*P62#=MG145HU_"0"Q7S@KD$039[5]O-%,8MHXIAH89FOE:MK&O)
MO`BX\W6N!&D.=R1"/*LTP6VLEPC>$(1]8Z%K,!`P`("`@(`("'*`@/*`AZ0A
MJ^MU^Z(FB)HB_!`!`0$`$!#8("&T!`>L(#R"&B+I7'/&AQ8X0Q]9*%AG+SNN
ML).*=-ZXULD3%76+I<PH0>C3529V5M()5U\D.TH"B`MR[XJ"B8X`.N!B.5\!
MQ:I;5UTB,[VQ8XRR]NZU]PB^T[L;=R,%4GT%%5/:^IE->6.#A$"QPT$=T;AT
MC?7A7DC(64,BY&M%JS5;;/=LER4DL6SV*X2:\K-.7J.ZB*9UUQ`B#5,B9022
M0*F@1,"@0A2[->^PF31X?3,HZ&6R52-'):T0`XSODVKM20QC`V6`&#1!1G7:
M4R_=$31$T1;#AL195L=$L64:_C:\SF-ZBLHA:+U$5>8D:M`JH(IN'82<PT:*
MM&Y(]NLF=V<3;C,BR0KBF"J6_2FXCA\BK903I\IE=,'(EE[0]VX(-)C:8PWX
M&$8&&AF2VO$MS@'G0(VJ\2PIEQ>\S6,D<=V=7(5<KTC;)ZG)LB&G(FLQ%42O
M4I./6P+;J<>PIJY))0X&'=:&`VSK:U.*8<*1M>9TOL;WAC7QY)<7ZL-!WR_D
MCNK&MEW0^\+A,(]V,/9L7P\POEF/(JH_QY:6::.-ZIF$ZCF-,BF.*[U(0<33
MK^DH<X$<5BQREFCVS5PF)@,N[(00`V\!<MQ/#GF#)TLDSWR;#^=EAQ?+[CFA
MKB0=P$IK99T.'C$>N-(]40*S)N'7/A6V2WH8:R0NSPU-25<RJ\9U25?M*%.P
MJBJ<W%6%TQ0<MVSR"!$RC\I#*`R0#GEQ31$#C$,:P@ND-[5(#JIH=*!>`9C7
M>*6@PB'>UYQL$38L:Z3R1>;%PB+=([BC##%62I1OC=Y'T6RNVF8K"]J>*G:<
M:J5MD*RQLQ&5Z0A:HNJ*:4J\9SLRU9J`0=PKA<I-[:!MD[\0H9;I[7S98=3,
M#YHC;+:6EP<\;@+6EP[@BMC,EB\"1%HB>X--JL:QCZ[W2]Q6+ZE5I>PY$G+&
M>H0]-C&Y5YV2M!'2S(\$U:B<A5)$KMNHF)-X`WB#RZWGUE+2TCJ^HF-91,9?
M+R>2&0C>)WH&*RY[6,,QQ@P",>XMS%X->*TV0CXI'`&24LADK#R[%K+B&3:J
MN*='*-T)&T,91RZ1@9&"CG+I-%RY;NU4FZYN:4$J@&*',^LV7^Q^<.V2.Q:P
M,O!T>6=#"`+P<0(@$`D6BQ1=II[FLOMN1A'N[RCC_ADX@HVRP%.>8CN!;/:;
ME-8\KL.W:LY!>7O5<C(V;GJHU7CGKMEW[B868:O%T3JD$C1<BVWFQW@F9CN#
MOD/J6U,O42Y39CB21"6XEK7F(!NES2T&&D0TK83Y):7!PN@1]8[JDSG@RXK&
MD71YES@B]I1N3)"K16/E^8B3JW&0NZ:BU/;P+)*5._>!944C':*<T"2I`V[V
MP0$8&YGR^Z9-EMJY1?(:\S-/($OQRXP@+NZ(Q"U[53Q(OB+8Q[D-/`M24/%6
M3,I6I6CXVH-LO=O;I/UW=>JT(]F))DWBU>CR#I^FT343CV;1R)43++F32YXY
M$P,*AR%-T:O$*&@IQ5UTZ7*IC"#GN#02=`$=)(M@+81.@%2/F,EMOO(#=\J=
M-^%OB/=8VG<PM\(9(5QG5WMCCK);2UMV#2">TYZ2.N#>5CC;LXR&I/3@G*&.
MU`D>.T7`IE`1"H<?P1M<S#754@5TP-+67A%P>(L@?%-\>);RMR*T[1(OB7?;
M?,("._HX=Q84W#_G`D_/U4^*;P6Q5;&9<SV.(-"+@ZAL2'@V5E)D=]R\RG3U
M(&20=$>@<4SD5`"[3[2A+YXPK4LJ!42M3,GZAIO6&=>+=6/P[P(NZ;-Y;:Z5
M`.O"!=='JZ(>JM@37!5Q95UQ56<W@'(,>_O!E2U",491RTM8#(59Y=U2Q\2U
MDEY,1+48]:1`#I$WFR8F+M$0`:<K-&79XF.E5DES)7CF)@WEAEI(AXY#=.E:
M"JIS$AX@-/##V5@Z!PH<2F5%:JACG"MYMZ]ZJDA>:8C$L6G/6BGQ,ZXK,I88
M1)X^:G?Q\?8&BK1;<`5$U4C;2[I1$)JS,.!X>)AK:J5+$J8);XD\AY:'!KH`
MP):01W%E]1(EQ+W`0,#W#I]A::M%8L%*L<Y4;7%.(.S5J3=0T]#.S('=1DHQ
M4%)VR<':K.&QE4%`$!$ASEV]01UTJ>HDU4AE33N#Y#VAS7#00=!M@5*UP<T.
M:8M*P6IEE-$31$T13+'V1;_B6W15_P`772S8\O$(?G(FV4^8>04XRVF*8Z1'
MK)1,ZS1<2`"K=7?06*&ZH0Q1$-5JRBH\1IG4=?*ESJ5^ECVAS3ZQW=XBT;A6
MKV,F-N3`"T[A7O/@/SH'$%Q6P*^'\X9!(XGH9H21:)P$3%U!CD1@UYGILE9V
MD&BS0E[6T7V*N!`"(+I#SI42F(<1_C[_`/L7V8YZRQ146<,MUU6_9-47*6JH
MVNY-)51<93IC@+\RFG@76:USFRIS0S\XQ?HWT;Z;(U)65%&V@IY6;@]\Z7/(
MBZ8QT-8&`\EDQIM<6B\]IB2;I764!)`JF5(P\H``;.3DY````/P-?QTKZ6X;
MS="_;E%47VW7:5*]<E=-=*5IO383AZ=6Z3BJJI9WN1+-78]_8*:ZMJ[QNSIL
M3(M(EHLA+QB4`*;YT90'1R+`4Q^4H[-?>,"DY7PG8G,S+7TV'.S!.QNKII<R
MIH7UCGM90R9K)+'-G2A3PF.+A-<'@%UK3!?',8FYAQ+:RS`**?7#!96$TU0]
MDBK;2M8Y]7-EOFN#I4PSXL:&F6"PD#QK5M:6P_%6DLK64*%'5`R!,!M:#<V+
M"0B#S[NZP]>7O*$BY<K*1EG!JQ=/Y-19,A%&8,C;QP3W@'Z+B6S'#LPMJ,OR
M<'D88Y@RZS#JZ7+F234/KY-,[$&S7N<957<EOJ*ITQK0Z0)!BX,O!>'H-H%=
M@CI&,S<4G8@''&W5U(][)HD-HYL]M$Z6UH$RFO/;(IVL<2V:9P@TN@5ICB,H
MT%4[;%3%.CHZ-I-NA^DP3:(G(^R1[9Y`.E:_,H!,1+I_'*.G*K))\HD5PJ=+
MINZ<0,`E#Y9MQRAA&6\R4V)Y7D2)&4\3I;U.V342ZJ6U].\TT]NNDOF2R]QE
MLJ',$Q[F:^#B'`@?1-D69L3QW`9^'Y@G3IV9*"HNSG39,RGF.9/:)\EVJFM9
M,#6A[I+7%C0[4Q:""">?-?%5]731%OC_`"8?^O7_`/@NOL/_`,`?_E__`/'K
MY?\`_-/_`.,?[ZOZ)M?V^7\DUY]><#^I''7_`#GE?[4:]SD;]:J/T;?RE9IO
M&/J+Q#XAI)W&4%JHWQW$Y':NK3"L)=E.4>3R1%U>*=)OP6NSNCPB"\S8DH%<
MJ8&0:\VKNKB/.$*!C:^MX2QKZHATYTDAA(+7B67$0Y`>ZQM[?,19H73IQ&9X
MQ:8;AA'N1.B*YYALQOY?(V-Z9C:-Q&U@[5B*+DE;%`89R':&:K%]?Y"K2E/;
MI0#JON:+5VR[$_2._2)&K9\0Y5B[2[-=>9AS9='.J:QT\S65!%UTZ6TQ#`X/
MY0=?=;9<,2W0IS)`EN?,OW@_=<!N1C;&)]18F&S!9&5>SSD6(I6*(LN$(S*E
M?J\>TPS;XEP:.H<PI$0#(,IEE$*K(,%^8`SR)C2I+(EY-B8%'6\S#Y+IM+1S
M)D]W:72G.)G,-KQ%QU4+P(C8YT0>ZLF4TN8PEW++2>4-T6V:?7*W#6[J_:#E
MBK6RF8U6N?#K0(RZ5&:J]:/&5GH%EI,Y/QC2(A95U)2]159+PQVKA-J\,FL@
M('(<@F$A.?.IFNU$^1,G"GJYI8\.=%T6O:TDD`!T8Q$18;"-^%S/%<TNNS'0
M()ML,-.[P+7KS,]PD?&&YS5*Q3.42&C>&^L7F&>5^1/<9F)SK7ZC/2J<=/OI
M-Y"+P]>F[7O-XEXS.1P0F\98%`VFN-PZG9<IY4V>VJ<ZH<PAPN`R'/:(M`#H
MN#;7@V;T%)J6B#07!Y+R#&P721H[H&F*^,'W:*L!LA9<NM)Q+7HNHQV3'DU(
MP6"++69WH%;L$O"N%RY:GG+FLW()&(AENFMF1#*G46*4VPI3%,Q*FF2=3A]-
M-GO?,,L-#IS7-BYH/O3>4R!(@3O).86W93"XQA[8$6CFBT*/Q>74KG@:OR*&
M!L</'+;)K^"R-6(Z@&R54,7D=0<A:(.^+4BC(2<I.*R<)(L$U5&XD,FN[7WU
M2%(8`E?0&GQ1[#53@TR0Z6XOU;YG*#7,OO@&P<'0CN`0"V,HLG'EN\6PQ@3N
M0B=&ZNQL<LL?V&@0DS6H7'KFOVZI,6*YZ=`M&U4F(,O3`-#(-'#!LX6K[5V[
M=$*R=I!S)SJE.F4XG#7GJQU7)JG2YSIHFRYA/+<2X.LMC$\H@"T&VR!T*I,,
MQLPAQ=>!W3;'?]53$E6K"7102K=?2Z#+)3['FX:-)T*>0:E8HS;3=;!T:828
ME!$KDFZN5$`(!MWDU7,^<8Q>^UMTVFUL8P/<C;#1&U:7G;YT0T[F\O@M1J9$
MG2!*K62(/IE&Q/44X")32>6!NJ1=O/.TR,RD<S3==,IR.C@9<AP`P&`>76>T
M3X@WWQ#;HY1L;S1;8.YH6;[]\Z(:=S>64:1T>P.^48,&3)23?+2<D=FT;M3R
M,DX*F1>1?F033,\?KD1(4ZRF\H8"``B(`&HW/>X`.)(:(")C`;PWAW%J23IW
M%>:U1-$31$T1<5\:&6V%4HQ\:LB-GUDOS7<=H+$37+#UI)R0RLBJD8#;KQ\Z
M0!)H(@`E$AU`Y2!MZV%4SID[7F(8PV=T[WJ;ZFD,+G7MP+S.K[([='G#[0WP
MY`VZ]G3L($2N@T*1ZM+9-$31%U'P[9FH^)J?Q%15RJK:[.,F8XK-9J]7ED9O
MQ:E9F'R#`V=4MDD*Y.5^;BV39E&G624;N"F,X3(0?8B(#Y_&\+J\2J:&92S#
M*$B>Y[WB[?#72W,Y(<US28F!!&B)4$Z6^8YA:87223ZT-VQ=.TSCFK+NLD\I
M4>!<F6&;XGYM]DF#IZ3J:Q5,Y6HM2K%!EL><^_.W=QG,P"T5+1ZR:A@CU"+`
MH*Z93#Y^JRE4-G_ZB[_4&,I&B4Y\&SFR9CWS!,@(@\H/8X0Y41"!4+J5U[D>
M(`VR.F!),?9!40DN(C"Y+SPXY28'8N);$D?@5A9H:,Q`O"9$DBX_QW"4:V<_
ME1U9U8VPLV*T>JXC&YV;<%"D1(*A1*)M668)BII*[#WWA+J75!8XS@Z4-9,=
M,9[B&1:3$!YO'=,%D29EQ[#H=>W;+3$6>RH%5KQ@V`KV6<8N,Q94F*K>\0PU
M-@KA8<?.WC:MSC',L!D=U%PE)0M;I]'0#B.ACG75Z2GSTHY44!/='>-=J*3%
MIT^FKQ2T[:F34N>YC9@!<TR'2@73+@!<"ZP0,&`"*W<R:2U]UMX.C".FR&G?
M6PZ!Q9TS$$?BQ:DOY>6L^).'S/\`C*(D).ID1B)FVWO+;RWTX[V,>O'FY7)N
MM*[DB"F^9H*QDMAQ#>U2K,N56)OJ!5M:V14UM/-<`^UK)<D,?`@#E-=XL-,(
MV+1\ATPNOP#7/:=.X!`^!;1MO&W@?QO9V6@U*U1$!$RO!+,0E'.R*5.):\/U
MEO%@O59;2SEVH0[>/1LR+:*7.7==@3E!,"ZY]-E3%^S&163);ISFUS73(Z34
MMEMEON@:3=)>-SNK1M--NW7D1Y=OXP$/8M6CL=YKP=AW)DCD*,NN;\F*PE.R
M2ICQ!:*BJ6M6,AY.M`D<2--4FWUU951>"J;]V\<OEFJW3)D0%)/D*MKK5N%8
MOB=`VBF2J2G#YLK66E]^7*9H?=#"^\\-`:"+K-)W%(^7-F,N$,;$B.[$`;NB
M-O>7QDO)O#AD*JY>K,#:;EC]A<<]QN>ZPP?8_=64$7$CC.5BK/373B/F6!&A
MF5VFUR-WNX*"S,I5`23#8F7-!08Y15--/G2Y4Y\JC-.\B8&V":"QX!:8QEM$
M6Z0ZR)TK+&3F.:X@.(9=-L-VP\"U_@[*>,*%ER#LM@.:%JCGA\M^-;"]JM,?
M*N6MON.*;!2W4F]A'$\Y6L+LDU+D4?/D5FJ+TI142;HA[#5S%L.KZS#72)'+
MJ16LFM#WB!8R<UX`==`:+K>2T@EN@DZ5M-8]TN#;77@;3N`@[RW,/$[C*#QF
M;&E>MN0GKZM8]X;*15,B.JBV!\\?XJSK:LK6*=;UZ3GG!(UA78RRIM8=F[<&
M!T#(B9^9(8`#E^8*^=7]OGRI(9,GU4Q\H/,`)U.R2UMX-M+BV+W-%EXFTJ/4
M/+[Y`M+B1'?:`+?6M5Q8>)/!,G:)UR#,6\QD_$^;\<Y1R[1L9OJ.S<2.39:%
MGJ]:O),\O$R1S8&,G$N"3CE@\CRR#:1V$2.=$3*:R,"Q>73L;&,JGJ9$V3)F
M31,,)0<US-<);8-((,L.:ZZ6VD`V!)F@#>:X$`F.C<C#@TZ%B<4<06':/,Q1
M9^]YDL$?C+B'QYG>HV:9KZ$K8<DMJ+05Z>K2Y9N-H,>FMUUP3+'*+.'R;6.,
M9-0-\`(:7$<%Q.KE.U,FE8^HHIE.]K7$-E&9,OWV\CEPMO`!I+K19:DR3,<#
M`-!<PM(WHF,=%JJ5_C!J;+$>"Z@\BIAI=*KFJC2&5+"@VZ4K+8,Q5D*9R3CJ
MM1#LBS<'#J(F;<\(=J<@B?O>V,*FSFRDQ.RS4OQ*KJ6.8:692S!*;&$*B=+;
M*F.<+;'-8VV/MG6:8Y-.XS'.]H6F'XQ$">\K*2S_`(2K^1\U7R%@*)D*+R?0
M[#`)T$<(OJ!49=W)YII%\*QO#!>TRII:1DJS$O@6EDE$N:?IHG!(=H;-Y>"X
MM/H:6CFOG2)E/.:[6:\3'@"1,EQED,$`'.;!A!BTD102IA8UI)!:=-Z)T$66
M;^XJD_Q658%>.,E<GK<JRXA&%/+BDTA7&#-]7S-G;.)L$4_.T6YJO*1V,UW5
M;!ZVWC23$@`?\<'9B3EVHAA.O9+O41?KH.)#H@EI$?&C-A-NGQ7:-""0[W*\
M!R(QM^[=M[B\^.IR!R`'4#7M%;31$T1-$31%8R<DQAXY]+2;E-I'1K59Z]<J
MB`$1;H$$YS#M$-IAV;"AU3&$`#E'60"XAK=)0")@-*\MKU:E,A7>7M`-2,D'
MBJ:3-`I"D4(P9I@W9F=&*`<Z\40(`J''EVCLZ@!KO4DDM`:-Q7I;;HNJP`-@
M`'H!LUV18%.OW6431$T1=RHYLQ98>%K&./9;(68\7Y-P76>(JK0D-C2$14B,
MOL\W3C6R1R<]=`M,06K0Z+A9Q&V!LY8/A?1B"`(`<3&(GY0X7B$G'ZBMER::
M?0U<RF>YTUULDR&EINLNF^Z$'2R'-NN)C#2:AE3!4.>&M=+>6DQW+MFB%N^.
MZNB5>)WAEA>*^\<34/D"]3S+)^`,F8RDZ0?$LA"2%-L=CX5F&&X$>_3FRN6%
MCC75R9#SRJ":/1V9@6$IMFYKBC`<=FY>E8%,DR6.D5DJ:'ZX.#VMJS.=R0T%
MI##8#&+K.ZH=1/-.)!`%UX,8Z0'WMZRQ2RT><*PK=.%^9P?8ZM/.KI3^%7A8
MPC@_(+>!1:OHL]1D<%S7$+C>SJ)N"JOZ2I:<1#,UUZJ8XE=.'!"D3*YY*]/D
MW%*7'F8K)F,%+-Q"JGSY9=$&^)[:>:W>?<G7)C1N`&)NK5M%-94":TBZ9CG.
M$=^]=([L'0*UMFWBFP/F9/)<HTR/G;%L["<2G&IFC%OB+5T2.LDUSB>0K00$
M!/S9;;$GQ\JT-5P93I%DGZ;F(D%DDP4/M3&[A6`8OA>HEND4E1*?0T4F;K'V
M2G4MZ\YK;AUD;]Z7`M@]H)@+5O*IYTJZ+K'`L8TQ.@MC'<MTV:+0MNN>-W@\
M&C\,N,XJ)S2PC^#C*O"GD/%]ED&$&Y@+2%*FVCSB4/&46*9QTO2)+("SQ>5Y
MV3E)DS]W&-$R=%WCB;G-RMF7M==73'4I?B=/5RYK07!S+[2*:,PDB8)<`R#6
M,NASCRE&*6IOS'DMC-:\$;T?%MW8:+`-U<CXDRK@C!7'IAOB"B<A6K(F+*WF
MQ7+-PD$\8R-0L<*T>6B=DU8..K4E/R*D^[:L'R)N>(NBFH<QB``;NT?1XCA^
M+8ME&IP:9)ER,0?2ZE@UH>UQ#&B\7!HN@D&R!5F9+G3:1TD@-F%D!;$:-]=9
M8SXRN%[&]:;XB4MMFOU/3Q%QF5P+ED#!KR?IQ++Q-7W'5FKE/>X?4NQ9>8HE
M9CZ.J=^/3VA5WCP>:3`H"<_GJ[+./5L\XB)<N34]IHG7)<\-?=I9<QKGB=<@
MV8XS!=Y)@!:=Q5IE+/F.UD`'7F6!T#!H(C>AI,=Y:6P=QCXUX?Z!Q@TF(;GM
M<S;>^5MX2+57J;*X_KV.LIWRG67$>0Y]C2U[#(^)$0&+;LZ3:-SJ/-YS&M1$
M><(W41Z>+9:KL8K,-JIAU<J7!E8QSQ,=,E2WMG2VE]T7SK6")Y-CG;A(,LVF
M?.?+<;`+'B,20""+86VCOE;??<8_"\OF3@.S0A()-U^&N-X6X3(,:QX>GK'*
M[]KB*FHUFY!Y7/')6.MU89.$`5BXL&#8ZGL1YP-S8/-9EG'QAF+X8X1%<ZJ=
M+)J`90,Y]YGN-R+'G0]]X^HHQ2SQ*G2^??ARK+3$<F%AWRN9\?Y#X;*/]U%C
M%QF/(;^@<3%"JK(,K0.')"-G:+8JIG>O94"#<T.0N2#^=CY:&@!0Z:@^3(BZ
M5()DC%(8==VLHL<J^P5[::2VLH9SSJG3@6S&OD.E7A,#"&D.=&Z6V@&VU3OE
MSW:M]UM]A-A=I!;#3#[RZ.S]YS:J6*F"^PC06[/,,CEGC-L#.[9!CIL\[BZA
M\2",/7F8U!2%MC>FS-HL=2;N2R82<=(I1KHQ#MQ$Y04'B8/D6HD55S%9Q.&M
MIZ)I9++;LV937G&_>87M8UY%VZYI<(AUEB@DT+FNA-=[G=8(#=+;;;(P!T0(
MBMRR_G;\8S%-RGBA3'8-(6S<&KWAP@LOMZJT\H<TPC\!059H^*YM@44SQU1K
MV;G]ADE)KI2BSA@NV*9'8GM'F2]G5?+J:?$!.C-9B8J72;YU;2:ASIDUIW7N
MD"6T,@`'!UMJC&'3`YLR]:)MXMC9XUI]4M@(*!6WCHX<$N-'%?%W19PL<[IM
M?D6"[>$X=7-8R:A.APQGQ=!S5TO3VWRD3DT(G(,>U%HF#-H5O'*F,8#@0Q1N
M4^4\;.6*C+E6V\V:\&+JD.E7>U:US62PP&5&63$Q,7#<6[:2?V5U._03SHCQ
MHV"%EG=TJWL7G%,`W/B3\W]G=:E3-`88'Q3E"-SM5*M6TW,5'Y3R2TR(YL+_
M`!LQ*\;(O:W8;9<#2`(I@V38)NSHE*();!S)R7C%+@>,80)K9SZNHE&0][K3
M*E&6&B:8&#FL9=B8WB`=U&T4YDB=)B"7N%TD[@A"/=@(+Q((0I"@0I2E*7:!
M2E``*4NT=@``;```#7U(VVKJ+[T1-$31$T1-$7H#P(X1>VBY$R],)NFM<I+E
M1*N"4RS?OY:CI'2,8AR"3GHV$;JF,L&T2J+G3(("`'#7\T__`-BOI`4&4<BG
M8C@3Y,[-6/RFNKHAK^R8>'!P!!C=GU;V@2C`.9);,F-(<997Z"V#9'GXIC(S
M?6!S,-HG$2=(UL\B%F^R4TDNW"XM:8@$+^B'AJQ"CE*WO6$PM+,J[$0CF5F'
MT*V%T_;J.7#6$@B(H]'<E5*K.R:!EB[H"+5-788I@`0_CCLTR/2[0\R3<-Q!
MU1+P:EI'S9\R0V_,:7.9(IPUMUT0:B;++Q")E-F0(,"/TSGW-]1DC`9=?0MD
M3,5J*ELN2R<ZZQP:UTZ<2;S80DRWAIC9,=+B"(A;W982JL71E9.^RJE:FVS_
M`"Y!R4BXM5?9)1<_CTZ#:"9,::[;GG+2A/2)NCK"S6$4N=(?>`.KTJ791E[#
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MVKJVSV!SGME.!ES&NC`6+&V#%-<A4'$W*R]O/'5?&*-]?5B.NT;/*"$U=TZ5
M7>\-R;QAXAO&R4<XZ4N1-LLJ@!!0,?:<03H8ULYP+"I,S%L0J<3-#A^7QB$R
MDE5\JH/N]>*&F[/7-E&2V5-E.UTQK93WRPTRBZ+B&7<*SSC&(S68=0R,/%76
MXT:)E3,HYD@>XT9K)^NI'3!-=,ES&ZIA=,8U\=8&P:"[)S7#W3H3QY55L-B=
M5O$CJX>-I#/&B+DJ#VJ15BQD6-2[W'8LWD_)281ST0`2K+-Q.0";P%+T<5V*
M97PGSO-F5M=,P++<RM[8"]C779E))J<*$H:HRV3*B;-[-/-H>^47,#;P:VCA
MNUC,.)>;);*2C9B^/,I.RD,>6WF5,RGQ'6'6![V2)<O7R186LF!KKUTN-NXX
M9&<3)XS:2SNP%0L=1M![H86AH[O-?X*C+WM&'BUWK+FG<6I&N6R9U"<\4RB#
M@H*`8!*2"?L!IL-K\`IL2F5HDUV&59KC<,O48C3X>[$&R9+GL@^493Y32X7P
M72YP#PX09-)VSSZZBQF?0RZ0S:.OIA1B]K-=0SZT41FS0Q\6S!,;,<&FX0U\
MHEI!!=QLB?G$DU-H#OD*81*.T-HE`1V<H]?7Y<E/$R6UXA:`;%^A9C;CRRVP
ME;\_R8?^O7_^"Z^R_P#P!_\`E_\`_'KY9_\`-/\`^,?[ZOZ)M?V^7\DUP=QQ
MPLO:F&+ZM6HYU.620F[+(,82.3Y^1=L8F(;=\W:"&THG18]-2YP=OL><+Z.O
M:9-GR:694U%0X,D!C07'0"7&`]>!@K-/87./BP7FO;N$K)EZCVT;9,19#708
MO223%:+7L%<D6+\B"S8CMG*UV5BY)NL5NY4)M*J'(8=?0*?,N&TKR^352`2(
M&-UP(WB'`CO*VV<UABUPCZQ]E0%7S?<J>4@IEK@O),/)UR'2@(MU7)V\5L_>
M=*:<6,64D$'9&!9LKF>>+.W!GO/G<KJG,J)Q,.VT,Y4P8Z6:R0YCW7B'!CK8
M78B\TW8-``A"`%BD[6Z!%YI!,;0#W-[>5,/-[RI27%N&#LF][[^G9B6R%&Q7
ML:[*#<5A<65<E=&RC"1[R37,)Q7;()*IF$1(8NW6?KE3'5GME/?E7;KKK+PN
M>+RKL2!O$D'=3M;K#>;%L(6"-FBU2BN\%%RJL'9:]#81O96%R;+,[4O)JV&>
MF9]JM$G@@0DK#.2TC.N$V\.H9N@`N-C=,=B>[J"=FJAGS&39E7)O2S%L+K0T
MQO6-`#=-ILM.E:NJ+Q#BX1&C0(>LH^CP`2B%AC[.7`=Z/)1A:8#5NL]M:T"9
M7'D8RAZ0]>5A2<-7)*1K3"-0*V<N&JJY3)%.)A/[+4ISC3&29!K9-QU^/BWO
M="2\!UV\`XDQ`(%JV[6Z[=OB%N]&W3;IM6/:^;M?LXNP02&#LI^+]H0DFTY7
M5K5D-S7G:$Q-HV*522@G%J5BF)9"71WUN823WTSJ)#\J54(;=V=*=SV3364^
MMED7779=X0%T<J[$P&B)WCI`*&K<2'7FWAH,!'>WE?J>;]?@J_6C>'JWU@TB
MZCGS@E&&PT%N1_%LG<:U?M&M+EX)JQ?'CWRJ*ZR)"*.4Q`%1/NEV:_7*G@`^
MME/@"!?NOL)!()>'$B(B`;`="=K=NO!]6WV5M""X8LK5B&C:]7L,VF'A(AL5
MG&1C&%,DU9MRF,?<3+SAC&,HJH8YSF$QU%#&.81,81&C-S#A<^89TZKE.F.,
M22ZTJ-TUKC><X%Q65^Y_S?\`P5W3Z$G]OK3SY@_RF3Y2UOLWPGW/^;_X*[I]
M"3^WT\^8/\ID^4E]F^$^Y_S?_!7=/H2?V^GGS!_E,GRDOLWPGW/^;_X*[I]"
M3^WT\^8/\ID^4E]F^$^Y_P`W_P`%=T^A)_;Z>?,'^4R?*2^S?"?<_P";_P""
MNZ?0D_M]//F#_*9/E)?9OA:ES.PL.`*@%TRE5YRJQCR0)`UXDJUZ(K9K8Z9/
MGT558@3F$JTO*I1RPIE$0`")G,(["CJW15M%B$TRJ2=+>YK;SH&-UL0"X]P1
M"W9!Y@T@PM/<&^O"6Q,LD9*N4O=;7%.E).8="N<G.M2MV;9,`(TCF29G0\TS
M8MRE3(7K@&T?9"(C[FDJ<-DL$MLU@8WU;>[HW5>8Z4T`1"S"5)M.Z!4H)T(%
M#8``HTY/TSKJ#$L/`AKF=_B4VME#VP5R6A7(_P`+77QO@':#_P#J=;><:#<F
ML[_$FME[ZN"8XO:GPE7DC?`%IW5IYQH?A6]_B36LWU7+B[(A_A*A+&],.B=U
M:V[?1'\XWO\`$MK[-]??DKR/]9TQZC3NK3MU'\(WO\27V;X3R5Y'^LZ8]1IW
M5IVZC^$;W^)+[-\)Y*\C_6=,>HT[JT[=1_"-[_$E]F^%9R6.KU#KI-92K2C%
MPLS9R"2*Y6V^HR?HE<,G)=QP<.:<H&`Q>7;L'E`-;,K*2:+TN8TM!(W=(L(T
M;B![3H*L/$^T^`WWJ(]EUMVB1SPLW@GB?:?`;[U$>RZ=HD<\)>">)]I\!OO4
M1[+IVB1SPEX)XGVGP&^]1'LNG:)'/"7@GB?:?`;[U$>RZ=HD<\)>">)]I\!O
MO41[+IVB1SPEX)XGVGP&^]1'LNG:)'/"7@JY*)<5&4K(IUR1.Q@V2<C+NBE0
MYJ/8JOF<8FZ<"*X&!(\A(((AN@8=]4O)LVB&#5TP<UA>V^\P:-\P)@/6!/K+
M%YL81M*C_0'ON57U"^VU+K&;ZV3H#WW*KZA?;::QF^B=`>^Y5?4+[;36,WT3
MH#WW*KZA?;::QF^B=`>^Y5?4+[;36,WT3H+P.JV5#\`/Q!'2^T[J+\Z"[]SJ
M?(ZS>;OHOWH+P>3HZOR.EYN^BXEXAKS(V14V/ZFDN]C8]Z);6\;!L36EF2GL
M8/?,8N^G'J"!U]FT!6W2[?8#J:GJJ&2_W:8ULS<!C9W="FEW&F+C:N?&-0L!
M$R@2'=B80]!+\577=D8GA;&^_LCZ_$K(FRH>,%E"4JVJ?C<`_/\``!#\58-6
M1BN''1.9W^);:Z5OA71,>7A3X2L29O@`W_%<:W&(T)T36GAXDULKG!7(8PR$
M8-I:C+"'H@#7NG6W;J/X1O?XEG6,WU^^2_(GUH2_J-.ZM.W4?PC>_P`2:QF^
MGDOR)]:$OZC3NK3MU'\(WO\`$FL9OIY+\B?6A+^HT[JT[=1_"-[_`!)K&;ZO
M4,/92=,9J3;T6<6CZY'I2TZ\(5F*,5&KR;"&1>NQ%V!@14E91N@&Z!AYQ8O)
MLVB&CL1H&O:QTU@>]T&BVTP+H"S>!/K)K)<0(B)4=\2[7X!?^HCV;4W::?GM
M6;S=]/$NU^`7_J(]FT[33\]J7F[Z>)=K\`O_`%$>S:=II^>U+S=]/$NU^`7_
M`*B/9M.TT_/:EYN^GB7:_`+_`-1'LVG::?GM2\W?3Q+M?@%_ZB/9M.TT_/:E
MYN^GB7:_`+_U$>S:=II^>U+S=]/$NU^`7_J(]FT[33\]J7F[Z^IFDVVNO$X^
M=K[^+>K1T3+I-G0(`JI&3L:UF(=\7FUE"\Q(Q;U%=/EWMQ0-H`.T`Q+JJ><V
M_*>'-#B(B.EI+7#UB""@>TV@Q"Q/>:5]P+_^Q[?4FME[ZS>"=YI7W`O_`.Q[
M?36R]]+P3O-*^X%__8]OIK9>^EX)WFE?<"__`+'M]-;+WTO!.\TK[@7_`/8]
MOIK9>^EX)WFE?<"__L>WTULO?2\%\C$291V"Q<;?Y4!_W0,(:SK)>^$B%M7!
MV#KKGG+=&Q#4HUVM/W>569-2))IF7(SCHY[-S+ENFJ<A%EV<+&.%2$$?9F(`
M=?7@]J&>OLXV?8MG>323<1JL/I2^52RH7Y\YSFRY,N)+0UKIKVZQQ(NR[SA:
M`%U<$H*;%<7I\/JZB72TDV8`^<^-V6S2YU@))@#=$+70"_IXH'!SEFCUV!IU
M?P_:(ROUUBBP8(G2CP.8B>TZSIRITX!6>/7!SK+*#RG5.8=?YKMH&![;-HN;
M,1SSFG#*VIS'B=2Z=.?"7`$V-ERQK.3*E,#94I@L;+8T;B_>F`9LV:8#ALC!
M\/Q*EE8?3RPQ@Y<8#2YQN6N<8N<=UQ)71$'B'B&K\-+0<13+C%QT^>,4FF[!
M9DU-(&AE%UHPKA="0(X%)HNZ4.4@&`@G-M$!$`V>)I\@;;:&AJL,P[#,4D4%
M8Z49[9;F,UFI+G2@YS9@=!CG.<&@@1,2"0(=^?G39-65=/B%=B&'SJRE$P2G
M/#W:O6AK9EUKF%L7!K03`F`@"`3'+VC'/$E=3(GM-.M<P9!W)/TC.$8<@E>S
M`-`E'8\PY2WEW_0$14,.T3"3;U1';)F#)&W3-3FNS#AF(U3F3)LP7A)'NDZY
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MI`X:^FF4%%BDI]))FR94-2;LF=,,Z;*(<XA\ITTF9JWAS6O-YH!M56LS%L6K
MVSV5E7ATQM3-ES)D=:+TR4P2I<P$-!;,;+`9?86N<P77$A6Q:!Q.%&P&&N7I
M8ULE(N;LYG*[!T>>EH60-*Q3^4,X>JF=+LI$PJD$1V;P[!`2\FH&Y.V^--:X
MT6+N=B51*GU1<Z6\U$Z1,,Z3,FETPWW2YA+Q&R-A!%BF=FG8T12`5>&-;0R)
MDFG#6O:)$J=+U4UDL-8+K7RQ=,-S1`VK-M('BS923^71AKP:2DYQ>R/7+HL,
M^%6<=,W\<Z?E2>N'""!G3"4715(F4J:B2@E,40``#JT^$^D?2U\[$Y5-BQKJ
MBK=53'/U$R]/>R9+?,@]SFM+Y<V8Q[6@-<QUUS2`(<V?B6PJHHY6'S)^&BCD
MTS:=C6ZUD)+7LF-9%C6N(:^6Q[2XES7-B""3&&S6'<\V"04DY3',TH\5311.
M9I&5Z+0YMN0$T@*RBU6;-,0('*)4P$P\HB(Z\OBNS+;!C5:[$,0P2J=5.:UI
M+)5-*;!H@(,DEC!9I(:"=)B5Z+#L_P"S'"J445%BU.*=I)%^9/F.BXQ,7S`]
MYMW"Z`T"`6P/)ED'R`>*OBE+>,?EXYKO/NMNE\YY->^VYMZ3S&_WL^7[-_;S
M?+U>37TC[)MI?V&^;O,E=V[ZSZ^Y=;'4]CU6MC?NW-;[G&]X]D(KP_VAY&^U
MSSCYTI.P_5W5WXNAK.UWKD+L8W;80T6Z%[V:_KXOYBKG+(7^,?PX?\W<[?VH
MHNNW1_N2M_'D>S,4[/>'^JW[ZZ-UQ%`FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB+Q$\^Y_BX\/G^=YC7^\C)VO?;/OWA5_V%_Y<M7:+3,_1GV0O!RJ0KVQ2S&%
MCN9Z:^%P"'2%!11VMVJSQ3?4`IQ+\I;FV<@[1V!KW\V<R1*,V9&X(1AW2!]]
M31#1$KHVN\/USER(+-):H&9]Z"2TJ\"7?+DKHJ1T++H1DZU91#J20E7,5.MW
M"::"#A,R8F]GM(8-478W22HAS9M^]`"Z.5:YL6DN`(!:08D'N+!GL`T'3P[G
MWEGH?!EQ<#`*N'M9C(FSEC305BDI9=&#?GEI=[!L6Y7*$>Y<HNU9%D!1241(
M<I'"!Q`"J`(6O/%*V^`)CILN-YH;RA=:'$PB!"!TQA81I"VUK;81)&E3J.P'
M:#M9.13L5*6B(F)EI<\RUDIEY'O$(:9<P#Q%B+.O.'9U^^C-1,HJ(I);"")C
ME#EUN,:I[[999.$USVMND-!%YMX1BX"$"#82>X5NV:T$6&)*SLIA"YUB-3>2
MKJL$=NI"+8Q,`G8&HV.P)2B$4)).!B%2)+2<<S>33=JN)!YXJXGW4SIIG4"U
M38O2U$RY+$RZ&N+G73=;"-CG;A(:2-R$+02`I!-:XP$?O*7$X<[CTV1B'5BH
M4?8HN[-J`XK;V?>EF%+`]*=Q'@U(A#.&+B/D(]%1V@N5?=.V3$^S;L*,9QVE
MN-FMESG2'23,#PT7;HL,>4""#R2(6$P6-<W3`W81BK8W#GDX4#':,HF2>-X2
M4F).(C99)U+0SF(AXJR.JU)M@2*0MI/6YMJ^1:(G6YU%7=*<5@,F&WGW#[T'
M%S6EX:'%L&N#G%H>#S+[2TDP@1:(6K.N9W_![*U%8(-[69R5K\D*`OX=ZLP>
M"V4%5N*Z`@!^95,1,5$]H\@B4/@:Z<B<RHDMGRXW'B(CI@MP8B(6L,P?5/"_
M]'U`_O=;:NX;[P_]/,_*4LKQ/7/LK%X[QO/9+DY&/AGD%$-86-)+3<_9Y0(B
M`AVCF280<;TYX5!TN"TO/RK1BV(FBH)W#DF]ND`YR[UU=)H);7S0]SGN@UK!
M><X@%Q@+/%:"XQ(L!W;%E[PP1,3'>6VX_A,RF])4S.G5/@SVNV^(P(SLT]9'
M@+.XF[!68B,GE"0Z[;G9ZQUEVR:]!4>B18I!<`@FH0X\Q^9,.89ET37B7*UG
M):#>9=:]Q;RH\EKPXW@VR-V)!"C-1+$=)@(^MILX=U?#?A,R]+INEJ>U@L@(
MMDZ^X(I2Y%W*=,963(%CQFRD623F,8+J,&UIJ[HKI0Q"`W;;JQO8;XDR<R89
M*(%47R";P]T`$"V6V:08$VECQ`;IB-,(NT2QXT1IT]P1]@K#.^'2VQK.XN9:
MT8^B'5*KUAM$A$2$_(DE)&&K%HG*9*+PI$8-=D[4&RP1VJ!%5T3+J.$`)M%0
M0+*W'*:8Z4V5+GN;->U@<&B`<]C7B]RHCD.B8`P`.\MA.:2``3$PX1'V%57X
M;+S&HVOQCG*-4Y*H5VH6E_`V&=>MYE]$WE%@%>&(190[]H[=+2TDE&+)'62,
MA);R)]FX8P&X[23#+U#)TR7->]@<UHNATN-Z,7`@707@P,6VA-<PP@"0219W
M/NCZBR8<*&5SRD/`(&J3JRS$R$*6M(61(TW&G>M[,ZK4A+MC-2(LHRYHU%\,
M6?G#**[A.>(B"A!&+ZQX;JWSG:P4[&WKY;R3`L#PTQM,N^V_99;`F!6.T2X1
M,8`:8>I[$;5I"V5";I3^/B[`@1J_D:[`68C4!4Y]JQL<>G),FS])5)%1K)-T
M5=QPB("*2H"7:.S;KKTU3)JV.F2#%C7N;'?+3`D;X.X=T*1K@X1&B,%4C/WO
M,W?]'<7_`-IE!UI-_7:3].?]%,6'>,WU?O%<JB(!U1`.01Y1ZP=4?@!MUZ!3
MK\$2^CR;2[=T2@;88=GL1/M(!AZPCR;>KR:(O3UOPQ8)G9W:M-5O'];=XQ=!
M`1\[D:*C[B?(UL4:1=!E+$=Y?+-5Y&'9.4WKT.];I-252:J!WO1`2%#P+L?Q
M>3)L9,GSQ4"\6RB6:ID3,#82VO#B+K>6(,)'+-JI:Z:!8"77MZR`T[@/#HWU
MA8'#?#_,7"`H49!Q4O8F?#O5KY/M5+-9BG>9-F:_C]])P+EX%YA8:2%HZFY,
M_1(Y=B=F9#<6%3FQ*,TW%,:E4KZR8]S9!K7RVFXVR4UTP!P&K<X1#66N#KT8
MB$4,R<&EYB!?(T#1;W/46O:E4N'^?=8O@+'3F=?6L-'R_8;=.0V09@)1K.8I
ME;*^CH@C.;F7T,Q&Z1%-/'@F(;X+2A5T#&%-,I[E34XU);43I$TO#)LEK&NE
MM@6S@T$Q:T..K+[WJ,@=)(D<Z:V\6F,"`+-^'L1[RQM=PYC.V\)MPRDS7BHG
M*$99YJ>:ME[ASJ;6E1KIJBG2(NN"\*^E+69)<7`\\VY(O\N])$4SMADGXI7T
MV8Y6'N#G8>Z6UI(9IF$'W0NA`,W+#X_(NVAR&8]L\2SXD-[=WX[WW[%QCO!Z
M(>J'7'9^'R:]0K*^B"`F*("`AO`'(.WEV]3DT*'0O,9;ZLLB?](]O_MD.N+6
M?K)]0>PC]/K!2]AU"?`_$#6TO2@W%M?'U6D[Q;:Q2X4[1.7MD[%UV,4?JJ(,
M4WTL[29-CO%D47"J34BJH"<Q$U#`4!V%$>34\^HETE,^JFQU4MCG&%I@+3#1
M:L%P8PO.@"*ZNM7"#F:@UZ3MDS'P[NLQ#&S2J\Y#/)%\P/$UF$IT^>1.92(;
M+1A9R.N[/O<W?D9O%U2+$,BF9/V5;#\RX763VTTISA/<6"ZX`&+W/;#28W3+
M=>+;S0(&)BM)=3*>0T1O$BSU8\5L%*C\)67H?R@)65&N57R:4:K7ZP*3DL[!
M%Q'7.MOK/7XF,4C(N3!2;791+Q!<KCHS1H^:*MUUTU=T#7&9CPV8V09!?,U\
MU\MMT"PL<&N)B1R8N:1")+2"`0I&U$LPNQ-YQ`]:PK]G>%G(4%DS&>)%)RAN
M[EE-"/6A4B3<I%Q,.K)H).6K*PS5E@(*/2='26``%D=\BHJ()$4,J)2#M)S!
M13J"?B09.%+3DWN2"70L):UKG&'XUTPM(A:MA4,,MTR#KC?NL@?9@N;U4S(K
M+('V;Z"RJ!]FW9OHJ&3/LV@`[-XH[-=L&(!&@A3:5\:RLK8=8_>TXB/^BN$_
M[8<8ZHU/Z]1?VAW^AFJ-_CR_QC^25R;KOJPFB+J?'_!]ES)N+*YEVK+U%2MV
M>_I8[CX]]+R32=2DCV^GT127>)=Y%8="$;V:^1:!MCTSXY%S*)ME")*F)P*S
M,F&T&(/PZH$S7RY.L)`!;"X^9`<J]>+9;SXMVR!<"1&!]3+9,,MT;P$>\3[`
M*M)S@_SQ7HNX2TA54R(4.DT2^VALJY5CY*-A<C6^2I5:;FCIAK&NE)89.)6<
M.D`*`-8X.E*&!(!$,RLRX1.F2I;)ELZ;,EL,(@NEL#W6M)$($`'==R1:LBHE
M$@1TD@>L(G[M]2UYP/96BI/*L5.6O%\(XPM5:U9LAG>35L<HPJUH6L35G6@&
M*I,BLO.,WE6=IN%@)WHV`15-\H@<%=5V9KPZ9+IYDJ74/;53'-EP:P7KMTEU
MKQR2'@@>/I!8"(+3M<LAI`<;Q@+!;"'=[OJ]Q:%D\2V6+Q+6,SFD*N_J5GLC
MNIBSBI]!_9*W.H-Y%ZS8VR'22`(9>9CHERY:I\ZHMT=,JBI$BK-Q5Z\O$9$S
M$9F&0F"IEL#XEL&N;8"6'VUTD`F`$3`1@83"8TS#*MO`1T6'U%K#5];IHBO>
M(C]\&(_Z(\%?]CE)U'@WZF[^TU'^F>DGQ#^,[V2M%ZZRE6T<+8CM.>,HU'$=
M*7AFMGN;F3;Q;FPNW;&%;!#P,K9)!Q(.6#"4?$11BH9<P`BV754.!2$(8Q@#
M7/Q3$J?"*"9B-4'&GE`1#0"XWG!H@"0-+AI('=4<V8V3+,Q_BA;IN?!#GNCP
MEALLA"QLK7JV-U,^FJ^I.2#`Z%+A,:6'GN<6@&9XU6V1.68@\,TD"LG[I3I"
M2B"*J!B#S*7-6$54UDACW-G/N0:ZZ#%[IK><8W#)??+;S1802"HF54EY#02"
M8:>['N[D#%4K'P5YMIA,O'N:52JI<,+U2/L0RD\X7+,S5SKS*UPD%65(>*E$
MEGRE??$7.M(&CF/.@9L1P=T',ZS(S1A=4:84NLF=J#RV#?%:QQ8YSKQ%EX0@
MV\[VQ`;:LMJI3KMV)O1AZUEOW%7%WX,,A4#.T-P[SU^PZ2_R:,D+YP:T6*+K
M=;D(U\ZC.\4O)6.G0CU].2D@T%*/1B6LF$@H<I6YE!$=W6ES/15F$NQJ3)J>
MQM(AR&ES@0#>`:]P#0#%Q>6W?;01E2Q\HS@'7/4\.C?CH7*\["R=:G)NMS3<
M&<S79B4@)AH59%R5K*PSY>-D6Y7#915NX*@\;'*!TS&(<`VE$0'7H)4UD^4R
M?*,93VAS3HB'"(-O<*G!#@'#00L5J197H#YJS_ZA?#/_`%[O_P#V27W7Q[;]
M_P#X_C?Z.1_M4A7L-_76>O[!7]NFOY<KWR:(FB)HB:(FB)HB:(H+\1_XDO\`
M1LU]7_\`BO[OEB\E_P"\_P"Y??7?>OJB^1KG+(7^,?PX?\W<[?VHHNNW1_N2
MM_'D>S,4[/>'^JW[ZZ-UQ%`FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+Q$\^Y_
MBX\/G^=YC;^\C)VO?;/OWA5_V%_Y<M7J+3,_1GV0O!JKS+ZO2C*9C3)$?,A<
M"W,LD5=(!<-EFBF^D;84^U%P8`V]0=@];7OYDID^494R-PPCP@J6`<('0NA:
M[GR_PJ)4(T*\S3.P3CWQFT.=HYEB)Q<-"H.I)^R>MI!1\VBX-NBFHDJCNDW^
M3Y8;;3=@M%-,9E\F]$1=&[RG.(`((@2XD@@[F\ADL-IC]W^59-AF&\DB$((C
MYD6';3=5L+6.Z`0Z#25IJSE6&7;<ZH<Z93`[$CD-H])(DD!Q$4P'5QN%T9FF
M<0=:6/:3'2)D+T>"S>B8:5MJV1)W8$<*D;'*]Z+7E:TTFEHJ.<M9%BX4AS+Q
M3]=C+3[VRR+%9^Q71759NY-^ISB1A%,Z0@F8!*&K`PVC,\5#V!TP$$7K1%K0
MP&!W0`('?M4C9;;T2+?N"VTRXALAG<QLDLE4'4M"OHY]!S+RHQ+J5@QC`BSH
MLXEXN0YFL>LYAD%ED]AA44`_L@*H<HZ-P.ANNEC6B6]I#FAY#71C:0-)@X@'
M<$-X+;4LT6P]54G&;\@.IIC8G+N'5F&$O6IX'9(*.:%=2M3BGL)"NGC1BDU9
M*"E%OC)*%(FF"H$()O9%VC.W"*)LITAH>)3FO;"\3!KR'.`)B=(B+3"U-4R$
M+8<:OG?$#DQT")TY*-CG:9DG*\E%1:4?(R,LW:UMBVL$BX04`%IYLPJ3%`BY
M"I[$DS`)1$YA'1N"8>V,6N<W1`F(#27DM`YI+W&%MI[B"4SU?N\*UG:;)*7&
MR3ULG#H*S-DEGTU**-4"M6QW\@N=PY,@V((D;I&5..Z0.0H<@:Z%/(ETM.RF
MDQU4MH:(F)@!`1.ZMVM#6AHT!:JS!]4\+_T?4#^]UMJ]AOO#_P!/,_*4LKQ/
M7/LK$4#(]AQP]EG4$C"/D)Z-;14U$6.)1FH>39L9F,L4<#EFHHB<%HZ=AFKI
M%1-0ABJHAMVE$2C)6T,BN:ULXO!8XEKFNNN!+2TP/=:X@Q&@K+V!X`,;/\GL
M+.N<XY-?6:EVR0LCB0DZ!8`M=;;O167AD+&-H?7!Q,N(0R_>U:0?S<BH9PJ5
M,AUDMU,P[I0U"W":!E/-IF2PV7.9<=#QKMP,#0[3`-`@-PVK&J9=+86$0/!!
M9>+XC<NP46VB:]:%*ZFU:,F"3Z!3/%2PL&5FNELZ"I)-%TUU&CV4R!)E<D'D
M6;*D3'D3*.HIF!X9.F&9/EZPDDP=:V)9+9&!W0);(;Q!.ZL&3+<8N$?\@'W@
MJZO$5?GD;,Q,HPIDPRG7+)X^+)5L%#@O'6JS72/%`R#YN4$F=DMKQP1-0%$]
MHI@)1YHNS`P.B;,9-EF:U[`0(/W"QDL[ATM8T1$#IWUC4L!!$01W>X![`5"Y
M<1.3[\XE'MH?0;U_-,&L7)/6M<BXM=Q'L+R&16#421J35L!65FWCD/S?.F1.
M9,YC[=[6:7`\/HFM93M>&,<2`7$P)EZHFV)M9IW(P(`66R9;+&QLXH>PKZ1X
ME\IRCA%\X<5Q*63<D<.)MG7&;28DB-6-GC89G)O43@+IG7&=P?%8`!2*([Y!
M,<_-DV:,P##I;2QHF:N$+I<2T1+"X@;A<6-O;AML$2L"2P66P]7U/9@M=Y&R
M1;<KV<UQN[Y&3L*L1!PKA^BU3:"Z:UZ,;Q+!9RFD(E5?*-6Q176'V2RHF./*
M.KU#0TV'4_9:0%LB\YP$8P+B7&'<B;!N"Q;L8V6VZW0K",_>\S=_T=Q?_:90
M=9F_KM)^G/\`HIB.\9OJ_>*E?"E?.&BF0=G2XA*86Z+O<K83E*PV;[K=_%15
M?<6UW:)-X\4CWJ;JFBHJQ0F8X!!9ZU6`4B*'3``JYBH\>JILLX+-U0%-/#SI
M!+K@8`(B#_&+':&D6D`K6>V>XC4F')=WX0]?>6T(^W<'==AF<FLE6;M8*_*Y
MLLLS7'=7F8UM>(W*+*ZM8&F,IDS8[%FK24F,!WH4(B48]R[<J>P`@@//?39G
MGS3+&LE27MD-:X/:3+,HRRYY;&)UD9E\1Y0#1NK0MJ"8"(!`MCHA"WU[8JK&
M6W@\C[G+2S9]77%,KTK8XJ$BIV@O%9RV0UTI>)H2LS)D6T4>-!6FS%>F%Y@5
MU$#I*+'5;%6%?8.'TV9WTK9;@\53VM+BV8+K',?.<YMICRVN8&0C$`!T(+%V
MH+8&-XPW=$"8\,1!6C._<(=R7R3+7MLU8*V"^01:E".JE'.SPU#QG9&MDW&3
MNAUBAP+-/*2#]]'&26:]-Z&FD19PH8`$=G4>9J42)=(20R2Z^X/(O3)K2VT3
M'S''4P:Z(-V\20`LW:AMT-W!;;NGU2398M86S*M78LLPQ+>7Q'9CSZ^-W%?>
MTO$$)#-EF25L=EMC",6F*?&/&LNVHB31!RY0(Q25.4.:VK%45/T*;#JA[Z:8
MYM3+#!-#@^<YQC<%PD->009D2`;Q&[9`#=K#%I@X`1TGN6;N^M_,,D\'\9-Y
M*(N-(E&=N";>U5PE00-$Q1+5D')EFK]=FR3-1<R3*-@:^]A&,V,85NZ9)'W&
M+E3HX[W&?09F?*D$:YKI=T/&LM-R7*8YS;KX$N<'NEWHAQM>T7E%<J"!I$.[
MO``[N_&$?745J>0>#TD(>,NT)$+R;.,<2L7.Q-><J'7D$<"X[J$G3IAL1BCT
MIE8[=WW=,G9#D.SFF(+[X$="IJQ4T69];K*5[A++@"TN&CM$QX>TQL+67`X;
MK'0A%L%LYE1>BTV>K^$3'@AZRYTXFY['-AM54>4"4K4PLE77S>R/*;6T:O60
M5\:YQQ66S%BE6JJJ9VSJ:[1)P"S==9`Q"HG=NC$%4>Y@$FND4\QE:V8T7P6A
M[B]_B-#B3>?87@D0(!TAK8P4LD/#3?B+=VTZ+>_]P7A>M]661/\`I'M_]LAU
M)6?K)]0>PIWZ?6"E[#J$^!^(&MI>E!N+:-&LDM3;+7[;`+D;3E9EF$[#N5$^
M>(WDHQ=-TS7,EO%W^:73`VS:'*'5U8FR)=53NIIPC*F-+7#?!L*P6A[2QV@B
M"Z0K7$UF>&J[FFEMSN5KTI/66RS[*?5?30VJ7MA:>64<6U5\^4-902+1V(->
MF`J9J'/<V(<\?6@P'"YM0VJU0;.:QK6EL&W`R_"Y`<GWQT80C9'0L:B43>A;
M8++(0CHWM)6[7'&YG28F7=OE3T%]=WD%9*R%U"C1\=86E?M2ME6E8=OWE<1<
M,JP$UPD-PCEFXVBN!E.<4(0X8EY4PF5(;32]<*0/:ZYK"6ES+L'&\"Z/(;H<
M-%D`2LMI90;=%Z[$&$;+(<04$M?$;DNXWC'>19AQ#C:<7D@R59RDTD562?BZ
MJR6B^EQLG+R+($TE&"8F1:D:MS\H\WM$1U=I\$H*6DGT4H.[/47KXB(\J,8$
M`'=-IB>ZI&R6-8Y@C==I6C5E3KK++J;!476574$`V`*BRAE#B`=8!.8=@=;7
M6````T`*54]965L.L?O:<1'_`$5PG_;#C'5&I_7J+^T._P!#-4;_`!Y?XQ_)
M*Y-UWU831%N>`X@,J5BMXNI\+9%FE6Q!D1YE6HU\HN0AU[N\F*_.A+V6+(Z3
M860S%_6FW1>D)B=LF*I$S`"IM<R=@^'SY]14S6`U%3)$I[K+VK`<V#3"+8AQ
MC`VF!.A1F3+<YSB.4YL#ZENC>TK<*O'GQ&O8>4@9J=JUGC;%!+5FW#;*?&6:
M4N<">#FJ\VC+/89@SJQ/&T9'6)X#;F7;<R9ES;1,7V&N8,HX(R:V=*9,EO8^
M\RX\M#'7FN):UL&B):V,0="B[))!O`$$&(@80.FP:-Q6`\;&9PA;#646U&:5
M>RT2*QQ(5UC"3C2.3JD-,VF?9,&JR-I+*E3"3N3\QT%7*S-1(Y$A0YLA2ZW^
MJV%ZUD\F<9\N<9H<7-)ON:QI)Y$-#&V@!T;8Q*SV:5$.,;P,=S38-[N+2,[E
M6P6'&-"Q,]BJHVK6.)"?E(!_%P18ZR.WMG<&<33BQ2K=T",\Y=B1!/GUF_22
MMV;9$%.:1(375DX?)DU\[$6NF&?/:T.!=%H#?%#01R0+;`81<XPB25*)8$PS
M(F\Z$;;+-Y:TU>6Z:(KWB(_?!B/^B/!7_8Y2=1X-^IN_M-1_IGI)\0_C.]DK
M1>NLI5L+%.4;EA:_P&3L?2"45<:P6:"$DED!<`Q4GJ[+UAZZ1(55$Z;Q*,FU
MQ;K$.4Z"^XJ00,0-4L0H*7%*-]!6-O4TR[>&B-UP<!ZD6B(T$1!TK29+;-89
M;_%/^5;BQ_QE\0N-X2/KD)>',I"-+5:KM(Q]M/(6EM;[3<'=!?R<U?4I2242
MNL@T?8VBUF2T@595HH"YB&VKGUS:S+.#5TTSYLH-G&6Q@+(,+&,$P!LN`Y`(
MFO#@V`-D="B?2R7F)$#`"RR`$=&]I*SLEQRYXF92>LTP;'S^\V2G+4*5R`2@
MQ4/:UJPX:3S!5@;Q;5A*XYWF%C=);7,<N`!S9@#?23,6%F5,)E2V2)>N%(R;
MK!+UA<R\"TQY5YPM:#8X;N^5@4DEH#1>N`QA&R/KK%6WC%RM>\VQG$%;8;'%
M@R-%H.R(KS%8DY:&.]<2"\JUFB1LI9'JL3-0$@N96*5C5V)(PX`+<A.7;)3Y
M:P^DPIV#4SI[*)Q'BN`=`"!;$-$6N%CPX.O;I*RVFELE:EI<&>KX-W=WUS3/
MS<A9IZ=LLL=%26L<S*S\HHV;(LVZDE,OW$D_.W:-RD0:H'=N3B1,@`4A1``Y
M`UW),IDB2R1+CJV-#1$Q,&B`M.FP:5.`&@-&@!8G4JRO0'S5G_U"^&?^O=__
M`.R2^Z^/;?O_`/'\;_1R/]JD*]AOZZSU_8*_MTU_+E>^31$T1-$31$T1-$31
M%!?B/_$E_HVZ^K__`!7Z_P#OB\E_[S_N7WUV=)V61:/W#&-I\_8`:D1%P[C7
ME6:MTUET^>*W`LW8HIT=0J1BF$03$GLM@&$0$`^J+Y&N<LR6=2`SMPSRRL6K
MSJ]=SF"D>NY037:J'KU*<&166:B];'41,EN&YLYR"/*4PAL$>W0VX-6MWWR/
MRGJ0.NR'G3:W[ZV".:S@/U.@/]D__P!GKF:D;ZKB9'<7P.;3@.SQ<#Z)_P#[
M/6-2-]8,V!A!4!SF8!$/%KJ"(?JH'6_XEK75=U-9W%2'/!@#;XL?_P"U#N+6
MPD$[J:WN*B;/IB_M7V_V5#N'6=1W5J9Q&XM?37&ICFNW&#Q[.OZU$WJRE;GK
MU2?V9-">FB.US-6YXU@,?SCHBK@NYM+M`#;-NS:&W&I`L)6PF$B,+%.1X@U0
M'8-2'J[.65'JB&T`_I#J[-9U`WTUG<6,^Z;9#*+098%H,RWCD)A>*">)WP1B
M7+I=BVDE6O0.=(R7>M5$B*"&Z91,Q0':`ZV[.-]8,TC<L5T/$6K]:`B.S>V=
M]QV[/1_4[J:=G&^FM[B@4OQO8[K[Q./GGU0A7RL]XK)M96[Q[%8UCZ!'RIH8
M2.6J>X]2CI=HLH!MA4R.D=\2BH0!T,D#VW>\*R)A.XI*PXJ6$JDX<1->9R:#
M1_(Q3I9C84W"3:4B'JT=*QRYTXXQ4WL;(-U$%TQV&35(8I@`0$-9$B.[WO"A
MF0W%>#Q++`(@-,V;.4=LR/('HC\[>36W9OPN]X5J9QWE9&XI2$=),35%,'B[
M=P[0:C.#SRK9HHW1<KD+WKY4T%7:13#UA4#6NH[O>37'>50W$\L78'B3RCU`
M[]CM$/2#O7K;L_=[RR9T-(7EKYTW+<1E2E\*U1L=-5[R.^,/'JTFW;V!9!9X
MV;T/)WY52=(,45FASJ*%-SA1$0`NS9RZ]/EB;-H6XA4R#"<*!\"1&!OR[8'3
MZBMTL^#9I`M$H^R%S#'8NX>MI0-BV?-R?PDSQ>KM'K(>EK7ZS8YHUK.K:H>V
M31H@IS'XLX<_8[V*+"/)M']TZP!MV;/SOK<9HQWX67U;5DUT[19WE-V&+.&[
M87;B.PCU!_?2L0=</SMK89JQX?GF=6U!7SXPLX%-8W%W#/L)O8=L8]4.3*UC
M#K?H76?K9F`6B;+ZMJV%?.MA"SN!3EABSA?`"@;#%E':&W:&6K('6'\Z#K(S
M?F*'OTOJFIYQG]Q9$<7\+H#L\B]F^V[9.XM9&;\Q'\]+ZIJQYQG]S[O65(<9
M\+H;?W%;,.S;_A>LG6_XEI];\Q?#2^J8GG&?W%3\F_"[M#]Q.S=7^%ZR?B,=
M9^MV8OAI?5,6#B4\;RUI7L6<+EH:24E8,772SO6EEM$$U>+YO>+'C8B!G7L;
M$5LIZ]!Q[,J%<8HD:)D63,^3(F!72BJX'4-<GYPS%3N#)+Y4MA8UQ&I%I<T$
MNY1)Y1MLY-O)`$`I3B=0"`T`"`W-\:;5ES8.X0`']XJW?;JM7<.HOKMF>$=?
M*ZIBQYUJ.YP!4QPEP@`.SR$6[[==J[AUCZ[YG^'E=4Q9\Z5'<X`OCR*<('\`
M]N^W9:NX-9^N^9_AY75,6OG:H[G`%\&PQP?E`1\@]N'9_P#.RT]P:Q]=\T?#
M2NJ8L^=*GN<`XE0-A[@_+L_<$MP[?_G;:OI?K;Z[9G^&E=4U;><ZGN<`7P.(
M>#\/\`=M^W=:OI?K'UWS./STKJFK!Q2I&]P*F.)>#\!$/(%;>3_YW6KZ7Z?7
M?,_PTKJF+'G6I_!X%"+CCWA59*5.'8XHO,!&6ZV-("SQK3/+IJ%RA4HR5GDZ
MP[[]UU^^<M._$*U?F3BCM)$3,BB"P-P7(>W39RS$\3)KWR7S)4LN83)!N.B&
MWA=(`-UQ;RXMY6B]`B5F)5!!)`B!'1HT#[\+;%<FX?\`@D*&W[GFZ#R_P]7#
MZ7ZC.?\`-@_/R>I8M?.E3W.`*F.`N"3^+Q=/M]7#Z7:Q]H&;/AY/4L6#BM2-
M[@'$OD<"\$@?Y.]T'_K[N'TNUD9^S8?S\GJ6+'G6JA&S@'$J8X(X)`_R=;I]
MORX?2[6#G_-@_/R>I8L^=*K?'`.)4AP;P2``C]SG=!V?_/VX_2W3Z_YLC#7R
M>I8L^=*K?'`%3'"'!('^3E<_M^W'Z6ZR<_9L'[1*ZEBQYUJAO<`7R.$^"0/\
MG*Y_;^N/TMU@9^S8?S\KJ6(,5J3NC@"^2X6X).<*'W.-SV;Q0_?^N/HA_4W6
M?K]FSX>5U+%GSK4]S@"X2X;>%_@9O4?FF>OW#U=IZ6;\36<82+<,,]72!38U
MJ)LJ2,%$JMV30Z+UQ'MCB0[HP%57'V1^7D#HY@S9C<BIIS33&-OT4A[HL:8O
M<V+G"(L!.YH&@*S58A/86786RVG1ND+I1/@_\W2CLW.%_(8;.IMXE;Z/X<=K
MC?7;-#;1/E=4Q5O.E3W.`*]3X5/-ZH?C?##?_0Y>)&]&_#CM2-SWFOX>5U+%
M@8M51A9P!79>&G@`1V;G#'?/P>(V\#_\-U*-H&;6Z)\GJ6<2V\ZU6^.`*Y#A
M]X"TPW2\,MYV!Z/$5=Q_^&ZW^T3.`_:)/4LXEN,6JX:1P!?`X%X#0$0^YCO/
M)_\`V+NWTLUG[1,W_*)/4L6OGBK[G`%\C@;@-`/\6.\_^8N[?2S6!M%S?\HD
M]2Q8=C-8!&S@"I'P5P&EV?\`=AO([=O^49=@ZFS^IFL_:)F_Y1)ZEG$L-QFL
M=S>`*-6'%'!1'G@H.-P-D.!B;I.)UZVQ;;B1ET@N<"VCI*RH5IR,Q7'K\[=.
M?@64B(19VK_>8%$5>C`X34FE9_S4^_-F3)#YDIEYA,@<AQ(:7<D@>*XMY46\
MK1>@1(W%JL@N-TEHB+-&Y'@)%MB^#\-7F]BCL^Y8R`/_`(EKU]+-8&TO.1_:
M)'4,XD\\UL(Q;P#B5/[FWS>W\5B__P#F6O7TLT.TO.0_:)'4,XD\]5N^W@'$
MO@>'#S>H?Y*U_P#_`#+WOZ6:?:7G.$>T2.H9Q+`QRL_!X`O@W#GYO4/\E6__
M`/F7O?TKT&TK.9_:9'4,XD\]UG<X`J8\._F]@_R5+_\`^9B]_2O6OVF9T^42
M.HEK88U6'=;P!4QX>_-Z@/\`BIY`_P#,Q>OI7K;[2\Z?*)'42^)8\]5N^W@"
M^!X??-Z@&W[E+('_`)F;U]*]8&TO.GRB1U$OB6IQRM_!X`OCR`>;U`0_[J.0
M!Y0Y/NF;W^)%;=9^TK.GRB1U$M9&-UIW6\`4'B<$<!-O3?S-OX<\EW"23F).
M"CY)?BAG`-'UJK+^+59K*85>K1#$$*M"Q2+$G2"*R&Q':Z766WC:LS=I.<*8
MB733:>6PM#B-0VUS^4YW+)/+<2ZR#;>2`%N[&:MINMNBR.C=-I-O^3>62'AD
M\V^'^21D3_S17_Z5ZB^U'/'RF1U$OB6//=;&$1P#B5/[F;S;_P#%'R)_YH\@
M?2K3[4<[_*9'42^):^?*[?;P!?(\-'FWP_R1\B?^:/('TJT^U'._RF1U$OB6
M//M=&$6\`XE\&X:_-O@&W[D;(G_FDR!]*M/M2SO\ID=1+XEGSY7;[>`*D/#?
MYM\/\D7(G_FER!]*=!M1SP?VF1\WEK(QNN.ZW@"^!X<_-O@.S[D/(G_FER!]
M*-9^U#/'RF1\WEK/GNNWV\`77/#1YM[S5W$;WRB$\39#I5XBP,Y4J3_.E\DA
MD8KJ!)P<D618=\DT!Y'*?,IJMQ$!$#$$#ZBF;5L[R],^21^AE]%;,QFL=9>$
M?4"W/+>;.X2^$7B?X%+OA*HVB$L%JXA+A2IEQ,WVUV5!>ON.&?/,^JV2:3,D
MZ;MEADH!L8%2%*H!2F+MV&$-1UV:,8SUE/&L$S$]DS#^Q2WP8QLLWFU=/#E,
M`.[HC!7Z7%ZY@F3FN`F,9$<D6$D#>WB5[3^3JK>Y'/;SKLFO@'U!RW\',ZQ_
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MH8`\6JCR[I`,.SEUVZ#]T5GX\C\IZV/ZN_U6_?5B9@_V_P!(O>I[E<=CU1)&
M^JPT*B:/?[?Z1>]J..QZUB%&\&*LC1\AO&_*#WX8?S(X]'^AZ+8`P5J:.D=T
M?G>^ZWYC<>C_`$/4@(BL0*M5(Z1V!\[W_5ZS-SV+2(WUJX&(6C<MXRO]O>1\
MA4#*1,E&8MSY4V$@J>4C7K"T9)KE4C:?)L7;-BNLU3C92!.JNX(8JS;8F=,I
MS<A<$@Z"%LS1;'2N9LJX)SC5(?(+_&4I?5X)EBF>9UE@A?,F3UN+*.:9.,7E
M4C8^66EGK^3E<A/VE@;3QGAI%B1H+)`"(FW-:N&F!W-];[NA7%0X8,MQN0FV
M17CN>CC1LE125*`7R3DFSN*K26.5FMAO=-FI:0V$O[><I*LD9OWU3=%:O),6
MJ',D0(XUM#=CW^ZM'&(A!8YQP\\3`UH$'5AEYF587F(LA8CRC7]C%69VQK$U
M&SUDFI-DC#3C*)MEE?-9(E89O&K&+,T`J1A#Y7H086G=WUN2-ZQ9&4X?,RJU
M4Z;&M564M62L8Y:J>3E[(ZEF@U6W9BMS*XO['"/6D//!/0M>)OQRC!/F572;
M%D9)<I""`'>M&"61W8"'>4?=\,W$(C=H!S#76?@*9$7C)UD%K6IE_#G55NM\
MD;BVL$M&JUYXG-+.X.5-#+L%15(V50Z4F804#=PT&.FQ9)&B&X%^U[A]XD8^
M'H[!Y*2"1JT[7`/W2,E/Y%LJ$W6Y5_:[)(.2.VU^E+7!QLG"&CE$V\9')21'
MB"!%R*%#<`PT]]1DB)L[R^(WAPX@WL=3H:ZV69E$8J;?EN$Q%W2_1,G8Z=,9
M!PY:@@63V);1<PS&O4RGRM<!4KANO(%(5V<Y%)-WN:#2(D<*R"(Z/NM6%D^&
M+B*+CV<K49=[@E(S!L?/I$4K]>EG\L[@)7)R%H91UDG&S]Q4D96OS-7/OM"$
M2=.(4Y%4@$YU5=AZO?621&,.\H/QJUVT0M%X*8JQ#,2TY'<2^*HN7F'R"JSF
M8F6>,K^V?OEG*4;&HNW;YTB=4YR-T`4,(F!,@#NAW\$/^K8AO]A=^7+4U,#<
MG66:H^RU7L?&2>TOSMD1Y`ZC%T/6-Z"6N)$1TA53%3EA%RGL?G9)?"^X'?HA
M_.=`1%"#%31A%2H@39%28\@=2/>>E_.=(BU8@;RF4;$2^POSIE>J/ZW/?0_H
M&L1$-*R!I4Y90TR.YLAY8>0?UM>^G_.-8!$%B!5Z:$FMH_.:7^AC[T/Z!K((
MAI"Q`JV/"3?LOG-+_%?K8^]/^<:S>&^$@5;=Y)O:'SEE_H6^[!K,1OK#@=XJ
M'5&&GSQTN92+LBZGC=<"G,^:69THGN3SPI&Z!YN&BW*3%!,`*@DBF=DDGL*V
M561`JIK%46A[0+H&K9HNCVHYI(CODF\?;`&Q;$$.%FX/8[D>/?6>/!3NW]1)
MGJ>"G_I_G?4`<V&D+$#O%6YX*=V_J',_0I_Z`?G?6L1OA9,8#2J(P4[L'YQS
M/4\%2'<^LQ&^%$(QW50/`SNZ/SBF_H1(]S:Q$1%HX5(-*L5(&>Y/G%-]?]:)
M'TOSMK>(WPMX%41@9[P%-_0B1[FU@PWPM2#O*W&`G]H_.&<ZH_K/(]S:UB-\
M+$"H+;8"R=\Z`*45:T`\<RE529,K6V2>)&KEAWV\DE%0$FU?,"[`4%)^HR9<
MZ0AQ7!8J2:ERG<S5SHW3[ENW3#E-M$7`@[D6ASH$B$(D3L%CH\W[X^ZR*E2E
M?L&P/G!.]7P/)>@/YVU3<YN^%'`JB->L'@"=^@TEW+K`<W?"PX%435ZP[?J?
MG?H-)>A^A=;AS=\+$##0J`UVQ;1_8]/=7P-)]RZPYS=\+8`JU/7;%L']CT]]
M!9/T?T+K`(BLD%4!KEC^MV?^@LGW+K8D;X6I5,U<L>WZG9_J>!9/N70.;OA`
M#!40KECYTO['9_X<OZRR?HA^=="YN^%F!@N1^$>`GEJOFLR,%-K%)Q59_2.*
M41(J`15.T-P42.)&Q@*JF/(8H\H#U==[,EE32QL_Y?3_`))5VLTR_P!$SV%U
M+XM63ZW+!]!)3N77`)$-*IP*I'K5E^MRP=7P)*>G^==`0M(&*H'K-E'9LK=A
MZ_ZR2G<FLQ$=*V@50-6;-M']C=A^@<IZ'Z$TO-WPMP#!6@UBS;1_8U8NJ/ZQ
MRO<FA(AI"T7P:L6?9]35B^@4KW)K4$1TA:O\56ZM8L_L?V-6+K_K%*^E^=-;
M`C?"U9&W2HE8*S:2R5,`M>MJ>_9S%,5M%VQNFL3Q=GS&2>I1D*]:/6G(!A2?
MG:M`4*0X*\^1%-2:66W)OB^][MT^V;HB00>ZV)TB$"2)VQ@ZS<WNZ/NLM6=6
MJ]HWOJ9L?6ZD#+#UO29Z@:1OA:P,%1&KVCZV+)]`);N/0D1TA8@8*@>K6G;]
M2]E^@$OW'K,1#2.%1@%43U:T\G[%[+]`)?N/1I&^.%9@8*@:JVK;]2]EZGUO
MR_<>M21OCA6PT*W&JVK:/[%K-U1_:_+]QZW!$-(651-5+5L']BUF^Q^8[BUJ
M'-CI"C(*H&JEJY/V+6;JA^UZ7[C#6\1OA;-!BHA5:K<31ST5:U;5A\8[0!#N
M(>V.E@3"=?`5(QY:"C7*9$1VD33(F=LFB4A4554@*<9ZDM#Q"`Y#=$![4;Q(
MMW3I)C$`V*1PY6C<'L=Q2`]3MGUJV?J_6],=Q:J@B*T@8J@-3MGUJ6?['ICN
M+2(6('>*^#5*V;!_8I:/L=F?1_06D1#2M(&.A4#U*V[/J3M'5^MV9[BUB\W?
M"W@5;FJ-MV_4G:.I];LSW%K(<W?"R`50-4+=O#^Q*T];]KDSZ'Z"UF\W?"S`
MKOO@;X4K9;[K%9;MZ-BIM3I<FC(UX4^D0DS:;`Q7$.CHB?F7S2OM!(8KL^Z'
M2]HH%'=%0P5YTT`71:2MI;"3>-@!7=W%A^_CYO'_`#K[3_Z3N)/7>R]^Z<9_
MZ>S_`&NF73I_>9WZ,?EM7<FO**JFB)HB:(FB)HB:(FB+GS_"5_UZ_P"C-KL?
ML/\`=?\`>E-^;_D?TENB._56P?HF/_M8VUQU"N:LU32\%G[AN>MT4ESC"9U2
MW%A.!-@P5+4V[2"`[=Y,/P-4\<QRHP'*]54T[&/>^?3M@Z,-,P[B]!E_#)6*
MS9E-.<YK0UIB(1\8#=]5;!'*,L&WYVQWR3GLFODYVDXJ/V>GX7\:]>,BX?\`
M#3N!O$J1LJ2X?K9&_).NRZB.TS%0?U:GX7\:D&0\./Y^=_-XE1\K$SX,C/DG
M79=8.TW%1^S4_"_C4GU`PWX>?_-XE\&RU-!^M<6/_P!IWV74)VHXN/V:FX7\
M:V&S[#3^?G\#.)4#9@FR[?G3%#R[/AW?9-:G:GBX'ZM3<+^-;#9[AA_:)_`S
MB5(V9)P!_4B)^3>=DU$=JV,#]EIN%_&MQLZPP_M$_@9Q*#V_BIB*"5BI<G5;
MKR,BVL#QHN_-)E;G:U6$<V.P+J+I<XDW3C85FHN85!+O@7=)O'$"C)+VH9@G
M@ZBCIG$$#2_2X@#VVZ3!:S=G^"R??:J>+"=#=P$G<W@5#W?'#4H]A'O91%S#
M+RT?(R45`S=)R)#VZ21C+!`54[=C3Y&#;V9U)O[#:HUJQ:$:BYD%'J71B*@;
M:&?M,S*7%K*.C<&D`D/):(@NM<'W0`&N),8"!B0H_J+@08'NJ:D`Z`6`$V@6
M`M!TN`%EL;%;V?CFJU.80\C8FCF-1FZZ[M+1JI3KTI-(1;6PUFI%3D:TE&'L
ML=*O[-;V+%JR59E=.'!SE*3Y6?9HS:=F6:7-E4=&2UP;X[H1(<ZQU^Z0&M))
MC`#U5N[(>`,(OU52(M+O%$81:/%NWHDN`A"*DU6XMF5R9&?P+:/,W21?*/2R
MT79:ZZB5HN7>P,K&SC&P-XQ["345,1ZR#EDZ31<H&+M.0"F*(U9VUC,=.ZY,
MHZ2]9"#GNC$`@@AQ!!!!!%A5F3L[P&?+UC*NINVZ0T:"0=+1`Q!L-JE:F?Y9
M%51!2/KB:Z*`NED5'BZ:R+4-[>=+)&<@HDV+N#M4,`$#8/+R:K';%CVD4=+`
MF&F9IX58^S+!;0:JHB!'0S1OZ%2)Q!RRJR+=%A6E7#A$'+=!-\L=9PV'<V.4
M4BNA.JV'G"_+"@)/9!R\H:T=MDQ]HCV*E@##\YTEN-F&"&`[741(CH9HW]"U
M1$\>%+FG\5%-)6IMY.<KE[N40QD3R;!>1IF-;"-7M]N0Y\X)$K\=+!L(NH8@
MKH`*I"BF0XELS-JV;);2\X?2EC7,:2#,,'3&WFM\;21N#0;#:JK-GV6'.#75
MT\.(<1&X+&D`G19I$(Z08BQ85_YPBH1D!'62092#-A,+29(=FXQUE1.Q2S*$
MAD;%,3\;51KGC(^JD9`N$W:TLFU-'$0.416VF`!#:KFU\UTEE#0%S0(G6\D$
MFZ&EVLNAQ((#8WNXMCL]RPV4V<^LJPQQ('N=IN@$D"Y&`B+80[JXC\Y9GR1M
M]$X/IR)2@UHX_%KC&T04O#NW*[>0:.<<Y*5CGC1V1<Y%6;QG(`H0Y!]D40$!
MV:]9D3:YCE9,QFEJJ*E:96$S7$>Z>,V=)!:07=VWU%FMV>8114S)]-4SWLGN
M:R)#/%<"Z\(#3R1#N%:<C,^7<@$V')V](^E_/]1OVJ8FW114?\_C5-NSO##I
MJ*C@9Q*>QO$->BB0-Y/J>[I+L_I:KNVM8HV,*&B_G])66[-<*/[14<#.)3V-
MXC;X42\J0];^GY/J?-]5G;8L6:/U"A_K.DIV;,,)<;:FHX&=%;%C.)6_%W``
MJ`[`Z[^4[H]+51^VG&6"(P^A_K.DK;-E&#.M-34\$OHJ?QW$_D%,H;"-^3D_
MI^5]`?SSJH[;EC;?X=AYZSI*TS9'@KOVJJX)?162'BFR('Q#;Z(2W=.HW;=L
M;`B,-P_^MZ2D&Q_!#^UU7!+Z*^1XJ,B@'XVU[?ENZ=1';SCGT;AW];TEL-CN
M!D_K=7P2^BJ(\5N1@_F33D_JA*];X+G9K0[>\<`CYMP[^MZ2D&QK`S^UU?!+
MZ*@E"XF[Y#Q4TV9QJ+%):\7J0,DLZO")EEY.SR+]R](6S2SY^9!ZX<'4(9$Y
M8\Q3;6::;<4R!<Q/;_CFMED8=AKO]7E>V<Z'N;;(RR`(:+IY;=#R7`E)>QS!
M9H)F5=7$.(')8VP&`L+;;-W0=(4T'BRR.`_C+/M^7[JUS#Z0&/?1F&_UO24H
MV+8$?VRKX)?15+[K7)'Y`S^B$OW3K0^D%CX_AF&_UO26_P!BF`_+*O@E]%4Q
MXN,D@/\`2[+Z(2_=.M7>D)CX_AF&_P!;TEN-B6`']LK."7T5\&XNLE!^9V/T
M0F.Z=1GTALP`_NO#?ZWIK8;$<`/[96<$KHKX-Q>9+#\SL/HA,=U:T/I$Y@'\
M+PW^MZ:W&P_+Y_;*S@E=%4AXP,F`/]+,/HA,=U:T/I%YA!_=>&?UW36XV&9?
M/[;6<$KHJF/&'DT!'\JQ_P!$)GNK6CO2.S"/X5AG]=TUN-A67OEM;P2NBM=W
M?BKO\O+XV7>PC=^>`R`WFV"B+K("J,>_3K%F8D?OC5Z<8L46Q4'ZB0'ETW<7
MSJI`,CSYD%"7\/\`22S"V35_\LPMI-*?;N;>]TEV`/)+SNW91;,@"X&Z'`Z3
M-AV!2W,:RMK;KW77<B6ZR!.D-Y-H'*-FYNA3DW&7D\`_I..^B,UW5KEGTD<Q
M#^%89_7=-3C8/ET_MM;P2NBO@>,W)X!_2<;]$9KNO6A])/,8_A6&<,[IK<;!
M<N_+JW@E=%4_NT,H>XHSZ(37=>HW>DMF0"S"<+X9W26WV"9<^75O!*Z*IFXT
MLHAM_*49R?U0F_0_1>H3Z36981\TX7PSNFMQL"RV?VZNX)715(W&ME(`_I&+
M^B,WW7K4^DYF8?PG"^&=TU(/1_RV?VZNX)717P/&SE,`V]`B_HC-]UZT/I/9
MF^B,*X9W36P]'W+9_;Z[@E=%4S<;F4P_,$5]$9SNO6A]*#,X/[HPKAG=-;CT
M>\M']OKN"5T5\EXWLJ`8OSOB1]D7D&1G-@^R#D'\N=343_2CS0T&&$85HWY_
M36X]'G+),.WUW!*Z*X]X..+O(E4JN<D(^/BSA,\6G$-9'9U'LNF?ILU:V[ER
MF`HNB[Z2:FW=$VTP[1VCMU[G:#Z3>9Z*NPUC,*PMP?@5#,M,ZPOE$D"#]`W%
M0PO87E_&)4V;.K:QAD5,R0+HE6ME.NAQBWQB-,+-Y==?=R95\&Q'T1G>[-?/
MG>E3FH']T83PS^FNG_AURS](5_!)Z"^1XY<JA^ML1]$9WNS4;O2LS4##S/A/
M#/Z:R/1TRS](5_!)Z"I&XZ<K!^MD/]$9[NW6A]*[-8_@^$\,_IJ0>CEE@_Q"
MOX)/07S]W5E?P9#_`$1GN[=:'TL,V`_N?".&?TUM_APRO](5_!)Z"I#QW98#
M]:X;Z(SW=NM?\66;/H;".&?TUN/1NRN?XAB'!)Z"^!X\<L<OSJA?HE/]VZC_
M`,6N;?H;".&?TUM_ALRO](XAP2>@J(\>F6@_6F$^B4_W;K3_`!<9M^AL(X9_
M34@]&G*I_B.(>3)Z"@UMXWLFRLOCUT[K<8[4@+J,PP41D+^9%@]\5+1&=,>C
M"3C-B5N#6252*,HFZC^=5*'-`Y%NHG>H?2[S:*>KCA&#`FFL!?,:7'6R[`'N
M)>=V[++9D`71N->#K,]&W+,MTMLO$<1NS'W7>YRG<FZXZ0WD6@<HV>UTN"F(
M\?67`']2(/Z)6#NW7+_Q>YO^A<'X9_35@>C+E0_Q+$?)D]!?(\?F7`#]2(+Z
M)6#NW6CO2_S>W^"X/PS^FMAZ,F5#_$L1\F3T%2'C_P`N@&WO/!?1*P]W:C=Z
M8><!HP3!N&?TUN/1ARF?XEB/DR>@O@?.!9>`/U&@?HE8>[M1'TQ<Y`_N3!N&
MHZ:W'HOY3/\`$L1\F1T%2'S@V7P']18#Z)6'N[6O^,?.7T)@W#4=-;CT7<I'
M^)8EY,CH*F;SA.7P_62O]79^J5B[NU@^F1G+Z$P;AJ.F@]%W*48><L1\F3T%
M\??"\P>!*_\`1.Q=W:B/IEYS'\$P7AJ.FMO\+F4OI+$?)D]!?`><.S"`A\XZ
M]U?"5B_%?[-8/IF9S'\#P7AJ.FM_\+64?I/$O)D=!06A\>F6J]#RC-K681FD
MZM]SF`1<2N1SF$\O8Y!\JL3QIL,H_3;NEE3*IE0.E'@4_P"5$4D1*772Q?TS
M\W&I9J<%P5P%-)B;\QW*U3;PC*<UH@;+IC,;"$QQ<"HJ7T7LL3Y9?4XEB(??
M<T0ERF<EKBUL0YL22`#>T.TBPKH/$_'O+V6QE@LE*HU-G(<TC%3T9(R9H]L^
M,<2\Q-].<+"V:N`$`(N4=Q,_XX`%'>+[39AZ6V'YAS`,%VAT5#A=)/NMDU,D
MO,ILPF%VHUA-QCK`V:.2UWCP:;S?'Y^]&J=@N#'%,ESZFOJ),3-D3`P3',`\
M:3<`O.;;%AM</%M$#WD%FGS`4Q9R2,4Q0,4Q7JABF*8`,4Q3%,)3%,4=H"'(
M(:_;0D4S@'-8PM(B"`""#H(.Z#N%?E4M@2"($&T'2#O%?OC)8?#<GVVK[;6>
MST_,9P+$`GC)8?#<GVVK[;3L]/S&<"0">,EA\-R?;:OMM.ST_,9P)`)XR6'P
MW)]MJ^VT[/3\QG`D`OP;%/CU9J3[<6]MIV>1S&\"0"Y%XDIF76S%P&G6DWRI
MT>**SG1,HY4,9(_W+G$$3?((FVE-N'$-OH"/HZ]%@LF2,-Q8!K0#0-W/_54Z
MLR`!*G?HQ^6U==>,4_X:D^W%O;:\]V>1S&\"K0">,4_X:D^W%O;:=GD<QO`D
M`GC%/^&I/MQ;VVG9Y',;P)`)XQ3_`(:D^W%O;:=GD<QO`D`GC%/^&I/MQ;VV
MG9Y',;P)`)XQ3_AJ3[<6]MIV>1S&\"0">,4_X:D^W%O;:=GD<QO`D`GC%/\`
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M@JBEA@K`E>J+*4P[&9C3.F97<2D61$[E`3!TA'>3`Q!$#!/3X#F:G8]HP^LB
MXMM#'`BZX.B#`P-EAW-*@J<7P&H<'=MIK`1`O!!B"+;=%MHW="T$PX),BMFY
M'$BA7IY=K7[C"P]&GJ9<[%BFO(6&5Q5)1$/`Q<[<W]KCJU`N,8]+;MB2(=#D
MI$ZK0$$D4D=67X7F,N@S#:]K2YI+@R$PP$P$DA@:7&_`F%H$#$DE595?@K9<
M'5]*YP#@`YP+1$L(`!-@%V(&@$V0%BQ3_@@S!/47)M>L]BDYNR6Q*@Q=2G7T
M?<G*-8K=.OY\JN:T#\+&WO0Q3JV2+AF@MWX/*(QK1D(NQ41(">IPO,4N?*F2
M<*K!*9?+@)?C.<S5QA=N1#0#"[=O%W)MMV%;@CY4QLW$:8S'!H:3,B6@.O6&
M,1;$:8P`ML5E&\!61(V&,@5XDY?`LWDA@G]-LLQ1)1RCEZUY9-7+6UG;5*6R
MX5%TZM'1W(R,FO(O%6Q'"RYC#N!H_#<S/G7_`#57!NB(80X>YMEQ;!H:UP#8
MB#8`&`"WE5>`RZ02#B5,Y\-)>#$WW/MMMM=PB/<6I'7`7F63OU@IP1]M)4RX
ML=0Q,OR5=(TMLG+N(7`43#UX9QA:Y&4L%2,YP^[4=L%&<8HR+(.0*HMT@BAK
M1PW,3:=D_P`V56NUT=6);BT",XET"T`.]T$#%T8"P0(5=M;@AG/DG$9!89-V
M^7B,82Q`.C$@W#$0'JVQ6T87@+R#3#H6BH)%0O\`"PT"TK3]U7)LR$8I"4/,
M%94K[6=>/Y2RLJ;(3V3FS[H@**$2)$)$YLVQ/FN=.PW-%1&3/PJN-,YQ+@)9
MMB^6Z,``TN`ED1L\8F._=95X!*<R=)Q.E;/8V`Y8YKQ")),(NCNZ%F0X&<@,
M+56+/!62Z1S>CDQK`5>HKTZNR=54HU)IDU39Z$GQD8-U:GCN[(7&:=/!:RC1
MJJX7;BJBH9#?-5.%9J=)?)F8-5DS-87.#)@=?>X.:YL#=%RXP"+28`P(C!66
MUN7FS&3&XK3G5W`UI=++;K6EI!L!,;SC81N1B1%8N,X+L[PCQE9(.4B(.PQ+
M*Q5V`J['']P=XFK%9M=;C*[.#6:S)7=:;@Y1T>#8O0;-GZ4.5=L)2M0,NNL;
M29@N8IC3)F8/B+Y3BUSG%L)CG-<7"\X,@X<HB);>MTP`"W;B6"M`>W%:-LQI
M,!>!8UIA$!I=9XHL!AW(DD\[<?6)9S&N'N"ND(0=@",J?$?B&F13N29"FY?)
M0.,+[%LSK<V1-(7;I!@)S%(`%V[=@;`UZG9_EC-DRNQVJJ<.JV.G83/-LMP%
MYT^2Z`CZ\%MBF.8!V&GIZ:MIY@DS&1@\&#6M<V\=X:(]TK54?5+..YLK\L/)
MUFB@^AK,S*>:#&&'U>CX-RJLS#@/RRG\L*;1]0M0B3979@>3W$KZVJ;\GYK,
M88=6=4Y6V9CR^--;3>6%.8ZFVT1+LK<R/*'49*^MJC,R9FXQAAE;U3N)7)69
MLN@VUU+U@6P(RD7(=T0J\V(;O68*^GZ6J$W).<2(#"Z[JG*]+S3EH"VOI>L:
MIRPH=V$O)5)X>K^MZWH?`USIF1,ZG1A-?U+E=EYMRN!;B%)UC5?&H-XVC^Q*
M?^ARWK:A=D+.Y;`83B$?T+N)3C-^5?I&CZQJIFQ_>=@_L1G_`*'+^MJ`Y`SS
M#]T8AU+N);C-^58_O&CZQJMQQ]>MH_L0L/5\&K_A[NM';/\`/5VS",0ZERG;
MG'*=G_,J/K6\:AU/QQ?$HR0*-/G!$;3;5/E%84B"ASM@?J;#-DY&5!=;8;V;
MD5$S.C;5110$W-%M8ID'/4R<PMP?$2-1*'B.?HEM&FXR'XD#<\6\Z%XZR,X9
M4:P@XC1#EN/CM;I)W(GA]MI@-"DQL>7W;]1UB^ACCVNN6=GF?/H?$>I<K(SE
ME*'[RHNM;QJAY.K]]9EC^AB_K:C.SS/I_@V(]2_B4OUSRC])T76M5,<<W_;]
M1=D^AB_K:T?L[SZ8?\FQ'J7\2W&=,H0_>=%UK52-CC(`[/V%V3Z%K^MJ$[.<
M_D_N;$NH?Q+=N=<G_2=#UK52-C?(.SZBK+U?!;CUM1'9QM`^A<2ZA_$I&YUR
M?]*4/6M5$V-<AB/)2;+]"W'K:B.S?:#']RXEU#^)2#.^3@/WI0]:U4!QGD3:
M/["+-U_UJ<>MJ-VS;:$?X)B74/XE*,\9-A^]:'K6J&6C%F0U9*DF-1;&84;:
MDL0QZN,@8AP@9M,!2<+2,>:(/\LV=*33>*;NU($1!05$[M!LYVALD5;?,N)B
M]3$>]O9'W2680#':S1XA+![:_P`FZZ&=G;)KGRB,4H3=F1]\:8<EPC&\+NGQ
MK=Z%L1)#8PR.(<E%M'T)<>UURSLTVAP_<F)]0_B5P9YR7']ZT'6M5,<7Y(V#
M^P2T?0EQZVHG;--HD/W'B?4/XEN,]9*C^]:#K6JB.+<E?6):?H0Y]KJ)VS+:
M,19@>*=0_B4GU[R5]+4'7-5(V+,ECMV4.U?0ASZ'\KJN=F&T<BS`L4ZA_$I&
MY\R2/XM0=<U4#8JR9L^H&U=7P0Y]KK0[+]I$/W%BOS=_$I6Y^R1'][4'7-5(
MV*<G;/J!M?T'<^UU&=ENTGZ!Q7YN_B6XS_D>/[WP_KFJ@;$^3^3]S^V?0=S[
M74;MENTJ/[AQ7YN_B4K=H&1OI?#^N;QKY#$V4!,4`Q];1$3%_69U\<'^]U!,
MV5[3#&&`8KH^3OXE(W:#D4&)Q?#^N;QKE+A3QGD21K.8U&%(LSPC;B>SLP<'
M;Q3A4J#UI96Z;IHJ)2^Q7;G'8<O5`=>^VD[,=H\_$,+=(P+%'AN7\/:84[S!
MS91!:;-(W1N+BY=SQDVDIZEE5BE#+<^OJ'M#IK1>8]T6N&^UPM!W5U`.(\I?
MP>VWZ#.O:Z^;/V4;3B;,OXM\W?Q+T/VA9#^F,.ZYO&OD<1Y3Y?W/;=U/`SKV
MNH';)]I\;,OXO\W?Q+(VAY#^F,.ZYO&J!L0Y4$/WN[?U?`KKVNHSLFVHG1E[
M%_F[^)2MVB9"^F<.ZYG&OCR095_@[M_T%=>UUH=DFU*/_;V+_-W\2W^T3(7T
MSAW7,XU;FP]E?^#FX?05U[749V2;4[?_`.NXQ\V?Q*5NT;('TSAW7,XU3'#N
M5]@_N<W#J#^LCKVNH3LBVJ?^.XQ\V?Q+<;1\@?3.&]>SC5N;#F6AZF-KD/P(
M-U[74?V0[5(?]NXQ\VF<2E&TC9\-.-8;U[.-12P85RVI(T\_DUMWRFS"IM5J
M:[XP?."<3^4+G?L31*P[^SI!4W9A+M2YG8H*J=VAV2;4V4U6TY=QF+Z:`]QF
M,B=;*,+NK=K-$;D9?/O\BZZ*?M&V?NF22W&L--V;$^ZL=`7'B,;PN:0+T':;
MMWE1$@-AC+FW][2Z=3K0;L?_`+NN1]C^U8_^W,8^;3.)7F[2MGD/WWAG7LXU
M3'#&7=@_N9W7J>`G?M=1OV/;5SHRYC'S:9Q+8;2MGD?WWAG7LXU1-A;+^S][
M*Z_0)W[74#MCFUG<RWC/S:9Q*0;3-G<?WYAG7LXU1-A7,&P?W,;M]`7?M=1'
M8WM:C_VUC/S:9Q*4;3=G4?WYA?7LXU0-A/,(C^]A=OH"[]KJ/[&]K?\`XUC7
MS69Q*0;3MG,/WYA?7LXU2/A+,0_X+[OU?`+SVNM3L:VM_P#C6-?-9G$@VG;.
M8_OS"^O9QJEY$<Q_P7WCZ`//:ZA=L9VN?^,XU\UF<2W^T_9Q].X7U[.-4PPA
MF3:'[EUYZH?K`\]IK#MC&UTBS+.-?-9G$I!M0V;_`$[A?7LXU%*M@O,)(Y\5
M+%%U3WK!8SJF1J"\:FX6-+NN<<`@B]DBK&,(`4RXJ%,N<@G%-(1W"]'%]CFU
MZ;4L=]7,:>!320/<9DRZ!+:+MXRV0@8\B!#(W;SX7C6H-INS>7*<#C>%M=K7
MD^ZL9&+B;T+SHQ'MH\KQH-C`;^PYPIW6YV0HY!@YJF5",,FK*#)MSQTK-`;:
M)(R'26*)@!42[%W`ANHD'V.TX@`>^V3>C'G'-^80<]459A&5:<AT[7,,J=41
MC"3(#A'E0]TFP@QILB\B'C-HVWK+.6\&/U1JJ;$LPSP1*U;A,E2=^9.(.Y[2
M7I>[3!H,?6>-CV$/',(F,03:1T8S;1[!JF8QB-F;1(B#=$ICF,<P)I$`-HB(
MCUQU_4/#\/H\)H)&%X=+$K#Z:4R5+8(P9+8T-:T1B;``(DD[Z_`=965.(5DV
MOK7F963YCICW&$7/>2YQ,("TDFRQ7NT/1#U0U<59-H>B'JAHB;0]$/5#1$VA
MZ(>J&B)M#T0]4-$7)?$:(>6#@2Y0_P`9^S]?_P#J]G_7H<%_=V+?V%O^U4ZL
MR/>IWZ,?EM76FT/1#U0UYY5DVAZ(>J&B)M#T0]4-$3:'HAZH:(FT/1#U0T1-
MH>B'JAHB;0]$/5#1$VAZ(>J&B*`;0WMNWD^Z1ZO_`(;-6?;_`-P_WE;^U_D?
MTEVW'?JK8/T3'_VL;:\4H%S#G24>Q&>>&YTP5*BN,-G1/?,FFJ&X,#3#[-U0
MIB_#)AKE9FQ:OPC*E5/H'ADUU13@DM#K/=#H(*]/EB@I<1J)DBK:72@UIA$B
MV\!N=PE2XV0+6`<D@EU?<+/L.OBYSUF8#W]O5R^BO>#*6`D^\N\M_&K<V1+:
M`\DBEU_S`R[#J+Z^9H^';U<OHJ9N3\OG\R[K'])439'MX=211[09=@U7=G_-
M0-E0WJI?14C<F9>/YEW6/Z2LS9,N8=231^AS#L&HG[0<V`65#.JE]%2-R7EP
MZ9#NL?TE;&RA=0ZDHCU_UNC^Y]0NVB9N`,*EG52^BIVY(RT?S#NLF=)0;(_$
M3:L;4:SWN14>S#.L1HR"L3#1D$,M)'.Y;LFS&/[Y*1\<5RZ=.R$*9==%(NW:
M8X``CK%-M`SG55#:=E5+:YQA$RI<!W3!A/`%%4Y/RM22'3YE.\M;O3'_`'W#
MV5J*O\=J<_<QQLH^<P&16+B::6.H3B5+0=UUW!7.ET9RW6DF\FXAYE1W,WU@
M#7O<N[!P(G1+^62@@,]1G3/<B2:@54MU/9!PDL,8M<[1JXB`88Q`AIT6J&FR
MUDZH>)8IWAY!-LUX@(M'/A;>$.#38I6QXS:G*``QF;<</MML1H8`VEZNJ(75
M<B*B-4,4!WB3ZB;A,P-AV*;%"<GLR[:,S/FT-GC3'#D7_P!79XG.\3Q>ZN@W
M)^2C[0>-=]^?XV]X^GN:5#+5Q\UZO0B%@BKVQO\`'J25ABG'DZ8P-M<LGE8A
MS2LJ@X08&$2N2N%V+!-/;O'?R;1(=G.@(;R\[[1)DS5.J&RW0:>7)EMC>,!I
M9O1=^*UQW%'-RKD>2S6:ISVQ(-V:\P@(G0[?@/5<!NJ05;C#F+"%A:3$L./K
M'4IIW7[-5;JVJ#:5BWS-G5)`[A)Q%/I:(E8A1K>8G<=MG"B7./DTC;J@[NJ=
M3M"S](NF75LFRGMO-<R1+@1%PW98(,6.L(CR2="N4N2\F3VN+Z9['M=`ATY^
M\T[CR".4VT$BT;MB^HOC(:RTNSK*&5*4E;)!M,/FE4.]J:M@6CX*0F(Z1?I1
M[<RJJC9%6`>&,)0$2@W5`0`4E`+7G;1=HLJ69QG>X-(!=V>7=BX`@1+/PAPC
M?"EE9)R-->)8E>Z&,!KWQ@"03"_W#P%6!.-RO+LZ[(M\XXW6C[=/FJE7>)R5
M4.WG[015HB:NQ:H;2NISG7Z`=%#Y<//)B!=ARB,3MHNTUKGL,QP=+9><.S2^
M2VWE'D6-L-NBPJ5N2,@EK77!=>ZZWW=]KMX<O3;H6-=<<'-O6[6,OL%8&RT?
M9WRLU"^*+J!CW%1M5&I\O#24F*Q$FDR$QD%B5-$P>S`#AM`PI@I$-H^TNX7/
MJ6L<'-%TT\L.(>U[P0-7:V$MUOJ=V&3D?(@<&MD.<"'&(G/@+KF-()OV&+Q8
MKX_&O$@QM,H3-V-S1E)D4XBWORR52,TK4JJY79)QLRL`B1@_.]:*H@D<0/SJ
M1R;-XA@"L[:7M1#Y;-:Z_-;%@[-+BX0!BWD6B!!CO$%6&Y$V?W7/,L76&#CK
MW\DZ('EV&(@N)?.)YANEA@N$5TO-L))HCQ>8ZF8Q=&-BE&JQAQ[DP6CM,Z*`
MHNVRC=T)B\IB'`P#R\FO8Y"VIYZJV8Y+JJMON>"3G`:F4TAPG2!;!@-D2(%5
M\7R%E2BDR'T<AP$Z>UCCK9ABPM<2!%UD2!:+5'H[+=X(">Z]BPY=GU/PH]<`
MZ[+7%?M4SPW15MZJ7T57EY`RJXP-._1\+,Z2G<=F*^@!=C^*ZH!]3D'U-GZ!
MU4F;6<^-)A6-ZF5T5>9LYR@81IG];,Z2GD;FC(!3$`)")V".P?V-P76$/SCK
MGS=L.T)HY-:WJ9705V7LSR8Z$:9_73>DMA1>;<B!N[)*)]#ZFH'N#7.F[:=H
M[/%KF=1)Z"N2]EN2'6FE?UTWIJ?L<Z9)(4N[)Q`<GULP'6VA[@]#7,F;<MIH
MC"O9U$GH+HR=D^1'^-23-'P\[IJ_-GG)@!R2L3]C,!W!JJ_;MM0!LQ!G42.@
MK3=D603IHYG7SNFK4V?<G@&T):(ZOUL5_P!#]`:C=MWVI`P&(LT?)Y'06[=D
M&0"/U.9U\[IJ@'$#E(!#9+Q/5#]J]?\`1]*/VZ@=MZVI@68BSYO(Z"E^Q[9]
M\CF=?.Z:U[CW.N0(Z)GFT4ZK<>W-?K^[70CZ7CIB@>2?6F1>2;M1&KMW+%1X
M]?+G575<"6265.8[PA'`J%"]C&WS:NV?*CB+;:20;9##^;;\+*:[U`T&4-$H
MN9`K2GV0Y`FM<9E)-<X3'-MGS+`TP`Y,PV`6"/*YP!4T-Q#Y5#J3$1]BU=^E
MVN(?2`VKB/\`S)GS>1T%=;L:V>']BF=?.Z:H&XBLK@/),Q'4^M6N?2W4?^(/
M:S]),^;R/BUM]C.SOY%,Z^?TU;FXCLM!U)J(^Q2M_2W4;O2$VM0_>3/F\CH*
M0;%]G1_8IGSB?TU0/Q(Y<`.2;APZO[5*V/\`\-U6/I$;7!_$V?-J?XM2MV*[
M.";:*9\XG]-6QN)3+X;-DY#_`&)5KZ6ZT=Z16UT:,39\VI_BU,W8ELV/[#,^
M<3^FK8W$QF(`Y)Z'Z_[4:S]+=5W>D;M?&C$V?-J?XM2G8ALU^0S/G$_IJW/Q
M.YD#J3T-U/K1K/I_U-U"?20VQ?2DOYM3_%K=NP[9F=-#-^<3^FM:WKB/R>_F
M,7'DW=2D7$;D1&4@W$C0\9/%X>8;U6TI)RL.I86[9]'RI6+A=$%X<J\H"*RA
M0(#<[@Y>IA?I(;9#35[ABC>31G13,$8S90MU<ES2+=$XLDQA%U^XTQS]B6S:
M5,DL913@)DVZZ%3-M%USH&]-!A%H/(#G6:(1(G9^*/-(;=E@A>M^T^L?2S7!
M/I*;9?I27\UI_BU?;L)V8'303?G,_IJD/%-FH`']D$+U/K/J_P!+-0N])?;,
M-&*R_FM-\6I!L'V7Q_4)OSF?\8K8_%5FT-NRQ0O6_:=5OI7J%WI-;:!HQ67\
MUIOBU,W8+LM.F@F_.:CXQ41XK<W@`_LBA>I]9M6^E>H'>D[MJ&C%9?S6F^+4
M@V![+/H^;\YJ/C%2'BOSA]<<+]AM5^E6J[_2AVV#1BTOYK3?%J3[`=E?T?-^
M<U'QBHGXL<Y!MV62%ZW[3*K]*M1'TH]MWTM*^:4WQ:D;Z/\`LJ.G#YOSFH^,
M5$>+7.@"/[)(7[#*I]*M:GTI-M_TM+^:4WQ2E'H^[*"/W?-^=5'QBH_=<9W`
MX;+-"AL.'[2ZI\<'7[U;=1.]*;;B!9B\KYI3?%+9OH^;)R8'#IOSJH^,7'W!
M]Q-YEKE7S@C$6&+03E.*[B"G7I5:K7'0'DY6U(+OET^DQRG,$55Y03)L(4.0
M```#7TG:EZ3>VF@Q'"&4N*RFMF9;PV8[_5:8Q>^22XVR]T[F@;BX&6=A^S3%
MY%7,Q"AF/?(Q"HD,A43VPERGW6-L>(D#=-IW2NL3<8&?`ZEHA>KL^HJI?2G7
MR\^E3MS^EY7S2E^*7J&^COLD/\.F_.JCXQ4C<86?0`=EHA/L*J7TIU$[TK-N
MH,/.\KYI2_%+<>CKLC^C9OSJH^,7VPXS\[LGS-V[F*W+M6[A-5Q%O*?7FS60
M1*.T[59Q',&CY`BH?%I*$.4>4!ZPS4?I:[;Z2KEU-3B--4T['@NE/I9+63!N
ML<Z4QDQH.^QP<.\L57HV;)JFFF2)%'44\]["&S&5,YSF'<<&S'.8XC><T@KU
M8P?F"C9QJI)R";,V<PQ*@A9JTN1L>0@GZI3;I3@4@"XCW8I',V<``%5(40$"
MG*<A?Z)[)MKN`;6LNC%\'>96)R0UM52N=&93S"#IYTM\"94P"#P#H<US6_AS
M:5LUQS9KCAPS$QK,/FDFGJ&@B7.8-[FS&Q`F2R8M)&EI:X[IZ`Q]Q-.UD?::
M^J:R9SCPE?.DZ`Q]Q-.UD?:::R9SCPE$Z`Q]Q-.UD?:::R9SCPE%JK(T=!'L
M6&2NX>%<KDR>=>+7>1=&<KQS]''E^,+R+4M;]C)L7XLN>1%:!3=S',JJ$YH&
M1WBJ?0HID[4U5U[P-1;`S!$:R78;@((C`PF$,C`QO709&1NNWKO=WQO??L]>
M"VKT!C[B:=K(^TUS]9,YQX2HTZ`Q]Q-.UD?:::R9SCPE$Z`Q]Q-.UD?:::R9
MSCPE$Z`Q]Q-.UD?:::R9SCPE$Z`Q]Q-.UD?:::R9SCPE$Z`Q]Q-.UD?:::R9
MSCPE$Z`Q]Q-.UD?:::R9SCPE$!@Q`0$&;0!#E`0;H[0'T0]AIK)G./"BU%AA
MC%A7+*BV81I&S;*&4T44FT;CYHBD;Q[G#N2E1QZ^DHH3F=G4,<[TR4TH<1-(
MI)O!5+KHXF^;KI9<YUXT\K=F'\VWX0`Z.;%G,);!2S?&&_=&_O=W_)O6+;O>
M]A[B:=K(^TUSM9,YQX5$OSO>P]PL^UD?:::Q_./"LQ*=[V'N%GVLC[336/YQ
MX4B4[WL/<+/M9'VFFL?SCPI$IWO8>X6?:R/M--8_G'A2)3O>P]PL^UD?:::Q
M_./"D2G>]A[A9]K(^TTUC^<>%(E</\5S1JGG#S>92-FY`-Q7VD#`1%,H&#[D
M[B1'E`"@`\I0'\#7JLO/<<*QF)/[O9_M=,K5/[U._1C\MJ[@[WL/<+/M9'VF
MO*ZQ_./"JL2G>]A[A9]K(^TTUC^<>%(E.][#W"S[61]IIK'\X\*1*=[V'N%G
MVLC[336/YQX4B4[WL/<+/M9'VFFL?SCPI$IWO8>X6?:R/M--8_G'A2)3O>P]
MPL^UD?:::Q_./"D2G>]A[A9]K(^TTUC^<>%(E:!Z*U\HW,]&0YGR[[_-<RGS
M>]]S-MWN;W=W>V]?9MUU[SNQ1B8]D_WI3?F_Y']);OCOU6L'Z)C_`.UC;7%4
M"YBSE%/9C/7#<T8D(=8(7.J@@HH5(NZ$#3"?#&Y-N\H&N7F3"*[&<JU4B@:U
MTUM13N,2&V>Z#25Z;+.(4V&U$R?5$B66M%@C;>!]@%3(V/+0(?TJU[=1]?7Q
MEV0LRPLE2NL:O=#.&!`^^/\`(*MS8WM8CR-6G7_-R.HOJ!F;X*5UC5,W.>`C
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MHN5S"//"50-QD//`:\/E29CGDQ<Z<";9;Y4(QW&O,/4&Y8M#FO*46EDV<UK0
M``)9`L>R9&`%D2RV$-)6F/O9\K*)4I6\VM3($S2K).SA9^=K]);2%D;6R1K\
MU;&]F28HD924],S-9:+$F!3Z4T3(**)`3!,$[3LF9U&L%-2R);)C`("H$&EH
M(;=MB&@.(NZ#I.[&&7F;*X#-;43'.:\F)E$Q#H%T;(7B6BV"F2GF_P"4=5]G
M4WTO)N*]#88;8>KG19*)C9R!#QA96*4NK*7;IBGXR2+ROPNP.C@BGWL#:"A5
M3%"F[(F>=89TNFIA-=/UKO=6D&RZ&D'<`+MV/*W(*T,UY1<P2IE14&4V5<`U
M;HBV),>[!MD-+8VK7R7FT;P9:<D97+=UL$_:KK-6VT3TL%)<NY2.LCK&$C,T
MIHBK'JHPU;+(8CB>@"CM<QS3G6R:@IF3%/9^2,ZFZV704C93)8:UHG"PM$P!
MYMM=":Z]N.,"1ICB7FO*S6\JKJ"\S2YQ,HV@W"6Z-$9;8;PLWH2K[W;)D"3.
MWGK*Q=24\G80D8N>@XV6CGR4?F".2-%23=ATABH@3,S]1)4H\ZFJS;&*(?+-
M^F[(.?2`#24A:&W8&:T@B,HVB-L=4V(W8GN*?ZV9.O!PJJD$.)LED:;^\-(O
MF"A-,\V9=Z*[CCP^07:D4E=)N]3E;=5^C+04].3=<K5/,](BJ15]#RT;6*^L
MW:/TG"CE%:5>+@/.&2YO:JR'GFJ:Z_0TVL,H,:[M/*:T.<^&\07.!+80(:T:
M(QQ(S=E23<A5SKC9A>1J70)(:V(LB"&MA&/MG;ZRC#S:DY'(-DTK--JKI1S&
MN.G:KJJ`9[3H,,;)U>NB@E'IMVRT&VQ+"D-($`73S<<&5Y5_E=69D#:%,C_J
M=)")<!KQ8\ZR\[3[;6OY.@60T6V)6;\F2X'M507Z"=4ZUHN71ZVK;W^Y"VLW
MFQU;+"-H=VY<'&-1-WJ<.W%<?MFS\U[O%Z%^]BCMV[66`5<@R#$45A!,6PD/
M^/%WQCE;/]H\F89C:6F@=,)[02+C&0!B2/>VNB+8V:+%+,SADB8R!J)]X:(R
MG$`WG.T0M\8B'=CIM7.W'O@*SXYHG!55TV,:SB(CBFQ33X78_BVZ1$8W&61V
M;`BB3))JP9)=&8#R)IIHI[`*4I0V!KOY(V5YYE/QZJJY$F_/P>>!"<UQ+WSY
M#NZ=PVGUU9Q'/N5:FEIY%'-F%M/-8XQE.;!C6N;$;FZ+`K".Q/;3@GNFK_5V
M\MBC`ZX>BKKA/V2YX=HII?6-4,K:'E=IMFS='P;E.XW#]R$"[!KW5`?JCB_0
M_HNJDS8_GQQLII76M5YFTK*0A&=-ZIRGL;AFZF,F(#7>KM^J6*#K@/Y-KGS=
MB^T!PLI976M5V7M0R>W3.G=4Y;#B\)7D=S8%=Y?^4L5V77.F[#]HK]%+)ZYJ
MMR]J^2VZ9T[J7J?L,%WTY2[H5OJ#^V>)]/\`GVN:_8-M+=&%))ZYBZ$G:[D=
MGC3Y^CX%ZR!L#Y`$.0M:ZO7M$3V75=^P'::3922>N8K3=L.11IGS^I>K4V`L
MAB'(2L]7ZZ8GT/Z+J-WH_P"TXF(HY.CX9BE&V/(8'O\`/ZAZH?<_9&VA["L]
M;]M43^(KMU`[T?-J!T4<GKV*3[9LA?#U'4/4'H^`,BK1LR=,*F=,+I=4R&1N
MU+>%V)6-^F8#J5Y!BS26*H0P'16*H^1,`D=**+@<XW<6]'O:@^?++*20?]5D
M@^[$0(EMB/='.<8;[2)9TRVM9`*.FVR9$EM<V9.J&DS'$1D'022#R0!:+;8N
MWR3$J5FX=\E#U$ZQ]E<1V77&/HZ[53'_`%*1U[%=;MKV?C]HJ.H>J)N'3)8C
MM!.K]3Z[(CLNHO\`#GM7^12.O8MOMLV?_**CJ'JV-PX9.'J)5?[+8CLNM#Z.
M.U@C]2D=>Q2C;=L]'[14=0]43<-N4!#D2JW7_;;#]EU7/HV[6C^Q2/G#%(W;
MAL\'[14=0]6YN&G*0]1&K?9=#]EU&[T:]K9_8J?YPQ3-VY[.A^TU'43%;FX9
M,JB'(A51ZO[;H?LNH#Z,^UT_L-/\X8I#MUV<_*:GYO,5L?A?RP/4;U7J?7?#
M=EU`?1EVO[E#3_.):W;MWV;C34U'S>8H#<>&+**4GCPJZ-+*HXO**#7G[]1V
M:IG!J[8E`*S1FVSQU).3)IF#F(T[:0W!,H53F4UDS]+#?1FVOMIZX&CIVWJ0
M@#7DWCK99A&6YK6Z(QFA\JR!;>+'-CG[==G3YDES)]4X,FQ<1(/);=<(F\TF
M$2!R2UUNF$09@?A8RX.W8VJG6_;A"]FUQ#Z,&V+Y#3?.9:O-V^[-!IJ:GYO,
M5(>%7+P@/Y6JG4^O&%[-J%WHN[9#HH:;YS+4@V_[,X_K-3\WF*V/PHY@-MV-
M:GUOVY0O9M0N]%K;*=%#3?.9:F;Z06S$::JI^;S%2'A.S$(#L:U/J?7E"]FU
M`[T5]LY-E!3?.9:D'I";,/E53\WF*B/"9F3W)4OLSA.RZ@?Z*>VDZ*"F^<RU
M)_B%V7_*JKYM,5(_"3F4=NQI4NM^W2$[+J(^BAMJ^04OSF6I&^D/LN&FJJOF
MTQ4!X1LT"(_E.H_9I"=EUJ?1/VU_(*7YU+4H](K99#]:JOFTQ40X0LU"<-C*
MH\IP_;I""/PP=8%=HZB=Z)VVTC]0I?G4M;-](O96#$U55\VF+CW@\X8,LV2K
MYQ6BV=:,G%<6'$'`O!<VN):[)&)M:#=Z1'GE`!=$JGPJA=I3!RAR"&OI&U'T
M6MLN(8AA#Z6AI7-EY;PV4[_698@^7)(</4!W=U<++>W;9Q@\FJE5]34M?/KY
M\]D*=[HRYK[S"8:"1I&XNLS<'>;AZC&H=7;]6T'V77S$^B5MO^CZ7YU+7IF^
MD?LI'[75?-IBI#P<YO';^4:A]F\'V;43O1'VX$Q&'TGSJ6MQZ2.R@?M=7\VF
M+Y;\%^;'#EL@X3I;%NLNDFN^5N40NDS1.<"J.E$&ZAW"Q$"")A(0!.;9L#EU
MF1Z(.VV=/9)G4=')DN>`Z8:EC@QI,"XM:"YP:+8-$3"`M6TWTF-E4J2^9*J*
MR;-:TEK!3O:7D"QH+H-!<;(FP:2O57"N+<>X2J:-?K[Z-<23HJ"]CL*[IH#^
M>DB)[IEU1YXPH,T3&,#=N4=Q$@]<PF,;^B&RK9)@.RC+C<%P647UTP-=4U+F
M^Z5$T"USM-UC;1+E@W6-WW%SC^']HVT7'MI&.NQ7%264;"6T\@'D2)9-C1HO
M/-A>\B+SO`!HW%WXB?"D=VZV[+KZ?J9O-=P%?/H%._$3X4CNW6W9=-3-YKN`
MI`IWXB?"D=VZV[+IJ9O-=P%(%:TOTI%'G<3['T.H)<BB('5G:8S51_8-=@$[
M5M9(Z1?2BQ@-N"A#JLI0J9C*@L+5-TBK>HY4T2:CDO'N/->?SC-):0!ZKPYF
MY"\6D;L!@[\7N[X^ZVSUX+9??B)\*1W;K;LNJ.IF\UW`5I`IWXB?"D=VZV[+
MIJ9O-=P%(%._$3X4CNW6W9=-3-YKN`I`IWXB?"D=VZV[+IJ9O-=P%(%._$3X
M4CNW6W9=-3-YKN`I`IWXB?"D=VZV[+IJ9O-=P%(%._$3X4CNW6W9=-3-YKN`
MI`IWWB?"D=VZV[+IJIO-=P%(%:LQ$^AF\!8A":AU3N,D9*<K`A+45T5!16Z3
M`IMU%J1%PL:#@K7FS'(Z(O*I";<?.%W(**&Z&)2YKIS.0\`2)0\68/:#GEQT
MQT08?:`-@%),!B-/BC?WN[_DWEM/OQ$^%([MUMV77/U,WFNX"HX%._$3X4CN
MW6W9=-3-YKN`I`IWXB?"D=VZV[+IJ9O-=P%(%._$3X4CNW6W9=-3-YKN`I`I
MWXB?"D=VZV[+IJ9O-=P%(%._$3X4CNW6W9=-3-YKN`I`IWXB?"D=VZV[+IJ9
MO-=P%(%<0<5LC'JYP\WH9)\S4*GQ76DRADW2!RD+]R?Q(EWCB4X@4-XX!M'K
MB'HZ]5EZ7,&%8R"T_N]FX?E=,K5.#J9WZ,?EM7;_`'XB?"D=VZV[+KRNIF\U
MW`55@4[\1/A2.[=;=ETU,WFNX"D"G?B)\*1W;K;LNFIF\UW`4@4[\1/A2.[=
M;=ETU,WFNX"D"G?B)\*1W;K;LNFIF\UW`4@4[\1/A2.[=;=ETU,WFNX"D"G?
MB)\*1W;K;LNFIF\UW`4@4[\1/A2.[=;=ETU,WFNX"D"M!=/8^4/I/36G1O+Q
MS?2.D(\QSGW,VS<YW?YO?V];;MUU]6_L5V!O=DT0M_65-^;_`)'])=&`0I1,
M8"E`QQ`3F```3B``4!,(!M,(%#8&WK:XB@7(6>WKMAG;AN79.%6JW>?.A.<1
M-NFW1@*<82[=@\F\4!^"&N'FZNK*#*53-HIKY4PU-."6F!A[I8O5Y3I::KJI
MLNI8U\NXTP.B-\!2$UJLFS]6Y#J_DX^MKX8<S9A`_7)_E>!?1FX#@L?U63Y*
MM3VVS`/).2/7_FX^MJ'ZSYB^6U'E*=N7\$A^JR?)6FLT<1\AA>`@9Z6<66<"
M=N$'6"1\.L8[QI'/#K/[3:UR`@N8\/1*C'/IA\4I><4;,S));5E$RFDI,=S/
M6S'L97SVW6%UKN`>JYQ#1W3O*M689E^B:QSZ22;[PWQ>$^L(GUEAK7Q?8ZI<
M;)S%ES,VC(Z%4.C)K;\H]6:+)3]KK"R1V4='NWQU6\U1IE)4I$S"DG&.%C[$
M4S*:B;C.<YI#)555%SM'*AN-.[W'-X0-)4QPW*[&ESZ>1`&!Y/=(_HGU(&*U
MZ/&J_-=)NG`>40+4W],-:K*YLI35MK6LL6"(A<*V:"D(R&E2V%#)R$@Z<(I`
M#8D9WL<%>+)D%%979V,9J$AL[SA4Q>'76@VQ8"9@(,(7(#?C>$`;0-9=!EY\
MUTOL5/<81>=`0`<0&D0C&,3ZD#&%D<M+<9+)2LURT4FQV"[,;0^M:,29(LM6
MD7L52Z)+Y!GK&P<V&&:=\H`D/'($;/6Y%&;M600YI4X&VZI-QO..M?*GU]3+
M+`V/+!@7.#`##08DQ!M$#$*R<-RN`UTNCD/#B8<F&@$QMTC<B+(PM6JXSSAS
M>6B:C9$SVEA6+!2H&SSTE)SC1L^H\W.1&6'BE)GXA-HX4[]P\SB5U'.C%5*0
MJKM)0I3)_#23<3SDR8^5YRJ3-;,+6@.,'@&6+P.\1,!'J%:2Z/++FMF&@IQ+
M+`7$CQ20_DGN@M@>[NPM5./\X.YD:2SNY(^_M&IX^GNI>)=24>$S!24A0K)D
MW)E;>-D@.FI.X>I]86&41*<!4?JI(`"13<[J*9BF<FSS3^=9]Z+H&\8.`>V7
M+<##Q9KG"Z=Z)MT*9E%E@RA-\W22V`CR18;I<]I@3:QHB1OV&%A4I:\<;&&@
M;'+98OC'&+RJ61E6)MBA>6%^:LY&3B3SS5FJ^J[#IC>5C(A)527;K,D@C.CJ
MJ&45:E*Z/2F8WG=\QC*#$*V:U[2X&)82`;L8.L()\4@\J($`ZQ796%958QSJ
MVAI998Z!@`ZV$866@@:019`GQ;5FW/&O0VR5P67S8Y11HKKH%B64:V$J0/N_
M"U=%I`JC#<W;W)9YN=F)(@7QBN2\V(`;DU2./;0298;6UD9@BWW0:(7HFWDV
M6\J%EJN^9\E"_>I*:##`\@[]VSG6V<F-MFE6-TXHLJL$L/2F,BM<FU?,,]%P
M4393Y--5&K09ROS%JB)5L@6EV89B+=P4`Z4$P*-U"+<TGN#OF.G'(S/FQ_:&
M5F+5TF?3M)+?&C!P:1XS8&+AOB$3'<,=5@N6I1D.I\.I)DF>8!UHW+T;&NL@
M/5T6:81F&X]ZD\J]@L]@RI+TXM4G)2!GXN93G32"#AC;;14F*T2DG!D6M3:5
M<5-TJ"D4F\10!-0BAP%(XZTGXYM$;/;(DXA63+[0YI$P0M:UQ!MY)%X>-`F(
M@+5+(PK)3Y+ILZBIF%KB""PQL<6Q'.C=.B.@[RS,GQO4V*;SSYSF:;5C*RG#
M+3DQ&0ERFX)DE88V+F8@Y9V&KC^'>`YB)MHY,""Z@HH."'4`@#JDW,.TB86M
M;7U@>^-T&<QKC=)!Y)((M:1:+2"`K3L&R*P.)HZ8M;")$MQ`B`1:`1H(-ALC
M:D7QLTN>G4:W#9V.]E7;\L7'<V:93BY>1%=BV,S@Y]Q%I0$ZNBO)MBJE9N5Q
M2Z2D)]T#@.H)V9-I4J49SZZN$L")]T$0+3%S?&;H,(@1@8:%-*P3(LR8)3:.
MD+R8#D&!-@@#H.D:"N+/.*Y1G[ECSA,G&MODYJ%D>*3&]@@GIUE027;O,?9$
M<1\B@FNDDLGSK1SO%WBE,!3\H!KVNSC.>='5&.2*S$:LOE8-.L+XW7-GR!PB
MT*KC>6LLR:2GG45'3M;-GL!+6PO,<UQ@>X8`^L%I"/NEM`"[+%*!\!QZ?\KK
M>;G7-HT8C5>7X%3E97RZ=-%3^2INQO-Q`2;+)+!R>Z/@?[W5"9GC.`)AB57Y
M?@5]F5<M$6T-/Y*F<??KJ&[LL\N'LMG(Y_X.J4W/F=!HQ.L\OP*]*RCE<Z:"
MF\GPJ?1V0[T7=V6N9#V/6=?\#7,F[0<\#1BM:/Y?@70E9-RH=.'TOD*;,LD7
MXI0W;=.!R=9WZ0_[W5"9M%SX!9BU=UG@5Z7DG*)TX=2^1X5?FR7D``Y+A.=M
M_P#`U5=M)S^/XO7=9X%.,D9/C^[:3R%1-DW(0!]6$[U?=?\`P-0NVE;0!_&*
M_K/`I&Y&R=']VTGD>%6@Y0R(`ALN4]U?=GP/][J!VTS:##]\U_6>!6&Y$R:?
MX92>1X5#:CE?(:D;([F0;2^%.U6Y`ZKR<5DE45$;`^*=B1=6(B#(MF(_*DFX
M)J%;)E!,JRX%!4US%=I>T-E0S_FU:P&GDF#77`09;>5`.?$NTN=$%QBXL83=
M$5-D7)CF._Y;2NA,>+6QT.-F@6#0!"P61.E2`V5,D!LV76P=NC[37*=M/VB0
M_?-?UG@5UN0LEG^&4?D>%4#Y6R5MY+O80Y.L]_X&H3M0VBQ_?6(=9X%*W(.2
MH?NNC\CPJB;*^2P_;Q8NO^;?^!JL[:GM'B?^=8AUG@4C<@9)^BZ/R/"K4^6L
MFALV7JQ]O?\``U"[:IM('\;Q#K/`IV[/LC_15%Y'A5$V6\G_`%]V/M[_`(&H
MCM6VDV_\[Q'K?`I&[/<C?15%U?A5N;+V4=@_L\LG7_-W_`U"_:OM+`LQS$>M
M\"F&SO(L?W31=7X5;FS!E(!Y+[9>I[N_X&J[MK.TSZ=Q'K3Q*9NSG(9'[IHN
MK\*AMHS-E%.1HY#9-MS(5[@BFFDVL*K`LF<L#.J][G:"<+)A+-#$3,J9L=1D
M3>2*H+@!3!-2[A^UC:>ZGKB,:KWW:0F)=?N>ZRA?:2]FK=;=#P)A@XMU9O7F
MUJG9WD,3)`\UT;8S@(!L+W)<;I$'7ANW26BP&]9`R@^8\JAMV7^S!_Q_X'\[
MUPSM=VH?3V)=;X%T&[.,A?1%#U?A5$<R96V#^Z!9^I[O'VFHG;7MJ/T]B76^
M!2C9OD'Z(H>K\*MC9FRP`\F0K/\`1`?::A?M@VI@68_B>GX7P*8;-=G_`-#T
M/5^%43YHRR&W9D.T=3P@/H?RFH3MBVJ1_?\`B?6^!2-V:;/OH>@ZOPJV-FK+
M8#R9$M/T0'VFH';9-JW_`)!B?6^!3C9EL]/\&H.K\*H&S9EW:/[HMJ^B(^A_
M*:B.V7:O_P"08IUO@4@V8[/(?N:@ZOPJD;-V7@$?W1K5]$1['JN[;/M8M_\`
M[#BG6^!2#9AL[A^YJ#J_"J`9PS`!BB&2+6`@8OZXC\<'\[U6?MIVM@&&8L4Z
MWP*=NR[9R3;@N']7X5R[PO9?RE%5O+B4;?;(R3=\2>;Y-T1N^$A5Y!]8VZCQ
MXH&X.\NY4#:<>N.OHFTS;#M4IL0PEM/F#$V!V7,.>83=+G2B7.-FD[J\]E?9
MUD.NI:N968313'R\2J9;2Z7&[+8\!C!;XK18`ND!SIF3:/[I5LZH_KD/8]?-
M'[:MK@%F8\5Z[P+TXV6[./H3#^J'&J1L[9EV_OEVWZ)#V/41VV;78?\`<>*]
M=X%(-EFSB'[DP_JAQKZ9\06:F#QH]3R/9'!VCE%P5N^=$=LG'-'`_,.VJB6X
MX;+`&Z<@[-XHB&T.KJ:DV[[8*&JE5DO,&(S'RIC7ALQ]^6ZZ8W7L(@YCM#FG
M2"=&E8J-D>S2KIYE*_!J)C9C"V\QEQ[8B%YC@8M<-+3N%>IV"\W0N:J\X>-V
M1XJR0A6:-FB-PYVC=RZ(H*+N,=F`07CWAD#B0IQ!9/8)3`.P#&_I;L6VRX3M
M@P%]5(E.ILPT8EMK)$"6->\&Z^2\V.E3+KBT$WV0+7`P#G?A3:ELPQ'9IB[*
M>=,$_!JHO---L#W-:1%LQGM9C+PO$<AT8M(B6C>.P/0#U`U]G7R]-@>@'J!H
MB;`]`/4#1%`[DX20F\8I'E'<<9Y?3-TVS286BTYLY:9;W`Q3]FC!3!;`Q`B`
MN19J+1B8*-R+]*WD2MU[=,TF5/(:'0E1B1&[RV6@WA=.Y&#M)%VV(W;H=9N?
M?'!WU/-@>@'J!JHM$V!Z`>H&B)L#T`]0-$38'H!Z@:(FP/0#U`T1-@>@'J!H
MB;`]`/4#1%^E`-X/8@/*'((!LZO7ZFB*!X[==-@I%07J\B5"Y7EDD[=32\\X
M$C*URK8S=1TYK];4:%8+IG;ILP05(S12(D5RY`H+&MUC;LUH@&DRV&`:&Z6`
MQ@'.C'3&(B23=;H6[Q`[U@]CUU.]@>@'J!JHM$V!Z`>H&B)L#T`]0-$38'H!
MZ@:(FP/0#U`T1-@>@'J!HB;`]`/4#1%R9Q&@'E@X$N0/\9^S];_^KV?]>AP7
M]W8M_86_[53JS(]ZG?HQ^6U=9[`]`/4#7GE638'H!Z@:(FP/0#U`T1-@>@'J
M!HB;`]`/4#1$V!Z`>H&B)L#T`]0-$38'H!Z@:(H!L#>V;.3[I'J?^&S5GV_]
MP_WE;^U_D?TE$,:3#O[J!>UK6^>DL;7BU6G&E`9?=`\1MLJB62Z`WOTOD$[>
MLSU`98I>%FHU9NV:,1E1CF#J`>$C5%W#=1,/%*'<6\\V0SF<S[PWLVJB*:@0
MF=5=Y<3@3=""I:>S:0IQVB90.MJCC^"56.Y7JJ:D<QKVSZ=QO$@0]T&X#:O0
MY=Q.1A4Z943PYS"UHY,(^,#ND;RG9L8SHAR.XWJ_DCCL&OD)V<XV1#6T_"[H
MKV8SQA0/O<_@;TE;FQ9/B/([C.O_`#1QV#6GV;8W\+3<+NBI1GO"1^;G\#>D
MM/9.X-:EF1[".LEQ<=:VU>B[)%Q,.\EI=K#-O&QNS8S<ET:.!FNI*N(MH+,%
M#+"0&BZR8D'G!$)*?(&9J0.%-.IFEQ!)BZ/)M`\71&WU0-Y5JC.&!53@Z=+J
M(!I&AN[Z^]'A*U,MYM;&KBO6&ON3R<@-GME7O$I.3-B&P38V6I4@,>L'[4)^
M!E()J1[6UGG2TBL.;6?2;QX4$W2W.EG=DG-9>UXFT8#6EH`O@77.OPL:#880
MMT-`T""A;FC+[6$:NHUA<'7H-)B&AI,"XBT`Q]4G3:I`;S?]/Z8WD45G;>0+
M+14K)/6]A=).K$%<GZG8JC$3ZQ8K?=P5+=4F.0B&R7,`P9IJ(D-L76$]4Y!S
M46EFMI"V!`B7<F\'!Q')TNO$N.Z8'<$++<WY>:Z^)=2'$@NL;RH$%H/*]K=`
M&\/5,<=4/-[5ZE+RQXV<DW[:6I]OIAF$G*M2,X]C>G+%6SR$2RA:Y#1D9,R+
M2*:-CN46Q%EDVX*.3.%SG5&.HV?9KJ`+TVB!#VNB#,B;L;H)+22`23`F`C9`
M6+-/F_+\DDEE41=(`@R`O&)(%ZPZ!$0C"V-JQ;[S:V-'Z-O;K1VQ"^1F$HRU
MHI6F<12E!X?I-"4Q[*`BFW!%C-'.U10EG+<J1I=JB1)P!@`1'0[/LY`L<VHH
MHRS-+?&LUP@\>):-UH/BFT*09ORO!X,JJY>KCHTRS$'Q[-ZS<5_$>;PI\)+6
M9^T306C;C(YBG+%69&<E9""?6'.IH%'(,RB1PV,\C#N86OIQK-NU51;LF2RQ
M$R@*IC:@F[.<X39;&&?1A\L2@UP+P0V3&X/$@;77B3:2!$V*:5G3+$J8YPE5
M1EOUA((9:9D(VWMX0&Y`FRU86?\`-L5"U1A&EI?N[/+A8F%D6N%AE8^6M;U>
M+KSZH,(U\Z=U(\.YC&M2DW$>F(L0>D(L=P5P#TPNM8;LYSC*?>D3J%C+A;=:
M9@:(N#B1`1C>`=IA9"%VQ;NSOEN8R[-95NF7PZ\6RR3`%L/&YI+8Z=WQK57G
M_-P4VQ0#JN/TFPQZKR5DV`&D4GW>*5E,@FR;WQB&,S7Y6%!6.M)QZ,DZ:.FI
M68BW4243$0&&7LUSI*F":RHHKP`!Y4P1`9JX$AH-K=)!!C:""I9N>,K36%NJ
MJP3&$&LL-\O%A<1839N0L-EBV.WX.5&<-CB!9K13:-Q5+1,W44&[UPW*C(0U
M>G*RU4?D;QJ2+M)2.L3HRJ92)E.N<#@`;NS7.=LDS<Z9.FFHHB^>TAT2\V%P
M=9R++6CUK%<.T3+#F26&35W9)BV`9S2VWE;Q6H[-YL^GVQ@V82YDUPCVQD8E
MRK+A(*Q"YKI:+WWQ9M)JNRL.J_+,7*12`7+5PD#-QS7-[2E.%F5LRSS)>72Z
MBAM-HC,$1<:R!(:#"#6FP@Q$8JN[/64GM@9-7>T@W6&!B3&!<1ND6C0JUH\V
MW7K92W%!>O!9P"]I0N!",9DJIVTNA28['H%19S-;F()5D-5C$TBIKLEA;KB+
MA`R*X)J$KR=EF>I%2*IM1AYFB666F9:"\S-+6AT;QC81$6&(B#+-S]E&;)=*
MU-8V\\.C!A@0VYH+B/%CN61B($`K3*?FGYN-QS/4"'R`V,DZDIV)ISB5F9]1
M''%!M-IJ\E/&K"D>R930Y#6KM5;-BR"SP[47*13@BFFHX(M?=LTS?,K65;WT
M$0`Y\"_W28UK@V]&66ZN\XFZ&Q@81)#2*7UYRV*=T@,K#'DCDLY+"X%T#K(Q
M@!"VPB.@N!U7YRS`-FKU/X2XUJI#F1=\7&.*[$,6*KQ04`+CS)0,T0YYN4PI
M(MF(EVB(FY`V[>KKIY`V-YGH'XU45=11D3<'FMB'/\9TZ28GD"RPKKXEM)P+
M$*:5)II52!(F-F&(;:UH+8"#C;R@M-QO#ADHX$W63?E]-QZ(=7Y3K29LFQUV
MBIHO*?T%39M*P-NF54^2WI*>1_#-D\XD$K)KU.N+@/0_G&JC]CV8':*JA\M_
M05MFU'`&BV55>2WI*<1O"YE,XE`&30-H@/*9SV#569L8S$\1%50>6_H*W+VL
M9=;IE57DMZ2V'&\*>5C[NQJPY2]<[KT>I_2VJ,S8?F9^BKP_RYG05R7M?RTV
MPR:OR6=-3MAPDY9.4!Z-'`&SJF4=`'4'KBVU4?L'S2X0%9AWES/BU;9MFRPW
M3)K/)9TUD1X1<LB&SF(OYLY[GU7=L!S6=%9AOES/BU*-M.5P?>*SR6=-4C<(
M66Q#\9BOFSGN;49]'[-A_;,-\N9\6MQMKRL/S%;Y+.FK<>#S+HB'RJ(ZO77<
MAZ'HM=FHG>CWFTBRLPSRYGQ:F&V_*H_,5OD,Z:@U(X3<M2\9+N$DFNZWNEVC
M1[X#<FZ^_&61^Q/S:5NBF<ET/?0'F#-RGBSI;IF*BC44SC;Q'T=\V"=+N5N%
MP[/*T.A;<$?>I9:>Z7>Z$VS`'Q6)>VW*\L%LR161+B;`UUA,1:7V&&ENAN@6
M*6&X-,P#_,H?YNZ[EUSCZ.V;R/UW#/+F?%J<;<\J#\Q6^2SIJD;@QS"(_C<-
M\W=]RZB/HYYP)_7<,\N9\6MQMURF![Q6^0SIJD;@NS$/43A>V'?<FH#Z-^<B
M?UW"^LF_%*0;=\I#\Q7>0SIJW-P4YE'9L)"?-WG<FHSZ-F<CHKL+ZR;\4IF[
M>\H#]GKO(9TU2-P39F'XB#[8>=R:C/HTYT^785Y<WXI;C;[D\?L]?Y#.FJ(\
M$6:!#X6"[8>=R:B=Z,V='"RNPKRYOQ2E'I`9.'[/7^1+Z:HFX'LTB/4@>V'O
M<FH7>C'G8Z*["NLF_%*0>D'DT?L]?Y$OIJ!7+@WS-$2V.&RG00"?OB,*0&)+
MVZ2%0]:LDB3OF>KPKR/91H=[A$RTX=M#E4`A3*]),V(>[0^B[G1\BL+Z[""X
M4I+8OC`ZR7HUDL.!A&V2#-W`+A>1',V_Y2F.8Z53UUUC[SHAK>3`BP"9!QB1
MR760MT@*;&X&<UFV[`@.V'O<>N/_`(6\\_+L)ZR;\4K+?2&R8/V;$/(E_&*F
M/`MFP?K?ZGNE]W'K0^BSGHZ*_".LF_%+<>D3DOY-B'D2_C%0'@2S:(_M>[9?
M=Q:B=Z*N>R(=OPCK)OQ2D'I&9*'[-B'D2_C%3-P'9N';RUWE_/+[N+49]%+/
MA/Z_A'63?BEN/2.R2/V;$?(E_&*@;@*S@(\@UWME_P!Q:A/HGY^/[?@_63?B
ME,/21R0/V;$?(E_&*D/`/G$1^&KG;+_N+6A]$S/WTA@_63?BEN/23R.!^K8C
MY$OXQ4AX!,Y"(CO5OMI_W#J$^B1M`/\`$,&ZR=\2MQZ2N1@/U;$?(E_&*F'`
M!G03%]G60]D7E%U(``<H=4>@<@:@?Z(FT(@PQ#!NMG?$J5OI,Y%!CV7$O(E_
M&+D7A$X*<P7"KYL7B3U_=@^*K/\`5GQ5W+TIPDH&TH-7AB%(S/\`*#*[=P1V
M".P>37O]HOHH9^KJ_"WRZ["&B7@&'RS>F3K2R402/<M!W-WN+E8)Z063<%D3
MY-53U[G3ZR=4-NLEF#)S@YH,9@Y0&G<[JZK'S?.=Q^+K/;<AW!KYV[T0-H1T
M8C@W63OB5VAZ3F1/DN)>1*^,7P/F]L\"/P]8[;D.X-1GT/MHGTC@O63OB5L/
M2>R(/V7$O(E?&*HS\W?FY9VU3D'E>:,#N$@>NFQW[IR@U$P<^HW;&:(D77*G
MMW"F.4HFV;1`-HZFI/0ZSU-JI<NNQ3")5$7@3'L=.>]K(\HM89;0YP$;H+F@
MF$2`M:CTH\ERZ>8^DHL0F508;C7"6UKG0Y(<X/):V.D@$@1@"5Z-4+"Y,:UE
MC5*I6'K.-9AOJK*)IG?RCTX!TB3E'("4SI\Y,&T1'V)"["$`I"@`?O\`R1E+
M*FSS+LG+&6&-E4$H1<XP,R=,/C3ISX<N8\Z3H:(-:`T`#\<9KS9C6=,;FX]C
MTW65LRP-%C)3!XLN4WVK&[@TDQ<XEQ)4R\5+)X&??,R^WUZWM5/SVKSL0GBI
M9/`S[YF7V^G:J?GM2(3Q4LG@9]\S+[?3M5/SVI$+7]UA[*PF\7M@B)LI9>_F
MCC@T+;P1,4M+N$@4)$M69O(HS'?8@/[(%&L*"H$'G!>@S24N4L^F?*GNOLY,
MF-MSGL%E\@QM_-Q?"-EV\1NR$'?B]S?&_P#>M]:*V!XJ63P,^^9E]OJGVJGY
M[5I$)XJ63P,^^9E]OIVJGY[4B$\5+)X&??,R^WT[53\]J1">*ED\#/OF9?;Z
M=JI^>U(A/%2R>!GWS,OM].U4_/:D0GBI9/`S[YF7V^G:J?GM2(3Q4LG@9]\S
M+[?3M5/SVI$+]"J63:'SF>]4.J0GH^F?9ZO)IVJGY[5B(6M\7P4[(0$TLC%6
M%04[_D-JX[ZC=E5DW#6W2B)DFOE`;,IE*-(0A>83:E-#$*.R.44:`F8;M?42
M&36@N9[S+-ES=8-.K)$=^/+YX#HJ29`$:/%&]O=S_+OVK8_BI9/`S[YF7V^J
M7:J?GM6D0GBI9/`S[YF7V^G:J?GM2(3Q4LG@9]\S+[?3M5/SVI$)XJ63P,^^
M9E]OIVJGY[4B$\5+)X&??,R^WT[53\]J1">*ED\#/OF9?;Z=JI^>U(A/%2R>
M!GWS,OM].U4_/:D0N0^).OS;?,?`6FO&.DCN.*.SIH%.4@"H?[EOB#4W2^SZ
MNXF8>7K`.O18)4278;BQ#@0*!L?G5.K$CWJ=^C'Y;5UYXJ63P,^^9E]OKSO:
MJ?GM5>(3Q4LG@9]\S+[?3M5/SVI$)XJ63P,^^9E]OIVJGY[4B$\5+)X&??,R
M^WT[53\]J1">*ED\#/OF9?;Z=JI^>U(A/%2R>!GWS,OM].U4_/:D0GBI9/`S
M[YF7V^G:J?GM2(3Q4LG@9]\S+[?3M5/SVI$+6G>27Z?WN[WN>G?=&<_T7=#G
M>9^YKV\YLWMF[L]/5S7R??+PN=AA'N]I6_M?Y'])<TTQE.1_'Y"5P>'_`!91
M*FTM&8;46QU6]'R?,J3+RL&5CK>]K+&_0[/#4Y>PL\BN^!Q2C[QECIDDU#N3
MJ*>.44;%U)Q(.7+7-_#8HU<+ME!B,[E%1!51$XE&MU#:43)F*;='9U-=V@_=
M%9^/(_*>A_5W^JW[ZMCS4SR_/:3[?==EUSR`JI)NK1>?LSVC$]'86>/G6;1:
M1O=!IBDE:?'*7@H5K<;`C#.9E[#TTY[-*BP24$R:#0`.=00$P@0##K4@#<"P
MV)WUS,YXN,^QD6E:YVN5R*KZ.![[F)W7W;S(<3<7RU.MS2DQ#=DI-N8YM#P-
MX<RS*8;'?LR/&,2OS:R9W`;VMK(1@%M#NE;"NN=<Y8\@UFMG4I+^]L4<@6AP
MTJMDN"T$[H..<4/[_,OG+!^Y/.UF64L0L8=(')UDW";LCI,-U3FT\F$+0%HV
MTZ3!0NC<9TH[J\I8;](/WK)K.2+%E8,<1]Y819XBK0-8D\E2\W6,@OHVW5UO
MBR6L[=E*"J0Z[L5DSLFZWLP##;L;0%L08V%2FX<6$A7B0TI%5_*]CK#J_P!Q
MI+^:CR)[)-M1:?E"<M4[2R.;0S+*,ZU.XR<LGH/A8*"D!E&Z:X';BKN;N]WE
MJ`Z&FWU5&K)QO5-)U>*Q3+58K)=*]5V\A7TQ?."5VPVV=;58:I3T5@F4YPLE
M(.+U#J'YQFW;J-W"G,.%%4%R):NN:`!%;M#K(J\:<260:\YL#;)@3C&92EX^
M)J&/JPVMA+[8T9#(L9C"+G6+VS3,;2++"V.=G8YPDNP>I)QS=Z4CDPB05#;@
M-W0.!:N!W#WU8'XUJF6BR60'$KDN.B8]O"2)(Z:>1->G)2%L#JQ,F$Y#MY^[
M1D:]9`\J$JD='I9'^V/5,1N<@I'4UY&F%BPT/O`15SC?B:LF2K378V+?285N
MTI9E?Q,VG.SZ;I:(QO<J=7*^]%BZ.D**EAC;7TARF?=,W53`A>J;9F#3"P0,
M5@Q&Z5I"-X\[,,A7(FS)NH!V7)64HO)*I;7873.E8;J;/)KR@Y/;G)O.))[?
M1HZ*'0@3V).4I0A!-T(HJ.3'0$<T@Q!/A6PY7C(;P<A)JSLK=:_!0=3)(3;:
M:DUV-NC;J^NM:J<'2G#$9T]=2<3B5M8.$'!Y$K4H.DQ562*"@DP;L-"SRH"!
M61C.+:.G($;9$O\`+;NL(PM;F)>:Z,\:MJZXMSN.:P%=FVSR?;2*=B>A*)*@
MFW0<M00'?Z1[),#[BY",+/46#>!A&U1FR<93>IRF1PGYZXH05$?UZL-CMI9T
M2=G[P_L^6:U,P#)M*S<7#IHM%,4NG#1=9VW*X1WQ'=/S9#:FX#H"`.,`"8KG
MCC:R%)7&I<&]F86*RNHB=XF\9V2&-).YEH[(UE<<9`?,5EX^043=QK\K5T`'
M34(15(PF(8`$!#7?P:`IL0(W:!WY<M6:8N#)X)-DH^R%^L;-90%/98IX.4>I
M,2(>CZ#G7$+6QT!57$QTJ8L+5:`$NRRV#Z-27H_HG2ZW>"P\F"E[*VVL-W99
M[$'+UIN3#_\`5:VNMW@A)@+5+6=PMP`79:K*'L0ZD]*AU_T7H&MB+`A)AI4M
M8W6Y`!-ENM`?`L$L'Q/Z,TN-CH"VB8!7Y[O=`#DN%I#E^N&7]/\`/FM;K=X+
M4DQ5JI>+KR_LQM75#]L4QW9K8-;#0%L"8*S/>;L!@_9E:PY`_;%,>C^C-:%K
M8Z`LEQAI*B%6N5^;,)(J]MMR!EK1:72:9INX-A%NYFW:K=3<FYI^Y."J0@8%
M$C$9J`.\W221$I`M3[CGMA`PEL'M3:&B/B@#AY0]L2;5A[C9:=`]CN?Y=]9P
M]\O.SZM+;]DDSW;JL6MW@L@G?5F>^WH!']FMNZW[99KTOS[I<9#0.!8).^J!
M[]>]@_LVM_4^N6:[MUD,9O#@6`3#2K0]_O@;/V;V_K_MFFN[M8<UN\%N"8%6
M0Y`OOU\7#[)YON[0M;O!8O.AI*H&R%?MAOV<W'K_`+9YOT?T=K:ZW>"U!,-*
MM3Y#O_U]7+J?71.>G^?M8+6[P6\3=*A=BOF2%W]..C=KFJ5K:4W+@P3MV="@
M@$-,)"MST3.-&\?\M5(45GY'#$0-S9D^=.D<D\H2PR8#")EP'BCVS=\$GU&P
M=NQ@"#EKB`ZW<WQOC?\`O6J0*9%R%L#]GETZOUTSO=^H`QF\.!0L<Z.DJW-D
M;(>Z/[/;K]E4[Z/Z/UJ6MW@I;SM\JR')&1=GU?7;[*Y[N_62QF\.!:Q,%;FR
M3D;:/[/[O]ED]],-"UN\%H"5:'R5D;^$"\=7Z[)_Z8:.:W>'`M@3'25:FR7D
M?E_=!O'5^NV?]'^N&LW6PT!"3#25;'R9DC:;]T*]=3Z[K"'6_KCK8-;#0.!:
M@F.DJU\IN2@4+LR)>PY2]2WV'T?ZXZPYK8:!HW@M[QWRN5.%?(5_95K,)&=Z
MN;0B_$WG1VN1K:9UN59VXLC8[ATL5%^0%7*Y^4ZAMISCRB(Z[N8>5/I2ZTB@
MD"VVP-,!Z@WE9K";[+3[TSV%TT;)^2]@_NBWSK?MQL7TRUP+K8:!P*C$WM)5
MH?*&3-H_NC7WJ?7C8_0_KEK`:V.@+>)LM*^6V7,K1[UJ_99,OJ#MDX1=M5AM
MLZL"3ANH"J*@HN'RK=8"G*`B4Y#$,'(("')K<L8;(!;7G;Y7OMP?<1$IQ"X[
M<2E@@'<59*N[;P<Y*I-3DKMB>`V*H,E#.-PJ2;DQ0VNV@;>BJ'#8(D.79SYL
MO5N@-!4\M]\6Z5UKJ)2)HB:(M?W9DY=S&-%$$`638WOICLXQUE>F;-PIUN;@
MN5U7Y2/9Q(](<)D%>53>1I@.*(H@Y5;JI7*5S6RIX)@3)@+6B/+9N.!)LW&%
MKMV-T.!W88!WJ=S?'W66K8&J:T31$T1-$31$T1-$31%K?%\:,7"3J!VKIJLO
M?L@2"P.6EJ:`N:2MLL^1<-B6^4EY%5HJU73W%&ZB<:IL$6:*#;FTB7J]^LFL
M((($F6+"PZ&`0-P-$8[A!=SB71*WF&)'J#>WNY]V^MD:HK1-$31$T1-$31$T
M1<-\6'[^/F\?\Z^T_P#I.XD]>KR]^Z<9_P"GL_VNF5JG]YG?HQ^6U=R:\HJJ
M:(FB)HB:(FB)HB:(N?/\)7_7K_HS:['[#_=?]Z4WYO\`D?TEYV8+G\+7#B[;
M52DNLCS#JDY+RGEF,=2+OAI[RM)"T.<P4*:7FK0"##B1EG"DW'S:+6OKF>OT
M(X&+A^H5D1),G&4=L%V]G*!+8L]\-S$S]*.`L'G=;GU4P5*.R`IB>[NBLA^2
M;1';R``\FNY0F&#5KOPY'Y3UM",AXC"UOWU+38D2';^R^,#_`(J7Z8ZYFMCN
M%5K@A"*PTK@B'FN]W?.RPKP(B8B[%&<\TVBQG81<743*("24()73!P.^F([0
M`>J`ZQK+=!6!+AH*P<SPTU&P/74C-R]8EGC^K3%'?+2$:5QTRH6!=NYFZ\Y(
M>4%-:,DUVJ9EB"&TPD#E#6VNWVK.K.^M>0'`QAZK]\RP2M=9I357FZ;+I+GE
M)3OG7K)T).?9/W,M8WS]V>69Q3)JJHHL8X,V+=`@E21(4,:T#<*UU9W2%6EN
M"+$,VX>.I,*6Z<2%A8VJ04%@X1"0GX^$C*VB_D$VT^BD^!Q`0C)H[15*=N_1
M9H`Y36%),2M:(QNK:X=]?A."C%:<E,RQ'M5!]/R<G-2IC)R"C5:5FX2=KLR^
M;1BED-%QB\O#6>11="U10!P+U910#*'$^MM;^"5@,LA>5B/`YBTLS%SS:;AH
M^0AW-6=LR1[F8:11UZ4W9M:NJ^@$[.$`_7AT8MF":ZK8S@18MMY0>83W<&;'
MVIBLAG=BC7@?Q:RG9*RHRU8/.RLQ'SSJ1>A*2:B,K%V!A;&3F+2DK0[;01$[
M-%MGQDF)&R"KENF=0AMPNS(G0MNG[O66"PGVRPTKP"89F8EM"/G5.".9-6#%
M@1DE)1+N/9QBEG49MH^4B;0QEF"1`NDL0X(KDYY&1724WTU!+K&M_!*!A'ME
M>P/`SBVJRL;-UN8J$))PPOAB7+!L\2".+*141"RB;5OXRBT30DF$`RZ0GS>X
MLNV(N<!7VJBUPLY)L6-68Z5<J\$^-5F*,:M+8_68H.7#PK9>NM%B*+NO&KG^
MDF4F#*/$#^/$QL26$Z11DW&Z4.<'6==^"L&428WE%A\WQAOO6C#!)T\(]!E+
M1Y`W9?IQVLV]C9.0Z1+^-W?AXY&1AF:Z"ZS@Z[15JD9N=(2%V8UPA"Z5M</.
M7P^\WUB.25%9_8*P\4-5RTQ8[I>?7.\K:97)$&4F92Z",N[9@\5Z.]=<\^;"
M?:DL00*(9US>:5C5G<<(+%AYN3"B<=WJ0F:HV:`B*6\W7L+>0$PV1Y<`>*3*
M%W3F%94EFDG3PCTRXNTSNURE4!-94AFM!]J5G5NTWEQEYQ3A\BJ/7>#XI,A0
MR\:'%WCB!(1%FJL>/9EQYDL$7"BBLX\=.RMTVA2&$YA.83`8QQ';M])@),^G
MQ%K1!PP]Y$3I]TEV*Q32N1.M%LH^R%&([%%5/S8CE.(+L';RPJP]7K?JJ'HZ
MX^JJ#;<[X58RHG2IU'X>JAMW]UJ%+MY>6#6'T_"X:SJJCF=\+#I)=9%3F/PI
M4C[H>6"#+R[>6!6^G(:SJZCF?S@FI)W?NX5.H[`M35`G[L\`7D#JP"O(`#U_
MGX&L:NH!\3OA9U!-D5.8_AXJ)P+^[=7"[.7V5?6^-V>'M!+J.9WPMC),`(A9
M(W#G41Y/+E60Y=OZ@+?3[34U1_-]\+74'?"HGX;JB;_#I60_N?6^G^LB54BR
MY_."V$DC="H#PTU(3`/EVK`=3E&OK<G+U=O?_6#(J3;<[X34G?"U_C[AEI@0
MLN5'+<%7BA>+Z)F;REHQ*KM4UKE#*S2;5E>IU-5M.'$723DZJ2SI-4%5&[8Q
MQ1)<K)55K6Q`?[E+M#XPY`Y,2UMK=!$"!"`<[2<S)!)\8&P>QZRF9N&&HB'[
M_56#^YY;WP:IF34GVG?"QJNZJ!N%VH#M'R^U4/[GEO?#K.IJ80N=\)J8[JI&
MX6J>8!_=_J@<FSZG5??%H)-2/:=\+&H(&E43<*M/-_E`U0/[G5??'K!DU)]I
M_."V$HC="MQX4*A_&#J8?W.*^^/63)J3[3OA8U/=5(>$VGB`_P#>%J7+M_:X
MK[Y--54\SOA-08:0J)N$BGC_`)0]1#D^MQ7WRZQJ:H^T_G!9U1A"(6N[KPC4
M\DIC8P9LA)H1R`V3Z1&T5O))UWG*U9BC/2SEWD6$-"1*8;6QW:*<BJ"KI-(&
MIBJF61N4TFJ,N?8UGN)L+X7N4WDB#77CNP):(`F]9`[LE$!W*`BW?TVBS[H>
MJIP?@_IY@#_O&4X/@UQ3WSZJ:JIYG\X*NV0X;H5(W!Y3A`0^Z.IGV.*>^?6N
MHJ>9_."WU1WQ]WKJW'@VI_\`&1I?V-J^^C6QE5)]I_."SJ8BPJD/!G3Q';]T
MG2OL:5]].L:FIYG\X+34'?5`W!?3A_RE:4']S2GOJ#63)JC^;[X61)(.D*D/
M!53AV_\`>7I(;?\`DRI[Z]-350][_G!9U).ZJ)N":G"(_P#>9I'+_P`F%?0_
MYUZ"54PAJ_YP6-1W0J8<$%.,H3_O-T@-IBA]3"FWJ^G;`U@RJF!]S_G!;:D[
MX7'/!MP>U>QU3.B[GB$J$(,7Q;\1$"BFYKPKC(-XFUMFZ4LB);0@9-"0+[,I
M!*;=#XLW+L])F>DJ)-12-:`^]AU,ZP@0)83#UE:K*<WF0(]Z9["ZY-P-4X0'
M_O/T;[&%/?;KS>IJO@^^%3[,Z,8A4C<"U.-M'[J"BAM_Y,G]]VFIJ?@^^$U!
MWPKB-X"J0ZDV"+GB7J[]LH[0*Z8PM7-WW=M04`SEO&&-9WA2/54`,"9A25*0
MWLA*8`V:R953N2_YP61),=(7K?37V-:!6(:GU-$D1`0+%%A'LFT>X(!4T2@!
MEEC%0**[MR?:HLJ;:=54QC&$1$1U4-#5.,2!'U0IPV`@-"DWC]6/=JO:;KL6
ML=@J>:.$)=*>/U8]VJ]INNQ:=@J>:.$)=*>/U8]VJ]INNQ:=@J>:.$)=*UAD
M.UT^1G<0K.(]>9-%Y-+(-G9:OWW+6G/B'>6)9Y9VYFX0]=3!)\=ITU%&36$S
ML$`:[JYG#>_1TE6R34AI#;TB!%^%X:R6;L`UU[1&Z2T61O673(P$-=;#D[^F
MT</>6S_'ZL>[5>TW78M4.P5/-'"%'=*>/U8]VJ]INNQ:=@J>:.$)=*>/U8]V
MJ]INNQ:=@J>:.$)=*>/U8]VJ]INNQ:=@J>:.$)=*>/U8]VJ]INNQ:=@J>:.$
M)=*>/U8]VJ]INNQ:=@J>:.$)=*>/U8]VJ]INNQ:=@J>:.$)=*_0OU8$0#IRH
M;1V;19N]@>F/RGJ:=@J>:.$)=*UGBFXU5A6Y1%(O>MNI>LA.4&"57&`,B#FZ
M3:[A9=JTG;,B[7D'BBCDSOGT3NN>YP[9J<QD"7L0HZI\]I/*.JEB-^]H8W=+
M6P@("$#"$`YPM,DP$NW[!NQW/4"V7X_5CW:KVFZ[%JCV"IYHX0H[I3Q^K'NU
M7M-UV+3L%3S1PA+I3Q^K'NU7M-UV+3L%3S1PA+I3Q^K'NU7M-UV+3L%3S1PA
M+I3Q^K'NU7M-UV+3L%3S1PA+I3Q^K'NU7M-UV+3L%3S1PA+I3Q^K'NU7M-UV
M+3L%3S1PA+I7%7%-;8)[FWS?*R#LYDVO%9:%5Q,V<E%-,>%+B-1W]@I;3!SB
MY0V%VCZ6O48!23V87C`<+3A[(6CY73*U('N4[]&/RVKM7Q^K'NU7M-UV+7E^
MP5/-'"%5NE/'ZL>[5>TW78M.P5/-'"$NE/'ZL>[5>TW78M.P5/-'"$NE/'ZL
M>[5>TW78M.P5/-'"$NE/'ZL>[5>TW78M.P5/-'"$NE/'ZL>[5>TW78M.P5/-
M'"$NE/'ZL>[5>TW78M.P5/-'"$NE/'ZL>[5>TW78M.P5/-'"$NE:/\9X;QV[
M\](/WO\`+[T7GNCK[W/?<T;N[S7-\[LV]?9LUU.RSNRZF'NG8XPB-':5-[2'
MX'])<U<,;S*[SB+R*6QM\8W2"2DKBK-V&,MS-Q-5N6"YVV.@INC0*V*J^L2M
MN:VQ:P$JDQF7S=*;8.Q67.Y*X*?SRB.A;IXBP`<Y<-FT`'YSYXZH;?VMU#7=
MH/W16?CR/RGH[]7?^,W[ZIJ$)L-[$O6^)#TO2USAI5;VJL5"$Y?8E^%'XD/3
M]+63XP6!XJ@V09ES5Z!?+1')M3R-9I%NL<>1XD95F9_`UV2EF17B2:B"BK0S
MEH4%2E.0QB;0`Q1Y0R4;:5P]COC%G)9VK7KG3HM6_P`53,+MINE5MV2)!3)F
M1F]\G'3QE8+*X(P9X]GZ+4T9N%7<%WQ3<=%44,X`X)ZERR6\%JE*_&KCY>%D
M)&&JD_)24:UAW3RN.G3./EP4L;6<LE9B&J#)K.NG]CL&-J^O9T&2*!Q+%F(*
MJB8<ZHEF\M0S<L513B=E)B.K=BI^)W#JFV')L;CU*SV&XUR)<J-7E$?W5]/,
MJVW*^>%7C$DT$2-7*I!<J"J4HE`I#GV+CN+`;"Q8$>*HDO7K)&0U5<1=[+CF
MB2U%-85XQL>[7/)K2EQ]8-!U!`SJ0>U1M9+\R(L_365;[Z*Z!^:$I#*'.,.[
M!;AL#W%DD,T7"GR$[#7^-1L-R?3\7"X_Q_"14#7T)N/D<KU_$L78F63/&J;@
M)5"1>VR,?23=VQB'T2*RJ8-#$*F)]2X^V6I;'0L*CQ?5=6CK6]:@S4;)+LX2
M8KU-DIN'4F[7`S1KT47T(:NM;&9>4CPQE.JK1Y4#K%:L0<&.FDH)D\W@5D,W
M%D\29X=93MU2:-V<4A6+DVSG*QV^T,UG21-`NE#AZ:5RGTYT@B_<U^VG4D"@
M!RF7*4R8D(&PV08K5S8'NV+13'C`M;)[7V=NK<(S;Q.2LJN,HS$9$2J[!I@N
M*99B<XIE*H47J@N[Y8'>.3M'R)S'3!6%DS%32(JU'6MZT16URVS[BMBR7%*Q
MB9244E:D[9LX2J)EDZPV,C.SQ<C25_IM4@H9M.P(2$6[@'D?>6"SAXBW5!H*
MQM\!,B9,=[UBPYD5F6_$C&NX)Y8U<:6V'CX2O4^7MC.QNX&!LE8E[L\8-H>N
M+UE^N63D!(W?=(6?I`5J0B>[RG$P)FN6+@BHG-\44;"SF2D_%1]/L*I-5VDU
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M+TM8*0%U4A11V?C2?R!?Q`VZU6(!0FIH-^]\INI-1*-MMPAS+6`0*`C.O-X#
MEKRJ[)1<#;=\ZPE?'-RNBE7$Y0L5/CMT^]LYW-'.MX.3S;(+=^YZ@W][N_Y-
MY2%5!#9^,I=;^9D]'X&H`L!62J"&Z;Y2EUOYF3T0]+3=3VRM!00V?C*7S,GK
M:RLG0J"B"')\I2Z_\S)Z7I:U6BH*((;OXREU?R,GH#Z6B'0K,4$-H_*4NJ/\
MS)ZVB#0J"J"'+\I2^%_(R>GZ6LC2BU];D40E:!L0;"4;B&]OMJVH/U.V`2BF
M:<52>(J;^SV46"DCLV@!>8%8Q;,CQ)WZ/\+G-YMGE\GUX+=GBN_%[N^-[[]B
ME1D$-GXREU?R,GK:K%0M`BK06[?:/RA'JC_,B>C_`"NL+=6ZC=OM-\H1ZGY$
M3T/Y71%;=';_`)`C\R)[71%9G;M]GXPCU?R(GI_[W65J-*H"W;[!^4(]?^9$
M]KHL;OKJ@9NWV#\H1Z@_S(GH?RNM#XRD5MT=OSA?E"/5+_,B>C_*ZV.A8"YI
MX<$$!KV4]J*0[.(?,H!M3(.P`GT-@!R=0-=G&_?:?^Q2/R5;J??&?HF>PN@Q
M;M]GXPC\R)[77%5<Z%;G;M]H_*$>I^1$]#^5UE:'0OQJ=2.=MW\>H=@_9K)N
M6;UD86KQHY2$#I.&SA'<5063,&TIBB`@.@T+`T+W"X4,JY`RMCPTI>ZZJT-&
M*H1T3<0W4&MW11(HBZ=D8G'GBOF"R(%<N"!T9=0_L-TQ3E#0B"M,<7")746L
M+=-$31%KR['$L_B@H)MSE4R$J4YED*HLHENT6Z*$.U/8W;:3;.!.0"[\(1>6
MW#&+N`S,[.2Y2B,FHT^\_A\]FFZ"#_+@SNWKH6[/%=ZG=WQO??L]=;#U36B:
M(FB)HB:(FB)HB_2]4/@AZ/H^ERZ(M9XJ.@>`GP0:LVO-9'R2DMT)*FHINERW
M&5,=ZLG1GS^*Z8X(<O/&=&2ECG*)GZ2;D5"ZO8@")S(DGW&7IOV"X+.6`8;T
M(LYA+8*29&(CS1O[W=_R;UBV7JBHTT1-$31$T1-$31%R7Q&_OP<"/^<_9_\`
MTO<0&O0X+^[L6_L+?]JIU9D>]3OT8_+:NM->>59-$31$T1-$31$T1-$4`^*_
M\2/^C9JS[?\`N'^\K?VO\C^DM$T"K7RB<<U4B8OALN^*<9NU,OM3Y*4RAFW*
MM4M,4X[[6Z(9M8V)O"^(<41%JM\X^E$XR9C3*(O$N;;$(NNF9/Q*BW%UYFAC
M%/\`B`X;D9AX+)J$%G@P+`JFCM4&!I9-W?5(<OXV8P[-FT=FNBW$*/#L!K)]
M;,9*EF93@%Q@(QF&'>5JFI)];+?*IV.>\%I@T1.F'LD+8!ZGCP=N]9E0V_GY
MIUO^*Z\M];,`%O;*?R@K`R]C!$!33O)*MS4_&X[=MH5#DV?J@T[FU@YNR_I-
M93^4%D9;QJ$.RSO)*L7=#Q4]:NF+ZQ@Z9/6SAF]:.7;%9L[:.DCH.FKA%1H9
M-9NX04,0Y#`)3%,("&P=8.<<N[M;3>6%D99QO<I9_DJ%2N!.&N<;2+.:9566
M:R\7!PDLWDHRN/$I.&JZSAQ6HF0*O$G!Y'5Y=VJ=BBIO)M15/S8%WS;=3G++
M7RVF\L+898QW<I9_DE6]@X?>&.U,Y:/L["I3[&>=Q#^<:2\96GS>8>P$>6(@
MG<DDXB3D>N(:(*#1J=0#"@U#F2;$_8ZT.=<L;M=2^6%D96Q[<I*CR2KE3"7#
MH>*2@E%X$T(WD6<NA#F0@!C$):.%`6$H@R&+%NE(LNBI<TL4H*)@F4`$`#6#
MGC*XTU])Y861E/,&Y1U'DE1_[FSA2+-,+(DSJS2P1;J'>L9QBU@&,J@XKS0S
M&#$7S.,1<*HQ30P)H)',9(@$3]CM33$N#GK*NDU])Y86XRGF+Y'4>25<,.'[
MA=AY.:FXLM7C)FQRK"<L$JQ95MK(S<U%2"<O&2TF[1B"KNY!A+)%=)*G$3D<
ME!4!WP`VM3GO*>[B%)Y83ZGYD=^QU/DE8^8X<.$^?AU*].H5*7@5$6+<\+),
M*R[C#-XIU(O8U#H:\09#FH]Y,.U42[-B9W2PAL%0^W!S[E'=Q"D\L+89.S-N
M453Y)5PPP%PMP\BWEXIQ7(N69JF79R<>VKC-^S6/#L:Z=1H[;Q!%VYE(&,;,
MC;A@WVS=),VTJ90#'V@90;_$:/K`GU-S,[]BJO)*R/D?X=`:M&/C%'="8/%Y
M%BS%6#%JT?NN^8.7K=`T6*23EP$T\`YP#:8':VW;SI]NAVA9.^DJ/K`L_4K,
M\8BAJO(*B@\,_"!WG:UX4:<$`RCYF(9PG>ZIA$MHJQ*HN)^.08=Y.C$9S3AN
MFHZ3`NZLHF4YMIB@(8.T7)@$/.=%#\<<:S]2LT']AJO(*ME^&/@Y6%H9=*F*
M&CZPXI3`QXVHF%E3G9'"3JK-1&"$4*^X3=JE,U+L1$%3AN^S-MU^T?)0TXG0
M^6%L,D9J.B@J_(*L%.%7@J4B"U\[.BC!$CU(E.%&*I_>M.,5FB615@1CWBZ.
M1JI8DP?B4"A^7`Y[\<$3#@[2LD#3BE#U@6?J-FS<H*OR"N"/.68PPPPJ/"'$
M5.X(E1'B^QO$=%3D(M&/BH5+'F3"%YENSCDDV39F5LDF0"EW"%$"@7J:];E/
M:#DRJEXF96)4C]5ADQY#7@D`3)0B>Y:%L,G9CI&/-315+-8VXV+"+SB00T=T
M@$^LM41F$<;&W-[(4<4>J/S^:AU_ZU#JD=I.2AIQ&E\L*N,HYE/[#4^0IZPP
M5B\VX)LD1P;`Y?G^TZOH?J3K4[3\CBQV)4@'XX4@R;F@VC#ZH_R"IS&X$Q.<
M2[^3(T`#_E"S]'^M`ZC.U/(+=.*4@_EA;C)&:W:,.J_(*V#&\/N'3@4#918!
MM#8.RQL>KMV]>''49VM;/6Z<6HQ_+"W&0\WG1AM9Y"G<=PY84,4N]E9@78`]
M6RL`ZW]9?2U&=L.SANG&*+K`I1L_SF[1A=;U961-PW8/$>7+4>']TT?])-:_
M;+LT&G&*+K&\:S]G>=C_``JNZLJF/#;@P>KER/#^Z>.^DFL';/LRW<9H>L;Q
MK;[.L\0AYJKNK*I_<W8)Y`\KT?R\GU41W^Y\Y-:G;/LQ&G&:'K&\:?9QGCZ*
MKNK*@U(X>,`2$5*KI9KA'92W*ZMCJ,[S59-)-9G9)!HLU.XA*I&M47+0Z(IJ
MMU2'>-E"BFX566*90US$-L.S6EG,EU&+T<MYD2G`.?=):]@<UP#B20X$%KAR
M7`@M`!",V>YTGB])PNM<T&Z2)9L<VQPTFT$$'NA2PW#7@$?ALQQP?W4QOTCU
M0^VS9:/XU0=:WC4@V:Y[W,(K^K*H'X:>'T0$!S-'AMZO[*HSK?V"]+6IVW[*
MQ_&Z#K6\:S]F>?-/FBOZLJ@/#/P\!U<T1_V51?TAUC[<=E7TYA_6MXUG[,\_
M'^#XAU95,W#/PZCLVYJCP_NKB_I#K3[<ME'T[A_6MXUG[,,_?0V(=452-PS<
M.0\@YLCP_NLBOI!K'VZ;)Q_'</ZUO&L_9=M`/\&Q#JBJ0\,G#<'5S;'A\&VQ
M7T@UJ=NVR3Z>P[K6\:R-EFT'<P;$>J*IFX9.&HW5S?'!R;/JOB?I!K'V\[(Q
MIQ_#NM;QK/V5[0_H7$>J*@MMX:N&IO)T%(,[Q"0/;JDT.1;(E/C3.">+U@<&
M1;MI:FOW$VY#H_.`T8*-'HE(*H+`DDJFI<I-N6R:=*J9DO'*!S94B^XA]X-;
M?8V\XM<`QL7!MY\6Q<&PB01@[+\_2B&S<'KVNF&ZP&41>=`NNMM$3`$PML!L
M4N'A>X9.OG./#^["'][VJ!V^['__`"##>N;QK8;)]HNY@N)=451'A<X8=H[<
MZQ_V80_O>UC[?MCO_D&&]<WC6_V3;1_H3$NJ*I&X6^%T=NW/$>&W_EA#>AL^
MM[6/M_V._P#D.&=<WC3[)=HYT8)B75%4?N6N%K^'J/\`LQAO>[K!]('8V-.8
M<,ZYO&L_9'M)^@\2ZHJB/"MPK#U<^QX?W90WO<UJ?2#V-C3F'#.N;QH-D.TK
M2,"Q/JCQJF;A7X4@`=[/\>`;!$=MSA@V!U_VN:P?2%V,@6YBPSKF<:R-CVTP
MFS`L3C^B/&MM-/-JX^D&C=\QMUB>,GB"3EH[;3L4LW<MER%417063KXD4253
M,!BF`=@@.OIM-C>'UM/+K*1XFTLU@>Q[2'-<UPBUS2#`@@@@C2%X.?23*2>^
MFJ6/EU,MQ:YK@0YK@8%I!M!!L(.@JL7S8M%$Y1-9K4``8NT>_,;R``\H_4Z(
M]34YQ.1#0[@\*AU;.ZN*^";S>M*N]3S\LXL-G14KW&'Q(U,A496/2*=M`7!!
MDW6/OP2V^LJ!3;Q@$H"/4*&O3YIJ:>EJ*-HO$/PVF?Y3(JY5RV->PV^],]A=
MF?>O:)]<]L^C49[W->8\YR-YW!X54NM.^O@?-=4(>K9[;]&HOWN:><Y&\[@\
M*Q<9W578^:^QTU>M'3F;L\DW;N$5UHYU.LDVKY-(Y3F:.3M8!!R#=P!=T_-G
M(?=$=A@'ET\YR-YW!X4$M@W2NU6.*9.+8LXR,;0D=&Q[9%FPCV1C-F;)HW("
M:#9JW2:E31123*`%*`:QYQI_PN#PJ6("NO)O8?R2.[95[FT\XT_X7!X4O!/)
MO8?R2.[95[FT\XT_X7!X4O!/)O8?R2.[95[FT\XT_P"%P>%+P6N[S3)&-F\5
MHOIV!BCRV1.]K!L\L$)&&G7WB3<WQ(EDUFX&1>SCT&S%5T5K%JL9`"-CK<_T
M9%PBK<I:V4^54.8Q[@V3$D-)NB^P1):X!HB0(N#FVPA>+2-V&(=`1Y/=WQ]U
MMBV)Y-[#^21W;*O<VJ?G&G_"X/"M+P3R;V'\DCNV5>YM/.-/^%P>%+P3R;V'
M\DCNV5>YM/.-/^%P>%+P3R;V'\DCNV5>YM/.-/\`A<'A2\$\F]A_)([ME7N;
M3SC3_A<'A2\$\F]A_)([ME7N;3SC3_A<'A2\$\F]A_)([ME7N;3SC3_A<'A2
M\%^AC>P;0^61W5#\TK?B-P'3SC3_`(7!X4O!:\QGCZ7<0$L=H\K[I(MZR"D9
MQ'S<)*HJ.$KA+D>D57K,##1[=XS>E4;KMU4E'R"J)B.EEW`**FN5V(26SFAP
MF`ZJ786N%EP0\9Q)!$""#=(,6@"`6\PB(]0;^]W?NWEL+R;V'\DCNV5>YM4_
M.-/^%P>%:7@GDWL/Y)'=LJ]S:><:?\+@\*7@GDWL/Y)'=LJ]S:><:?\`"X/"
MEX)Y-[#^21W;*O<VGG&G_"X/"EX)Y-[#^21W;*O<VGG&G_"X/"EX)Y-[#^21
MW;*O<VGG&G_"X/"EX)Y-[#^21W;*O<VGG&G_``N#PI>"X\XF:3,,LS<`J"ZC
M'?>\4UH02$BRIBE,'"QQ"K[R@]'`0)N(&ZFT=O6UZ3`ZV2_#,7<V]!M`TZ/_
M`%5.-]69!]RG?HQ^6U=A^3>P_DD=VRKW-KS?G&G_``N#PJM>">3>P_DD=VRK
MW-IYQI_PN#PI>">3>P_DD=VRKW-IYQI_PN#PI>">3>P_DD=VRKW-IYQI_P`+
M@\*7@GDWL/Y)'=LJ]S:><:?\+@\*7@GDWL/Y)'=LJ]S:><:?\+@\*7@GDWL/
MY)'=LJ]S:><:?\+@\*7@GDWL/Y)'=LJ]S:><:?\`"X/"EX+5/BE*=^^\6^TZ
M;]T/TO>YX_,<U]S5O?#\SO[^SK;NKW:Y5S7VW.Q0[L>TJ3VD?P/Z2YGPCE?-
MLOQ;R-7OV;Z](T5Y;;['1M&J>0,=RL8]ND`]R)SL&V(YQ^2V)P]?I3**(>N,
MID\@TFHY^Z>.%$R*(&\FHK(+ISB&_?QX;OZTYT_O>I^O,YY_[.J/[33_`/W5
M[')?Z]-_$;^6U72G4]77YY?H7U5FE61NJ/\`)UM5W>(K359K=0?@C^$.JQ^\
MIF[BQRGXFJKE88K4_4'^3KZIS/&5ANE<?<1=XDJY<J/!O\IRV%Z/(43*-E6N
MT3%QCQ20R!5UJ<2G599:8B9AI)@JREG[PD`@1-]8!;\RD)P3.0>AA].V;)F3
M&R6SYXF2VW22(,=>O.L(A:`+^AD8G2N=B,]\N:QFM,F5<<;P;>Y0NW1WR0W2
MZ$!NK163,T7FHV3*,>PR$]F)U0D>U*>F/X.QQV%JJ:PX^[^RMSPZI6GMFI%D
MKU-GWSU&=?/7\6^5$H*I;"I(EM4V'TTZ1)<Z4&RP2>7%IFNNONADR\&N:7``
MM`#AN'256FUE3*J9S1-+G0$"T>]MBV)>VT@AI)'J\H:`OC*.3KDGCFV1&&<V
M2-K<TC'N=LDH92=1L7(N3-8)JXI^+(61?,6;:.ND<VO4B[7&4:H%3EV]<,7>
M4$RBNJTFCIS5LF5U.&"9-DRS+B=TATPB)BTW`!=/BF9N6!3FLJ.SF533[]V5
M,<'W86@$,;"$"+UL=VX1:8E8-+B3SC!WJWR%]K<=3X5AC''D7&56ZF/6:Y&W
MAG9+W&Y'R3,3[=.5=IT^VR]=[VUDQ3"1T@9@J8`Z7O:AF8-ADVGELI7F8\S9
MA+F<IQ86L,N6&V<IH=>F#<-X>U5F5BF),F/FU+;@#&"ZX71&\\.>3$P:2`&F
M-L`8"\LLVXJ<E,)RYEGZ?62QJUB@I&E5Z2DI:#ML?5Y+%.,KBUH+YJ6#7)*Y
M3ND[;I!O7T0_*[US$R2&_P#E4`#GSL"H7RY>J>^^&.#W``M+A-F,+P8V2V-:
MTS#I:',,.4KDK&*QLQXF,9=+P6@DAT"QC@R$/'<7.#!NEKA'DJ87K(V7+'P[
M9-NL"\K^,I]Q.^+N,;#!]+MDK"%99>)CM:<M,-/P[*)776!ISXM$!71,W7.G
MS@&*50>;(H<.D8U(IIP=/DAEZ8T\@&,K676N:2=V$3"T`PW%:FUU=489-GRH
M27F9=81RB.7=B01#UO6[JTB/%UEJJ#;#6'%4A)3H9XD\</X69FXBJUFDA4L>
M8Y?2D1`6.=/#MI=O?I>8>R-85.HL+QL<PB!Q*)"V7Y<P^HU8E3VME=E$P%K2
MYS[\R8`7-;$C5@!LP`"!]6*BEXW6RFN<^42\SRP@D-#;K)9@'&$;Y)+-\>I!
M;'7XK928?HU.HU>KJWL9FK5F8AYVR/RH4JPV?,-KQDG&W1"'C'TK$N6D76RR
MAD!2!<Q')0`O-B54W)=ER7+;KZF8\4EQ[@YK1RVMDMF19>(!!+KL=%F_8NDW
M,$QX<R1+::AI:(7M!<\M@8"PP$8?>M49D>*W(A5G47'8TJ??UNYLIG;9_:+%
MT2MEID#D:;FJS;C-JN+R*N\PTQR9[%M@3,FI%RC5=42@.U2,Y;H"&S'U$S4D
M,A!C8NONE-:YD70+`9EUQC8YK@.Y*<>K0'-;(;K&EWMC`7&O<0;+'$,BT'2"
M#HA&'<=,F6:J'"%-$0.V),\3.,I<C90P'4;$E,<7]\5NH<"E`YT"N-T1```1
M#;L#7;V<RM3-S#))!+<#GMCOPGTX4N89NNHZ&:!`.JV&'\AZQ;#JE^!^*77*
MF@04<G<4U8=0/Y;\37)J`%TY?BA3&/\`AB?ROXH:XL\"U=.3H4[C.J3^3K:X
MM2!:NK)^\ILR^%#^3K#KAS@.^NM(T%71_BOP=4G@*ZW<5F;J_P`GH:J/`NJP
MW0K,W6_D]#43@(*1JAE46%>/DQ%45N9M%K;%4%\ZD-I$)QX0I>>=QD2=`$@]
MCS!"*I-]FX1=<H`H:SC$L,J)<!"--),+K6Z9;=QKW@QTWB07>,YC";HQ2.+F
M.C;":\:2=#COAL/4M`T!QTK-J=?\#\37#("Z+%8J?%?@_BZJO`5C<"LE.O\`
M`]?59P$5,S[ZM#ZKN`NJPU6BG5_!'5=P"L,T*U5ZG\GI:JN`BIV:58FZH_!'
M55X%JM#0H=9513?TXH*@D"UK32.49)RPYX.\TT<$BMV\9(%EQ%0@#T94[-+8
M`JBN`IE34M4+`ZFK3=B6TA/B-?#W64(Q+V:NPGEM$QWM0R#BYL%2XB93VP!G
M`>,1'D/W`UU[\4EHW;UD#(E/Q`_#UY\@+I,6+?J*HLWRR!=Y=%D[50+N[^\N
MDV4.B&X'*?:H4.3K]36\ADN942Y<RR6Z8T'<L+@#;N6;NXMISGLIWOE^^!CB
M-VT`D6;MJY0C,C9G<Q$8YC:\%D>&2A7+QL^J$O"%7C2HMW3Q9K/D,WAG\G9H
M\%CH"BD1NP=\VDJ4I3#L^QU^4=GDFNG2JRJ['3@SFL<RJE3H3+SFL#I!#IS)
M=.^X'WG%\Z5>?+)(M^6T69L\3:25-IZ;M4XB4YS74\R5%D`YQ;-LEO?.9>++
MH#)3[K'@`J[F<AYJ0CH)W$8Z([&0JM4E987$3*)NXF:E8>TO)N--"D6%=52,
M=1S(#I\^51`Y^9-OG73$O-HLI;.)M752,0Q?5ZJNJ94J[-E%DV3*G4S),S7$
M70)C9DZ#KA:\-U@NME.!Z=7F7/4NFIYU'AM\S*2GF3(RY@=+FS)<]TUFJ!B2
MQS)46WP6$W#>,QI%^2_7L(ZTI+1+T[]K$-7M2EBXYMB24PD2RS,=)R3J$'G%
M&[M&!;M7:<6=9%VH)QW"F`P%+RIV5,K&KH7RY\H4LRH<RJE'$*4F233R9DN6
MV=8',,]TV4ZI:Q\IH`O%I:2;TO,N9>Q539DF9VMDAKZ>8*.H`F`3IK)CW2K2
M'"4)<P2"YLQT3=!!@,YC2Q62PFMWC(905(Z4C&[))2(&'Z,DO#(.5TR-%$4W
M:0.#F*Y%!P=9PT,N*!SB)-@>>SS@^"X1YO\`,P;<G4\QSR)NNO%LYS6DN!+3
M=`,L/EAC)H9K6M`=;Z')V*8KB7;/.A-^5.EAH,O570937$72`X7C!]UY<^67
MZMSB6KV;X`9_*[QA,0CMH+S$D85<(R5DCJIKQE@.HFH>(KRAB'[X1YR',HX2
MV@FT4$!*8#'$AOV5Z&F-;1JFDJL)J9>MV;4X=JITTD.E5!()DTQ(.LED$NF,
ML;)<06N!>6G\L>E1A61J>II\2D/U>?)Q;K)4L`B9(`($V>`1<F`@-EN\::V(
M((:'#TMU^\5^.5YY^;H^I#BE_P`_'BO_`+_PU[+.GZS0?])I/]&KE;XTO]"S
MV%Z&:\:J::(FB)HB:(FB)HBU]=G)V\SC,A7`($=WP6RI!G'T2+DOB;;UBH%9
M,H*8)8AYQ$IA9KJQR!0*+@7.^@1!>Y2M#I4\PB1)CXH,.6S=+FW?5`<=R[`D
MC=@L=ZGWQP=];!U36B:(FB)HB:(FB)HB:(M;XO?)2$).JIOUWQD;]?V*W/R\
MA,@S5C[;*LA8H.)*!KKAJV1(@42-2H*H-@-S:3ETF4KA2]7L+)K`0!&3+.@-
MC%@,3!SHGNQ!.DM:>2-Y@@1^*/86R-45HFB)HB:(FB)HB:(N&^+#]_'S>/\`
MG7VG_P!)W$GKU>7OW3C/_3V?[73*U3^\SOT8_+:NY->455-$31$T1-$31$T1
M-$7/G^$K_KU_T9M=C]A_NO\`O2F_-_R/Z2YEQE-\)DIEBL.:3:[\>:)DB>F:
MKB=6U2A<?5/(-S4SI79VRQU#+(C%L%'[K'%O6,D'/(,W#[I)6Z*CHAR\=16K
M=^:"0A\_\-X3RIDF7>/.NPQ16*/.]XJ6`!M0*8_XV)O2VZJXVS`GY7JQC[RR
MEU]/=(O>-&9S03H7>P%V*-FS#A+0ZI@V(-W1>'.(&F"V"='%>SV4@Y^3DNO_
M`/@:^3ND;--#I\SAF]%>O;-SY&R2S@E])4!0Q+U1D7/S23[GU$Z3LP`@9\R'
MJSNBI1-V@;DEG!*Z2MSHX?ZAI)U^`>4[F]/4)D[*]VHF<,[HJ03=H>Y)9P2N
MDK8S?#`]63=_-)7N;4+I&R8>-43>&=T5*)NT?<DR^"5TE1%OA3J#*//@`>7Z
MWP&NH72-D)M=4S>&?T%()NTK<D2^"5TE:JM<%GV%5DG1MPY%`*<TL;=53'>3
M4`#-!W5$S<I1ZH#U-0.E;'!IJ9OE3^@I`_::?V>6?6D])6W0L!E4.MWR<%65
M(5-58.^P*J)DV[A%%09;YR$VCL`1$`U$Z5L9A!U5.A^-/Z"E#MJ$2X4TJ\>Y
M)Z2LPC.'<BIEB/#IKF;H,SK)I2A%3LVAEU&S,RA&`',T;'<JF33$=P@J'$H`
M)C;8WR]BI'*JYT(Q\:HTG=\338I&G:FTWFTTJ)$-$G1O>-W5^*,.'I8IP4DW
MBI!V%.!N_2A3!M`Y2'`S$Q3%`Q=H`/)M#;J`R]B`-M7.'\JHZ"EUVU=UAII1
MB-ULCI*V49\.9CB=65=F4WDS"<XS8J;R0F,D;?%CO;R1CF$H[=I1,.S9M'4+
MI.PR%M9.A^-4=!2A^ULVBFD^3(Z2I&;<-^S8:9>@`?$\Y.[.KM^%Z%LZO+U.
MKJ`R-@Q,363H_C5/Q:F;-VP:!32H>I(Z:ME6O#,IL!:8=*`50BI04&<.!54Q
MVIJ@!F([%4Q^%-\,7K#J(R=@8_;)^CG5/04D=L;OV64;8^+(Z:H"SX80$Y^_
M#L#*'`ZAR]_@,HIL``.H8L?O'4W2ARCM'8'I:A=*]'XV&MG[WC5/04K7[9P>
M3228QCXM/TU0,UX70$QAG'NTQM\X@>P;3GW"I;YORAM,?FR@7:/+N@`=0-0F
M3Z/)L-;/\JJ^+4H?MKW*23;^#3]->:/G+E.'UA7N$YW7I)Z]%#C#Q\:50,XF
MT_G1XA9.*X,4Z[(`3,5<4M@D`QNKL#9KWV0*78,\8RS#:R<9CL&FA]M082];
M(B>4P;L-%JH8K-VM"3+.+4\IK!-&J@)-LV#KHY+C9=O:;%K"-MW#X`$%1*0Y
M?0EYOK"&WJ10ZK/PG8;#E5L_^OZ"I,J-K/M*>5P2>DIW'7'AP#=`Z<ER\H_/
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M%`Z';^%!**F@G'C]=V>[7A5`6TYDXR2<4K99`\0AMMD.>1!1&,%(IRM]D:4X
M"#+\K<V&KN+8%Z*#I\O_`)G/;_JTGQ>T6^YMM.JEW;QTNO>Z1]]Y<5B15^D*
M&G4TDLMONC?;3QO1Y4(S/%C&["R["%BEYKCP9]=:8Y?ZMVKZ2:Y!P#T3=W%:
MG_\`[/BU:;6^D=N4=-Y--\8K<UPX+N7>7FO3^?EJZ_\`834)R_Z).[BM5PUO
MQ:E%;Z2)T4=-Y-+\8J)K?P4;.5Q-?1RV;?[1ZA.`>B)&W%:KAK?BUN*WTE-R
MBIO)I?C%0&W\$?7<37)_5RV_2/4;L`]$`6'%JKAK?BU**WTF-RBIO)I?C%0/
M;N![JF=38?V<MO7_`+!:B.`>AYNXM5<-=\6I6UOI.;E%3>32_&*D:W<#0_#.
MYSZ.6[\2!U$<O^ASNXM5\-=\6MQ7>D\-%%2^32?&*@-LX%>N[G/HY;_I#J(Y
M>]#4Z<6J^&N^+4@Q'TH=RAI?(I/C%`+E:>"0\QC@6$E+I($O._+$5L.6TC+Q
MWBM9B"FB6MUXT>X4!Z=$^Y,[L4)2B(CTD&^NEAV7/0T-+70Q6H+>R6EQJ(@:
MV5:S6R[U^,![A[M=+OS=]0S\0])S62==12@[6<BXVG@77763+LR%R[>/+Y-Z
M[NP4U/;>`WXI[.^AR3EQ^D&N&<M>A=NXO5\-=\6KK<0]*;<H:7R*3XU9"#D^
M!BR3,?`Q3N54E)5R1FP1=6FSQZ*SI4!YE`7CZ&;M$3K&#=)OG*!CB!0Y1`!Z
M&#9#]#K,&*R,$PS%JAV(U4P2Y;7S:N4USSXK;\QC6-+C8V\X1<0T6D!5,3S%
MZ3^#8=.Q6NHI`H:=A>\MDTTPM:-+KC'N>0-)N@P$2;`5O(W#M@81$#4ZR[0$
M=H#>)/:`[>7;^5.KMU]G/H<;'189-='^TS>-?+QZ1^U(VBHHX'_TTM4QX<\!
M#U:;9/LYD^Y=:GT-]C9TRJ_YU-Z2V'I([4Q^T4?S:6OD>'#`(_M.LOH_5U)]
M7M76A]#38T=,FO\`G4WC6P])/:J/VBC^;2U3/PU\/Y_AJ;9NH(?5W)\@#Z'Y
M4Y.KK4^ACL8^!K_G4WI+<>DOM6'[116?^FEKJ&LVR%IT#%UBM51M$P<*T391
MS!L^$$D$$]H\HBT$RBJAS"<YS")CG,)C"(B(Z_0V`Y.PC+&#T^`8%+93832R
MPR5+:VQK1Z\228ESC$N<22225\3QG%\2S!BD_&L8G/GXG43"^8]VESCW@`(`
M`6```"`6?)E`QCE*,*&PQBA_3X]<0#W'KK'#!#Q^]X5S+JX'\WW?ACJ;Q+G"
M+!47O'-Q5.A#IFYS?.WE!7<#\K&WMWG=FWDV[.IKUV<*`3*FAY4(852C1^`>
MZKE8.5+_`$+/87>WE1-X%#M\>X]>2\UCG][PJG=3RHF\"AV^/<>GFL<_O>%+
MJ>5$W@4.WQ[CT\UCG][PI=3RHF\"AV^/<>GFL<_O>%+J>5$W@4.WQ[CT\UCG
M][PI=3RHF\"AV^/<>GFL<_O>%+J>5$W@4.WQ[CT\UCG][PI=6O;ODB27G,6J
M,XMTDU;9`.K+E:S%R0378FI-Q;HI/2U9D,6X:A)+H'W)\2P_.E(;;TTK,!N4
MN&RQ*J`YXO&39%K--]ALOF,81][Y</P;RW8!!WXO<WQO_>M]:*V%Y43>!0[?
M'N/5/S6.?WO"M+J>5$W@4.WQ[CT\UCG][PI=3RHF\"AV^/<>GFL<_O>%+J>5
M$W@4.WQ[CT\UCG][PI=3RHF\"AV^/<>GFL<_O>%+J>5$W@4.WQ[CT\UCG][P
MI=3RHF\"AV^/<>GFL<_O>%+J!E$VT/G*'5]W^NTV:>:QS^]X4NK6N+,IR`P$
MZ5_%JN#I9$R0DU4<2%W,J#`+G+JM$A/?8MM+*$;D6YH@M`/#@F0I8\YFI4]E
MVOPMFN9<?`:F7&`9IN"/O9A;IMY<?'%Z*DF-$1#FC>WNY_EWULKRHF\"AV^/
M<>J7FL<_O>%1W4\J)O`H=OCW'IYK'/[WA2ZGE1-X%#M\>X]/-8Y_>\*74\J)
MO`H=OCW'IYK'/[WA2ZGE1-X%#M\>X]/-8Y_>\*74\J)O`H=OCW'IYK'/[WA2
MZGE1-X%#M\>X]/-8Y_>\*75QIQ/7P9#-/`"X&+!+H/%1:%]P'F_SNWA6XB4-
MS>Z,7<_IC;MV#U.IKTN!4%S#,8;>C>P]HT?^JISO]Q6I`A*G?HQ^6U=E^5$W
M@4.WQ[CUYKS6.?WO"JMU/*B;P*';X]QZ>:QS^]X4NIY43>!0[?'N/3S6.?WO
M"EU/*B;P*';X]QZ>:QS^]X4NIY43>!0[?'N/3S6.?WO"EU/*B;P*';X]QZ>:
MQS^]X4NIY43>!0[?'N/3S6.?WO"EU/*B;P*';X]QZ>:QS^]X4NK3WCF/C-XP
M=[P_QA.A]$Z5UON:=SG.?YC_`'-S70[%[CV>]^Q1C#_U.]%2^TA^!_27'F"(
M:\)^<"RFL]I=^;8ACY*SKTR\7+A*Q[BU5U>W;=R6<A*UDNM8&";NV.!8N7"S
M:R2=CKL@\>%*V`LPBL98?,*$Z.ZNM.(G]_#AM_K3G3^]ZH:\IGW_`+-J/[53
M_P#W%[3)'Z_-_1M_+:OQ7\3\77YUF+ZZQ6!NH.J<S0K8TK'K=7^3T`U3F>*I
MVJP/U?P/7U4FZ"K35SWQ+QMQF,4NHJALWLC89"[8M:]`93<_6@>0BN3:F6SM
MY&PU5-6Q0D$K7.E!(.6A#+(L^<,`"`"&I<,?(EU@?4D"4)<PQ(#H'5NNP:[D
MDWH0!TF"AKVSGTI9(CK"Y@L)%E]L;1:!",2-R*Y%F;]Q1X>EHS&D%77]\5:5
MBWR72E:?>+A6VBTK7,FW*K,(#(9VW2["PH$Q&PE:W9I['2$BF?>,W,JNDJ3H
M=EP6OEFKG/;+!>P0OL8Z`=+8XEGM2\%\SD!S6G=@"%S'S\7HWBGD-<^$M_M7
M.$2'N;!V[=(:RTM<0=$2OS+F2N+.#G5<85%K)6"7F,?RJ'C[&8>E8^-9STWC
MR_S\;:*S(-7,U5FTC4[;$140+.4DVX'5=`(MU3J$4"M24>`S&"MJ"ULMLT&X
M9H)(#V-+7"QT'-+G1:TV#2($*6IJ<=:>RR`XS#*<+UPP!+7D.!M;$$-;RB-.
M@Z5A[GDCBHFCVJNUVL.Y5E'0F*96F/"URX4.8N*@SV)Y)S9Y&<\7EHJL-;"Z
MD9R/FX)9;OA%L6AE>C"0BO.UI5'@4L,G3GAKB^:'\ICPRR:`T"]%Q:`QS'CD
MN<81T0N&JQI[G2I;'.:)<N[8YI<099+HP@V\2X.:;0T:%]V%GE#,&-,Q62Q-
M[>VO-+PPTHL'%50EFH#PV:#H+72]O:W$PDV,H`1,F>'BH]0KUZB];-3J%44(
MN<H4PZ@PZMIY$G5&EFU)>XNNS!J;&,#B1"T7W.L!!($`0IV,KJVFG3INL%1+
MD%@#2YONEKC`1!Y@!!(,#RG`K&W*W\2S:2RC0Z7&R5'JN/5ZJG4G["FW:]VN
M1JL;?,>&4G8>S3$:ZA+B6T423F32;()!Y+LE&O-))F.1<VJ\FFP(RY%74N;-
MJ)P??!>R6T.,N9R7-!#F79@9===#'1B3`A67SL9UD^FDATN1*NW3=<]Q`>RT
M.(@Z\PNB(EPAH)B5=RV7.)FN0F,7[^OO[!/WJSF>2D1&XEDV<'7J^:\P]84I
M\HYC'=DFH^8;UMVO-I2#TL<U,@D8%%MI02/0\VX!/F5#&/:R5*E0!,X%SG7'
M.O@$-:07`,+6WG1(@-U6FUN.21*+F/>]\V)`8;H87-;=,"X@@$N!-T6&W<63
M)E[-9)R`AW39HC-73)3_`!R-:DL:V"(:4"1;RKJ?;OVEP>/VL5D>K^2NJRKE
M>08\X1*0<M0$WLBMQY[\+P@R7S6DZJ33B;?$UI,P$!I!8`72GZY[`&NA%H=O
M7E?9B6*2YK6/$9DV>98:6.%PCE1O&`>W5L?$MC:6VVW5#G.0LQ3J\-(KL+R>
M;<P5LB):J(XJO57@*A;5<@X8=$K*LJLD+"XDAJQ'V$S&Q$7*S>(%4YLVU8J1
M]30X5):Z6#)U(>QS7ZZ6]TQFJJ!?NZ9=YYE7I1%YIA$614DNKQ2;,;,<)NL+
M7@LU;VM8Z_)@V.AT&B9=>#=(C`VP5*P94XI8&K3TFM66TD]E'J3N,>,<;V$/
M)Y#'R)?JH"+J!B3VJ7O3DT'$03]4Z;=)1-"06<`D"($YNO+PS+,^IERQ,+6-
M$'`S6^ZNU4M]CG7&RQ>=,:(D@EH;&,8S3:_,<F1-=J[SG.%TACO<VWW-\47B
M^P,)@-!+H0T:VXY7LY(XGX19&S-V36R/^(#%;VPMHU"3:QS><=8YNZ\LBP:S
M2#69:LTWZB@)).TDW29``JI2G`P:]!LQ9(EXGF*73$FF;@M2&$D$EHJ)`;$M
M):3"$2TD'<L4F9W3GX7A[Z@`3S5RBX"(%XRWQ@#`@1WP#OK5#+X4GP3?AAJ>
M=NJG)W/54J9]4NN5-W5U)6@>HI:Q^)_`_#UR)ZZ<G[ZF##JD_E1UQ:C0NS(T
M*6L^IZGX0ZXU0NM*^\KI3K_`]?7/?N^JK3%9*=3\`=5'JRS2K4WK?AAJI,TE
M6&Z5#JP!>@2)BMW;;?L=F.9-XRDV"ISC-/`,X31EGCYRJU<[-]%9,Y&RZ9@.
M@FFD)2!8Q<GM$L%S'0II(BUS'`>YML)EM:`YNAS2"]IBU[G.!)Q1^]NL(]U?
MI#A[8V\HDP.D$&Z1:T`0"S9^I_)Z>N$]=!NE6BG7_`_$U6>IV*S/U_Y.MJH_
M<5EJL5/BO@?B:J3-U6F;BLE/Y/5U4<K+%;'ZGX`ZA>I#I"M#]75<J5NA1&PD
M`[^IF%%=7F[*4X'192KLC<>\\N3G7*L:\:H1Z`@82<\](X:;YBD%/G#IG)>P
MYQ%-6@.:(TL(%\MI=[K*,&B8UQ>=VY*+)D`7!UUKVNBJ1&93F!,)PT->8<A]
MI+2`T;EYX<R,`1>+2,PIU_@ZX;M!]1=5BMN:5<*$0125<+KJ)HH(()G67765
M,4B2*"20&55644$`*4H"83"`!RZB;*F3WMD2FN?.>X-:UH+G.<3!K6M$27$P
M``$280M4VL9*89LQS62F@ESG$!K0!$EQ-@`%I)L`TKW2P)%Y,A\9P+'*K]![
M8TDB=$3W3'E8Z$YE((Z-L+S>%-]--4P$%#E#:0NZ0YCG*8P_VAV(X=M$PK9W
M14>TR>R=C[6BX($SI5/=;JI-5,C"94,%CG`1:(,>Y[VN<OY;[5Z[)6(YVJJK
M(<ITK!W.-\Z)4R=$ZR93LA%DEQM:"8$Q<T-:0U;EU];7SA-$31$T15$OQU/^
M7)_[P:P="+AK@.^HKB)_SV^*3^_-GKU6;/UFC_Z72_D%6ZSQV?H6>PNX=>65
M1-$31$T1-$31$T10BVHD5F<<',U=.#-[LHLFLVBYZ138F&GVM$7+UU#2;!E"
M-#D5%+I4HF\CQ44(CS(.%6ZR5JG)$J>`0(RMTM$>6RP7@2X[L&D.LC&Z"#NW
M0[\7[X^ZRU3?55:)HB:(FB)HB:(FB+]#JA\$/0]'T^31%"*"W4;0LD0[==L5
M2X79P@FYBIV'6.BXM$FKT@S>Q2TS(.4W2ICJ).B*)-'2)B*-D$$!(F%JK<'3
M6F()U;!I:=#19R0`(:"+2#$.),2MWPB/4&]O=Q3;55:)HB:(FB)HB:(FB+DO
MB-_?@X$?\Y^S_P#I>X@->AP7]W8M_86_[53JS(]ZG?HQ^6U=::\\JR:(FB)H
MB:(FB)HB:(H!\5_XD?\`1LU9]O\`W#_>5O[7^1_27--2C(B2\Y1!H)6WB5MM
MNIB&6;5.5;*%;B[MCK'5=O$.WBH1>`N5-R"WKV(HYVI&;M?8S$"O-RS)RJ!3
M`0JBQ?$J+<7:F<7\+'Y\X;EIUDJ_9C"9V*"*1"G,"H0-,.!MTZR`;.;*8.KR
M;=7G8708M@-93U\ILV6)L@@.C`&,P1L(WU<HZZIP]CY]*]S)ANB(TPC'V0%+
MSVW%VSEJK\?_`,!'K?V3UY$Y(RT=-')_G<:NG-N/-_:9O\WB5LI<,4D#V=/D
M@`0ZO1D?0`=G+*!R[!`?@#K7ZAY8=IHY/"[C6WUOS!\JF_S>)61[OB`!]E3I
M(=GYU0^FP:T.0,JD6T,C^=QK(SEF&,!5S?YO$K8UZPV'*-+DQZW]*M_IOK'V
M>93=8:&1_.XUM]=,R#]KF_S>)6Q[[A8-N]2)0=NT/Z5;_@_KQU]:G9QE`BV@
MD?S^DMAG?,PT5D[^;Q*U'(6#]\4@I$F*@$!0R14&O.`F)A*"ID^_8&!,3`(`
M80V"(;-NW6GV:Y-=_#Z?^?TEO]>LT-M[;._F\2HGR#@XNTIZ#,`&T0$!9MP#
M:7X;:'?L.4-:'9EDLZ<.I^%_261GW-6Y6SOYO$K0^1L#AR&Q_,CM$1V=$:CM
M,/(/Z^]4=OP=8.R_)1TX=3_S^DMAM`S8+173_P";Q*V5R/@(HASF.YK:'(&U
MFV^)'9L#Y_=8?]W6AV5Y&.G#:;^?TED;0LVPB*Z=_-Z*M#9+X>BCL''4SR<H
M?E-K]/\`6OV49$=IPRF_G]);?:+F\?M\_P#F]%4#9.X=O9;<;S0]7>V-&O6Y
M.7]D`"(:T.R7()TX73?S^DMAM(SB-&(3_P"9T5A75\X7'$C'2[O$C]Q*Q*#]
MO%R*T3'J/8U"5*V))),7)Y\5FJ<@1HD"P$$H*%3*!MH!K8;)<AMENE-PRF$M
MY%X1F0,-$1>MA$PCH6';1\WES9CJ^<7MC`P9$1TP-VR*KJ95X:BA[+&4X(;.
MH#)IU-O4^J,-0_8[L])_=5+PS.DI1M.SKI&(U'\SHJT-EGAD`>7%T]U>KT%G
MU>I]<NM?L;V=G3A-)_6=);':CGAO\2J/YG17FWYR"_\`#W.PG">QAJ!-Q9?N
MP*"M,*"R9E47B$J%DP'#5'Y^N`.JJX.D(`(%#80?9>CZ[*6R[(6$LQ2=3852
MMF3,,?+/OEH,R42#R]%@[JP_:%FW$93FUM?/>V4-8V-SDO%@<.3I`<>%0*.D
M>&L-T%*;:AV>@PB^KM#;U9L.KJB[9]DH^-A-'_6=-4AGW-C1$5]1_,Z*F\?+
M<+P;@GI%M'9L`=D?%_!\/:B.SC(Q-N$49]>;TUN-H><`+,0J/YG14WCISA3+
MN[]#N!NH`AWNBO1_YPAK1VS+(#_&P:AX9O34C=I.=1HQ&I'D=%3J.LW"*3<Y
MS'5Q-R=4(V)_!_;*&HG;*MG9M=@M"1ZLWIJ5FU#/0L;B=3#^1T5-V%LX.2E#
M?QI=#<G+LC(<.MR?MGU"[9+LV=IP*@/KSOC%*-JN?AHQ6J_J^@K\]PX-`^&Q
MA=1ZWZFPWOGUI]D.S(_P'#OZ[XQ;C:OM!W,5JOZOH*U/<^"\.0V+;L/5_6Z&
M_!_;1K7[']EYTX!AW]=\8M_M9VAC^+5?]7T%2&[<%0#[+%5W$.J(=[H;E#X/
MC3K4[&]EKA;E_#N&=\8L_:YM$W,7J_ZOH*"TJY\&C>*E4Y/%-M46"X7,Z)F=
M3KL$D+!:QOU8\#LVN1Y\CER5H<H*O#+(JO5`%8[9J8XH$M5VQW99.FM<<`H#
M"3+;:Z>X\E@$(E[8`0@&P(:+`YT(G8;6=H4H0E8O5M:;3#5Z3:3[WI)B2I6:
M^<$/7Q+>!_L7"^^S5'[%]E)TY=PWAG?&H=L&T=MOGBL_J^@K<U^X'.41Q'>1
MZX_.N&ZW]UFM3L4V3[N7,-X9WQJV&V+:4-&,UG]7\6K8<A<"_7Q!>A_L3#>^
MW6IV(;)#IRYAO#.^-6WVR;3!_&:S^K^+5N;(G`D&W;AV]CUA^=,+[[M:_8;L
MB=IRWAG#/^-0;:-INYC-;_5=!6Y\C\!P<@X:O@_V)A>M_=@&M?L*V/G_`-MX
M9PS_`(U2#;3M/^FJW^J^+5`V2N`H.KAB^C_8F%]^.L?81L==IRUA?#/^-3[:
M]I\?WW6\$KXM4#9-X!`ZN%K\/P(B$]^.M3L&V.?^,X7_`%_QJS]MFU$:,;K>
M"5\6H';\C\":\C05([#-R23:WALXE@>4BN3AUXKO#8$54&#I;*4&>LOC.UD3
M%D4DI)0I"G1!H8%A61N4>PW8Y)E5+!EK#@)D@M,'U#0>6PP<!,=?;9&X2T1`
M-ZR!P=M.TV80Z=C58YTLWF>]<EVB(]S-L"1N:=*EYLH^;\#X;".0!Y1_6B#]
M^>N=]@FQK_QC"^&?\:I!MQVJ@68Y6_U7Q:VY@BX<#5IR5!Q5-I<SCVYJF.%7
MF;3&QC9LZE%BF;ECHYVC-S2#>7<(J&YGG2)[X^Q3/S@E*/6P+9'LRRIBLG,&
M7\OX=38Q3DF7-8)KG2R06ES;\QP#H$@.A$1B"#:N?B^U?:'F+#IF#8SB]9/P
MR<`'RW%@:\`@@.N,:2(@$B,#H((L7I3Y,(OPE(^HU[!KZ3YSF\UO?XUX6\4\
MF$5X2D?4:]@UCSG-YK>_QI>*>3"*\)2/J->P:><YO-;W^-+Q3R817A*1]1KV
M#3SG-YK>_P`:7BGDPBO"4CZC7L&GG.;S6]_C2\5]%QE%%,4W?&1'=,!MGY5#
M;L';L_&-#B<TCQ6]_C2)7`?F^*''R%-XF2*/7J?0^.CBK;$%/H_LR)WI%(IC
M`9$=AQ!+:.SDY>IKU^<:^9+J:&#6VX52'=YGJJY6$WI?Z%GL+OKR817A*1]1
MKV#7D/.<WFM[_&J=XIY,(KPE(^HU[!IYSF\UO?XTO%/)A%>$I'U&O8-/.<WF
MM[_&EXIY,(KPE(^HU[!IYSF\UO?XTO%/)A%>$I'U&O8-/.<WFM[_`!I>*>3"
M*\)2/J->P:><YO-;W^-+Q3R817A*1]1KV#3SG-YK>_QI>*UY>,6LC36+5$7#
MEP1OD,%7)UX*&F%&K<U,N*(N&;U[-P2E:=<ZH4G3FZ,HX$AS-P:"1<[AO=I,
M4?JJ@$-$9-G*<(F^RP@!UX?@DL&[>B`UV['&#OQ?OCA[RV'Y,(KPE(^HU[!J
MEYSF\UO?XUI>*>3"*\)2/J->P:><YO-;W^-+Q3R817A*1]1KV#3SG-YK>_QI
M>*>3"*\)2/J->P:><YO-;W^-+Q3R817A*1]1KV#3SG-YK>_QI>*>3"*\)2/J
M->P:><YO-;W^-+Q3R817A*1]1KV#3SG-YK>_QI>*_0QC%`(#WQDN00'DZ*`_
M@#S`[!T\YS>:WO\`&EXK6N+,8QO>":!1*0B%0OV0N<*2%@()&1$+=*IIS"+.
M(G+0V7+(MTR',Z4<).71]JJS9HJ8S=.]7XG,US877#4R_;.=#D#DQ(8;#N0(
M&@.<(.,DQQO#U!['K+9/DPBO"4CZC7L&J/G.;S6]_C4=XIY,(KPE(^HU[!IY
MSF\UO?XTO%/)A%>$I'U&O8-/.<WFM[_&EXIY,(KPE(^HU[!IYSF\UO?XTO%/
M)A%>$I'U&O8-/.<WFM[_`!I>*>3"*\)2/J->P:><YO-;W^-+Q3R817A*1]1K
MV#3SG-YK>_QI>*XPXH:+'L,U>;^0(\>J%?<55H05,?HX&*0.%3B*7VI[J(`!
M]YL`;1VAL'J:]/@-?,?A>,.+6Q;A[#N_*J<;_=5JG)U4[]&/RVKL_P`F$5X2
MD?4:]@UYCSG-YK>_QJK>*>3"*\)2/J->P:><YO-;W^-+Q3R817A*1]1KV#3S
MG-YK>_QI>*>3"*\)2/J->P:><YO-;W^-+Q3R817A*1]1KV#3SG-YK>_QI>*>
M3"*\)2/J->P:><YO-;W^-+Q3R817A*1]1KV#3SG-YK>_QI>*>3"*\)2/J->P
M:><YO-;W^-+Q6F?$YEXV=X.EN^C_`'0/3.?V(\_O_<T[^Y^-\WN?_9VZZ7;'
MZCM$!>['"%L/UE2VW([MS^DN5L4Y(X;$>++O-1.'/'M2O%PR9D6*G+S'7*K,
M<M+9"CH[(!;+9+CB%F@6VH-9"+HQND2T@<#%:2T88H*)KCS/FE&=&E=`\3`[
M,V<->WP5G;^]NHZ[N'_NBL_'D?E/1WZN_P!5OWUAC&V;-TY2&V#NG'E`AMGL
M3"&PVT"CR]0=4"J;]Q>5];IW$AC^J6=[0L=DAK>C5:1!Y$L*[(B5\R!<F]^*
MZO\`;Z@Z<6NX5+(!GU7D)!^QE'D'&O6YED6?-.`(*:.K8C0MR1NJ?.)7BNA$
M)"PS2-UN#<]0<1R]3I<-CF'D`FF^(Z;(1\_523#%=RRLLCE=S)M7)7Z[N/1;
MIJ;C0"D2V[<I:"[%16+G^)27,./X>]6YS-0,!C2T6BSV"GXVC+Y'C>[A6ZU/
M5N8K[>+7J\,[A(*`LL_'`*1W)XQTT%4JIN;$QMXF`)BMG70(G0KJ2-Q>U^F6
MI)C)3=RFC$CCLI"2C*$UL;..:9BN]:E#U%K!0#>(=6)[AUA!3()O6;I$SURX
M,F0IC%:)[&\`G(B%#25*^W.#@L@9DH$YD=PUNM*JV0Z=%UV/C9FXTK'N-KE%
M$FPHCZ7CH]W&JYWN2\T>-%V"0MVJ2Z0'*F0IL-!(B;;?N[ZRX@6-,%9#C7,D
M1>V-CJU6M#"F3MSX28.<H4W?RSZE4IE"EJ]8IBV-Y1W*.BR;^E'C'47.$25Y
MZ39/P$HNNAI`9!P.[N+5KFPA&VU2C'U,O$/1\W4NKP$[!.9&GSS6MW^ZPL13
M,@6W)D@A;&A9.==P5CL4=9T6S9Q'&0L/-LG"J@J"LFH;88FP!@?46I(A;OK6
M)8K/-3J3X,)8X\F-;D<@5_HU="!;LKHP@F]*=LWCB0J;ZTY)KBB!+H@P1D9)
MB=FK,,@6<BFB?8X-@!VYH00/C&)6?L2O%I'U^[OHR0?R<Q*2TFHT8!'U`3U.
MO,<IN8MN&-4FD`JO(R<AC)9-XBG-$DS*&1$VPJQN9-D7H(+NZIO9,:*Y#A^'
M"3R958&W7*KVNKOKY(.XIJV!I&FHMK\8E5(]13<:,W=M&,6<,4A433>%3W`,
M5(I@S",(Z5@.A&&A:+>,.*>CU"1C:DK.S9)&2?SJO2T*F\GJ@VE,M9).]B*0
M`1KD94ZE8D(-^8LF215*V*OS)R'$$2N4-"R2PVG[K`LM<G/$]%T:;FF+NUS]
MQ?6B!B6$/7(VA1L?!5YICJ"?/[+'PKRO3LL]2F\C=,;.D%G:RC9%0`(*227.
M#GE"T1BM6W-%GW>!:8@LT\2#:O2MRL32P.G5-F[!&7N#=P=!C*I)V%E9ZG78
M#'6-W+5T,V\LCV1FI%!R"RJPB9H@5$3'$O/Z@NTK9P;8%EN,]M+,*IPB,;#*
M)S-@9\2..6T]+IH-FB<G-(8]O:<J_3:M`!JV2=/BJ'*1,`3*40`O)KOX/'L]
M=O\`8G?ERU8IH7)T-&J/LA?K(Y.3V1?D@^.+Z>N*[2JIT*4,SD]C[(O5#XH/
MC?@Z%:G0I.S.3V/LB_#%^*#T?@ZV0*3M#DVD]D7J#\4'H#Z>LNT+$O2I.T.3
M=#V1?B?B@]#X.M"MO"KE4Y/CR]4/B@]#X.LC0L@B"QJRB>WX<G7^*+Z/P=8`
M-JW.XK,ZB>T?9DZGQP>GZ>L@&"T&DJ!U3HJ4?-`@9H4#7"VJ*]&"`(07"D\Z
M.N90M>.=ITD5!^6BOL?B?:+H`7WPU9J8E[8Q][9IO<T<ZV&]#D\VQ3OC`1YH
MW_O_`.3>4@,HG^2$^2+Z^JFZJ[]"L#*)[!^6$Z@_%%]#X.LN6ZL3*)\ORPGR
M1?7T.A';JLE%$^7Y83J_'%]?61I48T*P443V_CA.J/Q1?7UAJDW%9J*)[/QP
MG4'XHOKZRU1C2K!11/;^.$^2+Z/P='+;<*U];1;'EL?"H9`3)W0%$14+65!*
MJ%9L9=J0SQRODE>:,8`-$[9+8(@`='%P.K-/'5SX?!?A<YO-L\OD_P`JZLCQ
M7^IW=\;WW[/7@I2JHGM_'"=4?BB^OJHM!H4CHE'MF2[?#4RB1J\O9I9P4&"#
M57F0:@@/.JR3MZ!BECF,<0O.JN#"`)`7:&TVP!R\AK27:%)`NL&E?U`8LK5H
MI^/:G6;G:UKO9X:(;LYBS+H%;J23HFT=NP/EBQ&J8E1*LK\N7*F"BGLS&US'
M$%Q($`K300(&TJ?ZU64T1-$31$T1>>?FZ/J0XI?\_'BO_O\`PU[+.GZS0?\`
M2:3_`$:N5OC2_P!"SV%Z&:\:J::(FB)HB:(FB)HBU7D5HT<6+#BSA9DFJQR8
MJY9).TJ4HNX<FQY?FIB1PVTHRB3Q-JY44$T`8LSS)5`Y6(O0'H43G"34@`P,
MB!A?L&LEFVY9",/?.1&'M[JD9&#OQ>[OC>^_9Z\%M37/4::(FB)HB:(FB)HB
M:(M28:1YBNV8A3E,B;*&5%4"D0HB":0*WV>473(7'RBD4?8\,J)CO1":,<1&
M2`'G/:Z.)F,Z6=WL\KX0_FV_"6Z(>+R.9R8*2;XP_%&_O=W_`";UBVWKG*--
M$31$T1-$31$T1<-\6'[^/F\?\Z^T_P#I.XD]>KR]^Z<9_P"GL_VNF5JG]YG?
MHQ^6U=R:\HJJ:(FB)HB:(FB)HB:(N?/\)7_7K_HS:['[#_=?]Z4WYO\`D?TE
MQ]1<B&L/%E"5JIY6*U4C;Y>U[93G'$'E[)9KE3B5^^1Z80>*['B&-IT-7V%R
MBR"$U'S@1D6]B5XU-TX6$6Q^.HCH72>:IE*#S_PW.UF17Y306>$N9,8A0#YP
M4M3>VG(H'*">Z/)U!UVZ$1P:M'X<C\IZW!`D/C;:W[ZG9LG1Q=G[$VOS1MW)
MKE"63NJN7`;BM395C"CL\4&H\FW\=;=QZ"62(Q6"\"R"M39;B@$0\3&8[/Y\
MU[AUDRB-U-9`Z%$XWB$QM(3]A@(.)I<A:H@S-:V0D5.5YW8(PRB)6[!6PQS-
M%219G%%,$TQ<$*(``$#K!K(E&/C(7B$2+%GC9DB2AM\16?5V<JK3J]?\P=76
M=23I*QK!O+$R6?:I$(+.Y:JP48U;)<^X<R4G%LD$&X+(MQ<+*NFB9$T"KN$T
MQ.(@4#J%+MVF`!QJR/;6+)>-Y7!\V0Y#G(?'S,#D,)#@91H!BF`1`2F`8[:4
MP"&S8.FJ=SE@3!",%AY+B'J40DBO*TR$CD7#UC&H*OW\:T36D9-TDRCF*1UV
M!"G=OG:Q$TDP]D<Y@``TU3A[98$P0\58J!XG\?6R.[[U.MU2TQ/2G3+OI7IR
M#FH[IC%3F7K7ID<T<M^DM%?8J$WMX@]4`UELHFT.^[A62\`>+!9,^?8,HA^Y
MM'CMZGRYER]?D^=?+K(DD^V*":-Y0.V<9>':([BF%W88]J#Z>.=*"9VBV5B!
M=32J:A$5$XEO*-VJLBH154I1*B!Q`3`&L&5`VN0O_!BI&TXEJG(MR.X_'L)(
M-%%'**;IE(1;ML=9DZ78O$2+H1JB1E&CULHBJ4!VIJIF(;88H@#4F$8K&M`W
M%]*<1M>)L_<NC3;0$0'GV'+LZOZT\NS61(<?;()HWEC3\0]2`H`.(802]+Z>
M`",7N].`_.@]#YS"'2^='>YSX?>Y=NW02''VR&:-Y>:GG,^(*)D:WPH+Q^/H
MZ*<P_&'0)8%"J1ZP+E;T+)K<S4R?>LA=U476T=[>#V`<FO2Y=E!LK$&OY374
M#Q_62[>\K=(\%LVP>]'V0M.1W%.X2`O["XHW(/5;0O6'TX<=4NPR"-!X3QJO
M>&\IW&\6:X;G[!8<=I0ZK:#_`!84=.P4_=X3QI?&\%.(_B]63`HC0(4P`.S9
MT6!ZP^G!#Z.G89&\>$\:R"W>4YCN,TR>X`XW@S;"[?Z7@.M\&`UGL,C>/">-
M"6"V"FS'C=!,@;<7P9N0.HA7@'K]?Q?Y.IK(PZGTV\)XT#VGVJOQXXR_P6PG
MS*O>]_0X?3;QX3QH7-&X%0-QSE#;^Y7!CLV]5*O=;^Y_3L%-O'A/&L7V\U41
MX["`(!Y*((?_`,*O>CZ5>VZQV"FWCPGC2^T^U4'I7':*<5+<]B^#>":XW,Y#
M'=4B0YE$]DD!1:@O#4R+;)E:D]@"*J9W:`!S;A994IE#6JN@IC,;!I'N3.</
M:BVUQ-N_H.D`"Q2/>V(@-P>PI2/'LB`[/)%`_,Z[[W=5NP4^\>$\:B,P#<5$
MW'V@&S]Q^`';M^(KOO<UCS?3;QX3QK-]N\J)N/YN7_`[7QY-OPE=][>G8*;>
M/">-+XWE0-YP-L4-OD:KX\OQM<][6G8*?>/">-"]H&A6X^<(;;>7#%='J_$U
MSWM:>;Z?>/">--8S>5,?.%-`V_N+5T=FWXBM];^YK0T-.-P\)XTOL-L%0'SA
M[,!$/(G7>3_>UOWLZ&@I]T'A/&LA[=Y0:V><09'DJ(`8=@VFY=$%#$1?4-B#
MX"P,\'0W",I1W[B3;G$V\*#%1H]VD!0%N;(HFI9IZ&G#)W)C[E^&8<IMMCA`
M]UT1N0B01NQS2UQN[GW_`+M-BEIO.+L2_P"`^N#_`/9K7O8U6[!3;QX3QJ,N
M;O+8F*?.%5:7MS6&FJA$XP2E2@R:VENWKYV"+E0^\FUFG#>(CUF$>Y4(4H+;
M3ID4$HJ`4NTX8[!3$>*>$\:RQ[3I$%Z$>/=H$`$),ABF`IBF*T8F*8I@`Q3%
M,5$2F*8H@("'((#M#6O8*7FGA*F@$\>[3X2+VFR[!IV"EYIX2D`GCW:?"1>T
MV78-.P4O-/"4@$\>[3X2+VFR[!IV"EYIX2D`GCW:?"1>TV78-.P4O-/"4@%]
MIWJT"H0!D2B`G*`AT-GU!$`'^8:&AI8>*>$I`+A'@$ML^SI?$@9L]*F+GCAX
MIUUAZ,V/OJJ79LH8WLTC;H"<XCL#8'+KUF;J2G?4T5YNC"J4:3S"K=8!?9^A
M9["[K\>[3X2+VFR[!KR?8*7FGA*J0">/=I\)%[39=@T[!2\T\)2`3Q[M/A(O
M:;+L&G8*7FGA*0">/=I\)%[39=@T[!2\T\)2`3Q[M/A(O:;+L&G8*7FGA*0"
M>/=I\)%[39=@T[!2\T\)2`3Q[M/A(O:;+L&G8*7FGA*0"@-TOUE+-8O3/*HD
M%?('-D!1Q5X\RIR4RX+<TFTEX5^[G#B5,1%K&JLWQ2@*_/"@BNDK<I:"FU4\
MAILD_AGV[-T.`;ZK@YNY")!&[&B#OQ?OC@]=3[Q[M/A(O:;+L&J?8*7FGA*T
M@$\>[3X2+VFR[!IV"EYIX2D`GCW:?"1>TV78-.P4O-/"4@$\>[3X2+VFR[!I
MV"EYIX2D`GCW:?"1>TV78-.P4O-/"4@$\>[3X2+VFR[!IV"EYIX2D`GCW:?"
M1>TV78-.P4O-/"4@%^A>[3M#YXEZH?F)F/7]`$-HZ=@I>:>$I`*`8WR#8EX*
M5,WG479$[M>D#@D[JTV5FJC:)(JC$SJO04.S:JI&]F=HJFJ\:'4%)PNNJ4RA
MKE;A],)K;S"#JF<]L>2+8.<2?5!`,(@`6+=[1'UAO[W=4^\>[3X2+VFR[!JG
MV"EYIX2M(!/'NT^$B]ILNP:=@I>:>$I`)X]VGPD7M-EV#3L%+S3PE(!/'NT^
M$B]ILNP:=@I>:>$I`)X]VGPD7M-EV#3L%+S3PE(!/'NT^$B]ILNP:=@I>:>$
MI`)X]VGPD7M-EV#3L%+S3PE(!<@<2ULGG>9.`E9P]*=1IQ26=9`W1FQ=Q3[E
MKB$2VB!4@`P<VL8-@[0Y=>DP.DIV8;BX:TP-`V-I^54ZLR`-5._1C\MJZ_\`
M'NT^$B]ILNP:\WV"EYIX2JT`GCW:?"1>TV78-.P4O-/"4@$\>[3X2+VFR[!I
MV"EYIX2D`GCW:?"1>TV78-.P4O-/"4@$\>[3X2+VFR[!IV"EYIX2D`GCW:?"
M1>TV78-.P4O-/"4@$\>[3X2+VFR[!IV"EYIX2D`GCW:?"1>TV78-.P4O-/"4
M@%J_QEFN^O?CI8=\/NBNC<_T=OLYG[FO=W.:YKFOA>ON[=7>RR;NIA[GV&,(
MG3VG?TJ3VD-RY_27(O#JFK#\2<19JQC^T55C><CY/J4M3P'B],C7:-#O<LV"
MO7.4LEI=!P\ST'-V1VO)MH]FT(R:FLQ>@KJJI`93R*B.A=B\1)3'SGPV`0IC
MCWGSQR$*8P[/%RG\NPH".S7=H/W/6_CR/RGH?U=_JM^^OA1!?8'Y77Z_\Q5]
MKKG-W56=H6.4;N-O]+N.I^0*^B/^\UEI%U8=I5@+=R50#=&<#L,4=G,*\NS8
M.SX363H6(&*\YY#AXXD&Z=L84B<:T)9C'9K)`6R.<UY\\MKC*V9$,DM^\AO%
MEG;Z1-#6CNHV5</Y([3OAT19J0P(BZ)B!WUDD0M[BN(#!W$_%MZ_(!D.ZC8X
MF*KM;:.+1>#2T>SA5ZOEMK8GMEK,6BYJMDL\7/S56,1]N.W:Q(X1(Y5%,ZJV
M1'O)%N\M2EX0\]S$$Q6N]CO%QLZF.LL8]47L>3%RO(-"[6/'$^P4Z1#J&CY-
M@1:K2AF:IE74C'+.VI@,0J!"-]+IW5L7<"VX[Q-Q-M9R+2B+//K0L,XOS*$D
M).]R#]PTK3FS9,<0C2V-GR"SN[3UAJDM5VK.1=F<.81:+<'.H4R@G5V$1NK4
M%L.ZHTKP[9BG*X;&-EDI]_5T(RZ6**L]JM<I=GC.ZS6#*?C^$CW+R2.O8U&$
M;DJQ6^<3$#'(W*DVYH2D.1(,Z1#[Z!PT@6^'_(L#><'\4%CA)AQ4IV;Q<YLE
MZJSYY6JI+4]M982NUFD/JVU&.NL1!P<0\A&MF%B];M')7+XL0S!!8'!S="*:
M#"PI$0MWE\V7!/$\K7+VG!Y`NB$_;9>5?2:B%P=N%G\.VRJN^B(>D(2SAC"X
MY?26*U^9WVBK!!)P0J*J@#\M*$=]8!$=%D%OA+'=\4KO#XRG5GUFL..[G4[#
M>)Z8(D:2D$8G'MXKLD_,LS8H,Y27/+6!L"@HII%<?+%@`.IK;>M6IW=Q<IS/
M#EQ)Q=2F*[0+=;:XVGWCVP3[2-N;M>2-).\JY&G'$50W<T=%E1F[VHV*)65*
MU69LU%FBB)P$XB8^L.38>^LQ;&T+*7_!?$<^I%D"!M=]>7^;LD"@,BUR--Q!
MV]0@\?UMFW>UR,2?5NDP\\]R,P=N9(3HIE79+K'*DHH9%(NPC`P-OJK((C:+
M%I^'KG%M`UF3O$NZR(YOE:GYJ%=Q3^PV.=J^4KD:W5&$J<!#5)E"+DK%,3VR
MZKJ90:-62[1X105N:*H9#47HQ)63=)AN*MQ^0,E!8ZX3H=XI*R3F+XE,;Q;B
M5D`>.7<H\9X^O;=P^<.W*15G3AZLD903F]F;>VCR[=>FP#Q*X#Y$[\MBM4FB
M<?\`Z1]D+2[-H[V%_*CH>0W4;+#\5Z1-1#1ZZK*6Q[1Y[#\IO/A0_,KCL>LH
MI:S9O=P/RD]^&'\R./1#^=ZQNK8!29FQ?[2_E!]\(/YC<]BUD([0I,VCY#<_
M4]_U`_,3KT1_G6MP1!8:JXQ\AL_4]_VDZ[%K!62#!6QXZ1]E\[I#XK\PNO3_
M`)UK"T5D:.D=X/G=(=HNO1_H6B`%0VL-)59A*"HE+OC)6BTMP5<!+R"B)4)Q
MV0C+GGT1%JHIL2`"1$"IG10(4")JK$*"AK%0`'M@`!JVZ`![46V$Z=,=)TD#
M0MWB!%D+!['KK+FC9+:/SMD>J/Y@=]AU`%$Y6:D;)<GSLDNO^M[STOYSK"VT
MJU5C9+E^=DE\+X/>>G_.-%F!5DI&R8EY(R3ZO@]YV#18(,%9FC)3;^I<GU1_
M6Y[V#65J08!6YXR4]E\ZY/K_`*W/>P:U.D+8`P5D:+E=H_.J4^AKWTOYQH[0
ML@%0VQ,I="0J9"M)EMTFSIMQ23+-L@?%&&EU3-%46<0^3DT@!+G>CN#M6^\F
M"AE=XA2'GDB+)A@#"7O`PM%MI$-Z(B;80MB)98Y)LW-[NA9U2+E>3YU2G5']
M;7O8-0*,@]]3?&F'+OEJUM*G7XETV%8`6E9B29.D(J#BRG`J\C(**)DWREV[
MJ:11YQ=00(4.41!&`6&-)L7O/0:BC0:97*:WE96;1KL6WC22DTY.[D'?,E]D
M<YU#'%%N4PB5%$HB1!$"IEY"AK16@(""EVBRFB)HB:(JB7XZG_+D_P#>#6#H
M1<-<!WU%<1/^>WQ2?WYL]>JS9^LT?_2Z7\@JW6>.S]"SV%W#KRRJ)HB:(FB)
MHB:(FB*#VYZ9I,XW2+(K,N^%Y,R%LG+R<826*%/M;LS!=I'P\FC/)$!MTCHC
MQ5@U`R`+BX%1%-!:U3MO2YQN@PE1C`&'+8(@DB[IA$!QMA"!)&[!$.[@^^.!
M3C55:)HB:(FB)HB:(FB+]#JA\$/0]'T]@:(H%CI^ZD8.47=NNF&1NU]8H+C,
MRTX;HD?;I9FW;G=3,)`/&AF1$>8Z&5)9NT*D":+APD4JIK=:UK)K0T0]REG0
M&VE@)L:YP,=,8@F,2`;%O,@'6;P]A3S51:)HB:(FB)HB:(FB+DOB-_?@X$?\
MY^S_`/I>X@->AP7]W8M_86_[53JS(]ZG?HQ^6U=::\\JR:(FB)HB:(FB)HB:
M(H!\5_XD?]&S5GV_]P_WE;^U_D?TESGB&9C%^-%UC?"K6G4''M*G+&UR(_H^
M2KUC^KS,W7D7G>O&-&P#/FG<?Y!E4""<]EF8B(@6D4@B!&LDX<AT=+Q*BW(E
M=FYOFW,#GOAO?-4D%E1A,ZI;C@%!3W1@J8IMV)G3-MVIAU^IJAF'':O`,JU5
M52,EO>Z?3M(?$B$9AW"+5Z'+F%R,6GS*:H<]K`UIBV$?&`W0=]3-3*T\7;LC
MH;\%)X/6])X&OCS]IN.-_,TO!,Z:]PS(&$NTS:CA9T%:GR[8"A^IL(/(/\R>
M]VZK/VIX\TP$BDX)GQBG&SS!S^>J>%G05F?,UC+MV1D%U^JB^ZW_`![4#MK&
M8`?>*/R9GQBE;LXP9VF=5<+.@M8AQBP)KZ?&*<C6S79)7HJD5WGM(,B2/>8M
MB&$-8Q*%8"Q!7C@_&-Z9TX&8\\*6YRZ/VI9L;3]K[)1=GTQ@^,(W8W=;>NQL
MO0A&R,5HW(&7#/[/VBKUL8>TA&$81U<(PMAIA;""^X#B]BK8A5757E://-;N
MSL3^I.8PTBZ;SK2HO&T?9E62R;T4Q[R/G::+@IA*8BIMW9M`0"K4;6<WT]_6
MT=&TRRT.BV;87"+8^Z[H$0K$G9WEB<6"75U)+P2V#I=H%A_-[AL4&D./^C1L
M_'UAS/5<)>2>KQZ94*[=GL:R=M[C(X^43G)UDW<05;3-=HES&$5D'+5)1TB8
MI#"'+K'VJYW=*,YE%0W`(VWP2+@F<D&<'.Y!#N2#`%;'9YE-CQ+?5U=XF%EP
M@<HLM(E0'*!%I%NA4T./RINGMSCT9.N)NL?Q=KF[.#^LWF+;H1%&D7$/<)"(
M?R:#./M#6N2S8S9V:,5>`DN)2#RG+M@?M;SPQLM_8J`MFN8UL+Y,7B+`0)T6
MWA:+P$1:IALXRE%X-76QEAQ=XD`&&#H'50,#881@5G:KQGC=W4PSJS>$D5H$
M4R22JM:N4?'$5,HL@L@RF9(6D-,+Q[MLJW=E9.'`LW*1T5MQ0ABA0J]M.<Z-
MK73Z/#@':/?"?7`G$B(((O`1!!$0KE+LLRM5DB54UQ#=)Y`'K$RH&!L,"8&P
MP*ERG$A<B!M&%JP<NSV2,F`;?0V]]=FWE#D]/7,?M[S:W128?Y,[XU7V['<M
MG355D/QI7Q:A#+C/<RDR2O1GB0\FU%[:V)')MYSGS.*)+L("WI!O2!2;T!,R
MC=NOR_#JAN[P;1#:;MVSO)E&<^AP\2A<MNSOSC2YGY[VS02/423LARA/<&LK
M*TN-Z$'2O:$!WYKVI(!]51>.\X!#3"595B9K&S\EROEMQA5N8).F&;R#0QM0
M7*I,RB_*89>N#2);I)#`4I.@*;!'V.W6=MRVAR#-#\-H!J9+)SXLG<F5,N7'
MGW;Q7:QD/Q@L2MDV1YMRY7UAUDUTMO*DVO9?O-]ZTBX^/XI4I4XP+&2>+5^]
MU)"P'A5+&2+Z-,BX-!(OR1:LGM[Z<UT8D@J5(1WMN\/4V<NN:[TAL\B1VGL.
M&ZB_<C=G^-",/?M,+5TF[%<GF=V?ME=KKMZ%Z3HT1]Z5ZIQ47T@[OB]3]NP1
M`!:S`".SJB`=]]HAJF[TDLZ#1189#\6?\>KC-A64W?M=?Y4GXI8%/C,M*TS)
M5YO&4=6;AXZ(E92.!K-@NRC9]:5;PSM81E@3!&16A'94]AA':@;:`<FW29Z2
M&>Y<IM0Z@PO4/<YK3=GVE@:7#W_<O-CZJV9L+R<^:Z2*ROUK`TD7I-@=$-/O
M.[=/`O._SCO$7;;7"<*C66K]5!"+XO:%+D100ETP7<-:)DMN1!R)I4Q^8,5V
M83`02FVE#E#EV^[V>^D3G'$6XV)M'AK=3@<V:TM;.\83I``,9QL@X]U<[&]C
M66\'DR'4U37.[14-DNO.E&#7-<XEL)0Y46B$8B$;%`([.<F02`%+IH[/1"Q>
MCZ4Z&N9-](W.K+12X;Y,[XU5F;%\MNTU5=PROBE.&&?Y8F[LI%)'8.SE"R]3
M:'H3X:Y\WTF,\RXD4F&>1.^.5V7L.RP_35XAY4GXI3B-XBID@DV42C=;JA9O
M1_YPZYLWTI<^RP84>%'^1/\`CU?E;!,JNTUF(^5)^)4\C^)B?3$H!0Z&.P0#
ME)9^IU>M8@US)WI9;0I?BT.$>14?'KHRO1ZRD^TUN)>5(^)4W8\4EC(7V-!Q
M]\*(\J5I'K?\Y-<F=Z8&TF7XM%@]GX%1\>NE)]&[)K_&K<4\J1\0KPW%99R[
M=E`QW\QM/OEU3=Z96TUO[#@W5U'_`!"MM]&C)1_;<5\N1\0K8_%E:2]3'V.A
M^"C:O?+JL[TS]IX_8<%ZNH_XA3-]&3)#M-=BOER/B%;'XN;60>3'N-_P4;7[
MYMFH'>FIM1`/^HX+U=3_`,2IV>B_D9VFNQ;RZ?XA0BG\6]K:1TP1/']"4!2X
M7%R)W_E0<*B=Q/O%C@D>T6@7I&1#G$J!&WSL(D`%9`#<":LXMZ:VU&1/EM90
M8'`TTEQY$PVNEM)]ZJ2T>H[W4:)H#XA8I?1AR/4-<Z978L"V8YH@9+;&D@6.
MIP28"UPY+M+21:I*;C$N!0Y,=XTZ_P#,+;[Z-<9WIO[51HP_`^KJ?^)5YOHK
MY#/[?B_ET_\`PZM3\9=R+M_<ZQD.S9_,+=Z7_*G4+O3CVK#^'X'U=3_Q*F'H
MIY!(_7\8\NG_`.'5L;C2NA>ICG&/7_,]O]]6HCZ<NU<#]WX%U=3_`,2I&^BA
MD$_Q#&/+I_\`AU;&XV+L'^#C%_4]SV_WUZA=Z=.U@"/F_`NKJ?\`B5,/1+V?
MG^(8SY=-_P`.IAC_`(VF2EG:-<HX\K#2IN@Z.XDZ@2?+*12ZBA`2?K-I*=?)
MOH](N]SR:8%6`/9$WQ#<-Z?)?IUYCF8_*D;0:"BEY;F"ZZ;1,FZV2XD0F.;-
MFS!,E@1OM;!X'*;>(N'@9J]$K"V8+,G9)KZM^.LY39=4Z5JYK0#%@=+E,+)A
MLN.=%D;'70;P]2X>NX_L$5'SD&WCY6(E6B+Z.D6+M==H\:."`HBN@J1<2G(<
MH_!`>0=@AK^A>%YAD8UATG%L)J9=1AE1+;,E399:YCV.$6N:0+01Q&U?B/$*
M"OPFNFX;B4I\BOD3"R9+>+KF.:8%I!T$>$6+)>(E4\#H_-G/9]7NVU7/[PXE
M3B5J[(M(KJ<[B$R$*<4QR:F5R=NODC<(B-)N@EZ82E`O$JM#KE(40L@IP0',
M41-TWH13="BK:@RJF\^W4662N>S1?@8P^#C,_D7E(P\EWXO<WQO_`'K?6BMH
M^(E4\#H_-G/9]<_MM5S^\.)1Q*_0HU5#;LB4PV]7=7=AM^#L7#;K/;JKG]X<
M27BOWQ&JW@HG;+SNC3MU7S^\.)(E/$:K>"B=LO.Z-.W5?/[PXDB4\1JMX*)V
MR\[HT[=5\_O#B2)3Q&JW@HG;+SNC3MU7S^\.)(E/$:K>"B=LO.Z-.W5?/[PX
MDB5^A1ZN40,$43:`@(?EAYU0':'YHT[=5<_O#B2)7GYYO&J0#RG<3Q7,>50&
MW'9Q6H([5G)=Q(E\33(3V"Q=H%(F`<NT=>PSE5U#*F@NNA'":0FP?!^HKE83
M>E_H6>PO0+Q&JW@HG;+SNC7C^W5?/[PXE3B4\1JMX*)VR\[HT[=5\_O#B2)3
MQ&JW@HG;+SNC3MU7S^\.)(E/$:K>"B=LO.Z-.W5?/[PXDB4\1JMX*)VR\[HT
M[=5\_O#B2)3Q&JW@HG;+SNC3MU7S^\.)(E/$:K>"B=LO.Z-.W5?/[PXDB5K2
M^TJ`3L&)!;Q"HI#D54KLR+K(H)D0&@W@2]++4!6AU6QW!2%W;&*<*"@E$#=\
M`8E->I*VH,FHO/MU-EDKX1FB_;&'P<7_`,B^I&$W7?B]S?&_]ZWUHK9?B-5O
M!1.V7G=&J/;JOG]X<2CB4\1JMX*)VR\[HT[=5\_O#B2)3Q&JW@HG;+SNC3MU
M7S^\.)(E/$:K>"B=LO.Z-.W5?/[PXDB4\1JMX*)VR\[HT[=5\_O#B2)3Q&JW
M@HG;+SNC3MU7S^\.)(E/$:K>"B=LO.Z-.W5?/[PXDB4\1JL'ZU$[8=C_`+@N
M-@Z=NJ^>>`<21*UAB>B0A8&P&?1*@"MD;)*S;I$AD=PJ+,;G+HM3`.0E22Z*
M*B2`&329@$*0@AWMVLQ2,:_B%=4:YEQ_YF7&R5IN"/O8AZYY?/Y45),)B/Q1
MO;W<_P`N_:MG^(U6\%$[9>=T:H=NJ^?WAQ*.)3Q&JW@HG;+SNC3MU7S^\.)(
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M]8E:N638K=R,*W69IING!U!X"BW%T'Q`M'3S.?#<BT;+NE>\^=#<VW2.LINA
M7Z>`FW$RF-L`3`'X.O.YTHZNLR?4RZ.5,FS!4TY(8TN('NML`#8O79.J)%-6
MS9E0]DMEQHBX@"-]NZ5?JUVP"`[(26'X$>Z'K?T+7P"9@..'11U75/XE]3EX
MQA`TU5/UC>-6"E:L0AR0,P/(/4CG?H?T+5*9E_'BZRBJNJ?T5:;C6#_*Z;K&
M<:QJM7LP[=E>F^O^MCSL.JC\NY@B?]1J^IF=%668W@ORNFZQG&N3;/PY\0#A
M3,,)2[!%UJH98DK/9>^#K'\[*7VMV*UT".HSTL8^Z8C`E9Q[AB$FT=='Z:13
M8V,(I[3ZN,PK%@9,R=A=>^=)#1#5O#'-:\OM%R,3&Z1&&[I7.?68<YTUDK$*
M1DF8"0=8R\"6W=(<-VW1W(*&5_A*SGC*6K;W',K%SL?5)W(#J"BL@4&1BD8Z
M`R3!T1O-Q+9+'#6!C$5&-CI:CYL)&I2'"26!7>.4#FBJ</QFLEO9585B#2]K
M(EDN88N87P)OM),6N@;?:B"UD3<,I'LF4^)4A<QSH!TR7"ZX"P0('C`G0(Q]
M=0*:X$\ON+NE8HF;?-8QY)R3^51Z#DV-5;BXX@+AF]D8M>@I]C3[J#=*U!'F
M:V!L\9;Z(J@GNJ&3U$*3'FTVJ=A->7AH`]P)C[@V2>499>SQ;T6$.MA&R*O/
MJ,'?/$P8C1AI))]V:(>ZNF"P3`UWC0@X$=S<64D."7)9+))/&CJR2]7O,R^"
M]05B9W"14@ZY*YRD\P3\?C<[]W(L:['7.)6:0,Y&(H(-7H-4GA1(<ADU*1H<
MR&0UIPFN$^4T7'-D.$7"2)33,@P%Q88O8XDEL2VT&(LF?@FM>X8E1&5->2X&
M<VP&;K"&\LP#A!KA``@`V$6W\QP@9/L<S8FTO%,H_&LO;X"R.,<054NSRMVT
M&&8:OE*9?W"!L4G(P3.P3#.`<1RXQ:*#-[WQ64<I&(!4M<\89F63+8^5A6)N
MKFRG-UADO#FQDOE-#'-EAQ:TN#A>)+;H#2#:K1K,#G.F,?B5"VE=,:ZYK&%I
MA,:\WFE\(D-(._>,8B`&J)/S?F56F+'F.:@NBP0EHJIM9YO+8V>2,3.35>?9
M)7<6=4)1E/FCYQ9K;(9--VF@=US5?20YTB9DQ2DU&9G5XK:G!L4<YKGEI;*F
M@M:X2H,L:V+1<>81A&83",8X>_`!2FFI\3H`QS6Q!F2B"X%\76N,";S+=/(`
MCHAL;$O"3F;&5AI,D_%]9V548Y)CWBZU1M2<_-$R4O1;#(/UWB[ET@$BPMM3
M6*!C@H"\>Y*)Q!P4PFX>+8-F7$),UDO!<3EOF.E$0D3+K=5K&@0$L6%CQO0<
M++%VL-Q/`:.8POQ6@=+8)@MFLO'67'$QOZ0YI]4'?6N5O-YW!-5&5C)"_P`-
M/I3=NG6CF.JD@FPK<S=&.38VP6VJ-BD3<L+E.1]M@T'KHZQBG)72;@$,X4'4
MCI.<R#*F8%7OD%K&D&1-B]LLR2UC^1`L:63"T0_.F,;H4#/JN)C9K,8HVS6O
M>Z(G2['/$P%S>78XA[03;X@A")6(E.`_-CVLR,3'G/6W$M!/85:'KU#LC>G0
MS%*ZTRXL*S`1L@21,--GU:P[2G&;E-0K@99P9,NP1(>$469V5#9K\"Q::UCP
MX.=)F&8XZN9++W$,'NC;[3+<"(7&@[XG=/P!U,93,7PZ67,(@V;+NM%]K@QH
M+CR'77!X,8WW>H3;@4S'%024#'0Z#SF<=5BK1=CL50O,[;Z?*5)9)ZUAJI/J
M+MUDL=SD@R;J/FAB).?9+<V.SF"HTYM!FR;.,^9@F,"-0][F,IWMES&S(@N>
MW5D:UH)#76C1'VT;4FJR[*8);,7PTALAK&ETZ6YS"RT-:Z_$2R0"6V'3;HA'
M;1P&<0EIA+BA(KG"2OTVVLMH8M*+;`KCMRSR-D^W(U;F)1*;5=5)6'RDLD8'
M"2BR<C%M%R%!/>3+K)HLRTM1)=+R_C&KIV%C#J)E\`R9,LOBUC83+T@&P@%C
MWM)C:<S)^`SJ>9+?C>&WII#GC72[KH3)C@T@N,6W9A]1S00-P0#C-Q+>:1CS
M@RJKVLVY4\+Q$XKJC9[(QT\Z<RKN*QI>F1/R]*)J2$D]=$9&4WU3G<*[!,<1
M-O#KJ9`RIG"95YEK9^$8A*;/P2H(!IIC!%]3(==`#`V.\T;U@@KV/YARUYNP
MZEI\1HYID54J\1/8XAK9;VE[C>)A&$7'=-IB52C\>7XPEW:3;!^!`2@]?]#:
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MC`,9T?(Y_05AF?<C#3C.%_.I/35FIB#+`CR8ROP_`J4[Z7YQ'51^S/:/`_\`
M(,9^9U'05J7G_(HTXUA?SJ3TU"JOA3,;6.D".L6Y`(JM9K2[*`42WL@%!U-O
M%FQ^9DU99<^^@8H\Z11-NL([Z**"9BI%LXWLVVB3JJ6Z3E_&BQM+3M_59K[6
MRFAULN1+`@8\D@O;XKWS'`O,>'9^R++E/#\:PH$SYA_693;"\D6.FN.C=!#3
MI:UH(`S1\.9=$.3%N0AZO[3Y[N'7!=LNVF?^/8W\RJ/BUUF[0<A1_?>$_.I/
M35DIAK+X[=F*\B#U.I3I_P!+\XZK.V6[3/\`Q[&_F51\6K+=H>0(?OS"?G<C
MIJQ/A;,0CR8IR+U_VFS_`'#J%VRS:;#_`+=QOYE4?%J9NT39^-..81\[D=-6
M9L)YD_@GR/U/K,G^X-5G;*]I\/\`MS'/F-3\6K+=HVSWZ=PCYW(Z:E-"X7\R
MWZUQM<5I%GJ3)TIOR5DL]?DXN*BF"8[7#DRCU!L#QUNCL2;IB)U3B`<A=XP>
MBR9L`VH9RS%(P)^$U^&TLPQFU-53394F3+'C.)>UM]VXR6TWG.AH$7#B9HVT
M[/<K8%.Q=F)45?4L$)=/33Y<V;->?%;!A=<;NN>X0:(Z3`'W/Q=C>`Q+1X2B
M5KI)XV'1/O.7BQUG3YZY4,X?OUMXPD2.\=*&/S:8%33V[I0``U_779]D7!MF
M^4J3*&!:PT%*T\I[BY\R8XETR8Z)@"]Y+KK8-;&#0`%_,S.V<,5SYF6IS/C%
MP5E0X<E@`:QC1=8P;I#&@-O.BYT(DQ6P=>T7E%K3(+)V[EL7*-60/",,BMGC
MU3O1/R1F+0*I:VXO".H2?A6\)NN'"9!=2"4BP$IQ1,V%55%9&]1O:V74!Q@3
M((%K1$WV&$'-=>T&QI:[=O0!!W8;'>I]\?=9:MEZHK1-$31$T1-$31$T1-$7
MGGYNCZD.*7_/QXK_`._\->RSI^LT'_2:3_1JY6^-+_0L]A>AFO&JFFB)HB:(
MFB)HB:(M>7ABZ>3.,56[0'*<??NFO%.]<X_,R;>)EQ:@Z*ZAYR';0P=(=)IB
MXD$I!D8%.9%MSRJ*Z%VD>ULJ>'&!,F`M:(F^PP@YI+K!&#2UV[>@"#NPP#O4
M^^/NL@MAZI+1-$31$T1-$31$T1-$6M<610Q$'.MSM7;15S?\@R:I7;"Q1XK#
M*VZ6D$W#=*RSMA>+-%6[@G-K(+),5@#>:MVR`D03O8A,UDUA!!`DRQ86G0P"
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M1^4]9B6R'D;[?OJ1J9-MQ-NQVR``#:(BP2Y`#;M'X;K`&N9JVPBJ]\Q@N?Z)
MQN1&0&:K]K)R-.9&@(.V1C[)M3)0&%@JMGDI*'K]BK[Z?=(LY*-E92)702]F
M18RA`#F_9%VA+84)>"LH?C!8A;[#0B6ID>VU6T8XJ$Y#D@%#+MI?+4>23H9T
MC[G-NXJ8;F$IG:0G0;K$,FH8IPV:SJV1@L%S[#N%(7BS=VN%NTY3I8;<AC^R
M6>G3\?7JP=Y,'M%0%(DU"Q$<MT526<E46*5`Z1A1=".U(YB[#:R)4LZ%B^_N
M*)8_XX$LD'@6T1+.:_)6FL-;C682]55"HSEAK;^2EHIE)PL7)N@<R17+F$<F
M!)$#K%13YPQ"D$!UC5RSOK)<\"*G+KB<D6@*F<Y`Q^U31E1@53N9*M-R)3Y0
M+OP*IUI(A4YP@G#:S'8Y#:'L.4-9U<O[BL![R.ZK,>*&6Z*U?%R!0#,7KU2,
M9/@?UHS)[)HJ%16C&;L)+H[J216.4AVZ9C+%.8"B4!$`T,J7!:ZR9#P+[-Q)
M6X7+UHG;*D=U'.4V<@T(6%.ZCWBS<[M!F_;%=BNR=KM$CJD25*10Z13'`!*`
MB&=5+AW5G6/L403XQ91W9EZ='7JI25D9*-22<5'MXATYB"/ZXO:XYQ)D*ZWD
M6DE`MS.$52@H0Q.41`-HAG52_760]\(J[3XK[(Y%H5ID"@.A?L'<LQ!LXK;D
MSZ)C^<[X2S$K=^H9[%Q_,GY]PD!T4=PV^8-T=@2I?W%::R9]P4*K7'%-VJ,8
M232VP4($FVK3IBSM47"P+]V6X0[2?KB#-!V_W'SR1B9!NJ"*!U5""L0A@!0=
MW1LJ42LZR8-*I7'C:NM.(V3-)!:IEW9&%20JE#J3&W6[O])1,O/-F3BOQ[PK
MMAMAH)TY,9QS0`DEM#;M#;G4RHP@>%9+W[D%"HOSC*DZJY;15ZBUGC2MT>V+
ML5:8JW>E@LA696FUYV5NX23%11*T(F9/DBB91@MLYX"E,038U4KNK:],'J*3
M,>.2T23V^,&][J;9;&<XA7;LM*1$=$L(24=1K.40(M(R2K9DHU.B]!+GRG%$
M':2S?>YY%4A<&5+C!8#WK@KSD/$/DZP5;A:4=S,2L2/XLZ#,QJ[.):)!TE*B
M9'(V<$604$%D3(NS;-@[#`8!VZ]/EYHE2Z^Y[:A>#NV7Y?$K5,]UV='X(^R%
MI)AQ'Y<3YO=L#8/[')_'!_/=5!+8=P*O%3%CQ-YD)LW;$U#9MV;8Q,>ILV?S
M74@DRH1NB*%QC"R"F##BGS8GNB6RL^MU8I(?PUM-5+WAP+(,#N<"F;/BXSHD
M)0)98\-@=>%0'\-;6!)E[P6+QTV1]12UCQD9_3``):(T`V#^L3<?B1_GVI-5
M*YH6+[MV'`%=*<:'$*3J6N,ZH=6!;#UOZ-K&JE\T<"S?.\.!6I^-;B(*'):X
MKJ!^U]KZ/]&TU4O>'`M0\D:!P*V-QM\19=@A:XK;RC]3S7K;-G\VUC52]X<"
MS>[@X%!*5QEY^A8J7:QLS!12"MRNDDJW;TZ&CDUWTK9'\A(2(HQ\F_1<*R;M
MR=<[@YRKN#G%15-(XB0MJJ`F3&NF0<[5,$3;8&@`6@:!9#0-`)%JWF/,0;(W
M1N=Q2<>.;B1^NR'^QQIV;5?5R^:.`*(O<-[@"ME..KB3*');8;J#U:VT[-K4
M2Y9]J.!;7SW.`*T/QX<2Y0VA;H7\&LLQ_P#S]+C(Z!P+(=$P@.!4#<>G$T`#
MLMT)U!_:PS[/IJV;P628;@X%):/YP7,S"SQRN1)%I8J@=049=G#QB<1+-T%-
MA>^$<Y;N`!9RS^&YE3V"Q=I=I1V&!JV&PM'`L-?`V@07JW5KZPNL#&V>JV=6
M:@I9`%V,@T?N3$.`#NJ(JD%0%&[MLH`D52.`*)*`)3``AK352^:W@"L"!$1H
M4@[YR7A%_P!NN>RZ:N5S6\`68+6F0#J/YK$AW@.9!6.R>UDXU99HPE#1+]O4
M+>D$H@YE;!$+P2Z;5PJB#QBE(O0!84BMA35561NT;6LE5%R#0Z00=(B"]EEC
M3>M@;KBUMD;T0`=V6!T.;]\?=N>JME]\Y+PB_P"W7/9=4M7*YK>`+2"=\Y+P
MB_[=<]ETU<KFMX`D$[YR7A%_VZY[+IJY7-;P!()WSDO"+_MUSV735RN:W@"0
M3OG)>$7_`&ZY[+IJY7-;P!()WSDO"+_MUSV735RN:W@"03OG)>$7_;KGLNFK
ME<UO`$@OM*3DN=3^>+_X<GYM<_'!_/=8,N5#Q6\`6(+AC@+D'Z=*XBP(^>$W
MN-[BF.;<=+EWCFNC,3'-NJ!O',/5$>4=>JS9+EFJHHM;^ZZ7<',*N5GCL_0L
M]A=R=\Y+PB_[=<]EUY;5RN:W@"J03OG)>$7_`&ZY[+IJY7-;P!()WSDO"+_M
MUSV735RN:W@"03OG)>$7_;KGLNFKE<UO`$@G?.2\(O\`MUSV735RN:W@"03O
MG)>$7_;KGLNFKE<UO`$@G?.2\(O^W7/9=-7*YK>`)!:^NQW3V;Q8LN5[('B\
MA]\6CDS-K*=YG04JXLPDRO)&<C%J^<R#P[8'C-)^[-S_`#`-P36571MTK6-E
M5`%UH=)@1HO"^PP@&F]HC`EHLC&(`.[-#OQ?OC[MQ;![YR7A%_VZY[+JIJY7
M-;P!:03OG)>$7_;KGLNFKE<UO`$@G?.2\(O^W7/9=-7*YK>`)!.^<EX1?]NN
M>RZ:N5S6\`2"=\Y+PB_[=<]ETU<KFMX`D$[YR7A%_P!NN>RZ:N5S6\`2"=\Y
M+PB_[=<]ETU<KFMX`D%^EE),#%'OE(<@@/\`3KKT?24$=-5*YK>`)`+7.+UI
M)A795N5PY9IC?,BKHMT6;&#`J;FZ32XJ':PDY-,G:KI4YEA>'53<N^<!5P@B
ML8Z87:]LM\YKB`3JI>^[0QNZYH(AHA:!H!(@5O,\;UA["V+WSDO"+_MUSV75
M+5RN:W@"T@G?.2\(O^W7/9=-7*YK>`)!.^<EX1?]NN>RZ:N5S6\`2"=\Y+PB
M_P"W7/9=-7*YK>`)!.^<EX1?]NN>RZ:N5S6\`2"=\Y+PB_[=<]ETU<KFMX`D
M$[YR7A%_VZY[+IJY7-;P!(+DCB/?OSYAX#C'?/#F3XH;.=,QG2YA3/\`<N\0
M)=],14$2&W1$-H;!V#KT."RY8PW%@&MMH&[@^54ZL2/>IWZ,?EM76_?.2\(O
M^W7/9=>>U<KFMX`J\$[YR7A%_P!NN>RZ:N5S6\`2"=\Y+PB_[=<]ETU<KFMX
M`D$[YR7A%_VZY[+IJY7-;P!()WSDO"+_`+=<]ETU<KFMX`D$[YR7A%_VZY[+
MIJY7-;P!()WSDO"+_MUSV735RN:W@"03OG)>$7_;KGLNFKE<UO`$@M=],>=(
MZ1TMUTC[H_<Y_I"W/;GW-FS<YW?YS=V=;;LU9N,C=@+O8-$!#]9WEO[6'X']
M):]Q5"9;B\SUNO&S7Q!6:O-LGY`M5^ALEX<LSBFKE52R+WGB,=Y8<IL'59J:
M034:GWODEIB+<=ZT^]Q60J[IO&J$Z%O'/$2_F<]<-K6/2*LN$)G<XE,JFD&[
MXOTU/;O*&*&T3G`/P==NALP:M)T7Y'Y3UM`F0^&^W[ZSRN-[@8!`L:ERE$NW
MIS+D$=H;>5;K;=<S6,NPBJ]UT8KS^9^;%F*W3E:71[E)5Z+>LZ(6907;)O$9
MB4J%>N=9E7ZKR+M]=L\;'6YC:T7+F-8R;5DE(1Q50(8CMXDKB\S?6>5I(M4K
M2\WG.LGV/IR*LLQ&V7'<_CF882R'>,4IV.QSBJHXY95>Q,C/OR]!OYBC1EA`
M`5*LUD6^XF?<.H)LWV1TK$'[UBF&%N">V8.[X-H*R7.U14K4J;7WD?=I^MRA
MTYBGIR[8MDCGK%E%KMCS#&5!)PW5Y_9T=,04'9L#9LR6W=6"UYT@*+M.`2>9
MDHARN#K2-`J.)*C$2YTJZ64*UQ3DYUDHKEL]!UTJ,4M*CLT>\(@<I0;"(AO"
M(EUB_+WUDM>1PJ#TGS:$M3',2J5ZYF4Z_*6AY#&E5V\RY!M.TR9IT6>0+;+-
M:(92?KB,T==)XS8L$%C))IF;`F4`#`>P#2D'PT+5['S7V8H1XNQ:VF,G4;E$
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M*W7:I$>BY-M4<&0450%K)<=/>6+KQN6>JI)D'S=MNO=@F;`HP;QQWU1GJE#M
M$QJKLE7),5:G59I+0BSET"K5_"(4Q!5N*?-B4Y]@&`"%'362HZ>\L-;,&XL9
M,>;JR#9XY6KVINPFJ2GD25R''1*!8F%LQ7<PUR"19E.WAC9PDY]6.?9!578N
M^9;KMP:(D-S@;PCG62XVFQ9NOT@;BC3WS:&3Y!"L.G<L\&T58<*D;66.\48H
M[^/Q$YVR,+(1#9_WO-#9)CR)IRC<FZF@Y01<MP*HBF!6LE[ZV@^.BQ8:1\V!
ME=Q!2D4UM-H<.9LB#^0<6.;KTJR;6YG>WN0&-L@FL-)U:4C7C.7G))--)9^\
M)S#P"F$P$$%-3,E[Y6`U\8P$%SIYP?AVRY2,<<(L;9&YIIXGQ.XRK9I]U(0"
M3Z?ET<=9`3/)/&44L5FR7DS,E%CE2*5%,PB4NP-FO3Y><)LNN#+2VA>3ZE^6
MK-,QUV=9^:/LA::8X-R:?F]V`3'^R<<'Q0#UW&JX(&E00*E['`653B&[7$AV
M[1#Y[1@;=NS9^:-;A[`(10L=I4O8<.^7#B4"UE$1Y/UXB@_#<AI?;OK-TQ4Q
M9\-&9E1*)*L@.T/#<.'I==WH'MWUC5N4L8\+6;S@`EJ2`\@_K]"_&B'7>:WO
MM-D5KJW!7*G"GG0W4J#?JA^O\)Z'Z-TO!+CE9J<)V=S!R4]`>0/U_A/1_1NA
M(WT;+<K<_"5GHVP"TU`1Y?VP0?7V;/S;MTO!9N.4'I_"?G)Y&2RC&I1JR)+=
M;VQCM++1%$BN6EA>MWB2AJ[(&9%<HN4SE5*ML?E4`0=@"^_JS4Q:]H?$'5L-
MM[06B'C6PAHAR8>+9!;39;[-^Z/8[O\`DWK%(AX0.('ZRVWV10/=VJUYN^HC
M+>=SOJV4X/.(,P<E*;=?]L<!W?K`(!6UQ^\.%6:G!OQ#F#8%(;".WZY:^'_Z
M_6(B*R&.C:K<W!IQ%"`[*.UZ@_MFK_=^MHC?"RYCE(Z3P-9CFK-',;M'-ZA5
MC*&6F)I&5BI9Z1JENF.SCF3)PN<\@]#V"9U`!%(=IS[0`"FQ>`6&RW1ML"]<
M:?3*_0JW%5*I1)(B`AD.89,T@,<PB8PG7=.US!SCM^\6,*BRQQ$ZBAA$>L`:
MQ5@0`@%)>;/\8?Y$?6T68A:QR$5,L_AX5@;%,.4$4VX.4*6HJ=PI2[B!`8FM
MHEE$G>S:.]7]LWS>\!0Z(+L0O4<=54PC[Q^'SV:;ED/TG(_E75(SQ7?B]W?&
M]]^SUX+9W-G^,/\`(CZVJ*CB$YL_QA_D1];1(A.;/\8?Y$?6T2(3FS_&'^1'
MUM$B$YL_QA_D1];1(A.;/\8?Y$?6T2(3FS_&'^1'UM$B%]I)GYU/V!_AR?$C
M\<'I:P="Q$+AK@-(?Q*XBO8&_P`=SBE^)'Z\V?I:]3FS]:HO^ETOY!5RL/+9
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M)$+]*FIO![`_5#XDWH^D&W6$B%K'%"*05Z>.U49+D6R/DE93O<A2T4T5S7"4
M(HW<A0R%B5)!+FPYX[L33!C#MD!Z5SA2W\0)US`8B$F7IO\`,'PEL-Z'(YG)
M@MYAY0CS1O[W=_R;RV;S9_C#_(CZVJ*TB$YL_P`8?Y$?6T2(3FS_`!A_D1];
M1(A.;/\`&'^1'UM$B$YL_P`8?Y$?6T2(3FS_`!A_D1];1(A.;/\`&'^1'UM$
MB%R5Q&D.&8.!':4W+Q06<`]B/+_W7N(#J<FO08+^[L6_L#?]JIU8D>]3OT8_
M+:NM>;/\8?Y$?6UY]5XA.;/\8?Y$?6T2(3FS_&'^1'UM$B$YL_QA_D1];1(A
M.;/\8?Y$?6T2(3FS_&'^1'UM$B$YL_QA_D1];1(A.;/\8?Y$?6T2(6O]TV_L
MW3;?ND=NS8.W9]S9U=G5U8B+_P#</]Y6WM?Y'])<:XC9X9D_.5/9QA-8LRKD
MN,L>7J[&I8WP%8:-"\/[6/@GB]O93-X->&M7M&6[`=\T;S<NNRF9-X5R";1"
M-:&<CKQ2CM@N\>(B3D(K.?#8YCG:K-<8?.R8JHB4#"0:[3S[OLBF#9O$`?@A
MKNT`C@]:#HOR/RGK))$A\-]OWU]+7NXE*(A8I$.0/YHGZ/\`0]<TL;O*HY[K
MT(K%K9!NQ0'999,/ANHHGV+6PELAH6"]T-*TC?\`BS#&5E:0-WN\M7F3NIKV
MHMC<F!>-*8MK@*>Q@2,V+1W+.IF6E+"ET<B*)RF`A@'V0AH6RQ80LM+R(Q*@
M=KXZX&N3D%7VV43SSJ;JTU=%7L9))FAX2M15996QK)S,HC&O$$4YN)D4#MTD
MP5<@FL14Z0)&`VMBV5$"`6`7FV)TK(SW&O5*Z>Q)3.<>];FI3+&O6)BY0E22
M4?+RAY)..;A&%A#/WR+X\.[!)PV36;'Z*KL4V$-LP&RHV@+:,PBR*D,-Q/*V
M2UGH\%EXTA:"Q+.?)$H+FYUS`OD&#A"9C'"C$C.8C@0E6IU%&BJX)`X3W]W?
M+MSJY9,(!:!TR$22M0J<<MB)5X.U'E;NBSG\5W3*;-L+F+5=$9TZ8A(#Q>.5
M(AP5F9V4GVZ;44]Y(!'880$0UBY+A&".,P;NZOR+XVK&X8W.6LMQD*5#T>13
MA)IS(6F"E9MC.'LPT\D9,TN';N+;7U92?W2Q0KM3!*-UDE4]P5"IBN2XV@+)
M<_?,563XX8EU59:[,<^=.JL$K')3$TP,]>MX_OP!^];E=)M#JN^]ST452D=%
M3,VWT52BH!DE`+FY*A&`6(S(PMBK6K\8]TN5FC:Y"V^TJ$EU,F][IM.0BG42
M[:XQLU=K+N0;*MB',NSL*EE1=,3EVAT<H[^P1*`Y$N43H"%SP-/W%:TC?.(R
M\J>FM_'"\13VWY5R=BI5M)N85J%7<8I8V>5G;A8W)E.CM*?)1D`V79.`$3J$
MF&F^4FU3<!LHD<D:2L`S(&T[BD0<<\DHN=9+,4J-;2ICZYN+:9XDE%-D6-H:
M5,\(LR58DF2SRTB^2%)OT?G52J$`A3"H3>S<E;PA!"9N^5]J<;CLRL8FCG]5
M3OS`1]IC3H/>>0<0$JX!E&2)G24<=LU)(.Q$B*:QTUE#$/L)[`VS(9)AH"V!
MF0TE8:4XY+%"R%T;368IJ(BZ(W@N_-@<O6ZD>>4FIRYUY6`:-FK%>17EX>3H
M[PCA,B1QV<I=I2*"7`9*C:T+`=,)%IM7)G'/G+)%IA>$Z1-D26FXXW%)C^?@
MWJ;MJX:J<]0L@GCY1DNB@!%B*LW@BF<!$HD4VAU==W!VM;(KPVP.H7`]T7V*
MW3O<&3K?S1]D*W8YHRL39N7N>+L'DV+(=S^EKBZMD!8J9>^.E2IGG++Q`#<R
M%8B[`VAL7;^CZ;8=8N,MLW4+W;ZE+3/>9B"7<R/92[/07;>B/YUUDRV;R%SM
M]2MGQ"YN(!-W)MH+R=9PV]$/SKH);-Y9:]V^5*V7$CG@@%W<IVH/@.6OH#^=
M-:ZJ7O('OC")TJZ-Q+9\#;^ZM;.O^:6OH_H36-5+W@CGOAI5D?B:S^&]LRQ;
M>3;L_++3T_SGK)E2X:`@>Z&DJQ-Q.\08=3+5NZONEIW'IJI6\%A[W@:2H%3N
M*'/01<F=CFNSOR'MMP%=PVE8!^4CL+'(%=,U5XJ`BFY'$>L`HJ(J)J.4#$%-
M=994IE#6:N4V^V\R!U;-PBRZ(&TDP.F,8'2`!8MW/?>`,=`]CU_NWE(C\4O$
M2&W9E^XAU?S2S[BU7U4JSDA:E[]]62G%3Q&!U,Q7(.7W2R]#]`ZR9,KFA`]^
M^K(_%;Q'@([,R7/J>ZF7<.M=5+W@M3,?#2K13BPXD@ZF9;H'5_-3+K?\1TU4
MO>""8_?75_"GQWV2)LZ=*SM//;+7[(_;-X>Y/DD5)*M2KLY&Z3:3,V12,\@7
MJQRAO`4RK50=OLDS"!8YL@0C+L*E;,AXVA>U6Z3XTOJ!JG$J=-POQI?4#UM(
ME%K'(;MNTF,4IJSB<*9]DENS0:FF(&+&Q+^*%O<A"$:S-?G'$Z;FVQG?1(]6
M.?!T3G@=`DBLBM>HFN=*J"&7H2(Q@XW>6P7HM<T-TPBX.;;"[$@B1@B'61Y/
M!:+=/&MG;A?C2^H'K:HQ*C3<+\:7U`];2)1-POQI?4#UM(E$W"_&E]0/6TB4
M3<+\:7U`];2)1-POQI?4#UM(E$W"_&E]0/6TB43=+\:7U`UB)1>>GFZ"E&H<
M4NTH<G'CQ7[.0/K^#7L\Z$]IH/\`I-)_HU<K?&E_H6>PO0O<+\:7U`];7C8E
M4TW"_&E]0/6TB43<+\:7U`];2)1-POQI?4#UM(E$W"_&E]0/6TB43<+\:7U`
M];2)1-POQI?4#UM(E%K:^N$&TYBI)280BC/<B"V19JR\+&#/JEH]U==Z46DK
M`33F=633;F=@U8JQKPH-17Z5S**R"]VC:72:@AI="3&,'&[[HP1B'-#=,(N#
MA;"[$@B1@L=9'D_?'W;JV3N%^-+Z@>MJE$J--POQI?4#UM(E$W"_&E]0/6TB
M43<+\:7U`];2)1-POQI?4#UM(E$W"_&E]0/6TB43<+\:7U`];2)1-TOQI?4#
M2)1:TQ69HK`30M';*01"_P"10,Y92L+,)"Z\=)KI[=1>"@:\S:.F#[G&ZK51
M!1VV42%-PX<KE.NI=Q"\)S;P+3J9=A#FV7&P/*<XD$0((,"#%H:(`23-(CO#
MV/5*V7N%^-+Z@>MJE$J--POQI?4#UM(E$W"_&E]0/6TB43<+\:7U`];2)1-P
MOQI?4#UM(E$W"_&E]0/6TB43<+\:7U`];2)1<.<6``&<?-X[``/^]A:>H`?Q
M3N)+UM>JR]^Z<9_Z<S_:Z96J?WF=^C'Y;5W'N%^-+Z@>MKRL2JJ;A?C2^H'K
M:1*)N%^-+Z@>MI$HFX7XTOJ!ZVD2B;A?C2^H'K:1*)N%^-+Z@>MI$HFX7XTO
MJ!ZVD2B;A?C2^H'K:1*+GW8'E*V;`V>7;;LV!U?N9NKKL?L/]T_WI3?F_P"1
M_27$E4;Y`LW&=5IRX3&)IVP4/(V0ZLXE8P>&K?C*J]J^4)&(KM=>Q\K(\3*5
MX&NR$*V<P[U!DU02BY9VNH[;KH`3BJ/<74.>8!]8\\<-K%@9N18L+G=81<J'
M33W?%^FI``&(FJ.\)U0#J;-=V@LP:M=N!\C\IZS=+I#P-]OWUG5,.VPX"`*P
M_6ZKQ?K#M]QZY9FM[JK&6XF-BQZN%+@<!V+0O+M_-KCK_P#$M;"<R&ZL&6XK
M4EMX-)"X7:IWV1D"(3=-(Q)$D8S(H,3A'6B)MJ`O$3PZRRIAE(=(IMU0FU$3
M%Y!$#!@S6$QM60QP$+%I`?-A,21["$0MEC1KK&MR,!XOA9(P\>Z>RE/AJ"ZM
M3A16G*2`3YJE7V;3=36(Q$405%N*AC&'.ME]U+C^Y&*1'FR&T+;7UR;V.0<R
MCR6C)9,KB6A4>CFB%+TJR;N9%A3&<W8#`;(;\#NI1T]?&(1`G/`5,0-ALV6#
M$Q62UY;"Q9.B^;B6QWD&.R/`SBKB9B*HYJ$:TE9:,=-4(U[$TR(=J*R"510L
M;PQD:(R.@W5?&8,CG6Z.@D540#(FRP8VK6X\B!@L?][;E"2D"]3M#A6+J\S'
MNZ[59"9:O*[!5QE:6=Z7I44W3K;1X$(_N43'O3JNUWKM-*/1:IJ%;[Q!:V7W
M4,MY%D(K)N?-\VR1M[F[3=Q>6&9)-0$M`=])R.13J[2OWZO9(;5Z/7B:=&OY
M:$5L=69%#OJM(.6S-(46ZR('.86N9&-J7'P@(06O9_S6*\[5VE4-8G#5FQA(
M:OMW'?N+E!-'0CO(CMN1]%3U+E:]*G5/DZ2_IIFL5%0C99$J2Z!51&;+(A:E
MR8#&Q26A^;@L>-W]=?5NP$.6K(V!G$,9*?1<M$X^UMJ\-B9+BG5D'#A.3FZP
MVD]\5.=1<B=-(Q&QN8#83I8T16#+>X0L6$>^:Z9OV@-WD15W+EPL\"9EE)U\
MG+6&*>^43;7Y9ZWATA[T-_*?)\V#<J"X[K;?5/T=/8UTKNK`ES!O+!2_FK9B
M?:.4)R?1FGLDU6).S$K-1SUY8)-.8K,]`STHS6I9H49*KR=.CA:$2:I-%4F_
M-N45RF-MQKI?=6=7,C9"'KJY#S85O0AI2NQMI1BX&;K$77YB)C9B*8L'\E`)
M()UNX@T:T9)LPL=?%JD9NFU*A&&,D3G6B@%V#G72H0Y2VN/[BB<AYI:Q2C*2
M;2EJ)-.YB0[_`,E*3<M`R[AW:B6NXVQK956#['RT&9XR7R#,LTV_1.@BR>[A
MD#*)(JDP)TO=CWE@,>-Y<V<>/"1?,;5;@]BUW=41BB<4^-JC%BG)JD*W!''>
M1",C.@2AF;1N@#>.$#"DF4A3;`*0"[`#T6!1GR,0U0)+:!QA"V%^7HANVJS(
MEFY.)@/<C[(5C'\-UU4W=V>HH;1V^RL"P<GT.]/7(NSH#W.9Y)5(LMC>;PJ8
M,N%V^J``%L-`#:&P-MB7]7]3=+DZWW*9Y)0MCNMX5,&/"=D-42[MCQY^#8W`
M=?\`K8.LW)Y_-3?)*R6QW6\*FC#@\R8J!-RQ8YY0Z]E<AR;0';^I0Z7)^C53
M/)*P`-$6\*F+#@JRFH!1+9,:`&S;RVAT'H_U('6!+J/@IODE9#1'2W3OJ]-P
M196';LLN,>7_`)4//I-K.IJ?@9ODE"T$0BWA"M3<#F61WMEEQAR[=G[*7G7_
M`+#:R9521[S-\DH&@#QF\*M!X%<NCU++B[J_74\^DNFJJ?@9WDE8<T'VS>$*
M"4W@>RU)QTRHA:\9+E;7*Y1XJ*W&RN/EC"PO6RJ::DW4HM<J**B8D*F@15DF
M`;K=99("J&LU5/5->T&3-!,IA\2&EH/M2>_!Q]L`;%N]@#ARFZ!NC>^[N[ZD
MQN`C,1MNRS8KY=O[:WW7_L'JOJ:GX&;Y!6A:#[9O"%:J<`.9C=2S8J^RQ]Z'
M]8M-54_`S?)*``>V;PA6IO-]9I$=H6;%'4^NU]](M:ZFI^!G>05J6@V7F\*M
MC^;US8;J6;$_7ZMN?=?^P.LZFJ^!G>05D-;SF\*ZYX4^#2MXCG37_+4]4K'=
MH]<P56(CGQ']?K@%`-V=,L]0:J/Y]3:((B*14V9?9$WE1`Y*\]E2>0);QOQ!
M!4\M@\;3ZB]'_&2O^&HSMU#V^JO9JCF.X"I8%/&2O^&HSMU#V^G9JCF.X"D"
MM8Y#N$.VFL3((6%F@$EDI!DN"-FG(DBZ):?;W@MW",!!3;6:145;$_*<HM&1
MQC`"AG7/I(-U[]%23C*J'.EN-V1'Q&GV[!9><TMTZ6!SMR[`DB1@B''>;]\;
M_P!Z)6SO&2O^&HSMU#V^J'9JCF.X"HX%/&2O^&HSMU#V^G9JCF.X"D"GC)7_
M``U&=NH>WT[-4<QW`4@4\9*_X:C.W4/;Z=FJ.8[@*0*>,E?\-1G;J'M].S5'
M,=P%(%/&2O\`AJ,[=0]OIV:HYCN`I`IXR5_PU&=NH>WT[-4<QW`4@5^A8X`P
M@`3,8(B(``=-;]4>0/YIIV:HYCN`I:O/GS=TW#H4_BA,O*,$@6X[N*Y1(5'2
M).<3-?2&*<F\<-XABG`0'J"`Z]CG.1.=4T%UKC#":3<_^FKE;XTO]"SV%Z"^
M,E?\-1G;J'M]>.[-4<QW`53@4\9*_P"&HSMU#V^G9JCF.X"D"GC)7_#49VZA
M[?3LU1S'<!2!3QDK_AJ,[=0]OIV:HYCN`I`IXR5_PU&=NH>WT[-4<QW`4@4\
M9*_X:C.W4/;Z=FJ.8[@*0*>,E?\`#49VZA[?3LU1S'<!2!6N+W;X=O.XI;H3
M[-(LCD,S1<$K',QA%DDZ-='O,.$(.%EV<PB91J4>BR:\;'B<I5>DBX2;MG%Z
MDI)QE5!,MQA)B.2#[=@LO.!&G2T.=N78$N$C!8[\7>[H^ZR)6Q_&2O\`AJ,[
M=0]OJCV:HYCN`J.!3QDK_AJ,[=0]OIV:HYCN`I`IXR5_PU&=NH>WT[-4<QW`
M4@4\9*_X:C.W4/;Z=FJ.8[@*0*>,E?\`#49VZA[?3LU1S'<!2!3QDK_AJ,[=
M0]OIV:HYCN`I`IXR5_PU&=NH>WT[-4<QW`4@5^A8X`1``FHS:/)_3K?V^G9J
MCF.X"EJUGBNY0LA!3RZ]E:O%4<A9$8&%Q.RTF#<K"WRK9!JV7L4)7GJ;9)H1
M,2HI)+,D1,)&SER@4BQ[^(4D]DY@$MP&IEGQ0(Q8#$W7.$8QM)#CI<UIB!),
M$"+/:CV.X2ME^,E?\-1G;J'M]4.S5',=P%1P*>,E?\-1G;J'M].S5',=P%(%
M/&2O^&HSMU#V^G9JCF.X"D"GC)7_``U&=NH>WT[-4<QW`4@4\9*_X:C.W4/;
MZ=FJ.8[@*0*>,E?\-1G;J'M].S5',=P%(%/&2O\`AJ,[=0]OIV:HYCN`I`KB
M3BKFHA?-_F]5$9-@J1+BNM)E3$=(F*D7[E#B/)OJ"!]A";ZA0VCL#:.O59?D
MSFX5C(+7`G#V;A^5TRMT_O4[]&/RVKMOQDK_`(:C.W4/;Z\KV:HYCN`JI`IX
MR5_PU&=NH>WT[-4<QW`4@4\9*_X:C.W4/;Z=FJ.8[@*0*>,E?\-1G;J'M].S
M5',=P%(%/&2O^&HSMU#V^G9JCF.X"D"GC)7_``U&=NH>WT[-4<QW`4@4\9*_
MX:C.W4/;Z=FJ.8[@*0*>,E?\-1G;J'M].S5',=P%(%:'[[1?E`Z=WP9]#\O/
M,]*Z0ET?G?N9]G-\[O;F_MZVW76U4WL=RZZ_V2,(6P[2IOS?\C^DO./A[95B
MJ<9K>6@F$\>2L%TRIB0]<M1JY(93I59K\GEW(??V?:*\.$6^@J!.7"8D%FB[
M.\*+.V,G$BJX>E#HQ.$HSH7=/$&JJCG/AN.BJJB?O1G0-])0Z9M@U^G[0WB&
M*;8.S7G,[39LG)]2Z2]S'=II[6D@_G=XA>NR;+ES*V:V8UKFW&V$`CQV[ZOE
M7[\-OY??=N.?0_HNOS\^NKH^_P`[K'\:^IRZ2D^"E>0WB5@K(R.S]4'_`%!_
M-KKT/Z+JI,KJ^][_`#^L?TE:;1T?P,KR&\2YJS;FW(%`D6,/2(R+L$DAC[).
M6K&-IM<Y!-$:3C`M>)+1\(:)CY=RZM$T\LJ"385DTV;<I#J*G'V)#2TKZJH!
M=/JJEK3,8P77O/*?&!,7BP73'=5>K[/3D-E4\AQ#2XQ:P6`@<W?<._ZAU@]X
ML+2UE%57L<C#0<Y*8XC<<0M@D+K$W.[,[G8L9Q<O:HEVM%>),]`0D=D4JHDC
M'[IRBNWYMP">T^Y$Z57%G)JZDS&AY>1,<6MNM>0T\N\"2SVP`(,1%;LFTK9A
MO4\D2R6!L6-$8EH)!NP,`ZV'KP.C"Y/XN;=3(Z]*0L&$M,TG)F0*RO'/K'-H
M(.J+C.AP=QL]K4<MB&,P?F?6>.CD$C%42%=ZD(B(".[6II%=/>P3*RJ;+?*8
M8B8_QYCRUK?&M$&EQT6`J>954;&PETU.9@>8BXSQ&L#B8W=\@>N%>Y2XLY+%
M]T+"S3!R6IQN4J-2;C;7%HD6:=1J%KQ%=\E2N0I%N*2J8Q=4>U=!!X43D32C
MUUG9U"E;F*-*FDXG6R+\NLJ=>9#WM;K)G*<V:Q@8.7I<'$C?(#86JY555!1S
M(.I9!DB:&N-QG)!8YQ<>3H!;;;8(G<6L7O&O>7>-[)?:S3G3QY7HWB-MI*K*
MVJ9CG\O1</R`0>/Y--X9,B4-*Y0E9F(4%%R0Q&+9PN`B8Z0".745<VJ933L0
MJ@U[J=EX3'D!\T1>(7[1+`=:-)`WUJVOI9DE\UE'31:)S@TL9%S9<0WVMA<2
MTZ#`1WEE('CIKM@G9INU2O*]=B:71),DE%'E)28E,AVAS8PLV-8J%3<(*.)3
M'#*NJ=^%E!03;NTG#?E5;J$#F5.'X]*E-)K9VM=,>(&=,`$MH;=F$WM$PNY`
MMB('00KTG$,(?>?V.5JFM;^:9$N<71:!=]K=Y6\8@V@A29;C'J"I2K1*.:;'
M'.YN5KT'-5^J3KR'M$E!5>3N4X%=?.)-F#MK$5N'7<++K%02$0!-,3JCN!S7
M4>8]#ZY['AH<X.J7@M#G!@O`.,"7.``$3NF`M5OSA@8)N4;'L#H`B2R#C!Q,
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MS";%P.L8Q)=L<""4R@I\M\C-!>]DNMGO#6!P<VIF%KXAY`8;W*="7,LL\1PC
M&$>HRKR_<ENF4DEKGO+2TR&19`@1=R;!RF>LX'1%6MNXBIJN9>C<6(%FYCI=
M4D)%S(MKF9L^0O#J/GIVBT-&(<.054<7.!I<TJ1X)@105;H$,`\]M+7ICC=1
MA+L2=B%8R$T``S9Q&K!:V9,O!_M'3)8NZ2"3N*S/FX33X@VA914KRYA,0R2#
M?(+F,@6CQFL>8_@@;JU4CQ09@D4H.M1:-=4RI+(6VP2=6E;;DVM,Z?7:I6H*
MS#$VEI-UQK:FENE"V%!N@8K(8TQ2J.`5,4G-#/-EU;'3*F;B.)C"V:MH>V:7
MF8][W,O,+9Q86-N$GE7M#8",5#+GT[V,DLH*$U[BXEKI36AC6M:0'7I=Z\;P
M`LA`$B.A<\<<&0W^0,1\']T;R4^1A;,_8IML<T?RSM==BE/8UNTHW3.8KI5$
M'39)YN"=,=@\NP=@Z]7LWKL;I,4S%1SJVJ>^1@U2V.NFD1942&Q$76:+-U:9
MEI<+G85A]7(I:=@G54HP$N6#==+>ZZ8-M&B(T16JV,S,@!-DS+A_91]Z(?GC
M69^,8Q']<J]/PTWI*K*PW#8_JU/U3.BI:RG)S:39-S(<G6EI`/0]!QKDSL:Q
MH?MM9U\WIKJ2L+POY+3=5+Z*EC*>G@W=D[.!RAU)B1#T/SSKC3\<QP1A75O7
MS>FNI(PK"3II*7J9?14Q86&PAN[+#/!R!U)J3]']%:XU1CV/#17UWSB=TUV)
M.#X.=-'2=3*Z*EK2R60"ALL=@#DZTW*!Z/H.]<6HS#F$&S$*_P"<SNFNK)P7
M!B;:.DZB5T%=#9K-]<MB^CLKW7KF3<QYCM_YCB&GY3/^,5L8)@GR*CZB5T%9
MFLUFVC^R6Q_1Z6[LU7=F3,EO_,L0^<S_`(Q6&X)@D/U*CZB5T%9FL]GWOJGL
MGT?EN[-FJDS,N9?I+$=W]JG_`!BLMP/`X?J-%U$KH*(5ZU6XS.2%>SVD#!9+
M&4H*V"Y[P(EEG(([HS[T7@IBELW>9V,=W^E0!#<U-BV9<QB=*N8GB$.RR=%4
M_3<$?>IEV,=-[W7X7EQ2AP+!+C[U#11ULS]G9SCSV1X.1S.3!94]IM/LOV46
M;J?7!,>A^C=<-^9LS0/_`#/$OG4_XQ=)N!8%9_J-%\WD]!6:EJM7+^RFS=3Z
MX9CT_P`^ZIS,SYG^D\2^=5'QBLLP'`?D%#\WD]!6*ELM@;=EKM`?W13/I?GW
M5<YHS1#]Z8E\[J/C%.,`P"S_`%"A^;R>@K4UNMW)^RRT_9',]W:K'-.:?I3$
M_G=1\8I6Y?R_\@H?F\GH+I?APXC;54+"PI=B&;N58L,@FV;(EZ5,V*&D79A(
M5Q$@=11T^9K*"`N&YC&W2@)T]T0,!OT;Z/VW_,V5,=D91Q_MF+9<KYX8QHOU
M%53S7F`?(B2^9+<;9LHDP`+Y<""'?%=LFQS`<PX1-S)@_9L.QNCDESB;LFGG
M2V");-@`UCP/>Y@`B2&OB""/6#7]/U^!TT1:_NR#I69Q@JV*\,FUR"DJ]%J:
MZ%1(T4JEI;;[_P`4U"QAFO25TP`)\IH45!+O;'?13!;I2T2IX=")DV1N:;[3
M9?MC"/O?+A^#>6[#R7?B]S?&_P#>M]:*V!JHM$T1-$31$T1-$31%42_'4_Y<
MG_O!K!T(N&N`[ZBN(G_/;XI/[\V>O59L_6:/_I=+^05;K/'9^A9["[AUY95$
MT1-$31$T1-$31%!+@@Y4F\9JH%=BDVO1U'@MQMP(E;J4VVMRB_"LJ$BS-1<K
M)@`3P'B.=$FP`>]#$+=,6B5/!A$RK/$Y[-%ZV/Z/EP_!O+=L+KO4[F^-_P"]
M;ZT5.]5%HFB)HB:(FB)HB:(OT.J'P0]#\7DT1:[QF&R#FQ$S\YS7_(9E.^`W
M83E-XWRI03:#?55988XB92@CT3<AMW;WO*#7<VW*[WUNCWF7HN<P:=79'?CR
M^?RHJ29I'XHWM[N?Y=];#U34::(FB)HB:(FB)HBY+XC?WX.!'_.?L_\`Z7N(
M#7H<%_=V+?V%O^U4ZLR/>IWZ,?EM76FO/*LFB)HB:(FB)HB:(FB*`?%?^)'_
M`$;-6?;_`-P_WE;^U_D?TEWKKQ2@7)^:H8\YG[AO9D<I-1"#SJKSJI1.786"
MI9-W8!B#M^6;>KR``ZIX[@C\<RO5TS)K)1;/IW1<(@VS!#2%Z#`,3;A4V94.
M8Z8"&B`,#XP.\=Y3T^,7!OU_C@^"BIZ&S\GU\D=LYJ'&RMI_)/27LFYXDC]D
MG<(Z*MCXK<F#ZH8P.0?YBIV?4#]FE0XQ[?3^2>DIFY\DC]CG\(Z*U9D/A'HV
M5.]0WH\7,GA4Y=M'K(R-C@G)8ZP-T&EAA';JN3L2YE*Y8&K5)-_&.C+,'I4B
M`LB?=+LVD[.\1IHZC$:9H<03R(VC0;28$;A%HW"M9N=:&?`SJ&H)`(L="PZ1
M8-!W1H.ZH_-<$N,K"^EY":+&R:LS&GB5FKV=N"T1$M%&K%D8]1@1LH0E$D.B
MQC<H/(1O'NR\R405`P;=0C9UBK`!+Q.E:`8^]B)T^,8Q>+38XD=Q;G.F'.C?
MH*DQ$/'L`L\40@TV"T0*I1?!)CJ&*]1:*0R[23K=CJTHVF7<U8>^T;<9%O)V
MYS,OY^6DI>:F;,X9-2O7SMRNZ519H)@<"I%#5>9LUQ:803BM('!S7"#(0+1!
ML`'``-B8``"TG=4K,\8:P%OF^I+7-(,7QB'>-$W8F,!$F)L"H1?`_C6(C@BT
M"5Z19C*OYIQXT/;'<W<A(RE1D*"^4EY*W3TY)3+=6DRKB+*W=JK-DF2HID3*
M&S9#.V8XO-=?.+4K3=#>2RZ``\/$`UP`Y8#H@`QM4\K/F%RQ#S;4NM)Y3KQB
M6EEI(,>22('<LT*W'@=QZ*]\5.M65$LE18PEO8JD?=`D(M5]+2CUD@W)()][
MT9*3FW"[@$#$!10Q=FP"$`('[+<7<)4,7I`9+HL-PQ!@`#XUL`T`14K,_P"%
ML,PC#*DZP0=RAH,8^ULC$JWG>!;&]B(^)))4P@R*::;E>*1DZ\\WDYJ6L1G3
M=]7Y:,>L9!U-3SY=RZ043<.NFKD6.<BRA35V[*,9ED:O&J6PV187#Q0V$'.(
M(`:T`$0$!``@*P_:+A<T%KL*J('><&[I,8AH,8DQ.DQ,=*A]S\WG2;>VI$,6
MRPU=JM2NMDNSJO59Q8ZN28?6:E66FO6J<I5[+!RD,T,E8Q5.DV5!!1-+F!3!
M,P[,R-E6,2#-F^>*)]1,E-8'/EWKH:]KP8.<X./)A$VB,8Q6DW:#A<P,8,,J
MV2FS"XAK[L26N;I:`1XT;+-R$%FE^`3&:S15B*=(3:*M7C+FD4)5N*"+Z-IL
M0N9FJA,)K,'1&&/(0J*Z!DUVRD8@JB<BI1.-$[(<=OAXQVDO`@^(3H+S;%]H
MC,?$&PWB""%=;M*P<-+?-%3`B'C#1!HLY-EC&P(@1`$6K%NO-Y8L=LC1[@*:
MLR4B64(X;+*6!1%XRCV-KC6RL@4\^/?"6%E>I=-607YQ^X"05%58XB`A']D&
M8`_6#'J,.O%WO>@DL)ARK!&6PAHY(NB`"W&TG!"+KL&JB+H'C[@#AS;3![HG
M28VE7LMP$T.;=MWLF]IKIRWL*EI!0Q)A(KF95:5]DLI(I(3*2,M'N$:G%F58
MNBK,%5HULL9$54$SEIMV+8[*89<K'J)K3+N>)H;%QL)?%I%]\'"#@'.`,'$*
MV[:G@[YFM?@U67WKWCZ3!HM%V!');88@EH,(@*TF?-_XYL%A<VV:+C22MCN9
MA;`I:GL$*]F2E:ZV;LX1=E/G>#+1R,>T;%3(@W62;B0QP,0><4WHY>Q7,,FG
M%))S#2-I0QS;@:ZY=<271;K(&),8D$Z+;!"1VU/`IE1VN;@=2ZIO`WXB]%H`
M$#<B(`:!W=\QBCGS:6+'<>,<XEH=QM644&5<VG(;BT"W5C%H56)&Y*W4UM&N
MJQ#A1J:+Z;WN,@H8@H;##MS]C.9&S-8W,&'"SQ=0RY$.#KVKC<OW@#?NWXP-
MY/M2P$MN.P6N.FTSG7X$72+\+]V%EV-V%D%QCYQWAD7JE-X286(LU8.T<\6.
M-JK#Q<6RZ$UC&J>/,CE9)()=+!!!DR:QX)E(7=*4NZ`<FO6;/MA=;0S<;JZC
M&J*8Z=@\YKC=<3%TZ2XO=RR3:+>Z5KC&U>CQ*CD4\C#*J3+IIK9@!<($-:YH
M8T!@@>4(=P&Q:HCN%"X*`398(,.3K\UZ(?U1UK,V)S'V^>J#R'])4&;7*5NG
M#:ORAT5.8_A#N1]S998`.3K\UU]G]4M49FPJ:_\`CF'C^0_IJZS;)2-'[KK/
M*;T5-X_@WNB@EV6BO!MV=4$OIGZ6J,ST?YS_`./8</Y#^FKDK;92,_A5;Y3>
M@I[&\%5U.!?V75L-H!U2I^C_`%TUSYOHZ3W_`/N##!_FW]-7Y>W:B9IPBN\I
MO04W8\#EW4*'[-:L7D^**GZ?]5=<V=Z-LQQB<R84/\V_IJ_*V_4;39@N('^4
MWH*_'@7NWU\53Y%/Z;:I/]&:8[_W-A75S.FK`](&D^@\1\IO05`>!*[".WQZ
MJ?R)/IMJ$^C%,/\`[GPGJIG34H](2D'\#Q'RF]!$>`/(+HP]&N=:<;HEW^CM
M3+[F]\+O\U)GW-NP=FW27Z*E;51[/F3#)EW3=D3G0COP>4?Z1^&2(:[!J]D=
M%Z8QL?4BP*'TWS?F2'L7)*IV!JR`MMN#<Z<K5)V$<*JM;$_;J.T&DM//W+J.
M>&3YQL\3.5J\0,59!-)(Y2%Z.)^B3B\Z>PC,.'V4\IOO$UVB6T:67`/Q2"YN
MA[G.!<8Z?TE<%IFECL)JB2YSK)TOVQ+K8AUHC`V@1T`"Q2<WF[<FCM_99!\O
M]3'/TQUR7>B!C!$/K#A_S:?TE:'I/X&/X16==*Z*H&\W1DTW[;H(.39^I;KZ
M8Z@=Z'6-._\`<6'?-JCI*5OI1X&/X/6==*Z*MS^;AR<;]M\"']BG7I?U1U$?
M0VQK_P`CP[YK4=)2#TI\"^AZSKI715`WFW,H#^W&`#^Q+L?_`(D&HCZ&6-_^
M1X=\UJ.DI!Z5.`C^#5O7RNBND,#\&[O#QW,W)M4K1<W`J(MYHJ3=LUAX\P"0
MS:(;KO%54G#HH_+US#OF#V!=A=N]^A-B>P?+FR=TS&,1J)6)9N>2UM0);F,D
M2C9<D-=%P<\>^3#RB.2V#8Q^-;5-M.)[1&LPRBES*'+;(%TDO#G3I@MO37-`
M!:T^(P6#QC%T(=,^)5G\$J_-VG=&OT5VVEY_>/$OB=X)XE6?P2K\W:=T:=MI
M>?WCQ)>"UW>J78RS&+3J5N4>"7(S<$E6,1*S)(Y52J6I,'\DZ@K!%-:W&E(8
MR9W\FD_C@44(B9L*RR*J5REK:;53P)C1[CND-CRV6`.:2X[MUI:Z`)O0!!W8
M1!UOM?4W1OBWU!!;$\2K/X)5^;M.Z-4^VTO/[QXEI>">)5G\$J_-VG=&G;:7
MG]X\27@GB59_!*OS=IW1IVVEY_>/$EX)XE6?P2K\W:=T:=MI>?WCQ)>">)5G
M\$J_-VG=&G;:7G]X\27@GB59_!*OS=IW1IVVEY_>/$EX)XE6?P2K\W:=T:=M
MI>?WCQ)>"^TZ79P43$8I0``Y1$17:``!O!RC^6-8-;30\?O'B2(7"/`+5IYW
M2^(\&\<=46_'#Q3H+`"S8!(JG=6I#E'>6+MV&((;0VAR:]9FZJIV5-%>=".%
M4IT'F'N*W6$7Y?Z%GL+NOQ*L_@E7YNT[HUY3MM+S^\>)5+P3Q*L_@E7YNT[H
MT[;2\_O'B2\$\2K/X)5^;M.Z-.VTO/[QXDO!/$JS^"5?F[3NC3MM+S^\>)+P
M3Q*L_@E7YNT[HT[;2\_O'B2\$\2K/X)5^;M.Z-.VTO/[QXDO!/$JS^"5?F[3
MNC3MM+S^\>)+P4!N=)LO?O&!C5^2<"2_&W%6<5(2Z3(QZ9;TQ=2+R(G8UI6V
M`E.*8OI%)\QYU0C?F.?7061MTU;3:J>-8T>X[I`CRV6`%I+CNW6EKH`F,`0=
MV.$'6^U^^.'UE/O$JS^"5?F[3NC53MM+S^\>):7@GB59_!*OS=IW1IVVEY_>
M/$EX)XE6?P2K\W:=T:=MI>?WCQ)>">)5G\$J_-VG=&G;:7G]X\27@GB59_!*
MOS=IW1IVVEY_>/$EX)XE6?P2K\W:=T:=MI>?WCQ)>">)5G\$J_-VG=&G;:7G
M]X\27@OTM*L^\'SI4ZH=5PS`.KUQ%<0#3MM+S^\>)+P4$QY2+26#D1&O/&13
MW"[*I(N8M_`.#)J6B3-TA5I/6";?.@=*B91-X15)J\1,15N@@B8B9;596TNM
M;RP?<V:"'>U%D6M:!#=;`EIB"28E;S'"/K#N[G<"G7B59_!*OS=IW1JKVVEY
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M^=YK9L_WVW5SM$F&MO>Y]AA&W3VE;^TC^!_2784>(C*SX"(B`.6&P!$1`-L:
MV$=@=0-HZ\BH5R9Q%_OW\-W]:LY_WOT_7E,_?]F5']JI_P#[J]MD?]?F_HQ^
M6U4%_AO5_#U^<)P%J^PRM"Q+@`Y>0/Y-NN;,T*[+)BL0J`;!Y`Z_6^#KFSA:
MKTLE<Q7>_P"0`RP\I%.?8[A(>F5''MWM2U]0DM^TLKY>+!51@H><9S,<TJ#M
MHSK:HM72[22*[DG*"!DDR`8QI&4E*:+M$\37/F3)C&W(<DL8UUX@@EPBX1`+
M8-!,25#,K*AE5JI;I;6,:QQO1BZ\YP@#$0,&F!@Z)(L&E:OLO&#7(>>KJ"%$
MM2]24"Z%O]H=K5]J>C/J9CX+Y)P01*,TZ>3M@B3JI1\FW;`8&3M8I=\^P^["
M,NS)DIY,V6*CD:MO*-\/F7`Z,`&M-KFDZ0/44@QYC9K6MEN,D7@]T1R"UEXM
MA$DD'DD#0=]8C[K*+/E5#&CFJSD=+2%<5*G7'#:)7GZY<X&2R*%T1LLLUGU:
MBI`0<)2T5D3,7CE=\LY!-L58PG*E2G9<>*$UH>PRVO\`&B;KF.$NY=%V_><7
MD&\`&@1=#=L2<P-?4B0&.#G-\726N%^_>,;L`&@B!,8V1MA:0_%[37%<G['8
M*M<HB#JE(=6B2M)V==6BIU_!5/'EILT/`P\;9I2QH.F37)<:"9GC9!LJ8RI2
M+'YH3#SJK+%3K629#Y3ILR=<#(NBT.?,:TN):&P.K=H)(LB+5>DYDIF->:AL
MQK)4F^70$'0:US@T`DV7QI$.ZHP7BU3EK95XEOCNT5ZL32=6.^LMB)#@Z8R$
MO=+M492"5@&LR>34;MRTU1TVE&I'39RD/RLI]I=M2=E@2Z>;-=/EOJ&%\&-O
M0($N6\.O%L(F^`6&!!TP5VGS$9LZ6ULE[9+@TEQNV$N>TMA>C[6(<(@J7.>(
MN#:HXP?3%(MU>ALM/3#5K!./J.P@&]8,WAWK*VSTT:V&CH5O+,9I-9M&JJ!,
MJ$26#HH&2,77#=EV:YU3+E3I4R=2MY;6B87%\7`L:VY%Q:6D%X&K$1RH&*ZD
MO,,IC)4R9*F-E3GFZXED+L`0\F]9>#@0WQS;R8A:J1RIF)S)46>6F*3'TFZ4
MG-&4RP"M%D7=G1IU"DHA[3X]"<+=F+`)"P5&SLU5U5&1@263'V(\X()[3L)P
M<2Y].UDYU9)G4\F\)@#-9,:X3"6ZLF#9C'``.M!TV6YDXIBA=)GN=+%+-ESI
ML+A+KC7-U8!O@<ICVDQ;81HML^'W%S7(FFN+G,8_O9(%H]>0R<PD>C%+9):O
M1#J7N(UF!"YK6)PC`LV*RVXJV3.LF4>;WMTPASW9.GSZT44BHD=H(O7?=>0U
M[@V7?=JPP%Q(%A(!TPB%>&;),JE-5.DSM2++T98O$`E]UNL+C=#3N1.Y&!7S
M-\6E"AB6IP[K%U31@7E1C84JS:O-I"]2%W-'!!%K,(O/EFTXQP$JD;OB];M6
M`E'D5$PD*;G-R;73]2UDV1>F-F.=:\B4)5Z]?==NWA=/(:7/[FF%]V:Z24V:
M]TN;=898;&Z#,,R%VZTNO`6CE.`;W5@C<6U/6<F,G0<C=XTF4M*.K(NUJC1D
MRC*Q7:7:+H\=Q3NTHV5$U1C;\P*NB++GW*Q5R-2+\UM-4F9)K`R!J*7M!+6A
MD9A)=,?-ER@'"66'6.DO@;T&BZ7EL;+4K-]*7&$BHU`!)?!@`:UK'S"07WN0
M)C8B[$F-T&"L5>)AC%24N>]U=_3*["7'+-5?3"KN$E6*,7CJ\4:E-KO*/F<P
M88>%>2%P3372.D=5$Y@,8"D+O&H3<GOGRF##IK*BKF2*>8&0>UQ=/E3IIE-!
M;RGALHD$$`BP6Z+,K-<N7,+JV6Z32B9/:7$M(NRGRV":2'1:TF8(@B(W;!;I
MCC*ET[#2^%.P)L'\6E/<0F.IE*-ED4D)5@C*4"[/DF<D@@LX10?-TUP*J0JA
MRE.`@!AV;=>AV94W9*O,U*7,>Z7@%0PN;$M==J:<$M)`):81!@+%#FZ?VG#\
M*J`'-$S$)+H.TB]*F&!A&T1MMTK`,P#:3D#U/Y77"J0+5O3$P4E9E#DY`^&+
M^&&N#5`0]9=NG)AZRE3(H;2\G7]?7FZL"!7=IB;%*V92\G)UQ_#UYJL`@N]3
M.-BDS4I=G4^)'_[VO,536VV?=%>BIG&SU%]+D+\:'4]?7-<T;RZ3'.CI6,5(
M3XT/Y-NJ;VMB;`K<MSM];`Q/E:XX<N3&U4MP<7(G1:R4&<5U(ZRL5%2@:)?M
M$=IUA5,/RDY`%5%788G+R#[/9QM%S/LPS-)S%E9YU\0R;(-XRZJ63;)F,;:Z
M)\1P%]CX.9;8?+9YR-E[:%EZ;@>8V#4P+I<X0$RG>![ZQQL$/;@FZYL0ZRT>
M\>#'SR5HZTS(02U9=S=LN4TM`.H>N0C^(/*V20?'8R3>L2\RR=R*!UQ!9VX,
MWD'9]JKQLV<F41)_<G#L4J,;P;#\8JZ6?1555A]/,?3SB3-D.?*:3*?$"#F$
MPNBQN@:%_)/':&1A>,5.&TU1*JZ>GGOEMG2R3+FM8XM$QD;;K@(C2-XD0)W%
MJTN4FB)HB:(FB)HB:(M3Y+2YV<P_^4VKH$\H(K"JXAJG+*L=RDW7==,U[-8(
M5[".1.8$Q>1",E*%3.9(K8&ZKAPAT*$PE5-I'^K\YXCRV6&ZUP=OW7EK8VWK
MP:#)+T._%[N^-[[\`ML:YZC31$T1-$31$T1-$31%YY^;H^I#BE_S\>*_^_\`
M#7LLZ?K-!_TFD_T:N5OC2_T+/87H9KQJIIHB:(FB)HB:(FB+6E_0(M.8G,9-
MFH+?(HKDZ3"UV57(;Q%NR0J1[N=FHIU`NBE5'>=QB3^0%$3H`W!NLX71O49(
ME5&FV1N.</SC-(:TAP[CBUL8&,0`9&:'?B_?'W6V+9>J*C31$T1-$31$T1-$
M31%JO$22",!8B(M6[4XY(R4=P#:)J\,1==2Z3)^DJ-JG-3L>NNJ@8F^Y752D
M'1@%5XW;N3*(DZ&)$F<R))]PE0B7.]HVR+VM/K`%HT-+FP)DF:1^*-_>[OW;
MRVIKGJ--$31$T1-$31$T1<-\6'[^/F\?\Z^T_P#I.XD]>KR]^Z<9_P"GL_VN
MF5JG]YG?HQ^6U=R:\HJJ:(FB)HB:(FB)HB:(N?/\)7_7K_HS:['[#_=?]Z4W
MYO\`D?TENB._56P?HF/_`+6-M<=0KFO-,=&R>?N&]O*/A8-@@\ZJ`N"B*6U0
M(*EE`N\N4Y/A3".S9M'9JGCF'89B65ZN3BM1V>0)].0Z+1$QF6<H$+T&`5E;
M0S9DZ@E:Z=!HNP)LO`Q@T@Z0!ZZG:E*HHC[*W&#J_FN.[#KY*_*62W:<4/ER
MNBO9LS-FD"S#QY$SC5FI1<?F^&N9B_\`'(P/1]%#55V3<CD6XL>LE=%3MS1F
MT:,-'D3.DK(]`QP.W;>#!U?S=%>G_.-57Y)R$X\K&"/\Y)Z*L-S7G$:,,'D3
M>DM?V;ATX<;A-5^R6Q>LV*P5-PD[K,S,M*U(24$Y;O$9%NK&NW+%19L9M(MT
MW"6P=B;@A5"[#@!M8;D_(\J6^5*QZ8R4_P`8";*`-D+1=WK/4L1V9<VS9C9K
M\'8Z8T@@F5,)$-$#'@4*K'"+PT5VOA!OK!%V<ZMVNN29&4L#6FK.G]\R(]FG
M=PL@MVT.V8-'<NC8'+0X(I$`S,_-GWQ$QC8JLIY$GS=8,>?+&K9+`;.E0#)8
M`:VUI)`N@V[MJQ38_F^0RZ<&:]YF.>294V)<^,3XT!82+-Q92/X7>%J'CVD5
M%+U.-CF*#!LS:-&5512;H1<J\G8Y-/9'[P`RFI)PZ3';M*NX4/MVG-MH3LEY
M!FO,R;F.:7DF,9\G=`:?:[H`'J`;RO2\T9QEM#&8'+#1"S53=PDCVV^2?7*^
MB<,W#$@R<QB,I6$(UVSDXYVP3:U(C-PPF8J*@I=DNW".YI1K)PL&R:+D$-U5
MNT13,`E3*`5)F1MG;W![LRS;X<"#KY$06DN!C=TASB0=PDG=4[<VYT`@,!E0
M((/N,VT$`$>-H(`!&\`%AF?"CPGQBE;6CY*K,5J<F9&J+HH54J]=2/($E1)$
MKF8&5:!WS(#@!*.T%O9AL,(B,,W(NSJ;K!,S1.(FGEC7R.59"WDVV6>HK$O-
MV=V7+N7Y1N"#?<9M@C&SE66VJ'2'`WP0R$2M!NTJ/WH7?OY4S!)K5&[<DI)I
M)H/I%N1!DF#5ZLFB38HGN&(9,AB[IBE$,#)VS]DT3AFVH$T-#8]HIXW08@&+
M+1IL.^8I]:,YNEF3]6Y)EEQ,-3.TG21!UA[H4\5X=>&Q1)@BK>XPR43"/:W&
M$.O5CECZ])-F+.1A&8'8#S$6_:1C=-9`NPBA$$P,`@4-G(=LVV5%SC]:9@<Y
MX>[W>GM<"2''D6D$F!TB)WUU&Y[VB0:WZNRR&M+1[C/L:81`Y6@P$1NP"B$Y
MP?\`!W8H-&LSTW4Y2NMY!W*MX5ZA3E8U&2?MUVC]ZDU&-!,CA^T<J)+F#\>2
M4,0^\41#6S-GVS*GGFIDYOGLJ2T-+A4TX<0""`3<T`@$;Q`(6'YTS_.DB1,R
MS)=)!B&F1.(!,03"]N@D'?!.^L:MP9\%RIYTZTY43*69HVC[`<R5.%258LCM
ME&C1T<8[?!!LJQ1.0I!*!3HIFZI"B$)V>[,82Q]<:@"426?ZS3<DF,2.1I,3
M'U3OE2?73:";Y^J\DZP`._U>?:!"`\;0(#@"O#\)?"&*!VIKG7>CJ,I".41,
M%,,FHPEHZ)AY1FH4\8;G&TE$P+%LN0=H*H,T2&VE3*`47;--DQ=?.<9X<"'1
M[336%KG.:?$TM<]S@=PN<1I*N-S]M(:TL;E>3=((([//M#@UI!Y6@AK0=\``
MZ`L?+<('!O-EGB35QJ\FG:1?#94I%.CO$IX9(8,9+ONDXBE$G_?`U9CC+\X`
M\Z=B@8VTR91"%FS/9+)U9DYTJ)9DPU9;54P++M^[=(9$7=8^$-%]T+"5N<_;
M2)@>V9E20YLR-X&GGD.O78Q%ZV-QD=^ZW>"X/\X_B;!=;@>%5U%Y47ETG7%U
M06$JFA)UQ95C$JT/)1UWR2:+5(J9D%D$B@)QYL`/LV;=FO7[.]D6QNG\]]@S
M09LV;@DUCHSJ8W6&=()?R61L(`B;+5!C>T3:7729`Q'`1(;)J&S)?N4]M^8&
MN#9?*<8Q!<8"VS3!:TCJ-PY&YL5,H3Q>0.H]J@>@'7)Z6J,W8MLB=&]FF'^=
MI_BU6E;2-IC1R,`:?\W/Z:F\?C[AG-N[^5[`7;L'D?5#T0Y.5/7/F[#]C+['
MYLA_GJ;XM7I>T_:HVQN76G_-U'34VCL<<+IA+OY>L!.4/UPIWH^FGZ>N;-V"
M[#W@W\X0_P`]2_%J]*VK[7&PNY;8?\W4]-3V.Q=PJ'W=_,\^7;[+]4:9Z/IH
MZY<[T>]@S['YT(_S])\6NA*VO;9&^+EAA_S53TU-F&)N$@Q0W\WSY>0?UTI(
M=8?10'7)G>CCZ/SO&SQ#^\4@_P#LE=.5MGVVM\7*C#_FJKIJ\4Q#P@F^&SI/
MA_9:C^G^=QU4=Z-OH\[N>A\YI/B%;;MJVY1LRDSJ:KXQ6Q\.<'ANKGBP!_9>
MB]S:A=Z-7H['3GL6_P#J:/XA2MVW;=&_^T6=35_&+<V!\7\+U;N0VNI6F3RA
M.0**+E@UD'M9D$*ZX.J)4IM-C%BW$[PI@W$550.5$WLB`"FZ8/K&QKT=-BN"
MYG.8<L8U*S%B]$P.EL?.D36TSB8">)<J6SECQ6/?>##:V#X$?.]J&V3:YBV7
MA@>/X8<$PRJ<6O>R7.ENJ&@1,DOF.=!FZ]K8%XL=%L0>H\99%A&\19-C-V8R
MN1\C+*`U+1SI%45M\HJ8ICTPS9@*X;_RT'@&ERJ;0D#&=<X8?V=78=.=,9:W
MWB7IUG,'/B?4AR.8+L%^99C3$?BC?WN[_DWK%L;RFPWN&3^0:]U:I>;)W.;W
M^):74\IL-[AD_D&O=6GFR=SF]_B2ZGE-AO<,G\@U[JT\V3N<WO\`$EU/*;#>
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M/-D[G-[_`!)=3RFPWN&3^0:]U:>;)W.;W^)+J>4V&]PR?R#7NK3S9.YS>_Q)
M=3RFPWN&3^0:]U:>;)W.;W^)+J^BY,AC&*7H4F&\8"[>;:CLVCLV_P!-Z'#9
MP'C-[_$EU<!>;WO<9'TWB:.JU?GZ9QT\5;E,$R-QW2*7I%4H'WG!?9@"H;=F
MT-H=77K\XT$V94T,"VS"J0;OP?J*W6#E2_T+/87??E-AO<,G\@U[JUY#S9.Y
MS>_Q*I=3RFPWN&3^0:]U:>;)W.;W^)+J>4V&]PR?R#7NK3S9.YS>_P`274\I
ML-[AD_D&O=6GFR=SF]_B2ZGE-AO<,G\@U[JT\V3N<WO\274\IL-[AD_D&O=6
MGFR=SF]_B2ZGE-AO<,G\@U[JT\V3N<WO\275JW(F0J^YLF&3JQ;M55MDU9=L
MHNGCX3-E?)U?D3K-0MAUI@SDS=<Y`"O"G,[AS;3=`Z<4W0HL/GMD5(#FP,B!
M]\M]TEZ;ED(C\YR/Y=U2,!NOAS>[OC>^_9Z\%M+RFPWN&3^0:]U:Y_FR=SF]
M_B4=U/*;#>X9/Y!KW5IYLG<YO?XDNIY38;W#)_(->ZM/-D[G-[_$EU/*;#>X
M9/Y!KW5IYLG<YO?XDNIY38;W#)_(->ZM/-D[G-[_`!)=3RFPWN&3^0:]U:>;
M)W.;W^)+J>4V&]PR?R#7NK3S9.YS>_Q)=7Z&3881`.@R?*(!^-M1_P!SI7+I
MYMG<YO?XDNK5>(<@5ME7+`5I#N6@+Y*R>Z<`T3QYS;AXYO,VNZ>'&@&;1(KN
M%E!W^F`:9W@^>)C/!5$>AB6'U#Y["YX,)$H".LL`EM@/=(G@Y',Y,%)-:;PC
MS1O[W=_R;UBVGY38;W#)_(->ZM<_S9.YS>_Q*.ZGE-AO<,G\@U[JT\V3N<WO
M\274\IL-[AD_D&O=6GFR=SF]_B2ZGE-AO<,G\@U[JT\V3N<WO\274\IL-[AD
M_D&O=6GFR=SF]_B2ZGE-AO<,G\@U[JT\V3N<WO\`$EU/*;#>X9/Y!KW5IYLG
M<YO?XDNKB_BBO,8_S7YOU=)J_(5EQ56A=4#D;[QB#PJ<1:&Q/=<B`FWG`#L'
M8&P!Y=>GP&AFLPO&&DMY6'M&[\KISO=Q69`]RG#_`.F/RVKM#RFPWN&3^0:]
MU:\QYLG<YO?XE6NIY38;W#)_(->ZM/-D[G-[_$EU/*;#>X9/Y!KW5IYLG<YO
M?XDNIY38;W#)_(->ZM/-D[G-[_$EU/*;#>X9/Y!KW5IYLG<YO?XDNIY38;W#
M)_(->ZM/-D[G-[_$EU/*;#>X9/Y!KW5IYLG<YO?XDNIY38;W#)_(->ZM/-D[
MG-[_`!)=6E_'"/\`&[O]T9YT7[H#H?-;J'2.<^YHW-[=Y_F]S;_OMNNEV.9V
M?41;?[''=A^L^HI?:0_`_I+I6._56P?HF/\`[6-M><4"Y1XA_P!_'AN_K3G3
M^]ZGZ\OGK_LZH_M5/_\`=7L\E?KTW\1OY;5]+?#>K^'K\[3`(GU%];E:%B7'
M7_D]'7.F`05R7I6*.4!,`"`;!,`#\`1USIVD*\PF'K+S1AN)_)$6[E)&YQO,
M5R%JO$X_BY256KYH:^3=)XC8#&>/DRMZ@VE;56F4&RETXQPJZ:($4YX7*V\!
M#+$[$_!Z28T-D'W5SY`($8L#I+GO\:#7$D7@`3H@-,%RY&)U+'/=.CJV-FP)
MA!Q$T-;H!(A&$80MB=$5^U'C2L]JIMGR>\Q?7(;'.+HB+F,OO2WMW,V6%8C;
MKI6;1+5.(AZP\B;##U>.I#B6.8T@FLNV,*21#J$`RE*KR](E3V4C9SC53W$2
MA<`:3=:YH<2X%I<7AOBD`VDPT6*?,$]TM\YTMHDR6Q?RB2`'.#B`&P-T"/C"
M.@**O>.:PIV0U01Q77U)^1@:V\@D'-[=L46-BE[1B6M2-?MJ:U7-*LTXX,N,
MW`/&35VU.+91$BBIQ$4ZDS*\DR>T.GNU37.#N0#%H;-<'-Y4#'5$0)!MB0-V
MVS,4[M`D-EM+W-$.41!T98(=%L1#6`Q`(L@%9V;B7RJKD&8QZ5O0ZO9O%"YT
M6%J\'9S6B;>9H-><94>"LSB-EJU`2D=2VQK>ZD(I0QAZ?&H*N'"9`3^5T6X%
MAPI15G6S)&M8]SBVZT2;DU[F@AS@7\@-=S7$`$QMF\]UKYKI+;C)MQS6MO1)
MF7I;0X@M$&\HD'=`)(&YEFF;+A5I^\5=2P,,IW8MGKM8K+3QJIY\9L0F\S5[
M%,868?4ZM/,@8\M$6UM;4\O'SJ3T\@\:N5&!]PIB)\N?A%)42I,\,-/2ZMSW
M&X_6F[(=--T/<)<QI+#<<PMN@MOC?O4^+U--,G2WOUT\/:UHB-6(S6R[7-#G
M-<+XO`WHD$--BB<GQI3D=C%Y<Y/'5:8V5Q#56S56N$N[][%3D+8'61FKQD]L
M2]6B6L%/1PXIEEB"X`K%=$S<I5A<'Y@:OU2D3*\4LN>\R`Y['NU8#FN;JB"&
MWR7-.N8+.4#&(NB\N@W,L^73.F3)3!/NM<T7R00[61!==`!&K<;;#9`Q,%(\
M)YSG<F7"D@]E4$(:W-\\28UM<D.#^/)#6G'3W'<,Z<-6Z+DSV-I%E<'3V"4S
M]J;I1@4*!3EY&.X+3X?33BQGNLHTPO6P-YDT37`&R!F,`/-/)L-BZF#XK45<
MV5K'V/;/)%@(+72S+%F\QQ(WQ;;I6DF_$5G&*2IZ\]"R,S"1>6LO2-JGXBK-
MBDR#C!M'9L<8QQU4E01*P->8Z3HRC>2,W'I)4H1!58"A)@`W9V7<$G&<)+FL
MFNI9`8USS[E.)IQ.FOW=61,BR-A,QP$=6J,K,6*L,ILT.<&SYI<X-'NDH"<9
M;&[E\%D'0M`8"??%FY?BML45WSL9ZY%S3:.H[I%I6ZK8&4K4[);!R)2H`MM@
M+P]C8QX_IU>AKB3ONJ5$"LS-70"012*J/(&4Z6<&4PF.8YTX1>]A$QC-5,?J
MW2@2!,>Z6=6(\J+;;8+L?62K9>GW6O:V7`-:06.=?8V^V80"6-#XO,!=@X0L
MB<XEQ12J\*,\\I-8@T(O'U4N-DA9?(3(;,56PN$!DWM69Q49)Q-CHM2CC*+2
M$P#U)-$Q#E.4O,J:XL[*<@3NSLG3'N?43);'-DFYR`;HF%SFN9-F.@&2[I)B
M($W@NM)S+-,O7/E,8ULECWM=,Y7*(B676EKI;!:Y]X;MEA6OK)Q</XMQDR=K
ML-&W>*C9.OU6BPS.P0S6$=.&N1LVTFP7EW:MP`\7'YJ'')*'`ZR#5ZZ;(@8O
M/&.;>5DN3.92T]2]TB:YCYDUQ8XN`,FEFLE"7SQK7D"PN:USH&Z`HCFR:PSI
M\B7K6`M;+;>`;9,GL>\O@(--QHW0'$#=BH-QOS)[)C#A3L:L<>)5L&>\:3:L
M4JZ9OE8U25Q]<WRD>H^CU5V#TS,ZXIBLB<Z2N[O$$2B`ZZ^RRG;2XKF.E:X/
M$K`ZEEX`B]=J:<1@8$1A&!$1H-JFS;.=487AE0X%I?7270B#"]*F&$1$&$81
M%AW%I]H`;"<@=0.M_O@U)4@=]02"5*60!['D#J!UO3UY^I`77DDQ4F9@&T.0
M/A@ZWIZXU0!!=>038I<S`/8\@?"^AKSU4!:NS3DJ1M0#9U`Z@];^6UYZJ:(F
MP+O4Q-B_5@#EY`]0/0UR9C6QT!=262L<H`;>H'4#K!JI,:V&@*P"5):#/W"L
M7*!E*"H]+:@?(-HQJQ2.X/*'<*E(:)<,R"`/F3X/8*I&]B)>7:40`P>DR/CF
M:\N9LH\3R.Z:,S"<UDEDL%QG%Y`,A\L>^2YGBO8;(6Q!`<.)FK"<NXWEVJH<
MUB4<"U3G3'/(:)0:(ZUKSXCV:6N%L;(&,#[/X@?RTG2Q>3\>A$SBEHN9)F,:
MV*.M+9A)I6:23>-6\M&0T&@5%)8H@5JHDJX9%V(+.'*A#+G_`+;T,W%I^&4=
M1CTB72XU,HY#I\F62YDJ:Z6TO8QQ)+VM=$!VAVD""_EKB\K#Y&)SY.$S7S\+
M;,<),Q[;CIDL&#'.9$W21:?8&@;.U97.31$T1-$31$T1-$4`NSM-M,8Q3.JF
MD+W(*35(JDQ&1?/*#5;2N"2;60K\VXGE1*@(@S9JQCGDY[I94TE$5K=,TNES
MR-R3'Q2?;MW0YMWU2'#<NQ((W8+'?B_?'!Z\?44_U46B:(FB)HB:(FB)HBJ)
M?CJ?\N3_`-X-8.A%PUP'?45Q$_Y[?%)_?FSUZK-GZS1_]+I?R"K=9X[/T+/8
M7<.O+*HFB)HB:(FB)HB:(H'<GG19O&*7)M?WT[,`&9BXO]I=O<B(,Y&%E7-@
M$H-OZ39+1SH/Q_I/,HJH+VZ9MZ5/.])CXI/MV#2"`W3I<'#<NQ((W8(AWXN]
MW1P>NIYJHM$T1-$31$T1-$31%^AU0^"'X?P0T103'CI-Y"RJB;PKP$KI>&IA
M+,1<V5J=K9I%$S(',3!5Y!IS(EV]#505=,]_FEG#@Y15-:K&ELUH(A[DPZ"V
M,6BV!<Z/J@@'2`!8MWB!]8>QZI4ZU56B:(FB)HB:(FB)HBY+XC?WX.!'_.?L
M_P#Z7N(#7H<%_=V+?V%O^U4ZLR/>IWZ,?EM76FO/*LFB)HB:(FB)HB:(FB*`
M?%?^)'_1LU9]O_</]Y6_M?Y'])=M1WZJV#]$Q_\`:QMKQ2@7,^;301<^\-WC
M"LJBQ&$SMNG2!P)N>"!I@@'Y6344_&MX>ILVAJ:JP:BQO+M92UP<9;9M.X73
M=,8S!I]==/#<2J,+UE13%HF&Z+1&R,?O*<&\DIAVC(R'R$KW'KP9V<Y>=I9.
MZPKL#/&-MT.E>0%1.WQ`?X:0D?P"RW<?IZB.S/+9TLG]85(,^8Z-#Y7D!6YH
M[#ANK(2?X'?8/PF>H7;+<KN,2R?UI4@V@Y@;H?)ZL+%+5+`CE%5NX3.NW70=
MM5VZS%VJW6:R"G.R#95!2,,DJW?J^S73,`D6/RG`P\NM?LJRO&]=J;T0??G:
M1HX-Q;?:'C\+I=(A`CWL;NE6[6D\/S!L+*/0-'LA1!N+)@P=,F8MP!0`;BU;
M1B2`H`"QP`F[N[#FY/9#MC?LERK,=?>VJ+HQB9SENS:/F&6VXPTX;"$-4-"M
MCX]X=CNUI`[3>D'!6Y'$@,>Y%^X(T%,6A%WHQ725B-!1)S0&,()[A=W9NALB
M=L@RDYH86U=P;FO="W39W5(-I>8P^^#3WSNZH;BLWF,.&M\_;R[^/([EFCAJ
MZ:RSF.<KR;9TQ3<HL7"$@I%&>)+,TGBQ43`<!3*J<"[-X=L8V-91##+:*P2R
M#$">X`@PC9HM@(^HM_M.S(7ZPFF+QNZEIT1XRK?R?<-#9=\Z325;.I)RV>2;
MINR?(N9)XR,`LWD@X2BBJOG;,P`*2JICG2$-I1#4+MB639@#7-K"UH(`[0Z`
M!T@#<!W5(S:MF>62]IIHN().I;:1H6+?X]X5GS4["2;F>L3E0*HQ>1CYTS.1
MJJHX;%.T6AE&YRMEUCG3`2B!#G,8NP3"(Z-V%Y+:Z^QM:'[XJ'@VZ;>ZI#M:
MS26W'&E+3N&2W<M'!%4`I?"JV4YY-5XW6YQ-?GD&4LDL"R3,L<BL"J4.4X*I
M1Q`;D-MVE0`$P]@`%U"[8)D>8.4RM(T?K+M^/LV^K:IF[8LW2S%KJ4.T^\MW
MH>Q8K8]:X4TRI$&3ER$;K&<-RD2GRE;N#"ION$"EB=B*YQ6/M.788=\W+[(=
ML;O1]R&Z),NLB;#_`*P[@/<L4@VTYP$`'TO4-^[=6$4IW!N""34ZSKHK9N[9
MH-.]LST5NS?E$C]F@W"#YE%H_(.Q=,I0(L'(<#:U=Z/F1"2\MK[Q()/:7Q)&
M@D[XW#N;BR-M.<`T,#J.Z`0!J&Z#IX59+53@O,!#+.WY@18*1"8FC9TX)12Y
M2@M%)B,"/-QBQ4P`[8-B)@*&TH[-1?X=,@'VE?:Z]^M/\;G?C=W3W5(-M^<A
M[:CC=N_J[?%.YZG<6+7J'`X+<6JZKD6G1#L1:FA9PS;H"RZ3E1CT<:Z*7057
M*!%#);O-F4(4P@)B@(:?X<L@7KP;B%^,8]K?&,(1CIC`D1TP,%L-N&<X7(T5
MV$(=G;H-L/4[B\Y_.1QG"VXK_"LQJ5AF16=<75!;2PNDK0"36#\0\DF=*D*M
M#DV&(NFB4H)@8X`([`V;=GKLE>C_`+.\$&+3Y4JMO3<*F2C&H<8ATV42!98>
M3I6M7MCSAC$H2ZN930IW":R$D#EMBT1@;1!QL6JF%!X9]A.=N3TNS8`_*K?Z
M/I0`^AJN_8AL[?XU/7?.#Q*DW;%G%FB;3=2.-3-C1.%4N[SMX?AR!M`$+J/_
M`+M='55VP39I,\>GK_G)'WE8&VG.S+1,I>H'&IBQH_"(`ASU\DB\NT=C>\];
M^5K0ZKO]'O9>X<JGQ#YT>)3LVY9Z;HFTG4#C4V84W@N*!>>R#+%V!R[&U^_^
M[5QU5?Z-VRF9XU-B/SL\2LLV^9_9HFT?S=O24O95'@:*4.=R+,[1#J%:9#'J
M_`JGIZK/]&'9$_QZ7$_GAZ*LL](C:(S1.H_FS>DKE2J<!_*!\BSH?`9Y%_$J
M8Z@=Z+6QPZ:7%/GAZ*G'I';2&Z)U%\V;TE9'JW`*'PV2)_;U/Z3R-[TM1N]%
M;8T[32XI\\=T5M_B1VE#\]0_-6])=#\->/N&"6M<LMA&V,YRX1T8"BQ9\MF3
MDV,6NKS+AS"MI^(C=\AU-TCA5`IS$`Q2F$H'V&]ID38QLTV:8J_'<N451YV=
M++&S9\XSG2VGQA*O0#"_0YP%XBP$`D'RV;=K^=<]8<W",;J9?FYKP\RY4H2@
M\CQ=9`DO#=+6DP!MA&$.F<=T&;D8NPJJS#1PHAD"_LMJ[ZU2(H),K3(M4&J2
M]E@H9ZB@W21`I&Z":S!N4.;:.'#<J:IOM-9B$EDQ@N.`,F6=#!I8#'DN<+=\
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MRY3D,,A&["F*([.D[=@"`\GRG0XG)AXKN\EX+@OS?]#DI"F<2A4GK(@L^.3B
MI;*<X"^PQTKPW2$Q!*F([HF2'J[!V:];F^OE2ZFABUUN%4IW.85;K"+TO]$S
MV%WEY,9?PA&_IKL.O)><Y/-=WE4O!/)C+^$(W]-=AT\YR>:[O)>">3&7\(1O
MZ:[#IYSD\UW>2\$\F,OX0C?TUV'3SG)YKN\EX)Y,9?PA&_IKL.GG.3S7=Y+P
M3R8R_A"-_378=/.<GFN[R7@GDQE_"$;^FNPZ><Y/-=WDO!:_NM!L+&;Q@DA+
MM46\A?C,I`J+VVM$W#8:7<'22#I&"KTLQDD>FM4C@WEEHZ.%0I5.D"Y(V;KW
M*7$)#Y4\EA);)B+&&V^P67G`BPFU@<Z%EVZ7$;M((=ZG<WQW?8B?66P/)C+^
M$(W]-=AU3\YR>:[O+2\$\F,OX0C?TUV'3SG)YKN\EX)Y,9?PA&_IKL.GG.3S
M7=Y+P3R8R_A"-_378=/.<GFN[R7@GDQE_"$;^FNPZ><Y/-=WDO!/)C+^$(W]
M-=AT\YR>:[O)>">3&7\(1OZ:[#IYSD\UW>2\%^AC&7VAMD(W9M#;R.1_W!1V
M#IYSD\UW>2\%K3%=&G)>!G5E9B.<F:Y$R1'$5-)7&6,",?<I=L1`[JV5V`?H
MBU,F9(&S=):.:D(5-HX<(%(J:]7U\F7.8`QPC)EG0P:6`Z&.<+=,20XZ7-:8
MA;S"`1^*-P;W<)X]];*\F,OX0C?TUV'5'SG)YKN\M+P3R8R_A"-_378=/.<G
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MW]-=AT\YR>:[O)>">3&7\(1OZ:[#IYSD\UW>2\%J7Q.?]_\`O!TIITG[H;IG
M/?+N8YO[FK?W?QOG-_9Z6S5_MDO5Z^!N]BA#=_65)[2/X'])=61WZJV#]$Q_
M]K&VO+*!<A<2O[]W#7_6K._][51UVZ']SUGX\C\IZV/ZN_U6_?5IKGJHFB)H
MB:(FB)HBIJ_"_@AK(0:5''O7^"/X8:V;NK7VJC+KK_`_$#6[?OH=Q1UWU?Y/
M0'1NCUU@Z0H\Y^*_!_#UGC6NZ%'7/Q?P1_"'6=SUT7!ET=9,\MT@2/2OIE_'
M..C8=>)E[0UK4%B%WC1N,E;$:V:&D\97$\9=%7RSQ!XNVGA?(,TFH'*8$QUM
MO>NMK(>MWX_=W%J5PZS6YK\+6\3)V5T];O;D,Q?IR3R41E9"26*U9)^O',<K
M(*3E;MR5D8]`8-7!CPT?*R23M(Y^96:E".AJR`+Q)6%XQ%6:]/X1%HY.81CU
M>(G&IV2-B&0&PHM1QY>>91GAE?GH::2)L*[,XVK&7`XG$3"(Z[N#_J]?_87?
MEL5FET3OT1]D*FWZ@?!#\,=<?C5)9=#JA^!^'K#M*D/BA9E/X;\`?Q-86@TK
M)I?"_@!^%K=;[BRJ'Q/P"_B:R5HJ+CJF^!^(.M.-9.A8-QU1^#K)3<4CQQ&Y
M!E\@59ABL);R@+2B(UM6%6,V>-G:1P4,[4=<B+6/:IE$[E1;\KE1*;G`$NT!
MU<6AI+O%1D?:Z5_2#@9K:V=`YF\G25MX6>X&L2[:/GXM@[EC6.1Z:]BF=BG[
M"[+%/5MJK<Z!VK%5(X':LV:!B-TX:\@S672"-3+T%I]H.:UMHT&,71\9SC:>
M@^-D81NCV/66YM45HFB)HB:(FB)HB:(M79%:NW,UB91L@Z719Y*1=/C-XZU/
MTV[;Q-N+<B[Q2MV&$91K8'3A,O2)=&3C"J&(06O2#MW"%^B<ULJH#B`3(@+6
M")OL,!>:XDP&AA:Z%MZ`(,C(0=^+W-\;_P!Z!6T=4%&FB)HB:(FB)HB:(FB+
MSS\W1]2'%+_GX\5_]_X:]EG3]9H/^DTG^C5RM\:7^A9["]#->-5--$31$T1-
M$31$T1:RR`B\5GL3*-FKQRBWR,95^9JQL3Q)HU-1+N@5T^5A+%!L(]H5VLD3
MGY1"48<Z<B8->DG;N6]ZC+1)J`X@$R+(EHB=9+L%YKB3"-C"QT(F]=#FNW9"
M#OQ?OC[K(+9NJ*T31$T1-$31$T1-$31%K#%"3U&"L!7I3E$<AY%.U*I'V:.4
M!BI<9=1KO$M5@LCUR&X;V*[=9"/4)L%JU:H[C=._B):9K+OP,N-K3;<$?$:T
M#U""[G.<;3),A$0YHWM[N+9^J"C31$T1-$31$T1-$7#?%A^_CYO'_.OM/_I.
MXD]>KR]^Z<9_Z>S_`&NF5JG]YG?HQ^6U=R:\HJJ:(FB)HB:(FB)HB:(N?/\`
M"5_UZ_Z,VNQ^P_W7_>E-^;_D?TEL&?K]\7E5WU2NL#7F;M%N+IE+TAQ95C/$
M""ATA%ZA;Z\"2!T"D#FA2.(&*([^P=T..HA!16[8@5O%FQA;I&PM2S..8RX,
M5$C0"BL3.KW.*B(Z0>"S3G6KN,Z*>)!1%,'*P`"@E,)M@&U?I:ULBEG4CV7F
M3BPQ!@1<)-EA!C&U;!S;A8X1!AN[RJ^2=;PE7?L8E??GK37T_,?Y8Z"TNRN:
M>'P)Y)UO"5=^QB5]^>FOI^8_RQT$NRN:>'P)Y)UO"5=^QB5]^>FOI^8_RQT$
MNRN:>'P)Y)UO"5=^QB5]^>FOI^8_RQT$NRN:>'P)Y)UO"5=^QB5]^>FOI^8_
MRQT$NRN:>'P)Y)UO"5=^QB5]^>FOI^8_RQT$NRN:>'P(.)E1#8,C71#_`)L2
MWOTTU]/S'^6.@LW97-/"K<^'"J?#O:X.W_DQ+_B7737T_,?Y8Z"Q<E:+IX?`
MK8V$6A_AG-;'^YN:#\*[AK(J)`T,?Y8Z"7)7-/#X%;FP-&G^&5K8_P!SDY[^
M-!42![1_ECH)<D\T\/@5L;A\AC_#&K8_W/3P?A7D-.TR.8_RQT%BY)YIX5;F
MX<J\;;O%K8[>K\X+#^)>]9[3(YC_`"QT$N2>:>'P*@;AHJYPW3)5L2B.W9WC
ML@!M`-FW8%]`-NS3M4GF/\L=!-7(YIX5;J<+U/5V\XUK1]O(.V$LW4]#ZONI
MIVJ2-#'^6.@ER3&-TQ]5:!SOYN+'V<D,8HNI]G4AQIE2%RBBI#5J4>&GUX:$
ML,*6OR02=W<`A&.BSXJG41W%P.B4`,!1,`W:3%I=)+GRQ*+M?(,NU_BQ+3>$
M&Z>3"VRU22S*EAP#?&;#2=\'[RM$/-K8Z1V;U@9J[/CJS*AM^1O(:H]JE<Q_
ME#H*/5R>;WUE$?-SXT2V;TA&*"'QU=FPV_!W;X&G:I6ZQ_ECHI<E0A=L]595
M+S?&+TQ`3&A5-G5WH&Q!M^1OX:SVF3S'^6.@L:N4-P\/@641X",4I;-YE7U=
MFSX:'M(;=G\KD,-.U2>8_P`L=!9N2MX\*RJ/`UB-+9O0584V=<8NX%ZG\KD4
M-9[5)YC_`"QT$U<GFGA50W`WAXWPU<JX_P!C[G^)D?6.U2>8_P`L=!9N2>:>
M'P*B;@3PP;X:L58?^(77\3)&G:I/,?Y8Z"7)/-/#X%LC&G#?5\/O9&2QTTJ-
M=D99!%J_D"UB;DGJK1$YE"M$G4M>'RS1L=0V\<B0D*H8I1,`B4NS5T^G?XS'
M^6.@@;*;XK2/7\"F5-H-SJ$=*,4;E5EAE;7;+2LJQQJV@TQ6M,^^G%$UFD99
MTT'3Q$SW=6>'#I#U4#++"*AS#J:IK*6I>UYE3!=EL9;-+O$:&Z2V(%E@T-%@
ML"D<]KC&!T`:=[UE+>]EY^NV"^PYQ[ZM5M92?!O\L=!:Q;O'A\"=[+S]=L%]
MASCWU::RD^#?Y8Z"1;O'A\"=[+S]=L%]ASCWU::RD^#?Y8Z"1;O'A\"=[+S]
M=L%]ASCWU::RD^#?Y8Z"1;O'A\"=[+S]=L%]ASCWU::RD^#?Y8Z"1;O'A\"=
M[+S]=L%]ASCWU::RD^#?Y8Z"1;O'A\"=[+S]=L%]ASCWU::RD^#?Y8Z"1;O'
MA\"A5MQW=;5)4*04NM30\1[HC;RIO<7LYM1X*4!/P0M6#F2LZBM<?&).F,$@
MTW79$RG2*($6/JU35M+3LG,$J8=;*N632V'*:Z)`;RAR?%-D8'2`MFO:T.$#
M:(:?!;ZBFO>R\_7;!?8<X]]6JNLI/@W^6.@M8MWCP^!.]EY^NV"^PYQ[ZM-9
M2?!O\L=!(MWCP^!.]EY^NV"^PYQ[ZM-92?!O\L=!(MWCP^!.]EY^NV"^PYQ[
MZM-92?!O\L=!(MWCP^!.]EY^NV"^PYQ[ZM-92?!O\L=!(MWCP^!.]EY^NV"^
MPYQ[ZM-92?!O\L=!(MWCP^!.]EY^NV"^PYQ[ZM-92?!O\L=!(MWCP^!?H1MX
M`0$;9!"`"&T/$YP&T/0Y+7MY=+])\&_RQT$BW>/#X%H[!/#S/8&B<BQ,)D9M
M.$R/FC)N:9%>5I14E&$MDV:)-OX1F5I9TTS1D6N42('.`K&*/LQ$=FNMBV,R
M<7F2)DV06&12RI`@_2)3;H<8LTG=W-Y2SIPG%I(A=:&Z=[UEO#O9>?KM@OL.
M<>^K7)UE)\&_RQT%%%N\>'P)WLO/UVP7V'./?5IK*3X-_ECH)%N\>'P)WLO/
MUVP7V'./?5IK*3X-_ECH)%N\>'P)WLO/UVP7V'./?5IK*3X-_ECH)%N\>'P)
MWLO/UVP7V'./?5IK*3X-_ECH)%N\>'P)WLO/UVP7V'./?5IK*3X-_ECH)%N\
M>'P)WLO/UVP7V'./?5IK*3X-_ECH)%N\>'P*(6>@7.RR=%DE;G54C4JW#:DR
M.\9M9=1T<:U8ZX+=BYD+,HM7WG-V$QP>M-UR"93H@/-K*`-F164LB7-8)4SW
M67<LFD0Y371(#>4.3XILC`Z0%LUS6@B!M$-/=!WK="E_>R\_7;!?8<X]]6JV
MLI/@W^6.@M8MWCP^!.]EY^NV"^PYQ[ZM-92?!O\`+'02+=X\/@3O9>?KM@OL
M.<>^K364GP;_`"QT$BW>/#X$[V7GZ[8+[#G'OJTUE)\&_P`L=!(MWCP^!.]E
MY^NV"^PYQ[ZM-92?!O\`+'02+=X\/@3O9>?KM@OL.<>^K364GP;_`"QT$BW>
M/#X$[V7GZ[8+[#G'OJTUE)\&_P`L=!(MWCP^!?H1EXVAMMD$(;>4/$YP&WTO
MJJTOTGP;_+'02+=X\/@4.I&/KC2XJ0C&]QJJP2-HM=H5.PQDQKZ(.+5/OYYP
MF=E#V-NW<.2+OS<\[5`[EXJ)EEC&.<=EFJK*:JF-F.E3!=EL;;-+O$:&BUS;
M!98!8!8+%L][7&,#H`TQT#U%,.]EY^NV"^PYQ[ZM5M92?!O\L=!:Q;O'A\"=
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MO`&Q4AP#8;7@\_8SB.#4$F=ALS5S'3""8--@$?;`KV&3<+H<4K9DJN9?EM8"
M!$BV/<(7)=DS-DA@*@-;#S6[MV?.Z--L^3:FU^:L<VJY\I"13UUW_-2C[+%]
MYPC9SDZJ`U])'_.3![#E&L><4]FB+JU99'EB2-5EC)1ZKT[5BR&ON55@!&54
M.U;(BLR*)MUP!A]@F.^'PH@/%R3Z1./X9FR72Y[J1/RY4D2S,+)<OLSB>3.)
M8UMZ6(PF`FQIOCQ8'K9MV(8-7Y<F5&3Y!DXY3QF!@<]^O:!;*`<XP?NL(TNY
M)\:([VM-VJ%'KKBW7"RPE;J[7H(+S\S(M6,4F:4=-V,:3IJZA4#*2+UVDB@4
MHB9950I2`)C``_NADQDU@FRG!TIP!!!B"#:""+""+01I7Y">Q\MYEO!;,:2"
M"($$6$$'01NA7E;LU>N,''6:J3<98J]+(F7C)F&>H2$:]2354;JF;NVQU$5!
M1<(G3.`#M(H0Q3`!BB`;K59%%^S<NGK)!RDJ[CC-ROFY#;5&IG2(.&X+%^)%
M9$0,7T0T1?;AVT:BW*Z=-VQGC@K1H5PLFB+IV=-14C5N"ABBNX.DB<P$+M,)
M2".S8`Z(KC1%C'LU$1SA!I(23)BX<IBJW3=N4FXK$Z8RCP$@JF(4PF?23=$H
M;=IE5B%#:)@#1%^1DY#33`TK$2L=*1A'$FS/(,'C=VR(ZA9!W%2[8SI!0Z)5
MXN38+MW!1-M161.0VPQ1`"*%8WS)B7,;6:?8FR90\ELZW*%A;`ZHMKA+2A"R
MQVJ3Y*.E%(5Z\*Q=K,G!%DR*"45$3E.7:40'1%LG1%K*WYIQ#CZSU>DWG)U#
MJ%PNRS=O4*M8[5"P]@LJSM^E%-$X2(?/$'TB+J46(V2YHA@47,"9=I^31%]P
MN9<1V1.@JU[)]`G$\K%G#XQ/$VZ!D"Y"+6&RSRR&I8M7ZH68L`U;**/19\]T
M8A!%3=`!T2"R<5DO'<Y4Y6^PMZJ,O2(-:S-YFWQEBB7U:BEZ9(2$3;D)":;.
ME8YFK6)2)=-WY5%"BT7;J$4W3$,`$4L8/F<HQ92<>X3=L)%HW?,7:)MY%RS=
MHD<-G"1N3>3614*8H]<!T18Z;LU>K16)K!-QD,$HZ68Q@23U!H>1>MXY]+KL
MV!%CE.\=)148Y<F33`QP004.(;I#"!%G-$5HJ^9HNVC!5RDF\?$<JLVQC`"K
MA-D"(NCI%ZIBH`N3>]#>#1%=Z(L8E-PZ\P]KR,I'K3T;'QTK(0R;QN>48QDN
MO(M8N0=L2J"Y;LI%S$.DT%3E`BIVRH%$1(;819/1$T16[IXT9$35>.FS1-5R
MU9I*.ETFY%';YPFT9-4SJF(4[EX[6(DD0/9**'`I0$1`-$5QHB:(L)8+-7:H
MQ0D[/.Q->CG,M!P+=]-2#6,:+S=FF&5>KL0BX>*HI*24[.R3=FT0`14<.ETT
MB`8YR@)%KY[G[!L;4E;Z_P`PXS9TA&-M,PM;G-WKB-;2B://M*K<Y$\T>1"/
M*RJEFD$(^14%3<9O5B(JB10P%$LP*E-"R+0<IUU&W8UNE6OU7<.GC!*P5"=C
M;#$&?QRYFT@Q%_%.738CU@X**:R(F!1(X;#``Z+"DKR4C8]:,;/W[-FXFGYH
MN(0=.44%922)'OY4S"/35.4[MX6,BW+@4TP,<$&ZA]FZ0P@17VB)HBQC>:B'
M;OH#629.G@!("+=LY274*,2Z;LI,AP2,<"*Q[QVFDL0=ADSG`#``Z(KQRY;,
MFSAX\<(-&;1!5RZ=.54T&S9L@F95=PX75,1)%!%(@F.<P@4I0$1'9HB^&SYF
M\%P5HY1<BU531<<R<J@)*K-&S](AC%$0VJ,WB2H;.J10H]?1%=:(HZXMU59I
M6A=U8X-LA2$3.;DLO*,DDJJW)$)6`R]A.=8I8=(L$N1X)G`I@#4X*_""`Z(O
MV%MM6LARIUZQP<Z<\%`V<A8B592(GK=I*^/6I\@-%E=^&L!(QR+)R&U%R""@
MIF-N&V$4AT1:Z7R[BYM>R8P<9`J*.0U!;%)3%9V/)8A5>1RLNS;C&&7!R5T[
MBD#N4DA`%%&Y14*42!MT68&$=Q;%T6$T1-$31%&YVY5*KOZS%V2SP$!)72:&
MMT]A,R[",>6FPECGTN,'7VSQ=%68EPBHQPYZ,W!1;F$%#[NZ0P@1:\+Q&8!-
M<:WCPN:L6FO=Q0:N:G4`O5;&Q61%\63.R/!Q'?'ILGTTD*\,B")#BJ#542@(
M)GV%F!6P("[4VU25KAJS:ZY89BB3:5:NT5"34=*2-0L2\3'3R,%9F3)PLY@Y
M=:$EVKLC=R5)4S9RFH!1(<HB6%=6:T5JEPCVRV^P0U7KL:+8)"=L$FSAXACT
MUXWCVG3)%^LW:-NE/G:2*>^<-]50I0Y1`-$5VPF8B4<2S2-DV$@Z@)$L1.-V
M;M!RO$2IH]A+%CI))$YSLGQHN4;.024`IQ0<)GV;IRB)%DM$6NZSES%]RL<U
M3ZI?ZE8;375)-&;K\1.,'LM'*0LF,+,E<,D%C+@$1,%Z(Z$`$&[GY4ING$"Z
M+,"MB:+"PUBL=?J$%+VBUSD16:U`,',K.6"?D6<1"P\8S3,L[D)24?K-V3!D
MV2*)E%53E(4H;1'1%EDE4UDTUD5"+(K$(JDJD<JB:J:A0.11,Y!$IR'*("`@
M(@(#HBPTI9J[".4&4O-QD<]=1TC+MF3MZ@B\<Q<.YBF<M(MVIS@X791CN=9)
MKJ$*)$CNT0,("H7:19S1%C4IB*</CQJ$BR7?I]+!5H@X2571,P".%ZFLFF8P
MHJM2R[43D-L,4KA,1#88!$BR6B)HB:(FB)HB:(FB)HB:(FB+0G$SQ*8HX2L-
MVS.69IPT+3*H@D`HM$TG4Y89EZ848>KUB-47;]]K%-N@YMN@!R!R&.<Q$B*'
M+U\"P/$,Q8G+PG#&7JJ8=VQK6C2YQW&M%I/K")("FD2)E1-$J4(N/W1/<7\X
MU;\Y/YY;CPE).T<"/#+4L?8:923YI#V6XQ\'*(RG>_?1<,9"_9#FJS5)>5*<
MQ140AV6ZT5**1UCCRC]KGY'V9Y2EMI\VUTR=B9:"6L+A".@B7+:YX&\7NM%H
M`7:=0X;2"[5S"9N\.(`GA4+O'%+_`*Q9CK)^-</VFFXZ;W;+TD_B,=IQ]+P[
M+05BD8B'<6";;)V-C:U8EB,%!M%7;PSA1(J*!!':8>35JDP#8M6T$_$J>;.-
M+3-!F1?.#F@N#6FZ61-YQ`;",2MFT^"O8Z8TNNMTVFSUH+G[B$\Z5Y[3A8RE
M%X8SDZQG4,B3S*&D:_#(8SQU86T^PL$BI$1+N(EX":D(MTBZET5&O*J42+IG
M*8`V;==G!L@[+<P4#L3PD3YM$PN#G:V8TM+1$@AP!$!`Z-!"FDX?A=1+ULJ\
M6#NG[X6\,F<77^L-X@L^%Z;?ZMC:(LG$#8BU#%D:WI6'Y49JU#'J2RE>DG,;
M:G+2NR;>+05<*E>J(ID21.(GVE$-<FARYL9Q*155-',GND4;+\TE\X761A>`
M+`7`F`%V-I%BB938-,:YS"XM8(FTZ."U9:#XF_\`6.K'E"^8@B,=4YS<<:),
M5KBL?'.*FU2CPEHIQ-0J32ZN;*E6IAW-1K85&R#1PLN('3YPB?.$WHYN!;%)
M%!)Q*9.FBFGQN>Z32\P(:Z+`V\`TF!)`&F!,"L&GP5LL3"XW7:+3'@A%:<X=
MO.,^?CXK9R=@L#5^J74]5EE8*U39\.T6OU&M32(J@K$S-NL,M&U]O)D%$=K<
MBZBX%V&$FX(&UT\:R5LDR]*9.Q=\R4)C;S&ZZ8Y[F[[6-!=#NP`[L5+.HL)I
MP#.)$=%IB?6`BLQQ-\?OG\^#QFQE^(*O4NG5F2<-F+2Z1N*,?W"D=\G8"+6)
M=6JJ2\O$QLJXV""3=THBHL)1!,#B4VR/`LG[(<RN,O!GS9L]H)+#-F,F0&DA
MCP"0-TB,-V"Q(H\(J3"227;T2#P$+E7[_=YROQ5[Z^4?&'3?&;O9O^1RL\WT
M/O/TS<YOG]F_S_+O=79R:[_V19'[1J]1/NZN/OSM,8>PI_-%#>A==HYR_O8U
M^1EY):DR]^HS#]%K?_X-?+]J/[KI_P!*[\E?0-GO[QG?HQ[*X1N'PRWX/X6O
MQWF7QBOU!@&@+0;>G3E_M$94:XVZ1*S#@J"0G*H+9H@&TSF0?'3(H9%@R1`3
MJGV#R!L#:80`?D$K*^+YSS#3Y:P.7K,1JIET1!NL;I?,F$`W9<ML7/,-%@B2
M`?I\W,.&95P6?CV+ON4-.PN,(7GGVLM@)$7O/):(Z;38"5Z69#P1,3V#ZCB*
MJ7&4AWU:M>))9.Y*N&RD\S943(=:MLH]BE)**G(XLJ5C$*D8).&J[8AN;3.7
M<#;K^IV3LMRLH97H<L29TVHET5.V4)DQUY[KNZ2=`C8UNAC`UHL`7\[\T8],
MS/F*LS!-E2I#ZN>Z862Q=:V.X!NG=<[2YQ+C:5H:4X,)F(-D1W5++,6!9\SH
M1ZNA:LB6R+<6D_C[:;]GR)MB]<;M*_7%LZ.+(LT?R<;%&.D18HD;E(V02+Z5
M<&(6H77#EQ*7:06@D+_=&+"@6K%<?*.5KE.4QE:%XG$</&RMDI=FG:7=GCXV
M/+84#H+%BTT9I<ZJIW!'"0AK"S$+=CWA>O4U.H2UD8UR=E*KQ/QN:X*W/LEW
MH9*TP8N;ZU9&7K7>8]?H=BQS5KDSCH\C+IK:32AR`MS!13`F5B*PM,X:>(6J
M\,]GQS#VVM5_*L5?6]QQ387MTOMQ!0S/O7'O3Y7M3Y&-=6U_:HI)^#Y1K%LF
MRBKP'(M`<@8VB$B/<6NGW`?EV:KYH.\Y*2RDVABI1\$A<KC=A/.U_%^0,'3&
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M](EJ!FRK344\=EBQ=O85U&RLL\<B<2;B>B`B$"N%\(^:%S+PX,\'Y(QUF(D_
MFK$5-S9%U2HW.UV![A7$5ES#BC(\387^+HHL.+X[2Y9HLD18ID[Q,JJ:#%1!
MH!"""1D$O`^HM^<+GFY\O8'X..)O@VNEWQCD&H9&:.WF*YFOQ5SIC1C,W.A1
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M&!IDRP5<*N"+*'>"43@5980RL6+!K\)O$`G'MX2(S"$;7&]+OK<\2%@MB[U:
MX1TY:*]AI%O.*'Z:SKJ6&+8:*F5#<ZY[X1;!V4'"R1E1PLQ6*><(W$"9`LI7
M,@P53M;RDU*H(R!;/;9?Q3K'E(S`>TX^*\.Q:/;?&UO#N82LJ[+.#-W24U6F
M;@R*0'WTB1"ICP6Y9EWUZB[3D29FJE8,QA;@;N<ESK=&>IS2/R:-924C:]5:
M[-UJ9JH66!C.;&<DV\@VA$US\T=%`FB15K:.#SB`?8\A*1'Y4FG,='7*BVA_
M'-LI3\1,24H&)F5?O5D\H5CI^0)MI)-LQ)*6IHB+5=-PN<Y_RNL?9HD0I`YX
M-;\XKMDBYN:B[SWUR-C3+2T59+G<!:3EVH7%%:\K.)!5^9LZ/75Y'%#V+AD@
M9(%9HN&*:8-BH((F`D5Z6:RM4T1<]<36)K!F?'E=J5;>13&0B,V</&2'"TPH
MY2:GA<2YTQ]DVP-4C-6[I09%Y!U1PDT*)03,Y.0#F(41,!9!@O'-YYH[.-=H
MN8*K0<G4Y:!RY@_)+1UC"QR,T%0K/$E>,XXOO\]>ZI+(UYX_AZEDRGX[0+/-
MN94%.=0!VDDITA7=Q!;7@O2C'_#OF5+&>>DG][@<#97S_FUYF%>1P\EXZ16.
MDCQ=!KI(1E(6:%J0VV8G(2A\Y+2*C!B55[(KF32`"%,?*U)$5*<M8%R=<L'4
MK'<=DM:?R#56=J3>9,G#N:O,S$M,X7RGCME84SUL'"T-*DG;NT<"=L<ID$DC
MG3-SA2`)-U:ZB>%;*U=G*1%5?(2=?QE#Y&LSZP106F[2LX3&2!86^8]K\`K)
M.'"2CZ/S%&NC2!72WRR"E%VQ5C$3003PLQ'KK4T=P?<1<7BRAP'CJ6Q7NJYK
M)?7:MQRW8G='D@"L,:_(W*5AJGC^G3DHI-2B+F83@1D2EC)-R+LCYPJ91/1(
MB*E$UPQY'QRTS%.5)\R8UR<M>8;\[@JS.9&7D+TVR3F;"N39>&DHRM0TO.PS
M^9IE-L-8<.(A!^[;H2!7#5,YE5$2Y6(K1-)X0^)W)-2H3.Z24=3J5/8=R1C^
MRPLC<[:]LS.D9!J.5XJ-H=TCI:'<3=W"-L=OB)-LY5DX)1HQ9)M7+`7;<#AA
M9)`724CPPYM6K5%B*]8XJH(05BK3E&O1M\N"T;0T(S%&&*6RLL'(][FSBV/*
M/.4"<.RB7B35G))3QE5U4E0.4Q(C=5A9.%+-#:$OR=3L41+NLE2<Z_OD39KS
M<W*<^BOGJR7BM)P$G,-;''TJ2KN-IQ*-:*IQKN/;=&*W,Q722;'1RL1"G.+^
M'7+U>PUFBB7VS05HN65<.4^MK6QQ,2DJN\OS+!K/%-D5L3IY"LUW[`TG!-GB
M<@!.>>)NU`.V1,D`*$B(Q6@);@4S7$5N_P!0I5]BVM%?1O#Y&4FIPUF?T^:1
MJM!:9;=WO&3ZVJT^T-H:J1UXR0E+5I=&/=*M6C1-B9-,&Z*NL+,0MFMN$[B`
M0R56)%?-KR5Q;&WVHN)RL3%FL3J=?X^C4F.5;$4LA'Q\,Q=7!_Q$P#-$BAT$
M68TIR]9E3245`A21"E62,!YDMN2,HHPZ-*CJ#D"^XRRDRO![7+H7*"F\7T&%
MAX^!;U-"JG:B:4M58:&&2++IF;,%UC%1.L0A396+%@5.%W+U+;8A@<6SK4(-
M*&Q@PRX[L64\BK2+6PU+*&/,A76Z0AI1O:'=O?WN/K#^-6;N'$84W2A.H<Q%
MUR:)$;JD/!G4LF5JTYO-?FD^HB5:HUXMKF)?(2R&1+E`6#*+FY7QE6[[$0B-
M84G&,[$<ZG"$=P:I4DRMGKGFC`F0KO71831%PQQO<'ZO&"PPY7C6IU1FV-[Y
M8<B,KO!.UV=XHEX:8VN,/B^_T%1-%1L:RT?(DI'20$7.DBJW053,(@<2B608
M+CFJ<!O$^V0PK3;K*X;G8>!L?!ADW+638V<L3"Q.;SPG6.P7J6B:/0QI(1PQ
MV3+6LT1!ZO+,AC8UR\(#94_-:PLQ"F7!!P5\6_#SDCB%N65LO8JGVW%/6YF\
M79QCBMS\#,8^X@Y6ZW*:3EX\LV^E(_(D>QK-V)&)RBA(`X,Z]&-@CP*0ZFB$
M@A=13G#'D.>X9KA@O(.7EL^3=LL];D'=GR1`1\&V<U>/MM-F92JO8R$"0;K,
ME(V`=@F(E$5%76Z;84-X,K$;8K0BW!AQ`H.FK4<M+RL%'\1,M=6)HBVJU.QR
M&.T:3B"HXSL5QF7U"MK>;R+CF+QV\8NFZ35-K.)/16,X0,JNF.%F*V=BSAAS
MI4LS5>TW'+QK7B^N2=T?(5E>;LJLP0M59/Z+P\)&YP$8R0(AC>ZSBUN%P!CO
M[`TBG"1A(W,&LK$0H]9.&3-UZB9:IR9*54HFN.\Y-JC9(.^V9>>M\1FK-D/>
MGA)-NPJ<`ZHI&-+CUFC@C:1?J.':Y2E.1(ICCA9B%G+Y@+.\=8[<SQE9VE<Q
M@G!V^:ITFC=KZ]N55EUN&5_A:K5.-J*$3)]]8Z#MK9M8B.PE!<&<G^5M3.2`
ML?*Q$>NH'1L&98ROPREQLK&Q>,*W=.(>Q6BQUG(2%SR2S+A".L+V?84]&`R`
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MR_-UV<@F"N2HF6FIR0;7*XQSJ_76PL^'-*<CY])NS<!5D'K7$MAC>_C`5GR#
M:R<\D@4Z0IFRL1"SF/.%_--:O^/;_,7U,[BKK4F.-#I7.XRD?"8\:+Y\=67'
M31L_33B[,DP:7ZJQZ$J\:IOI!.NIKJBB=%`NB1"]#=%A-$31$T1-$31$T1-$
M31%_)W_K+M[M,E8N#S`K>248TJTR-KN4LU0453Z;92RM;I4$]=@!S(J$@HZP
M/C(;4A,0[DQ@$>IK]#;#:2G9)Q+%W-C52VL8#O-@Y[@/QBUL;=Q>AP-C0V;-
M]L(#UK3]Y=J^=CXG+EYK_@KP%BCA19Q./YNP23+%E9L;:$CI)C1ZI3*N,A.N
MXF,DFR\:M9IMT=$$EW2*Q0%1PN<AU-@Z\ML\P*FSYFBLQ',)=.E,:9KFEQ!F
M/>^#02#&ZT1B`1H:(@*KA\AE?5/F5$7`6PWR3["\:/-I<;W%!Q@><LX+XOB,
MR@ZR2CC/R[KU)9U`UN"<-E[3B2R]]W#T*S$PS20<'2BD$DCG1WDDB;H".T=?
M3,\Y5P'+>1\3F8+3B09^HOP<YP-R<V`%XN(%I)MM*Z==2R*:BFF0V[>NQT[A
M&^IW_K`/_P!3#A?_`.C?#/\`VZ6G538]_P!C5_Z>=_H&+3!_U&9^,?R0O=SS
MC'^-1YI7_/)G_P#L=M^OD^2O^W\Q?],;_IF+DT7O%1^B_I!<5>>X\ZCQ%\$F
M2\7X?X<B5"NR-AH#W)=ON-HK+2V.7J*DR^K\-7XF.>N4V#-)$(5=9TX53554
MYQ$B8I@0XG]/LLR!@N::&HQ+&]8]C)PE,8UQ8!R0YSB0(GQ@``0-),8B%K"Z
M"35,=,GQ(!@`##UUVS1\&9=J_FP<18ZX.,D8VP#E?(5!H-VG<L72*4!DE/9/
MC6EXRC:&3=DT?D&ZV*3EEB-%E4E$VI#[2`444@+Y>KQ;#9^?*FMS-(GUF'R9
MTQC9+#;=E$RY3#$CD-`$0"([NDJJZ;+=7.?4M<^6TD0&\+`/4"JT3$.8D.`;
M/&!>/+.V*.)FPR%'R2SB[E!*<R^>U$U/.Z@D+&:2;1:TA:ZY/-5'#>1(3GQW
M43G.*R8G'6KQ+#'9OI,7RC25%#)$V42QV@/OP==@3!CFD`MT:8"!@L/FRNUL
MG4C',$19W8[G<.\O\_+V?DZV<X;G/&_=YW87>W_%O=YS=^%WMO+LZFW7[$L[
M;HLU?])>P_.>LO\`5SU_/A?/UCY"*C99,B,DR0>I)F$Q"."`<I3"&Z(@`]01
M#5&NPS#\3EB5B$EDZ6TQ`<(@%6Z.OK*!YF44Q\IY$"6F$0HJXQEC]WMZ3481
M?;U><9D-M^#M'7G)^S[)-3[_`(92/]5@7=E9US9(]YQ"I;ZCRKBOX\H]4?+2
M=<JT-#2+AN+19ZQ9IHN%&PJ$5,@*H;3`F91,HB`=40#T-6,$R1E'+E8_$,"P
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M;[-L;S-2X3B\[!L0<&4U<&AA-C1-;&`<=P/:XM!)`C`;L5V<'J6R9QDS#!K]
M'JCC6O*7QQ>;:\ZEP<53"O&_DFO81R14TH%]8FU@M[3&[R.NE:9N89"]XOO<
M\DYKTDQG&:RIE&*XKJIE<'0<M3`4AS7*K*F=]G^9IF*95D/JJ*9>#2UAF`L<
M0[5S9;8.!:80<(`P!:[2%NZEKJ"I,VE:7L.BR-AW"-/W6%>;&<6OF[O-H9TX
M.^(+@3SQ(\0MHIF49^0S)7XW+%8R"\?XPDH`D.[8H2-5AH>O0SU5F^?(HI'$
M#N5%B@O\K*4P>XPIV<\\X3B>#YLHVT4B;3M$EQE.E@30Z\#![G.(B&DG<A9:
MKTKMM=*F2:MEQI;88$6^O:O6OB)D?,K><8M6(.(G(O%[5J/=\>,H=O$F0R[6
ML4V)U'Q<VC;XVM7:H9#B7C@Z<'-K+_+&R"!Q,NLGTA0@$W/G6"R]J&2J>IP6
MBPV9-I9Q=&,ETUH);<+F/ED>,V&DG0#`&,>=(&*4372&2R6'N$C>B"%B..?S
M@/!?D'BO\VP2D\1^,;.PQ-Q12USR59(>>3=4VEUAWC>?KS69G+H4@5=!FO+R
MB20'([.4OLC'$A2B.I<IY/S/19>QSM5%/EOJ*`,E-+8/>\3&N+6L\:,`3H]2
M*S2T=2RGGWV.!=+@!NDQ&YI7C7Y_[.>&,_\`%?C*PX4R=2,L5R%P3'UZ8G:%
M88ZT0C.8/<K3)&BU)6*6<L#O"L'R2ATR*&,0#@!M@\FOI>Q_"<4P?+\^3BDB
M;3SW59<ULQI:XBXP1@8&$05T\(DS9-.X36EKB_01#<7H3PE\>W`;QO<"M6X'
M./FY(8@L^/*]4ZDQM$[9UZ9&V-O0V:+*E9"IF0CIJ1%;M,7'(D;O64H;FE%`
M4$I%VRXI$\=F+*.;<JYLF9KRA*-3(G/>\L:V^6ZPQ?+?+\9S";6N;:!"T.$3
M2J*2KI*LU5(+S7$F$(Z=((W1W1[*YFXJ^"[S,V*>';+5FPCQPR.0LWIU%\.)
M*ZKGBMY/+)W1HJU?,8<M4QK7HMZX<61!NI&HJ/5.A(J.P5,4QDR@'=R_F?:;
MB&-4TC%<*;)PK6#7.U#I4&&()OS7$`-L<;HO&$-U6*>JQ.9.:V;*#94;3=(L
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M<C`;BZ,G$*V4RZU_)[H!]E3[S>^&_,3><8NTMBW$V#>)JG9.@*8-YF:S?+SD
M%*-3A&KF+C95PQM=<N\]"+)QTQ+HM@Z29FJX$X&23,&]N]/[8<\G]HD]3*Z*
MD.*UX]LWR1Q+0#:P?ZO%.<03KAC'%?%'3+*\RE-81;98D[[*.L90]K0L#^F,
M+6::)E64Y^K+3Z"9V[I1BJB9-5,ZR8)"?=V9MBSNUX+ITES01$:F6(C=$0V(
MCW+5MYUKA:7-(]0+5/#1YL".K_$WQ3QW&R$O6.&#@6@[-:\U6A)TXK'C_'C&
MO)'&T=6IINZ9J-QNT`!)D.CKD5,D4C4IRJN"B'V#-VTR1093I<5P1S#B=>T:
ML&#M4&^^ES382QWN8!%KC'0%U:O$@RD9-D$:V9HW8;_!H75W`O1/,.\?^<D.
M'_#O#UQ85VYN*98KPF[R'?K%"08Q=:4BDY!J+J)RK.N^^1^^R8II@@)1`AQ$
MP;.7X[]L.>3^T2>IE=%<@XK7`1O-\D+M?CC\VUYFS@`P2[X@,W8GS3(51&U5
MJF,(:E96ODM:)JP6APLFR9Q;&3NL*Q5Z*R9N7:XG<I[C9LH8-XP`4V?M@SR/
MVB3U,KHK`Q:N)A>'DA1;S/-U\RWG'B%L$!PE\.^1ZYG"BU#RDP,WQ$E2LCQM
M%QTPQA)![CL\K?;H1A-P[N9:G661;(KHIK%,54.4-<7&MHF;<?IC15]412.$
M',EM;+#AO.N`%P[A,.XHJBNK)S+DQ_(W0+(^K#2OZD->*5!-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31%JW.4#:;5A3,-8H[E9E=;'BW(,#3WC9XK'.
M&EIF*E+Q]?<H2")BK,%D)9PB8JQ!`R1@`P#M#1!I7^8%P4Y@Q+P0\3-F/QM<
M'#+B&80<%.X_MN&,F,(]I9<?W5.39G6LB5>N+)W"2,\R/'KLSIOR@F=!T=9%
M8#@0QM5,8D6%?VY>:3S9YHK.%YRMD;@*Q5!8&S;(U&*C<IXZ>UD*!9S4YE*N
M)!H^AZFPF)2G/(!&4.7I+J!$2%4%N1T!3`B4,B"C=>&E?Y\KZ@6^W.\ZW:L0
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MRZY2_%&2CX]0P!UQ#1!;8OY0\X>>8\Q7QIXX?2?%%PS9!GKRM`F;-XV7PI%N
M\GMU1CC)H-:KEZI6!,(T&RSDQ6RJTNQ3(<@*&3(`%UB(4@:X&Q>.WF`ZW9U_
M.+R.9J!`6);%F`\29]O5^,=XH=1G2I6D62(I51G9ELT0BW<_.3"S,4TE2)D6
M.P6<D3$&^P,#2MG^*M^_ZN5A6E<5.5_."4+(3+GZ!E_A8<4RP0YO9OV[+)&1
MBR39\S=%W4DY*NJ1Q545`#D=$3.79NZ!8>2(+TMX$/\`5J)WAJXKL6YYS?GK
M'^7Z-B6:<W"$H<'1IZ*?35RBTU/$5_-NY:6=1H,J_*'3DE4BHG!9TU3(``01
M$,P6"^(@%Y<<.$JUQE_K,5H;H%*XC3\9'$C7G#J5>E0Z`PG*UD)Z_EG3H$R)
M#WO+OG'>`A-P-IA``$=8W5D^(N$,PVSB/\Y3YT++62^%VLS60<KV/*M@NF&8
MJ*=5T'$-1,-+(MZ'*IN[Q(-:FW0A*[7&3O==*$;K/%=A$A45*F+25D0:VW0L
M#YQO!/G-ZS/5+-OG'JK?T+)=6A<<5'(5SE\72[F21JZ4A.MJX4^,I5^T:K1J
M4JY<H]+1345*8^Z8Y4Q`@QW4:6Z&K^QS[Y"E]X(^[![[Q/E*^YQ\DG-]\"\Y
MY>-WR,[FSI//]]/&+Y\=&YSG>9UG<6D.5!?T"ZRM$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1:CS_P#O$9K_`'N_WI,C_OO?O3_4=,_OG_\`R\\-?U-Y
M[19&E?Y2F7OWY:U_BI?JA$_O#_O`?5&O]6/]3O=_]2MS6JFW-U?WR^:._P#I
MNW[_`!$?J2N/^*)]3'U)RW[^7_*_\F_J?LUD*-VG=7G)_JU/[\G$9_B9?O.4
M'_%>_5KZJGWU3?U%]S_SW;H%E^A?U^ZRHU_"E,__`%K<U?X@?[_?$W^._O[?
MO5Y-_5O_`)1^%?SIS^L;JD]KNJ9_ZO)_CS./\07_`!=;W_BZ_OB_J]C[^D_Z
M@>Z_2YO0([1NKUJ_UC3_`!3,/_XJO[_T7_C1_J?]0]R^HG^JWNS\[;-"L,T[
AJ\8O_P#@_P#Y#G_U$_\`PX_O;?WX?_G:QN+;VV[H7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>13
<FILENAME>orpn-20141231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 30-Mar-2015 [11:12:18] {AM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:orpn="http://bioblast-pharma.com/20141231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="orpn-20141231.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2012To01_22_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_23_2012To12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-23</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2014To02_06_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-02-01</xbrli:startDate>

      <xbrli:endDate>2014-02-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_22_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn01_22_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_22_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_22_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_22_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_23_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-23</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_23_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-23</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_23_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-23</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_23_2012To12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-23</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_ElectronicEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">orpn:ElectronicEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_ElectronicEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">orpn:ElectronicEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_NonemployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orpn:NonemployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2013To06_30_2013_PurchaseAgreementMemberorpnAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="orpn:AgreementAxis">orpn:PurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-06-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:RelatedPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2014_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:RelatedPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2012To02_29_2012_InvestmentAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="orpn:AgreementAxis">orpn:InvestmentAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>

      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2012To08_31_2012_InvestmentAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="orpn:AgreementAxis">orpn:InvestmentAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>

      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2014To08_05_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-08-01</xbrli:startDate>

      <xbrli:endDate>2014-08-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_PurchaseAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="orpn:AgreementAxis">orpn:PurchaseAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:RelatedPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:RelatedPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:RelatedPartyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To07_31_2013_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:ConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2012To08_31_2012_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:ConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>

      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2013To08_31_2013_ShareholdersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:ShareholdersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>

      <xbrli:endDate>2013-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2013To09_10_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>

      <xbrli:endDate>2013-09-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_27_2015To02_02_2015_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-27</xbrli:startDate>

      <xbrli:endDate>2015-02-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2015To02_16_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-02-01</xbrli:startDate>

      <xbrli:endDate>2015-02-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_ConsultantOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:ConsultantOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orpn:ConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To12_31_2014_NonemployeeStockOptionMemberusgaapAwardTypeAxis_SecondDecemberTwoThousandFourteenMemberusgaapAwardDateAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001596812</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orpn:NonemployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">orpn:SecondDecemberTwoThousandFourteenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="ILS_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:ILS</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2014To12_31_2014" id="Factid_1">20-F</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2014To12_31_2014" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2014To12_31_2014" id="Factid_3">2014-12-31</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2014To12_31_2014" id="Factid_4">2014</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2014To12_31_2014" id="Factid_5">FY</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P01_01_2014To12_31_2014" id="Factid_6">BIO BLAST PHARMA LTD.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2014To12_31_2014" id="Factid_7">0001596812</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2014To12_31_2014" id="Factid_8">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2014To12_31_2014" id="Factid_9">No</dei:EntityWellKnownSeasonedIssuer>

  <dei:EntityVoluntaryFilers contextRef="P01_01_2014To12_31_2014" id="Factid_10">No</dei:EntityVoluntaryFilers>

  <dei:EntityCurrentReportingStatus contextRef="P01_01_2014To12_31_2014" id="Factid_11">Yes</dei:EntityCurrentReportingStatus>

  <dei:EntityFilerCategory contextRef="P01_01_2014To12_31_2014" id="Factid_12">Non-accelerated Filer</dei:EntityFilerCategory>

  <dei:TradingSymbol contextRef="P01_01_2014To12_31_2014" id="Factid_13">ORPN</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn12_31_2014" id="Factid_14" unitRef="shares" decimals="INF">14230480</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2013" id="Factid_15" unitRef="USD" decimals="-3">270000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2014" id="Factid_16" unitRef="USD" decimals="-3">10583000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <orpn:ReceivablesAndPrepaidExpensesCurrent contextRef="PAsOn12_31_2013" id="Factid_17" unitRef="USD" decimals="-3">29000</orpn:ReceivablesAndPrepaidExpensesCurrent>

  <orpn:ReceivablesAndPrepaidExpensesCurrent contextRef="PAsOn12_31_2014" id="Factid_18" unitRef="USD" decimals="-3">274000</orpn:ReceivablesAndPrepaidExpensesCurrent>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To12_31_2012" id="Factid_19" unitRef="USD" decimals="-3">-229000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To12_31_2013" id="Factid_20" unitRef="USD" decimals="-3">-1145000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn01_22_2012" id="Factid_21" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn01_22_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_22" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn01_22_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_23" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn01_22_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_24" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn01_22_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_25" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn01_22_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_26" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn01_22_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_27" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:Depreciation contextRef="P01_01_2012To12_31_2012" id="Factid_28" unitRef="USD" decimals="-3">0</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P01_01_2013To12_31_2013" id="Factid_29" unitRef="USD" decimals="-3">0</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P01_01_2014To12_31_2014" id="Factid_30" unitRef="USD" decimals="-3">5000</us-gaap:Depreciation>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2013To12_31_2013" id="Factid_31" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_32" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_33" unitRef="USD" decimals="-3">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_34" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2013To12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_35" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To12_31_2012" id="Factid_36" unitRef="USD" decimals="-3">9000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To12_31_2013" id="Factid_37" unitRef="USD" decimals="-3">254000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2014To12_31_2014" id="Factid_38" unitRef="USD" decimals="-3">736000</us-gaap:ShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_39" unitRef="shares" decimals="INF">566357</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_40" unitRef="shares" decimals="INF">-566357</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="P01_01_2013To12_31_2013" id="Factid_41" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_42" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_43" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_44" unitRef="USD" decimals="-3">-26000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="P01_01_2013To12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_45" unitRef="USD" decimals="-3">26000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2014To12_31_2014" id="Factid_46" unitRef="USD" decimals="-3">31405000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_47" unitRef="USD" decimals="-3">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_48" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2014To12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_49" unitRef="USD" decimals="-3">31396000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2014To12_31_2014_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_50" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_51" unitRef="shares" decimals="INF">3200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_52" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2013To12_31_2013" id="Factid_53" unitRef="USD" decimals="-3">254000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_54" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_55" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_56" unitRef="USD" decimals="-3">254000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2013To12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_57" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2014To12_31_2014" id="Factid_58" unitRef="USD" decimals="-3">736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_59" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_60" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2014To12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_61" unitRef="USD" decimals="-3">736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2014To12_31_2014_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_62" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_23_2012To12_31_2012" id="Factid_63" unitRef="USD" decimals="-3">9000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_23_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_64" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_23_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_65" unitRef="USD" decimals="-3">9000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_23_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_66" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_67" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_68" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_69" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_70" unitRef="USD" decimals="-3">-1145000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_71" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_72" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2014To12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_73" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2014To12_31_2014_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_74" unitRef="USD" decimals="-3">-7022000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_23_2012To12_31_2012" id="Factid_75" unitRef="USD" decimals="-3">-229000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_23_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_76" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_23_2012To12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_77" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_23_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_78" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_23_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_79" unitRef="USD" decimals="-3">-229000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2013" id="Factid_80" unitRef="USD" decimals="-3">175000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_81" unitRef="USD" decimals="-3">24000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_82" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_83" unitRef="USD" decimals="-3">1551000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_84" unitRef="USD" decimals="-3">-1400000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014" id="Factid_85" unitRef="USD" decimals="-3">30674000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_86" unitRef="USD" decimals="-3">39000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_87" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_88" unitRef="USD" decimals="-3">39057000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2014_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_89" unitRef="USD" decimals="-3">-8422000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012" id="Factid_90" unitRef="USD" decimals="-3">75000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_91" unitRef="USD" decimals="-3">20000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_92" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_93" unitRef="USD" decimals="-3">283000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_94" unitRef="USD" decimals="-3">-229000</us-gaap:StockholdersEquity>

  <orpn:IncreaseDecreaseInReceivablesAndPrepaidExpenses contextRef="P01_01_2012To12_31_2012" id="Factid_95" unitRef="USD" decimals="-3">10000</orpn:IncreaseDecreaseInReceivablesAndPrepaidExpenses>

  <orpn:IncreaseDecreaseInReceivablesAndPrepaidExpenses contextRef="P01_01_2013To12_31_2013" id="Factid_96" unitRef="USD" decimals="-3">19000</orpn:IncreaseDecreaseInReceivablesAndPrepaidExpenses>

  <orpn:IncreaseDecreaseInReceivablesAndPrepaidExpenses contextRef="P01_01_2014To12_31_2014" id="Factid_97" unitRef="USD" decimals="-3">245000</orpn:IncreaseDecreaseInReceivablesAndPrepaidExpenses>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_98" unitRef="shares" decimals="INF">9182867</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_99" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_100" unitRef="shares" decimals="INF">14230480</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_101" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_102" unitRef="shares" decimals="INF">7551427</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_103" unitRef="shares" decimals="INF">566357</us-gaap:SharesOutstanding>

  <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="P01_01_2012To12_31_2012" id="Factid_104" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInDepositOtherAssets>

  <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="P01_01_2013To12_31_2013" id="Factid_105" unitRef="USD" decimals="-3">5000</us-gaap:IncreaseDecreaseInDepositOtherAssets>

  <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="P01_01_2014To12_31_2014" id="Factid_106" unitRef="USD" decimals="-3">4000</us-gaap:IncreaseDecreaseInDepositOtherAssets>

  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="P01_01_2012To12_31_2012" id="Factid_107" unitRef="USD" decimals="-3">74000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>

  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="P01_01_2013To12_31_2013" id="Factid_108" unitRef="USD" decimals="-3">-28000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>

  <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="P01_01_2014To12_31_2014" id="Factid_109" unitRef="USD" decimals="-3">1239000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="P01_01_2012To12_31_2012" id="Factid_110" unitRef="USD" decimals="-3">7000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="P01_01_2013To12_31_2013" id="Factid_111" unitRef="USD" decimals="-3">78000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="P01_01_2014To12_31_2014" id="Factid_112" unitRef="USD" decimals="-3">910000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2012To12_31_2012" id="Factid_113" unitRef="USD" decimals="-3">-149000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2013To12_31_2013" id="Factid_114" unitRef="USD" decimals="-3">-865000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2014To12_31_2014" id="Factid_115" unitRef="USD" decimals="-3">-4409000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2012To12_31_2012" id="Factid_116" unitRef="USD" decimals="-3">140000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2013To12_31_2013" id="Factid_117" unitRef="USD" decimals="-3">732000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2014To12_31_2014" id="Factid_118" unitRef="USD" decimals="-3">4441000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2012To12_31_2012" id="Factid_119" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2013To12_31_2013" id="Factid_120" unitRef="USD" decimals="-3">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2014To12_31_2014" id="Factid_121" unitRef="USD" decimals="-3">63000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2012To12_31_2012" id="Factid_122" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2013To12_31_2013" id="Factid_123" unitRef="USD" decimals="-3">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2014To12_31_2014" id="Factid_124" unitRef="USD" decimals="-3">-22063000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2012To12_31_2012" id="Factid_125" unitRef="USD" decimals="-3">86000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2013To12_31_2013" id="Factid_126" unitRef="USD" decimals="-3">416000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2014To12_31_2014" id="Factid_127" unitRef="USD" decimals="-3">2639000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2012To12_31_2012" id="Factid_128" unitRef="USD" decimals="-3">-226000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2013To12_31_2013" id="Factid_129" unitRef="USD" decimals="-3">-1148000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2014To12_31_2014" id="Factid_130" unitRef="USD" decimals="-3">-7080000</us-gaap:OperatingIncomeLoss>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P01_01_2012To12_31_2012" id="Factid_131" unitRef="USD" decimals="-3">295000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P01_01_2013To12_31_2013" id="Factid_132" unitRef="USD" decimals="-3">991000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P01_01_2014To12_31_2014" id="Factid_133" unitRef="USD" decimals="-3">36785000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2012To12_31_2012" id="Factid_134" unitRef="USD" decimals="-3">295000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2013To12_31_2013" id="Factid_135" unitRef="USD" decimals="-3">991000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2014To12_31_2014" id="Factid_136" unitRef="USD" decimals="-3">36785000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2012To12_31_2012" id="Factid_137" unitRef="USD" decimals="-3">146000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2013To12_31_2013" id="Factid_138" unitRef="USD" decimals="-3">124000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2014To12_31_2014" id="Factid_139" unitRef="USD" decimals="-3">10313000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2011" id="Factid_140" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2012" id="Factid_141" unitRef="USD" decimals="-3">146000</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2012To12_31_2012" id="Factid_142" unitRef="USD" decimals="-3">-3000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2013To12_31_2013" id="Factid_143" unitRef="USD" decimals="-3">3000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2014To12_31_2014" id="Factid_144" unitRef="USD" decimals="-3">58000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2014To12_31_2014" id="Factid_145" unitRef="USD" decimals="-3">-7022000</us-gaap:NetIncomeLoss>

  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="P01_01_2012To12_31_2012" id="Factid_146" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>

  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="P01_01_2013To12_31_2013" id="Factid_147" unitRef="USD" decimals="-3">26000</us-gaap:PreferredStockDividendsIncomeStatementImpact>

  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="P01_01_2014To12_31_2014" id="Factid_148" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>

  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="P01_01_2012To12_31_2012" id="Factid_149" unitRef="USD" decimals="-3">-229000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>

  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="P01_01_2013To12_31_2013" id="Factid_150" unitRef="USD" decimals="-3">-1171000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>

  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="P01_01_2014To12_31_2014" id="Factid_151" unitRef="USD" decimals="-3">-7022000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2012To12_31_2012" id="Factid_152" unitRef="USD_per_Share" decimals="2">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2013To12_31_2013" id="Factid_153" unitRef="USD_per_Share" decimals="2">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2014To12_31_2014" id="Factid_154" unitRef="USD_per_Share" decimals="2">-0.57</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2012To12_31_2012" id="Factid_155" unitRef="shares" decimals="INF">7551427</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2013To12_31_2013" id="Factid_156" unitRef="shares" decimals="INF">8423018</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2014To12_31_2014" id="Factid_157" unitRef="shares" decimals="INF">12259600</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2013" id="Factid_158" unitRef="USD" decimals="-3">299000</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2014" id="Factid_159" unitRef="USD" decimals="-3">32885000</us-gaap:AssetsCurrent>

  <us-gaap:DepositsAssetsNoncurrent contextRef="PAsOn12_31_2013" id="Factid_160" unitRef="USD" decimals="-3">5000</us-gaap:DepositsAssetsNoncurrent>

  <us-gaap:DepositsAssetsNoncurrent contextRef="PAsOn12_31_2014" id="Factid_161" unitRef="USD" decimals="-3">9000</us-gaap:DepositsAssetsNoncurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2013" id="Factid_162" unitRef="USD" decimals="-3">2000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2014" id="Factid_163" unitRef="USD" decimals="-3">60000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:AssetsNoncurrent contextRef="PAsOn12_31_2013" id="Factid_164" unitRef="USD" decimals="-3">7000</us-gaap:AssetsNoncurrent>

  <us-gaap:AssetsNoncurrent contextRef="PAsOn12_31_2014" id="Factid_165" unitRef="USD" decimals="-3">69000</us-gaap:AssetsNoncurrent>

  <us-gaap:Assets contextRef="PAsOn12_31_2013" id="Factid_166" unitRef="USD" decimals="-3">306000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2014" id="Factid_167" unitRef="USD" decimals="-3">32954000</us-gaap:Assets>

  <us-gaap:AccountsPayableTradeCurrent contextRef="PAsOn12_31_2013" id="Factid_168" unitRef="USD" decimals="-3">46000</us-gaap:AccountsPayableTradeCurrent>

  <us-gaap:AccountsPayableTradeCurrent contextRef="PAsOn12_31_2014" id="Factid_169" unitRef="USD" decimals="-3">1285000</us-gaap:AccountsPayableTradeCurrent>

  <us-gaap:AccountsPayableOtherCurrent contextRef="PAsOn12_31_2013" id="Factid_170" unitRef="USD" decimals="-3">85000</us-gaap:AccountsPayableOtherCurrent>

  <us-gaap:AccountsPayableOtherCurrent contextRef="PAsOn12_31_2014" id="Factid_171" unitRef="USD" decimals="-3">995000</us-gaap:AccountsPayableOtherCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2013" id="Factid_172" unitRef="USD" decimals="-3">131000</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2014" id="Factid_173" unitRef="USD" decimals="-3">2280000</us-gaap:LiabilitiesCurrent>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2013" id="Factid_174" unitRef="USD" decimals="-3">24000</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2014" id="Factid_175" unitRef="USD" decimals="-3">39000</us-gaap:CommonStockValue>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2013" id="Factid_176" unitRef="USD" decimals="-3">1551000</us-gaap:AdditionalPaidInCapital>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2014" id="Factid_177" unitRef="USD" decimals="-3">39057000</us-gaap:AdditionalPaidInCapital>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2013" id="Factid_178" unitRef="USD" decimals="-3">-1400000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2014" id="Factid_179" unitRef="USD" decimals="-3">-8422000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2013" id="Factid_180" unitRef="USD" decimals="-3">306000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2014" id="Factid_181" unitRef="USD" decimals="-3">32954000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2013" id="Factid_182" unitRef="ILS_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2014" id="Factid_183" unitRef="ILS_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2013" id="Factid_184" unitRef="shares" decimals="INF">16613139</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2014" id="Factid_185" unitRef="shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2013" id="Factid_186" unitRef="shares" decimals="INF">9182867</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2014" id="Factid_187" unitRef="shares" decimals="INF">14230480</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2013" id="Factid_188" unitRef="shares" decimals="INF">9182867</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2014" id="Factid_189" unitRef="shares" decimals="INF">14230480</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:EquityIssuancePerShareAmount contextRef="P01_01_2013To12_31_2013" id="Factid_190" unitRef="USD_per_Share" decimals="2">0.95</us-gaap:EquityIssuancePerShareAmount>

  <us-gaap:EquityIssuancePerShareAmount contextRef="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_191" unitRef="USD_per_Share" xsi:nil="true" />

  <us-gaap:EquityIssuancePerShareAmount contextRef="P01_01_2014To12_31_2014" id="Factid_192" unitRef="USD_per_Share" decimals="2">0.95</us-gaap:EquityIssuancePerShareAmount>

  <us-gaap:EquityIssuancePerShareAmount contextRef="P01_01_2014To12_31_2014_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_193" unitRef="USD_per_Share" decimals="2">6.07</us-gaap:EquityIssuancePerShareAmount>

  <us-gaap:EquityIssuancePerShareAmount contextRef="P01_01_2014To12_31_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_194" unitRef="USD_per_Share" decimals="0">11</us-gaap:EquityIssuancePerShareAmount>

  <us-gaap:EquityIssuancePerShareAmount contextRef="P01_23_2012To12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_195" unitRef="USD_per_Share" decimals="2">0.53</us-gaap:EquityIssuancePerShareAmount>

  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_196">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 0.85in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;NOTE 1:-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;GENERAL&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;BioBlast Pharma Ltd. (the "Company&amp;#8221;) was incorporated in Israel and commenced its operations on January 22, 2012. The Company is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is rapidly building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The Company's platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology. The Company seeks to identify therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism. The Company's objective is to conduct additional clinical trials for its drugs (the "Drugs") and, if those trials are successful, seek marketing approval from the U.S. Food and Drug Administration (the "FDA") and other worldwide regulatory bodies.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;b.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;The Company is engaged in the research and development of products in the biopharmaceutical field, has not generated revenue from the sale of any product, and does not expect to generate significant revenue unless and until the obtaining of marketing approval, and commercializing its Drugs. The Company has incurred losses in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7,022&lt;/font&gt; during the year ended December 31, 2014.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;c.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; During August 2014, the Company completed an Initial Public Offering ("IPO") in United States in which it issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,200,000&lt;/font&gt; Ordinary shares in consideration of approximately&amp;#160;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;31,405&lt;/font&gt;, net and its Ordinary shares began trading on the "NASDAQ Capital Market".&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>

  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_197">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 0.85in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;NOTE 2:-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.79in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP").&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Use of estimates:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; BORDER-TOP-COLOR: #000000; WIDTH: 0.75in; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;b.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;New accounting pronouncements:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In June 2014 the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 10-2014 ("ASU 10-2014") regarding development stage entities. The ASU removes the definition of development stage entity, as was previously defined under U.S. GAAP, from the accounting standards codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of income, cash flow and stockholders' equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments to ASU 10-2014 are effective for annual reporting periods beginning after December 15, 2014. The Company has applied the ASU in these financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In 2014, the FASB issued ASU 15-2014, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management&amp;#8217;s responsibility to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is currently evaluating the effect, if any, that the adoption of this guidance will have on the Company&amp;#8217;s financial statements.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;c.&lt;/font&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Financial statements in U.S. dollars:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company finances its operation in U.S. dollars. The majority of the Company's operations are currently conducted in Israel, a significant part of the Company's expenses are denominated and determined in U.S. dollars. The Company's management believes that the dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, the functional currency of the Company is the U.S.&amp;#160;dollar.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company's transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been remeasured to U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830, "Foreign Currency Matters", of the FASB. All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; d.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Cash equivalents:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; e.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; Short-term bank deposits:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Short-term bank deposits are deposits with maturities of more than three months but less than one year.&lt;/font&gt; Short&amp;#150;term bank deposits are presented at their cost, including accrued interest, which approximates fair value. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;As of December 31, 2014, the Company's bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.66%.&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;f.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Property and equipment, net:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Electronic equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company's property and equipment are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment," whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to&amp;#160;be recognized is measured by the amount by which the carrying amount of the assets exceeds&amp;#160;the fair value of the assets.&amp;#160;Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2014, 2013 and 2012 no impairment losses have been identified.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;g.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Long-term deposits:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Long-term deposits include long-term deposits for motor vehicles under operating leases, presented at their cost.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;h.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Research and development costs:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Research and development costs are expensed as incurred. Those expenses includes payments to third party clinical consultants, expenses related to conducting clinical trials, salaries and related personnel expenses, travel expenses, and share based &lt;font style="BACKGROUND-COLOR: transparent"&gt;compensation expenses related to research and development employees.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;i.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Income taxes:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company accounts for income taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2014 and 2013 the Company has not recorded a liability for uncertain tax positions.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;j.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Concentrations of credit risk:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Cash and cash equivalents are invested in major banks in Israel. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;k.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fair value of financial instruments:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company has no financial instruments that are measured at fair value.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The carrying amounts of cash and cash equivalents, &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 10pt"&gt; short-term&amp;#160;&lt;/font&gt; bank deposits, accounts receivable and accounts payable, approximate their fair value due to the short-term maturities of such instruments.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;l.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Basic and diluted loss per share:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Basic net loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year plus dilutive potential equivalent Ordinary shares considered outstanding during the year, in accordance with ASC 260, "Earnings per Share."&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;For the years ended December&amp;#160;31, 2014, 2013 and 2012, all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;m.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Accounting for stock-based compensation:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0px 0in 0.4in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation" ("ASC 718") that requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the option award is recognized as an expense over the requisite service periods in the Company's statements of operations based on the accelerated method.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company selected the Black-Scholes-Merton ("Black-Scholes") option-pricing model as the fair value method for of its stock-options awards. The option-pricing model requires a number of assumptions as noted below:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt"&gt;- The expected dividend yield assumption is based on the Company's historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Volatility&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt"&gt;- Since the Company's shares started trading on NASDAQ in July 2014, sufficient quoted prices of the Company's share are unavailable. Due to insufficient historical data for the Company, the expected volatility determination was based on similar companies' stock volatility.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt"&gt;- The risk free interest rate is based on the yield of U.S. Treasury bonds with equivalent terms.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Expected term&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt"&gt;- ASC 718 provides the factors to consider when estimating the expected term of an option: an option's expected term must at least include the vesting period and the employees' historical exercise and post-vesting employment termination behavior for similar grants. It also determines that if the amount of past exercise data is limited, that data may not represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior. In that circumstance, it may be appropriate to consider external data or the SEC staff's "simplified" method for the expected term. Accordingly, the Company used the "simplified" method, meaning the expected life can be set as the average of the vesting period for each vested tranche of options and the contractual term for those options.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <us-gaap:UseOfEstimates contextRef="P01_01_2014To12_31_2014" id="Factid_198">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Use of estimates:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_199">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; BORDER-TOP-COLOR: #000000; WIDTH: 0.75in; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;b.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;New accounting pronouncements:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In June 2014 the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 10-2014 ("ASU 10-2014") regarding development stage entities. The ASU removes the definition of development stage entity, as was previously defined under U.S. GAAP, from the accounting standards codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of income, cash flow and stockholders' equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments to ASU 10-2014 are effective for annual reporting periods beginning after December 15, 2014. The Company has applied the ASU in these financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;In 2014, the FASB issued ASU 15-2014, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management&amp;#8217;s responsibility to assess an entity&amp;#8217;s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is currently evaluating the effect, if any, that the adoption of this guidance will have on the Company&amp;#8217;s financial statements.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <orpn:FinancialStatementsDisclosurePolicyTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_200">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;c.&lt;/font&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Financial statements in U.S. dollars:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company finances its operation in U.S. dollars. The majority of the Company's operations are currently conducted in Israel, a significant part of the Company's expenses are denominated and determined in U.S. dollars. The Company's management believes that the dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, the functional currency of the Company is the U.S.&amp;#160;dollar.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company's transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been remeasured to U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830, "Foreign Currency Matters", of the FASB. All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</orpn:FinancialStatementsDisclosurePolicyTextBlock>

  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_201">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; d.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Cash equivalents:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>

  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_202">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;f.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Property and equipment, net:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Electronic equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company's property and equipment are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment," whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to&amp;#160;be recognized is measured by the amount by which the carrying amount of the assets exceeds&amp;#160;the fair value of the assets.&amp;#160;Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2014, 2013 and 2012 no impairment losses have been identified.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>

  <orpn:LongTermDepositsPolicyTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_203">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;g.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Long-term deposits:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Long-term deposits include long-term deposits for motor vehicles under operating leases, presented at their cost.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</orpn:LongTermDepositsPolicyTextBlock>

  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2014To12_31_2014" id="Factid_204">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;h.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Research and development costs:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Research and development costs are expensed as incurred. Those expenses includes payments to third party clinical consultants, expenses related to conducting clinical trials, salaries and related personnel expenses, travel expenses, and share based &lt;font style="BACKGROUND-COLOR: transparent"&gt;compensation expenses related to research and development employees.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_205">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;i.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Income taxes:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company accounts for income taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2014 and 2013 the Company has not recorded a liability for uncertain tax positions.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>

  <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2014To12_31_2014" id="Factid_206">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;j.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Concentrations of credit risk:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Cash and cash equivalents are invested in major banks in Israel. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>

  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2014To12_31_2014" id="Factid_207">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;k.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fair value of financial instruments:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company has no financial instruments that are measured at fair value.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The carrying amounts of cash and cash equivalents, &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 10pt"&gt; short-term&amp;#160;&lt;/font&gt; bank deposits, accounts receivable and accounts payable, approximate their fair value due to the short-term maturities of such instruments.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_208">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;l.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Basic and diluted loss per share:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Basic net loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year plus dilutive potential equivalent Ordinary shares considered outstanding during the year, in accordance with ASC 260, "Earnings per Share."&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;For the years ended December&amp;#160;31, 2014, 2013 and 2012, all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2014To12_31_2014" id="Factid_209">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;m.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Accounting for stock-based compensation:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0px 0in 0.4in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation" ("ASC 718") that requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the option award is recognized as an expense over the requisite service periods in the Company's statements of operations based on the accelerated method.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company selected the Black-Scholes-Merton ("Black-Scholes") option-pricing model as the fair value method for of its stock-options awards. The option-pricing model requires a number of assumptions as noted below:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt"&gt;- The expected dividend yield assumption is based on the Company's historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Volatility&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt"&gt;- Since the Company's shares started trading on NASDAQ in July 2014, sufficient quoted prices of the Company's share are unavailable. Due to insufficient historical data for the Company, the expected volatility determination was based on similar companies' stock volatility.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt"&gt;- The risk free interest rate is based on the yield of U.S. Treasury bonds with equivalent terms.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Expected term&lt;/font&gt;&lt;/i&gt; &lt;font style="FONT-SIZE: 10pt"&gt;- ASC 718 provides the factors to consider when estimating the expected term of an option: an option's expected term must at least include the vesting period and the employees' historical exercise and post-vesting employment termination behavior for similar grants. It also determines that if the amount of past exercise data is limited, that data may not represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior. In that circumstance, it may be appropriate to consider external data or the SEC staff's "simplified" method for the expected term. Accordingly, the Company used the "simplified" method, meaning the expected life can be set as the average of the vesting period for each vested tranche of options and the contractual term for those options.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <orpn:PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_210">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Electronic equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;15&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</orpn:PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock>

  <orpn:PropertyPlantAndEquipmentStraightLinePercentage contextRef="PAsOn12_31_2014_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_211" unitRef="pure" decimals="2">0.33</orpn:PropertyPlantAndEquipmentStraightLinePercentage>

  <orpn:PropertyPlantAndEquipmentStraightLinePercentage contextRef="PAsOn12_31_2014_ElectronicEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_212" unitRef="pure" decimals="2">0.15</orpn:PropertyPlantAndEquipmentStraightLinePercentage>

  <orpn:PropertyPlantAndEquipmentStraightLinePercentage contextRef="PAsOn12_31_2014_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_213" unitRef="pure" decimals="2">0.06</orpn:PropertyPlantAndEquipmentStraightLinePercentage>

  <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="PAsOn12_31_2013" id="Factid_214" unitRef="USD" decimals="-3">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>

  <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="PAsOn12_31_2014" id="Factid_215" unitRef="USD" decimals="-3">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>

  <orpn:ReceivablesAndPrepaidExpensesDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_216">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;NOTE 3:-&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; RECEIVABLES AND PREPAID EXPENSES&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Government authorities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;93&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;26&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;181&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;274&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</orpn:ReceivablesAndPrepaidExpensesDisclosureTextBlock>

  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_217">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;NOTE 4:-&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;PROPERTY AND EQUIPMENT, NET&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Cost:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Electronic equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;32&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;65&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Accumulated depreciation:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Electronic equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Depreciated cost&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;60&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.85in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; *)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Represents an amount lower than $&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.85in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Depreciation &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; expenses for the years ended December 31, 2014, 2013 and 2012 were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;, less&lt;/font&gt;&amp;#160;than $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;,&amp;#160;respectively.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>

  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_218">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Cost:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Electronic equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;32&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;65&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Accumulated depreciation:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Computers and software&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Electronic equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Office furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Depreciated cost&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;60&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.85in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; *)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Represents an amount lower than $&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2013_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_219" unitRef="USD" decimals="-3">2000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2013_ElectronicEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_220" unitRef="USD" decimals="-3">0</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2013_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_221" unitRef="USD" decimals="-3">0</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2013" id="Factid_222" unitRef="USD" decimals="-3">2000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2014_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_223" unitRef="USD" decimals="-3">19000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2014_ElectronicEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_224" unitRef="USD" decimals="-3">14000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2014_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_225" unitRef="USD" decimals="-3">32000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2014" id="Factid_226" unitRef="USD" decimals="-3">65000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2013_ElectronicEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_227" unitRef="USD" decimals="-3">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2013_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_228" unitRef="USD" decimals="-3">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2013_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_229" unitRef="USD" decimals="-3">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2014_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_230" unitRef="USD" decimals="-3">-3000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2014_ElectronicEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_231" unitRef="USD" decimals="-3">-1000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2014_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_232" unitRef="USD" decimals="-3">-1000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <orpn:ReceivablesAndPrepaidExpensesDisclosureTableTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_233">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Government authorities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;93&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;26&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Prepaid expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;181&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;274&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</orpn:ReceivablesAndPrepaidExpensesDisclosureTableTextBlock>

  <us-gaap:ReceivablesNetCurrent contextRef="PAsOn12_31_2013" id="Factid_234" unitRef="USD" decimals="-3">26000</us-gaap:ReceivablesNetCurrent>

  <us-gaap:ReceivablesNetCurrent contextRef="PAsOn12_31_2014" id="Factid_235" unitRef="USD" decimals="-3">93000</us-gaap:ReceivablesNetCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2013" id="Factid_236" unitRef="USD" decimals="-3">3000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:PrepaidExpenseCurrent contextRef="PAsOn12_31_2014" id="Factid_237" unitRef="USD" decimals="-3">181000</us-gaap:PrepaidExpenseCurrent>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_238">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 5:-&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'"&gt;&lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;OTHER ACCOUNTS PAYABLE&lt;/font&gt;&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160;&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Employees and payroll accruals&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;235&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;26&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;760&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;59&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;995&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;85&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>

  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_239">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Employees and payroll accruals&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;235&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;26&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;Accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;760&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;59&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;995&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;85&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>

  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="PAsOn12_31_2013" id="Factid_240" unitRef="USD" decimals="-3">26000</us-gaap:EmployeeRelatedLiabilitiesCurrent>

  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="PAsOn12_31_2014" id="Factid_241" unitRef="USD" decimals="-3">235000</us-gaap:EmployeeRelatedLiabilitiesCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn12_31_2013" id="Factid_242" unitRef="USD" decimals="-3">59000</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn12_31_2014" id="Factid_243" unitRef="USD" decimals="-3">760000</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_244">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 0.85in"&gt; &lt;div&gt;NOTE 6:-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;INCOME TAXES&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.85in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;a.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;Tax laws applicable to the Company:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; Taxable income of Israeli companies is subject to tax at the rate&lt;/font&gt; of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25&lt;/font&gt;&lt;/font&gt;% in 2012 and 2013&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; and a rate of&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 26.5&lt;/font&gt;% in 2014 and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; afterwards&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;b.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Net operating losses carry forward:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt;The Company has accumulated losses for tax purposes as of December&amp;#160;31, 2014 in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;684&lt;/font&gt;, which may be carried forward and offset against taxable income in the future for an indefinite period.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'"&gt; &lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;c.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Deferred income taxes:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160;&amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; Significant components of the Company's deferred tax assets are as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Operating loss carry forward&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;181&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;166&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;923&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;142&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Issuance expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;671&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Net deferred tax asset before valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,791&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;312&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,791)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(312)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt; Management currently believes that since the Company has a history of losses it is more likely than not that the deferred tax regarding the loss carry forward and other temporary differences will not be realized in the foreseeable future.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;d.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;No liability for uncertain tax positions was recorded as of December 31, 2014 and 2013.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 18pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;e.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowances in respect of deferred taxes due to the uncertainty of the realization of such deferred&lt;/font&gt; taxes.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>

  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_245">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;Significant components of the Company's deferred tax assets are as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Operating loss carry forward&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;181&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;166&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;923&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;142&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Issuance expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;671&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Net deferred tax asset before valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,791&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;312&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,791)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(312)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P01_01_2012To12_31_2012" id="Factid_246" unitRef="pure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P01_01_2013To12_31_2013" id="Factid_247" unitRef="pure" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P01_01_2014To12_31_2014" id="Factid_248" unitRef="pure" decimals="3">0.265</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2014" id="Factid_249" unitRef="USD" decimals="-3">684000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_250">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 0.85in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;NOTE 8:-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;SHAREHOLDERS' EQUITY&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; a.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; General:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;All Ordinary shares, options, per share data and exercise price included in these financial statements for all periods presented have been retroactively adjusted to reflect the issuance on January 26, 2014 of 6.55-to-one bonus shares (equivalent to a 7.55-for-1 stock split).&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; b.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; Share capital:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share in the distribution of dividends, if any, declared by the Company.&lt;/div&gt; &amp;#160; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; c.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; Issuances of share:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&amp;#160;&amp;#160; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 106px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;On January 22, 2012 (inception day), the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7,551,427&lt;/font&gt; Ordinary shares in consideration of their par value.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 106px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In February 2012, the Company entered into an investment agreement, according to which the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 471,964&lt;/font&gt; Preferred A shares in consideration of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250&lt;/font&gt;. In addition, in August 2012, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 94,393&lt;/font&gt; Preferred A shares in consideration of $&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50&lt;/font&gt;. The issuance expenses amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 113.4pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 106px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In June 2013, the Company entered into a share purchase agreement according to which, the Company&amp;#160;issued a total of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,130,159&lt;/font&gt; Ordinary shares in consideration of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,024&lt;/font&gt;, in two equal installments in 2013 and January 2014.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 113.4pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.35in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Prior to the closing of the share purchase agreement above and as a condition to it, the Company affected an equity restructuring, under which, all of the Company's Preferred shares (566,357 Preferred A shares) were converted into Ordinary shares at a 1:1 ratio&lt;/font&gt;. As a result and in accordance with ASC 718-20-35-6, the Company recorded compensation expense in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;183&lt;/font&gt; and a deemed dividend in the amount of $ &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;26&lt;/font&gt; in the year ended December 31, 2013.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 113.4pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="106"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;On February 6, 2014, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 782,537&lt;/font&gt; Ordinary shares to private placement investors in consideration of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,368&lt;/font&gt;, net.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="106"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div&gt;On August 5, 2014, the Company completed a successful IPO of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,200,000&lt;/font&gt; Ordinary shares at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11.00&lt;/font&gt; per share generating net proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;31,405&lt;/font&gt;, after deducting underwriting discounts and commissions and other issuance expenses.&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; d.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2013 Incentive option plan:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In December 2013, the Company authorized through its 2013 incentive option plan (the "2013 Plan") the grant of options to officers, directors, advisors, management and other key employees. The options granted have a graded vesting schedule of generally four years and expire ten years after the grant date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.3pt; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of the Company's options activity (for employees and directors) under the 2013 Plan is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.18in; WIDTH: 82%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%" colspan="9"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="22%" colspan="4"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="22%" colspan="4"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Outstanding at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;403,110&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;319,531&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;380,222&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9.21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;83,579&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Outstanding at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;783,332&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;403,110&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Vested and expected to vest&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;783,332&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;403,110&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Options exercisable at the end of the year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;429,589&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;134,370&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;As of December 31, 2014, the weighted-average remaining contractual term of the outstanding and exercisable&lt;/font&gt; options is 5.6 years and 2.3 years; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;the aggregated intrinsic value of the outstanding and exercisable&lt;/font&gt; options is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,664&lt;/font&gt;&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,174&lt;/font&gt;&lt;/font&gt;. As &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;of December 31, 2014, the unrecognized compensation cost&lt;/font&gt; is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;889&lt;/font&gt;&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;to be recognized through 2017&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; e.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div&gt;Options granted to service providers:&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The Company granted options to certain service providers and accounted for these options in accordance with ASC 505-50, "Equity-Based payment to non-employees".&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0in 0in 0pt 56.7pt" align="justify"&gt;&lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The outstanding options granted to the Company's service providers are as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.18in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"&gt; &lt;div&gt;Grant&amp;#160;date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;Exercise&lt;br/&gt; price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"&gt; &lt;div&gt;Expiration&amp;#160;date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;December 2, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;20,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;7.78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;December 2, 2024&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; *)&amp;#160;&amp;#160;All options were fully vested on the grant date.&lt;/font&gt;&lt;/div&gt; &amp;#160; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;f.&lt;/font&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; Share-based payment:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The share based expense recognized in the financial statements is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1.18in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&lt;br/&gt; December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;General and administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;653&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;210&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;736&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;254&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_251">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.3pt; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;A summary of the Company's options activity (for employees and directors) under the 2013 Plan is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.18in; WIDTH: 82%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%" colspan="9"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="22%" colspan="4"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="22%" colspan="4"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; average&lt;br/&gt; exercise&lt;br/&gt; price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Outstanding at beginning of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;403,110&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;319,531&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;380,222&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9.21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;83,579&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Outstanding at end of year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;783,332&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;403,110&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Vested and expected to vest&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;783,332&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.47&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;403,110&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"&gt; &lt;div&gt;Options exercisable at the end of the year&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;429,589&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;134,370&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0004&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>

  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P01_01_2014To12_31_2014_NonemployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_252">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.3pt; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The outstanding options granted to the Company's service providers are as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.18in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"&gt; &lt;div&gt;Grant&amp;#160;date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%"&gt; &lt;div&gt;Number&amp;#160;of&lt;br/&gt; options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;Exercise&lt;br/&gt; price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"&gt; &lt;div&gt;Expiration&amp;#160;date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="24%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;December 2, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"&gt; &lt;div&gt;20,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;7.78&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"&gt; &lt;div&gt;December 2, 2024&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn12_31_2013" id="Factid_253" unitRef="USD" decimals="-3">166000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn12_31_2014" id="Factid_254" unitRef="USD" decimals="-3">181000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="PAsOn12_31_2013" id="Factid_255" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="PAsOn12_31_2014" id="Factid_256" unitRef="USD" decimals="-3">671000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn12_31_2013" id="Factid_257" unitRef="USD" decimals="-3">312000</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn12_31_2014" id="Factid_258" unitRef="USD" decimals="-3">1791000</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2013" id="Factid_259" unitRef="USD" decimals="-3">312000</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2014" id="Factid_260" unitRef="USD" decimals="-3">1791000</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="PAsOn12_31_2013" id="Factid_261" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>

  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="PAsOn12_31_2014" id="Factid_262" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>

  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_263">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 7:-&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt; &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;CONTINGENT LIABILITIES AND COMMITMENTS&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 18pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt; The Company is engaged in an operating lease agreement for its office facilities. The rent expenses for the years ended December 31, 2014, 2013 and 2012&amp;#160;amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;88&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;14&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Future minimum payments under the lease are as follows:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.5in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;117&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;117&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;54&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;288&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 74.7pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 1.1in" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The Company has provided bank guarantees in the amount of&amp;#160;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25&lt;/font&gt; as security for the performance of its lease agreement.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 74.7pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; b.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;During 2014 the Company entered into a new operating lease agreement for its vehicles until 2017. Future minimum payments under the lease are $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8&lt;/font&gt;. The lease expenses for the years ended December 31, 2014, 2013&amp;#160;and 2012&amp;#160;amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25&lt;/font&gt;, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt; &amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; c.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;License agreement:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 113.4pt"&gt; &amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="120"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;(i)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company entered into a Research and Exclusive License Agreement with Yissum Research Development Company of the Hebrew University in Jerusalem Ltd., for the use, development and commercialization of TAT-MTS- Protein for protein replacement in mitochondrial diseases. The consideration to Yissum is composed of a tiered low single digit royalties on net sales and a sublicense fee that will not exceed the mid-high ten to twenty percent range of the sublicense consideration, but, if the sublicense arises from the sales of a product, the sublicense fee shall not be less than a low single digit percent of the gross sales of such product.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="120"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;(ii)&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;The Company entered into an Exclusive License Agreement with Ramot at Tel Aviv University Ltd. for the use, development and commercialization of our read-through platform. The consideration to Ramot is composed of a tiered low single digit royalties on net sales and a sublicense fee that will not exceed the mid to high single digit percent range of payments or other consideration that the Company receives in connection with a sublicense.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

  <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_264">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Future minimum payments under the lease are as follows:&amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.5in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;117&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;117&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;54&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;288&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>

  <us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="P01_01_2014To12_31_2014" id="Factid_265" unitRef="USD" decimals="-3">8000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>

  <us-gaap:LeaseAndRentalExpense contextRef="P01_01_2012To12_31_2012" id="Factid_266" unitRef="USD" decimals="-3">0</us-gaap:LeaseAndRentalExpense>

  <us-gaap:LeaseAndRentalExpense contextRef="P01_01_2013To12_31_2013" id="Factid_267" unitRef="USD" decimals="-3">14000</us-gaap:LeaseAndRentalExpense>

  <us-gaap:LeaseAndRentalExpense contextRef="P01_01_2014To12_31_2014" id="Factid_268" unitRef="USD" decimals="-3">88000</us-gaap:LeaseAndRentalExpense>

  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_269">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The share based expense recognized in the financial statements is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1.18in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&lt;br/&gt; December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;44&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;General and administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;653&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;210&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;736&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;254&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2013To12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_270" unitRef="shares" decimals="INF">83579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_271" unitRef="shares" decimals="INF">380222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2012_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_272" unitRef="shares" decimals="INF">319531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_273" unitRef="shares" decimals="INF">403110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_274" unitRef="shares" decimals="INF">783332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_275" unitRef="shares" decimals="INF">134370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_276" unitRef="shares" decimals="INF">429589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_277" unitRef="shares" decimals="INF">403110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_278" unitRef="shares" decimals="INF">783332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2012_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_279" unitRef="USD_per_Share" decimals="4">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_280" unitRef="USD_per_Share" decimals="4">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_281" unitRef="USD_per_Share" decimals="4">0.0004</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2014To12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_282" unitRef="USD_per_Share" decimals="2">9.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_283" unitRef="USD_per_Share" decimals="2">4.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_284" unitRef="USD_per_Share" decimals="4">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_285" unitRef="USD_per_Share" decimals="2">4.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2013_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_286" unitRef="USD_per_Share" decimals="4">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_287" unitRef="USD_per_Share" decimals="2">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To12_31_2012_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_288" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To12_31_2012_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_289" unitRef="USD" decimals="-3">9000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To12_31_2013_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_290" unitRef="USD" decimals="-3">44000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To12_31_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_291" unitRef="USD" decimals="-3">210000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2014To12_31_2014_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_292" unitRef="USD" decimals="-3">83000</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2014To12_31_2014_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_293" unitRef="USD" decimals="-3">653000</us-gaap:ShareBasedCompensation>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="PAsOn12_31_2014" id="Factid_294" unitRef="USD" decimals="-3">117000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="PAsOn12_31_2014" id="Factid_295" unitRef="USD" decimals="-3">117000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="PAsOn12_31_2014" id="Factid_296" unitRef="USD" decimals="-3">54000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="PAsOn12_31_2014" id="Factid_297" unitRef="USD" decimals="-3">288000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>

  <us-gaap:StockholdersEquityReverseStockSplit contextRef="P01_01_2014To12_31_2014" id="Factid_298">All Ordinary shares, options, per share data and exercise price included in these financial statements for all periods presented have been retroactively adjusted to reflect the issuance on January 26, 2014 of 6.55-to-one bonus shares (equivalent to a 7.55-for-1 stock split).</us-gaap:StockholdersEquityReverseStockSplit>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_299">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 0.85in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;NOTE 9:-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Balances with related parties:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Trade payable (d)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Other accounts payable (a) (b) (c)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;123&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;36&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 53pt; MARGIN: 0in 0px 0in 0.35in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Related parties' expenses:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;Amounts charged to: *)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;Research and development expense (c)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;145&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;99&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;General and administrative expense (a) (b) (c) (d)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;467&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;257&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;55&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM-COLOR: #000000; MARGIN-TOP: 0pt; BORDER-TOP-COLOR: #000000; WIDTH: 1604px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; HEIGHT: 53px; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000" cellspacing="0" cellpadding="0" width="1604"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;a.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt; In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately&lt;/font&gt; &lt;font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt; $&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; per &lt;font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt; month. During August 2014, the monthly fee was increased to an amount of $&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt;&lt;/font&gt; effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;80&lt;/font&gt;&lt;/font&gt; in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;70&lt;/font&gt;&lt;/font&gt; with regards to services provided during 2014&lt;/font&gt;.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;b.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and an office lease for a monthly fee in the amount of&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; approximately &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; $&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4&lt;/font&gt;&lt;/font&gt; &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; since September 10, 2013. The parties terminated the agreement on September 1, 2014.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;c.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; approximately &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; $&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt;&lt;/font&gt; per month. &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; During August 2014, the monthly fee was increased to an amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19&lt;/font&gt; effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;90&lt;/font&gt; in connection with the consummation of the IPO.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;d.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; On July 1, 2013, the Company signed an agreement with a consultant, who is also one of the Company's shareholders, to render advisory services. The Company pays the consultant an amount&lt;/font&gt; of &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; $&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1&lt;/font&gt;&lt;/font&gt; per month&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_300">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 40pt; MARGIN: 0pt 0px 0pt 40pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&amp;#160;&lt;font style="FONT-WEIGHT: normal"&gt;Balances with related parties:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 40pt; MARGIN: 0pt 0px 0pt 40pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 83%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 85.05pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 74%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Trade payable (d)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Other accounts payable (a) (b) (c)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;123&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;36&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;font style="FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 56.7pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;a.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately $6 per month. During August 2014, the monthly fee was increased to an amount of $15 effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $80 in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $70 with regards to services provided during 2014.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 56.7pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;b.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and an office lease for a monthly fee in the amount of approximately $4 since September 10, 2013. The parties terminated the agreement on September 1, 2014.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 56.7pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;c.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of approximately $15 per month. During August 2014, the monthly fee was increased to an amount of $19 effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $90 in connection with the consummation of the IPO.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 56.7pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;d.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;On July 1, 2013, the Company signed an agreement with a consultant, who is also one of the Company's shareholders, to render advisory services. The Company pays the consultant an amount of $1 per month.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>

  <orpn:ScheduleOfRelatedPartyExpensesTableTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_301">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 53pt; MARGIN: 0in 0px 0in 0.35in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Related parties' expenses:&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;Amounts charged to: *)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;Research and development expense (c)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;145&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;99&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"&gt; &lt;div&gt;General and administrative expense (a) (b) (c) (d)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;467&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;257&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;55&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;table style="BORDER-BOTTOM-COLOR: #000000; MARGIN-TOP: 0pt; BORDER-TOP-COLOR: #000000; WIDTH: 1604px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; HEIGHT: 53px; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000" cellspacing="0" cellpadding="0" width="1604"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;a.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt; In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately&lt;/font&gt; &lt;font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt; $&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6&lt;/font&gt;&lt;/font&gt;&lt;/font&gt; per &lt;font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt; month. During August 2014, the monthly fee was increased to an amount of $&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt;&lt;/font&gt; effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;80&lt;/font&gt;&lt;/font&gt; in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $&lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;70&lt;/font&gt;&lt;/font&gt; with regards to services provided during 2014&lt;/font&gt;.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;b.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and an office lease for a monthly fee in the amount of&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; approximately &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; $&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4&lt;/font&gt;&lt;/font&gt; &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; since September 10, 2013. The parties terminated the agreement on September 1, 2014.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-WEIGHT: normal"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;c.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; approximately &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; $&lt;/font&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt;&lt;/font&gt; per month. &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; During August 2014, the monthly fee was increased to an amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19&lt;/font&gt; effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;90&lt;/font&gt; in connection with the consummation of the IPO.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 28.35pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;d.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; On July 1, 2013, the Company signed an agreement with a consultant, who is also one of the Company's shareholders, to render advisory services. The Company pays the consultant an amount&lt;/font&gt; of &lt;font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; $&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1&lt;/font&gt;&lt;/font&gt; per month&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</orpn:ScheduleOfRelatedPartyExpensesTableTextBlock>

  <orpn:SharePurchaseAgreementSharesToBeIssued contextRef="P06_01_2013To06_30_2013_PurchaseAgreementMemberorpnAgreementAxis" id="Factid_302" unitRef="shares" decimals="INF">2130159</orpn:SharePurchaseAgreementSharesToBeIssued>

  <us-gaap:AccountsPayableTradeCurrent contextRef="PAsOn12_31_2013_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_303" unitRef="USD" decimals="-3">1000</us-gaap:AccountsPayableTradeCurrent>

  <us-gaap:AccountsPayableTradeCurrent contextRef="PAsOn12_31_2014_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_304" unitRef="USD" decimals="-3">2000</us-gaap:AccountsPayableTradeCurrent>

  <us-gaap:AccountsPayableOtherCurrent contextRef="PAsOn12_31_2013_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_305" unitRef="USD" decimals="-3">36000</us-gaap:AccountsPayableOtherCurrent>

  <us-gaap:AccountsPayableOtherCurrent contextRef="PAsOn12_31_2014_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_306" unitRef="USD" decimals="-3">123000</us-gaap:AccountsPayableOtherCurrent>

  <orpn:SharePurchaseAgreementValueToBeIssued contextRef="P06_01_2013To06_30_2013_PurchaseAgreementMemberorpnAgreementAxis" id="Factid_307" unitRef="USD" decimals="-3">2024000</orpn:SharePurchaseAgreementValueToBeIssued>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2012To01_22_2012" id="Factid_308" unitRef="shares" decimals="INF">7551427</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2012To02_29_2012_InvestmentAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_309" unitRef="shares" decimals="INF">471964</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2012To08_31_2012_InvestmentAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_310" unitRef="shares" decimals="INF">94393</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2014To08_05_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_311" unitRef="shares" decimals="INF">3200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P02_01_2012To02_29_2012_InvestmentAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_312" unitRef="USD" decimals="-3">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_01_2012To08_31_2012_InvestmentAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_313" unitRef="USD" decimals="-3">50000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_01_2014To08_05_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_314" unitRef="USD" decimals="-3">3200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P08_01_2012To08_31_2012_InvestmentAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_315" unitRef="USD" decimals="-3">5000</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PreferredStockConversionBasis contextRef="P01_01_2013To12_31_2013_PurchaseAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_316">Prior to the closing of the share purchase agreement above and as a condition to it, the Company affected an equity restructuring, under which, all of the Company&#39;s Preferred shares (566,357 Preferred A shares) were converted into Ordinary shares at a 1:1 ratio</us-gaap:PreferredStockConversionBasis>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="P01_01_2013To12_31_2013_PurchaseAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_317" unitRef="USD" decimals="-3">183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2012To12_31_2012_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_318" unitRef="USD" decimals="-3">55000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2013To12_31_2013_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_319" unitRef="USD" decimals="-3">257000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2014To12_31_2014_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_320" unitRef="USD" decimals="-3">467000</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2012To12_31_2012_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_321" unitRef="USD" decimals="-3">34000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2013To12_31_2013_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_322" unitRef="USD" decimals="-3">99000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2014To12_31_2014_RelatedPartyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_323" unitRef="USD" decimals="-3">145000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:DividendsPreferredStock contextRef="P01_01_2013To12_31_2013_PurchaseAgreementMemberorpnAgreementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_324" unitRef="USD" decimals="-3">26000</us-gaap:DividendsPreferredStock>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2014To12_31_2014" id="Factid_325">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_326" unitRef="USD" decimals="-3">2664000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_327" unitRef="USD" decimals="-3">2174000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn12_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_328" unitRef="USD" decimals="-3">889000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2014To12_31_2014" id="Factid_329">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P07_01_2013To07_31_2013_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_330" unitRef="USD" decimals="-3">1000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P08_01_2012To08_31_2012_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_331" unitRef="USD" decimals="-3">6000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P08_01_2013To08_31_2013_ShareholdersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_332" unitRef="USD" decimals="-3">15000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P09_01_2013To09_10_2013_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_333" unitRef="USD" decimals="-3">4000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_334">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt; &lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0px"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 0.75in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;NOTE 10:-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;FINANCIAL EXPENSES (INCOME), NET&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.85in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&lt;br/&gt; December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Financial expenses:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Bank fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Exchange rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;27&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Financial income:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;85&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Exchange rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;85&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(58)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;*)&amp;#160;&amp;#160;Represents an amount lower than&amp;#160;&amp;#160;$&amp;#160;1&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>

  <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_335">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.85in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"&gt; &lt;div&gt;Year&amp;#160;ended&lt;br/&gt; December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2012&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Financial expenses:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Interest expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;*&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Bank fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Exchange rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;21&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;27&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Financial income:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Interest income&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;85&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;Exchange rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;85&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(58)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;*)&amp;#160;&amp;#160;Represents an amount lower than&amp;#160;&amp;#160;$&amp;#160;1&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>

  <us-gaap:InterestExpenseBorrowings contextRef="P01_01_2012To12_31_2012" id="Factid_336" unitRef="USD" decimals="-3">0</us-gaap:InterestExpenseBorrowings>

  <us-gaap:InterestExpenseBorrowings contextRef="P01_01_2013To12_31_2013" id="Factid_337" unitRef="USD" decimals="-3">2000</us-gaap:InterestExpenseBorrowings>

  <us-gaap:InterestExpenseBorrowings contextRef="P01_01_2014To12_31_2014" id="Factid_338" unitRef="USD" decimals="-3">0</us-gaap:InterestExpenseBorrowings>

  <us-gaap:ExpensesAndLossesReportingCurrencyDenominatedValue contextRef="P01_01_2012To12_31_2012" id="Factid_339" unitRef="USD" decimals="-3">3000</us-gaap:ExpensesAndLossesReportingCurrencyDenominatedValue>

  <us-gaap:ExpensesAndLossesReportingCurrencyDenominatedValue contextRef="P01_01_2013To12_31_2013" id="Factid_340" unitRef="USD" decimals="-3">0</us-gaap:ExpensesAndLossesReportingCurrencyDenominatedValue>

  <us-gaap:ExpensesAndLossesReportingCurrencyDenominatedValue contextRef="P01_01_2014To12_31_2014" id="Factid_341" unitRef="USD" decimals="-3">21000</us-gaap:ExpensesAndLossesReportingCurrencyDenominatedValue>

  <us-gaap:OtherNonoperatingExpense contextRef="P01_01_2012To12_31_2012" id="Factid_342" unitRef="USD" decimals="-3">3000</us-gaap:OtherNonoperatingExpense>

  <us-gaap:OtherNonoperatingExpense contextRef="P01_01_2013To12_31_2013" id="Factid_343" unitRef="USD" decimals="-3">2000</us-gaap:OtherNonoperatingExpense>

  <us-gaap:OtherNonoperatingExpense contextRef="P01_01_2014To12_31_2014" id="Factid_344" unitRef="USD" decimals="-3">27000</us-gaap:OtherNonoperatingExpense>

  <us-gaap:RevenuesAndGainsReportingCurrencyDenominatedValue contextRef="P01_01_2012To12_31_2012" id="Factid_345" unitRef="USD" decimals="-3">0</us-gaap:RevenuesAndGainsReportingCurrencyDenominatedValue>

  <us-gaap:RevenuesAndGainsReportingCurrencyDenominatedValue contextRef="P01_01_2013To12_31_2013" id="Factid_346" unitRef="USD" decimals="-3">5000</us-gaap:RevenuesAndGainsReportingCurrencyDenominatedValue>

  <us-gaap:RevenuesAndGainsReportingCurrencyDenominatedValue contextRef="P01_01_2014To12_31_2014" id="Factid_347" unitRef="USD" decimals="-3">0</us-gaap:RevenuesAndGainsReportingCurrencyDenominatedValue>

  <us-gaap:OtherNonoperatingIncome contextRef="P01_01_2012To12_31_2012" id="Factid_348" unitRef="USD" decimals="-3">0</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OtherNonoperatingIncome contextRef="P01_01_2013To12_31_2013" id="Factid_349" unitRef="USD" decimals="-3">5000</us-gaap:OtherNonoperatingIncome>

  <us-gaap:OtherNonoperatingIncome contextRef="P01_01_2014To12_31_2014" id="Factid_350" unitRef="USD" decimals="-3">85000</us-gaap:OtherNonoperatingIncome>

  <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_351">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="TEXT-ALIGN: justify; WIDTH: 0.85in"&gt; &lt;div&gt;NOTE 11:-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;SUBSEQUENT EVENTS&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 78pt; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.85in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;1.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;During January 2015, a wholly-owned subsidiary was established in the state of Delaware named BioBlast Pharma Inc.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.85in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;2.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;On February 2, 2015, the Company appointed a new&amp;#160;President and Chief Executive Officer and a member of its board of directors. As part of the agreement the new CEO was granted &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 498,067&lt;/font&gt;&amp;#160;options to purchase&amp;#160;Ordinary&amp;#160;shares with exercise price of $ &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 8.47&lt;/font&gt; per share.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.85in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;3.&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div&gt;On February 16, 2015,&amp;#160;the Company's board of directors resolved to issue&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 24,000&lt;/font&gt; options to employees with an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.17&lt;/font&gt; per share.&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_27_2015To02_02_2015_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_352" unitRef="USD_per_Share" decimals="2">8.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P02_01_2015To02_16_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_353" unitRef="USD_per_Share" decimals="2">7.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:DepositsAssetsCurrent contextRef="PAsOn12_31_2013" id="Factid_354" unitRef="USD" decimals="-3">0</us-gaap:DepositsAssetsCurrent>

  <us-gaap:DepositsAssetsCurrent contextRef="PAsOn12_31_2014" id="Factid_355" unitRef="USD" decimals="-3">22028000</us-gaap:DepositsAssetsCurrent>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue contextRef="P01_23_2012To12_31_2012" id="Factid_356" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue contextRef="P01_23_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_357" unitRef="USD" decimals="-3">20000</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue contextRef="P01_23_2012To12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_358" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue contextRef="P01_23_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_359" unitRef="USD" decimals="-3">-20000</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue contextRef="P01_23_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_360" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares contextRef="P01_23_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_361" unitRef="shares" decimals="INF">7551427</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares contextRef="P01_23_2012To12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_362" unitRef="shares" decimals="INF">0</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_23_2012To12_31_2012" id="Factid_363" unitRef="USD" decimals="-3">295000</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_23_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_364" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_23_2012To12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_365" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_23_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_366" unitRef="USD" decimals="-3">294000</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_23_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_367" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="P01_23_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_368" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesOther>

  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="P01_23_2012To12_31_2012_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_369" unitRef="shares" decimals="INF">566357</us-gaap:StockIssuedDuringPeriodSharesOther>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue contextRef="P01_01_2014To12_31_2014" id="Factid_370" unitRef="USD" decimals="-3">4368000</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_371" unitRef="USD" decimals="-3">3000</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue contextRef="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_372" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue contextRef="P01_01_2014To12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_373" unitRef="USD" decimals="-3">4365000</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue contextRef="P01_01_2014To12_31_2014_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_374" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_375" unitRef="shares" decimals="INF">782537</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares contextRef="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_376" unitRef="shares" decimals="INF">0</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2013To12_31_2013" id="Factid_377" unitRef="USD" decimals="-3">991000</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_378" unitRef="USD" decimals="-3">3000</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_379" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_380" unitRef="USD" decimals="-3">988000</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2013To12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_381" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2014To12_31_2014" id="Factid_382" unitRef="USD" decimals="-3">1012000</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_383" unitRef="USD" decimals="-3">3000</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_384" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2014To12_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_385" unitRef="USD" decimals="-3">1009000</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares contextRef="P01_01_2014To12_31_2014_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_386" unitRef="USD" decimals="-3">0</orpn:StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_387" unitRef="shares" decimals="INF">1065083</orpn:StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares contextRef="P01_01_2013To12_31_2013_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_388" unitRef="shares" decimals="INF">0</orpn:StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_389" unitRef="shares" decimals="INF">1065076</orpn:StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares>

  <orpn:StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares contextRef="P01_01_2014To12_31_2014_PreferredClassAMemberusgaapStatementClassOfStockAxis" id="Factid_390" unitRef="shares" decimals="INF">0</orpn:StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares>

  <orpn:InterestOnShortTermBankDeposit contextRef="P01_01_2012To12_31_2012" id="Factid_391" unitRef="USD" decimals="-3">0</orpn:InterestOnShortTermBankDeposit>

  <orpn:InterestOnShortTermBankDeposit contextRef="P01_01_2013To12_31_2013" id="Factid_392" unitRef="USD" decimals="-3">0</orpn:InterestOnShortTermBankDeposit>

  <orpn:InterestOnShortTermBankDeposit contextRef="P01_01_2014To12_31_2014" id="Factid_393" unitRef="USD" decimals="-3">28000</orpn:InterestOnShortTermBankDeposit>

  <orpn:PaymentsToAcquireShortTermBankDeposit contextRef="P01_01_2012To12_31_2012" id="Factid_394" unitRef="USD" decimals="-3">0</orpn:PaymentsToAcquireShortTermBankDeposit>

  <orpn:PaymentsToAcquireShortTermBankDeposit contextRef="P01_01_2013To12_31_2013" id="Factid_395" unitRef="USD" decimals="-3">0</orpn:PaymentsToAcquireShortTermBankDeposit>

  <orpn:PaymentsToAcquireShortTermBankDeposit contextRef="P01_01_2014To12_31_2014" id="Factid_396" unitRef="USD" decimals="-3">22000000</orpn:PaymentsToAcquireShortTermBankDeposit>

  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="P01_01_2014To12_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_397" unitRef="USD" decimals="-3">31405000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>

  <orpn:ShortTermBankDepositsPolicyTextBlock contextRef="P01_01_2014To12_31_2014" id="Factid_398">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; e.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; Short-term bank deposits:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Short-term bank deposits are deposits with maturities of more than three months but less than one year.&lt;/font&gt; Short&amp;#150;term bank deposits are presented at their cost, including accrued interest, which approximates fair value. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;As of December 31, 2014, the Company's bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.66%.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</orpn:ShortTermBankDepositsPolicyTextBlock>

  <us-gaap:TimeDepositsWeightedAverageInterestRateDescription contextRef="P01_01_2014To12_31_2014" id="Factid_399">As of December 31, 2014, the Company&#39;s bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.66%.</us-gaap:TimeDepositsWeightedAverageInterestRateDescription>

  <us-gaap:MaturitiesOfTimeDepositsDescription contextRef="P01_01_2014To12_31_2014" id="Factid_400">Short-term bank deposits are deposits with maturities of more than three months but less than one year.</us-gaap:MaturitiesOfTimeDepositsDescription>

  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="PAsOn12_31_2013" id="Factid_401" unitRef="USD" decimals="-3">142000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>

  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="PAsOn12_31_2014" id="Factid_402" unitRef="USD" decimals="-3">923000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>

  <orpn:GuaranteeForPerformanceOfLeaseAgreement contextRef="PAsOn12_31_2014" id="Factid_403" unitRef="USD" decimals="-3">25000</orpn:GuaranteeForPerformanceOfLeaseAgreement>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P01_01_2012To12_31_2012" id="Factid_404" unitRef="USD" decimals="-3">0</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P01_01_2013To12_31_2013" id="Factid_405" unitRef="USD" decimals="-3">11000</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P01_01_2014To12_31_2014" id="Factid_406" unitRef="USD" decimals="-3">25000</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_27_2015To02_02_2015_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_407" unitRef="shares" decimals="INF">498067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P02_01_2015To02_16_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_408" unitRef="shares" decimals="INF">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <orpn:BankFees contextRef="P01_01_2012To12_31_2012" id="Factid_409" unitRef="USD" decimals="-3">0</orpn:BankFees>

  <orpn:BankFees contextRef="P01_01_2013To12_31_2013" id="Factid_410" unitRef="USD" decimals="-3">0</orpn:BankFees>

  <orpn:BankFees contextRef="P01_01_2014To12_31_2014" id="Factid_411" unitRef="USD" decimals="-3">6000</orpn:BankFees>

  <us-gaap:InterestIncomeOther contextRef="P01_01_2012To12_31_2012" id="Factid_412" unitRef="USD" decimals="-3">0</us-gaap:InterestIncomeOther>

  <us-gaap:InterestIncomeOther contextRef="P01_01_2013To12_31_2013" id="Factid_413" unitRef="USD" decimals="-3">0</us-gaap:InterestIncomeOther>

  <us-gaap:InterestIncomeOther contextRef="P01_01_2014To12_31_2014" id="Factid_414" unitRef="USD" decimals="-3">85000</us-gaap:InterestIncomeOther>

  <orpn:IncreaseInMonthlyFee contextRef="P01_01_2014To12_31_2014_ConsultantOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_415" unitRef="USD" decimals="-3">19000</orpn:IncreaseInMonthlyFee>

  <orpn:IncreaseInMonthlyFee contextRef="P01_01_2014To12_31_2014_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_416" unitRef="USD" decimals="-3">15000</orpn:IncreaseInMonthlyFee>

  <orpn:ConsultantBonusGrantInPeriod contextRef="P01_01_2014To12_31_2014_ConsultantOneMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_417" unitRef="USD" decimals="-3">90000</orpn:ConsultantBonusGrantInPeriod>

  <orpn:ConsultantBonusGrantInPeriod contextRef="P01_01_2014To12_31_2014_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_418" unitRef="USD" decimals="-3">80000</orpn:ConsultantBonusGrantInPeriod>

  <orpn:ConsultantBonusGrantInPeriodAddition contextRef="P01_01_2014To12_31_2014_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_419" unitRef="USD" decimals="-3">70000</orpn:ConsultantBonusGrantInPeriodAddition>

  <orpn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant contextRef="P01_01_2014To12_31_2014_NonemployeeStockOptionMemberusgaapAwardTypeAxis_SecondDecemberTwoThousandFourteenMemberusgaapAwardDateAxis" id="Factid_420">2014-12-02</orpn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant>

  <orpn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber contextRef="P01_01_2014To12_31_2014_NonemployeeStockOptionMemberusgaapAwardTypeAxis_SecondDecemberTwoThousandFourteenMemberusgaapAwardDateAxis" id="Factid_421" unitRef="shares" decimals="INF">20000</orpn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber>

  <orpn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice contextRef="P01_01_2014To12_31_2014_NonemployeeStockOptionMemberusgaapAwardTypeAxis_SecondDecemberTwoThousandFourteenMemberusgaapAwardDateAxis" id="Factid_422" unitRef="USD_per_Share" decimals="2">7.78</orpn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice>

  <orpn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate contextRef="P01_01_2014To12_31_2014_NonemployeeStockOptionMemberusgaapAwardTypeAxis_SecondDecemberTwoThousandFourteenMemberusgaapAwardDateAxis" id="Factid_423">2024-12-02</orpn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue contextRef="P02_01_2014To02_06_2014" id="Factid_424" unitRef="USD" decimals="-3">4368000</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue>

  <us-gaap:EquityIssuancePerShareAmount contextRef="P08_01_2014To08_05_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_425" unitRef="USD_per_Share" decimals="2">11.00</us-gaap:EquityIssuancePerShareAmount>

  <us-gaap:DeferredTaxAssetsOther contextRef="PAsOn12_31_2013" id="Factid_426" unitRef="USD" decimals="-3">4000</us-gaap:DeferredTaxAssetsOther>

  <us-gaap:DeferredTaxAssetsOther contextRef="PAsOn12_31_2014" id="Factid_427" unitRef="USD" decimals="-3">16000</us-gaap:DeferredTaxAssetsOther>

  <orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares contextRef="P02_01_2014To02_06_2014" id="Factid_428" unitRef="shares" decimals="INF">782537</orpn:StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#Factid_29" xlink:type="locator" xlink:label="loc_1" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_1">Represents an amount lower than $1.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_229" xlink:type="locator" xlink:label="loc_3" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_303" xlink:type="locator" xlink:label="loc_4" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_4">On July 1, 2013 the Company signed an agreement with a consultant, who is also one of the Company&#39;s shareholders, to render advisory services. The Company pays the consultant an amount of $1 per month.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_4" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_304" xlink:type="locator" xlink:label="loc_6" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_4" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_305" xlink:type="locator" xlink:label="loc_7" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_7">In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company&#39;s shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately $6 per month. During August 2014, the monthly fee was increased to an amount of $15 effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $80 in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $70 with regards to services provided during 2014.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_7" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_8">The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and office lease for a monthly fee in the amount of approximately $4 since September 10, 2013. The parties terminated the agreement on September 1, 2014.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_8" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_9">An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of approximately $15 per month. During August 2014, the monthly fee was increased to an amount of $19 effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $90 in connection with the consummation of the IPO.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_306" xlink:type="locator" xlink:label="loc_11" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_7" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_8" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_318" xlink:type="locator" xlink:label="loc_12" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_12">On July 1, 2013, the Company signed an agreement with a consultant, who is also one of the Company&#39;s shareholders, to render advisory services. The Company pays the consultant an amount of $1 per month.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_12" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_7" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_13">The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and an office lease for a monthly fee in the amount of approximately $4 since September 10, 2013. The parties terminated the agreement on September 1, 2014.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_13" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_319" xlink:type="locator" xlink:label="loc_15" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_12" xlink:from="loc_15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_7" xlink:from="loc_15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_13" xlink:from="loc_15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_320" xlink:type="locator" xlink:label="loc_16" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_12" xlink:from="loc_16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_7" xlink:from="loc_16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_13" xlink:from="loc_16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_321" xlink:type="locator" xlink:label="loc_17" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_322" xlink:type="locator" xlink:label="loc_18" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_323" xlink:type="locator" xlink:label="loc_19" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_9" xlink:from="loc_19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_336" xlink:type="locator" xlink:label="loc_20" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_338" xlink:type="locator" xlink:label="loc_21" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>orpn-20141231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 30-Mar-2015 [11:12:18] {AM} EST - www.datatracks.com -->
<schema targetNamespace="http://bioblast-pharma.com/20141231" elementFormDefault="qualified" xmlns:orpn="http://bioblast-pharma.com/20141231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://bioblast-pharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>102 - Statement - BALANCE SHEETS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>103 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>104 - Statement - STATEMENTS OF OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquity" id="StatementsOfChangesInShareholdersEquity">
        <link:definition>105 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS&#39; EQUITY</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquityParenthetical" id="StatementsOfChangesInShareholdersEquityParenthetical">
        <link:definition>106 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS&#39; EQUITY (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>107 - Statement - STATEMENTS OF CASH FLOWS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/General" id="General">
        <link:definition>108 - Disclosure - GENERAL</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>109 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpenses" id="ReceivablesAndPrepaidExpenses">
        <link:definition>110 - Disclosure - RECEIVABLES AND PREPAID EXPENSES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>111 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/OtherAccountsPayable" id="OtherAccountsPayable">
        <link:definition>112 - Disclosure - OTHER ACCOUNTS PAYABLE</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>113 - Disclosure - INCOME TAXES</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitments" id="ContingentLiabilitiesAndCommitments">
        <link:definition>114 - Disclosure - CONTINGENT LIABILITIES AND COMMITMENTS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ShareholdersEquity" id="ShareholdersEquity">
        <link:definition>115 - Disclosure - SHAREHOLDERS&#39; EQUITY</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactions" id="RelatedPartyBalancesAndTransactions">
        <link:definition>116 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNet" id="FinancialExpensesIncomeNet">
        <link:definition>117 - Disclosure - FINANCIAL EXPENSES (INCOME), NET</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>118 - Disclosure - SUBSEQUENT EVENTS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <link:definition>119 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
        <link:definition>120 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesTables" id="ReceivablesAndPrepaidExpensesTables">
        <link:definition>121 - Disclosure - RECEIVABLES AND PREPAID EXPENSES (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>122 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/OtherAccountsPayableTables" id="OtherAccountsPayableTables">
        <link:definition>123 - Disclosure - OTHER ACCOUNTS PAYABLE (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>124 - Disclosure - INCOME TAXES (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsTables" id="ContingentLiabilitiesAndCommitmentsTables">
        <link:definition>125 - Disclosure - CONTINGENT LIABILITIES AND COMMITMENTS (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
        <link:definition>126 - Disclosure - SHAREHOLDERS&#39; EQUITY (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
        <link:definition>127 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetTables" id="FinancialExpensesIncomeNetTables">
        <link:definition>128 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/GeneralDetailsTextual" id="GeneralDetailsTextual">
        <link:definition>129 - Disclosure - GENERAL (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
        <link:definition>130 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetailsTextual" id="SignificantAccountingPoliciesDetailsTextual">
        <link:definition>131 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesDetails" id="ReceivablesAndPrepaidExpensesDetails">
        <link:definition>132 - Disclosure - RECEIVABLES AND PREPAID EXPENSES (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetDetails">
        <link:definition>133 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetailsTextual" id="PropertyAndEquipmentNetDetailsTextual">
        <link:definition>134 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/OtherAccountsPayableDetails" id="OtherAccountsPayableDetails">
        <link:definition>135 - Disclosure - OTHER ACCOUNTS PAYABLE (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>136 - Disclosure - INCOME TAXES (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
        <link:definition>137 - Disclosure - INCOME TAXES (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetails" id="ContingentLiabilitiesAndCommitmentsDetails">
        <link:definition>138 - Disclosure - CONTINGENT LIABILITIES AND COMMITMENTS (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetailsTextual" id="ContingentLiabilitiesAndCommitmentsDetailsTextual">
        <link:definition>139 - Disclosure - CONTINGENT LIABILITIES AND COMMITMENTS (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails" id="ShareholdersEquityDetails">
        <link:definition>140 - Disclosure - SHAREHOLDERS&#39; EQUITY (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails1" id="ShareholdersEquityDetails1">
        <link:definition>141 - Disclosure - SHAREHOLDERS&#39; EQUITY (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails2" id="ShareholdersEquityDetails2">
        <link:definition>142 - Disclosure - SHAREHOLDERS&#39; EQUITY (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetailsTextual" id="ShareholdersEquityDetailsTextual">
        <link:definition>143 - Disclosure - SHAREHOLDERS&#39; EQUITY (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails" id="RelatedPartyBalancesAndTransactionsDetails">
        <link:definition>144 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails1" id="RelatedPartyBalancesAndTransactionsDetails1">
        <link:definition>145 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetailsTextual" id="RelatedPartyBalancesAndTransactionsDetailsTextual">
        <link:definition>146 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetDetails" id="FinancialExpensesIncomeNetDetails">
        <link:definition>147 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://bioblast-pharma.com/role/SubsequentEventsDetailsTextual" id="SubsequentEventsDetailsTextual">
        <link:definition>148 - Disclosure - SUBSEQUENT EVENTS (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="orpn-20141231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="orpn-20141231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="orpn-20141231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="orpn-20141231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_DocumentAndEntityInformationAbstract" />

  <element name="StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" />

  <element name="StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" />

  <element name="StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" />

  <element name="IncreaseDecreaseInReceivablesAndPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" />

  <element name="StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" />

  <element name="PaymentsToAcquireShortTermBankDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="orpn_PaymentsToAcquireShortTermBankDeposit" />

  <element name="ReceivablesAndPrepaidExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="orpn_ReceivablesAndPrepaidExpensesCurrent" />

  <element name="ScheduleOfGeneralTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orpn_ScheduleOfGeneralTable" />

  <element name="FinancialStatementsDisclosurePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_FinancialStatementsDisclosurePolicyTextBlock" />

  <element name="ShortTermBankDepositsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ShortTermBankDepositsPolicyTextBlock" />

  <element name="LongTermDepositsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_LongTermDepositsPolicyTextBlock" />

  <element name="PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" />

  <element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orpn_SignificantAccountingPoliciesTable" />

  <element name="PropertyPlantAndEquipmentStraightLinePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orpn_PropertyPlantAndEquipmentStraightLinePercentage" />

  <element name="ReceivablesAndPrepaidExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ReceivablesAndPrepaidExpensesAbstract" />

  <element name="ReceivablesAndPrepaidExpensesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock" />

  <element name="ReceivablesAndPrepaidExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orpn_ReceivablesAndPrepaidExpensesTable" />

  <element name="ReceivablesAndPrepaidExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ReceivablesAndPrepaidExpensesLineItems" />

  <element name="ComputersAndElectronicEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ComputersAndElectronicEquipmentMember" />

  <element name="ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" />

  <element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_SignificantAccountingPoliciesLineItems" />

  <element name="OtherAccountsPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orpn_OtherAccountsPayableTable" />

  <element name="OtherAccountsPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_OtherAccountsPayableLineItems" />

  <element name="IncomeTaxesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orpn_IncomeTaxesTable" />

  <element name="IncomeTaxesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_IncomeTaxesLineItems" />

  <element name="ContingentLiabilitiesAndCommitmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orpn_ContingentLiabilitiesAndCommitmentsTable" />

  <element name="ContingentLiabilitiesAndCommitmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ContingentLiabilitiesAndCommitmentsLineItems" />

  <element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="orpn_AgreementAxis" />

  <element name="AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_AgreementDomain" />

  <element name="InvestmentAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_InvestmentAgreementMember" />

  <element name="PurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_PurchaseAgreementMember" />

  <element name="ScheduleOfRelatedPartyExpensesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ScheduleOfRelatedPartyExpensesTableTextBlock" />

  <element name="SharePurchaseAgreementSharesToBeIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_SharePurchaseAgreementSharesToBeIssued" />

  <element name="SharePurchaseAgreementValueToBeIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="orpn_SharePurchaseAgreementValueToBeIssued" />

  <element name="ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ConsultantMember" />

  <element name="ShareholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ShareholdersMember" />

  <element name="FinancialExpensesIncomeNetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orpn_FinancialExpensesIncomeNetTable" />

  <element name="FinancialExpensesIncomeNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_FinancialExpensesIncomeNetLineItems" />

  <element name="BankFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="orpn_BankFees" />

  <element name="EmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_EmployeeMember" />

  <element name="ConsultantOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ConsultantOneMember" />

  <element name="ConsultantTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ConsultantTwoMember" />

  <element name="RelatedPartyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_RelatedPartyMember" />

  <element name="StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" />

  <element name="StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" />

  <element name="InterestOnShortTermBankDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="orpn_InterestOnShortTermBankDeposit" />

  <element name="GeneralLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_GeneralLineItems" />

  <element name="ElectronicEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ElectronicEquipmentMember" />

  <element name="GuaranteeForPerformanceOfLeaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="orpn_GuaranteeForPerformanceOfLeaseAgreement" />

  <element name="ColinFosterMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_ColinFosterMember" />

  <element name="NonemployeeStockOptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_NonemployeeStockOptionMember" />

  <element name="IncreaseInMonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="orpn_IncreaseInMonthlyFee" />

  <element name="ConsultantBonusGrantInPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="orpn_ConsultantBonusGrantInPeriod" />

  <element name="ConsultantBonusGrantInPeriodAddition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="orpn_ConsultantBonusGrantInPeriodAddition" />

  <element name="SecondDecemberTwoThousandFourteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_SecondDecemberTwoThousandFourteenMember" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>orpn-20141231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 30-Mar-2015 [11:12:18] {AM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#BalanceSheets" roleURI="http://bioblast-pharma.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfCashFlows" roleURI="http://bioblast-pharma.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfOperations" roleURI="http://bioblast-pharma.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#General" roleURI="http://bioblast-pharma.com/role/General" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ReceivablesAndPrepaidExpenses" roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpenses" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ReceivablesAndPrepaidExpensesDetails" roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#OtherAccountsPayable" roleURI="http://bioblast-pharma.com/role/OtherAccountsPayable" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#OtherAccountsPayableDetails" roleURI="http://bioblast-pharma.com/role/OtherAccountsPayableDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#IncomeTaxes" roleURI="http://bioblast-pharma.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#IncomeTaxesDetails" roleURI="http://bioblast-pharma.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ContingentLiabilitiesAndCommitments" roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitments" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ContingentLiabilitiesAndCommitmentsDetails" roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#FinancialExpensesIncomeNet" roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNet" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#FinancialExpensesIncomeNetDetails" roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetDetails" />

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" xlink:label="loc_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" use="optional" order="50" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_InterestOnShortTermBankDeposit" xlink:label="loc_orpn_InterestOnShortTermBankDeposit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_orpn_InterestOnShortTermBankDeposit" use="optional" order="80" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PaymentsToAcquireShortTermBankDeposit" xlink:label="loc_orpn_PaymentsToAcquireShortTermBankDeposit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_orpn_PaymentsToAcquireShortTermBankDeposit" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_DepositsAssetsCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesCurrent" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:to="loc_us-gaap_ReceivablesNetCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/OtherAccountsPayableDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingExpense" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaap_InterestExpenseBorrowings" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="loc_us-gaap_InterestExpenseBorrowings" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_BankFees" xlink:label="loc_orpn_BankFees" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="loc_orpn_BankFees" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" xlink:label="loc_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="loc_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="loc_us-gaap_InterestIncomeOther" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" xlink:label="loc_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="loc_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="20" weight="-1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>orpn-20141231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 30-Mar-2015 [11:12:18] {AM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#DocumentAndEntityInformation" roleURI="http://bioblast-pharma.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#BalanceSheets" roleURI="http://bioblast-pharma.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfCashFlows" roleURI="http://bioblast-pharma.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfOperations" roleURI="http://bioblast-pharma.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfChangesInShareholdersEquityParenthetical" roleURI="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#BalanceSheetsParenthetical" roleURI="http://bioblast-pharma.com/role/BalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#GeneralDetailsTextual" roleURI="http://bioblast-pharma.com/role/GeneralDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SignificantAccountingPoliciesDetails" roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SignificantAccountingPoliciesDetailsTextual" roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ReceivablesAndPrepaidExpensesDetails" roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#PropertyAndEquipmentNetDetailsTextual" roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#OtherAccountsPayableDetails" roleURI="http://bioblast-pharma.com/role/OtherAccountsPayableDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#IncomeTaxesDetailsTextual" roleURI="http://bioblast-pharma.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#IncomeTaxesDetails" roleURI="http://bioblast-pharma.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityTables" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ContingentLiabilitiesAndCommitmentsDetailsTextual" roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ContingentLiabilitiesAndCommitmentsDetails" roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityDetails" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityDetails2" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails2" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityDetailsTextual" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#RelatedPartyBalancesAndTransactionsDetails" roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#RelatedPartyBalancesAndTransactionsDetails1" roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails1" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#RelatedPartyBalancesAndTransactionsDetailsTextual" roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#FinancialExpensesIncomeNetDetails" roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SubsequentEventsDetailsTextual" roleURI="http://bioblast-pharma.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityDetails1" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails1" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_91" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_91" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_92" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91" xlink:to="loc_us-gaap_ClassOfStockDomain_92" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_92_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91" xlink:to="loc_us-gaap_ClassOfStockDomain_92_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_16" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_16" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_17" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_17" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_18" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_18" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_14" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_15" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_21" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_22" xlink:to="loc_us-gaap_StatementTable_21" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_21" xlink:to="loc_us-gaap_StatementClassOfStockAxis_134" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_134" xlink:to="loc_us-gaap_ClassOfStockDomain_135" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_135_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_134" xlink:to="loc_us-gaap_ClassOfStockDomain_135_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_23" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22" xlink:to="loc_us-gaap_AssetsAbstract_23" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_24" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_AssetsCurrentAbstract_24" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_538" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_DepositsAssetsCurrent_538" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesCurrent_26" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesCurrent_26" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AssetsCurrent_100" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_101" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_101" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_102" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_101" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_103" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_104" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_101" xlink:to="loc_us-gaap_AssetsNoncurrent_104" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_105" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_Assets_105" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_107" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_107" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_108" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_109" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_107" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_109" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_110" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_107" xlink:to="loc_us-gaap_LiabilitiesCurrent_110" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" xlink:to="loc_us-gaap_StockholdersEquityAbstract_111" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_111" xlink:to="loc_us-gaap_CommonStockValue_112" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_111" xlink:to="loc_us-gaap_AdditionalPaidInCapital_114" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_111" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_115" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_116" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_111" xlink:to="loc_us-gaap_StockholdersEquity_116" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_117" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_117" use="optional" order="26" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_29" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_StatementTable_29" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_30" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_29" xlink:to="loc_us-gaap_StatementClassOfStockAxis_30" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_31" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30" xlink:to="loc_us-gaap_ClassOfStockDomain_31" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_31_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30" xlink:to="loc_us-gaap_ClassOfStockDomain_31_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_40" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" xlink:to="loc_us-gaap_NetIncomeLoss_40" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_44" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" xlink:to="loc_us-gaap_Depreciation_44" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_46" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" xlink:to="loc_us-gaap_ShareBasedCompensation_46" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_InterestOnShortTermBankDeposit" xlink:label="loc_orpn_InterestOnShortTermBankDeposit_553" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" xlink:to="loc_orpn_InterestOnShortTermBankDeposit_553" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" xlink:label="loc_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses_56" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses_56" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_58" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_58" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_60" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_65" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_65" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_66" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_66" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PaymentsToAcquireShortTermBankDeposit" xlink:label="loc_orpn_PaymentsToAcquireShortTermBankDeposit_554" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" xlink:to="loc_orpn_PaymentsToAcquireShortTermBankDeposit_554" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_69" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_69" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_70" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_70" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_72" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_72" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_74" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_72" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_74" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_75" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_75" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_76" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77" use="optional" order="25" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_80" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_35" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StatementTable_35" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_35" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_37" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36" xlink:to="loc_us-gaap_ClassOfStockDomain_37" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_37_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36" xlink:to="loc_us-gaap_ClassOfStockDomain_37_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_539" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_37" xlink:to="loc_us-gaap_PreferredClassAMember_539" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_35" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38" xlink:to="loc_us-gaap_EquityComponentDomain_81" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_81_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38" xlink:to="loc_us-gaap_EquityComponentDomain_81_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_82" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_81" xlink:to="loc_us-gaap_CommonStockMember_82" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_84" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_81" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_84" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_81" xlink:to="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_85" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_41" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockholdersEquity_41" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_43" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_SharesOutstanding_43" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue_540" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue_540" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares_541" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares_541" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_542" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_542" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_543" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_543" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_45" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_45" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_47" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_47" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_48" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_48" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" xlink:label="loc_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares_546" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares_546" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" xlink:label="loc_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares_547" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares_547" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue_544" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue_544" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares_545" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares_545" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_49" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_49" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_53" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_NetIncomeLoss_53" use="optional" order="28" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_64" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_StatementTable_61" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_61" xlink:to="loc_us-gaap_StatementClassOfStockAxis_62" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62" xlink:to="loc_us-gaap_ClassOfStockDomain_63" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_63_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62" xlink:to="loc_us-gaap_ClassOfStockDomain_63_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_68" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_68" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_71" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_OperatingIncomeLoss_73" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_78" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_78" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_86" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_NetIncomeLoss_86" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_87" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_87" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_88" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_88" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_89" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_89" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_90" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_90" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_549" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_549" xlink:to="loc_us-gaap_StatementTable_95" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_95" xlink:to="loc_us-gaap_StatementClassOfStockAxis_96" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96" xlink:to="loc_us-gaap_ClassOfStockDomain_97" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_97_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96" xlink:to="loc_us-gaap_ClassOfStockDomain_97_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_548" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_97" xlink:to="loc_us-gaap_PreferredClassAMember_548" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_95" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_551" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550" xlink:to="loc_us-gaap_PrivatePlacementMember_551" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_552" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550" xlink:to="loc_us-gaap_IPOMember_552" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaap_EquityIssuancePerShareAmount_133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_549" xlink:to="loc_us-gaap_EquityIssuancePerShareAmount_133" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_453" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_120" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_StatementTable_120" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_120" xlink:to="loc_us-gaap_StatementScenarioAxis_123" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_454" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_123" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_454" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_454_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_123" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_454_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_455" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_454" xlink:to="loc_us-gaap_ProFormaMember_455" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_124" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_124" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_125" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_125" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_126" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CommonStockSharesIssued_126" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_127" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_127" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/GeneralDetailsTextual">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_GeneralLineItems" xlink:label="loc_orpn_GeneralLineItems_557" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ScheduleOfGeneralTable" xlink:label="loc_orpn_ScheduleOfGeneralTable_141" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_GeneralLineItems_557" xlink:to="loc_orpn_ScheduleOfGeneralTable_141" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_142" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_ScheduleOfGeneralTable_141" xlink:to="loc_us-gaap_StatementClassOfStockAxis_142" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_142" xlink:to="loc_us-gaap_ClassOfStockDomain_143" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_142" xlink:to="loc_us-gaap_ClassOfStockDomain_143_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_144" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_ScheduleOfGeneralTable_141" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_144" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_558" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_144" xlink:to="loc_us-gaap_EquityComponentDomain_558" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_558_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_144" xlink:to="loc_us-gaap_EquityComponentDomain_558_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_559" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_558" xlink:to="loc_us-gaap_CommonStockMember_559" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_145" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_GeneralLineItems_557" xlink:to="loc_us-gaap_NetIncomeLoss_145" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_555" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_GeneralLineItems_557" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_555" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_556" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_GeneralLineItems_557" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_556" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesLineItems" xlink:label="loc_orpn_SignificantAccountingPoliciesLineItems_560" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesTable" xlink:label="loc_orpn_SignificantAccountingPoliciesTable_171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_560" xlink:to="loc_orpn_SignificantAccountingPoliciesTable_171" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_171" xlink:to="loc_us-gaap_StatementClassOfStockAxis_172" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_173" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_173_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_173_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_171" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_562" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" xlink:to="loc_us-gaap_ComputerEquipmentMember_562" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ElectronicEquipmentMember" xlink:label="loc_orpn_ElectronicEquipmentMember_563" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" xlink:to="loc_orpn_ElectronicEquipmentMember_563" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_564" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" xlink:to="loc_us-gaap_OfficeEquipmentMember_564" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PropertyPlantAndEquipmentStraightLinePercentage" xlink:label="loc_orpn_PropertyPlantAndEquipmentStraightLinePercentage_175" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_560" xlink:to="loc_orpn_PropertyPlantAndEquipmentStraightLinePercentage_175" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesLineItems" xlink:label="loc_orpn_SignificantAccountingPoliciesLineItems_227" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesTable" xlink:label="loc_orpn_SignificantAccountingPoliciesTable_178" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_227" xlink:to="loc_orpn_SignificantAccountingPoliciesTable_178" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_179" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_179" xlink:to="loc_us-gaap_EquityComponentDomain_183" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_183_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_179" xlink:to="loc_us-gaap_EquityComponentDomain_183_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_183" xlink:to="loc_us-gaap_CommonStockMember_184" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_StatementScenarioAxis_182" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_182" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_228" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_228_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_182" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_228_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_229" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_228" xlink:to="loc_us-gaap_ProFormaMember_229" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_227" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_185" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TimeDepositsWeightedAverageInterestRateDescription" xlink:label="loc_us-gaap_TimeDepositsWeightedAverageInterestRateDescription_566" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_227" xlink:to="loc_us-gaap_TimeDepositsWeightedAverageInterestRateDescription_566" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="loc_us-gaap_MaturitiesOfTimeDepositsDescription_567" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_227" xlink:to="loc_us-gaap_MaturitiesOfTimeDepositsDescription_567" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesLineItems" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesTable" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesTable_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesTable_199" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesTable_199" xlink:to="loc_us-gaap_StatementClassOfStockAxis_202" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_202" xlink:to="loc_us-gaap_ClassOfStockDomain_203" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_203_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_202" xlink:to="loc_us-gaap_ClassOfStockDomain_203_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_214" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" xlink:to="loc_us-gaap_ReceivablesNetCurrent_214" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_215" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_215" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesCurrent_216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesCurrent_216" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_204" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_204" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_204" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_205" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_205" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_205" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ComputersAndElectronicEquipmentMember" xlink:label="loc_orpn_ComputersAndElectronicEquipmentMember_212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" xlink:to="loc_orpn_ComputersAndElectronicEquipmentMember_212" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_568" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" xlink:to="loc_us-gaap_ComputerEquipmentMember_568" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ElectronicEquipmentMember" xlink:label="loc_orpn_ElectronicEquipmentMember_569" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" xlink:to="loc_orpn_ElectronicEquipmentMember_569" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_570" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" xlink:to="loc_us-gaap_OfficeEquipmentMember_570" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_207" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_208" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_209" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_209" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_222" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_222" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_219" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_219" xlink:to="loc_us-gaap_StatementClassOfStockAxis_220" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_221" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_220" xlink:to="loc_us-gaap_ClassOfStockDomain_221" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_221_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_220" xlink:to="loc_us-gaap_ClassOfStockDomain_221_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_223" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_222" xlink:to="loc_us-gaap_Depreciation_223" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/OtherAccountsPayableDetails">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_OtherAccountsPayableLineItems" xlink:label="loc_orpn_OtherAccountsPayableLineItems_241" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_OtherAccountsPayableTable" xlink:label="loc_orpn_OtherAccountsPayableTable_238" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_OtherAccountsPayableLineItems_241" xlink:to="loc_orpn_OtherAccountsPayableTable_238" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_239" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_OtherAccountsPayableTable_238" xlink:to="loc_us-gaap_StatementClassOfStockAxis_239" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_239" xlink:to="loc_us-gaap_ClassOfStockDomain_240" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_240_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_239" xlink:to="loc_us-gaap_ClassOfStockDomain_240_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_OtherAccountsPayableLineItems_241" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_242" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_243" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_OtherAccountsPayableLineItems_241" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_243" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_244" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_OtherAccountsPayableLineItems_241" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_244" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesLineItems" xlink:label="loc_orpn_IncomeTaxesLineItems_256" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesTable" xlink:label="loc_orpn_IncomeTaxesTable_253" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_IncomeTaxesLineItems_256" xlink:to="loc_orpn_IncomeTaxesTable_253" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_254" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_IncomeTaxesTable_253" xlink:to="loc_us-gaap_StatementClassOfStockAxis_254" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_255" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_254" xlink:to="loc_us-gaap_ClassOfStockDomain_255" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_255_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_254" xlink:to="loc_us-gaap_ClassOfStockDomain_255_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_257" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_256" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_257" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_259" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_256" xlink:to="loc_us-gaap_OperatingLossCarryforwards_259" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesLineItems" xlink:label="loc_orpn_IncomeTaxesLineItems_267" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesTable" xlink:label="loc_orpn_IncomeTaxesTable_264" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_orpn_IncomeTaxesTable_264" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_265" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_IncomeTaxesTable_264" xlink:to="loc_us-gaap_StatementClassOfStockAxis_265" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_266" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_265" xlink:to="loc_us-gaap_ClassOfStockDomain_266" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_266_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_265" xlink:to="loc_us-gaap_ClassOfStockDomain_266_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_271" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_571" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_571" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_272" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_272" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_618" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_618" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_273" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_273" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_274" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_274" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_275" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_275" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_582" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579" xlink:to="loc_us-gaap_AwardTypeAxis_582" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_NonemployeeStockOptionMember" xlink:label="loc_orpn_NonemployeeStockOptionMember_585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584" xlink:to="loc_orpn_NonemployeeStockOptionMember_585" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_270" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_270" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_311" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_311" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetailsTextual">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsLineItems" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsTable" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_294" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_294" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_296" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_294" xlink:to="loc_us-gaap_StatementClassOfStockAxis_296" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_297" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_296" xlink:to="loc_us-gaap_ClassOfStockDomain_297" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_297_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_296" xlink:to="loc_us-gaap_ClassOfStockDomain_297_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_298" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_298" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_299" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_us-gaap_LeaseAndRentalExpense_299" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_GuaranteeForPerformanceOfLeaseAgreement" xlink:label="loc_orpn_GuaranteeForPerformanceOfLeaseAgreement_573" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_orpn_GuaranteeForPerformanceOfLeaseAgreement_573" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_574" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_574" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetails">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsLineItems" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsTable" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_303" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_335" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_303" xlink:to="loc_us-gaap_StatementClassOfStockAxis_335" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_336" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_335" xlink:to="loc_us-gaap_ClassOfStockDomain_336" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_336_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_335" xlink:to="loc_us-gaap_ClassOfStockDomain_336_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_338" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_338" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_339" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_339" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_340" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_340" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_342" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_342" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_307" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" xlink:to="loc_us-gaap_StatementClassOfStockAxis_307" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_307" xlink:to="loc_us-gaap_ClassOfStockDomain_308" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_308_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_307" xlink:to="loc_us-gaap_ClassOfStockDomain_308_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_309" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_324" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_309" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_324" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_324_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_309" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_324_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_325" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_324" xlink:to="loc_us-gaap_EmployeeStockOptionMember_325" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_319" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_319" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_318" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_318" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_322" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_322" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_321" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_321" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_326" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_326" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_327" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_327" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_329" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_329" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_330" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_330" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_331" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_313" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_331" xlink:to="loc_us-gaap_StatementTable_313" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_314" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_StatementClassOfStockAxis_314" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_315" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314" xlink:to="loc_us-gaap_ClassOfStockDomain_315" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_315_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314" xlink:to="loc_us-gaap_ClassOfStockDomain_315_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_316" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_316" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_332" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_332" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_332_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_332_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_333" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_332" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_333" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_334" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_332" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_334" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_337" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_331" xlink:to="loc_us-gaap_ShareBasedCompensation_337" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_609" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_344" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_StatementTable_344" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_345" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_StatementClassOfStockAxis_345" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_346" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_345" xlink:to="loc_us-gaap_ClassOfStockDomain_346" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_346_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_345" xlink:to="loc_us-gaap_ClassOfStockDomain_346_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_360" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_346" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_360" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementAxis" xlink:label="loc_orpn_AgreementAxis_347" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_orpn_AgreementAxis_347" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementDomain" xlink:label="loc_orpn_AgreementDomain_350" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_orpn_AgreementAxis_347" xlink:to="loc_orpn_AgreementDomain_350" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementDomain" xlink:label="loc_orpn_AgreementDomain_350_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_orpn_AgreementAxis_347" xlink:to="loc_orpn_AgreementDomain_350_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_InvestmentAgreementMember" xlink:label="loc_orpn_InvestmentAgreementMember_354" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_AgreementDomain_350" xlink:to="loc_orpn_InvestmentAgreementMember_354" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PurchaseAgreementMember" xlink:label="loc_orpn_PurchaseAgreementMember_358" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_AgreementDomain_350" xlink:to="loc_orpn_PurchaseAgreementMember_358" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_349" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_349" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_364" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_349" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_364" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_364_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_349" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_364_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_365" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_364" xlink:to="loc_us-gaap_EmployeeStockOptionMember_365" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_363" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_363" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_514" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_363" xlink:to="loc_us-gaap_EquityComponentDomain_514" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_514_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_363" xlink:to="loc_us-gaap_EquityComponentDomain_514_default" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_515" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_514" xlink:to="loc_us-gaap_CommonStockMember_515" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_513" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_513" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_610" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_513" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_610" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_610_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_513" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_610_default" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_611" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_610" xlink:to="loc_us-gaap_IPOMember_611" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_348" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_348" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharePurchaseAgreementSharesToBeIssued" xlink:label="loc_orpn_SharePurchaseAgreementSharesToBeIssued_373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_orpn_SharePurchaseAgreementSharesToBeIssued_373" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharePurchaseAgreementValueToBeIssued" xlink:label="loc_orpn_SharePurchaseAgreementValueToBeIssued_376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_orpn_SharePurchaseAgreementValueToBeIssued_376" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_383" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_383" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_384" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_384" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_385" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_386" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_PreferredStockConversionBasis_386" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_389" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaap_DividendsPreferredStock_393" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_DividendsPreferredStock_393" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_394" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_398" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_398" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_395" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_395" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_396" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_396" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_397" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_397" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares_619" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares_619" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue_605" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue_605" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaap_EquityIssuancePerShareAmount_608" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_EquityIssuancePerShareAmount_608" use="optional" order="39" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_518" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_518" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_367" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" xlink:to="loc_us-gaap_StatementClassOfStockAxis_367" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_368" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_367" xlink:to="loc_us-gaap_ClassOfStockDomain_368" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_368_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_367" xlink:to="loc_us-gaap_ClassOfStockDomain_368_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_369" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_519" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_369" xlink:to="loc_us-gaap_RelatedPartyDomain_519" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_519_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_369" xlink:to="loc_us-gaap_RelatedPartyDomain_519_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_RelatedPartyMember" xlink:label="loc_orpn_RelatedPartyMember_520" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_519" xlink:to="loc_orpn_RelatedPartyMember_520" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_518" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_374" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_375" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_518" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_375" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_521" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_380" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" xlink:to="loc_us-gaap_StatementClassOfStockAxis_380" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_381" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_380" xlink:to="loc_us-gaap_ClassOfStockDomain_381" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_381_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_380" xlink:to="loc_us-gaap_ClassOfStockDomain_381_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_382" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_382" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_522" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_382" xlink:to="loc_us-gaap_RelatedPartyDomain_522" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_522_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_382" xlink:to="loc_us-gaap_RelatedPartyDomain_522_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_RelatedPartyMember" xlink:label="loc_orpn_RelatedPartyMember_523" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_522" xlink:to="loc_orpn_RelatedPartyMember_523" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_390" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521" xlink:to="loc_us-gaap_OperatingExpensesAbstract_390" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_392" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_390" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_392" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_391" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_390" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_391" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_412" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_402" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_403" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_402" xlink:to="loc_us-gaap_RelatedPartyDomain_403" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_403_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_402" xlink:to="loc_us-gaap_RelatedPartyDomain_403_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantMember" xlink:label="loc_orpn_ConsultantMember_409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_403" xlink:to="loc_orpn_ConsultantMember_409" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ShareholdersMember" xlink:label="loc_orpn_ShareholdersMember_410" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_403" xlink:to="loc_orpn_ShareholdersMember_410" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantOneMember" xlink:label="loc_orpn_ConsultantOneMember_590" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_403" xlink:to="loc_orpn_ConsultantOneMember_590" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_404" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_404" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_413" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_413_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_413_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_414" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_413" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_414" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_411" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncreaseInMonthlyFee" xlink:label="loc_orpn_IncreaseInMonthlyFee_586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_orpn_IncreaseInMonthlyFee_586" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantBonusGrantInPeriod" xlink:label="loc_orpn_ConsultantBonusGrantInPeriod_587" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_orpn_ConsultantBonusGrantInPeriod_587" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantBonusGrantInPeriodAddition" xlink:label="loc_orpn_ConsultantBonusGrantInPeriodAddition_589" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_orpn_ConsultantBonusGrantInPeriodAddition_589" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_FinancialExpensesIncomeNetLineItems" xlink:label="loc_orpn_FinancialExpensesIncomeNetLineItems_433" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_FinancialExpensesIncomeNetTable" xlink:label="loc_orpn_FinancialExpensesIncomeNetTable_431" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_orpn_FinancialExpensesIncomeNetLineItems_433" xlink:to="loc_orpn_FinancialExpensesIncomeNetTable_431" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_438" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_orpn_FinancialExpensesIncomeNetTable_431" xlink:to="loc_us-gaap_StatementClassOfStockAxis_438" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_439" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_438" xlink:to="loc_us-gaap_ClassOfStockDomain_439" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_439_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_438" xlink:to="loc_us-gaap_ClassOfStockDomain_439_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:label="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_FinancialExpensesIncomeNetLineItems_433" xlink:to="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaap_InterestExpenseBorrowings_442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" xlink:to="loc_us-gaap_InterestExpenseBorrowings_442" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_BankFees" xlink:label="loc_orpn_BankFees_577" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" xlink:to="loc_orpn_BankFees_577" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" xlink:label="loc_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue_445" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" xlink:to="loc_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue_445" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_446" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" xlink:to="loc_us-gaap_OtherNonoperatingExpense_446" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_FinancialExpensesIncomeNetLineItems_433" xlink:to="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_578" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" xlink:to="loc_us-gaap_InterestIncomeOther_578" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" xlink:label="loc_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue_448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" xlink:to="loc_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue_448" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_449" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" xlink:to="loc_us-gaap_OtherNonoperatingIncome_449" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_450" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_FinancialExpensesIncomeNetLineItems_433" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_450" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_510" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_463" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_510" xlink:to="loc_us-gaap_SubsequentEventTable_463" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_464" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_StatementClassOfStockAxis_464" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_465" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_464" xlink:to="loc_us-gaap_ClassOfStockDomain_465" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_465_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_464" xlink:to="loc_us-gaap_ClassOfStockDomain_465_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_466" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_466" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_474" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_466" xlink:to="loc_us-gaap_EquityComponentDomain_474" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_474_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_466" xlink:to="loc_us-gaap_EquityComponentDomain_474_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_475" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_474" xlink:to="loc_us-gaap_CommonStockMember_475" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_473" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_TitleOfIndividualAxis_473" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_473" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_473" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_478" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_478" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_EmployeeMember" xlink:label="loc_orpn_EmployeeMember_482" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" xlink:to="loc_orpn_EmployeeMember_482" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ColinFosterMember" xlink:label="loc_orpn_ColinFosterMember_576" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" xlink:to="loc_orpn_ColinFosterMember_576" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_620" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_620" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_476" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_476" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_476" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_476" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_481" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480" xlink:to="loc_us-gaap_PrivatePlacementMember_481" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_492" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480" xlink:to="loc_us-gaap_IPOMember_492" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_479" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_479" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_486" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_479" xlink:to="loc_us-gaap_RelatedPartyDomain_486" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_486_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_479" xlink:to="loc_us-gaap_RelatedPartyDomain_486_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantOneMember" xlink:label="loc_orpn_ConsultantOneMember_487" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_486" xlink:to="loc_orpn_ConsultantOneMember_487" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantTwoMember" xlink:label="loc_orpn_ConsultantTwoMember_488" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_486" xlink:to="loc_orpn_ConsultantTwoMember_488" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_485" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_485" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_494" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_485" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_494" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_494_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_485" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_494_default" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredBonusMember" xlink:label="loc_us-gaap_DeferredBonusMember_495" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_494" xlink:to="loc_us-gaap_DeferredBonusMember_495" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_493" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_493" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_505" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_493" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_505" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_505_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_493" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_505_default" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_506" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_505" xlink:to="loc_us-gaap_EmployeeStockOptionMember_506" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementAxis" xlink:label="loc_orpn_AgreementAxis_504" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_orpn_AgreementAxis_504" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementDomain" xlink:label="loc_orpn_AgreementDomain_508" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_orpn_AgreementAxis_504" xlink:to="loc_orpn_AgreementDomain_508" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementDomain" xlink:label="loc_orpn_AgreementDomain_508_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_orpn_AgreementAxis_504" xlink:to="loc_orpn_AgreementDomain_508_default" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PurchaseAgreementMember" xlink:label="loc_orpn_PurchaseAgreementMember_509" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_orpn_AgreementDomain_508" xlink:to="loc_orpn_PurchaseAgreementMember_509" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_507" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_507" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_511" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_507" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_511" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_511_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_507" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_511_default" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_512" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_511" xlink:to="loc_us-gaap_SubsequentEventMember_512" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_490" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_490" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_575" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_575" use="optional" order="43" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_593" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" xlink:to="loc_us-gaap_AwardTypeAxis_593" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_594" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_594" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_594_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_594_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_NonemployeeStockOptionMember" xlink:label="loc_orpn_NonemployeeStockOptionMember_595" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_594" xlink:to="loc_orpn_NonemployeeStockOptionMember_595" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_596" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" xlink:to="loc_us-gaap_AwardDateAxis_596" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_597" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_596" xlink:to="loc_us-gaap_AwardDateDomain_597" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_597_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_596" xlink:to="loc_us-gaap_AwardDateDomain_597_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SecondDecemberTwoThousandFourteenMember" xlink:label="loc_orpn_SecondDecemberTwoThousandFourteenMember_598" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_597" xlink:to="loc_orpn_SecondDecemberTwoThousandFourteenMember_598" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant_600" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant_600" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber_601" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber_601" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice_602" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice_602" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate_603" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate_603" use="optional" order="13" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>orpn-20141231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 30-Mar-2015 [11:12:18] {AM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_DocumentAndEntityInformationAbstract" xlink:label="loc_orpn_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_DocumentAndEntityInformationAbstract" xlink:to="lab_orpn_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at the end of the year</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xml:lang="en-US">Deposits Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xml:lang="en-US">Short-term bank deposits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders&#39; Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balances</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders&#39; equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile loss to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" xml:lang="en-US">Stock Issued During Period Ordinary Shares Issued To Founders Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" xml:lang="en-US">Issuance of Ordinary shares to founders</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" xml:lang="en-US">Equity impact of the value of ordinary stock issued to founders during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" xlink:to="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" xml:lang="en-US">Stock Issued During Period Ordinary Shares Issued To Founders Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" xml:lang="en-US">Issuance of Ordinary shares to founders (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" xml:lang="en-US">Number of ordinary stock issued to founders during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" xlink:to="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Issuance of Preferred A shares, net ($0.53 per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Issuance of Preferred A shares, net ($0.53 per share) (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of Preferred A shares into Ordinary shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of Preferred A shares into Ordinary shares (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xml:lang="en-US">Deemed Dividend</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" xlink:label="loc_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" xml:lang="en-US">Stock Issued During Period Value Issuance Of Ordinary Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" xml:lang="en-US">Issuance of Ordinary shares, net ($0.95 per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" xml:lang="en-US">Equity impact of the value of ordinary stock issued during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" xlink:to="lab_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" xlink:label="loc_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" xml:lang="en-US">Increase Decrease in Receivables and Prepaid Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" xml:lang="en-US">Receivables and prepaid expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" xml:lang="en-US">The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities and amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" xlink:to="lab_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" xlink:label="loc_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Ordinary Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" xml:lang="en-US">Issuance of Ordinary shares, net ($0.95 per share) (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" xml:lang="en-US">Number of ordinary stock issued during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" xlink:to="lab_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" xml:lang="en-US">Increase (Decrease) in Deposit Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" xml:lang="en-US">Long-term deposit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInDepositOtherAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Trade payables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xml:lang="en-US">Other accounts payables</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from investing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PaymentsToAcquireShortTermBankDeposit" xlink:label="loc_orpn_PaymentsToAcquireShortTermBankDeposit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_PaymentsToAcquireShortTermBankDeposit" xml:lang="en-US">Payments To Acquire Short Term Bank Deposit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_orpn_PaymentsToAcquireShortTermBankDeposit" xml:lang="en-US">Short-term bank deposits</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_PaymentsToAcquireShortTermBankDeposit" xml:lang="en-US">The cash outflow associated with short-term bank deposit.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_PaymentsToAcquireShortTermBankDeposit" xlink:to="lab_orpn_PaymentsToAcquireShortTermBankDeposit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Issuance of shares, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Increase in cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Financial expenses (income), net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Financial expenses (income), net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xml:lang="en-US">Accumulated Deficit during Development Stage [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:to="lab_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xml:lang="en-US">Deemed dividend</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Loss attributable to holders of Ordinary shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss attributable to Ordinary shares as reported</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted loss per share (in dollars per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per share of Ordinary share, basic and diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of Ordinary shares used in computing basic and diluted loss per share (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Shares used in computing net loss per share of Ordinary shares, basic and diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesCurrent" xml:lang="en-US">Receivables and Prepaid Expenses, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesCurrent" xml:lang="en-US">Receivables and prepaid expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesCurrent" xml:lang="en-US">Receivables and Prepaid Expenses, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesCurrent" xml:lang="en-US">The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value and amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:to="lab_orpn_ReceivablesAndPrepaidExpensesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">LONG-TERM ASSETS:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposits Assets, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Long-term deposit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Depreciated cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Assets, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total long-term assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">TOTAL ASSETS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#39; EQUITY</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Trade payables</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Trade payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts Payable, Other, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Other accounts payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts Payable, Other, Current</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">SHAREHOLDERS&#39; EQUITY:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Ordinary shares of NIS 0.01 par value - 50,000,000 and 16,613,139 shares authorized at December 31, 2014 and 2013, respectively; 14,230,480 and 9,182,867 issued and outstanding shares at December 31, 2014 and 2013, respectively;</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid- in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#39; EQUITY</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par or stated value per share (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares, outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaap_EquityIssuancePerShareAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityIssuancePerShareAmount" xml:lang="en-US">Development Stage Entities, Equity Issuance, Per Share Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityIssuancePerShareAmount" xml:lang="en-US">Equity Issuance, Per Share Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityIssuancePerShareAmount" xlink:to="lab_us-gaap_EquityIssuancePerShareAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ScheduleOfGeneralTable" xlink:label="loc_orpn_ScheduleOfGeneralTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ScheduleOfGeneralTable" xml:lang="en-US">Schedule Of General [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ScheduleOfGeneralTable" xlink:to="lab_orpn_ScheduleOfGeneralTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_FinancialStatementsDisclosurePolicyTextBlock" xlink:label="loc_orpn_FinancialStatementsDisclosurePolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_FinancialStatementsDisclosurePolicyTextBlock" xml:lang="en-US">Financial Statements Disclosure [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_FinancialStatementsDisclosurePolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy regarding functional currency used in the operations of the business.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_FinancialStatementsDisclosurePolicyTextBlock" xlink:to="lab_orpn_FinancialStatementsDisclosurePolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_orpn_ShortTermBankDepositsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ShortTermBankDepositsPolicyTextBlock" xml:lang="en-US">Short Term Bank Deposits [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_ShortTermBankDepositsPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for short-term bank deposits.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ShortTermBankDepositsPolicyTextBlock" xlink:to="lab_orpn_ShortTermBankDepositsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_LongTermDepositsPolicyTextBlock" xlink:label="loc_orpn_LongTermDepositsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_LongTermDepositsPolicyTextBlock" xml:lang="en-US">Long Term Deposits [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_LongTermDepositsPolicyTextBlock" xml:lang="en-US">Disclosure of long term deposits of the entity which includes long-term deposits for motor vehicles under operating leases, presented at their cost.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_LongTermDepositsPolicyTextBlock" xlink:to="lab_orpn_LongTermDepositsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" xlink:label="loc_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives, Depreciation Rates [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" xml:lang="en-US">Tabular disclosure for rate of depreciation using the straight-line method over the estimated useful lives of the assets.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" xlink:to="lab_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesTable" xlink:label="loc_orpn_SignificantAccountingPoliciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SignificantAccountingPoliciesTable" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SignificantAccountingPoliciesTable" xlink:to="lab_orpn_SignificantAccountingPoliciesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PropertyPlantAndEquipmentStraightLinePercentage" xlink:label="loc_orpn_PropertyPlantAndEquipmentStraightLinePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_PropertyPlantAndEquipmentStraightLinePercentage" xml:lang="en-US">Property Plant and Equipment Straight Line Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_PropertyPlantAndEquipmentStraightLinePercentage" xml:lang="en-US">Property Plant And Equipment Straight Line Depreciation Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_PropertyPlantAndEquipmentStraightLinePercentage" xml:lang="en-US">Represents the rate of depreciation calculated using straight line method over the estimated useful lives of the assets during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_PropertyPlantAndEquipmentStraightLinePercentage" xlink:to="lab_orpn_PropertyPlantAndEquipmentStraightLinePercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xml:lang="en-US">Liability for Uncertain Tax Positions, Current</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesAbstract" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesAbstract" xml:lang="en-US">Receivables and Prepaid Expenses [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesAbstract" xlink:to="lab_orpn_ReceivablesAndPrepaidExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock" xml:lang="en-US">Receivables and Prepaid Expenses Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock" xml:lang="en-US">The entire disclosure for claims held for amounts due a entity and the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock" xlink:to="lab_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesTable" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesTable" xml:lang="en-US">Receivables and Prepaid Expenses [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesTable" xlink:to="lab_orpn_ReceivablesAndPrepaidExpensesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesLineItems" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesLineItems" xml:lang="en-US">Receivables and Prepaid Expenses [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesLineItems" xlink:to="lab_orpn_ReceivablesAndPrepaidExpensesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ComputersAndElectronicEquipmentMember" xlink:label="loc_orpn_ComputersAndElectronicEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ComputersAndElectronicEquipmentMember" xml:lang="en-US">Computers and Electronic Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ComputersAndElectronicEquipmentMember" xlink:to="lab_orpn_ComputersAndElectronicEquipmentMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" xml:lang="en-US">Receivables and Prepaid Expenses Disclosure [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" xml:lang="en-US">Tabular disclosure of the various types of receivables and the amounts paid in advance for capitalized costs for the reporting period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" xlink:to="lab_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xml:lang="en-US">Receivables, Net, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xml:lang="en-US">Government authorities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesLineItems" xlink:label="loc_orpn_SignificantAccountingPoliciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SignificantAccountingPoliciesLineItems" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems" xlink:to="lab_orpn_SignificantAccountingPoliciesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProFormaMember" xml:lang="en-US">Pro Forma [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProFormaMember" xlink:to="lab_us-gaap_ProFormaMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_OtherAccountsPayableTable" xlink:label="loc_orpn_OtherAccountsPayableTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_OtherAccountsPayableTable" xml:lang="en-US">OTHER ACCOUNTS PAYABLE [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_OtherAccountsPayableTable" xlink:to="lab_orpn_OtherAccountsPayableTable" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_OtherAccountsPayableLineItems" xlink:label="loc_orpn_OtherAccountsPayableLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_OtherAccountsPayableLineItems" xml:lang="en-US">OTHER ACCOUNTS PAYABLE [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_OtherAccountsPayableLineItems" xlink:to="lab_orpn_OtherAccountsPayableLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employees and payroll accruals</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesTable" xlink:label="loc_orpn_IncomeTaxesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_IncomeTaxesTable" xml:lang="en-US">INCOME TAXES [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_IncomeTaxesTable" xlink:to="lab_orpn_IncomeTaxesTable" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesLineItems" xlink:label="loc_orpn_IncomeTaxesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_IncomeTaxesLineItems" xml:lang="en-US">INCOME TAXES [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_IncomeTaxesLineItems" xlink:to="lab_orpn_IncomeTaxesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders&#39; Equity Note [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xml:lang="en-US">Share-based Arrangements with Employees and Nonemployees [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Operating loss carry forward</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Research and development expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred issuance expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Net deferred tax asset before valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Operating Leases of Lessee Disclosure [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsTable" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ContingentLiabilitiesAndCommitmentsTable" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsTable" xlink:to="lab_orpn_ContingentLiabilitiesAndCommitmentsTable" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsLineItems" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ContingentLiabilitiesAndCommitmentsLineItems" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems" xlink:to="lab_orpn_ContingentLiabilitiesAndCommitmentsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options Outstanding at beginning of year (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options Outstanding at end of year (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options Granted (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Number of Options Vested and expected to vest (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options exercisable at the end of the year (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price Outstanding at beginning of year (in dollars per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price Outstanding at end of year (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price Granted (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price Vested and expected to vest (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price Options exercisable at the end of the year (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">2015</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">2016</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">2017</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementAxis" xlink:label="loc_orpn_AgreementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_AgreementAxis" xlink:to="lab_orpn_AgreementAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders&#39; Equity, Reverse Stock Split</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementDomain" xlink:label="loc_orpn_AgreementDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_AgreementDomain" xlink:to="lab_orpn_AgreementDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_InvestmentAgreementMember" xlink:label="loc_orpn_InvestmentAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_InvestmentAgreementMember" xml:lang="en-US">Investment Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_InvestmentAgreementMember" xlink:to="lab_orpn_InvestmentAgreementMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PurchaseAgreementMember" xlink:label="loc_orpn_PurchaseAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_PurchaseAgreementMember" xml:lang="en-US">Purchase Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_PurchaseAgreementMember" xlink:to="lab_orpn_PurchaseAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ScheduleOfRelatedPartyExpensesTableTextBlock" xlink:label="loc_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock" xml:lang="en-US">Schedule Of Related Party Expenses [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock" xml:lang="en-US">Tabular disclosure of related party expenses during period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock" xlink:to="lab_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharePurchaseAgreementSharesToBeIssued" xlink:label="loc_orpn_SharePurchaseAgreementSharesToBeIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SharePurchaseAgreementSharesToBeIssued" xml:lang="en-US">Share Purchase Agreement, Shares to be issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_SharePurchaseAgreementSharesToBeIssued" xml:lang="en-US">The number of shares to be issued according to the share purchase agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SharePurchaseAgreementSharesToBeIssued" xlink:to="lab_orpn_SharePurchaseAgreementSharesToBeIssued" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharePurchaseAgreementValueToBeIssued" xlink:label="loc_orpn_SharePurchaseAgreementValueToBeIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SharePurchaseAgreementValueToBeIssued" xml:lang="en-US">Share Purchase Agreement, Value to be issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_SharePurchaseAgreementValueToBeIssued" xml:lang="en-US">The value of stock to be issued according to the share purchase agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SharePurchaseAgreementValueToBeIssued" xlink:to="lab_orpn_SharePurchaseAgreementValueToBeIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Ordinary shares upon initial public offering net ($11 per share) (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of Ordinary shares upon initial public offering net ($11 per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Annual Compensation Fee</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred Stock, Conversion Basis</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConversionBasis" xlink:to="lab_us-gaap_PreferredStockConversionBasis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Amounts charged to: *)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaap_DividendsPreferredStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsPreferredStock" xml:lang="en-US">Dividends, Preferred Stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantMember" xlink:label="loc_orpn_ConsultantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ConsultantMember" xml:lang="en-US">Consultant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ConsultantMember" xlink:to="lab_orpn_ConsultantMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ShareholdersMember" xlink:label="loc_orpn_ShareholdersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ShareholdersMember" xml:lang="en-US">Shareholders [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ShareholdersMember" xlink:to="lab_orpn_ShareholdersMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Income and Expenses [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_FinancialExpensesIncomeNetTable" xlink:label="loc_orpn_FinancialExpensesIncomeNetTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_FinancialExpensesIncomeNetTable" xml:lang="en-US">FINANCIAL EXPENSES INCOME, NET [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_FinancialExpensesIncomeNetTable" xlink:to="lab_orpn_FinancialExpensesIncomeNetTable" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_FinancialExpensesIncomeNetLineItems" xlink:label="loc_orpn_FinancialExpensesIncomeNetLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_FinancialExpensesIncomeNetLineItems" xml:lang="en-US">FINANCIAL EXPENSES INCOME, NET [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_FinancialExpensesIncomeNetLineItems" xlink:to="lab_orpn_FinancialExpensesIncomeNetLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:label="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xml:lang="en-US">Other Expense, Nonoperating [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xml:lang="en-US">Financial expenses:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="lab_us-gaap_OtherExpenseDisclosureNonoperatingAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaap_InterestExpenseBorrowings" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xml:lang="en-US">Interest Expense, Borrowings</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpenseBorrowings" xml:lang="en-US">Interest expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseBorrowings" xlink:to="lab_us-gaap_InterestExpenseBorrowings" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_BankFees" xlink:label="loc_orpn_BankFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_BankFees" xml:lang="en-US">Bank Fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_BankFees" xml:lang="en-US">Bank fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_BankFees" xml:lang="en-US">The amount of expense related to bank fees.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_BankFees" xlink:to="lab_orpn_BankFees" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" xlink:label="loc_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" xml:lang="en-US">Expenses and Losses, Reporting Currency Denominated, Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" xml:lang="en-US">Exchange rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" xlink:to="lab_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xml:lang="en-US">Other Income, Nonoperating [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xml:lang="en-US">Financial income:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="lab_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" xlink:label="loc_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" xml:lang="en-US">Revenues and Gains, Reporting Currency Denominated, Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" xml:lang="en-US">Exchange rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" xlink:to="lab_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BoardOfDirectorsChairmanMember" xlink:to="lab_us-gaap_BoardOfDirectorsChairmanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_EmployeeMember" xlink:label="loc_orpn_EmployeeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_EmployeeMember" xml:lang="en-US">Employee [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_EmployeeMember" xlink:to="lab_orpn_EmployeeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantOneMember" xlink:label="loc_orpn_ConsultantOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ConsultantOneMember" xml:lang="en-US">Consultant One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ConsultantOneMember" xlink:to="lab_orpn_ConsultantOneMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantTwoMember" xlink:label="loc_orpn_ConsultantTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ConsultantTwoMember" xml:lang="en-US">Consultant Two [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ConsultantTwoMember" xlink:to="lab_orpn_ConsultantTwoMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredBonusMember" xlink:label="loc_us-gaap_DeferredBonusMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredBonusMember" xml:lang="en-US">Deferred Bonus [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredBonusMember" xlink:to="lab_us-gaap_DeferredBonusMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_RelatedPartyMember" xlink:label="loc_orpn_RelatedPartyMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_RelatedPartyMember" xml:lang="en-US">Related Party [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_RelatedPartyMember" xlink:to="lab_orpn_RelatedPartyMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredClassAMember" xml:lang="en-US">Preferred Class A [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredClassAMember" xlink:to="lab_us-gaap_PreferredClassAMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xml:lang="en-US">Stock Issued During Period Ordinary Shares Issued Upon Private Placement Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xml:lang="en-US">Issuance of Ordinary shares upon private placement, net ($6.07 per share)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xml:lang="en-US">Equity impact of the value of ordinary stock issued upon private placement during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xlink:to="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xml:lang="en-US">Stock Issued During Period Ordinary Shares Issued Upon Private Placement Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xml:lang="en-US">Issuance of Ordinary shares upon private placement, net ($6.07 per share) (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xml:lang="en-US">Number of ordinary stock issued upon private placement during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xlink:to="lab_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_InterestOnShortTermBankDeposit" xlink:label="loc_orpn_InterestOnShortTermBankDeposit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_InterestOnShortTermBankDeposit" xml:lang="en-US">Interest On Short Term Bank Deposit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_orpn_InterestOnShortTermBankDeposit" xml:lang="en-US">Interest on short-term bank deposits</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_InterestOnShortTermBankDeposit" xml:lang="en-US">Represents amount of non-cash of interest on short-term bank deposit.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_InterestOnShortTermBankDeposit" xlink:to="lab_orpn_InterestOnShortTermBankDeposit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_GeneralLineItems" xlink:label="loc_orpn_GeneralLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_GeneralLineItems" xml:lang="en-US">General [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_GeneralLineItems" xlink:to="lab_orpn_GeneralLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computers and software [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ElectronicEquipmentMember" xlink:label="loc_orpn_ElectronicEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ElectronicEquipmentMember" xml:lang="en-US">Electronic Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_ElectronicEquipmentMember" xml:lang="en-US">Electronic equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ElectronicEquipmentMember" xlink:to="lab_orpn_ElectronicEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office furniture and equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TimeDepositsWeightedAverageInterestRateDescription" xlink:label="loc_us-gaap_TimeDepositsWeightedAverageInterestRateDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TimeDepositsWeightedAverageInterestRateDescription" xml:lang="en-US">Time Deposits, Weighted Average Interest Rate, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimeDepositsWeightedAverageInterestRateDescription" xlink:to="lab_us-gaap_TimeDepositsWeightedAverageInterestRateDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="loc_us-gaap_MaturitiesOfTimeDepositsDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaturitiesOfTimeDepositsDescription" xml:lang="en-US">Maturities of Time Deposits, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfTimeDepositsDescription" xlink:to="lab_us-gaap_MaturitiesOfTimeDepositsDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_GuaranteeForPerformanceOfLeaseAgreement" xlink:label="loc_orpn_GuaranteeForPerformanceOfLeaseAgreement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_GuaranteeForPerformanceOfLeaseAgreement" xml:lang="en-US">Guarantee For Performance Of Lease Agreement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_GuaranteeForPerformanceOfLeaseAgreement" xml:lang="en-US">The amount of guarantee given by the company as a security for performance of lease agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_GuaranteeForPerformanceOfLeaseAgreement" xlink:to="lab_orpn_GuaranteeForPerformanceOfLeaseAgreement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ColinFosterMember" xlink:label="loc_orpn_ColinFosterMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ColinFosterMember" xml:lang="en-US">Colin Foster [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ColinFosterMember" xlink:to="lab_orpn_ColinFosterMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other Nonoperating Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Financial expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Financial income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_NonemployeeStockOptionMember" xlink:label="loc_orpn_NonemployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_NonemployeeStockOptionMember" xml:lang="en-US">Nonemployee Stock Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_NonemployeeStockOptionMember" xlink:to="lab_orpn_NonemployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncreaseInMonthlyFee" xlink:label="loc_orpn_IncreaseInMonthlyFee" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_IncreaseInMonthlyFee" xml:lang="en-US">Increase In Monthly Fee</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_IncreaseInMonthlyFee" xml:lang="en-US">This element represents monthly fee increases to consultants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_IncreaseInMonthlyFee" xlink:to="lab_orpn_IncreaseInMonthlyFee" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantBonusGrantInPeriod" xlink:label="loc_orpn_ConsultantBonusGrantInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ConsultantBonusGrantInPeriod" xml:lang="en-US">Consultant Bonus Grant In Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_ConsultantBonusGrantInPeriod" xml:lang="en-US">This element represents bonus granted during the period for the consultant.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ConsultantBonusGrantInPeriod" xlink:to="lab_orpn_ConsultantBonusGrantInPeriod" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantBonusGrantInPeriodAddition" xlink:label="loc_orpn_ConsultantBonusGrantInPeriodAddition" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_ConsultantBonusGrantInPeriodAddition" xml:lang="en-US">Consultant Bonus Grant In Period, Addition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_ConsultantBonusGrantInPeriodAddition" xml:lang="en-US">This element represents additional bonus granted during the period for the consultant.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_ConsultantBonusGrantInPeriodAddition" xlink:to="lab_orpn_ConsultantBonusGrantInPeriodAddition" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateAxis" xml:lang="en-US">Award Date [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardDateDomain" xml:lang="en-US">Award Date [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SecondDecemberTwoThousandFourteenMember" xlink:label="loc_orpn_SecondDecemberTwoThousandFourteenMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SecondDecemberTwoThousandFourteenMember" xml:lang="en-US">Second December Two Thousand Fourteen [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_orpn_SecondDecemberTwoThousandFourteenMember" xml:lang="en-US">December 2, 2014 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SecondDecemberTwoThousandFourteenMember" xlink:to="lab_orpn_SecondDecemberTwoThousandFourteenMember" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options To Nonemployees Date Of Grant</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" xml:lang="en-US">It denotes the grant date of non-employee awards.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" xlink:to="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options To Nonemployees Outstanding Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" xml:lang="en-US">The number of non-employee options outstanding.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" xlink:to="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options To Nonemployees Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" xml:lang="en-US">It denotes the exercise price of non-employee options.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" xlink:to="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options To Nonemployees Expiration Date</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" xml:lang="en-US">It denotes the expiration date of non-employee awards.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" xlink:to="lab_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax asset</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>orpn-20141231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 30-Mar-2015 [11:12:18] {AM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#DocumentAndEntityInformation" roleURI="http://bioblast-pharma.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ReceivablesAndPrepaidExpenses" roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpenses" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#PropertyAndEquipmentNet" roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNet" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#OtherAccountsPayable" roleURI="http://bioblast-pharma.com/role/OtherAccountsPayable" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#IncomeTaxes" roleURI="http://bioblast-pharma.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ContingentLiabilitiesAndCommitments" roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitments" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquity" roleURI="http://bioblast-pharma.com/role/ShareholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#RelatedPartyBalancesAndTransactions" roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactions" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#FinancialExpensesIncomeNet" roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNet" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SubsequentEvents" roleURI="http://bioblast-pharma.com/role/SubsequentEvents" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#BalanceSheets" roleURI="http://bioblast-pharma.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SignificantAccountingPoliciesTables" roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ReceivablesAndPrepaidExpensesTables" roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#PropertyAndEquipmentNetTables" roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNetTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#OtherAccountsPayableTables" roleURI="http://bioblast-pharma.com/role/OtherAccountsPayableTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#IncomeTaxesTables" roleURI="http://bioblast-pharma.com/role/IncomeTaxesTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ContingentLiabilitiesAndCommitmentsTables" roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityTables" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#FinancialExpensesIncomeNetTables" roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetTables" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#BalanceSheetsParenthetical" roleURI="http://bioblast-pharma.com/role/BalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#GeneralDetailsTextual" roleURI="http://bioblast-pharma.com/role/GeneralDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SignificantAccountingPoliciesDetails" roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SignificantAccountingPoliciesDetailsTextual" roleURI="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ReceivablesAndPrepaidExpensesDetails" roleURI="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#PropertyAndEquipmentNetDetailsTextual" roleURI="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#OtherAccountsPayableDetails" roleURI="http://bioblast-pharma.com/role/OtherAccountsPayableDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#IncomeTaxesDetails" roleURI="http://bioblast-pharma.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#IncomeTaxesDetailsTextual" roleURI="http://bioblast-pharma.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfOperations" roleURI="http://bioblast-pharma.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ContingentLiabilitiesAndCommitmentsDetails" roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ContingentLiabilitiesAndCommitmentsDetailsTextual" roleURI="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityDetails" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityDetails1" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails1" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityDetails2" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetails2" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#ShareholdersEquityDetailsTextual" roleURI="http://bioblast-pharma.com/role/ShareholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#RelatedPartyBalancesAndTransactionsDetails" roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#RelatedPartyBalancesAndTransactionsDetails1" roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails1" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#RelatedPartyBalancesAndTransactionsDetailsTextual" roleURI="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#FinancialExpensesIncomeNetDetails" roleURI="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetDetails" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SubsequentEventsDetailsTextual" roleURI="http://bioblast-pharma.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfChangesInShareholdersEquityParenthetical" roleURI="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#StatementsOfCashFlows" roleURI="http://bioblast-pharma.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#General" roleURI="http://bioblast-pharma.com/role/General" />

  <roleRef xlink:type="simple" xlink:href="orpn-20141231.xsd#SignificantAccountingPolicies" roleURI="http://bioblast-pharma.com/role/SignificantAccountingPolicies" />

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_DocumentAndEntityInformationAbstract" xlink:label="loc_orpn_DocumentAndEntityInformationAbstract_2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_DocumentAndEntityInformationAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_91" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_91" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_92" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91" xlink:to="loc_us-gaap_ClassOfStockDomain_92" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_4" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_16" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_16" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_17" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_17" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_18" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_18" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_14" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_15" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpenses">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesAbstract" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesAbstract_188" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock_190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesAbstract_188" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock_190" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/PropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_189" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_192" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_189" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_192" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_231" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_231" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_232" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_246" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_247" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_246" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_247" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_277" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_277" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_288" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_260" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_260" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_263" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_352" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_353" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_352" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/FinancialExpensesIncomeNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_416" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_416" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_418" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_459" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_460" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_459" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_460" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_21" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_20" xlink:to="loc_us-gaap_StatementTable_21" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_21" xlink:to="loc_us-gaap_StatementClassOfStockAxis_134" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_134" xlink:to="loc_us-gaap_ClassOfStockDomain_135" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_22" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_21" xlink:to="loc_us-gaap_StatementLineItems_22" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_23" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22" xlink:to="loc_us-gaap_AssetsAbstract_23" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_24" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_AssetsCurrentAbstract_24" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_538" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_DepositsAssetsCurrent_538" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesCurrent_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesCurrent_26" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AssetsCurrent_100" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_101" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_101" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_102" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_101" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_103" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_101" xlink:to="loc_us-gaap_AssetsNoncurrent_104" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_Assets_105" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_107" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_107" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_108" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_109" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_107" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_109" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_107" xlink:to="loc_us-gaap_LiabilitiesCurrent_110" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" xlink:to="loc_us-gaap_StockholdersEquityAbstract_111" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_111" xlink:to="loc_us-gaap_CommonStockValue_112" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_111" xlink:to="loc_us-gaap_AdditionalPaidInCapital_114" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_111" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_115" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_116" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_111" xlink:to="loc_us-gaap_StockholdersEquity_116" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_117" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_106" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_117" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_152" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_UseOfEstimates_153" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_154" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_FinancialStatementsDisclosurePolicyTextBlock" xlink:label="loc_orpn_FinancialStatementsDisclosurePolicyTextBlock_156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_orpn_FinancialStatementsDisclosurePolicyTextBlock_156" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_157" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_orpn_ShortTermBankDepositsPolicyTextBlock_565" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_orpn_ShortTermBankDepositsPolicyTextBlock_565" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_LongTermDepositsPolicyTextBlock" xlink:label="loc_orpn_LongTermDepositsPolicyTextBlock_159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_orpn_LongTermDepositsPolicyTextBlock_159" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_160" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_161" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_161" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_162" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_162" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_163" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_164" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_152" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_165" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_167" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock" xlink:label="loc_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock_168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_167" xlink:to="loc_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock_168" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesAbstract" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesAbstract_194" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock_213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesAbstract_194" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock_213" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/PropertyAndEquipmentNetTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_195" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_197" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_195" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_197" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_234" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_234" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_235" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_249" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_250" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_249" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_250" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_290" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_290" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_291" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_269" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_269" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_582" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579" xlink:to="loc_us-gaap_AwardTypeAxis_582" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_582" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_NonemployeeStockOptionMember" xlink:label="loc_orpn_NonemployeeStockOptionMember_585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_584" xlink:to="loc_orpn_NonemployeeStockOptionMember_585" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_270" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_270" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_311" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_311" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_357" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_359" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_357" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ScheduleOfRelatedPartyExpensesTableTextBlock" xlink:label="loc_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_357" xlink:to="loc_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock_372" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_420" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_422" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_420" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_422" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_119" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="loc_us-gaap_StatementTable_120" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_120" xlink:to="loc_us-gaap_StatementScenarioAxis_123" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_454" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_123" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_454" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_455" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_454" xlink:to="loc_us-gaap_ProFormaMember_455" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_453" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_120" xlink:to="loc_us-gaap_StatementLineItems_453" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_124" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_124" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_125" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CommonStockSharesIssued_126" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_453" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_127" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/GeneralDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_140" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ScheduleOfGeneralTable" xlink:label="loc_orpn_ScheduleOfGeneralTable_141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_140" xlink:to="loc_orpn_ScheduleOfGeneralTable_141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ScheduleOfGeneralTable_141" xlink:to="loc_us-gaap_StatementClassOfStockAxis_142" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_142" xlink:to="loc_us-gaap_ClassOfStockDomain_143" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_144" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ScheduleOfGeneralTable_141" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_144" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_558" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_144" xlink:to="loc_us-gaap_EquityComponentDomain_558" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_559" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_558" xlink:to="loc_us-gaap_CommonStockMember_559" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_GeneralLineItems" xlink:label="loc_orpn_GeneralLineItems_557" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ScheduleOfGeneralTable_141" xlink:to="loc_orpn_GeneralLineItems_557" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_GeneralLineItems_557" xlink:to="loc_us-gaap_NetIncomeLoss_145" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_555" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_GeneralLineItems_557" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_555" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_556" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_GeneralLineItems_557" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_556" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_170" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesTable" xlink:label="loc_orpn_SignificantAccountingPoliciesTable_171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_170" xlink:to="loc_orpn_SignificantAccountingPoliciesTable_171" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_171" xlink:to="loc_us-gaap_StatementClassOfStockAxis_172" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_173" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_171" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_174" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_562" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" xlink:to="loc_us-gaap_ComputerEquipmentMember_562" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ElectronicEquipmentMember" xlink:label="loc_orpn_ElectronicEquipmentMember_563" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" xlink:to="loc_orpn_ElectronicEquipmentMember_563" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_564" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_561" xlink:to="loc_us-gaap_OfficeEquipmentMember_564" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesLineItems" xlink:label="loc_orpn_SignificantAccountingPoliciesLineItems_560" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_171" xlink:to="loc_orpn_SignificantAccountingPoliciesLineItems_560" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PropertyPlantAndEquipmentStraightLinePercentage" xlink:label="loc_orpn_PropertyPlantAndEquipmentStraightLinePercentage_175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_560" xlink:to="loc_orpn_PropertyPlantAndEquipmentStraightLinePercentage_175" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesTable" xlink:label="loc_orpn_SignificantAccountingPoliciesTable_178" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="loc_orpn_SignificantAccountingPoliciesTable_178" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_179" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_179" xlink:to="loc_us-gaap_EquityComponentDomain_183" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_183" xlink:to="loc_us-gaap_CommonStockMember_184" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_178" xlink:to="loc_us-gaap_StatementScenarioAxis_182" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_182" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_228" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_229" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_228" xlink:to="loc_us-gaap_ProFormaMember_229" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SignificantAccountingPoliciesLineItems" xlink:label="loc_orpn_SignificantAccountingPoliciesLineItems_227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesTable_178" xlink:to="loc_orpn_SignificantAccountingPoliciesLineItems_227" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_227" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_185" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TimeDepositsWeightedAverageInterestRateDescription" xlink:label="loc_us-gaap_TimeDepositsWeightedAverageInterestRateDescription_566" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_227" xlink:to="loc_us-gaap_TimeDepositsWeightedAverageInterestRateDescription_566" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="loc_us-gaap_MaturitiesOfTimeDepositsDescription_567" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_SignificantAccountingPoliciesLineItems_227" xlink:to="loc_us-gaap_MaturitiesOfTimeDepositsDescription_567" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesDetails">
    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesAbstract" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesAbstract_198" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesTable" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesTable_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesAbstract_198" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesTable_199" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesTable_199" xlink:to="loc_us-gaap_StatementClassOfStockAxis_202" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_202" xlink:to="loc_us-gaap_ClassOfStockDomain_203" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesLineItems" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesTable_199" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" xlink:to="loc_us-gaap_ReceivablesNetCurrent_214" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_215" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ReceivablesAndPrepaidExpensesCurrent" xlink:label="loc_orpn_ReceivablesAndPrepaidExpensesCurrent_216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ReceivablesAndPrepaidExpensesLineItems_206" xlink:to="loc_orpn_ReceivablesAndPrepaidExpensesCurrent_216" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_201" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_204" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_201" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_204" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_204" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_205" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_205" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ComputersAndElectronicEquipmentMember" xlink:label="loc_orpn_ComputersAndElectronicEquipmentMember_212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" xlink:to="loc_orpn_ComputersAndElectronicEquipmentMember_212" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_568" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" xlink:to="loc_us-gaap_ComputerEquipmentMember_568" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ElectronicEquipmentMember" xlink:label="loc_orpn_ElectronicEquipmentMember_569" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" xlink:to="loc_orpn_ElectronicEquipmentMember_569" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_570" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_211" xlink:to="loc_us-gaap_OfficeEquipmentMember_570" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_204" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_207" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_208" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_209" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_210" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_209" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_218" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_218" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_219" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_219" xlink:to="loc_us-gaap_StatementClassOfStockAxis_220" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_221" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_220" xlink:to="loc_us-gaap_ClassOfStockDomain_221" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_222" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_219" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_222" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_222" xlink:to="loc_us-gaap_Depreciation_223" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/OtherAccountsPayableDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_237" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_OtherAccountsPayableTable" xlink:label="loc_orpn_OtherAccountsPayableTable_238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_237" xlink:to="loc_orpn_OtherAccountsPayableTable_238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_239" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_OtherAccountsPayableTable_238" xlink:to="loc_us-gaap_StatementClassOfStockAxis_239" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_239" xlink:to="loc_us-gaap_ClassOfStockDomain_240" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_OtherAccountsPayableLineItems" xlink:label="loc_orpn_OtherAccountsPayableLineItems_241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_OtherAccountsPayableTable_238" xlink:to="loc_orpn_OtherAccountsPayableLineItems_241" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_OtherAccountsPayableLineItems_241" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_242" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_243" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_OtherAccountsPayableLineItems_241" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_243" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_244" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_OtherAccountsPayableLineItems_241" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_244" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_262" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesTable" xlink:label="loc_orpn_IncomeTaxesTable_264" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_262" xlink:to="loc_orpn_IncomeTaxesTable_264" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_265" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesTable_264" xlink:to="loc_us-gaap_StatementClassOfStockAxis_265" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_266" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_265" xlink:to="loc_us-gaap_ClassOfStockDomain_266" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesLineItems" xlink:label="loc_orpn_IncomeTaxesLineItems_267" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesTable_264" xlink:to="loc_orpn_IncomeTaxesLineItems_267" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_271" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_571" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_571" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_272" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_272" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_618" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_618" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_273" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_273" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_274" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_274" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_275" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_267" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_275" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_252" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesTable" xlink:label="loc_orpn_IncomeTaxesTable_253" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_252" xlink:to="loc_orpn_IncomeTaxesTable_253" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_254" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesTable_253" xlink:to="loc_us-gaap_StatementClassOfStockAxis_254" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_254" xlink:to="loc_us-gaap_ClassOfStockDomain_255" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncomeTaxesLineItems" xlink:label="loc_orpn_IncomeTaxesLineItems_256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesTable_253" xlink:to="loc_orpn_IncomeTaxesLineItems_256" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_257" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_256" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_257" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_259" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_IncomeTaxesLineItems_256" xlink:to="loc_us-gaap_OperatingLossCarryforwards_259" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59" xlink:to="loc_us-gaap_StatementTable_61" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_61" xlink:to="loc_us-gaap_StatementClassOfStockAxis_62" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62" xlink:to="loc_us-gaap_ClassOfStockDomain_63" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_61" xlink:to="loc_us-gaap_StatementLineItems_64" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_68" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_68" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_71" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_OperatingIncomeLoss_73" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_78" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_78" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_86" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_NetIncomeLoss_86" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_87" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_87" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_88" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_88" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_89" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_89" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_90" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_90" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_302" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsTable" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_302" xlink:to="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_303" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_335" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_303" xlink:to="loc_us-gaap_StatementClassOfStockAxis_335" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_336" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_335" xlink:to="loc_us-gaap_ClassOfStockDomain_336" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsLineItems" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_303" xlink:to="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_338" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_338" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_339" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_340" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_340" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_342" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_304" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_342" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_293" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsTable" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_294" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_293" xlink:to="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_294" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_296" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_294" xlink:to="loc_us-gaap_StatementClassOfStockAxis_296" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_297" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_296" xlink:to="loc_us-gaap_ClassOfStockDomain_297" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ContingentLiabilitiesAndCommitmentsLineItems" xlink:label="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsTable_294" xlink:to="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_298" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_298" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_299" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_us-gaap_LeaseAndRentalExpense_299" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_GuaranteeForPerformanceOfLeaseAgreement" xlink:label="loc_orpn_GuaranteeForPerformanceOfLeaseAgreement_573" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_orpn_GuaranteeForPerformanceOfLeaseAgreement_573" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_574" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_ContingentLiabilitiesAndCommitmentsLineItems_295" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_574" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_305" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_305" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_307" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" xlink:to="loc_us-gaap_StatementClassOfStockAxis_307" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_307" xlink:to="loc_us-gaap_ClassOfStockDomain_308" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_309" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_324" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_309" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_324" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_325" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_324" xlink:to="loc_us-gaap_EmployeeStockOptionMember_325" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_319" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_318" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_318" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_320" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_320" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_322" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_322" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_321" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_321" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_326" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_326" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_327" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_327" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_328" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_328" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_329" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_329" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_330" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_323" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_330" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_591" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_591" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_593" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" xlink:to="loc_us-gaap_AwardTypeAxis_593" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_594" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_594" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_NonemployeeStockOptionMember" xlink:label="loc_orpn_NonemployeeStockOptionMember_595" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_594" xlink:to="loc_orpn_NonemployeeStockOptionMember_595" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaap_AwardDateAxis_596" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" xlink:to="loc_us-gaap_AwardDateAxis_596" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaap_AwardDateDomain_597" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_596" xlink:to="loc_us-gaap_AwardDateDomain_597" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SecondDecemberTwoThousandFourteenMember" xlink:label="loc_orpn_SecondDecemberTwoThousandFourteenMember_598" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_597" xlink:to="loc_orpn_SecondDecemberTwoThousandFourteenMember_598" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant_600" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant_600" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber_601" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber_601" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice_602" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice_602" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate" xlink:label="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate_603" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599" xlink:to="loc_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate_603" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_312" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_313" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_312" xlink:to="loc_us-gaap_StatementTable_313" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_314" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_StatementClassOfStockAxis_314" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_315" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_314" xlink:to="loc_us-gaap_ClassOfStockDomain_315" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_316" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_316" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_332" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_316" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_332" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_333" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_332" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_333" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_334" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_332" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_313" xlink:to="loc_us-gaap_StatementLineItems_331" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_337" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_331" xlink:to="loc_us-gaap_ShareBasedCompensation_337" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/ShareholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_343" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_343" xlink:to="loc_us-gaap_StatementTable_344" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_345" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_StatementClassOfStockAxis_345" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_346" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_345" xlink:to="loc_us-gaap_ClassOfStockDomain_346" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_346" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_360" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementAxis" xlink:label="loc_orpn_AgreementAxis_347" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_orpn_AgreementAxis_347" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementDomain" xlink:label="loc_orpn_AgreementDomain_350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_AgreementAxis_347" xlink:to="loc_orpn_AgreementDomain_350" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_InvestmentAgreementMember" xlink:label="loc_orpn_InvestmentAgreementMember_354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_AgreementDomain_350" xlink:to="loc_orpn_InvestmentAgreementMember_354" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PurchaseAgreementMember" xlink:label="loc_orpn_PurchaseAgreementMember_358" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_AgreementDomain_350" xlink:to="loc_orpn_PurchaseAgreementMember_358" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_349" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_349" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_364" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_349" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_364" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_364" xlink:to="loc_us-gaap_EmployeeStockOptionMember_365" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_363" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_363" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_514" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_363" xlink:to="loc_us-gaap_EquityComponentDomain_514" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_515" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_514" xlink:to="loc_us-gaap_CommonStockMember_515" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_513" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_513" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_610" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_513" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_610" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_611" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_610" xlink:to="loc_us-gaap_IPOMember_611" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_609" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_344" xlink:to="loc_us-gaap_StatementLineItems_609" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_348" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_348" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharePurchaseAgreementSharesToBeIssued" xlink:label="loc_orpn_SharePurchaseAgreementSharesToBeIssued_373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_orpn_SharePurchaseAgreementSharesToBeIssued_373" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_SharePurchaseAgreementValueToBeIssued" xlink:label="loc_orpn_SharePurchaseAgreementValueToBeIssued_376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_orpn_SharePurchaseAgreementValueToBeIssued_376" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_383" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_384" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_385" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_386" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_PreferredStockConversionBasis_386" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_389" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaap_DividendsPreferredStock_393" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_DividendsPreferredStock_393" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_394" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_398" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_398" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_395" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_395" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_396" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_396" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_397" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares_619" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares_619" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue_605" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue_605" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaap_EquityIssuancePerShareAmount_608" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_609" xlink:to="loc_us-gaap_EquityIssuancePerShareAmount_608" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_362" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_362" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_367" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" xlink:to="loc_us-gaap_StatementClassOfStockAxis_367" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_368" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_367" xlink:to="loc_us-gaap_ClassOfStockDomain_368" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_369" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_519" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_369" xlink:to="loc_us-gaap_RelatedPartyDomain_519" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_RelatedPartyMember" xlink:label="loc_orpn_RelatedPartyMember_520" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_519" xlink:to="loc_orpn_RelatedPartyMember_520" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_518" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_366" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_518" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_518" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_374" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_375" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_518" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_375" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_378" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_378" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_380" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" xlink:to="loc_us-gaap_StatementClassOfStockAxis_380" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_381" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_380" xlink:to="loc_us-gaap_ClassOfStockDomain_381" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_382" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_382" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_522" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_382" xlink:to="loc_us-gaap_RelatedPartyDomain_522" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_RelatedPartyMember" xlink:label="loc_orpn_RelatedPartyMember_523" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_522" xlink:to="loc_orpn_RelatedPartyMember_523" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_521" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_379" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_521" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521" xlink:to="loc_us-gaap_OperatingExpensesAbstract_390" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_392" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_390" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_392" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_391" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_390" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_391" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_400" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_400" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_402" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_402" xlink:to="loc_us-gaap_RelatedPartyDomain_403" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantMember" xlink:label="loc_orpn_ConsultantMember_409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_403" xlink:to="loc_orpn_ConsultantMember_409" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ShareholdersMember" xlink:label="loc_orpn_ShareholdersMember_410" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_403" xlink:to="loc_orpn_ShareholdersMember_410" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantOneMember" xlink:label="loc_orpn_ConsultantOneMember_590" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_403" xlink:to="loc_orpn_ConsultantOneMember_590" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_404" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_404" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_404" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_413" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_414" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_413" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_414" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_401" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_412" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_411" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncreaseInMonthlyFee" xlink:label="loc_orpn_IncreaseInMonthlyFee_586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_orpn_IncreaseInMonthlyFee_586" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantBonusGrantInPeriod" xlink:label="loc_orpn_ConsultantBonusGrantInPeriod_587" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_orpn_ConsultantBonusGrantInPeriod_587" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantBonusGrantInPeriodAddition" xlink:label="loc_orpn_ConsultantBonusGrantInPeriodAddition_589" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_412" xlink:to="loc_orpn_ConsultantBonusGrantInPeriodAddition_589" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/FinancialExpensesIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_426" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_FinancialExpensesIncomeNetTable" xlink:label="loc_orpn_FinancialExpensesIncomeNetTable_431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_426" xlink:to="loc_orpn_FinancialExpensesIncomeNetTable_431" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_438" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_FinancialExpensesIncomeNetTable_431" xlink:to="loc_us-gaap_StatementClassOfStockAxis_438" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_438" xlink:to="loc_us-gaap_ClassOfStockDomain_439" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_FinancialExpensesIncomeNetLineItems" xlink:label="loc_orpn_FinancialExpensesIncomeNetLineItems_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_FinancialExpensesIncomeNetTable_431" xlink:to="loc_orpn_FinancialExpensesIncomeNetLineItems_433" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:label="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_FinancialExpensesIncomeNetLineItems_433" xlink:to="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaap_InterestExpenseBorrowings_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" xlink:to="loc_us-gaap_InterestExpenseBorrowings_442" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_BankFees" xlink:label="loc_orpn_BankFees_577" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" xlink:to="loc_orpn_BankFees_577" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" xlink:label="loc_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue_445" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" xlink:to="loc_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue_445" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpenseDisclosureNonoperatingAbstract_441" xlink:to="loc_us-gaap_OtherNonoperatingExpense_446" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_FinancialExpensesIncomeNetLineItems_433" xlink:to="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_578" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" xlink:to="loc_us-gaap_InterestIncomeOther_578" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" xlink:label="loc_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue_448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" xlink:to="loc_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue_448" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_449" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_447" xlink:to="loc_us-gaap_OtherNonoperatingIncome_449" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_450" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_FinancialExpensesIncomeNetLineItems_433" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_450" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_35" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_StatementTable_35" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_36" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_35" xlink:to="loc_us-gaap_StatementClassOfStockAxis_36" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_37" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_36" xlink:to="loc_us-gaap_ClassOfStockDomain_37" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_539" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_37" xlink:to="loc_us-gaap_PreferredClassAMember_539" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_35" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38" xlink:to="loc_us-gaap_EquityComponentDomain_81" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_82" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_81" xlink:to="loc_us-gaap_CommonStockMember_82" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_84" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_81" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_84" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_81" xlink:to="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_85" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_35" xlink:to="loc_us-gaap_StatementLineItems_80" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_41" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockholdersEquity_41" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_43" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_SharesOutstanding_43" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue_540" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue_540" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares_541" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares_541" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_542" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_543" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_543" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_45" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_45" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_47" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_47" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_48" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_48" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" xlink:label="loc_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares_546" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares_546" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares" xlink:label="loc_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares_547" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares_547" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue_544" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue_544" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" xlink:label="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares_545" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares_545" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_49" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_49" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_52" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_53" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_NetIncomeLoss_53" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_54" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_StockholdersEquity_54" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_57" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80" xlink:to="loc_us-gaap_SharesOutstanding_57" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_462" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_463" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_462" xlink:to="loc_us-gaap_SubsequentEventTable_463" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_464" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_StatementClassOfStockAxis_464" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_465" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_464" xlink:to="loc_us-gaap_ClassOfStockDomain_465" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_466" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_466" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_474" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_466" xlink:to="loc_us-gaap_EquityComponentDomain_474" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_475" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_474" xlink:to="loc_us-gaap_CommonStockMember_475" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_473" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_TitleOfIndividualAxis_473" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_473" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_478" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_478" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_EmployeeMember" xlink:label="loc_orpn_EmployeeMember_482" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" xlink:to="loc_orpn_EmployeeMember_482" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ColinFosterMember" xlink:label="loc_orpn_ColinFosterMember_576" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" xlink:to="loc_orpn_ColinFosterMember_576" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_477" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_620" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_476" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_476" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_476" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_481" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480" xlink:to="loc_us-gaap_PrivatePlacementMember_481" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_492" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_480" xlink:to="loc_us-gaap_IPOMember_492" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_479" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_486" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_479" xlink:to="loc_us-gaap_RelatedPartyDomain_486" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantOneMember" xlink:label="loc_orpn_ConsultantOneMember_487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_486" xlink:to="loc_orpn_ConsultantOneMember_487" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_ConsultantTwoMember" xlink:label="loc_orpn_ConsultantTwoMember_488" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_486" xlink:to="loc_orpn_ConsultantTwoMember_488" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_485" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_485" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_494" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_485" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_494" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredBonusMember" xlink:label="loc_us-gaap_DeferredBonusMember_495" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_494" xlink:to="loc_us-gaap_DeferredBonusMember_495" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_493" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_493" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_505" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_493" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_505" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_506" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_505" xlink:to="loc_us-gaap_EmployeeStockOptionMember_506" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementAxis" xlink:label="loc_orpn_AgreementAxis_504" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_orpn_AgreementAxis_504" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_AgreementDomain" xlink:label="loc_orpn_AgreementDomain_508" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_AgreementAxis_504" xlink:to="loc_orpn_AgreementDomain_508" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PurchaseAgreementMember" xlink:label="loc_orpn_PurchaseAgreementMember_509" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_orpn_AgreementDomain_508" xlink:to="loc_orpn_PurchaseAgreementMember_509" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_507" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_507" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_511" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_507" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_511" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_512" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_511" xlink:to="loc_us-gaap_SubsequentEventMember_512" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_510" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_463" xlink:to="loc_us-gaap_SubsequentEventLineItems_510" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_490" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_490" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_575" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_575" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_94" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_94" xlink:to="loc_us-gaap_StatementTable_95" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95" xlink:to="loc_us-gaap_StatementClassOfStockAxis_96" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96" xlink:to="loc_us-gaap_ClassOfStockDomain_97" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_548" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_97" xlink:to="loc_us-gaap_PreferredClassAMember_548" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_551" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550" xlink:to="loc_us-gaap_PrivatePlacementMember_551" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_552" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_550" xlink:to="loc_us-gaap_IPOMember_552" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_549" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95" xlink:to="loc_us-gaap_StatementLineItems_549" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaap_EquityIssuancePerShareAmount_133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_549" xlink:to="loc_us-gaap_EquityIssuancePerShareAmount_133" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_29" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28" xlink:to="loc_us-gaap_StatementTable_29" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_30" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29" xlink:to="loc_us-gaap_StatementClassOfStockAxis_30" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_31" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30" xlink:to="loc_us-gaap_ClassOfStockDomain_31" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_32" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_29" xlink:to="loc_us-gaap_StatementLineItems_32" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_40" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" xlink:to="loc_us-gaap_NetIncomeLoss_40" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_44" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" xlink:to="loc_us-gaap_Depreciation_44" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_46" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" xlink:to="loc_us-gaap_ShareBasedCompensation_46" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_InterestOnShortTermBankDeposit" xlink:label="loc_orpn_InterestOnShortTermBankDeposit_553" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_42" xlink:to="loc_orpn_InterestOnShortTermBankDeposit_553" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" xlink:label="loc_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses_56" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses_56" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_58" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaap_IncreaseDecreaseInDepositOtherAssets_58" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_60" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_65" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_65" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_66" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_66" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="orpn-20141231.xsd#orpn_PaymentsToAcquireShortTermBankDeposit" xlink:label="loc_orpn_PaymentsToAcquireShortTermBankDeposit_554" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" xlink:to="loc_orpn_PaymentsToAcquireShortTermBankDeposit_554" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_69" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_69" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_70" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_67" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_70" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_72" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_72" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_74" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_75" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_75" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_76" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_79" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/General">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_137" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_138" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_137" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_138" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://bioblast-pharma.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_149" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_149" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_150" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONTINGENT LIABILITIES AND COMMITMENTS (Details Textual) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ContingentLiabilitiesAndCommitmentsLineItems', window );"><strong>CONTINGENT LIABILITIES AND COMMITMENTS [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating Leases, Rent Expense, Minimum Rentals</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseMinimumRentals" onclick="toggleNextSibling(this);">$ 8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">88</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_GuaranteeForPerformanceOfLeaseAgreement', window );">Guarantee For Performance Of Lease Agreement</a></td>
        <td class="nump"><a title="orpn_GuaranteeForPerformanceOfLeaseAgreement" onclick="toggleNextSibling(this);">25</a><span style="display:none;white-space:normal;text-align:left;">orpn_GuaranteeForPerformanceOfLeaseAgreement</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ContingentLiabilitiesAndCommitmentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ContingentLiabilitiesAndCommitmentsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_GuaranteeForPerformanceOfLeaseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of guarantee given by the company as a security for performance of lease agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_GuaranteeForPerformanceOfLeaseAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7661868&amp;loc=d3e34039-112682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 16, 2015</div>
        </th>
        <th class="th">
          <div>Feb. 02, 2015</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 9.21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.0004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">380,222</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">83,579</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Subsequent Event [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 7.17</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">24,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Subsequent Event [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember;us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">$ 8.47</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_ChiefExecutiveOfficerMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember;us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">498,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_ChiefExecutiveOfficerMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>21
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#A_+]<%@(``"\>```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F4]OTS`8QN](?(?(5]2X
M_L,8J.T.`XXPB?$!3/*VB9K8ENV-]MOCI%LU3:55126>2Z,F]OO\XL/OD&=V
ML^F[XI%";)V=,U%.64&V<G5K5W/V\_[KY)H5,1E;F\Y9FK,M17:S>/MF=K_U
M%(N\V\8Y:U+RGSB/54.]B:7S9/.3I0N]2?EO6'%OJK59$9?3Z16OG$UDTR0-
M,]AB]IF6YJ%+Q9=-OKTC"=1%5MSN%@Y9<V:\[]K*I$S*'VW]*F7RE%#FG>.:
MV+0^OLL8C!],&)[\/>!IW_=\-*&MJ;@S(7TS?<;@FX[_=F']R[EU>7S(`4JW
M7+85U:YZZ/,)E-$',G5LB%+?E>.U[$UKG[F/Y(^+(Q\OXL(@P_N-@\_DD"`<
M"H1#@W"\!^&X`N'X`,)Q#<+Q$81#3%%`4(PJ4)0J4)PJ4*0J4*PJ4+0J4+PJ
M4,0J4,PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<RJ4,RJ4,RJ4,RJ
M4,RJ4,RJ4,RJ4,RJ4,RJ4,RJ4,RJ4<RJ4<RJ4<RJ4<RJ4<RJ4<RJ4<RJ4<RJ
M_Y=94Z[#B(^__VZ0<<R)/B:F;4?QPM]0=T-/)3<F4/TCA5P<7AS@Y>P3')7I
MJMLF-V@7/H3]W&/YN=:["\['7'`&.A_@N<$<=D]\'D0AM;3O,`]U@?O$7(Z>
M'_BJC*2A?JVI/I#-Q[IW\0<``/__`P!02P,$%``&``@````A`+55,"/U````
M3`(```L`"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````````",
MDL].PS`,QN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'V
MY\\_6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?
M>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0
M+3S5P6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)
M@Q7SG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSB
MIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`S4_#WD4"``!T'0``
M&@`(`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````O)G-;MLP$(3O!?H.`N^QO$O:28K(
M.:0HD&N;/@`AT9816S)$]L=O7\(M9`=HISX(<S%`"B8'].RW0_GA\>=^5WP/
M0]SV765D-C=%Z.J^V7:;RGQ]^71S9XJ8?-?X7=^%RAQ#-(^K]^\>/H>=3_E+
ML=T>8I%7Z6)EVI0.'\HRUFW8^SCK#Z'+3];]L/<I#X=->?#UJ]^$4N?S93E<
MKF%6;]8LGIO*#,^-6%.\'`]YZ_\OWJ_7VSI\[.MO^]"EO^Q1_NB'U]B&D/*B
M?MB$5)EQ*I:G)V)G6;,I_R$GGP=7SAV2HTNR'%TB.?:>+,?>(SDJ9#DJ2(YU
M9#G6(3E.R7*<0CFW;#FW2,XBDW"Z0H_IN,OD'*'S>XSV9Y\&/`RV4Z!1A,T\
M@<Q3-O,4,D_8S!/(/&4S3R'S+-O)%EK9LJO<PC)WDS)O#%9G[(U3?[*6FR,$
MNL64"![W!G(62`Y;#10C;#4"Y2@[I2M,Z<I.Z0I3NF5W+`L[EINT8Z5\UPOG
MFCH-R],G;`S"9HU`ULBD9W(%:P1V<<ONXA;^6([=Q1WLXHM)NWCM=_53Z[?=
MV<3C%.H']#-!8MCVA>X5]M$(M(M.:I<K:EMAZ%-VZ%,8^BP;Q!:"V+*#C87!
MQK&#C8/!QK&#C8/!AJT&BEE,VC-CZX?0?$E#?A-^^>+F<AH!F>T;:!MA$U`@
M`85-0($$5#9R%"+'TJT#O6/916YAE3OV7<K!NY2RNZ?"[NDF9>`54<?!>P-;
M#13#-L[HF_+-?Z6K7P```/__`P!02P,$%``&``@````A`,;!]CDI!```U@X`
M``\```!X;"]W;W)K8F]O:RYX;6R4EUUSHDH0AN]/U?D/%/>[RH>Z2<5L(8YQ
MJEC@R"397$VQ,D9J$2S`-?GWI\&/-(RAUILD(_9+]]M/-^'N^]LF4?Z(O(BS
M=*QJ7_NJ(M)E%L7IZUA]9+,OWU2E*,,T"I,L%6/U713J]_M__[G;9_GO7UGV
M6P&!M!BKZ[+<WO9ZQ7(M-F'Q-=N*%*ZLLGP3EG#,7WO%-A=A5*R%*#=)3^_W
MA[U-&*?J0>$V_QN-;+6*EV*:+7<;D98'D5PD80GI%^MX6ZCW=ZLX$4^'BI1P
MNW7##>3]EJA*$A8EB>)21&-U`,=L+QH?Y+OM9!<G</7&Z!MJ[_Y<I)\KD5B%
MNZ1D4-Y)'?S235T?5M^LK'B*Q;[X"*J.RMMSG$;9OOHJ6/M^/AF0P+Z^]!Q'
MY1JN]_O]\V=S$;^NR].'(-]#^K6#<)_ZMY+6Y9T<X58:<9*6<?G.:7IP/\Z@
MA97K%"K35"6_C>&/G$9:E3A6F5B.Y=J$!W-"6("BS!L4IG>'<3_,H3=K4<;+
M$%P_W]I`&K6[^-8!LQCY05P6<&_&/9\L+$8]MY$$BC?;.33C[;GE/I"`4Q=J
ML18$93&`-IP=&%PG`^:=JQDBF9J`SZNQK6#.9X[WC*L9H?A1.XT'XH(!#KK=
M`#?N6_O[`7UPZ8S:ELNX9=O>H\NH^\!]SZ$V;52OH]O>M&46Q";TR9HX8)WE
M3KF_(+Y%IYS\]$FC%0/<2ZW?UO$750/92RU"_GND?M59[A*&*S)1*IK$HL?F
M9'$J)N"^]5+EA>-A6LZ-U"0HJ6M[/PAGUD^";1_@OFD2AK97.U=EZU!K0AW*
MZ-$,D,-WQ_W39!PKZN:>,R6+@%<.L!<<#$OU(W4)P@5Q8!C`?JOR\#B4AXZP
MA85U\%AJ$H4SZL(X4\LY-K`>B-J59B>&>"0T"<;@<1)`"94GY`E^8CN'&$OM
M2BX;XX3!U"0RNP&'V(^YQ&C"SFVMN&[$&QEA/G6)S\\9YRS\A1/"G.H2IY<Y
MKS02>-2BNC"XN@0NQOU",*95EVCMIKYA"B97E\BMEVT3^PO)8&H/3T^\.[OI
MQ\F,,+>ZQ&TG_AQ9.P+1\SCJ$L3'9<RGH@SCI.!,O)6[QI--;U1T);S`ZQE>
M`U<$AQ:\W5,`O'X(X9(,"=[N*<#C-,)S:4CT=DP!V(42&N&Q-"1\NW5PTPT\
MEG!H6?3).!U[AQ-JZ$@D-^;I0C0>:D/:O)>B+W!CX+&$0ZN6[K%L=`DO!T,B
MN%NH`2`FV9!)EA]KI[%`UIJ88CBTRKJT)$ZSA3MM8H;A<(4,]L;$!,/A"ADF
M<%688%,BN'MMX81&N.NF1'"W$&Z6B2&$0ZNR;B&\+4R,#QQ:0MV+M-&R1FD2
MT-)_$B=XZMG`7N/'C%GSW*MW&[SVP$O%$M['JE_U"XTY&!Z>SKW3*^G]_P``
M`/__`P!02P,$%``&``@````A`.!L+BNI`P``:@L``!@```!X;"]W;W)K<VAE
M971S+W-H965T-"YX;6R45EV/FS@4?5]I_P/B?0(F0#Z4I"I!LUMI*U6K;?OL
M@).@`8QL9S+S[_?:-P'LS$S3/"2!>WPXY_B#N_KTTM3>,Q.RXNW:)Y/0]UA;
M\+)J#VO_^W^/#W/?DXJV):UYR];^*Y/^I\V??ZS.7#S)(V/*`X96KOVC4MTR
M"&1Q9`V5$]ZQ%BI[+AJJX%(<`MD)1DLSJ*F#*`S3H*%5ZR/#4MS#P??[JF`Y
M+TX-:Q62"%93!?KEL>KDE:TI[J%KJ'@Z=0\%;SJ@V%5UI5X-J>\UQ?++H>6"
M[FKP_4)B6ERYS<4-?5,5@DN^5Q.@"U#HK>=%L`B`:;,J*W"@8_<$VZ_]SV29
M$^('FY4)Z$?%SG+TWY-'?OY+5.4_5<L@;9@G/0,[SI\T]$NI;\'@X&;THYF!
M;\(KV9Z>:O4O/__-JL-1P70GX$@;6Y:O.9,%)`HTDRC13`6O00!\>TVEEP8D
M0E_,[[DJU7'M3]-),@NG!.#>CDGU6&E*WRM.4O'F)X*,HYXDNI#$H/Y2CR;1
M/"%)^FN6`!49@SE5=+,2_.S!JH%GRH[J-4B6P'QUACIZK^]9!8^:Y+-F,5S@
M0L+\/&^2Z2IXADB+"R1#R,SW>@BQ$=LK0N>G6?/1C0#D]IHA"5?S%.;T[=FX
M2M2#'(FQ+2"[A40V8OL&8F9#\EM(DO00R\;4MO&Q?`U>^T#>QY>D/:V)*T/(
MW,0?Q[$;[[@\FSK.\G&5Q&%/;2F&!3(._F/%&NPH=K+*$)(8Q5$Z7?1/-8:V
M6([1$''LYN/J?"A:@F%WW2]8@QW!<UM1AA`4/`OG0TPH>%PF)'9&YUA&/U'T
MCN3T=R1KL"/9"3%#"#[T(7$D;:VJLV7S<7&H60'#?KX_8`VVU:9.@AE"K@%'
MSBK=CLL0\+"Q\,#`\C7@(0E+LGXICTZ\CQ>Q!CN2G7V5(00?ZMC9CFNC"4>U
MX^(PT-*ZL+7JT_G7)YT>Y&AV<LP0@D?%++R)>5PF9.8XSL?E*'HG9@(G\CCG
M^[2;48[X8>F9W+(+9F'.A8=PDJ0+Z^.LBJV+A^/-^KCV7'PX"+`F!SJ.&X<Q
M[/&/5Y09Y3AT7T07#&X#$D7)(@V'%8)GC869Q]$T),[FUBV17@F7W90D)(Z&
M$QBM8,N#'4'#Q(%M65U+K^`GW<X0B+B_BZU6IELMTRSU!>AT.GI@7ZDX5*WT
M:K:'H>%D!E$([)7P0O'.O(!W7$&/8_X>H:=E\*J'2?2]/>?J>J&[L;Y+WOP/
M``#__P,`4$L#!!0`!@`(````(0!.8FR_M`(``-0&```9````>&PO=V]R:W-H
M965T<R]S:&5E=#,W+GAM;)1576_:,!1]G[3_8/F]<4((7P*J0M2MTB9-TSZ>
MC>,D5N,XLDUI__VN[9(2Z+J.!\#.\<DYY][<+*\?98,>N#9"M2N<1#%&O&6J
M$&VUPC]_W%[-,#*6M@5M5,M7^(D;?+W^^&%Y4/K>U)Q;!`RM6>':VFY!B&$U
ME]1$JN,M7"F5EM3"4E?$=)K3PA^2#1G%\81(*EH<&!;Z/1RJ+`7CN6)[R5L;
M2#1OJ`7]IA:=.;))]AXZ2?7]OKMB2G9`L1.-L$^>%"/)%G=5JS3=->#[,1E3
M=N3VBPMZ*9A61I4V`CH2A%YZGI,Y`:;ULA#@P,6.-"]7^"99Y!DFZZ7/YY?@
M!W/R'YE:'3YI47P1+8>PH4RN`#NE[AWTKG!;<)A<G+[U!?BF4<%+NF_L=W7X
MS$556ZAV!H:<KT7QE'/#(%"@B49>!E,-"(!O)(7K#`B$/OK?@RALO<+I),JF
M<9H`'.VXL;?"46+$]L8J^3N`$B>J)QD]DXQ!_?/U432:94DV^3<+"8J\P9Q:
MNEYJ=4#0-'!/TU'7@LD"F(_.@H[>Z]^L@CQ'<N-8/!>X,%">AW4ZGR_)`V3*
MGC&;@)EBU&.2(6)[1#C7CC8_V2"@MQ<-49R+3J&HKY?CJ-$=&FH<388"-J]`
MAHCM*XCI$))?0K*LAPQLI$,;;\MW8.B;D_C2^=FM-P$S]FWC`MR>;^0G&P,I
M4/K_3]0=6F'PVU=T',>]55_"3<`DZ<QW!3P?DRP^_9SWP`7^);O0$V\`!H[@
MP3IU]':X#GSNY$S9)F""C\EL//2Y#5=?HH=QY"C]1M`5IDMX^"37%=_RIC&(
MJ;V;'`GDT^^&H;:!H>9'`.DOP%#I:,6_4EV)UJ"&EW`TCJ9P,QW&4EA8U?E6
MWRD+X\3_K>'MP:$GX@C`I5+VN'"#KW\?K?\```#__P,`4$L#!!0`!@`(````
M(0"3?NB/EP(``)8&```9````>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)Q5
M76_;(!1]G[3_@'BOL1T[2:,X5;.J6Z5-FJ9]/!.,;51C+"!-^^]W@7PX296U
M>XF-.?><>RZ7F_G-LVS1$]=&J*[`211CQ#NF2M'5!?[U\_YJBI&QM"MIJSI>
MX!=N\,WBXX?Y1NE'TW!N$3!TIL"-M?V,$,,:+JF)5,\[V*F4EM3"4M?$])K3
MT@?)EJ1Q/":2B@X'AIE^"X>J*L'XG6)KR3L;2#1OJ87\32-ZLV.3["UTDNK'
M=7_%E.R!8B5:85\\*4:2S1[J3FFZ:L'W<Y)1MN/VBS-Z*9A61E4V`CH2$CWW
M?$VN"3`MYJ4`!Z[L2/.JP+?);#G!9#'W]?DM^,8,WI%IU.:S%N57T7$H-AR3
M.X"54H\.^E"Z3Q!,SJ+O_0%\UZCD%5VW]H?:?.&B;BR<=@Z&G*]9^7+'#8."
M`DV4YHZ)J182@%\DA>L,*`A]]L^-*&U3X-$XRB?Q*`$X6G%C[X6CQ(BMC57R
M3P`E6ZI`DFY)X+DE2=(HG>9)/OXW"PD9>8-WU-+%7*L-@J8!3=-3UX+)#)B=
MLQ'4YW5G8,G%W+H@'PIH`Z?QM,CB=$Z>H(1LBUD&S`2C/>:`(""^SP!4WY^!
M"SK.(!V?)!`@OBN.]$;_H^>"H#(#-UD\.A$,F,QWTM!@=BQXN;0.7.#4%S6-
MD_Q$(VQ/_7:23/:[1PZAIX85O2SHP`/!TRJ&[>RRX/@]@@X\$#QX\+VU#-M!
M,,]>-PA=-33XMJ9U04[WT)!9?.`/X@$3RIM.IR?J83Z$ZR.YKODGWK8&,;5V
M=S^!&NV_AK&TA+&4^G[8;\!8Z&G-OU%=B\Z@EE<0&D<3J+,.@R4LK.I]?Z^4
MA8'@7QN8_QRN7QP!N%+*[A9N=.W_419_`0``__\#`%!+`P04``8`"````"$`
MTB[/A.<"```+"```&0```'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R<55MO
MFS`4?I^T_V#YO=P"21J%5"6HVZ1-FJ9=GATP8!4PLIVF_?<[M@,%TJW=7A+P
M^<['=Z[>WCPV-7J@0C+>QMAW/(QHF_&<M66,?WR_NUIC)!5I<U+SEL;XB4I\
MLWO_;GOBXEY6E"H$#*V,<:54MW%=F56T(=+A'6W!4G#1$`6OHG1E)RC)C5-3
MNX'G+=V&L!9;AHUX"P<O"I;1E&?'AK;*D@A:$P7Z9<4ZV;,UV5OH&B+NC]U5
MQIL.*`ZL9NK)D&+49)M/9<L%.=00]Z,?DJSG-B\7]`W+!)>\4`[0N5;H9<S7
M[K4+3+MMSB`"G78D:!'C6W^3KK"[VYK\_&3T)$?/2%;\]$&P_#-K*20;RJ0+
M<.#\7D,_Y?H(G-T+[SM3@*\"Y;0@QUI]XZ>/E)65@FI'$)".:Y,_I51FD%"@
M<8)(,V6\!@'PBQJF.P,20A[-_XGEJHKQ8NE$*V_A`QP=J%1W3%-BE!VEXLTO
M"_+/5)8D.).$H/YL#YQ@'?G1\G46URHR`:9$D=U6\!."IH%ORH[H%O0WP-Q'
M9G4,L?XI5(A1D]QJ%L,%44@HS\,N]**M^P`YS<Z8Q&)6&`T8?XK8]PB=0$V;
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M-J<[&&`7=Z2D7X@H62M130MP]9P5%%'8;6Y?%._,ACAP!5O8/%9PZ5(8(<\!
M<,&YZE_T?3%<X[O?````__\#`%!+`P04``8`"````"$`H`=EM;$#``!E#```
M&0```'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R<5UMOHSP0?5]I_P/BO8"Y
MY*8DJR;=[J[T?=)JM9=G`DZ""AAAIVG__<XP0+#3INGFH0GF^/B<F;$]G7]Z
M*G+KD=<R$^7"9HYG6[Q,1)J5NX7]Z^?]S<2VI(K+-,Y%R1?V,Y?VI^7'#_.C
MJ!_DGG-E`4,I%_9>J6KFNC+9\R*6CJAX"6^VHBYB!8_USI55S>.TF53DKN]Y
M([>(L](FAEE]#8?8;K.$WXGD4/!2$4G-\UB!?KG/*MFQ%<DU=$5</QRJFT04
M%5!LLCQ3SPVI;17)[-NN%'6\R<'W$POCI.-N'L[HBRRIA11;Y0"=2T+//4_=
MJ0M,RWF:@0,,NU7S[<*^9;,U"VUW.6\"]#OC1SGX;<F].'ZIL_2_K.00;<@3
M9F`CQ`-"OZ4X!)/=L]GW30:^UU;*M_$A5S_$\2O/=GL%Z8[`$1J;I<]W7"80
M4:!Q_`B9$I&#`/AK%1F6!D0D?FJ^CUFJ]@L[&#G1V`L8P*T-E^H^0TK;2@Y2
MB>(/@5A+121^2Q*`^O:][_B3B$6CMUE<4M08O(M5O)S7XFA!U<":LHJQ!MD,
MF-%9`/$A';W7UZR"1R2Y19:%/;8MF"XA/X_+D'ES]Q%BFK28U3F&Z8AUA\!4
M@+Q>(S@?:GPYZIT4!*,4S`)J6]$`</?:?&/=%Q#C'J(I@0A=KP3!"QO(^X5#
M9EA>$:8IW4;M>C"@K1SJ*V.>PE<KL(L%3H)\#A0$T:AW1N$AS$#!8$!3`*L-
MO7>5<CD;.,F,@1'^%6$B*AO8$V;EK(>`@$VCX!1%3>%(5WA9&8)-98$1&\*0
MLF#B^;XA?3T$3()H/.T)-&&P,=X?.IQD"@Q[?DH>84C@>!($@2EP"`CUV&H*
M\:9ZX1BX'$*<9"J,#(6$N:!P"+BD</HO"G&2J=#<`(1IR\^?1I-3$FE+#@$L
M"(/QZ6338LC@W#2#^/8>;6:9&D_'#^6Y!4UICSB>_O$_WQB%L7['!-T#GL'O
M+@1&)[=^U$V,2FA!Y&'J^$PS809=0X<7'>L&\#`W#%R1!+H"=`.&I!4C4)>$
MT$C2VGBOV?,\+4FZ9#SSWR^9;@I-LG^JS+9N"/2Z9/W]]9+_Z3J"%NUL._JG
ML[R53""2S)S`.).QST.2SM+;DJFKHZ:GX/6.KWF>2RL1!^S8?-A2_6C?3=[Z
MV#\8XROL,G'<[5]`DU?%._Y_7.^R4EHYWP*EYXSAQJJI3:0'):JFU=H(!>U=
M\W,/[3R'_L1S`+P50G4/N$#_#\+R+P```/__`P!02P,$%``&``@````A`%?P
M*:TC`P``)@D``!D```!X;"]W;W)K<VAE971S+W-H965T,S8N>&ULE)9=;]HP
M%(;O)^T_1+YO/OD*`JI"U6W2)DW3/JY-XA"K21S9IK3_?L<^-,2A8_0&B/WZ
M]7->VS&+V^>Z\IZ85%PT2Q+Y(?%8DXF<-[LE^?7SX69&/*5ID]-*-&Q)7I@B
MMZN/'Q8'(1]5R9CVP*%12U)JW<Z#0&4EJZGR1<L:Z"F$K*F&1[D+5"L9S>V@
MN@KB,)P$->4-08>YO,9#%`7/V+W(]C5K-)I(5E$-_*KDK7IUJ[-K[&HJ'_?M
M32;J%BRVO.+ZQ9H2K\[F7W:-D'1;0=W/T8AFK][VX<R^YID42A3:![L`0<]K
M3H,T`*?5(N=0@8G=DZQ8DKMHOHE"$JP6-J#?G!U4[[>G2G'X)'G^E3<,TH9U
M,BNP%>+12+_DI@D&!V>C'^P*?)=>S@JZK_0/<?C,^*[4L-QCJ,@4-L]?[IG*
M(%&P\>.Q<<I$!0#PZ=7<;`U(A#[;[P//=;DDR<0?3\,D`KFW94H_<&-)O&RO
MM*C_H"@Z6J%)?#1)@/[8'_OQ;!R-)_]W"9#(%GA/-5TMI#AXL&M@3M52LP>C
M.3B_71&48K1W1FR'`*R"97A:)>ED$3Q!=-E1LT;-E'B=)G85FS<4TTX2`%<'
M!R7WX4SL"2S>94@SR(6,AXPHF=IX36&;7H,#`(GT`2Y/;,0`V*L\24^%V037
MJ!F=9NXU.#./WC.S$2\)%''*_*QFU,SLJD6SJ`O<<FV<WLDI+X<)]NKU:1BQ
MRS0^V6(8*!E9I#1.!DC]WFATVD0.TN0]2$;L(B7IS)UUC1IDFDR',?5[PVZD
M0P0[__J0C-@EBN,A$6J0*!I$N.EWCMX&,I=0[X1?=XC,H"%8VOGC\J%FC#MJ
MF@ZSPF[DAA==-]A)*W7A+A\P(QY`):=50"C4(-1-=$Z%_4AU\T\LN$R<T"YS
M6?40;!#'^BC"`SB@-I>7*6W8B5'AM81O[9K)'=NPJE)>)O;FRHDA_ZX5K\-U
M-%_'YA4S:-_`-6G;@ZX#;JF6[M@W*G>\45[%"K`,_2D</HGW'#YHT=IWZE9H
MN)_LSQ+^CS!X>88^B`LA].N#N4F[?SBKOP```/__`P!02P,$%``&``@````A
M`%[1\P&N`@``W`8``!D```!X;"]W;W)K<VAE971S+W-H965T,S4N>&ULE%5=
M;YLP%'V?M/]@^;T0()"`0JHF5;=*FS1-^WAVP(!5C)'M-.V_W[6=D$"KKGU)
ML.^YQ^>>:RZKZR?>HD<J%1-=C@-OAA'M"E&RKL[Q[U]W5TN,E"9=25K1T1P_
M4X6OUY\_K0Y"/JB&4HV`H5,Y;K3N,]]714,Y49[H:0>12DA.-"QE[:M>4E+:
M)-[ZX6R6^)RP#CN&3+Z'0U05*^BM*/:<=MJ12-H2#?I5PWIU8N/%>^@XD0_[
M_JH0O`>*'6N9?K:D&/$BNZ\[(<FNA;J?@CDI3MQV\8*>LT(*)2KM`9WOA+ZL
M.?53'YC6JY)!!<9V)&F5XYL@VR;87Z^L/W\8/:B+9Z0:<?@B6?F-=13,AC:9
M!NR$>##0^])L0;+_(OO.-N"'1"6MR+[5/\7A*V5UHZ';,11DZLK*YUNJ"C`4
M:+PP-DR%:$$`_"+.S,T`0\B3_3^P4C<YCA(O7LRB`.!H1Y6^8X82HV*OM.!_
M'2@X4CF2\$@2@?IC//3"91S$R?]9?*?(%GA+-%FOI#@@N#1PINJ)N8)!!LRF
ML@C\>;TR*,GDW)@DFPIH!=UX7$=IM/(?P<+BB-DXS`*C`1..$=M7$(L!XH.^
M0224_G&1)FDL,DP&>EO'QD$6UF93V/9B8R0`G/FX`),$;EXX$*7SB0*'F9\5
M7&R,%,S'"M[NCP'G&(HY>Q],3W:8I>U>&,5C7=M1]&S;2!)<W4M3WI9DP%-)
MDT,W#C.WDA;);"+I,AJG0W`D*?F()`,>2XK2J22'<2ZETRB,',/@HLMSJI/D
MIHE[V3B5-=W2ME6H$'LS*4*H<MAU0VP39'`C87I,]K<PW.R^/P1@N/2DIM^)
MK%FG4$LKH)QY"_!(NO'D%EKT]A78"0UCQ3XV\!6A<-=G'H`K(?1I80;@\%U:
M_P,``/__`P!02P,$%``&``@````A`,$*\X<I`P``V0@``!D```!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&ULG%9M;YLP$/X^:?\!\;V\!I*@)%4#Z59IDZ9I
M+Y\=,,$J8&0[3?OO=[:!\M)U[;[$\?'<P]US9Q^;Z\>J-!XPXX366].U'-/`
M=4HS4I^VYL\?MU<KT^`"U1DJ:8VWYA/FYO7NXX?-A;)[7F`L#&"H^=8LA&@B
MV^9I@2O$+=K@&I[DE%5(P):=;-XPC#+E5)6VYSBA72%2FYHA8F_AH'E.4IS0
M]%SA6F@2ADLD('Y>D(9W;%7Z%KH*L?MS<Y72J@&*(RF)>%*DIE&ET=VII@P=
M2\C[T5V@M.-6FQE]15)&.<V%!72V#G2>\]I>V\"TVV0$,I"R&PSG6_/&C0ZA
M:>\V2I]?!%_XX+_!"WKYQ$CVA=08Q(8RR0(<*;V7T+M,FL#9GGG?J@)\8T:&
M<W0NQ7=Z^8S)J1!0[0`2DGE%V5.">0J"`HWE!9(II24$`+]&161G@"#H4:T7
MDHEB:_JA%2P=WP6X<<1<W!)):1KIF0M:_=8@MZ72)%Y+`FM+XGJ6MPK<('P'
MB]^RP-JRA-8J"!;A:@FAO/+Z1>L(:^L86.["4>]^Q0U(5>JPOC]J6^NHRI(@
M@78;1B\&M#HHQ1LD#XX;`7-7#QU'7Z&_%0@J(TEN)(OB`NTY--7#SE][&_L!
M.B%M,7N-69I&CW''B+A#R+)+VF1J.`P,-B309P&5G&;A0V^^W%5=T-)I'+07
MCB/:OP`9(V*-&&;E+<>0I(-T:1WFK$'0^XSR@MYZ?U[2"<[%0&A_M>[YE;)[
MC5FH8R&ECJ>&9&HX#`RC&*&-IS&Z2WEZ_R&_]-N:H,5S/SC^)$R-6:F.>I9(
MI1`/GSECOT0_<Z$%!N2+,>CP,L$H-TABF-OK_23!T$_ZKI&B[F>6>&9)9I;#
MT#**)AQ'\Y]G5;),=9](L]<8=U0<=])#<0_J&CN966"4*$T\-134B=6C0=]!
M%68G'..RY$9*S_+:7T"I>ZN>2'N82$K3B3WV(CA:\.Z)_2:(0,*Y?1^VD\WN
M'6"R-.B$OR)V(C4W2IQ#"(XE[V^F9Y/>"-JHB^)(!<P4];>`3P@,-78L`.>4
MBFX#+[;[CY+='P```/__`P!02P,$%``&``@````A`"T#^+Y@!```Y@\``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULE%==CZLV$'VOU/^`>+^`0Q)(
ME.1J`]KV2JU45?UX)L1)T`*.,-GL_OO.>"!KFS3+OBS+S)G)\<QP;*^^OU6E
M\\H;68AZ[3(O<!U>YV)?U,>U^_=?S]]BUY%M5N^S4M1\[;YSZ7[?_/S3ZBJ:
M%WGBO'4@0RW7[JEMSTO?E_F)5YGTQ)G7X#F(ILI:>&V.OCPW/-NKH*KT)T$P
M]ZNLJ%W*L&S&Y!"'0Y'S5.27BM<M)6EXF;7`7YZ*L^RS5?F8=%76O%S.WW)1
MG2'%KBB+]ETE=9TJ7_XXUJ+)=B6L^XU-L[S/K5X&Z:LB;X04A]:#=#X1':YY
MX2]\R+19[0M8`9;=:?AA[3ZQ9<H6KK]9J0+]4_"KU/YWY$E<?VF*_6]%S:':
MT"?LP$Z(%X3^V*,)@OU!]+/JP!^-L^>'[%*V?XKKK[PXGEIH]PQ6A`M;[M]3
M+G.H**3Q)C/,E(L2",!?IRIP-*`BV9MZ7HM]>UJ[X=R;14'(`.[LN&R?"TSI
M.OE%MJ+ZET"L2T5))ET2>'9)6.1-)[,H5ED>1(9=)#R[R(47L6`11O#K#^*F
M71P\N[C(F\0S-ILC[6&@3\M654RS-MNL&G%U8#1A8?*<X:"S)23#\H70A/OE
M@[IAS!,&J5!`2^CYZR:,XY7_"GW*.\R6,)'KW#`3$Y'<040F).TA.`%`^,8:
M"OUUUAADLI[,S=_;$B12S<65)K8AU0P&(VC@UQEA$-1;JU$8+RQ*A)E^4+(-
MJ68P*$$[=4J/6XK@M0NKN[4K7`06%<+$JN'SF>E,=*?5Z91\:@T&0QC5\0P1
M;#*<!-:\;`DS)886_41WV@Q[GSUH\Z\P1+#),(RF9IFVA-'::1M2S6`4"SXE
MO5CCOE0,^FS""*-1L@VI9C`HX2:JB<?C"4.P59W!A!&&^L>L+R'1G7;_>I_=
MOX7)4.T.H)30[L=D,<XFRZQ6$H;(AJ8OT7W6'*;D8Z"RMV^-!1]S8E084>-+
MK-`6[<C^1CJ0UN^!)=4M)A]49*WEXZ:0D8X_%KH.I/.BL`]+JF-,7JC+&J_'
MW66DXH_5K@-UP_C1'[4%)H;7[O#-:8\C0ZT>3Y.4W:1I3Z%*N78[FM88&LX!
MR__;.!CJM<9R9)-)Y0VVT>!4H&T%72%M2ZI^'E<TJ!ZJ]-=YD;9_,GS:!M#Q
MLBTI'BM!%.[P0LG6>'TR?"3P1IT&0LCZ74`=KBRU2PSOH*U]Z*!\*./C:9+H
MFS0'PT<@.A)8SH3IS@%+<MXI)DKY>)8D_*`+L%K5N"T;F)*A*35,II2@/FL$
MU)X!K:=#]>V.\=D.`I<>>PO15;[CVNT%>I798./K4H&J](O$*Q5F)Q/1IRL2
M'>XKWAQYPLM2.KFXX/4']>%FI:O9EBWAP`LI+7L"5[9[]B<6PUTNOA.Q98O^
MEN??DL$MZYP=^>]9<RQJZ93\`#0"#R\V#=W3Z*459W4JWXD6[E?JWQ/<ISD<
MOP,/P`<AVOX%1_IV0]_\!P``__\#`%!+`P04``8`"````"$`/P.\WJX"``#B
M!@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R45=MNHS`0?5]I_\'R
M>R%`+@2%5&VJ[E;:E5:KO3P[QH!5C)'M-.W?[]A.*-"JV[XDL>?,R9DSP["Y
M?!0->F!*<]GF.`IF&+&6RH*W58Y__[J]2#'2AK0%:63+<OS$-+[<?OZT.4IU
MKVO&#`*&5N>X-J;+PE#3F@FB`]FQ%B*E5((8.*HJU)UBI'!)H@GCV6P9"L);
M[!DR]1X.69:<LAM)#X*UQI,HUA`#^G7-.WUF$_0]=(*H^T-W0:7H@&+/&VZ>
M'"E&@F9W52L5V3=0]V,T)_3,[0XOZ`6G2FI9F@#H0B_T9<WK<!T"TW93<*C`
MVHX4*W-\%66[)0ZW&^?/'\Z.>O`;Z5H>ORA>?.,M`[.A3;8!>RGO+?2NL%>0
M'+[(OG4-^*%0P4IR:,Q/>?S*>%4;Z/8""K)U9<73#=,4#`6:(%Y8)BH;$`"?
M2'`[&6`(>73?1UZ8.L?),EBL9DD$<+1GVMQR2XD1/6@CQ5\/BDY4GB0^D22@
M_A2/@SA=1(OE_UE"K\@5>$,,V6Z4/"(8&OA/W1$[@E$&S+:R!/QYO3(HR>9<
MV227"F@-W7C8)NEB$SZ`A?2$N?:8%48])AXC=J\@5CTD!'V]2"C]XR)MTEAD
MO.SI71W7'K)R-MO"=H.+D0!PYN,";!*X.7`@2:<*/&;^K&!P,5(P'RMXNS\6
MG&,HIO<^6D_[XS&IZ]XZ&1NS&P8'KHT4P>0./7E;D05/%3TWVW?#8^9.491&
M$TG#Z+/<D:+E6-'[9MDFC94EZ529QWBOXM5\HFP47?=!+\WO%/_(":8JMF--
MHQ&5![LO8BBVO_6K[#K*8"YAATSN=[#BW'W8!V#%=*1BWXFJ>*M1PTJ@G`4K
ML$KY)>4/1G;N0=A+`\O%_:SA7<)@XF<!@$LIS?E@UV#_=MK^`P``__\#`%!+
M`P04``8`"````"$`MH#L9(,"``"C!@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6R<5=N.VC`4?*_4?[#\OKD!X2+":@'1KM1*5=7+LW$<8A''D6TN
M^_<]MH&2@+J[?8$XF3.>F7/B3!^/HD)[IC27=8;C(,*(U53FO-YD^.>/U<,(
M(VU(G9-*UBS#+TSCQ]G'#].#5%M=,F80,-0ZPZ4QS20,-2V9(#J0#:OA22&5
M(`:6:A/J1C&2NR)1A4D4I:$@O,:>8:+>PB&+@E.VE'0G6&T\B6(5,:!?E[S1
M9S9!WT(GB-KNF@<J10,4:UYQ\^)(,1)T\KRII2+K"GP?XSZA9VZWN*$7G"JI
M96$"H`N]T%O/XW`<`M-LFG-P8&-'BA49?HHGBQ2'LZG+YQ=G!WUUC70I#Y\4
MS[_PFD'8T";;@+646PM]SNTM*`YOJE>N`=\4REE!=I7Y+@^?&=^4!KH]`$/6
MUR1_63)-(5"@"9*!9:*R`@'PBP2WDP&!D&.&$]B8YZ;,<"\-!L.H%P,<K9DV
M*VXI,:([;:3X[4'QB<J3]$XD\'\BB9,@&0WB0?HZ2^@5.8-+8LALJN0!P=#`
MGKHA=@3C"3!;9SW(Y[XSL&1KGFR1*P6TAF[L9[WA>!KN(4)ZPLQO,7$;L3@C
M;/*@YB()4GJ_)%O4EI2D[?WF=R!MQ.(.8GB!M#1"5._7:(L@7HRN8AM<^%VT
M<X_IN\[;K!=7-UH*^O^CP!:Y,?RK8!1U%'C,R+6U\VQQ_UE+%PQT-YGTU8&R
M15U=G7&9>PPHN-*>M+4OSICN2*6WHOJ`_?>4VZ*NJ%Y[P[G'M$7UVQ@XF"R/
M:ZE/RI\S_C5LR(9])6K#:XTJ5H"W*!B"-.5/&;\PLG&SO98&3@=W6<+'@,%\
M1`&`"RG->6&M7SXOLS\```#__P,`4$L#!!0`!@`(````(0"4R<(2PP(``#X'
M```9````>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;)Q576^;,!1]G[3_8/F]
M&`@?2112M:NZ55JE:=K'LV,,6,48V4[3_OM=XX2FI.VZO0"&<\^YYU[[LCI_
MD"VZY]H(U14X"D*,>,=4*;JZP#]_7)_-,3*6=B5M5<<+_,@-/E]__+#:*7UG
M&LXM`H;.%+BQME\28EC#)36!ZGD'7RJE);6PU#4QO>:T'()D2^(PS(BDHL.>
M8:G?PZ&J2C!^I=A6\LYZ$LU;:B%_TXC>'-@D>P^=I/INVY\Q)7N@V(A6V,>!
M%"/)EC=UIS3=M.#[(4HH.W`/BQ-Z*9A61E4V`#KB$SWUO"`+`DSK52G`@2L[
MTKPJ\$6TO)QCLEX-]?DE^,X</2/3J-UG+<JOHN-0;&B3:\!&J3L'O2G=*P@F
M)]'70P.^:53RBFY;^UWMOG!1-Q:ZG8(AYVM9/EYQPZ"@0!/$J6-BJH4$X(JD
M<#L#"D(?AOM.E+8I\"P+TCR<10!'&V[LM7"4&+&ML4K^]J!H3^5)XCT)W/<D
M418D<9K/W\%"?$:#P2MJZ7JEU0[!I@%-TU.W!:,E,#MG,ZB/SV/T^II5\.A(
M+AQ+@7.,(-Q`>^[721ROR#W4E.TQEQX#UQ$3C0@"V8PI01K'*;U<Y(.R`SME
M5W27RJ5_<2SSE,@SF=ESF8/SM^5<4(%!8S21Q+/1AL_`8Y)A1QW[2DX%DU<W
MT<&?"X*6'`G.TFPBZ#&G@D!^7$CG,(/>ONW0!4T=)A-!C\E\HZ-%GH[?GU4X
M^Q]]%S35?^+W%?:8=-"'21B&+^O#?OQW_RYHJC\MN,<L!OT\R.<OR[OA/SE:
M?R^_"YK*YR._M^\Q^_*G63S5]W/,'W/)=<T_\;8UB*FMFU$1I#V^'<?G13SL
MU_$#C*^>UOR6ZEIT!K6\@M`PR*'UV@]`O["J'X;(1ED87,-C`_\I#D<Q#`!<
M*64/"S=BQS_?^@\```#__P,`4$L#!!0`!@`(````(0!]V]DCY@(``!,(```9
M````>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;)15RV[;,!"\%^@_$+Q';]F.
M83F(+:0MT`)%T<>9EBB+B"0*)!TG?]\E:2NBG";IQ9:XLZ/9V26YNGEL&_1`
MA62\RW#H!1C1KN`EZ_89_O7S[FJ!D52D*TG#.YKA)RKQS?KCA]61BWM94ZH0
M,'0RP[52_=+W95'3EDB/][2#2,5%2Q2\BKTO>T%):9+:QH^"8.:WA'78,BS%
M>SAX5;&"YKPXM+13ED30ABC0+VO6RS-;6[R'KB7B_M!?%;SM@6+'&J:>#"E&
M;;'\LN^X(+L&ZGX,$U*<N<W+!7W+"L$EKY0'=+X5>EGSM7_M`]-Z53*H0-N.
M!*TR?!LN\SGVUROCSV]&CW+TC&3-CY\$*[^RCH+9T";=@!WG]QKZI=1+D.Q?
M9-^9!GP7J*05.33J!S]^IFQ?*^AV"@7INI;E4TYE`88"C1>EFJG@#0B`7]0R
M/1E@"'DT_T=6JCK#\<Q+YT$<`ASMJ%1W3%-B5!RDXNT?"PI/5)8D.I$DH/X4
MC[QHD8;I[&T6WRHR!>9$D?5*\"."H8%ORI[H$0R7P'RNS.H8:OU7J5"C)KG5
M+(8+JI#0GH=U$BU6_@-X6IPP&XN98S1@0A>Q/2.T@9HV'RWXH'<0#59,1<?0
MU)?;<=:HDUR-T<P5L'D!XB*V+R#F+B2_A*3I`''*B-TR7I>OP1D&\L&^)+H>
M>(U?&XM9F`;,XTEUVW$T2A,W-Q]'GWD=O3`?_V^[3IKHC@/WVQN+2<RXZ\9O
MIPOY:,&1!-MG+.EU"S5X(N7"0HM)C(6+V-6Y'0>3J8'CX'.!CMJ9JU9OMK?G
M5B=-5,>3G;.QF)&!TX5\M.!(@OWX?@,U>"+EPD"+L3,X2Z<.CJ-1^&R3W>_C
MZ'0&[>%LSZZ6BCW=TJ:1J.`'??"&T+!AU=X)&[@3S`GJ#P$XDWNRI]^(V+-.
MHH96D!IX<VB=L*>Z?5&\-R?%CBLXC<UC#9<OA=$,/`!7G*OSB[XWANM\_1<`
M`/__`P!02P,$%``&``@````A``IJ]%L."```,B<``!D```!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&ULI)I=;^NX$8;O"_0_&+Y?V_KR1Y!DL3(ED<`6*(IN
M>ZW82B(<VS(DY>2<?]^A2$G#&6]L;_=B??+HY5@S')*O;3W^^N-XF'POZJ:L
M3D]3;[:83HK3KMJ7I[>GZ1__3G]93R=-FY_V^:$Z%4_3GT4S_?7Y[W][_*SJ
M;\U[4;03B'!JGJ;O;7M^F,^;W7MQS)M9=2Y.<.6UJH]Y"W_6;_/F7!?YOAMT
M/,S]Q6(Y/^;E:6HB/-2WQ*A>7\M=(:K=Q[$XM29(71SR%NZ_>2_/31_MN+LE
MW#&OOWV<?]E5QS.$>"D/9?NS"SJ=''</ZNU4U?G+`?+^X87YKH_=_<'"'\M=
M7375:SN#<'-SHSSGS7PSATC/C_L2,M!EG]3%Z]/T-^]!!>%T_OS8%>@_9?'9
MH']/FO?J,ZO+_>_EJ8!JPSSI&7BIJF]:JO8:P>`Y&YUV,_#/>K(O7O./0_NO
MZE,6Y=M["],=048ZL8?]3U$T.Z@HA)GYD8ZTJPYP`_#_R;'4K0$5R7]TKY_E
MOGU_F@;+6;1:!![()R]%TZ:E#CF=[#Z:MCK^UX@\&\H$\6V0`.[>7H]FH1^M
MUO=$"6T4>-^_?BM+&P1>_X];6=DH\-I'@1QOK`8LK:ZD\#H,OK\:&QL%7L<H
M_CKRHN7UF9F;6>Z:1N1M_OQ85Y\36(DPC\TYU^O:>X#(?;>8N1WZY\_:!_I&
M!_E-1^EB06<TT//?G\/`?YQ_AS[=64U\21.XFBW7!,NUJQ%&`Q,QO)?G*I)>
MH9M;WU[*PX8!>>NL'S2&96\M>TT?6"$PAX(.587>H%4-8"5?7H-]$?4@MXA1
MZ&86<TD8$,V6:X+EQHTCN(;,5G)!L7*#I%P2!I&KR2YIEJY&7M*0]U*7-&-C
M.+6'/8?6WO.O%E^/>IK"VPQ=%0:D:K'1='MWUU=;"D0/QB@^G<.DU_1-E%*0
M42`I4`@XN<..27._WG=ZD)MZL")+*C8:E+H!4;?65U'DA3Z9,D&')!2D%&04
M2`H4`D[B<$3<G[@>Y"8>A@NW.6.C08E3(`Q8=Y4(O'!!ED!"!Z049!1("A0"
M3MIPJ-&T5Z#]>I_1@VC:=+Z-!J5-@>C!V.IA2#>17C.T.@49!9("A8"3.AP`
M-/7EU56N!]'4R4$0&PU*G0+1`YPZV8637C.D3D%&@:1`(>"DKJTZ.;/#J[.N
M!]'42:O&1F,7]=J/`K*FMT8PUD90D%"04I!1("E0"#AY@S^Y/V\]B.9-3J#8
M:$S>(3OVM^8RROIK?4+U*049!9("A8!3`P]ZG!;A^A;?C:)5(),;6]&8YY81
M8<FFV^T6LPWIH.3*]91%S!B1C"A,W&IH`X:6PM<;GV?L&C[D-Z.)Z([TV&IP
M$<RHD0BF21A)&<D8D8PH3-Q$M0%"B6J??L.T&]N$$^9'NV=$8WY;1@0C"2.I
M)685!?"I'_YS#].,#9*,*$S<$FC3<W\)C%7")>"'O(?\E'%VC`A&$D922\82
MT/SI^T@60V'BYJ^]S_WY&\?DYL]6/K)5-G]*A&>(\3D>\0N)O3HV4?JE/F-Z
MR8C"Q*V$MD.H$E=6O3%/N`+T,V6LOR"!4V*\_2TC@I&$D921C!')B,+$352;
M'Y3HC:O>6":<\(55CWR5G7)*A&?(V,YL12=6,A8N921C1#*B,'%+H$W0_24P
MU@F7X,*J1_[*EH`2X?5$?Z=!/@\FP\7!Y#&2,2(949BXR6LG1)*_[O0\XY_<
MY,E!'5O1.'%;1H0E9OY7%_Q@PL:DC&2,2$84)FX%M`^ZOP+&/;D5H*;/0Q;+
M3C\E8M#HZ2<?%)+AXCC]-$#&-)(1A8F3O/[6`B?_]3[7J8G'H_MT;$5HVAD1
MC"2,I(QDC$A&%"9NIL3'Z8WN^J<YG_NY,*2&SHIPQLS068UI='^YI!_F6(R4
MD8P1R8C"Q,T?6A7/](WYZU%DQD.R2<6^$>'\*1%68_/W5BQ_.B)E43-&)",*
M$S?_"][N^D;G7_!V$?&<L17A_*D+$X-&+_/UFI0P&2X/"YV1C!')B,+$35][
M*[3+75GHQHG!G(S?54;$D,4^-7!;1@0C"2,I(QDCDA&%B9LIL6ZW.1K]^P9M
M](A\V11;$9YHZNH$TR2,I(QDEO3+(UAX$6D1R08I3-P2:%>%)OO&$A@OYDXZ
M.9%BGUJX+2."D821E)',$EN"A4]V",E&*$S<_+6ENC]_8\3<_,E=Q'[OUOJ%
MNF5$,)(PDC*2,2(949BX&5^P<=<_O/O<QG$;;T6XZ<VPD0BF21A)&<D8D9:8
M'MC`SR.D_90C"%?>!AVD;D&T3[J_!8R[<EJ`?5_O4PNV940PDC"2,I(Q(@>B
MCPUZ\"CGJH\N.Z70?8!+\?76WZG)B1]1:V]%8P=L&1&,)(RDC&2,R(%T)7"_
M[E##15B.;M(7[)X67TG^@MV+J*L/J+G;,B(821A)&<D8D8PH3-R,H6OQ-.M-
M_Y9?)?4P.M_TVYO`B/!\4R*8)AD(=A'$/*>#J-]0,T8D(PH3MPI_R>8%EVP>
M.8!C*\)%8#:/:9*!Z/;UUF1#2X?+8_HTJ&0:A8F;_ETV#QX28G._I.[6BG#:
MU/@)IDDL,=_E^60)I4R?,2(9T<\TZ=OM[L1D;1Y1,D^;'(OZK=@6AT,SV54?
M^O$C'WY"&*AY-$IX#_#L!M2:\`P>F>KX?+@`3RR=\[?B'WG]5IZ:R:%XA9"+
MF?[QLS;//)D_VNK</5+Q4K7PK%+WSW=X-JV`IT(6,Q"_5E7;_Z%WJ>%IM^?_
M`0``__\#`%!+`P04``8`"````"$`GQH/'YL.``"0G@``#0```'AL+W-T>6QE
M<RYX;6SL7?MOV\@1_KU`_P>":8L>4)MZVI+/\B%6S#9`FAXN*5J@5Q241-F\
M\*&25&)?T?^],WS.2B*Y))=<I>T)%TN4./O--X^=';YNOWMV;.6SZ0>6YR[4
MX>5`54QW[6TL]W&A_OFC?C%3E2`TW(UA>ZZY4%_,0/WN[I>_N`W"%]O\\&2:
MH0(BW&"A/H7A[D;3@O63Z1C!I;<S7?AFZ_F.$<)'_U$+=KYI;`+<R;&UT6!P
MI3F&Y:JQA!MGS2/$,?Q/^]W%VG-V1FBM+-L*7R)9JN*L;]X^NIYOK&R`^CR<
M&.M4=O3A2+QCK7TO\+;A)8C3O.W66IO'*.?:7`-)=[?NWM&=,%#6WMX-%^HH
MVZ3$W[S=+-0K58E57GH;`/&;?^Z]\-M?Q7]>_>[5J\$_OOGV;S^8F[__^-OC
M[W[\1M7288A,L$&YS,M!J5CX.I:L)1K<W6X]ER@R`9J0K9M/KO?%U?$[<`90
M#W]V=QO\K'PV;-@R1'AKS_9\)00K@W[1%M=PS/@72\.V5KZ%/]L:CF6_Q)M'
MN"%RC.1WC@5FPHU:/$*_XZP03:K3#&$P.HUQ"]7)`94,W%BND_'3"9V8L:;5
M8[7ACQDKTJ)<+V%C'?O%$8=MQLIL1<;Q'U<+5=<AAPP'`Z25&JRCP>;+`8S7
MVV!7T]XT&^MC_5JH9HPO'ML-!QSK(JFL&%!_??VF-SK%#U:D79*&^XH`##BQ
M+%H0NB7Q?:WCJP\_Z7E"$VHQ*.#"U[;UZ,;3;;#?046W]JU=B,R=HK=3;2/=
MF*DG2@!YAOYH.6:@O#>_*#]XCN$B2#JU1K]F*@/&_<6+SQ@BHK,)YMCCA<$7
M.0832$2/TY:NH4)DB``L9-EV5ON.IU@=PI:[6RC#0]-W=?B@).\_ONR@-G1A
MQ8"FU>+?5?SZT3=>AJ.H0N+;(?!L:X,H'I=119J0N;QZT)</T;@$&2^*`J&Z
MOKSN0.C#_7PI'NER/A<M=*3#2[#0UU-\"1:JPW]+89PFL3,1!3*3IX06KB`'
ME]?S^7PVO)K-9O/)>#B91"2O$H^VW(WY;.*B4AA-QPBF@&`^GLVO1@!D,)E%
M0_6*8`P`KJ?3V70X'TW@_RC]=X]`-*=35;95"0))5B4()%DU6L1H`C)_$BG0
MSY$<JP2!)*L2!)*L>BTX`U]+MRI!(,FJ!($DJT:M-X&Q"GU2R;%*$$BR*D$@
MR:K"BL\D`\^E6Y4@D&15@J!OJZ;+JN7#@QXU8HXK,V'U<3(6%O'UQXI6C;!.
M77G^!MH?Z5&:(:Y4XVUWM[:Y#6%%ZEN/3_@W]';P[\H+0SC\<W>[L8Q'SS5L
M>*NE>Z1_2_:$`V1P+&RAAD_6^A,,QG0^8F[B(;H:(<MZ$UQ-3*XG@^O)='05
M+]@$#>V8&VOO'&N7C7W2+X%&Y+9:<<*AFPV2N$/>`]30"HGY./>(3!U9FG,'
M\(G4)3CW$*%CW@_GU9'LP:<CV8%31[('KXX0.J>"*V5RX^WAV.RA@75]-AC$
M33_><<H%$N`G/.8T"++/,9^5NYQ@M'*?NKI"?CF*C?L1OJ+J^(2F%7L<ZUFQ
MPPDM*_;@U9'UF]2ZC/"L=8'I^022`[Z9GS>#`0/%.Z9X#I)@DI^P01P?%.%.
M=Z?5K11/M`8)]:8K;AW((-S[".+WP(2B^:T43U0OX#>I"Z#,6)NV_0$G_K]N
MLUH#VG=WM\];<NH&G$^#YS;@F2'X%GKDR=NXKH@_P%A%.XT*=U*,W<Y^>;]W
M5J:O1R?91$-$6[$7GW^ZCPJB_'-TI,@QHP:D&HOYWO="<QU&)P%%QPZ*\(P+
M\`P303QXVHP/9ZJ<)!%XXN:CS?C0X#HY/O`B=7QP+N[Q1?H#GNZ4.#68@#IU
M&1Z1"*"-D2(`(\A`@*=G)1R`>\I``,O#%`$X:(X`X)1X19LX&))L!CZ0#PGC
M=S4DY)A42V;(#K4L2K\P?HF6.I-^6]%,\BTX>DXS?"@!T&K(HA0K*\40LT.D
MY13`AQ(*=)AUQ4QYT$#(_`XXR`%((X0D7080I($R1L1Y)<FY,"8O(_<"ZQ#B
M%)B*9$,`.%(@$$,,)<V_0XI!T@Q,O4'2%$PA,'-P>980&A/4$LP,*0D#X)$2
M%7F^'C(S1H\T$`BR,B3QAI&L%$DQR,J1N2E&LE(D@2`K0U)+R$J1%(.L'$E,
M(2M%$@C`B)0,22TA*T52#+)R9&Z*L:P422#(RI#$$N..4Z1&VZ9Q$Y7T3X?C
M>:,&JO*\K>RD#HM636#X=/=X^10O'<$8T6**K*7QBC@#3[/'YJGRY/G6S[#*
MQ"OCUK#!]%6\DC*TUG3+%]_8?32?82T:'^!ZWA8W>P%)VN`X]$8682&F?'QH
M9:M*G<&%\],"2WLB*C7'QDIE8_[`,=CF=J6#5&*(.@NR02#7"0;A+B`H1#!R
M9=,$LZ1T#-14B"=I.L-FIHA@<X4.S&'RJ<AFE<Y*!L>W7&,7YJE^1VN1B7#E
MQ*<K)\\T)'[:!Z&U?:'31OVT#:634(!U3#,4/3AE!\]G."]J*+K_VPZ32E$]
M%-N.NI*"%[-$F:BZ#NK!K4Y"BZ\(*:O0A"-KD9K^J[&(#K5.\WA:_5.G@G,Z
MM#)/&L&,+#1O4\::`.*>Z`HG];8(L#UW5I04`L)#3F555MK5KZRZVE(F/`>(
M!#0^['664:9'1R=K$798(#3Q>AJ&_>"MDR2H>5ET<"N>4@]DZ6SDCR+HE:I`
M='HKK2!;.\AAX[P3AV[L(+V@RPN6)FPR_M`QWL3\=>CL/QNTH[-/O%]I-`DD
MN!]_;0FXJ(;ZWRA9CM>=574XS4A0U;5OI-$*ZAA.M@R.KWTM6R'(0@:><JZD
MP3E.YPHMONJUS)Z=+D&_)D\[5Q/&EVJ6FA"/&G%UOAMT@TM,R!&2U+O&'<]4
MYU[YB<77PU*K">!B@Y\I8#J?L8O9BFX*NY;E:C\=QU)5TI%02M=9F3#D=1S>
M+<ECT%65G:QM6_0IZI#)V+ION&V7I7WCC;VAY:J$-+O9R:D'_Q"_<&7ZFCUD
MVY8!V3?<MA[>-U[A'MZW`N(]G$TRH`]_IU-^#N\>;EL/ET-O9SF\-\);:D`.
M<?8^"S4J\4DS[P`P?--Q2#8"3!@6TDS+#2[NQ*BJ";M1`FO"%E/3]SUGU*\I
MI,(5FG'[6&]FC=[JTYV*ER/B@;;ED7%3\?!X2K$S9;9+Z+VP3E?0=3@FDQ23
M\_&"Y+(YZ@SRK'@';A!?3%YE*L/.X.73:NMYBP'<PVJ>)\RJ>GW%C/>@0.(A
M#4P`62"]!*'&E''ZHA7V^`3;A>/JL+9U=":E]4`[9[U3Q'$%W/HD-\I^#4AG
M/*5"BS*G:(27DW3(<R<=NV^X#>@M225]G:%'Y^VJS,=X`YNZNX?;@%ZI>.M[
M+^,-K/?"I[)BB,W`\H.M>[AMO>$KH!?SFHRS!:K/DNGWS':A@52K*&X12`T*
MM*)YK.]$&_/=3@&:RD"O573OKN3>I66)C*MX/':(?,%9?1$6/?.!@78VG;WB
M\*J891OY:Y,U'+KJJ=1T7(EW"PFR>'7I!V!9EZM?;G.Y)>^45`2:C7,!J!MQ
M+U:+HT*@/O>=:H&.G-P;@"D6V?(`+,-ZD/"E#B_KYX+W.`57KAT0^JF<<>3H
M++E<H=<DAWT%\T!#RAI%3",*"YNWYS)1%4ZETKR.4'9P4+:",P%K/&X;TUO+
M%.?%(P[K)W>NZ*Z?;#HM/[E9Q/!-)Y>&H5S(3ZVV3='@9WF,!<"N>ELN<)RT
M7T0>;"\K"@HM5WZ%3^_3:!U'HF%UD+RZ+Y':98'>X3:HZ!AZF0JTPM?8J8'+
M\Q)X[5;YQ5/#\*CP9ZLZ%G&C@B7VAW8*%#/>@P)"3'`.&C1-(7UF^G'EI7^%
MZX&*X.,*MT-GK7T^6DFH5>`[DU"3JH"04&,T8)LUW9?NXC5@)IBO/]W5BH+"
MF&V:RMCRHG\LA<GKN"/+3L2-IMXF*R`Z40$_>8G?2=L]"9=*<R(]Z1H-WW(U
MJ$XO<VOY5'0C8[AU,7D0'/L8N.Q&QXIK./!TV-'@U\J%\GJ-U&?9!CE=[2T;
M'EN-QU;P)M1KN"FDY]S'&Y.[!I?)RLZR&V$^(+(@P=65E=5\([PQ.9$%=QNM
M*RM;3XQ!6R(+GI%76Q;<+#Y>J8WQMO$YK@G<&;8N+M@ED<5R/^7D?G+*CAB]
M!!>JS(.+RLKMB#-3KB.J7%=6;D>\N3N1!2K7E97;$1`261,8I*ZLW(Y@!2H+
MW*VNK,R.$Y;[*2?W5R?MR/HJW@V=!Q>5E=N1]=4QIZ]26;D=65]%E>OBRNT(
M4BGW\$5=6;D=V3PQX<P35,?<CBSW4T[N#S,JZ_$C3H^/I>2V@W>$([Q<G8>C
M6$IN-=;+QYQ>'DO)[<7Z]X33OV,IN:5`'M%H`E_P:Y39:,RR.^%D]][8I%F7
M=1B<9WA@+`U[O;<-?$!I*@BK#J(0'B?@DO1DKC\I2WAX:R:(C0><1GD$/3SO
M;,,U0L]_4?`&_YDXUNA33G&_][R,(U;""#[R`/J#:6PL]U$!7N()CO5AO+E[
M'3%9++#TX..^ZHB!O6,TK/_A@YGJB(&]8S%L4L7ZB4?,6W>WSRS$YE*<NGE$
MO+/<3^:&]1R6X1&`Y)'TWMR'OI'Y'QM2(TYBWN,C?S,9;(J(;N!T6#.^AR?\
MIB3BT2$2.UA#\P#_TSXD-.)>1`@NKGF$?+1">`)\8DTVAA$6EP@/'KJ1B3C(
M*)PR_F+X+D8+$[H'/EJ@4?X,$ZC^-\_YXY\CWD,#GG`?/1@Z6P\`41MS:^SM
M\&/VY4+-W__1W%A[!YPI^=7WUF<OC$0LU/S].^OQ*80HA@,,D&[>!6'T5]G[
MUD+]U\/]]?S-@SZZF`WN9Q>3L3F]F$_OWUQ,)\O[-V_T^6`T6/X;*'-L-[AY
M'DX6ZE,8[FXT+5@_F8X17#K6VO<";QM>KCU'\[9;:VUJP<Z'I!(\F6;HV-IH
M,)AK<\TQHL?0@Y";P(9?^8FR"?@/^;:%2C[$\*,F'L"'NR.G2F@!/D7[`PYR
M]Q\```#__P,`4$L#!!0`!@`(````(0!;,X9=:C0``%>O```4````>&PO<VAA
M<F5D4W1R:6YG<RYX;6SDG=MN6TF6IN\'F'?8$%PHNT`I=;!\R,YR@];!J6I9
M4HMT5B<2?4&16Q++%*GB)NU482[J'>9J+@;PL_A1ZDGF^U=$[%-L'I25787&
M`)U=%KEW'-9Y_6M%\+M__?ENE'Q*I]EP,O[]QL[6]D:2CON3P7!\\_N-#]WC
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M=IH<]F;1Q'[,X^$HG28'/'`SF48#GDW&F[U^/^49GA@P,/^JS]J=]B052>?A
M[FHRJG][?GEQ5O\L[&=R=S<9)YW9I/^QE71N>],T2\[G,Q,K1JR_EG.[^W`?
M[6=W>_.X_D(;V1B8?!R/>HN'NTBGPXGDIYE2^;2>K/[Q8P0BJ\]X_&/]D_K;
MQI3&=SU5_IB.1IL?QY//4";M92C7(#G)LGE,^+-)?3(_Q`^3T7P\ZTT?',.B
M50;Z>W&Y3.\GTYFQ<-:;Q9OZ,8U&>-L^;9\='"6=[X^.NIWDZ8?.8?+D67TY
M)^.D>SN99UB)K(46C](L2R:SVW3Z>9BE27:?]H?7P^6*N%<?].##Y>7163=I
M=SI,_6WT=2^[39@PZ>L?Z9_GPT^]43J>15OHW++IS5DZO4NN>N./R0`J9,/X
MN<NTGS+&%8NW<;%8][WA($E_QIQE,6FZDQFZU_>T[659&H]Y>G[V;K-[=/E^
MT2Y.)^,;MS:_K/HV+Z98TRGF3EO5+N\EYZUDG,[JC[H%8:7]B,U+ZIYWVZ=^
M.?41`LE/3]IO3TY/NB=',=UE!=+DOO=@E*J/<"ZF)Y@2V?`L/%9_JDJZT;!W
M-1P-9\.8QAULY='WYZ>'1Y>=WR9'__[AI/MC)`GG4\R2E"!SEF5RG9R==)+M
MK>T=%C!-D(MYFFPF^]NM[6W[SXBY\Z+U8F>OM;/W.KS8F\^0E>%?4,3>+,%+
MI'=7["9X"GL+E['72C!@R/1L^"D=/?Q+LO.\M;NWW7K^:ML>>=W:>;7;>O7B
M93*4.C,8K)L4YBZ?[A%SU"G8'@P@V&2,!$I(-Y/A&$6X'R*2T:-]?.=\9'9]
MD%X/^\,%DF/DNYV,!@0#OS59FT6.PDE/23Z2]MDAUB%F4WT9=4MR@1?`1:>S
M(2[L6?+TY+03V94#YS@RYSC$R\E4P8A<E.,JNN'(F3R%`H/):-2;(G;ATQ4C
M>H$I^%Y?='4![O&69^MZSY;X7G^ATVUWC]YCXCK)^7%R?G%TV>Z>G)^M:673
MG_OI_<QYTV30F_5^J>'=K:_K,LT(*/K.N@Y29'QB1F>A)7R7CHD;1B;GO<'=
M<&R!D+1CX2OGL*AGKF@TR2*3?8P^C_M#A@S&5^SM3^[29XV6[[1AC,,TO4-,
M!L-/PP'107V3>@4MGTV'5_.93%DRFR1>^!,L2,VHU%]_V\N&?=OP8#B:2QZU
MCT+PUA3'/Z;#FUN]W2,"[]VDR7AN)B=>0#+/>$Q:/KF[GQOEKM99@Y/92`^J
MLG?P??OLW5$G.3EK5.7UW'XDD'6:F=6O?^@US&+#Y*?W9G&C$+MD[2YD[2##
M@3-VBU\I6;U#9_62P7RJX.>P)-*=F:B^:-Z+:7J=$FH/DH,1WC1I+WSR;6^$
MQ"IRF"5_Z(VWDMU=2R\BY?(/FGQXWJQ\1U&A1F^02TGM-;Y6-KM.VC5?*R]E
MV1`%,=K>@YDN)D^?;&_M[Q6B'\E:>1UK#[)L51WY>8(Y:834@?`,6Q*G@8'6
MSIGG*=^Z/"FGB=$[!Y.Q3YK%E7A;J"JL66%%?M$@RRCCC=[A`J-7YD1M:04O
M7^^OR<OU1EBVW`4,BE*!\)Q\?$EIR@R*WEFRUV1^3SIZ/R7:GQ'*CGH$>L0B
M@00OMK9?_C(2/&[@9919N7J<[$P.\GY^-<(33:XQ5#)NY`5HY`Z1[\(8Z-<<
M>]D>`M=JZA<A+N&Y)=R-WGFD_ZH'F\UI+%1;!AL=D7T)=_+6N)5<0&)GB]IW
MRG?JUO/"2]A%D+"%[N/DXGSA=U^_?/U2'[FV_7;G^^3X]/R/"T/'`^7(UZ/)
MYRRYGD[N$N64+OSJ*8MIS+W:@S_-LYD4(Y.7F:;]"3$9@9)%.GPB4;/D.X0F
M3:-&V=IA>L]0PT:#_=-.Y/I=8+#:UI^,R?!3($DT.ULSXS^X[8UO\-E8E=+2
M+9&WT*Z4F$;;:$YT(Q]\M@Z-ZMRM<VN(J\DLY%O,K8LY$3L>4=[HOA$SJ,\2
M+6V=:>I+NW:1.H9G\=*"PFAISGHW!O'Y>EB^8O9!<O60K#7^N`^XS-85'4O0
MUT&%;"--#RH:(RU-KL!SQV.95):M#QY(BNHT7#D*F<>R]T'D$%I3L=XXZ9D5
M0;\^8UAF"&?R9"?"B-\=G9$HGM97<CZ]Z8V'?S&U:B4$%MED-"0M)"PR>A"A
M:![W`3LJ4BQ"8'!M6\-/[2M!V/U9I(:_RO"'P-48CSG!VT_=].=9\G8$(AS-
M=7;>/4IVOMVL;[$7T>+M</*6P'R67!`1WO62T]E@*WDJ9FV05]SWQ@]_^^O_
M?99\[DG'^Y,I\*=A!PC*23;MI2YE)81D^WVE5Y@Z;PD@H$P)L?Q<T%((Y[<`
M.E/(:X,#!"2]I#_"%X-A;`),D$M<#2>SM'\[GHPF-P\6GK(,_>_=<*9,#\/I
M<VK)5GAY])#<I3!P?',]'TG<IN0WF"9*'``\0&.RPI^'L]MDJMA7@CL?P:I-
M^_.&!!P<A627S!VH,EJE1ALPQ]5\.`(L0UN5&),S$/Z`CEXC*Q-O.0;SOLSZ
M>"#I804VJ4AZS[ZHO!!SL(7>8(!`96"]=U@X$FU1`(^0#MR:(?=\:FEUXYI^
M2ZH,(J4"#B3,@WD(/DC3>T95/J.B4TG__$";_=X\T\<0&A+;O%@,<B\VWC+*
MY"MEQQ88)2@#.;-X*H)F)(!3EAN6)EV;.=-DFIY1OZD,WP,7%#NK=,W2]*.Y
M1@$,L^'U@^=;RE3]TOYL],>N`[ERX!?<OYW<WSY0GPO;O4.^D)7LKK(>:#JY
M^I-#)269<`F/;>R$6P$M#`*7@'ST1IY9R-9@.K_)O.X<ZM\;ST1+P"Y9OPF"
MXE\0M[(YM:(L0U1;$#/]F-SUIA^10`G6O<PWQ+4X0W+S8:NSE1Q/*+Q(:C5V
MTBZ!1/#<:>SQ8=O-Z2H'R>?)=#3X#&T)/6Z$7U*W2JXH3"+?==-P%7U24]-T
M?(-R&H"B-<D8-D)<SGN*:!86Z%GD[-[,2]\8JZT-TQ&4P=TFX\DLD?8YNS)%
ML,9@S?G>,TH2TBN9`.BB<9V(#B:HEEX6P(7"P:PP3)(-;\:42]#!&0MU(_J:
MBB@X1];,1,#N&354KR(Q"]Q,9MVF`M.&?]&CLG'&X(KPV&9,:85V*,)S<9$(
MX-T2VWCRLK6]NQMP%'TGITB]6-XZPLLCGO2C3PX=(M.>WQ!J6CFV91H8#"R+
MOQ^E!I!ALGW*<^%2GO.0\CS=('Q&=+#J'WB$I9A+,P9^OAT"9`YG`8K?:U%[
M5AF@GII;\("!0-X4&2.58IN$^><A56QP_J]?GE`)>+Z][_)$L4*TK&7!BAMP
MW)AF9[OX)V3:.&MW#MO_GJ-6[TU?-B)Z=$[>G9T<GQRT5?<Z.#C_<-8].7N7
M7)R?GAQ0C*F+?=O56<36"TQX7QYCL0_OE.2J\<U5/GDW]LE=-N=C-!0#DQU"
MB5L036B1*L^FCB:I@C\J#$T'AF697_&%(FV`=)ST`FYG7A-&6&^^!^1V[XJ.
M5?X^W3#;\J[=OMAX%M'R@PN&%3F+@5D4PFOM;G$YPS5'XW846DZLX4`IH*T]
MGQLE)3/$I&`&QU@9Q5)2Z+O>1P#P,'TK^=-\<./B+,D.>.+\[MZ<4D43,>.E
M8:[2T1`3@#67B]+RUAG0@<6RU`J,J1()WW8YE$$?PZ)U`N2Y-QS9`WX"R(6Q
MOTVA/@/<4>VS]4'-M:;&;"4]5%-&C>7"?`(,..BL"#X*M6I,L<P]X))#B,B#
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M:4O2^JL2X\35]D41"XMDKN`JG7V6*5NP6IE=J;1U/#"R)%Y#!$*X!>;V8@M/
MI@#:B.#\G8B$IE,ZDZ7RBF-&Q1D,1:U+)L?8/!T^$ZV4XRG7P6JRW<W99-/8
M659X3)GVG-MJL8$W**ZU7/HLG,CV8W776D&XQ4Q,A<4@>ZK2+A\1:F@/4@;&
M)M7`@H4:8DE$8#)C,9A7>OC'HUE_.K3%ZUU-$+]=0`WR*<[%ZTFC]X-B7Q_N
M.:U_.OQ4FL-O_WI(@N'"EP5CC"?$01@?VAD:UN#G,K/,`'@O6*1HB+!C1C0%
M>B&)\;-%>W"Z09[A^I8L6I<0!'V3Z4W-BJJ**O;WQF2BLCY!NH#PZ&;*2D!%
M[QH,K(C#=HA4I+P5]V*!'G$-;F5@Y-6L;I6PJ\GW16;L9%R*U&12<H.B#>R;
MP0`<=<*8N];"1'7R*&'SW41Z<@"PF$[)`SKSJ]GDGN1I=WM_\_GVLV^3PXH_
M^*#G%//*O"2]*XKKT,4W!.(XV]9'0AXVT9CH(+$XHMA+*O.TO,@X>U)VMW_[
MZ__)H'!&>2`;%F/)]ZA://829H^YGA6;R[FI,->-[8G/M"?O=R8(B(%:C#Y"
MQ0>P=#(C_D>\\QTB.2;QL!X1SN97Z`J;@.F#"83Q^U7,N=[<CN],7+@2TXWU
MQ`K)%&^:9>J%"X$0=P5I@XE36"32@1Q5B6,SODN*AU/U;2`4WO(Z&;<LDQQ)
MQM!'(?F@9@48XF8.(`%-F7DT0HI1"X)TJ;U/%HPK:PEP(8HEDX4.F(7V/22-
MT6)(2]PLB&`%,)(:E8=P5+CK_8F>(H)&;\[\&,K6'0@O5$+J7M`(V5&FB)0P
MH@.JD*-*7DA$#=3M#&0Q8A[':#Q`B8ES*`.SY@/R*/BC-L/&A1;#+(T_'7TD
M2**]6W0_WQUVD$04-K,'9N^C,9^&2*#%Q$Q;&.M`2T<%[T%=-FS6,%<JE-D_
MX^V4S"&.+K6@]7H^`T\4J>>9\Z77Q$UR?NA-?75A3K]X,>OK%[>AR,IU"\F"
M5^1S%)EM7!D"K'LH^)?)7*.KL?7>V4&H[B1[J":F(=@RZ_,Q\5:B_EM/V,4S
M%2D5P0MQ/?O&A$\J,B<2*0HJ)UF-<=Y!*2JR:.^`J.X576S)QC'D)55,#JRU
M$=Z^IT\&/&ZC%21.1I]X&#TLK3:YP3`[XGC\P&"0?*TF`H@LK<"I]:QZ$@*\
MT16.*M%<71%:MC(NZ.)Y:88?Z:8S8T2.X819DEA2928IZQ8@5]Y/Y`(=.)!W
M%J%9+/H>,XGL8IHC01A$GQCJ7^HXC6Q%_0$3A%)5ZI:N'VSAB&YW&DQ=W<4%
M>F;_I+UJEQ_R#&H`6#D;^@ZEONH;EG[F0D1R"XIB'M$,PC0E:W/=[VS36G&1
MO%Z?N6A[13'J^U$7_[?9/57PWV^8M$X_I1MOE*4D=<`AILZB[MJ()HL>--J$
MGERWM>J.[A!'^049^]+>:-MRF[.OD"F+OK8HR!)]_^VO_UO&KMKPNT@=^Y,,
M5`[)&,V=R^OWIVK;),RPDF*(%TIH$"+50Y&M!Q%%L*PVPK^<.2K,:J7[.*'&
M8Q6KLL=PED7[#7/+:/1XMM8FEG\MW%%:N;WUXL5OZHQ]<QU]<M%8&C1$*^)8
M\[-.EA7"F45SQ$.CM0HL3ZG5%%GR==XM@M+B+_D.J@5]WY/JT'RGPM.>-KI)
M10493DDA2*H0?W,U(:\F`<Q254E&A,9&>;T;\`&'!U#0((E1D"$"Q0GT;^J"
M+2[1QD?T+N.>3:YGG]'"^E-',CEX,_DUU,FZ(NO/`$L.B5*NYU.R7$RT#;CP
MZ:J7D1&*F[V-XDJ#T\_07+G`D/+3<!I\:F3O.P?)W@M9\L!!HG':TSST?!16
MWMK`'8-=B\""F0DL&5NE!5\4[P^G\%-1*&@_(JDB#^*6QVC]WG3Z8$&B*UQ*
M`G`_0G?`C1X,W[Z2*>N+B7+76\EE^$,=WQ8V>,[AR'CV%F3=*`:/T4""\^#H
MR-FM)G+?FPXS!\^*[\O6P)!ZQ(4(@@T(M=6GP<AF1UU#A(LY^,RM(,#P5GXN
M)(NDG>KU'#`Y2!JLQ3@;8)R_[!B34AS0FR4VS29?OWA2`.ZKP[RV-YO)D9&=
M%F%2P_Z*1>'$^BJY??VBSPJ3%/RT6RHQ3MLA;FZ'D($3$"Q!_&(7!43GE,?5
MG_E2@T;S@W7EIL\98)D`"]DR3K08N*&LTW+//>,E?^XB#&5Z^`BA"&E\#8VL
M-+)9-]$GT:F)6,/C1[R%5_]*."&1NQTIU=V$"A,GX:@8"(1V*)./(S`D(ZNL
MM@+(`OGR>$X$B-9X&WUR2=#:6'0R`D;F=_GCQCD?[[,4J:=%2!3`NX:\Y+F`
M<VSLB#,;/LB07@Q!!-$E=#`O"4J<@3:Q%(32^?LA8T5X>$")B50^?\F5!:D#
M$A!/`Q(6WL&:H:MCH*(P')HQ)7<K?V`6=T%+9_X>4CHRG\,R%%$W$C*E6C1Y
M2!L*A,.(&R<&>26SWL\-_J&+Y(=D0>85H^%+I:6W('D<:V-[7SZ7[?7C=S7^
MAIBBI,/`C7O6#\AU!4ND85BZH*^AX4C-`.;\L,^&5@)5N#YDEIL;(!Q5\8)?
M99&72+-+*9]#_[&;#K!6OX.@(X=K%O%Q`2^)*YI-+YJ7#7:O-&U@M^;*#77A
MS],Q&9-L(\.8'S9K,.I]UL;1'LODL8K0T>$`YH^,*.55:G2)CQM+[,>;9*XJ
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MRRS`T4FS&R<?"`UJ@'P[VF9"+8C^Q"9'W,"2L)XKPJ5K]HF]U4=8/$(E_G2.
MNR(X)C'[V[])GOJ86$`NRC3,0,^]4%5DR34/8W^M7$E?Q6SFQ&=A@A&<ZYXM
M)MBKT):@L&LZD)\JF0DYND7R58]D_Q39S`.!FCJ;K#32C`*==_`@(23[&#FP
M`F8#%YA-YZ4,M]RA`]"IKI7*'M`-6+%X+A=Y07ER=E6-472+)2VLD^6R?Y12
M]'@KBQH%S;&ZE!S:H24&X%DF*2?K\;@M0)&\UGL5%6D+@ZJMDP<X@IF`J*!2
MWBSH4AD!D+7+7V=7&<X''JH5QP7Z"/H(I!0D#T$!XRHX@*)3M`I]8NZ(HLP,
MHHJ/*4T24:.+,%?E!P6ZWO0(S:9#:"H<D8*5I_:AL6%S`H^(3"V1$*<0&/II
MT'\'$^>?R#:YFAEB:9#3;3H`&0-UGH*WN4IZW.SS,5K^<1&1LJR<>FPYE[M(
M.ANVW/@BU%,.#E=R#\??10P<+48#UZ)FIRJ+)([8*6]8!G.IP`2.Z19^H,_^
M?++I?1Z6^*.X/"D0RW6KB.7@$\4JZ=G!HCHW5\R&;)>Q(^-AB6;1UD;1)V]7
MG$&+R.Y>$%Z@%*`XI6"@@$O"!:Y:>N+@_0C\6'Q&KG38,C0II7*UJLN!032?
MU,/2]_\K)Z83<`ZPJ<GE`G+35SJS'C41H2(AL6S8$\RU+<GU-4:@NY;]'_6`
M(,8WCL@=!=A;&W4;?XP*AN%4-I6_"$#6UR_AY',MET/4@'[+"W.:G;FRC!4^
MT7_@-$;+>^$"Y(/KD/'0K$84GFD0!UH\B3"<&(?@4$`M!;'-0,M(&N^B3]I%
M1X!<GU6T,6L2+S$]G!R+Q+1;,HBYIBT;81$K7NZ\(AF0;0US<1+='6HH?[CA
M,/B$Q\'AS>3D746BE+<]!OG(O\FY$SG*K9@E+H_O4ZU"BPKDK#`(+IT1'S-)
MAJ>)3Q&3'NC70)71@5F-/*\RRS.@UZE/KDS4U%:ZL_.*Y0`JD=8846E-Y5\8
MFS"O\;J86@O6\[.'YEG9D@F'L"8>O<$5S,B2S"^P6]?9@./OZY.[R2`%=!"_
M#(T-HN5]C6U$ML43S,[V2XPL*.9:AP)?M#V`D%-*2*>?A.&1O5J%'2W3@L0O
MBI3XZX6UAHKA0F[R"U5</A>)IY;MAV567]#07+2U]S]N=OH$"VFV^1Y0$*H\
MW:A\C*`T$2,$IR6"^VQ2\@M!5;1TBA#4UK';4;%QR)R_O=()91+"T,&F.<F.
MT"IBH<GGFCI-=87/4<C@:#Q7_C!('M1&ZPP23^C_+OA_V5_$2&X$VM[XYLUW
M?9J>S4+=49S8T2?38P(*]TB73K4L4>O4Y82:I;Z][MVI:N)&T`??V*!V4U%<
MXT`5Q8$\/ZHN38FVWZ`DJ,+;0A;(Z]$%RUXT#A"(#)=TU`WK,@W(#@#FD<A\
M&M1-5M01/LB!XO=B4#8#8>V2!Q?4AI<EQ`/KYM#`Q$^A(DIC/;$YZL?H]5>\
M)/NB:4[[_.HDXQ2WRK!HP;/Y`_\DYG2"$PA*(MV3N3(5M+9"8DLKVJ`>OL>6
M/?YA#MD<")G-A<?K_$3RY[E)J"P'`\"1FE(;!*5`;S[.FR*)&ES@1%A4C%2P
MQVY>,$R^-)C+7W.I^I33,\^PG5"HORV7JHSN+_+)PH+^UBEI4KSNS0?,J#+L
MDNP+/TO=KU(7^F=S3ZJEQ+!A:9$^F2T03ZP<UE7;ZIPV@BOR<9_/%,E<HM)>
M2`LB8AP%.Z.G_MDD"/XQ1Z<D)==D0WA/J6B(\QSPY?VEW)J>RP5(.Q%M\%K.
M.G];_!.-J#YW-Q<@H=JH#D8Y;,0"*:!M4E'&=F[-S(=-$T#3WY;,#H.F'!K`
M/\K*`,/,-L/K+ABP2$0+4\NBHI"K%#!?37`6)7EA-M^-?3MA2:-,)Y_<*XH/
ME%9YE,GC)VSQ7HO.YZ9WL2=146<DSD5ZQ4OV::@O`5C*]*'>-,CD&HKZ&S8#
M*BT03LB3+ZD`N1#]\?!T<B5*P0$"55U^IX=R4N9+"-NRNH9-7ZZ*$8&[4M<5
M0Q8]!!76<M"-1C`R=5NW\V9)Y^A`4<3U-?S;0/7O1W9!UD8`?D7$2`:(MPAG
MK>U6"("^#TX#$-F!"@V#@16XHV75$9E1B:HX)[`IA`WA)A)O'P/7O=!H7992
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MYLJHF`R.\0+KQ"=Y\QED?`(_\UC"]1)7,_+\*K):0NZ:29[0[ZMV'U6#->F.
M<?3)=NOK%TQD?E]9E(2<=[\_NDS\<:-.<M'^4=H728N_\<T&A:Y3]'J9<LE4
M&6YUX5XLWH.@I\65;^46WY5*MA\)S)NCX+YL`F+>*;T?0D5L@?5=V,)90"!W
M_?N3LX/S]T=)M_T?L:4Y<;6_+G6)LI`O/#.]X/E5IZQ>Q'O4E%8VP\=PS,L:
M'SV8YQU`)-"\8H\1`-#9+_OL&DF'18`ISYJ#[T"#3()WE>D.746[^[\1KF'U
M>\4!_&,/4=8_<:`^/]]]L94_]MQ]ISYT0Q`B63M3HQ"^A)B!2,1W`1A:*L'7
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M4]EV<0!,7QF67U%CIS5\AV8VRJ(5_\=`&VA<**<']10M`YQ1P2J*\.F,TSG>
MB1B'%U4U[1"9P#]7"JW8A=R=VF)EW"(5[;(Y753-$I4I@(I@MM2JS+)=[X2V
M+SQP3DY'GP!J&`RCO@GQN4RF_G8JJCI`_B1TUS>:H(3H@F#IF$193*S\Z#VY
MS%N9']B\4H4GK_`6QPX<B=V(O&NEGNH`T=X/SNWT,>%C4K_P$R?Y_J1K=U?6
MQ9(=DZRY6J]V?6`'<>BJL]/):SG.]8=8Y4M?-OC2$E<@?>EB`&QVR36IW2OI
MW8"J6*IKU@S@%$=@[9T]R4)QRM&NXPZ&Q$R?>/J8&.[K%V<]L9RX]B>O*!L\
MV7'^E`OVDF,[Y^"JOO,[87N.Q!2'?7^L-:A9H7*)@?R12MC7+Q95?OU2\8]U
M/G9+=)+5\!"&BG-<HGPS[PF6I]4JZ&SN4CDGO[LO(TT[A1K3G7J*'!AGR`A2
M"T"*#`J']HL.9(YD\)`1T#AA>:8E09_P&'1&J3X/L0"EP8!7\Z[4VP>^J4%?
M/HZP3UXYJ-:M^I>P&RZC$\R\6^/W+L&[KFW3U_"[S@VBKO@6L%,D426,7$JC
MV(E3H?61RGRM4?$2HYOWU1VI@)?)4H5IVH%+KDO_1QTCODOREPY+ISP#F^"R
M&/]]>C6%0YS>5^>61`*+^H=TRHWAM+C8M3V<XE40Q\,$#RUL6W%D5"3IZXX>
M?XM%;L2X/W?S?;>SR5E#D%V&U!#(J?V;,"6_=HVOL$D3JBGC@:X](2ABIWG?
M#Y:]=.\#`N6WAGE@7D64KE<V0=\E=&1V',:B#4,5S!NUOTP>>O3MH`S8:T5C
MVI>#(X1*Z88^8]0U$*UA2+GS<PV\MN\[+C;5P1#\)4$J\?AGV,.U(6R;?^!5
M:(B0VHA&I3$KBV]QP\\,4"IZ2DW3K"@OQKH%,EI/!'/WDM0&UF(!VTFFQLY+
M*[?4\HE<8A*$9?H%WDQ5W<]G,7?C)XID6P>*UY=2CGNNDLQ+;!%XUBSITF?:
M_C3\5)8\NR/J\;(VF4\5I@PV.80RF<,EI,ON+W(6H<(%<<^MX1\N09K:A*@B
MGX$YN0SE[@.%<1TXM0V$F"\H,M$)S2?.VO/HF`*P8A-WB4=)'"/F=M:X&KRC
M^[WS<^:"H)#[,]1X"0BU^)URB+$J/G@5QP?O[#:?461*VRC">?6F^=#11&L3
M%':5*8?RRF3E$+(5G+!XOB$"8X2F8;:+E*I43Y9D2N<8T&K/]XJ$[<A"T2M/
MQ^9THL.(V$@=O]4]C2YL*&>%,L_.U9:N,7MAR-%SV1'2]GU=$*"C4]19YJBK
M*ZT]+9=:Y%U?ZDD6MKGC2U(9*,0LOG&E8Q4T?PU]1,`N=JM&0&'$=..ZSD>(
M0LN2%P.S<AR3O"7U4"63$W!J\T,D1-I/D@WHZ,YJ^!:&\.8=IPDQSA;IRZ0%
M$=:+C&6;U,OZ#C]`_SHVT_!_0FI?FX:CV%`[D3Q(^Y02("\-LJ7A(D$/MQS:
MO#9)1('FJS_.2^SQET;K5E5_A0/R]/"LBO7[ZSM>MO;WN8]H]V5$539756=G
ME*$NA'1M$O'RQ\DQ7IJPSBJG+*2T6:+D<K@E;$/XOP7&>?#A6M7<I2#0N3C"
M$AC@U_W\Y4[K]8OGS7<FQPLGF"3\/<'IY#=FL+_BQJC:2OTDKY^W]E[OK3T'
MX95FZ2(2&J`""WBPR"G8D_TFRH7+6/:64<U+'J!)GWBZ%+45?9V23Z-;99RO
M7_RFZ->VWQR!G;O\;L5V:V?_]5K,?[++O5W`7)+ZS_3E_%DU&37Z86E<&L$W
MRG]-N_([#PFZH]U>V$47K%/BH:MZ%)Y[I^]4JVF#5Q0[;&S2`IWBXBB6J1SC
MJ(.[+&KN[B"H39PA0X0KP`32/LSM.\H%]#,'2GD\G60K_?1>SJBH76`'W7D)
M6Q+WVNV_>-':VW]9^J;MS1W70Q+4:4W$IC*CEE+4#17!1(\[*7>4W`\GUI$-
M`FHW`=F^H!^X)""#B8ZY15_[Y3J,S;W]30QO>9<Y(M%OZMP2GR!OGE*1&;QR
MO-%5)"2DQ>\:&$^KSR:[+\*G2D!1W@$OA&0O@!XQUH$ARDV`]Q/517LQ?,FO
MF^SOQ68'9N+JJG=JLQ!9"I6[V51DE9Z@IB_(=(F9(TEC.5[+_3TFU<6(</YJ
M.*$9?8)3'0K53<K(P^)[WHR3SB7S'"G7%I?!%>[;N11#IQ7($[/:"3N-F5__
MYN[$@*C(I,3?!/*SSF#S!R[%%SY"W@+9<"\N'7#!5F1C.*)7CX!-'4]P`W0\
MHCRNNJJH<QSYE9-QP5V]5B54\>LF")6+795YV_AR,]'X_CY&>^""^:PA,?5]
M>-`A%'KAMT-#IKC+O"D0-S#XQ`E-?4BJ'^Y#$S'<YC]RLYCK(=!!+;.Y841K
M%T!6+=3I:49)K@1(E-7/RPWFJN;3%.BB-,(??OT@7+RC.4C*:42T',JA+XY9
M4B?72$@5/C[%CC&8W]G%%8Q=TE-L25B;Q5NR1D\5HN4;,.W/-__,&R<-D=-/
MR.H22.;,?O+CZY?)=5T$_-3UC\./AM0_]Y7[^L<A#JU_;CI0__"\]#-%:`J7
M&1:7((N>]>??&0KDN_@*=+8V#!9(3&L:X`>8"X\]ZT@K^`/!$L_K<YV[KH$0
M6%MYBS6*UGX"_;-IDK8%974+B$/4"Z&_?#-T/G!C!8BO)`Y[96<7\A8&+QWE
MUF>W<FN6L14%>8'I^ULO/`2HAW:W]MQ?_V+3]FZ`4SB'Q'[Q.'@V_:",4-\\
MR5]S%IS["\(I3<$_=UYRW]/2_<[''FI6+VS%_>@<JH05\/&UF&#(O#^A!E>\
M\4"N7\;&VO,F:#!OYUVT[F3>-*[6=*&^=]I..5E0(!\#A%-PT4"V5[G;N25&
M/IDGI`HO+_#&^]PJQ8^`)1LNQ=Q\2QA&<Y.#4K5A73>2:W9\.Z?66V9*F*ZT
M:0F4WQ*VHV'EV*8EML#4B2MI$(NZ]!_YAJSX<PR>06+-[[D^!66O8;D6[^`K
M,9Y2,Q'=Q1NV#R6PL8'L*+6KMFM';DCD<2&@:VKT^"AA4BY#/K!IS'R76\D?
M,3X>N*Y3($<@I0(EX#!Z[NB4']RBHZBM_AC_>V2NR:A[V3[KM`_LY[>BU_S!
MXPL[+-W%X.47`2V^:_5R\4N/P2=>Q_C$VW#QD`694S^/9<@-Q6.6.P!X]RT8
M3P<1T&9%3HM=428[(VY6[&F/GV2[XK]^]$;8FI^27XKSK4B10+3M6"0@*L*C
MRY=GDV^3N-%F$?O"N$UK\""-,P2ERZ0)E(+4E7:0-.R;F,E%EP:(U))(W<#,
M>H5T5C%ORUW\&7EU#9"^X-O5V2@4)8H=3!L"+B'I)'SWAR?P/3K);*E,$2:!
M@MM512Y9\A4-M-,;$A\N!9L)6UWM4'&U.[AO:RYNX[@G?@WW%R=/7EB<:W<#
MJ:_9*BM%(NW=H7VMN`KXUU^<KVY<8U]U]"<[^Z5ZYA"`?J`+E$9<DYY35U&0
M'SBL.K>6F(O2PAT$Y0U$*?/A1Q7YD`<KF*/LK+U,U!;`&WU&^.]"ROILXF5Q
M"_JBR5YN.TC35;<A;N[&2@6P05&3BOR@;&"8>JD4N1\0X,=?(2S(DA<?!>8U
ME=X"O`XEOEP:7>02GNR3"NF&<2=.3B3"(LQ*^*)ED"+8:,+M/W;5+`,>Z0#@
M-QD]]R->E`X8\LB3YRJ"]-.DHRN:[6?K=G"N"GL="[R!(!9W7<(2(<B3;T)N
MI_2N0R8CBK8K2HCO]&3EY5QVW:R5DGS8O[9:(FY9(\E44-ZR#/X2E;2BDZ1K
MD=:A)4HO?T6U>_TKJEW/8[\1LY^\?K3BU3WGN3^)X7YINY:6+M6.8,X>:6/+
M1M5GH1R@=J>YLJI=6&D[:9\LV%;?V?')&3^+?-(^S=N2^0%3:QT$JVUHM75>
MEFQ>O7@2R:/5W<G1.^X#_V:E!7%5F6-G.XXCCO,[\1;Z[Q-#?<D)_!-U*ORN
M_D$4*[Q5KP">).IKIH;GCH>K6:8^3+$T[`L4BP*+?&'N^_K[+N1=T90K,)Z^
MW+@MM_/A;8?&:;6]'/W`_X]NW>]P,RO(),!)<N2NS5H<!S8\NY)9#3]]XYUU
M"9D%$^->.&*+T<.F\R+4A*EB#P7@RV\3V1/)#3FZKP33+*^5F12E'!(UZGZS
M9,P-Q(/D;>UG=)#3R`RCRSDX2+2$E6<%,N>YH;V_Y^);R^75CO'URP7PJ-WJ
M9`)_<#M,KQ%[>D(,SSJW/AI=:ZRHZ,[Y#Y8F#WAEUY7S1PB6T-VV8M/BSM/"
MB6@-:O\X.#JW?8?PXOGK5ZWM%R_!57QJBG$/T/37+P'?_?K%/$(X8Q0.O13X
M8/)JZWGIUP"7TH5?E':$^?JE1!GRP'A#^&JN*ODDEZ@8DI^)I@0!1*]?IB@M
M.$]&?:55?>(&-1#3ZQB;F/GDY=9.>84QE+CB5R62I^''(R+]_:"D&K8!P!%G
MZ?=U[-&'Y"?_O\N$&:;0;JTD75C*Q;1T#_&C!@I]]G4U+\Q$A_X[?]-..;M:
MO<:#<">#_4.P``@,BOVH]75T>T/2U2$MLW?T]=L/S*]#)*B"EYEQFD=(Z\SY
MAG`&XS'4UGUG;@V/F;Z2>Y4;>+R7><P*O'?K]GY^S%L'Y6M>$IUDY-?+W)4F
M[H_U!>Y8MX#\$!"T0CI.BEM`'K.RHW!]P@716T?XQV/>MA<\8"(32?^/)2JM
MY-SLD7$:DB%L@O?%?>I6^A&7M91KI4IWE<9GD4*OD+>@Z(,$S5<YY51-'RT<
MQCTHCOO11EI;L`3\@IL!!4L,P*J37,G3!8N\7'6DJZSD*Y>QY$34PA4L)=,:
M6V\^4K-P.L[YYY4-;S(1AA7G9E8SH'R89:VY#T/9%"7&XW+BP56MRL=U5D_;
M^:_K[U^O)7GA7L^QM6@AEO+4VO_DVTYU`5A:#:=72?8O;,9M\,P-W5$+5[_(
MI"3MXK8D80GEYQ`BZ])HZVA-\M.I+M8]P5=FT:\NEG0*JI3'*)NO\ES$-4LG
M6ZF99;$_\L>X0`3<Y1N+5M#2O>,3]W,NXA_&PMVA-]#O\=(S142J2[!6RRF7
MKH?XRM_(XDWSHI^#OUP/0%[,P)*:!Q3UH@%57DDX142/PX'+M:]Z')6SX5S4
M'&'=(:4MRT<!ZQ!S54:\%E%<A@M?BEYN'U4\]4MYM@9?_2^D)D\/N6=^R"%%
M^2A*>*#9"W[W.7DOV"OCAT0&:53+).G:RG__LTZ[`$0OTRQK5>3X'4$^;1@.
M/'2BVG)ZAH/5)2;V1)0IXXI<!X+U[NH9:S%9\&-X]?6MC!,\C:)`04H?7XB]
M\$>J5\VSC#[!V?H0N"UX)(3`**:[$YQ(!--5B4.@H<(G.@SJNSYJN*=[X=)=
M)KKHPNZ%KZW:\=K2%YRK.R?Q@9#0?N(FD0^^4"*AYA&"8OLUAJ@HKCMP1!;+
M.%I)Z`V@[1E71\-X#I4H:E,@IZMG+0*M$XT,&W-:-A0Q>*]<5I#.(*0X_XA;
M[-]7+JFK;7C)ABPOVQ3Z7%NTD(]B!_I1W>H]>(_[Q8$Z'5>'O4'G%MFCE?'O
M,FU:]?)"25H:)Z]:<M!A4J0XCUT:=\A;UTE(#)P?\851TY!ZU)];9\DKK?^B
M6'W5EA>\MXPW]=B>9!"@:+J0)=4`?M6"*D\O6T8>Y@MXJO2ZU@E<&7)MBW:4
M_\)4@0E8UFC!FIVB]+FP-^'U:4MQNHZ1'.BH,O4I.U)>?W;=E&`5]=8<9QE=
M2\NV]*(53NV]UUVMG)7RT3@_P#N/?-::\Z_-A'@QESC+4'AH)6%-^I0*=IVL
MRU^O/_UN[H\#\D//4\7A<,N=\R.FM%PK:8=*>OW=Y3,I-(KL0].ADCS<(\PK
MD@F=+`F(2PCK6TES&+C\K?JR7=N>7*;+&O@EX!6]<^KJ#TW'JT>S5B`"QD>]
M5%N";XM32]SCQEG2E?>X@3Q<;0EU<Z_>LO'R:":TYM70[]IVHVY%&]O_H%O1
MXQO%NJNF*;/B[Q^MMN@ZC_[^"58Q[^^?(4C\FMQ=/>%2A4YV4.F5R;IB6WXO
M]PJPUM6GGN>A^R*%7SEF\K\6#UK78,,K7./;(L`D>>OQ$O=8%9L)-.U.]&MP
M`9C`51"W)UA1$\)_U*1E&76&[A\U\U&H;UVHOO6/FS4T41J]HVD;83H?422[
M"X&%11A6??Q599A<DNLO!OA!5=1VM0_.`R8+7UVN<JL@D^VED`F5XJUDVY\A
MJ:^9KAV^I'JLUK#ZEYRDVDKT*X1J(ZI_:6_Z.ZEWZU_:G+NO[<WHRZ;3HBVB
M49)D*IP.H.GH4&-]U&78C96:ED$WB]A?!E&78JBA6$3Z7]+(ABS_,F]9IYZ6
MMZRK)%G?T+[O2'_I&I*RY(5.&$;AWZ^Y=*_2B@'^KJ7O^J7OA:5S\73CVBWH
M:\+;BL-RMK\L@'(?[NDFP^#8V2426/>[ZQZ<JU-PL4@\<GB3G_KHY2(L96T0
MG",JA+I;H&6H&`=0`@9(KATJDTG;NL_J@_V:7*P((*B2/['0N(E?<]Z*]*R8
MMXC@5Q81\+&^^=U*(P+82E5:JR'H"#HB-[.LU?UJ6YW`%^$P9Y[=++:W=C@Z
M?B%@P&H$X<"%4O(8@S:")DTONWKWTG>IBE"O;9?./CH1#OD04<Y)<9YW]4[R
M+);<IU`&PQ&L]%(G$A6=E0N(M[:0D/05^<.=-KD8IZ.;=H4K)SJ&D2U#L4E*
M(9&:<OY_/;(:,:5TH*,B^6L7$P&SN+%>_7LJN14=#J8[]>D.BX/U-?[5GUR[
MR+8*T*F6LDKG-I;"D94#$]':*M6QH#_UIW[:_<_63WO\]SPJLM8Z8BL-=/^M
M&V+9<T2&O>BC;JE?<.EV_^G=\?\M6N,;!.RQVF.Y=3,<MC`I25WO<IW?Y5RD
M5\U%%KSQTPY*LEA9'KV754D+APVVDG!&H;Y\?C.`S,.WJM>_+&<>45JRT-`0
ML84V;RO>EFR0;SBMO%J?%+\63O4L,C7@ZW8X1P=NK(;-N8SC-$J;2R.]M9M>
M#$S02T20M$PLF;GQ>7HP_%F:^IL6J(033XM675K..47=18^M;BE8Y0**'D`O
M@5%L4#PQM%;S:#_U9O`<9EY95[*$-+0$U\=U&;)OI*Y_66\:7^JPUHFUEW?J
ME+),DPN[JL$)1D.^M@9`T]#V^$M2WG@Q[W2K6)U:1=#?!/83W,;D?&\X8>2>
M%O6H!P%=;ZQOLFSVYO\)````__\#`%!+`P04``8`"````"$`T^,Y,W0"```V
M!@``&````'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)2474_;,!2&[R?M/UB^
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MG+X.!?AN4"5JMFW=#[W[*N2F<5#M`@+R<<VJQRMA.204;)(L8'#=`@!<D9*^
M,R`A["'\[V3EFA+GXZ0X3W,*<K06UEU+;XD1WUJGU9\HHAYJ;Y(]F>1`_[2?
M)=FDH,7XWRXD$H4`KYACB[G1.P1-`^^T/?,M2&?@_'I$0.&UEUX<C@"LA2K<
M+T:3.;F'S/$GR?)4D@T5JU<4YWL)`:P]&T1\R.:SGD/MWF?TATH,UQ?&Z=X^
MA+&,DE$(($U2.MQ>O;D]@(-D'<*]#^7%0Z@B';YU&25%@"K2^!M*5H<2.A[3
MG.8OH0W@1O\#Y\5'<$<I649)A*.C+$]'DR/^U:%D2B?99/Q&5:'C/YXX+SYB
M.^JG992\RW8H>9TMCGZ<C)YMQ"TS&]E9U(H:^BA-SL'"Q,&/"Z?[,`EK[6!@
MPVT#WV<!8Y(F(*ZU=L\+_VG9?_$7?P$``/__`P!02P,$%``&``@````A`#]-
M^"=D!```]@\``!@```!X;"]W;W)K<VAE971S+W-H965T,BYX;6R45TV/HS@0
MO8^T_P%Q[X`-Y$M)1@.MWAUI5EJ-9F;/A#@):L`1)IWN?[]EEQ-C,]T;+ND.
M]2B_>E5^L5>?7^O*>V&M*'FS]LDD]#W6%'Q7-H>U__/'T\/<]T27-[N\X@U;
M^V],^)\W?WQ:77C[+(Z,=1YD:,3:/W;=:1D$HCBR.A<3?F(-1/:\K?,.OK:'
M0)Q:EN_42W45T#"<!G5>-CYF6+;WY.#[?5FP1UZ<:]9TF*1E5=X!?W$L3^*:
MK2[N25?G[?/Y]%#P^@0IMF55=F\JJ>_5Q?+KH>%MOJV@[E<2Y\4UM_HR2%^7
M1<L%WW<32!<@T6'-BV`10*;-:E="!5)VKV7[M?^%+#-*_6"S4@+]*ME%]/[W
MQ)%?_FS+W;>R8:`V]$EV8,OYLX1^W<E'\'(P>/M)=>"?UMNQ?7ZNNN_\\A<K
M#\<.VIU`1;*PY>[MD8D"%(4T$YK(3`6O@`!\>G4I1P,4R5_5WTNYZXYK/YI.
MDED8$8![6R:ZIU*F]+WB+#I>_XL@HE-A$JJ31,!>Q^F$SA.23/\_2X",5(&/
M>9=O5BV_>#`UL*8XY7(&R1(R_[XB*$5BOTBP>@7("FC#RX8FJ^`%E"LT)$7(
MS/<,Q$9DOT',;I``:-VX0<5];E+U"'KW,4?YDL-Q>DNORD@1,E/JRKJRW@.+
M``C2)_#QPA(,!/N5SYV%$1*;A7L/K(7C,0M+\-J'&HSD"V=AA,Q5RTB8S",[
MGO7C=!;>HA8I&-7[U9!@FU1DTF(;$)+@'-&0.FIE&(]5W+QK49J.H23!#B5R
MJQ0I(027I+/8CF96U$AL,8+)OU\D"78847O-%"$H4D3G<V>_91C7C!?OD)*_
M0W=O<@FVYSARQB5%2&^.>P\L-19C%I9@1PVG`RE"L%I3J^I=UH\9E2PZ!-SC
M?B$4VB%D$N/`:`PRFIHI14I6U'36YC3.@=$]^YL]<NV-($9S<F6RHN\8+Y&&
M>/?`*+2CDTFL=4*+O<[Q(G$ZF^DD2#H*34VV6-(P[R>&]@J?-V>,')-)2<^"
M==-Z3^S%1[DR&=IRY/0BU1A4A<!ON;WY,QU'4>+W-!GER_+8XNRRV!G;5&-P
MV<5BP*IOS#W.MEBCK)D,O3EVO5ECKK\7<X=UIN/(FD3F=9O7*(,F:*_]"8K-
M/M:C?;5@>>Y3QPG]EO)'>W''B-4Y,@0Y/SY9$+37_J:/74O6&+U_G$'+K"@U
M>\]F-\JMR="N8Y-82X,8O>L78>+80J:3Z`V0).\TC8[R;86V_2AV9CC5&%SX
M81Y3IZN9#2!Q:,;-$HV.LF^%=JB9;8VB:8P6+9P.CB$:H`=]9DJSB3D>?N?I
M&7W:&C6G:2G<M*2%X&DRHD,OMP$#+\=K%MY":M8>6,:J2G@%/\LK%(7SWNTI
M7N]2LDS5[<YYGLEKGSQ,![<`W+I.^8']G;>'LA%>Q?:0,IS,8(^U>&_#+QT_
MJ4O"EG=PWU+_'N%^S>`V$$X`O.>\NWZ1"]QN[)O_````__\#`%!+`P04``8`
M"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]O
MVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IA
MEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(
MH4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ
M)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"
M-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9
MVP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!<QM6)M85W?_-)UZ8+Q=,WP%,$H
M9UKKUUM7=G+Z!L#4,J[7ZW5[M9R>`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51
MK;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]<YVM]MT\`9D
M\<TE?/]*JUEW\084,AI/E]#:H?U^2CV'3#C;+85O`'RCFL(7*(B&/+HTBPF/
MU:I8B_!]+OH`T$"&%8V1FB=D@GV(XBZ.1H)BS0!O$ER8L4.^7!K2O)#T!4U4
MV_LPP9`1"WJOGG__ZOE3].KYD^.'SXX?_G3\Z-'QPQ\M+6?A+HZ#XL*7WW[V
MY]<?HS^>?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P
M;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.
M<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$
M'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z
M@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<<NDA(",Q*
MA!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>],9&R;,UM`?H6
MG'X#0[TJ=?L>FT<N4B@Z+:-Y$W->1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#
M[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ
M4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_
MJ]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C<AT&]
MSAPZ27X02T)XU)D,#!Q<(+!9@P17'U$5#D*<0-]>\S210*:D`XD2+N&\:(9+
M:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&W
MUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1
ML;:[]5'F%N.%BW21#/&8I#[2>B_[J&:<E,7*DB):#QL,^NQXBM4*W%J:[!MP
M.XN3BNSJ*]AEWGL3+V41O/`24#N9CBPN)B>+T5';:S76&A[R<=+V)G!4AL<H
M`:]+W4QB%L!]DZ^$#?M3D]ED^<*;K4PQ-PEJ</MA[;ZDL%,'$B'5#I:A#0TS
ME88`BS4G*_]:`\QZ40J45*.S2;&^`<'PKTD!=G1=2R83XJNBLPLCVG;V-2VE
M?*:(&(3C(S1B,W&`P?TZ5$&?,95PXV$J@GZ!ZSEM;3/E%N<TZ8J78@9GQS%+
M0IR66YVB629;N"E(N0SFK2`>Z%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>
M\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D
M-9PDU0$-D*"P'ZE0$+(/9<E$WRG$:NG>94FRE)")J(*X,K%BC\@A84-=`YMZ
M;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF
M_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+A
MP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[
M.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P
M8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:<J@:&''I@\
M@.2W',W2K;\```#__P,`4$L#!!0`!@`(````(0#1_PA5!`0``)`-```9````
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;)1778^K-A!]K]3_@'A?P$`^B))<
M+8%MK]1*5=6/9P).@A9PA)W-[K_O#(9@FVTV=Q^R<')F.&<\V)/UM_>ZLMYH
MRTO6;&SB>+9%FYP597/<V'__]?*TM"TNLJ;(*M;0C?U!N?UM^_-/ZRMK7_F)
M4F%!AH9O[),0YY7K\OQ$ZXP[[$P;^.;`VCH3<-L>77YN:59T077E^IXW=^NL
M;&R98=4^DH,=#F5.$Y9?:MH(F:2E529`/S^59SYDJ_-'TM59^WHY/^6L/D.*
M?5F5XJ-+:EMUOOI^;%B;[2OP_4["+!]R=S>3]'69MXRS@W`@G2N%3CU';N1"
MINVZ*,$!EMUJZ6%C/Y-52D+;W:Z[`OU3TBM7KBU^8M=?VK+XK6PH5!O6"5=@
MS]@K4K\7"$&P.XE^Z5;@C]8JZ"&[5.)/=OV5EL>3@.6>@2,TMBH^$LISJ"BD
M<?P99LI9!0+@TZI+;`VH2/;>_;^6A3AM[&#NS!9>0(!N[2D7+R6FM*W\P@6K
M_Y4DTJ>22?P^"43T28CO^,L9F<V_SN)*19W!)!/9=MVRJP5=`\_DYPQ[D*P@
M\^!,ZKAY_3^KX!&3/&.6C;VP+7#!87W>MN$R6KMO4-.\Y\13#M$9NX&!!<2T
MR0`H:8-`#TH'#JX?>+H9@W*IQCY?JD$_DE'_\.18`I#[9LC7G[O[A+'0*<F4
M$D:>SDD_XXQUT1P%/^((R1L;LM\,A&3,VY4WEISNO>F`G0DD)I`J@*8M_!%M
M2(970-46&>6-)4?19@*)":0*H&F#ME8[`5M\`=C]CL`@HWZ1T7JQY$1=OT>.
M3SSUSVC_G4H.'94)UW[Z%.J-D4C^6(!4`31[\ZF]$+CW[6&0:<]0$$O.K+,7
M+#W?-]9HIQ*6P6QA6$[D]XH%!=`LP,9AKE``F_1]"QAD6ICI18PE9U2P,X'$
M!%(%T#3B6:YLE/>U(?FK#I<<19L))":0*H"F+=*U/=;A&&36S^QPR5$TFD`B
M`?D.+!QB;(&IPM<4$UA>M9PH^>NN[:),S6;;]B1%]`1)>D3VMA_"&Z@W3JJ&
MZ,+QO%'Z`(5_W:M$GE+:=AS-]6?&/4D5+L-&))EP4A71E>+1HBB]W[%$'D3W
M-^6>-.K939!D@J0JHBO$TT11^%C?$GD&Z;4T&[<GJ4IEV(@D$T[:([*;ETZX
MT+;I<;UT%WCN&"X>:&5Y6NDN)JVL'&GRA(8I%]]:U86)X"2,'-G<8;3TYN-;
M*97+05?.@35MCW1'JXI;.;O@$!O`CG]#;P/VLX_3D8''9`53VQ1/<"!'W+T%
MP#Q\SH[T]ZP]E@VW*GJ`1WD.GL2MG*CEC6#G;BK=,P&3<'=Y@E\^%.9!SP'R
M@3$QW.`#;K^EMO\!``#__P,`4$L#!!0`!@`(````(0!--_K=<P0```P0```9
M````>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;)Q7VXZC1A!]CY1_0+R/<7/Q
M,);MU8`A66DC15$NSQBW;31`6X#',W^?*IK&3>'UDKP84W7JT*>J^K;Z\E'D
MQCNOZDR4:Y/-YJ;!RU3LL_*X-O_Z,W[R3:-NDG*?Y*+D:_.3U^:7S<\_K:ZB
M>JM/G#<&,)3UVCPUS7EI675ZXD52S\29E^`YB*I(&GBMCE9]KGBR;X.*W++G
M\X55)%EI2H9E-85#'`Y9RK<BO12\;"1)Q?.D@?'7I^Q<*[8BG4)7)-7;Y?R4
MBN(,%+LLSYK/EM0TBG3Y]5B**MGEH/N#N4FJN-N7$7V1I96HQ:&9`9TE!SK6
M_&*]6,"T6>TS4(!I-RI^6)NO;!DSU[0VJS9!?V?\6FO_C?HDKK]4V?Y;5G+(
M-M0)*[`3X@VA7_=H@F!K%!VW%?B],O;\D%SRY@]Q_95GQU,#Y?9`$0I;[C^W
MO$XAHT`SLSUD2D4.`X!?H\BP-2`CR4?[O&;[YK0VG<7,>YX[#.#&CM=-G"&E
M::27NA'%/Q+$.BI)8G<D\.Q(_!ESYPND>!#F=&'P5-^>^9[G+OSGQX%N%PC/
M+I#9,]OWF-=^<N*HX1NM='AV+(MIGU]T@?#L`KT'<BV9\;:`VZ1)-JM*7`V8
M%9#3^IS@'&-+H%*5DPGK:_F]4D(-D>0565HNJ%(-_?>^<?W%RGJ'GDD[3"`Q
MSZ;18]@0$2H$-@C2;JDAHH98,UB@J)<%34!E.=#6]QM2J<"@H0J;BI`0781-
M1"A$+^(.Z_,P)E(QM]1XWA`2*PA.0UTHM*TN]+%`!,/<TDK@L/GP0X'$M(M%
M6X20&K;4$%%#K!D&@X6IH@^V;;9G7!)^4!B,6YN0@KYU'$::)Y`8OVT^HBF4
M/@8-T!.PN3L4OM4)2%$CW4?(XQ^0#Q(`2O4$/*X6@JEJ,NA`8MQ6->G54/GZ
M3E0&G)]$1?3`%RL?[3U8+Z:K03!50YH\D!BIQB8%#I6SEZ,,]^3H/F=8Z%CY
MJ!R8U=/E('@HQ_7)M`XDII-#G*%R]G*4`>70_M-]5([R43EXN-)6]L>]AF"Z
M,I!^"B1&6QFH84L-$37$FF$P,5[^RV`1/,R]PTAZ`XF1N?=)GX7*V>=>&>ZU
MT@-?K'PT][C43$]^BZ:"R)B##B05D=D;]LY>46]!280K&C@)5]P[1Z)PLYW<
M44QNS?JB[?K^<"H&'>@[9>J]-U625.)'JG3G2)5RCE3ASCI=E=R'=57>"Q4E
M,7(K>O*(YI!)]VT>;3M+%T#F=S3P$F>LDPTF%,,]>+HLN6-#PE6J@Y8`3D,W
M4S@V;<>F:&R*!Z;A,''WU(;Y?\^?<A/6RS+:X`.X`>&Z@2F['0,8J5YX0ZE4
M;,>F:&S""U9'W[>8O##)\W;!JR,/>9[71BHN>!GR8-?NK?*B%N!%#6M`[?8R
MM._8(WL))\,Q_I4Y0.3<\4`6U%W0ZC\"=[%S<N2_)=4Q*VLCYP<8WGR&%Z!*
MWN;D2R/.[?EX)QJXA;5_3W#KYG!6G\\`?!"B42^8A/X>O_D7``#__P,`4$L#
M!!0`!@`(````(0`0T#2'FP0``#T2```9````>&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;)1878_J-A!]K]3_$.7]$L(W"+BZX+B]4BM5U;WM<P@&HDUB%&>7
MW7_?F3@)]GC+Q\MF.3X^G!F//3'+K^]YYKV)4J6R6/EAK^][HDCD/BV.*__G
M#_YEYGNJBHM]G,E"K/P/H?ROZU]_65YD^:).0E0>*!1JY9^JZKP(`I6<1!ZK
MGCR+`D8.LLSC"CZ6QT"=2Q'OZTEY%@SZ_4F0QVGA:X5%^8B&/!S21#"9O.:B
MJ+1(*;*X`O_JE)Y5JY8GC\CE<?GR>OZ2R/P,$KLT2ZN/6M3W\F3Q_5C(,MYE
M$/=[.(J35KO^X,CG:5)*)0]5#^0";=2->1[,`U!:+_<I1(!I]TIQ6/G?P@4/
M9WZP7M8)^B<5%V7\[ZF3O/Q6IOL_TD)`MF&=<`5V4KX@]?L>(9@<.+-YO0)_
ME=Y>'.+7K/I;7GX7Z?%4P7*/(2(,;+'_8$(ED%&0Z0W&J)3(#`S`7R]/L30@
M(_%[_;RD^^JT\H>3WGC:'X9`]W9"53Q%2=]+7E4E\W\U*6RDM,B@$8%G(Q*.
M>Z/!>#I[1F78J,"S50F?5QDU*O!L50;/JT#L=5K@V:I,GE>9-"KP;%4>STN@
M5ZI>>!97\7I9RHL'NPG60IUCW)OA`I3;%=?KT]7`_Y4`K#V*?$.56@M65T'=
MOJU'T_$R>(-:2QK.YA/.<&ASMIHS];U.9SB9V1S6<K#\\,LC5SBTIW"78<H&
MD(HN'U!U-!]#V$>?[X`V?)QDAS^8V!8V+F4T)9SM9YRIK<,^X0P))W(Y`UN%
MNXS1])IG*R&P@9Y/"$Y:^?`MW3J.AF11-IHSJO<^KN.6`HP"$06X`5BF8;^:
MIF^O'I+AI#+-3DC"-IICF*4`HT!$`6X`EEDX%DRSN`7OEQQ.(AF>SNU5WFC.
M3.]'>VRKQZX!,0I$%.`&8/F'8\/T?SO92":^9WW;VT9SKMZV%&`4B"C`#<`R
M"V?+XV:1?*\R-,<P2P%&@8@"W``LL_A>10[G^Y6!DTB&G<K0',-T"^#1338J
M,\?(D16U8^UAS`W`"F5NAW*[2)!,0I@15QO-,4*@`*-`U`)UD*0]\780WX_,
MAA#"Z6\NPFWG-9M:IX=)0S*\.PASD*A#T#[=,[P;=?QC\WNZB$+=,JT3?$:Z
M]:8AF7'H:5>$.9RH0S".*=G[O!MUXL">9<1Q9QUTA[/]C\@Y$VK2U>W609B#
M1`["3<2N'>Q/CWO6W>QV(PHUR?1,$>9P(@?A)F)[QC9E>'ZL'86ZN5GY=DZ=
MAF1Z-WIB_3+''$[D(+Q#R$:VX\!V9<1QIUYT<[/\S\@1L<&K$)Q+IG^*,(<3
M.0@W$=LS=JW'/>L>=Z=>C$989W@;4H0Y2.0@W$1LS]B\'O>L6YV=9WJTAT8_
M;#Q3A#F<J$/JJB#O0KP;=<X5[%B/^]?]S?;OG.]&$VS\4X3!-=ZNI:A!].O:
MW#D7#;[.O[[%Z\M<+LJCV(HL4UXB7_&&'L);7X?J7P^VX0(N3QA_-P"7]W-\
M%'_&Y3$ME)>)`TSM]Z90UJ6^_NL/E3S7]YN=K.#:7O][@I]I!+RV]WM`/DA9
MM1_P"[H??M;_`0``__\#`%!+`P04``8`"````"$`IUVW\;\$```5$@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6RL6-MNXS80?2_0?Q#TOI9U\16V
M%[%N7:`%BJ*79T6F;2&2:$A*G/W[SHBF1`[3Q%GT)8H.SQSR<(84Z<W7UZJT
M7EC3%KS>VNYD:ENLSOFAJ$];^Z\_DR]+VVJ[K#YD):_9UO[.6OOK[N>?-E?>
M/+5GQCH+%.IV:Y^[[K)VG#8_LRIK)_S":F@Y\J;*.GAM3DY[:5AVZ(.JTO&F
MT[E3945M"X5U<X\&/QZ+G$4\?ZY8W0F1AI59!^-OS\6EE6I5?H]<E35/SY<O
M.:\N(/%8E$7WO1>UK2I??SO5O,D>2_#]Z@99+K7[%T.^*O*&M_S834#.$0,U
M/:^<E0-*N\VA``<X[5;#CEO[P5VG;F`[NTT_07\7[-HJ_UOMF5_3ICC\6M0,
M9AORA!EXY/P)J=\."$&P8T0G?09^;ZP#.V;/9?<'O_["BM.Y@W3/P!$:6Q^^
M1ZS-849!9N+-4"GG)0P`_EI5@:4!,Y*]]L]K<>C.6]N?3V:+J>\"W7ID;9<4
M*&E;^7/;\>H?07)O4D+$NXG`\R;B+2=N,)VCQCMQ_BT.GK+S8.S\G<#@%@A/
MV:$[6<YFP7RY>+]+:.W]PO-S7<YO@?#\9)>+6R0\[^K2$2GJ,QYE7;;;-/QJ
MP3*")+27#!>ENP8QF6HQ3T/R_ROWD'04>4"57@O2VD+!ONR"A;MQ7J#(\AMG
M+SC0Q\`AC%`RL*)0-J)`3(&$`JD".&!Q\`EE1'WZL##>+FEI"X-T6]Z<N!(4
MU96G,T+)&%Q)8)P(;Z''Q)(B8Q()C#&SF1Z32@K$:,YA(:C.WW>,9%BN2I*\
MU4KO:"\X_?[3IRFD0$2!F`()!5(%T$8/J_'^T2-Y:\-$#"46+$@Z]H*S%$4:
M!+0&1?-H+E+Y"Y^HQ92>J'38K?2I2Q6ZYA)VCOM=(IFZ]/6.]H(SZUUZ<Y^D
M,!3-BDL)]$O7)44>R]:A'"6`]"5AI[*1%B+L<O>;1#(Q.0^(2<$97804B"@0
M4R"A0*H`6HI@B=\_>B1_M(P$1QD]!2(*Q!1(*)`J@#9Z/)K1;7Z!7^\/=D",
M(VDP5I3@!'VMN0'9ED+1ZL)>.RQ*=THR&:D2=+^)[U%(5`6?R*<?*&@SM?K!
MF<(X.E-T50K.;>^9DTT_%*W:3`4+8B52);P9D8COD4A4">,K\H&"-E4X5+6J
MWO^T]&SXFHIC'G[?]R84FE!D0K$))2:4:I`^<CPFD/40P&+X[+%'G#;4#XY1
MVWLPC)7AJBR?KH!P9,E--C*AV(02$THU2/>-AP3B&X]!G_6-,J38:3GOT;#I
MFVX/(VOT/01**#99B0FE&J3[QN/%_^!;G%)@?,->!K<#\E5R!0D',[#\*=D*
MPI$E348F%)M08D*I!NF^\<!!?,]_(-_BW*(Z"A;D;+.'&^D;^28'IG!DC;Z'
M0`G%)BLQ(;P#WWJ$0.%;W&G%#:=BS8F%K"Q;*^?/>%]=P3=J0,5=&LH4+M,>
M7CV-%A]:_#=;`GD!-V*@X:T(;PWW`+./R%O#6=_$$QC46_B#.X4.^MN[T3/^
M*-#W[0Q-<"F_9"?V6]:<BKJU2G:$29A.\#K;B&N]>.GXI;_F//(.KN/]OV?X
M^87!'CV=`/G(>2=?<*J''W1V_P(``/__`P!02P,$%``&``@````A`%YPKF`]
M!```W0X``!D```!X;"]W;W)K<VAE971S+W-H965T-#0N>&ULG%=;CYM*#'X_
M4O\#XKT!`B$7):DVP)Y3J96JH]/VF<`D00M,Q)#-[K\_]DRXC(F2;%^6C?W9
MX\_V>&:67]Z*W'AEE<AXN3*=D6T:K$QXFI7[E?GSO^?/,],0=5RF<<Y+MC+?
MF3"_K#_]M3SSZD4<&*L-\%"*E7FHZ^/"LD1R8$4L1OS(2M#L>%7$-?RL]I8X
M5BQ.I5&16V/;]JTBSDI3>5A4C_C@NUV6L)`GIX*5M7)2L3RN(7YQR(ZB\58D
MC[@KXNKE=/R<\.((+K99GM7OTJEI%,GBZ[[D5;S-@?>;X\5)XUO^&+@OLJ3B
M@N_J$;BS5*!#SG-K;H&G]3+-@`&FW:C8;F4^.8O(\4QKO90)^I6QL^C];X@#
M/_]=9>FWK&20;:@35F#+^0M"OZ8H`F-K8/TL*_"C,E*VBT]Y_2\__\.R_:&&
M<D^`$1);I.\A$PED%-R,QA/TE/`<`H"_1I%A:T!&XC?Y/6=I?5B9KC^:3&W7
M`;BQ9:)^SM"E:20G4?/BMP(Y%U?*R?CB!+Z-$_>F`6CEJO!M#&ZOX%T,X'LQ
M&(]'L\G$\V=3B/-&;*"52\&W6<H=31U[[EXWM%2"9+[#N([7RXJ?#6AB"%`<
M8]P2S@*<8:)=*-?U1$.&T>8)C:0IH`5TQ^O:\YVE]0H532Z8C<),3:/%C'5$
MT""P?.@V;`0]DZEN$S40;!Y@T-*`&GV<!AKI-,:^OMY&0::R+S#&@`I"*HAZ
M`BU$Z(I^B+<SC&"H1"][GD_RMU$8N0ME_@(J"*D@Z@FTV*`!'X\-P2L3:+:5
M]7R7Y$UA9K(WG/%LHJL#I>Y"#_MXCQ0AZJ&UJ*%?'X\:P21J6X]JHR">#'H^
MIS$WVK9=&P'V/V48-4K:J/Y'8D8PB=GW2-`*TZ4RH(*0"J*>0,LG;-;'\XG@
M>QVJ,+W8J""D@J@GT&+#DYW,*6>*P__.J$([FD+:K`JCZDXV6:!T#HS$MML=
MF]0@[#L@<S"ZXT`C.?]#DFA'2-+>5I!F0Y(,!$JKL?1\L@'"O@N7[M$['C2:
MN$Z_F+='H43#F%:',P[AS5`4#$7A4!1I(CTF/%E(@^%!J,[@]@YRK]T@2EJ*
M0;ML+B!''Z$DHT&':B?.4!1I(IT1'D2$47<Y>)R1.L_T6,FQO$$JT($:(]>F
M>ZE#=8Q:PT84:2B=$1Y?A)$'$^"C-5*GH,YH1L:JHT`:(\^?ZZB@0S7AAT-1
MI(ET1GBT$4;^'W2=.B$U1E,Z`>"^?J5&9)0%':ICU!HV(KS[7WR!2#%2=WEU
MMRQ8M6<!RW-A)/R$]_0I'*JM5+TA-H[7/"(&F@7<L\`SD8?PZK@F?W)L\"1?
M%,0"MAIHY.08:,:@N>9MX[B@<7%]JS6"Q\4QWK/O<;7/2F'D;`>D[!'NITH]
M3]2/FA_EC7++:WA6R'\/\(QD,+7L$8!WG-?-#UR@?9BN_P<``/__`P!02P,$
M%``&``@````A`$:!R22#`P``I`L``!@```!X;"]W;W)K<VAE971S+W-H965T
M,2YX;6R45MN.HS@0?5]I_P'Y/0&36R<*&75/JW='VI%&<]MG!TQB-6#&=CK=
M?S]5%"%`.KODA>OA')\J5U'K#Z]YYKU(8Y4N(L;'`?-D$>M$%;N(_?C^-+IC
MGG6B2$2F"QFQ-VG9A\V??ZR/VCS;O93.`X;"1FSO7+GR?1OO92[L6)>R@#>I
M-KEP<&MVOBV-%$GU49[Y81#,_5RH@A'#R@SAT&FJ8OFHXT,N"T<D1F;"P?KM
M7I7VQ);'0^AR89X/Y2C6>0D46Y4I]U:1,B^/5Y]VA39BFX'O5SX5\8F[NKF@
MSU5LM-6I&P.=3PN]]+STESXP;=:)`@<8=L_(-&+W?/7`%\S?K*L`_53R:%O7
MGMWKXU]&)?^H0D*T(4].;+_)3,9.)I`YYF%&MEH_XZ>?X%$`(K8"H(C]=9*Y
M#U'%;V3:UR?)IRIM7XR7R%0<,O=5'_^6:K=WH#2#,&`T5LG;H[0QI`&TQN$,
M66.=`04<O5SA?H(PBE=:G4K</F*3^7BV""8<X-Y66O>DD))Y\<$ZG?]+(%Y3
M$4E8D\#Y2._#<+S@P7*R^%\2GQ94>7T43FS61A\]V&D@:4N!^Y:O@/A]0^`$
ML?<(CM@"0AXQ"U%]V01K_P7B%M>(!T+`L4'P!N&#9*,+6L-U$8RZ&%A<R`,]
M:,N$[\M,;I%!,&2FM?A)PTJZA)A6^Z;M9GJ+#((C!A::&$U[,H2`8X.8-8A.
M%"'OPZ.(X*[NO&$E>X285IGEL^7\CE\)Z_P6701W=1<]74*@;KH9C7@XFL"N
M27%_C?BRP7:<PR8<[AS!W17<-:SDG!#MB%_1Q=_`X'I!<%>7]PN&(&UA?J5B
MEEUE;$$3Z'[_7;'X46\%YY22=8+,*.G3<!),[\Z+[,2<@]QP\Q6ZI]VOIQK3
ML7\NAJXXMI;!D>?4B-I%QL\U1,9K#(EO>^VLJXW]9K@V=:>.=K_2.&'FE>H4
M1H!KKF]J8)SZ4T>Y7VLUIA/R<S5T;0/H!MN([N7[7$1UR`E#'28,^#77-_4U
M_!'WA,/S#JZ%3ZWMW%+#*W7&;VIN%;KK.NQ76(UIA_RJ^$U]#>:D"^<7)7;9
MVL)^V&D&HKD@EV8G/\HLLUZL#SC3<-BDS=-F2*NGI^8%C#NEV,G/PNQ48;U,
MIO!I,,;1Q-#`1#=.E]74L=4.!IWJ<@_3L(3?>C`&<*JU.]W@>-;,UYO?````
M__\#`%!+`P04``8`"````"$`45-Z190"``#'!P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6R<5=N.VC`4?*_4?[#\OG%"N"TBK!:A;5=JI:KJY=DX
M#K&(X\@V"_Q]CVV62U(5RDL2PYR9,V/G9/JTDQ5ZX]H(56<XB6*,>,U4+NI5
MAG_^>'D88V0LK7-:J9IG>,\-?II]_##=*KTV)><6`4-M,EQ:VTP(,:SDDII(
M-;R&?PJE);6PU"MB&LUI[HMD17IQ/"22BAH'AHF^A4,5A6!\H=A&\MH&$LTK
M:J%_4XK&O+-)=@N=I'J]:1Z8D@U0+$4E[-Z38B39Y'55*TV7%?C>)7W*WKG]
MHD,O!=/*J,)&0$="HUW/C^21`--LF@MPX&)'FA<9?DXF\R3&9#;U`?T2?&O.
MGI$IU?:3%OD747-(&_;)[<!2J;6#ON;N)R@FG>H7OP/?-,IY03>5_:ZVG[E8
ME1:V>P".G+%)OE]PPR!1H(EZ`\?$5`4-P!5)X8X&)$)W_KX5N2TSG`ZCP2A.
M$X"C)3?V13A*C-C&6"5_!U!RH`HDO0,)W`\D22_JC0?)8'B=A82.O,$%M70V
MU6J+X-2`IFFH.X/)!)B=LQ3R^;LSL.1JGEV1+P6T@>UXFZ6C=$K>($)VP,R[
MF-X104#\V`&HGG?P;V4'SC!<SY3[1U[?W3Q@^GY'SX722Z';K+HBB.1"<-`2
M#)BN8/\>05?4=CAL"09,DHY]]G&4GL*_B!8.U^W1.G!;>-02#IBNT^&ET&W1
MNJ)KT09,5W!TCZ`K:CML1QLPIVB3TV9?1.M&^W^_-ZZHW<"X%7'`=!T_WB/H
MBJY%'#!=01BH=UCT56V/[9`/H%/*\0D14@ZC.$RJAJ[X5ZI7HC:HX@6\^7$T
M@I.HPR`."ZL:/Y&6RL(`]8\E?#`YC*LX`G"AE'U?N%%__`3/_@```/__`P!0
M2P,$%``&``@````A`(.&T.\_"```]R(``!D```!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&ULK)K;<N)&$(;O4Y5WH+A?0!)'E>V4D=`Y5:G4)KF6038J`Z(D
M>;W[]NG13&L.S>)#<K.L/[I_-/_T](P0-[]]/QX&WXJZ*:O3[=`:38:#XK2M
M=N7IZ7;XU]?@RW(X:-K\M,L/U:FX'?XHFN%O=[_^<O-:U<_-OBC:`2B<FMOA
MOFW/[GC<;/?%,6]&U;DXP3N/57W,6_BS?AHWY[K(=UW2\3"V)Y/Y^)B7IR%7
M<.OW:%2/C^6V\*OMR[$XM5RD+@YY"]??[,MS@VK'[7ODCGG]_'+^LJV.9Y!X
M*`]E^Z,3'0Z.6S=^.E5U_G"`<7^WIOD6M;L_B/RQW-954SVV(Y`;\PNE8UZ-
M5V-0NKO9E3`"9ON@+AYOA_>6F]G.<'QWTQGT=UF\-LK_!\V^>@WK<I>5IP+<
MAGEB,_!05<\L--XQ!,ECDAUT,_!'/=@5C_G+H?VS>HV*\FG?PG3/8$1L8.[N
MAU\T6W`49$;VC"EMJP-<`/P[.):L-,"1_'OW^EKNVOWMT)F/9HN)8T'XX*%H
MVJ!DDL/!]J5IJ^,_/,@24ES$%B+P*D2LV6@YFTWGR\7[5:9"!5Y1Y>,B\''=
M>.`5QS.RES-K-O_`>.9"!%[[*_FH)PNA`:]"`]RYXB$LR.["X17C1PMKLG*8
M@U?R+"@9/H.L=OCLV,J0KZ7VDP__Z5.G]FRQ[&;_6BI.N:7,^7OK9LQKL"MI
M/V_SNYNZ>AU`GX#+:,XYZSJ6RX2QF/F%].7]L^J&LF8J]TSF=@C&0^$VL"2_
MW3GSV<WX&RRCK8A9TQA+C_`P@JT9)NN;8&."P`2A"2(3Q"9(3)":(%/`&(SK
MW0/#_@_WF`QS#\>]1B#MM`VK,`)3?!-L3!"8(#1!9(+8!(D)4A-D"M"L<@RK
M+G=+K"<6#7U1K:?)0K=@S6,LWA=9N7B$^(1L"`D("0F)"(D)20A)"<E4HMD#
M'5BKI.OVL&A8L>"ULM[FAC\B:++JZ\H3R)KWR$<$5]9KV<N5KK6145AP`44A
M11%%,44)12E%&:+NZC7WH%]K[O$N-F)]O-V7V^=UQ3?4"ZXZT*UX#V,BG:DX
MQ+4@JH,"J0YR-(6]H#?06DT-`_L@%`\("0F)"(D)20A)"<DXL?A5:\[!?OO?
MG6,BNG.<\%-8YZXGR%)6'B?+2;==V!/+M*Q_O[>,DX7=:X2<6-8211S=]T@&
MH$I,5!).Y)48S3;MWT>-C!.[&XWF)VR!FI\7*@Y.15AR+%HWCI-9=P+EQ@DB
MVYPO2'?$[6(VA`0D*R0Q$2$QR4I(3$I(IF9I9K`['O5P<=T,%JV;P8FCKBS'
MFN@S[/$@6W8YGY`-2D_[R@E(4,C)3,9$G"RE]3')2DA62K(R-4LS:/4A@UBT
M;A`G79OKSUV6>:KB08X<ER\(7);2L8SM8R."X*4/@CL4W?S@@I)C&6LP%$'J
M#F.MC(^+>-!BSA>R_C&Q4)!#2-ZCF?::5X:0"275#'4(VGRQD_\'*KH+UV=,
MH`5\JF*KT?H\$:46M4".W+HWB!:=9X:A`=4(,4%VETB@&>P0_?78$^-Z8JJ5
M4*WT75J9IJ6[RX[9:K_XU#8.!T)SF0CDJ!7H6,;]B8=1LLI\@6:RN6P$FHMM
MRUAL`14)442>[R-$:M%=<)V/1%FY"29*K101WP*-M9>)=[F&[C8[J:MN7^_.
M[+!I=!^!E)+T!-(*ER?.E>U*1,VETP%-##%*)D:(9&),$Q.,DHDI(IF8:8FZ
M,^R4KCKSN3ID*L;BYPCJ$`\2GB60O#!?(*WH>!06G7$G%*"(/%R%*"(+)4(D
MSDI&BZ4:"29(C1313XI-'8QN*3N[JY:^46SBJ"]/>FN+(^,P8#0]3T1I]<<3
MM?H32)H>T,10H+G<_B-$\KIBFIA@E$Q,$<G$3$O4S6+']0^8)4[W4GO-OHZ$
MVC,.!D;9>")*Z2\^(EE)&T2K;I=9&ETSP+>EER$B6>:10+"]7]UF^&4K%Y10
MK?1=6ADF=M>EV\L.[ZJ]GUO>_!8`N@BNY37<7G6NPWFXWTLO;#,\2BM1H07%
MC6(;(68YL`GT:F2/"$28HA;VF5(MZIG5S:(QB3%52?H,J9+V[.HU99J:;CV[
M55"M?Z,-\#L+S6..M!8JD*Q`W^)HI>[;0LN1$Q:(,*7>0LR441$BN9QCFIA@
ME$Q,$<G$3$O4K6$W":HUGZM*IF)L.APIM>7![3*+4HK&%\A2PC8]XT5#ESZ1
M"47*4O:/"!'O'Z3RB$:""5(C1:2>FLE:R$04'Y9N+CODJ^:^47?\GD"K.XZT
MNA-(K3N.M+H36EK=D<S0$IFR?")$LGQB@92"33!*)J:(9&*F)6K6V.8MS:?J
MKE/1ZTX@I:`\@=2ZZQ.A]?=MCMP=;C`,_&</%[[,EOKQ):#2H4"KJ\H11DVY
ML'%^CJEN@AE7=5.,XKJ&;*;)ZO/!#OUJJ9KS\;4Z@]%O/9"QF8PQ(1Q-Y1VD
M)Z(4Y%.TH2B@**0HHBBF**$HI2C3D.[8QVYD;'HC(]!4G5'',DK,DU&X2?L4
M;2@**`HIBBB**4HH2BG*-*2;Q8[H:GE=[X3P#2XI(XZ4<Q5_4LX?*QZ+^JGP
MBL.A&6RK%_84'`YB=S<][A_1WW<-R^!K>'3?=2V3V_!(GYV-3.ZX\$B%\ONI
M>\^_?#83;/;C@,L?P3[CXH=,77@20#_$F[K>)>Y/77AZ0>/]F0M?S5.>35WX
M@IYR?^YNNK5JC"&<N_"U-HU/YBY\4PU\W"?`SP[.^5/Q>UX_E:=F<"@>84(F
MW7.1FO]P@?_1BI[R4+7P@X.NO>SA!R8%/%2;C&!5/%95BW^P#^A_LG+W+P``
M`/__`P!02P,$%``&``@````A`(N?#*DT!P``71T``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3$N>&ULK)G=;]M&#,#?!^Q_,/Q>6Y(M^0-)BEC?P`8,0[<]
M*[82"[4M0U*:]K\?3[S3'8]NXF1[J>J?2(KD\7B,=//Y^_$P^E8V;56?;L?N
MQ!F/RM.VWE6GI]OQ7U^23\OQJ.V*TZXXU*?R=ORC;,>?[W[]Y>:E;KZV^[+L
M1F#AU-Z.]UUW7D^G[79?'HMV4I_+$]QYK)MCT<'/YFG:GINRV/5*Q\/4<YQ@
M>BRJTQ@MK)MK;-2/C]6VC.KM\[$\=6BD*0]%!_ZW^^K<*FO'[37FCD7S]?G\
M:5L?SV#BH3I4W8_>Z'ATW*[SIU/=%`\'B/N[.R^VRG;_@YD_5MNF;NO';@+F
MIN@HCWDU74W!TMW-KH((1-I'3?EX.[YWU[DW'T_O;OH$_5V5+ZWQ_U&[KU_2
MIMK]5IU*R#:LDUB!A[K^*D3SG4"@/&7:2;\"?S2C7?E8/!^Z/^N7K*R>]ATL
MMP\1B<#6NQ]1V6XAHV!FXOG"TK8^@`/P[^A8B=*`C!3?^^M+M>OVM^-9,/$7
MSLP%\=%#V79))4R.1]OGMJN/_Z"0*TVA$4\:@:LRXDV6OC\/E@NP\HKF3&K"
M56D:CW]%<2X5X2H5O8FW]%T_$'Z_H@AW^X#AJIYXG6(@%>$J%5UW,O?\Q;)/
MU2N/7$A-N+[/5]BDO:]P'7QUY\Y;(:ZD&ERO\W2*1='76%1TQ=U-4[^,8./"
MLK?G0K0!=PW65'%AK$.Y_:S:H,R$D7MAY78,T4,AM;!%OMVYJ^7-]!N4]5;*
M;"[(4(E028@:%F8C&\0V2&R0VB"S06Z`*21AR`24]O^0"6%%9$+%L%%`I\:S
MPE822B6R06R#Q`:I#3(;Y`8@8<.^M,.>08^ZW%W4>@LEZ"-DO5<TK`W*N-A'
MQ'*&C$2,Q(PDC*2,9(SD)B'Q0CLQXWT]3B$,.P-R-Q0VG'Y6H"BT@+HRA%PJ
M%%X0,K<(<1$:U_4N"N'>154^&TG,W>@Y=M$-0DHM8B1F)&$D921C)#<)"10:
MK1DH-I^).%"Z?;7]NJGQ7+JP1C-H,MAZA`T:/Q)O-NS!4)+E0"(D<RCT8<W<
MU9RN63P(J1PEC*2,9(SD2+S^\21^6*+_'+^P0>-'8L8OB1$_DJ73]VK/<>W0
MA_M#Z$@6WI##=)`1_1YLS&CZLN&^LI$CN9`(,:L:I]"%!8<S7ZVX$*81(Q%M
M:UA-S['<"5'(6PT!1$@6NE!B2?IIKB^OA&FE2&:ZKV62Z-3DIA99<3ABKP]4
M"--`D?0;9#AH?9_F/42AF0XBD@1ZXI`?=Q50M5C:#N3Q3>\FS&@J"83Z<Z.9
M%%IAG5&;N6F39,F%E;P^3;TTS9-$"R@X[9QO11Q**;,D))H%0Y7$"BTP,=9.
M2;B15&EH(YE"ID.>8]G*B2V:$3&U&#OD0ZT2SF*[H"1:D%7T%W2A0BEEEI1$
MOMY.L40!-I69=>(DW$C*C63:B%ZY"XG"2-`AFB@QYQB)>KV5B)/=VF(203-1
M;2N4B-0)*@:Z"\12*M!M(.&*J9+232=32&_8G"C2^,1@8\3WL4*0TY%V=>,B
MFFF_0H6T7Y%$OIYO8X66_?8(K&:4<".ITM"EDTDD2\>JG)S8H-EXUS3G#N.<
M6MJ-1-;180412BE2`&B+%(!$.JL)5TPE"G2B,X5THG.B2$,6TY11`&\4N)R]
MM$\;\>X`:OZ-0T1*D2V/BD:)Q,H6'AK6B9MP&ZE">A3)%(+38.C5GF/UZEQ)
M]3FB"1'CU?4)P6$,-IBN`40+TP%XRV#W0#G%Z:J-7$1&JX@E\L6T`G\$4QN)
MO&O44:ILF&>%-/O&66'Z0Q,BQBPC(1]K$<*(=:@BL@J'G14H10H'$>D:$F'7
M8'EB-E)7*NCT9Q)!TS`+AYVIIBV:)S&E&7EZ8R?A3$<*!Y&Q_J&+R%CA2"+2
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M_*Z9$;[LV.>@1,8D@M]N\+WZL6R>RK`\'-K1MGX6WV5@?+V[&3!^--IXXJM1
M_]<#N^/!G7X\87=F<*<_#:P[4;"&UTZ01YLOUG'?72R>+M;P=H;+PZ>L^XM/
M!F<O^PH.7;"S`4<O^7D_!_M]WBR'-OX:WA)RAS:>`T_`[V.#"GS<.A=/Y>]%
M\U2=VM&A?(0D._UKPP8_C^&/3C;FA[J#SUI]C][#9\P27D4[$VA*CW7=J1_P
MZ.GP8?3N7P```/__`P!02P,$%``&``@````A`!;<X@WA!```C!$``!D```!X
M;"]W;W)K<VAE971S+W-H965T,3(N>&ULK%C;;JM&%'VOU']`O!]CC,$QLGT4
M&W.13J6J.FV?"1[;*,!80.+D[[OG!G-Q4R?JR^%XL6<Q:^V]YY+5][>ZLEY1
MVY6X6=ON9&I;J"GPH6Q.:_O/G_&W!]OJ^KPYY!5NT-I^1YW]??/K+ZLK;I^[
M,T*]!0Q-M[;/?7\)':<KSJC.NPF^H`;>''%;YSW\;$].=VE1?J"#ZLJ93:>!
M4^=E8S.&L+V'`Q^/98$B7+S4J.D928NJO(?Y=^?RT@FVNKB'KL[;YY?+MP+7
M%Z!X*JNR?Z>DME47879J<)L_5:#[S9WGA>"F/PSZNBQ:W.%C/P$ZATW4U+QT
ME@XP;5:'$A00VZT6'=?VHQMFKF<[FQ4UZ*\273OI_U9WQM>D+0\_R@:!VY`G
MDH$GC)]):'8@$`QVC-$QS<#OK75`Q_REZO_`UQ25IW,/Z?9!$1$6'MXCU!7@
M*-!,9CYA*G`%$X!_K;HDI0&.Y&_T>2T/_7EM>\'$7TP]%\*M)]3U<4DH;:MX
MZ7I<_\V"7$[%2&:<!)Z<9.9_FL3C)/`4),'DP??GP</B_JG,.0L\.8O[>1+X
M'#4%GIS$^[2<!>>`YXV)?&`F=";].#R%#Y("<Z##,DH+),K[?+-J\=6"KH.<
M=9><]+`;+FU+5`9C&&KEWTH%:H20/!*6M0TJH`HZJ._7S<R=KIQ7J,F"QVS-
M&%>-V(D(4H"$-M*!O0[$.I#H0*H#F00X8,+@!-3E_^`$82%."`U;`4C6:+)%
MA!@2Z<!>!V(=2'0@U8%,`A39T$FR[-M+@L@S"8;F5_*L97'+8ES6_"2-.P.)
M#&1O(+&!)`:2&D@F(XI.Z/7[=9)@Z`CP3"KHF9JW+0M:0#U)09X:M+L9-+:&
M,D582>Z?(@FF4Q1EL^6(W(7N?*'-9P@2PR(#V1M(;"")@:0&DLF((C10A;)%
M9T(6\/Y<%L];S#:3&[7HP>+"EAS"H>IGB$^W0AJSX\A8BA%#`ECIAIRYR[GJ
MT7X($A[%!I(82&H@&4-\^GE%/Z1(3O27]!,.53]#9/T<D?0S9#%E:_34U:4/
M[P?IG&,VK&C)$$/7^:FKE7PZO!<<&><PC2`'3&GWN9%P.&"(C)-@53%#9,4<
MD11SA)ZN:%7L#20V1B5&3&H@F3Q*22]4U_VJ2+"JBB$>G/*&&IWIB=JQH-ER
M2$MT8YB[#+329D$^,17V:,]77\<&:W(/:ZJR:M_,9%+%)Q<DRD9]J0\HB6H@
MASS8"R0'-:T[$34?+>20/V[?>P$]4,<6P;ATTV**399$#!E94@$Q%G^IVIXI
M)*I%Y+1R=X?`IJL7$X?\4>6.0W+M<"@8^V8OH+'Q8W-@(J+&@:F`QH&9,E#5
M1XXEDKZOE0`[V\!V+5:<+=FZH:W\8(!V'/)&)R(.!63C$0=7LV=$5$!+8+G4
M"BDVB1,QY$/B5$0QX@>--U-X5=?(*><#UW[B"W3$?Q[:^5E)MHU!U"+V17:G
M9%>&&K4GM$-5U5D%?B'WQ258,J#L+AL%(6R%D`@=7X1[VA$:GBQ"V#',>+@3
M/]*9:?%;<E>^$;^=A7#&-7FV7@B'0A-_G(>/[,ZM?\`/X>0"`YSA!=R%+_D)
M_9:WI[+IK`H=0?N4'EA:=IMF/WKN^Q/NX19,4W"&OWH@.`1/)U`+1XQ[\8-\
M8/@[RN8?````__\#`%!+`P04``8`"````"$`'LN&PPH)``#:)P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6RLFDMOXT@.@.\+['\P?&_;)?DE(\X@
MUAN8!1:+V9FS8BNQT+9E2$JG^]\OZZ4J%C6.T[V75N<KDBJR6"Q*UL-OW\^G
MT;>R::OZLAVSR6P\*B_[^E!=7K?C__Z1?%F/1VU77`[%J;Z4V_&/LAW_]OC/
M?SR\U\W7]EB6W0@L7-KM^-AUU\UTVNZ/Y;EH)_6UO,#(2]V<BP[^;%ZG[;4I
MBX-0.I^FWFRVG)Z+ZC*6%C;-/3;JEY=J7T;U_NU<7CIII"E/10?S;X_5M=76
MSOM[S)V+YNO;]<N^/E_!Q'-UJKH?PNAX=-YO\M=+W13/)_#[.YL7>VU;_$',
MGZM]4[?U2S<!<U,Y4>IS,`VF8.GQX5"!!SSLHZ9\V8Z?V";WE^/IXX,(T)]5
M^=Y:_Q^UQ_H];:K#[]6EA&C#.O$5>*[KKUPT/W`$RE.BG8@5^'<S.I0OQ=NI
M^T_]GI75Z[&#Y5Z`1]RQS>%'5+9[B"B8F7@+;FE?GV`"\._H7/'4@(@4W\7U
MO3ITQ^W8]R9L/EN"].BY;+NDXA;'H_U;V]7GOZ0,4Y:D#4_9@*NVL9PL5C.?
M?<*(KXS`51GQYC?O"J-BYG#]^;N"D\((7)61]62]6,R7ZQ6@&SXOE2)<E2);
M]'&[H;=2>G#5L[YY']BG8H)P5?++R8K-`O^#^05*#Z[WS&\JTT)D651TQ>-#
M4[^/8.O"RK?7@A<"M@%;.KVDAWW"_5V^0:)Q(T_<RG8,/D,NM;!)OCUZ;/DP
M_0:)O5<R.RK#L$2H)7@6<[.1"V(7)"Y(79"Y(+?`%(+01P*R^_\0"6Z%1T+[
ML-/`"HWCMI;0*I$+8A<D+DA=D+D@MP!R&_:C[?9P7='KS(6A@J!U7F%W=E*&
MR1+"ES$D)"(D)B0A)"4D(R2W"?(3RLC]?G)AV!$0,RNAUXZC2@CN:`D%6"@<
M%#);`TT1*M+]4^3"8HHZ;7:2S.=][H6$1(3$A"2$I(1DA.0V05Y!!;W?*RZ,
MO9+$$Z>DJ`IA3TS<F3?'<8^4(;B8Q?%FO1":(=2M^V?(A?$,%3%[/B0D(B0F
M)"$D)20C)+<)\HIW@%9EO[VQN3#V2A&X6`%T*W8OI),P(B0F)"$D)20C)+<)
M<A2.K?L=Y<+844GL;4-(1$A,2$)(2DA&2&X3Y!6#5O%^MX0T]DLA>^<89!:5
M>:8:J5.7WWD[!D4CY7G>\-Z!.O^9:<K#%PJK3IB=,+`=V_&G**(HIBBA**4H
MHRA'""\#/S>M;<0;)&\Q@6KWV19)'L#(=84@LZT]YO>!EN6.GT(\9==]S"**
M8HH2BE**,HIRA'`T^/%J1>-V46'J,+976Z)`/#$I_PB*E*(E%5.44)12E%&4
M(X3]^U27P/HVP62S1&C3]<BL,O.<9B)2MIQ-9TXU/$U^V-Z_#/)HAE4UTU0(
M#H\^\P*W=>&/F3SQS,$64113E%"44I11E".$/>;GN>7QSV]#U1C8P5`(;\.%
MNPU[*1W%B!$44Y10E%*4490CA*/!#WTK&A]L0]4BV"Y+A(HN01&L/$\`2RJF
M**$HI2BC*$<(^\?/>LL_^50ZX8_$W;':?]W5D+5PE`SX[</3IZ@K3U`P1?K:
M;DNTL)I));4PCRN10DLXFOO-P0*S%87YV$CI?$@H2BG**,H5DI/`D>#]P2]'
M0C89J`!(A"*AD!T)B58S^4@_8R0(O8`)@C)CPIZR7DJ\&9@QYXC+C(`VDRLT
M$!)>(NV0#"0!O);262"D<6.DD.V[1I;O&OE]U8PI2C0RBJE&1C&C*-=(**(E
M]S[540EIQS_99"W@W.GSUW.[O%`I>D'O7Z004F2!TQ[&2FK-1%*PM?-,D%##
MJ4*^W5$2PYEC>.G<.$>&<<B<)NV#E*"=F">1;X=LX=P_-$(Z2R.*8H76G@A/
MX#FYGE"55"/3X678"IN;[EM4GURKB(=]'(M/M6@>;=$40EG@><Y;GE!)H?21
MMD!1QR=64BI7EBN2*U+%LI(J%<@5;24S5JR$GCFU*$<SPB'A'=BO%E'^MIIW
M0Z:N[11"6>.YG5UHI+1#D4)K4R)BC>9R5SFYEU`CJ=8P1C*-I!$2(.D!3!<F
M@@/$.STK0!_L']47VI&0R%JTD/\T`/&REC92:&5F'"NT-+82JIAJ*5-E,XV,
M8HX4L7^\4;/\$]WCDO]@,M1"`.Y/#]7AF;OL/(E\R%RKNKJ]LY8R>R%2:&$>
M?6*%UOR&WQ[9*B#[0]W,F$FU91/$3*'54IB!7V5PZYIKE8&%YQV>$QCXG>-S
MC98GVT2T,R1"!=_SS>LW^>2G%%&*2,6U'22%5L*[+T-1DA*6G5297MLE5=D)
MI)V!,-EF</XX_>@'^X,VGIY$D#2Z!H0:F:6-%`I,Z8LU,IF?4,542YDTS30R
MBCE2Q/[Q!NV7TT!V>2@-)'+2P$GR$-:-5`J)`GN3D88A5HJ!?6I[[KF04/.I
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M,C*'$>&$.[+>P*]?`S,+-O#[T0!G<'?X26-H!.XN0^?>@_DP(OH3,K*`$9$"
MS@B\*=OPUUGT/A$+-C&\PJ$C\#((=(9&X$NJI\&X<&<&+.W`E4%Y<&3(CZ?Y
MYDE^J>6XL0/_AMS;P;J+99_V"O!EU;5X+?]5-*_5I1V=RA=(IYGHEQOY;9;\
MHU-'^W/=P4=5XI0_PC=T)7P-,>,[\:6N._T'Q&C:?Y7W^#\```#__P,`4$L#
M!!0`!@`(````(0`>4QP>U`4``-\5```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;*Q868^C1A!^CY3_@'A?X\;XE.W5<"4K;:0HRO',X+:-QK@M8([]
M]ZGJ`_I@9[Q17L;#1U7QU5=%5]/;SV_UQ7NA35NQZ\XGDZGOT6O)#M7UM//_
M^C/_M/*]MBNNA^+"KG3G?Z.M_WG_\T_;5]8\M6=*.P\B7-N=?^ZZVR8(VO),
MZZ*=L!N]PITC:^JB@\OF%+2WAA8'[E1?@G`Z701U45U]$6'3W!.#'8]525-6
M/M?TVHD@#;T4'?!OS]6M5='J\IYP==$\/=\^E:R^08C'ZE)UWWA0WZO+S9?3
ME37%XP7R?B-14:K8_,()7U=EPUIV["80+A!$W9S7P3J`2/OMH8(,4':OH<>=
M_T`V>1CYP7[+!?J[HJ^M]K_7GMGK+TUU^%I=*:@-=<(*/#+VA*9?#@B!<^!X
MY[P"OS?>@1Z+YTOW!WO]E5:G<P?EGD-&F-CF\"VE;0F*0IA).,=();L``?CK
MU16V!BA2O/'?U^K0G7?^;#&9+Z<S`N;>(VV[O,*0OE<^MQVK_Q%&1(8204(9
M!'YED/!]AYETB'J'__!4X,>IPZ^B/C!WV08B<RYD6G3%?MNP5P^Z$ZBVMP)[
MG6P6OJ<4%!%Z3;\G*6B)01XPRLY?^AZHU4(?O.S#V7P;O$#M2FD3NS;$M$B4
M!18*PZ8VD-E`K@$!9-2G!<7X']+"*)B6(A0K0,O3RD%9*)?4!C(;R#7`R`'Z
MQ,YA!J_(>'.K2J`3M+%1B87),18V1+0Q"ITX2.H@F8/D.F(PA\ZVF8?SR7=?
M3,4=W:`/00^MC986>6&TA,)K1BO3*!DU&AK2(`NT=++ORXO&G**J;RR1H4D2
M!TD=)'.07$<,?O!6ZOSP#5W"*O51(Z";R50B8B'D91=("$W5:TG"R-0RE6[P
MTQN%LW5O9'"%%4#G^KZ6:&PRE(BFI8.D#I(Y2*XC!C\<_,YJ-UF"F-VY*I]B
M!BE"9XWPGL&J)M8ZC&'2%L@:GCHH%$U[A;A;(HS"5;^8I`*)=/475K=GO8WJ
MMUR/8^2V-G,;R0&&FDH"C<TD!#*?]?P2B0S+1"J1L+?)'*]<]S+X$4A4%_]]
M@MS:9"BA>20&S)0,+[206!J$ZYY?*J&9WKUD;2V(F8J,^KSL";&JD!N!S:1P
M`&D=]4%28ES!"J?*&<,JC)68+U12%K=$&LSX-DJ.1>&C09FT6HHP(QGH+F8&
M.'ZT#,0.X`??"5RSK7Z2T%`M2]1$&AC5$F'6PTN22:O5FNLSMQ:GW`ABYH73
M2<OK@\K(6:971D!0&56LA`A($SZ5T!K:OG_Y1QI,.*Z)J/+*FE>Y$=A,PYJE
M'Z31CU#%.282&C1-7"AUH<R%<@,R:>+XNE]M.>QTM24$RUNO8Q@Y.\3>2N67
MXGX?6V_(+W.AW(!,YCC?[F<NIZ'.7$(#@80X4.I"F0OE!F32Q)FFT;QW&T#D
M+-0)"PC&OA(QD5;63L!:BM(QJS`*^T%G$L9!I1'^H''%6(/767&*H:)8V`CZ
M5^N(6?\TN>;W5LHQ'1P5E+E0;D`F<QQA]S,7`\]@+B!#X!X:DB&AM0RD9,0J
MC(8USZ")Q;J?)K<VYZF"IEHCC&#I"):-8+F)F5QQ_&B2\B&S)OA5/K;9TC8J
M^"UM318)P>-4?9,!&N0-(VM_D(Y;#5UN4K;FXOO]&[H#4$+0OP--8:5!J6N5
MN5!N0"9-G"RVLA$_[_A(63&3],8-!60HVT.ZLM8L3P='W6IH;Y/R#XTT.#]R
M&D!`7%@169P0B8.-FC8GFM#+I?5*]HRG/S"V]ML>%D=3,5EL<+F%VCAW5G"'
MK^;VG7`*YUF\[9P[(=SABY=U)UUM8!/O/@6.QA[&[&,X,N,[;BM.C`\8B1//
M-O`=/A(_@OA<(3O0?`/?FJY#O-S`=],(3B)@-!J)0"@8K.`3]`^!X[5;<:*_
M%<VINK;>A1ZA`%.^G6S$`9VXZ-@-"@.';*R#@S7^[QD.4BF<1DSQX_;(6*<N
M\`']T>S^7P```/__`P!02P,$%``&``@````A`-%-;E'J!```=1$``!D```!X
M;"]W;W)K<VAE971S+W-H965T,3`N>&ULK%C;;NI&%'VOU'^P_'XP!FR"!1P%
M\$UJI:HZ;9^-&<"*[4&V"<G?=\_-G@M).5%?XK#8>WG6OLT,R^]O56F]HJ8M
M<+VRW='8ME"=XT-1GU;V7S^B;T^VU799?<A*7*.5_8Y:^_OZUU^6-]R\M&>$
M.@L8ZG9EG[ON$CA.FY]1E;4C?$$U?'/$395U\+$Y.>VE0=F!.E6E,QF/?:?*
MBMIF#$'S"`<^'HL<[7!^K5#=,9(&E5D'ZV_/Q:45;%7^"%V5-2_7R[<<5Q>@
MV!=ET;U34MNJ\B`]U;C)]B7H?G-G62ZXZ0>#OBKR!K?XV(V`SF$+-34OG(4#
M3.OEH0`%).Q6@XXK^]D-4G=J.^LE#=#?!;JUTO]6>\:WN"D.OQ4U@FA#GD@&
M]AB_$-/T0"!P=@SOB&;@C\8ZH&-V+;L_\2U!Q>G<0;H]4$2$!8?W'6ISB"C0
MC"8>8<IQ"0N`OU95D-*`B&1O]'DK#MUY94_]D3<?3UTPM_:H[:*"4-I6?FT[
M7/W#C%Q.Q4@FG`2>G,1=C-S9V/\)CBGG@&>_D(<7,./.\!0+&#UYWLQ_FC^N
M`BQI*.`I5O#3D9AS#GC>6<@G(81^I"^')W><2`I,1X?ED9;%+NNR];+!-PMZ
M#3+57C+2N6ZPL"U1#XRAKY"/"@0J@Y`\$Y:5#2H@]RU4]>O:78R7SBM48LYM
M-G=L5(NML"!E1VAW.A#J0*0#L0XD.I!*@`-!Z",!U?@_1(*PD$@(#1L!#*&9
M:+*%A7#9Z4"H`Y$.Q#J0Z$`J`8IL:"!=]A3&ROV!(/)-G*#UE7R[JJP-LW%9
MZY-T;@UD9R"A@40&$AM(8B"IC"AZH>=EO9_K),;0&1`[J;"U_&VX$;Q1,IJJ
MT=C>-1I:1%DB3)3'ETB,Z1)%^6PX,M3@UD!V!A(:2&0@L8$D!I+*B*+*5U6Q
M23,B`[<[%_G+!K-]XTY"IC!1V)PA'*I8AGATUZ,V6XX,=;=CB`_C34K03$U0
MV!N).$8&$AM(8B`I0SSZ>D4_3$<YJU_23SA4_0R1]7-$TL^0^9@.YLG8U:7W
MW_?2.<>D'V-Q;T.&.W!H]9WTWPN.E'.8@2!G26G+N9-P.`>(C!-C53%#9,4<
MD11SA!ZD:%6$!A(97K%ADQA(*GLIZ87J>EP5,595,<2#,2'5J*?6Z)89319]
M6G8,(0-;<O-5MY!SDZ"^KA=:YB*#-.:D4,D?DR;<:,Z*2GME*I,J87)AJ7*<
MOM0&E$2-'X<\==%S-1);;C6=#1$4CL.X#`7T1+6Y3]K.%IDLL7`94I-PR&=M
MIT4]53C4")$#RL/]`?NK7DH<@EH2O;CED%PY'/*'K@D%-+1]9#K&PFIHKD1`
MPQM3Q5'51TXBDKZO50`[SL#.+#1NR"X-3045(*`MAY1T,RN?;#O#654KWY`[
M^CZK[KDV,2.3.!8N,/8^)DZ$%2NMR4*MSU3A5:-&#C2?1.T'OD!#_->Y#:Z6
M1K4PB*:.O9%='MDMH4+-"6U16;96CJ_D8KB`D/0HN[3N_``V0HBZCL^#D+:5
MAL?S`/8+TQXNO\\TH9K]AER*[]AO)@$<:TV>S32`\Y^)/\^"9W:YUE_@!7!N
M`0>G_P(NO9?LA'[/FE-1MU:)CJ!]3(\K#;LVLP\=C_L>=W#=I2DXP\\;",Z[
MXQ$4V1'C3GP@+^A_,%G_"P``__\#`%!+`P04``8`"````"$`#@<#W^X-``#K
M2P``&````'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*R<6V\C-Q*%WQ?8_R#H
M/98EM=1MPW8P;I*[`;+`8K&79XTLCX6Q+$/29))_OX=-LLGB81RUD)<X\['(
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M"=.]0$0VL-NGW]3FN$9&,<S5;&%'6N]?X0#^.]IM[=)`1E:_=G^_;Y].+_?C
M^?)J45_/IS`??=X<3V9KAQR/UM^.I_WN?\ZHBZ@?9.8'P5\_R*RZJJ?7-_,:
M@WS0<>X[XF\X>G55S19UTQW^@YZ5[XF_L6>S6%3+Y@^."8^ZB/$W./N1KQ.7
ML"[_:G5:/=P=]M]'6-1(R?%]94^1Z>UR/`J)=S[W4_%[,X$IL(-\LJ/<C^OQ
M"$D^8OG\\C"=7]]-?L&4K[W-8\%&6K3!PLZO'5;E0.?`)&""B/JP,(=_0EAV
M%!M6<.@Q@!CG+(LA6(0N*@<Z!R8!(@8LIS2&\KD09L`:8]6+&9A*WQZ=S=2M
M>IO@EH@BHHF8E`B/L8S/]]@:8]4A^F319.E\]$8X8F(TEW&U1:.X_(2+.%_.
M=]$:=RZ&V7ST)"Z)EH@BHHF8E`C_<`ZF_MGS<;:X@OG`,]*.(UUWI)+YKK)4
M]D8A8D5$$S$I$=%@1TBC^7@)6V/ILB=-?P*V1!013<2D1/AGZX=D]_O8/VLL
M_7-DUFE;MV.U/4G6ZRQ+LO(#(6O)HE[T,R$\O!GBH366'GJ2K%<BBH@F8E(B
M_)M"Z],4V@6[G%]%]3I?0^Q(TOMN\/MQ)4__99\IE_-HU2]:1IJ1$4A&977E
M[(6!'94\]P@K+YGC.O>\MXJ>$])A^#B)1B#IN563\SUWVH--.#CP:#=D.PW+
M'K4!81>*P<RR:5#!2B[KI@]9NFDUY'PWO>*D;GH4D])."2E&FI$12+J9*5I7
M'DU1%0[?D*>]WL54.Y0M[YL^8WYY]U:AH_)CH6-`FI$12(9EY>?\[%OK[,1T
M*'&@M>4ZK!*D&&E&1B#IIM65Q$V;_1IU_6`QQ&*F"!R2N:]BT>!SWUN%1"L_
M5A*G9F0$DD%9,4J"^EASIEZZTI7O4;KR":G0,5II1D8@Z:85J?/=])*6NNFE
M,*DVISU*]Y&X0W0Y5\%*%"I5K&6EFU:8SG?3RUCJID.SU$U":NI1UU$X`/$7
M#M@UNL`>/K!<ZX:1YYA'V0K-"N0V6O4KE)%F9`22(5D).CNGR%Q^;@44UU[+
M2#'2C(Q`TLU,Z2[-/$O@S*$L\_E51[2*F>\[!J39R@@D0QJDBC-618^JJA>&
MEI%BI!D9@:2;F2I^O(7-6/@\PA(,>6HC2O:&*J^<RU:_4SK;6S\#UK'3K[04
MZ@;`29FN8V\5D6(KS<@()+-94+F++OEFK'(>92LYJ]S::!6F0S'2C(Q`,JA!
M*C=CE0L(+;'FK/(".EI%STD+-5L9@:3G@X1OQL+GD5C<7OB@%4DPN?#%CJE5
M+`>EFU:1SM^DG7Z)Q>U17,GMC)!BI!D9@82;\X(\SAM[$W>H0G8C287T2*[N
M15[#1:M^C3#2C(Q`,JI!"CEGA0PHN;/!2#'2C(Q`TLU,(3_>I^<LA`&Y6^[N
MCJ&SLM5#7,J+6)VY&BYTQ(Z46,7:1;HY2/7FK'H>X=96F.&6D6*D&1F!I)N9
MZMEZXZ)]>LZ"Z%&VDO.*(UJ%.!4CS<@()(,:I)%SUDB/JG2).*L$*;;2C(Q`
MTLV"1DX7W67XZ66[_OJXQV3@-"NL\#D>1W2+\M.<]=$CE#HAHVU`L812'E5R
MS6>UB8Y682P3QNI.<QG0('V<LSYZA)TW'*WU"-M60"J@>'6C`XHGBQ%C23<'
MB>&<Q=`C>U8E&T$LV-QE=K2*GKNQL'(#TL%JT3U@FF=GAPG-70\9Q2"MG+-6
M>F2G,XDB+Z."59I_-U8R2SI8U>XQ698*XYM=#Q&%77[G*WYG+>72(YNG)(J\
MI`I6\910`25S$=!-%T66"1-:>2JJ0<K966=!.#&MDMN3WBI!BI%F9`22N<Z4
M\^([3_9Q2W;OS*-LK\^*P39:A?6O&&E&1B`9U""=M?[EGCN47EUZJP0I1IJ1
M$4BZF>EL84]'^1@V=1R9W/0HD21OE54ML;1V54L82YSFRUA/2C<'*2?$D-ST
M,AG/JM9;B6R2E68K(Y!T,U/./\@F2R1.*^NYG:^X:RRS@J^-5G&Y]AT#TFQE
M!)*>#Y+(BB72HR2;+2/%2#,R`DDW!TEDQ1(94+I<G95<KLM8/OOEZL="GI.9
MB;(HW1RD@15KH$<BF\XJ08JM-",CD'!SD8F<W7@ONU[L1I+:X5&VE+,ZKHU6
M8=TJ1IJ1$4A&-4CU[.WC;.?U"*=Y\*EEI!AI1D8@Z6:F>A_O%0N6MH!2-YU5
MMI2SJD>%CG(IQ[)"NCE(QQ:L8QXEZ[9EI!AI1D8@Z6:F8W8I7_9D?,$:YU&V
ME/-:+EJ%9:,8:49&(!G5(-E;L.QYA`TU^-0R4HPT(R.0=-.*3W)[[.(";N%4
M++USYE&6^[R`BU8A3L5(,S("R:`&*>*"%3&@Y+83(\5(,S("23<'*>*"%3&@
M=!LI*F)>P(6.8ANI?Z>`6PQ2Q,XZDQ.2O]9;)3N+8J09&8%$-I<%1;SHME,W
MD(S`([F2Z[RVBU;]2F:D&1F!9%"#!'')@N@1/`\^M8P4(\W(""3=S`31[B*7
MY9ZU<NE0EONLQFNC58A3,=*,C$`RJ$'RN63Y]$CDWEDE2+&59F0$DFX6Y/.R
MW+-Z+AW*<A\K9W=7*EK%W/<=`])L902200U2SR6KIT>I>C)2C#0C(Y!T,U//
MCPO!)4MD0,D.[I$L!.NL^%:AH]S!8[DHW1RDATO6PX`2/62D&&E&1B#IYB`]
M7+(>!H26>*%7Q^K8+U??,0:C8L>X7,G*""OI^2")7#H]3$NE@*)/+2/%2#,R
M`@DWZS]+(KN!I$0&)'.?%]K1*B1:,=*,C$`RJ$$26;-$>I34(BTCQ4@S,@))
M-S.)_'BKJ%D'`TJV"H^RK2(KL%7H*+>*6!)*-P>)7LVBYY'(IA>]>`-/L95F
M9`22;A9$[[+;'S6KGD=2]9I8';MM)%K%I<RJQU9&(!G5(-6S[]9FMS\\2LJ+
MEI%BI!D9@:2;F>I=7.W5+(@>9;G/*^UH%7/OQDI"UVQE!))!#=+(FC4RH.1Z
MG9%BI!D9@:2;5I:2Z_4_V$:\B,5GF(^U1^DVXI#<1IJLPE:AH]A&FE@+2C<'
M"6+-@N@1[OF&&6X9*4::D1%(N-D4!/&R6T_=2%(1/<J6<E;(M=$J!*H8:49&
M(!G5($5L6!$]2LZEEI%BI!D9@:2;F2)>O(TT+)8>9;F/Y;';PJ-5S+T;*PE=
MLY412`8U2#\;UD^/$@=:1HJ19F0$DF[^:?K9L'YZ9!]>Q#*\R<OP:!63[_4S
MOJNAV<H()*,:I)\-ZZ='(OG.*D&*K30C(Y!TLZ"?EQ4O#0NH1UGR\SH\6L7D
M>P%-DT_(B(XRJD$"VK"`>I1DNF6D&&E&1B#IYB`!;5A`/<H2G!7=;;2*"79C
MH6-`FJV,0-+S09K:L*9Z)!+LK!*DV$HS,@()-V\*FGK1CY&Z@:2D>I3E/E[*
MN&T]6H5$*T::D1%(!C5(4O$%B+PR]RAYT<=]X\%]8V"W.7S9M)O7U^-HO?]F
MO]^`0O7AKL?NXQ*/S>+6;BN(BEJ6:.E>]:&6&BU=34HM#5JZ^HI:;M#2+=.\
MY>8:W[?HWMO*6VKT0:%5\@U]4*R46O"U#-0'I9896KJJ-3].,T=+=S>;6BJT
M=`G.6VH<!U?FA>/4&`U7F:46C(8KM5(+9@$71Z46S`(FKM2"64!17VA9XCBX
M#UIJP7%PZ['4@M%P&ZW4@CG%;:I2"^8'=X8*+37F![=7"BT+'`>/KTHM&`V/
M8@HM2XR&YQFE%LP"'B&46C#;N`]?:L'\X-9WH66!X^!%@E(+CH-G]Z46C(;G
MT*46S`*>Y99:,`MX?%IJP6SC&62AI4(\>+VLU`(/W&:;K]$*QW&O+5`+CH.W
M?TJC87[<'6[J@_EQ0I.WS)$W]^8KM2!O>$>^<)PYO,:;J:46Y,V]>DJC(1Z\
MIUSH4^$X>*.PT#)#WO"CKU(+/'`O'^?'F>$X>,VMU`=YPP]O2BW(&W[84FI!
MWMPKI?EQIH@4/Q0N])G"`_PVM]0"#_`#UU(+/'`_E\J/,\/\X$J\T&>&O.%7
M?H46'*9X%!RD&"6"+)Z[4QP;O_4O'&&*8[OOH>3^3C$S^%UXJ4]S^XC?@W)+
M.VUNVV(+?M-Z:W]#RGWP;OFM?7.<6_#)I4_%-6-=+M@_VD56XG:1%_BGZO:3
M^Z13'CKFO9OV2=^`3RV]K[YL_K$Z?-F^'4>OFV=(^77W^OW!?:S)_>.T?T=A
M@P\N[4_XR%+WOR_XJ-8&GYJYMC_;?M[O3^$?B'C2?Z;KX?\```#__P,`4$L#
M!!0`!@`(````(0#;DH-\@`,``/X*```8````>&PO=V]R:W-H965T<R]S:&5E
M=#@N>&ULK%;);MLP$+T7Z#\(ND>;-UFP'=@6TA9H@:+H<F8DRB(BB0))Q\G?
M=T:;1<EQ':"7T'H9/KYY0PZYNG_),^.9"LEXL39=RS$-6D0\9L5A;?[Z^7#G
MFX94I(A)Q@NZ-E^I-.\W'S^L3EP\R91290!#(==FJE09V+:,4IH3:?&2%O"?
MA(N<*/@4!UN6@I*XFI1GMN<X<SLGK#!KAD#<PL&3A$4TY-$QIX6J203-B`+]
M,F6E;-GRZ!:ZG(BG8WD7\;P$BD>6,?5:D9I&'@5?#@47Y#&#O%_<*8E:[NIC
M1)^S2'#)$V4!G5T+'>>\M)<V,&U6,8,,T'9#T&1M;MT@=%W3WJPJ@WXS>I*]
MWX9,^>F38/%75E!P&^J$%7CD_`E#O\0(P61[-/NAJL!W8<0T(<=,_>"GSY0=
M4@7EGD%&F%@0OX941N`HT%C>#)DBGH$`^&OD#+<&.$)>JO'$8I6NS<G<FBV<
MB0OAQB.5ZH$AI6E$1ZEX_J<.JC+J2+R&!,:&Q+>FWFSAOX=DTI#`V)`L+<^?
MN;/Y.Y1,&Q(8WYV.75M3.1T2138KP4\&;%](7I8$#X,;`'%K<6U(9_I;GH/9
M2+)%EK6Y,`VP4\)&>=ZXGK.RGZ&X41.SNQ"C1^S;"*PDTH8]P`:]G6BHQ7\0
MC2PHNEUNUP+G++R!PC:BG1+V`$TA%'JH</KFSFU=Q$FP1S4775W!KHZI3UUE
MTGZ$A'U$4P4%[JNZ?(Y:-1@,NP(R[!5U8,BN"=(U3W3-^XM!Y^VA2023;I>(
MP97$MAZ[!CD7=3]"PCZBK3W7U\:S,'$`O.X3SM)%-$C=DG`C[SND[^54MREL
M@F#H&3[K@C2I<-1NMPF#=84-XG=[?S]"PCZBK8W7Z[!E>`L+;+UN%,[3931(
MSZ@.Z7LP[SRHVT(3I!NUZ((TL4M=['6%&*PK;)#EV:@1$O81;6T7;KRA4SXT
M_G\Z54W4A;10SZLSU#?+[WQH>BB*`"[=K647I2O&CMNK[76[H`L-_6J@*?I5
M,]>W>WWGY%0<Z)YFF30B?L2;VX?+HD.[5\76P_D#?(>OC4NX%T`;OA`_":`3
MCO'M--C6_7.XP"R`WC">L%L$<!@NX,L`:@^XW1'!ZZ,D!_J-B`,KI)'1!')T
MK`547-3OE_I#\1)*`F\0KN#=4?U,X9U)H5<X>)`2SE7[@0MT+]?-7P```/__
M`P!02P,$%``&``@````A``,_T><+!@``_A<``!@```!X;"]W;W)K<VAE971S
M+W-H965T-RYX;6R46&V/HS@,_G[2_0?$]Q:2OE?362W0O5MI3SJ=[N4S0VF+
MMI0*F)W=?W]V'$AB9KK,EV%J/S9^;"<.>?CPO;QXW_*Z*:KKSA?3T/?R:U8=
MBNMIY__S]Z?)VO>:-KT>TDMUS7?^C[SQ/SS^^LO#2U5_;<YYWGK@X=KL_'/;
MWK9!T&3GO$R;:77+KZ`Y5G69MO"S/@7-K<[3@S(J+X$,PV50IL75)P_;>HR/
MZG@LLCRILN<RO[;DI,XO:0OQ-^?BUG3>RFR,NS*MOS[?)EE5WL#%4W$IVA_*
MJ>^5V?;SZ5K5Z=,%>'\7\S3K?*L?`_=ED=554QW;*;@+*-`AYTVP"<#3X\.A
M``:8=J_.CSO_H]CNY=(/'A]4@OXM\I?&^M]KSM7+;W5Q^%)<<\@VU`DK\%15
M7Q'Z^8`B,`X&UI]4!?ZLO4-^3)\O[5_5R^]Y<3JW4.X%,$)BV\./)&\RR"BX
MF<H%>LJJ"P0`?[VRP-:`C*3?U?.E.+3GG3];3A>K<"8`[CWE3?NI0)>^ESTW
M;57^1R"A79$3J9W`4SL1<BK7"[%8OL/+3'N!I_:RF8IYJ%S<>?E<F\%3F\GI
M>K&8+]<K8'#'$+2*.CS?'W5`>51E2=(V?7RHJQ</>ATRU=Q27#EB"YZ[>E`<
M?87>*A!4!IU\1"_*%^2^@:[Z]BC"\"'X!IV0:4Q$F)7O&8R+B#L$EAW=)ERP
MMP0!$.A90"4YBQGTYNM=U06-1F[0<NE&%+T"<1$Q(6Q6<N5"D@[2T=H/O2X6
MO8W#"WK+YG6?#X)A/=@)#D7O5V4T(LQ<+0=,<<P%"1?L+8$3&S3P^-@0O/.!
M>%_\)>\/@JQ5]TQ6H91NZ+&C%V)N4D;-0GI#;>\82+GI_3DTH.EM&K@`?MXZ
M:,13S>*-"&/BB;D@X8*])7!B7`YC%"O<('_2X6CG9EV$LSX-U!&$F:NTLY3&
MMHZ5*R&=@%76EU2$<]?Y_G4'#C=8.G;^[[<X@CDA%G1$&"*TFK$5'=M:N6#Q
M)IVV7ZJ=`+>T-QH(CR;6#GJ?`((Y`19B1!@B,)%K-Z6QK>4UZ71]^)T`PS=@
M)_\;-_QQ_8]&O/_9MA<1QNI_+DBX8&\)G!BQR\;G6*'=),_X/J@Q79+Y9A*[
M>F%*KP<3!K3S#;D],W@CV0('V.AF46A&A'5LI#&:"-/&KI:ME*37]OW22^XT
MC,#Q-9X##3M[YY^Q;$;*X\Y?T,%!<GVL]5VQV(I(>K6A02\E@Y5)BMM4.-C&
M\Z`Q:/,0(8LD$MVL5-N%,$V@NB9VU"MFG/1:0\-V9Y:7RP*GW'@6-!-=%H-R
M$(C*,9G/0P:(!0%T/=;+05]U>L.DDV!B)F)N/+ID<`".)T/C$I)D)A#/>80?
M%\Y*C0>29"#9VQ(W0IQHXR.D^6>G>\::(A*$T=F6\#W*$+%&4+J9,NF5)M<C
MAJ[`N3:>!DU!FX80@QW5'I63)3MFQ.J-N&.J#F!GI:37&A:V.T/:+0:.M_$L
M:!BZ+%@@D2"0J<:0B#U3)\P^T?;V8+#Q;Q'!P3>>"(U)M^]9OB-AS5*]^W!)
M,L#L;8F3:OFN":S0[N""`[M[D(DTB%(]6Z[6;!N)-8!:9K-A#9?TZKYG>@GV
MF-P8?RX5-H/'G7@D?7JZW6/>0&=I#;I#B;R\2:E3&TJ=Y#XE"&M\_TA$\^KP
M0Z@&$17X:A"LP6(-("I"LNHFO=I0H==J@[EYH5L=G'G64AA9'9J4;G7,Q-35
M(1`%(%=F+=+ZD+9:6/$I==*K#2';P'ASZ>#@>S\=&I<N'79>B"2!Z(-9A(OU
MH$(V8,`WT?;65N5ZM#+@4GK7D,:/5&@V.%AV>8N&HG@H2H:BO2-R8V)C&;L&
M9_@[K['@YG.P,O@W;:1!>.JTSAWF1*.[B5P!JN.=&,-.A%>M*CL*18SHZI3N
MZ,J\/N5Q?KDT7E8]X[4H-F\OI2O;"*YL57:9/)9;N'J"5S'Y1[F`.UYUN<HT
M0*V[_0UZ%=R^WM)3_D=:GXIKXUWR(X013O&RLJ;[6_K15C=UF?94M7#OJOX]
MPSU[#I=,X13`QZIJNQ\05-#?W#_^#P``__\#`%!+`P04``8`"````"$`.>FS
M`2,#``!0"0``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)16VV[B,!!]
M7VG_P?)[<X,`082J$'6WTE9:K?;R;!*'6$WBR#:E_?L=QR0DIJWH"Y#Q\9DS
M9^P,J]N7JD3/5$C&ZQC[CH<1K5.>L7H?XS^_[V\6&$E%ZHR4O*8Q?J42WZZ_
M?ED=N7B2!:4*`4,M8UPHU2Q=5Z8%K8AT>$-K6,FYJ(B"1[%W92,HR=I-5>D&
MGC=S*\)J;!B6XAH.GN<LI0E/#Q6ME2$1M"0*],N"-;)CJ])KZ"HBG@[-3<JK
M!BAVK&3JM27%J$J7#_N:"[(KH>X7?TK2CKM]N*"O6"JXY+ER@,XU0B]KCMS(
M!:;U*F-0@;8="9K'^,Y?)A%VUZO6G[^,'N7@-Y(%/WX3+/O!:@IF0YMT`W:<
M/VGH0Z9#L-F]V'W?-N"G0!G-R:%4O_CQ.V7[0D&W0RA(U[7,7A,J4S`4:)P@
MU$PI+T$`?***Z9,!AI"7]OO(,E7$>#)SPKDW\0&.=E2J>Z8I,4H/4O'JGP'Y
M)RI#$IQ()J#^M!XXP2+TP]DG6*8G%OCN6&;.-`CGBRNTN*:NUJ:$*+)>"7Y$
M</1`N6R(/LC^$IBU/Q-PV533._:>8>"4)KG3+#&>8P3;)33Y>1U-5^XS-"8]
M03:7$'^,V'8(W07-FI@`?)Y9PWZ/"P7T58##PRK>[FXG5H.UV"[/Q@2&>8(^
M3:MD^P9B/H8DEY#P';%P#*X7J\$Q!O*S![-QYHV!1*WMGA.=LQKM'R\G9GG:
MWJ*AI7`8KE>IP99*RY^-@;1YC"X[D`P"H^;"1;M>B09;2FR_#,3X-7,\2^C6
M+)^%)H/`2-?L,[HTV-*UL/IH(.?$6SN0#`(C)7#QKG=(@RTEMD,&LFA/E&]?
M4[-XEID,`B-5>H0.7BT?7TH-'JN:6XDW!G).O+4#R2`P4A)]1HD&CY5$MC\&
M,E#2!0:W-!IW%X:<INUN:3CIEXU2,\',J[FB8D^WM"PE2OE!3Z<`6M%'^\%Y
M%^A;:\4W_A+>I!!W^P48:`W9TT<B]JR6J*0Y4'K.'`ZV,"/1/"C>M`-AQQ6,
MLO9G`?]<*+R+/0?`.>>J>]`)^O]"Z_\```#__P,`4$L#!!0`!@`(````(0`*
M0(3F+@<``(`@```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULG%K;CN)&
M$'V/E']`?@=?N!C0,*NUW9U$2J0HRN79`V:P%C"R/3N[?Y]J5]MT58/';!Z6
MF;K9ITYU50V=IT_?3L?1UZRL\N*\<?R)YXRR\[;8Y>?7C?//WW*\=$95G9YW
MZ;$X9QOG>U8YGYY__NGIO2B_5(<LJT<0X5QMG$-=7]:N6VT/V2FM)L4E.X-F
M7Y2GM(9?RU>WNI19NFN<3D<W\+R%>TKSLX,1UN60&,5^GV^SI-B^G;)SC4'*
M[)C6\/[5(;]4;;33=DBX4UI^>;N,M\7I`B%>\F->?V^".J/3=OW;Z[DHTY<C
MX/[FS])M&[OYQ0I_RK=E417[>@+A7'Q1&_/*7;D0Z?EIEP,"E?91F>TWSF=_
M+:>^XSX_-0GZ-\_>*^/G474HWG\I\]WO^3F#;`-/BH&7HOBB3'_;*1$XNY:W
M;!CXLQSMLGWZ=JS_*MY_S?+70PUTSP&1`K;>?4^R:@L9A3"38*XB;8LCO`#\
M.SKEJC0@(^FWYO,]W]6'C3-=3.:A-_7!?/225;7,54AGM'VKZN+T'QHUB+H@
M@0X"GSH(E-=`WZGVA4_M&\PF_LQ;//#\F8X!GRT(^''@"P#,)@/PV3H_GH&%
M#@*?+8K%)%C._?D`'"YRTE"<I'7Z_%06[R,X-Y#UZI*J4^BO(7+++3+1L7V/
M;&!9!?FLHC2Q@,<**O3K\V+^Y'Z%HMIJDPA-0F=T-0FI27S#9$E-DALF*VHB
M;)/0HR;RAHG?F;B0F2X]4&YF>FZ7?)L%9<RRL.C"-HF*T"1L3HG*7,P%"1<(
M+I"&@+PKE/?P=U7&&P="=72$`7M7-%DV=+(,QCVZI$<G>G3RMHY`A",W'*(R
M9A"G#"*:S*YTM`)5P@QSTNI4AU/<"2Z0K8!Z$P30`DP$ZKQ-H2/W%Y9R8DAF
M#`F:S&Z29>H"CLI4CKE6F%KF*6_K"%KH*(^C54X,+6\F:&+PAH)Y`S^<S_U9
MP)I+PET$%\A6T,,>M*_'\2@GAH>W!31!]H(50QN;6D9"8NJ"%:L*86J9IS1U
M=[J?VN#8</BX6)43@\NXB-#$H*\5T-0WIRQI==VQXP*)`B1_OEA,Y]?GD6I<
M43C]9TX9,QAL&$5H@JRQ*12;.I;YQ-0Q/V'JF)]L=6I9,X>4#PW$Y*D?6&--
MD2W8DR)M@]#&0<#>,B9ZYIST*051VI$ET5\C4[QJ?AMU^0%>G/9DU#$\D8\V
MB#?DYX]H>8M,J';)1HP@ZEN`S4??.8>^&OG#`>."8`)>7C.)>T@3<>,81U!+
M^EJHY20LB21A^@ZCK\:]@6G8)&R\:/$NKTG3V'"10#(9\%@'0"7S3(B2>8H^
MI23*\34NK5NU'SP.&;<*0B=?U?QV\VB;9*PE-YLB]E7+1U@22:*,>^E4VX"!
M[8,SB;L#P<0.3J3^Q(0.?(?&'F5"/`,V:P71CKE:$O6U!BB1:E4PP`ZL75PP
M"&@VL"/?7$)6JVLA-9S%1,T2EA#E:LFFE2#J*[`FL+RCI*C5QO`X:MPS"&K6
M8"._W46NY8L2+%_?6\P]WE@3RTE8$ME)Z&)!8:GUP8#U0>7BLF'""5FF([_=
M4-13@SGC."9J1D1"E):O(&KF*^\H*5JU1`Q'BRN'B=;>%=`&J1K[_HRQ&_OM
MWD))T%VH1RFTY]W0\DYH@CAX:#MJK-F`81TDTC9ZAECK`E$'C/U$:W5EPY\J
M]`\Y0?1C^):*LTS"7Y44\T,;4F!O2,OK"MWP%&D;8V'0$@2R\I?!<L&<$LM)
M6!+926AU4#A0@&;1#NNW@?)B5#(V(FVCV?!\-EACK4>J><-ESA[;*@5QOC*%
M'?>.DN+^H1TIP/W'/+1+=B8C;6/2B5YM)J#CAJSN$\M)6!+92?KHO+$'S6"@
M]W?>X,8>Q#NOMD$0L^F"Z6.MOT,G/J!S9CD3Q-FBL]W`^G"KI<7HO:J,!^#&
M58?0R2HM4E]D-[M2-T"U!,&$RV`^M0XG]Q%6%-E)^E#]T#(4V,O0BN4TTC:(
M80JMD#$2:P.DD^4D8=[3%2MG0;S9L^4=)3V>-Q:B`7S:"Q'?\Z+`6HBT1.<"
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M_'B`F_X,KE>\"1COBZ)N?X$'N]W_._#\/P```/__`P!02P,$%``&``@````A
M`+_X($2F`P``"@P``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULE%9=
MC^(V%'VOU/\0Y7WR21)`P&HA2;M2*U75;OML$@/6)'%DFV'FW_<Z)HSM3!EV
M'@9R?'RXY_KZYJZ^O+:-\X(9)[1;NZ$7N`[N*EJ3[KAV?WPOG^:NPP7J:M30
M#J_=-\S=+YM??UE=*'OF)XR%`PH=7[LG(?JE[_/JA%O$/=KC#E8.E+5(P",[
M^KQG&-7#IK;QHR!(_1:1SE4*2_:(!CT<2(5S6IU;W`DEPG"#!,3/3Z3GHUI;
M/2+7(O9\[I\JVO8@L2<-$6^#J.NTU?+;L:,,[1OP_1K.4#5J#P\3^994C')Z
M$![(^2K0J>>%O_!!:;.J"3B0:7<8/JS=K^&R#`/7WZR&!/U#\(5KWQU^HI??
M&*G_(!V&;,,YR1/84_HLJ=]J"<%F?[*['$[@+^;4^(#.C?B;7G['Y'@2<-P)
M.)+&EO5;CGD%&049+TJD4D4;"`#^.RV1I0$90:_#YX74XK1VX]1+LB`.@>[L
M,1<ED9*N4YVYH.V_BA1>I91(=!6!SZM(F'BS*,GF/Z,27U7@<U1)?UYE=E5)
MWU4B+YHG89)^[LA7V1F2G2.!-BM&+PY4,/CG/9+W(5R"\IAEE9-;WO\O[9!O
M*?)5J@Q:D%$.M?*RB=-LY;_`^597SO8CSMSD[*:<16)2<D7)7.?V4Z')*$:&
MK`D97:D!/MB^>8=3M;W'4*<?5]AH56XRK28S,X#ME!*G"Y.SFW(2V^F4$IDB
MQ0<,*^OEE*+]CI$-J$X]&_>S(,EPH[13B+/`C&ZK.+/A0LESV-E`;@.%#90:
M8`0+E^'Q8"5Y[4(F;B63VK$JBA:K`N9#+3]%D75\N;&<!9%],L9Z&,ZLLRV-
M=5W><`F-2G<I+^?G!2HWF6[CS+HB6\5)!G=9DH2SR*J;G6*\)R2W@<(&2@TP
M7$!;T5W<+RQ)-J-/K2:Q593WT'8VD-M`80.E!ABQ0E]Y/%9)_NP2*(X6K`WD
M-E#80*D!1K!RU-%Z]_W$2K*56/L2*(H6ZPC(AFZ1\SMKQ9VU<ER3[WZ]&2],
M,X_5NMQDFIK6NN)HKFP@5X"Z#3&,>?!GMK+"WE)J@.$")B+C3!ZS,>RR?5@M
M97LE:48F2'Y%5-N*PUE@]9UBLD7.<#*'@ZRRHD8R-26TF!WQ#C<-=RIZEN-6
M"$WCAJI1,)>CX##,W19@$NO1$?^)V)%TW&GP`;8&7@8]@JE93CT(V@\OTST5
M,(,-7T\P<V-X700>D`^4BO%!5LQMBM_\!P``__\#`%!+`P04``8`"````"$`
M_?DZPI`3``#Q9P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RLG5UO
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M^Q[^`[I_>KA[W1_V7X]7U-VU-A2O^>;ZYIIZ^O3A_H&N0+G]XG7W]>/EYVC3
MK]:7UY\^#`[ZOX?=SX/SOR\.W_<_R]>'^^[A>4?>IGE2,_!EO_]=B=;W"I'R
M-6@7PPS\^_7B?O?U]L?C\7_V/ZO=P[?O1YKNA*Y(7=CF_J]L=[@CCU(W5W&B
M>KK;/Y(!]/\OGAY4:)!';O\<_OWY<'_\_O%ROKQ*5K-Y1.(77W:'8_&@NKR\
MN/MQ..Z?_E\+1:8KW4EL.IF3]=C)"<6%4:1_`XIGCDYV#I=`_YI.G"LX,?C2
MZ-&_1B]:7"WB9+4>KOV$YLIHTK^L&5FGG5"D53>82O\:Q7A^M4Z2Q7*](O-/
M:-X83?J7AUQ=Q>LD2I9JHDYH1A13>HII$HWN_$Q5GMB(_@</>]Z51A0+>E0;
M%-%IBZ]U:`Z1GMT>;S]]>-W_O*#M@^P^O-RJS2C:J'XYQO5%CU'_JZ"G:%>]
M?%;=?+RD.:-X/M!*_>-3O+CY</T'K:X[([-%F4A*I"RAEI+J-O-![H/"!Z4/
M*A_4/FA\T/J@\T'O@&ORY.A.FLN_PYVJ&^5.=L26@>-?SW<LP2J9#W(?%#XH
M?5#YH/9!XX/6!YT/>@<(WU'T"=^%MUF.."5-&ZH;<<E,^F2K92*]H:J`2H%D
M0'(@!9`22`6D!M(`:8%T0'J7"(?1SC[!84J:5CEYWZ[1Q%N!6R-$0SI"L71K
M&A)R5KNPD?;/"38JZ<%&CN*M)HOEN!12(!F0'$@!I`12`:F!-$!:(!V0WB7"
M/71_G.`>)2W=HTD\Y#'#EIF.Q,Y@%"_D#&8!H3B9CT+"1-K4)YBHI*6)FBP6
M=@:!9$!R(`60$D@%I`;2`&F!=$!ZEPCWJ&3?O8&>WK64M'2/(?2/L^*\^4I'
M(5X7&9`<2`&D!%(!J8$T0%H@'9#>)<)CE&9-\)B2EA[3Q`TH(!F0'$@!I`12
M`:F!-$!:(!V0WB7"/2JGG."?05PZR"!W5[#(AED4+\<5;](M-?3'2U*T4G&2
MC%+23I4#G1_Y=!?V)Y*1S7-21!FB'%&!J$14(:H1-8A:1!VB7B#I+)7T3'"6
MSI'H9LT+?JMNW#0W%/;NW'@SF%HI5LP0Y8@*1"6B"E&-J$'4(NH0]0))_ZDD
M:(+_3,[D^L\@-]@`9:H$4MN-E<H1%8A*1!6B&E&#J$74(>H%DLY2"=H$9YE\
MSG661F('&9&-ORA>CWN#V4$"4E3UCU+23I463;!39U$4)!S;6W4:HZ?+&A4G
MGE&IE6+%#%&.J$!4(JH0U8@:1"VB#E$OD/2?2N-<_ZGB?;Y6AU&_.*/BXBG2
M":!PI4'Z(&LHEE@J&0IZKU3(N)7TG,S%%OW25)4_N::>3I-H_<'-PF1@=F6F
M1FIA488H1U0@*A%5B&I$#:(648>H%T@Z2Z5.KK/4O*YOSIE7DW2Y2\0@=UY'
M-!S4C(O3+&'3*N9U:4MK::I*8UQ3WYA7G?6(N#-HYM0P$;(LP/(`*P*L#+`J
MP.H`:P*L#;`NP'K)A.-4CB4<I^9X18>K;RW=05'F>XR<*;9(3;&M[/04<ZN<
M8KO`I:73\KP8\SQ&[A0'6!9@>8`5`58&6!5@=8`U`=8&6!=@O632<7[.IZ8X
M3M043SQ=C3$=9*1"S&Z_2_^HQA$;[WT!E@=8$6!E@%4!5@=8$V!M@'4!UDLF
MW:Q2MO.WH-AD>,X6R4C$IQ%S6!:0RP.L"+`RP*H`JP.L";`VP+H`ZR63CE.Y
MFNNXL].'6&=Y[C9N$.TL'&>I16H/\HXT,MOJQJ_=J:2I*L]S33U]FU$)D$H+
MW3G62)9/"SO<L#&F1M$Y6\@0Y8@*1"6B"E&-J$'4(NH0]0))_ZGDSO7?V7<;
MI>AY4B,QTR-2,VW/"\S=9FQU9]K&@[1T6J(88Z+(R&:%*:(,48ZH0%0BJA#5
MB!I$+:(.42^0=)9*U=QI?6-9F,S.718:B<D<D9VN:&&GRTQJ0"I>VJF7=JI\
M;H*=)OUS[33(G51`60PH1U0@*A%5B&I$#:(648>H%T@X:Q[*#-^5-@P]R<7+
MB&;/R1K\4R0KQ9MYABA'5"`J$56(:D0-HA91AZ@72+IV6BH[QU36(*?D3!%E
MB')$!:(2486H1M0@:A%UB'J!I+/\]/7TYC+'')61##9[&*3ON5;*!IOI:WBW
M9Y#*4:I`5"*J$-6(&D0MH@Y1+Y#TW[2\=(YYJ4%.-I(BRA#EB`I$):(*48VH
M0=0BZA#U`DEGA7+1*+E2;^X<OS_<_;[=TWY%ZS$0A',ZGAJ"Y/,<\U*#8N<!
M,J/YF*IF!BW$@X^%/?,P,:B[)RF.U,(J,BH158AJ1`VB%E&'J#>(4GTR0KK5
MSYM5WC?=K9A.SS720YIU#"@S4NN9?B-H%GE91&X%V'T%HA)195`TL^]VU%9L
M.-::15YVWU@!'JU%U"'J#0HY6.6VYV<V<YT*NX4)H]G-&%5I@&4CH[W1N75[
M9]TYB]$#/[[(8F1"=>6%=^F(L6K%S+&N'IGH;NE9TK"88TD[,J'J6](Y8FQ)
MSTQ;(J-\6LTPQYJ!D7.9:8!EAM%NXLZ!/?,V^X09@!X'LOD%]Z:>VMCI6]DS
MMT&U=,18M6+F&%>?94C#FHXA[<A.&M(Y8FQ(SRPT!:H<F+`.=/4@UH%!SE6F
M<V29853KLETYBSF768Q,7J9W/E8Z8MQ=Q<RQI#;,&;5A,6?4=F0G1^T<,1ZU
M9Q9RKBIK7.>^;Q<WQ9%35<T-<JXT#;!L9/:6F3-S+K\P3-Y&5]XV7%HIOOB*
M.W,,J4=F!VV8.8.VMCMW87F#=E:*!^VYLX#'U14(CP?2#HH%SCL&<5EH&938
M;3A%E#&REY@SLHH%(RM5(JH86<6:D55L&%FIEI&5ZA#UC`9%L?TNIE55@[CG
M+%UH)91?.7NCERRD1I$J9Y["C/N:+88,8T&OUD?>;2U'M<(@52B.XT4W7A5<
M&JE$/_Y<7,WD_\7Y;YZ%%0Y5&Q09"^?133+W-OT&U5J#3EO8&:GS+>S%4'(6
MZ98L0OY=F\Q"]>)-KD:)N&>N[$F1SAZ-(J6R=G)-7S,]`?/U+(Z]_3M'M<*@
MQ!X5E8S60Y30@]1(3*5W_ZZPT]J@R-BRGB<K3ZM!K9;'M:9TC+0I9P15+_J5
M4T9W&3%E;^Q22MR;&XUHX;'7TX5&8I5IM+1WCARE"H.6-NDI&5G%"A5KE&I0
MJF4IVWW'R';?"T7IK+^EPE3/#WP?:N3%M[>9I$91Q+?I:[8<PG*UGL_G$-]:
MQE$K3$]+FP"5C'1']*&-=\92X>BU09$9/;1U-JC6\E!4[/UZZ^Q8B@T2RVTV
MPZVS%T/)B5-UY:GLYS_[%XKJX-&`>X_6Y:F;<BXT$M&OD8A^HSBSJS@WFHY8
M85`TLX=6Y<BL:H6J=4"L0;%V%+,C=".S(_1"5;K2KU;?M\=C$4OOYZMEX:T!
M+PI3(^4$<V801V%X#>C.';7"J-$:.!&%)4MQ%.*R@)YKSZ#PL@"UEH<Z:5#'
M4FS0&<O"'4K.I5_T^G-YYK+`8I@.MX?)=&\*&CGQGAFI2"P+$"M&,1NTY<AL
MT%:&.2/4`;$&Q=I1S([0C<R.T`M5Z4J_>/5=>=;AXP)K6H/4L>>X6<8K[Z`D
M92GK[XS[XLTYODG67KZ1HUIAT%O+0ANZU%$87<V]6JG"GFO/H&B^F/NG-@VJ
MM6<9U+'4A&6A+T%O"7(NWZJ5SUP66"PO&-G2*0VP+,#R`"L"K`RP*L#J`&L"
MK`VP+L!ZR81#J8+%V^^['D<./<G\DQ%-I[-`O$A/K11GJ1FB'%&!J$14(:H1
M-8A:1!VB7B#IVFF%<Z*K9#>#862WOA11ABA'5"`J$56(:D0-HA91AZ@72#K+
MKT]/%SL)%J(&N>\Z6&3C+UIX&W06DHK7]IQ!VJF*)3==?<-.75N)2=6(D@4.
M]S0!E"'*$16(2D05HAI1@ZA%U"'J!9+.4N7-!&>9BLD6?%MU9J0*,K&#K+T3
MEM1*L4LS1#FB`E&)J$)4(VH0M8@Z1+U`TG^J-IG@/U/*N/[32`0;H(Q.F)27
M':D<48&H1%0AJA$UB%I$':)>(.DLE4M/<)9.O<7*-$@&FU>SIZH*TB%I@PU0
MCE(%HA)1A:A&U"!J$76(>H&D_U1V/\%_NA@0_M.(:GWV3$K'=$-D690ARA$5
MB$I$%:(:48.H1=0AZ@62SE(9Z@1G*7$O-S)(/C%<>\EZFK"8O5UDAGF/*;W;
M6A[0+(*::^^<NPQH5B.C6Y7-Y=;>.6\]B@WF2I>]E;J?588EG*:/,;8UB)Y@
MV+`S4O01$[/,B*G7+>T%++UD-.?^'<TBJ`G/O0*:E6&.:;44$QY:^KGXZ=QB
M$)=!Q2BRZRTUC%*OT14!L1S%BH!8B6)50*P68O(B_:SX7=4X'4/["XH1?5`W
MO)`>W<!3""/BG$)D!JU7@Q+]`M?,)G[Z<3\J%0;1O4B-M+KR:_X2=2J#(C:/
M?GS(6[&UT)).FY8=TU$^>$<C=V\V4@[*$.6("D0EH@I1C:A!U"+J$/4"26>I
M;/K\O7FIDV_W1F:0.K2V6\7:/_.W4G9AF43>+K\<I0I$):(*48VH0=0BZA#U
M`DG_3<O:EYBU,[+'<RFB#%&.J$!4(JH0U8@:1"VB#E$OD'262ITG!)O.M$6P
M:41?FG$8I>J$C](%]?'9&'^1_V,^&4O1RAZEXK4]E9=VJA1U@ITFHW5*"3I0
M-$99.P%E+#4H2@M4*CC!`ITY"D\Q<EV%+%LBRP.L"+`RP*H`JP.L";`VP+H`
MZR63CIN6:RXQUV1$+4ZD>+>?U$KQ!&>(<D0%HA)1A:A&U"!J$76(>H&D__S$
M\XVT"C/,I4'N?@8H0ZD<48&H1%0AJA$UB%I$':)>(.&LU;0<=!"7.2@CYV6O
M-,`R9EX!Y"?DCAB'91%@98!5`58'6!-@;8!US`*OE*W^EK1VZ,5SI\ETA3N1
M9495O<<UKO'HQBOM<BMEG:D[<VJ4$J4J1#6B!E&+J#,H"KG13W3?51VL,/\U
MR'VC'5%FT*_?:+<"UG]Z,*?GTDA%=&P9?E>]<B2XH]HPIZ/&#F?Z\0ZC6BO`
MW72B&[FVIR7&*TR,#7),3!%EK#BSV4,^,GOO+E"U#(A5`5:C:A,0:P.L$ZK2
M/],2WQ4FO@:I$]UQ$<8W7D69&BFW##5(O04_*L(KBSE+Z6+5/RLJL-^2->2N
MX%4RE9$R]:S_,6B-_39G]=O:?NU5Q3-O3^I$]W)"_.3Z?;L!YMSJNR-*L-5A
MZ.ANYV>,]#N+1LAY,25C/?N.:FX0'7BH);IT?F9QZ*7`7DKNQ:83%2.S8?AO
MN=;82\,JMI>6D7D14O[R2R?ZD'Y6>?SYJ?E*I_UN:FX0!3[O0ZE!(LJU(I6>
M+)4;*2JP&!6H6+*4W3PJ1G:/J5&Q82FKV#*RBIU0E)Y1I83KF?=%(!<DXT5N
M5QI1!/)UIP:)>--2JC@8XS2P+1@I/>VKN;>\"^RX-.CTJR052^DW-^+$6[DU
M=MRP"BVP7UO<LI3NV$OY.M&MG`Z_%/*GX[S7/^A7Y?WS,8.&,-1#ZM^-U[^F
M_;1[_;9+=X^/AXN[_0_UF_!T%_GT8<3Z!^NWRWBCSJ5H1J%E3BU#V$/+@EJ&
M8:%E12W#ZH:6-;4,+P5`RPVU#+N3WS(G"^A-I8!M"]*A-T0"+<ELH]YO"+70
M;_/K$V5_G(3&H2?"(1VZ4KU!^#IQLE&_;A'0B<D'=&(?:B&K]=[B]S8GJ^G-
M^H#.G*RF+Z)#+31S]*UOH"4BV^C,-M1"MM&O?(5:R#;ZY9Y`2TP6Z),>W^J8
M+*"?P0GID$=UQN7KD`'!\2D\@M%!9@6MBL@J_<V-/T)$5NE]'EK(*BK=T%ZJ
MDC8JQ<<62J\W.:6GV$(9\T;EQ-A"*?!&9;G80G\>XG.(;]7%!.2WRL$AKA9&
M@']>;#[K/S_A7SI%1#`@ELEF2^=?:"H=Z&W28`L=XFW4F1GJ;,F-VZ`;J9K>
MI,$6JJG)6:'0I_*06D)NH2\OZ?J#89&L-^KA&MI&3R4W:;"%GCINU#,TU*&G
MBILRV$+/%C?J21GJT./$C7I@ABW;1$U"<!82NAY]6X5YH_5"CW2Q-_H.=J,^
M4L,6^LQUHSY+PQ;ZV'6COF0-M:RH)30.?4!(+:&E29^Y44MH'/IXG5I"-PCZ
M_GJC/IY&"^A;:=()M6S)ZFUP'/HJ>:.^#L3>Z*/CC?H>$%OHTV.R(.0#^B"6
M6D(^H$\WJ27D`_J^D%J&<:['J:,_N/)R^VW7W[Y^>W@^7#SNOM+-=S;\<,"K
M_I,M^C^.YBN!+_LC_:D5.D*AOW5!?UIG1W\58*9^DNWK?G_D_Z`+N1[_6,^G
M_PH```#__P,`4$L#!!0`!@`(````(0#"73#'D@@``!<E```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;*R:VV[B2!"&[U?:=T#<#V";LY*,`L;GE5:K
MV=UK`DZP!C#"SF3F[;?:W>7NZF*8$.W-,/FH^NG^N_H$OOO\_;#O?,O/55$>
M[[M.;]#MY,=-N2V.+_?=O[\$GZ;=3E6OC]OUOCSF]]T?>=7]_/#[;W=OY?EK
MM<OSN@,*Q^J^NZOKT[S?KS:[_+"N>N4I/\([S^7YL*[AS_-+OSJ=\_6V23KL
M^^Y@,.X?UL6Q*Q7FY_=HE,_/Q2;WR\WK(3_64N2<[]<UM+_:%:<*U0Z;]\@=
MUN>OKZ=/F_)P`HFG8E_4/QK1;N>PF<<OQ_*\?MI#O[\[P_4&M9L_F/RAV)S+
MJGRN>R#7EPWE?9[U9WU0>KC;%M`#87OGG#_?=Q^=>>:.NOV'N\:@?XK\K3+^
MWZEVY5MX+K99<<S!;1@G,0)/9?E5A,9;@2"YS[*#9@3^/'>V^?/Z=5__5;Y%
M>?&RJV&X1]`CT;'Y]H>?5QMP%&1ZLAF;<@\-@'\[AT*4!CBR_MZ\OA7;>G??
M]<:]T63@.1#>><JK.BB$9+>S>:WJ\O"O#')$HUH15XG`JQ)Q1KWI:#0<3R?O
M5_&4"KPJE5EOZ(XFTUN:,E0B\(K]@?^^LQ_0UL8,>,7DGCL=.:/Q#6:,E0B\
MHADW&SI1&O"J-,#:*P,`L[EI.+QB?&_B#&:>L/]*G@/U)H=?%)X<6M?H\K74
MMG+@/VVJ'J]KJ5@OCE$P[_6H+PNXF0_^NEX_W)W+MPXL,M",ZK062Y8S%\(X
M$V1#VKGQLZD!Y2Q4'H7,?1>,AZJO8#Y_>_`&X[O^-YB#&Q6SX#$.C5ABA)@E
M0M:WP<H&@0U"&T0VB&V0V""U06:`/AC7N@>&_1_N"1GA'O9[@4#;Z5I6802F
M^#98V2"P06B#R`:Q#1(;I#;(#$"L@O6)6'5YJ<5Z$M&PJ))ZFE`+%C+&D8NJ
M*)<E(SXC*T8"1D)&(D9B1A)&4D8RDQ![8+F]P1X1#3,6O#;FV]3R1P5Y;5DM
M,6U&\F8TSV_S3'$]F4FS8:&\H=DBNFDV5NU"DN%8MY$1GY$5(P$C(2,1(S$C
M"2,I(YE)B!FP=]U@AHBF9B@RF&DW%'*T03XB**5V\-VI-8@K'85>!QR%'$4<
MQ1PE'*4<98B:UA.K8*<@5LEMIR<VWGI7;+XN2GE\NK!*>+"]R$U'B%`'%3$=
M5,AT4*(A;-ZM@<YL2&?!J@UJ_6,D9"1B)&8D821E))/$D:TFSHDK"-^P;W1.
MB%#G)'&-Q4*1:5N,OB330;._NP/'MJQ]O[5,DHG;:H22.,X413SJ>Z0#4"5F
M*HDDNB76[IBV[Z-&)HG;](;X"6LA\?-"Q<$Q%DM.1%/C)!DU]XVF+)>*Z'W)
M5T2;NV(D8%DABXD8B5E6PF)21C(SBY@A3K8WN-&$4SL4\LS)Y3D#.LA+%>7J
ME<[G:-7*#]OZ"7A8J-!(1T4*3?48Q#PQX8DI3\Q((G5+'`O-N7B]=N"D8A>/
M0LVRUQZ<'78LEHF>[J"O$CTH:V,-TYMT4XDKC(+Q;J/@BDH'(\`H4\MSK'D9
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M@"+ZV!4J1(I.Z:I3%"V4F&LD7"-%)#6LY3Y#C<9E:JDXU9N6_J+8U"7`]$XB
MZXQ@+7I+./L*.TG]243J3R%=#0%/#!4:Z_-`A$BW*^:)"4;IQ!213LQ((C5+
M'.1O,$N=^[7VPI'(.B)89;-44:3V9"(<$;!"5Q@U:W:9J;5J!OBV]C)$I,L\
M4@BV^*O;C/ITK95PK?1=6ADF7JA%6'6)O1^;WD+%VF8DFD`OVKWTPC8CHTB)
M*BTH;FT[,CC'M6ILCPC@3F05?*B08ZA%+7.:4;0&,>8J29NAVY2V[&J;,J)&
M*UM<(FZH;'GG($NH1&0)54A7C>](-#/W;:7EZ6D2J#!C`H28J:,B1'HZQSPQ
MP2B=F"+2B1E))-:X]BWJ0U79J-"J5,BHAJ5"9@EBHA&V:IDL&C;UN4RHT%2O
M'Q$BN7[8E<<U$DS0&BDB&,.?SX6,:%%SQ67H_77GRKN367<*F76'R*@[A<RZ
M0RVS[GAFB)FZ?")$NGQBGIA@E$Y,$>G$C"12:^PKS<?JCM]T7'5AT>O'4B%2
M=Y@(AY-V:-D5<:4R'?!?G'(_C:SOK0,N'2HTNZH<8=10"EM'FICK)IAQ53?%
M**EKR69$EHZ'..&;I6J/QY?R!!/\5[^MP9=R]O:DD/F].4<^1RN.`HY"CB*.
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MPT`-FM\#SO+!%OE'K=::I[*&!U*:96<'#R#E\+OIH`=U\%R6-?XA/J!]I.GA
M/P```/__`P!02P,$%``&``@````A`(GA[28!"0``MR@``!D```!X;"]W;W)K
M<VAE971S+W-H965T,38N>&ULK)I;;^.V$L??#W"^@Z'WQI;D.^(4L767"A1%
M>\ZS8RN)L+9E6,IF]]MW>!,Y'*V==/N2RT_#,?F?(3FD=?_KM^-A\+6\-%5]
M6CGNW<@9E*==O:].+ROGKS^C7^;.H&FWI_WV4)_*E?.];)Q?'_[[G_OW^O*E
M>2W+=@`>3LW*>6W;\W(X;':OY7';W-7G\@1/GNO+<=O"OY>787.^E-L];W0\
M#+W1:#H\;JN3(SPL+Q_Q43\_5[LRJ'=OQ_+4"B>7\K!MH?_-:W5NE+?C[B/N
MCMO+E[?S+[OZ>`873]6A:K]SI\[@N%NF+Z?ZLGTZP+B_N>/M3OGF_Q#WQVIW
MJ9OZN;T#=T/143KFQ7`Q!$\/]_L*1L!D'US*YY7SZ"X+WW.&#_=<H/]5Y7MC
M_#UH7NOW^%+MB^I4@MH0)Q:!I[K^PDS3/4/0>$A:1SP"OU\&^_)Y^W9H_ZC?
MD[)Z>6TAW!,8$1O8<O\]*)L=*`IN[KP)\[2K#]`!^#DX5BPU0)'MMY4SA@^N
M]NWKRO&G=Y/9R'?!?/!4-FU4,9?.8/?6M/7Q_\+(E:Z$$[#D3N"W<O)I'S/I
M`WY+'^[=?#(93^>SCW<$LIIW!'[_XXZX$`/NA/W1TY4K.KA*3?:';.H9HZ!-
MAR(</+K!MMT^W%_J]P%,&7#0G+=L`KI+UW,&*J["11?I'P4:(LR\/#(W*P<T
MA1@VD)U?'[R%>S_\"AFUDS9K:F-9;)0%2Q_F-K!!:(/(!K$-$AND-LALD-N@
M,,`0A.O4`\'^#?68&Z:>&O=:`4-.+.9&6:@F@0U"&T0VB&V0V""U06:#W`:%
M`9!4OB55_\*A\HE9PQ*!\LG#$JR%#4P!I<&&D("0D)"(D)B0A)"4D(R0G)#"
M)$@>6!=))GF3.UB2K@O%VL'<!=6-F>=;2DDC^'##:(R--KU&>H:BWD*W4&^O
M]Y%9\SZJ0*TET1F_(20@)"0D(B0F)"$D)20C)">D,`D28_HI,9@U%D,2V$N,
MZ$RLZ'1&2L.`D)"0B)"8D(20E)",D)R0PB1(']@5/I$LS!KK(\B8%S=\6]@0
M$A`2$A(1$A.2$)(2DA&2$U*8!(G!ZF&ZW]ZQVJ-]K79?UC4D`6PW/3/*AWU5
M[+;,"=9(D`FOX81&DNC5,1!DNC#RS%U8JT#8&:D\BPB)"4D(2069\(]'`L#'
M_[P`S`D60!!3`$D,`029C41],G+ML7?/N[%+'SKUXLZ&US@CUUIJD^ZY\I%*
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M).M$4TJ!S!W:)2B@**0HHBBF**$HI2BC**>H0`@KQDH^4[$;"S0SMQ9HA6`[
M[%8&;S&WLTR;J;D9L,L5[FW>S<2PAT4]+.YA20]+>UC6P_(>5F"&=6.EX"=T
MDY6CF5$"H8PB*'`)"BF**(HI2BA**<HHRBDJ$,+*L+K05$9<MWRR_'-%=0F+
MILJ6M42>7E,W"NG\"20:0^&ALW$\PMD8:BOE/J(HIBBA**4HHRBGJ)#(X[W'
M&K+2\N<U%`4JTE`@I*%$IH8"S7]81;J=@99/H)D.6"RM7/C]@TK2L%".4LD,
M1YE$NC_6-4FN#92;0J(^<5FU:HI[8\D3Q2U24=:[L`'H'%LL<(YM7&&%]E6!
M?%V`AM)*W&OS,BFB#6.)9CKW$X5T%9/2AIFRT@USA73#`C5$F>A]KH#GYGA_
MD,@LP"0R"S"*0HGF.J,B:A5+9+A/E)6XHV>7K*E">LP9;9@K*]VP4(@WQ,K8
ME?_U-/)HB2\1*L_\D;54;:25F482^;`W=/E':O&P^T19GXVM^Y:(>HXE0ETB
MGA-I-7?YO+83/Z5^,XE\<U4F?G/LU[?.K@7RBV-A'Q]NQ((>$Z#P9Z6(D48;
MB5"6"BM?KY6ALM(GL$@AG6PQ=9\H*YULJ4*Z8::0,7\EFND33:&L>K*4E=+F
M8L=V8P\VUX_?Q,!F8==\$J$T\4?6<6\CK5#F*E]0^5U+764VY1DVGEIGEHBZ
MCB6Z?F9)I)4+$O`]:6)Y3JGG3'F^VN?<\CRQ9EN!'./L90<).T;N1%=,'SNU
M>.(\8FY4"AF7T!0%%(44113%%"44I11E%.44%0AAQ=C!@2@VF]_^+H%]$VL=
M8!32$W$C$5O\=99ZUGH4J(;F,NR/=&V"N\P*>;/+-Y8H4?>C8`HTUJO#QB,H
MH"BD**(HIBBA**4HHRBGJ$`(*]-[8!C!4GM#(GI$8`L;BZX92H&L4%I7"H%J
M"'IV`?='^D(#=YB5NI\(I:B,42@%0J$D*(#:E8W&L`HIBBB**4HH2BG**,HI
M*A#"RK#ZUE2&G_W&_'V)6]$4I3%222(SF@)9T;3N&@+8<7@:X&CJZ8OZS&H2
MU.?K6<?-<84KD1&G#44!12%%$44Q10E%*44913E%!4)8&;O"9=&<^GQ?NB$2
M+7;AS&-/38EP,,<Z3/PT%*B&.)AZ=\5=9@6:F8`W^BGJ.3/IX"#&)QV[=Q"N
MQ?M"XHV28WEY*3?EX=`,=O4;>Q<(2J^'^PZ+%Y76WGC)=B]P09Y,X0FOW,B3
M.3SAA:7]Q!_!>T_\:R_K";P0]<A/1Q9?PXM2_(AI<P\^HJ]7/GQ`#W\<+Q_%
MP=1V-%G"=\4]PX/1]0YNMH2O"WOL71`*+B?[GL!'B'7<^NQ@OH3OXFB+8+$,
M>1%NV<>+)7QCU6/OSI;L5J;OR7P9POT!?0)7&LND]PG<48"WOC9K%T2!ZS+P
M-NRZ!J^-G;<OY6_;RTMU:@:'\AE2:<1GUD6\>";^:>77'D]U"R^,P;(#;R_!
M"X(EG&E'K-AYKNM6_<,^H'OE\.%O````__\#`%!+`P04``8`"````"$`[1$J
M^Q<$``#>#```&0```'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RL5UV/HS84
M?:_4_X!X7PA?":`DJP1"NU(K5=5N^\R`$ZP!C+`SF?GWO;:!V#"-HJHOX^%P
M[_$]]\,XVZ_O36V\H9YBTNY,QUJ9!FH+4N+VLC-_?,^^A*9!6=Z6>4U:M#,_
M$#6_[G_^:7LC_2NM$&(&,+1T9U:,=;%MTZ)"34XMTJ$6WIQ)W^0,'ON+3;L>
MY:5P:FK;7:W6=I/CUI0,<?\,!SF?<8%24EP;U#))TJ,Z9Q`_K7!'1[:F>(:N
MR?O7:_>E($T'%"^XQNQ#D)I&4\3?+BWI\Y<:=+\[?EZ,W.)A0=_@HB>4G)D%
M=+8,=*DYLB,;F/;;$H,"GG:C1^>=>7#BS'%,>[\5"?H+HQM5_C=H16Z_]+C\
M#;<(L@UUXA5X(>25FWXK.03.]L([$Q7XHS=*=,ZO-?N3W'Y%^%(Q*'<`BKBP
MN/Q($2T@HT!CN0%G*D@-`<!?H\&\-2`C^;M8;[ADU<[TUE:P67D.F!LOB+(,
M<TK3**Z4D>9O:204323N0`+K0.(ZEN\&FU"P//#T!D]8!\_(<L/`"=9\^P>.
M_N`(Z^#H6&$0^.MP\]@1W@K!L`Z.WEWO@PW7@Q^L3T5JRT2+NJ4YR_?;GMP,
M&`9()>UR/EI.#&1CP>364PG_K8)0.DYRX"P[<V,:4!P*;?>V]P)W:[]!JQ2#
MS7%IX^@6R6C!^X+3IG/@-`<R!;!!T20+:O\_R.(L7-88T'$$[CIG*I/18G1)
MY\!I#F0*H&F`+IQK\&`B/Y^EL1+<":9&J83KK?4\'Z6-/`=$HI,%DBZ0TP+)
M5$2+',9`C?QQQ-P8N@^RH#2/-PMY,-([S->-DLEH2OX".2V03$4T%3"3J@HY
M&A8?:%;AXO5(Y$GTB3H/1D`.!N<0XL:0CA*)5"6NOYHID49N.'5>*A$?ZC]E
M:;W1O4Z3S;A9IO)HVF#456V?:(`3;Q3!C741$@F\*;YD0.1)+(9W0-S)YK3P
MRE0O+3Y(S_/Q<6,]/HD$OCB*W)43Z)E*Y'LWFF)+)>)!0%-^G6@V.*>!EF?F
M;>\XL_QG*JNFAE]OE$/V<;:YL:Y&(L%Z5#,+*Y'O/?^N9H&<)+*1',O050<M
M]$@/_3\-`>?0%4GD7I]9)A/Y7JV/1*+[1)PD$D8B*\'L+,A4!DV0`R/T?#&$
MM1[[`$$YQC%+!DBMP`!%$,>#AAJM'%G:,-3[--.(=1G\R_=T3\%9/R_!`(FF
MD<SR5B=O!PWJ+RA!=4V-@ESYC6T#(4ZHO$VF00QG#F1AAL,M\R#&?H8?^>WS
M$_NC&\-'<,ES]&+XQBSQ@Q\?Y-=KOH$?PW$.#O;T`FZ777Y!O^?]!;?4J-$9
MM*S$*=[+^ZE\8*2#,L,=DS"X5XI_*_@=@>`:LK+@&#T3PL8'OL'TRV3_#P``
M`/__`P!02P,$%``&``@````A`%6YYP,`#0``:3T``!D```!X;"]W;W)K<VAE
M971S+W-H965T,C8N>&ULK)M9;R,Y#H#?%]C_8/B][3I\%CH9Q'5?P&(QN_OL
M=IS$Z#@.;/?U[X<JB2515#M.9O=A,_T524D418ERU><_?NZ?!]^WQ]/N\'(S
M]$?><+!]V1SN=R^/-\/__)E]6@P'I_/ZY7[]?'C9W@Q_;4_#/V[_^8_//P['
MKZ>G[?8\``LOIYOAT_G\&HW'I\W3=K\^C0ZOVQ=X\G`X[M=G^.?Q<7QZ/6[7
M]YW2_GD<>-YLO%_O7H;20G2\QL;AX6&WV2:'S;?]]N4LC1RWS^LS]/_TM'L]
MH;7]YAIS^_7QZ[?73YO#_A5,?-D][\Z_.J/#P7X3E8\OA^/ZRS.,^Z<_66_0
M=O</9GZ_VQP/I\/#>03FQK*C?,S+\7(,EFX_W^]@!,+M@^/VX69XYT?MQ!^.
M;S]W#OKO;OOC9/SWX/1T^)$?=_?-[F4+WH9Y$C/PY7#X*D3+>X%`><RTLVX&
M_G4<W&\?UM^>S_\^_"BVN\>G,TSW%$8D!A;=_TJVIPUX%,R,@JFPM#D\0P?@
M_P?[G0@-\,CZ9_?WQ^[^_'0S#&>CZ=P+?1`??-F>SME.F!P.-M].Y\/^?U*H
M&U%O)%!&X"\:"4?^Q)N]PP:TUG4$_J*-=_=CIFS`7V5C/IK[WC*<7S^6N;(!
M?Y6-V7N'`FNK&PK\52;\X-UC\2$4Y,R`[Y698#0)IO-%-S47IL/'^1#_T0_B
MDNI81D479,GZO+[]?#S\&,#*A;9/KVN1!_S(#X<##"_9>A]POXLW"#1AY4Z8
MN1F"2R&43K!(OM^&T^GG\7<([(V267$9GTK$*"&B6)A-;)#:(+-!;H/"!J4-
M*AO4-FALT!I@#)[LW0GS\?]PIS`CW(F.6"'0_@TLWZ$$JB0V2&V0V2"W06&#
MT@:5#6H;-#9H#4!\!]''?#>!=>W.=!AY0@MR&HF\&?7-2LKX,J>)P(H921A)
M&<D8R1DI&"D9J1BI&6D8:4U"'#>Q''?984(:5CO,@K%6YY;'I-`$_O1"P<P2
MBGNA/N8821G)&,D9*1@I&:D8J1EI&&E-0IP(@4:B[[(3A73G1!SZ2A+P&)*8
MD821E)&,D9R1@I&2D8J1FI&&D=8DQ#VPXQ+WR'UB)/;=\]-N\W5UD(<(A]M"
MV`_D+B&,4*])$LRTUQ0)>Y)(,H'M4L?BQ*,!F_9"Z/Z,D9R1@I&2D8J1FI&&
MD5:2H!L&<23LD7_?D<((=:0DLKW.V3$CB20+K]N?`\^?6#[LG_<^9"1GI)#$
M]W1V+7LA<1"`AD+:4-4_QX9J1AI&6DD<+A6ECGF&<<0@G%,Q"(4T]9TBWK*/
MN9BC!)&9.(/9@@XM55)PN,.Q98B(XMP*X%Q+H6*!+>I^E8B(+;L3%=K2G:@1
M$46[$XV6PDZTV&+7"1+)RW>Y74A3MRMBNIVC1"+($,;JGRTMKRL]8X?/$,&N
MJ=/&W#IQYEH*!UPH9'2KE.AR'RHTI==!C>AB'QHMA7UH%9)]($X75<,[@KT3
MIVY'9`PP=K!$,5@YV*T4Q4P_]XP.TCJ>YH88FBN0&3TI%3-:K5#,:+7NV<56
M&T,,6VV1N9PKCO5F)OG0+@?]M$,=D3'2V,&2GNGM+T4&?W$,F6)T3YQ;:3;7
M4JA8H#&C(V7/=*,5,OB+NK5BEQMMM!0JMFC,Y7'(1\3CEW.W.+5:642AJ<YU
M,4<)(CW$%)%6S!!IJ9RC`I%6+!%IQ0J1EJH1::F&HQ91ITC7/@3[>YPEQ*VU
M+]$43L%&4K3.`;&X!P#%0.\[B4*^-^D.#Q.X/O*M'2SE:IE"H7EV\Y=6>98K
MJ:G8H[_?3D8>_5^0?K)Z6/"F2H6PAZ&_G(96MJ^X6JW0Y1XV2NKZ'K:D*3J+
MH@3Y^TE&%C(0++C,5KY$4[)5SJU;F%A)A;I0213R/3D!X<(+`BM_IUPMP_;T
M-46.:-'-Y'(4^&0JK6V[X$9+A;`OBW`ZM[0JKE5CN[HK#2+9E2N"JB5VZ92)
MLLB<LC>RE*RBR-Q(!`L/IRL6E[CV*I-HIB<UY5*90C.=FG-$6K'@BB67JKA4
MC5+:?(-(FV^)(G66*'U,9WUL$Y4%%/&A1%9\6\DD]J44B6]ERYMU83E?A&'(
MXINI9<K23!^`<D32T&0TL:Y$"MYZJ9"O6G>ESHJKU=@4A$2?JEGJ;%`*.T26
MF^?QU-F2INC$B0+KTL3]>7B%[>2M"SE?UFEDYB0BT:^J.7./48J>7L6I,F9L
M11G:]Q;]6LI[IE4+KEHZQ"HN5O=BNH6F9[J%EJA25XJJZ9(KK[HN\57MI9?=
M2B%K#5A1&"LIL@:PCKNT!J2,H98I2[`&+D1ACE(8A7Q9,,NETKF\+)A:C4U=
M[%"#4MBA*Y:%V12=2U&,79K+*Y>%JNG,R92(+`N)C'A/?*5(E@43RWHQ';1Y
MSW30%HH9+90.L8J+U;V8;J'IF6ZA):K$E8%=O'YH:^BLT'.M0B$<7/MD&<RM
MNYD8I?0FG*`M3,[!<KJPSALI5\L4>F-9H)2,0G\46@5:P2V7"N&R\,-):-_2
M5%RMQJ8N+PN4NGY9D*;H7+Y5*U^W+`)>+"O4S1)M\GW%8M`7BSHHPJD5%"LE
M17_J6%A2L9;"\UO"4<I1QE'.4<%1R5'%4<U1PU%+$'6I*/7,Y';Y9`N7KW9)
MB4@G@)BCA*.4HXRCG*."HY*CBJ.:HX:CEB#J++MR>\-9O$0+%#*N7V('2Y")
M*E(G-)Z9E#D0P[#,#%5DN8,5#E8Z6.5@M8,UR!R7/'"91X/L8VE?6+'2OD+$
MG9PE70=NAN3FRE]:EPJIED+'91SE'!4<E1Q5'-4<-0K!.RUB2FGXB1+%7*L?
M<Z,JAHQSB+C8%I6HCJ*8HT2AW_]\I`6T_YCE7$GY<$1S_SI4&!)HJ%3,Z&*E
MFU-VK)*NU@)HIB%FJ'-%\6$Z]XVUK6H5TXNJHC&]R%`2*$5/:Z8]TR5WII@Q
MX-PA5CA8R54KAUCM8`U1I?X1Y^-W^$<>I\TB,)"(WCTNK4O$6$D9Q]-$H1!B
MJ<^%K!).46K>A=7".FIEW&Z.&A<O)PLEA5=_5M(HN=WJ*KNUMJM'%7B6^8:8
MIQ,B2@!S0CZ6#51QH:-Q!:X7V8"4F%.[PE1"1JF8H)ZNZ%.%9O(7Y]F438IL
MRK"2HQ5]G"@0J81AWSN7ZKEAI4(5;:5&I*XFZ0^(#;%!_"QNAHF?+R>&3ISN
M4@J999Y"T"JFID2AF4X?*2)=KV1<,4<IG3P*1'I62ZY8H916K!%IQ88H4L^\
M50%<=<D1\@)`(8A`]$ZLD#''B4(S2*@7T@)*R6F?A]9U8<8-YZ@"!XG?&RY0
M2M92P=1:N24W7*'*1<,U2DG#5C':$+-T.NSJR$X(UQ5D85\UH?-7"O&"3-3;
M[UD;LGJ`!GJ_AE-K@*O.)BP@'94Q1PE'*4<91SE'!4<E1Q5'-4<-1RU!=,;L
M>D+,V!5O/,I3OUD:A%,KKE>P4KK3LNE&AA(NE7*4<91S5'!4<E1Q5'/4<-02
M1-TH3OSF3OA&AE8%`@U#:X-;A5+*NA:PCIBQEL+%DG"4<I1QE'-4<%1R5'%4
M<]1PU!)$72K.[>]PJ3SFFZ<]<5J#4X3Y/B1'"4<I1QE'.4<%1R5'%4<U1PU'
M+4'46>)(_PYGJ0I`[[&K4"&KW+>.2W$OIC?&1#%1V/1)E;^5YM#,G)H+:QO+
M'9I%S\P4%"RL7YK+7JSK+G6974W8>]5U1P=>9(020:6/"S)6R(<?OI`EBHER
MQ_":M16E#LW,J<G>O'%H%HH972NI&/60?;Q_(ZGQ<WRH$/RLC>..%9OJ72%Q
MB*5<+'.(Y5RL<(B51(P,4ES(D)7SH3#HK-`C-R+XE;I[I<1?LO<@E(AY!%=H
M(4M(^,[-LZK3E"ME"JGZ$#Y'LJZ.<ZY3*.1C]Z:SP-(JB19UFGWLOAP9\&U:
M=Q`PTHU"QGE.?GTF/PS:;X^/VWC[_'P:;`[?Q)=E$W$4[;'Z["T(HCLX&$)H
M64_@1CT2-\ZN)R$\Z0H<6R>$)W!0<NB$$WC2==72N0NGT9W\\LYZ`ILWZ'0_
MV[,G,WC2)0+K"7S&=^?L,WS>UZT62WXE!NGL+S3@X'<3L.\T!.-S#6\%8W`-
M`>[AHA32/7<57*U%XO*,/X&[LDA<A_$GL/5$*TA#_`GL-I'(G?Q)"D]$;N1/
M8+>(<N<3V#,BD0&Y#FP3D4B$_$F[`-<[719,HA5<E'(5N$R/8N<3N%('%[@<
M#;?#\,1E#>ZT(W$AR]LI%I%XE9(_J!:1>'>2/Z@7$;Q=[>#+"%X`=G#?B\3K
MJZXG/CQQM9',(O@2@6LD,"O=38@5P^4\@M?LN?QJ$:V<#<2+2+RVRC72123>
M4^4/LD4$;[8[^#*"=Z\='(8MWA5V/?'A2=?&N!\'?.CZNG[<MNOCX^[E-'C>
M/D"Z\KJO4H[R4UGYC[-Z<^7+X0R?N,)>`1\ZPB?-6_@4S!O!2?_A<#CC/Z#I
M<?^1].U?````__\#`%!+`P04``8`"````"$`AB";Y2P*``!8+P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6RLFMMNXS@2AN\7V'<P?#^Q)?F,)(.V
MSH<%%HO9W6NWHR1&VU9@N[NGWWZ+(BFR^&MB)]B;=N=3L43^5:2*E.Y___.P
M'_RH3^==<WP8>G?CX:`^;INGW?'E8?CO/Y+?%L/!^;(Y/FWVS;%^&/ZJS\/?
M'__^M_N?S>G;^;6N+P/R<#P_#%\OE[?5:'3>OM:'S?FN>:N/=.6Y.1TV%_KS
M]#(ZOYWJS5/;Z+`?^>/Q;'38[(Y#Z6%UNL5'\_R\V]91L_U^J(\7Z>14[S<7
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MZNG<$/_I.F"4P*8CF5QMKD:;R^;Q_M3\'-`"0`[.;QNQG'@KCU)-9ZETT>7M
M7Z4MY:OP\D6X>1A27"@CSS37?CP&L_']Z`?-CZVR6:.-QRU";2$F@W`;N2!V
M0>*"U`69"W(7%"XH75!98$3"=>J18/\/]80;H9X>]UH#(Z?O2*4M=)/(!;$+
M$A>D+LA<D+N@<$'I@LH"3"I:@9A4_<N@SB=A30N>E4_^TI%@+6UH"F@-0B`1
MD!A(`B0%D@')@11`2B"539@\M+9^0!YA33.6M+;FFS.;ULJ(UBC+R!$Q[(RT
MB!&0&$@")`62`<F!%$!*()5-F&2TY']`,F'=2J8'NE9D:?('2`0D!I(`28%D
M0'(@!9`22&43)L;,$4.NXW?B>71YW6V_K1M9*_1,NX#6:[F*"R=<(TDFUAQ3
M-IY9K2*%`OJU,BW@*U9LK'0$$D0IH@Q1CJA02/:+24-/)98GGY)&..'22&)+
MHVQL:31:M,]$?^Q-'%6,0:>*1D;A%%&F4>?9T3LW!MISH5'KF6DD-AUV&="3
M)E1UZCP1UEP,26PQE,VDFUV1(H$95XPH@78ID`R;Y8@*NQT;+*V(;+"?2@CA
MA&L@R936JVX6^,L9CW>HF@66+A(MZ='0M?/<=K&^W5PF$O>:=+?6H4[Q/MDM
M]\GY?9Q'2F'?ATDJ:MAW-?VC>2.UKI:1P@U7M?7\,)S.ND0*%?("N6V2E:)L
M:9G%RLRR2M!9VN,L0[,<G17,BJLAZD5[.GTJPT1Q[XHAD9-C<YX-H6YH)YEB
M5[),M_1EFGF^LZ@DRH`ZT&6:;F/=+;OI;KENJ>X6.'.E8#?C`HLJ\SV!;TPW
M6:Q2':5'LQ8U%8D^,2A$%"&*$26(4D09HAQ1@:A$5#'$%1.5)R@V7]Q1@?#^
M8N^IFM4HLE;(;P]`VM(A-,A:Q7SG:1=I7_2P[M:Z8&QJ4MYE4?G97;[23U4H
MVOV4:&*R-?0`18AB1`FB%%&&*$=4("H150QQ9409:"O3KB]C2MTK$JGRT99(
M(A;*#ID@>;XS.2-QE"56)QY*LU[P#HOJS.[PE7ZJ8L[NIT0LE(`BT1LQ>TW`
M8T0)HA11ABA'5"`J$54,<65$368KTX9RTIX)7HNF*N=LE21BT>R0'<T%?V1$
M5+/V1--,7]YG45G9?;X2356(V?V4R(I3Z`&*$,6($D0IH@Q1CJA`5"*J&.+*
MB`+)5D9$<Q:TV[`K(NG"RWH42<2"V2$KF!,3)G5JIGS19+!6V6D7<M9E<L^[
M_'X_6W->H2G4SCGNVBV#KKCNZAVKVS-G<&M?6U&^=*/SETY"AY:9?K9'/2SN
M84D/2WM8UL/R'E;TL+*'59QQ*=V"YXJ46-CX6-@@BA#%B!)$*:(,48ZH0%0B
MJACBRO06-M,/GGSX6.0H1#\Z@4*-VK=&<JXI-*%99+)QXAQ]Q\9*^TH0I8@R
M1#FB`E&)J%+(;WO/-70KK4_M5WPLP!2B.^MQAQK9&LJ&B_%?'9*H-F2@W20*
MS<U#)57(H^59O("@PQ93C;3!RBP+[2A'1X5"IC^F0&W]E,9`NZD4ZA-7%$KV
M,^'*U%5UE1G86KSOHZK&V?4MN_6\[52HK'QSGADI%)CCNU@CXS[!AJE"<Q.W
M3"-36N78L-!6IF&ID6E8L88\$T4!]P&Q9+U'VQX=B+4OD740$"ID;5`C1+%"
M"^,K0:M4(<M]IJW,:42ND1ES@0U+;64:5AKU/$Q%A?8!951!9T:SIFTVI%$P
M=I:J4%FQ-)(-V?DNGE"IAA[-!#']O(DI.-H$3=!SVM<E\)PIJX77.EXZB9^C
MWT*AP%Z5P6_)_09.I5$QOSQ+1:WZ@5C(TI9EJ416&H6T=(CPL"Q5R*R5L;8R
MLSS1R"1;JI#E/M-6)MERC4S#0B-[_LI.S,T!7*6M>K)4E)ZV,N))(H2\_24$
M95Z[%;$S5R*V``9CYW`R5`U9YFI?M()VCV=(A+B[Y:S-L,G,.5%+T'6JT/L'
M:EGG69W;3AW/.7HNM.=W^UPZGJ?.;*N88Y:]8E9`C#RK8KKM\*QUPW<"&ID3
M_A!1A"A&E"!*$66(<D0%HA)1Q1!7S-W(M/71+8=G].AUDUDC,Q%#A<1&RF0I
M')[IAGQ;9VH3WN6/;1@"W#`H9._1$46(8D0)HA11ABA'5"`J$54,<65Z-PS7
M#\\"W")H9(=26CFA=`_/=$,>2E.N\@Z[U?G[!20]0"#E)&*A!!2IAI95C"A!
ME"+*$.6("D0EHHHAKHPHC-VGC7?3X1F]%0*5%+*C*9$33>>L(=*^>#1-.<'[
M+.I3N\]7HBG,G556(BM.H2C-^+EGA"A&E"!*$66(<D0%HA)1Q1!71I29MC(W
M'Y[1*V4022$[F!+Q8,+AF?9%BG9K<3`V3U?>95$;V5V^$DQ92MF%('V!VD9.
M;&"D:_E!J?Q([U"?7NJPWN_/@VWS77PL2K74XWV'U9>LOK?Z(C]E=:[0:=E*
M'"N1<[CBTY6VQG*O!&/Z,+;=:L,5:D,+:X^W8$)7VG(0VLSH2EL[.E<B?[**
M:;.`WF@GOQ)[=;Q"6_.5V'WC%?J:]TMOSTB`_O'3\'O\K`/J;@__,B'_O:+0
MR/LZM)ZNZ&L=[&@T6]'G*SU\OHK;NLF1*9NOZ%..'OO%BCZ?0)XM5O0Q!/+(
M#TBZOJ'1.T_2J%<,CP9'KZ'0V]JCL-);C;XK"[K2]F#4#86^:W[;O-3_V)Q>
M=L?S8%\_4RJ/VS.ZD_PR6OYQ45\)?&TN]$4S+7OT02I]P5[3MZ!C\:;RN6DN
M^@^Z]:C[)O[Q?P```/__`P!02P,$%``&``@````A`,<84A&&!```H0\``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULK%?;CJLV%'VOU']`O)\0()`$
M)3G*C8O42E5UVCX3XB1H`$>8F<S\?;=M3'Q)TQFU+R$LMA=>:^]M[,7W][JR
MWE!+2MPL;7<TMBW4%/A8-N>E_<>/^-O,MDB7-\>\P@U:VA^(V-]7/_^TN.'V
MA5P0ZBQ@:,C2OG3=-7(<4EQ0G9,1OJ(&GIQP6^<=W+9GAUQ;E!_9H+IRO/$X
M=.J\;&S.$+6?X<"G4UF@'2Y>:]1TG*1%5=[!_,FEO!+!5A>?H:OS]N7U^JW`
M]14H#F55=A^,U+;J(LK.#6[S0P6ZW]U)7@AN=F/0UV718H)/W0CH'#Y14_/<
MF3O`M%H<2U!`;;=:=%K::S?*7-=V5@MFT)\ENA'IOT4N^):TY?&7LD'@-N2)
M9N"`\0L-S8X4@L&.,3IF&?BMM8[HE+]6W>_XEJ+R?.D@W0$HHL*BX\<.D0(<
M!9J1%U"F`E<P`?BUZI*6!CB2O[/KK3QVEZ7MAZ-@.O9="+<.B'1Q22EMJW@E
M':[_XD%,T4#B]21P[4F\X,LDDYX$KCV).YH%P22<33\_$XAD<N`JY'QY(M.>
M`ZX/)O+$!N@I]G*X"ALD!>9`A^>"I7:7=_EJT>*;!?T";I-K3KO/C>:V)7+*
M&88L_U.2(;N49$U9EC:H@/P1J,RWE3^9+IPWJ*:BC]F8,:X:L141M'0H[4X'
M]CH0ZT"B`ZD.9!+@@`F#$U!1_X,3E(4Z(31L!'"WQM-DBP@Q9*<#>QV(=2#1
M@50',@E09/NJ[,?-+/),@Z%MI3Q[KI;%#8_A"Q%+X]9`=@:R-Y#80!(#20TD
MDQ%%)_2ZF=X1[??N4A8O&\R7G@?Z?2AH7N:4`QH%K)3J?*:F<\.#`K:6<OT]
MPA<R5M@<":'A!B)W/E&)]D.0*(S80!(#20TDXTC`7J]8`MK_LR64@UDB)KGA
MB*R_1R3]')F.V5+AC5U=^O!<L,8]AS<T5C+$T.4&.'S5OG1X+CBRGL,T(E2-
M>%`#\(4214"#5<4<D17WB*2X1_QA_GL#B8U1B1&3&D@FCU+2"\NQG-[GJFBP
MJHHC/FP3AAKU]$1M>9`W'V3M'@QSYZ&:FST/"JBID#L_4!_'!FOR&=949=7>
MF<FDBD]T?VI\`K^X,E`.U3Z.^+`>2?9I0K=]T.1N'T>"^P=DWR,SYM4T'&M>
M&12)09$J%,%<9<AD!L486)YD8YX7$`U6'>!(<!>WY8A<+1P)[XVR[Y%[H\?&
MJ,08E1JC,GF4HLJ%BI9E\2W/%_/-2%2Y/12$0S*W/>3?+=CU4`AKT5`79G^(
MJ)`E?3[7ZB8VB1,QY"EQ*J(X\4SCS11>U36Z;7K2)3_P%>SXUWTBWWS!%U0L
MRAO8*-#"81;Q-_(#"-^EUJ@]HRVJ*F(5^)4>+F@?#"@_^.PF$7SV@%''@VC/
M#B(:G@01?!W,>#A`K=G,M/@-/5@]B-]X$6RK3)Z-'\$^Q,37DVC-]T7.\`8X
M(%WS,_HU;\]E0ZP*G4#CF%5CRX]8_*;K_3W@#HY&S.H+'(41;)/'(\CY">-.
MW,";G>%PO?H;``#__P,`4$L#!!0`!@`(````(0">2L%'$@8``-46```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*Q8VXZC1A!]CY1_0+RO,9B[;*_&
MW*6-%$6;Y)G!V$9CC`7,[>]3?8.^>&>]H[R,Q\=5ASY5U=5%K[^^M6?MI>Z'
MIKML='.QU+7Z4G7[YG+<Z']_3[_XNC:,Y65?GKM+O='?ZT'_NOW]M_5KUS\-
MI[H>-6"X#!O]-([7T#"&ZE2WY;#HKO4%?CET?5N.\+4_&L.UK\L]=FK/AK5<
MND9;-A>=,(3]/1S=X=!4==Q5SVU]&0E)7Y_+$=8_G)KKP-C:ZAZZMNR?GJ]?
MJJZ]`L5C<V[&=TRJ:VT5%L=+UY>/9]#]9MIEQ;CQ%X6^;:J^&[K#N``Z@RQ4
MU1P8@0%,V_6^`04H[%I?'S;Z@QD6IJ\;VS4.T#]-_3IP_VO#J7O-^F;_K;G4
M$&W($\K`8]<](=-BCR!P-A3O%&?@SU[;UX?R^3S^U;WF=7,\C9!N!Q0A8>'^
M/:Z'"B(*-`O+04Q5=X8%P%^M;5!I0$3*MXUNP8.;_7C:Z"MWX7C+E0GFVF,]
MC&F#*'6M>A[&KOV7&)F4BI#8E`0^*8FY\!W'=GWO?A*PQ"N!3TKB+&S+\?Q?
M68E'2>#S\RN!O8%7`I^4Q%Z8]M+]>40,$EV<K+@<R^VZ[UXUV`$0O^%:HOUD
MAH&NL2R1F$YY^U':(%^(Y`&Q;'30!AD9H-9>MBL[6!LO4!\5M=FI-J9H$3$+
M5`R(-I:!1`92&<AD()>!@@,,",(4"2BT_R$2B`5%@FG8,6`.C27)9A;,)9:!
M1`92&<AD()>!@@,$V2M1]NWMR?*,C&$C<GFV3$^4LR,V)MF(*(V1@L0*DBA(
MJB"9@N0*4O"(H!-:`)_>CW4B8]@1$+.YH)VE))08V?#!&<DU/1E-V5601$%2
M!<D4)%>0@D<$[="Y[M>.C+%VMN(=04`H0R(%B14D49!403(%R16DX!%!E2NJ
M(JUK@1K[>&JJIUU'CH<;F5Y!BR*-"W&(8@GBX,,-VT04F0LZ)H@+_7+*O!G8
M8GDDDQ&+6JH@F8+D"E(0Q,&/%_1#N^6S^BG]B$/43Q!>/T4X_03QEKC36TM3
MEC[]/DFG'-940MED@TX+X%B)X<NGWQE'03G40*"1D3O#;B0<#DB6<60L*B8(
MKY@BG&**K*;U)PJ2*EZ98I,K2,%[">F%ZKI?%3(651'$@9XPU:AEN6*0(V)D
M!9.L^(:;&4AN"3'R39Q_TY=Z7JJP9@19P1`Y+49AS4565WIHP;,*@3*!]OY(
M86LQ5!1:\;%RI,='LQ$KR%B%$@KY%@Y-8$E5G:HN&8/P+(X[3BZRF+8T,13,
M!7=D,19HNKE[+\`A+9<-A:2ZD<[XB%KQA3,[LO@D%*)UXGIRG:@L&86@4AA+
M/K/,Q6,MI993"%QB2-#DPX7D4WT2C0+2!J.04#66Y4L[;+9B@F(*^5PS89!-
M=I14>ZE*DC&/F21G$"%1`D04P')A(6*`T,S$!>CC_FG2"6MNY3L*<4F+*"04
M"''TYA4GU,J=N5+5,6-6<SO.&30[%H*CJ`_-19P^5`"6B]XZ?_`RRHX*DPQ4
M$%>6NQV%5J!EZF26);WJ1,QJGIAB"CGNQ)50R$=GT\O6]`)E?Y#GDY3ASI`Q
MYCF(.84\%]/`Z[%8@05SN9%X-%I)@3&=7YR@T#N]O#,()+1[:R6-SQ%U%$J$
M./I\D"CD875?;D6)6'`\&:7V^99*>0+"<R-,/(U8/V@"X\+TD_U!YC6A:`@$
M1</J*#(IQ%<(@8*Y]274*I@K/U4=,V8UEVG.H-FQ$!Q%?6BPXO1]KD&2Z4R0
M32"I#*0BCTQBQ:4OIE#`;S)E7$B8%7]J*^="JM)GS!$2/NUAA3YG5A_2%P*]
M&%4TV'T0U>_=%::0G[8@,AX*8240MYW)'1RYUFGK_EA']?D\:%7WC.[78%C8
MKB>87/[%;@AO&E"-,NZ%";Z[D/#,"V$@5^WA$O$!EYUDOT.7BS?L=U8(%Q$J
MSVX5PIN[BC_8X0.YI)0?8(?PNJLZ[)P07A@!-R8'N%2\EL?ZC[(_-I=!.]<'
M",H2=[F>7$N2+R--R&,WPG4BSLT)KH]KN,%8+J!6#ETWLB_H`=.%]/8_````
M__\#`%!+`P04``8`"````"$`F'C8E)4$``"F#P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6RL5]MNJT84?:_4?T"\'V.,P3:R?>0+-^E4JJK3]AGC
ML8T"C`4D3OZ^>VYX+DZ:J'T)87G/FEEK[SW,++^_UI7U@MJNQ,W*=D=CVT)-
M@8]E<U[9?_Z,O\UMJ^OSYIA7N$$K^PUU]O?UK[\L;[A]ZBX(]18P--W*OO3]
M-72<KKB@.N]&^(H:^.6$VSKOX;4].]VU1?F1#JHK9S(>!TZ=EXW-&,+V,QSX
M="H+M,?%<XV:GI&TJ,I[6']W*:^=8*N+S]#5>?OT?/U6X/H*%(>R*OLW2FI;
M=1%FYP:W^:$"W:_N-"\$-WTQZ.NR:'&'3_T(Z!RV4%/SPEDXP+1>'DM00&RW
M6G1:V1LWS%S7=M9+:M!?);IUTO]6=\&WI"V//\H&@=N0)Y*!`\9/)#0[$@@&
M.\;HF&;@]]8ZHE/^7/5_X%N*RO.EAW3[H(@("X]O>]05X"C0C"8^82IP!0N`
MOU9=DM(`1_)7^KR5Q_ZRLKU@Y,_&G@OAU@%U?5P22MLJGKL>UW^S(*IH()EP
M$GAR$G<Q<J?CX`L<4\X!3\$QFOO^-)C//K\0B*1JX"G4?%G,C'/`\\%"/G`!
M6HI.#D\^<"(I,`<Z+!4TL_N\S]?+%M\L:!<PN[OFI/G<<&%;(J6,84CR>SF&
MY!*2#6%9V:`"TM=!8;ZLO:FW=%Z@F`H>LS5C7#5B)R)(Y1#:O0Y$.A#K0*(#
MJ0YD$N"`"8,34%#_@Q.$A3@A-&P%<+=FHLD6$6+(7@<B'8AU(-&!5`<R"5!D
M>Z9L#W:&QSTM\DT&0?=*^7876C:W+(;M1S2=.P/9&TAD(+&!)`:2&D@F(XI>
MZ'DSS2/2]_VE+)ZVF.U`#_1[4-BLW`D'-`Q8*M7[5$WKE@7Y=$ME^CG"]C-:
MX`P)H/$&(G>A$45#D"B0V$`2`TD-)&.(3Z=7+`'M_]D2PD$M$8O<,D36SQ%)
M/T-F8[IE3,:N+GWX7;#&G&,R-%@RQ)!M!SBT?2<=?A<<&><PC0A4(Q[4`'QD
M1!&08%4Q0V3%')$4<\0;UA\92&R,2HR8U$`R>9227MB6Y?1^K(H$JZH8XD/U
M2#7JJ\6^8T&3Q2!KSQ"RE4C#`G58Q+F)J2_KA9:YV"!-."E(?9\TY4$S5E3:
ME)E,JMA$3JG&E_"+&P/A4-UCB*^N>*;:L&-!WO3N'A]V_XY$')E35>Y<VVUC
M@R+A`^XI21D2L&[3S,YD`L47V)QD7SXN'Q*L&L`0*!_1?CN&R+7"D.#>)A%'
M[FT>&Z,2'G-OI90C][DR>92BRH7"E&6Q@\\7TTU)5+D<@H0/>CDDIY=#`>Q$
M[Q=R)*("5LDS;7>,3>)$#($J?Y\X%5&LF"8+M1PSA5=UC1R>/FB2G_@*=OS;
MZ0'.!'J5<(AFCLW(;B'LK%JC]HQVJ*HZJ\#/Y(9!5CZ@[/:SGX;PT0/7==P/
M(WH;T?#$#^';8,;#+6I#ZTZ+WY+;U8/X[22$PY7)L_5".(68^&8:;MBIR!EF
M@%O2-3^CW_+V7#:=5:$3:!S3:FS9/8N]]-S?`^[A?D2MOL!]&,%A>3R"8CIA
MW(L7F-D9;MCK?P```/__`P!02P,$%``&``@````A`/6<5K&%`P``WPH``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK%9=;YLP%'V?M/^`>"\$$I*`
MDE1)4;=*FS1-^WAVP$FL`D:VT[3_?O=B(!C2-I7V$N#D^OC<<^UK+VZ?\\QZ
MHD(R7BQMSQG9%BT2GK)BO[1__[J_F=N65*1(2<8+NK1?J+1O5Y\_+4Y</,H#
MI<H"AD(N[8-29>2Z,CG0G$B'E[2`?W9<Y$3!I]B[LA24I-6@/'/]T6CJYH05
MMF:(Q#4<?+=C"8UY<LQIH32)H!E1H%\>6"D;MCRYABXGXO%8WB0\+X%BRS*F
M7BI2V\J3Z&%?<$&V&>3][$U(TG!7'P/ZG"6"2[Y3#M"Y6N@PY]`-76!:+5(&
M&:#MEJ"[I;WVHMCS;'>UJ`SZP^A)=MXM>>"G+X*EWUA!P6VH$U9@R_DCACZD
M",%@=S#ZOJK`#V&E=$>.F?K)3U\IVQ\4E#N`C#"Q*'V)J4S`4:!Q_`"9$IZ!
M`/BU<H9+`QPAS]7SQ%)U6-I^Z/CSP`NF$&]MJ53W##EM*SE*Q?._.JI*J67Q
M:Q9XUBRA,_&#V=S[`,FX)H%G(P5$?U3*I&:!9\TRGCK!;#2^0HJKS:F\CHDB
MJX7@)PL6,&0O2X+;P8N`N#%9.]+:_IKK8#>2K)%E:<]L"_R4L%2>5F,O7+A/
M4-ZDCMD,8SPSXJZ)P%HB;=P!7-#;BH9B_`?1R(*BF^DV#7#.PN\I;"*:(7$'
M,!1"I;L*+Z_9QCT,7MKP>W;/'YDS;W2,WF^5.7<#).XBAAHH[/5J,!A6`V36
MD=,KU:8.,C7WW;H4U%D6AD38D==+Q.!*8E.'38W,VV+>#9"XBQAS3\VY<0^,
MY]A47NDU3=UPG"E#(W[5V'256@0W1<_%N":`1\?J<5MY0R1LKNL-PF!3F48F
MD[-!`R3N(L;<>*3VFL0<>NF[!N$X4X9&N@:U"!K46T%Q36`:-+EL4&B*?'O+
M8;"I3"/A]&S0`(F[B&&0!Z=;WZ$`NM?;(JI1IHH:ZAITAJJ^VB9?MTB<&3A,
MBX(VRI2)#;53R'?DZ?8+G:#=9M!_<+9J%6EF?7SK(R6G8D_O:)9)*^%'/)KG
M<!:T:'MM6%>,/7R#UPF<J8_[$739"_@X@H8WQ->3:*W;9)\HB*`%#`=L9A&L
M_`MX&$'!`7=;(KA>E&1/OQ.Q9X6T,KJ#'$?.##:"T!<4_:%X"26!.P97<*^H
M7@]PD:1PIHT<"-YQKIH/G*"]FJ[^`0``__\#`%!+`P04``8`"````"$`MDC1
MK'L-```:1P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6RLG-MN([D1
MAN\#Y!T$W:_E/DHV;"_433)9(`&"((=KC2S;PEB6(6D.^_8IGIHL_AR/6MF;
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MLWU^.=%R-^21=NSV\7>Q.:XIHC3,5=GHD=;[5YH`_3O9;75J4$16W\W/;]O'
MT\O]M&JOFOEU59#YY-/F>%);/>1TLOYR/.UW_[5&A1O*#E*Z0>AG&*2HKUL]
MQ@?]*M>/?OI^5XNFJ=O%_...M>M(/WW':-8?_$4:UKA+/WW'\_YBZSK23]>Q
MJ*[*15,T/W!R9@-MUDVL3JN'N\/^VX0V`X7R^+[26ZNXI='\@ME)#TOXHQ6D
MI=.#+/4H]]/Y=$*+<Z2T^_I0E>W=["NERMK9=&A3<(O>6^B\T,.*%,@4J`C,
MR*/!+5K[/\`M/8IVRT^H\R#X628^>`O?1:1`ID!%@/E`>1C[D-]#?@6T,>V6
M:`6**HEO9VT*NUMT@'L@`H@$HF+"9DP;X/P9:V/*.O(^2IHY#V=GC4ISZIB<
MZ`<2NA5ES;L)-S8E]#!V436#$9LT;;[S)ZV-S:3]^G:.A"3I@0@@$HB*"9L?
M.1'/3^_0.1TO_B@[>X_J<?C4+:EI.:,H)=NV'XR\QP*(!*)BPKRA,R+VYN.D
MUL9\RI;41H3B_:X+B.@8^WA8;0R9MQBRP^19YXSXF7;#C?K!:`@.$`E$Q80%
MYV:,%]J8!\>1=CBO>D<H6<(*IP>S&+I%1E4(!YMA027!^8$VUGR.'D7[!9%`
M)!$IAO@TM2Y$^6!DK9Q?L&OHM$S#[%"R;]+4"%9#;B"2B!1#W"NM%)%7'V>Y
M/EF3!'&(9N[GU",2B"0BQ1"?IM:':)H7GUB%$YIRF&[G$(]]?9ULRV#E_12(
M)"+%$'=*2TKDU$]B[P0HGKE%>'3I^GC$R$XGF&Q620`Z,^;]M(RD/J!HFY=A
MF[N*RPY?QL,7=2@D>$ST*7]^3*PF4-[X1>D*B]@T`0EO93KR"21JHC.MK:Y"
MN7ZV.!8H-0XEJ9;6>\'*>R40242*(>Z5UH?SP^K4)`YK+#"V:BH`"402D6*(
M3U/K1C3-_R/X3H%B%RQ*@E^E^WRP"L$')`M`BB'F%96:S*N/][FQY@+G$.YS
MRO(Q(P^Z$[9K!16]&9/V>50?!Q0Z%G5:(.>M?E`AZ],@7NF?Q`1UQPQ`88I$
M'Y%`)!$IAOC2972G;"[0_!)UQZ$D']-:.5@-^8A((E(,<:=&Z4Z)NN-0)A]'
MZ8Z^=P)%<Y6<AIVS8OGH%(7V5:A!ZU1W0L?8*M14/":C=*=$W?$HSD=G%9!`
M*XE(,<2GF5&G:J%O?+F[4&>K4XGJY!!/R":I`_I@%1+2CD4=/9)HI1CB7HU2
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M@E`IV?HZ6/F.PJ.P#-*CQMXB3W:'\LUX-%:C%,]8)P>,E3?=$GF1UB^N(XN_
M[1BMDO16<^-%D81"N6;;@Z]%(HB97"=Q')(=1:^RJ")1B;Q([AGWWBIL">%1
MO!9NK!OC11()Q3IP)T;IGYYJ<A/&H3JZ38=(()*(%$-\FHF8ZK-^<7-)\5$-
M0NM3NW,H.>R3FJX/5KZC0"01*8:85_H`.[]$,-9\'SB$.ZQ.M/'CW#369N20
MB%65G*>=MXJ4Q:&D^`AUKCVN?4>V6]M0W/&8C!)`*C'2A'2H#INC1R00242*
M(3[-1`!_$F!4.IUMM)5XTK5)W=8'JR'I$$E$BB$^\U%*1V&$`%N42;I1XD05
MBALY3KKD^.V\59QTMB-/NC;4LB[IW/`\Z8)&\9AH63B[5J>S#F)B$4LZ0,)U
MC*PD(L40GV:B./H4O.P2K$8U<D@G3E"C-CD$^F`5$M*.11T]DFBE&.)>C9*@
M&B7(H4Q")JKQDTTZ*$,(0%4E4MK5SBI.2(N2A$PR6?B.E!91?,/P+";-*&4P
MUEP9'(I2K4<D$$E$BB$^S41F+K]IVN`UF$-)0J;E4;#RV2<0242*(>[5*`EJ
M4((<HI3W<^H1"402D6*(3S.1(!W\BSY*;U"='$IBGY9$P<K[*1!)1(HA[M0H
M=6I0G1S"PZ`9I4[&&DJB)/DZ;Q4=!@XEAT%:$OF.[#"8_Z`D:K22G*U.QCHY
M#$"*>F<5G0\"D42D&.)+EU&GB^['-"A.#O%\G*?54K`*^8CBA%:*(>[4*'%J
M4)P<BM2Q1R00242*(3[-1.DNKPR:005]##N'DN`G!5<?K'Q'@4@B4@PQK]I1
M*FBL>>([%`<?D4`D$2F&^#0S*GA1XK<H@@XEL0]EK+U?$ZR&V".2B!1#W*E1
M(MBB"#J$!W&;Z-;'59FQAH,X4:+.6T4'L4/\()XG]:SP'?E!'&HW'I-1XM2B
M.'ED[C^ZI7-6`0FTDH@40WR:HY2N=1=*X?YCYQ&=9J%4G8=2U<W<=8QG#DB&
ML7QJ*H;XS$<I76ME+7X$PZ,PIQZ10"01*8;X-/\HI6M1Z3SBL4\*CSY8^:@*
M1!*18H@[-4KI6E0ZAS(;/A&GGVSX08!"\E554D!UK;.*-[Q%R89/3@KA._(-
M'X9G,9F/$B!CS07(H:C,ZA$)1!*18HA/,R-`^O)FY&/O<Y0?A[C\+$*=:D^"
M8#5D(R*)2#'$71HE/W.4'X=BZ4<D$$E$BB$^S43+=-UUD?3/\1K,H23V:<T;
MK$+L[5B1ZQ*M%$/<J5$R-T>9<PA/`OTHV_E7,L8ZE?[TZ<C.6T4G@4/\)%@D
M!:OP'=E)L`BE%8_)*&6:HS(Y1/>J_#KUB`0BB4@QQ*>94::+[@G,49D<2O(Q
M*:CZ8.7]%(@D(L40=VJ4,LU1F1R*-D2/2""2B!1#?)J)S%U^%@P*Z$/8S2U*
M8A_*5'<.#U:^HP@=/9*(%$/,J<4H!3367`$=BF./2""2B!1#?)H9!;SLSO@"
M1=`A?0,WE,.+M!P.5C[2`I%$I!CB7HT2P06*H$,L^-8J0@*M)"+%$)]F1@0O
M##ZJX,*)&0]^6@\'JQ#\H:-'$JT40]RK42JX0!5T*(ITCT@@DH@40WR:HR1U
MX2[0HHL]AY+L3LKF/ECY:`I$$I%BB,]\E*0N4%(=8@&V5A$2:"41*8;X-#.2
M>MFC!PO45(>2X(>K$7NN!ZL0?#L6=?1(HI5BB'LU2E/I)>OT$T^'HAK/OD9M
M7\?=;0[/FW[S^GJ<K/=?]"O25!,^W`W8OK_=+5IZ@=L\.0(M<VHQGY]`RS6U
MF$>JH$6_#FZ>K(*6DEI,SD-+12WFDTMHJ:G%N`<M#;68<C-I6;8WMTMRE)8D
M:>GF-&NZ@,NUT*SI.BC70K.F2X]<"\V:ZG=L6<Z;VZ5])1YF0+&FPA'[='.*
M-55?N98%M9B*%4:[H1:3?&E+2Y[2O=+,:"UY2C<<L6795K=+NGV`+5U+JT!W
MNG(MM`IT)RG70I[2S9M<"WE*=T"P95G3RM%'1]C2->0/?0*::R%_Z#([UT(K
M1Q_<Y5IHY>C3+VQ9-K1R=,\46[J&_*&/77(MY`]]=I%KH96CCPMR+;1R=,L=
M6Y9U<;NT=RK2-:W)'WH6!OMT-?EC3]NDS[(F?^S53M+2U>0//>20&XW\L9^:
M)GV6)8U&CUIG^I0T&CVUGFNAT>C);VQ9EK3:].P4MG05K;9]8#"9`3T23"W9
MU:XH.O2H;&XT6@5ZJ"W70JM`#X9AR[+0GF;G5I`_]J63=&X%_1UZM0E'ZPKZ
M._1Z$+8L2UIM>IL"6[J2_*'W4G(MM-KVV=QT!GK+97HL%[?+(OM':,;Y"=,"
MT)NPF3]>T`+0VZ2Y%IJPO0N<3JN@"=-;D+D^S:U^80];>EJ`/MLBJ$6_OH=]
M1%7=ZN>-L86^HF29#:5V)F/?Z=CG.#F2';\FQ<G9T^EH#L?9$!+Z9I+WU?/F
M[ZO#\_;M.'G=/)$L7YMGM@_VNTWL+Z?].UW"T?>3[$_TG23FOR_T'30;^H:%
M:_WZT=-^?_*_D,.SX5MM'OX'``#__P,`4$L#!!0`!@`(````(0`:*#B6@P8`
M`/08```9````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;*Q9R8[;1A"]!\@_
M$+Q;W$1J@23#X@XD0!`XR9E#41(QHBB0G!G[[U/-ZF9OFL5.+I;U6/W8]6KI
M4L_F\[?F8CQ775^WUZWIS&S3J*YE>ZBOIZWYU]?DT](T^J&X'HI+>ZVVYO>J
M-S_O?OUE\])VC_VYJ@8#&*[]UCP/PVUM67UYKIJBG[6WZ@I/CFW7%`-\[4Y6
M?^NJXC`N:BZ6:]N!U13UU42&=?<1CO9XK,LJ:LNGIKH.2-)5EV*`_??G^M8S
MMJ;\"%U3=(]/MT]EV]R`XJ&^U,/WD=0TFG*=GZYM5SQ<P.]OSKPH&??X1:-O
MZK)K^_8XS(#.PHWJ/J^LE05,N\VA!@^([$97';?F%V>=N[9I[3:C0'_7U4LO
M_-_HS^U+VM6'W^IK!6I#G$@$'MKVD9CF!P+!8DM;G8P1^*,S#M6Q>+H,?[8O
M656?S@.$VP>/B&/KP_>HZDM0%&AFKD^8RO8"&X!_C:8FJ0&*%-_&SY?Z,)RW
MIA?,_(7M.6!N/%3]D-2$TC3*IWYHFW_0R*%42.)2$OBD)&XP<^9V\`,<<\H!
MGY3#F2U]?QXL%["1-UX.3T</X).]_&,+%W0A?+*%;[X(2F9\$7PR^]G"L5?>
M_0U:J/08N*@8BMVF:U\,J`;0LK\5I+:<]<HT6,30Q2F&KX408D=(OA"6K0E[
MA^CTD'?/.V_N;ZQGR)62VNQU&T>V")D%20Q"&ZE`K`*)"J0JD*E`+@`6B#`I
M`?GR/RA!6(@2S(<]`[@TKN(VLV!+(A6(52!1@50%,A7(!4!RV]/=]J#P[Y<L
MBS=9!,4IQ-M9K62W]FCC8'&2<(8:$FE(K"&)AJ0:DFE(+B*2OU#2>IAGI&J&
M<UT^[EML,'?\]R"Q,=T)!Q0,2"KD>Z#XCT:N-Z5"2)'EA$2(S$'OB<A9S66B
M>#)B"9)H2*HAF8;DB+CCZR5)P/?_+`GA&"5AF]PC(OI/$<%_1);VV#)<VU%=
MGYXSU@21A3MIF$XVI.T`AR?+ETW/&4>.R!TA`EF(.SD`9PA+`F(L>XP(J9XI
MFJZM;"=$(W<U.1`ALN")$E-D/MDDVJH4$8^75T81+DTNKI(B#IU:C/C;CA)C
MV5%$QIIA_=[QE7X?HI''G8@H`J4YZ>.LE+*)*7<PIH2C-)5$(TTI`N?@ZZ09
M-5IAGLD)DHN<DDID+!7.QK=5(L:R2H@L@)[OS%?<#=%(3`=$O&`*?DR1!4JB
MU$BB,:0:0S8Q\*VXMD*4BT22#C`7B#K@C/"#+9-PR/(@LH"W"O(LY-B$:"0F
M$2(^KY\8D0";B*><KHG&D&H,V<3`MZ++(Q))\CA0\*(^;^?):"TK02%H'*Q%
MA102\X)"`:_XF$&\Y!-]8<JL>(/)&,2+,Y<6ROZ1B4FH@Y^*/\P!:@)0R./[
M"AG$]Q51R.<C5<R@Y5@0@=)X$ITD92MXUF04HFFC9$TN<<AJD$%*4..=:./8
M!:,""^V>C`U0"LHQH3@14BLI`7"AE``4XO2)OC"E4,"%SAC$A<ZEA;++9)CZ
MN,MT].)[VCL(O7-@4"NQV!G$=QXS+CP@E-,U80NX7RF#^-B1,0A*>NH]KJVT
MYIQ9C5RR(&24^K@@.'B!OCP'$%J(&W"TL\&A$QO/VHA"0JN(*>23R>1YI_RF
M2G2.E''P$R9CD'A6Z1U0XI(%(2.5(,C/M0B<RR2=$%(21STDR!4#J2@>](A"
M4M=`*Q^[AJ:3QI$R#BY_1B%H&F+BJ`>IM!]9)S*1"3J]TSQP?I,$H4.>>%2(
M4Q[]W8R0U"DHQ),P<;2%*86D3D$7<G%S::'L'YFE!/]^+@]P()/<1@B."E%W
M+0^H%=]JY"`40'2G2M=G3F:%/26PY2$DH8^%_$K9"J!_G3=C5IARVADC;E>6
MD8QB;\CXM;W!!/'>CW0'!SI)1X3F_#`-J94`13H4ZU"B0ZD.93J42Y#L-YFQ
M!+_?*0^<R"3_$)J+X7;MI1S/T)FL6$..="C6H42'4AW*="B7(,EEN([]`9='
M:WEXI)!P2.'U+-[R-55WJL+J<NF-LGTB5Z\PY^TV$XSWPM%\#?<%((:*^^MX
MO*=5\-1?P\]JW1[NE[^,#4:QW\.]\SBVJK@+]]%W>/;>&BYP[O#/@7]L?2J1
MLX0WC">\]F0%3\86;DV/X,[Y5IRJWXON5%][XU(=01A[_$73X:TU?AEHG3VT
M`]PVCR5WAK\N5'"99<\@QXYM.[`OL%MK^GO%[E\```#__P,`4$L#!!0`!@`(
M````(0"!@9NT^@,``((,```9````>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;*Q7VXZK-A1]K]1_0+R?$"Y))BC)40C0'NE4JJI>GAEP$C2`(^Q,9OZ^RS9F
M#*335.K+$!9[+Z]]LSV;KV]U9;V2EI6TV=KN;&Y;I,EI43:GK?W'[^F7)]MB
M/&N*K*(-V=KOA-E?=S_^L+G1]H6=">$6&!JVM<^<7T+'8?F9U!F;T0MI\.5(
MVSKC>&U/#KNT)"ND4UTYWGR^=.JL;&S%$+:/<-#CL<Q)3/-K31JN2%I291SZ
MV;F\,,U6YX_0U5G[<KU\R6E]`<5S697\79+:5IV'WTX-;;/G"G&_N4&6:V[Y
M,J&OR[REC![Y#'2.$CJ->>VL'3#M-D6)"$3:K98<M_;>#5/7M9W=1B;HSY+<
MF/';8F=Z^ZDMB^]E0Y!MU$E4X)G2%V'ZK1`0G)V)=RHK\&MK%>2872O^&[W]
M3,K3F:/<"T0D`@N+]YBP'!D%S<Q;"*:<5A"`OU9=BM9`1K(W^;R5!3]O;7\Y
M6ZSFO@MSZYDPGI:"TK;R*^.T_DL9R8AZ$J\CP?,.R2>.?N<8](Z>._.>%NYB
M*9;_Q!-?I6X\NR67CSDN.T<\.\=_6=)1&9,%B#.>[38MO5GH:N2$73(Q(VX(
M-IUY);JOQ3^5`C40)'O!LK57MH4L,_3/Z\X/W(WSBIKGG4TTM1E9'+2%*+"@
MC<=`,@92`W`041\6BO@_A"581%A:4*2!CSB]890';:%=XC&0C('4``8QH*_,
M&.X/@ZZ`,$;;&Q5P_5%^(V6C!EDF^#!!X@F23)#41`:*,0&F8M%,WF+6S\##
M[21XT)!(C-%/HTQ'RB@`>V_D+OQ1.7JCOAX3))D@J8D,`L1B9H"?ET08RRCT
MVI%"(%DCAPD23Y!D@J0F,M"'"3;UJ6F>K6#/SV7^$E&D"B-S1[>/J56S+#B&
MLA7B^1^R.R3HD5@A`;9^HQK!L!I);Z3C3SNB)T$TB`1[B1G)'<786[5D83R4
MK!!OW0L\*,27!Y':73I$G0)BOTDZQ.N]4I-GH$]</8Q]\W-]PGBH3R$^)LE(
MUV*8KD-OI-,5=\A'WI,.$;G`ICMJ_]2T'\A?_Q?YPG@H7R$^JF?(7X[D=T9&
MQA5B5"7I;%92OCM*0&K:#^2[Z+/'TR^MAP%TD(\$&1&L1A%HJX_.CS5DE$!#
M:QG$*`NI_BH=AD&(P^OA'L*V/:Y"!QG,ZH:E#OB:M"=R(%7%K)Q>Q>WI"0)[
M5-WLXF6(J41_C7#<^/9R#$9X)&Z"=^PC+\0Y-N6)_!#'Q13?!^%>'43C!8(0
MV^_4(5J$V/:`.[T#;H"7[$1^R=I3V3"K(D?$.)>[7:OND.J%TPN*CWL@Y;C[
MR9]GW/4))GXN#J<CI5R_B`7Z_QYV?P,``/__`P!02P,$%``&``@````A`"'F
M.:--`P``\0L``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@``$`````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````G%9=;YLP%'V?M/\0\;Z2MM$T583*
M)4YCB0(#IUN?+(\X#2J%"+M1NU^_"R1MTMU8W5Z0L>_'N><>S/4NGQ_+P48U
MNJBKL7-Z,G0&JLKK15'=CYTYGW[YY@RTD=5"EG6EQLZ+TLZE__F3ES3U6C6F
M4'H`(2H]=E;&K"]<5^<K]2CU"1Q7<+*LFT=IX+6Y=^OELLC5I,Z?'E5EW+/A
M\*NKGHVJ%FKQ9?T:T.DC7FS,_P9=U'F+3]_RES4`]CVR7I=%+@U4Z=\4>5/K
M>FD&]#E7I>?N'WJ`+E/Y4U.8%W_HN?NO7I;+4@40V%_*4BO/?=OP9DJVI"6R
M:+3O;<S%1N6F;@:Z^`VTG3F#7U*K%L[8V<BFD)4!6*U9_]*MR[4VC?^C;A[T
M2BFC/1<,^LUNN6^[ORY&_NA;9P&K0\LV0H\$#@XQ\L*42L?+1#8&@3R"SK]A
M[E#TB'M`NRX*4BT$K0SP)5C5=[NH]Y&_UG!%0A(%5&0S2GGV`1,!T$`H*V6@
M=]"HUT@M<3V,C!-.;VC$,Q%/19S0E'`61WCT0^-@1J)KF@D6`2*2T@_$?^]R
M^A$?DLW$-(Q_X)BN:0280SP0NX[8E`4DXH($03R/.(NN11*'+&`XWI0&E-V2
MJQ`*(]%$)"E-")L(^C.A1UA)TI8V?M?9T^]SEK1\BHAR%%3,9S3=P<E$0N[:
M;*@IBX+XA@I.?E*\^"#N*FK3A8Q<L9!QM@4.GFC,KE6S.)S0-!,M6GZ'VJ4T
M!&4``:0M;2N]GA.>$M1ERB+0)R/AEJU.&UT%Q[C(YE<98&CQTUMXXE5FUC8>
MT9#5YPS%;^\]GN=X\P67O]`TN`!:<[A.4(]]'=CL['+`"T#T8$MAEP6>PJH+
M@5:\_:K%1!E9E%IP^,T]';O"K*T^1^/;)35"?>SRP"5ED0>4AJ:QN^`,'Y'4
MECTTS8&F_M70V@^["G&>[#Y'>MC^=`YOLIU>T(HQI>_TA=-J\\#KL'EPA<*R
M?U%X&KL/3I?=!Y>\_<L]0MK[.WW7E$XT^Q0<S%;OIJFPJ![T?,WKB31J-RX>
M;GK9"L:;!0Q2N_.W#6\&DV)3MD&"E:SNU6)G\_=!.]S>]A.\?SHZ&9X/86[=
MV_/<MUG=_P,``/__`P!02P,$%``&``@````A`!R$&OZ5````J0```!````!X
M;"]C86QC0VAA:6XN>&UL/(Y!"@(Q$`3O@G\(<W=G];"()%E0\`7Z@)`=32"9
M+)D@^GOCQ4M#T5#=>G[GI%Y4)18VL!]&4,2^+)&?!NZWZ^X(2IKCQ:7"9.!#
M`K/=;K1WR5^"BZRZ@<5`:&T](8H/E)T,927NS:/4[%K'^D19*[E%`E'+"0_C
M.&'N`K#:JVK@/(&*_0.H]$NT&O\C]@L``/__`P!02P,$%``&``@````A`!@A
M+JTR`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````)R17TO#,!3%WP6_0\E[FV;%/Y0V
M`Y4].1"<*+[%Y&X+-FG(C7;[]J9=5R?Z).0EG'-_.?>DFN],DWR"1]W:FK`L
M)PE8V2IM-S5Y6BW2:Y)@$%:)IK50DST@F?/SLTJZ4K8>'GSKP`<-F$22Q5*Z
MFFQ#<"6E*+=@!&;18:.X;KT1(5[]ACHAW\4&Z"S/+ZF!()0(@O;`U$U$,B*5
MG)#NPS<#0$D*#1BP`2G+&/WV!O`&_QP8E!.GT6'OXDYCW%.VD@=Q<N]03\:N
MZ[*N&&+$_(R^+.\?AU53;?NN)!#>]],(#,M8Y5J#NMGSW9MO$L1M17]KE9)#
MNE)Z$`%4$M\K#^F.RG-Q>[=:$#[+V46:%VG!5FQ6QE-<O5;TZ!KG^00T8X!_
M$X\`/N3^^>?\"P``__\#`%!+`0(M`!0`!@`(````(0#A_+]<%@(``"\>```3
M``````````````````````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&
M``@````A`+55,"/U````3`(```L`````````````````3P0``%]R96QS+RYR
M96QS4$L!`BT`%``&``@````A`,U/P]Y%`@``=!T``!H`````````````````
M=0<``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&``@````A
M`,;!]CDI!```U@X```\`````````````````^@H``'AL+W=O<FMB;V]K+GAM
M;%!+`0(M`!0`!@`(````(0#@;"XKJ0,``&H+```8`````````````````%`/
M``!X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"+0`4``8`"````"$`3F)L
MO[0"``#4!@``&0`````````````````O$P``>&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+`0(M`!0`!@`(````(0"3?NB/EP(``)8&```9````````````
M`````!H6``!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!`BT`%``&``@`
M```A`-(NSX3G`@``"P@``!D`````````````````Z!@``'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"+0`4``8`"````"$`H`=EM;$#``!E#```&0``
M```````````````&'```>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+`0(M
M`!0`!@`(````(0!7\"FM(P,``"8)```9`````````````````.X?``!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L!`BT`%``&``@````A`%[1\P&N`@``
MW`8``!D`````````````````2",``'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"+0`4``8`"````"$`P0KSARD#``#9"```&0`````````````````M
M)@``>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+`0(M`!0`!@`(````(0`M
M`_B^8`0``.8/```9`````````````````(TI``!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L!`BT`%``&``@````A`#\#O-ZN`@``X@8``!D`````````
M````````)"X``'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"+0`4``8`
M"````"$`MH#L9(,"``"C!@``&0`````````````````),0``>&PO=V]R:W-H
M965T<R]S:&5E=#,Q+GAM;%!+`0(M`!0`!@`(````(0"4R<(2PP(``#X'```9
M`````````````````,,S``!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L!
M`BT`%``&``@````A`'W;V2/F`@``$P@``!D`````````````````O38``'AL
M+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"+0`4``8`"````"$`"FKT6PX(
M```R)P``&0````````````````#:.0``>&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;%!+`0(M`!0`!@`(````(0"?&@\?FPX``)">```-````````````````
M`!]"``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`%LSAEUJ-```5Z\`
M`!0`````````````````Y5```'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`
M%``&``@````A`-/C.3-T`@``-@8``!@`````````````````@84``'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0`_3?@G9`0``/8/
M```8`````````````````"N(``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"+0`4``8`"````"$`^V*E;90&``"G&P``$P````````````````#%C```
M>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0#1_PA5!`0``)`-
M```9`````````````````(J3``!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL
M4$L!`BT`%``&``@````A`$TW^MUS!```#!```!D`````````````````Q9<`
M`'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"+0`4``8`"````"$`$-`T
MAYL$```]$@``&0````````````````!OG```>&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;%!+`0(M`!0`!@`(````(0"G7;?QOP0``!42```9````````````
M`````$&A``!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!`BT`%``&``@`
M```A`%YPKF`]!```W0X``!D`````````````````-Z8``'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"+0`4``8`"````"$`1H'))(,#``"D"P``&```
M``````````````"KJ@``>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`
M%``&``@````A`%%3>D64`@``QP<``!D`````````````````9*X``'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`@X;0[S\(``#W
M(@``&0`````````````````OL0``>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;%!+`0(M`!0`!@`(````(0"+GPRI-`<``%T=```9`````````````````*6Y
M``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`BT`%``&``@````A`!;<
MX@WA!```C!$``!D`````````````````$,$``'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"+0`4``8`"````"$`'LN&PPH)``#:)P``&0``````````
M```````HQ@``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(
M````(0`>4QP>U`4``-\5```9`````````````````&G/``!X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A`-%-;E'J!```=1$``!D`
M````````````````=-4``'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M+0`4``8`"````"$`#@<#W^X-``#K2P``&`````````````````"5V@``>&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`BT`%``&``@````A`-N2@WR``P``
M_@H``!@`````````````````N>@``'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+`0(M`!0`!@`(````(0`#/]'G"P8``/X7```8`````````````````&_L
M``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`.>FS
M`2,#``!0"0``&`````````````````"P\@``>&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L!`BT`%``&``@````A``I`A.8N!P``@"```!@`````````````
M````"?8``'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+`0(M`!0`!@`(````
M(0"_^"!$I@,```H,```9`````````````````&W]``!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L!`BT`%``&``@````A`/WY.L*0$P``\6<``!D`````
M````````````2@$!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4
M``8`"````"$`PETPQY((```7)0``&0`````````````````1%0$`>&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0")X>TF`0D``+<H
M```9`````````````````-H=`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L!`BT`%``&``@````A`.T1*OL7!```W@P``!D`````````````````$B<!
M`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`"````"$`5;GG
M`P`-``!I/0``&0````````````````!@*P$`>&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+`0(M`!0`!@`(````(0"&()OE+`H``%@O```9````````````
M`````)<X`0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`%``&``@`
M```A`,<84A&&!```H0\``!D`````````````````^D(!`'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"+0`4``8`"````"$`GDK!1Q(&``#5%@``&0``
M``````````````"W1P$`>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(M
M`!0`!@`(````(0"8>-B4E00``*8/```9``````````````````!.`0!X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L!`BT`%``&``@````A`/6<5K&%`P``
MWPH``!D`````````````````S%(!`'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"+0`4``8`"````"$`MDC1K'L-```:1P``&0````````````````"(
M5@$`>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(M`!0`!@`(````(0`:
M*#B6@P8``/08```9`````````````````#ID`0!X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L!`BT`%``&``@````A`(&!F[3Z`P``@@P``!D`````````
M````````]&H!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`
M"````"$`(>8YHTT#``#Q"P``$``````````````````E;P$`9&]C4')O<',O
M87!P+GAM;%!+`0(M`!0`!@`(````(0`<A!K^E0```*D````0````````````
M`````*AS`0!X;"]C86QC0VAA:6XN>&UL4$L!`BT`%``&``@````A`!@A+JTR
M`0``0`(``!$`````````````````:W0!`&1O8U!R;W!S+V-O<F4N>&UL4$L%
3!@`````Z`#H`OP\``-1V`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDXAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Details Textual) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 10, 2013</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 4</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantMember', window );">Consultant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_ConsultantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantMember]" onclick="toggleNextSibling(this);">6</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_IncreaseInMonthlyFee', window );">Increase In Monthly Fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_IncreaseInMonthlyFee[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantMember]" onclick="toggleNextSibling(this);">15</a><span style="display:none;white-space:normal;text-align:left;">orpn_IncreaseInMonthlyFee<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ConsultantBonusGrantInPeriod', window );">Consultant Bonus Grant In Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_ConsultantBonusGrantInPeriod[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantMember]" onclick="toggleNextSibling(this);">80</a><span style="display:none;white-space:normal;text-align:left;">orpn_ConsultantBonusGrantInPeriod<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ConsultantBonusGrantInPeriodAddition', window );">Consultant Bonus Grant In Period, Addition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_ConsultantBonusGrantInPeriodAddition[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantMember]" onclick="toggleNextSibling(this);">70</a><span style="display:none;white-space:normal;text-align:left;">orpn_ConsultantBonusGrantInPeriodAddition<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ShareholdersMember', window );">Shareholders [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ShareholdersMember]" onclick="toggleNextSibling(this);">15</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_ShareholdersMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantOneMember', window );">Consultant One [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_IncreaseInMonthlyFee', window );">Increase In Monthly Fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_IncreaseInMonthlyFee[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantOneMember]" onclick="toggleNextSibling(this);">19</a><span style="display:none;white-space:normal;text-align:left;">orpn_IncreaseInMonthlyFee<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_ConsultantOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ConsultantBonusGrantInPeriod', window );">Consultant Bonus Grant In Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_ConsultantBonusGrantInPeriod[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantOneMember]" onclick="toggleNextSibling(this);">$ 90</a><span style="display:none;white-space:normal;text-align:left;">orpn_ConsultantBonusGrantInPeriod<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_ConsultantOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ConsultantBonusGrantInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents bonus granted during the period for the consultant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ConsultantBonusGrantInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ConsultantBonusGrantInPeriodAddition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents additional bonus granted during the period for the consultant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ConsultantBonusGrantInPeriodAddition</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_IncreaseInMonthlyFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents monthly fee increases to consultants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_IncreaseInMonthlyFee</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ConsultantOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ShareholdersMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_ShareholdersMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 65</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">19</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember', window );">Electronic equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember]" onclick="toggleNextSibling(this);">14</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= orpn_ElectronicEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= orpn_ElectronicEquipmentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment[us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= orpn_ElectronicEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment[us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= orpn_ElectronicEquipmentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember]" onclick="toggleNextSibling(this);">32</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_OfficeEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_OfficeEquipmentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember]" onclick="toggleNextSibling(this);">$ 1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_OfficeEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_OfficeEquipmentMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="4"></td>
      </tr>
      <tr>
        <td colspan="4">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Represents an amount lower than $1.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONTINGENT LIABILITIES AND COMMITMENTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Operating Leases of Lessee Disclosure [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Future minimum payments under the lease are as follows:&#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.5in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div style="CLEAR:both;CLEAR: both"> Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="47%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">288</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.  Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 1,3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details 2) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 736</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 254</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">$ 9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">83</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">44</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 653</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 210</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES (Details Textual) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_IncomeTaxesLineItems', window );"><strong>INCOME TAXES [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">26.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 684</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_IncomeTaxesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_IncomeTaxesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FINANCIAL EXPENSES (INCOME), NET (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="5">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract', window );"><strong>Financial expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense</a></td>
        <td class="nump"><a title="us-gaap_InterestExpenseBorrowings" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseBorrowings</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_InterestExpenseBorrowings" onclick="toggleNextSibling(this);">$ 2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseBorrowings</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseBorrowings" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseBorrowings</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_BankFees', window );">Bank fees</a></td>
        <td class="nump"><a title="orpn_BankFees" onclick="toggleNextSibling(this);">6</a><span style="display:none;white-space:normal;text-align:left;">orpn_BankFees</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="orpn_BankFees" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_BankFees</span><span></span></td>
        <td class="nump"><a title="orpn_BankFees" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_BankFees</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue', window );">Exchange rate</a></td>
        <td class="nump"><a title="us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" onclick="toggleNextSibling(this);">21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Financial expenses</a></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingExpense" onclick="toggleNextSibling(this);">27</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingExpense" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingExpense" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Financial income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
        <td class="nump"><a title="us-gaap_InterestIncomeOther" onclick="toggleNextSibling(this);">85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeOther</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_InterestIncomeOther" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestIncomeOther" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeOther</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue', window );">Exchange rate</a></td>
        <td class="nump"><a title="us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Financial income</a></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherNonoperatingIncome" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncome</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses (income), net</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">$ (58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">$ (3)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">$ 3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="6"></td>
      </tr>
      <tr>
        <td colspan="6">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Represents an amount lower than $1.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_BankFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense related to bank fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_BankFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The reporting currency-denominated expense (including losses) amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ExpensesAndLossesReportingCurrencyDenominatedValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate amount of interest expense on all borrowings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.7,8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of interest income earned from interest bearing assets not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherExpenseDisclosureNonoperatingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherIncomeDisclosureNonoperatingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The reporting currency-denominated revenue (including gains) amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenuesAndGainsReportingCurrencyDenominatedValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 0.85in"> <div style="CLEAR:both;CLEAR: both">NOTE 2:-</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">SIGNIFICANT ACCOUNTING POLICIES</div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.79in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP").</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">a.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Use of estimates:</div> </td> </tr> </table> &#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;&#160;&#160;&#160; <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; BORDER-TOP-COLOR: #000000; WIDTH: 0.75in; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">b.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">New accounting pronouncements:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June 2014 the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 10-2014 ("ASU 10-2014") regarding development stage entities. The ASU removes the definition of development stage entity, as was previously defined under U.S. GAAP, from the accounting standards codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of income, cash flow and stockholders' equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments to ASU 10-2014 are effective for annual reporting periods beginning after December 15, 2014. The Company has applied the ASU in these financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In 2014, the FASB issued ASU 15-2014, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management&#8217;s responsibility to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is currently evaluating the effect, if any, that the adoption of this guidance will have on the Company&#8217;s financial statements.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160; <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">c.</font> <div style="CLEAR:both;CLEAR: both">&#160;</div> </div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Financial statements in U.S. dollars:</font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company finances its operation in U.S. dollars. The majority of the Company's operations are currently conducted in Israel, a significant part of the Company's expenses are denominated and determined in U.S. dollars. The Company's management believes that the dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, the functional currency of the Company is the U.S.&#160;dollar.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company's transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been remeasured to U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830, "Foreign Currency Matters", of the FASB. All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> d.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Cash equivalents:</font></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> e.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Short-term bank deposits:</font></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Short-term bank deposits are deposits with maturities of more than three months but less than one year.</font> Short&#150;term bank deposits are presented at their cost, including accrued interest, which approximates fair value. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">As of December 31, 2014, the Company's bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.66%.</font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">f.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Property and equipment, net:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Computers and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Electronic equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company's property and equipment are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment," whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to&#160;be recognized is measured by the amount by which the carrying amount of the assets exceeds&#160;the fair value of the assets.&#160;Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2014, 2013 and 2012 no impairment losses have been identified.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">g.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Long-term deposits:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Long-term deposits include long-term deposits for motor vehicles under operating leases, presented at their cost.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">h.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Research and development costs:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Research and development costs are expensed as incurred. Those expenses includes payments to third party clinical consultants, expenses related to conducting clinical trials, salaries and related personnel expenses, travel expenses, and share based <font style="BACKGROUND-COLOR: transparent">compensation expenses related to research and development employees.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">i.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Income taxes:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company accounts for income taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2014 and 2013 the Company has not recorded a liability for uncertain tax positions.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">j.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Concentrations of credit risk:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cash and cash equivalents are invested in major banks in Israel. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">k.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Fair value of financial instruments:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has no financial instruments that are measured at fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The carrying amounts of cash and cash equivalents, <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 10pt"> short-term&#160;</font> bank deposits, accounts receivable and accounts payable, approximate their fair value due to the short-term maturities of such instruments.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">l.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Basic and diluted loss per share:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic net loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year plus dilutive potential equivalent Ordinary shares considered outstanding during the year, in accordance with ASC 260, "Earnings per Share."</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify">For the years ended December&#160;31, 2014, 2013 and 2012, all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">m.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Accounting for stock-based compensation:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0px 0in 0.4in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation" ("ASC 718") that requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the option award is recognized as an expense over the requisite service periods in the Company's statements of operations based on the accelerated method.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">The Company selected the Black-Scholes-Merton ("Black-Scholes") option-pricing model as the fair value method for of its stock-options awards. The option-pricing model requires a number of assumptions as noted below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-SIZE: 10pt">Expected dividend yield</font></i> <font style="FONT-SIZE: 10pt">- The expected dividend yield assumption is based on the Company's historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-SIZE: 10pt"> Volatility</font></i> <font style="FONT-SIZE: 10pt">- Since the Company's shares started trading on NASDAQ in July 2014, sufficient quoted prices of the Company's share are unavailable. Due to insufficient historical data for the Company, the expected volatility determination was based on similar companies' stock volatility.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-SIZE: 10pt">Risk free interest rate</font></i> <font style="FONT-SIZE: 10pt">- The risk free interest rate is based on the yield of U.S. Treasury bonds with equivalent terms.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-SIZE: 10pt">Expected term</font></i> <font style="FONT-SIZE: 10pt">- ASC 718 provides the factors to consider when estimating the expected term of an option: an option's expected term must at least include the vesting period and the employees' historical exercise and post-vesting employment termination behavior for similar grants. It also determines that if the amount of past exercise data is limited, that data may not represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior. In that circumstance, it may be appropriate to consider external data or the SEC staff's "simplified" method for the expected term. Accordingly, the Company used the "simplified" method, meaning the expected life can be set as the average of the vesting period for each vested tranche of options and the contractual term for those options.</font></div> <font style="FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>30
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U
M,3,X,S(U.#`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A
M-C,U,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0D%,04Y#15]32$5%
M5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"04Q!
M3D-%7U-(14544U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/1E]/4$52051)3TY3/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y4
M4U]/1E]#2$%.1T537TE.7U-(05)%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/1E]#2$%.1T537TE.7U-(05)%
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-4051%
M345.5%-?3T9?0T%32%]&3$]74SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D=%3D5204P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y324=.249)0T%.5%]!0T-/54Y424Y'7U!/3$E#244\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y214-%259!
M0DQ%4U]!3D1?4%)%4$%)1%]%6%!%3E,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y04D]015)465]!3D1?15%525!-14Y47TY%5#PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]42$527T%#
M0T]53E137U!!64%"3$4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y)3D-/345?5$%815,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y#3TY424Y'14Y47TQ)04))3$E424537T%.1%]#3TT\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y32$%214A/
M3$1%4E-?15%52519/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4D5,051%1%]005)465]"04Q!3D-%4U]!3D1?5%)!/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1DE.04Y#24%,7T584$5.
M4T537TE.0T]-15].150\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y354)315%514Y47T5614Y44SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],
M24-)13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M24=.249)0T%.5%]!0T-/54Y424Y'7U!/3$E#244R/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4D5#14E604),15-?04Y$7U!215!!
M241?15A014Y3,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E!23U!%4E197T%.1%]%455)4$U%3E1?3D547U1A8CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]42$527T%#0T]53E137U!!
M64%"3$5?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^24Y#3TU%7U1!6$537U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D-/3E1)3D=%3E1?3$E!0DE,251)15-?04Y$
M7T-/33$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M2$%214A/3$1%4E-?15%525197U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E)%3$%4141?4$%25%E?0D%,04Y#15-?04Y$
M7U1203$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&
M24Y!3D-)04Q?15A014Y315-?24Y#3TU%7TY%5%\\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y'14Y%4D%,7T1E=&%I;'-?5&5X='5A
M;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-)1TY)
M1DE#04Y47T%#0T]53E1)3D=?4$],24-)13,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S`N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y324=.249)0T%.5%]!0T-/54Y424Y'7U!/
M3$E#244T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#,Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4D5#14E604),15-?04Y$7U!215!!241?15A014Y3,CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!23U!%4E197T%.1%]%455)4$U%
M3E1?3D547T1E=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,RYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E!23U!%4E197T%.1%]%455)4$U%3E1?3D547T1E=#$\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,S0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/5$A%4E]!0T-/54Y44U]0
M05E!0DQ%7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S4N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y)3D-/345?5$%815-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.0T]-15]405A%4U]$971A:6QS7U1E
M>'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,S<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#
M3TY424Y'14Y47TQ)04))3$E424537T%.1%]#3TTR/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,X
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].5$E.1T5.5%],24%"24Q)5$E%
M4U]!3D1?0T]-,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S.2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-(05)%2$],1$524U]%455)5%E?1&5T86EL<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T
M,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-(05)%2$],1$524U]%455)5%E?
M1&5T86EL<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#0Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4TA!4D5(3TQ$15)37T5154E465]$971A:6QS7S(\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M-#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y32$%214A/3$1%4E-?15%52519
M7T1E=&%I;'-?5&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y214Q!5$5$7U!!4E197T)!3$%.0T537T%.1%]44D$R/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#0T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4D5,051%1%]005)465]"
M04Q!3D-%4U]!3D1?5%)!,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E)%3$%4141?4$%25%E?0D%,04Y#15-?04Y$7U12030\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-#8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&24Y!3D-)04Q?
M15A014Y315-?24Y#3TU%7TY%5%\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0W+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4U5"4T51545.5%]%5D5.5%-?1&5T86EL<U]497AT
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#0X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(
M4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53
M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E
M/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD
M;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB
M;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*
M("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O
M9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?
M838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R
M-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S
M+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4R4$%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C
M=6UE;G0@26YF;W)M871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT
M($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D))3R!"3$%3
M5"!02$%234$@3%1$+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XP,#`Q-3DV.#$R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT
M($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO;BUA8V-E;&5R871E9"!&:6QE
M<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5')A9&EN9R!3>6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D]24$X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N
M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,C,P+#0X
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^,C`M1CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M5V5L;"UK;F]W;B!396%S;VYE9"!)<W-U97(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5F]L=6YT87)Y($9I;&5R<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#=7)R96YT
M(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X
M9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5.54%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D)!3$%.0T4@4TA%
M1513("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#55)214Y4($%34T544SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,"PU.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAO<G0M=&5R;2!B86YK(&1E<&]S:71S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPP,C@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE
M<R!A;F0@<')E<&%I9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(L.#@U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDY/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQ/
M3D<M5$5232!!4U-%5%,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO;F<M=&5R;2!D97!O<VET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@
M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!L;VYG+71E<FT@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y43U1!3"!!4U-%5%,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,R+#DU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#55)214Y4($Q)04))3$E4
M2453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4<F%D92!P87EA8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PR.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W1H97(@86-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(X
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY32$%214A/3$1%4E,G($5154E463H\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)D:6YA<GD@<VAA
M<F5S(&]F($Y)4R`P+C`Q('!A<B!V86QU92`M(#4P+#`P,"PP,#`@86YD(#$V
M+#8Q,RPQ,SD@<VAA<F5S(&%U=&AO<FEZ960@870@1&5C96UB97(@,S$L(#(P
M,30@86YD(#(P,3,L(')E<W!E8W1I=F5L>3L@,30L,C,P+#0X,"!A;F0@.2PQ
M.#(L.#8W(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@<VAA<F5S(&%T($1E8V5M
M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'D[/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M
M(&EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y
M+#`U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@X+#0R,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S:&%R96AO
M;&1E<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S`L-C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5$]404P@3$E!0DE,251)15,@04Y$(%-(05)%2$],1$52
M4R<@15%52519/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,R
M+#DU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,S`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W8S8X,#)?8V$Q-5\T-S<T
M7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O4VAE970P,RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14-%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0D%,04Y#12!3
M2$5%5%,@*%!A<F5N=&AE=&EC86PI("A)3%,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!P87(@;W(@<W1A=&5D('9A;'5E('!E<B!S:&%R92`H:6X@9&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,"XP
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-C$S+#$S
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"!S:&%R97,L(&ES<W5E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30L,C,P+#0X,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3@R+#@V-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K+"!S:&%R97,L(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-"PR,S`L-#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PQ.#(L.#8W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W
M-S1?.&8S8U]A-C,U,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O
M<FMS:&5E=',O4VAE970P-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!-044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4U1!5$5-14Y44R!/1B!/4$52051)3TY3("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S
M(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#0T,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-S,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8S.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!E<F%T:6YG(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<L,#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PQ-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEA;"!E>'!E;G-E<R`H:6YC;VUE*2P@
M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`R,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,30U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$965M960@9&EV:61E;F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,;W-S(&%T=')I8G5T86)L92!T;R!H;VQD97)S(&]F
M($]R9&EN87)Y('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`W+#`R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PQ-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960@;&]S
M<R!P97(@<VAA<F4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C4W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!/<F1I;F%R>2!S:&%R97,@=7-E
M9"!I;B!C;VUP=71I;F<@8F%S:6,@86YD(&1I;'5T960@;&]S<R!P97(@<VAA
M<F4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R+#(U.2PV,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+#0R,RPP,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW+#4U,2PT,C<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$R-V,V.#`R7V-A,35?-#<W-%\X
M9C-C7V$V,S4Q,S@S,C4X,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`O5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%05%"23X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY35$%414U%3E13($]&($-(04Y'15,@24X@4TA!4D5(3TQ$
M15)3)R!%455)5%D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3
M:&%R92!D871A/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^5&]T86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M
M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M=6QA=&5D($1E
M9FEC:70@9'5R:6YG($1E=F5L;W!M96YT(%-T86=E(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E!R969E<G)E9"!#;&%S<R!!
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E<R!A="!*86XN(#(R+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@*&EN('-H
M87)E<RD@870@2F%N+B`R,BP@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F($]R9&EN87)Y('-H87)E<R!T;R!F
M;W5N9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F($]R9&EN87)Y('-H87)E<R!T;R!F;W5N9&5R<R`H
M:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPU
M-3$L-#(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@4')E9F5R<F5D($$@<VAA<F5S+"!N970@
M*"0P+C4S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@4')E9F5R<F5D($$@<VAA<F5S
M+"!N970@*"0P+C4S('!E<B!S:&%R92D@*&EN('-H87)E<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-C8L,S4W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!B87-E9"!C
M;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(R.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,3(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,CDI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@
M<VAA<F5S*2!A="!$96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#4U,2PT,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-C8L,S4W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F(%!R
M969E<G)E9"!!('-H87)E<R!I;G1O($]R9&EN87)Y('-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F
M(%!R969E<G)E9"!!('-H87)E<R!I;G1O($]R9&EN87)Y('-H87)E<R`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38V+#,U
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#4V-BPS-3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$965M960@1&EV:61E;F0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!/<F1I;F%R>2!S
M:&%R97,L(&YE="`H)#`N.34@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!/<F1I;F%R
M>2!S:&%R97,L(&YE="`H)#`N.34@<&5R('-H87)E*2`H:6X@<VAA<F5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-C4L,#@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA
M<F4@8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L,30U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PQ-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q
M+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PT,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R
M,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#$X,BPX-C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!/<F1I;F%R>2!S:&%R97,L(&YE="`H)#`N.34@<&5R
M('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@3W)D:6YA<GD@<VAA<F5S+"!N970@*"0P
M+CDU('!E<B!S:&%R92D@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#8U+#`W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F($]R9&EN87)Y
M('-H87)E<R!U<&]N('!R:79A=&4@<&QA8V5M96YT+"!N970@*"0V+C`W('!E
M<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S8X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,S8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F($]R9&EN87)Y('-H87)E<R!U<&]N('!R
M:79A=&4@<&QA8V5M96YT+"!N970@*"0V+C`W('!E<B!S:&%R92D@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X,BPU,S<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!/<F1I;F%R>2!S:&%R97,@=7!O;B!I;FET:6%L('!U
M8FQI8R!O9F9E<FEN9R!N970@*"0Q,2!P97(@<VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,2PT,#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L,SDV/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E
M(&]F($]R9&EN87)Y('-H87)E<R!U<&]N(&EN:71I86P@<'5B;&EC(&]F9F5R
M:6YG(&YE="`H)#$Q('!E<B!S:&%R92D@*&EN('-H87)E<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E(&)A<V5D
M(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@W+#`R,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<L,#(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@,C`Q-#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,"PV-S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M.2PP-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#@L-#(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N
M(#,Q+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PR
M,S`L-#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X
M9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5224%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-4051%345.5%,@
M3T8@0TA!3D=%4R!)3B!32$%214A/3$1%4E,G($5154E462`H4&%R96YT:&5T
M:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>2!)<W-U86YC92P@4&5R
M(%-H87)E($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P+CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<FEV871E(%!L86-E;65N="!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='D@27-S=6%N8V4L
M(%!E<B!3:&%R92!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-BXP-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^25!/(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5Q=6ET>2!)<W-U86YC92P@4&5R(%-H87)E($%M;W5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D($-L87-S($$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17%U:71Y($ES<W5A;F-E+"!097(@4VAA<F4@06UO=6YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$R
M-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A
M-C,U,3,X,S(U.#`O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M2D5!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY35$%414U%3E13($]&($-!
M4T@@1DQ/5U,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#0^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O
M;2!O<&5R871I;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#<L
M,#(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,2PQ-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R
M,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!L;W-S('1O
M(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@;VX@<VAO
M<G0M=&5R;2!B86YK(&1E<&]S:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD(&QI86)I
M;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE
M<R!A;F0@<')E<&%I9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C0U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&]N9RUT97)M(&1E<&]S:70\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4<F%D92!P87EA8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PR,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W1H97(@86-C;W5N=',@<&%Y86)L97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L-#`Y*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@V-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-#DI/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO
M=W,@9G)O;2!I;G9E<W1I;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&]R="UT97)M(&)A;FL@9&5P;W-I=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(R+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q
M=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E
M9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C(L,#8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C
M=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@
M;V8@<VAA<F5S+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,V+#<X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDY,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPW.#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!I;B!C87-H
M(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,"PS,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@=&AE(&)E9VEN
M;FEN9R!O9B!T:&4@>65A<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,30V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A="!T:&4@96YD(&]F('1H92!Y96%R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#4X,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M9"!C;VQS<&%N/3-$-3X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T
M;W`^6S%=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0T('9A;&EG;CTS
M1'1O<#Y297!R97-E;G1S(&%N(&%M;W5N="!L;W=E<B!T:&%N("0Q+CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S
M8U]A-C,U,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E
M=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D=%3D5204P\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N
M(&%N9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/<F=A;FEZ871I;VXL($-O;G-O;&ED871I;VX@86YD(%!R97-E;G1A
M=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<R!$:7-C;&]S=7)E(%M497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`M-38N-W!T.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#4V+C=P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/"]D:78^(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(&)O;&0@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%=)1%1(.B`P+C@U:6XG/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DY/5$4@,3HM/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY'14Y%4D%,
M/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^("8C,38P.R`\=&%B;&4@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!724142#H@,3`P)3L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L969T
M.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-C)P=#L@0D]2
M1$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@=&]P
M.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=.
M.B!L969T.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@,C-P
M=#L@0D]21$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'
M3CH@=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^82X\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV('-T>6QE
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M(&]N(&1E97`@=6YD97)S=&%N9&EN9R!O9B!T:&4@9&ES96%S92UC875S:6YG
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M:6-A;"!T<FEA;',@9F]R(&ET<R!D<G5G<R`H=&AE(")$<G5G<R(I(&%N9"P@
M:68@=&AO<V4@=')I86QS(&%R92!S=6-C97-S9G5L+"!S965K(&UA<FME=&EN
M9R!A<'!R;W9A;"!F<F]M('1H92!5+E,N($9O;V0@86YD($1R=6<@061M:6YI
M<W1R871I;VX@*'1H92`B1D1!(BD@86YD(&]T:&5R('=O<FQD=VED92!R96=U
M;&%T;W)Y(&)O9&EE<RX\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)
M3CH@,'!T(#!P>"`P<'0@-S0N-W!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D
M:78^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q
M,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P,#`P,#`[(%1%
M6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],3U(Z(",P,#`P,#`[(%=)
M1%1(.B`V,G!T.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P,#`[(%9%4E1)
M0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C,#`P,#`P)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P,#`P
M,#`[(%1%6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],3U(Z(",P,#`P
M,#`[(%=)1%1(.B`R,W!T.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P,#`[
M(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C,#`P
M,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SYB
M+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
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M;W-S97,@:6X@=&AE(&%M;W5N="!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^-RPP,C(\+V9O;G0^(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E
M;6)E<B`S,2P@,C`Q-"X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XU
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P
M="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/32U#3TQ/4CH@(S`P,#`P,#L@5$585"U!3$E'3CH@;&5F=#L@0D]2
M1$52+51/4"U#3TQ/4CH@(S`P,#`P,#L@5TE$5$@Z(#8R<'0[($)/4D1%4BU2
M24=(5"U#3TQ/4CH@(S`P,#`P,#L@5D525$E#04PM04Q)1TXZ('1O<#L@0D]2
M1$52+4Q%1E0M0T],3U(Z(",P,#`P,#`G/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/32U#3TQ/4CH@(S`P,#`P,#L@5$585"U!3$E'3CH@;&5F
M=#L@0D]21$52+51/4"U#3TQ/4CH@(S`P,#`P,#L@5TE$5$@Z(#(S<'0[($)/
M4D1%4BU224=(5"U#3TQ/4CH@(S`P,#`P,#L@5D525$E#04PM04Q)1TXZ('1O
M<#L@0D]21$52+4Q%1E0M0T],3U(Z(",P,#`P,#`G/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/F,N/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S='EL93TS1"=,24Y%+4A%
M24=(5#H@,3$U)3L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M4TE:13H@,3!P="<^($1U<FEN9R!!=6=U<W0@,C`Q-"P@
M=&AE($-O;7!A;GD@8V]M<&QE=&5D(&%N($EN:71I86P@4'5B;&EC($]F9F5R
M:6YG("@B25!/(BD@:6X@56YI=&5D(%-T871E<R!I;B!W:&EC:"!I="!I<W-U
M960@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#,L,C`P+#`P,#PO9F]N
M=#X@3W)D:6YA<GD@<VAA<F5S(&EN(&-O;G-I9&5R871I;VX@;V8@87!P<F]X
M:6UA=&5L>28C,38P.R0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXS,2PT
M,#4\+V9O;G0^+"!N970@86YD(&ET<R!/<F1I;F%R>2!S:&%R97,@8F5G86X@
M=')A9&EN9R!O;B!T:&4@(DY!4T1!42!#87!I=&%L($UA<FME="(N/"]F;VYT
M/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX\=&%B;&4@8F]R
M9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX
M960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^
M/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X
M,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W8S8X,#)?
M8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O4VAE970P
M.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-)
M1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0
M;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QT86)L92!S='EL93TS1"=-05)'24XM
M5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!J=7-T:69Y.R!724142#H@,"XX-6EN)SX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY.3U1%(#(Z+3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^4TE'3DE&24-!
M3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`F(S$V,#L@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,"XW.6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^5&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA=F4@8F5E;B!P<F5P
M87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S
M(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R`H(E4N
M4RX@1T%!4"(I+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I;B`Q+C%I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX]
M,T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX\+V9O;G0^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[
M(%=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SX@/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$X
M<'0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/F$N
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY5<V4@
M;V8@97-T:6UA=&5S.CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`F(S$V
M,#L\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I
M;B`P<'@@,&EN(#`N.3DY:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y4:&4@<')E<&%R871I
M;VX@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@
M=VET:"!5+E,N($=!05`@<F5Q=6ER97,@;6%N86=E;65N="!T;R!M86ME(&5S
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M(&5S=&EM871E<SQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#XN
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CPO9&EV/B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B8C,38P.SQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"
M3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@
M/'1R('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%9%4E1)0T%,+4%,
M24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/32U#3TQ/4CH@
M(S`P,#`P,#L@0D]21$52+51/4"U#3TQ/4CH@(S`P,#`P,#L@5TE$5$@Z(#`N
M-S5I;CL@0D]21$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!"3U)$15(M3$5&
M5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#
M3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!724142#H@,"XR-6EN)SX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SYB+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^3F5W(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N
M=',Z/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M#3$5!4CH@8F]T:"<^("8C,38P.SPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X(#!P="`W,"XY<'0[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)R!A
M;&EG;CTS1&IU<W1I9GD^26X@2G5N92`R,#$T('1H92!&:6YA;F-I86P@06-C
M;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@*")&05-"(BD@:7-S=65D($%C8V]U
M;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`H(D%352(I(#$P+3(P,30@*")!4U4@
M,3`M,C`Q-"(I(')E9V%R9&EN9R!D979E;&]P;65N="!S=&%G92!E;G1I=&EE
M<RX@5&AE($%352!R96UO=F5S('1H92!D969I;FET:6]N(&]F(&1E=F5L;W!M
M96YT('-T86=E(&5N=&ET>2P@87,@=V%S('!R979I;W5S;'D@9&5F:6YE9"!U
M;F1E<B!5+E,N($=!05`L(&9R;VT@=&AE(&%C8V]U;G1I;F<@<W1A;F1A<F1S
M(&-O9&EF:6-A=&EO;BP@=&AE<F5B>2!R96UO=FEN9R!T:&4@9FEN86YC:6%L
M(')E<&]R=&EN9R!D:7-T:6YC=&EO;B!B971W965N(&1E=F5L;W!M96YT('-T
M86=E(&5N=&ET:65S(&%N9"!O=&AE<B!R97!O<G1I;F<@96YT:71I97,@9G)O
M;2!5+E,N($=!05`N($EN(&%D9&ET:6]N+"!T:&4@05-5(&5L:6UI;F%T97,@
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M96YT:71Y+"`H:6EI*2!D:7-C;&]S92!A(&1E<V-R:7!T:6]N(&]F('1H92!D
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M;G1S('1O($%352`Q,"TR,#$T(&%R92!E9F9E8W1I=F4@9F]R(&%N;G5A;"!R
M97!O<G1I;F<@<&5R:6]D<R!B96=I;FYI;F<@869T97(@1&5C96UB97(@,34L
M(#(P,30N(%1H92!#;VUP86YY(&AA<R!A<'!L:65D('1H92!!4U4@:6X@=&AE
M<V4@9FEN86YC:6%L('-T871E;65N=',N/"]D:78^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@
M,'!T(#<P+CEP=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86PG(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>"`P<'0@-S`N.7!T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!F
M;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<@
M86QI9VX],T1J=7-T:69Y/DEN(#(P,30L('1H92!&05-"(&ES<W5E9"!!4U4@
M,34M,C`Q-"P@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S
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M;W)T:6YG('!E<FEO9',@96YD:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$V
M('=I=&@@96%R;'D@861O<'1I;VX@<&5R;6ET=&5D+B!4:&4@0V]M<&%N>2!I
M<R!C=7)R96YT;'D@979A;'5A=&EN9R!T:&4@969F96-T+"!I9B!A;GDL('1H
M870@=&AE(&%D;W!T:6]N(&]F('1H:7,@9W5I9&%N8V4@=VEL;"!H879E(&]N
M('1H92!#;VUP86YY)B,X,C$W.W,@9FEN86YC:6%L('-T871E;65N=',N/"]D
M:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M-05)'24XZ(#!I;B`P<'@@,&EN(#!I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y
M/B8C,38P.R`\=&%B;&4@<W1Y;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P
M)3L@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T
M9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@
M=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XW-6EN
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/
M4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$-S(^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#
M3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XR-6EN.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@
M(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,C0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M,24Y%+4A%24=(5#H@
M;F]R;6%L.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^8RX\+V9O;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z
M("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],
M3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z
M("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)
M3D4M2$5)1TA4.B!N;W)M86P[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SY&:6YA;F-I86P@<W1A=&5M96YT<R!I
M;B!5+E,N(&1O;&QA<G,Z/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T
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M('1H92!#;VUP86YY(&ES('1H92!5+E,N)B,Q-C`[9&]L;&%R+CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`F(S$V,#L\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P
M:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
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M:6-A=&EO;B`H(D%30R(I(#@S,"P@(D9O<F5I9VX@0W5R<F5N8WD@36%T=&5R
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M<')I871E+CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX\+V9O;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'
M24XZ(#!P="`P<'@@,'!T(#@U+C`U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\
M+V1I=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\=&%B
M;&4@<W1Y;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P)3L@1D].5"U325I%
M.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XW-6EN.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@
M(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-S(^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D
M,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,"XR-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C0^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M,24Y%+4A%24=(5#H@;F]R;6%L.R!-05)'
M24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^
M(&0N/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.TQ)3D4M2$5)1TA4.B!N;W)M86P[($U!4D=)3CH@,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SY#
M87-H(&5Q=6EV86QE;G1S.CPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T
M86)L93X@)B,Q-C`[(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T
M:69Y/D-A<V@@97%U:79A;&5N=',@87)E('-H;W)T+71E<FT@:&EG:&QY(&QI
M<75I9"!I;G9E<W1M96YT<R!T:&%T(&%R92!R96%D:6QY(&-O;G9E<G1I8FQE
M('1O(&-A<V@@=VET:"!O<FEG:6YA;"!M871U<FET:65S(&]F('1H<F5E(&UO
M;G1H<R!O<B!L97-S(&%T(&%C<75I<VET:6]N+CPO9&EV/B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^)B,Q-C`[)B,Q-C`[(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^/"]F;VYT/B`\=&%B;&4@<W1Y;&4],T0G8VQE87(Z8F]T:#M7
M24142#H@,3`P)3L@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M
M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.
M1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!72414
M2#H@,"XW-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D
M-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-S(^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C
M.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A
M;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XR-6EN.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%
M4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,C0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M,24Y%
M+4A%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^(&4N/"]F;VYT/CPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%
M1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M
M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'
M2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.TQ)3D4M2$5)1TA4.B!N;W)M86P[
M($U!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX@4VAO<G0M=&5R;2!B86YK(&1E<&]S:71S
M.CPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@)B,Q-C`[(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'
M24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/E-H;W)T+71E<FT@8F%N:R!D97!O<VET<R!A<F4@
M9&5P;W-I=',@=VET:"!M871U<FET:65S(&]F(&UO<F4@=&AA;B!T:')E92!M
M;VYT:',@8G5T(&QE<W,@=&AA;B!O;F4@>65A<BX\+V9O;G0^(%-H;W)T)B,Q
M-3`[=&5R;2!B86YK(&1E<&]S:71S(&%R92!P<F5S96YT960@870@=&AE:7(@
M8V]S="P@:6YC;'5D:6YG(&%C8W)U960@:6YT97)E<W0L('=H:6-H(&%P<')O
M>&EM871E<R!F86ER('9A;'5E+B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"P@=&AE($-O;7!A;GDG<R!B86YK
M(&1E<&]S:71S('=E<F4@:6X@52Y3+B!D;VQL87)S(&%N9"!B;W)E(&EN=&5R
M97-T(&%T(&$@=V5I9VAT960@879E<F%G92!I;G1E<F5S="!R871E(&]F(#`N
M-C8E+CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE.
M.B`P<'0@,'!X(#!P="`W-"XW<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I
M=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\=&%B;&4@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!724142#H@,3`P)3L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/
M5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L
M969T.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-31P=#L@
M0D]21$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@
M=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^(#PO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
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M24XZ(#!P="`P<'@@,'!T(#4V+C=P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I
M;CL@34%21TE..B`P:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
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M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I
M;CL@34%21TE..B`P<'0@,'!X(#!P="`P+C@U:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF
M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)
M1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B
M;&4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@<V]L:60[
M($)/4D1%4BU,1494.B`C.65B-F-E(#!P>"!S;VQI9#L@34%21TE..B`P:6X@
M,&EN(#!I;B`Q:6X[(%=)1%1(.B`V,"4[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($]615)&3$]7.B!V:7-I8FQE.R!"3U)$15(M5$]0.B`C.65B-F-E
M(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3`E/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$."4@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0W)3X@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/D-O;7!U=&5R<R!A;F0@<V]F='=A<F4\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-R4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^,S,\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D5L96-T<F]N:6,@97%U
M:7!M96YT/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0W)3X@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXQ-3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
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M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#
M3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
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M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.T-,14%2.B!B;W1H)SX@/"]D
M:78^(#PO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TU-BXW<'0[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@-38N-W!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P
M:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
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M,38P.W1H92!F86ER('9A;'5E(&]F('1H92!A<W-E=',N)B,Q-C`[07-S971S
M('1O(&)E(&1I<W!O<V5D(&]F(&%R92!R97!O<G1E9"!A="!T:&4@;&]W97(@
M;V8@=&AE(&-A<G)Y:6YG(&%M;W5N="!O<B!F86ER('9A;'5E(&QE<W,@8V]S
M=',@=&\@<V5L;"X@26X@,C`Q-"P@,C`Q,R!A;F0@,C`Q,B!N;R!I;7!A:7)M
M96YT(&QO<W-E<R!H879E(&)E96X@:61E;G1I9FEE9"X\+V1I=CX@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`M,C@N,S5P=#L@34%21TE..B`P<'0@,'!X(#!P="`X-2XP
M-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/32U#
M3TQ/4CH@(S`P,#`P,#L@5$585"U!3$E'3CH@;&5F=#L@0D]21$52+51/4"U#
M3TQ/4CH@(S`P,#`P,#L@5TE$5$@Z(#4T<'0[($)/4D1%4BU224=(5"U#3TQ/
M4CH@(S`P,#`P,#L@5D525$E#04PM04Q)1TXZ('1O<#L@0D]21$52+4Q%1E0M
M0T],3U(Z(",P,#`P,#`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N
M,C5I;B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M9RX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GDG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DQO
M;F<M=&5R;2!D97!O<VET<SH\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>"`P<'0@
M.#4N,#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@
M,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y,;VYG+71E<FT@9&5P;W-I=',@
M:6YC;'5D92!L;VYG+71E<FT@9&5P;W-I=',@9F]R(&UO=&]R('9E:&EC;&5S
M('5N9&5R(&]P97)A=&EN9R!L96%S97,L('!R97-E;G1E9"!A="!T:&5I<B!C
M;W-T+CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@+3(X+C,U
M<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y
M/B8C,38P.SPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O
M;G0^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q
M,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P,#`P,#`[(%1%
M6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],3U(Z(",P,#`P,#`[(%=)
M1%1(.B`U-'!T.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P,#`[(%9%4E1)
M0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C,#`P,#`P)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/F@N/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY297-E87)C:"!A;F0@9&5V96QO
M<&UE;G0@8V]S=',Z/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ
M(#!P="`P<'@@,'!T(#@U+C`U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[
M($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
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M;VYT/CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-
M05)'24XZ(#!P="`P<'@@,'!T(#`N.#5I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P
M.SPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QT
M86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P
M="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
M,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P,#`P,#`[(%1%6%0M04Q)
M1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],3U(Z(",P,#`P,#`[(%=)1%1(.B`U
M-'!T.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P,#`[(%9%4E1)0T%,+4%,
M24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C,#`P,#`P)SX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-,
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M+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#@U+C`U<'0[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N
M/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A
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M96QY('1H86X@;F]T('1O(&)E(')E86QI>F5D+CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&QE9G0^)B,Q
M-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.
M5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P="!4
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M;&%R9V5S="!A;6]U;G0@=&AA="!I<R!M;W)E('1H86X@-3`E("AC=6UU;&%T
M:79E(&)A<VES*2!L:6ME;'D@=&\@8F4@<F5A;&EZ960@=7!O;B!U;'1I;6%T
M92!S971T;&5M96YT+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q
M,R!T:&4@0V]M<&%N>2!H87,@;F]T(')E8V]R9&5D(&$@;&EA8FEL:71Y(&9O
M<B!U;F-E<G1A:6X@=&%X('!O<VET:6]N<RX\+V1I=CX@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`W-"XW
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^/"]F;VYT/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-+4-/
M3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"3U)$15(M5$]0+4-/
M3$]2.B`C,#`P,#`P.R!724142#H@-31P=#L@0D]21$52+5))1TA4+4-/3$]2
M.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M3$5&5"U#
M3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#X\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q.'!T)SX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SYJ+CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^0V]N8V5N=')A=&EO;G,@
M;V8@8W)E9&ET(')I<VLZ/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@+3(X+C,U<'0[
M($U!4D=)3CH@,'!T(#!P>"`P<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C
M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%
M3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@
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M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].
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M05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I
M;CL@34%21TE..B`P:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@
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M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O
M;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L
M:6=N/3-$;&5F=#XF(S$V,#L\+V1I=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^/"]F;VYT/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-+4-/3$]2.B`C
M,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"3U)$15(M5$]0+4-/3$]2.B`C
M,#`P,#`P.R!724142#H@-31P=#L@0D]21$52+5))1TA4+4-/3$]2.B`C,#`P
M,#`P.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@
M(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#X\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q.'!T)SX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SYK+CPO9&EV/B`\+W1D/B`\=&0@
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M24XZ(#!P="`P<'@@,'!T(#<T+C=P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I
M;CL@34%21TE..B`P<'0@,'!X(#!P="`W-"XW<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y4
M:&4@0V]M<&%N>2!H87,@;F\@9FEN86YC:6%L(&EN<W1R=6UE;G1S('1H870@
M87)E(&UE87-U<F5D(&%T(&9A:7(@=F%L=64N/"]D:78^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#<T+C=P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE.
M.B`P<'0@,'!X(#!P="`W-"XW<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y4:&4@8V%R<GEI
M;F<@86UO=6YT<R!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"`\9F]N
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M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`M,C@N,S5P=#L@34%21TE..B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS
M1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/CPO9F]N=#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!T;W`G/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/32U#3TQ/4CH@(S`P
M,#`P,#L@5$585"U!3$E'3CH@;&5F=#L@0D]21$52+51/4"U#3TQ/4CH@(S`P
M,#`P,#L@5TE$5$@Z(#4T<'0[($)/4D1%4BU224=(5"U#3TQ/4CH@(S`P,#`P
M,#L@5D525$E#04PM04Q)1TXZ('1O<#L@0D]21$52+4Q%1E0M0T],3U(Z(",P
M,#`P,#`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=724142#H@,3AP="<^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^;"X\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@
M<&5R('-H87)E.CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TR."XS-7!T.R!-05)'
M24XZ(#!P="`P<'@@,'!T(#@U+C`U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P
M:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,"XY.3EI;CL@1D].5#H@,3!P="!4
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M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@
M,&EN(#`N.3DY:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@
M,&EN(#!P>"`P:6X@,"XY.3EI;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/D9O<B!T:&4@>65A
M<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q
M,BP@86QL(&]U='-T86YD:6YG(&]P=&EO;G,@:&%V92!B965N(&5X8VQU9&5D
M(&9R;VT@=&AE(&-A;&-U;&%T:6]N(&]F('1H92!D:6QU=&5D(&YE="!L;W-S
M('!E<B!S:&%R92!S:6YC92!T:&5I<B!E9F9E8W0@=V%S(&%N=&DM9&EL=71I
M=F4N/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.T-,14%2.B!B;W1H)SX@)B,Q-C`[
M/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^/"]F;VYT/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-+4-/
M3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"3U)$15(M5$]0+4-/
M3$]2.B`C,#`P,#`P.R!724142#H@-31P=#L@0D]21$52+5))1TA4+4-/3$]2
M.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M3$5&5"U#
M3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,3AP
M="<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^;2X\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D%C8V]U
M;G1I;F<@9F]R('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CH\+V1I=CX@/"]T
M9#X@/"]T<CX@/"]T86)L93X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`M,C@N,S5P=#L@34%21TE..B`P:6X@,'!X(#!I;B`P+C1I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@
M86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I
M;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/E1H92!#;VUP86YY(&%C8V]U;G1S(&9O<B!S=&]C:RUB87-E9"!C
M;VUP96YS871I;VX@:6X@86-C;W)D86YC92!W:71H($%30R`W,3@L(")#;VUP
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M92!A8V-E;&5R871E9"!M971H;V0N/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@
M,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0G/CPO9F]N=#XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P
M>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!S96QE8W1E9"!T:&4@0FQA8VLM4V-H
M;VQE<RU-97)T;VX@*")";&%C:RU38VAO;&5S(BD@;W!T:6]N+7!R:6-I;F<@
M;6]D96P@87,@=&AE(&9A:7(@=F%L=64@;65T:&]D(&9O<B!O9B!I=',@<W1O
M8VLM;W!T:6]N<R!A=V%R9',N(%1H92!O<'1I;VXM<')I8VEN9R!M;V1E;"!R
M97%U:7)E<R!A(&YU;6)E<B!O9B!A<W-U;7!T:6]N<R!A<R!N;W1E9"!B96QO
M=SH\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4
M+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J
M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/"]F;VYT
M/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S
M=&EF>3X\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D5X<&5C
M=&5D(&1I=FED96YD('EI96QD/"]F;VYT/CPO:3X@/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T)SXM(%1H92!E>'!E8W1E9"!D:79I9&5N9"!Y:65L
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M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^
M)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T
M:69Y/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(%9O;&%T
M:6QI='D\+V9O;G0^/"]I/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
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M=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI
M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M/"]F;VYT/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I;B`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N
M/3-$:G5S=&EF>3X\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G
M/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]F;VYT/CPO:3X@/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T)SXM(%1H92!R:7-K(&9R964@:6YT97)E
M<W0@<F%T92!I<R!B87-E9"!O;B!T:&4@>6EE;&0@;V8@52Y3+B!4<F5A<W5R
M>2!B;VYD<R!W:71H(&5Q=6EV86QE;G0@=&5R;7,N/"]F;VYT/CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2
M1TE..B`P:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#XF(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)
M3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/&D^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9"!T97)M/"]F;VYT/CPO
M:3X@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXM($%30R`W,3@@
M<')O=FED97,@=&AE(&9A8W1O<G,@=&\@8V]N<VED97(@=VAE;B!E<W1I;6%T
M:6YG('1H92!E>'!E8W1E9"!T97)M(&]F(&%N(&]P=&EO;CH@86X@;W!T:6]N
M)W,@97AP96-T960@=&5R;2!M=7-T(&%T(&QE87-T(&EN8VQU9&4@=&AE('9E
M<W1I;F<@<&5R:6]D(&%N9"!T:&4@96UP;&]Y965S)R!H:7-T;W)I8V%L(&5X
M97)C:7-E(&%N9"!P;W-T+79E<W1I;F<@96UP;&]Y;65N="!T97)M:6YA=&EO
M;B!B96AA=FEO<B!F;W(@<VEM:6QA<B!G<F%N=',N($ET(&%L<V\@9&5T97)M
M:6YE<R!T:&%T(&EF('1H92!A;6]U;G0@;V8@<&%S="!E>&5R8VES92!D871A
M(&ES(&QI;6ET960L('1H870@9&%T82!M87D@;F]T(')E<')E<V5N="!A('-U
M9F9I8VEE;G1L>2!L87)G92!S86UP;&4@;VX@=VAI8V@@=&\@8F%S92!A(')O
M8G5S="!C;VYC;'5S:6]N(&]N(&5X<&5C=&5D(&5X97)C:7-E(&)E:&%V:6]R
M+B!);B!T:&%T(&-I<F-U;7-T86YC92P@:70@;6%Y(&)E(&%P<')O<')I871E
M('1O(&-O;G-I9&5R(&5X=&5R;F%L(&1A=&$@;W(@=&AE(%-%0R!S=&%F9B=S
M(")S:6UP;&EF:65D(B!M971H;V0@9F]R('1H92!E>'!E8W1E9"!T97)M+B!!
M8V-O<F1I;F=L>2P@=&AE($-O;7!A;GD@=7-E9"!T:&4@(G-I;7!L:69I960B
M(&UE=&AO9"P@;65A;FEN9R!T:&4@97AP96-T960@;&EF92!C86X@8F4@<V5T
M(&%S('1H92!A=F5R86=E(&]F('1H92!V97-T:6YG('!E<FEO9"!F;W(@96%C
M:"!V97-T960@=')A;F-H92!O9B!O<'1I;VYS(&%N9"!T:&4@8V]N=')A8W1U
M86P@=&5R;2!F;W(@=&AO<V4@;W!T:6]N<RX\+V9O;G0^/"]D:78^(#QF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\+V1I=CX\=&%B
M;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO
M=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A
M-C,U,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W
M8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O
M4VAE970Q,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E)%0T5)5D%"3$53($%.1"!04D5004E$($584$5.4T53/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E8V5I
M=F%B;&5S(&%N9"!0<F5P86ED($5X<&5N<V5S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96EV86)L
M97,@86YD(%!R97!A:60@17AP96YS97,@1&ES8VQO<W5R92!;5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF("<^(#QT86)L92!S='EL93TS1"=C;&5A<CIB;W1H
M.U=)1%1(.B`Q,#`E.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT
M<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%
M4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/
M54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`P+C@U:6X[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M(V0T9#!C.#L@0D]21$52+5))1TA4.B`C9#1D,&,X.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0X,CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B!N
M;W)M86P[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\<W1R;VYG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/DY/5$4@,SHM/"]F;VYT/CPO<W1R;VYG/CPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C
M.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X
M.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1'1O<#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B!N;W)M86P[($U!4D=)3CH@,&EN
M(#!I;B`P<'0G/B`\<W1R;VYG/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/B!214-%259!0DQ%4R!!3D0@4%)%4$%)1"!%6%!%3E-%4SPO9F]N=#X\+W-T
M<F]N9SX\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@)B,Q-C`[/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!7
M24142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,&EN(#`N.#5I;CL@5TE$5$@Z(#@W)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#8R)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,30\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M,24@8V]L<W!A;CTS1#(^(#QD:78^,C`Q,SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0V,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,B4^(#QD:78^1V]V
M97)N;65N="!A=71H;W)I=&EE<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY,SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR-CPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY0<F5P86ED(&5X<&5N<V5S/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ.#$\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0V,B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
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M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXR.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P="<^
M/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I
M=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P
M)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q
M-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X
M,"]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY04D]015)462!!3D0@15%525!-14Y4+"!.150\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P
M97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!$:7-C;&]S=7)E(%M497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68@)SX@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O
M=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@
M/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]2
M1$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'
M4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M5TE$5$@Z(#`N.#5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#@R/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[3$E.12U(14E'2%0Z(&YO<FUA;#L@34%21TE..B`P:6X@
M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQS=')O;F<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^3D]412`T.BT\+V9O;G0^/"]S=')O;F<^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"
M3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#
M2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/
M4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$=&]P/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[3$E.12U(14E'2%0Z
M(&YO<FUA;#L@34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y
M/CQS=')O;F<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^4%)/4$525%D@
M04Y$($5154E0345.5"P@3D54/"]F;VYT/CPO<W1R;VYG/CPO9&EV/B`\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`F(S$V,#L@/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^(#PO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.
M5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,&EN(#`N.#5I;CL@5TE$5$@Z(#@W)3L@0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#8R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,C,E(&-O;'-P86X],T0U/B`\9&EV/D1E8V5M8F5R)B,Q
M-C`[,S$L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#8R
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$
M,CX@/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,3,\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,B4^(#QD:78^0V]S=#H\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU,1494.B`Q,W!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY#;VUP=71E<G,@86YD('-O
M9G1W87)E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C$Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/C(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M3$5&5#H@,3-P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,B4^(#QD
M:78^16QE8W1R;VYI8R!E<75I<&UE;G0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M3$5&5#H@,3-P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
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M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXS,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,B4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C8U/"]D:78^
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M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY!8V-U;75L
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M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+4Q%1E0Z(#$S<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/D-O;7!U=&5R<R!A;F0@<V]F
M='=A<F4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
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M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+4Q%1E0Z(#$S<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/D5L96-T<F]N
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M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M3$5&
M5#H@,3-P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ/"]D:78^(#PO
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M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/D1E<')E8VEA=&5D(&-O
M<W0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C8P/"]D:78^(#PO=&0^
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M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
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M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T)SX\
M+V1I=CX@/"]D:78^("8C,38P.R`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M3$E.12U(14E'2%0Z(&YO<FUA;#L@34%21TE..B`P:6X@,&EN(#!P="`P+C@U
M:6XG(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SX@*BDF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M297!R97-E;G1S
M(&%N(&%M;W5N="!L;W=E<B!T:&%N("0F(S$V,#L\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX@,2X\+V9O;G0^/"]F;VYT/CPO9&EV/B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[3$E.12U(
M14E'2%0Z(&YO<FUA;#L@34%21TE..B`P:6X@,&EN(#!P="`P+C@U:6XG(&%L
M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F
M;VYT/B8C,38P.R8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[34%21TE..B`P:6X@,'!X(#!I;B`P+C@U:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y$
M97!R96-I871I;VX@/&9O;G0@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$Q-24[
M($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/B!E>'!E;G-E<R!F;W(@=&AE('EE87)S(&5N9&5D($1E
M8V5M8F5R(#,Q+"`R,#$T+"`R,#$S(&%N9"`R,#$R('=E<F4@)#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/C4\+V9O;G0^+"!L97-S/"]F;VYT/B8C,38P
M.W1H86X@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$\+V9O;G0^(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/F%N9"`D/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^,#PO9F]N=#XL)B,Q-C`[<F5S<&5C=&EV96QY+CPO9F]N
M=#X\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED
M=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X
M,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q
M,S@S,C4X,"]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/5$A%4B!!0T-/54Y44R!005E!0DQ%
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E!A>6%B;&5S(&%N9"!!8V-R=6%L<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(%!A
M>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@1&ES8VQO<W5R92!;5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/CPO9F]N=#X@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[5TE$
M5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%
M1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M
M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#`N.#5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D
M,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#@R/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G)SX\<W1R;VYG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^3D]412`U.BT\+V9O;G0^/"]S=')O;F<^/"]F;VYT/CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52
M+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$
M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M
M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O
M<#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P
M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)R<^/'-T<F]N9SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]42$52($%#0T]53E13(%!!64%"
M3$4\+V9O;G0^/"]S=')O;F<^/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\
M+W1A8FQE/B`F(S$V,#LF(S$V,#L\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SX\+V9O;G0^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$58
M5"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!I;B`P+C@U:6X[(%=)1%1(.B`X-R4[($)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0V,B4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C,E(&-O;'-P86X],T0U/B`\9&EV/D1E
M8V5M8F5R)B,Q-C`[,S$L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#8R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N
M/3-$,CX@/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,3,\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY%;7!L;WEE97,@86YD('!A
M>7)O;&P@86-C<G5A;',\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'
M2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
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M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(V/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY!8V-R=65D
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M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW-C`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C4Y/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/CDY
M-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.#4\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E
M<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO
M=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R
M-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A
M,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T,3,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3D-/
M344@5$%815,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC
M;VUE(%1A>"!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@
M)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z(#$P
M,"4[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[(%=)1%1(.B`P+C@U:6XG/B`\9&EV/DY/5$4@-CHM/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@/&1I=CY)3D-/
M344@5$%815,\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M,C@N,S5P=#L@34%21TE.
M.B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D
M:78^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q
M,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C@U:6XG/CPO=&0^(#QT9"!S='EL93TS
M1"=724142#H@,"XR-6EN)SX@/&1I=CYA+CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD:78^5&%X(&QA=W,@87!P
M;&EC86)L92!T;R!T:&4@0V]M<&%N>3H\+V1I=CX@/"]T9#X@/"]T<CX@/"]T
M86)L93X@)B,Q-C`[(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#$N,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&YO<FUA;"<^(%1A>&%B;&4@:6YC;VUE(&]F($ES<F%E;&D@8V]M<&%N:65S
M(&ES('-U8FIE8W0@=&\@=&%X(&%T('1H92!R871E/"]F;VYT/B!O9B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX@,C4\+V9O;G0^/"]F;VYT/B4@:6X@,C`Q,B!A;F0@,C`Q,R8C,38P
M.SQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!N;W)M
M86PG/B!A;F0@82!R871E(&]F/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@,C8N-3PO9F]N=#XE(&EN(#(P,30@86YD(#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!N;W)M86PG/B!A9G1E<G=A
M<F1S/"]F;VYT/BX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!
M4D=)3CH@,'!T(#!P>"`P<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P
M.SPO9&EV/B`\=&%B;&4@<W1Y;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P
M)3L@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T
M9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@
M=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XX-6EN
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/
M4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$.#(^/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C(U:6X[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52+5))1TA4.B`C
M9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0R-#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5=%24=(5#H@;F]R;6%L)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/F(N/"]F;VYT/CPO9F]N=#X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[
M($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"
M04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@
M0D]21$52+5))1TA4.B`C9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1T;W`^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M5T5)
M1TA4.B!N;W)M86PG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M3F5T(&]P97)A=&EN9R!L;W-S97,@8V%R<GD@9F]R=V%R9#H\+V9O;G0^/"]F
M;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`X-2XP-7!T)R!A;&EG
M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M5T5)1TA4.B!N;W)M86PG/B`F
M(S$V,#L\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-
M05)'24XZ(#!I;B`P:6X@,'!T(#$N,6EN)R!A;&EG;CTS1&IU<W1I9GD^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M5T5)1TA4.B!N;W)M86PG/E1H92!#;VUP86YY(&AA<R!A
M8V-U;75L871E9"!L;W-S97,@9F]R('1A>"!P=7)P;W-E<R!A<R!O9B!$96-E
M;6)E<B8C,38P.S,Q+"`R,#$T(&EN('1H92!A;6]U;G0@;V8@)#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/C8X-#PO9F]N=#XL('=H:6-H(&UA>2!B92!C
M87)R:65D(&9O<G=A<F0@86YD(&]F9G-E="!A9V%I;G-T('1A>&%B;&4@:6YC
M;VUE(&EN('1H92!F=71U<F4@9F]R(&%N(&EN9&5F:6YI=&4@<&5R:6]D+CPO
M9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@
M,&EN(#!I;B`P<'0@.#4N,#5P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M)SX@/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V9O;G0^/"]D:78^(#QT86)L
M92!S='EL93TS1"=C;&5A<CIB;W1H.U=)1%1(.B`Q,#`E.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@
M4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C@U:6X[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52+5))1TA4.B`C
M9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@]
M,T0X,CX\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C
M.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#`N,C5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(T/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M5T5)1TA4.B!N;W)M86PG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P="<^8RX\+V9O;G0^/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z
M("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],
M3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z
M("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U714E'2%0Z(&YO<FUA;"<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SY$969E<G)E9"!I;F-O
M;64@=&%X97,Z/"]F;VYT/CPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T
M86)L93X@)B,Q-C`[)B,Q-C`[(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#$N,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG
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M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@4VEG;FEF:6-A;G0@8V]M
M<&]N96YT<R!O9B!T:&4@0V]M<&%N>2=S(&1E9F5R<F5D('1A>"!A<W-E=',@
M87)E(&%S(&9O;&QO=W,Z/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#@U+C`U
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@
M5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!I;B`Q+C%I;CL@5TE$5$@Z(#@S)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#4X)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3@E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,30\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M,24@8V]L<W!A;CTS1#(^(#QD:78^,C`Q,SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0U."4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U."4^(#QD:78^3W!E
M<F%T:6YG(&QO<W,@8V%R<GD@9F]R=V%R9#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
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M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
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M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3@E/B`\9&EV/E)E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!E>'!E;G-E<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY,C,\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$T,CPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4X)3X@/&1I=CY)<W-U86YC92!E
M>'!E;G-E<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV-S$\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3@E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D
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M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#4X)3X@/&1I=CY.970@9&5F97)R960@=&%X(&%S<V5T(&)E
M9F]R92!V86QU871I;VX@86QL;W=A;F-E/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXQ+#<Y,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,Q,CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U."4^(#QD:78^
M5F%L=6%T:6]N(&%L;&]W86YC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^*#$L-SDQ*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@S,3(I/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4X)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0U."4^(#QD:78^3F5T(&1E9F5R<F5D('1A
M>"!A<W-E=#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T)SX\+V1I=CX@/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@+34V+C=P
M=#L@34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0[($9/3E0Z(&)O;&0@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T
M:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P:6X@,&EN(#!P="`Q+C%I;B<@86QI9VX],T1J=7-T:69Y/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
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M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN
M(#!I;B`P<'0@,2XQ:6XG(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U714E'2%0Z(&YO<FUA;"<^(#PO9F]N=#XF(S$V,#L\+V1I=CX@/'1A8FQE
M('-T>6QE/3-$)V-L96%R.F)O=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@
M,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N.#5I;CL@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D
M-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#@R/CPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X
M.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,"XR-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C0^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U714E'2%0Z(&YO<FUA;"<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SYD+CPO9F]N=#X\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@
M(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/
M4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@
M(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI
M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5=%24=(5#H@;F]R;6%L)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DYO(&QI86)I;&ET>2!F
M;W(@=6YC97)T86EN('1A>"!P;W-I=&EO;G,@=V%S(')E8V]R9&5D(&%S(&]F
M($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S+CPO9F]N=#X\+V9O;G0^/"]D
M:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^("8C,38P.R`\=&%B;&4@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"
M3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-C)P=#L@0D]21$52
M+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@=&]P.R!"
M3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L
M969T.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@,3AP=#L@
M0D]21$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@
M=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^92X\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
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M<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I
M>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D
M/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S
M.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R
M7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T
M,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M3TY424Y'14Y4($Q)04))3$E42453($%.1"!#3TU-251-14Y44SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/CPO9F]N=#X@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[5TE$
M5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%
M1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M
M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#`N.#5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D
M,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#@R/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/B`\
M<W1R;VYG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3D]412`W
M.BT\+V9O;G0^/"]S=')O;F<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P
M87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI9VX],T1J=7-T
M:69Y/B`\<W1R;VYG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M0T].5$E.1T5.5"!,24%"24Q)5$E%4R!!3D0@0T]-34E4345.5%,\+V9O;G0^
M/"]S=')O;F<^/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^("8C,38P.R`\
M=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P
M<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,
M24=..B!L969T.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@
M-C)P=#L@0D]21$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!
M3$E'3CH@=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=724142#H@,3AP="<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^82X\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!N;W)M86PG/B!4:&4@0V]M<&%N>2!I<R!E;F=A9V5D
M(&EN(&%N(&]P97)A=&EN9R!L96%S92!A9W)E96UE;G0@9F]R(&ET<R!O9F9I
M8V4@9F%C:6QI=&EE<RX@5&AE(')E;G0@97AP96YS97,@9F]R('1H92!Y96%R
M<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P@,C`Q,R!A;F0@,C`Q,B8C,38P
M.V%M;W5N=&5D('1O("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXX.#PO
M9F]N=#XL("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ-#PO9F]N=#X@
M86YD("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXP/"]F;VYT/BX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^/"]F;VYT/D9U='5R92!M:6YI;75M('!A>6UE;G1S('5N9&5R('1H92!L
M96%S92!A<F4@87,@9F]L;&]W<SH\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^
M(#PO=&%B;&4^("8C,38P.R`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^
M(#QT86)L92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S
M;VQI9#L@0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ
M(#!I;B`P:6X@,&EN(#$N-6EN.R!724142#H@-C`E.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@
M(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@(SEE8C9C92`P<'@@
M<V]L:60G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1L969T/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#0W)3X@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX@665A<B8C,38P.V5N9&5D
M)B,Q-C`[1&5C96UB97(F(S$V,#LS,2P\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E
M(&-O;'-P86X],T0R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/E1O=&%L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0T
M-R4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0T-R4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^,C`Q-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXQ,3<\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0T-R4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^,C`Q-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
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M.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#<E/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(P,3<\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T-R4^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
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M;VYT/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.T-,14%2.B!B;W1H)SX@
M/"]D:78^(#PO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TQ)3D4M2$5)1TA4.B!N;W)M86P[($U!4D=)3CH@,&EN(#!I;B`P
M<'0@-S0N-W!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TQ)3D4M2$5)1TA4.B!N;W)M86P[($U!4D=)3CH@,&EN(#!I
M;B`P<'0@,2XQ:6XG(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!H87,@<')O=FED960@8F%N:R!G=6%R
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M.R!-05)'24XZ(#!I;B`P:6X@,'!T(#<T+C=P="<@86QI9VX],T1J=7-T:69Y
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^/"]D
M:78^(#QT86)L92!S='EL93TS1"=C;&5A<CIB;W1H.U=)1%1(.B`Q,#`E.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<CX@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N
M<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C@U:6X[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52
M+5))1TA4.B`C9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T
M;W`@=VED=&@],T0X,CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$
M1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C(U:6X[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52+5))1TA4.B`C9#1D
M,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0R
M-#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.TQ)3D4M2$5)1TA4.B!N;W)M
M86P[($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@8BX\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P
M87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[3$E.12U(14E'2%0Z(&YO<FUA;#L@34%21TE..B`P:6X@
M,&EN(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/D1U<FEN9R`R,#$T('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A
M(&YE=R!O<&5R871I;F<@;&5A<V4@86=R965M96YT(&9O<B!I=',@=F5H:6-L
M97,@=6YT:6P@,C`Q-RX@1G5T=7)E(&UI;FEM=6T@<&%Y;65N=',@=6YD97(@
M=&AE(&QE87-E(&%R92`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^.#PO
M9F]N=#XN(%1H92!L96%S92!E>'!E;G-E<R!F;W(@=&AE('EE87)S(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$T+"`R,#$S)B,Q-C`[86YD(#(P,3(F(S$V,#MA
M;6]U;G1E9"!T;R`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,C4\+V9O
M;G0^+"`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,3$\+V9O;G0^(&%N
M9"`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,#PO9F]N=#XN/"]F;VYT
M/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[3$E.12U(14E'2%0Z(&YO<FUA;#L@5$585"U)3D1%3E0Z("TR
M."XS-7!T.R!-05)'24XZ(#!I;B`P:6X@,'!T(#@U+C`U<'0G(&%L:6=N/3-$
M:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@)B,Q-C`[/"]F
M;VYT/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[
M5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52
M+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#`N.#5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C
M9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#@R/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P
M8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R
M86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N,C5I;CL@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$
M15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#(T/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[3$E.
M12U(14E'2%0Z(&YO<FUA;#L@34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B!C+CPO9F]N=#X\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,
M1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$
M+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52+5))
M1TA4.B`C9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M,24Y%+4A%24=(5#H@;F]R;6%L
M.R!-05)'24XZ(#!I;B`P:6X@,'!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^3&EC96YS92!A9W)E96UE;G0Z/"]F;VYT
M/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TR."XS-7!T.R!-05)'24XZ(#!I;B`P
M:6X@,'!T(#$Q,RXT<'0G/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$
M)V-L96%R.F)O=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R
M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T
M9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#$N,C5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#$R,#X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%
M4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/
M54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)
M1%1(.B`P+C(U:6X[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M(V0T9#!C.#L@0D]21$52+5))1TA4.B`C9#1D,&,X.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0R-#X@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^*&DI/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z
M("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],
M3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z
M("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L
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M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P
M<'0@.#4N,#5P="<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\=&%B
M;&4@<W1Y;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P)3L@1D].5"U325I%
M.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XR-6EN.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@
M(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,3(P/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T
M9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#`N,C5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(T/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXH:6DI/"]F;VYT/CPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@
M0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!
M0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"
M3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1'1O<#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN
M(#!I;B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0G/E1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!%>&-L
M=7-I=F4@3&EC96YS92!!9W)E96UE;G0@=VET:"!286UO="!A="!496P@079I
M=B!5;FEV97)S:71Y($QT9"X@9F]R('1H92!U<V4L(&1E=F5L;W!M96YT(&%N
M9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!O=7(@<F5A9"UT:')O=6=H('!L871F
M;W)M+B!4:&4@8V]N<VED97)A=&EO;B!T;R!286UO="!I<R!C;VUP;W-E9"!O
M9B!A('1I97)E9"!L;W<@<VEN9VQE(&1I9VET(')O>6%L=&EE<R!O;B!N970@
M<V%L97,@86YD(&$@<W5B;&EC96YS92!F964@=&AA="!W:6QL(&YO="!E>&-E
M960@=&AE(&UI9"!T;R!H:6=H('-I;F=L92!D:6=I="!P97)C96YT(')A;F=E
M(&]F('!A>6UE;G1S(&]R(&]T:&5R(&-O;G-I9&5R871I;VX@=&AA="!T:&4@
M0V]M<&%N>2!R96-E:79E<R!I;B!C;VYN96-T:6]N('=I=&@@82!S=6)L:6-E
M;G-E+CPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/"]D:78^
M/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M
M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF
M,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE
M971S+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY32$%214A/3$1%4E,G($5154E463QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G
M($5Q=6ET>2!.;W1E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VMH;VQD97)S)R!%<75I='D@3F]T
M92!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/'1A
M8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/
M3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE.+4)/5%1/33H@,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@=&]P)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%=)
M1%1(.B`P+C@U:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/DY/5$4@.#HM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SY32$%214A/3$1%4E,G($5154E463PO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z("TU-BXW<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$
M)V-L96%R.F)O=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R
M9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T
M9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#`N.#5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#@R/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52
M+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]5
M3D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$
M5$@Z(#`N,C5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C
M9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(T/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^(&$N/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P
M8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R
M86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P
M8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@1V5N97)A;#H\
M+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#@T+C0U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)
M3CH@,&EN(#!P>"`P:6X@,2XQ:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/D%L;"!/<F1I;F%R>2!S:&%R97,L
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M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M.#0N-#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\=&%B;&4@<W1Y
M;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P)3L@1D].5"U325I%.B`Q,'!T
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,"XX-6EN.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C
M.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#(^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"
M3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#
M2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,"XR-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C0^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX@8BX\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@
M(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/
M4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@
M(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<@86QI
M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B!3:&%R
M92!C87!I=&%L.CPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@
M)B,Q-C`[(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#@T+C0U<'0[($9/3E0Z(#$P<'0@
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M86YY+"!D96-L87)E9"!B>2!T:&4@0V]M<&%N>2X\+V1I=CX@)B,Q-C`[(#QT
M86)L92!S='EL93TS1"=C;&5A<CIB;W1H.U=)1%1(.B`Q,#`E.R!&3TY4+5-)
M6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N
M=#L@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`P+C@U:6X[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52+5))1TA4
M.B`C9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED
M=&@],T0X,CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H
M)SX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-D
M-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,
M1494.B`P:6X[(%=)1%1(.B`P+C(U:6X[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52+5))1TA4.B`C9#1D,&,X.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0R-#X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B!C+CPO9F]N=#X\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%
M4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/
M54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52
M+5))1TA4.B`C9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T
M;W`^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@
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M8F]T:"<^("8C,38P.R8C,38P.R8C,38P.R`\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"3U)$15(M
M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@,3`V<'@[($)/4D1%4BU224=(
M5"U#3TQ/4CH@(S`P,#`P,#L@5D525$E#04PM04Q)1TXZ('1O<#L@0D]21$52
M+4Q%1E0M0T],3U(Z(",P,#`P,#`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/32U#3TQ/4CH@(S`P,#`P,#L@5$585"U!3$E'3CH@;&5F=#L@
M0D]21$52+51/4"U#3TQ/4CH@(S`P,#`P,#L@5TE$5$@Z(#(S<'@[($)/4D1%
M4BU224=(5"U#3TQ/4CH@(S`P,#`P,#L@5D525$E#04PM04Q)1TXZ('1O<#L@
M0D]21$52+4Q%1E0M0T],3U(Z(",P,#`P,#`G/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C$N/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SY/;B!*86YU87)Y(#(R+"`R,#$R("AI;F-E
M<'1I;VX@9&%Y*2P@=&AE($-O;7!A;GD@:7-S=65D(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/B`W+#4U,2PT,C<\+V9O;G0^($]R9&EN87)Y('-H87)E
M<R!I;B!C;VYS:61E<F%T:6]N(&]F('1H96ER('!A<B!V86QU92X\+V1I=CX@
M/"]T9#X@/"]T<CX@/"]T86)L93X@/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$;&5F=#XF(S$V,#L\+V1I
M=CX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/32U#3TQ/4CH@(S`P,#`P,#L@5$58
M5"U!3$E'3CH@;&5F=#L@0D]21$52+51/4"U#3TQ/4CH@(S`P,#`P,#L@5TE$
M5$@Z(#$P-G!X.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P,#`[(%9%4E1)
M0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C,#`P,#`P)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P,#`P
M,#`[(%1%6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],3U(Z(",P,#`P
M,#`[(%=)1%1(.B`R,W!X.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P,#`[
M(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C,#`P
M,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXR
M+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
M>2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^26X@
M1F5B<G5A<GD@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&EN
M=F5S=&UE;G0@86=R965M96YT+"!A8V-O<F1I;F<@=&\@=VAI8V@@=&AE($-O
M;7!A;GD@:7-S=65D(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`T-S$L
M.38T/"]F;VYT/B!0<F5F97)R960@02!S:&%R97,@:6X@8V]N<VED97)A=&EO
M;B!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,C4P/"]F;VYT/BX@
M26X@861D:71I;VXL(&EN($%U9W5S="`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U
M960@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#DT+#,Y,SPO9F]N=#X@
M4')E9F5R<F5D($$@<VAA<F5S(&EN(&-O;G-I9&5R871I;VX@;V8@)"8C,38P
M.SQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`U,#PO9F]N=#XN(%1H92!I
M<W-U86YC92!E>'!E;G-E<R!A;6]U;G1E9"!T;R`D/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^-3PO9F]N=#XN/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B
M;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#$Q,RXT<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF
M(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!T;W`G/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/32U#3TQ/4CH@(S`P
M,#`P,#L@5$585"U!3$E'3CH@;&5F=#L@0D]21$52+51/4"U#3TQ/4CH@(S`P
M,#`P,#L@5TE$5$@Z(#$P-G!X.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P
M,#`[(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C
M,#`P,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H
M)SX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],
M3U(Z(",P,#`P,#`[(%1%6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],
M3U(Z(",P,#`P,#`[(%=)1%1(.B`R,W!X.R!"3U)$15(M4DE'2%0M0T],3U(Z
M(",P,#`P,#`[(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/
M3$]2.B`C,#`P,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SXS+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@:G5S=&EF>2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^26X@2G5N92`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M82!S:&%R92!P=7)C:&%S92!A9W)E96UE;G0@86-C;W)D:6YG('1O('=H:6-H
M+"!T:&4@0V]M<&%N>28C,38P.VES<W5E9"!A('1O=&%L(&]F(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/B`R+#$S,"PQ-3D\+V9O;G0^($]R9&EN87)Y
M('-H87)E<R!I;B!C;VYS:61E<F%T:6]N(&]F("0\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SXR+#`R-#PO9F]N=#XL(&EN('1W;R!E<75A;"!I;G-T86QL
M;65N=',@:6X@,C`Q,R!A;F0@2F%N=6%R>2`R,#$T+CPO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q,3,N-'!T.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS
M1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#$N,S5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@
M86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
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M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SXQ.#,\+V9O;G0^(&%N9"!A(&1E96UE9"!D:79I9&5N9"!I;B!T:&4@86UO
M=6YT(&]F("0@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,C8\+V9O;G0^
M(&EN('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S+CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2
M1TE..B`P<'0@,'!X(#!P="`Q,3,N-'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#!I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B`\
M=&%B;&4@<W1Y;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P)3L@1D].5"U3
M25I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E
M;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,2XQ:6X[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52+5))1TA4
M.B`C9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED
M=&@],T0Q,#8^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!724142#H@,"XR-6EN.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C0^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@-"X\+V9O;G0^/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$
M15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=2
M3U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%
M4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M=&]P/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[34%21TE..B`P:6X@,&EN
M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/D]N($9E8G)U87)Y(#8L(#(P,30L('1H92!#;VUP86YY(&ES<W5E9"`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@-S@R+#4S-SPO9F]N=#X@3W)D
M:6YA<GD@<VAA<F5S('1O('!R:79A=&4@<&QA8V5M96YT(&EN=F5S=&]R<R!I
M;B!C;VYS:61E<F%T:6]N(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SXT+#,V.#PO9F]N=#XL(&YE="X\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^
M(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I
M;B`P:6X@,'!T(#$Q,RXT<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`Q,3,N-'!T)R!A;&EG
M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N
M=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN
M(#!I;B`P<'0@.#4N,#5P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^/"]D:78^(#QT86)L92!S='EL
M93TS1"=C;&5A<CIB;W1H.U=)1%1(.B`Q,#`E.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.
M1RU,1494.B`P:6X[(%=)1%1(.B`Q+C%I;CL@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#$P-CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/
M4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+
M1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[
M(%=)1%1(.B`P+C(U:6X[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@(V0T9#!C.#L@0D]21$52+5))1TA4.B`C9#1D,&,X.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0R-#X@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`U+CPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C
M9#1D,&,X.R!0041$24Y'+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2
M.B!T<F%N<W!A<F5N=#L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@(V0T9#!C.#L@0D]21$52+5))1TA4.B`C
M9#1D,&,X.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`^(#QD:78^
M3VX@075G=7-T(#4L(#(P,30L('1H92!#;VUP86YY(&-O;7!L971E9"!A('-U
M8V-E<W-F=6P@25!/(&]F(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`S
M+#(P,"PP,#`\+V9O;G0^($]R9&EN87)Y('-H87)E<R!A="!A('!R:6-E(&]F
M("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ,2XP,#PO9F]N=#X@<&5R
M('-H87)E(&=E;F5R871I;F<@;F5T('!R;V-E961S(&]F("0\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SXS,2PT,#4\+V9O;G0^+"!A9G1E<B!D961U8W1I
M;F<@=6YD97)W<FET:6YG(&1I<V-O=6YT<R!A;F0@8V]M;6ES<VEO;G,@86YD
M(&]T:&5R(&ES<W5A;F-E(&5X<&5N<V5S+B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.
M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\
M+V9O;G0^/"]D:78^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M0TQ%05(Z(&)O=&@G/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)V-L
M96%R.F)O=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R
M/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)3X@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C
M.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@5TE$5$@Z(#`N.#5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#@R/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%
M1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M
M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z
M(#`N,C5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D
M,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#(T/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^(&0N/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS
M<&%R96YT.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.TU!4D=)3CH@,&EN(#!I;B`P<'0G(&%L:6=N/3-$:G5S
M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@,C`Q,R!);F-E;G1I
M=F4@;W!T:6]N('!L86XZ/"]F;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`F(S$V,#L@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,2XQ:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S
M=&EF>3Y);B!$96-E;6)E<B`R,#$S+"!T:&4@0V]M<&%N>2!A=71H;W)I>F5D
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M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XS<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G(&%L:6=N/3-$;&5F=#XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P
M>"`P:6X@,2XQ:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO
M9F]N=#Y!('-U;6UA<GD@;V8@=&AE($-O;7!A;GDG<R!O<'1I;VYS(&%C=&EV
M:71Y("AF;W(@96UP;&]Y965S(&%N9"!D:7)E8W1O<G,I('5N9&5R('1H92`R
M,#$S(%!L86X@:7,@87,@9F]L;&]W<SH\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P
M<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.
M5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4Q%1E0Z(",Y96(V
M8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;B`P:6X@,&EN(#$N,3AI;CL@5TE$
M5$@Z(#@R)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z
M('9I<VEB;&4[($)/4D1%4BU43U`Z(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$
M15(M4DE'2%0Z(",Y96(V8V4@,'!X('-O;&ED)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S4E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0T-24@8V]L<W!A;CTS1#D^(#QD:78^
M665A<B8C,38P.V5N9&5D)B,Q-C`[1&5C96UB97(F(S$V,#LS,2P\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S4E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,C(E(&-O;'-P86X],T0T/B`\9&EV/C(P,30\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0R,B4@8V]L<W!A;CTS1#0^(#QD:78^,C`Q,SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0S-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q,"4^(#QD:78^3G5M8F5R)B,Q-C`[;V8\8G(O/B!O<'1I;VYS
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/E=E:6=H=&5D/&)R+SX@879E<F%G
M93QB<B\^(&5X97)C:7-E/&)R+SX@<')I8V4\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P
M)3X@/&1I=CY.=6UB97(F(S$V,#MO9CQB<B\^(&]P=&EO;G,\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L
M<W!A;CTS1#(^(#QD:78^5V5I9VAT960\8G(O/B!A=F5R86=E/&)R+SX@97AE
M<F-I<V4\8G(O/B!P<FEC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0S-24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#,U)3X@/&1I=CY/=71S=&%N9&EN9R!A="!B96=I;FYI;F<@;V8@
M>65A<CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0P,RPQ,3`\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,"XP,#`T/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'
M2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^,S$Y+#4S,3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`P,#0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0S-24^(#QD:78^1W)A;G1E9#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXS.#`L,C(R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY+C(Q
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C@S+#4W.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^,"XP,#`T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S4E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M3D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/C<X,RPS,S(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^-"XT-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'
M2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^-#`S+#$Q,#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^,"XP,#`T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,S4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
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M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXT+C0W/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT,#,L,3$P/"]D:78^(#PO=&0^
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M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXP+C`P,#0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0S-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXP+C`P,#0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\
M+V1I=CX@/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$;&5F=#X\
M<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I
M;B`Q+C%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@=V5I9VAT960M879E
M<F%G92!R96UA:6YI;F<@8V]N=')A8W1U86P@=&5R;2!O9B!T:&4@;W5T<W1A
M;F1I;F<@86YD(&5X97)C:7-A8FQE/"]F;VYT/B!O<'1I;VYS(&ES(#4N-B!Y
M96%R<R!A;F0@,BXS('EE87)S.R`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SYT:&4@86=G<F5G871E9"!I;G1R:6YS:6,@=F%L=64@;V8@=&AE(&]U='-T
M86YD:6YG(&%N9"!E>&5R8VES86)L93PO9F]N=#X@;W!T:6]N<R!I<R`D/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^,BPV-C0\+V9O;G0^/"]F;VYT/B!A;F0@)#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C(L,3<T
M/"]F;VYT/CPO9F]N=#XN($%S(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/F]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@=6YR96-O9VYI>F5D(&-O;7!E
M;G-A=&EO;B!C;W-T/"]F;VYT/B!I<R`D/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^.#@Y/"]F;VYT/CPO
M9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^=&\@8F4@<F5C;V=N
M:7IE9"!T:')O=6=H(#(P,3<\+V9O;G0^+CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X
M(#!I;B`Q+C%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\=&%B;&4@
M<W1Y;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P)3L@1D].5"U325I%.B`Q
M,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XX-6EN.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T
M9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M.#(^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X
M.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,"XR-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C0^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX@92X\+V9O;G0^/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&
M5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#
M3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(
M5#H@(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P/B`\
M9&EV/D]P=&EO;G,@9W)A;G1E9"!T;R!S97)V:6-E('!R;W9I9&5R<SH\+V1I
M=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`M-38N-W!T.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#4V+C=P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ
M(#!I;B`P<'@@,&EN(#!I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`Q+C%I;B<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/E1H92!#;VUP
M86YY(&=R86YT960@;W!T:6]N<R!T;R!C97)T86EN('-E<G9I8V4@<')O=FED
M97)S(&%N9"!A8V-O=6YT960@9F]R('1H97-E(&]P=&EO;G,@:6X@86-C;W)D
M86YC92!W:71H($%30R`U,#4M-3`L(")%<75I='DM0F%S960@<&%Y;65N="!T
M;R!N;VXM96UP;&]Y965S(BX\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@+34V+C=P=#L@34%21TE..B`P:6X@
M,&EN(#!P="`U-BXW<'0G(&%L:6=N/3-$:G5S=&EF>3X\<W1R;VYG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`F(S$V,#L\+V9O;G0^/"]S=')O;F<^
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!I;B`P
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M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@
M,&EN(#!P="`X-2XP-7!T)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^("8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z
M(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU,1494.B`C.65B-F-E
M(#!P>"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`Q+C$X:6X[(%=)1%1(
M.B`X,R4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V
M:7-I8FQE.R!"3U)$15(M5$]0.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52
M+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0R-"4^(#QD:78^1W)A;G0F(S$V,#MD871E/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$V)3X@/&1I=CY.=6UB97(F(S$V,#MO9CQB
M<B\^(&]P=&EO;G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,34E
M/B`\9&EV/D5X97)C:7-E/&)R+SX@<')I8V4\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,C0E/B`\9&EV/D5X<&ER871I;VXF(S$V,#MD871E/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,C0E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,C0E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#(T)3X@/&1I=CY$96-E;6)E<B`R+"`R,#$T
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,38E/B`\9&EV/C(P+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,34E/B`\9&EV/C<N-S@\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(T)3X@/&1I=CY$96-E
M;6)E<B`R+"`R,#(T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T)SX\+V1I=CX@
M/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,&EN(#!I;B`P<'0@.#4N
M,#5P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`F(S$V,#L\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M-05)'24XZ(#!I;B`P:6X@,'!T(#@U+C`U<'0G(&%L:6=N/3-$:G5S
M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@*BDF(S$V,#LF(S$V
M,#M!;&P@;W!T:6]N<R!W97)E(&9U;&QY('9E<W1E9"!O;B!T:&4@9W)A;G0@
M9&%T92X\+V9O;G0^/"]D:78^("8C,38P.R`\=&%B;&4@<W1Y;&4],T0G8VQE
M87(Z8F]T:#M724142#H@,3`P)3L@1D].5"U325I%.B`Q,'!T)R!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X
M.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!724142#H@,"XX-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#(^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&
M5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#
M3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@
M,"XR-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P
M8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,C0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SYF+CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T
M9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@
M=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T
M9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE.
M.B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B!3
M:&%R92UB87-E9"!P87EM96YT.CPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@
M/"]T86)L93X@/'-T<F]N9SXF(S$V,#L\+W-T<F]N9SX\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@
M,&EN(#!P>"`P:6X@,2XQ:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/CPO9F]N=#Y4:&4@<VAA<F4@8F%S960@97AP96YS92!R96-O9VYI>F5D
M(&EN('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!I<R!A<R!F;VQL;W=S.CPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A
M;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)
M1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M-#8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
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M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$-#8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E
M(&-O;'-P86X],T0R/B`\9&EV/C(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV
M/C(P,3,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CXR
M,#$R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#0V)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
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M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C@S/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0T/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/C8U,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-#8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#0V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C<S-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY/"]D:78^(#PO=&0^(#QT
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M25I%.B`Q,'!T.T-,14%2.B!B;W1H)SX@/"]D:78^(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E
M<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO
M=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R
M-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A
M,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T,38N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY214Q!
M5$5$(%!!4E19($)!3$%.0T53($%.1"!44D%.4T%#5$E/3E,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E
M9"!087)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(%!A<G1Y(%1R
M86YS86-T:6]N<R!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68@)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&3TY4.B!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!724142#H@,"XX-6EN
M)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY.3U1%
M(#DZ+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
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M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@
M,2XQ:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(
M5#H@;F]R;6%L)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#Y"86QA;F-E<R!W
M:71H(')E;&%T960@<&%R=&EE<SH\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@-38N-W!T.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#4V+C=P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!N;W)M86PG/B`F(S$V,#L\+V9O;G0^/"]D:78^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M
M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P:6X@,2XQ:6X[(%=)1%1(.B`X,R4[($)/4D1%4BU#
M3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0U."4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,C,E(&-O;'-P86X],T0U/B`\9&EV/D1E8V5M
M8F5R)B,Q-C`[,S$L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#4X)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$
M,CX@/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,3,\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3@E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-3@E/B`\9&EV/E1R861E('!A>6%B;&4@*&0I/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3@E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#4X)3X@/&1I=CY/=&AE<B!A8V-O=6YT<R!P87EA8FQE("AA*2`H8BD@*&,I
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C$R,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,V/"]D:78^(#PO=&0^(#QT9"!S
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M13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%
M05(Z(&)O=&@G/B`\+V1I=CX@/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O
M;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P=#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B`F(S$V,#L\+V9O
M;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.
M5#H@-3-P=#L@34%21TE..B`P:6X@,'!X(#!I;B`P+C,U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S
M=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SX\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/CPO9F]N=#Y296QA=&5D('!A<G1I97,G(&5X<&5N<V5S
M.CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`U-BXW<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG
M;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(
M.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P:6X@
M,2XQ:6X[(%=)1%1(.B`X,R4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($]615)&3$]7.B!V:7-I8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0T-B4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#,U
M)2!C;VQS<&%N/3-$.#X@/&1I=CY996%R)B,Q-C`[96YD960F(S$V,#M$96-E
M;6)E<B8C,38P.S,Q+#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0T-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L
M<W!A;CTS1#(^(#QD:78^,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,3,\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A
M;CTS1#(^(#QD:78^,C`Q,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#8E/B`\9&EV/D%M;W5N=',@
M8VAA<F=E9"!T;SH@*BD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T-B4^(#QD:78^)B,Q-C`[
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-#8E/B`\9&EV/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!E
M>'!E;G-E("AC*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$T
M-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXS-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0V)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#8E/B`\
M9&EV/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(&5X<&5N<V4@*&$I("AB
M*2`H8RD@*&0I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0V-SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(U-SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXU-3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV
M/B`\9F]N="!S='EL93TS1"=,24Y%+4A%24=(5#H@,3$U)3L@1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^(#PO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`M,C@N,S5P=#L@34%21TE..B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG
M;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N
M=#X\+V1I=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`F(S$V,#L\
M+V1I=CX@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P
M,#`P,#`[($U!4D=)3BU43U`Z(#!P=#L@0D]21$52+51/4"U#3TQ/4CH@(S`P
M,#`P,#L@5TE$5$@Z(#$V,#1P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T.R!(14E'2%0Z
M(#4S<'@[($)/4D1%4BU224=(5"U#3TQ/4CH@(S`P,#`P,#L@0D]21$52+4Q%
M1E0M0T],3U(Z(",P,#`P,#`G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q-C`T/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-+4-/3$]2.B`C
M,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"3U)$15(M5$]0+4-/3$]2.B`C
M,#`P,#`P.R!724142#H@-3)P=#L@0D]21$52+5))1TA4+4-/3$]2.B`C,#`P
M,#`P.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@
M(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#X\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#(X+C,U<'0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX\+V9O;G0^82X\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV/CQF;VYT('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4+5-)6D4Z(#$P<'0[1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N+'-E<FEF)SX@26X@075G=7-T+"`R,#$R+"!T
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M+V9O;G0^(#QF;VYT('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4
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M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXV/"]F;VYT/CPO
M9F]N=#X\+V9O;G0^('!E<B`\9F]N="!S='EL93TS1"=,24Y%+4A%24=(5#H@
M,3$U)3L@1D].5"U325I%.B`Q,'!T.T9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;BQS97)I9B<^(&UO;G1H+B!$=7)I;F<@075G=7-T(#(P,30L('1H92!M
M;VYT:&QY(&9E92!W87,@:6YC<F5A<V5D('1O(&%N(&%M;W5N="!O9B`D/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.T9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;BQS97)I9B<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^
M,34\+V9O;G0^/"]F;VYT/B!E9F9E8W1I=F4@:6UM961I871E;'DN($EN($%U
M9W5S="`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D('1H92!C;VYS=6QT86YT
M(&)O;G5S(&EN('1H92!A;6]U;G0@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#M&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86XL<V5R:68G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
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M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/C<P/"]F;VYT/CPO9F]N=#X@=VET:"!R96=A
M<F1S('1O('-E<G9I8V5S('!R;W9I9&5D(&1U<FEN9R`R,#$T/"]F;VYT/BX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/"]D:78^(#PO=&0^
M(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4
M+4E.1$5.5#H@+3(W+C<U<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@.#0N-#5P
M=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@
M86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\=&%B;&4@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"3U)$
M15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-3)P=#L@0D]21$52+5))
M1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$
M15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^
M(#PO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`R."XS
M-7!T)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/F(N/"]D:78^(#PO
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M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/B!A<'!R;WAI;6%T96QY(#QF;VYT('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@)#PO9F]N=#X\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^-#PO9F]N=#X\+V9O;G0^(#QF;VYT('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@<VEN8V4@4V5P=&5M
M8F5R(#$P+"`R,#$S+B!4:&4@<&%R=&EE<R!T97)M:6YA=&5D('1H92!A9W)E
M96UE;G0@;VX@4V5P=&5M8F5R(#$L(#(P,30N/"]F;VYT/CPO9&EV/B`\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z("TR-RXW-7!T.R!-05)'24XZ(#!P="`P<'@@,'!T(#@T+C0U
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M;F]R;6%L)SX@)B,Q-C`[/"]F;VYT/CPO9&EV/B`\=&%B;&4@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"3U)$
M15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-3)P=#L@0D]21$52+5))
M1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$
M15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,C@N,S5P="<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^8RX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GDG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/CQF;VYT('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@06X@86=R965M96YT('=A<R!S:6=N960@;VX@075G=7-T(#(P
M+"`R,#$S(&)E='=E96X@=&AE($-O;7!A;GD@86YD(&]N92!O9B!I=',@<VAA
M<F5H;VQD97)S+"!A<R!A(&-O;G-U;'1A;G0@=&\@<F5N9&5R(&UA;F%G96UE
M;G0L(&9I;F%N8V4@86YD(&]P97)A=&EO;B!S97)V:6-E<R!F;W(@86X@86UO
M=6YT(&]F/"]F;VYT/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@87!P
M<F]X:6UA=&5L>2`\9F]N="!S='EL93TS1"=,24Y%+4A%24=(5#H@,3$U)3L@
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^("0\+V9O;G0^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$U/"]F;VYT
M/CPO9F]N=#X@<&5R(&UO;G1H+B`\9F]N="!S='EL93TS1"=,24Y%+4A%24=(
M5#H@,3$U)3L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^($1U<FEN9R!!=6=U<W0@,C`Q-"P@=&AE
M(&UO;G1H;'D@9F5E('=A<R!I;F-R96%S960@=&\@86X@86UO=6YT(&]F("0\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ.3PO9F]N=#X@969F96-T:79E
M(&EM;65D:6%T96QY+B!);B!!=6=U<W0@,C`Q-"P@=&AE($-O;7!A;GD@9W)A
M;G1E9"!T:&4@8V]N<W5L=&%N="!A(&)O;G5S(&EN('1H92!A;6]U;G0@;V8@
M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CDP/"]F;VYT/B!I;B!C;VYN
M96-T:6]N('=I=&@@=&AE(&-O;G-U;6UA=&EO;B!O9B!T:&4@25!/+CPO9F]N
M=#X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M,C@N,S5P=#L@34%21TE..B`P<'0@
M,'!X(#!P="`X-2XP-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QT
M86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P
M="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P
M,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P,#`P,#`[(%1%6%0M04Q)
M1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],3U(Z(",P,#`P,#`[(%=)1%1(.B`U
M,G!T.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P,#`[(%9%4E1)0T%,+4%,
M24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C,#`P,#`P)SX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U=)1%1(.B`R."XS-7!T)SX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SYD+CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&9O;G0@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z(#$Q-24[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
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M<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$Q-24[($9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`D/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/C$\+V9O;G0^/"]F;VYT/B!P97(@;6]N=&@\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^+CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I
M=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/"]D:78^/'1A8FQE(&)O<F1E<CTS
M1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^
M/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?
M-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T,3<N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&24Y!3D-)
M04P@15A014Y315,@*$E.0T]-12DL($Y%5#QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!);F-O;64@86YD
M($5X<&5N<V5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W1H97(@26YC;VUE(&%N9"!/=&AE<B!%>'!E
M;G-E($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QT86)L92!S='EL
M93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G
M5$585"U!3$E'3CH@:G5S=&EF>3L@5D525$E#04PM04Q)1TXZ('1O<"<^(#QT
M9"!S='EL93TS1"=724142#H@,'!X)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`P+C<U:6XG/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DY/5$4@,3`Z+3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^1DE.04Y#24%,($584$5.
M4T53("A)3D-/344I+"!.150\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M-38N-W!T
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P=#L@1D].5#H@8F]L9"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I
M9GD^)B,Q-C`[/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO
M9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F
M=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%
M4BU,1494.B`C.65B-F-E(#!P>"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I
M;B`P+C@U:6X[(%=)1%1(.B`Y,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[($]615)&3$]7.B!V:7-I8FQE.R!"3U)$15(M5$]0.B`C.65B-F-E(#!P
M>"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$-3,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0S-24@8V]L<W!A;CTS1#@^(#QD:78^665A
M<B8C,38P.V5N9&5D/&)R+SX@1&5C96UB97(F(S$V,#LS,2P\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3,E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,30\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@
M/&1I=CXR,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,3(\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$-3,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4S)3X@/&1I=CY&:6YA;F-I86P@
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M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+4Q%
M1E0Z(#$S<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-3,E/B`\9&EV/DEN=&5R97-T(&5X<&5N<V4\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/BH\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXI/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR/"]D:78^(#PO
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXJ/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^*3PO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M3$5&
M5#H@,3-P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-CPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#4S)3X@/&1I=CY%>&-H86YG92!R871E/"]D:78^(#PO
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M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR,3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0U,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4S)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(W/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3,E/B`\
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M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[
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M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+4Q%1E0Z(#$S<'@[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3,E/B`\9&EV/DEN
M=&5R97-T(&EN8V]M93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C@U/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M3$5&5#H@,3-P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0U,R4^(#QD:78^17AC:&%N9V4@<F%T93PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'
M2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0U,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#4S)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C@U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXU/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4S
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$-3,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@U."D\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH
M,RD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G
M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M-38N-W!T.R!-05)'24XZ
M(#!P="`P<'@@,'!T(#4V+C=P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#`N.#5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y
M/BHI)B,Q-C`[)B,Q-C`[4F5P<F5S96YT<R!A;B!A;6]U;G0@;&]W97(@=&AA
M;B8C,38P.R8C,38P.R0F(S$V,#LQ/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^/"]F;VYT/BX\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y
M;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\
M+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X
M9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY354)315%514Y4($56
M14Y44SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@
M179E;G1S(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/'1A8FQE('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(&)O
M;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+4)/5%1/33H@,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[(%=)1%1(.B`P
M+C@U:6XG/B`\9&EV/DY/5$4@,3$Z+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD:78^4U5"4T51545.5"!%5D5.
M5%,\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>"`P<'0@-SAP=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1L969T
M/B8C,38P.SPO9&EV/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!724142#H@,3`P)3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XX-6EN)SX\+W1D/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^(#QD:78^,2X\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV/D1U
M<FEN9R!*86YU87)Y(#(P,34L(&$@=VAO;&QY+6]W;F5D('-U8G-I9&EA<GD@
M=V%S(&5S=&%B;&ES:&5D(&EN('1H92!S=&%T92!O9B!$96QA=V%R92!N86UE
M9"!":6]";&%S="!0:&%R;6$@26YC+CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I
M;CL@34%21TE..B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^
M)B,Q-C`[/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[
M(%=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C@U:6XG/CPO=&0^(#QT
M9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@/&1I=CXR+CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD:78^3VX@
M1F5B<G5A<GD@,BP@,C`Q-2P@=&AE($-O;7!A;GD@87!P;VEN=&5D(&$@;F5W
M)B,Q-C`[4')E<VED96YT(&%N9"!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<B!A
M;F0@82!M96UB97(@;V8@:71S(&)O87)D(&]F(&1I<F5C=&]R<RX@07,@<&%R
M="!O9B!T:&4@86=R965M96YT('1H92!N97<@0T5/('=A<R!G<F%N=&5D(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`T.3@L,#8W/"]F;VYT/B8C,38P
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M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`M,C@N,S5P=#L@34%21TE..B`P<'0@,'!X(#!P="`X-2XP-7!T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A
M;&EG;CTS1&IU<W1I9GD^/&(^)B,Q-C`[/"]B/CPO9&EV/B`\=&%B;&4@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!724142#H@,3`P)3L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7
M24142#H@,"XX-6EN)SX\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I
M;B<^(#QD:78^,RX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GDG/B`\9&EV/D]N($9E8G)U87)Y(#$V+"`R,#$U+"8C,38P
M.W1H92!#;VUP86YY)W,@8F]A<F0@;V8@9&ER96-T;W)S(')E<V]L=F5D('1O
M(&ES<W5E)B,Q-C`[/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#(T+#`P
M,#PO9F]N=#X@;W!T:6]N<R!T;R!E;7!L;WEE97,@=VET:"!A;B!E>&5R8VES
M92!P<FEC92!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^-RXQ-SPO
M9F]N=#X@<&5R('-H87)E+B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ
M,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C
M83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R
M-3@P+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14)/04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4TE'3DE&24-!3E0@04-#3U5.5$E.1R!0
M3TQ)0TE%4R`H4&]L:6-I97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y5<V4@;V8@17-T:6UA=&5S+"!0;VQI8WD@6U!O;&EC>2!497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,2XQ:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L
M:6=N/3-$:G5S=&EF>3X\+V1I=CX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/B`\+V9O;G0^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,3AP="<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^82X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GDG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/E5S92!O9B!E<W1I;6%T97,Z/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B
M;&4^("8C,38P.SQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!
M4D=)3CH@,&EN(#!P>"`P:6X@,"XY.3EI;CL@1D].5#H@,3!P="!4:6UE<R!.
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M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/"]D
M:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P
M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE=R!!
M8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S+"!0;VQI8WD@6U!O;&EC>2!497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@-S0N
M-W!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!A;&EG;CTS1&IU<W1I9GD^/"]D:78^("8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]4
M5$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT
M<B!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!615)424-!3"U!3$E'
M3CH@=&]P)SX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P
M,#`P,#`[($)/4D1%4BU43U`M0T],3U(Z(",P,#`P,#`[(%=)1%1(.B`P+C<U
M:6X[($)/4D1%4BU224=(5"U#3TQ/4CH@(S`P,#`P,#L@0D]21$52+4Q%1E0M
M0T],3U(Z(",P,#`P,#`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#`N,C5I;B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^8BX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/DYE=R!A8V-O=6YT:6YG('!R;VYO=6YC96UE;G1S
M.CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>"`P<'0@-S`N.7!T.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<@86QI
M9VX],T1J=7-T:69Y/DEN($IU;F4@,C`Q-"!T:&4@1FEN86YC:6%L($%C8V]U
M;G1I;F<@4W1A;F1A<F1S($)O87)D("@B1D%30B(I(&ES<W5E9"!!8V-O=6YT
M:6YG(%-T86YD87)D<R!5<&1A=&4@*")!4U4B*2`Q,"TR,#$T("@B05-5(#$P
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M;V-K:&]L9&5R<R<@97%U:71Y+"`H:6DI(&QA8F5L('1H92!F:6YA;F-I86P@
M<W1A=&5M96YT<R!A<R!T:&]S92!O9B!A(&1E=F5L;W!M96YT('-T86=E(&5N
M=&ET>2P@*&EI:2D@9&ES8VQO<V4@82!D97-C<FEP=&EO;B!O9B!T:&4@9&5V
M96QO<&UE;G0@<W1A9V4@86-T:79I=&EE<R!I;B!W:&EC:"!T:&4@96YT:71Y
M(&ES(&5N9V%G960L(&%N9"`H:78I(&1I<V-L;W-E(&EN('1H92!F:7)S="!Y
M96%R(&EN('=H:6-H('1H92!E;G1I='D@:7,@;F\@;&]N9V5R(&$@9&5V96QO
M<&UE;G0@<W1A9V4@96YT:71Y('1H870@:6X@<')I;W(@>65A<G,@:70@:&%D
M(&)E96X@:6X@=&AE(&1E=F5L;W!M96YT('-T86=E+B!4:&4@86UE;F1M96YT
M<R!T;R!!4U4@,3`M,C`Q-"!A<F4@969F96-T:79E(&9O<B!A;FYU86P@<F5P
M;W)T:6YG('!E<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R
M,#$T+B!4:&4@0V]M<&%N>2!H87,@87!P;&EE9"!T:&4@05-5(&EN('1H97-E
M(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P
M="`W,"XY<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
M;F]R;6%L)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@@,'!T(#<P+CEP=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG(&%L
M:6=N/3-$:G5S=&EF>3Y);B`R,#$T+"!T:&4@1D%30B!I<W-U960@05-5(#$U
M+3(P,30L(%!R97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<RU'
M;VEN9R!#;VYC97)N("A3=6)T;W!I8R`R,#4M-#`I.B!$:7-C;&]S=7)E(&]F
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M=&EN9R!P97)I;V1S(&5N9&EN9R!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-B!W
M:71H(&5A<FQY(&%D;W!T:6]N('!E<FUI='1E9"X@5&AE($-O;7!A;GD@:7,@
M8W5R<F5N=&QY(&5V86QU871I;F<@=&AE(&5F9F5C="P@:68@86YY+"!T:&%T
M('1H92!A9&]P=&EO;B!O9B!T:&ES(&=U:61A;F-E('=I;&P@:&%V92!O;B!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO9&EV
M/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E
M.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:6YA;F-I
M86P@4W1A=&5M96YT<R!$:7-C;&]S=7)E(%M0;VQI8WD@5&5X="!";&]C:UT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'
M24XZ(#!I;B`P<'@@,&EN(#!I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B`\=&%B;&4@<W1Y
M;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P)3L@1D].5"U325I%.B`Q,'!T
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!724142#H@,"XW-6EN.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C
M.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-S(^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D,&,X.R!"
M3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D%#
M2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!724142#H@,"XR-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C0^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M,24Y%+4A%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!I
M;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^8RX\+V9O
M;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q
M-C`[/"]D:78^(#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.U1%6%0M04Q)1TXZ(&IU<W1I9GD[($Q)3D4M2$5)1TA4.B!N;W)M86P[
M($U!4D=)3CH@,&EN(#!I;B`P<'0G/B`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SY&:6YA;F-I86P@<W1A=&5M96YT<R!I;B!5+E,N(&1O;&QA<G,Z/"]F
M;VYT/CPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@
M,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M92!5+E,N)B,Q-C`[9&]L;&%R+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[0TQ%05(Z(&)O=&@G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P
M>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
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M($%C8V]U;G1I;F<@4W1A;F1A<F1S($-O9&EF:6-A=&EO;B`H(D%30R(I(#@S
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M;F-O;64@;W(@97AP96YS97,L(&%S(&%P<')O<')I871E+CPO9&EV/B`\+V1I
M=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L
M92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H
M($5Q=6EV86QE;G1S+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@
M,'!T(#!P>"`P<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CPO9&EV/B`\=&%B
M;&4@<W1Y;&4],T0G8VQE87(Z8F]T:#M724142#H@,3`P)3L@1D].5"U325I%
M.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C9#1D,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!724142#H@,"XW-6EN.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@
M(V0T9#!C.#L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-S(^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C9#1D
M,&,X.R!"3U)$15(M3$5&5#H@(V0T9#!C.#L@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!724142#H@,"XR-6EN.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z("-D-&0P8S@[($)/4D1%4BU224=(5#H@(V0T9#!C.#L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,C0^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M,24Y%+4A%24=(5#H@;F]R;6%L.R!-05)'
M24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^
M(&0N/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1'1O<#X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.TQ)3D4M2$5)1TA4.B!N;W)M86P[($U!4D=)3CH@,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SY#
M87-H(&5Q=6EV86QE;G1S.CPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T
M86)L93X@)B,Q-C`[(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T
M:69Y/D-A<V@@97%U:79A;&5N=',@87)E('-H;W)T+71E<FT@:&EG:&QY(&QI
M<75I9"!I;G9E<W1M96YT<R!T:&%T(&%R92!R96%D:6QY(&-O;G9E<G1I8FQE
M('1O(&-A<V@@=VET:"!O<FEG:6YA;"!M871U<FET:65S(&]F('1H<F5E(&UO
M;G1H<R!O<B!L97-S(&%T(&%C<75I<VET:6]N+CPO9&EV/B`\+V1I=CX\=&%B
M;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO
M=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&]R="!497)M($)A;FL@1&5P
M;W-I=',@6U!O;&EC>2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/'1A
M8FQE('-T>6QE/3-$)V-L96%R.F)O=&@[5TE$5$@Z(#$P,"4[($9/3E0M4TE:
M13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(V0T9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#`N-S5I;CL@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z
M("-D-&0P8S@[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#<R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(V0T
M9#!C.#L@0D]21$52+4Q%1E0Z("-D-&0P8S@[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)!0TM'4D]53D0M0T],3U(Z('1R86YS<&%R96YT.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@5TE$5$@Z(#`N,C5I;CL@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B`C9#1D,&,X.R!"3U)$15(M4DE'2%0Z("-D-&0P8S@[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#(T/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[3$E.12U(14E'2%0Z(&YO<FUA;#L@34%2
M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/B!E+CPO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ("-D-&0P8S@[($)/4D1%4BU,1494.B`C9#1D,&,X.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!"04-+1U)/54Y$+4-/3$]2.B!T<F%N<W!A<F5N=#L@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@(V0T9#!C.#L@0D]21$52+5))1TA4.B`C9#1D,&,X.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1T;W`^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M,24Y%+4A%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!I;B`P:6X@,'!T
M)R!A;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^
M(%-H;W)T+71E<FT@8F%N:R!D97!O<VET<SH\+V9O;G0^/"]D:78^(#PO=&0^
M(#PO='(^(#PO=&%B;&4^("8C,38P.R`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I;B`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L
M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SY3:&]R
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M97)A9V4@:6YT97)E<W0@<F%T92!O9B`P+C8V)2X\+V9O;G0^/"]D:78^(#PO
M9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A
M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y+"!0
M;&%N="!A;F0@17%U:7!M96YT+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<@86QI9VX],T1L969T/CPO9&EV/B`\=&%B;&4@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,'!T.R!724142#H@,3`P)3L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@
M,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L969T.R!"
M3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-31P=#L@0D]21$52
M+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@=&]P.R!"
M3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^(#PO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`P
M+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
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M="`P<'@@,'!T(#4V+C=P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2
M1TE..B`P:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/CPO9F]N=#Y0<F]P97)T>2!A;F0@97%U:7!M96YT(&%R92!S=&%T
M960@870@8V]S="P@;F5T(&]F(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;BX@
M1&5P<F5C:6%T:6]N(&ES(&-A;&-U;&%T960@=7-I;F<@=&AE('-T<F%I9VAT
M+6QI;F4@;65T:&]D(&]V97(@=&AE(&5S=&EM871E9"!U<V5F=6P@;&EV97,@
M;V8@=&AE(&%S<V5T<R!A="!T:&4@9F]L;&]W:6YG(')A=&5S.CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2
M1TE..B`P<'0@,'!X(#!P="`P+C@U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F
M=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%
M4BU,1494.B`C.65B-F-E(#!P>"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I
M;B`Q:6X[(%=)1%1(.B`V,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($]615)&3$]7.B!V:7-I8FQE.R!"3U)$15(M5$]0.B`C.65B-F-E(#!P>"!S
M;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$-3`E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$."4@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0W)3X@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/D-O;7!U=&5R<R!A;F0@<V]F='=A<F4\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-R4^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^,S,\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D5L96-T<F]N:6,@97%U:7!M96YT
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0W)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.T-,14%2.B!B;W1H)SXQ-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
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M4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
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M4F]M86X[1D].5"U325I%.B`Q,'!T.T-,14%2.B!B;W1H)SX@/"]D:78^(#PO
M9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TU-BXW<'0[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@-38N-W!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!
M4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
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M92!F86ER('9A;'5E(&]F('1H92!A<W-E=',N)B,Q-C`[07-S971S('1O(&)E
M(&1I<W!O<V5D(&]F(&%R92!R97!O<G1E9"!A="!T:&4@;&]W97(@;V8@=&AE
M(&-A<G)Y:6YG(&%M;W5N="!O<B!F86ER('9A;'5E(&QE<W,@8V]S=',@=&\@
M<V5L;"X@26X@,C`Q-"P@,C`Q,R!A;F0@,C`Q,B!N;R!I;7!A:7)M96YT(&QO
M<W-E<R!H879E(&)E96X@:61E;G1I9FEE9"X\+V1I=CX@/"]D:78^/'1A8FQE
M(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T
M.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^
M/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9R!497)M($1E<&]S:71S(%M0
M;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@+3(X+C,U<'0[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CPO9&EV/B`\=&%B
M;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!724142#H@,3`P)3L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=.
M.B!L969T.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-31P
M=#L@0D]21$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'
M3CH@=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SYG+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^3&]N9RUT97)M(&1E<&]S:71S.CPO9&EV/B`\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q
M-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.
M5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P="!4
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M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT
M9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N
M="!%>'!E;G-E+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`M,C@N,S5P=#L@34%21TE..B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS
M1&IU<W1I9GD^/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[(%=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z
M(",P,#`P,#`[(%1%6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],3U(Z
M(",P,#`P,#`[(%=)1%1(.B`U-'!T.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P
M,#`P,#`[(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2
M.B`C,#`P,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/F@N/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY297-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@8V]S=',Z/"]D:78^(#PO=&0^(#PO='(^(#PO
M=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#@U+C`U<'0[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF
M>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S(&%R92!E>'!E
M;G-E9"!A<R!I;F-U<G)E9"X@5&AO<V4@97AP96YS97,@:6YC;'5D97,@<&%Y
M;65N=',@=&\@=&AI<F0@<&%R='D@8VQI;FEC86P@8V]N<W5L=&%N=',L(&5X
M<&5N<V5S(')E;&%T960@=&\@8V]N9'5C=&EN9R!C;&EN:6-A;"!T<FEA;',L
M('-A;&%R:65S(&%N9"!R96QA=&5D('!E<G-O;FYE;"!E>'!E;G-E<RP@=')A
M=F5L(&5X<&5N<V5S+"!A;F0@<VAA<F4@8F%S960@/&9O;G0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@=')A;G-P87)E;G0G/F-O;7!E;G-A=&EO;B!E
M>'!E;G-E<R!R96QA=&5D('1O(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!E
M;7!L;WEE97,N/"]F;VYT/CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$
M,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\
M+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X+"!0;VQI8WD@6U!O;&EC>2!497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XX
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!A;&EG;CTS1&IU<W1I9GD^/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTM0T],3U(Z(",P,#`P,#`[(%1%6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU4
M3U`M0T],3U(Z(",P,#`P,#`[(%=)1%1(.B`U-'!T.R!"3U)$15(M4DE'2%0M
M0T],3U(Z(",P,#`P,#`[(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,
M1494+4-/3$]2.B`C,#`P,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.T-,14%2.B!B;W1H)SX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
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M24XZ(#!P="`P<'@@,'!T(#@U+C`U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P
M:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
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M(')E86QI>F5D+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I
M;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/E1H92!#;VUP86YY(&EM<&QE
M;65N=',@82!T=V\M<W1E<"!A<'!R;V%C:"!T;R!R96-O9VYI>F4@86YD(&UE
M87-U<F4@=6YC97)T86EN('1A>"!P;W-I=&EO;G,N(%1H92!F:7)S="!S=&5P
M(&ES('1O(&5V86QU871E('1H92!T87@@<&]S:71I;VX@=&%K96X@;W(@97AP
M96-T960@=&\@8F4@=&%K96X@:6X@82!T87@@<F5T=7)N(&)Y(&1E=&5R;6EN
M:6YG(&EF('1H92!W96EG:'0@;V8@879A:6QA8FQE(&5V:61E;F-E(&EN9&EC
M871E<R!T:&%T(&ET(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1H870L(&]N
M(&%N(&5V86QU871I;VX@;V8@=&AE('1E8VAN:6-A;"!M97)I=',L('1H92!T
M87@@<&]S:71I;VX@=VEL;"!B92!S=7-T86EN960@;VX@875D:70L(&EN8VQU
M9&EN9R!R97-O;'5T:6]N(&]F(&%N>2!R96QA=&5D(&%P<&5A;',@;W(@;&ET
M:6=A=&EO;B!P<F]C97-S97,N(%1H92!S96-O;F0@<W1E<"!I<R!T;R!M96%S
M=7)E('1H92!T87@@8F5N969I="!A<R!T:&4@;&%R9V5S="!A;6]U;G0@=&AA
M="!I<R!M;W)E('1H86X@-3`E("AC=6UU;&%T:79E(&)A<VES*2!L:6ME;'D@
M=&\@8F4@<F5A;&EZ960@=7!O;B!U;'1I;6%T92!S971T;&5M96YT+B!!<R!O
M9B!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,R!T:&4@0V]M<&%N>2!H87,@
M;F]T(')E8V]R9&5D(&$@;&EA8FEL:71Y(&9O<B!U;F-E<G1A:6X@=&%X('!O
M<VET:6]N<RX\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4]
M,T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A
M8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N8V5N=')A=&EO;B!2:7-K+"!#<F5D:70@4FES:RP@4&]L:6-Y
M(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#<T+C=P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CPO9&EV/B`\=&%B;&4@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L
M969T.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-31P=#L@
M0D]21$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@
M=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^(#PO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`Q.'!T)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SYJ+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^0V]N8V5N=')A=&EO;G,@;V8@8W)E9&ET(')I<VLZ/"]D:78^(#PO=&0^
M(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4
M+4E.1$5.5#H@+3(X+C,U<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@.#4N,#5P
M=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@
M86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I
M;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
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M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P
M>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I
M;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
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M15A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX]
M,T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I;B`Q:6X[
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M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@
M;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S+"!0;VQI8WD@6U!O;&EC>2!497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1L969T/CPO9&EV/B`\=&%B;&4@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-+4-/3$]2.B`C,#`P,#`P.R!415A4+4%,24=..B!L
M969T.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!724142#H@-31P=#L@
M0D]21$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!615)424-!3"U!3$E'3CH@
M=&]P.R!"3U)$15(M3$5&5"U#3TQ/4CH@(S`P,#`P,"<^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^(#PO9F]N=#X\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`Q.'!T)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SYK+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^1F%I<B!V86QU92!O9B!F:6YA;F-I86P@:6YS=')U;65N=',Z/"]D:78^
M(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#<T+C=P
M=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@
M86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P
M="`W-"XW<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y4:&4@0V]M<&%N>2!H87,@;F\@9FEN
M86YC:6%L(&EN<W1R=6UE;G1S('1H870@87)E(&UE87-U<F5D(&%T(&9A:7(@
M=F%L=64N/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#<T+C=P=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J
M=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`W-"XW<'0[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L
M:6=N/3-$:G5S=&EF>3Y4:&4@8V%R<GEI;F<@86UO=6YT<R!O9B!C87-H(&%N
M9"!C87-H(&5Q=6EV86QE;G1S+"`\9F]N="!S='EL93TS1"=,24Y%+4A%24=(
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M<RX\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED
M=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16%R;FEN9W,@4&5R(%-H87)E+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`M,C@N,S5P=#L@34%21TE..B`P<'0@,'!X(#!P="`X-2XP
M-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!A;&EG;CTS1&IU<W1I9GD^/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTM0T],3U(Z(",P,#`P,#`[(%1%6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU4
M3U`M0T],3U(Z(",P,#`P,#`[(%=)1%1(.B`U-'!T.R!"3U)$15(M4DE'2%0M
M0T],3U(Z(",P,#`P,#`[(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,
M1494+4-/3$]2.B`C,#`P,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.T-,14%2.B!B;W1H)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F
M;VYT/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$X<'0G/B`\
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M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M
M,C@N,S5P=#L@34%21TE..B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#`N.3DY:6X[
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M92!W:71H($%30R`R-C`L(")%87)N:6YG<R!P97(@4VAA<F4N(CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2
M1TE..B`P:6X@,'!X(#!I;B`P+CDY.6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#`N.3DY:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF
M>3Y&;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,30L
M(#(P,3,@86YD(#(P,3(L(&%L;"!O=71S=&%N9&EN9R!O<'1I;VYS(&AA=F4@
M8F5E;B!E>&-L=61E9"!F<F]M('1H92!C86QC=6QA=&EO;B!O9B!T:&4@9&EL
M=71E9"!N970@;&]S<R!P97(@<VAA<F4@<VEN8V4@=&AE:7(@969F96-T('=A
M<R!A;G1I+61I;'5T:79E+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$
M,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\
M+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VXL($]P=&EO
M;B!A;F0@26YC96YT:79E(%!L86YS(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M0TQ%05(Z(&)O=&@G/B`\+V1I=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@
M/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@
M,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/32U#3TQ/4CH@(S`P,#`P,#L@5$585"U!
M3$E'3CH@;&5F=#L@0D]21$52+51/4"U#3TQ/4CH@(S`P,#`P,#L@5TE$5$@Z
M(#4T<'0[($)/4D1%4BU224=(5"U#3TQ/4CH@(S`P,#`P,#L@5D525$E#04PM
M04Q)1TXZ('1O<#L@0D]21$52+4Q%1E0M0T],3U(Z(",P,#`P,#`G/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$X<'0G/B`\9&EV('-T>6QE/3-$)T-,
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M($U!4D=)3CH@,&EN(#!P>"`P:6X@,"XT:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SY4:&4@0V]M<&%N>2!A
M8V-O=6YT<R!F;W(@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&EN(&%C8V]R
M9&%N8V4@=VET:"!!4T,@-S$X+"`B0V]M<&5N<V%T:6]N("T@4W1O8VL@0V]M
M<&5N<V%T:6]N(B`H(D%30R`W,3@B*2!T:&%T(')E<75I<F5S('1H92!M96%S
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M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^
M)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P
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M87-S=6UP=&EO;G,@87,@;F]T960@8F5L;W<Z/"]F;VYT/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE.
M.B`P:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#XF(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@
M,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/&D^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO
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M(#!I;B`P<'@@,&EN(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B8C,38P.SPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P
M:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\:3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0G/B!6;VQA=&EL:71Y/"]F;VYT/CPO:3X@/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXM(%-I;F-E('1H92!#;VUP
M86YY)W,@<VAA<F5S('-T87)T960@=')A9&EN9R!O;B!.05-$05$@:6X@2G5L
M>2`R,#$T+"!S=69F:6-I96YT('%U;W1E9"!P<FEC97,@;V8@=&AE($-O;7!A
M;GDG<R!S:&%R92!A<F4@=6YA=F%I;&%B;&4N($1U92!T;R!I;G-U9F9I8VEE
M;G0@:&ES=&]R:6-A;"!D871A(&9O<B!T:&4@0V]M<&%N>2P@=&AE(&5X<&5C
M=&5D('9O;&%T:6QI='D@9&5T97)M:6YA=&EO;B!W87,@8F%S960@;VX@<VEM
M:6QA<B!C;VUP86YI97,G('-T;V-K('9O;&%T:6QI='DN/"]F;VYT/CPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@
M34%21TE..B`P:6X@,'!X(#!I;B`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#XF(S$V,#L\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!
M4D=)3CH@,&EN(#!P>"`P:6X@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^/&D^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SY2:7-K(&9R964@:6YT97)E<W0@
M<F%T93PO9F]N=#X\+VD^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^+2!4:&4@<FES:R!F<F5E(&EN=&5R97-T(')A=&4@:7,@8F%S960@;VX@
M=&AE('EI96QD(&]F(%4N4RX@5')E87-U<GD@8F]N9',@=VET:"!E<75I=F%L
M96YT('1E<FUS+CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,&EN(#!P>"`P:6X@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A
M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M)SX\+V9O;G0^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!I;B`P<'@@,&EN(#%I;CL@
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M;"!D871A(&]R('1H92!314,@<W1A9F8G<R`B<VEM<&QI9FEE9"(@;65T:&]D
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M=&EO;G,N/"]F;VYT/CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V9O
M;G0^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P
M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$R-V,V.#`R7V-A
M,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U
M.#`O5V]R:W-H965T<R]3:&5E=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)
M0TE%4R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0L($5S=&EM871E9"!5<V5F
M=6P@3&EV97,L($1E<')E8VEA=&EO;B!2871E<R!;5&%B;&4@5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-
M05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P=#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@
M34%21TE..B`P<'0@,'!X(#!P="`P+C@U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/E!R;W!E<G1Y(&%N9"!E
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M+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N.#5I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX]
M,T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@
M,3`P)2<^(#QT86)L92!S='EL93TS1"="3U)$15(M0D]45$]-.B`C.65B-F-E
M(#!P>"!S;VQI9#L@0D]21$52+4Q%1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-
M05)'24XZ(#!I;B`P:6X@,&EN(#%I;CL@5TE$5$@Z(#8P)3L@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4[($)/4D1%4BU4
M3U`Z(",Y96(V8V4@,'!X('-O;&ED.R!"3U)$15(M4DE'2%0Z(",Y96(V8V4@
M,'!X('-O;&ED)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L
M:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0U,"4^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0X)2!C;VQS<&%N/3-$,CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXE/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,"4^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#<E/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,"4^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^0V]M<'5T97)S(&%N9"!S
M;V9T=V%R93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0W)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SXS,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
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M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#<E/B`\9&EV
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M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY/9F9I8V4@9G5R;FET=7)E(&%N9"!E
M<75I<&UE;G0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#<E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C8\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z
M(&)O=&@G/B`\+V1I=CX@/"]D:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P
M('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO
M='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q,C=C-C@P,E]C83$U7S0W
M-S1?.&8S8U]A-C,U,3,X,S(U.#`O5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4D5#14E604),
M15,@04Y$(%!215!!240@15A014Y315,@*%1A8FQE<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5C96EV86)L
M97,@86YD(%!R97!A:60@17AP96YS97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE<R!A
M;F0@4')E<&%I9"!%>'!E;G-E<R!$:7-C;&]S=7)E(%M486)L92!497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P
M,"4G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T
M.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,&EN(#`N.#5I;CL@5TE$5$@Z(#@W)3L@
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#8R
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$-C(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O
M;'-P86X],T0R/B`\9&EV/C(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^,C`Q
M,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0V,B4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0V,B4^(#QD:78^1V]V97)N;65N="!A=71H;W)I=&EE<SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY
M,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXR-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I
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M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXQ.#$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0V,B4^(#QD:78^)B,Q-C`[/"]D
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M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$-C(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
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M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR.3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P="<^/"]D:78^(#PO9&EV/B`\+V1I=CX@/"]D
M:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B
M;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T
M7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K
M<VAE971S+U-H965T,C(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY04D]015)462!!3D0@15%525!-14Y4+"!.150@*%1A8FQE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;5&%B;&4@5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF("<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4
M+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)
M1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M-C(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
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M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P
M,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^,C`Q,SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY#;W-T.CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+4Q%
M1E0Z(#$S<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-C(E/B`\9&EV/D-O;7!U=&5R<R!A;F0@<V]F='=A<F4\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M,3D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU,1494.B`Q,W!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY%;&5C=')O
M;FEC(&5Q=6EP;65N=#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$T/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU,
M1494.B`Q,W!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#8R)3X@/&1I=CY/9F9I8V4@9G5R;FET=7)E(&%N9"!E<75I
M<&UE;G0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,R/"]D:78^
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M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-C4\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/C(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/D%C8W5M=6QA=&5D(&1E<')E
M8VEA=&EO;CH\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M3$5&
M5#H@,3-P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0V,B4^(#QD:78^0V]M<'5T97)S(&%N9"!S;V9T=V%R93PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/C,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^*BD\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M3$5&5#H@,3-P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0V,B4^(#QD:78^16QE8W1R;VYI8R!E<75I<&UE
M;G0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU,1494.B`Q,W!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R
M)3X@/&1I=CY/9F9I8V4@9G5R;FET=7)E(&%N9"!E<75I<&UE;G0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0V,B4^(#QD:78^1&5P<F5C:6%T960@8V]S=#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^-C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/C(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I
M=CX@)B,Q-C`[(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M,24Y%+4A%24=(
M5#H@;F]R;6%L.R!-05)'24XZ(#!I;B`P:6X@,'!T(#`N.#5I;B<@86QI9VX]
M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`J*28C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U)E<')E<V5N=',@86X@86UO=6YT
M(&QO=V5R('1H86X@)"8C,38P.SQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/B`Q+CPO9F]N=#X\+V9O;G0^/"]D:78^(#PO9&EV/B`\+V1I=CX\=&%B;&4@
M8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z
M9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\
M=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U
M,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W8S8X
M,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O4VAE
M970R,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D]42$52($%#0T]53E13(%!!64%"3$4@*%1A8FQE<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4&%Y86)L97,@
M86YD($%C8W)U86QS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@06-C;W5N=',@4&%Y
M86)L92!A;F0@06-C<G5E9"!,:6%B:6QI=&EE<R!;5&%B;&4@5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E
M)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@
M5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!I;B`P+C@U:6X[(%=)1%1(.B`X-R4[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F=#X@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0V,B4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C,E(&-O;'-P86X],T0U/B`\9&EV
M/D1E8V5M8F5R)B,Q-C`[,S$L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#8R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS
M<&%N/3-$,CX@/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,3,\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY%;7!L;WEE97,@86YD
M('!A>7)O;&P@86-C<G5A;',\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
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M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(V/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#8R)3X@/&1I=CY!8V-R
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M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW
M-C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C4Y/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-C(E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#8R)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/CDY-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.#4\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^/"]F;VYT/CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R
M/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T
M9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U
M.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W8S8X,#)?8V$Q
M-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O4VAE970R-"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.0T]-
M12!405A%4R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y38VAE9'5L92!O9B!$969E<G)E9"!487@@07-S971S(&%N9"!,:6%B
M:6QI=&EE<R!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'
M24XZ(#!P="`P<'@@,'!T(#@U+C`U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y3:6=N:69I
M8V%N="!C;VUP;VYE;G1S(&]F('1H92!#;VUP86YY)W,@9&5F97)R960@=&%X
M(&%S<V5T<R!A<F4@87,@9F]L;&]W<SH\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P
M<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.
M5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,&EN(#$N,6EN.R!724142#H@.#,E.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3@E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#(S)2!C;VQS<&%N/3-$-3X@/&1I=CY$96-E;6)E<B8C
M,38P.S,Q+#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0U."4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD
M:78^,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CXR,#$S/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#4X)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4X)3X@
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXQ.#$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-C8\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/CDR,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
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M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3@E/B`\9&EV/DES
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C8W,3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#4X)3X@/&1I=CY/=&AE<CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$V/"]D:78^(#PO
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M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U."4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-3@E/B`\9&EV/DYE="!D969E<G)E9"!T87@@
M87-S970@8F5F;W)E('9A;'5A=&EO;B!A;&QO=V%N8V4\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$L-SDQ/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
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M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
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M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4X
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M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,2PW.3$I/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^*#,Q
M,BD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-3@E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4X)3X@/&1I=CY.970@9&5F
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M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV
M/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED
M=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X
M,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q
M,S@S,C4X,"]7;W)K<VAE971S+U-H965T,C4N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY424Y'14Y4($Q)04))3$E42453
M($%.1"!#3TU-251-14Y44R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@
M0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG($QE
M87-E<R!O9B!,97-S964@1&ES8VQO<W5R92!;5&%B;&4@5&5X="!";&]C:UT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF("<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO
M9F]N=#X@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^1G5T=7)E(&UI;FEM=6T@
M<&%Y;65N=',@=6YD97(@=&AE(&QE87-E(&%R92!A<R!F;VQL;W=S.B8C,38P
M.R`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4
M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+4Q%
M1E0Z(",Y96(V8V4@,'!X('-O;&ED.R!-05)'24XZ(#!I;B`P:6X@,&EN(#$N
M-6EN.R!724142#H@-C`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/
M5D521DQ/5SH@=FES:6)L93L@0D]21$52+51/4#H@(SEE8C9C92`P<'@@<V]L
M:60[($)/4D1%4BU224=(5#H@(SEE8C9C92`P<'@@<V]L:60G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#0W)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.T-,14%2.B!B;W1H)SX@665A<B8C,38P.V5N9&5D)B,Q-C`[1&5C96UB97(F
M(S$V,#LS,2P\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E1O=&%L/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0T-R4^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0T-R4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M,C`Q-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.T-,14%2.B!B;W1H)SXQ,3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T-R4^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^,C`Q-CPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[
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M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
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M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-#<E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/C(P,3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M-30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0T-R4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
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M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.T-,14%2.B!B;W1H)SX@/"]D:78^(#PO9&EV/B`\
M+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T
M86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W
M-S1?.&8S8U]A-C,U,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O
M<FMS:&5E=',O4VAE970R-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15A$04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4TA!4D5(3TQ$15)3)R!%455)5%D@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I<V-L;W-U<F4@
M;V8@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT<R!B>2!3
M:&%R92UB87-E9"!087EM96YT($%W87)D(%M486)L92!497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)
M3CH@,'!T(#!P>"`P<'0@,"XS<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$;&5F=#X\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/D$@<W5M;6%R>2!O
M9B!T:&4@0V]M<&%N>2=S(&]P=&EO;G,@86-T:79I='D@*&9O<B!E;7!L;WEE
M97,@86YD(&1I<F5C=&]R<RD@=6YD97(@=&AE(#(P,3,@4&QA;B!I<R!A<R!F
M;VQL;W=S.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS
M1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q
M,#`E)SX@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",Y96(V8V4@
M,'!X('-O;&ED.R!"3U)$15(M3$5&5#H@(SEE8C9C92`P<'@@<V]L:60[($U!
M4D=)3CH@,&EN(#!I;B`P:6X@,2XQ.&EN.R!724142#H@.#(E.R!"3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L93L@0D]21$52
M+51/4#H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU224=(5#H@(SEE8C9C
M92`P<'@@<V]L:60G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0S-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#0U)2!C;VQS<&%N/3-$.3X@/&1I=CY996%R)B,Q-C`[96YD960F
M(S$V,#M$96-E;6)E<B8C,38P.S,Q+#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0S-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0R,B4@8V]L<W!A;CTS1#0^(#QD:78^,C`Q-#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#(R)2!C;VQS<&%N/3-$
M-#X@/&1I=CXR,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#,U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I
M=CY.=6UB97(F(S$V,#MO9CQB<B\^(&]P=&EO;G,\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS
M1#(^(#QD:78^5V5I9VAT960\8G(O/B!A=F5R86=E/&)R+SX@97AE<F-I<V4\
M8G(O/B!P<FEC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/DYU;6)E<B8C
M,38P.V]F/&)R+SX@;W!T:6]N<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY7
M96EG:'1E9#QB<B\^(&%V97)A9V4\8G(O/B!E>&5R8VES93QB<B\^('!R:6-E
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#,U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
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M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S4E/B`\9&EV
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M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^-#`S+#$Q,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`P,#0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
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M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C`N,#`P-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,X,"PR,C(\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/CDN,C$\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`P,#0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0S-24^(#QD:78^)B,Q-C`[/"]D:78^
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M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,U)3X@/&1I=CY/
M=71S=&%N9&EN9R!A="!E;F0@;V8@>65A<CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S@S+#,S,CPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT+C0W/"]D:78^(#PO
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M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXT,#,L,3$P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`P,#0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0S-24^(#QD:78^)B,Q-C`[
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M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
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M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#,U)3X@/&1I=CY697-T960@86YD(&5X<&5C=&5D('1O('9E<W0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/C<X,RPS,S(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0N-#<\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C0P,RPQ,3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/C`N,#`P-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,U)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,U)3X@/&1I=CY/<'1I;VYS(&5X
M97)C:7-A8FQE(&%T('1H92!E;F0@;V8@=&AE('EE87(\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0R
M.2PU.#D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$N,S,\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/C$S-"PS-S`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C`N,#`P
M-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P="<^/"]D:78^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M#3$5!4CH@8F]T:"<^(#PO9&EV/B`\+V1I=CX@/"]D
M:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B
M;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@
M16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($%L
M;&]C871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6U1A8FQE(%1E
M>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`X
M-2XP-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)R!A;&EG;CTS1&IU<W1I9GD^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#@U+C`U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y4:&4@<VAA<F4@8F%S960@97AP96YS
M92!R96-O9VYI>F5D(&EN('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!I<R!A
M<R!F;VQL;W=S.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$
M14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P:6X@,2XQ.&EN.R!724142#H@.#,E.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$-#8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0S-24@8V]L<W!A;CTS1#@^(#QD:78^665A<B8C,38P
M.V5N9&5D/&)R+SX@1&5C96UB97(F(S$V,#LS,2P\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$-#8E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,30\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P
M86X],T0R/B`\9&EV/C(P,3,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N
M/3-$,CX@/&1I=CXR,#$R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#0V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C@S/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0T/"]D
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M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
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M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C8U,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
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M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#8E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#0V)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C<S-CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
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M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY/"]D
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M4F]M86X[1D].5"U325I%.B`Q,'!T.T-,14%2.B!B;W1H)SX@/"]D:78^(#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I=CX@/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\+V1I=CX\=&%B;&4@8F]R
M9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX
M960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^
M/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.;VYE;7!L;WEE92!3=&]C:R!/<'1I;VX@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@
M4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&ES8VQO<W5R
M92!O9B!3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G1S(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6U1A8FQE(%1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P<'0@,'!X(#!P="`P+C-P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1L969T/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE.
M.B`P<'0@,'!X(#!P="`X-2XP-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^5&AE(&]U='-T
M86YD:6YG(&]P=&EO;G,@9W)A;G1E9"!T;R!T:&4@0V]M<&%N>2=S('-E<G9I
M8V4@<')O=FED97)S(&%R92!A<R!F;VQL;W=S.CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`X-2XP-7!T)R!A
M;&EG;CTS1&IU<W1I9GD^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^("8C
M,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G
M/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(SEE8C9C92`P<'@@
M<V]L:60[($)/4D1%4BU,1494.B`C.65B-F-E(#!P>"!S;VQI9#L@34%21TE.
M.B`P:6X@,&EN(#!I;B`Q+C$X:6X[(%=)1%1(.B`X,R4[($)/4D1%4BU#3TQ,
M05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE.R!"3U)$15(M5$]0
M.B`C.65B-F-E(#!P>"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P
M>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG
M;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],
M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0R-"4^(#QD:78^
M1W)A;G0F(S$V,#MD871E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$V)3X@/&1I=CY.=6UB97(F(S$V,#MO9CQB<B\^(&]P=&EO;G,\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,34E/B`\9&EV/D5X97)C:7-E/&)R
M+SX@<')I8V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C0E/B`\
M9&EV/D5X<&ER871I;VXF(S$V,#MD871E/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C0E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-B4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$U)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C0E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#(T)3X@/&1I=CY$96-E;6)E<B`R+"`R,#$T/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,38E/B`\9&EV/C(P+#`P,#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,34E/B`\9&EV/C<N-S@\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#(T)3X@/&1I=CY$96-E;6)E<B`R+"`R,#(T/"]D:78^
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M86X[1D].5"U325I%.B`Q,'!T)SX\+V1I=CX@/"]D:78^(#PO9&EV/CQT86)L
M92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U
M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R
M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V
M,S4Q,S@S,C4X,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q,C=C
M-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`O5V]R:W-H965T<R]3
M:&5E=#(W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4D5,051%1"!005)462!"04Q!3D-%4R!!3D0@5%)!3E-!0U1)3TY3("A4
M86)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6U1A8FQE
M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P
M="`U-BXW<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
M;F]R;6%L)R!A;&EG;CTS1&IU<W1I9GD^/"]D:78^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@-#!P=#L@34%21TE..B`P<'0@,'!X
M(#!P="`T,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;"<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/B`\+V9O;G0^)B,Q-C`[)B,Q-C`[/&9O;G0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&YO<FUA;"<^0F%L86YC97,@=VET:"!R96QA=&5D('!A<G1I
M97,Z/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#0P<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@-#!P=#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG(&%L:6=N
M/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)U=)1%1(
M.B`X,R4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494.B`X
M-2XP-7!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0V/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/D1E8V5M8F5R(#,Q+#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^,C`Q-#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@8V]L<W!A
M;CTS1#(^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G(&-O;'-P
M86X],T0R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#<T
M)2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^5')A
M9&4@<&%Y86)L92`H9"D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#$E)SX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SXR/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)
M1%1(.B`Q)2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,BXU<'0[(%=)1%1(.B`Q)2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@5TE$5$@Z(#$P)2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!724142#H@
M,24G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^3W1H97(@86-C;W5N=',@<&%Y86)L92`H82D@
M*&(I("AC*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^,3(S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H
M)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^,S8\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<@86QI
M9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M
M86PG/B`F(S$V,#L\+V9O;G0^/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'0[(%=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0[(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@-38N
M-W!T)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`R."XS-7!T)SX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO
M9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^82X\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DEN($%U9W5S
M="P@,C`Q,BP@=&AE($-O;7!A;GD@<VEG;F5D(&%N(&%G<F5E;65N="!W:71H
M(&$@8V]N<W5L=&%N="P@=VAO(&ES(&%L<V\@;VYE(&]F('1H92!#;VUP86YY
M)W,@<VAA<F5H;VQD97)S(&%N9"!A(&1I<F5C=&]R+"!T;R!R96YD97(@;6%N
M86=E;65N="P@9FEN86YC92!A;F0@;W!E<F%T:6]N('-E<G9I8V5S+B!4:&4@
M0V]M<&%N>2!P87ES('1H92!C;VYS=6QT86YT(&%N(&%M;W5N="!O9B!A<'!R
M;WAI;6%T96QY("0V('!E<B!M;VYT:"X@1'5R:6YG($%U9W5S="`R,#$T+"!T
M:&4@;6]N=&AL>2!F964@=V%S(&EN8W)E87-E9"!T;R!A;B!A;6]U;G0@;V8@
M)#$U(&5F9F5C=&EV92!I;6UE9&EA=&5L>2X@26X@075G=7-T(#(P,30L('1H
M92!#;VUP86YY(&=R86YT960@=&AE(&-O;G-U;'1A;G0@8F]N=7,@:6X@=&AE
M(&%M;W5N="!O9B`D.#`@:6X@8V]N;F5C=&EO;B!W:71H('1H92!C;VYS=6UM
M871I;VX@;V8@=&AE($E03RX@5&AE($-O;7!A;GD@9W)A;G1E9"!A;B!A9&1I
M=&EO;F%L(&)O;G5S(&EN('1H92!A;6]U;G0@;V8@)#<P('=I=&@@<F5G87)D
M<R!T;R!S97)V:6-E<R!P<F]V:61E9"!D=7)I;F<@,C`Q-"X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#PO
M=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M+3(X+C,U<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@.#4N,#5P=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG(&%L:6=N/3-$
M:G5S=&EF>3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P=#L@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`U-BXW<'0G
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#(X+C,U<'0G/B`\9&EV('-T
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M8V4@4V5P=&5M8F5R(#$P+"`R,#$S+B!4:&4@<&%R=&EE<R!T97)M:6YA=&5D
M('1H92!A9W)E96UE;G0@;VX@4V5P=&5M8F5R(#$L(#(P,30N/"]D:78^(#PO
M=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4E.1$5.5#H@+3(X+C,U<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@.#4N
M,#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86PG(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#!P=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ
M(#!P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86PG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)
M1%1(.B`U-BXW<'0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#(X+C,U
M<'0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/F,N
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY!;B!A
M9W)E96UE;G0@=V%S('-I9VYE9"!O;B!!=6=U<W0@,C`L(#(P,3,@8F5T=V5E
M;B!T:&4@0V]M<&%N>2!A;F0@;VYE(&]F(&ET<R!S:&%R96AO;&1E<G,L(&%S
M(&$@8V]N<W5L=&%N="!T;R!R96YD97(@;6%N86=E;65N="P@9FEN86YC92!A
M;F0@;W!E<F%T:6]N('-E<G9I8V5S(&9O<B!A;B!A;6]U;G0@;V8@87!P<F]X
M:6UA=&5L>2`D,34@<&5R(&UO;G1H+B!$=7)I;F<@075G=7-T(#(P,30L('1H
M92!M;VYT:&QY(&9E92!W87,@:6YC<F5A<V5D('1O(&%N(&%M;W5N="!O9B`D
M,3D@969F96-T:79E(&EM;65D:6%T96QY+B!);B!!=6=U<W0@,C`Q-"P@=&AE
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M<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@.#4N,#5P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG(&%L:6=N/3-$:G5S=&EF
M>3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P
M=#L@5TE$5$@Z(#$P,"4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P=#L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`U-BXW<'0G/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#(X+C,U<'0G/B`\9&EV('-T>6QE/3-$
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M87ES('1H92!C;VYS=6QT86YT(&%N(&%M;W5N="!O9B`D,2!P97(@;6]N=&@N
M/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/CQT86)L92!B;W)D
M97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE
M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\
M+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE($]F(%)E;&%T960@4&%R='D@
M17AP96YS97,@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%2
M1TE..B`P<'0@,'!X(#!P="`U-BXW<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3X\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`U,W!T.R!-
M05)'24XZ(#!I;B`P<'@@,&EN(#`N,S5I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/CQF;VYT
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^4F5L871E9"!P87)T:65S)R!E>'!E;G-E<SH\+V9O;G0^/"]F;VYT/CPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#4V
M+C=P=#L@34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF
M>3XF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\
M=&%B;&4@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!I;B`Q+C%I;CL@5TE$
M5$@Z(#@S)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z
M('9I<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI
M9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#0V)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($-/3$]2
M.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S4E(&-O;'-P86X]
M,T0X/B`\9&EV/EEE87(F(S$V,#ME;F1E9"8C,38P.T1E8V5M8F5R)B,Q-C`[
M,S$L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#0V)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@
M/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@
M8V]L<W!A;CTS1#(^(#QD:78^,C`Q,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I
M=CXR,#$R/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0T-B4^(#QD:78^06UO=6YT<R!C:&%R9V5D('1O
M.B`J*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#0V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
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M3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXY.3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,T
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#8E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T-B4^(#QD:78^1V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS92`H82D@*&(I("AC*2`H9"D\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
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M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
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M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C4U/"]D:78^(#PO=&0^(#QT
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M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TR."XS
M-7!T.R!-05)'24XZ(#!P="`P<'@@,'!T(#@U+C`U<'0[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF
M>3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CPO9&EV/B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M#3$5!4CH@8F]T:"<^("8C,38P.SPO9&EV/B`\=&%B
M;&4@<W1Y;&4],T0G0D]21$52+4)/5%1/32U#3TQ/4CH@(S`P,#`P,#L@34%2
M1TE.+51/4#H@,'!T.R!"3U)$15(M5$]0+4-/3$]2.B`C,#`P,#`P.R!72414
M2#H@,38P-'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0[($A%24=(5#H@-3-P>#L@0D]2
M1$52+5))1TA4+4-/3$]2.B`C,#`P,#`P.R!"3U)$15(M3$5&5"U#3TQ/4CH@
M(S`P,#`P,"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$V,#0^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],3U(Z(",P,#`P,#`[(%1%
M6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],3U(Z(",P,#`P,#`[(%=)
M1%1(.B`U,G!T.R!"3U)$15(M4DE'2%0M0T],3U(Z(",P,#`P,#`[(%9%4E1)
M0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/3$]2.B`C,#`P,#`P)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/CPO9F]N=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\
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M5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/CPO9F]N=#YA+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
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M=#M&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86XL<V5R:68G/B`D/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#M&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86XL<V5R:68G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#M&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86XL<V5R:68G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C8\+V9O;G0^/"]F;VYT/CPO9F]N
M=#X@<&5R(#QF;VYT('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4
M+5-)6D4Z(#$P<'0[1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N+'-E<FEF
M)SX@;6]N=&@N($1U<FEN9R!!=6=U<W0@,C`Q-"P@=&AE(&UO;G1H;'D@9F5E
M('=A<R!I;F-R96%S960@=&\@86X@86UO=6YT(&]F("0\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M+'-E<FEF)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ-3PO9F]N=#X\
M+V9O;G0^(&5F9F5C=&EV92!I;6UE9&EA=&5L>2X@26X@075G=7-T(#(P,30L
M('1H92!#;VUP86YY(&=R86YT960@=&AE(&-O;G-U;'1A;G0@8F]N=7,@:6X@
M=&AE(&%M;W5N="!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.T9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;BQS97)I9B<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^.#`\+V9O;G0^/"]F;VYT/B!I;B!C;VYN96-T
M:6]N('=I=&@@=&AE(&-O;G-U;6UA=&EO;B!O9B!T:&4@25!/+B!4:&4@0V]M
M<&%N>2!G<F%N=&5D(&%N(&%D9&ET:6]N86P@8F]N=7,@:6X@=&AE(&%M;W5N
M="!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.T9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;BQS97)I9B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:
M13H@,3!P="<^-S`\+V9O;G0^/"]F;VYT/B!W:71H(')E9V%R9',@=&\@<V5R
M=FEC97,@<')O=FED960@9'5R:6YG(#(P,30\+V9O;G0^+CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/"]T
M86)L93X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M
M,C<N-S5P=#L@34%21TE..B`P<'0@,'!X(#!P="`X-"XT-7!T.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU
M<W1I9GD^)B,Q-C`[/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],
M3U(Z(",P,#`P,#`[(%1%6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],
M3U(Z(",P,#`P,#`[(%=)1%1(.B`U,G!T.R!"3U)$15(M4DE'2%0M0T],3U(Z
M(",P,#`P,#`[(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/
M3$]2.B`C,#`P,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/CPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#(X+C,U<'0G/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^8BX\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q,34E.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@5&AE($-O;7!A;GD@<VEG;F5D(&%N
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M14E'2%0Z(#$Q-24[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`D/"]F;VYT/CPO9F]N=#X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SXT/"]F;VYT/CPO9F]N=#X@/&9O;G0@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z(#$Q-24[($9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B!S:6YC92!397!T96UB97(@,3`L(#(P
M,3,N(%1H92!P87)T:65S('1E<FUI;F%T960@=&AE(&%G<F5E;65N="!O;B!3
M97!T96UB97(@,2P@,C`Q-"X\+V9O;G0^/"]D:78^(#PO=&0^(#PO='(^(#PO
M=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M+3(W+C<U<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@.#0N-#5P=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J
M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B`F
M(S$V,#L\+V9O;G0^/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTM0T],
M3U(Z(",P,#`P,#`[(%1%6%0M04Q)1TXZ(&QE9G0[($)/4D1%4BU43U`M0T],
M3U(Z(",P,#`P,#`[(%=)1%1(.B`U,G!T.R!"3U)$15(M4DE'2%0M0T],3U(Z
M(",P,#`P,#`[(%9%4E1)0T%,+4%,24=..B!T;W`[($)/4D1%4BU,1494+4-/
M3$]2.B`C,#`P,#`P)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SX\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`R."XS
M-7!T)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SYC
M+CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
M>2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^/&9O
M;G0@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$Q-24[($9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B!!
M;B!A9W)E96UE;G0@=V%S('-I9VYE9"!O;B!!=6=U<W0@,C`L(#(P,3,@8F5T
M=V5E;B!T:&4@0V]M<&%N>2!A;F0@;VYE(&]F(&ET<R!S:&%R96AO;&1E<G,L
M(&%S(&$@8V]N<W5L=&%N="!T;R!R96YD97(@;6%N86=E;65N="P@9FEN86YC
M92!A;F0@;W!E<F%T:6]N('-E<G9I8V5S(&9O<B!A;B!A;6]U;G0@;V8\+V9O
M;G0^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B!A<'!R;WAI;6%T96QY
M(#QF;VYT('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SX@)#PO9F]N=#X\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,34\+V9O;G0^/"]F;VYT/B!P
M97(@;6]N=&@N(#QF;VYT('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q,34E.R!&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX@1'5R:6YG($%U9W5S="`R,#$T+"!T:&4@;6]N=&AL>2!F
M964@=V%S(&EN8W)E87-E9"!T;R!A;B!A;6]U;G0@;V8@)#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/C$Y/"]F;VYT/B!E9F9E8W1I=F4@:6UM961I871E
M;'DN($EN($%U9W5S="`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D('1H92!C
M;VYS=6QT86YT(&$@8F]N=7,@:6X@=&AE(&%M;W5N="!O9B`D/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^.3`\+V9O;G0^(&EN(&-O;FYE8W1I;VX@=VET
M:"!T:&4@8V]N<W5M;6%T:6]N(&]F('1H92!)4$\N/"]F;VYT/CPO9&EV/B`\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U)3D1%3E0Z("TR."XS-7!T.R!-05)'24XZ(#!P="`P<'@@,'!T(#@U
M+C`U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/32U#3TQ/4CH@(S`P,#`P,#L@5$585"U!3$E'3CH@;&5F=#L@
M0D]21$52+51/4"U#3TQ/4CH@(S`P,#`P,#L@5TE$5$@Z(#4R<'0[($)/4D1%
M4BU224=(5"U#3TQ/4CH@(S`P,#`P,#L@5D525$E#04PM04Q)1TXZ('1O<#L@
M0D]21$52+4Q%1E0M0T],3U(Z(",P,#`P,#`G/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#(X+C,U<'0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/F0N/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SX\9F]N="!S='EL93TS1"=,24Y%+4A%24=(5#H@,3$U)3L@
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^($]N($IU;'D@,2P@,C`Q,RP@=&AE($-O;7!A;GD@<VEG
M;F5D(&%N(&%G<F5E;65N="!W:71H(&$@8V]N<W5L=&%N="P@=VAO(&ES(&%L
M<V\@;VYE(&]F('1H92!#;VUP86YY)W,@<VAA<F5H;VQD97)S+"!T;R!R96YD
M97(@861V:7-O<GD@<V5R=FEC97,N(%1H92!#;VUP86YY('!A>7,@=&AE(&-O
M;G-U;'1A;G0@86X@86UO=6YT/"]F;VYT/B!O9B`\9F]N="!S='EL93TS1"=,
M24Y%+4A%24=(5#H@,3$U)3L@1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^("0\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^,3PO9F]N=#X\+V9O;G0^('!E<B!M;VYT:#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/CPO9F]N=#XN/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^
M(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[
M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$R-V,V.#`R7V-A,35?
M-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`O
M5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^1DE.04Y#24%,($584$5.4T53("A)3D-/344I+"!.
M150@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3W1H97(@26YC;VUE(&%N9"!%>'!E;G-E<R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-C:&5D=6QE(&]F($]T:&5R($YO;F]P97)A=&EN9R!);F-O;64@*$5X
M<&5N<V4I(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)
M3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(SEE8C9C92`P<'@@<V]L:60[($)/4D1%4BU,1494.B`C
M.65B-F-E(#!P>"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C@U:6X[
M(%=)1%1(.B`Y,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&
M3$]7.B!V:7-I8FQE.R!"3U)$15(M5$]0.B`C.65B-F-E(#!P>"!S;VQI9#L@
M0D]21$52+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$-3,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
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M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$-3,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,30\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CXR,#$S
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,3(\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3,E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
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M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#4S)3X@/&1I=CY&:6YA;F-I86P@97AP96YS97,Z
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+4Q%1E0Z(#$S<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-3,E/B`\9&EV/DEN=&5R97-T(&5X<&5N<V4\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/BH\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P
M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXI/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXJ/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^*3PO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M3$5&5#H@,3-P>#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
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M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-CPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXR,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P
M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U,R4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@
M(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#4S)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C(W/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C
M,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3,E/B`\9&EV/D9I;F%N
M8VEA;"!I;F-O;64Z/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P
M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+4Q%1E0Z(#$S<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3,E/B`\9&EV/DEN=&5R97-T(&EN
M8V]M93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C@U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M3$5&5#H@,3-P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0U,R4^(#QD:78^17AC:&%N9V4@<F%T93PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z
M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0U
M,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#
M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
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M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#4S)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C@U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/
M3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXU
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/
M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4S)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($-/3$]2.B`C,#`P
M,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3,E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@U."D\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P
M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,RD\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($-/3$]2.B`C,#`P,#`P.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`M-38N-W!T.R!-05)'24XZ(#!P="`P<'@@
M,'!T(#4V+C=P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^)B,Q-C`[/"]D:78^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,&EN.R!-05)'
M24XZ(#!I;B`P<'@@,&EN(#`N.#5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T:69Y/BHI)B,Q-C`[
M)B,Q-C`[4F5P<F5S96YT<R!A;B!A;6]U;G0@;&]W97(@=&AA;B8C,38P.R8C
M,38P.R0F(S$V,#LQ/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT
M/BX\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED
M=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X
M,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q
M,S@S,C4X,"]7;W)K<VAE971S+U-H965T,CDN:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$594T%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D=%3D5204P@*$1E=&%I;',@5&5X
M='5A;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D
M871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@
M,C(L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY'96YE<F%L(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(R.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#<L,#(R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PQ
M-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@R,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO9"P@4VAA<F5S
M+"!.97<@27-S=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#4U,2PT,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D=E;F5R86P@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VL@27-S=65D($1U<FEN9R!097)I;V0L(%-H87)E<RP@3F5W($ES<W5E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M($ES<W5A;F-E($EN:71I86P@4'5B;&EC($]F9F5R:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,Q+#0P-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q
M-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X
M,"]7;W)K<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)4$%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],
M24-)15,@*$1E=&%I;',I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!U=&5R<R!A;F0@<V]F='=A<F4@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!0;&%N="!!;F0@17%U:7!M96YT(%-T<F%I9VAT($QI;F4@1&5P
M<F5C:6%T:6]N(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,S+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16QE8W1R;VYI8R!E<75I<&UE;G0@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY324=.
M249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T
M>2!0;&%N="!!;F0@17%U:7!M96YT(%-T<F%I9VAT($QI;F4@1&5P<F5C:6%T
M:6]N(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3V9F:6-E(&9U<FYI='5R92!A;F0@97%U:7!M96YT(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M<&5R='D@4&QA;G0@06YD($5Q=6EP;65N="!3=')A:6=H="!,:6YE($1E<')E
M8VEA=&EO;B!097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W
M-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T,S$N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5%1$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-)1TY)1DE#
M04Y4($%#0T]53E1)3D<@4$],24-)15,@*$1E=&%I;',@5&5X='5A;"D@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6%B:6QI='D@9F]R(%5N8V5R=&%I;B!487@@4&]S:71I;VYS+"!#=7)R96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1I;64@
M1&5P;W-I=',L(%=E:6=H=&5D($%V97)A9V4@26YT97)E<W0@4F%T92P@1&5S
M8W)I<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D%S(&]F
M($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@0V]M<&%N>2=S(&)A;FL@9&5P;W-I
M=',@=V5R92!I;B!5+E,N(&1O;&QA<G,@86YD(&)O<F4@:6YT97)E<W0@870@
M82!W96EG:'1E9"!A=F5R86=E(&EN=&5R97-T(')A=&4@;V8@,"XV-B4N/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-
M871U<FET:65S(&]F(%1I;64@1&5P;W-I=',L($1E<V-R:7!T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3:&]R="UT97)M(&)A;FL@9&5P
M;W-I=',@87)E(&1E<&]S:71S('=I=&@@;6%T=7)I=&EE<R!O9B!M;W)E('1H
M86X@=&AR964@;6]N=&AS(&)U="!L97-S('1H86X@;VYE('EE87(N/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C
M83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R
M-3@P+U=O<FMS:&5E=',O4VAE970S,BYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^4D5#14E604),15,@04Y$(%!215!!240@
M15A014Y315,@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296-E:79A8FQE
M<R!A;F0@4')E<&%I9"!%>'!E;G-E<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V]V97)N;65N="!A
M=71H;W)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296-E:79A8FQE<R!A;F0@4')E<&%I9"!%>'!E
M;G-E<RP@0W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W8S8X,#)?8V$Q-5\T-S<T
M7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O4VAE970S,RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14=3044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4%)/4$525%D@
M04Y$($5154E0345.5"P@3D54("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H
M;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&5D(&-O<W0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M<'5T97)S(&%N9"!S;V9T=V%R92!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A
M;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D
M(&1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16QE8W1R;VYI8R!E<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]S=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D97!R96-I871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9I8V4@9G5R;FET=7)E(&%N9"!E<75I
M<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P
M97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@
M/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A
M;CTS1#,@=F%L:6=N/3-$=&]P/E)E<')E<V5N=',@86X@86UO=6YT(&QO=V5R
M('1H86X@)#$N/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S$R-V,V.#`R
M7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X
M,S(U.#`O5V]R:W-H965T<R]3:&5E=#,T+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D)!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY04D]015)462!!3D0@15%525!-14Y4
M+"!.150@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&0@
M8V]L<W!A;CTS1#4^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P
M/ELQ73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T
M;W`^4F5P<F5S96YT<R!A;B!A;6]U;G0@;&]W97(@=&AA;B`D,2X\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?
M838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R
M-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S
M+U-H965T,S4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1$%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/D]42$52($%#0T]53E13(%!!64%"3$4@*$1E=&%I;',I("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY/5$A%4B!!0T-/54Y44R!005E!0DQ%(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;7!L;WEE97,@86YD('!A>7)O;&P@86-C<G5A;',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT
M<R!087EA8FQE+"!/=&AE<BP@0W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Y.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U
M,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W8S8X
M,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O4VAE
M970S-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14%,04,^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^24Y#3TU%(%1!6$53("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S
M86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^24Y#
M3TU%(%1!6$53(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S<R!C87)R>2!F;W)W
M87)D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$X,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDR,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@:7-S=6%N
M8V4@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@9&5F97)R960@=&%X(&%S<V5T(&)E9F]R92!V86QU871I;VX@86QL
M;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<Y,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5F%L=6%T:6]N(&%L;&]W86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PW.3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,S$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!D969E<G)E9"!T87@@87-S970\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q
M-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X
M,"]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5414%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DE.0T]-12!405A%4R`H1&5T86EL<R!497AT
M=6%L*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^24Y#3TU%(%1!6$53(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W1I
M=F4@26YC;VUE(%1A>"!2871E(%)E8V]N8VEL:6%T:6]N+"!097)C96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BXU,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P97)A=&EN9R!,;W-S($-A<G)Y9F]R=V%R9',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A
M-C,U,3,X,S(U.#`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W
M8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O
M4VAE970S."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14)"04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^0T].5$E.1T5.5"!,24%"24Q)5$E%4R!!3D0@0T]-34E4345.5%,@
M*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H
M97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T].5$E.1T5.5"!,24%"24Q)5$E%
M4R!!3D0@0T]-34E4345.5%,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$V/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG($QE87-E<RP@1G5T=7)E($UI
M;FEM=6T@4&%Y;65N=',@1'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W
M-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T,SDN:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5,2D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3E1)3D=%
M3E0@3$E!0DE,251)15,@04Y$($-/34U)5$U%3E13("A$971A:6QS(%1E>'1U
M86PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#3TY424Y'14Y4($Q)04))3$E42453($%.1"!#3TU-
M251-14Y44R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG($QE87-E<RP@4F5N="!%>'!E
M;G-E+"!-:6YI;75M(%)E;G1A;',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!E<F%T:6YG($QE87-E<RP@4F5N="!%>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W5A<F%N=&5E
M($9O<B!097)F;W)M86YC92!/9B!,96%S92!!9W)E96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@3&5A<V5S+"!2
M96YT($5X<&5N<V4L($YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X
M,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q,C=C-C@P,E]C83$U
M7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`O5V]R:W-H965T<R]3:&5E=#0P+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%4TM!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY32$%2
M14A/3$1%4E,G($5154E462`H1&5T86EL<RD@*$5M<&QO>65E(%-T;V-K($]P
M=&EO;B!;365M8F5R72P@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K($]P=&EO;B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R
M92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T
M:6]N<R!/=71S=&%N9&EN9R!A="!B96=I;FYI;F<@;V8@>65A<B`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`S+#$Q,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q
M.2PU,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS($=R86YT960@*&EN('-H87)E<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X,"PR,C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,RPU-SD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYU;6)E<B!O9B!/<'1I;VYS($]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R
M("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M.#,L,S,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#`S+#$Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@5F5S=&5D(&%N9"!E
M>'!E8W1E9"!T;R!V97-T("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW.#,L,S,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#`S+#$Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO
M;G,@97AE<F-I<V%B;&4@870@=&AE(&5N9"!O9B!T:&4@>65A<B`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(Y+#4X.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S
M-"PS-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@97AE<F-I<V4@<')I8V4@3W5T<W1A
M;F1I;F<@870@8F5G:6YN:6YG(&]F('EE87(@*&EN(&1O;&QA<G,@<&5R('-H
M87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,#`P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@879E<F%G92!E>&5R8VES92!P<FEC92!'<F%N
M=&5D("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@.2XR,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E
M(&5X97)C:7-E('!R:6-E($]U='-T86YD:6YG(&%T(&5N9"!O9B!Y96%R("AI
M;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-"XT-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP,#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&5X97)C
M:7-E('!R:6-E(%9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="`H:6X@9&]L
M;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0N-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#`P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!E>&5R8VES92!P
M<FEC92!/<'1I;VYS(&5X97)C:7-A8FQE(&%T('1H92!E;F0@;V8@=&AE('EE
M87(@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C
M7V$V,S4Q,S@S,C4X,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q
M,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`O5V]R:W-H965T
M<R]3:&5E=#0Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%3TE!0SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY32$%214A/3$1%4E,G($5154E462`H1&5T86EL<R`Q*2`H3F]N
M96UP;&]Y964@4W1O8VL@3W!T:6]N(%M-96UB97)=+"!$96-E;6)E<B`R+"`R
M,#$T(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYO;F5M<&QO>65E(%-T;V-K($]P=&EO;B!;365M
M8F5R72!\($1E8V5M8F5R(#(L(#(P,30@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP
M96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!
M=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F5B87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@0GD@4VAA<F5B87-E9"!087EM96YT($%W87)D($]P=&EO;G,@5&\@
M3F]N96UP;&]Y965S($1A=&4@3V8@1W)A;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/D1E8R`R+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R96)A<V5D($-O;7!E
M;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R96)A<V5D(%!A>6UE;G0@07=A
M<F0@3W!T:6]N<R!4;R!.;VYE;7!L;WEE97,@3W5T<W1A;F1I;F<@3G5M8F5R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E8F%S960@
M4&%Y;65N="!!=V%R9"!/<'1I;VYS(%1O($YO;F5M<&QO>65E<R!%>&5R8VES
M92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+C<X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R96)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R
M96)A<V5D(%!A>6UE;G0@07=A<F0@3W!T:6]N<R!4;R!.;VYE;7!L;WEE97,@
M17AP:7)A=&EO;B!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y$96,@,BP-"@D),C`R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R
M-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A
M,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T-#(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4T04%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-(
M05)%2$],1$524R<@15%52519("A$971A:6QS(#(I("A54T0@)"D\8G(^26X@
M5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#<S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS
M92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92UB87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!!9&UI;FES=')A=&EV92!%
M>'!E;G-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF
M,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE
M971S+U-H965T-#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R-$-)/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-(05)%2$],1$524R<@15%52519("A$971A:6QS(%1E>'1U
M86PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T
M82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y&96(N(#`V+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIA;BX@,C(L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,#4L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,CDL(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R
M<R<@17%U:71Y+"!2979E<G-E(%-T;V-K(%-P;&ET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y!;&P@3W)D:6YA<GD@<VAA<F5S+"!O<'1I;VYS
M+"!P97(@<VAA<F4@9&%T82!A;F0@97AE<F-I<V4@<')I8V4@:6YC;'5D960@
M:6X@=&AE<V4@9FEN86YC:6%L('-T871E;65N=',@9F]R(&%L;"!P97)I;V1S
M('!R97-E;G1E9"!H879E(&)E96X@<F5T<F]A8W1I=F5L>2!A9&IU<W1E9"!T
M;R!R969L96-T('1H92!I<W-U86YC92!O;B!*86YU87)Y(#(V+"`R,#$T(&]F
M(#8N-34M=&\M;VYE(&)O;G5S('-H87)E<R`H97%U:79A;&5N="!T;R!A(#<N
M-34M9F]R+3$@<W1O8VL@<W!L:70I+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D($1U<FEN9R!0
M97)I;V0L(%-H87)E<RP@3F5W($ES<W5E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPU-3$L-#(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!)<W-U960@1'5R:6YG(%!E
M<FEO9"P@5F%L=64L($YE=R!)<W-U97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,S$L-#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@
M07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T
M:6]N<RP@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG
M($-O;G1R86-T=6%L(%1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C4@>65A<G,@-R!M;VYT:',@-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP
M96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!
M=V%R9"P@3W!T:6]N<RP@17AE<F-I<V%B;&4L(%=E:6=H=&5D($%V97)A9V4@
M4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C(@>65A<G,@,R!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M27-S=65D($1U<FEN9R!097)I;V0@3W)D:6YA<GD@4VAA<F5S($ES<W5E9"!5
M<&]N(%!R:79A=&4@4&QA8V5M96YT(%-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S@R+#4S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D($1U<FEN9R!0
M97)I;V0@3W)D:6YA<GD@4VAA<F5S($ES<W5E9"!5<&]N(%!R:79A=&4@4&QA
M8V5M96YT(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#,V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,S8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$979E;&]P;65N="!3=&%G92!%;G1I=&EE<RP@17%U:71Y
M($ES<W5A;F-E+"!097(@4VAA<F4@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE03R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!)<W-U960@1'5R
M:6YG(%!E<FEO9"P@4VAA<F5S+"!.97<@27-S=65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I
M;F<@4&5R:6]D+"!686QU92P@3F5W($ES<W5E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E=F5L;W!M96YT(%-T86=E($5N=&ET
M:65S+"!%<75I='D@27-S=6%N8V4L(%!E<B!3:&%R92!!;6]U;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O
M8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VL@27-S=65D($1U<FEN9R!097)I;V0L(%-H87)E<RP@3F5W($ES<W5E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO9"P@5F%L=64L($YE=R!)<W-U97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5E
M9"!$=7)I;F<@4&5R:6]D($]R9&EN87)Y(%-H87)E<R!)<W-U960@57!O;B!0
M<FEV871E(%!L86-E;65N="!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<X,BPU,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I;F<@4&5R:6]D
M($]R9&EN87)Y(%-H87)E<R!)<W-U960@57!O;B!0<FEV871E(%!L86-E;65N
M="!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP
M;&]Y964@4W1O8VL@3W!T:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS
M+"!/=71S=&%N9&EN9RP@26YT<FEN<VEC(%9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#8V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L
M($]P=&EO;G,L($5X97)C:7-A8FQE+"!);G1R:6YS:6,@5F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3<T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!397)V
M:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@3F]N=F5S=&5D($%W87)D
M<RP@0V]M<&5N<V%T:6]N($-O<W0@3F]T('EE="!296-O9VYI>F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E($%G<F5E
M;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R92!0=7)C:&%S92!!9W)E96UE;G0L(%-H87)E<R!T;R!B92!I<W-U
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3,P+#$U.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4@4'5R8VAA<V4@06=R965M96YT+"!686QU92!T;R!B92!I<W-U960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#(T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@
M02!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET@?"!);G9E<W1M96YT($%G<F5E
M;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO9"P@4VAA<F5S+"!.97<@27-S
M=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-"PS.3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-S$L
M.38T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO9"P@5F%L=64L($YE=R!)
M<W-U97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M87EM96YT<R!O9B!3=&]C:R!)<W-U86YC92!#;W-T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($$@4')E9F5R<F5D(%-T;V-K
M(%M-96UB97)=('P@4'5R8VAA<V4@06=R965M96YT(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C:RP@
M0V]N=F5R<VEO;B!"87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^4')I;W(@=&\@=&AE(&-L;W-I;F<@;V8@=&AE('-H87)E('!U<F-H87-E
M(&%G<F5E;65N="!A8F]V92!A;F0@87,@82!C;VYD:71I;VX@=&\@:70L('1H
M92!#;VUP86YY(&%F9F5C=&5D(&%N(&5Q=6ET>2!R97-T<G5C='5R:6YG+"!U
M;F1E<B!W:&EC:"P@86QL(&]F('1H92!#;VUP86YY)W,@4')E9F5R<F5D('-H
M87)E<R`H-38V+#,U-R!0<F5F97)R960@02!S:&%R97,I('=E<F4@8V]N=F5R
M=&5D(&EN=&\@3W)D:6YA<GD@<VAA<F5S(&%T(&$@,3HQ(')A=&EO/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S
M960@4&%Y;65N="!!=V%R9"!!8V-E;&5R871E9"!#;VUP96YS871I;VX@0V]S
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:79I9&5N
M9',L(%!R969E<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R-3@P#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A,35?-#<W
M-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T-#0N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5/3D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/E)%3$%4140@
M4$%25%D@0D%,04Y#15,@04Y$(%1204Y304-424].4R`H1&5T86EL<RD@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@
M4&%R='D@5')A;G-A8W1I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R
M861E('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PR.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!A8V-O=6YT<R!P87EA
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5L871E9"!087)T>2!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VX@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1R861E('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@86-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,ETL6S-=+%LT73PO<W5P/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELR72Q;,UTL
M6S1=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT9"!C;VQS<&%N/3-$-3X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI
M9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0T('9A
M;&EG;CTS1'1O<#Y/;B!*=6QY(#$L(#(P,3,@=&AE($-O;7!A;GD@<VEG;F5D
M(&%N(&%G<F5E;65N="!W:71H(&$@8V]N<W5L=&%N="P@=VAO(&ES(&%L<V\@
M;VYE(&]F('1H92!#;VUP86YY)W,@<VAA<F5H;VQD97)S+"!T;R!R96YD97(@
M861V:7-O<GD@<V5R=FEC97,N(%1H92!#;VUP86YY('!A>7,@=&AE(&-O;G-U
M;'1A;G0@86X@86UO=6YT(&]F("0Q('!E<B!M;VYT:"X\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@
M("`@(#QT9"!V86QI9VX],T1T;W`^6S)=/"]T9#X-"B`@("`@("`@/'1D(&-O
M;'-P86X],T0T('9A;&EG;CTS1'1O<#Y);B!!=6=U<W0L(#(P,3(L('1H92!#
M;VUP86YY('-I9VYE9"!A;B!A9W)E96UE;G0@=VET:"!A(&-O;G-U;'1A;G0L
M('=H;R!I<R!A;'-O(&]N92!O9B!T:&4@0V]M<&%N>2=S('-H87)E:&]L9&5R
M<R!A;F0@82!D:7)E8W1O<BP@=&\@<F5N9&5R(&UA;F%G96UE;G0L(&9I;F%N
M8V4@86YD(&]P97)A=&EO;B!S97)V:6-E<RX@5&AE($-O;7!A;GD@<&%Y<R!T
M:&4@8V]N<W5L=&%N="!A;B!A;6]U;G0@;V8@87!P<F]X:6UA=&5L>2`D-B!P
M97(@;6]N=&@N($1U<FEN9R!!=6=U<W0@,C`Q-"P@=&AE(&UO;G1H;'D@9F5E
M('=A<R!I;F-R96%S960@=&\@86X@86UO=6YT(&]F("0Q-2!E9F9E8W1I=F4@
M:6UM961I871E;'DN($EN($%U9W5S="`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N
M=&5D('1H92!C;VYS=6QT86YT(&)O;G5S(&EN('1H92!A;6]U;G0@;V8@)#@P
M(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@8V]N<W5M;6%T:6]N(&]F('1H92!)
M4$\N(%1H92!#;VUP86YY(&=R86YT960@86X@861D:71I;VYA;"!B;VYU<R!I
M;B!T:&4@86UO=6YT(&]F("0W,"!W:71H(')E9V%R9',@=&\@<V5R=FEC97,@
M<')O=FED960@9'5R:6YG(#(P,30N/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L
M:6=N/3-$=&]P/ELS73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V
M86QI9VX],T1T;W`^5&AE($-O;7!A;GD@<VEG;F5D(&%N(&%G<F5E;65N="!W
M:71H(&$@8V]M<&%N>2!O=VYE9"!B>2!O;F4@;V8@:71S(')E;&%T960@<&%R
M=&EE<RX@56YD97(@=&AE(&%G<F5E;65N="P@=&AE(')E;&%T960@8V]M<&%N
M>2!R96YD97)S('1H92!#;VUP86YY('=I=&@@;V9F:6-E('-E<G9I8V5S(&%N
M9"!O9F9I8V4@;&5A<V4@9F]R(&$@;6]N=&AL>2!F964@:6X@=&AE(&%M;W5N
M="!O9B!A<'!R;WAI;6%T96QY("0T('-I;F-E(%-E<'1E;6)E<B`Q,"P@,C`Q
M,RX@5&AE('!A<G1I97,@=&5R;6EN871E9"!T:&4@86=R965M96YT(&]N(%-E
M<'1E;6)E<B`Q+"`R,#$T+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS
M1'1O<#Y;-%T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N
M/3-$=&]P/D%N(&%G<F5E;65N="!W87,@<VEG;F5D(&]N($%U9W5S="`R,"P@
M,C`Q,R!B971W965N('1H92!#;VUP86YY(&%N9"!O;F4@;V8@:71S('-H87)E
M:&]L9&5R<RP@87,@82!C;VYS=6QT86YT('1O(')E;F1E<B!M86YA9V5M96YT
M+"!F:6YA;F-E(&%N9"!O<&5R871I;VX@<V5R=FEC97,@9F]R(&%N(&%M;W5N
M="!O9B!A<'!R;WAI;6%T96QY("0Q-2!P97(@;6]N=&@N($1U<FEN9R!!=6=U
M<W0@,C`Q-"P@=&AE(&UO;G1H;'D@9F5E('=A<R!I;F-R96%S960@=&\@86X@
M86UO=6YT(&]F("0Q.2!E9F9E8W1I=F4@:6UM961I871E;'DN($EN($%U9W5S
M="`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D('1H92!C;VYS=6QT86YT(&$@
M8F]N=7,@:6X@=&AE(&%M;W5N="!O9B`D.3`@:6X@8V]N;F5C=&EO;B!W:71H
M('1H92!C;VYS=6UM871I;VX@;V8@=&AE($E03RX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?838S-3$S.#,R
M-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S$R-V,V.#`R7V-A
M,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE971S+U-H965T-#4N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$561$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)%
M3$%4140@4$%25%D@0D%,04Y#15,@04Y$(%1204Y304-424].4R`H1&5T86EL
M<R`Q*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$-CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^06UO=6YT<R!C:&%R9V5D('1O.B`J*3PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO
M<&UE;G0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T+#0T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S,R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
M(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C,Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E;&%T960@4&%R='D@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!;6]U;G1S(&-H87)G960@=&\Z
M("HI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!E>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDY/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES
M=')A=&EV92!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\<W5P/ELQ72Q;,ETL6S-=+%LT73PO<W5P/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5TL6S)=+%LS72Q;-%T\+W-U
M<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5TL
M6S)=+%LS72Q;-%T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0W/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@
M/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A
M;CTS1#8@=F%L:6=N/3-$=&]P/D%N(&%G<F5E;65N="!W87,@<VEG;F5D(&]N
M($%U9W5S="`R,"P@,C`Q,R!B971W965N('1H92!#;VUP86YY(&%N9"!O;F4@
M;V8@:71S('-H87)E:&]L9&5R<RP@87,@82!C;VYS=6QT86YT('1O(')E;F1E
M<B!M86YA9V5M96YT+"!F:6YA;F-E(&%N9"!O<&5R871I;VX@<V5R=FEC97,@
M9F]R(&%N(&%M;W5N="!O9B!A<'!R;WAI;6%T96QY("0Q-2!P97(@;6]N=&@N
M($1U<FEN9R!!=6=U<W0@,C`Q-"P@=&AE(&UO;G1H;'D@9F5E('=A<R!I;F-R
M96%S960@=&\@86X@86UO=6YT(&]F("0Q.2!E9F9E8W1I=F4@:6UM961I871E
M;'DN($EN($%U9W5S="`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D('1H92!C
M;VYS=6QT86YT(&$@8F]N=7,@:6X@=&AE(&%M;W5N="!O9B`D.3`@:6X@8V]N
M;F5C=&EO;B!W:71H('1H92!C;VYS=6UM871I;VX@;V8@=&AE($E03RX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO
M=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S)=/"]T9#X-"B`@("`@
M("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1'1O<#Y/;B!*=6QY(#$L(#(P
M,3,L('1H92!#;VUP86YY('-I9VYE9"!A;B!A9W)E96UE;G0@=VET:"!A(&-O
M;G-U;'1A;G0L('=H;R!I<R!A;'-O(&]N92!O9B!T:&4@0V]M<&%N>2=S('-H
M87)E:&]L9&5R<RP@=&\@<F5N9&5R(&%D=FES;W)Y('-E<G9I8V5S+B!4:&4@
M0V]M<&%N>2!P87ES('1H92!C;VYS=6QT86YT(&%N(&%M;W5N="!O9B`D,2!P
M97(@;6]N=&@N/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELS
M73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1T;W`^
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M;WAI;6%T96QY("0T('-I;F-E(%-E<'1E;6)E<B`Q,"P@,C`Q,RX@5&AE('!A
M<G1I97,@=&5R;6EN871E9"!T:&4@86=R965M96YT(&]N(%-E<'1E;6)E<B`Q
M+"`R,#$T+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;-%T\
M+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#8@=F%L:6=N/3-$=&]P/DEN
M($%U9W5S="P@,C`Q,BP@=&AE($-O;7!A;GD@<VEG;F5D(&%N(&%G<F5E;65N
M="!W:71H(&$@8V]N<W5L=&%N="P@=VAO(&ES(&%L<V\@;VYE(&]F('1H92!#
M;VUP86YY)W,@<VAA<F5H;VQD97)S(&%N9"!A(&1I<F5C=&]R+"!T;R!R96YD
M97(@;6%N86=E;65N="P@9FEN86YC92!A;F0@;W!E<F%T:6]N('-E<G9I8V5S
M+B!4:&4@0V]M<&%N>2!P87ES('1H92!C;VYS=6QT86YT(&%N(&%M;W5N="!O
M9B!A<'!R;WAI;6%T96QY("0V('!E<B!M;VYT:"X@1'5R:6YG($%U9W5S="`R
M,#$T+"!T:&4@;6]N=&AL>2!F964@=V%S(&EN8W)E87-E9"!T;R!A;B!A;6]U
M;G0@;V8@)#$U(&5F9F5C=&EV92!I;6UE9&EA=&5L>2X@26X@075G=7-T(#(P
M,30L('1H92!#;VUP86YY(&=R86YT960@=&AE(&-O;G-U;'1A;G0@8F]N=7,@
M:6X@=&AE(&%M;W5N="!O9B`D.#`@:6X@8V]N;F5C=&EO;B!W:71H('1H92!C
M;VYS=6UM871I;VX@;V8@=&AE($E03RX@5&AE($-O;7!A;GD@9W)A;G1E9"!A
M;B!A9&1I=&EO;F%L(&)O;G5S(&EN('1H92!A;6]U;G0@;V8@)#<P('=I=&@@
M<F5G87)D<R!T;R!S97)V:6-E<R!P<F]V:61E9"!D=7)I;F<@,C`Q-"X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF
M,V-?838S-3$S.#,R-3@P#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C7V$V,S4Q,S@S,C4X,"]7;W)K<VAE
M971S+U-H965T-#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$6$%'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E)%3$%4140@4$%25%D@0D%,04Y#15,@04Y$(%1204Y304-4
M24].4R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`Q,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6PN(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D%U9RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!=6<N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!!9&UI;FES=')A=&EV92!%
M>'!E;G-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;B!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;BP@17AP96YS97,@9G)O;2!4
M<F%N<V%C=&EO;G,@=VET:"!296QA=&5D(%!A<G1Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G-U;'1A;G0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D
M(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(%!A<G1Y(%1R
M86YS86-T:6]N+"!%>'!E;G-E<R!F<F]M(%1R86YS86-T:6]N<R!W:71H(%)E
M;&%T960@4&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);F-R96%S92!);B!-;VYT:&QY($9E93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;G-U;'1A;G0@0F]N=7,@1W)A;G0@26X@4&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N<W5L
M=&%N="!";VYU<R!'<F%N="!);B!097)I;V0L($%D9&ET:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5H;VQD97)S(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4F5L871E9"!087)T>2!4<F%N<V%C=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5L871E9"!0
M87)T>2!4<F%N<V%C=&EO;BP@17AP96YS97,@9G)O;2!4<F%N<V%C=&EO;G,@
M=VET:"!296QA=&5D(%!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N<W5L=&%N="!/;F4@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R
M86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!);B!-;VYT:&QY($9E93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G-U;'1A;G0@
M0F]N=7,@1W)A;G0@26X@4&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W8S8X,#)?8V$Q-5\T
M-S<T7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O4VAE970T-RYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14-'044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1DE.04Y#
M24%,($584$5.4T53("A)3D-/344I+"!.150@*$1E=&%I;',I("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0U/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&:6YA;F-I86P@97AP96YS97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;FL@9F5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-H
M86YG92!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1FEN86YC:6%L(&5X<&5N<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9I;F%N8VEA;"!I;F-O;64Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T
M(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AC:&%N9V4@<F%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FEN86YC:6%L
M(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEA;"!E>'!E;G-E<R`H:6YC;VUE*2P@
M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO
M=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@
M("`@/'1D(&-O;'-P86X],T0U('9A;&EG;CTS1'1O<#Y297!R97-E;G1S(&%N
M(&%M;W5N="!L;W=E<B!T:&%N("0Q+CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\Q,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,3(W8S8X,#)?8V$Q-5\T-S<T
M7SAF,V-?838S-3$S.#,R-3@P+U=O<FMS:&5E=',O4VAE970T."YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14Q'04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U5"4T51545.
M5"!%5D5.5%,@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`Q
M-BP@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N
M(#`R+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;7!L;WEE92!3=&]C:R!/<'1I;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G1S(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($=R
M86YT<R!I;B!097)I;V0L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2XR,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@
M4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@1W)A;G1S(&EN
M(%!E<FEO9"P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,X,"PR,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX,RPU-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K($]P=&EO;B!;365M8F5R
M72!\(%-U8G-E<75E;G0@179E;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G1S
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($=R86YT
M<R!I;B!097)I;V0L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXQ-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($=R86YT<R!I;B!097)I;V0L($=R
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H
M:65F($5X96-U=&EV92!/9F9I8V5R(%M-96UB97)=('P@4W5B<V5Q=65N="!%
M=F5N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-U8G-E<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N=',@8GD@4VAA<F4M8F%S960@
M4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@1W)A;G1S(&EN(%!E<FEO9"P@5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`X+C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I
M;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@
M3W!T:6]N<RP@1W)A;G1S(&EN(%!E<FEO9"P@1W)O<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0Y."PP-C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S$R-V,V.#`R7V-A,35?-#<W-%\X9C-C
M7V$V,S4Q,S@S,C4X,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Q
M,C=C-C@P,E]C83$U7S0W-S1?.&8S8U]A-C,U,3,X,S(U.#`O5V]R:W-H965T
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M(E-H965T,#$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,U+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S.2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#`N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#0Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970T,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#,N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0T+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970T-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0W+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T."YH=&UL(B\^#0H\+WAM
M;#X-"BTM+2TM+3U?3F5X=%!A<G1?,3(W8S8X,#)?8V$Q-5\T-S<T7SAF,V-?
0838S-3$S.#,R-3@P+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E24CI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details Textual) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 06, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 22, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Aug. 05, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">All Ordinary shares, options, per share data and exercise price included in these financial statements for all periods presented have been retroactively adjusted to reflect the issuance on January 26, 2014 of 6.55-to-one bonus shares (equivalent to a 7.55-for-1 stock split).<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">7,551,427</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">$ 31,405</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years 7 months 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 3 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares', window );">Stock Issued During Period Ordinary Shares Issued Upon Private Placement Shares</a></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares" onclick="toggleNextSibling(this);">782,537</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue', window );">Stock Issued During Period Ordinary Shares Issued Upon Private Placement Value</a></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" onclick="toggleNextSibling(this);">4,368</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" onclick="toggleNextSibling(this);">4,368</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Development Stage Entities, Equity Issuance, Per Share Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount" onclick="toggleNextSibling(this);">$ 0.95</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount" onclick="toggleNextSibling(this);">$ 0.95</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">3,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">3,200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Development Stage Entities, Equity Issuance, Per Share Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 11.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares', window );">Stock Issued During Period Ordinary Shares Issued Upon Private Placement Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">782,537</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue', window );">Stock Issued During Period Ordinary Shares Issued Upon Private Placement Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,664</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,174</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">889</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_AgreementAxis=orpn_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SharePurchaseAgreementSharesToBeIssued', window );">Share Purchase Agreement, Shares to be issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_SharePurchaseAgreementSharesToBeIssued[orpn_AgreementAxis=orpn_PurchaseAgreementMember]" onclick="toggleNextSibling(this);">2,130,159</a><span style="display:none;white-space:normal;text-align:left;">orpn_SharePurchaseAgreementSharesToBeIssued<br>/ orpn_AgreementAxis<br>= orpn_PurchaseAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SharePurchaseAgreementValueToBeIssued', window );">Share Purchase Agreement, Value to be issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_SharePurchaseAgreementValueToBeIssued[orpn_AgreementAxis=orpn_PurchaseAgreementMember]" onclick="toggleNextSibling(this);">2,024</a><span style="display:none;white-space:normal;text-align:left;">orpn_SharePurchaseAgreementValueToBeIssued<br>/ orpn_AgreementAxis<br>= orpn_PurchaseAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Investment Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[orpn_AgreementAxis=orpn_InvestmentAgreementMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">94,393</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ orpn_AgreementAxis<br>= orpn_InvestmentAgreementMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[orpn_AgreementAxis=orpn_InvestmentAgreementMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">471,964</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ orpn_AgreementAxis<br>= orpn_InvestmentAgreementMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[orpn_AgreementAxis=orpn_InvestmentAgreementMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ orpn_AgreementAxis<br>= orpn_InvestmentAgreementMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[orpn_AgreementAxis=orpn_InvestmentAgreementMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ orpn_AgreementAxis<br>= orpn_InvestmentAgreementMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts[orpn_AgreementAxis=orpn_InvestmentAgreementMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ orpn_AgreementAxis<br>= orpn_InvestmentAgreementMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Purchase Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred Stock, Conversion Basis</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Prior to the closing of the share purchase agreement above and as a condition to it, the Company affected an equity restructuring, under which, all of the Company's Preferred shares (566,357 Preferred A shares) were converted into Ordinary shares at a 1:1 ratio<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost[orpn_AgreementAxis=orpn_PurchaseAgreementMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">183</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost<br>/ orpn_AgreementAxis<br>= orpn_PurchaseAgreementMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends, Preferred Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DividendsPreferredStock[orpn_AgreementAxis=orpn_PurchaseAgreementMember;us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember]" onclick="toggleNextSibling(this);">$ 26</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DividendsPreferredStock<br>/ orpn_AgreementAxis<br>= orpn_PurchaseAgreementMember<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_SeriesAPreferredStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_SharePurchaseAgreementSharesToBeIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares to be issued according to the share purchase agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_SharePurchaseAgreementSharesToBeIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_SharePurchaseAgreementValueToBeIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of stock to be issued according to the share purchase agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_SharePurchaseAgreementValueToBeIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of ordinary stock issued upon private placement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of ordinary stock issued upon private placement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 405<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityIssuancePerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional share-based compensation cost recognized as a result of an occurrence of an event that accelerates its recognition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_AgreementAxis=orpn_PurchaseAgreementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_AgreementAxis=orpn_PurchaseAgreementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>GENERAL (Details Textual) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">11 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 22, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_GeneralLineItems', window );"><strong>General [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (229)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,022)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (1,145)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (229)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">7,551,427</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_GeneralLineItems', window );"><strong>General [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceInitialPublicOffering[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 31,405</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceInitialPublicOffering<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_GeneralLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_GeneralLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FINANCIAL EXPENSES (INCOME), NET (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.85in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended<br/> December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Financial expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>)</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Bank fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Exchange rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Financial income:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Interest income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="53%"> <div>Exchange rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(58)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify">*)&#160;&#160;Represents an amount lower than&#160;&#160;$&#160;1<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EONAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableTradeCurrent" onclick="toggleNextSibling(this);">$ 1,285</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableTradeCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_AccountsPayableTradeCurrent" onclick="toggleNextSibling(this);">$ 46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableTradeCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">995</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember', window );">Related Party [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableTradeCurrent[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableTradeCurrent<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_AccountsPayableTradeCurrent[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableTradeCurrent<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">$ 123</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">$ 36</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">On July 1, 2013 the Company signed an agreement with a consultant, who is also one of the Company's shareholders, to render advisory services. The Company pays the consultant an amount of $1 per month.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately $6 per month. During August 2014, the monthly fee was increased to an amount of $15 effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $80 in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $70 with regards to services provided during 2014.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and office lease for a monthly fee in the amount of approximately $4 since September 10, 2013. The parties terminated the agreement on September 1, 2014.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[4]</td>
              <td style="vertical-align: top;" valign="top">An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of approximately $15 per month. During August 2014, the monthly fee was increased to an amount of $19 effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $90 in connection with the consummation of the IPO.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_PropertyPlantAndEquipmentStraightLinePercentage', window );">Property Plant And Equipment Straight Line Depreciation Percentage</a></td>
        <td class="nump"><a title="orpn_PropertyPlantAndEquipmentStraightLinePercentage[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">33.00%</a><span style="display:none;white-space:normal;text-align:left;">orpn_PropertyPlantAndEquipmentStraightLinePercentage<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember', window );">Electronic equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_PropertyPlantAndEquipmentStraightLinePercentage', window );">Property Plant And Equipment Straight Line Depreciation Percentage</a></td>
        <td class="nump"><a title="orpn_PropertyPlantAndEquipmentStraightLinePercentage[us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember]" onclick="toggleNextSibling(this);">15.00%</a><span style="display:none;white-space:normal;text-align:left;">orpn_PropertyPlantAndEquipmentStraightLinePercentage<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= orpn_ElectronicEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_PropertyPlantAndEquipmentStraightLinePercentage', window );">Property Plant And Equipment Straight Line Depreciation Percentage</a></td>
        <td class="nump"><a title="orpn_PropertyPlantAndEquipmentStraightLinePercentage[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">orpn_PropertyPlantAndEquipmentStraightLinePercentage<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_OfficeEquipmentMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_PropertyPlantAndEquipmentStraightLinePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the rate of depreciation calculated using straight line method over the estimated useful lives of the assets during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_PropertyPlantAndEquipmentStraightLinePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_SignificantAccountingPoliciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=orpn_ElectronicEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EEDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liability for Uncertain Tax Positions, Current</a></td>
        <td class="nump"><a title="us-gaap_LiabilityForUncertainTaxPositionsCurrent" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilityForUncertainTaxPositionsCurrent" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimeDepositsWeightedAverageInterestRateDescription', window );">Time Deposits, Weighted Average Interest Rate, Description</a></td>
        <td class="text">As of December 31, 2014, the Company's bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.66%.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfTimeDepositsDescription', window );">Maturities of Time Deposits, Description</a></td>
        <td class="text">Short-term bank deposits are deposits with maturities of more than three months but less than one year.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_SignificantAccountingPoliciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current portion of the amount recognized for uncertain tax positions as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfTimeDepositsDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the maturities of time deposits (including certificates of deposits, individual retirement accounts and open accounts) held by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MaturitiesOfTimeDepositsDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsWeightedAverageInterestRateDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the weighted average interest rate for all time deposits held by the entity, including methodology and assumptions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TimeDepositsWeightedAverageInterestRateDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>GENERAL<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 0.85in"> <div style="CLEAR:both;CLEAR: both">NOTE 1:-</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">GENERAL</div> </td> </tr> </table> &#160; <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both">a.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">BioBlast Pharma Ltd. (the "Company&#8221;) was incorporated in Israel and commenced its operations on January 22, 2012. The Company is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is rapidly building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The Company's platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology. The Company seeks to identify therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism. The Company's objective is to conduct additional clinical trials for its drugs (the "Drugs") and, if those trials are successful, seek marketing approval from the U.S. Food and Drug Administration (the "FDA") and other worldwide regulatory bodies.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both">b.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">The Company is engaged in the research and development of products in the biopharmaceutical field, has not generated revenue from the sale of any product, and does not expect to generate significant revenue unless and until the obtaining of marketing approval, and commercializing its Drugs. The Company has incurred losses in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,022</font> during the year ended December 31, 2014.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both">c.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> During August 2014, the Company completed an Initial Public Offering ("IPO") in United States in which it issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,200,000</font> Ordinary shares in consideration of approximately&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,405</font>, net and its Ordinary shares began trading on the "NASDAQ Capital Market".</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EADAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>RECEIVABLES AND PREPAID EXPENSES (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ReceivablesAndPrepaidExpensesLineItems', window );"><strong>Receivables and Prepaid Expenses [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Government authorities</a></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent" onclick="toggleNextSibling(this);">$ 93</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_ReceivablesNetCurrent" onclick="toggleNextSibling(this);">$ 26</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ReceivablesNetCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">181</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ReceivablesAndPrepaidExpensesCurrent', window );">Receivables and Prepaid Expenses, Current</a></td>
        <td class="nump"><a title="orpn_ReceivablesAndPrepaidExpensesCurrent" onclick="toggleNextSibling(this);">$ 274</a><span style="display:none;white-space:normal;text-align:left;">orpn_ReceivablesAndPrepaidExpensesCurrent</span><span></span></td>
        <td class="nump"><a title="orpn_ReceivablesAndPrepaidExpensesCurrent" onclick="toggleNextSibling(this);">$ 29</a><span style="display:none;white-space:normal;text-align:left;">orpn_ReceivablesAndPrepaidExpensesCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ReceivablesAndPrepaidExpensesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value and amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ReceivablesAndPrepaidExpensesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ReceivablesAndPrepaidExpensesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ReceivablesAndPrepaidExpensesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3,4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details) (Employee Stock Option [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Employee Stock Option [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding at beginning of year (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">403,110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">319,531</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">380,222</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">83,579</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding at end of year (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">783,332</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">403,110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options Vested and expected to vest (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">783,332</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">403,110</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options exercisable at the end of the year (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">429,589</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">134,370</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Outstanding at beginning of year (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.0004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.0004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price Granted (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 9.21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.0004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Outstanding at end of year (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 4.47</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.0004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price Vested and expected to vest (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 4.47</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.0004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price Options exercisable at the end of the year (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.33</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 0.0004</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 10,583</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 270</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term bank deposits</a></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsCurrent" onclick="toggleNextSibling(this);">22,028</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsCurrent" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ReceivablesAndPrepaidExpensesCurrent', window );">Receivables and prepaid expenses</a></td>
        <td class="nump"><a title="orpn_ReceivablesAndPrepaidExpensesCurrent" onclick="toggleNextSibling(this);">274</a><span style="display:none;white-space:normal;text-align:left;">orpn_ReceivablesAndPrepaidExpensesCurrent</span><span></span></td>
        <td class="nump"><a title="orpn_ReceivablesAndPrepaidExpensesCurrent" onclick="toggleNextSibling(this);">29</a><span style="display:none;white-space:normal;text-align:left;">orpn_ReceivablesAndPrepaidExpensesCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">32,885</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">299</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>LONG-TERM ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Long-term deposit</a></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsNoncurrent" onclick="toggleNextSibling(this);">9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsNoncurrent" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsNoncurrent" onclick="toggleNextSibling(this);">69</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsNoncurrent" onclick="toggleNextSibling(this);">7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">32,954</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableTradeCurrent" onclick="toggleNextSibling(this);">1,285</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableTradeCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableTradeCurrent" onclick="toggleNextSibling(this);">46</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableTradeCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">995</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">2,280</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">131</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.01 par value - 50,000,000 and 16,613,139 shares authorized at December 31, 2014 and 2013, respectively; 14,230,480 and 9,182,867 issued and outstanding shares at December 31, 2014 and 2013, respectively;</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">24</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid- in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">39,057</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">1,551</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(8,422)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(1,400)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">30,674</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">175</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 32,954</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 306</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ReceivablesAndPrepaidExpensesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value and amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ReceivablesAndPrepaidExpensesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.10-17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="6">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Amounts charged to: *)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development expense</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,441</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 732</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">2,639</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">416</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">86</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember', window );">Related Party [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Amounts charged to: *)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development expense</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">145</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">99</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">34</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">$ 467</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3],[4]</sup></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">$ 257</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3],[4]</sup></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember]" onclick="toggleNextSibling(this);">$ 55</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= orpn_RelatedPartyMember</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3],[4]</sup></td>
      </tr>
      <tr>
        <td colspan="7"></td>
      </tr>
      <tr>
        <td colspan="7">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of approximately $15 per month. During August 2014, the monthly fee was increased to an amount of $19 effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $90 in connection with the consummation of the IPO.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">On July 1, 2013, the Company signed an agreement with a consultant, who is also one of the Company's shareholders, to render advisory services. The Company pays the consultant an amount of $1 per month.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and an office lease for a monthly fee in the amount of approximately $4 since September 10, 2013. The parties terminated the agreement on September 1, 2014.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[4]</td>
              <td style="vertical-align: top;" valign="top">In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately $6 per month. During August 2014, the monthly fee was increased to an amount of $15 effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $80 in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $70 with regards to services provided during 2014.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orpn_RelatedPartyMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ERIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">11 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Equity Issuance, Per Share Amount</a></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount" onclick="toggleNextSibling(this);">$ 0.95</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount" onclick="toggleNextSibling(this);">$ 0.95</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Equity Issuance, Per Share Amount</a></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">$ 6.07</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Equity Issuance, Per Share Amount</a></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 11</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Equity Issuance, Per Share Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">$ 0.53</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 215<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityIssuancePerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EADAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_OtherAccountsPayableLineItems', window );"><strong>OTHER ACCOUNTS PAYABLE [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 235</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 26</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">760</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">59</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts Payable, Other, Current</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">$ 995</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableOtherCurrent" onclick="toggleNextSibling(this);">$ 85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableOtherCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_OtherAccountsPayableLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_OtherAccountsPayableLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Cost:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Computers and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="62%"> <div>Electronic equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="62%"> <div>Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Accumulated depreciation:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Computers and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>*)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Electronic equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Depreciated cost</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.85in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> *)&#160;&#160;&#160;&#160;&#160;Represents an amount lower than $&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.</font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EALAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INCOME TAXES (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_IncomeTaxesLineItems', window );"><strong>INCOME TAXES [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carry forward</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 181</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 166</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">923</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" onclick="toggleNextSibling(this);">142</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred issuance expenses</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">671</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOther" onclick="toggleNextSibling(this);">16</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOther" onclick="toggleNextSibling(this);">4</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOther</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred tax asset before valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">1,791</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">312</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(1,791)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(312)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_IncomeTaxesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_IncomeTaxesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">Significant components of the Company's deferred tax assets are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Operating loss carry forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>166</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"> <div>Research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>923</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Issuance expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>671</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Net deferred tax asset before valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>312</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,791)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(312)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Net deferred tax asset</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,022)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (1,145)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (229)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">736</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">254</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_InterestOnShortTermBankDeposit', window );">Interest on short-term bank deposits</a></td>
        <td class="num"><a title="orpn_InterestOnShortTermBankDeposit" onclick="toggleNextSibling(this);">(28)</a><span style="display:none;white-space:normal;text-align:left;">orpn_InterestOnShortTermBankDeposit</span><span></span></td>
        <td class="nump"><a title="orpn_InterestOnShortTermBankDeposit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_InterestOnShortTermBankDeposit</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="orpn_InterestOnShortTermBankDeposit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_InterestOnShortTermBankDeposit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses', window );">Receivables and prepaid expenses</a></td>
        <td class="num"><a title="orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" onclick="toggleNextSibling(this);">(245)</a><span style="display:none;white-space:normal;text-align:left;">orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses</span><span></span></td>
        <td class="num"><a title="orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" onclick="toggleNextSibling(this);">(19)</a><span style="display:none;white-space:normal;text-align:left;">orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses" onclick="toggleNextSibling(this);">(10)</a><span style="display:none;white-space:normal;text-align:left;">orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Long-term deposit</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDepositOtherAssets" onclick="toggleNextSibling(this);">(4)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDepositOtherAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInDepositOtherAssets" onclick="toggleNextSibling(this);">(5)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDepositOtherAssets</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInDepositOtherAssets" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInDepositOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade payables</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableTrade" onclick="toggleNextSibling(this);">1,239</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableTrade" onclick="toggleNextSibling(this);">(28)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableTrade" onclick="toggleNextSibling(this);">74</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Other accounts payables</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherAccountsPayable" onclick="toggleNextSibling(this);">910</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherAccountsPayable" onclick="toggleNextSibling(this);">78</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherAccountsPayable" onclick="toggleNextSibling(this);">7</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(4,409)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(865)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(149)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_PaymentsToAcquireShortTermBankDeposit', window );">Short-term bank deposits</a></td>
        <td class="num"><a title="orpn_PaymentsToAcquireShortTermBankDeposit" onclick="toggleNextSibling(this);">(22,000)</a><span style="display:none;white-space:normal;text-align:left;">orpn_PaymentsToAcquireShortTermBankDeposit</span><span></span></td>
        <td class="nump"><a title="orpn_PaymentsToAcquireShortTermBankDeposit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_PaymentsToAcquireShortTermBankDeposit</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="orpn_PaymentsToAcquireShortTermBankDeposit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_PaymentsToAcquireShortTermBankDeposit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(63)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(22,063)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance of shares, net</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" onclick="toggleNextSibling(this);">36,785</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" onclick="toggleNextSibling(this);">991</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" onclick="toggleNextSibling(this);">295</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">36,785</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">991</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">295</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase in cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">10,313</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">124</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of the year</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">270</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the end of the year</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 10,583</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 270</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Represents an amount lower than $1.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities and amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_IncreaseDecreaseInReceivablesAndPrepaidExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_InterestOnShortTermBankDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents amount of non-cash of interest on short-term bank deposit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_InterestOnShortTermBankDeposit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_PaymentsToAcquireShortTermBankDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with short-term bank deposit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_PaymentsToAcquireShortTermBankDeposit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other obligations due by the reporting entity that are payable within one year (or one business cycle), not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) (ILS)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);"> 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);"> 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">50,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">16,613,139</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">14,230,480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">9,182,867</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">14,230,480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">9,182,867</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FINANCIAL EXPENSES (INCOME), NET<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other Income and Other Expense Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.75in"> <div style="CLEAR:both;CLEAR: both">NOTE 10:-</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">FINANCIAL EXPENSES (INCOME), NET</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.85in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended<br/> December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Financial expenses:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>)</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Bank fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Exchange rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Financial income:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>Interest income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="53%"> <div>Exchange rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="53%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(58)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify">*)&#160;&#160;Represents an amount lower than&#160;&#160;$&#160;1<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3,6,7,9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 3, 6, 7, 9<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2PAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">BIO BLAST PHARMA LTD.<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001596812<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Non-accelerated Filer<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">ORPN<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">14,230,480</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">20-F<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_TradingSymbol</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001144204-15-019667-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-15-019667-xbrl.zip
M4$L#!!0````(`$E!?T;3=>9S)JP``&[%"P`1`!P`;W)P;BTR,#$T,3(S,2YX
M;6Q55`D``ZF.&E6ICAI5=7@+``$$)0X```0Y`0``[%W[<Z,ZEOY]J_9_8#RU
M<W>JV@D//]/=F7)>]WIN.DXEOJ_=VDH1D!U-8_`@2.+9VO]]CP1V`&,$&&R3
M4-4/VT@ZWSGZI'/TY,O?7F>&\(QL@BWS:T,Z$AL",C5+Q^;T:^.7\56SUQ#^
M=OKO__;E3\VF\",RD:TZ2!<>%\*%ZJAC6]6^DV5^03J2CGH"?%#$YC?5;LJB
MU!;^6Y).)/E$ZOV/\+^#;_\G7-Z/A:;P\O)RI$,)#BOA2+-F0K.YE'.F$I`!
MY?Q^=G<MR$>2_^SUT3;P"?U7`-@F.;'L.:!^<ISYR?'Q([8>#94XS?F3:L]4
M6N8Q(&A)LB(U_`P&-K^O,E`,M+`CRYY"2E$YIH\?0?@R.7VJXU6&8.+.L?=P
ME72MZ!>%I97Z_?XQ>[I*2G!<0BA4.O[]V_6]]H1F:A.;Q%%-+80%)V"/IL?$
M:LE2-RF'EV*904=S&VFT>C?FZ1^KMF9;!CJ>J)K31*]S0S55Q[(75_!]69!F
MN:9C+\)F(T@[FEK/Q_Y#6C-*4Y2:;W6CN;8-W-N4SW_*JC2<44<X/@\\B$F.
M7K6G^/3T24P&;#XCXL1G\9[%:&.J6"/Q>=@CFD4*9R%8B\\`#^*2.W-[0WIX
M$I/!)<VIJLY7>28J>60UZS^(4?W52.#/[]<!4KN.G4`;>-J`%BP(7VA#."&,
MXG=H(K"&<>(LYNAK@^#9W*#\9;\]V6CRM4%;>'/9BH]>B=X0CJ$@KZ,XMTP'
MO3K"/=(<Z']8)P$BO&Y"\Q]BH/.M*#W`'RA''EOT@\P^>Y!6.9#I8&?A_[;Z
M%>OT]PE&ML!@HY":2Y.?#W]NG(K0@MO]3D^2OQQ',R]%'4=DA1#,D8TM/8H`
MVK7M0'>+3BEH6D&BM"SG[=FRJ(`Z>BB3++\)U_TL04@!X<N??!OZ9?,,*\D/
MBO31#`M_%*E,PRH!PRI5-*R2Q[!*^89M!0S;JJ)A6WD,VRK3L++R?KH"63F8
MKD!^8RS]W*DR8^4<C*69.B48=D!&9N7Z5B_.=V(ZR>63HBU3%:H%+-,JU3*5
MBR`#EHF$@F5QII*6V4EKDJIG&:D`R]#QV@6>(9/-%/%';.%V]G!NS6:6>>]8
MVO=O:/:(;)?0(>N]`ZX`"G4N_^F"9I!J;IGPE0Q>,=FQH:..#TTIL)4\_X$.
M0%[G!M:PXRDBZ$NK?&WX`_$3CEK+9&M&^7(<*^)-Y^,X;`?=HP0X<&NC";)M
MI)\;*B&#6!ZP1Z,)L\D[X<"Z2LLDL09YWQP8Z#JF/8=JW*I8'YKGZAP[JE'W
M"<MDB09ZY]S0-'?F&G0&^P)-J'H7KHW-Z05Z1H8UIQJ!$:>H)LN*+)DL]L[8
M$S_#5D<:!Q9I5&(N,4RA.E`YK$"E@A2JXYQJQ#E5I%8=)KV3,*D2Y`LML]71
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MWHYJWJR,4%,E?LYT[CK(ICWT/-K1W-H6R'`6T.9,9V#JJT1GB_%BCJI-G53*
M!<8X<69ZSZ/=UL.E@33'MDRLU>R(58Y>JWFRT4KOFQRC"41JJ"9&8K<1:Z3W
MS`NE=BC5<R@[6]ZO'4KU',K.R%$[E$HYE/)XL6$P>V.9:#8WK`5";)0WFM,)
MQB!-!B^JK5>?$!$U6)^0I'P]KDVXIN$RF3+>+T-31Z]('UM#0EQD$V^ZTONW
MVEQ*J]\R_49S[8EDU;B.H299I4EV8#U99#VI)E?5R+7[5<?:SU6:)3O;(5VS
MI,(L*6\*+_[U0P]WB"#5UIY@4!I8BK]\G8-=0]L7AJ9FS=!JM?_:TE1JJVJ3
M)5&I9:(4)MI34'.H+V(*4\Q[%Z(!YAOH,VQBXMA@Y6=4DRQ`LE1&JFF6,`M0
M]V05[LD.=0X@3+&Z)ZMX3W:H-`M/-=4]685[L@.;:-I`L;HGJWA/=F@TZ[PY
M3/BLB/Y=("ZT496@P=1&@0V]=+EK]5,UB<16["(ZL-\VJ+P_A]?)X?`@DR*6
M/>U-0W9V(.`60"V"74[P][&MFD1E[T`C9XO@DVH2Y\V#I=>1$6O=6.]['K,F
M1_7(4>+TI1QX+;W\(/>]N:6A^8R(P[I@CHMYN`>QB`Q6)QDWG_"M_LG.C=YI
MH[TVTR4/?U.<*$VHCOU-<V5_Y3++)/?+"*EZ`<;W5K.I->-KQA?(^%X>QO=*
M&D3T`F]OA\_M^H3;(9UPRTX5+U-[=Q.T:<>;==>8:ZCZ83K&0YTGCJ[=UR.D
M2HR0*KF:6G.K>MPZU'XKNKY5<ZMZW#JT%8=N8,6A&SB::A+7H+-.-;,XS(J:
M:G]]5C?/$D6WY$%H>-JEYE75>'6HDQM*@%?*P_V3:J,GR]"136IF<9BU;JS]
M]5G9N:64QZU^@%O]!TFLMZN]BTT>P)A^'IKUFU(9J_>48UU*K39;@Z/+</#Y
MX?P)H\GE*])<:C?O]+H=)-<8.W16<VCJ^!GK+AB;3<&YCP3]TZ7;MI[1^N5W
M@4?5/^X=:X'`12&;+5CP9-PFPVY(L%?VM]FKKKK9V-]FBWAR&>Q?KD![[)<Z
M'OL+.6[UH1I#T23,@Z&"I\2B;2/[6C7+)'5V-]'S-A(8F:B.;E./FU;6JJ=Z
M4K&KIE8UAN35X%7&2X@>[A&4JE\@C:48OUCC)\LEJJE?6:[M(+2>E2I0;086
M=W]1;NEO1O3F!M+5PH=EOFMBC_:$3J)$J3=#*G%M=.K#8TF6Q2V?!470TC:4
M_\O]Q8;",;%:LM0]@13YRWX`A;U9LX@4-K1"T5J@66_<&0SQ'<N.4CTUM*#!
MHR7&"+Q`IC7#9K)(GJFC,M<+73X-:)["AL/K^W)M"`+>NPWG[IKIPI!H@E0<
M__*G9O/28/-3`G1AM,=L-KVD.L(G%Y;FSOQ!DN"WZSLTV>B\&@S>%8T']`>I
M`;U(\^K+<;2DI5;T]P'\J-,'5X8ZS2Q";IQ.5(,@3T:HK*"0I?!;UEE=>AU9
M9F%*(]0K;BPX3O(5)IIJ_(%4^PI^(9EEMSS98:F10C?+]>#ED]QNG%[]$2<W
M4&A0\B7S47=HRJ8R3>=&G64W=:=Q>C8<"6?7@_NQ</O3X.[;0+@>7QQY..)$
MK$,X!Z2V:K!!]L]HD1E#-QS0;"PX*/G<M>U0Q>3E6J]QV@P2;5/!ZVK_A@SC
M9]-Z,>^AW4-(I'N3"YD1]!NG-U90[0T%KR/XU3)<$R*,Q14VD)V=<9(8%1TI
M,::N/?/<H;EE.]B<TDGW'%R7H,OZ@W;EO)+7$3!DYU`C4\O.SC5)IBJ;3573
MD$'=$M(%5F(02DA$$`&,P70*;3%[M(SLLJ%?&]W=WGBB0F7%&/KM16S,@9.1
MZ]!#-C1/6'+X.%58(GRE'H@E].-!04<:GD%?#A'"S57C5&K)BMCJB:&Z2!"^
MA+J:TU8)/9U-_Z,3:L^J@>A+@9QSU;87D/Y7U7!1`F(EC+@=0$PCS`#<)O4+
M7>@J`&LFZ45#CABYDPQ9$ML])3]H?W.0AB#=HX$(9+RUT5S%NK]R1?R6D][&
M78Z-^PQM:L%%(HV8ML=C0RL?U&5-W"#'6SR\MLBF7BRT%S<,KY\,KRG[IHP5
MEP=+:.]F.$`3.5@DJ=5.#X:U?7\%WILG7Z\T"DE>MXHL)2,)0%B7LAV.?._T
M#(&7]P<^U\LH0^"5_8'?^BV*(45:>U2D\%?^A33C^+=LFO$#@T+;1H<?303Q
M\R*';/"W;QW=8N%?H+D-N=E6D\RN0^9XM@"0H)P<&!)<!L=]%8<A8:C/<5MA
MEY4$@U4Z&RGI7H/UALTLECJWS&=H19!K-/$^.QCBA'ND04H'H^SN5LGHY/("
MV[F6VW<3"L>%2J$JK9AUMNZ%%(Z/;E;:/(5&`4K&**!"9BHUQE`RQAB%V8UZ
MS#.50.,`<##LRN<:%<YX.CRDBA>Z%;2$7I\W<FZWR@:7X$HY(457Z>0!%\\0
M+SHZ%(_3YT=V[4Y':7>YS$^IUQZLM+7G:8E\*S7+-=-`_X?KW=%!QM8&7W'!
M%NA,G0S-RU<-47WND*-B$^F7JFT"A.S16BM]M%80Q#UJOGU[:J6?!'D'YMJ^
M8:6?=GD'YBHTQ&MQ0KRF'/99[\%^I<9^+=[ZR4[LF116WJ`7]B3'TCPG,%2D
MEMA./7I:X2@-?`$=,2?>[!^2MMOWH^GGQ/:L:K%](&<:3I&4?N>0*KK<'JS-
MF1$LR0Y>1+OC]MV6^"&Y(HMBFMJ/*%"BVELW]+:<;28^E\)I7!LKXC$Z!+Y#
M4&\$.S"0L9^QACQQ=TBSIB8K)69_0(I!2)L3)D8G#\I6X!`-5D"32C]I^"$-
MO'WC33^[^"$-7&ALT.:$O'6?4?J(JLV)P3^>]1.V,&><@OZ(!BO`Q:5?M_^0
M!M[:Q772#T$^I($+=7$=SMQ\W6>4/N3N%#O?7VGKRTKRZG2',XKK?RRRQIAK
M>P?7J<=PB08NMO_EC.=J0I?=^W+&>'NT?N8C"06T_?3#K6)/4Q00-J9?OR@8
M>K$=0OKA1=%JE-K.NL6>D$FC7L$#OV[Z;2P%0]^Z;733AY@%0R^T;733;_4H
M6HURVP9O'T97E.6BV@8OQ.YR(I(BC]65$K]VTWOT@J%OWTYWXGY+#VJ[.W'%
MNX\5NX6>.$US,F[#8F:/XTRE;LQ.G*V/Z149:/8XSE1NE:O`UDVUM^NCJF4%
MG#V.4Y7:[9A#,86J4VJC[?&<J]2*V^)1G(*1&T\X[E41.]U2N5]`)-SC;06,
MV1E7I`+;-][T?K9P\,4V7HZGA9IH=\NMC));+\_E]EJ1T+A@!</!<9_C>,OU
MNP4$QWV>WRVU*RP@1.YG/]]:)/Y"6V^?MR<M<G--\=J4VG;[W.,%<EI'X;]C
M6+.12M`%\OX?FHF7SF0^^MCGN&9)?+ON)B.6$O38O-6QS[L2J7](>B1<S<8[
M[^E/&&ZC2.@X9LI;O@H8_O2#?GO#'MR^U)-[G>!IP`*N]"AR"-1/<?"SX!M)
MBHQBH3EGN9^M)#6VK@5)3+&-O2S\!40DDIAB/WH7!J$MN:RV4$!8(HD*7XNU
MX[T\)=8[M0LTMPAV1LX3L@>$("?'O6EB^@7^-``*!+W9ITDBQSF'`^\=XTZZ
MY)/CC%LEX(:PSG*AK=VJ"^K^Z%V7FS8Z)=&$XWZ[/.AQ,`H%GT07SL"X*??V
MC3Z)-)Q1KR1'IEB*@N_1+)PU.W,DWBB9@ST.1:'8$X@C\39$\GA3.OBD>WTY
M@^.^)!:`_@8Y]/+46]NB1Y/UL\4O!,%0>#2G-_J"%QL`F&=V`\4Y*(!-%W[S
M'UIF#G\E<2]M:JTMNVP!<"?J)C&0-VSN==8V2ARZNDF<Y:TWMUIBF=5[APA2
M;8U>"1R8]O#'B3G(RAM\M\)-,%%\$5B3F,;S\(J\6ZQ)-.$X]%:K)>4'"SW=
M<E^?!@,6&P&Y@#'.XM9030>*H,,85D`.1J3?T94>1N$*)-"$=[EQF"1[U"'I
MXGF.6^\H!2FQH7,:FL^(E.$<,UR9O!VTG2B:Q$)>%+"V0^K0E4VB*W_J7(Q0
MMEB%.>]KSL%3CIOOA<\9<>07`S>);;QAN[0'O$F$X<V5=R(CQHR`5\'5-A?V
M\ZY=!E:'K1HC-3^PI-KFK3)#4-XK#UG22TMXVZ:[8D_,B@SZ"`TAG5S9UHQ>
MWZ&:&AK9]RI]>7;<JF&:NN5=R2SWPX,6/H;"4"=4/.^VY'Y?VA?J)%)P7*'2
MZ?:VM?8&=W*%3<A;0AS#NVXXRI_M\.U$VR3>\8Y]17A7`6V3^,K;+[;&UV+U
MC7_CCW<(*SH%EH.Y'-<KM<).+0N:$C1)8B7'/TN17;E[UB2)<;P)=%&1TKP5
M:AM=TK_12HJ\-BS]!0A[>0%7A/^\ZWW3\9^#^<8RK7!@DWLDPKM?MQD95VV2
MO"W$A(;(N]-V1P@3&ACOZMAV+R?$K$>S(K!XD\G93E*MM@6P1?_`5:PTPVIC
MP'`V!_$YB)C^H%(6("4HD415[L`S$HCN59$DZJ0_M+2-$B&^#9Y5;+#E62NP
MC\;?`7FF$JSE8-56AY3XB,I1*(%AO"M)87#>78N6]Z]1`M7:'(_)Z:6R:[2\
M*1K"F>5[)[!&%T:PX=)WL&8F63OB0P.O.@_H(H,JXI&HO.G!`5(,[B0N*>EQ
MT]=0[Q1W$F-:Z7$'=YAEQ/T;PM,G^'WP#+YZBFY<N@UN-&%9`]O4MJ=/T$VG
MW?*7#URI*B8Q+<7K^GIT<ZG4.V@5DTB9XI5^DBRWZ?W91>OH;87+_.Y=WA6)
M<C]RX4Y03%X,4;/Q;AR7>Y'9D$04_@9!XB6"0%O+:A3>A7MK;P&,E5<`KNB;
MG3ENLI\+U\:57/"Q&6S&&43*T>G7C3(+PA>U'6<$V1%S`]R":)Q!8S>&]9LK
M<@MB<4:)G;A.@`<D@QEXTZ%B)T9^9JE1I3D#-47N1Z\SCI<;L[$T<S_,NZPI
M,F64(+,8>%%;<???1GOHW`#9ALOL[Y#G=-G)\((RBX$7L1_OJJ1^/S>^:ZP^
M8L.;^L]L-=[9424\CER7M16:J)%XIS_ER,HN'TY@.,B;Q(V:AK?\%IGYCPC:
M`DC4*KS[$?J9@&PXKYO!,+S]G-'K,39(W!Y8U%"\_GSMZ']*9-'72ZT?$LY@
M/=Z.C[7+-_C2"\4;-6KFZP:RXPTT8XBTMK@%2.)=`Q0-)'B2"T0:L2OONI_U
MX",KUD!'<*O:(YM-PWHO(UI.?F0P;-!1#*_O-TZWB$>B%-L9;<)0+.RHE94]
MP/8.,0Y<Y\FR\;^B\PB)5FZEF#_H="3Z"JY8M%'1Q:",&C7%7%5;%"/=V#8H
MO9<M9;!CBJFFM</D&Z1N#RYJOC231&N'K/.B2WGV/0(QSV'\)-$%P8Q:,L5Q
M^Q263,#I]:S+_6'+MC^8T=@\^PQH]*Z<A-ZHWPY,62>`*!IP`>>^HQ?J!+5\
M)?C$Q,;7AF.[\/6X`/@)T['1FW$.P][1FVSQ,YCUUE`U9MN0P=U'@G6LV@MO
M7^(F@Z==PND<B=T]J3F\'>71+-4BCPBM7-J!7J5<<"I%[]A)(&E;R:?ER)ZJ
M)OX7VPIX;IG$,K#.OGBWP!#`R+Z.)OYV0M58@2<7F&B&15P;C<$89P8HD:,E
M=AJG?S&<SSI^%HBS,-#7QK?!W8_#FQ-!G#OP]_6S<#6Z&9\($OT^QC-$A!OT
M(MQ9,]7\Y/WP2;A'-IX(C;],G<]"I+CSZ\O!W<FCY3QY)36O!M^&UW^<1(KZ
MS)[=#__KTA/U>7SY^[@YO+FXI,*;[<Y1%WX4(N#8_\MG'LY'"+U3@&T(JH&G
MYM<&O2@?3Q8,.X5^#-A7>DS`GDM%@N"%'R*%__#I!T*+_<%7\DV1MX)I8:N2
M'79L.F3RYGATRS3[+/PVO!C_1/.+_Y%1KZ6)FF>C\7CTC977@,PVC$=HBQ0T
M9!ADKM*MJ:OO<U77_>]O`.TENE\O[\;#\\%U<W`]_!%L[UCS0#)]F8Q5F)_$
M-^I*$?&HU\8FCQ_>1X%^9DEO1N-+03IIKE7+L:.G`Y!5XH^7-Y=W@^M$@<>.
M'?A,J]'[JL[FG_\L=<2<]9NW:DNKS[/1W<7EG2^L>3ZZ'H&E_NR-'CX+06,;
M:`*Y_?2@Y%IB7]V./']+=S?\\:?Q6LH8;*L<UY=7T0Q9ZS<EDXI775;VK;IZ
MM+MF=(:M,_"MCG`+OF^F"M>.?B3\I_.$A`:]7DDU%UYKZ<FR]/FOPHM*!&QJ
MECVW;#J>AR_"D-@J,@2(_L&IS<#A:?1WAPC6V^Y^RQ3^KIHN!"N"+'\2J-\_
M$L8@Q1<B8"*H@F9@$VNJT23T?D#A$5L.TIY,R["F=%K(2TEE8(?*=BSP[NP0
M-AOR^)F-A3!#*ITVF[B&0"?]U3F&ICJQ;&$.<*A#%EZP\R38=!Z$PG8-QU:;
M[.L4F<C!FJ!C0C=EDS64M#0=9#RZV&!#+172/B.;(`%LXDP@,+`$:R+,;4MW
MZ99!.BJ"4`'Y0JEIYZ"7Z4"(0%6`#@#B!P(!S`PY`%VG2@@F/5C#,&.Z0LBZ
MJ%A,/Q!A;J@@UYZ!"4$#]IX8:G`=H3F42F>WEL-"P$7E^P4U-=4E]&<P-)B8
MR9W3,SV$T)Z,6F:%%#2V)A"F"1#YN%Z=4G`$T0T7Q@H:%*^"&V8S3%0246<H
M5+SJ/+'J#-N5(/2=4&/0/8^4QGZ](9?6Q9M^K/2L.%1&&3`($SY_6I`W/#/@
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M"T)^SDP(E0EM%%LZ-4#J3<%D,"V7:59N,]CP)-.CD5QS%.!`>":NPG\N5S^:
M1?G-]&T.XA@%<?`8X@"3ZQ-X$ZPG>*)G&JA*F4X'/<+4/XAR/$SSU=^B>&U$
MEHN-;KO^7_P5!3D3WDE%->7V#QZ4:P1<>E0U/@(4'O&`=WR7IS\Z;+2[W:13
MJK%VRNRE[[`_L&L:K.:2JBQR0GH=9F#UJQ3M68*\W1J@C)=R7,KQHY#C:HER
M/"UQ;JYOKYI_OT*P@=`[@^^3[+NM$"*\@SL9>\^P/B9=&DS^7$1.V=R@*-P5
M<`A-G3DW]]Z3`>;['=KK>/</)]?W=V"8@L#\'2Z!BUF(E$G0UZD.>D9W00NQ
MH\`\12CI-;KM=@.V,"E'[VS@671)^;D7+@/,?`?L9-^:1I6$6N)-G\$ZC?=(
M^N0JXD%@]]N#Q-H:X`"Z3#&A(DHO](D^`YK!YN=.'=<_)[?CA\OQ_Y(@Y^<W
MINE.6HGG[JH2@GLB01N+4_HH``?#G9YS"<NN:1K*N^6YYQ/]C6H?-Q*<7&Z&
MG[1PS?&/=O0Q6&2L4TG.@?J%%M"1V>$G&,+R[^$M*GA3^X3WAX6$]V58O/*P
M>+?,L/@#W'S]!8"]?23CBXN[WV\?KV]_)?=W-]<7UU</.83+BW7\008S>Q'_
MVQJ>[6TPHO$^"1@=UAUP.ECR+R#$*#7!XZ!SQ>9>CP(L;6MX',BC=4K(XG`9
M&/XZ:#G']T$P)@:_T[D;>4Q)O?;#"8O8_#H>WY_\N&@-E(;)3JM3I.4MD(P1
MSJ8/Q<<P$!_%8FPW<W$OZVIS`V,!+9U1_"'BG8[\[K"X!/8Z1`O0.=]/?E:Q
M]84(YK.S?"0S%[VAL>TN$];<,L<S`$P09I(YE*S$IJR9JD/@O<HSNP,#13/E
M3QKM7`-(0'OF3T.S6@$W8S9G!PCIT'_L,4_4T.E+<)R`R]OD@<3#$QB,[F-C
M'\OD]C([EO'F`*G.(.%0*T'9/?%?`(]G1R?O[`$S1:-L?<Z&KP:[E"C@<*FN
M'\'#0RE<#8M..<REX35>>*<1Y4/S>%MH_^*%*NN"]8R(6'8/?PL_WEJQ@3S&
MMFQ!-)CE%`ML\>N8WF7=DEIDK+H>/!0VVC-8B9IGX(+989`?2;3B6"J,V5J%
M/;D<S2H?7,*#"Y'Y9-D[5GY:9TEMX5AF&$]ONQA/F9Y6+E'2]8%!;HJM"0V6
M'@!=#'&&R^WNX'B6>8:$M)+PDRP3/O-4W!TMIGRLF?1"R0H?IJ`SCR'82ML<
M7G\DR-U-1_\O;2H:;L@Y,2V3!M^[-G75*7X'!H21:5==F^0?GDE9D):ITC#.
M1:*`%7JHIJ;8FD,^6_`?<%6_C!\^8W"6QU\S+_U]CIH>KAT__`Z7=MI-]A+V
M=_`7?&_39\5FH<GXF2'/Z<'T#C0=N-&%]]ET9G$3"PP)"M:#'IB#2^Y^!VO"
M89E(8#Z^Z);G@"/.[D0#"_-=(N.P$1TRQDC4"2%2+8T%\_"5+*)MTZ=WOJ3`
M$HGLF<@F`3L)_JNRA3Y1]Q7#",MAC65B1(\(?V0+#!?<(K!_09()C[$CDL`.
MG<$Z7!]/OLG+34#,.UGQ<C"%?]!_1%QA[!-/+RFS%9NNU63;&3='_3!&:+GA
M-NBL1U0#3$MG2B:&]<K@<6+%<Q\(9:G4#7@3O`KL66HL-^85QS?5T!9=L<GP
M+'B8;Y)2=JFCVOH\[BTLWJV$35RC8P5FN+.GQ@ZYN4WZ@_X2>X</_D2W'9>?
MK2YYAFD1PP+3V%X!`7<:=`PPZ;!%^#@'3SBFBL8#3_[;%N[GO*'`%QK'&&QA
MC,.88T"9C8_Y2;C]BFEZ"0+E1C,[*=!-=O:M3%Q8;7A(W!GXA\0+Q]O*?`Y.
MCQ:2'E^ED[V990>UJA6MQZ(_HO,]5`JA2D`2'#3YC_&C%&3&2,E$IRG-7RVD
MO`L+1(YMDA\>O">PZ705GC]H]ML_GI/+A+_Y.UZ'N1I<:#Y9'AZ!D2O&3>"8
MCYG?^8[LX#=HIBA,%))X3\-G6*X1XNY\D,G:&7YTT(^<XV%?]$ST<5GRB,^_
MB<N5Z#HU\>YGRZ^WX^]F?JZ%1M`+S[=C1=N`?<LU+9?&/&R'YP."QD&!XGA/
MJ)78N:EF`:)\^/'X;[-W<TY.6%],VFTF*"A/$,V6$J<\Y`("#$/>FL5%,-S*
M$W$7<F3]EC9P,7U1#(\U:.4"E"V&94+"I8THK!(^E,EU>,2SIP=A>,/@P7K_
MG#.5ELQV9S/15"\7,G>Q$H_@Y7@<L.A>J@90"E_I0H@^#O(6AWJ$'2[_<H(/
MBCN4Z_Q#<-NTOM961PF7+O;M_?CR\OKVU\BA9:[A^.+_^_7KW>^WEX'SY]J*
MZ>`ID>E&]_!'L3M2OF5PQ5>>@-&.^9O,Z4XORK]N857<0P?WC[SX>X!.<8",
M8;>,;)S24=@M$87=_CH4)C)IN-I,1<497\4"-'E)`[6UJ3Q8V.;E=HJHNU_L
M=J_!7V8XJKJ-_[+D"(0YB9IE&.!(G.>:UE/R<70N9T>!O<%U/YI3\9*C-+ZX
MC3)3_FW9:$KY[F.LWB.J56+=44(+QB_\B)<Z@967R#X&LG87GQB>:N#S-&I:
MW('7_&1J%ZTGDS]V<:$;GD;Q>UB)RC18M!I"!W[G#+/&*,``;U?!R'O1P3[D
MIF'<L0UPR;'@1RQXSK63,#OALW]-Z"M;Z`E0IO\GG@N&+4+@.=Q_F'@\2H+E
M,JG5Q>S%H+8EDEL<L$*\RY*C@A6P!%`-$[>*ZA,T;.:38G`NB5-BBO08I?IQ
M(J131F.Z38!EGG7<0O_,KD5N+;/IT][R-T49-ABI4M#G8;Y1XI49.3>9H<>+
M6*".!1PO3GXDHUZ[04Z^``4".LA%0&"_*>"5V,Y)(R`U]&);9&P8\=629_`T
M_2--GLC/(G'A6H/PUPS<9Q?9R`>,.%-*T3&CLP5LFA%>?'+7?0%@TXE!U5BF
M4$RTPTOBXB?NSO#8&^Q`*$Y8\)-EI0)[PR/J[N;4[\%%QGM&@U9[4&2U6TFY
M6M(%E"Z@=`'W/_#7MDC?/V8/;N,M6M9+)J\=PP%D[#3,GT"6@Y]64?KU_B9I
M&A>\X'UJV6X3O1\RU9^GX&$9.ER"=A'.E/8/O-#!\1/H-)U[82_4=G54,>B/
MX).9L1C:IC,%?`]^[L>L/IM2--W<J8/6$R\+A6?BX'6'':Z693@MR\@I+O]6
MZGBIXX55$U+'I_F72AU?+QU/'B(=]J28?Q+-GQ)SS,H^3P0OPZ\?2O7_8/H_
MJ?9G%NL[A,6Q<0/@R7.Y!<!^LDS>-R%UO,)>ZN-_T/ZXY.T9X3'5<O!(VU0-
MCY^AJZKML4`//(/B;SS0&BLE=LA$@3OQ<)RV<I4F8X:'A5X0C51P.@G8*TM"
M2`<#,99GL1\X',Q^@FOYI"VB\%%;T<\L*@PO;[=.3[]?E&GU"O)4F-=4<+\C
M6:U79@>.0;_J-A3%^AJ;U_KMEL@^*3&1/9A7QD^_@F%EK!5#E6GLZQOIYB\D
MCM3P*,F7SB8T'AYQ%=^XX&8%M@'!/.EH``RJ;9NJ.CLN:H&JC_YBN7>*H?H7
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M(D(4"3EQPAA]?X(,!BQ@XF""+1'U?:FD(3`IQ`VOW:0#M^.W1TH4.P.Z4%5*
M)Y,-,#73-0W%YU),E2TP<@6_EC*D>F)(Z-)%$28*<FPT(.N#G>$QD,[12MP)
M^U\1(F<'"8QA50\S#GEAK#5Q7\&5JXJ(BD--':5Q@`V!66IK<9LZA1L$'3SR
M1LE:@MA>QO9ZDA!$EZT[FW-%6+=7F#5M6R96+P2!LJK5LY2L-3%6RI:LQ7'.
M]I*V,Y"$(;JDW=E4*T+2WDTFNHH56[:I8QE7\G"B:K4M96Y-C)BJK%D19.ZI
MI`MA6KTMK*6^)7*%G*N6-:?W('(,4O,6EQ_?8T,Z^LH:_MA$AQMT.ZBV7BAS
M?;@@O5,L8`W2`1KDWE!,?_3559A_`KPYI28.."0XYLIE!0TXMO"9]SA3=5OU
M9M@]B%7!FSA`TJ51D;BJV/8[2TP,)U1ADV`\UB<SY9W-UWK"I:N8$8"<V2)?
M@S]XYZ&H:[!KX;53:O`Z=M;I6'=(6-_[],[G+<X56W>B/FVKU@"/Y*7BS.KP
M3&R1A!?!T\*6<XY?C<XKB)]H;)K8TWLL3:%%KB<X4W$:IBU@,;\_U"6\F6\,
MMH##.V/;Y%H1O?HH>3;U_R["&!OX!7]%A?09<,9R*.B;BF,]HW<PN,-,T.35
ML6KX<1SW@)ZYQ49\3GR2"SHJ\^T&;`&E+,.['7\?RXG%/!/V;(<:!FL_R!-&
MX=\]ML<XK!4;WL7PY!=,1Q7>_MQ.G6IUKT<N1MAV1ZW>8)FT/92B7YGR*5#*
M9]&)F<\E)F;>6.8S+P=(5EJ(DX]9.`O7R%A:W"V_.(*RGJFIG]!0FEDN_/N%
M@AK%\3J\AZ_?$@-TE\%&.C>6U5Z4I'&D8I"*02J&]>^8EJ@8OBX;4,R,VBJ5
MQ&8YS%)M1%"LWDO>])KW0,*)-^$49NPVQN:^!.W6?%T#;KKR'K;/=J>ZK;%&
M;>]$-723#:A&O]`SL.LN+"R\/VC9R]N>8>\WUF0WN,FU=<6`ZQW%`!?7;Y46
MW`,J"YQ>DQJQ=DVN#5Y2_`N6)(*#//V90&E!O+(LEZ$*_6MX&,_YSUKXTL'=
M=#8WK'=*G34UQ_71H)75!U2E.PM5E\L:,$C=68KNU$O4G=>\M9RKO.TZUTYJ
MRLJCT<%4$^Y'Z;$M719R'O8QY.QO_B->>8(J%+MPLM[\Z&2IMOY$>5M.SPG#
MDL'@M_>@@.S5'Y>BT0FU6715><N:%!>N,NH-R0OYPQZH7!&",N/SW"B[)ABL
MDC6`A;79A[?AC>N&VK$Y>D'L-JJ)HZ;"X\GPF*CIJ:&\^NV'6./Y)U87S]O6
MLS`\;[L:6V5@EZBAZGT!(X`F>^+[XP"P9[_?$!]'_V$E'=L<=AM8&C03E7Y\
MW(_@\J$B#F]U8.A_4N.=MS7`,#Z/$-L4B.:_6:'8_*,?.Y!R6-1U>-RH@WD5
M3+DA[JO5=%PZYXT?%#PAL*(C!49M/ED2+YA\P?:=14:BR91\&@U[$N/28*@"
MY?,B8S?`'W\"B?K=0F.G)?Q[E`B<W*GKV29AK,MY$)F"CZ/P&SPPG@IG4U*D
M7J34X'3)YQ%]!2G"[PUD:9RG$1&]+TM<JDZY/3T#Q+I^M^`$+`'_.8!KA4D)
M?)BGZ8EF&R"M+,,+'HU[$)C!@'7@`][]"Y[XS-\/.P%<ZP0#J!SLC:S%D1ML
M2;">)VK2B>[RJ44`IF(_LUX8&=S(8!^TOR<_^,6Z.'4#))3N_!BB)\&@?!PH
MN""L_!86X[J<?%ID21^/X$"FEVBAC&-[$.=(7+:&L,=D+RJ&9?1UB';_H?;/
MD';_<??/V&56]K]+]"?8^"73#=I8X_Q@,&1`<MJZ\Z<P#D;%`?<:V35?8DW(
M'=?V8ITYYY9+V:@JT&B.]_3O8-ITH(]XZ&PY-?",#-"B<QLTN3YG#\)+,-T#
M-9R:ZAQ:]IBY?!N4'`0Y7"S;&^8!\>:MO+L]&[+!.HPYT<R,%OEMU2"+28+8
M=-?C9,-^QR&3J?9E\5ZQ^/KP=B1(,,Q8<E+#]W]!Q1GO#8)6[@RCOC$ZI&^Z
M$W22PX%PC)`M?]YA["62_BJ'(CVFTK1`8DR:?D2AR8<R)*1.6NCX:6%L8@G.
MBZ!O/(F.33>Q%16]$'\*7?@->@\6F]P:W#6EVC.+0-@VWBQ'S94>&Y`&N#3`
MZV*`_UFB`?XED4@ZR3+?A#'#*_/>ZP5(AM++W->H87X8Z(:_8SUF:XZ'@]K0
M5$ZVL]+S:2RHO$0;[$YG\'T26/+A`M[[9.LH"173::X4A]$TAA2*0[V8Z!3<
MB,Z;;*I26"0J3';($GP_5][QRT:\W;&?K!?+/-?X+#G6FS!J]IQLYLSLM1B1
M2RM+O'B&M,6D+5876\PHT1;[K#BZRK.O=,/#P`B6S&!^&$_]$L80.Y9X:+MU
M=G:V=Q"";ROVY$UN)VN\R[M`Q9(9HM/46+M\TV,'>J#?[C`TA8,EV2-`Y7DN
M%O&Q8TT-]"#\A^*I,9M50"XSZ:CP%Y.YX3F<B/$T,XS\QFR4A>?%ZNTR'HV+
MPR<WEF6H=%E1Y)5BXZDTA_4!']PZJ3OY'`XC?+'L<",=0DT\=`X.JR,HH^D3
MB6+"!J:^)$B#A]WB!87TC67Q:GPH*R]EY(VM8UD$@6S-8$A'9XDUS.X,TG=P
M<"H0;S.@YIH=?R_6N)=LE]7OP=*2%-J2+-;>FY5H[\5F5F.^C>-:ZI]-KH_C
MR?HBFWT)'=$_"%U7T'")E,19FHZ[C`J6IN9V1F#X7,2O;)('?`B)?WG"YY_C
MY2<_\LB?C=:8[:?LQN>7\^(4EG(8'HEE%(]$IF,T"R**UG!H4&<SW>I#Y)?7
M$.65#6B?*1H+Z805)K[W`V]W+=MI!1!&:V5=(DP,]N!M_GO)8DL$O-Y]SWZK
M;^QJ_NBI9QL4O)_CBY.^F%G1G-LZ"F@RLS0\B,;]2O1;\`_]V"/1H(ZU?6`F
M0XBE<&(&@\'16<Z>_8)ML\#RT"W-"::[1T?52^>\)ZQU(`=J^`TM>';UF@*=
M`^.A)+!'*3H<:O@IN_#E9T,!T?&@3BV#.LW?J.T"H?QPDO@:F#^+P(-,U1@3
M^?GZR,5`@UAUS4538'9S9N*<D?G(D&>5F!NI.(XW"Y[`$E#1!Z6&];IF#N*!
M;>*!TJZ^*?Q70:XY`(AIXAIYUZFA+=*`OMP]23VRR4B19C\X1G@HK1-R-)*[
M4QUHW&8IYO@<6V?YZZQC$WMLZ$CBF1IO/12^!I0,>J?)&@X\?XL>:O"^27-%
M]\]L@INYW@L.ZRRLQ*3,`9D;BLE4'3P]?8NO-?@ZI.0_)NXA_[0PJ(&I^OMQ
MS$,0\8@;'SP@!S8(ZQ#EV@H/MYCD=OQP.?Y?)+Q_>$#+/$KC>-@#5$?[ZC\>
M$^>H!F@X"BSU8';@[)EAF4B+7/)C/=V,/2G&B&"F*4P+Q1[&*S]"5G\)L1'6
MIG!.Q>A-R.J./H-7VI$)^8%KM-CMDHN.B8N^8H+?!$?^)L;1[J^#[.P'+R@>
MKIF`3]@,W4>;^6#OY,E"\<X\O%C`'.EZ705^S79*$NB&1A++M=B++`-'.BPJ
MY=8^<[/]U'MV_,+K57W'.JQZC:_#;\/(3?[SZ.,')W7=S./CG[$3DQMV<\+G
M88HT/IO[O[PN%U\31`$^)`TQ:JNZP\VPN>6XS>!V?OTL8(Y`Z#_1J?*B6S8/
MI_A"GSGYV.D1EF0X5E1''!0E3N+UL@#B'!<=OILI(6!?`Q[G\AZ0<!/[-NB&
M:5._U13X.Y$F`S7)JO^(HV"9)W*^W_C18K(`+K:M)\04IB$;GL,,3#-"9;B$
M`"S6;9&]/M[#LX%EE;B4)\J3:$`)L\A(;&OI&\!L!BK5UZ@/5Q>HZB<3V+\3
M!VM164?&D[C_MT`#+3*.9\G'RSA8<T_\(N-A#0PSF0M4!1?A28W)"C=I6#49
MG$'Z=D2*:'!=[,#1KR'`=B?JE/)XB>]?^G05)&9[V(D%*9/#A`U@_$NW;6RR
M]O@@N#TZ2GC"(DN;Q??])[$P_SEO9\6N:1K,A3B?Z&]4^[A1ERI^,A!^TL+5
MQ#_:T<<@/OSS3Y[3?%:4^?D#B"C8)$"_&\6C[RT#R==Y!)+Y;("-].FO?_GK
M7PCY.;CK=X?>3:[\\!L[O'7ATJ]T\LO)?;OS#?Z/QN&CU>E^Z_'/)T37`'NP
M#;KVK7,V.OF4DMP[YX&3=7'W(A1!*Q]5D""S^K<_"_N8#(,^)E4<D!Y2_I%2
MXGG4[[QM1Q!5WS'Q.V&F"7TV7F;N`[H%8!_,E:C,*%G"%@OYZZR6")34##U:
MY@<P!^'7\?@^BJK.HM(X[$"@_!G-Y(:5_-O3GOU2-S,>_$K&ISXD'K-88;?)
M`[G&YTVE%<<RN;9C;@[K5*`S2/SN)6%S"/\%\'AF$K[S/'1%XSU0G`U?C4:#
MPA,U^`E+T-4Z2I)>T>,%>X8;%FO<P(ZXF.IC!MR2>]SPW,A9M8&-T/+(6E#8
M>BV6VA3UJ.'6#=I7S%R!C?8,%Q6L9VA^"YD@N\6*8ZDP9FL5FL"1.6U!?*,I
M:?ZDC2/`1LR4LBW3PE8:C#288?7._QT:5SN83V<U-)]RK^](T$^D=E9^6F=H
M;8&X#-OJ;1?;*D-S9R;2;)_DLSZEAUMJ:Y)Z2L_?64Q.VJM!WE.)-A32BA+E
M]<P3W%]E)L\VB8#Y5_5RK@=3:KOL.50534?_+VTJ&FX(SCDR:?"]:U-7G0:S
MCS)EQ#4>59B4MT%"31LUJ(AE7SU@2BE+#?EL83K'#R=?Q@^?3WXD.M@:H+TS
M+_U]SA)(,*WF=[BTTVZRE["_@[_@>YL^*S9/98ZU5`5CX1F[R;G,LN`V&=YG
MTYGUXD?G-`K&19B!L^3N]P:&2_"<8XYC9"S/,=[YG6A_L9[HH>W8B/)B8R3J
MA!"IEL8B`?A*%M1AC?K8D@)#):NM'IA1\%_5C[WQ]GO+866V$:^.CQX1_L@6
M&"Z8A;I0=H8K8DBB&(4S_89B-+"(N86(H9T5+P=+^0?]QZ`I/`8E*4]=<*TF
MV\ZXM>H?L(:&'<N#8#T0&]&0&=Z9%\^1L.4$M9T/?NY1`]X$KP)SEQK+;7T6
MZ[*XXZ6LV&1X%CS,MU@INQ0[+LX3F<T+=Z.Y\,(AU\W8Q!G^5`QH4O,9+M2X
MR?J#_A)[1W"^S#K)L;3^)<\P+=:C'W9T.01^E!5[J6%HEJ>`ZRZ9*IH_#,;,
MAH'SA@)?:&%CYAB'\5:*S`7`4@.6<V::7H)`@S2K)_JLFRS\J$Q<6&W8**TS
MX"GGBV?WRGP./I$6DAY?I9.]F546S)8O6H]%?_!3;J8[0"F$*@%)<-#D/]YS
M<1)Z]I&2>0B)H_FKA93'&E[9)OGAP7OBO5.[[4&SW_[QG%PFW-'?@^Y[7&@^
M@8^#9RU7C)O`;Q_[G?J`'2Z8Y^I1EGA($N]I^`S+-4+<V^?;-^IVAA\=UL8&
M3PFB9Z(+[/`\1O;&Q.5*=)V:>/<S>[<:O)NYP59PYA0V69Q8EHN)7S$'W/$/
M8'AQDN,]H59B)4.:!8CRX<<DM,W>S3DY87TQ:;>9H*"\P"1;2ISZ)[.*#9I6
MT?P\T#F>)KDN;RT?Z^T)6A4[SK.#H*"C97#^P1;30,C]E`8_P!`^E,EU>,2S
MIP=9OX;!ZUV2J4N)W=E,--7'V=[6G0[<<<N>F^<A*T:<&/'9OGYX%SP@0?WP
MS$CFWE',1>]9-8`1^/H6#BCBT9\X=>U8_[+._06O5.MK;764\%ACWP9#8T-_
M74^,1,T8G!#=PQ_%[DBYSJE1M.V8.\UB"NE%^=<MK(H'(,"[Q?Q;AGGT^<.Y
MLMV"?.UJ4=@M$87=_CH4)KID!!-U$YS$N"EVB)-78%1-GD!OL\TK)ND*NOO%
M;O<:_&5&VZK;^"]+#H"8#ZQ9A@%^TIK,^`UC2'7-F(J;4]RT06L1SU*"LI@T
MOK@)QCI*^G-HDWFHL7H:-NDU--#\T3V\(R5O0=G`;)XH18)-`UI\8GBFPT<4
MF!:/3VC^*)UP9$'F0C<\B^/WL(;CTV#1:@@=N-4SK*;'UN3P=A5LV!<=;*5@
MD'#DMP>XY%CP`S(\%\=)6-7PV;\F#`7$,M/]M'.`P/,;L4\\'@3"=IFIU<7,
M8?P3<1#)+0Y8(<YSR4'/:B9+,W&KJ%'.4S@P(TZ)*=)CE)HQ&Q%8YEG'+?1/
M+%ODUC*;/NTM?U-4@X^!.+^;&!!0XI59%8Q9D=6+6!R2ERV>_$A&/6SP\,5O
MJ'D1$-AO"CA=MG/2"$@-G?06&1M&?+7D&1QI_T"73R%F@<9PK4%T;V:9U$4V
M\@$CO$.H#H)Y`9MFA!>?W'5?`-ATXE=EI2.(Z7(^Q4FT9F/C5?Q!#/[8+R>>
MS5='+VYK+RQ]FHH]A,>FAO^YBEJ<[>^Z=81WW?+OJ;,RXTRZ<M*5DZ[<_AF"
MZZJP!=J\2CVQC;=HX_*1'7?L(M4^,P=_*YEO4B/3,HT+9M#$NFU.]><IUC3H
M<(F6:*D?=I.UJ:+IW)MZH;:KHXI!OP*?S(R^T,9,MNYTIU@Q!2:8.^4#F-@!
M!#Q3Y7T3P&*JHP&TE1V3-G[N;;06W?=[`_/S30WO9(>C^]L_W9K8/WLUA%]I
M\-0RQ?Y0VSJ)D*"_6WK9I,3TLD`>\*!-(`P:V,RNRN2R+)=E<%KG'M[%U[KF
M1M^%)&=G$QJW!ES%#QGAD'5&>RQ[2?4'&&+O#:R%!'^?Z6QR&?N+G8C[31D3
MDU4=L%6Q^6C3T,VP^4S8.RGJ,.4Y=.(98("\1$GX0;Z^/Q;(PAFI;,YC=A5+
M:5DY14\3SPL0+I-NF+Y8A"RF%9<<`J=]ES/Z=*I2A@8'[!0M[<4L_KY@]@=\
MY[_\%#6R_Q#0-3?C^P>`0,7PV]RA'\D=:*@O-W=_G),7,!5A:2D_9NF*`H\F
M?<'ZT$;:UDBI\[#9?G?^EJ7'X\H`QP]1.^#*QW_=7$4.48*CT[N9YN-%30T4
MX5HS_\(__#4-VU%H9A#?U?V/'-<JOMUA31LEN\'>C\'>*1[T-&OPQ9-.1(@B
M(2=.&*/O3Y#!@`6`RK<.67U?*FD(3`IQPVLWZ<#M^.V1$H6#@"Y4E=+)9`-,
MS71-0_&Y%%-E"XQ<P:^E#*F>&!*Z=%&$B8(<&PW(^F!G>`RD<[02=\+^5X3(
MV4$"7_!Q#S8_`W>LB?L*KEQ51%0<:NHHC0-L",Q26XO;U,'2(`CCYHV2M02Q
MO8SM]20AB"Y;=S;GBK!NKS#9Q[9,3+H+`F55JV<I66MBK)0M68OCG.TE;6<@
M"4-T2;NSJ5:$I+W#KHJ8:&R;.FN^G3B<J%IM2YE;$R.F*FM6!)E[*NE"F`8L
M"VM9V7-4_)EI>9^K-H,4@O7I!4^6H0E\P%IZ3<A\^?$]MHFAKY1WT-7A!MT.
MBH2RYDOUV&#-(!V@05@F&B_M#Y/1&B>L;33%TWKX%ZMSL(DZ5<QGWGDDWJD8
MO]"PNH-&M4VIZ>9^BVEVK!_V5WZB;,82-@5F8P.^!G_P?@!1JS_LK$S)E`W]
M,#7>GE!WHB'W3X`5/@3`UIVH>\JJ-?A3Q_V1'YZ)C0OP(JI%C6#B[:_9"IX!
M(WPXT]-[+$VA1:[],>5!VH)-X]-/^<U\8WBG:1K?)M>*Z-5'B3]V*@5CK)TU
M_!75?V7`&<NAH&]@&FM.]([%T5HQ4*++QG'<`WKF%NMS/_%)+FB#R+<;L,6G
M`66N)S'SG26!8IX)>[9##8,U!<H8$(IM:&)X\NM\HL(DG)KBLG;4=<XBW30A
M--$$X<8RGQ^I/;N$?7#T/(IG>J(FCY8_ISI-2S+%5-04TZ(309]+3`1%EN89
M^9K/U*+E?Q[.&/C]C;/%W0KG81B+/Z%A-K-<^/<+!;4-*M#OY.=7CH*NQ)D:
M^,J,"EY4EG74<)MHJG1YQ%>`7K%5K*NXC!K'7?'R67[O#LJM+Y6;5&Y2N27?
M,2U1N05L[;?/B#I",D=`F'G82_.^I>J+H%B]E[Q])Y?7;'`RJ$5LIL#:Z+$&
M]T%G%5]?.L$P9X<[Y;JML9XL(.<-W60#H]"7]@SL'P@+"^\/F@_R#B?8YH6U
M"PQN<FU=,>!Z1S$4.VA3&]P#:M>Q3),:L<X,K@V>9?P+EEC#)ASRX0?I6-O*
MZES>!"ICR'9BX?8R7(:3L]:5'@MO!6RAV=/&P#7KG_&HO.WOW@YJ80$47'>R
MG>XO5-TOZR,A=7\INE\O4?=S+@;)\[;K`"*IZ2L_@0CZRW-?5H]MZ;)CAF$?
MCQG\S7_$*T_0!,"&8:Q+,CJZJJT_^3W?/2<,10<3>MZ#HL%7OW&]1B?49A%U
MY2UKI$^XRJB-%6_?%K9K"X>U\L$[E%T3M+C/:H7/&A[#V_#&==.'V,"C(%X?
MU4%24^%G"/"8J#^;H;SZ'198"^`GUI*--Q#F$SM9A[C8*@.[2@U-AQ<P8FBR
M.W$X#%0A?FMBG-&$U9-L<]AM8"G13%3Z9R)^U)ZW=W?(S+)Q2_ZD!FOY;K*C
M&WXJ8%,@FO]FA=\%:QIP<-R(@SB#>0/$?;6:CDOGO+&8PD>1AL=(C-I\LB1>
MT(.<[3N+R$0CQ/A<`/8DQJ5!>VL^XC5^`_SQ)Y"HW]@L=D+&OT>)P,F=NIYM
MDJ=HBC<RA3^9]95B?@;CJ7"(&$7J14H-3A2#8:XK2!%^;R!+8V?SB.A]6>)2
M=<K]@1D@UO4;&R9@"?C/`5PK3$K@PSQ-QT[>S$=AE<?4L0PO>#3N06#&`]:!
M#WB#$WCB,W\_[`1PK1.,`G&PC:,61VZP)<%ZGJA))WHX*Y7-F,5QNQG<R&`?
MM+\G/_@%VMC_'"24[OP8HB?!H'QN&[A0K.0:1[*ZG'Q:9,RD6M@2O=?A@Q."
M0[A>HMLC#E`PV61<E/<(>TSVHF)81E\U]EN6.2$+7>VP3SV.I46(<1#Y!8A7
MW64CR;?W5T[K[:\4,`Y,^BL"^RLB]'K991CKOTOT@Q("@DE=E4D(8H.($,8Q
M*N40XB#LL2^Q/J^.:WNQIFESRZ5LV`EH8L=[^G<PSC30HSQDN9P:>/80:/^Y
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M+-'8_Y)(L)YDF8K"F/P%>_%5:=>\`<E0L)G[&O5-#@\#X.\H`[[*H:)R0U,;
MFJI5<%9Z68V%%)!$Q_-.9_!]$ECRX0+>^V3K*`D5TVFN%(=14^X4BL.:+/09
MPJS21G0F9U.5PB)18;*#J.#[N?*.7S;XR<`;C_[RI-)818;&1P.QGIU17_!D
M*V]F&\:(O,X6W49F6MJVNU)L/+QP[JG]@#E!^Z>DC$2UZD1/2I6VG[3]MEV[
M4:+M]UEQ=)5G].F&AT$?+%W#G$.>3BB,X7<LL=YVZ^SL;.\`"]]6[(V=W$[6
M`)MW8XLEF$0GW&C_85GK,R6FQPY909_>8=@-YY*Q1X"*]5PLIF5'S1KH7?@/
MQ9/\=ZK8+7*924>%OYC,#<_A1(PGS&%4.V83+3PO5O>:\6A<'#ZYL2QKJ,N*
MDP-ERV!EZK9U4G?R.1Q&^&+9X4:RT>JPUT$"001ED$F0*NIM8#I2@C1X2#%>
MV$O?6&:XQF?Z\9)BWF`^EMD1R-8,AG1TENS$[-P@I0KG[@'Q-@-JKK,!N\86
M39NN[)K/*!\N8OGH=PSM8U.[9O%-0`E6(.\>I#P3U9Q=WZ:CAITYI(4LJH5<
MK!T[*]&.C8URQ=PNQP79TN1V1KRP161S-J'[^@>APPL:7I.2.$M3OY=1P=(T
M\,X(#+JXXB%-\H`/(?$O3_A88+S\Y$<>0;71RK3]]/#X6%]>R,726\-CS(Q"
MJ\@DCF;-1%$O#@W:(LQF\"'R2]&(\LKF%L\4C87&PFHLWZN#M[L63OOVEQRM
ME76A,3%HAK?Y[R6++5?P>O<]^ZV^$:_AG7#ILXUCRGD^N6+ZYE)S;NLHH,G,
MTC!Y`/<KT<_%/ZAECT1'(=96AIE"(9;"B3P,!D=G^:'V"[;E`XM*MS0G&'H<
MI1<L'7^<\$*`'*CA-\SAF?QKBMD.C(>2P!ZEZ'"H/S<;Z>&SH8#H>%"GED&=
MYF_4=MDT\,37P/Q9!!YD1<>8R*\-02X&&L0N"UPT!>X$9R;.&9F/#'E6B;G'
MBN-XL^`)+-D9?6MJ6*]K9H@>V"8>*.WJF\)_%=0U`(!8DJ"1=YT:VB(-Z,N]
MB-0CFXP4:?:#8X2'TCHA1R.Y.]6!QFU6SH#/L756*\$ZPK''A@XRGDWRUF;A
M:^;,4762]4)XCAD]U.!]V>:*[I]]!3=SO1<<>EI8M4R9`S)'EQ%5'3P]?8NO
M-?@ZI.0_)NXA_[0P6(-E(?MQS$,0R8D;'SS0"#8(ZT#GV@H/(YGD=OQP.?Y?
M)+Q_>$#+//KD>-AC6$?[ZC\>$^>H!F@X:C#U8'9P[YEA25*+7/+C4=V,/2G&
MB&"F*4P+Q1[&JXQ"5G\)L1'607%.Q:A4R.J./H-7VI$)^8%KM-CMDHN.B8M8
MZ=`$1VCK.$8-J\'0F-Y?!]G9#UY0/%PS`9_\WGH`O6$S'^R=/%DHWIF'%SL(
M0+I>UZVB9CLE"71#(XGEK.Q%EH$C'18P<VN?N=E^N00[5N*UT;YC'598Q]?A
MMWGE)O]Y]/&#D[INYF%YI<LZK[EA]S9\'J:UX[.Y_\MKP/$U013@0](0H[:J
M.]P,FUN.VPQNY]?/`N8(A/X3G2HONF7S<(HO])F3CYUD84F&8T4UZT$!["1>
MFPT@SG'1X;N9$@+V->!Q+N\Q"S>Q;X-NNS;U6\N!OQ-I,E"3K-*4.`J6%"/G
M^XUE+28+X&+;>D),8>JXX3G,P#0C5(9+",!BW5S9Z^,]@AM8PHM+>:(\&0F4
M,(N,Q+:6O@',9J!2?8WZ<'6!JGXR@?T[<;#NF75\/8G[?PLTT"+C>&5#O/2&
M-0_&+S(>UL`PD[E`57`1GD"9K$B8AA6ZP=FJ;T>DB`;7Q0Y2_;H/;`VD3BF/
ME_C^I4]703*]AUV+D#(Y3-@LR;]TC5C=1$X5=L:1/)>HSR':#J=BB1:\2_OV
M7@71QM_98.L;G&L='YC]%<O:'W%!>V2/==JB'K<5-SF^7+5:1/>E8K*GY&1W
M8?983G:7D]WE9/>:3DZ2D]W+(`V!24&0"6URLKN<>"DGNXN%'3G9_9`EKISL
M7@%JZBB-:S#S4$YVEX0@DFR5D]VEG7L8QHJ<["X)0V1)*R>[2VOVT(P8.=E=
MTL4ZD5OY9'?QDQYRSUC8+!7BP3\HOM%->D]M/#10_'Z28;;#V+DSHRR';T'T
M(WS&;ZRNW',P:6/IBSZ_/[[/Z?A-=U)I$IT3XH$"8J^:@QHZ(1I`!0SAX$')
MIW:KUUN'G6P@"D-`Y*+DA(+N.A1T!H*A@-L..8'?6P=^^W0_\(.$HIM@$L(7
MR_X]F(/`Y@;X4Q`N<`X>FY.W#/1>:NW]V-I_?[B,+[W9@[5'V4R;OKR`1:<S
MDP:%+9KMTM>PUYD#>W1O4RQ7\<?(.9>ZHQH65HKNDUM5S/"%1!J&:E#%YIII
M8<9J/-LGKDEVK,O?X*1;ZVMM=91._0B^#4RJL$F`GC`8,H8?1O?P1\5S4X)$
MFY2AQA\:/YU)+2K(_DBOBG<]T,T3K`MD:1[8<"`\&5][&IY1*/^1)/KZ!1;4
M0N)+/!O+09G]'.C>O!*];N\>KTCOO,GT>2+K,OF^';(;2MGS8C>YSCM+OEY=
M7%W_<_SYYNJ!C&\OR?W7J_OQ]26Y^G_W5[</5P\[;_DRTSAA6!?7F4241+>L
M-+5`]OAWCX9;9JJ)F6GF,G2:@$X[]_.9>);1:3?IS>WMQ@L!X0IW=2<`"\HB
M*VN3N[UX+ME@`1^9C;Z.>^_W#_\*@0S)ZK5B]9U#V-ND0,5IHM-9GF6*G]&1
MJA%EY)0G)PDG#\+9)8_C@$2*U"!'M=UB`;@S6Q\[_.T#08"D<$GADL)+5]D;
M'M6O1L7&V5%K49&EL'_%HEZ35Q-[[M3B\V"*2TO("=9MTQ+VINM<P2L\-PD_
M?[<#E/MDW50&>H8(.RLP:UQ2<"')4X=+P>M!SZ#@;H&I8>)3L""J-S\K)$OU
M^HD-09OFRI1N8;F`)03.<D5`*6JY8(04)_\*Q%*&_.N,.I(?ZL8/`B)$0'[8
MR1ZHS*`5@1L$,0>*]<3%,>[%X'-Q?!<1SA-W::PA*CKRCCE*XB_!>Y7$GP\Z
M)/&+K>2+]?FKWVH1[+FUQGP/.$FS/-8Y4ASWIL@H_):($-"MV<G-[PYW22B3
MC%`_/_]X&&&W>/_9,?-!H;7>415+_/7%=<NO8=WXMA67Z1K3I76U^51K#F6U
MYO%4:VY<OK>L!7^!=9I]6:>Y4YVFH'MZ__7N'I3<OUAUYM7__GY]_]O5[6.#
MW%X][KS-:VLS<]4^9&&=-9QT+^M)*Z\GW<V[$[0:H([G]KM#F_^L`?$+1*O<
MX2HK>22;'A^;'DPQ9RW.68^9',HMT:RW#!<C(V&KLZ<+RW$7QZ\=T0FC".")
M(..*.TZ7N2-'3=R'G2LB<T.$.!_*6U\G8Z6=GC#GY=DZO-S)0>(?'98`GE")
M(H(??N]6[''4A]\B4G#]RS5+3M^H>H>E=BZY:#=+.Y<[>TI\LTW$T$GIX!Y*
M1?I.T6))RI*4Q2/E9M5;+;5UR39;EK:N:GZ9^`:=K#[/"2&'XM[TCMJ_D>P@
MV4$,^T$$;CC*LW-QO`0Q^%Z\[3S,,T?9G$$2_]$>N,OF#,(0OR!*O]S#]NJW
M7@1[KY[>CX"YXP)Z/SN=UI\.)#O4C1T$1(B`[""/_FMJ%Y0;#!BKJC?S#,6E
M&M'HW*:JKN`P:YE<+^CN2O=(Q@:.COAE;$#&!FIO`\CD_%J;A[4,!=4G:ZI<
MO_^H6]"+2,DBY?^)`6\&U?[MQZKW5>IF`7QVF9HOOL=R0)JYW'&'E8U*DI0L
M"+@"4G*],NM$H&2!E76YCK3,S#^LTT=Y&']XJE]R@]!N>^VYH5[F@PC<<)1G
M\>(X"6+PO7C;*<\?Y>'[T1&_/'R7A^_'I/3+C0]<!DEW5".JY<B(P"J37\P1
M<G*68OYY^6W)![7C`SE*42;D%V4/E#1),?HC.>-J__=M/#?,'].T='Q8;N.V
M_O9C;!\V_/05K16'FB[F!1)E9GFP&,-ZI39QI_#-=\FMS6VMG1;;G<00LZ6#
M*H]S;)AP])5$7Q99I3<N!RPD``;E$)][AM?RRU;/U<Q$S66L.&:!RA*X[W0&
MWZ=D[;:HH_ZX4C*QD+$H>:>*[1!J:N`E!".K2*_3(#CYAOV[QPX6X4.7`#=2
M\EV>>SE([&4#5(SC+-E>7PSD^/+.(KOD]6A$6:YK;2<1%:$%I.:<JJ[^0HWW
M#%F6I8.8AA=RSNXNHW(W'K.[SW#=42'#=6LVX#(O4;KK',H*7RU'8,K9>D(<
M0LL1F'7983D"\P`VL49L*D=@EGEN>,SD($=@'G2VD!R!*0!X(L@X.0)3$G>A
MX!TI<<M$GSHF^M2J.$AVV:@`/*'R>P1/6I`C,`^"@N4(3)EV<PC:68[`/%#)
M)KL3R!&8U>^M).5:DK)LM"&FMB[.9I.--F1K`=E:8&>!*4=@2G:0[%"]_2`"
M-QSEV;DX7H(8?"_>=A[FF:/LM"&)_V@/W&6G#6&(7Q"E7^YA>_5;+X*]5T_O
M1\#<<0&]'SD"\TC804"$",@.\NB_IG:!'(%9N84H\NY*]TC&!HZ.^&5L0,8&
M:F\#R.3\6IN'M0P%U2=KJER_7X[`%(R21<K_$P->.0*S/KI9CL`4C\'%<-=%
MD&=R!*:D9)F9+S/SI;*6(S`%LN?J>?HH#^,/3_5+;A#:;:\]-]3+?!"!&X[R
M+%X<)T$,OA=O.^7YHSQ\/SKBEX?O\O#]F)1^N?$!.0*S]J/_Y`A,.0)3\H$<
M@2D3\N4(S!J-*#S8$9B'-E!N^S%RO]J6XR1'R(V=.S,<'=?[%N1WAK?\QL8@
M>0X^>.ES/[\_OL_I^$UW4K/GSDZ(9^K\5;\_7)X0#6Q:H'#GEY-F[^13%T3D
M!H"R9><(9)0HDP^8W?9J,*N`D9\OY@1?1SCX4@OL"DAG_9R9J=M;#63GK!HH
M<^>F_AHX^]7`F2M'#5;#V*N&8E.+/%V]R-/!'HN,%1C&IPC#9X/B!WC`>&;9
MKOY?]OW2AY<KZ(<;"\*\X*L$;[F2^N@X<):SL%]C.1T&UO)6D;TUAEBSEY!8
MM<9<WK*MM\;(:W8.!W=YRK?>&MNS8+Q9]MP\_TI5JK^@Z^C`-?<VG2NZ=O4V
MIZ9#G=C<<;QBCU'BO5XAH\1S"*+(L=RU'<N]6WBQ3D.`<X2PKJ-@"]ID\:=X
M"[?W58[VEJQ^K*PNXBCH<B>#[T<9QS`NO#:$4^X,<>%$BM0@1[7=8@&X,UL?
M._QY9Y=*"A=MAX\=?DGAHF=0;YQ,OE/&]*_6"[5-%OM5/'=JV;JK4Z>J1#D1
M$N=%K!JI_]SP<ON>G%76DDQ2\*'.#2^WWTGWM.HM%B5968#BI6)4KW_B2*A_
MY%C5AHN0G5[/A@T"AJ`%K-78K7W)2#8PJ1T_"(@0`?EAMT&[Q\P-@I@#Q7KB
MXACW8O"Y.+Z+".>)`O5LD`U+CHGX9<,2V;#DF)1\L3Y_]5LM@CU7TY8,LC5)
M[FY^=[A+0IEDA/KY^<?#"+O%^\^.F0\J;4ZR[`^&=R&;7.Q>OI0N'(L]Y):Z
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M[=WC%1F<-Q-4Q/Y(/F=%QZ:-[*I2-K[8G:[C]MX]_OWJ*QE?7``:'Q\`P'^-
M/]]<Y;/9RZRHK"9DA<J[XIXL2X]EZ?&&SI$0$!Y46=G^FRQ+CRL(BPN!#,GJ
MM6)U$2M(9>FQ)!Q9>BPUB-0@-0)0%F;*PDQ)X9+")877,!>JW(F-5[.Y8;U3
MZK"ISG/EW;8,@RAXAJ08LB2Y;EM\N`6=NV4Z]095[[$D84G">Y&PK$FN7B<7
MEY^9I9/]#`Y9H[Q'A$WP;9<UF;O*PZ$<K"CY0?)#B*:!S&&NWCZ01<K'[<S(
M.DU9I"R)7Q*_)/X#5O+YG5&(J>1%L.=J6ILIBY3S[R9Z5EGH7C*"9`1Q&&%T
MU'P@2I$R0[60=<E[5H*F"TH?U"G5/(/>339YX-YS&L_DG$99+"5N9I',?ZU5
M(OS^FRR+I2IPSX5`AF3U6K&ZB#4OLEA*$HXLEI(:1&J0&@$H2TED*8FD<$GA
MDL)K>"8KBZ7$.**OY1;+2I.D'R*+I20)UYR$9;%4]3JYN.-Q62PEBT-D<<@6
M\E`62TE^D/P0H4D62PE@'\ABJ>-V9F2]B*P7D<0OB5\2_P$K^?S.*,14\B+8
M<[)&9%]$'(I?(XNE)"-(1GB6Q5+5%DL5,H)HZ2O9A@I=DK5/+56Z+BO(/?A*
M#<5-W+?U:,1^>ZL!DFO?G.=24_5A_<Z:I?8&^ZUU<1NV1V=W]1H'9XDE+GUC
M'DM+HZ^W>FE#W.E=UG9MJM:,/BION<R6[/<+J0+,J(?SA]JA7%Z8`XDJQ]`V
M>,5'XC\L'-2WW>3(#/\LK202D_:RM98_32\UZ'%!=;#1AJ?^:,/M]&)\7E_\
MD=>W%W>_79''\?^[>JA.'WU,5$4VNZ-6;X#[FJ(<]M_1H-5F/VY*1=DS"Y=K
MX:U);5<J*XRT%JEH.9&$UW:S*$YIY4AK(&*(H;PZ1)G/#5UE:'8MXDXIN;!F
M<\5\/]^)!,.M+(0:68UNH@(7"1'^VVEU\*?]R#`?2RME@7*3E^,?D,X0K3,I
M3ZP)N79LA1HZB';$.>@%HCO$\9[^3567[0=LD^*R;;%!\28,.+P_;^LPKV>1
M[F#1V`S^^!X00$!;=5FZ)RO3R7N6YXI-P'<J#)N`P"1"\\7`:6N0"7:?+:$$
M0"<NM5\56W,2RUB4(CEP:?7*04ZB+G42]>81DG)1T2T1%=W^NO8465.;]Q:U
M&;R>^;R40'IJ+9?(.P:_Y-CM7&R''3?TEKK$FE/09""O"#B+#KQ$56S[G4PL
M)OC/=]SQ8OV+#)P&NJ(4W)*42EF*DH)@9;9J*9`^1M8\F2H.5M1X,X]%<`)Z
M`4IA1N;<L^<6?@&7@5V9V8Z#&R\`!9JCR@P#;WCM=WF:3:>C?F)3&N1UJJM3
M,E/>R1-EY*W#ZGT"9Y:4-9DXP`K*LZ*;CHO0Q(UL?[D3S_5LRL!53/A2HQ/=
MU,$&!`;2+2U#-I9`"?E3?23/'->VS.<,"RKVPTJ8I74EK2MI76VJC%5I71V6
M=75))]2V0=7X>@34"G7R-J@BR5SCN%DFIHA-)P8+8H'R-2E3RX1.)O`5,S!<
M.IM;M@*VJJ;#MT"?*MST1-U72KG&9I8L6K;<TF!W*6"SN+Q*V(C.4IA6!W6N
MF*JN&/!F>#*SB2.C!FZ(C!:'>`ZW(6)+#B]N%7;B2AX`=_I$5Q5VU@0(,*D/
M6"SN^L$A6H!1%O[S80;K14%0#<-Z=1:#L\623)EAG;P@*:+3H\\O0:/'GFST
MN$7OGL%(]GT0O(G7_ILL&SUNO?<'V*9+LKKPK"YBOS[9Z%$2CFST*#6(U"`U
M`E"VP9-M\"2%2PJ7%%[#>M+\FD9D*>R[1'I",CEAA^T_F&)B$<`[G!YX.8":
M(:@ZHX[P>UAO$A6JL/,@2/94]FFL7J7F5[&:I5*_4H<JMCIE9YH:?:&&-9]A
M\9ILU'BDX!5?8YX#S%G-%;J[1.T.?#.K[9P@:7=33=OO5KVY4M,6[+Q>.XZG
MF"JM7+.*8%N)`%[I\<:Z^@&G0^FZ'H#K>I2TNTM#A8.A7$'T:K$>[)T[I?8Q
M6T]"M$^O(P)JZRU4%I:K\VX?/0+J2NZ[9/$=S&8+HL*+,U1S3\PZ&.M-!/!$
MR$Z5_=!%H89Z$[L<!B")7TSB%T3)[YV1OY62QWXSBY6IY(E.+)MBV;>GN+IE
M$@4K5#%P?LQFH`C@'5#,L3A*S_37&\.SRB+H1T*]QQQ!+Y>:>QUY5EV]KB[7
M(?^G.-I8!'NMTA"D6.?;N84@A:#]+'GW`U/?/TIZKYC>Q=3P1T#_H/"/FOH%
MT?CE>N?B6/9B"+[JW>[#BD+N3<V'%84\$F*7(7A)_&(2OR!*OERW/CL$?\RV
M7K4C2H4HMA9F)&FY;LY1)PJ+0?9"%7!+-C@^-JAZ,._^+TE-6QR<MH;+ABT&
MO^$3-IZI64'SY6IGGI#?%%-YIJPD7N5#5@T<'6+H]`4>Y4X5>)6.97UN>CH*
MF>J.:]GOV)#;'X^BNSB0;X8)#H;^)X4GP0-,>)_+GX3/2!AD-GU6;.SFS'Y:
M['K#)Y9@!<22%NBONF&PYS]1>!@@[+^LLSH?8@+K<"AE3:KY0)-JYI:4N)M)
M^.0L.#FM1$XKV7^X1=:\(SFM9(<-%&5:R:T5#L1@JH9XH$QL5T'%@;,M+$?'
M;`!0+PJ.YE!1[FFI65\D'/$5C&7=E4HV&PZ\>K8SMW(*&N>\3)H'J]EPMG."
M!YII>W_1XHY(=>%B7VB==N=NDGH7KLQ86X+K4C>LHVK^$7V/Z1*#=SW[YP)Z
M9U0UZ#2O`=L;HKG@8=-@,,Y0`""[FRJ(!C!*=3`Z$U-V'%=Q/6;T,NN53T5.
MF,;![!P^O$=_H=&5NL,G4\,+GDTF8/#FC$Q@A[!U.'.<"`27Q$UF^%'SPN'C
MH=QRWX.%<"M8"1[O>.HT?$!")O&GK=[$%1YC<$\DFV+FH;]-3&Z<<VN27=,T
ME'?+<\\G^AO5/FXT1SXR'#E5I4RHV"J3B_SY)\]I/BO*_/R:32UZ5-XN=4<%
M'P,<@4?ZYGXV+/7/3W_]RU__0LC/P;4/ZI1JGD'O)L&<)KAOS&8*C4WM)IJB
M](CO"1]#@&9<^.,KG?QR<M_N?(/_HVYXM#K=;SW^^83H&E"N`E2A?>OV!R>?
M4O2?\F(W%^ID'3OM[F(7/-=(CGB2(Y[DB*?\SBN%@/"@QG?LO\ERQ%,%I]5"
M($.R>JU87<1)/7+$DR0<.>)):A"I06H$H!R`(P?@2`J7%"XIO,8IRONC0HYX
MVI>Z!=O08Y^7(T<\U:XLXMA)5HYX$D"EYE<`)4<\B2.TQ`6OKIV`Y8@GX0IT
M)>W*$4\UTK1RQ-,A2"NQ6F`=@A\@1SP=A.MZE+0K2U:KUZO%>K!RQ).<>9-[
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M`UTZV/7O$\YLB0#:?"6YP]"+P=!+P3"L"0RK>K6/5L#08S"<Y@)$V!WHQG*<
M"^P-Y+<&2BUZ[-R92Q=[%EOL[P^7\;4V8;&G(Y`T[6BUR]^YT!O?!?J?6@:P
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M;,JMP^;]*?`J>*!N@64]QRFQ8*]J9*J\@+^*L[YLZMJ6PHQXXYTH&B(``\P6
M_#(Q<"P7SB?2@WXHEDG^H9@>KKM[ZD\%M";DM#48-%VK:9GH!IN>XT-%?J!@
M/@.S8I<R>*9"AG@E+*S9@96B!>W,P?G\<7$X5UZ83R#^P-A)6E#2@I(6U,XR
M^4E:4.):4`],`ZK*7'=SL:.2,V9KI@-P9F?*8,#0TP0L!6]N,2-`MXD?L>+#
M,?&,`U4N$)6KJ_H<YW*B*?%BX8!.DSQS"Y4_+;AS1BD&R-)S"?FL3\NW2ORA
M\YKNN+;^Y`7S-P&END9-#0#1)W#'>P/C<8:"Y]5/[_''I93]BNF_4J=)G29U
MVC9B4Y4Z35R=%K259/*5"5-A`@1I_HZ)Y:Q/&QPZ;*KP#FM0>Z=]BD<X1SFI
MO=NK&O1.B9/:[V*AD"X+A73)#SIP-XOC$$UY_[&1,*(PB`*V4*X29=@8##J-
M?G>8#'.D;440<&`N.F"?V>&\=&XS@GQF]?MK9MQO,!X]+TFT\W'HX@3E34,G
M4G9)V56Y[.J6*+NN3?*%/ME<>('@2@HJ-FF+19<Q9&O"?U^HX[))$\JS35ET
MN4$45;50S#RC9_@ZU=5IX=*N/^PTSD[[25EW;P=9T>-5XNZ[/%?2';03BV@1
MP"AR.+ZM@>\?>\^P-1G(+0(O9_U&[ZRW(UH2,C*W)2T@Z#%^C!"T52?*S/),
M_\`AUQT:)%\O_-%;I]-K]4L[*Y`*3RJ\RA5>KUR%]P_/I"B/>ZN4G1_BG'NV
M.E4<&NF[#'67>$[$>;Z`5^`Z5S%0QN8J6+N-3J_=Z`S.MK?X\U6!C78WJ8F9
MWG-?+4+_XP'@NND`_`8_BH9?$/4LD!QZ3>U.7PKF,G,B>@.ADB+N;=VRD9V0
MCS"U%KG+/WE8SH=/U@L_R5#`?$`BYU87/D=WD[RML/QD9$83B5)WWPGPAFM[
MJNO9\+(&\4Q@D("=,5<B>?#QP8G944%*P^#TM-$;##,LK!_)*\5#*PL,9ML-
MA$J:-14`@G3..X1Q9LI,&B-0<)5GN`Q(V#<N>9C=]*J[4S)^N"##SJC9;3=[
M@^9I$F2;XL7P:A6^`!N+,[]O;P5'-]SJRETD=$8I&Y3M$M%PY[3P?"AC$;E*
MR.YI<A'^Z]ZI8H.P1]1<4I7.GF#?>QT6M\E01%*\;"U>VGO+%GG^%QU>^0EL
MY9Q=@1TLS_\.X_RO+\__A#W_NXM%W?SDR1)."$;=QJ"WYGP`\T1L_05S1.:&
MHG)+BX?]++L$9Z+?Z)V.4LZ$2=TM:+E85R&#6@+-77+J<*$G+D<#W6C0:@]*
M@2YIF"7RD(M^R>H0H#2MI&DE3:NMCC2D:;5H6OEVC7_<-<BR:C`285`6AB&.
MIZK4<2:>0:[O[W(/CO8:W7:[T6XG#Y^R(S"\E";W&$BGE7Y[5,_#<VXQPQ:M
M&UB!I5*J.;DOHM=I]-O)$[`&428N+$2CFJ>R%;#0UZNMLS\TW5$Q'..PF`WL
MV`QL4=9#`/^V<&SCXNE=2X16'4MY/V<=NYKU<[995F7C2:TN$Z:E5L^-L36I
MU84-F/`SPVO0.286J/HELABB,&M6$91S:?*U&1UB+!YI*YX[M6S]OYA6,[4M
M[WE*=-#L#)EZ%C+)#WC[";O@'OX^^9$][QGHD1W0^*7)&":R)A,PFVQ8G:;;
M5,7P$)@6VHONL$^P?.79/Z@+#8<_Z3NA8`-:[Q2,!I8)%#R1O2(H2%;P3SR@
MP;@36B6.W[D*U^#7*QGO9&)Y-CO.<?S:Z#FLA+C4#+YDADX$@*:X&=FM^6>J
M\O^V>CN=YFR2LUHK$BW6^BJD.GP,[LELAG["PBEP0*^L4A[/D7_`XOJ0J!DA
MA@SQHW^LC(\(>0K,9SRQGE@XE,4YK^[$T8]]B7_BR#-^;E@^TR)H,?-VR>%A
M6D>?T:=3\%[:4>_EI+9>_'U!YW'>&,7>/^I^'SX'U/C-^/X!@%!AEY6Y0\'U
M_.?5UR\W=W^<$Q"1.FM%F5#92Q<5*._T!>OM];1$267;;=,G667941OTBTQO
M:$X=,(>Q5I&]0<[]L'<';G]@RA]G(M)6]F$KD4>`BH%0SQ90\2_0XQ$Z6-)&
M]&=@^$3?]#J-H]G^_7N?5PFWY.&Z\?`VTPOBR.EVXRS>7\`4AHG%W.]=(9;D
ML!\Y],0D!RG#I0P_4J;-ZCE_ZR5M+VN"/S[9/[$+?3=93"*0@KT(Y'3B@KV[
M@*D_*#8B`OL]1B7*"[659QK_*FAP&/^.'="*24J25J0\D?)$RA.!Y4F51N9^
MPS/K8'D6!&'>(Q"K`C!/#5%+!,@=EO!+"J\U@'*'Y0Y+^"6%EVUV;SBA<34J
M\IM.FV5TWWFNXRHFZX:BN.2)/NNFZ3=OP!RL'4B@7*A+G\R^S\C1S6`N9^1H
MO]UK=#IMN<&%@B?4<-U#).-V"QZ^R_GS@5/QH>QOKW/6&/0Z<H.EF*HS&4LQ
M)8@YO9]GL<Z<_I47052USQL#5XJTVNYDJSA.#[!2DL(:M1O=;E>2P/8DD"L"
M2E%IDB<VXHFS5K<R"Z[.#'$H^S_J-0;#,TD!4B1*EA#"(1"!)01Q"(J-KXOC
MXHLA_39DY3+]^&W.SM9QM=QNT0-6.^^V)'Y)_'*[Y79+62>)7R3JD"9\P3']
M5(H,SKVH.#E&!.]MK?_>`\[2+(_U23E$!WXXZC5Z/1GGWX4&CC>J=>A<T6_U
MAY(ECID`JDTKK#4-U$\L;IK2<Z3,((/\@G@(,L@O`U\+OG]<^DCG7T3P*MAN
M2?Z2_.5^R_V6XDZ2OVCT(0WY@D/]_Z0.GS'.9A'P@>.NQ888'+,3=_1^O(SU
MRZ"69`89XI<$($/\4AI*9I`A?O$\`QGBES$OZ?3+F)>,>4GRE_LM]UM,\*2X
MJQP?DOS%-N2+\]\RL_O]<;#^F`$V=51QV<!7/],?/\IL_R-W\_O=L\9@)%M8
MR)B79(:/G59OEQ%_DA,.A@!Z_49O*$\`I#24S"!/`!*.PT\NFM#Q!P6@7]Q<
MC;^>`XJG20#3\*4@88M:>/W^S_W([\,]GT:`)V&,_S&Q3#=X96)_/J1>]*'Q
MP:&V/OFPL"D1*/BPX(]"'IP7DGX;?_WU&J@'/L,_/AORW]*$V>!?-,@#+O*$
M*(;^;/YR@E0>KL]Q;<M\SB"MV`\%;#7CNNO;RRM<>UL''@KATDV$B_VWT^KH
MY@X0_MMS7'WR?I+WAHX==#\OJ4IQL"+I=1H$9VTWF$?ZZD_/:_HC\XA-9XK.
M1C>H\'Y;45U/,8A+[5G@Q%KQ0G:6XA:ZO$G:\6<U$MTA@]8I<WX==D>WU>-_
MY<L2N#CE^=FFSPIFW.FP?-UT=)6\*(9']UG^=WDS6%[/ZC9.3_L+HB""`0$4
M>/&=X8K%MPA0;I[O6\X%GFE3U7HV]?\"W:C6;$Y-1\'=AS_\G,T0I2*3P\@/
M+6030ZZ\9I$G%!8AUMRI;7G/4T3J,+F--9?$RVT79J($D*@&"#0.R1_7EX]_
MQQ>VOU]$'A@*MD;M7T[`8E*I@6--51!%X=]S1=."OT-K,6XNQJ.K2VUFK:^U
MU5$8WKZY^O(8^S:PBX/+&0(C<[#I&[P@_4U8GDU--[J'/XK=X</9;HT&^&?*
MVN8/C8?74XORKUM8%;L8[CY!N<WVP[7F(3)&R0FP&824-LAV=#O*16&W1!1V
M^^M0F&`FQE#YRRI"6XNR2M!M*G9?EITE//,I`%@Z`(A\T55*YK;UHH/X<,ZK
M\Z22PK<Y.&T-T5%,F?CLO\%O7`(_6896@!@N39VT]U8FN;M3$7]R95>X,_$(
MUM(%&$B*^1[29V`H`YVJU';!?5BD5V:)*JIJ>>R6B66CX>70R,HVV<^VIIAP
MWZON3LGXX8(,VH/FH-T@)U?_\73WO?E9<>#VN?(^`U[%-YJ6V:2SN6&]4^J<
MK!$IQ1-_;$/X;TMW).FJYB954XR20$6QWG%U1)DO`N-H>TPYC-:B:'8CCOC@
M9!&^#5ZI`Q1O&-:K+[>+)-"L;1@-6NW!"EHLA?J*8$0>E+QA$=!%(1XSQ&/V
M<]QJ3UL39_3I%':O';5S3-H5B[\OH)O[':/8^T>][\/G@,%Q,[Y_`"!4(`AE
M[M"/Y.Z?5U^_W-S]<4Y>=$=G`>Z$<;%T48&9D;Y@O6>1#JIMF:RQ7:_]W8>Y
MYA-YC\]Q[?:73%N**%=37+I#&'YW*`LY;2EX?H)(>]HY703_UL,P3X0$:X(_
M/MD_Q4-[<I?KM,L965=7/'9+XWL[MT'_RIVMT<YFR>2KM[ENLQ#LD0KF_;,H
M<YZA7DJ_['5D4?^A\D7F5-=]Q[,4N4@(D3N>^X[G72,I=USP'9=27?C*B>)&
M6F=M?G@DW^4G\CN0P,&4SH@WS;#`\>89RK[;;L#3)05L42PG[OYFJ/9A:SB2
MNWMP0KM[U$*[@K3EXC.*Y6E4C>#\VX\Q2,-/8\,(SRM?J4W)Q#.,=]:%$@_M
M379RR0XR"4;65AV=A\^4>6\R[TWFO>W%K9/6IH)V84-7Z"-!][F\Q+D,_,6M
M#5_V9F;JG.2N2LG#%'#2?(HG*ZW)_-C0HI"5+SOG\A1F*V&2D(,;3OB&8\]G
MTTEDQ^M<VTYT4S%573%@#:!RD2Q8?4DZ/Z@HXV3GZJN24S'W3>LI(BFG\*2:
MG8*:+D.G">BT]SFSC$=H^Y6=PA0`C,`GZPO0YG^RCIUJD*:!:H$P1PNH^!?V
MHPG104V-:OAKD$H1>/G1);U.XV@(H,03>,G%DHMW/T/MQ)F\NX"I'0]5Y'[G
M#&V!^[M+&QVYO_7EYUU&B-1SOZ42%@:8RC)9!&!)84`O'M2\^YI*DBUGWXX(
M5$FB]=RW(P)5DF@^UMN&62(+4!<TTR7+H/M*':K8ZI25N&OTA1K6'"/[.^QR
MN="*FNBT&7A;&X&[@+MIS\J\DO4J`SU#7HT*;,XK*5BTKJN"4_!NW=8+S$N4
M%"PIN'@*;E:]PU42L"#68WZ505G6XZ_4I+9B\/Y(VDPW=<?%PN<7&N21[-*F
MH%S`!:R(R14!I9B:`I<(58:E#(EX.JC,+)7\4.:X@./CAYTLA&Z1$[0E/TA^
MJ!D_%#A;2WQN$,1B+C;>*H[[*X;@$\>[#\#=YM1$A!FCHJ*CHA&CDOC+:HQR
MP,2_-SHD\4OBE\0O(G5("[?@F'#U6RV",U/T:$R!8K\"CL84*>8[[)U*1J@=
M(QS(C%B1@EO=0649#9(1)".(PP@RRAM^SGNZU_IYQH6-,,YL:<,VE#5WB'60
M\M_.4'G.&TZQ:YJ&\FYY[OE$?Z/:Q[4M&\+GV^$G+5Q,_*,=?0SP_?-/GM-\
M5I3Y^8-KJ7].+0/'_?`Q5;>62R]U1S4LQ[/I(WUS/QMPS:>__N6O?R'DY^#&
MZ)*[">L8PZ9;7<3FCXYM6S&?>:.0S^_1-?>\I\SX5;&U\/%L8B_\\95.?CFY
M;W>^P?^Q^/?1ZG2_]?CG$Z)KL&N*ZNK:M^Z@<_(I138[]PHAZ]KQ;$6%6=/D
MVJU>-$QNB^8EB='1)7;&B2W=;P6WP^+CG5?&Q/%F,\5^#V891W.G@D9ON+$O
M0('D!QRQ%@Y&X[GINDU5U[*='XEG`K&R1V#U,+DW%+.$/C1EXJH&76K*&3[5
M/;3A4Z*.,>F)T\M^?V`$KM`O82O[B;XY9QOUS0G_++UKCE#;7^7<&LG#Q\?#
M.\^AZ,99O+\8:BFX:\[N^UUE^>TQDT.A37:$8G\IPX4!1C+M*N1D1`9K//A3
M"O8BD+.FF]8?%$/BR;Z7R@NUE>?$5%%:XTFCDE:D/)'R1,H3L>2)<`-N#\KR
M+`A"P:=95J(A:HD`N<,2?DGAM090[K#<80F_I'!!"RA6HR*_$N$LH_O.<QU7
M,3'C@"@N>:+/NFGB']:$O./9[?8D<##C2@]HPG!6R[=VK]$ILB5&73=8\"'#
M`O1]$XF,VRUX^%%/53[L_>UUSAJ#7D=NL!13=29C*:8$,:?SJT?.,J=_Q2'A
M_$BCBGT6H>:FBK9:FV&E)(4U:C>ZW5WF3AT]">2*@&-O-2<23YRUNI59<'5F
MB$/9_U&O,1@66(EZN!0@1>*!LD2U#H$(+"&(0U!L?%T<%U\,Z;=+Z[&"_?BZ
MM1ZKZW:+$;"J6]\]4=$AB5]NM]QN*>LD\1\Q\0MBPA<;TT^ER%!3JSHY1@3O
MK9+&:B(Y\,-1K]'KR3A_@5T&#S"J=>A<T6_UAY(ECID`JDTKK#4-U$\L"MA\
M521FD$%^03P$&>27@:\%WS\N?:3S+R)X%6RW)'])_G*_Y7Y+<2?)7S3ZD(9\
MP:'^?U+'I1IK`4_?YE3%/UR+O,#7Q^S$';T?+V/],J@EF4&&^"4!R!"_E(:2
M&62(7SS/0(;X9<Q+.OTRYB5C7I+\Y7[+_183/"GN*L>')'^Q#?GB_+?,['Y_
M'*P_9H!-'55<-O#5S_3'CS+;_\C=_'[WK#$8R186,N8EF>%CI]7;9<2?Y(2#
M(8!>O]$;RA,`*0TE,\@3@(3C\).+)G3\00'H%S=7XZ_G@.)I$L`T?"E(V*(6
M7K__<S_R^W#/IQ'@21BS_F#[R=R$)\O6J/W+":#07PK#Y'FGW?[^(V'7-`WE
MW?+<\XG^1K6/)T2E!LY#4W7SF=V'?\\53?/_#I]OAY^T$/SX1SOZ&*#[YY\\
MI_FL*//S2]U1#<OQ;'HW>9@J-OVL.%2[L&9S:CH*NCMCVU;,9SJCINM\?H^N
MN5?>\;OQJV)KC_3-_6Q8ZI^?_OJ7O_Z%D)\+>CQ1+=.%/[[2R2\G]^W.-_@_
MCI1^M#K=;SW^^=NM9=+9W+#>*7UPX2;NM?W&IL=[#BZ+/_1]3L=ONG-"=.V7
MDR^*ZNK:M^Z@>_(I13._C;_^>@U,`70`__C2A=-%FM\:_(L&>:"V/B$G>9)@
M:AG\OZW>W-U\02=$,?1G\Y<3E":%\0H36]>WEU>XJ+8.0BAKZ:-!JSW8:?'_
M]AQ7G[RS]3^"OVW%:N[]R9'DF??6Q80\=,F1X!3S_8-#'&J_Z"HE<]MZT8$C
M'0($1Q2'3"S#L%Z=\R(P$L*OF_R?"/Y,J/"U$Z#TX+T)$?\A];8/C0\.XN?#
M@ESWR2\IE_&YA>X\5R$W3%\MDL(?UY>/?\?+X\J1B\@EEL$9?3J%#6M'S3?\
M*VZNOCQF_KZ`;OBGT^J,8N\?];X/GP.:_V9\_P!`J$`#RMP!Q7<'&O'+S=T?
MY^1%=W1FCB2"B$L7Y5LA"Q>L%><+K+EE:$WXT:`)6R(Q)+Z_I#=V1+F:XM9A
MA&>UW2Y%VM/.Z4'-_)6[G+W+&3'RJQJ/X)4[NTHF7[W-=9O9[$<JF(6;K5SZ
MF.XLLJC_",`B3\#KON-9BEPDA,@=SWW'#W+<NMQQ*=5KG.=2W`"RK,V_I"J+
MEI)N@V!(M:KS"A$2G<2;/5'@,+H,9=]M-^#ID@(.8MA@AFH?MH8CN;L')[2[
M1RVT*SADEN>_F>>_=$)MFVJ/RMO8<:CKW,TIQI#,YQO+<2X4VWZ?6#8^PDF>
M[8Z=.S,\T^VESFCA;\_4^96_/UR>$(VJ.M"I\\M)LW?RJ7-Z"GP6@W'S112S
M_GYJ_?TUZQ]U"EL_?`B^NWK#/::)O3:US]2D$]UULHGAPG+<+39JL!K053#F
ML-"*D9'>]=/5R#@=KMGU,C#RJPT4M<4&#U?#U.MT5\/$WK?WJM*8'JWAK^'9
M&E1OMJQ_*H;'<8^I`XJITBTP=[8GYA9?GN]Z4S@];>^+TQT6?*,K3[JANSIU
M;ND6<N>TL[O<2;XSOR6F\=DM:HG`\S/=9>H:9,(%+`@4!355N#I2]EME5*56
MWBLD0RJO?)=$DLMB=HEJ4,7F-E\L%67Q47&#;5WF1ICOF<AIL3.,[70(0>MK
M;764SF@)O@W\R.!RED`3V=I-WZ]PP3Z#Y=FPX]$]_%'QE)MV:S3`/U/>*7]H
M/'*86E20T9)>%;L8[CXA+W[JBFO-0V2,NNN2WS*2HC*3H=@C'->VS.>EN5$I
M&KB]>[PBP_/F8L)3\CD[!'U*V;%BMZBZ?;F`[V!=5[>/Y.9Z_/GZYOKQ^NJ!
MC&\OP4?^[;?KQ]_@IX>==VV9UQ?ZC(OB@`/K(VJ;;,0@RRS::D33CI(B6$W:
M0T[LUA*:;*:C"XL.?40Z"Q?[LN&T.W>3U+1P9<;:$ER0NF$=E:43JC=DQT!F
MC^;NMF]06CM$1!8(?G-H<E!HJ=@(#\;PM3Q&6:U$=P@UGY5GJA'@5\4D5N`?
M`@&`&T"49YLR!YZ`GTC`0R#69()9L!,@56Y(M-@342*Q;I;@7#CLXJ"@%5^A
MP0O"*%.OP\\&V+][K`TF?.A&S*;,+"_(P?TN3PT_&B4D1"/?I_NG':$%@8#E
M^H)VXOFM8FV?_+*(TT*YD#5_\5PP3LE,-_69-R-S'F)RP%(&6XS1HD_0&3G;
M2Q.;MU<1AYX*/8B]_K1]W)G0N\:\\\^YZP^_WU;/D']AKX&0>)F(COX,9'7T
M#0CM4H_S<S^YWT3W'D^69@>P@ZP*S`3\LM;C2F/JT7(50]*#H,F=A:?]["!O
M#CHKZ%#ASVFRLT1/2OBVCP,_=13%@C6)W4'2@B\].+@,CJ)9I-JLG0*PL6DW
MC=HGIFTO2SN=R@8+U(`_!!&A^2F;W43H:54D4EBGE5J(T-I"?PAMAL26G34@
M#4%D9]7FIU2O^0</)7X.L&AF>_D[.+SD_(,3OY6:KM*$$P/ZG6,`Y<5<Q0H1
ME%K#O*<4[HXJ*WRK`7>M**$J+ETEA\2+]9TZ2WE)XH]"$%:_!^>%_9OKVZMF
M8!`$W)?58W'8;PT/K,7BQK!W6AU,_"T8]'@:XE1Q@K::&GE2S#_)LZ>P/ISP
M0%@5IF_QI$!B32*4Y9I<UQTD*4[!CI^J9^ON>YC..*?V!!&']2_6A*5#IM(D
M6^)LHV@D+(LIA"RFV#&=NEH4=DM$8;>_#H6;LF3^)4OD:8W`$6CS*BU-V7B+
MBA:7EZ!1S&>6_Q[O+TU8B@9+PW<MHA`3'K<^%_^%3G60I)CE[.H&/G38(MMD
M0N>;79\@15X6P%^U2UU`K!R@O`*!E!&0=X%`)V5BE%`@L%]R>X$F2R*KO=D=
MM7JLI[N(#<_3WTNK1EHUTJHIT*I1I553+ZOF1E=1P4<F2@Z%5?GHGBW43*?3
M:_67J`(I\A?D5:=4>=7I%E48+&7^Z@K^I;(B)0-^T'^44CO/-@F;(/UQN0OY
ME3H@FM0I<S.NWE3#<_072@)1/0Z]R5?=G9)_Z8X#WF)XTR5]H88U9Q<$+_"G
M%/^=/MD@;W\WX7&V@_%1`.(?."%+,>B,W+A:JQ%Z>IY#&T2+/0Q7HUJS&<YZ
M`*#_RQK[X*,?QX_-WQX?FN3>MEP*C\1'S/W/-IT;BLK7"W_.=-=2IY:IV?`,
MHND.NIE^);IJF0[.9^(/!E3XH.G8!VHVMQS*YBTKQ-49N@SKE3@@>D&F:_JS
M[A+;>E<,K&PG<+])`?\*^MBX<(4XWI/A8W!"*8"H(`(-`]0OUK^K%+W2*;K?
M6G.J/T^)2]DBW%=8^CM&D+$:@[#&>`%"8\],++Y!GCRW0?2%JQ1;9]ZT;<WX
M3VR!#"A`F.:I<%?J%ERL,U7\A3ZA9^XXN'P3;EI`0;!,?X'/K(M6^!;'`P+Q
M7R2,D[FUXR@5O%3P4L%OI>"EAA=)PYOKM?I790;2'E34(S7(^`46&]/:J*AW
MT-.69X,Z5K2F.[4M#S0<:&87CT67J%^^AM*U+[Z:*>!,Q1;JWS`\#GB`K:-V
M&@!\13Q0;U.5`@K9N31<:E*57<?0'5]@/HJQ/NV`MVL>F&X]&/6E99;<W>0&
MS!-*\VD[V*]9V\$C:;TC.^?(SCE5]T&1G7/J4-PA.^<<)CW(SCFR]<=APB\[
MY\C..;5B'T%JYZHN79:=<V3GG!V0<"35Q[)S3@U$J.R<(RZ)2.AK55)\(+*S
M!J0AB.RLVOR4ZE5VSI&=<V3GG",5O[)SCNAZ6G;.$2]$(#OG'`IWR<XY^77.
MJ4_FU.:Y3VNRIKY2T_7G.__&DW'P&\5P=LB96C-_>]2.3^S==!WI];/+QZ;&
M?_9O6;+8;FRQW=1BU\S'CJTT\XW[+*L76U9ZEO":$=>=?@*)N2]MU?:NF7,]
M&FV_M`=U2C7/H'>3J]G<L-XI?:#VBZ[2[*'B.,M999_N)E^I:CV;^G^I=@^B
MR])PX+BS3\;?62$9?WF7([*,M-3"XG4+FR]R:79QWD*XS/5C-K&#M$.>D'B"
M+A*8@>M32]`;:J*;BHEIR@">XE*>?J@["X/^<D;&SC2U;4&**+F1V9F-G5'L
M[E%OR]3&PE,3=SK/=QDZL0N+O4\652+UYS1I-I:7G%``,)T<8"DH!W`!VOQS
M`'N#>`[@:`$561FB\.N3_1.[LO0<4:$(H,2D/\G%DHMWSS5;D>CK']?L$E*6
M^YTSM`7N;T_N[U'Q<_=H]ELJ86&`R8-IZ\J2PH!>/*CM^L$J]^VX0)4D6L]]
M.R)0)8GF8[UM>**^`'51V9(9!EVB?UFL,\D.NUPNM-OF#^Q-Q+F"5W@)#GXN
M.X&F,M`SY-5HEZB"I.`"MW';JLL#HN"M,VWQ<[_`5%I)P9*"BZ?@9M4[7"4!
M"V(]YICLG6$]_DI-:BL&[QNG86\JQ\4<M9=H&DE5-%!8(FH)\?Y<$5"*J2EP
M]4QE6,J0B*>#RLQ2R0_%U:E*?MC10NAVVI(?)#](?O`1<G;,W""(Q5QLO%4<
M]U<,P2>.=Y]S@>/>V%@ATVJ!CKP/D23QEQ#?D<1?2,VN6-0AB5\2OR3^X[5P
MBXT)5[_5(C@S:SW9'G"29GEL[(`XOGV1:09;(D)`GWZGF.^P5V"O1LD(`@6Y
MCH<1=@OV%MD<3#*"9(2Z,(*,\H:?\YY/NKY]42$MGLIY2P(81BI"=UPJK%7-
M0D^<[.?9;/P@)C-_?H\NN>>#T\:OBJW=S?%"YU>XT'6N3?ZN7]D8W@WZ$'T+
MP7)A4?Q9O[&6`YZ#Z^+?7)L:!:0_6M>.XU';N?J/I[OO_-_C-]U)]M09MF,M
M@UA;%B?>->CZ]LO)IU%O,#R+H3E_Z*M#<*+=4"$([JQ'<&_4[G:[M<+PG><Z
MKF(B`]]ZB*$D?L?.G1GU]2H$K]T-\-HY&_0Z^>%U`>@JL5J,..BMQVJ_W>MT
MV@>*U6)D0'\]5H>C7J^7HPPH'*M7;SA#V$$U7!&M#M9CM=/K]X8YTNH"T%5B
MM1A:/=U``G3/!J,<+8+"L?I/ZKA4&YL:-CE4740&?E6]N!V6+VXWQ86`>U`,
MP8_*%\Y5[4'L!7]0#&[`(EZHK3Q3GP7IO0W^4NFVW%FR;^FW.;6_,4#B.]$_
M^=1NM=OM?B%*<A4^Q-N&0J31J'U@V^!LY2=MOA7EN>>C3E%;DA]NQ-N6PIWZ
M47>3;>F>?#IK=;?Q/RO<E,)%5C$;T=MP(_JM_E!\@;6WV2"4.NE7I$[V0U-M
M-JT8AAI4PE!B;5G,'Q6*H4XK8J@-\2'>-A3#(L,-6:33ZO4$W81-IG%\"UKU
M`%M>1HUZ@A$@,2Q>FZHU`Q3[3?IO_&.U#-2M&5"Q-LR1(W1^*3D`-TX4DN\%
MW]EJ^,[:[6)!3#HD^6_@67LU@/U^N1`6L8EGG=4P=COMHH%,.C`%;&-WS:"8
M7KD0%K*-O=4PG@YV`3(U$^F+YWIV,`[)%]K.I4<O/-N&CZM44VJU_353A3K#
M]HK93&O6L2,4U^;CJX53#YPM`%DS8FI'0**E[`[+U*9T6VC6S*`:]'<$)ES+
MCN!L`<*:>57=T<JI7\L6L,#]:&!-+4,+[:>O(*MLAUM>#W-#=S<1!:FUCTX^
MC0V#W-G@`BCV.Q\<Y#2(Q6VB!H'%^M.$-,556%\8ZIM#9,ZL0]U4#4\+IPHY
M2^8*32R;*/"J.0NM.'`S7`K+U<A4>:'DB5*3V-2U+5P:".%WHF@XYP<N<"WX
M96*`W\+&%NE@1,+S*0'A]P_%]'#=W=,&0?"(-2&GK<&@Z5I-R\14*M-S?*C(
M#Q3P]J(8*#C@F0H9XI6PL&8'5HHCLQQ$XX^MF-!:C_7T1GVE!@`-%J;MOC^"
M\>D@0(#+C,%T.VQ8,2.Z\LIN(PM)=,7ES66,6.*E32P!,C:5*<#($VSC!F@)
M9G.%6:RXA'A.W@:Y=JF"H'0VIFO-U]4%^2.N0D#:K=%`-[<=H'E[]WA%SLYW
MZ=L5G[&UQ1N_7MV,'Z\NR?WXZ^._R.?QS?CVXNJ!C&\OR>/7\>W#^.+Q^N[V
M8=>,T@5R"G)9>?)LUD2PO*=VKICEAK.]<)8;G^^EFYOSXM))=!L!7&06K'QP
M31_\63%02SKD57>GH$"95B)S4$LZ]0?[+<UVSIM-!J>M(4KEK*F'P6^EL`I9
M(AP*PP"7IKG/#CR"T8$Y5KC&VX</1L+T0B^HAK=.XXP*VN1N+SZT:+"`C^I'
M"0JW]U6.-I*L?JRL+N(XLW+'$^Y'&55V.)&$DR*<<N<>"B=2I`8YJNT6"\#Z
M3X&J"'YQ1D-)"I<4+BF\9BI;L`Z]60K[T58T2N;*.XNK_:#]N,.>'TS'NFJ;
MUN2WT8?0I*;<X3V[3.F69"]&(U.QV4`,3&20?.>825X0W9Z?F9.[,WXP+;A$
M`&^5F1Z7*:6!GX_`*A%^(;LL2_*6Y"W)^Q@4=;%.^)T[I3915-7R,!LX],:5
M'\D/3_"/*KWRRMV3`W%':N65=[IRKGGEA"_]\G*)OKH&^B+0_#;I[;E52Y32
MBKF<OLQ"(VE%=<#1Y#R'6=^]1,YWK#JBW>H-:ED>0<JAQJ_);/T/X?#U@\O;
M7RXR909^U1GXNRG_^-E[[N.DR@:FKCF3^=AQ\:WL#>+YCZ,%5&"Q=80.:FI4
MB_ZL/M^^RNVO,C%2\O#Q\?#!Y,87`G%=R4&$[2\WPUUNO^#28)>4HGI*_X,[
MH\G2ZN,9/YQ1IXK]S/JNG)._R7,90<`[S&'6Q8,OY+FS)&YQ-'B%Q"TGLTOB
MEL0MB;N>UFA^J;VYQY@.)CGL*,$K.;=Q/7Q"2B)Q]T\PZ5)S\MPIQ:9&^R?)
M4Y*GP/MW^'9<L5'%H+L^ZQVM1?WU@YP6F?M=.'A;GQWL`NZF^:WE9G$78_QU
M^H.J]_3`2;80M5I3$MU)PYZ=";^%]:90H8H&#H%B>[LDEQP,Q0IB"\J87JV%
MT\[M,6L>XRL`7NFU"@R>#*I(\JR1=*TYN993%2K._DH[L."8H#^/DH4$E<1$
MRB@J&'6&D#T;:UDD7V004;AN$<48G/W3H23\J@F_TL!._0A]M^:D`TGHE1.Z
M4!'-(R'\P5$?)*UHA;*TE\C-]>U5,[2'.X/O4U#OU=$A@"'7+@K-[JC5&RSK
MHS`:M-J#8IJ!Y-;DHOC&+GDA?K%)S7)*3+1Y2,B;9EH4+LP7CI*:%ZX-6DJ<
MMOO;C&/.FCO\D02$/NCAL_RW,DFV\%[_QYNK+^G?UO>;"#@9UIS5;V+#`<:K
M<;@HP=8C<="-(3L;[(RUK<3%&FI+$U"QC%6O)DD;JBI_[WRI)Q$N'RSR@Y76
M#A98UG3TK%4N,U9B&FN%=FLP(/A+KDTR]I[AM0V"E=<-XDXIN;!F<\5\)P[8
M`U0CBDF49YM2EE['QCXK1+5,QS-<Q80;7Z<6T1TP'QR+6"8EUB3^E`\.<::*
M3:>6H5';X<$YHNDV55W+AA=:Q,:^+C:!I2G/["T-,M%-'#/-KK;F%*-XEDE@
MX2^Z2IT6>8PM<ZZ\.^R-T:+8FEG=,:Y&F<]MZTV?*2XUWA?M@V(P^]UZ.MOZ
MH04^94>:/UV4Y)E_$-C#`I$]@Z=.6^32L\'T\"D:";K/"9K];+R3":7D57&(
M;JHV51Q6C)XDE>_$0W%GL`*MX&L!'V&$6Y_-J*8S$F]%;!U#0L`NSS8P"(*>
MY)@GR_00,^Q[H1$R:J]`"```0)F(%!`83%J%@,YF7(SX`NKZ_BXI2`+,($6`
M$8O7*D:-$#-<A1B&"IL^*[;F(-D'LI2`;'S1-0!;X]P3]N,);FU58_FM\.+S
M=Z6'K>%R5[K?ZN?@2F_H,2[XA/MX>IN[:,E.A=)%*S7V42^'YRDOTW8'*/(.
MTSUN:N[R2ZQ7O.+I/;!S==<!F9KHJMHBOS-KEFF+X#E<`P=7!D_C=J^3T,[L
MA=9D`J(Y$M',9C:#KPTT7<C$LF%A<<LFK:)66[I[H2UA41<>2UTTI0OSW_)Z
M5G_YD@M'EZ.CY_1`YR[KC@F_,.>NQXT=GTR)2^T9.%F!)1B1/!A(L7O9K?W6
M\:KM+*+8IQVV5/:B*OO"5;)Z0(ISG-"2X%/[VM.*>9Y<[)`GZKY2:B;4'(OK
M1#HT'B%J$'A:/,*T4XB(ZT=3:D,1M.'*$`9&AOSX3=&H*RH^M"M:SHH*YBC;
M12UV7/]9,MZP;>Q%4)NBA%-U&0J0UL'"2[0#L@[N3/(/#P0J=Q]ZQ1\KQ<^1
M%.U%=RS[?9?CHJ1`@U>6K\V%5.";Z._"PL3%!J#E@^6#\SF6^"EV7,\5^9-E
M@T1BVM5?)%.RYZAC/Q)V3=-0WBW//9_H;U3[N%9+A\^WPT]:N.;X1SOZ&"SR
MYY\\I_FL*/-S?Q+4O6*[[X]@0CH*L]F<2]U1#<OQ;/I(W]S/AJ7^^>FO?_GK
M7PCY.;CU09U2S3/HW6390Q[Q?>']*&9=^.,KG?QR<M_N?(/_HQW[:'6ZWWK\
M\PG1-=@_O%_[U@/]_"FERE*VV.:6$%FG&7>W%',;P_:1(.$U'?V_M*EHJ-$Q
MLF32X'O7IJXZ#:--RZ)4A8[LZK>7F<3]+2W37&`MZ%PFLLL3%OHF\;_/BH'1
M""<X9TV<"90\7TVDS=K0U=EPYMG6#A`:_^>1V[8=/!N(XC4^$D_>WZ2T<FL+
M?ML2D*!>(7`).P$EA-3\!*9TX<M(%6`\&0JH"%C+VK$FB55&$T1.MUUQ,#2,
M;#XKK%+495?N2D(KF]"ZVZYXB[E6@J!,D&6(L'.;CJ22HF&3G2V:8A9*]O;9
M_<JADMC:EP6BBL0@\&L_/_W0;?<;W=ZHT1T,?EQ69[D)FT2UGP'7=UO,NO2-
MV&'_^VVQ".ZSAJD9[\PFWKPQQ>J%=+9>1SZRFJUB16'QSLO;L<IWW:K\*M]P
M://6Z]IE8MTFE%3"!E:^`$E!>&FG;A2TJ>!]G>HNW4?:UDPA5>AX+>KU@P'Q
M8``Y^+T2R"#;%L([=XJGQZK*YY6&UEC4,FP?G2JB(A5)>VZM,;N[C(W.D5SR
M,;4D6>1+%KW36E#%BE-DH1NA"'T"6F*>?FCIM[_?MQ=+V6=22_+V@F0[MG7[
MYI/E6RM7O^R1^CVXQO6(]4-X;LU!-L#[\77X(-^=QHL*<DCZ[PQ*:+0P:I?8
MO&#8WJXAP#'T`,@U\;_$W!EIG*S7/(6KMS*+X@^Y:#TMROO%E3-+H2.%3KV%
M3ID%Q;4K^$U+$C#B<K8*STJIV#S;VBZ4TDU*MP.0;F461-:V8)%+HIADVY7Y
MZU.\M&T%4E#!9-ES<\G-5WP\T/ZE2YWC*EVJIAAIT$OH%-".;/WX7Q`T"%LI
M+7_J$='\FO3T/@2CL+**DDJK4`KHK#@:7*[H\X*%*YP;=G2XR%TQ@R&F?1=M
M#)]^_7\ZK4[LYG754'>@ZK_<W/UQ3D!_Z/#H]3T>?%0E3WEW&PB72+W?:F!(
M&IV;S3P9%CD%N&Q@2AKPTP&>6E<UL16T^0SSB6]E;_!]+/]\M("*?U'%CM"!
M!I,6_1D4<T7?;%[55?_MWW^HH^3ARC>Q1CP<M>K)7-W2G>YTOE]:8H*?MZB4
M*WF_MX&XKN0@PO;ODLHG&,1UW7X1I<$N]33UE/Y',9=Y/.,9U>I4L9]9)/V<
M_$W.7A8$O"J%7/[#Y<L#7\A9\Y*XQ='@%1+WWN!+XA88/$G<DK@/V1J=L/\5
M98U6O]4;PU=/.28N>/D(JASA$U(2B;M_@DF7FI/G>O@D>0H,GB1/29YBVW'%
M1A6_4H<JMCIE^<`:?:&&-6>I>7Z"RQ8-&P[2F"\!O*W/#G8!=]/N`AN*JJ#*
M_RM_^2!(R2M_9S/$5Z<_J'I/#YQD"U&K-271G33LV9GP6UAO"LTGQ4I2;`AK
M;Y?DDH.A6$%L01G3J[5P"L`KQ>(3R$LM`%[IM0H,G@RJ2/*LD72M.;D6`*\D
M7['MP&)C@K]2D]J*P7N/:#/=U!T7^P2\T"@J&+5SW:+1_D&Z!FN3C7OSMQ5-
MV`\QB+@E(@1PB7<R./NG0TGX51-^I8&=^A'Z3KJ_.Y"$7CFA"Q71/!+"'QSU
M0=(&?4[8'T5.=F<O*[3_=L[]E<J>MKMJ,_9Y32&(3S<,2O<1CP.2:/.0D#?-
MM"A<:#05)34O7!NTE#AM][?I(Y/=A2H@]$$/G^6_E4FRA??Z/^(HW=1OZ_M-
M!)P,:]ZC5]5J'"Y*L/5(''1CR,X&.V-M*W&QAMID/VS9@%PHA,L'UZ3)>]8J
MEQDK,8VU0KLU&!#\)<?7'W[1/B@&L]^MI[.M'UK@4W:D^=-%29[Y!VM16!RR
M\VOK*AZ*.X,5:"U^,(%X"!FU5R"DO"$*XB%FN`HQ6PU\2-QZ#-,?AJWA<E>Z
MW^KGX$KOVGQX'T]O<Q<MV:E0NFBEQC[JY?"4.>RBZ##=(0_36&WI[H6V9'/]
MHC=IT90NS'_+ZUG]Y4LN'%V%C4PY2K6=113%39:4RKXZ97]0`UN*%C*U&P@C
MM6%UVG!E"",VEJ=HU!45']H5+6=%!7.6SQ/*<_UGR7C#3H.*Q+,I2CA5EZ$`
M:1U4.O"H:$%;VX%*28$&KRQ?FPNIP#?1WX6%B0]XJM764ZF2XZR0`^X]6YV"
ML3(.F(E]ZSQ:G^FUXW@LWA0?9'7J#[+J/5KPN==FG[\M/.4W%@#`UX1?C=]T
M)S7QJGM"/%/GCV;\"!=H5`5;V'!^.;F^_7+RJ=OIM3N#LP#6C98<0!D,_1JK
M*FLB?:^\,VS8BD8O/-M&T9&`;NS<F>%XKMZW.#XY0)Z##UPV.NSS>_R7#'A[
M,7A_?[B,`]OLG7P",FI'H\I6K#H?`/OY`]A?#6`W)P#O0`#;E>S@8#6`O=-5
M$,:7G0^$!6SAZ1H:[?:V!7$%Y_Y3,3Q:CJP9KB/-;I\!MOEJTUOXX(*$Y3]Q
M5_$>5)2E<>D$JHO]Y"P9#-@%&.%#EWU.+7VT7DP.!X-.OSN,#3K<:#&Y@-"-
M@0#K/V.?OUV;+]1QV6:LV:AOZ'509WQOTPD%RM'8*N+$_.`"Q>+E%X;B.'<3
M=D'&'I^M1U1_V#D[[5>"IU$,3R.?@2O!4Z>]'D]G_=Y9KU(T]1F:V@,NY\#E
M3T#J/3FZIBOV^X."IL\R2#OK(>UUF5=7$*Q,9@C/.9WN&NDXV`A%26#SP)`X
M/+/&=JL:0;EPRQKS;5-.60TE6`J([@#5>!%&XB\LQQ5W]]?8?8,$6E9!N("-
MQ-(N+(#-=L!0^ZPX^C);H1<;(KRY/90?,DY//MW#/ML8-6&A$,-R,#+NQUB8
MG"5S?UFQ,(WR9+WP$Y?@C(:GR>%S=#<9YE%8-)L'>NA_/-W%A`?'M3W59936
M@/W`<,WK5%>G#:(81BK$\W__IW?VT2$AM'Q9#OEA<'K:Z`V&L5_&_F\_DE=J
ML\@.;`*^6S=A97<V..L*!H3X`Q0,D'?..X2=&<5V?=5.+K`Z/NLS'A+@<L%3
M9_'ML0V6.C^A^OP>7>+3T_A5L36PMZF!QU7).Y&V!*66-89W9Y1T*(K`3!K[
M?JN'L:F-$XT>_*#)<A,]1&0W=\>K,UHC8I(R9@T(^4"<))W<(3Y;9W0,RP<Y
M,:`]=Y"[[=4@]T_W`CEH:PS77T9-C:NDZFYGC4G13\"[$H`\H"V6HKMKS.BS
MLW*A+9B8UX4S^X/=P;W4,:W<U)RD`A)3QW77Q3V38<$EL&7:"$_K->%36A/>
MS=G^W7FNXX*U!=;2'Q1;$5!M##:)\DR_TID"TL1\!BL%)`J85(KQ2.U9=Q,Z
M2H$^`&-P\*_A;Z>7*1U>[LIS,[`6EW`-;])-1U>97[,R&GLUFQO6.Z5L/_F3
MXN3$O[D&P_6-:H\6\X]LYXJ9M_S?&;2U)B#;/3WMYV-`K8,\;_J\>J.VJCL8
M-DZ^J%,ZCM<%ASO##!P7`GH:R2&T_#0Z>W-O+>82`Y?@.YQ'RU6,M`U\:[G_
MH@"A:CV;^G_3L?82<+S&OAV-DLJQ,,`+).,-A55G!S%[!F*V^Z_>;YU1CG)V
MAZ4OFB69QD-P_/S%MF9QF^(/W9W&;TEA8A@[\1F&^OPB3+7(PVSIK;'!.RFC
M92_XBD57=GPL9W2ML>!/ZX>N7@Q=O6\/L42@7!"VQ@GHI*UB@3%V%L/8V;>.
M?P*[QBN-(_':5*T9#<WH&TOE(FH1:VN<B;2?F"O2V*DU7RH`Q?[R'W6I.QC=
M].PHAV9[X=WKGWQ*9=>ETD,W3\XD4;)><3V/5N21ADM]`H[9+9GT;:.LJ%3^
M:$;:8F;B9E92J9]9V8ZWJ<TU=7,Q+S5X96LXT,UMWWI[]W@%J#UOEI?2^>7Z
M=GQ[<3V^(5?_[_[J]N'J@?QP?7MQ]]O5CPUR>_4H3(+UX+0U7)9?'?RV%8%N
MFV,M=*>Q&"7<,#I,(*^MFU$GL&2>]M*N8^?D?\[HTZE*&9;]\<BQW.C,W\/-
MT<WHG]9H$'O_&69,^L^YN+NY&=\_`!"J91C*W*$?R1WP]I>;NS_.R8ONZ*RU
M8F)F\])%^1T5%RY8G\'NTP$R<)8$VJ;=M0JZCMH;M$-,;^B.'1V'L<Z'@U[.
M;<S+!J:D]J6Q<=_Y0)M/J]+X5O8&WY\@3P#5`F&.%E#Q+ZK8$3HP?UW#7Y_L
MGWC!$E69*19=TNLTCH8`]F]:+[FX\DVL$1<GU-/BZI;N=*<39_+N8AOJH*..
M</N]#<1U)0<1MK\GMU]*@X@<NF*2PX&I\!QG9`FJUVLRY:PJ`'?FX&.'/^\Q
M6I+"1=OA8X=?4GA-`)04+BE</*-TPU$YJU%1W("D+!/U"VN7I2M&,`O1.=_Y
M;"PGP-<"*NH\U[J"M^G\UM+@JVA>:UWWKUSPA!TO7!I\DCP%!D^2IR3/"@R\
M8.XC3YWH]!;F/FYF_Y9C]%VCS4X=-[#YJB(*$4:@EP">4,.L\Q==!8*9(<K^
M=A2[6>`(^JH$4?$TNW;V;F6@9PVAKGJ'I=`5CH#%`%,*W;I9C^6&##\KYI_8
M$]TY9E]"Q`"P2('#/75Q@3C($&^G56^U>%LK^%'&$5#R3HIZE\HB2<F2DB4E
M"T7)@AQ%EQN5O'I3I]C?`/OOR9#D#MG0]?.X"D:(@+&BG>S3;D>R0]W80<#:
M*0'9H5ZF@>0&R0W"<<,N160'PPV"&,K%A:MR+RLZ&!])Y.VLLH)2\&#`WBB2
MZ4V2(21#2(80`CS)$`*B2#*$V-9RN6'EZK=>!$>IGF$#`1$B8-A@MYCRL&IV
M.`1J$%P>2O:H;7JNY`[)'6)@2<:<A;2BJ^H3H+-VZK)+@&"[6J/`0BW0(8,(
M-2)^$3I7"D3\>Z-#$K\D?DG\(E+'H1J^]>R?P&WA8W:&CC82(KA;OU-,>#2H
M>J_%V]LCB&$)3LHR1UA2LJ3DXZ1D@4W.<G-^A2B.$\$)J?0L2NS6#**<197;
MO.&H"X4E-TAN2*"I,@].<H/D!N&XX:AU@R!Y"C+;5P8`#C=!H3IT"'E,)8G_
MF,YHJT.')'Y)_)+X1:0.:?&6G)E;_=:+X.Q(UU^Z_H+D,DAV$+I9:NW98:=3
M9,D-DALD-\BXL#A6LHP+R^B`C`O+N/!1$[\,C<G0F"1^2?R2^(_`XI5Q80%=
M_QYPEF9Y3_A^<7:\R`G`6R)"D$8.6XF]'P:CRB;H2JHO->)UF%2_4U3KAYXD
M>DGTQ1!]K<*[E;4G$X$-XL;N3ZX"FQQ_4`#ZQ<W5^.LY8'>:!#`-7PH2MJB%
MU\OG^NC.]R4?&7U>WUY>W0)U-`>GK2'2TF_CK[]>`PW!%?#/&_MO\!L^`9G&
MT-@3TN3:X%\TR`.U]<D)40S]V?SEY-^>X^J3]Y,U5)8W1&W=C$&CFQP:_&]K
M-,#?.#0[`O*W'V.@A)^^TKE-'6JZ#E%,HLPLSW2)8;U2F[A3Q<RZY;OH(YO#
M-K'@%A\/"=GP(;7(#XT/#B[OPX)`B,@''X9_M)82$Q-9R,:PK;9&[5].0$KX
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MK^#5SAF_)Q@Q^,=G1/_]9TAG_G-`D]^,[Q\`"-4R#&7N@#:[`S7WY>;NCW/R
MHCOZT\(QQM)%^5;%P@5K"3A@?-3>,<SL%.-1*;;UV<4&V,V*&189P"D;F&KS
M$G:'-A^#-+Z5O<'W)\@30+5`F*,%5/R+*G:$#FIJ5,-?G^R?V)675*6S)QJ[
MI-=I'`T![!^IE5Q<^2;6B(NW.6N)[W2G$V?R[F+[>+`_Q-SO*@_;RB('$;9_
MEQB$8!#7=?M%E`:[S).HI_2O4H7O=O)<)[V>(X1%IE)4!>#.''SL\.>=.R(I
M7+0=/G;X)877!$!)X9+"Q3-*!4\26#VSB?(S%$=.;3HV\/+-8\H!/B&3E,7=
MOW+!$ZE)=S7P2?(4&#Q)GI(\*S#PZCF;R+?YJB(*$>I^1"QZ*[*R0Z!BMIT,
MP;\=Q6Y6EJ1?G"`JGF9K-;*E\N'Q4N@*1\!B@"F%;MVLQW)#AI\5\T\RH=0Y
M9E]"Q`"P2('#6O6!/*UZJ\7;6L&/,HZ`DF73.DG)DI*/DY(%.8HN-RHIQ/A*
ML;SC"EK1ENIQU;85;;DQSVY'LD/=V$'`VBD!V:%>IH'D!LD-PG%#98UL1.`&
M00SE<N>\B^,.BR$(Q=O.&G2KK3I`>U@=;"5#2(:0#"$90C*$`"B2#"&VM5QN
M6+GZK1?!4:IGV$!`A`@8-M@MICRLFAT.@1H$EX>2/6J;GBNY0W*'&%B2,6<A
MK>BJ^@3HK..R[!(@V*[6*+!0"W3(($*-B%^$SI4"$?]A3@F4Q"^)7Q+_@1J^
M]>R?P&WA8W:&CC82(KA;OU-,>#2H>J_%V]LCB&$)3LHR1UA2LJ3DXZ1D@4W.
M<G-^A2B.$\$)J?0L2NS6#**<197;O.&H"X4E-TAN2*"I,@].<H/D!N&XX:AU
M@R!Y"C+;5P8`#C=!H3IT"'E,)8G_F,YHJT.')'Y)_)+X1:0.:?&6G)E;_=:+
MX.Q(UU^Z_H+D,DAV$+I9:NW98:=39,D-DALD-\BXL#A6LHP+R^B`C`O+N/!1
M$[\,C<G0F"1^2?R2^(_`XI5Q80%=_QYPEF9Y3_A^<7:\R`G`6R)"D$8.6XF]
M'P:CRB;H2JHO->)UF%2_4U3KAYXD>DGTQ1!]K<*[E;4G$X$-XL;N3ZX"FQQ_
M4`#ZQ<W5^.LY8'>:!#`-7PH2MJB%U\OG^NC.]R4?&7U>WUY>W0)U-`>GK2'2
MTF_CK[]>`PW!%?#/&_MO\!L^`9G&T-@3TN3:X%\TR`.U]<D)40S]V?SEY-^>
MX^J3]Y,U5)8W1&W=C$&CFQP:_&]K-,#?.#0[`O*W'V.@A)^^TKE-'6JZ#E%,
MHLPLSW2)8;U2F[A3Q<RZY;OH(YO#-K'@%A\/"=GP(;7(#XT/#B[OPX)`B,@'
M'X9_M)82$Q-9R,:PK;9&[5].0$KXKV?"XKS3;G__D;!KFH;R;GGN^41_H]K'
M$Z)2PW#FBJJ;S^P^_'NN:)K_=_A\._RDA4N+?[2CCX%$^?DGSVD^*\K\_$&=
M4LTSZ-WDSIU2^]8RK3FU%1=><LT:I%R]S:GIT$>\]9&^N9\-2_WSTU__\M>_
M$/)S\)2@J8I_\6?+MJU7>(1#5,`1W/653GXYN6]WOL'_N^U.]]'J=+_U^.<3
MHFNP&XKJZMJW7N_TA'BFSN_X_>'RA&A4U4&8.[^<-'LGG]K1VI>^==_E]6++
MZZ66-UR]O"ZHQA)6V(^ML)]:X2A_!/H7.&-3N[$<^`"L:-E()!>>;5-3?;^D
MIC733<6EVC\5PZ,[;/S9ZG7W$IC=?D6%P;2"6OKMC?="((!6$%>_LX;\.SGO
MTH)4\A^Y/7WUN]O0U[+W[KF^5;32VT:R%+2^55O?7[.^X4X+_$I?J.DQ$OE5
MT<TB)$M_L#$7;KV:HL!912AK-.0@L0_"0+2*M-8HU3S!66+F[$!5F^O9)>_<
M;VFK*&2-*AVLYM0\5K=BMP=KE.)HI^4]>$\._8\'WL'5"[H(H:VZPP([)Y]2
M/E/*;]O<O2&QTRGF""0>R`\*693AC^O+Q[_C$]$?V,H5#/RP,%2$3DK<X=C`
MD4@=KZ5#'JXU7W?*YKMO(2#<#UP(A-S>/5Z13N=\ERR^N(<8?^;#[Y\?KO[W
M=_!+R=4_X=\/U<58/F8Y^,-1Y-YOX1!C5&N=6[\U3>U*3H71T"*Y+">&\-IN
M%FEU,OSPG6GJTK,!-/(/Q?04^YV`D!@TB$)>IY9AO#>M5Y/"XT#DZ)J.O[\J
M#@%'"G9#=\"A)KI)0&S!"T$/$6M"+JFAO"HV):8R@Y\_Z]9G0W%<<C]5[)E"
M0*2M7GRQ1+LBLA,CX]&@U1[L1,D;QJ@D,4?TU\V3F.],\H4^V9R2&SXQ(WU>
M6+.Y8KX393ZW=-"2&I"X25^C/;JW*9`XZ%.BF!JYF.IT0J[>J.JY^@LE=Y.)
MKE*;_::0&9T]P1]`[;KK@/Y1;`W_T'2;JJYE.RTR=LA<L5W\%M^N/-N4SO#A
M^!>\EUQ<W3%6>K85MIH\0W:D?S9JM$^'B=!=!*DU=W7+=&!GR=RSU:GBT.C'
M.QMH`[`7?>,`X\++7W5W2N@;M54=?*JY#>A`Z+[+=^6C5C^Y;`*V$&%+$$9L
M-+NC5F^P+,:=D^R`=3]E")&GS(B^%">Q4[6BQ$GGU)<GT9;$!,N'+#E`@'$L
MXP78&WA-=QR/)K<S-[;I]AO@2209)\;F=#8WK'<:<+%B9C%RG@L:MCK+V7CO
M`\(:G3DL<]46?#I$S6>0Q!K2$S4=!3=O;-O831,5A_/Y/;KF7GG'[\9@9VEW
M?)M_13WB7)OWL"N6]@?%,W*JC5_`DWRF5_YNW[/-3GN)W2%ZAH-'J]W]!O_'
MS]^8_@O5GZ_]?F-JSW-PQ8^ZBT<IUR;LA:YYBC%^TYUO*7CC-Z1^>GR?4[PE
MY8^F(I??@&R^,;CCKG,7/&?0$S$TEX<]<3:NZ[OW?.,ZIWSCKGQ6?W"!RO@K
MXKO`OX%=`P&@/5K7*)-LY^H_GNZ^\W_GLX^]#?<1!840^WA)YY8#UMS8<:CK
M\!";F\3XV+DSE\6A!FM"QK$H3^:;]EU..JZS)@[<[;:[HT3L:>6J+'MNGC.*
M8@2C<9>1(SDP&-F^./SW1^N+Y0&-V4YVF+3;6Q-Q'*P_&MUS326"]@V(>6:9
M["4)3D*7&2F8,QZ2O&4BD6?PTP9GL?7"";A;$PI$IET8BN.,,_'"?KJ;L)5D
MX&1]5+I&^!B#Y8$B3#'N%5V[-B^4N>XJQJ[TLB8LWJP?P8Q5U9MY!IYV7%(P
M1W27O^62OE##FB->`$'/=$>,G:X_OZX<6?S;DD3.:?S\F\<`XCBYOOT"VGLP
MZ/2[PWU0P[\M%3?[BY[3[GK<[$4P2:R$YE'VHQAUL;.C[17MZ;JC^+/D$=7:
M)12RYCS(>7,#K2(8<R#+-59?1X2MS%?1G:XQ%+MG?2&`+EAY;9Y5D!<"N(0J
ME8-'&PG=S===$*0Y\/'9>D@'IZ?@%>P"[K9:Z7?8$7"97V#I]X:BLO7OF/TR
M7&-D]6&3=[)+EZZQ$J!S(/;AFNS#WB&@:7].&:[)=*P_CO)5E\,UYAXPX.`0
M**M@?3M<;TP*B<`E3E)!(FRP@0,YZ@YZ._B/RX&K"%TYB++30GS*_3#%*!"_
M5DP5"V<2+]@^6W.XQDX].^NLE3XKEU0*3'GPQIK8Y7KU+@`:<J#Y-6%*\7&0
MKWH>K;&/ST;KS6,1D%*L]AVML8U%1-`*IVBTQH;M@%,IYJ[G;3&,UEBG@DK%
MO"V!T7[6I0`XR%DJK@]KGM6!,HH6B_N=F>^-H,CJK-"P&@W76]&=-CBYH]YJ
M=*R&IB1\Y"!+-@N:"HB)W)7+!D%51AG#TQK@8W_*.&N721E!_?V=^3"U;/>1
MVK//BOFGGW6T?4GBV88VX.KW[K_$%<[NV8:QR:*7N,+T/%MW^AMS-[98II^8
MYSQ:8Q7XTJ8Y[?F&=M%&K\]MP:LH8'TU=@4+7D4/ZTY3N[PCUB[K#@ZJ[FU+
MI51SOMC6+!`=U_!.'8Q%[\G0U;L)2#:L2"M'+YRMB4GU.OUV,@=B8PB2NB`#
M-\Z]!9>_[U'`>S8JOH!7-:AB\Z*9A5*2>.+_%H6X45NT>%^T>/_;I<WAM+[6
M5D=A_^&;JR^/L6^#!G!AU8J>:'[6]#N[N;9BPO(PQS6ZAS^*W1&6F`Q9AZ=4
M6SG^T'C_X]2B_.L65L5K<G3SA+SX-3]8#A,@8]A-U)]DU"SQC]AM;KJDM==&
M_?7*16&W1!1V^^M0>'-]>]4,>BH'O?,2W;U8AR\W>DYN13I^!5M8D"?PYA6[
M6WEMT;+"N=QVC,GL)M@],_($4ALT`Q?;YYMOY+(RIK`(JMR>=9V]&];EB>!E
M^"58/Q[^P6K69HH+GH>KP].M"9E9<`%VPH-_V93"WZ8[=<B3YQ*#.@[_"30^
M>0?5E60[OJD^_@?MCTO>[O??PSIA5K2K8_*/XS:(;JJ&AWJ,**IJ>ZP"GEO&
M#?(ZU=4IEAC;UAN8$"XL=J+`G2\86VGE*DW&#B^V5WDI<J_#BA/[B6)GK$E,
M`/8*Z\2"_=];#RVB68:AV`XK:7ZRV`\<#H18@6MY\0Q1>/5,]+/M5_JW6Z>G
MWZ^3:<*7ZFULG*4-6=ROX-)4I5'@*WT%3%U21[5U5IZT@WEW=O)IDYW^O__3
M._M8QFY'5O#VX*<1^%O(TG>3^-/VP1@VI_U4DEB)<+$!)(L%7CQ^\ZB\\9*K
M:Y/Y%8[S%02/8JO3L:G%(L,;EZ+UVVM"(YU^-U7YM=U*"H0DO9=K(BAGW5XN
MD#`1\*NGL%8,](MEWU-[@G8'BVK=4,6AX["!P^:K7Q=<B65:;?CRA4950:,H
M=AE`:08-+F_I]@&6?GOS'/F5;\YCF<O#*N".KR'P9)Y[X4M=)8W6!50&NR]U
M;;'L5K6RO]J6DU$^(TQI>+^]P<E._VS4/MVFGGA[%)6_"P+7>??;&QPO=5,5
M&,7M"1.E:,%]H4N/45:)OPVSD8(W;//:%>*LLV'EX2ZO72&:.FO,A--(.Z7?
MG&ZJS-L49E=(K,5Z9_TQR8KW[;ZD53NR1G,7M:15N[5&-:<Z2:Y8EG^8H]JH
M8J[-W]#$-=YA>S>,MYN.9[C`@G=F(E'A*V6)#?>*[;X_8G0)%PX7?WZ/_[(H
M03KKE/E9_`AJ<=5Y@Y4+3&NT?F>P!4S1TCY;IL?%7R#]*MJR=5F\L2.B5:LO
M"LQ<8%R3H#O*&\8@9:H*6-?HO>&&L`8@I(Z]0)<_K5?W3TO4_:-U"PYWT+_J
M$L"XF["W;H2HV+U+#"7VKL"X^?9`X:E:$&MY?+4>IY;G**;VQ?)L<,\6;\45
M+:*TV\:>')U^L]-MMKMAD*D@5!2(\#O/=6"W,=1VZ['XD]!HWZ!G0:+S1;&X
M*G!?5G?T$FI/-FWI-6P-1X7L2V;?IT+>,]=M]@3$A-B;PGH&=8N43TEL%%T&
MV(W0BY]/,TSH[AH3NKCBXW!&"'.\@Y01>"![RIA/=TK",XK!`Y\'G%RN[^_2
M+CKOROR@8,0E.].OWQULR(&=3BLQTF3%<M<&@3/\G%5!Z^X:D[F_.M";Z7AM
MO:8TP:RQ<SNG6RRJL'K$32A_@RA-0968/_^?9O.+9;FW%DA$D%[,Q(5U-)L!
M8@S=_/-\`I>8<,D-_$'>V%>VA6>#4]>=G__TT^OK:^OMR39:EOW\$VCPWD_X
M\T]XX8E_O0LR\I<3P`LU-:J=?,*'!X\W+-6_:FHC#O['QTSW+'DW7*>XEAU\
M:2A/U&#??@/#XB=_Q>DU;['>X!9XP<R`Q^/Y)36;OS\DEX%=8SU;I:EU?+F%
M97Q:,QJ.?-=I_?Q38H%+UCVVU<1;%5L](?[A;"=<D.6_U_][8ENS$"/\*[AO
M#>S^%3]-`.O-"`=IA"[=I<VWJ;=\F_8$MU<:N+UV;U-P^V)09?_DTYU)_N$9
M[X0?3O<2+=<=_1EG"""UAJ=HO`\QBC+?G<3D">R13$`D6>R,U6^=GCSA9M)K
M:AG8)*N!K8UM9'>;*-J+[E@VO(S:+V#F.2WR&%O"7'EWV-.B%\:X![L?=UB'
M8G;@6P#_]!<)JE\B0?4W):C3?/@G`]S3$L$=;`KN4`S^&9Y\NC;)V'OV,(D(
M0^2-4AC(GV80M"N/\]-,,15N]#?(!)0^&(#L:G\T$2CQ'1DMEAP%XN*[TQC;
M$7\2"4=$+,EEQB.C9$(IFYF@^S%3UE8]Q<8#0B<3M#->*-%G,PKF,;ZI14(,
M+V;/A$,84@M_PA!7,.`D]I)1&[^$"TW?H&&;$=X\FW$,^?@'HSV)H^!MN/*P
M4'+IRX9M_GB;/H.KQ=JY!Z@G@,H7':P=HG',(60%2*_A(CL/<V?G*AAO=/+I
M<5,^XY?P<3A/[P&#82*1S:.K;."'C@SQ.V.AQ-P/3F_!E<'3.+,Y"5ID+[38
MJ7JTT8SU^'<&4CZ96#;.(8DQQ@+EI#BM#^`A%S_0N<LSR3IMKJPY=?JK)Y@V
MQ8?*I2:7`$7'[FT416RC0R4V3.5+4!9(,I_BK)AL\@VH)^J^4FHF9]<@%41T
ME[2%X&EQ=;"3+.=DM4)<@WC-65Z?Y2BOE:5"]&QKB9T_89^50=C+C:+338VB
MS@I?=T^MT<G?:<Q)Q`BRL@P:*6!E2XFD,]J82+IB"%581]KW+,=VKI'SB7NU
M0%5=(>@]2T84M[)2";-7)]L2T]J/P[SL](1EABSAG__*E@O_S8/A@YS"K%F"
M:2#$7F0))C%6EDG`8BPMBX#S7]E2`NZV-R;@G.*<F02<?Z0S+P(68V69!"S&
MTK((N,3`=;>S,0&OB%SO"W")3FFWNS'`H^(`'I4(\,9'>ZB-BP+XK#R`>QN'
M'5!Z%W1V&RF&$@#>V(7NYA1GR0(XGY@!K"II?]_`'_#]SS_A(_1S_#<#X/\'
M4$L#!!0````(`$E!?T8"&H.PUP@``(AX```5`!P`;W)P;BTR,#$T,3(S,5]C
M86PN>&UL550)``.ICAI5J8X:575X"P`!!"4.```$.0$``.U=6V_CNA%^+]#_
MH/H\*XZ3/:>[P:8'CITL#&2;(,D6+8IB04OCF%B)=$G:CE'TOY>4+:]E2;PX
MOM!)G^+(G-%\\PV'PXODS[^_I$DP`<8Q)9>-ULEI(P`2T1B3Y\O&MZ>;\&,C
M^/TO?_S#YS^%8?`%"#`D(`[ZLZ"+!'IB*/K!<_F@==(Z^1C(#^>GX5?$PK/3
MUJ_!/UNMB];91>OCOX+_M+_^-[A^?`K"8#J=GL12@\@TG$0T#<)0W2?!Y$<?
M<0BD881?-H9"C"Z:3=7^I<^2$\J>FV>GI^?-O&%CWO+BA>-"Z^EYWK;5_/O7
MV\=H""D*,>$"D>BGE%)3)=?Z].E3,_M6-N7X@F?RMS1"(G.5T:Z@MH7Z+\R;
MA>I2V#H+SULG+SQN2!\$P6=&$WB`09`9<"%F([AL<)R.$F5X=FW(8'#9H&Q$
ME)L_M,[F\K]<H43A>QP""-X(E*)O#[VEO7U,^PGB(AP-$4N1<GQ3M6FNR36E
M':^TY%&R"RD0P>\&'<2'-PF=NEA4([]ER^Y&*J0EI9N:MJI@"[;-^UCB8,Q2
M8@MW?X`(\`3U$^!M$M\S&"$<7[^,@'!P<9!!SZXM[8)`.-F:P4MU6[#[3@R!
MM:.(CF7TW*.9NJ6#G=7B.[++W8U:+5NPLB?'IA2>T(M3-!:DMFN%NXNJA+=@
M4X<2(0=MF9-N,>KC!`N<A7*'IBD66:YR,-)*VWZL=O>PB](M8+C!1(Z<&"5Y
MNI@S_%<0#C;KE.S41G?W6NA:6ARA)!HGV?!X*^TK6`XO`D@,<6Z[4KYI59!5
M3?)^"8T*]TA4O499T3V+6V1%V0#Q?E:9C7GXC-"HJ=S6A$3P_$KFR/"TM2C0
M?EE<_JYNKH)*_KG^]UB.'8DRZAX8IK'T"`-9W'5A_C>_?X+ZD&16?=],3>[8
M_4*5U"K[[AF=8$G8U>P;!VG<HO(AS^U(X$G6R^9=;RROK99%M>!?JWC%'2N1
MUF9%SR`6Y3;(CX4P*Q?GBQ9-/D[33%N(9;SE\@-&T]?PMS"+;M<-8RX1T9'Z
M3]6!E,7`Y&1.SN6F@)^'0GX^8.C,T\,MY89(6&WG`;';"?H*JE=Q>LQ<%T8,
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MPSY7!V1QDNUP/-%V)/$R<"D7+(4]H'4[(5^H&BS!F_/`X8J'$@3I'PE:S.X3
M1(3L!JH+C%03W4C@H.3-1<(F3C"7!'E$2#<UU[8U][/;N0+X`-N=A8V+]@3A
M))M)4[6I3LFCH-&/(4VDU_@5XCC2#TANFOZ_<^7<FS:AZGBWJI;S3"O"*EO[
M1EL=*97&>TS-`W"0CE#E6Q<FD-`LWRY6XC4D&>0\H$L3=.ND&<#X7(TL#I=*
MR]MQB@GF0H&>@)E!H^1Q<6B$8U]!'&`LHX06H9KYT\AXP)Q5LM1`\'H)"`;`
M&,392-W%JB0F\>*4W;(@[*4C%&FG`$YJ?*-T\[+%#;>G=7_Q:8P#E/O&?>:*
MG>2]FR?[=S265&NGPN6F'L1ZT;WK(5PVV>,*;[&HPATHJ1?QAIHRCHH3834@
M/":K=@4D.VBNVUC0B!T1:7H@'A<%<X`=RVS7\:X_Z5-=1]]UO&"@>A.B+3J(
ML9DL,/^&DK'[0?^2O#>,=?0]R1*.Q[FPF,#-7:NF_;$05F/^3GI<S;Z6]E1F
M/0$.LKZ3X0#%>L/Q?4U,BH_TK<X*C<<CS**'240K=IFS4%5C#Z+>EI;UK%0%
MQ^,QH^H@J451II/RBSS#(*)%<CR\94=!G7DK2ATS;T4D'A?=3OG=D-$]8,DI
M-5:U])BJE65:XU2HU-0#FNR)*9OO<^:+8SRWZUY6F3W202,LE)'U6:].XJA(
MJD7A<1=Z4.]/(!!?(T;D%)K+K#U.E9LA[L(`1Y6'_ER$CXI!&T!^3I*L7B;D
M-'?R84*]UXZPM$T=#306:C7M#QCNSO24H[\2DL<C31&?F;2:]L=,6@TDZR%G
MKUE*]ZZN0^PX[W2*MD<@U^DHH3.`!\C&*J?5'0M9#\9P"ZK6>X8%,(]3FP3,
MQHY4:F2.DT(-(#\3G,-[X`Z0[Y9G#V_58TO\9BS&#+YB@M-QFC^YT-5.HZTU
M'/A4MMX\<T]R5>1!]W(DM_:4MR5BCU.G)90>>9K2?P!B5B?W[76]FUA8!>WQ
M$H<]&GE7V%Y`K&A[3R&Q`MO/I1+SRT0/\:S;SH[+[[.GJ9)NU2HSAGH1#_J,
MD912+ZE%X_,#-_E[3Q;&7E'&Z%0M?VIXT\AX0)PI$,MO[JE%LY,ZIV9M53TP
M?@/U[][[^?T1^7C-<H\+A7P\D/,U]3P(\`<84::@S:O>:-8%0E,Y?`B(31N.
MFR@[(E9?`W,G[[78T0@V3_LN`U@NX0&9KQ^_<C`>]]H\=\]-S1!8C%N%UAY0
M90B\N@&K`,/C*?D#3(",LS3Q!6'RJLRZ@:[C(W@#D'ZNB%;\]L@!IE?=Q0.:
MTH[Y8>F5Y5G]<TA&R4,]2;!FUA>F?P5%G8`'7<.2G/+3!=6(/$Z#)9-_+JM(
MT[/G6`:431&+G:C4:?&1WT*L&FG5H3LFKGLD>U\@Y]7OYG`AW*CJ^%DW0O2X
M)"V!D1_R:_E!C97?`9#(KH#```M>_4,!'<J=PF,KMSO^$-J*&SR>K)8SI6'R
M4R=P_%1K9T`?O"1+5>US/R<)G2Y^(-::N2II'VG<L)2K@O?:]Z9\7OY.;N:G
M_P%02P,$%`````@`24%_1F(YV2_W+0``SQ\#`!4`'`!O<G!N+3(P,30Q,C,Q
M7V1E9BYX;6Q55`D``ZF.&E6ICAI5=7@+``$$)0X```0Y`0``[7U;;^0XDN[[
M`OL??&J?W>6\VFY,[\*7JH*QU7;"=G>?P6(AR$HZK6VEY):4+GL6Y[^?H/+B
MO#!XD4@IE..7:4^62,47'T4R@A'!O_W'ZS0Z>&%I%B;Q+Y\Z/QU].F!QD(S#
M>/++I]_NOQZ>?#KXCW__UW_YV_\Y/#SXQF*6^CD;'SR\'5SZN7^?^L&?V;+]
M0>>GSD\G!_!'[^CP5S\][!YU!@?_U>G\W.G^W#GY[X/_/?OU_QU\N;L_.#SX
M\>/'3V/H(2]Z^"E(I@>'A_P]41C_^>!G[``$B[-?/CWE^?//GS_SYU\?TNBG
M))U\[AX=]3XO'_PT?_+GURS<>/I';_ELY_/__?7[7?#$IOYA&&>Y'P?OK7@W
MHG:=T]/3S\6_PJ-9^'-6M/^>!'Y>J$HIUP'Z!/]_A\O'#OE/AYWN8:_STVLV
M7LD%SXSSU6O6.QA\GO_C)U#7P<'?TB1BM^SQH)#UY_SMF?WR*0NGSQ''6/SV
ME++'7SXEZ7/,&>EWNO-7_=ME$LRF+,[/XO&7.`_SMZOX,4FG!<!/![S?WVZO
M5B(\A,E#Y&?YX?.3#P]QRC[S9S[+N_D,4E:4\]R/.&5W3XSEF8%@6^TL2'('
M`Y9QK-G-XX6?/7V-DA\F$B'M;4OVY,<3EEW%=_!Z]I1$8_@^O_PU`VK*RBKK
MT;+T-\]\CH&Q4U:QZQW4I]D1_!#G3RP/`S^RK^:M[FU_566EEW5B0<;Y@A-=
MLMP/H^R>O>8S(_&0]C9&13B)PT<`"O->$"0SF/CBR2B)PB!DV>)])J-`J[N:
MY#;7LU&O%E#<LH"%+_Y#Q#)8=48I>_;#\9?79Q9G9;2OUYT%N4=I`I-3_L:7
M2OBLG_EW?\UR<XE5'3F7U7R,:/9G0?(;F(/2Q3B$2>F-$VNN8FDO%J2\@FWV
ME-W[KQ6^.TD?3B2L))J=^6MG9;POOEN3R0KMPH)\%TDQ]\'8_A[Z#V$4YF$Q
MJ5PDTVF8%^M\:;9+]%TK(B=0'(V:$DLTWH=+";LV1.RZE;'$AD'9E95=0L2=
M%;`MS=\6&U4^QNY3/\[\H+`0RNP5]#NM%4/'"8A.S2C,AU*)OBT@^AK&\*;0
MCY;;Q/EZ5VHSI]&7C:]W]I"QOV8PM7YYJ;0,J3IR.=.8#')9)RL9_318BKGX
M<[WOE=LMC///XW#Z>?',9S^*/BEQ(0[`I?^.>_X&!=RBMZHBP=\P>&"X'X[9
MHS^+<HL""OJV*&XR]</8C;2+KBL+6_1S.&73!Y;:E'2SWZIB/H%$:3![8(<K
M%5@45MA[59'C)#^S^BTM.UP)!B,VC$.^#GR'[C9>!#,6B\=LO'P5EZBBO[OP
MR<-;HR38>%7$#PZ25`BJ`)2QX*=)\O)YS,+/?"[D?Q23XN%19W$V\&_PD[=\
M^]I+`1>[RMDT6_8>^0\L*M[IJ9IX_7=5U2QV877IBUP\[O4VQ'WG]BS=%!S&
MU[+KQ5`SFM0?TV2JK\#%BQ,]^6<9R)(\\]_X<IFDL$#]\@D6I?E0_CD`VPA&
MYI>H<`O#Y\`F_(_W?X^2C(U_^92G,U:-O$<_>R@T,<L.)[[_/&>017FV_&6;
MRL7/WLIK?0&?2';S>)<GP9]GKZ%H""K;>*<=AZQ*)D4ERRO.-AG60R3FN=L4
M9>LR7FXLN0*N=A_V3KL.2<)V`^\,Z>E<S!."1DQ0K[T$>3N[,Y=$;>XR'3+U
M#DO,6$U+V'RQOV63,,O!N,RO_2FV?(D>]3I'+GD1[5"KKF(H##$/@SIYN``D
MJ1]=P?[M]3_9FY2(K6>]CLOUQB$3(AQB*H;U4'$Q2_F1[]<P"_SH[\Q/O\3C
M2_CJ$3:PQ[V.T[7%!2%2*&).CNO\/+Z&$4LO0*!)DLH_CHTGO<ZP;4Q@*,0D
MG-1#PGWJ\Q"ZN[?I0Q(AZM]XQNL<MTWQN_*+57Y:Z[*03*=)7.P?"O]?=C/+
M><0?EU2^1D@:>IV3MI&C"0JQ18_J=0K<0[<*1P!_Q!NTC85MZ1%U=^I1]QF(
M,N;B?(U\[&/8>,9KW6*P(SZB\8I6N.D`'[$T3,;RS9'P6:]UJP(*`V&BHKEM
MRL1\PS87[BO\IO*9[CSOG;:5$2$4A)6:O<+OVVA]3E9/>ZU;G"5`$#YJ-:W_
M8%'TGW'R([YC?I;$;'R59;-W],+M$]+&Z[ATV#O<.<GP(!S59'//Y?L]B69Q
M[J=SPP?[8H3/>EM?=VLX$>%`N*C5UE[X`F[9<Y+RJ#;N^$0G,5D3K].Z':X2
M#D+08LX&D)\W#VB='=MN9@.5/J>U<&;V77)>BS_L=1L[.EH)@QW9BA_TNB[]
MK,+36H7Z%,=X[U)_G-%NG]ET>BY7#:U#6@E?"F+%:/;L@+;3<[IZ6#BA+;2N
M??!7X-FS,UK`U)9#6F.R'!_3EB?M+,M@R3][X(>802XA;/-!K]N@[5)J(1/(
M[^2DMBH5B^VB-B-;SWO=!@T8B:YEI(@@.#FZK3"W^=D33\&!__!PZ1<_XM'=
M9_F%GZ9OL*G_W8]FLLV?5GNOVZ")HZ8$F>^TD3DY^2U/Z2489%D(HJX#EE`H
M?-X;]!KTL)7E3`+%VLGP;N("_\63IA/C)&BW];H-GLN8\F&&RLD)LJ7E2G>9
M\CI'#49ZE?U>!!#<'`Y79>,ZB0/#_<-N$P#88`Q8R3T$!L/-J;*M5>==:NV%
MY[T)`&PP-$Q/_3KKSS8B-\?2Y2E;%F<81?X\L66M0H.$-EDS`$K`?BI#G1J5
MF[-L>S.CP8P(@,A84V8TB9&X.="N2HV2$!">C&&DO2#-A79S9%U>XYL5)0HG
MU486L,:V0;<+4`"!K;B1C\@,FINC;BO<ZCN1\$8`LL$`JW*4*&D58G1S3EYA
M6MPLK,1CB9F&G86W`I@$O!0J&I#95`5+?HC>.'M%J2QC]M9;`<P&X^JLLK<+
M"V&O,:_&+DRCR=/K-)G)5HTK#`UR%-R8JZ/4KD6V<C29\F9SG5-A1(ALS!>R
MEH&A/#_9>A0`$?!]J!2.G)@(L2#D-.;U.!N/P[DP(S\<7\47_G.8^Z)\+44+
M@$?`B"Y'E102PEACCHY;7L$I9N,O?AJ'\22#M7<VG14%P"Y!Y4$HFQ_5C0$T
M`2N\'(^ZZ!!*&W.0[*(U6N(`%`D3O`QE&!J$(K(>E0J>%`"\?Q:X!"E"[;#V
M<&CQ500M#(ONM2\LVJ6I:QH6W=,.B\8MV4__O&'1/9>F<*6HZ%,EKT(P>Q84
MW7-J]UJ(B>8Z1VPH,9H]BXCN==H2$&W(%-EPZ&N6\P5_E"8O(6P;SM]^@SGY
M*EY<FQ-/SH(\?)F[R(HJ[3/X[?U.'0T_E)T7>#T"'F&C!=,B;F)AVX!L7I/Z
M>Y+)ULF-Y[P^`3>Q14Y0TK<@$POK/AO_SRR;7ZEPG]PRV*(%8<0VQ+Y/-'6D
M$W'GX'5>GX`CU/E(<J8Y>D'I*0O"Q?V`Z$!:?\SK$W"O.N-'/!QV\#LI:%;!
MCN(%I<Y]0'B13'DDMXI0<0.O3\!]5S.U$DU8"X!'<A.NP$!/69;?Q'=/29K?
MLW1Z[L=_+J)5!>QIM/(&`PJ1GO5PJ*T/:M'SH(:4P9B[9//_K@%?'/EHK.[Z
MG7B#?X;=GZ$^[$7JHY_WMCS2U!O\>S?JQAL0F,,-J1!^U>:HJ07R[V)83$KS
MZPQ5P<@ZS;T!@4"[2FP;HZ46[[\KN"B$T(AG40?>D,`<[HAI%"^U!`(!?L'-
MI&9KMJ`#;T@@\L$1URA>:JD+U?8KSERRWI#`^EZ')Z^JCJBE2R"0KN(7,%X<
MNOH-7^`-"<2`V'#UE\%M+S,#L0E@PEM8Q6?!7[,P92:6OU9C,'@)^.<L<B(P
M#@P402U;8T=T-,%5\J7K=^(-"1S<.1L,)?5!+0>DFGZ<K0C>,0&+P_G8L:`C
M:@DK"*3%U<;N=AJ&+_"."9PDVMAIE,%-+3<&,`6,C;.OH"%>7IN7Y[U)[_R(
MW3PJ`XO5C;UCNIN2,O0AZY">'JBEWE33B[-YPCLFX`5Q/F8LZ(A:8I"X1-_\
MLHMMAY`L0-&@&^^8@%?$:"TQ1D<M5ZB>$I7';?-&Z,.29Q8UE7[RY,<3EEW%
M15S$9F91"Q-23AK,&B^7D.*T<+AI0LH)ZM@72/V1D+(3I>YR4:J2D,+I4O`J
M!+-O"2E.%Q<;"2EHAB."9M\24HY;DY!BQA39A)01],72E(T+L<]^W=@:"4U_
MP?/>@$*^"/*)8*8[BH-8_L=J#,YW93QJ-8F+/:;F,B5JYSDM*^YXJ4(!$<O^
MV))3.2$*G_=.B&51HMH7LX:#(I8:88LMHBN8)=I4"UEC!ZUK58^4B]C.L]X)
M@:,)_$M!-AI"%-2J^(LK'"DIDK;S3@B<+IC2I49$+6MAMXK1Y2P-X\DE>V%1
M4IROP_0R86HRC3KR3@B<`QBS:PZ1VM4!58M!]0F4.33T:0DQ4$LK*#RSV<TL
MSW(_'L.8DM&R_:S7)Y`>9L:*$(*]+``D4J\8#,5%T^/YESL_FKE)000_?9M+
M-?_W^^1K,HOYJ,'./"KVZ`THI.]KL68%J;VP?YODSG^URN[\5P#=EJG2#E1J
MH?X(H&)$%OD*JH5/UA8@$S`FS!="-29J$?:(V(L%I!R/:XT!=.O63DU0U&XD
MD`W`BR1^@?D$1+UYG/^=AP\1NV,!/,GC9$I^K,I^O3X!.\3:=ZP'EUKXO'1`
M.Q@9FAU[?9IA*B5G!CV\U,+H-XI.(-Z5RY!'V<7C["K^\AHP?CZT7:M9ZH2R
M\@:O3R!IVVBTV`1N+UK>;'-?S'JKJ-S'S=VJX:Y>VA<LJ32#$<VV\QH8[06Q
MFU'Y;F%8X%+>&0!MR]1>%:2]L/3J5O=OSTD\2L,7@#V*_*#`;LNY@O8-:B!P
MCN#$#E=@MA=![H9Z:ZX7O'-01%NV][9!4XLLERU(U^Q'\2]EK;Q5>Z]/($3)
MFC6W"8O:G1721:D"HUL=>(.VN%%+X))?5D'3VBIP/&S75KQE?\W"+,S!GDQ?
MPH#-,?,J@9,Y6ZK,$=>O]@9M<]C6HA%D!#;F)"Q7")M">4PC;G?%1X@X:31Q
M:"TAM(5Y0L,&-SOE\H2&+M<ZTSPAKCYLA=N1^B-/:#MY8.ARO:D2?#V47)<F
M`[-G>4)#IVN&A3RA(9Z.*D:S9WE"PQ[1*.NJ3)'-$[IE&0/%\%3GM9#&13E>
M"7G2=MZ0YL$(OKRIX1#+'OK&8MBG12#OV7@*RN7U*?+PA:F94[3TCFD:WSAW
M.H"(91"MZE]J&3Z"I[UCFN8/SA(&@EBVT'42)YN2JK\HM(UWW+9Y4`Z%6&I0
M.<?!"<U#70DG.^(3RP5:Y=S.]SSO\0-<Z!74J^FSO!J=23?>"<W37)Q%8W34
MLH8VAN'9BQ]&18WW9"U=;9%S<>YG8:#[/:I[\DY:-XN6`$@M:V@9ZS-BZ?)J
MI3#@V^,PFN7O#D91`JV\I7="\\`.IU,'$+7DHC]8.'D"X<Y>8#6?L.L9UP=8
MI5S^M1P<?5;+=>B=TDQXP<FN@%.>RT2O$-@(?HCS)Y:'`<C;0F__H-_8GJ>L
MN_^44EFP0G]:_O[3C[I@`B?@*=6Z8*<EZH*=[E]=L%/J=<%.3:I-G>Y?7;#3
MUM0%,V2*K+_?4ETP"ID/R">B,+]W<1#S[-_-'K)P'/+8SZ+@N-82A;7Q3JG6
M`Y,L45(PQ#SY:R)>^U/X\S[UX\P/N'S*&5'=V!NXO?)5?PV3DH(0J0F/V!%`
M#9026_6<<4NVJMAV&+W&.BAJ`!@IG)9J?F?8RH@C(W;0<#6Z41*U>@804`C_
MK<3-%AAJ1P)S-](R&VWI'CV;\CM!90YB23.OTZ-YLBWQE:CQR)W[-7H&S_V(
MRWCWQ!B_M;7E_K_^H#'+MZS_K]-UN9\S=0`6"M1R`!9R[Y4'\"Y@L9^&B:[W
M;_UY4(?+6:J*7540I:!T%PHQQ]]2P-_B[)D%X6/(QNJ=-]8&1KG3=&!S/^"N
M_A'"Y)"(.0.MDT;,2K+*'F$'8?(U@3V#AD6T_B!@HI!V+?]@,`-H%P@QG^!:
MX`ALVF[28BS.,X:7VTV9XUW=&L8QS9()DAV*-BQB+L,UN><)PF>S_"E)PW](
MXR\DK0`EA6^O+'EB.,2<@CORSK.]30B;MP!T-`-03<A:AT+,L[<CJUZ!95DS
MP$DSVM2$LAT\4M]>C2Z)1?K&):\Q%F7WT,G,U!N!%*M9]"QS+@B?\P:#$O,,
M5C$G>&+C&7<"+EZ#.0PD3WL=IX6%A5X#B68V1YQ2[KWR&EB)&^HXK22LY3U0
MLJ9P(8@Q$7,C5`U/Z;@M%&PA@*C0.K("('B(>0TL<$343U"=++).`C=WUW6<
MENVK95K$<1'S*-BY%6TP<!H'9ND2NT+_LJ,[(2QB7@-KA!&=+:TQIYHT*;@0
M2MQD-Q@02)N2?"Y*,W0=!S&?0;E$XDZ3A4:US3.)[,2B>VJK+MGD284Q;R:@
MJ,4'C=(D8&R<?07XR_"8*ZYJ/QK-'J(PN'E\9*G<,:?=!ZB@0<>J,:^&N,A$
M$-V%DSA\#`,_SL^"@(<X\3&9@,`ARQ9./"O>.^F+E#X]O=;>8&CQO@+9*^5>
M/V5+K^.T+`_N`331H\@OJ(GLPT>XXRPX)N(CU&30V%]XO(?^0K=5F6SX"X^-
M7%!X@:;V^@N/V^,O-"6+K+\0-CLPW^1OHXA/(_&8VY%%A;WSMWMXMV*2U&@-
MZ(GX#BM-E]I(B7D34;FYU,JO5*,U;#"<)MIH3ZW:#!D2O`V5F/>Q%H)IS<OU
M,$W96_D\RUFZDEO'9REJ`2@)Y&%I?WBH'Q/'9LV;B1B68/4$>9K$8:`F0]X`
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MO1Q8:L&2]S`I7;)G+FNV=0G!59RSE&7Y+<Q%ERP+TK`06\*[>6?>8-AT^&3U
M$5`6-K7+5W[U\UD*NF?9S>,Z)CWR-5H#[`93VBVQK8U3?CE+C3[I6Q:P\(7O
MV+.S>#Q*V;,?CA<WK%D-GI6^2.F,UFOM=8]*F`IE!)8ZH]4MO<ZIRUT*[HPV
MT:/`&:V+;*^<T5:"9[M'-"QW7085EKL8'S$'=-7`S.X1,=>S6.N(6PS!0\SG
M;($CHN9Y=;+(NIG7)I%KEJMM/N'S7K?3H+NYXFJH@8R8`WH3G9HSX?.`K&FC
MO#IG$F36W,]E]I0X)]IM`473)K/+'>8&2JG7N48+:AF3M!Z.!'-!*=O)<6BT
MS,S2;PSJ;\PE]5X(!8_^4Y4_U^P"AJC+]4E:&%V7!,SA;X)P'VPU]]D\W2.7
M"Y]9>74C>M&S!CW(Q$PZ]UD?W4Y[TGH*A@P)WH9*S!ZLA6!:%F,]3#LP)I%-
M[C(SA6_@C!-%M!H#GI8D\!2?F&";:P"3F!UI,PN+P)6=)4G4PN;:FK2:A44@
M:J+*!Z6`1BQ$R5(6UK'3FSAK^8`DR.@%)(F!?DOE-=KD#6%I)U#*O9K!J8.0
M6"3361#,IK.(W\]QR9Y3%H0^%PW^CEBA^WA\-DW2//Q'\3N*4,*[K5>`_B@O
ME%HCQ*XNJ`5*H>)>,[F+'6\&0"FOR-6FA14^,JF9<B=NJ:3,EOARNXWY<FKU
MY79JC[<Q):&J+[?S$7<C.G1W>KNI([]MITP`#GX=:GL#<+HT?+$*K2.N`00/
M,8>K!8YHN5,MDD4V`&=]#RVA:_TQP$.YT([68KB+1^H<K7'_>),_L701-)Z-
M_#<^C]N,GA;U+]L!JAMYW7Z)9`(#\:0ATF@#K]MKIDR'AK($;D<%CH_]V,X<
MW*-1C$-!G/'NJT>O_D;EE;WOU+UL8_?50S?*&)Y]VWWUCUJS^S(EB^SNZ\OT
M.4K>&+MEA4-SF>09RD(XM=L"\@;/MLLMA8;@B)UH`U)87LUH1-L`P@:WV=7H
M4X`B5IMC"V&!6HLXK!6@;#HAH0IU<EA4HJ7G-S[=^Z].*AZN]:ZTCD3/>MV!
MO?",M1=(;:'MYT`(EU,(;@+A&A%8/F*I/PR>G6W/@,8U`&*^C.V<`3J7M-?.
M<7O[F@T[9X`&<F-X]LW.&0Q:8^>8DD77SGE\9$$>OK#5W,%+E5PDO"[&+(PG
M-S#W%+Y8V<RHWPGHHND*(+HK8%EPQ"R?A7CQA-_`>>&GZ=MCDO[PT[&,4+P1
M8&PP9J44@2HP4INGT6TSD?WRT%[U[_+[9:>W$9CNEX?B.MYBJ3_VRSO+Y[#Q
M1#L)7\;[Y2&]'+K*>S&W9=EL[)>':+84AF??]LO#86OVRZ9DD=TO7[)'EJ9L
M#)/&69:Q/"NUOS+HQ>LZO8.W_(9K=PTLC8[8EGE'_JNXN#<[RVY9QD!S3V?Q
M^)*]L"A1Y0>8=N4-VL^V%D1B!PT[(."/Y6_+(C+)E/_77Z0RG+,8J,FS.]C%
MLW,?=FCK#UPDF=&PL/`Z^)2:/E2L/'2LJ8%8+N#NC,@/;XP6"-[`&W8:S!*R
MM!:\`R&6_+<CJBKI3]P`!F#3I\.525H#0BRG;T?4W_UH-I\=HBCYX<>!+)=$
MHS6@;OJ$N#)]&"IJ.74[@J^%)<C3ZA0M`6[3->PJDRA"1":7KEA_GY((WI_-
M;_,I'"B-E$(3[P7.TM2/)VQ>8^7]D9'_QG\ZX]:'S!UJKW-O<-*8B^$]'4F)
M(\.`Z.?G57P'&`:-)?#9HAGQ'=I5T3XXE.>8U'7;-IX#'3=>8=L1I^*!(T!/
MS-%<'OP[MGC,4X6N_:FZ^)>+UX%>G>[XM)W=`K:1^<29%HBYR/=D=-%RTS<^
MS.HK4W>=Q&P1KUX<,-P4KY(7T)*U`>D;M"O<?_Z",VVU.JAY[\.,;W!F:;6E
M&390YR#EGS(CU.Z;P,0C4.O+[4[8B<J(G26\[PR7N3)W+'T)`X8`C@I9X*^;
MQUL6)),X_`?`96F8C+E#.],9BL[>Z?7<ULJE,"@=*X]*6L8\9'%2).*O7$NP
M$/#+E<.\^.`<I&MHO%7FAS'NP^N>EEAZR@LO#6/3;0]"-Q/>9JY9P1;!#.4^
M>"\LA\.=N@RVT@^',^,1F4OE*(EY+RJ'8)TZC6:W$29WBL9%8WB(^0`L<$3+
M_K9(%MDPN?>(+P;;I^P6T"X".GX%I4]G4_Z+'^GE(,B[`#TT'111=14M!YF8
MW5W(#*#G,B[DEO`K?!Z0-9U>8HM,"3[71>._S7RPC'+&OB8IV"6/_,;Y.`#[
M9B[3)&4,B5LT:>X-&@]TL;)]-8)+++`,GS'D\1/2=H"TZ1`8]S/J"J<T"HVD
M>=Y.N[QW9,^O7YM=WG-Z/;`EN[RW>P=8"90?=OGV=KS7HY&F9L:CJ5U>H-PS
MN[S7HYZ^5FA=V]0K\.R970Z8VF*7&Y/5%KO\ZRR?I4OC<G%NDEW.-*Z.-NL(
M=-(J&UVPHE8!3LQ2UX1P%=__2/[._-3`2Z/N"S32*@N_^E#8QD[LN%H?!;R5
MV1L/J]Z\GMLBM"1'Q!9ZVFX%#$?U<0#HFTY:K)G[.6(J3H?=/(X&[[2GGLC1
MZWXD<FA%M/>.7)I?KA,Y"IH1*]JNBCY<+CN6EM.+,AM*\"BX-G;+X!=JMM<M
MX_:22QMNF2,T01/#LV]NF:.3UKAE3,DB[);ADES!_NV5C>^3JRR;K39D\_]5
MS*AZ'8`.&K^9I=;IU40MY)PTN.@\@T/Y;>MU`+L=&LEO)E29D[T-F)P/IC:R
M:4WN=;*NFOT;\[9\,4A14[8!I`12U$R^13&O"H#$:@>5-COGR+*;69[E?CP.
MX\GU3$&]]7=Y/:<W)]>7XR.SW-THC5AUI*HHO_%`.%[`KTAF4M6_<O`VT&J#
M!X7M&(JHVJB5=ZH*]'>6Y6S,;Y!]?69!SA<2_E.=<Z6N",!W@^<8[1BW9KJ4
ME[IJWV#^\@JV<9AQB]7YJ-UY%ZAT/[)X'0Y/1&G(.*1;<$=_(_,'"R=/_)-\
M8:D_80L%L%$:2HLHUB0!J-]I$-\^C%DC52(CN87%?80;(5>CV9X40$.#EQ\1
M&=&VU8F,ZL9<^>YW20U-V]4$`[(^?`PU:!CY'!H[QK"X*VMHW&M*X/5Z^U&]
MJ9XMMEJ5R$BN_UXV-$:NVTB0W/(X_+M.T-O.PZ#;YDSHI33*2+2-![U>I_8D
M/)4"%=$\:W)_Q'CMA&UT7)XXFP4A"`@S#M3J[-]UR;T.]>N2"ZWKQ_YT]N^Z
M9,!$ZRS?(EED`[7FMSJ\KPJ+0H"*N5#2"M`V7OS+?#94`B(63(7(J_SLI.U@
M)^#TS$=[EE2R843B.CAB85+.:*0UD;KBDVP`E/BBP&7I*U4HE$9K0-]@J2*#
M#T[,K#9"8E%1WU@,UGT$8I^-IZ#O+.<9<B],EUFM]H"\P6I%E;DUP-B*8"-C
M3QQ@HW`J8F;H2Y#(HW`H^*U*E7>FX;T:'C4WW,MZK_JUEW96*5#/>]7_*-8L
MLF7[C1>%DA%F[+WJ[V'UIS[YZD]]HX)"_3VL_M1O3_4G4[+(>J_N6,IK6XS2
MQ5VCA=S*7;BDE=<;$CCTQ#X99"Y4P;'FNT**5ZXJRB)KT.Y#`(=.6KQRT<'D
M=UWU>/5*=#X2/>;U!DZ'L'*UP-0E4^JZZ-9\.=;52F."KZ9?U5Q>PK>"Z/DJ
M?F%946]H)8;\HCJT`<C==/UFX4@5:%R!P9K'`]'Y:)8&3^M%ON4:1QX'69NN
M;JBK;RD":OE#M55%Z-.IBJ!MTIE@HY9+4UNZ^[!=M0WZE;/<A[C/IC%SOD:V
M:>PXFJ!=M4]I+LW#<G6#88NJ&PS+5#<8H@ZY!I,:ELO2'",_]$ABGLRAZT85
MM0.H+@]E7;M2<4C48O"W)%7.M\+GO8'3L,T27E6<`.2;PV')8\U;S!BM!=$^
M=<IEK[&8%EX^.(GU/*P[SP(T`LN<Y(-!W.%B'`@US17KF3UDX3CTT[<[ORA`
MIW,@B+4!B&U<Q>1P$,::.WM_%_+:G\*?]ZD?9WZ@%?VG;NP-.\WZ@#5I0;C4
MQ(><\C97'L8]J<26/W?LJM;!;F.^GJO1C7+]6ST#4"C4*='\H,2$;8%!^&BN
M?@B'M1$5=LM>X.^Y*7KW'(6R:W\T6L.R0Z&$EV'HDR8LA,T2SA7D1*((VMOQ
MTA>_9O?).2M\#6,!0P:MO5Z3%[>:,60,"V'(WMV38F%^]Z,9*TO05F,`0J'R
M355^A*@0>IJK3\`_\+F`E[,TC"?SNB/SL77-?A3_)'=QZ73@]4Y:\\F508;0
MVI@#!9&]&)(56-UL#]`)9!Y8(54$#.&T,8_*\A*EQ=:,B\KOZ;Y(LEQ&I:P9
M`"7@9S%C4(T'(:XQ?\MFJ-U%$O.M%0AW[F=2GXNT'4!MS2)I``CACEB2CT;)
ME[,@8!&_$6VS)1^FLGG7P>M`L11*3YE-T\[T@,21-^8%N@Q?PC&+Q]GFQR$9
M(T@+KW?:NBV6%`K"5+,5<!_48_+!N%CE+>.ZA=_Y78RI'_#LM'N63KNJF:)>
M:8"6]NWWFE(3,GJ;K9M;01%X[3),$1V'H[>$-$!+^_QR3:D)&;UT:^7J%PJ^
M`KQAG(5!8?.YV(NIW@DJ;IW5Y5@9R'AKMHJMG0]O$VY-D^+62T')K3,676L#
M&7+-1:DM0R)9^A(&3/S!72=%P@A,XQQI=I_D?K1MYUPG^=]9?LN"9!*'_Q#Z
MXIV_$U1,LZB%9,`Y5@8RWNSE_R&NS9L4)EU^YE[XK>?__MMS$H_2\`74,XK\
M8.TX"3VXL=&Y-R1QT9;!P8X]U`C]]O(4*\J*[8:L]0U*;LVNQS)HA/O&'-+S
M(_ZEYQQ@%5C.ILDLECDG9<T`:.NL*S4>A+C3VFL9W;*(NS1'?IJ_G?L1ES<[
MB\=K@3G9HKA1$U6-UJ5;$^F[1HTC55-OT&"<[.J*9D3*[/QMXU]4A9'*].?U
MABZW[M+Z27KD(-OW\F`_BB[ME&`9TJE_49Y7[$1>BGK?:C,-G2Z3-FHS#7>*
M0ZCP[%MMIN$)L<!I>V21K<VD-YLH9E#]3D`7=(H>V)Y23=5`K%KYNI#*[W?W
M8=B5./4R:,^QIC2HR5P'2*PVN072:$VZ+MES4(D<\0JMOU]>W&?W26_0)5#=
M#AO_`H\-!H%86?"S(.`NAFSDO_&9'`;7F%W,TI1)O2^25E[OF$!@1A5K40F.
M6.WO+7EO\B>6&E.XW@I0$O".6J1P%QR9PN#ZSK3.WGG3FDN$).)-.W:Y-ZSH
M3>OB!??+@_WPINT8S2<NMS5UF'['ZB+V8M3[YDT[<9HN;<.;=H(F2F-X]LV;
M=M*A9=A9).O#F[:T@$]<7@77[)1JJH9]\Z9U75+KQIMV(KE*3`QPW[QI76)W
M^KEDKS7>-`+Y6=CXU_6FT;MD[^:9I_N%\61Q8UQV]I`5&0V2+P9MX_5.B;D\
M32U%!31B?C3IS8[2*4_2#I`Z7;)TB^1*B<`F."4N:E7J%1<X2DA4M`2X!(IA
ME:)1"YF\*CU)?VB#-R>Z](KVFRL.3\,KVC]R^:55\XH6Y-CTBA9@]\$K6K>1
MWS]JN9%?,%_9R"_40,R16M5>[!\YM4U<&/D%#=IF8@&0F&?5`FFM-?*-V7/@
M:D6,_`N0&%[DJV[#VGX.I"20W8:-?8&!+P;@^OK']6NYY0K>?1(V`\3,<X6*
M,0BN[X)\I_8F9KK#>/6H-Z#F!=$>R5L8K#D$+16#CL'H8N]9:OQ-7*GR+9JD
M%6C$9>17LWLR)6YBGDA$7N72+FT'\P6-K9F2#2,2U\$1\TDZHY'69LT5G\HK
M::AZ*I5E^K7:@PH(Q.)J?'6E/)?K&*G=JHFL.DN_[5=0TOIB]$>8/ZTW,?>1
MZ/8,ZB+@R*[B:+.B`'OW<J(W2`<I\S-V%?^:Q/E3]/:5H14M1,]Z`PHE=<OP
MI(!D[TI,I;EQGL2S[!N(G5_%\WH9:KMCMPV(3:!\4&DFU-#L77!9@I&S\;A0
M91EFEFT!!C%GAS6&-B'*+[.L\93N:QC[<1#ZT7+6G:_QURPO5?D#&3?X6V0G
M;;I-O7Z9$I+&HF*'9#K-0,3:S\+,U"<8SEJ8]N'(RVXB0+_GLAB#EO-$GS[D
M"%0.CM@Q5=58\GZ/1F:W0NMBJC`\Q$ZE+'!$R]%AD2RR\?Y%MN5B]K@,,SY5
MSU)VG<3),GQ))RI2NQ.OWV_0HJVR7);%2BRH_PJ6ZI1ER\C`\R1-DQ\@M/P8
M`6D#""G$2QHR@KDGI2!=G[N=^_&?8':C>^3EOWN#8P(&;C65"P`1.VY;A6S&
MX^])!G_<LN<DY;CFB>G!VR6+DRG,)&!$JLK!FW<&2B.0TV_GNRJ+GM@17:&,
M=>SJ*&6L">`CX"VTPZX<(['SN4+8^6I?;:NCTP=HH,&)VMI.1Q\JM4.[Y8(^
M1U"`T=CCK#T-*Q.!RL2&+,@W-SOHZ!W%O;!X5JP6WT`[E=9=X[Y`@_M">$GL
M]D[:'*VZ<[V8++KS%@"/P*F#%6JE".T=V-DA<%=.];X);>/U!PU&%]I84A70
MY(=[-1X9W<T>,O;7C&<0OO`K<YO/XMJ22':FI&KB#9K;E&S)I$S*$CSN]8<N
MX_JD.5=RE2('#2B&CW.E';_RD$Y0+DJ;\7G2$+\3O;5G%4.G#AH;YTE#-!(3
MP[-OYTG#06O.DTS)(GN>M,(XOR.'WW"6Q'P+H3LGBMH!8I<>LWKF11P8L2.B
M+4&5GY[P>:_OMK*P^0R)ZQ]Q7..PB-5\LD88T>G2&G,.ZCU96NJ2Z32)BSE>
MF4RP\RP@(W!:)/E<D(5-C(/8N<]]F//$M*MX'+Z$8S!^%>N8\'E`YM)D<[I^
M20`1.][9D7253<!3"Y["Y_OD2YR'&BGSACV!-IP>]6BO=1*N-,G5`4KMH*=1
MWFDMF74,`&6:7F.'1^<)O\3[\3),60"OR"Z>_#"=^K%R294W!-`$CH5*?:IB
MTG7@.L^Y6EZ:+:\QL/F4UW=:+;@^)E!L-21<P3-?DRQGJ:JZP]:#WN"80-B*
M+>4C\.RE5UDR#)Y"]OCEE04SGDM[\_@8!A+B-%IY0PI7,UF<S)18Y7E8S1P!
MA>.07P3N<R5HG1A@;4`S[?6,R4$AO#7F95D3\MJ?PI]K>8/*G:6Z,<S_3C],
M?8>9G!:$2TU\"*F-.5YJ()66A>"07:5AT)@39Y2&+W[.1I$?%`Y%Y0(J;@`@
M"91CT/W4Q%3*D"&T-5=/9W2C9&KUC->G4+N[&CE;8)`S\\8<+;67C75ZY9K3
MO8TI2H1J$B5Q2E48=5L0Q4E96+V+?-8!(JRUMYCOR9#6;L4E?:KM2M=%E9M2
M137[U&K:K'\#0M\*@@%1M(OB-?<_$EU%KQX%(0DX>DLI>@L#HNC&?!Z7[)&E
M*1OSXV'X]N?U`E/XH"?%)I1[?]Y]05]>@V@V#N-)40/WW,^X,MZFQ<E_/!XE
M69ZR/$R+EN<L!HYRF!#N`</-H_!%\@U)X[(!92[/[YWN<X@H#QGOC?F*EM(6
M-:(XMC0!,!PV3_)XU\^[;N!3+C(_<+3*!=W=2\$<H1',162XR;\%5_I'!GEC
MOK,]'.2T=K__Q*-=N3EOS)>X@5OIGA(\#?`(A.NYGJPT!LVZ.A"6FRL54(@"
MX-DK&]\G5UDV8VDVCW&<_Z]B5ZG7`8!O;6"@"4(DLZ0Q3Z9,=CZ^E<N07@?>
MX(A&FI`)5^9L;P-&V&[,F5DCV[0V$'72KEJQ>XUY19=Q5L6IS!R0<MU&VP!4
M`E%0)E^CF%@%0(1#>R[1LTG*B@T&LH[N/@2"M2XY%D.!J->>(W3U3G1N$ST&
MPCEU@"K7*TQ?,JVNBX[HU=X=9.7U2F-EJ*9@Y1QOKQ[B:)8&3V#$KJ20>_.1
MQT'H!LN^X.-4H&XI`D3=S85-;<U_\#Z-"$9!"X#G\FS+>?PB"@EAK#&WA4!8
M=7P;UL8;N+V7QBA6$:5`F[5U4`AOC3DBK/-&8QUR1:"R+@*5RC]*"T3X/$"D
M$.0F_X2T:%O'@U#5F+_@W8..>-ZS\[<=+_O9#YY458"8WPJ3+:^%^8.%DZ><
MC<]>6.I/V)=76)+"C(W2,)#6?JI/"J]/X=K64L6EZE82,E8;<VXH%6"$_UN:
M9-)=G/VW>0,*U0N<C+VRRD#&6*_^,H!KEU#/G4N+0H"=1DH`EM7W=YUB@94[
M]P:GS>T25S<HEY\0E;4(;;T#%.5R$R,O8&B)9F1&L*NB?:B/.,>D]@]L/`?P
MZ1R+VN54/'`$Z(D53"P/_AU;/!Y%?LSS8M0FK(/7@5YI1+$)V+:]NU5I@5BI
MQST97;1\*XT/,P=%*I'3@NLD9@:GO,HV(#T%H\39YR\X?U"K@UB9R@+CI9]K
M[2R6SP$2.O42:MM9;*(G5KUR):%RVMYZ$M#0*+LFT+&"C'4`Q$I15J*#X`)8
MDA?5VE7B(`]9N^X8V''C2Q844^W]C^3^*9EE?CS^FLS2G#'%,J;9'#`1R&T3
M?@""Q<@(E+4RE!A!?.9]4/L,'A`_WWVRMK9F'/W-8^'[0REU]4)O>$3!S^_$
M!U.'YNQ5OJQEJ-W,\BR'CR:,)]<SZ1SB]K6@/`IU4]HR[!#]V:NV6<O@4QUS
MNGXE*(W"47E;!IU`=\Y+@-I&\!RF\SPDF+?K&G'K[P2UN71;[]^0VU6>O/ZI
M\.CS;Y^YH/R5A>+_/U!+`P04````"`!)07]&FU<@GRE```"I>P,`%0`<`&]R
M<&XM,C`Q-#$R,S%?;&%B+GAM;%54"0`#J8X:5:F.&E5U>`L``00E#@``!#D!
M``#E?6UOY#B2YO<#[C_P>A:+[D.ZNJIKWKIG9A=9MJLVL2[;9V?-[*"Q&,@2
MT]:V4LJ1E*[R'.Z_'X.4E)(HODDIDED+[$Z[;`;%"#X1#`:#P3_^ZY=M@IYQ
M7L19^J=OWKQZ_0W":9A%<?KXIV\^K=^?_?X;]*__\C__QQ__U]D9^H!3G`<E
MCM##"[H(RF"=!^$O14V/WKQZ\^KWB/SP]O79QR`_^^'UF]^@G]^\^>G-#S^]
M^?U_HO^[_/C_T.7]&IVASY\_OXI(#R7MX568;='9&7PGB=-?'H("(S*PM/C3
M-T]EN?OI^^^A_9>'/'F5Y8_?__#Z]=OOZX;?L)8_?2GB3NO/;^NV;[[_CX]7
M]^$3W@9G<5J401H>J*";(;HW/_[XX_?TKZ1I$?]44/JK+`Q**BKEN)"P!?SK
MK&YV!K\Z>_/#V=LWK[X4T3=$!@C],<\2?(<WB`[@I_)EA__T31%O=PD,G/[N
M*<>;X5$D>?X]T'^?XD>8+/C"C_"%-[^%+_RJ^O55\("3;Q"T_'2W$C+T8Z>O
MBNA[,DI;X[S%>9Q%E^FX`?>I[8_\O@SR<L+8V_0V1[_.RB`9->XVI<T17^-Q
M<C[0694O,9IXG'Q;E,<><<F/UEBHG#03^/<5&4-G=/A+B=,(1_7X@%IB5VGG
MU!Y3$PG=9F&GPP2,<Y9W^<WR70H+T:_?_,`L[*_@-W^[R,+]%J?E,B7&H8S+
MEU6ZR?(M->[+AP*6I;+NB`Z?=O\W`]J:^YK_SE!S7&3[/,1&O#.I=L<4/)B,
MB:QYA!*6=IR>?;K_YE]J,D3H$"-$+4KT<TW[GW]DW^\QM<R[4Q#D83U"\J."
MJZK%]V%&%N1=>=9A<)-G6V.95T/)C`73GBP=5%4\47X*'+YZS)Z_CW#\/0`-
M?J"(.WO]IEK5?T5^U8RD-8!U\'#0SQ;,Y,VM(4LQ:B&8.@BBK1W"1T?T-6+T
MY6X*DDU0/-"A[XNSQR#8,:3@I"SJW_0A4_WZ;V3]+S$,Z#P)BN)F<U]FX2_+
M+W$Q@!L-&FO@T1E_'T&T"<HVB#8BUH<T<P@=[2FH\6,H_[DL#3-T=_@Q!ON6
MEM?!5F1EAIM:M3""T?:Q4:U.AW8(&KJU*S)!MVV*6LKS0N&<0#$/DA5QM[[\
M.WZ18H%KZP`,_'@%:*@:(MH2D:8^X$$@;1X04E'/A8CS?9Z3[[Z/BS!(_HJ#
MG&R.+XBY$H!"W-PJ+B2CYA81UA2QM@@:$]<V@H"58W.A$GT;(7IRG]=LO(\3
MG)^3CSYFN=QH]%HZ,!G]L0H,!FV&ZG8^6(M!(?.V0B+AN4"PS@.(`]^_;!\R
M3O@5#[TV5B>^/[[^E%=_1ZR!V[D>E&5[EB6"G-DWR+;;+*4>ZOU30.;H9E]"
MC!Q&(W<4I(0NO`8Y)R(7@E*Q'<<",4+4HO3!1NC,T8![H3U!<X<\UJ1;19B#
M-7$2VJA&)PQGP-_]B%^TY3@4L^"%.-?,+LGG(OCD^R00F8E>&ZMSVQ]??W*;
MOR-HX'9V!V79GEZ)(.?6W.;\3+)%$+1UHLO]\0J5FC7T9&,@E?:0HDM$/3<B
MV(Z$#>`]^=U0'%+1W@DRAL8M1$>U=ZQ`0IO[@1"A](=0HA"]':3`WE4?)ZW6
M#E'2'K,*(S2^X!U".*F+\2$0^;R[CK_@)/GW-/N<WN.@R%(<K8IBCW,!1A0T
M#O8:XO$+MAE`</8+4*":!#$:'S88BNG@]Q9:<S$OA/Z<)?NT#'(6&A&9%T%;
M!Y#AQRN`2M.01:L<VQ6IL'E@2"4]<R2#A4SO\"[+2XBEE$$I7';D)"ZB%Z+1
MB^(659B[(4",P@>TR&=B(%*A,0T.3MQO-N_C-$C#F#A161$K<H/,R-V=P\NY
MZJ.M(8-C^880U91>9`B-F3CAD;WVK#D`I"A?2-30'<A$.4('.#E/#))+5X@/
MI\E`RZ+`9:%AA/H-K2.!&RD7@:,-E/9C\D"?<?Z0-?FR$\9[?W^YOG</UV$(
M].$JFW_;<*U6=VW4<NT=@9<?]S"&%XTOYA>8U>,__W1W=WF]1@S;/_D";@%@
MAC$N18L]J)\'Q=,RC>`_EW_?Q\]!0@95+,OS(,]?B$O[YR#9RY9N37KKJJ#+
M%P<M0H""-$+TAQ;I`@4EJJD1)7>K+),Y#.$'?""=B9T==QW('DLP9^431@_X
M,4Y3F#BR&X!?O.!`$,`Z$K^'JUOVN<7D;TH^;9I'(R/3-Y<C+(P]\WE!MOYD
MLU5T;+K$7`K:6S>/HG%SIP95.]1S&=R:/MW1WS]E>7E6XGR+'H+T%Q15=.XU
M0HJ;O@9H@,9)E`E4\GV2?=;9V,G)7$:5AKB01I.H_:44OD:1A!,CB1XI9L6B
M1]JZ>W*1;8,XE;F?`XWM^YI#(U;=$6(-/<"-6-[<2JP0M@,C=!6G>$5^U+I5
MUFKLSN"T1RR),D(S1-MY`!&QN(4&12!K)^L4!>Q3ED0X+\"%+%_,%BP9O<N5
M2\J7=`EK4_[SK][^^`?$Z'U=T-0S*%G9=*?/`3;9<,ZS[2Y+Z:Y&\W[L,)T[
M+`KXX(Z`&<@.[?R[*BN;$2'&U--A#UO7N`17[C;/GN,(1^]>/A4X6J4W.RB!
M1+;+R[",G^,RQL5YEI)?[,GOJC]FJ8XG?ZP/6$?KT233AS7IF&T*ZJZASM2W
MT#N*T^]0\P%T^`+92#??0(>/>!.)GTU65$X;NGD"+419(YR@Z=*].3BN$O7M
MQAP:9-7`K-(PV^*KK)`M5KUV+M2],\XAK64-T+?0Y#NT+,L\?MB7<%*.R@S=
M!NY#72HNX-?''J&X+)97PZP$6;;*2LTP/LMFAU>M`>LATBN;'FS?IY:ZK7QC
M![[JP(CY39)@7V35-!B<F&EQ]2Y(H';D;`JH8R"T!DI-#2K@TF=G$C`E<'U>
M9R)K][9$K*'\-D:NGA;S;J+_VA<E[*B*=7:'@=,XP1V#M\XT72>=M)U9/F<_
MZV<>J7%)0X?/@`5L/H1X1XK\V7`_Y,W&QXTP\T:8"?D`_"8E0J7G^WLFML&-
MD@^93S.J+)<X-;N^6G2@-&I62-K:=Y\T*E.P-@MU%0JK'I+&P*M%&WU+](QZ
M'\5WSIV-8P[;JM^A*O2AB6JK.3S$_L8TNB)/W6DU<Y&QTQ[E0*).\V?GR3G3
M!FHY#X>;^X'T&\'$3RCD3)UN>ODTNMCG!/WLNOM-3C0AR%^8<K"_K[/WV3X%
M[UR4C#NY1[M%GR?Q/KAE9U>2(\2ZJ^L?U!W6U9&J1NL,U9W.FL<K#4P=7Q#0
MCBX'V>;`.5L6P*'<5.0S,1M5=_,'K>@L_%:1F7B[(VY<G>_Z#(WA'UDC`8J/
MF$U]2PXH8E@!*K8JOW)<*WRZ2>A4$#^6/;#L$[\+B,L.1ZDX+51+LHC`C7<\
M-/)!%_D,'E")4+NIVR5;?_A4F=CP0^7PK;N=0NP,^IX*X-A>W-EOC[JZUUV>
MP/+><'_<]9W]Q8UVS2`,S37>PD9VOO5>R/SU?ON`\_].BWO7)$Q?W8?L@>4S
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M5C`G8P9CH=VQ+]9"7Q)C''.']N(8?KLUDW%"/OVQ[<<HC7&4RKJ,(EJ0,TAN
M@SA:I95#=!%#EEH:%:OT\DN(X6[]'2Z#.,7199!#N2*9)3G:%]PFK$Z2C2*M
M\M`W@L[!%Z^Z7Z#F`_!;]@E0O/HCJ/[*O)=K5&9F/E%=8+P%`UP1N[<>1]88
M:?+HL=3E^&>$U"VJXSLWFVX\W_!P4-&7%Z>"*GX-C@-I5ZB)C=UL^@>$_AT#
MFG(O.?\[1/U^_(TRPN[T^,^4Z3&)/J=R_J>E[CH'?P:Z/L%H\4&>.QSB^!FN
MQ17+-")NZXX8U,LOD%,AME?&W=@U5>9<"D.==1?@9+0ZH1'`JAM4]^/&TS@2
MQWWF=A5S>";F3.S0=.[63S"#=?@Z:L+7+3.3-^]9,(,#,PZ_I[<C4;#-]FE)
MVF/T.2Z?("B<LNJ<Z-LLI_\X1(G#ES`AG=/Z"$&2H%V0LYH105%DD(A,#!ST
M@NBI?D(+TL+[[`7<#((J$N534"*B^"B$BEWQ)B8$03%XA8A.5C4ZL*:'='RT
M):-Z0;O*<0ZB9[KR;,AP'[.,^,WDAP+GSW&(JR\^4&'`O9QL&X?H`:=X`[4C
M@62S+_=Y;8P+U]9XI!WK&.))1NSXCN,AX^,(GJ.J,R]<1R7'!KYC*X/L9)Q'
M8_[-O4?/$\F,):!*(3L5MU%/V77\1A--=WF27M7`I>?[K`ZNT1GZ$+D'I^>#
M7&F>FU>T565FMV&JD9Q=9>DC*\]<569V'X4R09[Z"%P%.ZL:E6UQ4[%.+Q%E
MF,*%W@C&/J`J4(:@54?5HWJ6BBD80)-:_BY-\C(,8=M0W`8OX/.N\R"2O12B
MVX$'9EG`F:9AKJE11;Y`M`/?<IDTF:2_)[M`VLB#'`4S'*I-M!J$3A,(Z<K1
M':)9\N!@!Q[HF(`SW:1!H.8TS3<5T^21,1/4S/BL:S(\:F0$*L%X*G5R)3HX
MM>,3JXL[M,L^6CU<EQ7K9A&+LJ23>Z4_CF(<M^:M9T9BE3[C8LYBVL8?\,5H
MF$O&T'@T'SC]8MK39=4OIATWPCD!@S)2B30-RR0-LF=@[G"!B3CA@;L+_(R3
M;$??$V!G1A*[H:"S;@Y4?/#'Q:P]/7YL4=2'X6X5=A(W48N;F4^_M>XV'&UJ
ML&QJ;!H4+:7IVPD#C9EP.$LV-76*8?CW?9QC^@3A&N?;=T'Z2Q4.%AW&:A+;
M/7S5Y:@/HYH.RG%4E(B2(J!%0%P?83A,?!G+G=G+DG8.2<?R`LDM=%^2[4MP
M)K@TDV*86==GHT:ZUCD+':%H]EP";G#$M2'^2OER2V:M).8+\B&I\9+X!R:=
M6'<6C#@4VI7R8%=J^@6B/2SHTM5TXO9H=!JS9%!/$/W,-FA7T5'FL)PYFZNQ
M.5[[2_-8L-K3R0\X)3N&A`QE&6WC-(9-`]E68+6CKJ2TKGUJ7OHHK"@H\+HT
M?KCKTS@*NASYX++/P9![0Z&I1'WK8*1!SD.#[^,T2,,90X/&'_`E-&@N&</0
M8/.!TP\-3I=5/S2X:81S`J'!D4JD&1J<I$'V#$QS-*+UVMY@:^NJ/SQF[KR[
M.??J/!OCP3-VIN-/O'@V3H*4ODHH86)QGYMG(<91\9[PT^0?Y_=!@F\VRB?E
M=(CM[VMU..*V>!41,].'%/T<`2%L_"[G?/U,<YT:Q5K[OD'KFH%[A=&''K=5
M-<3=J?BCL_FA)^=_SNIW>IC/,DTL-&Z\:XGE:_0SY_$O71D*&#+93,-_P&(]
M$]L%V7CT-E`_94]B%LRZL6X$#+D<W#Y!,(7^T.IA4=\8'$A,=:G=$_EMN(E3
MIM/`._T!'WISK\=CL-O7VO'`M;B89VG6]=35D68)C?TE6#)^;AEIM6TVA%7S
MF?>$RB73@(W*Z@=)$T&&R[-`\YW$Z[6ZNYV?':MKNDI'N.5:3T'L:3G;,,`+
M-%E*;-!%M@UBV7-'@O;6M5LT;D'AGJ8A^IDU]>`NGE3T?>!HR-VB^Y9MMUE*
M;W-_Q'";7>:C\6WM.V(#X^5K7T(;Q.HS_,R:>0`2H:@YET(N9YM5)P?KVBF!
MHJ!S4"%2S@=?][%3Z/'L4.C1(SAI30Y?ME![9BS"+`SWVWT"CL<%WL1A7+*2
M$JW$ROLR>,1JW!EV9!^(IIQRR#QT@*H>ZBHC[=Q:VHE/6!TUPQQX)TROS8.(
MJM8R->"M&J"=^_<K6GY0>B1ATHV#PPDC+OECBKH@-5NEFPX6]9[M4'2!=>+Z
MP&(2NU5UW,B;ZKAC0,H?7HQ%J-5CC,/1Y/(YB!-Z*S]KN5A/60*/V;T+BCB4
MZ*-Q3RX.*@QY'0K!=\[04=,-Y,>V_>JJIP6B??D0C9C,/1"BH"SS^&%?UCQ7
M-`,USN;*S2<K6TI]M`_[.((#P=FG/!EBO/\T0%!4-2FQ!^9KI%H/G+B,UVF+
M@9VJ6/@MSNN7AN,0+A[%R9Y,ARS$HZ*T'^Q1\L*%?2H*."EAQ1,KH\-NE#$Z
MM]Z!.5,'!B+6ABEA4RJ15DJ,LB0)\F+^\MM:6<3F3#:VY<`69T87\/QW5Q3N
MS8NFPG&!/1-MLV<^_H+CQR?R_25!,]D=L:*5-QLZQ)M#@5Y]JS*V0^O&9C3G
M?237':&J)W2H_%F5>FUUYYUY.KX8@DH,:2.&OKM0%R4AJ^MN3\_B.#T?,GGS
M%H?5LG-'D]:]2!*IAETLO#2,TTQ)WUX>PXZ8FM$"AZ\>LV?B9L?,@I(?^H:3
M_.IO%]45V56ZR?(M3;&YBE.\(IO:H>PV-8DUXZ<Q>BX\435'K?;H9Z!`E,1A
M!%%W+FILF4V$Q1<`]P]%',50"IEF=]+-Q?)++'W<3TQC_]T^R?@YPU=E&E<'
M<-#*@QBT<@:XE^+TQ#^AO(.TPO_Y/L^';V4;T-HM[J#)C^JQC_Y+)@M4T3HL
MFG\DUBR]8R+-\3OEJ=*J7#&2M_70\RIE1LOW$PK(/>D_ME*]'O40)/1B0O&$
MB6L7!246/<.R0/&&^'[I(\ZK%UG@B90X(K14%D2`<1HF^ZAZA(7\H2GDF3=L
M+5":E=4,)%F0=O\6%.@S3A+X;Y"^H(R6`P61TRCFH67U2@/Y79`DV6?@H$"X
M@`A@3#B)Z$,K].V"?;[+6-6`'$=[FHY=[,.G=E\@J""M)<=>C-GM\NQ+3!9@
M^J(+CG/ZO1P'2?P/&F9DKVYUGXRA;YJ31NR,D_1*S#L(B*4Y#[X?$V9%6;T9
M4^6.#[P:0VC\>C3&Q/AWRHV86WZ+1_FT*OTU89^-0^-BLIC$_O&\>/3<03QM
MND"'QMY<`C;@XNKF^L/9^O+N(UK>WU^N[W]R[Z:I$,0E!6C!QYX&5.5^BOZX
M)!H@)K&N`9+1\V?:K"GB5<$M_@UX\/#%$!5^^OC7`X_5>[C#Q7:NL3S=14;F
MXNZMC(N!6[?MBE'=@E%$,XZ?KV]\WW8,.]W:4+/<.S")S!IR032#.*BL\!RX
MB.YU6T<W!JX(:RJ&.R_/P+OSP*O3\N9<7K[3&#!-B:$;2;9\!9)7NUQZ;[I>
MFULD*_'K#+5"K+K'YQ`J;];+JVHKX0L6Y0ATA;NK.'B($WJ9F]CT=J81NQVD
ML6_6[\(Z=@VXXSSR`VGC11%'Q)>]]13.5LMWJZO5>G5YCY;7%^C^WY9WE_]V
M<W5Q>7?_S[]Z^^,?T.7_^;1:_]6]XIB"LZ]:XY#I1/G.M<-4,B*7"L9S(%&I
M)CSOHT*I.3G_='=W>;U&+57R(&*EAI-$0:18LGH%BWNV3GP`J47EXG*5A(>!
MFU1#SRHZ/FL<QXO.HXIVMN@3QNU>D3648.!*FIX&.%-E^DB>L2IWJ5RK<H\'
MM2I3`C]56<'+\..-3G=[%N;"H98/Z8="R\7*X=*'-?)=O?!9-7U5E^#7&C0+
MQM7'P,F!Q#W8Q3!1^Z3.4B7'1$.\BG\8Q07:C:LX`(MY+'LW\FX#KW9N9DP*
M@AT>;-_,XQO^131:%Q;_##E5$D7AF[JLX5./5E;"9X%HJP6M9NSZ+HW&V/M7
M8;(-NE[=H]>O7K\A_EQ>9;V=H=^\7KQ^3?^?1CK?_';QVS=O%V_>_MA<N=V7
M3UD>_P,NW)3H`H>TK@5Z^V:!``>4BOSP=H%(ZQV&\J`X>?D#>O/KQ0]O7R]^
M_7O6\8^+-[__8?'[W_X.Q52`])?9X7Y%\SF#;[A76Q'D)<64!O#NO):2;$LF
MHO"E?M*0^]^MG(0.E9,<;\+&<`!YE6>LA*F$!0]J/@GW+3H(LODZ;1G$*8[J
M>[)\/1^)-N@0.WBG5H,C/H>>$:'F9ONW`V6=YKH#J?UF[0C.VFQ$K)5[G=%'
M'?_&JQGD_#D^GG!L[.%QL?8QL2>1`ETF6+K$UW,N//8\V%V@H:I1=1]BXK#'
MF>H^YG![!^&%X7%SF^[JS_Y<P90)G-]E*Z7M9(-]&^0W.1U<1#<4=;4/O3VW
MF-KE-ES"DWQG?@N7X')6K"]B^_1#G1YO=NKF[!6,O1UCKV#LL8W[N!H]CK;&
M*K!*=LMZ2'6B@JRRQK()C^BI'D_E4N4&>)"K6E5.Y$#AC7KILU*I%1??\DIG
M1.B2Z(H<6@YUA(5,3?2CIG"O&\W8=?3"N^BP'@\=A5A4`5H/M:&+(Z4F#('(
MH1:TB@F9J$*'S+T^=+G04XH6C6>:H<5-3STR%3=.=60`94I%$4+,]K,Q]>N3
MM9>WI`49)-HB)W/TB(R0"_YN8+]8_B54^*!I)]7Q>]W7XK"A0:P_IU4XS?@<
MR8O]MW/D^!M^0D<'?!8?V,X?@S3^!RU3<IZE19;$$?T'*])1U%5K;C;-8UA-
MB(-[>WQ`X8[4O_U'O(\D%_Z8_=`O?1_UT'-=FJCI&\[@#T^0';I7)M/85(2C
M`HA[J?OXZ#D1U;J(BS#)BGV.U_A+^8X,\Y>YM&SP4Z>E<,/2FD7W#I]"/\/'
M$/W:J2NB!&Y'U4DEUB;4);P/GW"TAYJ''W"*\R!90P[B@-9(6]NM/2@<,W\J
MPAJBFPVJFA+\06.'T-,0>Z<&F([,K5\Y(9N86X+A$,[Y-.I^28A<73@9YD!P
MQP%2Y^K67CD2ZND07'!0SH7%L]GX,8TW<0A%3[C!Z2SDNAW8/[W5Y8PS7`="
M-`A!KQ91LPGD#G]'S)X]<'XJB.&]+$I6VU("PGY#ZV#C1MH'U2=6U[-ILF!X
M>D$_5__U"E3#@N^#1R9UFT^/?6Y!-\]2\F/(?#<F6O:_.K;,O"L'CX\9<\L_
M%_.Y8]<ZG?B-R[%SS3](-66B)WC\T@V&&J@C^K"[.S#D3_Q\O6#_J@O*R5QJ
M%<">R&V+,2C(?%#)'>,RQX]!3F^.;`@\JV1Y=OV1_+5^[P0J1U?5K\G>MBF5
MO2_B%!?.JR^/`7QG!S8>[18/0H/B:9E&\!^(F#\'R<&2Z*P[FO3VCT8U^>).
M%0D!C4_1'UJD?J\N1M/('3F:S^&4R-%3EI=KG&_?!>DO=6E:S?5#C]9R5$F/
M'_[I)T*&@`X!(6IJ)7NV4(QD3[5`0%'^`KIFQ2D?0`15@67GAM\$H=V0FS$\
M/2BZK&_K];OPIQBS&JF*PLP^6WW3.=4N'#R7[8=BZJ`?AF9?26;7XJNY&"HB
MSVR]KV;>G*>NA8<ZPZA=)K]QY^MW<9[B\*EZN087K;K$37M8$K89@1)ZQJ0Q
MO!BS3R-X.[)Y("?!`7U!:,>.OMBM=_9N#)3O=KUP:,*[LV888=OF1=P"$];!
M+VPE0E5/R+`Q2E8*+6H'5W%U>.+OXC(J]EAK*RFL(O1[B3"81_YNJ^$DVD,G
M>Y)]'7S1=U[$)-9Q*!E]'WRL*2)M_8:9:D+ZV-*;#9OYX(3-M&21J+NX^.4\
MQU%<PD^RX(>,RD$VN(P'/GVZU1I!HP5B!-4_?(:;QG3Q>=6:<V4/=.^#.*?W
MYEK9.ZNT*/-]*YPO@9\FO74@ZO+%A=`)775!M),0UJ+U&Y9&$]H'Z(C9M'@#
MH*IO4>=1ZZ^[2DK[]P"4O'`I\G45EB8UWF\<:LX6ES)O,E43H@#"L$-](!]]
M*O!FGUS%S[AHGF@"LPV']32-31DR..XW[,87CBP?PX!7\Q'$OH+H9Q:H_2%$
MOU3E1/H2PIA9;*3!/@ER%!WB'A"QR.$I7[)<16WQP`GF(XU^0(I<_/A$5#9.
M,=KB\BF+4/:,V;.YN)'UGLDZ@;'5D1/V8I/KH,8<VMJ)@,RGJE-.J:399=)<
M9PU*RR=4.KQPYU.K#]>K]ZOSY?4:+<_/;SY=KU?7']#MS=7J'.H0>9(/K3U-
MW8,:PSGRX)CFW<N:?%M1?DB+VI_#F0Y/ALL44'I3M<A@UK3/8$13-H?C=5^M
M4E=DD2+>'VR4@T>AA3/NQA/W2<BE\''3`>2ANA<$W:!#/VXNS\_#\5+"<<</
MG)W]:9Z?-O]WN#I2*JCG->C4A4$25I4KF7]7^W9HM&^'HGU>>XJ$@SB+O/7V
MY"9"SZ'3L0_V*V2^O,_R3T0R.93RI"'I@I;$-7@U0]V%LXJ9&MR)*F>R+)V&
M&$XA4$/NT7,MIA,I*CYI-HL3UN$['.+XF;[$Q>YQ0AGIZF!-=B_.A-CNFJO+
M$6]W&[KZ5C!0UF>K?ER:,Y^SCCD<,6$>[#<TKF=JT/JSUY"`4+K3\`*!QK.E
MO<L8C[\QMDVOT,+(?CRR>'HE$I3&SZC\@1U7^PALKZND,,)5+Y8:)D&\+=`3
M3B+Z[V#+'HJ+]L1AKA/)0%+4@][6[]^Q1R2"Z!DJ_;".V"L&]%T42`P#KSXH
MT><X2=`#^3H;;T1^43XQYYOXXU#B";SS>(NAHBN]G!)6=U98%C,J\_CQ$5.7
M'3_3,`2,INXV?`KR1\A)>R3^0U$B7!\;P6?("#.R2WC!K%XL])YF^39(6NEM
MX4L(S^'%+)T.YZXW`V-U67_Y.TJ)BIE70K/J,&;=^+,^ZNFN?*GTMES+F+G5
M7D)/`<.3D.LE7L>C5/?4T@N`CH?E\<_$I)9<>B:F0^F1^R8Z$U/O5KTX%-.?
M)_V%VNFAV*&4D1CM`OB9=V&_VHL^=V,,G0?6S73^N%(OHR9O+DL'T>M5B;=#
M![%&U!Y9O#9/YE:/G@M1<J]-'S=Q^N9/,&L>>'8?\JP8E1)0$?KCT=6<&"8"
M4#*7]9:-&3K/"@].3?00I>UN#L#):G7!P[-[AR-;\G."JVJ9RVV6EU4E32$3
M$CTZWB=<5"X\EG1DSSFV^Z;IHJQWJJ_M_A>HI]&+KDH?6Y=_9%)*\2,,4Z7-
MEH35SBQP;PN.K3\#Q2-G4!X/5E^9+VA"[,\J+/,$%=L-+]Q`\RG37N+\=0(A
M4_`BVP8Q=VZC%6-J4?L#Q`Y/HY)#&;7/6.3G33^\)YBT";O>\VR[VX/+"]])
M<%CF61J'S1<_XNT#S@<`9D)L=\^KR]'`VT*,C@&KH6Q;.T;L>L-K-&>=_>Z(
M";.0%J!UN6MD9Q[%6R0<3\L2\.E"UK$D,'#SJLJB?89'?_<%`D9H:FW>$Y9Y
MHL"F.IPGHP6'%"J6>9&8.TF!1AW(3[Q8=:PZ-,U@KW&ISL@5M'=0:V9XW!+M
M7B#24I%6.WG<FF_QZ0[_`Z2[IW1!K)YJA0?2W'M<4MCPA6Z4F+'IX[?U40UX
M07L'?OSPN'G/O;-\>8)WT]%7&60>(%V*%WXWH03+7'=FE:=FNM0>W9V5Q4J4
M]V>]B):,F#?]B[3.XR7W(4[!0_R4%CL<DG'B2!DED=`XR`P0CY]_LXJU7:!6
M:X]B(,JYX`_]M2;":O3M/63L"N,@HH8N8FK=D0Z$SQ!MX4$80R[>@7B84+86
MH1"\U/LG8O;R?9#H/&<FI;(/$BD/'&*JUNPTKVKOU]T8]9QP8-*=$.OOY!75
MT.J1X:B^I!CKWJ*9W*.K%_9&\"YX?J]`55<'U)(UL=6;OQGK$W$@>+UO&@A<
M)'SJ#%P9-#Y.MPX30T=)0?BJ:;9!V@KB8[+\,=`A3C&="HT)&^B;\@GGO>]+
M\^HE!':WR;*1<R]#K__M\J[>$]^CV^5?E^^N+MUG*^M-06?[JRG_(T-"&4I1
M$+F'ABQP(H*'/_$2K3E1XL1Y=.1RNTNR%XSO,$W,:IDW==19@]9^75<-?KC*
MKA7-6<Z(VFN?)Z'I*6RQ[=HN>"$?3.`5)KK'<;^":T./*U%KACNK^[:>CZ!6
M(@F-B[V7</P#NZN^G^B)KHSAPI^C'"6&!G9U.@!R\"['82^I$1>34KE[G6.0
M!_$#'9U8@D=Q,8TY$;[.H9H0I\@R>O7%CPB7@@M-<'FU&=>9&`U\>11RNL`;
M3*QH1,:WI%4:E^G$:)-ACPX#3::\RV),=5\4OZPWZHZ>3GAI%!+$D:4),)@0
M06B435&C@6]G-TXP,$[.'EZ?WWR\1.OE?WA3@%PDW<[V7R[:X\RM,B@TW-;9
M',M"0-UY]B?P(Q.W:,+=AWDV&QR6\3-N!@7O)IQGD*JSC]/'&U9^+$ME=]A,
M.K$?^#'AD`N5U,2HY6T!/;K#@`EBG.M;JZQBL?L%RGQ&N3#*R.FTA]J;NBC>
M5584YT&>OVRR_'.01S*4RHBLHU+*`1?T;FH`0FO4:>X><.K)Z`-,=R8L^O<E
M<:J>LB3">0&7G,J7ZZS4B4ZH".U[ZRI..*>\1?#/OWK[XQ\0(T-`YU6L0F^2
M.`_;8(9<`\XL?&'0AR<PU`MLR!'I;:S#>$KUD.I3%`3>_7L7%#A:YCF9,4S?
MGEQG-P]0$_]#ED6P:;W'^7,<2DO53^W0/IS'<LYA&SHZ>X">4+LK5FRX>S)W
MG:6X^857AG@2#CC8'P$$+B*!AW'#96F<%M0G;O/P[N70YC9XH175P<W1+T<X
M^1L.HX73Y2.+'[85J=U_5ZL>7CH-JX\@^A7W,:+9,"6.,AX54/:TC@N.CMH!
M&O5B77/,>.SKQD`\?8',-XZVSN*G,7O@*P&^0FB.JO;NU7D$6/L*.QJI#E5R
M!96YR`I=W.$"$Y$]D57[`C_C)%-5SS/ORKURJKG5TM`X154_J.Z(^GZMKCQ3
M5'/&.XQ%AZ8>)=>,!;-2;XV0[%!YX;B]^EU]_[OM'Z31.YSB35P6PPX$%"TU
M4?"C?,Z]$3B.U+0,!4WSJ/]P*(_0]GQ!O>H/+L0.LKC`K#.;,K,<XZ+8TZ(^
M'AN<(RJ@TB@=7?M<;@0@>=[(YV<$[HU'/7(]3QX:>Z:U(@8D8W7KAK>AHO:X
M>9PXA+FJD+N(P#W,177.!V$^:[GVK`P28Y"+AG^-2^++5BR4A`7Z9C-ZP&1?
M!J7GDGVU*"=)]AD6'P\50EK+70=1]A2"K#_;N*0!*K(^L5R$1YR&G9O)&B<.
MAOU85Q]3/@=JD];TU!_L].!K$OJHR>WC=<+,>@9CG;-?TX[\!++L%%@?R5Z=
M`H^;X5%@=GX>?`A*8K)'*&XV5YBL%(99#":=.$S3TN!0DK9%J>'8BM&/J<KK
M)J5+=V+%*5YFLSJI0'FE)64K;9YJ3Z-+TA1W?7K;9<JU^>)LZ`VM*WAYO497
MJ^6[U=5J#=4%E]<7Z/SFX\?5^N,EW*)W?A`Z:OYZ]<K'3-Z\:+M2)=V;]>$=
MZJXD2?JZR+OR)GU_S(2:0E`PF\Y6[#LRJ"H"^#%.X^U^"[\)$KTT:E47KE=K
M&7>JM7J!H.TAT%YU@*H>O%NBE3.I6*`UI]$>4NFPB/:P851#D\!2T-XZ!D7C
M-@.<>WQ)Y=\'DX;P;=HX"+RMT@A_P=$Z6Q7%ODFH9?^[_!+++9Q>!P[LFR9G
M/-AH++*B1&6&&"W-KB[J].J?@=J+W8?)!/*&S7SV+`;VFPW0I%P\C7WUT;]D
M_RCAZ++BSB`Z;\8<+:74K\W\3)#CS@OFQ)OM4B+W95#2@5[!EV#L\B5#2N6H
MD(B(!T$=D:8YJMM[LR!HS,EP$1&-"7%Q>T:@%"*=8"M:<;,OBS)((^(S7N\5
M1>9G^);#.S?'DY?L.H[(Y$LM/N18TZ^1'P[?6R#VQ9E.LMF;8P3<>:DZS[8A
M1/8'6$$KHK8H4`"'XH]QFL(_2)L7'.3HVSA%!7RW^&Y6&5VFRB>=O9`03B-]
MV;BYZG5DHR6^!3:+Q3H=,_^!-*1YPQ3`JKR?6;YV<J9^6&9S&GOV19J^3[\Y
M;^J29H:>'3'RQHS2$6%]599+HH?'MEU*)3P=Z_5G7!`DP*/!7W8X+"$"`[^R
MZ;OJ#^'D[)R!=.<T?FP8[/7K:B`04X1?VW2#+5G%"4+G365+=+@ENF?RZZ_+
M?)H:@F/;U'%6X'0,[>47G(=Q`>'&V2WJP+=.SG0.R6M.&]GZWLQFL,3Y_$90
M1WR\M<,'*MCEPLOIU4X7?OSZ=KM"I3RV=5-HY`F8,5ERU#$[/QU#)4NGFFR9
M/,FT.CYLCJ99'N1FB0^NU^3CRL>)=3OP*F^AP]FHO(4%@CX\>LS8;")-\A=$
MLVC_62A:JXX-5?GBL83&V3-00^,7O9.$:./*J?'H363E7(C>1U),Q`EX#WS0
M_R\X?GR"'=\SSH-'7#E(^#:/0UG:H+41G(X?8BQ;:X>J]3A0-9!ZDX41'<I7
M==IJ*/-&-$$E&ER+9@<4>B>R498D05X@PC';DWU-A[/S"K1_@*LKRI-PNL=9
MVQE/>/5-K4=KF3#G;?`4:*[U[)BC\&]-.ZJ,QZQK\OQ0Z0&RF]7M6(<HLTI>
M98S;!]`G:7F/;QN,K>]<AL$C"SSYR,C1)F/JP/RSTW//A!^GWZ=MT6W/D<K(
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MOA8VF7^"H-^X5\5Q@%74O3)"JW?*N4K7G[._DH7/H&";3E^^JFB'W]%:N@`U
MA9,WTAFBO9V$?DJ9)SCZ[<FH*`_;D5HJPJR/BDJ^BH^GJJW>/%;6-L]'4%?H
M[K045B8`@JC?G9+*<@`>K[0"]'JGMM-5U5_UG.KGNGREQ2F+'FKG1(T\6E'L
MY2-1;!J/'BZ7-M3(;EGK_@C[^&C^[KSXF5B@G:K3$FE:/%J%"P5/61(U-U7N
M\#-<2Z5_N-\EL2R`H$5M_TA3BR?N.+)%16\I-9>4*NKJ,@FE=V]?#":..Z8R
MG;5CV!7A*=%P,T>V17@&U+(NSL]\9((=MC"N3W22H(0#S[Q\6>=!6@0A/>[4
M>/1+3>K@+$?)#7^00TD0I4%M(J\>\]*=)_X$QV22W./.[)4CHUZ\0:/>.T<2
M8'K[3->(6=4%[)QO'*U22'>D[EYME87GARH"NXNC;.1\JD3=%K563.=G@GHS
MT%D[-<4_`1&W9):>R.9.$P_"YG;1(!YU'PMU2_^0H)!\!P=:8K>X7PN?<+1/
M\,U&9,1H'7N=A<V\*_L[.7-NN6U=U07D+\K\,`_+_X^=:VZ_-VFB+6(;Y_#N
MUFU>O5],MZ/*)!LIE7W$2GG@P$E;HR5JVE=!!O>&TF!2.+SISHA/9O/=2^<O
M@N<F)_;GH0$=YGN<%5U`NG[WS\X?J#P*`LPMJG+ZW6^#NT-4/)-BTHDWF^!!
M#N5[8-=G!^,G37>3JYJQ"3N:8;6H<B;5CNF(/NSN?0SY$QK1F[X1K;O0=D,G
M\QEEX1YV,S3A?R9^28-]$N0HZKS5E5><[RCGN.8\VN=PMLOJR[QRO$$<`^3.
MKG$\BJ>H']PMXO:K]+?%.GN':4&Z2*AXFM2654Z7I\';A8B/02S8?<("+B`_
M8!13>J=*-I;#]1-&:5.XM^"Y0D$89CFM<T1^#9?W:".TJX42U%]SKF]&R.UJ
MV@C8'EW'_APD>SQ6Q3AB'S2,YTA?P2BMY_JEY@_4ZYER`MI%=^5?DW()(*NA
M6U*\6LY<84.XH+X#*V_#-/\:?Z9_DM:HUNS`3?Z*#F>#*2RLT&Z$&&E3HXI1
MPQ67SZS%7)FX>D7MQ[((?P@(YFFM>E"_('^IU[[]+DM1G,9E'"1$#Q^2."3-
M-IC*(<4E^O:?WKQIW5?WK(*]$9X'<WH,P>Q<5ZDEF:"J?7I?-)7CRT11*;'G
M>JID\)AJZJUJ#L-74S-EV+6GF'4J\<VF&29,VWE6E#)]E)-95T,%%]S!=)TH
M#B^'-YI(X4I)W%Y1,61FF:9[HD>=`CKOL0<)\#K0ZNN*/JXLJDCG&.L\2R%5
MEDCY75!((^8*.OM*HN"#TY+ND>0"'4@0I?$`8CI3PV%,?UY.H,+9,@QQ`E=%
MNI2@,3)_:I;/G4[M,KG4CO^$3^M[W1[@B^[U:$[T':U&EC;T'-Q%K`/[&AGM
M$AIW]PT'QB^^?G<XK%+DKMORF$S86&ZS/;A^(<'8(RU#^A/ZWQYL,910$EX0
ME./(GC)<Q,]QA-.HZ"ZP$E404EA7!/'8^_AI6B[Z.5ON,:28@3Z"M,1OV05Z
M4"\,#\:/3-QAN/U$?D^</:HB9,.TQOGV!Y6'9'LT;APHZS)W]^I0,RK4&A:"
M<;G77H?X'_317(+_=*R.N&2KB-4W,UJ=4:,Y.:LS3N;NRD]_S59G`OZ/;74F
M@_\$PCV\@5T1CN*TB$-ZH#!'S$?]S=,)_&C(SYIWTGR9'?EY8@OF1.6,[\K)
M('F2WD27(4M.`_?14_8->`E:<P'\5.U9@3GC:BY%I8,'M''^'(=XV'A=9_3>
M.'$]@)=B#371^N'JZZS\*R[O<)@]IO$_!M-%+7S3W0/>,\A/_``X^Q@2J?H"
M-5]D*ETL^!,:TJ9$+[A$AV^Z5^G9X2A\@WQ>++JY&*=\Q&2HL=.+;L)25;T+
M;<[+5:G%+;NZ-K9TE2!_G^P`BWU"G$9%M0V^G=VL_(%Q]N?YT,2#Z^)2X7:2
MRN62G7HUHRIK)Y_<H98.+EWTQSKHGE:-?)EBL9#YFP,2"3N__5R?FKXG[+5O
MQ_XE+I_:))HKPJB>?;DG;2`+[0)BBT.:`""H6VSE,^FX>P/6K]5I`DXT;V&/
M`XESK;F*4[PJ\79$I8`6J2^X;W.C#6ST,Y`A2N>94R6;*$U<"F;)8DI5^81S
M]BY=]4JM;EZ5@M!^<I6*$R[#"@A0]=A@_4:U5J*5U40EK0GBLI4,9L<5V.B_
MJJ&9E0@U[,<Q%-5\*I')?E&_^>9MJ=!1\RN'KM'DNJAO10=XG:59G1_(AEX-
M>41Q0+,.'5:X,N1<5N**X;O=5XW^;ZONOO.\8N`8&(BK7(W'P(3]_/LX#=(P
M#I)ZN6`?O<:EJ#J;'IG=G;Z:BSX0WZ^NE]?GJ^45NOR/V\OK^\M[M+H^O_EX
MN4#7EVOW%=5,)J<3%#":F5F`(]N_Z)/Z`B#9_D4%(B\V,::SI8DF/S8QG)/0
MMI^Z&QK-3MQXE+H<#KN3%?6BN\QZ<Z=D"H,--)OR9C^Y]PW,03GH"8]`I#W%
M6Z4E)J"H7P]_E^5Y]IF,2Q:ODM!85RO9^/E2^ZSM09$.S=WJSB@N*DUQKR=*
M#/750A-`$QR:=T'ZRWL\6"&E]W>[KDEK7/UYA3]!'0)'4-0:WF:^X6E5)I.,
M#XJ/!?2J(FQ'*]UH2F="';*:`=?5Q?K8[/AHP\"TF+)5!QK3Z"HKR`]W>)?E
ML%*Q5\+#EPN<9ENR7!.QJA*HQW1F/\EJ#,=<]E0=>(98'^L&7L&K.D)U3ZC5
MU4*6Z6AKX3D2\^$3Y"@BN&KN?CD:#V$N?VLB?IW$Y:=MG_3Z<!F/'[EY8L0^
M[YU&LG?8.L6T`U\V3B9HE)P@^+UM8F.DP]78,'5:.]LJ=<<LW%[4"D,;^K$]
MTAPYTP/W:B`!B6A')$2(S4269YSNZ:+W(8C320[@B+X<I+J8\\OGOK`^J/M'
M>SD)[^\8K'OF_(U&+Y_N,PFZ%@^R]P\%_ON>;)TOGZ$2H(:G)R:Q?Q@M'CUW
MW-PT1:RM5UD^JFG@CHJUYL`=C+12'L0TSH$D35S@D>174H)J+E1@<I]=TQV0
M\G&XP>:N,21\VJT''_<)!CIB5V#&Z8-KZ[B$I)E5&D&%K7V0*-Y6$[2W#AC1
MN+G@-+2#N/2AI3?OIDEEWP>-AN`=HJ:Y"P`7`Y[BW3J[3,M8XZJB<4_ND:;D
M=3`_OVH,YR&LN4>W'4=.IQ*B)G-I#[SO,KBYO[F(<QR23Q3G3T&<;X-4^7JO
MBM`Z-)6<<$>)0`#6L"%!-8T'E_;,)JB//I/9L>B.!:`2M%CE=;`E/[8NL"B-
MHPZQ?5=-AR/.<0O8*ER]&.V-Y=.?'LZ),YP;FX\`Q,]!B6^3(*3%2Y1V343@
MH.R_8.1\O7_:$#4M/;)><O'S%?[5LI^0C5/7P9#?,>^WLIN9PXU16"#%_21+
MA-I))I%)U&*9ZZI6LJ"J$;AG!V?M\DN8[*$\&5?&#"*QMUE1YK@DBRNMAX13
MO(G+XMW+FO!`%MVA#\DWDAZ,S7[I;O<\\T7"Z\+@[[)TSXY1;O.,=$;+$,$A
M2FN$Q:*]CZXK5)+?PF>I7UGWUJE+Y,N&VP?Y#ZX"'@SLZ#5K;E+%JC/8U%7E
MFO9H)<5K2#-?5B&)I`4U;`1B/LILKS]GNK/=:NIJMMNCE<PV:>;?;'.2%LRV
M0,P6,W5N;Y1;CU8;^UDYK?%Q&2VW-Q[,O%"27!++L!CM>YK4B8!5B+H0E0?1
M6LD.JUCM/(C7)65X9,Z/.O,-9Y'@)*=OT.=3NGS>A'CFAZ;(FYL;EX[46VG4
M!UN[52BAH>]I@C\V7R)R*=X<A[L'"ZVR,LE$$U:$];2,GR'>E1:W61*'LJIU
MHWKSI,"_BF?=^MYUV6YJI)N^$.T,L=[0S]5__4JE&0\%O=K[!CAPEWY#OJ<(
MA`DIG"?A',:NS,.ASH`O81[%'*C2<08GP!F"KC3*&(I)7&/H2E+V@T_FNO*A
MT(?N/"A@))@$IY9(?>`LIG&-I,[X->V1-WL0Y5QHV"2W.X#>@)1[`$%[UR@2
MUZ_FC)$W.P&IZ!7`.7*\MUV)51[N'6II-]H[.%;%^P/.YUPAY4ZH5R5B>\9A
M612X+-CU'-GMEUX[Z\:@/T[NP6WZ]T5U;4SPV/WD49;PSLC5Q*'2QTI0R/Z.
M`MK:O:D:!$+?1$E08#-)J@ZR)41X2XT<J<'V#E*DAL?-9T@U85EHB)8>&#<M
MV?,)4DK!3WF'`_+W5D6QQ]'%'L*SMSB/L^@FC^(TR-FK7P7[^Z==EO:SM42W
M<(_8M^6W/HXC#\Z[HFF?C`ZQCA'K&=5=LU>OBKH1]([X-#^'5W?GE`]0!$1W
M:#W?6B`%$\@>)+&K)+&K>UJ@%)?HVW_Z[:O7OT,[G+/6W[DL$363;"[_OH?;
M$O%V%X2TPE3YA-$S-(9_9(VT*,1BAIYAF:&((0\ZV-&QN2Y(=4SSTWW3YNBV
MQYV197^?R<K6G9^4F6TD,IN=98U.U]`*)70T2XN^C=.*\)2MKE!0UWMPM/[;
MF]BN\3FFC1VR/!:W[-%_[8N2)HVNLV44Q8"Q(+D-XFB5G@>[F&POAY_%O<-D
M02[BLGY;DW%=O9`)#52E:>;_M/W`POS2Y&(5AT_"G=+#1Q%\%1'C5'UW(7E/
MMOEZ\_9LM5JT!N"V4(X#R=+N$!-7V.K0_<;9EM)R$1NK&CO!TZR+>=VD]T]9
M7JYQOH6RKA=XEY%!B%Q(%95=WU#)@[#ZVDV**`D"&D3+!E=4Q];A'QD?*7Z$
M"+34D1O/3@;^%2$Y*X$=6D0X8E1.*R$;,W2'=Z0]-=2',LEIEIZ%0?$$/\=J
MCEU[47J*U7&/3+3*GM]SC<MS(O;;/'N.(QR]>_E$+-8J7=&7P"$],RSC9V*9
M<`$YF7&Z)[^[8;4OLU26@S&U8^L^RV1)<#L&LDV"'E'=)7IX0=]"KP3AWZ&F
M8W3H>8$.?:-#YRX/7F81"]7T/9,$^;]:$$'3EWO?XCB*T?<<CJD5-@^'LA#C
MB+YX6P<,5N"O$)]G_Y#$X<UF@V'')STPTN[#P2&2/G_\P1*C94\E-^&4BAPQ
M>E1WX![7QG/)'T"-FL@)7NP'G!(-2*Y4#X#Q[>QZJ@/C[*.E:N)):I]4NAWG
M12Y:>Y8(]E)[XD?!(<A.JYB'D,*ZE1&/G;]RR5JBIJGBM-I6],&<!7:9JL@V
MY6>((OASZ*Y`4M_J:<%H2F&2!(=EGJ5QJ(:VBL!RN1+)R+FSRZ:M-]">P@/6
MY,%>)185BKI%6?0@9/'MD,TF#K&^;1>TM_\FB&#<W/L?M)TWT!\Y_,T^)^X>
MO!@.IMTG'=#"$??"AQI$-@N);G$5$2K^@N/'IQ)'2S*-P2.NXT=W04F:%&$>
M[X;"<ITREN:=.2@G.H)COJKM%M>QW6*!ZGY0U1%J8JC0U0*U.G,/UO%3SM<;
MG3;?]F#^,2#V@X8Y;C;M4>OA6HO:.I#U>.HC]T`%D>\>CKW"J<&<]8%I/&'V
M;_*O@R\L#QL.X%@9J"3)/D-P0X)$+6IG-_WE/`EO_A,R5&?^-Y2H(75S=C:-
MMP,;@9P-%Q4--*`GJG"@C;LIT;=]D`=D^<#OL_P6YYL,B@B'^&9SA8,"+Q]S
M3--WA$$Y77++L3IMKK@07DV)""EJT:*;#:+4J"%W>2X[GL/N`[:/#;^/\3-.
MX1`+LMD@$R1(7U!0H``5.`0#_X+(5R#/K1$)H4^H2(+Z>ZY/;@WAW(V"CL&R
MQ>US_28A'4YQ!Y<>V;NAUUCZW*:<SOYV6L$'MR]M7M%D!)#'E;;>5B=4[JV]
MUN1P>U/]F9E4M9"T>9\59(N@JEG(-;1=L9`?*1]Y)FT0:^1!3$(NX5ZM0JEX
M+;_AVW[DM`*=S(8(2=R\T#L\^N$'>3L/\5:-7:9<&#!P>'*W>F?>@\P)%7H&
MG]A50L<A^ME3J";@KRG<8[\9NP;T5Y+7:ATA7SC\_EO3'L*^"QLEZH<P8[&>
M2?B$HST\X5&7ZJ\RE(=KC<$V,V15QS95]O(_<,2RF<_)"J;W:.-\W[1?5V5&
M^7$)^=6W8'?5O`517U@07VXX?!,(#U^M[SC0[U8O"'I6.F]N<')58^P@T^+U
MIL]!'FD4W^NULW]QJ#=.[I8/_-VOZGJ#HN5NC(CEZKH8:?LYBW<OW!L*=.2'
MX:<1%)6$%Y[4Q=-F^9PGY4PG2TUPK9\!W*-*;3-B1J^LZ3$!,R%(0EPU7*\%
M<-&555N5QTOD-'9#)XKQ<UGZA^;5(W55V5U/(BHZT]$)KNC/Q:3[=F$.D;I5
M^C%+RZ?DY3T6EL,9;FO[;MW@>/DK:*P9V2&BJB$B+=W>.M,:^?HI+A!.V%W\
M_'#Q;%MQL2'PCJNNZ+WAL'DOI'!]4B$#4^]FF0I)1WG2AI93_P`'(*N4^;;B
M.+&,QM4C-X/CE[QVPRK@4P(`/B-QB7E#5D38?Z!\/=*3K(@O4$'/\-@)7_TY
MUYJ@@T'!JS\J`,ZD&?6E\#$:<J#U1U-:_)AJS**IQ>"K[DB8$^E0<"@O\76I
M4Q^XVFHUC%K+$8Z+H-2*<!S:N8EPM,8Y'.&`!GY%./JB'8QP#,O5`0B4P0FN
MI3L@"$,";2AX$Q`0B%@(AR-OP^\Q&6=T@4.Z<5M_SM9/V;X(TN@]F:`28\6.
M7)O<<OT[;:ZXLP!*B6I2^D1C38QJ:A^N6(UGL>'MAP4"0/@2@C"$8K=6VA@<
M3E&;P6I$K=!:%5E[Z$?66)BD6&>M^$D!>GVSH<N_4-'F^Z!EU9Q1<H.5MOBC
MN_;C@^A=5;&2-:L^6(6-JT^B=8;:'V5+R,V&>>9.BS-:%.:J1!%.LQ+B.L3]
MI@XZBD`25;FA)KX9P!><AWMF5]&N`;*CG]Z8K)M]69"-"SP3SBIYVC%<`Y\]
M9?,U)$5;1JSU;<0^_O58,AVY0E9^VA2A[1BPK!)9=NCFZ[)F0NV=T:8I5-<;
MRW;Y!>=A7.#;/!Z\JS;_)T_9HO6E9\N:U=]%],-?CR53R;/GE>%:##MH+S)L
M7Y<Q&U38&0V91%L],F*[F!6Y`U?2EA7K?O.TS5A/?O;L6/UANLO\F@R90J*<
M)6L$\=]FDSFLM;.:,K'*.JP9<!4'#W%""QS(;UHJ*=W7"N!XT:H3(+QB.9D!
MK7LCYEQ`%=JHYJ0DG-`G`]T?KVAB2UD00`8LB^4:GV*\(?Y'N(?GZ%FE)?$=
M4RTJ^V4;I3QPV1#0&C7-4=7>@S,+@SGABA^J)H3PP?BZ(N3DW^1?Y`>PZ931
M_P]02P,$%`````@`24%_1BQW&4.Z-0``I[L#`!4`'`!O<G!N+3(P,30Q,C,Q
M7W!R92YX;6Q55`D``ZF.&E6ICAI5=7@+``$$)0X```0Y`0``[7U9<^-(DN;[
MFNU_T.8\9Z5XZ2CKFC&=:;)1B32EJGK;QM;"(#`H80L$U`"H3/78_O?U`$@*
M).,$`@P'4B]=V9F(8'S^>5P>?OSM/W[,PX-7FJ1!'/WVJ??+X:<#&OGQ-(B>
M?OOTQ\/UYY-/!__Q[__S?_SM?WW^?/"51C3Q,CH]>'P[N/0R[R'Q_+_25?N#
MWB^]7TX.X`^#P\^_>\GG_F%O=/!?O=ZOO?ZOO9/_<_#?9[__OX.K;P\'GP^^
M?__^RQ1ZR/(>?O'C^<'GS^QWPB#ZZ]%+Z0$,+$I_^_2<92^_?OG"OO_QF(2_
MQ,G3E_[AX>#+ZL-/Q9>__DB#C:^_#U;?]K[\[]]OO_G/=.Y]#J(T\R+_O17K
MAM>N=WIZ^B7_5_@T#7Y-\_:WL>]EN:B4XSH0?L'^W^?59Y_97WWN]3\/>K_\
M2*>?0`8'!W]+XI#>T]E!/H!?L[<7^MNG-)B_A&S@^=\])W3VVZ<X>8F8F(>]
M?M'^WRYC?S&G47863:^B+,C>;J)9G,SS47\Z8/W^<7^S'OYC$#^&7II]?GGV
MX"/&PQ?VS1=Y-U]@E#7'>4]]&KQZCR%-X3<F"7WQ@NG5CQ<:I30U&*BB'PLC
MG23Q"TVR-R:*?RZ"%R:6.YH9C%'8@X71C;-GFISY?KR(LG3BO3%)&`R-W]S"
MN&Y@%9G3!^^'$9L;K2R,XB(&Y8V>0-ZW@?<8A$$6Y'IR$<_G0<9X,!F=5F\6
M1OT-?I<^Q^$4UE6F,-F;P2!YC:W,UY"M_!,/]/C<"]D:RJ###A"EGL^6!;-9
MJ]&;A5%?!Q'T'7CA:D4H%,QL^LHZL<'VXC&E_UR`]ER]&BKD;E,+XUGR\>V9
M4J/!;+6S(9G@*0IF@>_!/E0L43#[)G$8^##O5O\U$9=>?TV/_"'?K6R->]5;
MTWNR\:BU>FMN?S8>KZ*?AO9JXV'*.K&[;QL/C=-V/WNX\4@-^FQD/S=?`H1=
M[&=OKS#[M?ML=)\W'KBZ*]M[+,@(%.Z99K#"AU4WW*U.+(RQN.V'ES3S@C!]
MH#^RA='P!.V;WEV7OV=K>UUWMZ=QF\O9J->F3PGFTM?KKKES@OF(51TU/E9S
M'='LKZ$SCKF(I;W8/>68#X[7N)$QF?,LZ</&^I7!EIX?CL:S\0LS!1M>^T4=
M[.>4:,ZT2:=[Q6"N&17Z;N3D6V%[%O?1Y`A[-H;8:W:,?1MC[#<[Q@H'&F57
M^[GS5#G+Z'>Z5PPFRFS4ZUY1F*M2A;X;O8V:JY1&7Y9W]HMG#_8)^)UZSQ"Z
M/39@0:^^\B@ZVI^DJ]H$JG5O&Y>7/E^'\?>J1\-2>WMV#'/+1?-W?ENW_-)(
M7Q*:@A3SD_4M#&QCR*#'-)K2Z6K0K.>:O@"YOP+\;AC[&S\5,D^).%&)A_T-
MD?W`V6/*?$2R54>A]TC#O'NBW9:4CCBZ0UT*)??<2*G_RU/\^F5*@R]L].P/
M.8S/A[VEW\:_P5^MQU(:PD/QH+XS=MGG9+`QW#*C9\GFT+W$7W4.?]R@<]?O
M9/G%EY=\\G_VGX-PK0FS))Y7D.IR++$>J$4*PXM?V-^QV14GL"#]]@E.$0!Q
M1I.$3F\+"0DAY.//Q5B/T9F7/N:]+M+/3Y[W4M!*PRQ=_<TVO\N_)NMUZ@+F
M"JQ5W[+8_^OL1Y!R2%:V(:<]EU2K^-ID5P\-G^-^JS@N`[N,YUX02<C=_9B<
M]EVRJL<3GUL!&#ZI`P>DUEB*83>D-R`1WDQ5-2'#]LQ3'2Q\0H>("2VVH7OZ
M%+#=)\KNO+EH7^5]2GJ'"!G<X&2712$0/GTC]/1=`'PX6-_`&?3'?](W*7];
MWY(>QJU2BT`>$CZ#1X@9O%@D3$#700I7QG]0+[F*II>PPPA(%'U.>DXWQVH\
M2L'PJ3Q&3&6AEM=!2),+0/$4)_*IN/$EZ1VUCT`1#CYW)XBY>T@\%ISQ[6W^
M&(<"UC:^(;WC]O&UBX#/U"EBII:+?SR?QU%^H,[-<.EXD;$0%`9/OO])&I+>
M2?LXU80E,!(<(F9Z)8L'Z%9QN6"?D%'[R-L>OX`E%[8<79;.8/Q3AN$Z]$13
M;^,;TL*-;@>`@"@7!AG3Z32A21!/Y<=,[K>DA3N>$(B`P#887XKS<H'H&OY.
M97G9^9Z<MI=(+A@!F9@-+YMXV.5'G\KUUZ2%YQ4)%`&-^`TP?Z=A^)]1_#WZ
M1KTTCNCT)DT7-)$>1`5M2,_I,U6=,Z@,D8!:S):9`M2?<;@`\2?%+5<T/[G?
MDAY&\[86E3PD`@KQ6V269J9[^A(G['F?O>`(5UI9$])KX15#"4C`:QUK#<CF
MR[;'1(.>%/)D!39<*:2_H/*ET&H,E_03\TE19;B7L/&&<;I(*'/`.H=^_ZHT
M<DX_I'?J]#W(5-R;LZ4&9/LN&'N>0J)<&D:3QXZ;P&HHD]`K/&56XY',,^VV
MP/MIO;VG`6!Z,[)*-Z"=*)PF-'G9G(_5`;=^.G+SQ[B8B\5/LZ401I,LO%"V
MVVFT(K!/N9I_6_)<C0Z4X3UTQVPJ5NP1A(!C5JIXXL_'6JA;/S7+N90<S,CU
MS[]+6&-&2EJ1_O#(U8SD#$MGVLF:`1RG9FIMB?/GEAI:ZR>03KHO!Q.K]//Y
M8):#]#<6,XVI9M0/Z1\?NYI\6@/5F8YF'9'^B5.K=0V>^%.V"OS63V).R)F#
M.9O[.VR,XB[.=":IO"'I'QVZFI7\D9E-2.T^`*C3UP83.OB3SQ!JZ^>=3H9'
M!Q.Q/*SR6#2FHJHI&8QJQIG9AV4V'0UZ`;`H)J0>*?PI:0RW]9-2DLG4P5S,
M;4?%")BQ3/U(H=>0#'O.[HF;(\O_WW)X9C/1J!\`C.*@JD,+?R96@-OZN;B3
MN]?%L71K##H'4D$3,APY>Z_8'I/6T5/4A@R/G#X-Z@E:<,B4@VK]G-E,,>WD
M'K>,J1W/UGOI)$X#1:8"D^:D[_!*MQR>*&L!_T/2=QJ:9RQ<T05M!]-'OH+M
MR/'>P*FGF(0K!:E\)!_)"B(0A%-?,4VF!!9-`1P\^0HL3-Q;2=X"\<>DC^+E
MUGRF;B+`DZB@QG-^FE*ML_7FAZ2/PL(B($;PXKZ+P%*N@E>:/,8IO75/Y-)#
M59O/K>])'\46RF%*1BD/A*4<!AB891GGV)L8_(<9YU^],+]R91=>DKP%T=.?
M7KB0'8BUVI,^BIU63*A@D]7&9BD3`@:%N*0O[.J0;@A+H@#<[\EH@,(P9\JX
M!(REA`GU**[B3"ZF4+LMZ3L-"#9ETPR7I?P*&.:N[IS=5._>(0JSG^E<Y8"P
ME4$ABS,O1,#D71SYAF>NW28@&A16*L-SEPB(K?P+&.;KYG;SCEA[NWUO`L)!
M<>V5DZ>SZVYCLI7'`0/APCB)O*2FD'19,Q`2BMMR%>+5N&SE@,!`OL$LY\P$
M1'=G,Y+Y6&SE@\"R52O)!-B(+L':VW`Q;%MI']RSM>G0ONN;J''0TNT"1(?B
MVF1DQS0#9RMG!(;EN81<W]`I;@0"0A'E8D:H4BFX*&WEG<"@!ML%AA-O2C5N
MU.)6("(4MC`5B8)=0`7,5FX*A-SG[GC&W)=;@8B<)O*RROTN,`'WK;2=[8K(
M:-DG/;=YUNLQ+<(C<!-IH4&MTDE/MENZS<IN<W=7H10H02LM;J4DO,J7S:U/
M01@H+&PJN@1OF5PT`FI;:5L[FTZ#`LC$"Z8WT87W$F0>+U.XH@6(!H6QI1K1
M4E`"OEMI3KMG)0HC.KWRDBB(GE(XK2SFBSRPZ9+.`C^0A[2I&H/`4-AKJFF!
M+CZ!0AB;X3`HQ*ZDC+9V$`@2<TT5PD5X!`1WT')7PV('HNJBK4:"5:`6QH:[
M;;78=RB9K#;HND:H@W"9W='HO.`+&Y&>NPCK/U(ZGEVE63"'W4/VSK'Y(0P9
MQ[ND0JC\6<3#TH6@F#OZO220)([@CWY1?3@7SUOQOSIQA*9=@1!1'*NK*40U
MM&[#;`3>@NL8L??*T^_!QFK^C?L`4:`X6)D17Q%F%P)P^'[/^BN#5GL0%XHS
M5[7EP`"BVT`>P1KP[3E.L@>:S,^]Z*^5_Y7FW-=I2T9'*&[/%>:\/CP\Q4@;
M\$C3G^ZZ78#$43R$5IOQ9BC=5CD53/K;.'IBBFTXWQ7-`#"*-\X*4UT+&9XJ
MIW5LI2D%:;(MZY*^TC#.-7<9#5&@EAI+E:U)#T?ND&IS6QL@GJJI%C+ZZJ_P
MHB8@%!2OH-58EZ/"4W:USFLGW%%9"6Z&XCY(_[J`80<9^Y/TX5/8"D2#X@VT
MXJ%=!0Q1!=;JI%][09(_\9:RP=Q$()U%R5HAH5^K/<BKQ=8]`XB(RKU65XG5
M*^"$)GE68/V57]$29-1BFYX6.$1E9&L\C3)XYUY*60IW=JK)"1KGJ.#0<Y.O
MB\$K99<;]0I1H3>090OM`;4!-U#"%M,+6Y[:IAOO:T<5DOP+KME"2\'J/6GZ
M1TIGB_`6-":%JV="8?_)CR3LK2F7J?).;O,W`#QZN\S1CNMJ0V)H?:9(:=Z#
M*A/68;W%TZ&U2:E;-%!K]E7JC/3=U@TV%3QGNM7`W?IY)2B_Z&X+;+@(X^D(
MW9-$K<>(<OU!%`^/FAP8OD9LP6S]M..5670XYQHHMEAAC[-T*?2?Z701TO%,
MIUR@<F>TT2V(`\4U4<F8X)Y8&WKKYVNI]J*[:=I$!49W.?[72G6Y5`$8XC*+
M0U1SAAKU2/HC%&]\2IY4D[,"ZM;/2XV2CN[FJZ/"CJ?.Z@V,X?#FL<'=4@^N
M3N/9+05%-"V5H]T)0$7Q3EN!'_Y<-H7>^NF[6\S1W6Q]MX:?)8D'!!:K1SQ^
M9#%G7^-XFD>>T.0U\+7LLM4Z)/TC!'LR_VF@C./\[?T;.`[F-[SO7C)5EAJQ
M]1MD=(S"0:L.S:HMW8J(NA#@46""7U%4.MGXCHQ.4+AU6.:3KS0<Y%VHAE)=
M8N\"B:;,GG3GS:FRGDH3/P=DX/`FV-40DW=A&T)P&T8B>$.YBR,Z?PGC-TKS
MN-+B`?QW.G^D"4=5E&T`*@IK3W,T<MY0U`+I0N47I4A%$KW5J?E3NW,0-`KW
MM;UL>+;$U85PE_<;8BV1:]S.+?\2Z1^C,+[94B:^JC8B-+>Q.+8OG%>KS:.X
M)PFD%.9C84YJLWOJQT]1\"^0$4V"&+Y+-0O%-O6;9(`C>5JSNMRP^.R')>W=
M4>F]"/VRO"V[_Y?KT;NS<94'5QZ1AC5+U90,1A5\#6TO(Z)15GA$TNL*8*.P
M0NG1HYK2)IC=FI5$`>!<*!M^@NI`<(,^R.`8A8FI"OT5P=JW*NUYA5['QJQ0
M%B^O3KW><G^@8AS,[4GM;ZK7D`P=%A]?:U8^QKLXBE?/6\5XEX.ML#2;=`@B
M0#%#=8A2+<_FN%O_0K@\0GU[II2Y'3%)/],L\`&-BS="C9+T,@W6J6C?Z[E[
M_]LH[JP#I+#2]/HX+O':XA5,-`ZJ+CR>K7%]\VGDP<U+\8C&_1[$@<.VR"%)
M0><NC$Z\C"U1_1&E+]0/9@&=JI^W1&W($$<6.PEGHLU1BJ@+><LF27P=PZ8H
M?)'B?P@"P/$,)6>(3RL/2B<>D':*5NFLP^^&N2&.[*,5%N$M#%UX=2D5'X"3
MZ3C)L4[S#`RKV'N%5Z>B-0@6UZJ\12*?<FU@EEXP,"1I+V'.`:9GB^PY3IBM
M6T\%MEN!A'"LWE6IYP.R9-Y'2?E-FB[,Z"Y:@&10))*M2749C*6$8BAI'B^R
M-/.B:1`]F7!=:@8R0A&J69/P'426<HOMLKYGF]-7&M'$"R]9L9$P?Z!<N#$W
MC9,G+PK^E6.[B*,T#H.IM\S.,BGA+MD[WC,ZZQB/;?1/>L,*-F;E^\V2!)$E
M2O(U#`C%.[Q%Z4H?;G:Q=\IH=0%S-!W/\H5'UW"UW0;$XO010,F8XO+$Q],%
M*U89F=)\M?LQ"`+7A9C/E&!'%<#I@M%J+9`BK(NY!,51OK!I3F%>.Q"/T_MP
MW6DLQM0%V]86.N5LYGY/1CBRJ6MPQB=;@JIC-B^E/7KG6Q`#"F<I"4?*NT\9
M"<IT^,M5269@YGX'D)S>2@T75PF&+J2VOZ-9X=QQ&Z>R_7+C.Y"34Z.AA!/^
MO.*,WI+I**,)AKJ=A5'L<I&P](^YTW-A.[FCW_-_DA^%=#H`\;:+<Q-87<A6
M/TEBG])I>@TB8]B8.]--%&3,.67Q&`;^>`90Y-9$[3Y`;$YMR<;:8(BL@53V
MF#(/+TV.G4@]?&S1*JC,UBRT$"I;PD!16`M5HN29`#7!?9@#=XPR;KWVC=@S
M-@TVXZ3?0M/@,7;3X+&1:?"X(Z9!89+7\S>-#"\:K4%4",R$M::W-LHN&`[%
M67_AEY4S7Z,U&>$HZ*7-JJ%2;"/MB*'Q90&W^#5('7,CKP6(!$4`D#9[0A.D
M&!T*3SK!X?TJI'Z6Q%'@JZF4-P"L*';TBDSJ@.N0?QQ<W`.?ZD]?[O<@%10>
ML#4GKP0;"E>Y*O=NY0.#7FN0@M/@L1J'-6.4;LV9IG6=OF6)%SP]Y]Z!$YJP
M8F#>D]#28M@-R-.]V=J$.P[UE2#;LF`Z]Y+4,60Z])VT;\^T5TJM87LF"@<*
ME2BKVC,;*6;6&?\HMRF1C5A4V#7%^+I@V[3C*]5#DNY1S1F?;`FJ+A@ZZ_E*
M]7!D#99P)#14\)!TP5!I*9&"VZSD-A?I75Q=,#W:S:S0[Z,XCTDX$Y`L1]2%
M]*-5,ROT^RC<6!4,"1\1=J"X=9AT:7SJNXW$K+$6&Z.T9&AT.F%71;[>0(7_
MB'R:L!(K#]Z/59:G]&*1,'E+IK)N%[`TML9`E?/+G^YF<+O@;_D0S.DE?6'X
MTK]39H:CT[-7FGA/]";**+"8L3+IES3UDR"'*M$6\\[(Z,B]!V9]O:D*O`$'
MS?VKT.]>MDCR4H+C65D0>CJCT1IDA7S?T5(2;:0"K6A1'DIYC?@J;KN"8X]6
M*7O1J4>K,>F=GE@[I4E_46K*5K>$@;HW9QJ(E'-`TP79*9.V%1?=_J%[*XDN
M>PHK"1];%\S8=5UT^X>X#-A\I@1V3@$<E#7.I)JLO$SKM0;X[D^^U::L,<HN
M6+-+>.]HIKXY<[\G_9Y[7VL3YOB368+-DD4;@TO>IF34C'._!ZFX-XS49UR"
M#;,WK12XF%'MMB`!Y(NXE%U#G)8,WUF<>:$[3ZR5'UK9!0U6,8?!I$+/.`T?
M+&5;X+WG[FEPE9]"[!&L70!=W@7`1.$`H,F'Z!'1!&P7;L'-1[?U#W%D!C:B
M5O@8J0>W"Y?EYL/<^C@*4&JS:J@4VTA1WK17<5KLZ&$<^J35&,"W)J`MYXES
M1#,`VH6KMLU@1A3>1!6YUT*'XL*]CV!&%$Y$=6:Q`AR*>S2J8$8<Q<YK3EX)
MM@Z%KPJ%)+.6ZS<&`:/0A49/\5MHN^"!)L3Z-9$G:I0W!/&B*`FA2Z6A(I0P
M6G(Q<Y_?\<SW%_-%7C/YDL+@_2`G"_X<TF66_[-YG&3+"@!"V4ATQM9/@.1Q
MGQJUM,NN-&H[JIT6BAC1)S8BG'O5':UD:85F("3<Q]-Z"](:H2W/M.WU"-43
M@,,P[(9?`GH5/-E:^!+0PST7-_FH^Q+0^_"'XWDB(:FQ;42C0!7D(+M@ZZ_M
M&-='8<E7,"4P[@G@="&DNW&K0!^%:=_&+-=%VP7[?OD^(E&`\F<`'H7OJRY-
M?))W$=D/`-_S47J</=-D&1"33KPWIN<N76F*$;"',AA4`L=XG41&DE:D/["7
MR8@G+&G4A[`!#`N'C4(E.<X[B`+4QV%VY_0P<!_8HR#-^.@ZZ$AJHMI'UR&.
MBXJ<*?VCZU!X)7'L:<)38-DQ5-T(P#J]=IC/2UU,73AD7LU?POB-TGN:V\!7
MD?V!S.];NRV(R7V\G0:1_'FK"0^%9XFUUZ=D8:@$PC8@':=WD7KD*V!UR`ME
M2SJYQ+1H%[4"";F/WJI#O!Q8-\([B@J)#]X/I_7!UJ.X#%(_C--%0C7NH9)6
MI+]5EZ'.6:@D(^GU<_L[&`2*(`NEG#C''CZ6C\OFSGG_R'V\(I\KXSOF44="
M(6K?,=WF6-)D2O^.*<Z<Y/B.6=);Y=62]RU`<Y_H2&?R*1!TX?YXN1PIX#M+
M4YJEXQ>:>"SI$ZN^?.$ER=LL3KY[R52VSAKT0OIN2VLJ.!6]:!CBZ]"E<@?[
M3937YTW3>R`.A/Y\%DTOZ2L-8Y7KHFE79-0%7=$"V:$+Z8X`V`EV^7>KS`KQ
MG/W76WIHGM.(SH(LS<M]GWLIG98_N(A3(Z6R\',PB=T;OFHKGC5!="B"8W<E
M9P8"HZV--2!'/:</DY9VL7<H*"J.-42Q*@J#WP!4W[W]LS;%)2BV@BRV#%\(
M"/[3"Q<%+6$8?_<B7^9@J]$:Y.7>`EJ;>A&N+@4Y[(`N&?SE<0Z*EB`J5`:B
M:BK`PV0MN`&;`=QA0$,#=O`1!COX"(4WHE).6G;PD7`+_*GMX"-4.UV)*V,[
M^$BXM_UD=O`1CE10<J;T[>`CX:;5>COXR'U:19W)IT#0!3OXU6Q&_2QXI6N8
MK)+%1<SJ'RR"Z&EI\(TCV3*KWPD(#M43R!:C_,EI"J\+9=\J/8?(7@=&[IV<
M37E7P;%?]6W/=XGU5@5;3VFB.[M(K,>C?8G8:4&V],S%`549ZKSQ(3E"$=TH
MDZ?B2/H.X^.>L7WF.W+ZGB*ARO2:<?11I2,_EA^A,`W(>=*^8QPY+]%A><[*
M[B/BCPD.OT?S6;J)H`OW$;ZOP/(95T*JM!W!D2=40!N?8S6@#OG:?*41G#Y#
M%F8ZG0=1P,X>[,*EYEW1DKAUI*G$O`ZD#KG-K&]9Q0GT5OYFS?F:N'VOKL2Q
M"$9=CY/-)\H'YT_6=W$4;T)53VEA&W+<OF5<#J:N]PFB%^D[FFE-X(WOR`DN
MUW4M1G<`U'4PP39I)ZMA%U>%X#68TFB:;ED(;N8OJHQU^MV0$Q097XT4P1B?
MK7+0&';MC5EP]NH%81Z:'E_$\WD<Y1)YCD,`F)Y[:>#K+@CJGLA)"S>!"A!K
MNZM@6U6NO"2"33"=T&3E=QOX['83A(OLW7+->UZ2MR0G*!)"&FF$#B2!!AB;
MVS`L%W^GP=,S`#N#P7A/]&[!TN2/9SGV\2)+,R^:@CST=:):A^045SH6'56I
M@52@0<:VO5T-VO-#5?'6^I1+;.W9!V#9`AID^0N6PVCPTBCR,2W'ZL,8C?SB
MC/HA@T-[GG(:\I5ZT.FVAT&CN*M7D#3',\0,]<?;V/93Q6#@WM78C$/31[,<
MX<>K602"P'71YS.E_6Z6PT'IFZ>AS[(W,N,^8%ZX=Z2M,XDK(N["6]N[?Q/U
M4II>+S+8]7X/HF"^F$^\M^)8M=`HC6[6$<P>]S&$YHPK#/D&T#OT<*<)_R9Z
M^![_@WJ)GO>@9E\@3?=.A7M6I&WT77P(5$H`?I7:TZ9U;V3@-ENK(WW:PM^A
MH'=-&=37(I"<^[P)>]:<`K.E^'G'097Z]B6'P99NS$S]TT'[S$S]4Q0.?14D
M7<?,E*/^,#/MA-V=NH\V,^/0U,R4(_PP,T4@"%QN!'RFM,U,.9P/,U,>IG7:
M(ELQ9Q)71-Q!,],]7;LQ+P^5[&^\T.`R)^P"A-8RTU+.LM8Y7`&Z"T&G.5"0
M5`%,[2G*_1[$T3*KD$0')`CM1Y]:V!>^+KS$BS)*K^-D0I-9#->LR*?C60'D
M*:%4D"O3I#D9(4A15I=B<\"6+#-(-P-YVBII.Q!/*QZA:B[[:Z26C"X.`\^9
M\]+2Y9'56,S>'+KOE/TOB\'<Q9F.(47>D`P.1\XNT.N2I?P4IV<)K#I/1>C_
M^=O[-TOSWAE+<J!?L+OF;X"@D#@'J.D4W,SMBN+#A+/CG7&(XUYOEV=C;Z)#
MH3G@YS+S#`YQQ0#PF=+W)CH4WM_:%88_SH=_`^>!'RSBX"9-%^NUM/A?Q0J@
MUP$(#(?'_SZ6`Q.1=,-:),;[`#^N7"_T.B"#/HHG(A-ZS15D&V\7C$2K\I;Y
M"EJ`_YVRF`A9!)&H#8@%1=)($Q+Y:J"`Z-9:9.E,J5IE18NL["G"7N<@:!3!
M#?LYI5H25Q=L6I5E44S3M!3%541W-:&FHM\B@QZ.PY0EA;*LKG*Q63+$O=`D
MB*=PG4@RI_YR=:7TE=FR6=VG'(^J_$@#OP:LX+@9HE9FH>`L54K!X/K9\C6Y
MCR-.&;4:"\1F*\M&L2A?16[3ZM05TI\T9;'C45X)S<\30;"_VJ=ZZPX!Z,.1
M+!6UUIM)TU;1FRXLZ5<_:.('*;O9-*[S.[\%=.#(1(A:N05BLY4)):-)RW6X
M-,VW\H(L14<G22`M`[>G$0!Q.!YU4>N[D3!M97-IS6U3:)WBWF.:F@_V1@$T
MXGC&=CLG;`M4,"^,G[VZ<,9IT_[P8:FQ*TS!/#!^W?M9+KZ.)DB]@0'5'^;Z
MO<A8,)U:F5K!XKW,T:S1'`$9##XLIW:%*9@'%A)"8'$Z[W7)ZWQTVG.VRK3*
MZWQTBL/:K$%GTU[GN2BZX'5>8()?4?B9;GP'\#OFMY/SR5<:#O(N>)17E]B[
M0*+I)/2B.V^N]C%MXN>`#!0>J1P-L6WH40D!9<J#NSBB!JZGRC8`%87K:7,T
M;JJ-ID"ZX,.>"^;2R[2VH=5W`!_'B\G>MJ%-Y%WP35_#4NX@6U^""%`\#7!X
M41!8'C_*E`3?J!^S&HI^OL@\?(\?GN-%ZD73ZWB19)0JEG#-YB``%/9L+B^<
MA=@(5H=20F*/(1BY35ZRUTW`EKCLIT.PL>RPD3^JP3T*;'0/<>FLE+(9/9[E
M+Z/"A:JI'R1'AUVQJ>;JPEL-FY6=);]JS`JJXU"ZCY\%@7?%SVX_RBJ0H"TO
M:LPZJWJ[:OHG0=(X3-!MT56.]&PY../6TY<@R7M@.\N^%+7\FR!K'";R]FCJ
MKOAL>3$C3-O5[](+ZJ!7H;">Y:Q)RF?0C0]AR#BFIX9@!5=!#IXN/$A:3H/5
M0_%"Q"-+02L?2A=>'FOGLNKA>`62,\6G5P2G"[FLMLJXW[)?8I3(YZZD%8@&
MQ_N.]NQ5@NG"6YT`I'(J2]N1P0#%S4[)H!'Q96Q=>*V[!TY`GL^L:C9]I6'\
MPM"N<JRK<DIIM`91H3B7:?#)5P1MC%U(+_651C3Q0L!Z-IT'4<!.K5GP2G45
M0JL]B`O%&:ZR2AB@[$1NI[6$=-[_=CX&0>`P1YL?V;<PN'UD:_+QU_A!%P2"
MPEE#1)7):VN!Q?X#%1;+E,-Z?8W9IX85*O(YMD\-46QZ.H+5LT\-/RKM\4P%
M0URVC!)9QO:IH=".\9/9IX:XK!9\IO3M4T.AW:)=]JEO-&'U92:K$><@E7<4
M22LR.$+AYB,B33"#58#<VJ@$[\/KPDZ"I7;W(Y`!KC.G<&T5C=VMQ4A%A'!I
MY'U&!B/WA>(Y(I8141XY2C_MF^B5IGF=K/68Y9[9P@8`TGTY,*[@.00I4+BU
MH0BHFBP2_]DKU:>3$R7X'`"Z+]:I2Y,40Q=L(WNKW3+$X>"N?4<PP>76T;=E
M!5B.4-@$3.@U5Y!MO([=:E%68#E"830P89&O!PJ(CCU5+=N+"L$P2W(<P?]-
M=6U&O'8@'Q3/I!7L1F(X#7A[.ICIF_"42S_W>S)"YK8F)DTPL<6H;.5D=6LB
MC.?S.-(S(.U\"W)`L7Y+2!(8!_E(;&43=;M,+Q[38!IXR=LW+P_BU#'KB]J`
M7-JV/,NAV$J4Z9;B=V0L[\9X]I!X4>KY6LYKZL;DJ(?"&JR@4L"_)CQ;*1[=
M.C!.QLI5>_T-X,;ACZ+)$)_?+3BV,A3B.%G?5G,T.D)2$]?\#+V%0<!FNZQI
MNYX&]_2559_(_^';2QB8.8#LM`;)HL@W(F)1Q+DF,($28`B9W[$$YW^;/L3G
M-#<:3#G$&K0F@V-<IRTIL<;`!"X5&.+*=Q#\Z84+6I77K<:`'I<?155:N;@$
MK+;-M@5K4('J<I$$T5-1@*+0XSOZ/?\G^:ZLTP$9G+1H@E?!)M"&=IF^!(!S
M]:^A#)OM05ZX3&-U=($'3:`*[;*/+:/]5TY)#)\7^?0B3C.9!LB:@7106,W,
MB%<C$O#=+NO9IC/911RQ(RH@.O=2J05-V@[DTZ(#@`$D`>4MLZ9532QRYOLT
MI`G(=*,EFQ*RS:&!GP,V<%D`]/:2QB0AT,MV&?<N@]=@2J-INCD1):HE:$$&
M2)+<&VF'%(R`X):9_6JF'1*7-+JGS(P*?P^K=A[?LO#"!YK,^ZIU:;^C`2[;
M>`1V)2B!TK?,.EI3>N+Z12+I]1I4^@JC`2[;:+UU)2B!TK?+K])B+<@;$%(0
MI8&?7[F;.&>J?A-X:>']M6%Q",+*VN7<:7&2;\IH3TOPUH\",RV\=C<M#X&F
MMLM>O_:WI<EKX%/^Y+Z+\_@:6A2K21_BS`NW[XMW<?8/FMU3/WZ*@G]Q'WH:
M_TW@!5=\GY:>-BP.@9KNZR%!]%C(-W^/$]@7F)]2_B12_/L?+W$T28)7D.DD
M]/S2NZCP,=%&Y^2HUR)3D&W<`JUQ7#ZL)D#12<]:W\!,BTYTEF$+5*9=SQ:%
M0\WJ409DD0O@;!XON$5#=)J!=%IX3U4C$O!=Y\UBSPF/[FG(3-\3+\G>SKV0
M`4W/HFG)C3)=9D!RD?JH/+KRD#22'ZF:DL&1N_3<ZZI(HE&>OVW\BW8Q8X/^
M0``H;C1Z1`GN-]6!?V1=VDF`<X3CYE"=4Y&;B13Q1W(F%HV*:WOF,\6G5P2G
M"\F9]&:`8L;K=P*"PW'?L[T$F(J@"PG)R\B4:\+NQV2$X^YO2IU:`<KX4":3
M*@]6GA%G]TLRZJ.(MQ,)G'/]%H'H0BYP@?;>:L1FJ9J"/'%LVGM:K+>`=R$I
M^)GO,UM".O'>F%``[)1>+!(F=8EB2%J1P3$*)Q@]"OGT*^%9RI*5L7BQ6T3T
MC[-GFAC37VX%\D%A>[5(_RX\2[FQ=HN(H[6\]3IG>CL^^<E-;\>HS]:;1%DU
MO1V+([-;M75;-KV=H#BTU^#4V/1V(CSA_V2FMQ,<B33D3.F;WDZ$B30^3&]2
MX\4)BDIOUI<`4Q%\F-XB,NJCT`53ZO1-;WWGE?^:,;VA"(T2"5S7]-:1,GR-
MFM[Z.#;M/2W66\"[8'H;O["8SR!Z6M8;U+G7"MN0P2F*\[L>?7SJ%>`L&=UV
MK2[(RK5*5P5).Y`2BCU;0:-HVBN16;*ZN3>Z*NJ.2OA7M`0YH=@4*FF`%C9;
M2>>WE0"MX=5AT<<FS:_#P\.?V_PZ/$0Q4_6(LFE^S8%WP?RZ;^O,\!#%[EZ#
M]=K6F5P$7;#8UK7.#`_17?-UJ-.VSN3XW)IP!=:9"X"W"#-/52AL^SN`A.Z]
MK2QLCF6&#P%E$<IRS6PY+[M?DB&.]/`&S(A`H+1GOJO1.**ZDV;]*1GALVMH
MSYLM%%TP:=Y$<(FA[T%L[)<8$_)CCJ05B!&%OYCU<XT2<Q=LF`*0RC.-M!TL
M9BB.-TH&C8@O8^M"E4V%O499R$.K/8@+Q>J@P6DEJU8991<J;C;YXC7L_507
MX"W@G2BW*8"Z,A-?@[#+@OQ[D#V7FYAKCV[/(&/,]K@M73#2(S,1."[M*2RH
M[B?42^E-]'L<9<_AVS459A#A?4M&.#)65Z%7`<IQ<4[EI>\\CA;I5\":W41%
M4A/U[6^W#6!%$1E>F4`U.,?U-RL0>3:=!FRX50A=M07LZ.QBUHC=!-E`.<X]
M/UM>!Y$7^8$7KO:4XEA\1S.'"5KR\)QB('#*-O&ED38DP_Z1M5DD%ISH=5&G
M&1D.4!Q:=`3)F3E:Z+KP4F@W4&,X<!ISJT^=X-58#JP+KWMUXS&&`Q1;HH(I
M/KTB."@?\\1J+#-8Z#8%X$[-F%5GJAF^+@1+Y!O8$NAED/IAG"X2>A='\<J1
M3?<XH=4)&0Z=[MMF!//GN2E:2T^3&)QW;Z*,`F$KY]3S.$GB[P!8_@`F:`/2
M06'5-.53]/0AA6GI`;2>$@CV@G,O^NN:BK,9K_Z=C(Y16"+J$<:!9.DY$L,,
M75]!HNEMG,(?[NE+G#"9%&D<_+=+&L5S6`'ARJ\J/&'>&0@<10X,.W.Z*OX.
MA6OD@BS+3>VI+VH"LD%AB;:C&W*4M@(V6)9]]_P7YZ-ZQT.=/D!V3C<8:Z=#
M?;"VWC8QK!6K(U"!/A>$QKFP]#7LQBB2JAER*#\0[N"S]<Z(@?)[^DJC1;Y#
M?O6"J-9IP[@OD'YWU*4B>EMOH!B4:6=++61J<M0H6H!H4)@1K2B&%*.MEU/W
M!XU=A.J3IK`-&8Z<ND[;.$@HP-5^4CTMF(_H$UM2'K848,_/JVN#>SJ>73RS
M^F@@K;*O?U$-Q,4CZWIH2]/^QH`T3K]:[<E@Z/R)3AGMN?$A&:"XZ.M+5_$F
M]P[JX]UU-_\_*JK?J3)]9QT(K^8_US/K`(4=5\Z3]B/K0%QCL%6D3E9#S3&>
M*:,(N-^3$8X7=`%/?%(E2+KPQKK6\V)78E4SXXB==7079%X[XM87IOJB+`3C
M-H33TO/+)CCEVLS]GB!+2BID3/!J(L34A2A0P#6/HWQ=4Z[0.]\2'&E&Q0P)
M-ETNCBX$<:[<E+UPX@73F^C">PG@(JQD5MJ.G*`(W#-E68VI"[&;9[Z_F"]R
MC_=+.@O\("NJSI92K\'"]Z0.XC3KB)R@N"X;ZX0YR"[$<NY6JM4YIKV;]9`D
ME#<^FVTBZ$3<Y:Y52$KE]L?$K;^B@B$1G5P4MMX=7_(`'QA1DCE],2@J@X\7
M69IYT106)1FQV]^2(8H\"V:\<D'8>@&L3ZLH0Y%^@?>'^#I>1$QO18_%-7LD
MHR&NI5G&NQ6LUEX(:^2.M:D8Q=]:U8SB;T%<[5GJ[8"U%9:)P7E`((Q\)JA<
MD91M05PH+N[FQP`U*H$2M#(^00!YN7%6TX)28Q!8"T\-FK`$>K#G$(7F%X.+
M.((AI@!S/"O^G`5P/?I&??@R"[A[BY5^"0[7>&MKB!Y@@5H9FPG=YZZ73J0&
MM$JS8^+69]K^FJ2'6*!7K0RR.)O^WT6:Y>Y/#['`#'L9O`93&DW3F^CJAT_9
MX^H]RSP1T>F5ET2*(#Q+OT!P.-P:Z9I-Z`*ETS=N;CK=[>4ZE:_5[*]9J87Q
M;/-V8'B/DO8%QPA<?D)5+U`:*`5.1'L.VS!3A/?[H`5-D'<&0FK/IE07ID`7
M]AS/4=_&\L=+'$V2X!5$-@D]/Y>;+3.<L&\0(8K'TD:L+@K4`L79<^Q&,XIC
MS4PG[AR$V)X+E6W8`MTQ-NMB./[*MN$[^CW_EZJW\G5[@B,DR-KM>Q.80!V,
M+;G(;]DUM&&K`S)JC[&_`C*!/A@;==WK@\[U+9?`HY?2*?-LH5&:TWA/_[D(
MTB"CWVCR&OBTD-8]]>.G*.]%%9#:]$^34?L>%?8B$X'VMM(4?4>7$>`L@XA$
MV3:^(Z/VO3/L`A#0V,J\.G7=B$;MN>4H4`A8-3:\%OXF5U%5*Q@&)Z)1>ZP<
M<A`"4HV]-GFD[CN4>/&8PE;#XA9>V3;EOIKL]HAT@H8%3<CPJ.]LJFR.21DN
MS/D<AH]C8Y.*5S!QA'@^`H9WLN0>X=CNA)2)=CPIH(_(X0@$@<OFQF>*3Z\(
M3A>"AYN),1T>X7C1JSJ/Q:"Z$%=L)]AT>(QCK59SQB=;@JH+$<7UXDV'QRB6
M:PE'@J6:CZ0+`<0/0<8JZ-W`Y>LUF,*51+%"<[\'<6`\2"M79@F8+H03[\!;
M5YH#5.ES\/(07T59L*JC;,*ZO"<0(0I3A(1?3870P=F%..3SV$NFX]EED%`?
M?B*]>/:"9.Y%RD5>WA`$A,)%KQ*O?!71`>PVZ%C@0G$U?PGC-ZJH_+[Y%1GB
M2!%A@3\A.L=QQ<)R?_#-=9QF-)$3MO,A&1VCN";9XDP`T'%]5$O'Z>>`SJY^
M4'_!2E&/9[/`E_"MT8H<]5%$E%I<<)5H'1=>M6?.#J8!\[ORF.2T+)ZB-B!.
M%$N`L:5$#LAQ859+1+\CN_/F\,=2D5/E.5S=&/8T%`N`@DH!_YKP&BC@ZB+!
MXJ8_I4:&15X#D`@.WS%-[OC,R[#9"@EVRO;-9*PD>/T-&9ZB.';7XW0+CJV(
M7J<T"JI3I^=OY7]1[-OZG<!BB<-/V'`C-T5H*RP7C6XH=_+=CV$JH3BTF7*G
MUH`R/EN!LK9OVZO:\>-(82#A?`K(4)@[13+G7JH%*&K'E#;,S\/W6)>?]:>`
M#(45LA(_6RALA7HZ72DO5PFV2P[99TG""FVPPQ^S%;Q;#JY^^.&"N0;FOH+G
MS)%[XKWE/M]GT702IUE"LR#)6Y[3B,Z"#-:J!\`PGG%_2+XY.Q\;\(SBE=1T
MST<B.%OQKR@FR'D<+7*!)#%(@,F*E6EZ%^J[0&'!R'T&Q2)2'DF:^U&X`*#P
MZD"BHO+YTY3X;<7WXID8R@LUYVN0!8K5M6FV-72L+!!;`;Q.E6.<CQ\D1G^P
M'(-Y`.(J6&19@DF^]^MU`!)KI;>+"3I;$;QH]8'-(N6.J-<!&1VB6%),^#77
MD&V\MF)ZW?JL+OT!<A-G@5ZYJ0C;@%Q0&'!,6.3K@0*BK8!8NS:"LZ>$YENF
M8)'?_0C0H#B6ZB[D(@2V(EL;XD.XS/(^`T1.;34B&<N8*(_<5CRJ72XFB\1_
MAAO,>LAR&YK@<T#H]#5"+'4..U(,M@),G;N,E)<-^#T-AQ%."Y`)"OMU%7<1
M(1Q!&%6[#*4<A&H?$5$;,NKA\!20T:;-=!F3@.MVV?RV,"K/H=SO01XX/`?D
MA&FQ7$8D8+A=QJLM?+<ZU9P$34`J:-R\:BS96W@$++?+"O5N+A:8F=/SMQV3
M\MEW%E60(T^_PI=9>A,5*8G^3H.GYXQ.SUYIXCW1JQ\T\8.43I+`E^8[V-\H
MR/`4HRYNZ99`'_<M)H&*M\NPII2:D="^)O)<5`W\&AGAB$1M1&6KBD.@FG4L
M>OM.MK.*VD['LXMG)@_`F0MC(W'4).?FF6:![R@%SVJ<2^?*C='IY./1:4^V
MWEQ=X%-FY=FL"8GC:4Y?NH()N@OJ(R?/=F*44Q2F<@Y5"DZY0#Y2\43D%(<)
M2<H3GUL!F"[DX9FLAIIC/-,(,>%\3T8XZJP(>.*3*D'2A60[=L,%3U'PJ[\8
M2X%T(<U.TT&"HQ&:&[N82`'YFNBZD)S'5HC@"$EZ>4WJ1"NZ&%L7LO6810B.
MD&1KKT7I%IPN)-+9S7ZL<STJ&7Z0%0;1OAAM07";`L=F1L-5N:T)37)3TMD\
M7D0RZXRL&>D-</B."FCCDZQ&9"N)SG:%#Y<&1"]]O@[C[ZEC"^%Z'&:&P9UF
MI'_B?%$TM`?V<:V%(J%JF0'[XC#G5BV*=LV``QSWD%VJ3,V``^&5X^<R`PYP
MW#2D/&F;`0=BWZ)6D5KW4#K`<=<PGJ6;"+I@][NC&=N#)DG,2D1/S]_^2.GT
M)AJ_T`3HB)[.X.;UFI<E9^%B0;2`OUO^8QSIG"#L_``9X-JY-Q6!KS46D5LR
M06*H-%6M8-@0Q;9ND5&ARFR!MF1UQ,#\1FT]5A@O\H.0;D!^B#7EJ['P-/%S
M9(ABXVI<#QN3G26[*@9UOJ0P9C_(92I1P_)G!$<Q\,;8Y2O3C@0LF64Q*`'?
M=\[8]Y`,47BO[%DQ)+*P9.UMI'3\3911X"<;1]^>XR1[H,G\W(O^`C6/TX"W
M(VFT(B,<)5'WI`':$JEM!CXM%"&B3RQ3EM.U`D284-#V2UK\MR2T965AC5.-
M?B<$QY-\XV<50XG82O/>T-*RC07F(`U>F7VB2.I"7[Q@>O6#K9;<,O%5NB$C
M%+N/(9'<%<4<=^UD[ZA7F.5B.LZ>:7*6IC237;EUFI,1"M>N6KIBC+=VGGC4
M.G+F^^S=-9UX;VRB/"3>5/:DIM<!.4*Q^S2D)T+$MA+)8[C;<&27SXM-[&9G
M%4X'!$?)U88T18C85A)Z#)I2[XS7V.,!P5'>=1]6X[I2LI5+/XMAHF#4Q9OH
M%:Z:#3YH&?X`.<(5WE+C0:L*<EOY^1NYA:VRLC[$9_X_%T%"3>P\6HW):(3"
M$FR14<YUS$`4M;/X(SIA[\`&\8+,LK=)Z$497$.9]^,+^T3F>*_="3E"\33>
MF"I5E$CMN@.(-*J>;!O;R\@QBCM>XYIG04JVJBR@/5]=!Y$7^0V>KPQ_@!RC
M>*FW<;ZJ@MQ6T0(,MTN0AT_I-+T&Z:Y"!L9)$2A4!!)(`]A4C<DQYJ-8%?(%
M^Z>>)&QE]<>@.?5DVM@:17#D"FI<XRQ(R589`??[)I,$'%+9?]AL>X5YQRR"
M><ZD;;.AS$/>H!N"I&BOR1YHC,]680&L&G(&<RA)WF!J_.F%"W/5V&I/CMMG
M=]('9JN&P$NN;S#()/L95`*%`:$)E1!GYC:V;!<J<165+0%[#B;]2B/8')TD
MF!LG3UX4_"M'PTH)QF$P+10D]ZI8(QW/EKN[%[Z'OFI<^JST3WJ#8U<SM1:`
MRR#UPSA=)/0!-.,<AOE74[+B_!2(#85/AT4=X"\:S0C.?@SNOF/4@Z<HF`4^
MLZ(6#]6P@$Y`.#Z<S%TL-KNCT`GW$#8BO:T4&/OT#Y?)5F>RZW5`>CB</54D
M\.>E"<:]S;:_?6%C?81K1B[5_P]02P,$%`````@`24%_1E0!):1B#0``:)L`
M`!$`'`!O<G!N+3(P,30Q,C,Q+GAS9%54"0`#J8X:5:F.&E5U>`L``00E#@``
M!#D!``#M76UOX[@1_G[`_0?5!8H]H(ZC9/=NDV[NH#AR5H!CN[%RW4-1'&B)
ML8F5*:]>DAA%_WN'E&3KE7JQ-Z=M]657%F?(9_B0P]%08C[\\K*VI"?LN,2F
M5SWYY+0G86K8)J'+J]Z#/NJ_[TF__/S]=Q_^U.]+MYAB!WG8E!9;Z09Y2'>0
M\=F-]"7Y1#YY+\'%^6G_#CG]LU/YG?1/6;Z4SR[E]_^2_JW<_4=2Y[K4EYZ?
MGT],J,'C-9P8]EKJ]UD[KK'":R1YR%EB;X+6V-T@`U_U5IZWN1P,%L1>6,CU
M^IL5<M:(*0Z@F;?RV;D,T"V\QM0;V<[Z!C\BW_*N>E]\9)%'@LV>!+92]])V
M-K1B?5QA)\LP/Y^?V,X21$[EP:>[\9RCC6JV"/V<D'Y9.%8D?SY@Q0ODXDB<
ME9K>3B$N_&X0%.Y$+4&]G\90<;Q2(A`FU/40-?8@,J!#$^6+BXL!+XU$?;>_
M1&BS$WY$[H*+A@6\X_JG<G_7=9>&[5//V29M=+%QLK2?!F$A4SM/J?F.`\.P
M2"\LS6G/Q"1?!PIRQ/&+L<J79R4Y"H0^8=?+5PG*<JRAB!ANO@XO8BIR4L4E
M1KX"%.2(`P'>=H/=7&IX28XMKK=Q"AJ!DIQ63+QQL,'F?^'XNA@@QW!L"P,"
MP^OCEXV%*/)L9SN"W[L.L2GUU_F5F)XS8(@'(-0'*>P08Z=7KA0J@">1I`^(
M4AM<#+@F_IO=V6P(?;3#GW"#C>]+!E@'=8E=/-QK0N_`K;NQ#9]Y&H6:*O6(
MM]6@5I!@;?4D`ATDE-BU'R$P\2.AA".53V7PCY%Z_!*JDH*ZI%AE'P;I&K[_
M+EV][V)S2G_FU\"A"[5Q7>8X0OU01*R[;Z2NIH$LP[<*&PW5!@DZ8E4VY>D:
M6<S9S5<8>VY`3/*6F(DSZ/XY=!4.J;A6QLIDJ$KSCZJJS[N>K]KS,P0.VUMA
MCP":'!J2Y6).SH6<2&\2=?W0<23@:->-[O1QNF&A'0`(ITE!F9B;MRENYKJB
MJW?J!'B9CJ3I3+U7=&TZZ69.55:&*T27V-7H'(3PRK9,"+75+SZL`5F:1,)B
MWMX)>1M^5":WZES2)C#)E'OUXW1\H][/__+G\XN_2>K?'S3]MX[0PPG-<9*-
M-,54_W@HU9V';4H]<E<CRW[.<;#[(C%Y/XG)4^8?I=%X^H_.OXHX";(8X0R+
M?HC[_3T+PXEK6+;K.QA^W*H36,O&73^+QCY94O((/@(>@@S^K$_H<F9;Q"`X
MF@-"$3$G%VE.YMKM1!MI0V6B2\IP.'V8Z-KD5II-Q]I04[LY(>+J'AN8/*&%
MA5UXRIPY>(.(J;YL,'4CKL0B0J[DTS17]^I0U7Y5KL>PUBB3&VEVK\X4[492
M/\W4R;PC2TC6S+$A(/>V++4`Z_^&+083[`4T%16*"9+3!,WN6;0.JSUCARW\
M,[;,_%6:J'K'C8";*<1%3NC+X+%VR^9+0$QNB9B5LS0K4_VC>A\YM[DT4WYC
M4Z@C1$"(1N$2Z^@E\F/Q&^+N/T]WOS893N]425<^=1Y*V.E#FZ_D8.^8H`6Q
M`#M?-8;V>DT\'O0&9%01%)/T-DW2<,K7??!6TEA3KK6QIFOA*@/LW6DZCY<[
M^D216U&RH69>07Z7B=&Z_$&3X,QBFR[PV.UMP[0IFR.Z@ZB+C%C.KHJ@F+`?
MLX':&!XQ(4!36#`0YEJ#V:3?*Y.Y,NP2>F7\C0@%*@BRHF@Y6()V(9N@7,S6
M3VFV1MH$^-&4\2Z0EMX$B]8/7>A6ZO7\A8N_^&"O^K1?H3)WQ91D,@7SA^LY
M^#BV'*F_=BO/(3F#&KF#:CD$N6X.07H35=RE/1O3J/,<0@420T$AA6>9U$(I
MA4&U'8&-\T%Q`JL(B@G,I![*<D,=@P<DB>+<B47$K&52$X*$44=8T\Q1G"U!
MN9BJ3!HC/XO4L50SG10G)WM;S$DF:Q%/+75,'"G'%&>HNKB8N4Q*HUJ^J>.T
M6>(I$2P6E8H9R^0TBM]LZ#@Z2C8J&2!6%1>SF,EU5,Q,=:0>EJ**<UDJ):8P
MDQLI2U=UW-5XG^4&>XA8KHY?/#_U=DNJ2,Q2)B<2ONLBO0FKD<)Z.E8:IT#"
MGJR0`XDDA9R=UT^"A/5V'![*86*^U5$0,YK)BE1EM)N=!^>W$K.SDJ28RTRN
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MXLH_`?J_GG#L'W8*ZCU^E/CQHI?LY,:KGDO6&_:M?'!OY>#'JQX[JK4?'<?Z
M.QA]\K*V(A'6@N"@4TYVNI_"AJ,JPL,JQ<>?0B5\(XI@=Q"![TF#(QH&C-0U
M+$EB.\VRT**N6:""K?9:!!.@KD6I.7-<NX+Y%C_4%'[%#SWEM\`LV_$DFCE,
M670Z<'`.\]@V>%4"%?:K'^GUV:V^?-8_ET]>7'/?^W5`[&VL!R+2:P`B_^SE
MBLU'"JS==U5;%!Z>7-`P;S17<8`MSXWN]/=5U;)?<)"Q"%".6GC=WU?1"$C>
M`=%5D,3UHA\'8\D[=+H2F+CB[M>A'&7.IZX"9:?$KPZ%D#V[N@J&O59PV=]7
MT`A%^D#L*A@B'79Q</OIL[(K`8B4^%4#"-ESM_EB0_&2/5%6\UR6XR2TF/NZ
M8&Y3_O%@&!6=9PR"=Y3FQ:>/5X44KT7=5](`H?`,^BHC)=)A%PTFK/B4]$H=
MDM8ZE*?\`][K(;'II#$8\='XS5=>7E<Q1>&?IN"`Q*?#*PN7_54,&*]!6,K_
MHL,EW"-TJ7EXS9ZJ>A(*I:YZGN.SH)5+09A(;%/G>J;OA.?14V)9[.VK2-:%
MQUMHU&>EMX[M;Z)&"%0?/`&SN/?W:B@+3)Q[MO%9<UT?FS<^PS[CV*:.22AR
MMGS[P0W*=7L$BS3;B/@560Q@W/"U#<X!%/),?T266]/V0'81I-NN>H:#3>)5
M[Y)#K#IF1P5W4T,DD#Q./WW5#HG0U^L1WHWL-J-N^IALXAL<-"7V%'2.1J%Y
M>,JYP<'_&BTYO+.]_5+;E'KC93_VR@=,F^9.&>Z"7IBA;?`9LZT87WSBX/D*
M5D`=.^MK1#_?X(WM$J_-PZ&B`07F"X?.D#]V'</Z(-/AE1IOXD4=VZNA+QK_
M$+28O@5#)?S@3P^.'7WE^,'T+E>@Z1C^`FNID5Z`L,"@W=[)_I#T?4:=?T^U
M99GS:POF3V1F\$>%+KWH_BO/Y7J0BXC,&?!N.^VM!K7`SK%-ETRWW2:6HBQR
MQ.&'*S,+!;%S]/6*"LVNV:/V@XL??6M,GMAKWNR/:A$.]1[*@J_AV]85QS6I
M:/27'@;6*I=6`6W=`3('_&2Y\L:$8H@%#+9UM=Q9S0;`)KA[G"7K8/:+\#99
MHMOSV%L19A,C]TM"VV9X?=A-[&_=+*Z"MHFA;$:PIM*/&6T;SC&<!68.[?7&
M]^"AG4U\"QN>8U-B[%S`'5XOL),:Q*:]1H2^KID5<1XX:]NX.#?$WF05;M&P
MKHJSP,S"X_3:Y)T$(&N8U2+22N`5I[P2I^NUB:(LMG(C6D1(/JK"I:#:&7IM
MXJ<ZYN9&MXC/>F@+3%:6#N:_E1?R^C8!F2:!UMF?E$^1F0)6!O^&AR$MB$TR
MB`I]!'MMAAL8:;0FOA)@*WK,]1UCA5S</EL*D94F6./O["<>$]H6%-:#7)B/
M1`[.=%:P#Z';USC8NVC#3DI%H+7LY/MS16:V:^NDH@'%2YSK6RQ'U)H9FH4D
MHB[\C+$UZ/-`E6UUY)^IV:90JA1J;1-;%#A5`EE@(-L"&>'7W6NON;^XAUA@
M@[K>6/86X];,H32@4M\UI>T!GXNJU`+]V6ZA!3%4A<FS?831&@/R0!W^!M;#
MQJ8SASQ!U3,+&?MEMM71P5'L^SJ=U_:7<>K:4?ADYV$H!W?PK;V54X:\P.#P
M/8\6K?!91$5+88MW.>KO;-SZR`$OCO'(=F!(\Q=X^6ME8QQ_5FCOJU&5#2A<
M7RU"1[8+P[@U-.9@*D`_`2;"2(A[J.F&U=T:0\3P2EYAU>B=3;V5M87(M,6Q
M<S[<TFCNVJ:^>\N&KD:#M:3%-HIA-[!5,4T2`/TF;=[#+PI[L&%3\P8;?*A#
MC*RO;-]%U!S9O@/.JCU3M#)248:%?5?+-A'8LW'P_8<#W;7D<M?;O4CX#J_R
MC!PS\`6N;L><A'L#0=/TD?=U<FB84/!'9`V_CF6OTI=3WV,K+@2HRXD?'VU_
M=";V:UKX*CVKOF#'("Z&*-_8+4WA^W>\FF^Z5U/6O5*/;DC0"VR>_(]-_;1Q
MK$<_#()O"7GG_A=02P$"'@,4````"`!)07]&TW7F<R:L``!NQ0L`$0`8````
M```!````I($`````;W)P;BTR,#$T,3(S,2YX;6Q55`4``ZF.&E5U>`L``00E
M#@``!#D!``!02P$"'@,4````"`!)07]&`AJ#L-<(``"(>```%0`8```````!
M````I(%QK```;W)P;BTR,#$T,3(S,5]C86PN>&UL550%``.ICAI5=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`24%_1F(YV2_W+0``SQ\#`!4`&```````
M`0```*2!E[4``&]R<&XM,C`Q-#$R,S%?9&5F+GAM;%54!0`#J8X:575X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`$E!?T:;5R"?*4```*E[`P`5`!@`````
M``$```"D@=WC``!O<G!N+3(P,30Q,C,Q7VQA8BYX;6Q55`4``ZF.&E5U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`!)07]&+'<90[HU``"GNP,`%0`8````
M```!````I(%5)`$`;W)P;BTR,#$T,3(S,5]P<F4N>&UL550%``.ICAI5=7@+
M``$$)0X```0Y`0``4$L!`AX#%`````@`24%_1E0!):1B#0``:)L``!$`&```
M`````0```*2!7EH!`&]R<&XM,C`Q-#$R,S$N>'-D550%``.ICAI5=7@+``$$
?)0X```0Y`0``4$L%!@`````&``8`&@(```MH`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 0.85in"> <div>NOTE 11:-</div> </td> <td style="TEXT-ALIGN: justify"> <div>SUBSEQUENT EVENTS</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 78pt; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.85in"></td> <td style="WIDTH: 0.25in"> <div>1.</div> </td> <td style="TEXT-ALIGN: justify"> <div>During January 2015, a wholly-owned subsidiary was established in the state of Delaware named BioBlast Pharma Inc.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.85in"></td> <td style="WIDTH: 0.25in"> <div>2.</div> </td> <td style="TEXT-ALIGN: justify"> <div>On February 2, 2015, the Company appointed a new&#160;President and Chief Executive Officer and a member of its board of directors. As part of the agreement the new CEO was granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 498,067</font>&#160;options to purchase&#160;Ordinary&#160;shares with exercise price of $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8.47</font> per share.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>&#160;</b></div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.85in"></td> <td style="WIDTH: 0.25in"> <div>3.</div> </td> <td style="TEXT-ALIGN: justify"> <div>On February 16, 2015,&#160;the Company's board of directors resolved to issue&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 24,000</font> options to employees with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.17</font> per share.&#160;</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPMAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,441</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 732</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 140</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">2,639</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">416</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">86</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="nump"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">7,080</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">1,148</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">226</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses (income), net</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(58)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(3)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">7,022</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">1,145</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">229</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Deemed dividend</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendsIncomeStatementImpact" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendsIncomeStatementImpact</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendsIncomeStatementImpact" onclick="toggleNextSibling(this);">26</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendsIncomeStatementImpact</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockDividendsIncomeStatementImpact" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockDividendsIncomeStatementImpact</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Loss attributable to holders of Ordinary shares</a></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ 7,022</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ 1,171</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ 229</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.57)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.14)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.03)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of Ordinary shares used in computing basic and diluted loss per share (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">12,259,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">8,423,018</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">7,551,427</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"><strong><font style="FONT-SIZE: 10pt">NOTE 5:-</font></strong></font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"><strong><font style="FONT-SIZE: 10pt">OTHER ACCOUNTS PAYABLE</font></strong></font></div> </td> </tr> </table> &#160;&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Employees and payroll accruals</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>235</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>995</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">NOTE 4:-</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">PROPERTY AND EQUIPMENT, NET</font></strong></div> </td> </tr> </table> &#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Cost:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Computers and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="62%"> <div>Electronic equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="62%"> <div>Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>32</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Accumulated depreciation:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Computers and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>*)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Electronic equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Depreciated cost</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.85in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> *)&#160;&#160;&#160;&#160;&#160;Represents an amount lower than $&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.85in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Depreciation <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> expenses for the years ended December 31, 2014, 2013 and 2012 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>, less</font>&#160;than $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>,&#160;respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Employees and payroll accruals</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>235</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>760</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>995</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">a.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Use of estimates:</div> </td> </tr> </table> &#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> &#160;&#160;&#160;&#160; <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; BORDER-TOP-COLOR: #000000; WIDTH: 0.75in; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">b.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">New accounting pronouncements:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In June 2014 the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 10-2014 ("ASU 10-2014") regarding development stage entities. The ASU removes the definition of development stage entity, as was previously defined under U.S. GAAP, from the accounting standards codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of income, cash flow and stockholders' equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments to ASU 10-2014 are effective for annual reporting periods beginning after December 15, 2014. The Company has applied the ASU in these financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">In 2014, the FASB issued ASU 15-2014, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management&#8217;s responsibility to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is currently evaluating the effect, if any, that the adoption of this guidance will have on the Company&#8217;s financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_FinancialStatementsDisclosurePolicyTextBlock', window );">Financial Statements Disclosure [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">c.</font> <div style="CLEAR:both;CLEAR: both">&#160;</div> </div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Financial statements in U.S. dollars:</font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company finances its operation in U.S. dollars. The majority of the Company's operations are currently conducted in Israel, a significant part of the Company's expenses are denominated and determined in U.S. dollars. The Company's management believes that the dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, the functional currency of the Company is the U.S.&#160;dollar.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company's transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been remeasured to U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830, "Foreign Currency Matters", of the FASB. All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> d.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Cash equivalents:</font></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ShortTermBankDepositsPolicyTextBlock', window );">Short Term Bank Deposits [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.75in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="72"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> e.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Short-term bank deposits:</font></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Short-term bank deposits are deposits with maturities of more than three months but less than one year.</font> Short&#150;term bank deposits are presented at their cost, including accrued interest, which approximates fair value. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">As of December 31, 2014, the Company's bank deposits were in U.S. dollars and bore interest at a weighted average interest rate of 0.66%.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"></div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">f.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Property and equipment, net:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Computers and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Electronic equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company's property and equipment are reviewed for impairment in accordance with ASC 360, "Property, Plant, and Equipment," whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to&#160;be recognized is measured by the amount by which the carrying amount of the assets exceeds&#160;the fair value of the assets.&#160;Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2014, 2013 and 2012 no impairment losses have been identified.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_LongTermDepositsPolicyTextBlock', window );">Long Term Deposits [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">g.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Long-term deposits:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Long-term deposits include long-term deposits for motor vehicles under operating leases, presented at their cost.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">h.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Research and development costs:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Research and development costs are expensed as incurred. Those expenses includes payments to third party clinical consultants, expenses related to conducting clinical trials, salaries and related personnel expenses, travel expenses, and share based <font style="BACKGROUND-COLOR: transparent">compensation expenses related to research and development employees.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">i.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Income taxes:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company accounts for income taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2014 and 2013 the Company has not recorded a liability for uncertain tax positions.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">j.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Concentrations of credit risk:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cash and cash equivalents are invested in major banks in Israel. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">k.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Fair value of financial instruments:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has no financial instruments that are measured at fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 74.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The carrying amounts of cash and cash equivalents, <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 10pt"> short-term&#160;</font> bank deposits, accounts receivable and accounts payable, approximate their fair value due to the short-term maturities of such instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">l.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Basic and diluted loss per share:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Basic net loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year plus dilutive potential equivalent Ordinary shares considered outstanding during the year, in accordance with ASC 260, "Earnings per Share."</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.999in; FONT: 10pt Times New Roman, Times, Serif" align="justify">For the years ended December&#160;31, 2014, 2013 and 2012, all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 54pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">m.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">Accounting for stock-based compensation:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0px 0in 0.4in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based compensation in accordance with ASC 718, "Compensation - Stock Compensation" ("ASC 718") that requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees and directors. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the option award is recognized as an expense over the requisite service periods in the Company's statements of operations based on the accelerated method.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">The Company selected the Black-Scholes-Merton ("Black-Scholes") option-pricing model as the fair value method for of its stock-options awards. The option-pricing model requires a number of assumptions as noted below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-SIZE: 10pt">Expected dividend yield</font></i> <font style="FONT-SIZE: 10pt">- The expected dividend yield assumption is based on the Company's historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-SIZE: 10pt"> Volatility</font></i> <font style="FONT-SIZE: 10pt">- Since the Company's shares started trading on NASDAQ in July 2014, sufficient quoted prices of the Company's share are unavailable. Due to insufficient historical data for the Company, the expected volatility determination was based on similar companies' stock volatility.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-SIZE: 10pt">Risk free interest rate</font></i> <font style="FONT-SIZE: 10pt">- The risk free interest rate is based on the yield of U.S. Treasury bonds with equivalent terms.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-SIZE: 10pt">Expected term</font></i> <font style="FONT-SIZE: 10pt">- ASC 718 provides the factors to consider when estimating the expected term of an option: an option's expected term must at least include the vesting period and the employees' historical exercise and post-vesting employment termination behavior for similar grants. It also determines that if the amount of past exercise data is limited, that data may not represent a sufficiently large sample on which to base a robust conclusion on expected exercise behavior. In that circumstance, it may be appropriate to consider external data or the SEC staff's "simplified" method for the expected term. Accordingly, the Company used the "simplified" method, meaning the expected life can be set as the average of the vesting period for each vested tranche of options and the contractual term for those options.</font></div> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_FinancialStatementsDisclosurePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding functional currency used in the operations of the business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_FinancialStatementsDisclosurePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_LongTermDepositsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of long term deposits of the entity which includes long-term deposits for motor vehicles under operating leases, presented at their cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_LongTermDepositsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ShortTermBankDepositsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for short-term bank deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ShortTermBankDepositsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 0.85in"> <div style="CLEAR:both;CLEAR: both">NOTE 8:-</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">SHAREHOLDERS' EQUITY</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> a.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> General:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>All Ordinary shares, options, per share data and exercise price included in these financial statements for all periods presented have been retroactively adjusted to reflect the issuance on January 26, 2014 of 6.55-to-one bonus shares (equivalent to a 7.55-for-1 stock split).</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> b.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Share capital:</font></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share in the distribution of dividends, if any, declared by the Company.</div> &#160; <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> c.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Issuances of share:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;&#160;&#160; <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 106px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both">1.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">On January 22, 2012 (inception day), the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,551,427</font> Ordinary shares in consideration of their par value.</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 106px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both">2.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">In February 2012, the Company entered into an investment agreement, according to which the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 471,964</font> Preferred A shares in consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250</font>. In addition, in August 2012, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 94,393</font> Preferred A shares in consideration of $&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>. The issuance expenses amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 113.4pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 106px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 23px; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both">3.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">In June 2013, the Company entered into a share purchase agreement according to which, the Company&#160;issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,130,159</font> Ordinary shares in consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,024</font>, in two equal installments in 2013 and January 2014.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 113.4pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.35in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Prior to the closing of the share purchase agreement above and as a condition to it, the Company affected an equity restructuring, under which, all of the Company's Preferred shares (566,357 Preferred A shares) were converted into Ordinary shares at a 1:1 ratio</font>. As a result and in accordance with ASC 718-20-35-6, the Company recorded compensation expense in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">183</font> and a deemed dividend in the amount of $ <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">26</font> in the year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 113.4pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="106"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">On February 6, 2014, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 782,537</font> Ordinary shares to private placement investors in consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,368</font>, net.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 113.4pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.1in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="106"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div>On August 5, 2014, the Company completed a successful IPO of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,200,000</font> Ordinary shares at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11.00</font> per share generating net proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,405</font>, after deducting underwriting discounts and commissions and other issuance expenses.&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> d.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2013 Incentive option plan:</font></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">In December 2013, the Company authorized through its 2013 incentive option plan (the "2013 Plan") the grant of options to officers, directors, advisors, management and other key employees. The options granted have a graded vesting schedule of generally four years and expire ten years after the grant date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.3pt; FONT: 10pt Times New Roman, Times, Serif" align="left">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company's options activity (for employees and directors) under the 2013 Plan is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.18in; WIDTH: 82%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%" colspan="9"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="22%" colspan="4"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="22%" colspan="4"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>Number&#160;of<br/> options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> average<br/> exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>Number&#160;of<br/> options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> average<br/> exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>403,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>319,531</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>380,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>83,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Outstanding at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>783,332</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>403,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Vested and expected to vest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>783,332</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>403,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Options exercisable at the end of the year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>429,589</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>134,370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">As of December 31, 2014, the weighted-average remaining contractual term of the outstanding and exercisable</font> options is 5.6 years and 2.3 years; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">the aggregated intrinsic value of the outstanding and exercisable</font> options is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,664</font></font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,174</font></font>. As <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">of December 31, 2014, the unrecognized compensation cost</font> is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">889</font></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">to be recognized through 2017</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> e.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div>Options granted to service providers:</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company granted options to certain service providers and accounted for these options in accordance with ASC 505-50, "Equity-Based payment to non-employees".</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0in 0in 0pt 56.7pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The outstanding options granted to the Company's service providers are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.18in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div>Grant&#160;date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%"> <div>Number&#160;of<br/> options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div>Expiration&#160;date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="24%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="24%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>December 2, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>20,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>7.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>December 2, 2024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> *)&#160;&#160;All options were fully vested on the grant date.</font></div> &#160; <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">f.</font> <div style="CLEAR:both;CLEAR: both">&#160;</div> </div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Share-based payment:</font></div> </td> </tr> </table> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The share based expense recognized in the financial statements is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1.18in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended<br/> December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>General and administrative expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>653</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>210</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>736</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>254</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 0.85in"> <div>NOTE 6:-</div> </td> <td style="TEXT-ALIGN: justify"> <div>INCOME TAXES</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.85in"></td> <td style="WIDTH: 0.25in"> <div>a.</div> </td> <td style="TEXT-ALIGN: justify"> <div>Tax laws applicable to the Company:</div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> Taxable income of Israeli companies is subject to tax at the rate</font> of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font></font>% in 2012 and 2013&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> and a rate of</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 26.5</font>% in 2014 and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> afterwards</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"><font style="FONT-SIZE: 10pt">b.</font></font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"><font style="FONT-SIZE: 10pt">Net operating losses carry forward:</font></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal">The Company has accumulated losses for tax purposes as of December&#160;31, 2014 in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">684</font>, which may be carried forward and offset against taxable income in the future for an indefinite period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'"> <strong>&#160;</strong></font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"><font style="FONT-SIZE: 10pt">c.</font></font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"><font style="FONT-SIZE: 10pt">Deferred income taxes:</font></font></div> </td> </tr> </table> &#160;&#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> Significant components of the Company's deferred tax assets are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Operating loss carry forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>166</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"> <div>Research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>923</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>142</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Issuance expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>671</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Net deferred tax asset before valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>312</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,791)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(312)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Net deferred tax asset</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: bold 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"> Management currently believes that since the Company has a history of losses it is more likely than not that the deferred tax regarding the loss carry forward and other temporary differences will not be realized in the foreseeable future.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 1.1in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"> </font>&#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"></td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"><font style="FONT-SIZE: 10pt">d.</font></font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-WEIGHT: normal"><font style="FONT-SIZE: 10pt">No liability for uncertain tax positions was recorded as of December 31, 2014 and 2013.</font></font></div> </td> </tr> </table> &#160; <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 18pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both">e.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowances in respect of deferred taxes due to the uncertainty of the realization of such deferred</font> taxes.</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONTINGENT LIABILITIES AND COMMITMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"> <strong><font style="FONT-SIZE: 10pt">NOTE 7:-</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"> <strong><font style="FONT-SIZE: 10pt">CONTINGENT LIABILITIES AND COMMITMENTS</font></strong></div> </td> </tr> </table> &#160; <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 62pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">a.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt; FONT-WEIGHT: normal"> The Company is engaged in an operating lease agreement for its office facilities. The rent expenses for the years ended December 31, 2014, 2013 and 2012&#160;amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Future minimum payments under the lease are as follows:</font></div> </td> </tr> </table> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.5in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div style="CLEAR:both;CLEAR: both"> Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="47%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">117</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">288</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 74.7pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 1.1in" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company has provided bank guarantees in the amount of&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> as security for the performance of its lease agreement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 74.7pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> b.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">During 2014 the Company entered into a new operating lease agreement for its vehicles until 2017. Future minimum payments under the lease are $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>. The lease expenses for the years ended December 31, 2014, 2013&#160;and 2012&#160;amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font>, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font> &#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> c.</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">License agreement:</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 113.4pt"> &#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="120"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">(i)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company entered into a Research and Exclusive License Agreement with Yissum Research Development Company of the Hebrew University in Jerusalem Ltd., for the use, development and commercialization of TAT-MTS- Protein for protein replacement in mitochondrial diseases. The consideration to Yissum is composed of a tiered low single digit royalties on net sales and a sublicense fee that will not exceed the mid-high ten to twenty percent range of the sublicense consideration, but, if the sublicense arises from the sales of a product, the sublicense fee shall not be less than a low single digit percent of the gross sales of such product.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify">&#160;</div> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 1.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="120"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt">(ii)</font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company entered into an Exclusive License Agreement with Ramot at Tel Aviv University Ltd. for the use, development and commercialization of our read-through platform. The consideration to Ramot is composed of a tiered low single digit royalties on net sales and a sublicense fee that will not exceed the mid to high single digit percent range of payments or other consideration that the Company receives in connection with a sublicense.</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" border="0" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 0.85in"> <div style="CLEAR:both;CLEAR: both">NOTE 9:-</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">RELATED PARTY BALANCES AND TRANSACTIONS</div> </td> </tr> </table> <font style="FONT-WEIGHT: normal">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 1.1in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-WEIGHT: normal"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Balances with related parties:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-WEIGHT: normal"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Trade payable (d)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Other accounts payable (a) (b) (c)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>123</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-WEIGHT: normal"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 53pt; MARGIN: 0in 0px 0in 0.35in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-WEIGHT: normal"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Related parties' expenses:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Amounts charged to: *)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Research and development expense (c)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>General and administrative expense (a) (b) (c) (d)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>467</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <table style="BORDER-BOTTOM-COLOR: #000000; MARGIN-TOP: 0pt; BORDER-TOP-COLOR: #000000; WIDTH: 1604px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; HEIGHT: 53px; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000" cellspacing="0" cellpadding="0" width="1604"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>a.</div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"> In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately</font> <font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"> $</font><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font></font></font> per <font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"> month. During August 2014, the monthly fee was increased to an amount of $<font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font></font> effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $<font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80</font></font> in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $<font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70</font></font> with regards to services provided during 2014</font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>b.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and an office lease for a monthly fee in the amount of</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> approximately <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> $</font></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font></font> <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> since September 10, 2013. The parties terminated the agreement on September 1, 2014.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-WEIGHT: normal"> &#160;</font></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">c.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> approximately <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> $</font></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font></font> per month. <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> During August 2014, the monthly fee was increased to an amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19</font> effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90</font> in connection with the consummation of the IPO.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">d.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> On July 1, 2013, the Company signed an agreement with a consultant, who is also one of the Company's shareholders, to render advisory services. The Company pays the consultant an amount</font> of <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> $</font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font></font> per month<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2BAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details Textual) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Represents an amount lower than $1.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RECEIVABLES AND PREPAID EXPENSES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ReceivablesAndPrepaidExpensesAbstract', window );"><strong>Receivables and Prepaid Expenses [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock', window );">Receivables and Prepaid Expenses Disclosure [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Government authorities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>274</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ReceivablesAndPrepaidExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ReceivablesAndPrepaidExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the various types of receivables and the amounts paid in advance for capitalized costs for the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ReceivablesAndPrepaidExpensesDisclosureTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.3pt; FONT: 10pt Times New Roman, Times, Serif" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">A summary of the Company's options activity (for employees and directors) under the 2013 Plan is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.18in; WIDTH: 82%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%" colspan="9"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="22%" colspan="4"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="22%" colspan="4"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>Number&#160;of<br/> options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> average<br/> exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>Number&#160;of<br/> options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> average<br/> exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Outstanding at beginning of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>403,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>319,531</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>380,222</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>83,579</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Outstanding at end of year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>783,332</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>403,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Vested and expected to vest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>783,332</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.47</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>403,110</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Options exercisable at the end of the year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>429,589</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>134,370</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0004</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The share based expense recognized in the financial statements is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1.18in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended<br/> December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>General and administrative expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>653</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>210</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>736</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>254</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=orpn_NonemployeeStockOptionMember', window );">Nonemployee Stock Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.3pt; FONT: 10pt Times New Roman, Times, Serif" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">The outstanding options granted to the Company's service providers are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1.18in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div>Grant&#160;date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%"> <div>Number&#160;of<br/> options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Exercise<br/> price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div>Expiration&#160;date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="24%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="24%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>December 2, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>20,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>7.78</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>December 2, 2024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=orpn_NonemployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=orpn_NonemployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Details 1) (Nonemployee Stock Option [Member], December 2, 2014 [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Nonemployee Stock Option [Member] | December 2, 2014 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant', window );">Sharebased Compensation Arrangement By Sharebased Payment Award Options To Nonemployees Date Of Grant</a></td>
        <td class="text">Dec.  02,  2014<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber', window );">Sharebased Compensation Arrangement By Sharebased Payment Award Options To Nonemployees Outstanding Number</a></td>
        <td class="nump"><a title="orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber[us-gaap_AwardDateAxis=orpn_SecondDecemberTwoThousandFourteenMember;us-gaap_AwardTypeAxis=orpn_NonemployeeStockOptionMember]" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber<br>/ us-gaap_AwardDateAxis<br>= orpn_SecondDecemberTwoThousandFourteenMember<br>/ us-gaap_AwardTypeAxis<br>= orpn_NonemployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice', window );">Sharebased Compensation Arrangement By Sharebased Payment Award Options To Nonemployees Exercise Price</a></td>
        <td class="nump"><a title="orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice[us-gaap_AwardDateAxis=orpn_SecondDecemberTwoThousandFourteenMember;us-gaap_AwardTypeAxis=orpn_NonemployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 7.78</a><span style="display:none;white-space:normal;text-align:left;">orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice<br>/ us-gaap_AwardDateAxis<br>= orpn_SecondDecemberTwoThousandFourteenMember<br>/ us-gaap_AwardTypeAxis<br>= orpn_NonemployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate', window );">Sharebased Compensation Arrangement By Sharebased Payment Award Options To Nonemployees Expiration Date</a></td>
        <td class="text">Dec.  02,  2024<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It denotes the grant date of non-employee awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesDateOfGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It denotes the exercise price of non-employee options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It denotes the expiration date of non-employee awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesExpirationDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-employee options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsToNonemployeesOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAQBI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit during Development Stage [Member]</div>
        </th>
        <th class="th">
          <div>Preferred Class A [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jan. 22, 2012</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jan. 22, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue', window );">Issuance of Ordinary shares to founders</a></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">20</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(20)</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares', window );">Issuance of Ordinary shares to founders (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">7,551,427</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of Preferred A shares, net ($0.53 per share)</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther" onclick="toggleNextSibling(this);">295</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">294</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueOther[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueOther<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of Preferred A shares, net ($0.53 per share) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">566,357</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(229)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(229)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">20</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">283</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(229)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">7,551,427</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">566,357</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred A shares into Ordinary shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">(1)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Preferred A shares into Ordinary shares (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">566,357</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">(566,357)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Deemed Dividend</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">26</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(26)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares', window );">Issuance of Ordinary shares, net ($0.95 per share)</a></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" onclick="toggleNextSibling(this);">991</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">988</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares', window );">Issuance of Ordinary shares, net ($0.95 per share) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,065,083</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">254</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">254</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(1,145)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(1,145)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">175</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">24</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,551</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(1,400)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,182,867</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares', window );">Issuance of Ordinary shares, net ($0.95 per share)</a></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares" onclick="toggleNextSibling(this);">1,012</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,009</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares', window );">Issuance of Ordinary shares, net ($0.95 per share) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,065,076</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue', window );">Issuance of Ordinary shares upon private placement, net ($6.07 per share)</a></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue" onclick="toggleNextSibling(this);">4,368</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">4,365</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares', window );">Issuance of Ordinary shares upon private placement, net ($6.07 per share) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">782,537</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Ordinary shares upon initial public offering net ($11 per share)</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues" onclick="toggleNextSibling(this);">31,405</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">31,396</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary shares upon initial public offering net ($11 per share) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">736</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">736</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(7,022)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(7,022)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 30,674</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 39</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 39,057</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">$ (8,422)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">14,230,480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_PreferredClassAMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of ordinary stock issued to founders during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of ordinary stock issued to founders during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedToFoundersValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of ordinary stock issued upon private placement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of ordinary stock issued upon private placement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_StockIssuedDuringPeriodOrdinarySharesIssuedUponPrivatePlacementValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of ordinary stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_StockIssuedDuringPeriodSharesIssuanceOfOrdinaryShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of ordinary stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_StockIssuedDuringPeriodValueIssuanceOfOrdinaryShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RECEIVABLES AND PREPAID EXPENSES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ReceivablesAndPrepaidExpensesAbstract', window );"><strong>Receivables and Prepaid Expenses [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock', window );">Receivables and Prepaid Expenses Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.85in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="82"> <div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">NOTE 3:-</font></strong></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;TEXT-ALIGN: justify; LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> RECEIVABLES AND PREPAID EXPENSES</font></strong></div> </td> </tr> </table> &#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.85in; WIDTH: 87%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Government authorities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>93</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>Prepaid expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>181</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>274</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ReceivablesAndPrepaidExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ReceivablesAndPrepaidExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for claims held for amounts due a entity and the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ReceivablesAndPrepaidExpensesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 40pt; MARGIN: 0pt 0px 0pt 40pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;&#160;<font style="FONT-WEIGHT: normal">Balances with related parties:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 40pt; MARGIN: 0pt 0px 0pt 40pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="WIDTH: 83%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 85.05pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div style="CLEAR:both;CLEAR: both">2013</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 74%"> <div style="CLEAR:both;CLEAR: both">Trade payable (d)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> <div style="CLEAR:both;CLEAR: both">2</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> <div style="CLEAR:both;CLEAR: both">1</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">Other accounts payable (a) (b) (c)</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">123</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">36</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><font style="FONT-WEIGHT: normal"> &#160;</font></div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>a.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately $6 per month. During August 2014, the monthly fee was increased to an amount of $15 effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $80 in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $70 with regards to services provided during 2014.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">b.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and an office lease for a monthly fee in the amount of approximately $4 since September 10, 2013. The parties terminated the agreement on September 1, 2014.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">c.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of approximately $15 per month. During August 2014, the monthly fee was increased to an amount of $19 effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $90 in connection with the consummation of the IPO.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 56.7pt"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">d.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">On July 1, 2013, the Company signed an agreement with a consultant, who is also one of the Company's shareholders, to render advisory services. The Company pays the consultant an amount of $1 per month.</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock', window );">Schedule Of Related Party Expenses [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 53pt; MARGIN: 0in 0px 0in 0.35in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-WEIGHT: normal"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Related parties' expenses:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 56.7pt; MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 1.1in; WIDTH: 83%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="8"> <div>Year&#160;ended&#160;December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2012</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Amounts charged to: *)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Research and development expense (c)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>145</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>General and administrative expense (a) (b) (c) (d)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>467</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <table style="BORDER-BOTTOM-COLOR: #000000; MARGIN-TOP: 0pt; BORDER-TOP-COLOR: #000000; WIDTH: 1604px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; HEIGHT: 53px; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000" cellspacing="0" cellpadding="0" width="1604"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>a.</div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"> In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company's shareholders and a director, to render management, finance and operation services. The Company pays the consultant an amount of approximately</font> <font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"> $</font><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font></font></font> per <font style="LINE-HEIGHT: 115%; FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"> month. During August 2014, the monthly fee was increased to an amount of $<font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font></font> effective immediately. In August 2014, the Company granted the consultant bonus in the amount of $<font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80</font></font> in connection with the consummation of the IPO. The Company granted an additional bonus in the amount of $<font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman,serif"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70</font></font> with regards to services provided during 2014</font>.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>b.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and an office lease for a monthly fee in the amount of</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> approximately <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> $</font></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font></font> <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> since September 10, 2013. The parties terminated the agreement on September 1, 2014.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -27.75pt; MARGIN: 0pt 0px 0pt 84.45pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-WEIGHT: normal"> &#160;</font></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">c.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> An agreement was signed on August 20, 2013 between the Company and one of its shareholders, as a consultant to render management, finance and operation services for an amount of</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> approximately <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> $</font></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font></font> per month. <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> During August 2014, the monthly fee was increased to an amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19</font> effective immediately. In August 2014, the Company granted the consultant a bonus in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90</font> in connection with the consummation of the IPO.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -28.35pt; MARGIN: 0pt 0px 0pt 85.05pt; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="BORDER-BOTTOM-COLOR: #000000; TEXT-ALIGN: left; BORDER-TOP-COLOR: #000000; WIDTH: 52pt; BORDER-RIGHT-COLOR: #000000; VERTICAL-ALIGN: top; BORDER-LEFT-COLOR: #000000"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 28.35pt"> <div style="CLEAR:both;CLEAR: both">d.</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> On July 1, 2013, the Company signed an agreement with a consultant, who is also one of the Company's shareholders, to render advisory services. The Company pays the consultant an amount</font> of <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> $</font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font></font> per month<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ScheduleOfRelatedPartyExpensesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party expenses during period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ScheduleOfRelatedPartyExpensesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>78</ContextCount>
  <ElementCount>171</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/StatementsOfChangesInShareholdersEquityParenthetical</Role>
      <ShortName>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/General</Role>
      <ShortName>GENERAL</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - RECEIVABLES AND PREPAID EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpenses</Role>
      <ShortName>RECEIVABLES AND PREPAID EXPENSES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - OTHER ACCOUNTS PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/OtherAccountsPayable</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - CONTINGENT LIABILITIES AND COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitments</Role>
      <ShortName>CONTINGENT LIABILITIES AND COMMITMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ShareholdersEquity</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactions</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - FINANCIAL EXPENSES (INCOME), NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/FinancialExpensesIncomeNet</Role>
      <ShortName>FINANCIAL EXPENSES (INCOME), NET</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - RECEIVABLES AND PREPAID EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesTables</Role>
      <ShortName>RECEIVABLES AND PREPAID EXPENSES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - OTHER ACCOUNTS PAYABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/OtherAccountsPayableTables</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - CONTINGENT LIABILITIES AND COMMITMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsTables</Role>
      <ShortName>CONTINGENT LIABILITIES AND COMMITMENTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/FinancialExpensesIncomeNetTables</Role>
      <ShortName>FINANCIAL EXPENSES (INCOME), NET (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - GENERAL (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/GeneralDetailsTextual</Role>
      <ShortName>GENERAL (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/SignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - RECEIVABLES AND PREPAID EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ReceivablesAndPrepaidExpensesDetails</Role>
      <ShortName>RECEIVABLES AND PREPAID EXPENSES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>134 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/PropertyAndEquipmentNetDetailsTextual</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>135 - Disclosure - OTHER ACCOUNTS PAYABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/OtherAccountsPayableDetails</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>136 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>137 - Disclosure - INCOME TAXES (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>INCOME TAXES (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>138 - Disclosure - CONTINGENT LIABILITIES AND COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetails</Role>
      <ShortName>CONTINGENT LIABILITIES AND COMMITMENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>139 - Disclosure - CONTINGENT LIABILITIES AND COMMITMENTS (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ContingentLiabilitiesAndCommitmentsDetailsTextual</Role>
      <ShortName>CONTINGENT LIABILITIES AND COMMITMENTS (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140 - Disclosure - SHAREHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ShareholdersEquityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>141 - Disclosure - SHAREHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ShareholdersEquityDetails1</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>142 - Disclosure - SHAREHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ShareholdersEquityDetails2</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>143 - Disclosure - SHAREHOLDERS' EQUITY (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/ShareholdersEquityDetailsTextual</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>144 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>145 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetails1</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>146 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/RelatedPartyBalancesAndTransactionsDetailsTextual</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>147 - Disclosure - FINANCIAL EXPENSES (INCOME), NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/FinancialExpensesIncomeNetDetails</Role>
      <ShortName>FINANCIAL EXPENSES (INCOME), NET (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>148 - Disclosure - SUBSEQUENT EVENTS (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioblast-pharma.com/role/SubsequentEventsDetailsTextual</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_EffectiveIncomeTaxRateContinuingOperations had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Columns in Cash Flows statement 'STATEMENTS OF CASH FLOWS (USD $)' have maximum duration 365 days and at least 17 values. Shorter duration columns must have at least one fourth (4) as many values. Column '1/23/2012 - 12/31/2012' is shorter (343 days) and has only 2 values, so it is being removed.</Log>
    <Log type="Info">Process Flow-Through: 102 - Statement - BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jan. 22, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">	Process Flow-Through: Removing column '11 Months Ended
Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)</Log>
    <Log type="Info">	Process Flow-Through: Removing column '0 Months Ended
Aug. 05, 2014'</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>orpn-20141231.xml</File>
    <File>orpn-20141231.xsd</File>
    <File>orpn-20141231_cal.xml</File>
    <File>orpn-20141231_def.xml</File>
    <File>orpn-20141231_lab.xml</File>
    <File>orpn-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONTINGENT LIABILITIES AND COMMITMENTS (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_ContingentLiabilitiesAndCommitmentsLineItems', window );"><strong>CONTINGENT LIABILITIES AND COMMITMENTS [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">$ 117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">117</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" onclick="toggleNextSibling(this);">54</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">$ 288</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_ContingentLiabilitiesAndCommitmentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_ContingentLiabilitiesAndCommitmentsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock', window );">Property, Plant and Equipment, Estimated Useful Lives, Depreciation Rates [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.85in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Computers and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Electronic equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Office furniture and equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure for rate of depreciation using the straight-line method over the estimated useful lives of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">orpn_PropertyPlantAndEquipmentEstimatedUsefulLivesDepreciationRatesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>orpn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
